PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Bruening, W; Pelletier, J				Bruening, W; Pelletier, J			A non-AUG translational initiation event generates novel WT1 isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR GENE-PRODUCT; FACTOR-A-CHAIN; WILMS-TUMOR; GROWTH-FACTOR; UROGENITAL DEVELOPMENT; KIDNEY DEVELOPMENT; PROMOTER ACTIVITY; POINT MUTATIONS; SUPPRESSOR GENE; MESSENGER-RNAS	The Wilms' tumor (WT) suppressor gene, WT1, is mutated in a small set of WTs and is essential for proper development of the urogenital system. The gene has three sites of transcriptional initiation and produces mRNA transcripts containing S'-untranslated regions of more than 350 nucleotides. The mRNA, through two alternative splicing events, is predicted to direct the synthesis of four protein isoforms with molecular masses of 47-49 kDa. In this report, we identify and characterize novel WT1 protein isoforms having predicted molecular masses of 54-56 kDa. Mutational analysis of the murine wt1 mRNA demonstrates that the novel isoforms are the result of translation initiation at a CUG codon 204 bases upstream of and in frame with the initiator AUG. We show that these isoforms are present in both normal murine tissue and in WTs. Like WT1, the larger isoforms localize to the cell nucleus and are capable of mediating transcriptional repression. Our results indicate that regulation of WT1 gene expression is more complex than previously suspected and have important implications for normal and abnormal urogenital system development.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	McGill University								ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BERNARDS A, 1990, EMBO J, V9, P2279, DOI 10.1002/j.1460-2075.1990.tb07399.x; BOECK R, 1994, EMBO J, V13, P3608, DOI 10.1002/j.1460-2075.1994.tb06668.x; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; Bruening Wendy, 1994, Seminars in Developmental Biology, V5, P333, DOI 10.1006/sedb.1994.1042; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GOODYER P, 1995, ONCOGENE, V10, P1125; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRUNERT S, 1994, EMBO J, V13, P3618, DOI 10.1002/j.1460-2075.1994.tb06669.x; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARRSON SH, 1995, CELL, V81, P391; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MOFFETT P, 1995, P NATL ACAD SCI USA, V92, P11105, DOI 10.1073/pnas.92.24.11105; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; NAGPAL S, 1992, P NATL ACAD SCI USA, V89, P2718, DOI 10.1073/pnas.89.7.2718; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; RACKLEY RR, 1993, CELL GROWTH DIFFER, V4, P1023; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828	47	115	124	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8646	8654		10.1074/jbc.271.15.8646	http://dx.doi.org/10.1074/jbc.271.15.8646			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621495	hybrid			2022-12-25	WOS:A1996UE73000026
J	Floer, M; Blobel, G				Floer, M; Blobel, G			The nuclear transport factor karyopherin beta binds stoichiometrically to Ran-GTP and inhibits the Ran GTPase activating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; RAN/TC4; MUTANT; RAF-1	The heterodimeric karyopherin functions in targeting a nuclear localization sequence (NLS)-containing protein to the nuclear pore complex followed by Ran-GTP and p10-mediated translocation of the NLS protein into the nucleoplasm. It was shown recently that Ran-GTP dissociated the karyopherin heterodimer and, in doing so, associated with karyopherin beta (Rexach, M., and Blobel, G. (1995) Cell 83, 683-692). We show here, using all recombinant yeast proteins expressed in Escherichia coli, that karyopherin beta binds to Ran-GTP and inhibits GTP hydrolysis stimulated by RanGAP (the Ran-specific GTPase activating protein), Inhibition of RanGAP-stimulated GTP hydrolysis by karyopherin beta was dependent on karyopherin beta concentration relative to Ran-GTP. Complete inhibition of RanGAP was observed at karyopherin beta concentrations that were equimolar to Ran-GTP. In gel filtration experiments, we found Ran-GTP and karyopherin beta to form a stoichiometric complex. Ran-GDP bound only weakly to karyopherin beta. We propose that stoichiometric complex formation between karyopherin beta and Ran-GTP renders Ran-GTP inaccessible to RanGAP.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, CELL BIOL LAB, NEW YORK, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University								ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; BECKER J, 1995, J BIOL CHEM, V270, P11860, DOI 10.1074/jbc.270.20.11860; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; GORLICH D, 1995, CURR BIOL, V5, P383, DOI 10.1016/S0960-9822(95)00079-0; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; IMAMOTO N, 1995, J BIOL CHEM, V270, P8559, DOI 10.1074/jbc.270.15.8559; IMAMOTO N, 1995, EMBO J, V14, P3617, DOI 10.1002/j.1460-2075.1995.tb00031.x; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212, DOI 10.1073/pnas.91.21.10212; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NISHIMOTO T, 1978, CELL, V15, P475, DOI 10.1016/0092-8674(78)90017-X; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; TRAGLIA HM, 1989, MOL CELL BIOL, V9, P2989, DOI 10.1128/MCB.9.7.2989; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0	32	116	117	3	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5313	5316		10.1074/jbc.271.10.5313	http://dx.doi.org/10.1074/jbc.271.10.5313			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621381	hybrid			2022-12-25	WOS:A1996TZ28600007
J	Peterson, BZ; Tanada, TN; Catterall, WA				Peterson, BZ; Tanada, TN; Catterall, WA			Molecular determinants of high affinity dihydropyridine binding in L-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1 SUBUNIT; SKELETAL-MUSCLE; CA2+ CHANNELS; IDENTIFICATION; RECEPTOR; AZIDOPINE; BLOCKERS; DOMAINS; SITE	The pore-forming a subunit of L-type voltage-gated Ca2+ channels is pharmacologically modulated by dihydropyridine (DHP) Ca2+ antagonists and agonists, Site-directed mutation of amino acids within transmembrane segments IIIS6 and IVS6 to those characteristic of DHP-insensitive channels revealed 2 mutations in IIIS6 (I1049F and I1052F) and 4 mutations in IVS6 (Y1365I, M1366F, I1372M, and I1373L) with increased K-D values for (+)-[H-3]PN200-110 binding, A tyrosine residue (Y1048) in IIIS6 that is conserved between DHP-sensitive and -insensitive Ca2+ channels was also altered by mutagenesis, Y1048F had a K-D for (+)-[H-3]PN200-110 binding that was increased 12-fold, and Y1048A had a K-D at least 1000-fold higher than that of wild-type. These results support the hypothesis that transmembrane segments IIIS6 and IVS6 both contribute critical amino acid residues to the DHP receptor site and that Tyr-1048 within transmembrane segment IIIS6 is required for high affinity DHP binding, even though it is conserved between DHP-sensitive and -insensitive Ca2+ channels.			Peterson, BZ (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948, T32HL007312] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07312, P01 HL 44948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANGALORE R, 1994, MOL PHARMACOL, V46, P660; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; HOCKERMAN GH, 1995, J BIOL CHEM, V270, P22119, DOI 10.1074/jbc.270.38.22119; KALASZ H, 1993, FEBS LETT, V331, P177, DOI 10.1016/0014-5793(93)80321-K; KASS RS, 1991, J GEN PHYSIOL, V98, P63, DOI 10.1085/jgp.98.1.63; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NAKAYAMA H, 1991, P NATL ACAD SCI USA, V88, P9203, DOI 10.1073/pnas.88.20.9203; PETERSON BZ, 1995, J BIOL CHEM, V270, P18201, DOI 10.1074/jbc.270.31.18201; REGULLA S, 1991, EMBO J, V10, P45, DOI 10.1002/j.1460-2075.1991.tb07919.x; SERRANO L, 1991, J MOL BIOL, V218, P465, DOI 10.1016/0022-2836(91)90725-L; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; STRIESSNIG J, 1991, P NATL ACAD SCI USA, V88, P10769, DOI 10.1073/pnas.88.23.10769; STRUBING C, 1993, BRIT J PHARMACOL, V108, P884, DOI 10.1111/j.1476-5381.1993.tb13482.x; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANG SQ, 1993, NEURON, V11, P1013, DOI 10.1016/0896-6273(93)90215-D; ZHENG W, 1991, MOL PHARMACOL, V40, P734	18	100	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5293	5296		10.1074/jbc.271.10.5293	http://dx.doi.org/10.1074/jbc.271.10.5293			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621376	hybrid			2022-12-25	WOS:A1996TZ28600002
J	Okada, T; Masuda, T; Shinkai, M; Kariya, K; Kataoka, T				Okada, T; Masuda, T; Shinkai, M; Kariya, K; Kataoka, T			Post-translational modification of H-Ras is required for activation of, but not for association with, B-Raf	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; DOMAIN; YEAST; P21(RAS); CYCLASE	B-Raf is regulated by Ras protein and acts as a mitogen-activated protein (MAP) kinase kinase kinase in PC12 cells and brain. Res protein undergoes a series of post-translational modifications on its C-terminal CAAX motif, and the modifications are critical for its function. To elucidate the role of the post-translational modifications in interaction with, and activation of, B-Raf, we have analyzed a direct association between H-Ras and B-Raf, and constructed an in vitro system for B-Raf activation by H-Ras. By using methods based on inhibition of yeast adenylyl cyclase or RasGAP activity and by in vitro binding assays, we have shown that the segment of B-Raf corresponding to amino acid 1-326 binds directly to H-Ras with a dissociation constant (K-d) comparable to that of Raf-1 and that the binding is not significantly affected by the post-translational modifications. However, when the activity of B-Raf to stimulate MAP kinase was measured by using a cell-free system derived from rat brain cytosol, we observed that the unmodified form of H-Ras possesses an almost negligible activity to activate B-Raf in vitro compared to the fully modified form H-Ras(Ser-181,184) mutant, which was farnesylated but not palmitoylated, was equally active as the fully modified form. These results indicate that the post-translational modifications, especially farnesylation, are required for H-Ras to activate B-Raf even though they have no apparent effect on the binding properties of H-Ras to B-Raf.	KOBE UNIV,SCH MED,DEPT PHYSIOL 2,CHUO KU,KOBE 650,JAPAN	Kobe University								AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BHATTACHARYA S, 1995, P NATL ACAD SCI USA, V92, P2984, DOI 10.1073/pnas.92.7.2984; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; FUJIYAMA A, 1991, J BIOL CHEM, V266, P17926; GIANNAKOUROS T, 1992, LIPID MODIFICATIONS, P135; GUNN C, 1987, GENE, V67, P21; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; ITO T, 1993, J BIOL CHEM, V268, P3025; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KIKUCHI A, 1994, J BIOL CHEM, V269, P20054; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MASUDA T, 1995, J BIOL CHEM, V270, P1979, DOI 10.1074/jbc.270.5.1979; MINATO T, 1994, J BIOL CHEM, V269, P20845; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; QUI MS, 1991, J CELL BIOL, V115, P795; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOTRM SM, 1991, ONCOGENE, V5, P345; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	39	64	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4671	4678						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617731				2022-12-25	WOS:A1996TX69700021
J	Ahn, AH; Freener, CA; Gussoni, E; Yoshida, M; Ozawa, E; Kunkel, LM				Ahn, AH; Freener, CA; Gussoni, E; Yoshida, M; Ozawa, E; Kunkel, LM			The three human syntrophin genes are expressed in diverse tissues, have distinct chromosomal locations, and each bind to dystrophin and its relatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; GLYCOPROTEIN COMPLEX; PROTEIN; TORPEDO; DOMAIN; HYBRIDIZATION; ASSOCIATION; JUNCTIONS; HOMOLOG; CELLS	The syntrophins are a biochemically heterogeneous group of 58-kDa intracellular membrane-associated dystrophin binding proteins, We have cloned and characterized human acidic (alpha 1-) syntrophin and a second isoform of human basic (beta 2-) syntrophin, Comparison of the deduced amino acid structure of the three human isoforms of syntrophin (together with the previously reported human beta 1-syntrophin) demonstrates their overall similarity, The deduced amino acid sequences of human alpha 1- and beta 2-syntrophin are nearly identical to their homologues in mouse, suggesting a strong functional conservation among the individual isoforms, Much like beta 1 syntrophin, human beta 2-syntrophin has multiple transcript classes and is expressed widely, although in a distinct pattern of relative abundance. In contrast, human alpha 1-syntrophin is most abundant in heart and skeletal muscle, and less so in other tissues, Somatic cell hybrids and fluorescent in situ hybridization were both used to determine their chromosomal locations: beta 2-syntrophin to chromosome 16q22-23 and alpha 1-syntrophin to chromosome 20q11,2. Finally, we used in vitro translated proteins in an immunoprecipitation assay to show that, like beta 1-syntrophin, both beta 2- and alpha 1-syntrophin interact with peptides encoding the syntrophin-binding region of dystrophin, utrophin/dystrophin related protein, and the Torpedo 87K protein.	CHILDRENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115; CHILDRENS HOSP,DIV GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115; HARVARD UNIV,SCH MED,MED SCI TRAINING PROGRAM,BOSTON,MA 02115; NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DEPT CELL BIOL,KODAIRA,TOKYO 187,JAPAN	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; National Center for Neurology & Psychiatry - Japan			Gussoni, Emanuela/AAL-6150-2021	Gussoni, Emanuela/0000-0002-9915-3677				ADAMS ME, 1995, J BIOL CHEM, V270, P25859, DOI 10.1074/jbc.270.43.25859; ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; AHN AH, 1994, P NATL ACAD SCI USA, V91, P4446, DOI 10.1073/pnas.91.10.4446; AHN AH, 1995, J CELL BIOL, V128, P363, DOI 10.1083/jcb.128.3.363; BECK JS, 1993, AM J HUM GENET, V53, P974; BUTLER MH, 1992, J BIOL CHEM, V267, P6213; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; CARTAUD A, 1993, J BIOL CHEM, V268, P13019; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DUBOIS BL, 1993, GENOMICS, V16, P315, DOI 10.1006/geno.1993.1191; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCNALLY EM, 1994, P NATL ACAD SCI USA, V91, P9690, DOI 10.1073/pnas.91.21.9690; MONACO AP, 1986, NATURE, V323, P646, DOI 10.1038/323646a0; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; PETERS MF, 1994, NEUROREPORT, V5, P1577, DOI 10.1097/00001756-199408150-00009; Sambrook J, 1989, MOL CLONING LABORATO; SUZUKI A, 1992, FEBS LETT, V308, P154, DOI 10.1016/0014-5793(92)81265-N; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; WAGNER KR, 1994, J NEUROCHEM, V62, P1947; WAGNER KR, 1993, NEURON, V10, P511, DOI 10.1016/0896-6273(93)90338-R; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YAMAMOTO H, 1993, J BIOCHEM-TOKYO, V114, P132, DOI 10.1093/oxfordjournals.jbchem.a124128; YANG B, 1994, J BIOL CHEM, V269, P6040; YANG B, 1995, J BIOL CHEM, V270, P4975, DOI 10.1074/jbc.270.10.4975; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	42	153	159	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2724	2730		10.1074/jbc.271.5.2724	http://dx.doi.org/10.1074/jbc.271.5.2724			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576247	hybrid			2022-12-25	WOS:A1996TT48800061
J	Asano, S; Tega, Y; Konishi, K; Fujioka, M; Takeguchi, N				Asano, S; Tega, Y; Konishi, K; Fujioka, M; Takeguchi, N			Functional expression of gastric H+,K+-ATPase and site-directed mutagenesis of the putative cation binding site and the catalytic center	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SARCOPLASMIC-RETICULUM CA-2+-ATPASE; ION-TRANSPORTING ATPASES; H,K-ATPASE BETA-SUBUNIT; ALPHA-SUBUNIT; H+/K+-ATPASE; MOLECULAR-CLONING; CDNA CLONING; MEMBRANE TOPOLOGY; COMPLEMENTARY-DNA	Gastric H+,K+-ATPase was functionally expressed in the human kidney HEK293 cell line. The expressed enzyme catalyzed ouabain-resistant K+-dependent ATP hydrolysis. The K+-ATPase activity was inhibited by SCH 28080, a specific inhibitor of gastric proton pump, in a dose-dependent manner. By using this functional expression system in combination with site-directed mutagenesis, we investigated effects of mutations in the putative cation binding site and the catalytic center of the gastric H+,K+-ATPase. In Na+,K+-ATPase, the glutamic acid residue in the 4th transmembrane segment is regarded as one of the residues responsible for the K+-induced conformational change (Kuntzweiler, T. A., Wallick, E. T., Johnson, C. L., and Lingrel, J. B. (1995) J. Biol. Chem. 270, 2993-3000). When the corresponding glutamic acid (Glu-345) of H+,K+-ATPase was mutated to aspartic acid, lysine, or valine, the SCH 28080-sensitive KC ATPase activity was abolished. However, when this residue was replaced by glutamine, about 50% of the activity was retained. This mutant showed a 10-fold lower affinity for K+ (K-m = 2.6 mM) compared with the wild-type enzyme (K-m = 0.24 mM). Thus, Glu-345 is important in determining the K+ affinity of H+,K+-ATPase. When the aspartic acid residue in the phosphorylation site was mutated to glutamic acid, this mutant showed no SCH 28080-sensitive K+-ATPase activity. Thus, amino acid replacement of the phosphorylation site is not tolerated and a stringent structure appears to be required for enzyme activity. When the lysine residue in the fluorescein isothiocyanate binding site (part of ATP binding site) was mutated to arginine, asparagine, or glutamic acid, the SCH 28080-sensitive K+-ATPase activity was eliminated. However, the mutant in which this residue was changed to glutamine had about 30% of the activity, suggesting that amino acid replacement of this site is tolerated to a certain extent.	TOYAMA MED & PHARMACEUT UNIV,FAC MED,TOYAMA 93001,JAPAN	University of Toyama	Asano, S (corresponding author), TOYAMA MED & PHARMACEUT UNIV,FAC PHARMACEUT SCI,2630 SUGITANI,TOYAMA 93001,JAPAN.			Asano, Shinji/0000-0003-1443-8970				ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; ASANO S, 1988, J BIOCHEM-TOKYO, V103, P672, DOI 10.1093/oxfordjournals.jbchem.a122327; ASANO S, 1990, J BIOL CHEM, V265, P22167; ASANO S, 1994, BIOCHEM J, V299, P59, DOI 10.1042/bj2990059; ASANO S, 1989, J BIOCHEM-TOKYO, V106, P1074, DOI 10.1093/oxfordjournals.jbchem.a122967; ASANO S, 1992, J BIOL CHEM, V267, P6590; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BRIVING C, 1988, BIOCHIM BIOPHYS ACTA, V946, P185, DOI 10.1016/0005-2736(88)90391-4; CANFIELD VA, 1990, J BIOL CHEM, V265, P19878; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; FARLEY RA, 1985, J BIOL CHEM, V260, P3899; FORTE JG, 1975, GASTROENTEROLOGY, V69, P175; FUKUSHIMA Y, 1992, BIOCHIM BIOPHYS ACTA, V1106, P71, DOI 10.1016/0005-2736(92)90223-9; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; GOTTARDI CJ, 1993, J CELL BIOL, V121, P283, DOI 10.1083/jcb.121.2.283; GOTTARDI CJ, 1993, J BIOL CHEM, V268, P14342; HORISBERGER JD, 1991, J BIOL CHEM, V266, P19131; JACKSON RJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P9, DOI 10.1016/0005-2736(83)90391-7; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JOHNSON CL, 1995, BIOCHEM J, V309, P187, DOI 10.1042/bj3090187; KAWAKAMI K, 1985, NATURE, V316, P733, DOI 10.1038/316733a0; KEELING DJ, 1988, BIOCHEM PHARMACOL, V37, P2231, DOI 10.1016/0006-2952(88)90586-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P2993, DOI 10.1074/jbc.270.7.2993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAS MV, 1994, J BIOL CHEM, V269, P18651; MACLENNAN DH, 1990, BIOPHYS J, V58, P1355, DOI 10.1016/S0006-3495(90)82482-6; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MAEDA M, 1990, J BIOL CHEM, V265, P9027; MAEDA M, 1988, BIOCHEM BIOPH RES CO, V157, P203, DOI 10.1016/S0006-291X(88)80033-0; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MATHEWS PM, 1995, AM J PHYSIOL-CELL PH, V268, pC1207, DOI 10.1152/ajpcell.1995.268.5.C1207; MORII M, 1995, BIOCHEM PHARMACOL, V49, P1729, DOI 10.1016/0006-2952(95)00090-M; MORII M, 1990, BIOCHEM BIOPH RES CO, V167, P754, DOI 10.1016/0006-291X(90)92089-I; MUNSON KB, 1991, J BIOL CHEM, V266, P18976; NOGUCHI S, 1992, BIOCHEM BIOPH RES CO, V182, P659, DOI 10.1016/0006-291X(92)91783-M; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; OHTSUBO M, 1990, BIOCHIM BIOPHYS ACTA, V1021, P157, DOI 10.1016/0005-2736(90)90028-M; OKAMOTO CT, 1990, BIOCHIM BIOPHYS ACTA, V1037, P360, DOI 10.1016/0167-4838(90)90038-H; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; SACHS G, 1976, J BIOL CHEM, V251, P7690; SHULL GE, 1988, J BIOL CHEM, V263, P8646; SHULL GE, 1990, J BIOL CHEM, V265, P12123; SHULL GE, 1986, J BIOL CHEM, V261, P6788; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; SONG I, 1993, BIOCHEM BIOPH RES CO, V196, P1240, DOI 10.1006/bbrc.1993.2385; STEKHOVEN FS, 1981, PHYSIOL REV, V61, P1; TOH BH, 1990, P NATL ACAD SCI USA, V87, P6418, DOI 10.1073/pnas.87.16.6418; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; WALLMARK B, 1985, J BIOL CHEM, V260, P3681; WALLMARK B, 1987, J BIOL CHEM, V262, P2077; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	55	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2740	2745		10.1074/jbc.271.5.2740	http://dx.doi.org/10.1074/jbc.271.5.2740			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576249	hybrid			2022-12-25	WOS:A1996TT48800063
J	Lang, IM; Schleef, RR				Lang, IM; Schleef, RR			Calcium-dependent stabilization of type I plasminogen activator inhibitor within platelet alpha-granules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; VITRONECTIN; PLASMA; PAI-1; IDENTIFICATION; PROTEINS; THROMBOLYSIS; AGGREGATION; DEFICIENCY; PREGNANCY	Type 1 plasminogen activator inhibitor (PAI-1) is known to be synthesized in an active conformation but it is rapidly converted into an inactive conformation (t(1/2) 1 h) upon incubation at 37 degrees C. This study was initiated to investigate the mechanism that account for the presence of active PAI-1 in anucleated platelets that have a mean life span of 9-12 days in the circulation. Stabilization experiments with a functional immunoassay indicated that the activity of PAI-1 in both platelets and in isolated alpha-granules was prolonged in comparison to the rapid inactivation of this molecule in their lysates (t(1/2) 1 h). Although combined ligand blot/immunoblot analysis revealed that vitronectin was the major PAI-1 binding protein in platelets, vitronectin/PAI-1 complexes were not detected in alpha-granules using a two-site immunoassay. Co-incubation of alpha-granules with a number of agents that disrupt pH gradients (e.g. ionophores) had no effect on the stability of PAI-1 activity, whereas incubation of alpha-granules with the calcium ionophore A23187 reduced the half-life of PAI-1 to the levels observed for PAI-1 in solution. Addition of calcium ions to intact alpha-granules was an effective means of neutralizing the ionophore's effect on PAI-1 activity. Fractionation of alpha-granule proteins on molecular sieving columns using conditions known to be present within storage granules (e.g. a high calcium concentration) revealed the presence of PAI-1 in fractions with a molecular mass of > 10(6) daltons. Immunoabsorption of PAI-1 from these column fractions followed by negative staining revealed 25-nm diameter complexes of alpha-granule proteins under the electron microscope. PAI-1 activity associated with these complexes was prolonged in the presence of calcium ions and these high M(r) complexes were shown to be composed of a defined set of proteins that can be dissociated from PAI-1 by chelation of calcium ions. These data indicate that PAI-1 is stabilized by its packaging with other alpha-granule proteins in a calcium-dependent manner.	Scripps Res Inst, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA	Scripps Research Institute				Lang, Irene/0000-0003-0485-2692	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049563, R01HL045954] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49563, HL45954] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AILLAUD MF, 1985, THROMB HAEMOSTASIS, V54, P466; BITHELL TC, 1993, WINTROBES CLIN HEMAT, P511; BOOTH NA, 1985, J CLIN PATHOL, V38, P825, DOI 10.1136/jcp.38.7.825; BOOTH NA, 1988, BRIT J HAEMATOL, V70, P327, DOI 10.1111/j.1365-2141.1988.tb02490.x; BOOTH NA, 1990, FIBRINOLYSIS, V4, P138, DOI 10.1016/0268-9499(90)90391-V; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; DECLERCK PJ, 1988, BLOOD, V71, P220; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; DIEVAL J, 1991, BLOOD, V77, P528; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; ERICKSON LA, 1984, J CLIN INVEST, V74, P1465, DOI 10.1172/JCI111559; ERICKSON LA, 1986, BLOOD, V68, P1298; ESTELLES A, 1989, BLOOD, V74, P1332; FAY WP, 1994, BLOOD, V83, P351; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; FRANCIS RB, 1986, BLOOD, V68, pA333; GOGSTAD GO, 1980, THROMB RES, V20, P669, DOI 10.1016/0049-3848(80)90155-3; GOMBAU L, 1994, J BIOL CHEM, V269, P3875; JANG IK, 1989, CIRCULATION, V79, P920, DOI 10.1161/01.CIR.79.4.920; KEIJER J, 1990, FIBRINOLYSIS, V4, P153, DOI 10.1016/S0268-9499(05)80047-5; KELLY R B, 1991, Current Opinion in Cell Biology, V3, P654, DOI 10.1016/0955-0674(91)90037-Y; KLUFT C, 1985, SCAND J CLIN LAB INV, V45, P605, DOI 10.3109/00365518509155267; KONKLE BA, 1993, ARTERIOSCLER THROMB, V13, P669, DOI 10.1161/01.ATV.13.5.669; KRUITHOF EKO, 1987, BLOOD, V70, P1645; KRUITHOF EKO, 1987, BLOOD, V69, P460; KRUITHOF EKO, 1988, THROMB HAEMOSTASIS, V59, P7; KRUITHOF EKO, 1986, THROMB HAEMOSTASIS, V55, P201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG IM, 1993, CIRCULATION, V87, P1990, DOI 10.1161/01.CIR.87.6.1990; LANG IM, 1992, BLOOD, V80, P2269; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; LEE MH, 1993, BLOOD, V81, P2357; LEVI M, 1992, CIRCULATION, V85, P305, DOI 10.1161/01.CIR.85.1.305; LINDAHL TL, 1989, THROMB HAEMOSTASIS, V62, P748; LOSKUTOFF DJ, 1989, PROG HEMOST THROMB, V9, P87; MIMURO J, 1987, BLOOD, V70, P721; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1989, BLOOD, V74, P1989; RENDU F, 1982, BRIT J HAEMATOL, V52, P241, DOI 10.1111/j.1365-2141.1982.tb03886.x; RINDLER M J, 1992, Current Opinion in Cell Biology, V4, P616, DOI 10.1016/0955-0674(92)90080-V; SCHLEEF RR, 1991, J CELL BIOL, V113, P1413, DOI 10.1083/jcb.113.6.1413; SCHLEEF RR, 1988, J BIOL CHEM, V263, P5797; SCHLEEF RR, 1989, J CLIN INVEST, V83, P1747, DOI 10.1172/JCI114076; SCHLEEF RR, 1990, J CELL BIOL, V110, P155, DOI 10.1083/jcb.110.1.155; SCHLEEF RR, 1985, J LAB CLIN MED, V106, P408; SCHNEIDERMAN J, 1991, TRENDS CARDIOVAS MED, V1, P99, DOI 10.1016/1050-1738(91)90001-U; SEIFFERT D, 1990, FIBRINOLYSIS, V4, P197, DOI 10.1016/0268-9499(90)90014-B; SIMPSON AJ, 1991, J CLIN PATHOL, V44, P139, DOI 10.1136/jcp.44.2.139; SIMPSON AJ, 1990, BRIT J HAEMATOL, V75, P543, DOI 10.1111/j.1365-2141.1990.tb07796.x; SPRENGERS ED, 1986, THROMB HAEMOSTASIS, V55, P325; SPRENGERS ED, 1987, BLOOD, V69, P381; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; STRINGER HAR, 1995, J BIOL CHEM, V270, P11205, DOI 10.1074/jbc.270.19.11205	54	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2754	2761		10.1074/jbc.271.5.2754	http://dx.doi.org/10.1074/jbc.271.5.2754			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576251	hybrid			2022-12-25	WOS:A1996TT48800065
J	Morikawa, Y; Hinata, S; Tomoda, H; Goto, T; Nakai, M; Aizawa, C; Tanaka, H; Omura, S				Morikawa, Y; Hinata, S; Tomoda, H; Goto, T; Nakai, M; Aizawa, C; Tanaka, H; Omura, S			Complete inhibition of human immunodeficiency virus gag myristoylation is necessary for inhibition of particle budding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COA SYNTHETASE; BACULOVIRUS-INFECTED CELLS; TYPE-1; PROTEINS; GENE; HIV; PR160GAG-POL; PRECURSOR; TRIACSINS; PR55GAG	Myristoylation of human immunodeficiency virus (HIV) Gag protein is essential for virus particle budding. Two reactions are involved; activation of free myristate to myristoyl-CoA and transfer of the myristoyl residue to the Gag N-terminal glycine. We have investigated the effects of triacsin C, an inhibitor of long chain acyl-CoA synthetase, on release of HN Gag virus-like particle (VLP) produced using the recombinant baculovirus system. First, inhibition of acyl-CoA formation by triacsin C was confirmed using the membrane fractions of insect Sf9 cells as an enzyme source. Second, when HN Gag protein was expressed in the presence of triacsin C (0-48 mu M), Gag myristoylation was inhibited in a dose-dependent manner. Budding of Gag VLP, however, did not follow similar inhibition kinetics but appeared unaffected up to 24 mu M, yet was completely abolished at 48 mu M when the myristoylation of Gag protein was also completely inhibited. The ''all-or-none'' inhibition of Gag VLP budding suggests that although inhibition of acyl-CoA synthetase blocks the production of myristoylated Gag protein, only complete inhibition of Gag myristoylation prevents VLP budding. Thus, relatively few myristoylated Gag molecules are sufficient for plasma membrane targeting and VLP budding.	KITASATO UNIV,KITASATO INST,MINATO KU,TOKYO 108,JAPAN; KITASATO UNIV,SCH PHARMACEUT SCI,MINATO KU,TOKYO 108,JAPAN; OSAKA MED COLL,DEPT MICROBIOL,TAKATSUKI,OSAKA 569,JAPAN	Kitasato University; Kitasato University; Osaka Medical College								BERG T, 1972, EXP CELL RES, V72, P571, DOI 10.1016/0014-4827(72)90034-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAZAL N, 1994, J VIROL, V68, P111, DOI 10.1128/JVI.68.1.111-122.1994; DOERFLER W, 1986, CUR TOPICS MICROBIOL, V131, P1; FREED EO, 1994, J VIROL, V68, P5311, DOI 10.1128/JVI.68.8.5311-5320.1994; GHEYSEN D, 1989, CELL, V59, P103, DOI 10.1016/0092-8674(89)90873-8; GONDA MA, 1985, SCIENCE, V227, P173, DOI 10.1126/science.2981428; GOTO T, 1990, ARCH VIROL, V111, P87, DOI 10.1007/BF01310507; HAYASHI M, 1992, BIOCHEM BIOPH RES CO, V188, P1280, DOI 10.1016/0006-291X(92)91370-6; HOCKLEY DJ, 1994, J GEN VIROL, V75, P2985, DOI 10.1099/0022-1317-75-11-2985; HONG SS, 1993, J VIROL, V67, P2787, DOI 10.1128/JVI.67.5.2787-2798.1993; JOWETT JBM, 1992, J GEN VIROL, V73, P3079, DOI 10.1099/0022-1317-73-12-3079; KAPLAN AH, 1993, J VIROL, V67, P4050, DOI 10.1128/JVI.67.7.4050-4055.1993; KARACOSTAS V, 1989, P NATL ACAD SCI USA, V86, P8964, DOI 10.1073/pnas.86.22.8964; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; KORCHAK HM, 1994, J BIOL CHEM, V269, P30281; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB RA, 1978, VIROLOGY, V91, P61; LANGNER CA, 1992, J BIOL CHEM, V267, P17159; LEE PP, 1994, J VIROL, V68, P6644, DOI 10.1128/JVI.68.10.6644-6654.1994; LEVY JA, 1992, RETROVIRIDAE, V1; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MISHINA M, 1978, EUR J BIOCHEM, V82, P347, DOI 10.1111/j.1432-1033.1978.tb12029.x; OMURA S, 1986, J ANTIBIOT, V39, P1211, DOI 10.7164/antibiotics.39.1211; PARK J, 1992, J VIROL, V66, P6304, DOI 10.1128/JVI.66.11.6304-6313.1992; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; PIDGEON C, 1993, J BIOL CHEM, V268, P7773; ROYER M, 1991, VIROLOGY, V184, P417, DOI 10.1016/0042-6822(91)90861-5; SAERMARK T, 1991, AIDS, V5, P951, DOI 10.1097/00002030-199108000-00005; SCHULTZ AM, 1983, J VIROL, V46, P355, DOI 10.1128/JVI.46.2.355-361.1983; SCHULTZ AM, 1989, J VIROL, V63, P2370, DOI 10.1128/JVI.63.5.2370-2373.1989; SHIODA T, 1990, VIROLOGY, V175, P139, DOI 10.1016/0042-6822(90)90194-V; SHOJI S, 1989, J BIOCHEM-TOKYO, V103, P747; SMITH AJ, 1990, J VIROL, V64, P2743, DOI 10.1128/JVI.64.6.2743-2750.1990; SMITH AJ, 1993, J VIROL, V67, P2266, DOI 10.1128/JVI.67.4.2266-2275.1993; SPEARMAN P, 1994, J VIROL, V68, P3232, DOI 10.1128/JVI.68.5.3232-3242.1994; Summers MD, 1987, MANUAL METHODS BACUL; TASHIRO A, 1989, BIOCHEM BIOPH RES CO, V165, P1145, DOI 10.1016/0006-291X(89)92722-8; TOMODA H, 1991, J BIOL CHEM, V266, P4214; TOMODA H, 1987, BIOCHIM BIOPHYS ACTA, V921, P595; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARMUS H, 1988, GENE DEV, V2, P1055, DOI 10.1101/gad.2.9.1055; VERONESE FD, 1988, J VIROL, V62, P795, DOI 10.1128/JVI.62.3.795-801.1988; WILLS JW, 1991, J VIROL, V65, P3804, DOI 10.1128/JVI.65.7.3804-3812.1991; WILLS JW, 1991, AIDS, V5, P639, DOI 10.1097/00002030-199106000-00002; WU XJ, 1994, J BIOL CHEM, V269, P12375; YUAN X, 1993, J VIROL, V67, P6387, DOI 10.1128/JVI.67.11.6387-6394.1993; ZHOU WJ, 1994, J VIROL, V68, P2556, DOI 10.1128/JVI.68.4.2556-2569.1994	48	57	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2868	2873		10.1074/jbc.271.5.2868	http://dx.doi.org/10.1074/jbc.271.5.2868			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576268	hybrid			2022-12-25	WOS:A1996TT48800082
J	Renaud, F; Desset, S; Oliver, L; GimenezGallego, G; VanObberghen, E; Courtois, Y; Laurent, M				Renaud, F; Desset, S; Oliver, L; GimenezGallego, G; VanObberghen, E; Courtois, Y; Laurent, M			The neurotrophic activity of fibroblast growth factor 1 (FGF1) depends on endogenous FGF1 expression and is independent of the mitogen-activated protein kinase cascade pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; FACTOR PREVENTS DEATH; AFGF MESSENGER-RNA; PC12 CELLS; NEURONAL DIFFERENTIATION; PHEOCHROMOCYTOMA CELLS; GENE-TRANSCRIPTION; HEPARIN-BINDING; BOVINE RETINA; ACIDIC FGF	The expression of fibroblast growth factor (FGF) 1, a potent neurotrophic factor, increases during differentiation and remains high in adult neuronal tissues. To examine the importance of this expression on the neuronal phenotype, we have used PC12 cells, a model to study FGF-induced neuronal differentiation. After demonstrating that FGF1 and FGF2 are synthesized by PC12 cells, we investigated if FGF1 expression could be a key element in differentiation. Using the cell signaling pathway to determine the effects of FGF1 alone, FGF1 plus heparin, or a mutated FGF1, we showed an activation to the same extent of mitogen-activated protein (MAP) kinase kinase and MAP kinase (extracellular regulated kinase 1). However, only FGF1 plus heparin could promote PC12 cell differentiation. Thus, the MAP kinase pathway is insufficient to promote differentiation. Analysis of the PC12 cells after the addition of FGF1 plus heparin or FGF2 demonstrated a significant increase in the level of FGF1 expression with the same time course as the appearance of the neuritic extensions. Transfection experiments were performed to enhance constitutivly or after dexamethasone induction the level of FGF1 expression. The degree of differentiation achieved by the cells correlated directly with the amount of FGF1 expressed. The MAP kinase pathway did not appear to be involved. Interestingly, a 5-fold increase in FGF1 in constitutive transfected cells extended dramatically their survival in serum-free medium, suggesting that the rise of FGF1 synthesis during neuronal differentiation is probably linked to their ability to survive in the adult. All of these data demonstrate that, in contrast to the MAP kinase cascade, FGF1 expression is sufficient to induce in PC12 cells both differentiation and survival. It also shows that auto- and trans-activation of FGF1 expression is involved in the differentiation process stimulated by exogenous FGFs through a new pathway which remains to be characterized.	ASSOC CLAUDE BERNARD,CNRS,INSERM,XR118,UNITE RECH GERONTOL,F-75016 PARIS,FRANCE; CSIC,CTR INVEST BIOL,E-28006 MADRID,SPAIN; FAC MED NICE,INSERM,U145,F-06107 NICE 2,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur			Desset, Sophie/AAM-8212-2021; desset, sophie/G-5756-2013; Oliver, Lisa J/L-3070-2015	Desset, Sophie/0000-0002-4897-4977; desset, sophie/0000-0002-4897-4977; Oliver, Lisa J/0000-0002-5588-7564				ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BUGRA K, 1993, EUR J NEUROSCI, V5, P1586, DOI 10.1111/j.1460-9568.1993.tb00228.x; BURGESS WH, 1991, J CELL BIOCHEM, V45, P131, DOI 10.1002/jcb.240450203; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAMON DH, 1992, EXP CELL RES, V201, P154, DOI 10.1016/0014-4827(92)90359-G; DICKSON G, 1986, EMBO J, V5, P3449, DOI 10.1002/j.1460-2075.1986.tb04668.x; ECKENSTEIN FP, 1990, NEURON, V4, P623, DOI 10.1016/0896-6273(90)90120-5; ELDE R, 1991, NEURON, V7, P349, DOI 10.1016/0896-6273(91)90288-B; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0; FLOTTRAHMEL B, 1992, NEUROREPORT, V3, P1077, DOI 10.1097/00001756-199212000-00011; FONNUM F, 1973, J NEUROCHEM, V21, P1109, DOI 10.1111/j.1471-4159.1973.tb07565.x; FOX JC, 1993, IN VITRO CELL DEV-AN, V29A, P228; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GODSAVE SF, 1991, DEVELOPMENT, V111, P523; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUILLEMOT F, 1992, DEVELOPMENT, V114, P743; HATTEN ME, 1988, DEV BIOL, V125, P280, DOI 10.1016/0012-1606(88)90211-4; HEUER JG, 1990, NEURON, V5, P283, DOI 10.1016/0896-6273(90)90165-C; HICKS D, 1988, FEBS LETT, V234, P475, DOI 10.1016/0014-5793(88)80141-8; Hill DJ, 1992, GROWTH FACTORS, V7, DOI 10.3109/08977199209046926; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JACQUEMIN E, 1993, INT J DEV BIOL, V37, P417; JACQUEMIN E, 1990, NEUROSCI LETT, V116, P23, DOI 10.1016/0304-3940(90)90380-R; JANET T, 1987, NEUROSCI LETT, V80, P153, DOI 10.1016/0304-3940(87)90645-8; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; LAPPI DA, 1989, BIOCHEM BIOPH RES CO, V160, P917, DOI 10.1016/0006-291X(89)92522-9; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; LIPTON SA, 1988, P NATL ACAD SCI USA, V85, P2388, DOI 10.1073/pnas.85.7.2388; LUCAS CA, 1980, NEUROSCI LETT, V18, P333, DOI 10.1016/0304-3940(80)90307-9; MCAVOY JW, 1989, DEVELOPMENT, V107, P221; MOTHE I, 1993, MOL BIOL CELL, V4, P737, DOI 10.1091/mbc.4.7.737; MULLER SR, 1990, DNA CELL BIOL, V9, P221, DOI 10.1089/dna.1990.9.221; NAKANISHI Y, 1992, P NATL ACAD SCI USA, V89, P5216, DOI 10.1073/pnas.89.12.5216; NGUYEN TT, 1993, J BIOL CHEM, V268, P9803; Oliver L, 1992, GROWTH FACTORS, V7, P97, DOI 10.3109/08977199209046399; PAYSON RA, 1993, NUCLEIC ACIDS RES, V21, P489, DOI 10.1093/nar/21.3.489; PERALDI P, 1993, ENDOCRINOLOGY, V132, P2578, DOI 10.1210/en.132.6.2578; PETTMANN B, 1986, NEUROSCI LETT, V68, P175, DOI 10.1016/0304-3940(86)90137-0; PHILIPPE JM, 1992, BIOCHEM BIOPH RES CO, V188, P843, DOI 10.1016/0006-291X(92)91133-B; REILAND J, 1993, J CELL SCI, V105, P1085; RENAUD F, 1992, BIOCHEM BIOPH RES CO, V184, P945, DOI 10.1016/0006-291X(92)90682-B; RENAUD F, 1994, J CELL PHYSIOL, V158, P435, DOI 10.1002/jcp.1041580307; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; RIEGER F, 1980, DEV BIOL, V76, P238, DOI 10.1016/0012-1606(80)90376-0; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SCHNURCH H, 1991, DEVELOPMENT, V111, P1143; SCIMECA JC, 1991, BIOCHEMISTRY-US, V30, P913; TCHENG M, 1994, EXP EYE RES, V58, P351, DOI 10.1006/exer.1994.1025; TESSLER S, 1990, J CELL PHYSIOL, V145, P310, DOI 10.1002/jcp.1041450216; TSAO H, 1990, J BIOL CHEM, V265, P1571; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; VOULGAROPOULOU F, 1994, DNA CELL BIOL, V13, P1001, DOI 10.1089/dna.1994.13.1001; WALICKE PA, 1988, J NEUROSCI, V8, P2618; WELLINGER RJ, 1986, J VIROL, V60, P1; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	62	64	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2801	2811		10.1074/jbc.271.5.2801	http://dx.doi.org/10.1074/jbc.271.5.2801			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576258	Green Published, hybrid			2022-12-25	WOS:A1996TT48800072
J	Chen, YR; Yu, CA; Yu, L				Chen, YR; Yu, CA; Yu, L			Functional expression of subunit IV of Rhodobacter sphaeroides cytochrome b-c(1) complex and reconstitution of recombinant protein with three-subunit core complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; OXIDOREDUCTASE; CAPSULATUS	Subunit IV of Rhodobacter sphaeroides cytochrome b-c(1) complex was over-expressed in Escherichia coli JM109 cells as a glutathione S-transferase fusion protein (GST-RSIV) using the expression vector, pGEX/RSIV. Maximum yield of soluble active recombinant fusion protein was obtained from cells harvested 3 h after induction of growth at 37 degrees C in LB medium. Subunit IV was released from the fusion protein by proteolytic cleavage with thrombin, When subjected to SDS-polyacrylamide gel electrophoresis, isolated recombinant subunit IV showed one protein band corresponding to subunit IV of R. sphaeroides cytochrome b-c(1) complex, Although the isolated recombinant subunit IV is soluble in aqueous solution, it is in a highly aggregated form, with an apparent molecular mass of over 1000 kDa. The addition of detergent deaggregates the isolated protein, suggesting that the recombinant protein exists as a hydrophobic aggregation in aqueous solution. When the three-subunit core cytochrome b-c(1) complex, purified from RS Delta IV-adapted chromatophores containing a fraction of the wild-type cytochrome b-c(1) complex activity, was reacted with varying amounts of recombinant subunit IV, the activity increased as the subunit IV concentration increased. Maximum activity restoration was reached when 1 mol of subunit IV/mol of three-subunit core complex was used. The reconstituted cytochrome b-c(1) complex is similar to the wild type complex in molecular size, apparent K-m for Q(2)H(2), and inhibitor sensitivity, indicating that recombinant subunit IV is properly assembled into the active cytochrome b-c(1) complex, A tryptophan residue in subunit IV was found to be involved in the interaction with the three-subunit core complex.			Chen, YR (corresponding author), OKLAHOMA STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,STILLWATER,OK 74078, USA.							ABATH F G C, 1990, Peptide Research, V3, P167; ANDREWS KM, 1990, BIOCHEMISTRY-US, V29, P2645, DOI 10.1021/bi00463a004; CHEN YR, 1994, BIOCHEMISTRY-US, V33, P10207, DOI 10.1021/bi00199a050; CHEN YR, 1995, J BIOL CHEM, V270, P11496, DOI 10.1074/jbc.270.19.11496; GENNIS RB, 1993, J BIOENERG BIOMEMBR, V25, P195, DOI 10.1007/BF00762582; JOHNSON KS, 1989, NATURE, V338, P585, DOI 10.1038/338585a0; KIRAUCIUNAS A, 1989, BIOCHIM BIOPHYS ACTA, V976, P70; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LJUNGDAHL O, 1987, BIOCHIM BIOPHYS ACTA, V891, P227; LOWRY OH, 1951, J BIOL CHEM, V193, P265; PURVIS DJ, 1990, J BIOL CHEM, V265, P1208; ROBERTSON DE, 1993, BIOCHEMISTRY-US, V32, P1310, DOI 10.1021/bi00056a016; Sambrook J, 1989, MOL CLONING LABORATO; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SIBER KR, 1992, P NATL ACAD SCI USA, V89, P295; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spande T.F., 1967, DETERMINATION TRYPTO, P498; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRUMPOWER BL, 1994, ANNU REV BIOCHEM, V63, P675, DOI 10.1146/annurev.bi.63.070194.003331; USUI S, 1991, J BIOL CHEM, V266, P15644; YANG XH, 1986, J BIOL CHEM, V261, P2282; YU CA, 1982, BIOCHEMISTRY-US, V21, P4096, DOI 10.1021/bi00260a028; YU L, 1995, J BIOL CHEM, V270, P25634, DOI 10.1074/jbc.270.43.25634; YU L, 1984, J BIOL CHEM, V259, P5752; YU L, 1991, BIOCHEMISTRY-US, V30, P4934, DOI 10.1021/bi00234a014; YU L, 1987, BIOCHEMISTRY-US, V266, P3658	26	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2057	2062		10.1074/jbc.271.4.2057	http://dx.doi.org/10.1074/jbc.271.4.2057			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567659	hybrid			2022-12-25	WOS:A1996TR32000041
J	vanKoppen, CJ; Heringdorf, DMZ; Laser, KT; Zhang, CY; Jakobs, KH; Bunemann, M; Pott, L				vanKoppen, CJ; Heringdorf, DMZ; Laser, KT; Zhang, CY; Jakobs, KH; Bunemann, M; Pott, L			Activation of a high affinity G(i) protein-coupled plasma membrane receptor by sphingosine-1-phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATION; CHANNELS	Sphingosine-1-phosphate (SPP) has attracted much attention as a possible second messenger controlling cell proliferation and motility and as an intracellular Ca2+-releasing agent. Here, we present evidence that SPP activates a G protein-coupled receptor in the plasma membrane of various cells, leading to increase in cytoplasmic Ca2+ concentration ([Ca2+](i)), inhibition of adenylyl cyclase, and opening of G protein-regulated potassium channels, In human embryonic kidney (HEK) cells, SPP potently (EC(50), 2 nM) and rapidly increased [Ca2+](i), in a pertussis toxin-sensitive manner. Pertussis toxin-sensitive increase in [Ca2+](i) was also observed with sphingosylphosphorylcholine (EC(50), 460 nM), whereas other sphingolipids, including ceramide-1-phosphate, N-palmitoyl-sphingosine, psychosine, and D-erythro-sphingosine at micromolar concentrations did not or only marginally increased [Ca2+](i). Furthermore, SPP inhibited forskolin-stimulated cAMP accumulation in HEK cells and increased binding of guanosine 5'-3-O(thio)triphosphate to HEK cell membranes. Rapid [Ca2+](i) responses were also observed in human transitional bladder carcinoma (J82) cells, monkey COS-1 cells, mouse NIH 3T3 cells. Chinese hamster ovary (CHO-K1) cells, and rat C6 glioma cells, whereas human HL-60 leukemia cells and human erythroleukemia cells failed to respond to SPP. In guinea pig atrial myocytes, SPP activated G(i) protein-regulated inwardly rectifying potassium channels, Activation of these channel occurred strictly when SPP was applied at the extracellular face of atrial myocyte plasma membrane as measured in cell-attached and inside-out patch clamp current recordings, We conclude that SPP, in addition to its proposed direct action on intracellular Ca2+ stores, interacts with a high affinity G(1) protein-coupled receptor in the plasma membrane of apparently many different cell types.	UNIV ESSEN GESAMTHSCH,INST PHARMAKOL,D-45122 ESSEN,GERMANY; RUHR UNIV BOCHUM,INST PHYSIOL,D-44780 BOCHUM,GERMANY	University of Duisburg Essen; Ruhr University Bochum			Pott, Lutz/E-5304-2011; Heringdorf, Dagmar Meyer zu/A-7705-2018; Laser, Kai Thorsten/B-8698-2015	Heringdorf, Dagmar Meyer zu/0000-0003-1246-9677; Pott, Lutz/0000-0002-4000-4132				BECHEM M, 1985, PFLUG ARCH EUR J PHY, V404, P10, DOI 10.1007/BF00581485; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; BUEHRER BM, 1993, ADV LIPID RES, V26, P59; Bunemann M, 1995, J PHYSIOL-LONDON, V489, P701; BUNEMANN M, 1993, PFLUG ARCH EUR J PHY, V425, P329, DOI 10.1007/BF00374183; CLAPHAM DE, 1994, ANNU REV NEUROSCI, V17, P441; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; KAIBARA M, 1991, J PHYSIOL-LONDON, V433, P589, DOI 10.1113/jphysiol.1991.sp018445; KIM S, 1995, J BIOL CHEM, V270, P5266, DOI 10.1074/jbc.270.10.5266; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; SIFFERT W, 1995, J CLIN INVEST, V96, P759, DOI 10.1172/JCI118120; SPIEGEL S, 1993, ADV LIPID RES, V25, P105; VANKOPPEN CJ, 1994, EUR J BIOCHEM, V222, P525; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155	26	192	196	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2082	2087		10.1074/jbc.271.4.2082	http://dx.doi.org/10.1074/jbc.271.4.2082			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567663	hybrid			2022-12-25	WOS:A1996TR32000045
J	YonedaKato, N; Look, AT; Kirstein, MN; Valentine, MB; Raimondi, SC; Cohen, KJ; Carroll, AJ; Morris, SW				YonedaKato, N; Look, AT; Kirstein, MN; Valentine, MB; Raimondi, SC; Cohen, KJ; Carroll, AJ; Morris, SW			The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1	ONCOGENE			English	Article						acute myeloid leukemia; fusion gene; myelodysplasia-myeloid leukemia factor 1 (MLF 1); nucleophosmin (NPM); t(3;5) chromosomal translocation	ACUTE NONLYMPHOCYTIC LEUKEMIA; MAJOR NUCLEOLAR PROTEINS; TRANSLOCATION T(3-5); NUCLEAR PROTEINS; NUMATRIN; DNA; B23; PHOSPHORYLATION; LEUKEMOGENESIS; IDENTIFICATION	A t(3;5)(q25.1;q34) chromosomal translocation associated with myelodysplastic syndrome and acute myeloid leukemia (AML) was found to rearrange part of the nucleophosmin (NPM) gene on chromosome 5 with sequences from a novel gene on chromosome 3. Chimeric transcripts expressed by these cells contain 5' NPM coding sequences fused in-frame to those of the new gene, which we named myelodysplasia/myeloid leukemia factor 1 (MLF1). RNA-based polymerase chain reaction analysis revealed identical NPM-MLF1 mRNA fusions in each of the three t(3;5)-positive cases of AML examined, The predicted MLF1 amino acid sequence lacked homology to previously characterized proteins and did not contain known functional motifs. Normal MLF1 transcripts were expressed in a variety of tissues, most abundantly in testis, ovary, skeletal muscle, heart, kidney and colon. Anti-MLF1 antibodies detected the wild-type 31 kDa protein in K562 and HEL erythroleukemia cell Lines, but not in HL-60, U937 or KG-1 myeloid leukemia lines. By contrast, t(3;5)-positive leukemia cells expressed a 54 kDa NPM-MLF1 protein, but not normal MLF1. Immunostaining experiments indicated that MLF1 is normally located in the cytoplasm, whereas NPM-MLF1 is targeted to the nucleus, with highest levels in the nucleolus. The nuclear/nucleolar localization of NPM-MLF1 mirrors that of NPM, indicating that NPM trafficking signals direct MLF1 to an inappropriate cellular compartment in myeloid leukemia cells.	ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL & ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT PATHOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN USA; JOHNS HOPKINS UNIV HOSP, DEPT PEDIAT ONCOL, BALTIMORE, MD 21287 USA; UNIV ALABAMA, MED GENET LAB, BIRMINGHAM, AL USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Johns Hopkins University; Johns Hopkins Medicine; University of Alabama System; University of Alabama Birmingham			Raimondi, Susana C/N-8166-2018		NATIONAL CANCER INSTITUTE [P01CA020180, K08CA001702, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 20180, K08 CA 01702, CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BERGER R, 1987, CANCER GENET CYTOGEN, V28, P261, DOI 10.1016/0165-4608(87)90212-3; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; CHAN PK, 1986, J BIOL CHEM, V261, P14335; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHATTERJEE A, 1991, BIOCHEM BIOPH RES CO, V180, P805, DOI 10.1016/S0006-291X(05)81136-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; FEUERSTEIN N, 1991, EXP CELL RES, V194, P289, DOI 10.1016/0014-4827(91)90367-4; FEUERSTEIN N, 1990, BIOCHIM BIOPHYS ACTA, V1087, P127, DOI 10.1016/0167-4781(90)90196-9; FEUERSTEIN N, 1991, J BIOL CHEM, V266, P16200; FONAGY A, 1994, CANCER RES, V54, P1859; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; HERNANDEZVERDUN D, 1991, J CELL SCI, V99, P465; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; KEYES LN, 1992, CELL, V68, P933, DOI 10.1016/0092-8674(92)90036-C; KOEFFLER HP, 1986, SEMIN HEMATOL, V23, P223; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; LOOK AT, 1995, ADV CANCER RES; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MORRIS SW, 1992, GENE CHROMOSOME CANC, V5, P385, DOI 10.1002/gcc.2870050414; OSHIMURA M, 1976, CANCER, V38, P748, DOI 10.1002/1097-0142(197608)38:2<748::AID-CNCR2820380218>3.0.CO;2-U; PERLAKY L, 1992, CANCER RES, V52, P428; PETER M, 1990, CELL, V60, P791, DOI 10.1016/0092-8674(90)90093-T; PI D, 1986, CANCER GENET CYTOGEN, V20, P171, DOI 10.1016/0165-4608(86)90122-6; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAIMONDI SC, 1989, LEUKEMIA, V3, P42; REDNER RL, 1994, BLOOD, V84, pA375; ROWLEY JD, 1976, BLOOD, V47, P705; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SCHMIDTZACHMANN MS, 1987, EMBO J, V6, P1881, DOI 10.1002/j.1460-2075.1987.tb02447.x; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; SHARP RA, 1987, LEUKEMIA RES, V11, P629, DOI 10.1016/0145-2126(87)90035-X; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SMADJA N, 1986, CANCER GENET CYTOGEN, V20, P173, DOI 10.1016/0165-4608(86)90123-8; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; TAKEMURA M, 1994, BIOCHEM BIOPH RES CO, V199, P46, DOI 10.1006/bbrc.1994.1191; VALDEZ BC, 1994, J BIOL CHEM, V269, P23776; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WERNERFAVRE C, 1985, CANCER GENET CYTOGEN, V16, P279, DOI 10.1016/0165-4608(85)90056-1; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8	47	253	263	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					265	275						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570204				2022-12-25	WOS:A1996TR53800006
J	Huang, SC; Huang, J; Kloek, AP; Goldberg, DE; Friedman, JM				Huang, SC; Huang, J; Kloek, AP; Goldberg, DE; Friedman, JM			Hydrogen bonding of tyrosine b10 to heme-bound oxygen in Ascaris hemoglobin - Direct evidence from UV resonance Raman spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOGLOBIN; PROTEINS; DYNAMICS; BINDING; SUUM	The hemoglobin from Ascaris suum, a parasitic nematode, has a spontaneous dissociation rate for the dioxygen ligand that is 3 orders of magnitude less than for mammalian myoglobins or hemoglobins. In this hemoglobin, the distal histidine is replaced with a glutamine which is capable of forming a stabilizing hydrogen bond to the bound dioxygen. A single hydrogen bond from a glutamine is, under typical circumstances, not sufficient to account for the low off rate for oxygen. Several studies point to a second hydrogen bond to the heme-bound dioxygen originating from tyrosine B10 as the source of this unusual reactivity, In this study ultraviolet (UV) resonance Raman spectroscopy is used to directly observe the formation of this hydrogen bond upon oxygen binding. The study reveals that both oxygen and carbon monoxide induce similar conformational changes in the globin upon binding to the heme; however, in the case of oxygen, a strong hydrogen bond involving a tyrosine is also observed. Similar studies on the QE7L mutant of this Hb suggest that the glutamine plays a role in stabilizing a rigid tertiary structure associated with the distal heme pocket. This conformation maintains the tyro sine in an orientation conducive to hydrogen bond formation with a heme-bound dioxygen ligand.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PHYSIOL & BIOPHYS,BRONX,NY 10461; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110	Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)					NIGMS NIH HHS [1 RO1 GM 44343] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044343] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED AM, 1991, CHEM PHYS, V158, P329, DOI 10.1016/0301-0104(91)87076-8; ASHER SA, 1986, J AM CHEM SOC, V108, P905; Asher Sanford A., 1993, Analytical Chemistry, V65, P59; AUSTIN JC, 1993, METHOD ENZYMOL, V226, P374, DOI 10.1016/0076-6879(93)26017-4; BAERE ID, 1994, P NATL ACAD SCI USA, V91, P1594; CHO NJ, 1994, BIOCHEMISTRY-US, V33, P5932, DOI 10.1021/bi00185a034; DAVENPORT HE, 1949, P ROY SOC LOND B BIO, V136, P225; DEBAERE I, 1992, P NATL ACAD SCI USA, V89, P4638, DOI 10.1073/pnas.89.10.4638; FINDSEN EW, 1988, BIOCHEMISTRY-US, V27, P8719, DOI 10.1021/bi00424a005; FINDSEN EW, 1985, SCIENCE, V229, P661, DOI 10.1126/science.4023704; FINDSEN EW, 1985, J AM CHEM SOC, V107, P3355, DOI 10.1021/ja00297a056; FODOR SPA, 1986, J RAMAN SPECTROSC, V17, P471, DOI 10.1002/jrs.1250170609; FRANZEN S, 1995, J BIOL CHEM, V270, P1718, DOI 10.1074/jbc.270.4.1718; FRIEDMAN JM, 1994, METHOD ENZYMOL, V232, P205; GIBSON QH, 1993, J BIOL CHEM, V268, P16993; HILDEBRANDT PG, 1988, BIOCHEMISTRY-US, V27, P5426, DOI 10.1021/bi00415a007; JOHNSON CR, 1984, J AM CHEM SOC, V106, P5008, DOI 10.1021/ja00329a065; JOHNSON CR, 1986, J AM CHEM SOC, V108, P3186; Keilin D, 1925, P R SOC LOND B-CONTA, V98, P312, DOI 10.1098/rspb.1925.0039; KITAGAWA T, 1992, PROG BIOPHYS MOL BIO, V58, P1, DOI 10.1016/0079-6107(92)90009-U; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; KLOEK AP, 1993, J BIOL CHEM, V268, P17669; NAGAI K, 1987, NATURE, V329, P858, DOI 10.1038/329858a0; PERUTZ MF, 1993, CURR BIOL, V3, P249, DOI 10.1016/0960-9822(93)90174-M; PHILLIPS SEV, 1981, NATURE, V292, P81, DOI 10.1038/292081a0; RODGERS KR, 1992, J AM CHEM SOC, V114, P3697, DOI 10.1021/ja00036a019; ROUSSEAU DL, 1993, J BIOL CHEM, V268, P5719; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; SCOTT TW, 1984, J AM CHEM SOC, V106, P5677, DOI 10.1021/ja00331a044; SHERMAN DR, 1992, P NATL ACAD SCI USA, V89, P11696, DOI 10.1073/pnas.89.24.11696; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; SU C, 1989, J AM CHEM SOC, V111, P3457, DOI 10.1021/ja00191a068; Takeuchi H., 1986, ADV SPECTROSCOPY SPE, V13, P113; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224	36	35	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					958	962		10.1074/jbc.271.2.958	http://dx.doi.org/10.1074/jbc.271.2.958			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557711	hybrid			2022-12-25	WOS:A1996TP88900054
J	Kunath, T; OrdonezGarcia, C; Turbide, C; Beauchemin, N				Kunath, T; OrdonezGarcia, C; Turbide, C; Beauchemin, N			Inhibition of colonic tumor cell growth by biliary glycoprotein	ONCOGENE			English	Article						biliary glycoprotein; BGP; carcinoembryonic antigen; CEA; growth inhibitor; tumor; colon carcinoma	ANTIGEN GENE FAMILY; INTERCELLULAR-ADHESION MOLECULE; CARCINOEMBRYONIC ANTIGEN; ECTO-ATPASE; ENDOGENOUS SUBSTRATE; CYTOPLASMIC DOMAIN; TYROSINE KINASE; EXPRESSION; RECEPTOR; MEMBER	Biliary glycoproteins (BGPs) are members of the carcinoembryonic antigen (CEA) family. These glycoproteins function in vitro as intercellular adhesion molecules and, in the mouse, serve as receptors for the mouse hepatitis viruses. In previous studies, BGP expression has been reported to be generally downregulated in colon and liver carcinomas of human, rat and mouse origins. We now demonstrate that introduction of murine Bgp1 cDNA isoforms into a mouse colonic carcinoma cell line, negative for endogenous Bgpl expression, significantly alters the growth properties of these cells. Cells bearing two Bgpl isoforms were growth-retarded and exhibited a reduced ability to form colonies in an in vitro transformation assay, when compared to parental or control neo(r) cells. Furthermore, tumor formation was inhibited by 80% when cells bearing a full-length Bgpl isoform were injected into BALB/c syngeneic mice, while cells expressing a Bgpl isoform lacking most of the intracytoplasmic domain produced tumors as readily as the parental cells. These results indicate that a biliary glycoprotein isoform is involved in negative regulation of colonic tumor cell growth, by a process which requires its intracytoplasmic domain. The precise mechanisms causing Bgp-dependent tumor growth inhibition remain, however, to be defined.	MCGILL UNIV, CTR CANC, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, DEPT MED, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, DEPT ONCOL, MONTREAL, PQ H3G 1Y6, CANADA	McGill University; McGill University; McGill University; McGill University				Kunath, Tilo/0000-0002-8805-7356				AFAR DEH, 1992, BIOCHIM BIOPHYS ACTA, V1134, P46, DOI 10.1016/0167-4889(92)90026-8; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BENCHIMOL S, 1989, CELL, V57, P327, DOI 10.1016/0092-8674(89)90970-7; BRATTAIN MG, 1980, CANCER RES, V40, P2142; CHEN W, 1991, J CELL BIOL, V114, P310; COUTELIER JP, 1994, EUR J IMMUNOL, V24, P1383, DOI 10.1002/eji.1830240622; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; EDLUND M, 1993, FEBS LETT, V327, P90, DOI 10.1016/0014-5793(93)81046-3; GOLD P, 1965, J EXP MED, V122, P467, DOI 10.1084/jem.122.3.467; HIXSON DC, 1985, CANCER RES, V45, P3742; HSIEH JT, 1995, CANCER RES, V55, P190; KIMBALL PM, 1978, BRIT J CANCER, V37, P1015, DOI 10.1038/bjc.1978.147; KUPRINA NI, 1990, HISTOCHEMISTRY, V94, P179, DOI 10.1007/BF02440185; LIN SH, 1989, J BIOL CHEM, V264, P14408; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; MCCUAIG K, 1993, GENE, V127, P173, DOI 10.1016/0378-1119(93)90716-G; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; OBRINK B, 1991, BIOESSAYS, V13, P227, DOI 10.1002/bies.950130505; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; OIKAWA S, 1992, BIOCHEM BIOPH RES CO, V186, P881, DOI 10.1016/0006-291X(92)90828-9; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; ROSENBERG M, 1993, CANCER RES, V53, P4938; SIPPEL CJ, 1993, J BIOL CHEM, V268, P2083; SPORNS O, 1995, P NATL ACAD SCI USA, V92, P542, DOI 10.1073/pnas.92.2.542; THOMPSON JA, 1991, J CLIN LAB ANAL, V5, P344, DOI 10.1002/jcla.1860050510; TURBIDE C, 1991, J BIOL CHEM, V266, P309; VALIQUETTE M, 1990, P NATL ACAD SCI USA, V87, P5089, DOI 10.1073/pnas.87.13.5089; VEGA MA, 1989, P NATL ACAD SCI USA, V86, P2688, DOI 10.1073/pnas.86.8.2688; VLERNINCKX K, 1991, CELL, V66, P107; YOKOMORI K, 1992, J VIROL, V66, P6194, DOI 10.1128/JVI.66.10.6194-6199.1992	40	154	157	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2375	2382						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570189				2022-12-25	WOS:A1995TK70200022
J	Nguyen, HQ; Selvakumaran, M; Liebermann, DA; Hoffman, B				Nguyen, HQ; Selvakumaran, M; Liebermann, DA; Hoffman, B			Blocking c-Myc and Max expression inhibits proliferation and induces differentiation of normal and leukemic myeloid cells	ONCOGENE			English	Note						c-myc; max; myeloid differentiation	IMMEDIATE EARLY RESPONSE; DNA-BINDING; TERMINAL DIFFERENTIATION; ONCOGENE EXPRESSION; GROWTH ARREST; PROTEIN; LINE; APOPTOSIS; HL-60; AMPLIFICATION	Given the central role c-Myc plays in growth control, differentiation and apoptosis, understanding how c-Myc functions will increase our understanding about normal cell development, and how alterations in these processes can lead to malignancy, C-Myc is a negative regulator of terminal myeloid differentiation; therefore, it was of interest to determine what effect blocking c-MSc expression would have on proliferation and differentiation, Tn this work we showed that blocking expression of either c-Myc or Max, its molecular partner, in myeloblastic leukemia M1 cells activated the differentiation program in the absence of an exogenous source of differentiation inducer; the cells assumed an intermediate stage myeloid morphology. Moreover, when both c-Myc and Max expression were concommitantly blocked, many of the cells underwent terminal differentiation, Finally, extending these studies to myeloblast enriched normal bone marrow (BM) cells has shown that blocking expression of either c-Myc or Max accelerated GM-CSF-induced differentiation along both the granulocytic and monocytic lineages, Thus, it can be concluded that blocking either c-Myc or Max expression in myeloid cells at specific stages of development activates and accelerates the terminal differentiation program.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL CANCER INSTITUTE [R01CA051162, R01CA043618, P30CA012227] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA51162, 5 P30 CA12227, 1RO1CA43618] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DALLAFAVERA R, 1982, NATURE, V299, P61; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GERWIRTZ AM, 1988, SCIENCE, V242, P180; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIEBERMANN D, 1981, INT J CANCER, V28, P285, DOI 10.1002/ijc.2910280306; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; SCHNEIDER MD, 1987, MOL CELL BIOL, V7, P1973, DOI 10.1128/MCB.7.5.1973; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028	29	31	31	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2439	2444						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570196				2022-12-25	WOS:A1995TK70200029
J	Dabrowski, A; Grady, T; Logsdon, CD; Williams, JA				Dabrowski, A; Grady, T; Logsdon, CD; Williams, JA			Jun kinases are rapidly activated by cholecystokinin in rat pancreas both in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; C-JUN; ONCOGENE; CERULEIN	Stimulation of pancreatic acini from male Sprague-Dawley rats by both cholecystokinin (CCK)-8 and anisomycin caused an increase in p46(ink) and p55(ink) activities. Both forms of c-Jun amino-terminal kinase (JNK) were slightly activated at 5 min, reached a maximum at 30 min, and remained significantly increased at 60 min of CCK stimulation. By contrast, p42(mapk) was activated fully by 5 min. In pancreatic acini stimulated with different concentrations of CCK for 30 min, the minimal and maximal JNK responses were observed at 30 pM and 100 nM CCK, respectively; p42(mapk) activation was, as previously reported, much more sensitive, with maximal activation by 1 nM CCK. Carbachol and bombesin also stimulated JNK activity, while vasoactive intestinal peptide did not. Neither activating protein kinase C nor increasing intracellular Ca2+ significantly activated JNK. In in vivo experiments, rats were infused intravenously for 5 and 15 min with a secretory (0.1 mu g/kg/h) or supramaximal (10 mu g/kg/h) dose of the CCK analog cae rulein (CER). Secretory doses of CER induced a 4-fold increase of both forms of JNK in pancreatic tissue at 5 and 15 min, while at the same time points, supramaximal stimulation with CER caused 4- and 27-fold increases, respectively, of these kinase activities. The secretory dose of CER slightly increased the activities of both forms of mitogen-activated protein kinase, while the supramaximal dose induced a 10-fold increase of p42(mapk) at 5 min. In conclusion, JNKs and mitogen-activated protein kinases are rapidly activated in rat pancreatic acini stimulated with CCK as well as in pancreatic tissue during in vivo stimulation with CER. The large response to supramaximal CER stimulation may be of importance in the early pathogenesis of acute pancreatitis.	UNIV MICHIGAN,DEPT PHYSIOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,DEPT INTERNAL MED,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			; Dabrowski, Andrzej/T-8656-2018	Williams, John/0000-0002-6063-7615; Dabrowski, Andrzej/0000-0002-5996-394X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041122, R01DK035912, R37DK041122, R01DK041225] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 35912, DK 41122, DK 41225] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DUAN RD, 1995, AM J PHYSIOL-GASTR L, V268, pG1060, DOI 10.1152/ajpgi.1995.268.6.G1060; DUAN RD, 1994, AM J PHYSIOL, V267, pG401, DOI 10.1152/ajpgi.1994.267.3.G401; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMPEL M, 1977, VIRCHOWS ARCH A, V373, P107; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LOGSDON CD, 1986, AM J PHYSIOL, V250, pG440, DOI 10.1152/ajpgi.1986.250.4.G440; LU L, 1992, AM J PHYSIOL, V263, pG327, DOI 10.1152/ajpgi.1992.263.3.G327; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHICK J, 1984, J CELL BIOL, V99, P1559; SCHOENBERG MH, 1992, FREE RADICAL BIO MED, V12, P515, DOI 10.1016/0891-5849(92)90104-O; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SOLOMON TE, 1983, AM J PHYSIOL, V245, pG99, DOI 10.1152/ajpgi.1983.245.1.G99; SOLOMON TE, 1987, PHYSL GASTROINTESTIN, V2, P1173; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; WILLIAMS JA, 1993, EXOCRINE PANCREAS, P167; YAN M, 1994, NATURE, V372, P794	47	97	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5686	5690		10.1074/jbc.271.10.5686	http://dx.doi.org/10.1074/jbc.271.10.5686			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621433	hybrid			2022-12-25	WOS:A1996TZ28600059
J	Miller, MA; Lipscomb, JD				Miller, MA; Lipscomb, JD			Homoprotocatechuate 2,3-dioxygenase from Brevibacterium fuscum - A dioxygenase with catalase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOSINUS-TRICHOSPORIUM OB3B; PROTOCATECHUATE 3,4-DIOXYGENASE; 3,4-DIHYDROXYPHENYLACETATE 2,3-DIOXYGENASE; GENTISATE 1,2-DIOXYGENASE; EXTRADIOL DIOXYGENASES; SUBSTRATE BINDING; SITE FE-2+; PURIFICATION; PROTEINS; IRON	Homoprotocatechuate 2,3-dioxygenase (2,3-HPCD) cleaves the aromatic ring of its substrate with insertion of both atoms of oxygen from O-2 to form alpha-hydroxy-delta-carboxymethyl cis-muconic semialdehyde, The enzyme has been purified from the Gram-positive bacterium Brevibacterium fuscum and characterized, The enzyme appears to have a range of quaternary structures with predominant components of alpha(4) and alpha(6) (alpha subunit M(r) = 42500 +/- 1500) and binds similar to 1 Fe(II)/subunit. Although the substrate K-m values are similar to those of other Fe(II) ring cleaving dioxygenases, the turnover number is lower by 90-97%, and the enzyme exhibits much higher stability to metal chelators and H2O2. The stability to H2O2 is shown to derive from an endogenous catalase activity of 2,3-HPCD (stoichiometry: 2 H2O2 --> 2 H2O + O-2) that is novel for dioxygenases, H2O2 is a mixed-type inhibitor of the dioxygenase activity, suggesting that dioxygenase and catalase activities are both catalyzed by the enzyme, but at distinguishable sites. In contrast, catecholic substrates, including homoprotocatechuate and p-nitrocatechol, are nonessential activators of the catalase activity, The plot of 1/v(i) of catalase activity versus 1/[H2O2] is parabolic in the absence of catecholic substrates and linear in their presence, indicating that these reactions proceed by different mechanisms, A mechanism for catalase activity is proposed in which 2 H2O2 molecules bind simultaneously to the iron to account for the observed parabolic kinetic plot, Electron transfer between the peroxides mediated by the iron would yield 2 H2O and O-2. Catecholic substrates are proposed to modify this reaction by excluding one H2O2 from the Fe(II), thereby causing the kinetic plots to appear linear, Electron donation by the catecholic substrates would facilitate O-O bond cleavage of H2O2, but outer sphere electron transfer from a second H2(O2) in another step would be necessary to complete the reaction, p-Nitrocatechol is shown to bind differently to 2,3-HPCD than to other Fe(II) ring cleavage dioxygenases. Possible explanations for this observation are considered in the context of the proposed catalase and normal dioxygenase mechanisms which may also have bearing on the unique catalase activity and low dioxygenase turnover number of the enzyme.	UNIV MINNESOTA,SCH MED,DEPT BIOCHEM,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities				Lipscomb, John/0000-0002-8158-5594	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024689, R37GM024689] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM024689, R37 GM024689, GM07323, GM24689] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; ADACHI K, 1964, BIOCHIM BIOPHYS ACTA, V93, P483, DOI 10.1016/0304-4165(64)90332-0; ADACHI S, 1993, BIOCHEMISTRY-US, V32, P241, DOI 10.1021/bi00052a031; ARCIERO DM, 1983, J BIOL CHEM, V258, P4981; ARCIERO DM, 1985, J BIOL CHEM, V260, P4035; ARCIERO DM, 1986, J BIOL CHEM, V261, P2170; ASADA K, 1975, J BIOL CHEM, V250, P2801; BERTINI I, 1994, BIOCHEMISTRY-US, V33, P10777, DOI 10.1021/bi00201a027; Blumberg W., 1967, MAGNETIC RESONANCE B, P119; BLUMBERG WE, 1973, ANN NY ACAD SCI, V222, P539, DOI 10.1111/j.1749-6632.1973.tb15286.x; BOLDT YR, 1995, J BACTERIOL, V177, P1225, DOI 10.1128/jb.177.5.1225-1232.1995; BOLIN JT, 1995, SCIENCE, V270, P976; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chapman P. J, 1972, DEGRADATION SYNTHETI, P17; ELTIS LD, 1993, J BIOL CHEM, V268, P2727; FOX BG, 1989, J BIOL CHEM, V264, P10023; GELASCO A, 1993, J AM CHEM SOC, V115, P7928, DOI 10.1021/ja00070a069; GIBELLO A, 1994, BIOCHEM J, V301, P145, DOI 10.1042/bj3010145; HAMILTON GA, 1963, J AM CHEM SOC, V85, P1008, DOI 10.1021/ja00890a044; HARPEL MR, 1990, J BIOL CHEM, V265, P6301; HARPEL MR, 1990, J BIOL CHEM, V265, P22187; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; Hildebrandt A G, 1978, Methods Enzymol, V52, P342; JOLLIE DR, 1991, J BIOL CHEM, V266, P21853; KITA H, 1965, J BIOCHEM-TOKYO, V58, P116, DOI 10.1093/oxfordjournals.jbchem.a128172; KOJIMA Y, 1961, J BIOL CHEM, V236, P2223; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPSCOMB JD, 1992, MET IONS BIOL SYST, V28, P243; LUNDELL DJ, 1978, J BIOL CHEM, V253, P3422; MABROUK PA, 1991, J AM CHEM SOC, V113, P4053, DOI 10.1021/ja00011a001; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NAKAI C, 1983, J BIOL CHEM, V258, P2923; NOZAKI M, 1970, BIOCHIM BIOPHYS ACTA, V220, P213, DOI 10.1016/0005-2744(70)90007-0; ONOKAMIMOTO M, 1973, J BIOCHEM, V74, P1049; ORVILLE AM, 1992, BIOCHEMISTRY-US, V31, P4602, DOI 10.1021/bi00134a010; ORVILLE AM, 1993, J BIOL CHEM, V268, P8596; PESSIKI PJ, 1994, J AM CHEM SOC, V116, P898, DOI 10.1021/ja00082a009; POULOS TL, 1980, J BIOL CHEM, V255, P8199; QUE L, 1981, J BIOL CHEM, V256, P941; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; SAWYER DT, 1993, J AM CHEM SOC, V115, P5817, DOI 10.1021/ja00066a057; Schonbaum G. R., 1976, ENZYMES, V13, P363, DOI [10.1016/S1874-6047(08)60245-0, DOI 10.1016/S1874-6047(08)60245-0]; Segel I.H., 1975, ENZYME KINETICS; SENOH S, 1966, BIOLOGICAL CHEMICAL, P378; SHU LJ, 1995, BIOCHEMISTRY-US, V34, P6649, DOI 10.1021/bi00020a010; SUGIMOTO H, 1985, J AM CHEM SOC, V107, P5712, DOI 10.1021/ja00306a018; SUGIYAMA K, 1995, P JPN ACAD B-PHYS, V71, P32, DOI 10.2183/pjab.71.32; TYSON CA, 1975, J BIOL CHEM, V250, P1765; VALENTINE JS, 1994, BIOINORG CHEM, P253; WALLING C, 1975, ACCOUNTS CHEM RES, V8, P125, DOI 10.1021/ar50088a003; Whiting AK, 1996, BIOCHEMISTRY-US, V35, P160, DOI 10.1021/bi951979h; WHITTAKER JW, 1990, METHOD ENZYMOL, V188, P82; WHITTAKER JW, 1984, J BIOL CHEM, V259, P4476; WOLGEL SA, 1993, J BACTERIOL, V175, P4414, DOI 10.1128/JB.175.14.4414-4426.1993; WOLGEL SA, 1989, THESIS U MINNESOTA M	55	68	68	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5524	5535		10.1074/jbc.271.10.5524	http://dx.doi.org/10.1074/jbc.271.10.5524			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621411	hybrid			2022-12-25	WOS:A1996TZ28600037
J	Boesch, JS; Lee, C; Lindahl, RG				Boesch, JS; Lee, C; Lindahl, RG			Constitutive expression of Class 3 aldehyde dehydrogenase in cultured rat corneal epithelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOMA-CELL LINES; LIVER; GENE; PROTEIN; PURIFICATION; OXIDATION; CLONING	Mammalian Class 3 aldehyde dehydrogenase (ALDH) is normally associated with neoplastic transformation or xenobiotic induction by aromatic hydrocarbons in liver. However, Class 3 ALDH is constitutively expressed at it's highest specific activity in corneal epithelium. Tissue specific, differential gene expression is often controlled by alternative, independent molecular pathways. We report here the development of an in vitro corneal epithelium culture system that retains constitutive high expression of the ALDH3 gene. This model system was used to establish, by enzymatic assays, Western and Northern analyses, histochemical and immunocytochemical staining, and 5'3' RACE methodologies that constitutive and xenobiotic induction of Class 3 ALDHs occurs from a single gene. Our results also provide a plausible explanation for the very high Class 3 ALDH activity in mammalian cornea, as the primary mechanism of oxidation of lipid peroxidation-derived aldehydes. Further studies with corneal epithelium suggest the presence of additional mechanisms, other than Ah-receptor-mediated, by which the ALDH3 gene can be differentially regulated in a tissue-specific manner.	UNIV S DAKOTA,SCH MED,DEPT BIOCHEM & MOLEC BIOL,VERMILLION,SD 57069; UNIV S DAKOTA,SCH MED,DEPT ANAT & STRUCT BIOL,VERMILLION,SD 57069	University of South Dakota; University of South Dakota								ABEDINIA M, 1990, EXP EYE RES, V51, P419, DOI 10.1016/0014-4835(90)90154-M; ALGAR E, 1993, ENZYMOLOGY MOL BIOL; ASMAN DC, 1993, J BIOL CHEM, V268, P12530; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTHALA G, 1983, DNA CELL BIOL, V2, P329; COOPER D, 1985, LAB INVEST, V52, P243; DIPERSIO CM, 1991, MOL CELL BIOL, V11, P4405, DOI 10.1128/MCB.11.9.4405; DOWNES JE, 1992, CORNEA, V11, P560, DOI 10.1097/00003226-199211000-00013; EVCES S, 1989, ARCH BIOCHEM BIOPHYS, V274, P518, DOI 10.1016/0003-9861(89)90465-7; Freshney RI, 1994, CULTURE ANIMAL CELLS; HARPER K, 1988, BIOCHEM BIOPH RES CO, V152, P940, DOI 10.1016/S0006-291X(88)80131-1; HARTLEY D, 1995, ENZYMOLOGY MOL BIOL, V5; Hogan MJ, 1971, HISTOLOGY HUMAN EYE; HSU LC, 1991, J BIOL CHEM, V266, P12257; Jagger J., 1967, INTRO RES ULTRAVIOLE; JONES DE, 1988, P NATL ACAD SCI USA, V85, P1782, DOI 10.1073/pnas.85.6.1782; KING G, 1993, BIOCHEM MOL BIOL INT, V31, P49; KORKALAINEN MK, 1995, CHEM-BIOL INTERACT, V94, P121, DOI 10.1016/0009-2797(94)03325-3; KRUSE F, 1993, INVEST OPHTH VIS SCI, V34, P163; KRUSE FE, 1990, INVEST OPHTH VIS SCI, V31, P1903; LIN KH, 1986, IN VITRO CELL DEV B, V22, P263; LIN KH, 1984, CANCER RES, V44, P5219; LIN KH, 1988, CANCER RES, V48, P7009; LINDAHL R, 1983, CANCER RES, V43, P5972; LINDAHL R, 1984, J BIOL CHEM, V259, P1991; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; LINDAHL R, 1984, BIOCHEM PHARMACOL, V33, P3383, DOI 10.1016/0006-2952(84)90109-6; LINDAHL R, 1976, BIOCHIM BIOPHYS ACTA, V452, P345, DOI 10.1016/0005-2744(76)90184-4; LINDAHL R, 1978, BIOCHIM BIOPHYS ACTA, V525, P9, DOI 10.1016/0005-2744(78)90194-8; LINDAHL R, 1991, BIOCHEM PHARMACOL, V41, P1583, DOI 10.1016/0006-2952(91)90157-Z; MARSELOS M, 1988, TOXICOL APPL PHARM, V95, P339, DOI 10.1016/0041-008X(88)90170-6; Mcdevitt D., 1982, CELL BIOL EYE; MITCHELL DY, 1987, TOXICOL APPL PHARM, V87, P403, DOI 10.1016/0041-008X(87)90245-6; NEBERT DW, 1990, ENVIRON HEALTH PERSP, V88, P13, DOI 10.2307/3431045; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; TAKIMOTO K, 1992, ARCH BIOCHEM BIOPHYS, V298, P492, DOI 10.1016/0003-9861(92)90440-8; TAKIMOTO K, 1991, BIOCHEM BIOPH RES CO, V180, P53; VASILIOU V, 1992, BIOCHEM BIOPH RES CO, V187, P413, DOI 10.1016/S0006-291X(05)81508-6; ZIESKE JD, 1994, EXP CELL RES, V214, P621, DOI 10.1006/excr.1994.1300	41	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5150	5157						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617795				2022-12-25	WOS:A1996TX69700085
J	Doerr, ME; Jones, JI				Doerr, ME; Jones, JI			The roles of integrins and extracellular matrix proteins in the insulin-like growth factor I-stimulated chemotaxis of human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE; TYROSINE KINASE; LINES INVITRO; MIGRATION; ADHESION; RECEPTOR; FIBRONECTIN; EXPRESSION	The effects of insulin-like growth factor I (IGF-I) on the migration of two human breast cancer cell Lines, MCF-7 and MDA-231, were examined using a modified Boyden chamber. 10 ng/ml was the optimal IGF-I concentration for stimulation of migration, The majority of IGF-I-stimulated migration in both cell types was due to chemotaxis, MCF-7 cells failed to migrate on membranes coated with gelatin or fibronectin and migrated only in small numbers on laminin, In contrast, when vitronectin- or type IV collagen-coated membranes were used, the MCF-7 cells migrated in large numbers specifically in response to IGF-I but not to 10% fetal calf serum, epidermal growth factor, fibroblast growth factor, or platelet derived growth factor-BB. An IGF-I receptor-blocking antibody inhibited IGF-I-stimulated migration in both cell types, In addition, a blocking antibody to the alpha v beta 5 integrin (a vitronectin receptor) inhibited migration of MCF-7 cells in response to IGF-I through vitronectin but not through type IV collagen, Similarly, blocking antibodies specific for alpha 2 and beta 1 integrins significantly inhibited migration of both cell types through type IV collagen-coated membranes but not through vitronectin-coated membranes, We conclude that: 1) IGF-I stimulates migration of these two cell types through the IGF-I receptor; 2) interaction of vitronectin with the alpha v beta 5 integrin or collagen with the alpha 2 beta 1 integrin is necessary for the complete IGF-I response in MCF-7 cells, and 3) because migration represents an in vitro model for metastatic spread, integrins, extracellular matrix proteins, and IGF-I may play coordinated roles in the metastasis of breast cancer in vivo.	UNIV N CAROLINA, DIV ENDOCRINOL, DEPT MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007129, K11DK002024] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 07129, DK 02024] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ARATEAGA CL, 1969, J CLIN INVEST, V84, P1418; ARTEAGA CL, 1989, CANCER RES, V49, P6237; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; CAMACHOHUBNER C, 1991, J CELL PHYSIOL, V148, P281, DOI 10.1002/jcp.1041480214; CLEMMONS DR, 1990, ENDOCRINOLOGY, V127, P2679, DOI 10.1210/endo-127-6-2679; COOPMAN PJ, 1991, J CELL SCI, V98, P395; Damsky CH, 1991, CURR OPIN CELL BIOL, V3, P777, DOI 10.1016/0955-0674(91)90049-5; FURLANETTO RW, 1984, CANCER RES, V44, P2122; GOCKERMAN A, 1995, ENDOCRINOLOGY, V136, P4168, DOI 10.1210/en.136.10.4168; GRANT M, 1987, J CLIN ENDOCR METAB, V65, P370, DOI 10.1210/jcem-65-2-370; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HENSON DE, 1995, CANCER-AM CANCER SOC, V76, P237, DOI 10.1002/1097-0142(19950715)76:2<237::AID-CNCR2820760213>3.0.CO;2-J; HENSON DE, 1994, CLIN EXP METASTAS, V12, P195; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JONES JI, 1993, P NATL ACAD SCI USA, V90, P10553, DOI 10.1073/pnas.90.22.10553; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KIM JP, 1992, J CELL PHYSIOL, V151, P443, DOI 10.1002/jcp.1041510303; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; MCGUIRE WL, 1992, J NATL CANCER I, V84, P1336, DOI 10.1093/jnci/84.17.1336; PEKONEN F, 1988, CANCER RES, V48, P1343; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; STRACKE ML, 1989, J BIOL CHEM, V264, P21544; TERRANOVA VP, 1986, P NATL ACAD SCI USA, V83, P465, DOI 10.1073/pnas.83.2.465; VERHASSELT B, 1992, EUR J CELL BIOL, V59, P449; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; ZUTTER MM, 1993, AM J PATHOL, V142, P1439	31	196	202	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2443	2447		10.1074/jbc.271.5.2443	http://dx.doi.org/10.1074/jbc.271.5.2443			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576205	Green Published, hybrid			2022-12-25	WOS:A1996TT48800019
J	Garlid, KD; Orosz, DE; Modriansky, M; Vassanelli, S; Jezek, P				Garlid, KD; Orosz, DE; Modriansky, M; Vassanelli, S; Jezek, P			On the mechanism of fatty acid-induced proton transport by mitochondrial uncoupling protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; ANION UNIPORT; RECONSTITUTION; MEMBRANES; ALBUMIN; PROBE	Uncoupling protein mediates electrophoretic transport of protons and anions across the inner membrane of brown adipose tissue mitochondria, The mechanism and site of proton transport, the mechanism by which fatty acids activate proton transport, and the relationship between fatty acids and anion transport are unknown, We used fluorescent probes to measure H+ and anion transport in vesicles reconstituted with purified uncoupling protein and carried out a comparative study of the effects of laurate and its close analogue, undecanesulfonate. Undecanesulfonate was transported by uncoupling protein with a K-m value similar to that observed for laurate as it activated H+ transport, Both laurate and undecanesulfonate inhibited Cl- with competitive kinetics, Undecanesulfonate inhibited laurate-induced H+ transport with competitive kinetics, Undecanesulfonate and laurate differed in two important respects, (i) Laurate caused uncoupling protein-mediated H+ transport, whereas undecanesulfonate did not, (ii) Lauric acid was rapidly transported across the bilayer by nonionic diffusion, whereas undecanesulfonic was not, We infer that the role of uncoupling protein in H+ transport is to transport fatty acid anions and that fatty acids induce H+ transport because they can diffuse electroneutrally across the membrane, According to this hypothesis, uncoupling protein is a pure anion porter and does not transport protons; rather it is designed to enable fatty acids to behave as cycling protonophores.	ACAD SCI CZECH REPUBL,INST PHYSIOL,DEPT MEMBRANE TRANSPORT BIOPHYS,CR-14220 PRAGUE,CZECH REPUBLIC	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences	Garlid, KD (corresponding author), OREGON GRAD INST SCI & TECHNOL,DEPT CHEM BIOCHEM & MOLEC BIOL,POB 91000,PORTLAND,OR 97291, USA.		Jezek, Petr/B-9264-2012; Modriansky, Martin/A-6338-2008	Jezek, Petr/0000-0002-2720-9395; Modriansky, Martin/0000-0001-7692-0338; Garlid, Keith/0000-0002-6777-1235; Vassanelli, Stefano/0000-0003-0389-8023	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031086] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31086] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL RP, 1973, PROTON CHEM, P98; GARLID KD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P151, DOI 10.1016/0005-2728(90)90237-X; Garlid KD, 1995, METHOD ENZYMOL, V260, P331, DOI 10.1016/0076-6879(95)60149-X; GARLID KD, 1983, J BIOL CHEM, V258, P7974; HAMILTON JA, 1986, P NATL ACAD SCI USA, V83, P82, DOI 10.1073/pnas.83.1.82; JEZEK P, 1990, J BIOL CHEM, V265, P19303; JEZEK P, 1994, J BIOL CHEM, V269, P26184; JEZEK P, 1990, J BIOL CHEM, V265, P10522; JEZEK P, 1990, J BIOL CHEM, V265, P19296; KAMP F, 1992, P NATL ACAD SCI USA, V89, P11367, DOI 10.1073/pnas.89.23.11367; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; MAYINGER P, 1992, BIOCHEMISTRY-US, V31, P10536, DOI 10.1021/bi00158a017; MODRIANSKY M, 1994, BIOPHYS J, V66, P333; NEDERGAARD J, 1992, NEW COMPREHENSIVE BI, V23, P385; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; NICHOLLS DG, 1973, EUR J BIOCHEM, V37, P523, DOI 10.1111/j.1432-1033.1973.tb03014.x; NICHOLLS DG, 1979, BIOCHIM BIOPHYS ACTA, V549, P1, DOI 10.1016/0304-4173(79)90016-8; OROSZ DE, 1993, ANAL BIOCHEM, V210, P1; PEDERSEN JI, 1975, BIOCHIM BIOPHYS ACTA, V398, P191, DOI 10.1016/0005-2760(75)90182-4; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; RICQUIER D, 1984, FEBS LETT, V178, P240, DOI 10.1016/0014-5793(84)80608-0; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; STRIELEMAN PJ, 1985, J BIOL CHEM, V260, P3402; SUN XC, 1992, J BIOL CHEM, V267, P19147; WINKLER E, 1994, J BIOL CHEM, V269, P2508	25	289	296	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2615	2620		10.1074/jbc.271.5.2615	http://dx.doi.org/10.1074/jbc.271.5.2615			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576230	hybrid			2022-12-25	WOS:A1996TT48800044
J	Lin, HB; Falchetto, R; Mosca, PJ; Shabanowitz, J; Hunt, DF; Hamlin, JL				Lin, HB; Falchetto, R; Mosca, PJ; Shabanowitz, J; Hunt, DF; Hamlin, JL			Mimosine targets serine hydroxymethyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID MIMOSINE; DNA-REPLICATION; CELL-CYCLE; PURIFICATION; LIVER; MITOCHONDRIAL; PROTEINS; PHASE; INITIATION; METABOLISM	The plant amino acid, mimosine, is an extremely effective inhibitor of DNA replication in mammalian cells (Mosca, P.J., Dijkwel, P. A. and Hamlin, J. L. (1992) Mol. Cell. Biol. 12, 4375-4383). Mimosine appears to prevent the formation of replication forks at early-firing origins when delivered to mammalian approaching the G(1)/S boundary, and blocks DNA replication when added to S phase cells after a lag of similar to 2.5 h. We have shown previously that [H-3]mimosine can be specifically photocross-linked both in vivo and in vitro to a 50-kDa polypeptide (p50) in Chinese hamster ovary (CHO) cells. In the present study, six tryptic peptides (58 residues total) from p50 were sequenced by tandem mass spectrometry and their sequences were found to be at least 77.5% identical and 96.5% similar to sequences in rabbit mitochondrial serine hydroxymethyltransferase (mSHMT). This assignment was verified by precipitating the [H-3]mimosine-p50 complex with a polyclonal antibody to rabbit cSHMT. The 50-kDa cross-linked product was almost undetectable in a mimosine-resistant CHO cell line and in a CHO gly(-) cell line that lacks mitochondrial, but not cytosolic, SHMT-activity. The gly(-) cell line is still sensitive to mimosine, suggesting that the drug may inhibit both the mitochondrial and the cytosolic forms. SHMT is involved in the penultimate step of thymidylate biosynthesis in mammalian cells and, as such, is a potential target for chemotherapy in the treatment of cancer.	UNIV VIRGINIA,DEPT BIOCHEM,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT PATHOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,BIOPHYS PROGRAM,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia; University of Virginia; University of Virginia			Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368	NCI NIH HHS [R01 CA52559] Funding Source: Medline; NIGMS NIH HHS [R01 GM37537, R01 GM26108] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052559] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026108, R01GM037537] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHASIN LA, 1974, P NATL ACAD SCI USA, V71, P718, DOI 10.1073/pnas.71.3.718; DAI YM, 1994, VIROLOGY, V205, P210, DOI 10.1006/viro.1994.1636; DEWYS WD, 1973, EUR J CANCER, V9, P281, DOI 10.1016/0014-2964(73)90094-7; DEWYS WD, 1973, CANCER CHEMOTH REP 1, V57, P41; DIJKWEL PA, 1992, MOL CELL BIOL, V12, P3715, DOI 10.1128/MCB.12.9.3715; FELDMAN ST, 1994, CANCER RES, V54, P494; GARRETT RH, 1995, BIOCHEMISTRY-US, P896; GARROW TA, 1993, J BIOL CHEM, V268, P11910; GAVILANES F, 1983, J BIOL CHEM, V258, P3155; GILBERT DM, 1995, J BIOL CHEM, V270, P9597, DOI 10.1074/jbc.270.16.9597; HAMLIN JL, 1994, BBA-REV CANCER, V1198, P85, DOI 10.1016/0304-419X(94)90008-6; HAMLIN JL, 1976, EXP CELL RES, V100, P265, DOI 10.1016/0014-4827(76)90147-6; HAMLIN JL, 1993, COLD SPRING HARB SYM, V58, P467, DOI 10.1101/SQB.1993.058.01.053; HAYASHI H, 1990, ANNU REV BIOCHEM, V59, P87, DOI 10.1146/annurev.biochem.59.1.87; HEINTZ NH, 1982, P NATL ACAD SCI-BIOL, V79, P4083, DOI 10.1073/pnas.79.13.4083; HOYES KP, 1992, CANCER RES, V52, P4591; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; KAO FT, 1968, P NATL ACAD SCI USA, V60, P1275, DOI 10.1073/pnas.60.4.1275; KOSTERMANS D, 1946, RECL TRAV CHIM PAY B, V65, P319; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALANDE M, 1990, EXP CELL RES, V186, P332, DOI 10.1016/0014-4827(90)90313-Y; LALANDE M, 1990, EXP CELL RES, V188, P117, DOI 10.1016/0014-4827(90)90285-I; LEDERMAN HM, 1984, BLOOD, V64, P748; LEVENSON V, 1993, NUCLEIC ACIDS RES, V21, P3997, DOI 10.1093/nar/21.17.3997; LIN JK, 1965, J FORMOS MED ASSOC, V64, P1004; LIN JUNG-YAW, 1962, JOUR FORMOSAN MED ASSOC, V61, P997; MARTINI F, 1987, J BIOL CHEM, V262, P5499; MASUDA T, 1987, J BIOCHEM, V101, P643, DOI 10.1093/jb/101.3.643; MEISLER NT, 1990, J BIOL CHEM, V265, P1193; MILBRANDT JD, 1981, P NATL ACAD SCI USA, V78, P6042; MOSCA PJ, 1995, NUCLEIC ACIDS RES, V23, P261, DOI 10.1093/nar/23.2.261; MOSCA PJ, 1992, MOL CELL BIOL, V12, P4375, DOI 10.1128/MCB.12.10.4375; OGAWA H, 1981, J BIOCHEM, V90, P381, DOI 10.1093/oxfordjournals.jbchem.a133484; RAMESH KS, 1980, BIOCHEM J, V187, P623, DOI 10.1042/bj1870623; REDDY GPV, 1993, CRIT REV EUKAR GENE, V3, P279; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; RUECKERT RR, 1960, CANCER RES, V20, P1584; SCHIRCH L, 1980, J BIOL CHEM, V255, P7801; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; SKOOG L, 1971, EUR J BIOCHEM, V19, P81, DOI 10.1111/j.1432-1033.1971.tb01290.x; SNELL K, 1980, BIOCHEM J, V190, P451, DOI 10.1042/bj1900451; STRONG WB, 1990, J BIOL CHEM, V265, P12149; TOBEY RA, 1972, EXP CELL RES, V75, P460, DOI 10.1016/0014-4827(72)90453-3; WALTERS RA, 1976, BIOCHEM BIOPH RES CO, V69, P212, DOI 10.1016/S0006-291X(76)80294-X; WANG Y, 1995, EXP CELL RES, V217, P84, DOI 10.1006/excr.1995.1066	51	50	53	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2548	2556		10.1074/jbc.271.5.2548	http://dx.doi.org/10.1074/jbc.271.5.2548			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576220	hybrid			2022-12-25	WOS:A1996TT48800034
J	Bouton, C; Raveau, M; Drapier, JC				Bouton, C; Raveau, M; Drapier, JC			Modulation of iron regulatory protein functions - Further insights into the role of nitrogen- and oxygen-derived reactive species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; ACTIVATED MACROPHAGES; HYDROGEN-PEROXIDE; RNA-BINDING; PEROXYNITRITE FORMATION; RESPONSIVE ELEMENTS; ESCHERICHIA-COLI; MESSENGER-RNA; TUMOR-CELLS; ACONITASE	Iron regulatory protein (IRP) is a cytosolic bifunctional [Fe-S] protein which exhibits aconitase activity or binds iron responsive elements (IREs) in untranslated regions of specific mRNA. The modulators of these activities are the intracellular concentration of iron and, as recently described, NO synthase activity. In this study, we attempted to establish in in vitro experiments whether peroxynitrite (ONOO-, the product of the reaction between NO and O-2(radical anion)), as well as oxygen-derived radicals (O-2(radical anion) and H2O2) and various NO donors, allow IRP to bind IREs using cytosol extract of macrophage-like RAW 264.7 cells. Neither the addition of a bolus of ONOO- or H2O2 nor O-2(radical anion) generation significantly affected IRE binding even though they inhibited its aconitase activity. Moreover, we show that 3-morpholinosydnonimine (SIN-1), a chemical which releases both NO and O-2(radical anion), enhanced IRE binding activity of IRP only in the presence of superoxide dismutase (SOD). S-Nitrosothiols and the NONOate sper/NO plus glutathione (GSH) activated IRE binding by IRP whereas oxyhemoglobin prevented enhancement of this binding by SIN-1/SOD and sper/NO plus GSH. cis-Aconitate, an aconitase substrate, also abolished the effect of SIN-1/SOD on IRE binding by IRP. These results imply that neither O-2(radical anion) nor ONOO- can convert [4Fe-4S] IRP into IRE-binding protein but rather suggest that an active redox form of NO converts IRP into its IRE binding form by targeting the [Fe-S] cluster.	INST CURIE, SECT RECH, INSERM U365, F-75231 PARIS 05, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie			Bouton, Cecile/J-8663-2013					BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BEINERT H, 1993, FASEB J, V7, P1442, DOI 10.1096/fasebj.7.15.8262329; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CROW JP, 1995, BIOCHEMISTRY-US, V34, P3544, DOI 10.1021/bi00011a008; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; FLINT DH, 1993, J BIOL CHEM, V268, P22369; GARDNER PR, 1995, J BIOL CHEM, V270, P13399, DOI 10.1074/jbc.270.22.13399; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GUO B, 1994, J BIOL CHEM, V269, P24252; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P11735, DOI 10.1073/pnas.89.24.11735; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; HEINZEL B, 1992, BIOCHEM J, V281, P627, DOI 10.1042/bj2810627; HENDERSON BR, 1993, J BIOL CHEM, V268, P27327; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; HOBBS AJ, 1994, P NATL ACAD SCI USA, V91, P10992, DOI 10.1073/pnas.91.23.10992; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IOANNIDIS I, 1993, BIOCHEM J, V296, P341, DOI 10.1042/bj2960341; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P446, DOI 10.1016/0003-9861(92)90433-W; JAFFREY SR, 1994, P NATL ACAD SCI USA, V91, P12994, DOI 10.1073/pnas.91.26.12994; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KUHN LC, 1992, J INORG BIOCHEM, V47, P183, DOI 10.1016/0162-0134(92)84064-T; LANDER HM, 1993, J IMMUNOL, V150, P1509; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; MARAGOS CM, 1993, CANCER RES, V53, P564; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MURPHY ME, 1991, J BIOL CHEM, V266, P19378; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; ORIA R, 1995, BLOOD, V85, P2962, DOI 10.1182/blood.V85.10.2962.bloodjournal85102962; PANTOPOULOS K, 1995, P NATL ACAD SCI USA, V92, P1267, DOI 10.1073/pnas.92.5.1267; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; PANTOPOULOS K, 1995, RNA, V1, P155; Pantopoulos Kostas, 1994, Trends in Cell Biology, V4, P82, DOI 10.1016/0962-8924(94)90179-1; PEYRET P, 1995, J BIOL CHEM, V270, P8131, DOI 10.1074/jbc.270.14.8131; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROY B, 1995, BIOCHEMISTRY-US, V34, P5411, DOI 10.1021/bi00016a012; SAMANIEGO F, 1994, J BIOL CHEM, V269, P30904; SATO H, 1994, BIOCHEM BIOPH RES CO, V201, P38, DOI 10.1006/bbrc.1994.1666; SCHMIDT K, 1994, BIOCHEM J, V301, P645, DOI 10.1042/bj3010645; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SWENSON GR, 1994, NUCLEIC ACIDS RES, V22, P2627, DOI 10.1093/nar/22.13.2627; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; VERNIQUET F, 1991, BIOCHEM J, V276, P643, DOI 10.1042/bj2760643; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; WINK DA, 1993, CHEM RES TOXICOL, V6, P23, DOI 10.1021/tx00031a003; WINK DA, 1995, ARCH BIOCHEM BIOPHYS, V319, P402, DOI 10.1006/abbi.1995.1310	57	89	92	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2300	2306		10.1074/jbc.271.4.2300	http://dx.doi.org/10.1074/jbc.271.4.2300			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567693	hybrid			2022-12-25	WOS:A1996TR32000075
J	Kusano, S; Ding, QQ; Fujita, N; Ishihama, A				Kusano, S; Ding, QQ; Fujita, N; Ishihama, A			Promoter selectivity of Escherichia coli RNA polymerase E sigma(70) and E sigma(38) holoenzymes - Effect of DNA supercoiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATIONARY-PHASE; GENE-EXPRESSION; BINDING PROTEIN; IDENTIFICATION; PRODUCT; INVITRO; NUMBER; SHOCK; RPOS	The functional specificity was compared between two sigma factors, sigma(70) (the major sigma at exponentially growing phase) and sigma(38) (the essential sigma at stationary growth phase), of Escherichia coli RNA polymerase. The core enzyme binding affinity of sigma(38) was less than half the level of sigma(70) as measured by gel filtration column chromatography or by titrating the concentration of sigma required for the maximum transcription in the presence of a fixed amount of core enzyme. In addition, the holoenzyme concentration required for the maximum transcription of a fixed amount of templates was higher for E sigma(38) than E sigma(70). The transcription by E sigma(38) was, however, enhanced with the use of templates with low superhelical density, in good agreement with the decrease in DNA superhelicity in the stationary growth phase. We thus propose that the selective transcription of stationary-specific genes by E sigma(38) holoenzyme requires either a specific reaction condition(s) or a specific factor(s) such as template DNA with low superhelical density.	NATL INST GENET,DEPT MOLEC GENET,MISHIMA,SHIZUOKA 411,JAPAN; GRAD UNIV ADV STUDIES,SCH LIFE SCI,MISHIMA,SHIZUOKA 411,JAPAN	Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Graduate University for Advanced Studies - Japan			Kusano, Shuichi/I-5225-2019	Kusano, Shuichi/0000-0001-6293-486X				ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; ARNQVIST A, 1994, MOL MICROBIOL, V13, P1021, DOI 10.1111/j.1365-2958.1994.tb00493.x; BALKE VL, 1987, J BACTERIOL, V169, P4499, DOI 10.1128/jb.169.10.4499-4506.1987; DING QQ, 1995, MOL MICROBIOL, V16, P649, DOI 10.1111/j.1365-2958.1995.tb02427.x; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; HENGGEARONIS R, 1993, CELL, V72, P165, DOI 10.1016/0092-8674(93)90655-A; HIGGINS CF, 1988, CELL, V52, P569, DOI 10.1016/0092-8674(88)90470-9; HSIEH LS, 1991, J BACTERIOL, V173, P3914, DOI 10.1128/JB.173.12.3914-3917.1991; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1988, TRENDS GENET, V4, P282, DOI 10.1016/0168-9525(88)90170-9; ISHIHAMA A, 1991, CONTROL CELL GROWTH, P121; JAWORSKI A, 1991, J BIOL CHEM, V266, P2576; JISHAGE M, 1995, J BACTERIOL, V177, P6832, DOI 10.1128/jb.177.23.6832-6835.1995; KAJITANI M, 1983, NUCLEIC ACIDS RES, V11, P671, DOI 10.1093/nar/11.3.671; KELLER W, 1975, P NATL ACAD SCI USA, V72, P4876, DOI 10.1073/pnas.72.12.4876; KOLB A, 1995, NUCLEIC ACIDS RES, V23, P819, DOI 10.1093/nar/23.5.819; KOLTER R, 1993, ANNU REV MICROBIOL, V47, P855, DOI 10.1146/annurev.micro.47.1.855; KUBORI T, 1995, IN PRESS J MOL BIOL; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; MAGASANIK B, 1982, ANNU REV GENET, V16, P135, DOI 10.1146/annurev.ge.16.120182.001031; MULVEY MR, 1989, NUCLEIC ACIDS RES, V17, P9979, DOI 10.1093/nar/17.23.9979; NEIDHARDT FC, 1984, ANNU REV GENET, V18, P295, DOI 10.1146/annurev.ge.18.120184.001455; NGUYEN LH, 1993, BIOCHEMISTRY-US, V32, P11112, DOI 10.1021/bi00092a021; NOMURA T, 1986, NUCLEIC ACIDS RES, V14, P6857, DOI 10.1093/nar/14.17.6857; OZAKI M, 1991, MOL GEN GENET, V230, P17, DOI 10.1007/BF00290644; OZAKI M, 1992, NUCLEIC ACIDS RES, V20, P257, DOI 10.1093/nar/20.2.257; SPASSKY A, 1984, NUCLEIC ACIDS RES, V12, P5321, DOI 10.1093/nar/12.13.5321; TANAKA K, 1995, NUCLEIC ACIDS RES, V23, P827, DOI 10.1093/nar/23.5.827; TANAKA K, 1993, P NATL ACAD SCI USA, V90, P3511, DOI 10.1073/pnas.90.8.3511; UEGUCHI C, 1993, EMBO J, V12, P1039, DOI 10.1002/j.1460-2075.1993.tb05745.x; WEICHART D, 1993, MOL MICROBIOL, V10, P407, DOI 10.1111/j.1365-2958.1993.tb02672.x; YIM HH, 1992, J BACTERIOL, V174, P3637, DOI 10.1128/JB.174.11.3637-3644.1992	33	122	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1998	2004		10.1074/jbc.271.4.1998	http://dx.doi.org/10.1074/jbc.271.4.1998			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567650	hybrid			2022-12-25	WOS:A1996TR32000032
J	Vainikka, S; Joukov, V; Klint, P; Alitalo, K				Vainikka, S; Joukov, V; Klint, P; Alitalo, K			Association of a 85-kDa serine kinase with activated fibroblast growth factor receptor-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; FAMILY; DOMAIN; SH2	Fibroblast growth factors (FGFs) transduce a variety of biological signals via four distinct tyrosine kinase receptors. We have characterized the phosphorylation of FGF receptor 4 (FGFR-4) and its association with a putative substrate, p85, using transfected L6 myoblast and NIH3T3 fibroblast cell lines. FGFR-4 was phosphorylated in vivo and in vitro mainly on serine and threo-nine residues in several peptides and to a lower degree on tyrosine residues. When analyzed further by in-gel kinase assay, immunoprecipitates of ligand-activated FGFR-4 contained a serine autophosphorylated polypeptide doublet of 85 kDa. Analysis of the major autophosphorylation site Y754F mutant of FGFR-4 showed that binding of p85 and its serine phosphorylation were independent of receptor autophosphorylation at this site. Okadaic acid treatment increased the basal autophosphorylation activity of p85 but decreased FGFR-4 tyrosine phosphorylation. In contrast, orthovanadate treatment increased the tyrosine phosphorylation of FGFR-4. These data show that a serine kinase is associated with activated FGFR-4 and suggest a role for serine phosphorylation in FGFR-4 function.	UNIV HELSINKI, HAARTMAN INST, MOLEC CANC BIOL LAB, SF-00014 HELSINKI, FINLAND; LUDWIG INST CANC RES, UPPSALA BRANCH, S-75124 UPPSALA, SWEDEN	University of Helsinki; Ludwig Institute for Cancer Research			Alitalo, Kari K/J-5013-2014; Joukov, Vladimir/K-3525-2019	Alitalo, Kari K/0000-0002-7331-0902; 				ALITALO K, 1983, J CELL PHYSIOL, V115, P305, DOI 10.1002/jcp.1041150314; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Boudewijn MT, 1995, NATURE, V376, P599; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUTCHCROFT JE, 1991, METHOD ENZYMOL, V200, P417; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHN AD, 1995, EMBO J, V14, P4288, DOI 10.1002/j.1460-2075.1995.tb00103.x; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; PARTANEN J, 1993, PHILOS T R SOC B, V340, P297, DOI 10.1098/rstb.1993.0071; SHAOUL E, 1995, ONCOGENE, V10, P1553; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WIEDLOCHA A, 1996, IN PRESS MOL CELL BI	18	31	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1270	1273		10.1074/jbc.271.3.1270	http://dx.doi.org/10.1074/jbc.271.3.1270			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576110	hybrid			2022-12-25	WOS:A1996TQ52500006
J	Stapleton, D; Mitchelhill, KI; Gao, G; Widmer, J; Michell, BJ; Teh, T; House, CM; Fernandez, CS; Cox, T; Witters, LA; Kemp, BE				Stapleton, D; Mitchelhill, KI; Gao, G; Widmer, J; Michell, BJ; Teh, T; House, CM; Fernandez, CS; Cox, T; Witters, LA; Kemp, BE			Mammalian AMP-activated protein kinase subfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-COA CARBOXYLASE; FATTY-ACID; PHOSPHORYLATION	The mammalian 5'-AMP-activated protein kinase (AMPK) is related to a growing family of protein kinases in yeast and plants that are regulated by nutritional stress. We find the most prominent expressed form of the hepatic AMPK catalytic subunit (alpha(1)) is distinct from the previously cloned kinase subunit (alpha(2)). The alpha(1) (548 residues) and alpha(2) (552 residues) isoforms have 90% amino acid sequence identity within the catalytic core but only 61% identity elsewhere. The tissue distribution of the AMPK activity most closely parallels the low abundance 6-kilobase alpha(1) mRNA distribution and the alpha(1) immunoreactivity rather than alpha(2), with substantial amounts in kidney, liver, lung, heart, and brain. Both alpha(1) and alpha(2) isoforms are stimulated by AMP and contain noncatalytic beta and gamma subunits. The liver (alpha(1) isoform accounts for approximately 94% of the enzyme activity measured using the SAMS peptide substrate. The tissue distribution of the alpha(2) immunoreactivity parallels the alpha(2) 8.5-kilobase mRNA and is most prominent in skeletal muscle, heart, and liver. Isoforms of the beta and gamma subunits present in the human genome sequence reveal that the AMPK consists of a family of isoenzymes.	ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA; DARTMOUTH COLL,SCH MED,DIV ENDOCRINE METAB,HANOVER,NH 03755	St. Vincent's Institute of Medical Research; Dartmouth College			Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014	Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082	NIDDK NIH HHS [DK35712] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035712] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUAN K, 1994, GENE, V149, P345, DOI 10.1016/0378-1119(94)90174-0; BERI RK, 1994, FEBS LETT, V356, P117, DOI 10.1016/0014-5793(94)01247-4; BIELKE W, 1994, GENE, V139, P235, DOI 10.1016/0378-1119(94)90762-5; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; CARLING D, 1994, J BIOL CHEM, V269, P11442; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; FERRER A, 1985, BIOCHEM BIOPH RES CO, V132, P497, DOI 10.1016/0006-291X(85)91161-1; GAO G, 1995, BBA-MOL CELL RES, V1266, P73, DOI 10.1016/0167-4889(94)00222-Z; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HAYGOOD MG, 1993, BIOTECHNIQUES, V15, P1084; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KUDO N, 1995, J BIOL CHEM, V270, P17513, DOI 10.1074/jbc.270.29.17513; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOUIS NA, 1992, J BIOL CHEM, V267, P2287; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; SADDIK M, 1993, J BIOL CHEM, V268, P25836; STAPLETON D, 1994, J BIOL CHEM, V269, P29343; VERHOEVEN AJM, 1995, EUR J BIOCHEM, V228, P236; WITTERS LA, 1990, BIOCHEM BIOPH RES CO, V169, P369, DOI 10.1016/0006-291X(90)90341-J; WOODS A, 1994, J BIOL CHEM, V269, P19509; YANG XL, 1994, EMBO J, V13, P5878, DOI 10.1002/j.1460-2075.1994.tb06933.x	26	542	572	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					611	614		10.1074/jbc.271.2.611	http://dx.doi.org/10.1074/jbc.271.2.611			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557660	hybrid			2022-12-25	WOS:A1996TP88900003
J	Abe, S; Yagi, T; Ishiyama, S; Hiroe, M; Marumo, F; Ikawa, Y				Abe, S; Yagi, T; Ishiyama, S; Hiroe, M; Marumo, F; Ikawa, Y			Molecular cloning of a novel serine/threonine kinase, MRK, possibly involved in cardiac development	ONCOGENE			English	Article						serine/threonine protein kinase; cardiac development	FIBROBLAST GROWTH-FACTOR; POLYMERASE CHAIN-REACTION; PROTEIN-KINASE; PHOSPHORYLATION SITES; REGULATORY PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; ENDOTHELIAL-CELLS; PHORBOL ESTERS; P34CDC2 KINASE; MAP KINASE	We have isolated a novel member of putative serine/threonine kinase from a rat heart cDNA library using polymerase chain reaction methods, The novel kinase is transcribed as 2.6 kb mRNA encoding for a protein of 629 amino acids with the long C-terminal non-catalytic portion, Amino acids analysis revealed that the N-terminal catalytic domain is 87% identical to the male-germ cell associated kinase (MAK), a cdc2-related serine/threonine kinase found to promote meiosis during spermatogenesis, Therefore, we designated this novel kinase as the MAK-related kinase (MRK), MRK protein, with a molecular weight of 66 kD, was shown to phosphorylate itself and the exogenous substrates, histone H1 and myelin basic protein, In addition, phosphoamino acid analysis confirmed the serine/threonine-specific protein kinase activity of MRK, Although MRK was ubiquitous in adult rat tissues, the expression of MRK protein in embryos was restricted primarily to embryonic myocardium during early organogenesis, This finding suggests that MRK may be a participant in cardiac development.	RIKEN,INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,TSUKUBA,IBARAKI 305,JAPAN; TOKYO MED & DENT UNIV,SCH MED,DEPT INTERNAL MED 2,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,SCH MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	RIKEN; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)								AKHURST RJ, 1990, DEVELOPMENT, V108, P645; BARNETT JV, 1994, DEV DYNAM, V199, P12, DOI 10.1002/aja.1001990103; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BOGOYEVITCH MA, 1993, CIRC RES, V72, P757, DOI 10.1161/01.RES.72.4.757; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V64, P573; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONSIGLI SA, 1991, J CELL PHYSIOL, V146, P379, DOI 10.1002/jcp.1041460307; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEWEILENMANN CM, 1987, BASIC RES CARDIOL, V82, P507; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUMONT DJ, 1992, ONCOGENE, V7, P1471; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ENGELMANN GL, 1994, CELL MOL BIOL RES, V40, P93; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8993; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; JIN Y, 1994, J MOL CELL CARDIOL, V26, P1449, DOI 10.1006/jmcc.1994.1164; JINNO A, 1993, MOL CELL BIOL, V13, P4146, DOI 10.1128/MCB.13.7.4146; JOUANNOT P, 1975, AM J PHYSIOL, V229, P355, DOI 10.1152/ajplegacy.1975.229.2.355; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KORHONEN J, 1994, ONCOGENE, V9, P395; KRANIAS EG, 1982, NATURE, V298, P182, DOI 10.1038/298182a0; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; Maniatis T, 1989, DECONTAMINATION DILU; MARCELLE C, 1992, ONCOGENE, V7, P2479; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MUSLIN AJ, 1991, DEVELOPMENT, V112, P1095; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; OELRICHS RB, 1993, ONCOGENE, V8, P11; ORR UA, 1992, DEVELOPMENT, V115, P289; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RAZ V, 1991, ONCOGENE, V6, P753; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SHIGETA H, 1992, ENDOCR J, V40, P641; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; TORRES L, 1991, MOL MICROBIOL, V5, P2845, DOI 10.1111/j.1365-2958.1991.tb01993.x; WILKS AF, 1989, GENE, V85, P67, DOI 10.1016/0378-1119(89)90465-4; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WU Y, 1994, EMBO J, V8, P147; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P	52	38	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2187	2195						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570168				2022-12-25	WOS:A1995TK70200001
J	Masuda, S; Byford, V; Kremer, R; Makin, HLJ; Kubodera, N; Nishii, Y; Okazaki, A; Okano, T; Kobayashi, T; Jones, G				Masuda, S; Byford, V; Kremer, R; Makin, HLJ; Kubodera, N; Nishii, Y; Okazaki, A; Okano, T; Kobayashi, T; Jones, G			In vitro metabolism of the vitamin D analog, 22-oxacalcitriol, using cultured osteosarcoma, hepatoma, and keratinocyte cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-INDUCING ACTIVITY; TUMOR PROGRESSION; SYNTHETIC ANALOG; CALCITROIC ACID; 1,25-DIHYDROXYVITAMIN-D3; PATHWAY; MODEL; 22-OXA-1-ALPHA,25-DIHYDROXYVITAMIN-D3; IDENTIFICATION; HYPERCALCEMIA	Using four cultured cell models representing liver, keratinocyte, and osteoblast, we have demonstrated that the vitamin D analog, 22-oxacalcitriol is degraded into a variety of hydroxylated and side chain truncated metabolites, Four of these metabolic products have been rigorously identified by high pressure liquid chromatography, diode array spectrophotometry, and gas chromatography-mass spectrometry analysis as 24-hydroxylated and 26-hydroxylated derivatives as well as the cleaved molecules, hexanor-1 alpha,20-dihydroxyvitamin D-3 and hexanor-20-oxo-1 alpha-hydroxyvitamin D-3. Comparison with chemically synthesized standards has revealed the stereochemistry of the biological products, Although differences exist in the amounts of products formed with the different cell types, it is apparent that 22-oxacalcitriol is subject to metabolism by both vitamin D-inducible and noninducible enzymes, Time course studies suggest that the truncated 20-alcohol is derived from a side chain hydroxylated molecule via a hemiacetal intermediate and the 20-oxo derivative is likely formed from the 20-alcohol, Biological activity measurements of the metabolites identified in our studies are consistent with the view that these are catabolites and that the biological activity of 22-oxacalcitriol is due to the parent compound. These results are also consistent with recent findings of others that the biliary excretory form of 22-oxacalcitriol is a glucuronide ester of the truncated 20-alcohol.	QUEENS UNIV,DEPT BIOCHEM,KINGSTON,ON K7L 3N6,CANADA; QUEENS UNIV,DEPT MED,KINGSTON,ON K7L 3N6,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3A 1A1,CANADA; UNIV LONDON LONDON HOSP,COLL MED,DEPT CHEM PATHOL,LONDON E1 2AD,ENGLAND; CHUGAI PHARMACEUT CO LTD,TOKYO 171,JAPAN; KOBE PHARMACEUT UNIV,DEPT HYGIEN SCI,KOBE 658,JAPAN	Queens University - Canada; Queens University - Canada; McGill University; University of London; University College London; Chugai Pharmaceutical Co., Ltd.; Roche Holding; Kobe Pharmaceutical University				Kremer, Richard/0000-0002-7053-2139				ABE J, 1987, FEBS LETT, V226, P58, DOI 10.1016/0014-5793(87)80550-1; ABE J, 1989, ENDOCRINOLOGY, V124, P2645, DOI 10.1210/endo-124-5-2645; ARNAUD SB, 1983, ASSAY CALCIUM REGULA, P65; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN AJ, 1992, BIOCHEM BIOPH RES CO, V189, P759, DOI 10.1016/0006-291X(92)92266-Z; Calverley M. J., 1992, ANTITUMOR STEROIDS, P193; CALVERLEY MJ, 1993, TETRAHEDRON, V49, P739, DOI 10.1016/S0040-4020(01)86276-1; DUSSO AS, 1991, ENDOCRINOLOGY, V128, P1687, DOI 10.1210/endo-128-4-1687; DUSSO AS, 1992, ENDOCRINOLOGY, V130, P3129, DOI 10.1210/en.130.6.3129; HENDERSON J, 1991, CANCER RES, V51, P6521; HOLLIS BW, 1980, BIOCHEM BIOPH RES CO, V95, P520, DOI 10.1016/0006-291X(80)90815-3; JONES G, 1993, TRENDS ENDOCRIN MET, V4, P297, DOI 10.1016/1043-2760(93)90049-K; JONES G, 1994, 2 INT FOR CALC TISS, P30; KAMIMURA S, 1993, ENDOCRINOLOGY, V133, P2719, DOI 10.1210/en.133.6.2719; KOBAYASHI T, 1991, CONTRIB NEPHROL, V91, P129; KOBAYASHI T, 1994, J BIOCHEM-TOKYO, V115, P373, DOI 10.1093/oxfordjournals.jbchem.a124346; KUBODERA N, 1993, CHEM PHARM BULL, V41, P1659; KUBODERA N, 1994, BIOORG MED CHEM LETT, V4, P753, DOI 10.1016/S0960-894X(01)80195-5; LOHNES D, 1987, J BIOL CHEM, V262, P14394; LOHNES D, 1992, J NUTRI SCI VITAMINO, P57; MAKIN G, 1989, BIOCHEM J, V262, P173, DOI 10.1042/bj2620173; MASUDA S, 1994, J BIOL CHEM, V269, P4794; MIYAURA C, 1981, BIOCHEM BIOPH RES CO, V102, P937, DOI 10.1016/0006-291X(81)91628-4; MURAYAMA E, 1986, CHEM PHARM BULL, V34, P4410; OKANO T, 1989, J NUTR SCI VITAMINOL, V35, P529, DOI 10.3177/jnsv.35.529; QAW F, 1993, J BIOL CHEM, V268, P282; REDDY GS, 1989, BIOCHEMISTRY-US, V28, P1763, DOI 10.1021/bi00430a051; REINHARDT TA, 1981, BIOCHEMISTRY-US, V21, P6230; SEBAG M, 1992, J BIOL CHEM, V267, P12162; SORENSEN H, 1990, BIOCHEM PHARMACOL, V39, P391, DOI 10.1016/0006-2952(90)90039-N; STRUGNELL S, 1990, BIOCHEM PHARMACOL, V40, P333, DOI 10.1016/0006-2952(90)90696-I; SUDA T, 1990, ANNU REV NUTR, V10, P195, DOI 10.1146/annurev.nu.10.070190.001211; TAKIZAWA M, 1992, CALCIFIED TISSUE INT, V50, P521, DOI 10.1007/BF00582166; YAMADA S, 1984, J BIOL CHEM, V259, P884	34	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8700	8708		10.1074/jbc.271.15.8700	http://dx.doi.org/10.1074/jbc.271.15.8700			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621502	hybrid			2022-12-25	WOS:A1996UE73000033
J	Pao, CI; Lin, KWM; Zhu, JL; Wu, GJ; Farmer, PK; Phillips, LS				Pao, CI; Lin, KWM; Zhu, JL; Wu, GJ; Farmer, PK; Phillips, LS			In vitro transcription of the rat insulin-like growth factor-I gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; MOUSE ALBUMIN PROMOTER; INVITRO TRANSCRIPTION; BINDING-PROTEIN; HEPATOMA-CELLS; LEADER EXONS; LIVER; ACTIVATION; SERUM	Although the liver is the major source of circulating insulin-like growth factor-I (IGF-I), relatively little is known about the regulation of IGF-I gene transcription in this tissue. Since transcripts are initiated largely in exon 1, we established an in vitro transcription system to evaluate activation of transcription via the major exon 1 initiation site. Transcription of a G-free cassette reporter was directed by rat IGF-I genomic fragments, and the adenovirus major late promoter was used as an internal control. Tissue specificity was demonstrated by a 60-90% decrease in transcripts with spleen extracts as compared with liver. 54 base pairs (bp) of upstream sequence were sufficient to direct IGF-I gene transcription, and activity increased 5-fold with 300 bp of upstream sequence. DNase I footprinting revealed four protected regions between -300 and -60 bp; binding was confirmed by gel shift analysis, and tissue specificity was demonstrated by reduced shifts with spleen extracts. The necessity of transcription factor binding to such sites was established by competition analysis, which revealed a specific decrease in IGF-I transcription in the presence of a competing fragment. Use of this in vitro transcription system should permit analysis of the function of individual transcription factors involved in regulation of IGF-I gene expression.	EMORY UNIV,SCH MED,DEPT MED,DIV ENDOCRINOL & METAB,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DEPT MICROBIOL IMMUNOL,ATLANTA,GA 30322	Emory University; Emory University					NIDDK NIH HHS [DK-48124, DK-33475] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033475, R01DK048124] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMO ML, 1991, MOL ENDOCRINOL, V5, P1677, DOI 10.1210/mend-5-11-1677; ADAMO ML, 1991, BIOCHEM BIOPH RES CO, V176, P887, DOI 10.1016/S0006-291X(05)80269-4; BABISS LE, 1987, GENE DEV, V1, P256, DOI 10.1101/gad.1.3.256; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; De Simone V, 1991, CURR OPIN CELL BIOL, V3, P960, DOI 10.1016/0955-0674(91)90114-E; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREGORI C, 1993, NUCLEIC ACIDS RES, V21, P897, DOI 10.1093/nar/21.4.897; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; JACQUEMIN P, 1993, BIOCHEM BIOPH RES CO, V196, P376, DOI 10.1006/bbrc.1993.2259; JANSEN E, 1992, BIOCHEM BIOPH RES CO, V187, P1219, DOI 10.1016/0006-291X(92)90433-L; KATZ N, 1992, EUR J CELL BIOL, V57, P117; KIKUCHI K, 1992, J BIOL CHEM, V267, P21505; KIM SW, 1991, MOL ENDOCRINOL, V5, P1964, DOI 10.1210/mend-5-12-1964; KULIK VP, 1995, J BIOL CHEM, V270, P1068, DOI 10.1074/jbc.270.3.1068; LOWE WL, 1992, BIOCHEM BIOPH RES CO, V189, P972, DOI 10.1016/0006-291X(92)92299-D; LOWE WL, 1994, END SOC 76 ANN M AN, P330; LUND PK, 1991, MODERN CONCEPTS INSU, P111; MURPHY LJ, 1987, ENDOCRINOLOGY, V120, P1279, DOI 10.1210/endo-120-4-1279; NITSCH D, 1993, MOL CELL BIOL, V13, P4494, DOI 10.1128/MCB.13.8.4494; NOLTEN LA, 1994, MOL ENDOCRINOL, V8, P1636, DOI 10.1210/me.8.12.1636; PAO CI, 1995, J BIOL CHEM, V270, P24917, DOI 10.1074/jbc.270.42.24917; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; Saiki R, 1989, PCR TECHNOLOGY PRINC, P1; SCHWANDER JC, 1983, ENDOCRINOLOGY, V113, P297, DOI 10.1210/endo-113-1-297; SHIMATSU A, 1987, J BIOL CHEM, V262, P7894; SU TS, 1989, CANCER RES, V49, P1773; THOMAS MJ, 1994, ENDOCRINOLOGY, V135, P1584, DOI 10.1210/en.135.4.1584; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; VAULONT S, 1989, MOL CELL BIOL, V9, P4409, DOI 10.1128/MCB.9.10.4409; Weinmann Roberto, 1992, Gene Expression, V2, P81; WOLFFE AP, 1994, CURR OPIN GENET DEV, V4, P245, DOI 10.1016/S0959-437X(05)80051-6; WUARIN J, 1990, J MOL BIOL, V214, P865, DOI 10.1016/0022-2836(90)90341-I; Zaret Kenneth S., 1993, P135	37	9	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8667	8674		10.1074/jbc.271.15.8667	http://dx.doi.org/10.1074/jbc.271.15.8667			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621498	hybrid			2022-12-25	WOS:A1996UE73000029
J	David, M; Petricoin, E; Larner, AC				David, M; Petricoin, E; Larner, AC			Activation of protein kinase A inhibits interferon induction of the Jak/Stat pathway in U266 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA; RECEPTOR; CAMP	Activation of early response genes by interferons (IFNs) requires tyrosine phosphorylation of the Stat transcription factors and is mediated by the Jak family of tyrosine kinases, Recent evidence suggests that ERK2 serine/threonine kinase modulates the IFN-stimulated Jak/Stat pathway. In this report we show that in the myeloma cell line U266 protein kinase A specifically interacts with the cytoplasmic domain of the IFN alpha/beta receptor, Treatment of cells with the adenylate cyclase activator forskolin inhibits IFN beta-, IFN gamma-, and hydrogen peroxide/vanadate-induced formation of complexes that bind to enhancers known to stimulate the expression of IFN-regulated genes. Immunoprecipitations followed by anti-phosphotyrosine immunoblots indicate that tyrosine phosphorylation of the alpha chain of the IFN alpha/beta receptor, Jak1, Trk2, as well as Stat1 and Stat2 is reduced as a consequence of incubation of cells with forskolin. In contrast, dideoxyforskolin, which fails to activate adenylate cyclase, has no effect on IFN induction of the Jak/Stat pathway. These results indicate a novel regulatory mechanism by which protein kinase A can modulate the Jak/Stat signaling cascade.	NIH,DIV CYTOKINE BIOL,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; US Food & Drug Administration (FDA)								ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BOUDEWIJN M, 1995, TRENDS BIOCHEM SCI, V20, P18; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DAVID M, 1993, J BIOL CHEM, V268, P6593; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; PETRICOIN E, 1994, MOL CELL BIOL, V14, P1477, DOI 10.1128/MCB.14.2.1477; PLATANIAS LC, 1992, J BIOL CHEM, V267, P24053; REICH NC, 1990, P NATL ACAD SCI USA, V87, P8761, DOI 10.1073/pnas.87.22.8761; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	20	65	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4585	4588						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617715				2022-12-25	WOS:A1996TX69700005
J	DeMar, JC; Wensel, TG; Anderson, RE				DeMar, JC; Wensel, TG; Anderson, RE			Biosynthesis of the unsaturated 14-carbon fatty acids found on the N termini of photoreceptor-specific proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NH2-TERMINAL BLOCKING GROUP; MYRISTIC ACID; ALPHA-SUBUNIT; NEONATAL ADRENOLEUKODYSTROPHY; SACCHAROMYCES-CEREVISIAE; LIQUID-CHROMATOGRAPHY; RETINITIS-PIGMENTOSA; CATALYTIC SUBUNIT; RHODOPSIN GENE; MYRISTOYLTRANSFERASE	In the vertebrate retina, a number of proteins involved in signal transduction are known to be N-terminal acylated with the unusual 14 carbon fatty acids 14: 1n-9 and 14:2n-6. We have explored possible pathways for producing these fatty acids in the frog retina by incubation in vitro with candidate precursor fatty acids bearing radiolabels, including [H-3]14:0, [H-3]18:1n-9, [H-3]18:2n-6, and [H-3]18:3n-3. Rod outer segments were prepared from the radiolabeled retinas for analysis of protein-linked fatty acids, and total lipids were extracted from the remaining retinal pellet. Following saponification of extracted lipids, fatty acid phenacyl esters were prepared and analyzed by high pressure liquid chromatography (HPLC) with detection by continuous scintillation counting. Transducin, whose alpha-subuuit (G(t alpha)) is known to bear N-terminal acyl chains, was extracted hom the rod outer segments and subjected to SDS-polyacrylamide gel electrophoresis and fluorography to detect radiolabeled proteins. G(t alpha) was also subjected to methanolysis, and the resulting fatty acyl methyl esters were analyzed by HPLC. The identities of HPLC peaks coinciding with unsaturated species of both phenacyl esters and methyl esters were confirmed by reanalyzing them after catalytic hydrogenation. The results showed that 14:1n-9 can be derived in the retina from 18:1n-9 and 14:2n-6 from 18:2n-6, most likely by two rounds of beta-oxidation, but that neither is produced in detectable amounts from 14:0. Retroconversion of unsaturated 18 carbon fatty acids to the corresponding 14 carbon species showed specificity, in that 18:3n-3 was not converted to 14 carbon fatty acids in detectable amounts. Myristic acid (14:0), 14:1n-9, and 14:2n-6 were all incorporated into G(t alpha). A much less efficient incorporation of 18:1n-9 into G(t alpha) was also observed, but no radiolabeling of G(t alpha) was observed in retinas incubated with 18:3n-3. Thus, retroconversion by limited beta-oxidation of longer chain unsaturated fatty acids appears to be the most likely metabolic source of the unusual fatty acids found on the N termini of signal transducing proteins in the retina.	UNIV OKLAHOMA,HLTH SCI CTR,DEAN A MCGEE EYE INST,OKLAHOMA CTR NEUROSCI,OKLAHOMA CITY,OK 73104; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; UNIV OKLAHOMA,HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,OKLAHOMA CITY,OK 73104	University of Oklahoma System; University of Oklahoma Health Sciences Center; Baylor College of Medicine; University of Oklahoma System; University of Oklahoma Health Sciences Center				Wensel, Theodore/0000-0003-3518-9352	NEI NIH HHS [EY07001, EY04149, EY00871] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY000871, R01EY004149] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AVELDANO MI, 1983, J LIPID RES, V24, P83; BARTLEY W, 1962, BIOCHEM J, V85, P332, DOI 10.1042/bj0850332; BAYKOUSHEVA SP, 1994, J BIOL CHEM, V269, P18390; BOWEN P, 1964, B JOHNS HOPKINS HOSP, V114, P402; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CARR SA, 1982, P NATL ACAD SCI-BIOL, V79, P6128, DOI 10.1073/pnas.79.20.6128; CHEN H, 1993, J CHROMATOGR, V578, P124; CHEN HM, 1993, CURR EYE RES, V12, P851, DOI 10.3109/02713689309020390; COOK HW, 1991, J LIPID RES, V32, P1265; DIZHOOR AM, 1992, J BIOL CHEM, V267, P16033; DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903; DURONIO RJ, 1992, P NATL ACAD SCI USA, V89, P4129, DOI 10.1073/pnas.89.9.4129; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; GORDON JI, 1991, J BIOL CHEM, V266, P8647; HADJIAGAPIOU C, 1990, BIOCHIM BIOPHYS ACTA, V1046, P167, DOI 10.1016/0005-2760(90)90184-Y; HAMOSH M, 1992, LIPIDS, V27, P848, DOI 10.1007/BF02535863; HANSEN HS, 1993, TRENDS BIOCHEM SCI, V18, P164, DOI 10.1016/0968-0004(93)90105-V; JAFFE R, 1982, AM J PATHOL, V108, P100; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2625; JOHNSON RS, 1994, J BIOL CHEM, V269, P21067; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KISHORE NS, 1991, J BIOL CHEM, V266, P8835; KISHORE NS, 1993, J BIOL CHEM, V268, P4889; KOKAME K, 1992, NATURE, V359, P749, DOI 10.1038/359749a0; KOLETZKO B, 1992, EUR J CLIN NUTR, V46, P45; KUPKE IR, 1978, J CHROMATOGR, V146, P261, DOI 10.1016/S0378-4347(00)81892-7; KURONO G, 1972, CHEM PHARM BULL, V20, P559, DOI 10.1248/cpb.20.559; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOUIE K, 1988, BIOCHEMISTRY-US, V27, P9014, DOI 10.1021/bi00425a020; LU TB, 1994, J BIOL CHEM, V269, P5346; LUTHRIA DL, 1995, J BIOL CHEM, V270, P13771, DOI 10.1074/jbc.270.23.13771; MARTINEZ M, 1994, LIPIDS, V29, P273, DOI 10.1007/BF02536332; MCILHINNEY RAJ, 1990, TRENDS BIOCHEM SCI, V15, P387; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; MOSER HW, 1987, CRIT REV NEUROBIOL, V21, P240; MRKLEY KS, 1960, FATTY ACIDS THEIR 1, P12; NEUBERT TA, 1992, J BIOL CHEM, V267, P18274; NUMA S, 1984, FATTY ACID METABOLIS, P93; OHGURO H, 1990, COMP BIOCH PHYSL, V4, P763; OLSON EN, 1985, J BIOL CHEM, V260, P3784; OULHAJ H, 1992, COMP BIOCH PHYSL, V4, P897; OZOLS J, 1984, J BIOL CHEM, V259, P3349; PALCZEWSKI K, 1994, NEURON, V13, P395, DOI 10.1016/0896-6273(94)90355-7; PAPAC DI, 1992, J BIOL CHEM, V267, P16889; POLLTHE BT, 1987, EUR J PEDIATR, V146, P477, DOI 10.1007/BF00441598; ROSENFELD PJ, 1992, NAT GENET, V1, P209, DOI 10.1038/ng0692-209; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; RUDNICK DA, 1992, P NATL ACAD SCI USA, V89, P10507, DOI 10.1073/pnas.89.21.10507; SCHLESINGER MJ, 1993, LIPID MODIFICATIONS, P23; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SPRECHER H, 1968, LIPIDS, V3, P14, DOI 10.1007/BF02530962; SPRECHER HW, 1972, FED PROC, V31, P1451; STJULES R, 1992, EXP EYE RES, V54, P1; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; UMBARGER KO, 1992, J BIOL CHEM, V267, P19494; VOSS A, 1991, J BIOL CHEM, V266, P19995; WANG N, 1993, BIOCHEMISTRY-US, V32, P13703, DOI 10.1021/bi00212a040; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; WOOD R, 1983, J CHROMATOGR, V254, P237, DOI 10.1016/S0021-9673(01)88338-2; YANG ZH, 1992, J BIOL CHEM, V267, P23197; YONEMOTO W, 1993, J BIOL CHEM, V268, P2348	63	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5007	5016						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617777				2022-12-25	WOS:A1996TX69700067
J	Miao, HQ; IshaiMichaeli, R; Atzmon, R; Peretz, T; Vlodavsky, I				Miao, HQ; IshaiMichaeli, R; Atzmon, R; Peretz, T; Vlodavsky, I			Sulfate moieties in the subendothelial extracellular matrix are involved in basic fibroblast growth factor sequestration, dimerization, and stimulation of cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-LIKE MOLECULES; ENDOTHELIAL-CELLS; BINDING; PROTEOGLYCANS; SEQUENCE; RELEASE; SURFACE; DEGRADATION; RECEPTORS; CHLORATE	The growth promoting activity of the subendothelial extracellular matrix (ECM) is attributed to sequestration of basic fibroblast growth factor (bFGF) by heparan sulfate proteoglycans and its regulated release by heparin-like molecules and heparan sulfate (HS) degrading enzymes. HS is also involved in bFGF receptor binding and activation. The present study focuses on the growth promoting activity and bFGF binding capacity of sulfate-depleted ECM. Corneal endothelial cells (EC) maintained in the presence of chlorate, an inhibitor of phosphoadenosine phosphosulfate synthesis, produced ECM containing 10-15% of the sulfate normally present in ECM. Incorporation of sulfate into HS was reduced by more than 90%. Binding of I-125-bFGF sulfate-depleted ECM was reduced by 50-60% and only about 10% of the ECM-bound bFGF was accessible to release by heparin. Incubation of I-125-bFGF on top of native ECM resulted in dimerization of the ECM-bound bFGF, but there was a markedly reduced binding and dimerization of bFGF on sulfate-depleted ECM. ECM produced in the presence of chlorate contained a nearly 10-fold less endogenous bFGF as compared to native ECM and exerted Little or no mitogenic activity toward vascular EC and 3T3 fibroblasts. In other studies, we investigated the interaction between chlorate-treated vascular EC and either native or sulfate-depleted ECM. Exogenous heparin stimulated the proliferation of chlorate-treated EC seeded on native ECM, suggesting its interaction with ECM-bound bFGF and subsequent presentation to high affinity cell surface receptors. On the other hand, heparin had no effect on chlorate-treated cells seeded in contact with sulfate-depleted ECM or regular tissue culture plastic. Altogether, the present experiments indicate that heparan sulfate proteoglycans associated with the cell surface and ECM act in concert to regulate the bioavailability and growth promoting activity of bFGF. While HS in the subendothelial ECM functions primarily in sequestration of bFGF in the vicinity of responsive cells, HS on cell surfaces is playing a more active role in displacing the ECM-bound bFGF and its subsequent presentation to high affinity signal transducing receptors.	HEBREW UNIV JERUSALEM,HADASSAH HOSP,DEPT ONCOL,IL-91120 JERUSALEM,ISRAEL	Hebrew University of Jerusalem; Hadassah University Medical Center								AVIEZER D, 1994, J BIOL CHEM, V269, P114; AVIEZER D, 1994, CELL, V79, P1005, DOI 10.1016/0092-8674(94)90031-0; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BENEZRA M, 1993, BLOOD, V81, P3324; BERNFIELD M, 1991, ANN NY ACAD SCI, V638, P182, DOI 10.1111/j.1749-6632.1991.tb49029.x; CARDONCARDO C, 1990, LAB INVEST, V63, P832; CASTELLOT JJ, 1986, J CELL BIOL, V102, P1979, DOI 10.1083/jcb.102.5.1979; DAWES J, 1979, THROMB RES, V14, P845, DOI 10.1016/0049-3848(79)90004-5; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; GILAT D, 1995, J EXP MED, V181, P1929, DOI 10.1084/jem.181.5.1929; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GOSPODAROWICZ D, 1983, J CELL PHYSIOL, V114, P191, DOI 10.1002/jcp.1041140208; GOSPODAROWICZ D, 1980, P NATL ACAD SCI-BIOL, V77, P4094, DOI 10.1073/pnas.77.7.4094; GOSPODAROWICZ D, 1976, P NATL ACAD SCI USA, V73, P4120, DOI 10.1073/pnas.73.11.4120; GOSPODAROWICZ D, 1977, EXP EYE RES, V25, P75, DOI 10.1016/0014-4835(77)90248-2; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HABUCHI H, 1992, BIOCHEM J, V285, P805, DOI 10.1042/bj2850805; HANNEKEN A, 1995, J CELL BIOL, V128, P1221, DOI 10.1083/jcb.128.6.1221; ISHAIMICHAELI R, 1990, CELL REGUL, V1, P833, DOI 10.1091/mbc.1.11.833; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; ISHIHARA M, 1993, J BIOL CHEM, V268, P4675; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Lindahl U., 1989, HEPARIN, P159; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MASCARELLI F, 1993, GROWTH FACTORS, V8, P211, DOI 10.3109/08977199309011024; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; VLODAVSKY I, 1983, CANCER RES, V43, P2704; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; VLODAVSKY I, 1980, CELL, V19, P607, DOI 10.1016/S0092-8674(80)80037-7; VLODAVSKY I, 1993, MOL CELLULAR ASPECTS, P327; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	45	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4879	4886						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617759				2022-12-25	WOS:A1996TX69700049
J	Tehrani, MA; Mumby, MC; Kamibayashi, C				Tehrani, MA; Mumby, MC; Kamibayashi, C			Identification of a novel protein phosphatase 2A regulatory subunit highly expressed in muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE PHOSPHATASES; RABBIT SKELETAL-MUSCLE; SIMIAN VIRUS-40; B-SUBUNIT; A-SUBUNIT; PURIFICATION; ACTIVATION; INHIBITOR; FORMS	Differential association of regulatory B subunits with a core heterodimer, composed of a catalytic (C) and a structural (A) subunit, is an important mechanism that regulates protein phosphatase 2A (PP2A). We have isolated and characterized three novel cDNAs related to the B' subunit of bovine cardiac PP2A. Two human (B'alpha 1 and B'alpha 2) and a mouse (B'alpha 3) cDNA encode for alternatively spliced variants of the B' subunit. The deduced primary sequences of these clones contain 12 of 15 peptides derived from the purified bovine B' subunit. Differences between the deduced sequences of the B'alpha splice variants and the cardiac peptide sequences suggest the existence of multiple isoforms of the B' subunit. Comparison of the protein and nucleotide sequences of the cloned cDNAs show that all three forms of B'alpha diverge at a common splice site near the 3'-end of the coding regions. Northern blot and reverse transcription-polymerase chain reaction analyses revealed that the B'alpha 3, transcripts (4.3-4.4 kb) are widely expressed and very abundant in heart and skeletal muscle. The expressed human and mouse B'alpha proteins readily associated with the PP2A core enzyme in both in vitro and in vivo complex formation assays. Immunofluorescence microscopy revealed that epitope-tagged B'alpha was localized in both the cytosol and nuclei of transiently transfected cells. The efficiency of binding of all three expressed proteins to a glutathione S-transferase-A subunit fusion protein was greatly enhanced by the addition of the C subunit. Expression of the B'alpha subunits in insect Sf9 cells resulted in formation of AC . B'alpha heterotrimers with the endogenous insect A and C subunits. These results show that the B' subunit, which is the predominant regulatory subunit in cardiac PP2A, is a novel protein whose sequence is unrelated to other PP2A regulatory subunits. The nuclear localization of expressed B'alpha suggests that some variants of the B' subunit are involved in the nuclear functions of PP2A.	UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NHLBI NIH HHS [HL31107] Funding Source: Medline; NIGMS NIH HHS [GM49505] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049505] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAYLA X, 1994, J BIOL CHEM, V269, P15668; CLARKE PR, 1993, MOL BIOL CELL, V4, P397, DOI 10.1091/mbc.4.4.397; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; GORELICK FS, 1988, J BIOL CHEM, V263, P17209; HARPER JW, 1993, CELL, V75, P805; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; ILARIA R, 1985, J NEUROSCI METH, V15, P165, DOI 10.1016/0165-0270(85)90053-6; JAKES S, 1986, BIOCHIM BIOPHYS ACTA, V888, P135, DOI 10.1016/0167-4889(86)90079-0; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; KAMIBAYASHI C, 1991, J BIOL CHEM, V266, P13251; KAMIBAYASHI C, 1995, ADV PROT PHOSPHATASE, V9, P195; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; RUEDIGER R, 1992, MOL CELL BIOL, V12, P4872, DOI 10.1128/MCB.12.11.4872; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; UEMURA T, 1993, GENE DEV, V7, P429, DOI 10.1101/gad.7.3.429; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P4883, DOI 10.1128/MCB.12.11.4883; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; WHEAT WH, 1994, MOL CELL BIOL, V14, P5881, DOI 10.1128/MCB.14.9.5881; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023	39	103	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5164	5170						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617797				2022-12-25	WOS:A1996TX69700087
J	Hsieh, KP; Wilke, N; Harris, A; Miles, MF				Hsieh, KP; Wilke, N; Harris, A; Miles, MF			Interaction of ethanol with inducers of glucose-regulated stress proteins - Ethanol potentiates inducers of grp78 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; CALCIUM IONOPHORE; BREFELDIN-A; THAPSIGARGIN; CELLS; INDUCTION; PROMOTER; TRANSACTIVATION; INHIBITION; A23187	GRP78, a molecular chaperone expressed in the endoplasmic reticulum, is a ''glucose-regulated protein'' induced by stress responses that deplete glucose or intracisternal calcium or otherwise disrupt glycoprotein trafficking. Previously we showed that chronic ethanol exposure increases the expression of GRP78. To further understand the mechanism underlying ethanol regulation of GRP78 expression, we studied the interaction between ethanol and classical modulators of GRP78 expression in NG108-15 neuroblastoma x glioma cells. We found that, in addition to increasing basal levels of GRP78 mRNA (''induction''), ethanol produced greater than additive increases in the induction of GRP78 mRNA by the ''classical'' GRP inducers A23187, brefeldin A, and thapsigargin (''potentiation''), Both the ethanol induction and potentiation responses modulated grp78 gene transcription as determined by stable transfection analyses with the rat grp78 promoter, Ethanol potentiated the action of all classical inducers of grp78 transcription that were studied, In contrast, co-treatment with the classical GRP inducers thapsigargin and tunicamycin produced only simple additive increases in grp78 promoter activity, Transient transfection studies with deletion mutants of the rat grp78 promoter showed that cis-acting promoter sequences required for ethanol induction differ from those mediating responses to classical GRP inducers, Furthermore, linker-scanning mutations of the grp78 promoter suggested that the ethanol potentiation response required a cis-acting promoter element different from those involved in induction by ethanol or classical inducing agents, While the ethanol induction response required 16-24 h to be detectable, ethanol potentiation of thapsigargin occurred within 6 h, The potentiation response also decayed rapidly after ethanol removal, In addition, the protein kinase A inhibitor R(p) cAMPS and protein phosphatase inhibitor okadaic acid both increased ethanol potentiation of thapsigargin while S-p-cAMPS, an activator of protein kinase A, decreased ethanol potentiation, Taken together, our findings suggest two mechanisms by which ethanol regulates grp78 transcription, both differing from the action of classical GRP inducers such as thapsigargin. One mechanism (potentiation) involves a protein phosphorylation cascade and potentiates the action of classical GRP inducers, In contrast, GRP78 induction by ethanol involves promoter sequences and a mechanistic pathway separate from that of the ethanol potentiation response or classical GRP78 inducers, These studies show that ethanol produces a novel and complex regulation of grp78 transcription which could be of particular importance during neuronal exposure to GRP-inducing stressors as might occur with central nervous system injury.	UNIV CALIF SAN FRANCISCO,ERNEST GALLO CLIN & RES CTR,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94110; UNIV COLORADO,DEPT PHARMACOL,DENVER,CO 80262	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; University of Colorado System; University of Colorado Denver					NIAAA NIH HHS [AA07750, AA06399] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007750, R01AA006399, R37AA006399, R29AA007750] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BARBE MF, 1988, SCIENCE, V241, P1817, DOI 10.1126/science.3175623; BUCK KJ, 1991, ALCOHOL CLIN EXP RES, V15, P460, DOI 10.1111/j.1530-0277.1991.tb00544.x; CAO XJ, 1995, J BIOL CHEM, V270, P494, DOI 10.1074/jbc.270.1.494; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DORNER AJ, 1992, EMBO J, V11, P1563, DOI 10.1002/j.1460-2075.1992.tb05201.x; GAYER GG, 1991, J BIOL CHEM, V266, P22279; Gordon A. S., 1992, G PROTEINS SIGNAL TR, P191; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; LEE AS, 1983, J BIOL CHEM, V258, P597; LEE KM, 1993, J BIOL CHEM, V268, P9945; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; LI WWF, 1993, J BIOL CHEM, V268, P12003; LIU ES, 1992, J BIOL CHEM, V267, P7128; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; MILES MF, 1991, J BIOL CHEM, V266, P2409; MILES MF, 1994, MOL PHARMACOL, V46, P873; MILES MF, 1992, BIOCHIM BIOPHYS ACTA, V1138, P268, DOI 10.1016/0925-4439(92)90003-6; MILES MF, 1993, P NATL ACAD SCI USA, V90, P10831, DOI 10.1073/pnas.90.22.10831; PRICE BD, 1992, J CELL PHYSIOL, V152, P545, DOI 10.1002/jcp.1041520314; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; ROY B, 1995, MOL CELL BIOL, V15, P2263; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; WOODEN SK, 1991, MOL CELL BIOL, V11, P5612, DOI 10.1128/MCB.11.11.5612	27	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2709	2716		10.1074/jbc.271.5.2709	http://dx.doi.org/10.1074/jbc.271.5.2709			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576245	hybrid			2022-12-25	WOS:A1996TT48800059
J	Kaibara, C; Matsui, T; Hisabori, T; Yoshida, M				Kaibara, C; Matsui, T; Hisabori, T; Yoshida, M			Structural asymmetry of F-1-ATPase caused by the gamma subunit generates a high affinity nucleotide binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOPHILIC BACTERIUM PS3; HEART MITOCHONDRIAL ATPASE; ESCHERICHIA-COLI F1-ATPASE; ISOLATED BETA-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; ALPHA-3-BETA-3 COMPLEX; SINGLE-SITE; INDIVIDUAL SUBUNITS; CATALYTIC SITES; COUPLING FACTOR	The alpha(3) beta(3) gamma and alpha(3)beta>(3) complexes of F-1-ATPase from a thermophilic Bacillus PS3 were compared in terms of interaction with trinitrophenyl analogs of ATP and ADP (TNP-ATP and TNP-ADP) that differed from ATP and ADP and did not destabilize the alpha(3) beta(3) complex. The results of equilibrium dialysis show that the alpha(3) beta(3) gamma complex has a high affinity nucleotide binding site and several low affinity sites, whereas the alpha(3) beta(3) complex has only low affinity sites. This is also supported from analysis of spectral change induced by TNP-ADP, which in addition indicates that this high affinity site is located on the beta subunit. Single-site hydrolysis of substoichiometric amounts of TNP-ATP by the alpha(3) beta(3) gamma complex is accelerated by the chase addition of excess ATP, whereas that by the alpha(3) beta(3) complex is not. We further examined the complexes containing mutant beta subunits (Y341L, Y341A, and Y341C). Surprisingly, in spite of very weak affinity of the isolated mutant beta subunits to nucleotides (Odaka, M., Kaibara, C., Amano, T., Matsui, T., Muneyuki, E., Ogasawara, K., Yutani, K., and Yoshida, M. (1994) J. Biochem. (Tokyo) 115, 789-796), a high affinity TNP-ADP binding site is generated on the beta subunit in the mutant alpha(3) beta(3) gamma complexes where single-site TNP-ATP hydrolysis can occur. ATP concentrations required for the chase acceleration of the mutant complexes are higher than that of the wild-type complex. The mutant alpha(3) beta(3) complexes, on the contrary, catalyze single-site hydrolysis of TNP-ATP rather slowly, and there is no chase acceleration. Thus, the gamma subunit is responsible for the generation of a high affinity nucleotide binding site on the beta subunit in F-1-ATPase where cooperative catalysis can proceed.	TOKYO INST TECHNOL,RESOURCES UTILIZAT RES LAB,YOKOHAMA,KANAGAWA 226,JAPAN	Tokyo Institute of Technology			Hisabori, Toru/E-5205-2014	Hisabori, Toru/0000-0003-2046-0277				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; ALOISE P, 1991, J BIOL CHEM, V266, P10368; BAR-ZVI D, 1992, Journal of Biological Chemistry, V267, P11029; BULLOUGH DA, 1986, J BIOL CHEM, V261, P14171; CROSS RL, 1982, J BIOL CHEM, V257, P2101; DUNN SD, 1980, J BIOL CHEM, V255, P113; FUJIYAMA Y, 1990, FEBS LETT, V271, P111, DOI 10.1016/0014-5793(90)80384-U; GAO F, 1995, J BIOL CHEM, V270, P9763, DOI 10.1074/jbc.270.17.9763; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3728; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; HARADA M, 1991, BIOCHIM BIOPHYS ACTA, V1056, P279, DOI 10.1016/S0005-2728(05)80059-3; HIRATSUKA T, 1982, BIOCHIM BIOPHYS ACTA, V719, P509, DOI 10.1016/0304-4165(82)90240-9; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; HISABORI T, 1986, J BIOCHEM-TOKYO, V100, P663, DOI 10.1093/oxfordjournals.jbchem.a121758; HISABORI T, 1992, J BIOL CHEM, V267, P4551; HISABORI T, 1984, PLANT CELL PHYSIOL, V25, P483; HISABORI T, 1994, J BIOCHEM-TOKYO, V115, P497, DOI 10.1093/oxfordjournals.jbchem.a124365; ISSARTEL JP, 1984, BIOCHEMISTRY-US, V23, P6591, DOI 10.1021/bi00321a048; JAULT JM, 1994, BIOCHEMISTRY-US, V33, P14979, DOI 10.1021/bi00254a005; KAGAWA Y, 1989, FEBS LETT, V249, P67, DOI 10.1016/0014-5793(89)80017-1; KAIBARA C, 1993, FEBS LETT, V321, P46, DOI 10.1016/0014-5793(93)80618-5; KASHO VN, 1989, BIOCHEMISTRY-US, V27, P6949; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; MIWA K, 1989, P NATL ACAD SCI USA, V86, P6484, DOI 10.1073/pnas.86.17.6484; ODAKA M, 1994, J BIOCHEM-TOKYO, V115, P789, DOI 10.1093/oxfordjournals.jbchem.a124410; ODAKA M, 1990, BIOCHEM BIOPH RES CO, V168, P372, DOI 10.1016/0006-291X(90)91718-8; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; OHTA S, 1980, J BIOCHEM-TOKYO, V87, P1607; OHTSUBO M, 1987, BIOCHEM BIOPH RES CO, V146, P705, DOI 10.1016/0006-291X(87)90586-9; RAO R, 1988, J BIOL CHEM, V263, P5569; SAIKA K, 1995, FEBS LETT, V368, P207, DOI 10.1016/0014-5793(95)00644-O; SATO M, 1995, J BIOCHEM-TOKYO, V117, P113, DOI 10.1093/oxfordjournals.jbchem.a124696; TURINA P, 1994, J BIOL CHEM, V269, P13465; WONG SY, 1984, BIOCHEMISTRY-US, V23, P5004, DOI 10.1021/bi00316a027; XUE ZX, 1987, FEBS LETT, V223, P391, DOI 10.1016/0014-5793(87)80325-3; YOHDA M, 1987, J BIOCHEM-TOKYO, V102, P875, DOI 10.1093/oxfordjournals.jbchem.a122128; YOKOYAMA K, 1989, J BIOL CHEM, V264, P21837; YOSHIDA M, 1977, P NATL ACAD SCI USA, V74, P936, DOI 10.1073/pnas.74.3.936; YOSHIDA M, 1990, J BIOL CHEM, V265, P2483; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480	42	69	69	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2433	2438		10.1074/jbc.271.5.2433	http://dx.doi.org/10.1074/jbc.271.5.2433			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576203	hybrid			2022-12-25	WOS:A1996TT48800017
J	Metherall, JE; Li, HJ; Waugh, K				Metherall, JE; Li, HJ; Waugh, K			Role of multidrug resistance P-glycoproteins in cholesterol biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL-REGULATED GENES; MUTANT HAMSTER-CELLS; DEHYDROEPIANDROSTERONE SULFATE; PLASMA DEHYDROEPIANDROSTERONE; TRANSCRIPTIONAL ACTIVATION; CYSTIC-FIBROSIS; FAMILY; EXPRESSION; TRANSPORT; RECEPTORS	Multidrug resistance (MDR) P-glycoproteins were first recognized for their ability to catalyze ATP-dependent efflux of cytotoxic agents from tumor cells when overexpressed. Despite extensive study, little is known about the normal substrate(s) and normal cellular function of these proteins, In the accompanying manuscript (Metherall, J. E., Waugh, K., and Li, H. (1996) J. Biol, Chem, 271, 2627-2633), we demonstrate that progesterone inhibits cholesterol biosynthesis, causing the accumulation of a number of cholesterol precursors. In the current manuscript, we use several criteria to show that the progesterone receptor is not involved in this inhibition, Rather, we demonstrate that progesterone inhibits cholesterol biosynthesis by interfering with MDR activity, We show that a steroid hormone's ability to inhibit cholesterol biosynthesis is correlated with: 1) its general hydrophobicity and 2) its ability to inhibit MDR activity, The only exception to this finding is beta-estradiol, which is a more potent inhibitor of cholesterol biosynthesis than expected based solely on hydrophobicity and MDR inhibition, We further demonstrate that nonsteroidal inhibitors of MDR also inhibit cholesterol biosynthesis, Since MDR activity is required for esterification of LDL-derived cholesterol (P. DeBry and J. E. Metherall, submitted for publication), we investigated the relationship between these phenomena and show that inhibition of cholesterol esterification does not cause inhibition of cholesterol biosynthesis and that inhibition of cholesterol biosynthesis does not cause inhibition of cholesterol esterification, We propose a model in which MDR is required for transport of sterols from the plasma membrane to the endoplasmic reticulum (ER), Inhibiting this transport prevents cholesterol esterification and cholesterol biosynthesis by preventing sterol substrates from reaching ER-resident enzymes.	UNIV UTAH,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah	Metherall, JE (corresponding author), UNIV UTAH,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.							ALTUVIA S, 1993, J BIOL CHEM, V268, P27127; ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; ARAD Y, 1989, ARTERIOSCLEROSIS, V9, P159, DOI 10.1161/01.ATV.9.2.159; BANIAHMAD A, 1993, J CELL BIOCHEM, V51, P151, DOI 10.1002/jcb.240510206; BARRETTCONNOR E, 1986, NEW ENGL J MED, V315, P1519, DOI 10.1056/NEJM198612113152405; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BUSCHMAN E, 1991, MOL CELL BIOL, V11, P595, DOI 10.1128/MCB.11.2.595; BUSCHMAN E, 1992, J BIOL CHEM, V267, P18093; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; CHIN JE, 1989, MOL CELL BIOL, V9, P3808, DOI 10.1128/MCB.9.9.3808; CYPRIANI B, 1988, BIOCHIM BIOPHYS ACTA, V972, P167, DOI 10.1016/0167-4889(88)90115-2; CYPRIANI B, 1988, J STEROID BIOCHEM, V31, P763, DOI 10.1016/0022-4731(88)90284-1; DAWIDOWICZ EA, 1987, ANNU REV BIOCHEM, V56, P43, DOI 10.1146/annurev.bi.56.070187.000355; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; Endicott J A, 1991, DNA Seq, V2, P89, DOI 10.3109/10425179109039677; EVANS MJ, 1993, MOL CELL BIOL, V13, P5175, DOI 10.1128/MCB.13.9.5175; GODSLAND IF, 1987, AM HEART J, V114, P1467, DOI 10.1016/0002-8703(87)90552-7; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GORDON GB, 1988, J CLIN INVEST, V82, P712, DOI 10.1172/JCI113652; HERRINGTON DM, 1990, J AM COLL CARDIOL, V16, P862; HSU SIH, 1989, J BIOL CHEM, V264, P12053; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; LANGE Y, 1988, J BIOL CHEM, V263, P9366; LANGE Y, 1994, J BIOL CHEM, V269, P3411; LING V, 1992, CANCER-AM CANCER SOC, V69, P2603, DOI 10.1002/1097-0142(19920515)69:10<2603::AID-CNCR2820691034>3.0.CO;2-E; LISCUM L, 1992, J LIPID RES, V33, P1239; LOVE RR, 1994, J NATL CANCER I, V86, P1534, DOI 10.1093/jnci/86.20.1534; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; Metherall JE, 1996, J BIOL CHEM, V271, P2627, DOI 10.1074/jbc.271.5.2627; METHERALL JE, 1991, J BIOL CHEM, V266, P12734; QIAN XD, 1990, J BIOL CHEM, V265, P18753; RAO US, 1994, BIOCHEM PHARMACOL, V48, P287, DOI 10.1016/0006-2952(94)90099-X; REINHART MP, 1987, J BIOL CHEM, V262, P9649; RIORDAN JR, 1989, SCIENCE, V245, P1066; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SARTORIUS CA, 1993, J BIOL CHEM, V268, P9262; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SLOWINSKASRZEDNICKA J, 1989, ATHEROSCLEROSIS, V79, P197; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; VANDERBLIEK AM, 1988, GENE, V71, P401, DOI 10.1016/0378-1119(88)90057-1; ZHANG L, 1994, J BIOL CHEM, V269, P15973	46	103	109	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2634	2640		10.1074/jbc.271.5.2634	http://dx.doi.org/10.1074/jbc.271.5.2634			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576233	hybrid			2022-12-25	WOS:A1996TT48800047
J	Saitoh, M; Nishitoh, H; Amagasa, T; Miyazono, K; Takagi, M; Ichijo, H				Saitoh, M; Nishitoh, H; Amagasa, T; Miyazono, K; Takagi, M; Ichijo, H			Identification of important regions in the cytoplasmic juxtamembrane domain of type I receptor that separate signaling pathways of transforming growth factor-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; TGF-BETA; CELL-PROLIFERATION; MEMBRANE-RECEPTOR; ACTIVIN; EXPRESSION; CLONING; TRANSDUCTION; INHIBITION; COMPLEX	Proteins in the transforming growth factor-beta (TGF-beta) superfamily exert their effects by forming heteromeric complexes of their type I and type II serine/threonine kinase receptors. The type I and type II receptors form distinct subgroups in the serine/threonine kinase receptor family based on the sequences of the kinase domains and the presence of a highly conserved region called the GS domain (or type I box) located just N-terminal to the kinase domain in the type I receptors. Recent studies have revealed that upon TGF-beta binding several serine and threonine residues in the GS domain of TGF-beta type I receptor (TPR-I) are phosphorylated by TGF-beta type II receptor (TPR-II) and that the phosphorylation of GS domain is essential for TGF-beta signaling. Here we investigated the role of cytoplasmic juxtamembrane region located between the transmembrane domain and the GS domain of T beta R-I by mutational analyses using mutant mink lung epithelial cells, which lack endogenous T beta R-I. Upon transfection, wild-type T beta R-I restored the TGF-beta signals for growth inhibition and production of plasminogen activator inhibitor-1 (PAI-1) and fibronectin. A deletion mutant, T beta R-I/JD1(Delta 150-181), which lacks the juxtamembrane region preceding the GS domain, bound TGF-beta in concert with T beta R-II and transduced a signal leading to production of PAI-1 but not growth inhibition. Recombinant receptors with mutations that change serine 172 to alanine (S172A) or threonine 176 to valine (T176V) were similar to wild-type T beta R-I in their abilities to bind TGF-beta, formed complexes with T beta R-II, and transduced a signal for PAI-1 and fibronectin. Similar to T beta R-I/JD1(Delta 150-181) however, these missense mutant receptors were impaired to mediate a growth inhibitory signal. These observations indicate that serine 172 and threonine 176 of T beta R-I are dispensable for extracellular matrix protein production but essential to the growth inhibition by TGF-beta.	JAPANESE FDN CANC RES,INST CANC,DEPT BIOCHEM,TOSHIMA KU,TOKYO 170,JAPAN; TOKYO MED & DENT UNIV,DEPT ORAL PATHOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,DEPT ORAL & MAXILLOFACIAL SURG 1,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,DEPT ORAL & MAXILLOFACIAL SURG 2,BUNKYO KU,TOKYO 113,JAPAN; LUDWIG INST CANC RES,CTR BIOMED,S-75124 UPPSALA,SWEDEN	Japanese Foundation for Cancer Research; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Ludwig Institute for Cancer Research				Nishitoh, Hideki/0000-0002-8652-4109; Ichijo, Hidenori/0000-0002-5005-6438				ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BOYD FT, 1989, J BIOL CHEM, V264, P2272; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FRANZEN P, 1995, BIOCHEM BIOPH RES CO, V207, P682, DOI 10.1006/bbrc.1995.1241; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FRANZEN P, 1993, EXP CELL RES, V207, P1, DOI 10.1006/excr.1993.1156; FROLIK CA, 1984, J BIOL CHEM, V259, P995; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LAIHO M, 1991, J BIOL CHEM, V266, P9108; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MATSUZAKI K, 1993, J BIOL CHEM, V268, P12719; MIYAZONO K, 1994, ADV IMMUNOL, V55, P181; OHTSUKI M, 1992, MOL CELL BIOL, V12, P261, DOI 10.1128/MCB.12.1.261; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; Ten Dijke Peter, 1994, Progress in Growth Factor Research, V5, P55, DOI 10.1016/0955-2235(94)90017-5; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1993, ONCOGENE, V8, P2879; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WIESER R, 1995, MOL CELL BIOL, V14, P2199; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	36	69	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2769	2775		10.1074/jbc.271.5.2769	http://dx.doi.org/10.1074/jbc.271.5.2769			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576253	hybrid			2022-12-25	WOS:A1996TT48800067
J	Echtermeyer, F; Schober, S; Poschl, E; vonderMark, H; vonderMark, K				Echtermeyer, F; Schober, S; Poschl, E; vonderMark, H; vonderMark, K			Specific induction of cell motility on laminin by alpha 7 integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; MELANOMA-CELLS; CYTOPLASMIC DOMAINS; TUMOR PROGRESSION; RECEPTOR; BINDING; FIBRONECTIN; EXPRESSION; MIGRATION	Laminin, the major glycoprotein of basement membranes, actively supports cell migration in development, tissue repair, tumor growth, metastasis, and other pathological processes. Previously we have shown that the locomotion of murine skeletal myoblasts is specifically and significantly enhanced on laminin but not on other matrix proteins. One of the major laminin receptors of myoblasts is the alpha 7 beta 1 integrin, which was first described in human MeWo melanoma cells and Rugli glioblastoma cells. In order to investigate and directly test the role of the alpha 7 integrin in cell migration on laminin, we expressed the murine alpha 7B splice variant in human 293 kidney cells and 530 melanoma cells which cannot migrate on laminin and are devoid of endogenous alpha 7. Northern blotting of the transfected cells showed that the alpha 7 mRNA was expressed efficiently, and the protein was detected on the cell surface by immunofluorescence and fluorescence-activated cell sorter analysis. Cell motility measurements by computer-assisted time-lapse videomicroscopy of the alpha 7-transfected cells revealed an 8-10-fold increase in motility on laminin-1 and its E8 fragment, but not on fibronectin. Mock-transfected cells did not migrate significantly on laminin or on fibronectin, Similarly, transmigration of alpha 7-transfected 293 cells through laminin coated filters in a Boyden chamber assay was significantly enhanced in comparison to mock-transfected cells, These findings prove that alpha 7 integrin expression confers a gain of function-motile phenotype to immobile cells and may be responsible for transduction of the laminin-induced cell motility.	UNIV ERLANGEN NURNBERG,INST EXPTL MED,D-91054 ERLANGEN,GERMANY	University of Erlangen Nuremberg								ALBELDA SM, 1993, LAB INVEST, V68, P4; ALBINI A, 1987, J CELL BIOL, V105, P1867, DOI 10.1083/jcb.105.4.1867; BISCHOFF R, 1986, DEV BIOL, V115, P129, DOI 10.1016/0012-1606(86)90234-4; BODARY SC, 1990, J BIOL CHEM, V265, P5938; CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRIST B, 1983, ANAT EMBRYOL, V166, P87, DOI 10.1007/BF00317946; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COLLO G, 1993, J BIOL CHEM, V268, P19019; DEWEL GO, 1994, MOL BIOL CELL, V5, P203; DURBEEJ M, 1995, J CELL BIOL, V130, P79, DOI 10.1083/jcb.130.1.79; GEE SH, 1993, J BIOL CHEM, V268, P14972; GOODMAN SL, 1989, J CELL BIOL, V109, P799, DOI 10.1083/jcb.109.2.799; GOODMAN SL, 1987, J CELL BIOL, V105, P589, DOI 10.1083/jcb.105.1.589; GOODMAN SL, 1993, MOL CELL ASPECTS BAS, P345; GULLBERG D, 1989, J BIOL CHEM, V264, P12686; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; KERN A, 1993, EUR J BIOCHEM, V215, P151, DOI 10.1111/j.1432-1033.1993.tb18017.x; KLEIN CE, 1991, J CELL BIOL, V115, P1427, DOI 10.1083/jcb.115.5.1427; KRAMER RH, 1991, CELL REGUL, V2, P805, DOI 10.1091/mbc.2.10.805; KRAMER RH, 1989, J BIOL CHEM, V264, P15642; LANGUINO LR, 1989, J CELL BIOL, V109, P2455, DOI 10.1083/jcb.109.5.2455; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LIOTTA LA, 1983, LAB INVEST, V49, P636; LIOTTA LA, 1986, CANCER RES, V46, P1; MCCARTHY JB, 1983, J CELL BIOL, V97, P772, DOI 10.1083/jcb.97.3.772; MCCARTHY JB, 1984, J CELL BIOL, V98, P1474, DOI 10.1083/jcb.98.4.1474; MCGARVEY ML, 1984, DEV BIOL, V105, P18, DOI 10.1016/0012-1606(84)90257-4; MELCHIORI A, 1995, EXP CELL RES, V219, P233, DOI 10.1006/excr.1995.1223; MENSING H, 1984, INT J CANCER, V33, P43, DOI 10.1002/ijc.2910330109; NATALI PG, 1993, INT J CANCER, V54, P68, DOI 10.1002/ijc.2910540112; OCALAN M, 1988, DEV BIOL, V125, P158, DOI 10.1016/0012-1606(88)90068-1; ROGERS SL, 1984, J CELL BIOL, V98, P212; SOBEL ME, 1993, SEMIN CANCER BIOL, V4, P311; SONG WK, 1993, J CELL SCI, V106, P1139; SONG WK, 1992, J CELL BIOL, V117, P643, DOI 10.1083/jcb.117.3.643; SONNENBERG A, 1990, J CELL BIOL, V110, P2145, DOI 10.1083/jcb.110.6.2145; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0; TRINKAUS JP, 1985, J NEUROSCI RES, V13, P1, DOI 10.1002/jnr.490130102; VANEVERCOOREN AB, 1982, J NEUROSCI RES, V8, P179; VONDERMARK H, 1991, J BIOL CHEM, V266, P23593; VONDERMARK K, 1987, METHOD ENZYMOL, V144, P490; WERB Z, 1989, J CELL BIOL, V109, P877, DOI 10.1083/jcb.109.2.877; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; ZIOBER BL, 1993, J BIOL CHEM, V268, P26773	49	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2071	2075		10.1074/jbc.271.4.2071	http://dx.doi.org/10.1074/jbc.271.4.2071			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567661	hybrid			2022-12-25	WOS:A1996TR32000043
J	Pemberton, LF; Rughetti, A; TaylorPapadimitriou, J; Gendler, SJ				Pemberton, LF; Rughetti, A; TaylorPapadimitriou, J; Gendler, SJ			The epithelial mucin MUC1 contains at least two discrete signals specifying membrane localization in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; MDCK CELLS; MONOCLONAL-ANTIBODIES; CYTOPLASMIC DOMAINS; PLASMA-MEMBRANE; KIDNEY-CELLS; EXPRESSION; EPISIALIN; ANTIGEN; PROTEIN	The MUC1 gene product (PEM, polymorphic epithelial mucin) is a cell-associated glycoprotein expressed on the apical surface of most simple secretory epithelia, The transmembrane and cytoplasmic domains of MUC1 have been shown to be highly conserved between mammalian species, and it has been shown that this molecule interacts with the actin cytoskeleton, Apical targeting signals in polarized cells have yet to be defined. The mechanism by which MUC1 is targeted and maintained on the apical surface is not known; correct localization, however, would be predicted to be crucial for function, In order to determine which domains of MUC1 were important for this localization, mutational analysis of the protein was undertaken, Using cytoplasmic tail deletion mutants, fusion proteins of MUC1 and CD2, and site directed mutagenesis, it could be shown that MUC1 appeared to contain at least two motifs involved in apical localization. The first was located in the extracellular domain and was sufficient to confer apical localization on the fusion protein. The second was the Cys-Gln-Cys (CQC) motif at the junction of the cytoplasmic and transmembrane domains, This sequence was necessary for surface expression. These results suggest that MUC1 contains two discrete motifs important in its apical localization.	IMPERIAL CANC RES FUND, LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND	Cancer Research UK					NATIONAL CANCER INSTITUTE [R01CA064389] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA64389] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACRES RB, 1993, J IMMUNOTHER, V14, P136, DOI 10.1097/00002371-199308000-00009; BRAGA VMM, 1992, DEVELOPMENT, V115, P427; BURCHELL J, 1989, INT J CANCER, V44, P691, DOI 10.1002/ijc.2910440423; BURCHELL J, 1993, EPITHELIAL CELL BIOL, V2, P155; CORBEIL D, 1992, J BIOL CHEM, V267, P2798; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GENDLER SJ, 1990, J BIOL CHEM, V265, P15286; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HENTOFT N, 1991, TRENDS BIOCHEM SCI, V15, P291; HILKENS J, 1988, J BIOL CHEM, V263, P4215; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; HILKENS J, 1984, INT J CANCER, V34, P197, DOI 10.1002/ijc.2910340210; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; LAFONT F, 1994, NATURE, V372, P801; LAN MS, 1990, J BIOL CHEM, V265, P15294; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; LISANTI MP, 1991, J CELL SCI, V99, P637; LITVINOV SV, 1993, J BIOL CHEM, V268, P21364; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; NEAME SJ, 1993, J CELL BIOL, V121, P1299, DOI 10.1083/jcb.121.6.1299; PARRY G, 1990, EXP CELL RES, V188, P302, DOI 10.1016/0014-4827(90)90174-9; PEMBERTON L, 1992, BIOCHEM BIOPH RES CO, V185, P167, DOI 10.1016/S0006-291X(05)80971-4; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; ROTH MG, 1987, J CELL BIOL, V104, P769, DOI 10.1083/jcb.104.3.769; SEWELL WA, 1986, P NATL ACAD SCI USA, V83, P8718, DOI 10.1073/pnas.83.22.8718; SPICER AP, 1995, J BIOL CHEM, V270, P30093; SPICER AP, 1991, J BIOL CHEM, V266, P15099; SPICER AP, 1995, IN PRESS MAMMALIAN G; SWALLOW DM, 1987, NATURE, V328, P82, DOI 10.1038/328082a0; TAYLORPAPADIMITRIOU J, 1981, INT J CANCER, V28, P17, DOI 10.1002/ijc.2910280104; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; VOS HL, 1991, BIOCHEM BIOPH RES CO, V181, P121, DOI 10.1016/S0006-291X(05)81390-7; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; WODARZ A, 1995, CELL, V82, P67, DOI 10.1016/0092-8674(95)90053-5; WRESCHNER DH, 1990, EUR J BIOCHEM, V189, P463, DOI 10.1111/j.1432-1033.1990.tb15511.x; ZARETSKY JZ, 1990, FEBS LETT, V265, P46, DOI 10.1016/0014-5793(90)80880-R; ZOTTER S, 1988, Cancer Reviews, V11-12, P55; ZRIHANLICHT S, 1994, EUR J BIOCHEM, V224, P787, DOI 10.1111/j.1432-1033.1994.00787.x; ZRIHANLICHT S, 1994, FEBS LETT, V356, P130, DOI 10.1016/0014-5793(94)01251-2	50	53	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2332	2340		10.1074/jbc.271.4.2332	http://dx.doi.org/10.1074/jbc.271.4.2332			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567697	hybrid			2022-12-25	WOS:A1996TR32000079
J	Ito, H; Ohtsuka, T; Tanaka, A				Ito, H; Ohtsuka, T; Tanaka, A			Conversion of chlorophyll b to chlorophyll alpha via 7-hydroxymethyl chlorophyll	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOPSEUDOMONAS-CAPSULATA; BIOSYNTHESIS; LIGHT; COTYLEDONS; MEMBRANES; PROTEIN; PLANTS; LEAVES; OXYGEN; GENES	Chlorophyll b is synthesized horn chlorophyll a by the oxidation of the methyl group on the ring B of the tetrapyrrole ring to the formyl group, Previously, we reported that chlorophyllide b could be converted to chlorophyll a in isolated cucumber etioplasts indicating the conversion of chlorophyll b to chlorophyll a, To identify the intermediate molecule, we used barley etioplasts instead of cucumber. Chlorophyll a and an additional pigment were found after incubation of chlorophyllide b with isolated barley etioplasts, The pigment has the same retention time and absorption spectrum as 7-hydroxymethyl chlorophyll, which has the hydroxymethyl group on ring B instead of the formyl group of chlorophyll b. Authentic 7-hydroxymethyl chlorophyll was prepared by reduction of chlorophyll b by NaBH4. Chlorophyll a accumulated during the incubation of 7-hydroxymethyl chlorophyllide with etioplasts. These findings indicate that chlorophyll b is converted to chlorophyll a via 7-hydroxymethyl chlorophyll. Chlorophyll b and 7-hydroxymethyl chlorophyll accumulated within a short period of incubation of chlorophyllide b with etioplasts. However, chlorophyll a accumulated with a concomitant decrease of chlorophyll b and 7-hydroxymethyl chlorophyll, These observations also suggest that chlorophyll b is converted to 7-hydroxymethyl chlorophyll and then to chlorophyll a. Both steps required ATP.			Ito, H (corresponding author), KYOTO UNIV, FAC SCI, DEPT BOT, KYOTO 60601, JAPAN.		Ito, Hisashi/A-4211-2012; Tanaka, Ayumi/D-9003-2012	Ito, Hisashi/0000-0002-2482-5870; 				ANDERSON JM, 1986, ANNU REV PLANT PHYS, V37, P93, DOI 10.1146/annurev.arplant.37.1.93; BAUER CE, 1993, J BACTERIOL, V175, P3919, DOI 10.1128/JB.175.13.3919-3925.1993; Beale S. I., 1990, BIOSYNTHESIS HEME CH, P287; BELLEMARE G, 1982, J BIOL CHEM, V257, P7762; BOLLIVAR DW, 1994, J MOL BIOL, V237, P622, DOI 10.1006/jmbi.1994.1260; CHUNAEV AS, 1991, PHOTOSYNTHETICA, V25, P291; HOLDEN M, 1961, BIOCHEM J, V78, P359, DOI 10.1042/bj0780359; HOLT AS, 1959, PLANT PHYSIOL, V34, P310, DOI 10.1104/pp.34.3.310; ITO H, 1994, J BIOL CHEM, V269, P22034; ITO H, 1993, ARCH BIOCHEM BIOPHYS, V306, P148, DOI 10.1006/abbi.1993.1492; JOO CN, 1973, CAN J BIOCHEM CELL B, V51, P1527, DOI 10.1139/o73-203; KUPKE DW, 1963, SCIENCE, V140, P49, DOI 10.1126/science.140.3562.49; MARRS B, 1981, J BACTERIOL, V146, P1003, DOI 10.1128/JB.146.3.1003-1012.1981; OMATA T, 1980, PHOTOCHEM PHOTOBIOL, V31, P183, DOI 10.1111/j.1751-1097.1980.tb03702.x; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; PORRA RJ, 1994, EUR J BIOCHEM, V219, P671, DOI 10.1111/j.1432-1033.1994.tb19983.x; PORRA RJ, 1993, FEBS LETT, V323, P31, DOI 10.1016/0014-5793(93)81442-3; RUDIGER W, 1980, EUR J BIOCHEM, V109, P193, DOI 10.1111/j.1432-1033.1980.tb04784.x; SCHNEEGURT MA, 1992, BIOCHEMISTRY-US, V31, P11677, DOI 10.1021/bi00162a002; SENGE MO, 1993, PHOTOCHEM PHOTOBIOL, V57, P189, DOI 10.1111/j.1751-1097.1993.tb02276.x; SHIOI Y, 1983, BIOCHIM BIOPHYS ACTA, V756, P127, DOI 10.1016/0304-4165(83)90033-8; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; TANAKA A, 1981, PLANT PHYSIOL, V68, P567, DOI 10.1104/pp.68.3.567; TANAKA A, 1983, PLANT CELL PHYSIOL, V24, P101, DOI 10.1093/oxfordjournals.pcp.a076502; TANAKA A, 1994, PLANTA, V192, P92; WALKER CJ, 1994, BIOCHEM J, V299, P277, DOI 10.1042/bj2990277; YEN HC, 1976, J BACTERIOL, V126, P619, DOI 10.1128/JB.126.2.619-629.1976; ZSEBO KM, 1984, CELL, V37, P937, DOI 10.1016/0092-8674(84)90428-8	28	105	110	13	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1475	1479		10.1074/jbc.271.3.1475	http://dx.doi.org/10.1074/jbc.271.3.1475			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576141	hybrid			2022-12-25	WOS:A1996TQ52500037
J	Wu, PG; Lee, KB; Lee, YC; Brand, L				Wu, PG; Lee, KB; Lee, YC; Brand, L			Solution conformations of a biantennary glycopeptide and a series of its exoglycosidase products from sequential trimming of sugar residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; TRIANTENNARY GLYCOPEPTIDE; COMPLEX; LECTIN; FLEXIBILITY	Linkages between sugar residues in branched oligo saccharides exhibit various degrees of flexibility. This flexibility, together with other forces, determines the overall solution conformation of oligosaccharides. We used the method of time-resolved resonance energy transfer to study the solution conformations of a biantennary glycopeptide and its partially trimmed products by exoglycosidases. The N-terminal of the glycopeptide was labeled with 2-naphthyl acetic acid as a fluorescent donor. Either terminal sugar residue, Gal6', on the branch bearing 6-linked Man (antenna 6'), or Neu5Ac on the branch bearing 3-linked Man (antenna 6) was labeled with 5-dimethylaminonaphthalene-1-sulfonyl as an acceptor. The distance and distance distributions between the terminals were measured. In the intact biantennary glycopeptide, the donor-acceptor distance distribution of antenna 6' is bimodal with a majority of the population in the extended conformation and that of antenna 6 in one very broad population. The Neu5Ac on antenna 6 is oriented toward the N-terminal at low temperature and adopts a more extended form at high temperature. The removal of individual sugar residues along one of the two antenna in the biantennary oligosaccharide has a small effect on the distance distribution of the remaining antenna for both antennae 6 and 6'. Together with previous studies of the triantennary glycopeptides (Rice, K. G., Wu, P. G., Brand, L., and Lee, Y. C. (1993) Biochemistry 32, 7264-7270), our results suggest that both steric hindrance and inter-residue hydrogen bonding are very important in the folding pattern in oligosaccharide structures.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University					NIDDK NIH HHS [DK 09970] Funding Source: Medline; NIGMS NIH HHS [GM 49994] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK009970, R01DK009970] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049994] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOURNE Y, 1992, J BIOL CHEM, V267, P197; BUSH CA, 1992, CURR OPIN STRUC BIOL, V2, P655; Carver JP, 1991, CURR OPIN STRUC BIOL, V1, P716, DOI 10.1016/0959-440X(91)90170-X; CUMMING DA, 1987, BIOCHEMISTRY-US, V26, P6676, DOI 10.1021/bi00395a017; DAUCHEZ M, 1992, BIOCHIMIE, V74, P63, DOI 10.1016/0300-9084(92)90185-H; HOMANS SW, 1987, BIOCHEMISTRY-US, V26, P6571, DOI 10.1021/bi00395a001; LEE KB, 1995, J BIOL CHEM, V271, P1462; RICE KG, 1991, BIOCHEMISTRY-US, V30, P6646, DOI 10.1021/bi00241a003; RICE KG, 1993, BIOCHEMISTRY-US, V32, P7264, DOI 10.1021/bi00079a024; RICE KG, 1993, CURR OPIN STRUC BIOL, V3, P669, DOI 10.1016/0959-440X(93)90048-P; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WRIGHT CS, 1992, J BIOL CHEM, V267, P14345; WU PG, 1991, P NATL ACAD SCI USA, V88, P9355, DOI 10.1073/pnas.88.20.9355; WU PG, 1992, BIOCHEMISTRY-US, V31, P7939, DOI 10.1021/bi00149a027	15	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1470	1474		10.1074/jbc.271.3.1470	http://dx.doi.org/10.1074/jbc.271.3.1470			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576140	hybrid			2022-12-25	WOS:A1996TQ52500036
J	Orlinick, JR; Chao, MV				Orlinick, JR; Chao, MV			Interactions of cellular polypeptides with the cytoplasmic domain of the mouse Fas antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS; EXPRESSION	The mouse Fas/APO-1 antigen represents a 45-kilodalton transmembrane receptor that initiates apoptosis by a poorly defined signaling mechanism, The cytoplasmic domain of Fas does not display any known enzymatic activities but is capable of interacting with a number of proteins that were identified recently using the yeast interactive cloning method. To investigate direct biochemical interactions from cellular lysates prepared from Fas-responsive cells, a series of recombinant glutathione S-transferase-mouse Fas fusion proteins representing different regions of the mouse Fas cytoplasmic domain was used, Polypeptides of 25, 50, and 70 kilodaltons were found to associate with the Fas intracellular domain, and this binding was stable in the presence of 1 M NaCl. These interactions were also detected using a mouse Fas fusion protein containing an lie to Asn mutation, which is responsible for a lymphoproliferative disorder in certain strains of mice (lpr(cg)). Furthermore, the binding of cellular proteins to Fas could be blocked upon incubation with a polyclonal antibody directed against the cytoplasmic domain of Fas. The strong association of cellular proteins with the cytoplasmic region implies that constitutive interactions may exist to regulate apoptotic signaling through the Fas antigen.			Orlinick, JR (corresponding author), NYU,COLL MED,DEPT CELL BIOL & ANAT,DIV HEMATOL ONCOL,550 1ST AVE,NEW YORK,NY 10012, USA.			Chao, Moses/0000-0002-6969-3744	NATIONAL CANCER INSTITUTE [R01CA056490] Funding Source: NIH RePORTER; NCI NIH HHS [CA56490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; Harlow E., 1988, ANTIBODIES LAB MANUA; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; RON D, 1992, BIOTECHNIQUES, V13, P866; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SONG HY, 1994, J BIOL CHEM, V269, P22492; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WONG GHW, 1994, J IMMUNOL, V152, P1751	24	7	8	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8627	8632		10.1074/jbc.271.15.8627	http://dx.doi.org/10.1074/jbc.271.15.8627			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621493	hybrid			2022-12-25	WOS:A1996UE73000024
J	Gee, NS; Brown, JP; Dissanayake, VUK; Offord, J; Thurlow, R; Woodruff, GN				Gee, NS; Brown, JP; Dissanayake, VUK; Offord, J; Thurlow, R; Woodruff, GN			The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha(2)delta subunit of a calcium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; DEPENDENT CA-2+ CHANNEL; 1,4-DIHYDROPYRIDINE RECEPTOR; RAT-BRAIN; STRUCTURAL CHARACTERIZATION; H-3 GABAPENTIN; ALPHA-2-SUBUNIT; PROTEIN; SITE; MICE	Gabapentin (1-(aminomethyl)cyclohexane acetic acid; Neurontin) is a novel anticonvulsant drug, with a mechanism of action apparently dissimilar to that of other antiepileptic agents. We report here the isolation and characterization of a [H-3]gabapentin binding protein from pig cerebral cortex membranes. The detergent-solubilized binding protein was purified 1022-fold, in a six-step column-chromatographic procedure, with a yield of 3.9%. The purified protein had an apparent subunit M(r) of 130,000, and was heavily glycosylated. The partial N-terminal amino acid sequence of the M(r) 130,000 polypeptide, EPFPSAVTIK, was identical to that reported for the alpha(2) delta subunit of the L-type Ca2+ channel from rabbit skeletal muscle (Hamilton, S. L., Hawkes, M. J., Brush, K., Cook, R., Chang, R. J., and Smilowitz, H. M. (1989) Biochemistry 28, 7820-7828). High levels of [H-3]gabapentin binding sites were found in membranes prepared from rat brain, heart and skeletal muscle. Binding of [H-3]gabapentin to COS-7 cells transfected with alpha(2) delta cDNA was elevated >10-fold over controls, consistent with the expression of alpha(2) delta protein, as measured by Western blotting. Finally, purified L-type Ca2+ channel complexes were fractionated, under dissociating conditions, on an ion-exchange column; [H-3]gabapentin binding activity closely followed the elution of the alpha(2) delta subunit. [H-3]Gabapentin is the first pharmacological agent described that interacts with an alpha(2) delta subunit of a voltage-dependent Ca2+ channel.	WARNER LAMBERT PARKE DAVIS, DIV PHARMACEUT RES, ANN ARBOR, MI 48105 USA	Pfizer	Gee, NS (corresponding author), CAMBRIDGE UNIV FORVIE SITE, PARKE DAVIS NEUROSCI RES CTR, ROBINSON WAY, CAMBRIDGE CB2 2QB, ENGLAND.			Offord, James/0000-0003-4180-0146				BARTOSZYK GD, 1986, CURRENT PROBLEMS EPI, V4, P147; BORSOTTO M, 1985, J BIOL CHEM, V260, P4255; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUST PF, 1993, NEUROPHARMACOLOGY, V32, P1089, DOI 10.1016/0028-3908(93)90004-M; CRAWFORD P, 1987, J NEUROL NEUROSUR PS, V50, P682, DOI 10.1136/jnnp.50.6.682; CZUCZWAR SJ, 1990, NEUROPHARMACOLOGY, V29, P943, DOI 10.1016/0028-3908(90)90145-H; DEJONGH KS, 1990, J BIOL CHEM, V265, P14738; DESMEDT LKC, 1975, ARZNEIMITTEL-FORSCH, V25, P1408; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; Gabapentin Chadwick D., 1992, RECENT ADV EPILEPSY, P211; GOA KL, 1993, DRUGS, V46, P409, DOI 10.2165/00003495-199346030-00007; GRAHAM RC, 1965, J HISTOCHEM CYTOCHEM, V13, P150, DOI 10.1177/13.2.150; HAMILTON SL, 1989, BIOCHEMISTRY-US, V28, P7820, DOI 10.1021/bi00445a044; HILL DR, 1993, EUR J PHARM-MOLEC PH, V244, P303, DOI 10.1016/0922-4106(93)90156-4; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; ISOM LL, 1994, NEURON, V12, P1183, DOI 10.1016/0896-6273(94)90436-7; JAY SD, 1991, J BIOL CHEM, V266, P3287; KIM HL, 1992, P NATL ACAD SCI USA, V89, P3251, DOI 10.1073/pnas.89.8.3251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; LEUNG AT, 1988, J BIOL CHEM, V263, P994; LITTLE HJ, 1986, LIFE SCI, V39, P2059, DOI 10.1016/0024-3205(86)90356-5; NAKAYAMA N, 1987, J BIOL CHEM, V262, P6572; OLES RJ, 1990, SOC NEUR ABSTR, V16, P321; PALMER GC, 1993, EPILEPSIA, V34, P372, DOI 10.1111/j.1528-1157.1993.tb02424.x; ROCK DM, 1993, EPILEPSY RES, V16, P89, DOI 10.1016/0920-1211(93)90023-Z; SHARP AH, 1989, J BIOL CHEM, V264, P2816; STEWART BH, 1993, PHARMACEUT RES, V10, P276, DOI 10.1023/A:1018951214146; SUMANCHAUHAN N, 1993, EUR J PHARM-MOLEC PH, V244, P293, DOI 10.1016/0922-4106(93)90155-3; TAKAHASHI M, 1987, P NATL ACAD SCI USA, V84, P5478, DOI 10.1073/pnas.84.15.5478; TAYLOR CP, 1993, ROY SOC MED INT CONG, V198, P13; TAYLOR CP, 1993, EPILEPSY RES, V14, P11, DOI 10.1016/0920-1211(93)90070-N; TAYLOR CP, 1994, NEUROLOGY S5, V44, pS10; THURLOW RJ, 1993, EUR J PHARM-MOLEC PH, V247, P341, DOI 10.1016/0922-4106(93)90204-M; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAMIL A W, 1991, Neurology, V41, P140; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q	37	960	1021	1	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5768	5776		10.1074/jbc.271.10.5768	http://dx.doi.org/10.1074/jbc.271.10.5768			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621444	hybrid			2022-12-25	WOS:A1996TZ28600070
J	Steinebach, V; deVries, S; Duine, JA				Steinebach, V; deVries, S; Duine, JA			Intermediates in the catalytic cycle of copper-quinoprotein amine oxidase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; SUBSTRATE OXIDATION; METHYLAMINE OXIDASE; ARTHROBACTER P1; MECHANISM; STEREOCHEMISTRY; COFACTOR; DOPAMINE; QUINONE; ENZYME	Investigations on the reduction of copper quinoprotein amine oxidases (EC 1.4.3.6) by substrate indicate that the nature of the reduced enzyme species formed varies, as judged from the spectroscopic data reported in the literature for different enzymes and substrates. The availability of substantial amounts of overproduced, homogeneous Escherichia coli amine oxidase (ECAO) enabled us to investigate this aspect with a number of different approaches: quantitative titration of enzyme with substrate, stopped-flow kinetic spectrophotometry (anaerobic and semianaerobic), EPR spectroscopy of stable intermediates in the catalytic cycle, and conversions with H2O2 as the oxidant. Reduction of ECAO by a variety of substrates led to spectra (UV/Vis, EPR) identical to those that have been ascribed to the semiquinone form of the topaquinone cofactor. The extent of semiquinone formation was enhanced in the presence of KCN, but the properties of the artificially induced semiquinone were different from those of the spontaneously induced one, as shown by the spectroscopic data and the reactivity toward O-2 and H2O2. On titrating ECAO at high concentrations with substrate, evidence was obtained that disproportionation takes place of the semiquinone formed, the reaction most probably proceeding via intermolecular electron transfer, leading to a topaquinone- and Cu1+-containing enzyme species that is able to perform substrate conversion. The latter, as well as OH ., is probably also formed when H2O2 replaces O-2 as oxidant, explaining why substrate conversion with concomitant enzyme inactivation occurs under this condition. Formation of the semiquinone was always preceded by that of a hitherto unknown species with an absorbance maximum at 400 nm. The structure proposed for this species is a protonated form of the aminoquinol cofactor, the Zwitter ionic structure being stabilized by amino acid residues in the active site having opposite charges. Based on the properties observed and the moment of appearance during conversions, a proposal is made for the sequence in which the three reduced enzyme species convert into each other.	DELFT UNIV TECHNOL,KLUYVER LAB BIOTECHNOL,2628 BC DELFT,NETHERLANDS	Delft University of Technology								BELLELLI A, 1991, J BIOL CHEM, V266, P20654; CASTELLANO FN, 1993, BIOCHIM BIOPHYS ACTA, V1157, P162, DOI 10.1016/0304-4165(93)90060-L; COLEMAN AA, 1989, J BIOL CHEM, V264, P19500; COLEMAN AA, 1991, J BIOL CHEM, V266, P6795; DEKKER RH, 1982, EUR J BIOCHEM, V125, P69, DOI 10.1111/j.1432-1033.1982.tb06652.x; DOOLEY DM, 1991, NATURE, V349, P262, DOI 10.1038/349262a0; DOOLEY DM, 1990, J AM CHEM SOC, V112, P2782, DOI 10.1021/ja00163a047; HARTMANN C, 1991, BIOCHEMISTRY-US, V30, P4605, DOI 10.1021/bi00232a035; HARTMANN C, 1990, FEBS LETT, V261, P441, DOI 10.1016/0014-5793(90)80611-L; HARTMANN C, 1993, BIOCHEMISTRY-US, V32, P2234, DOI 10.1021/bi00060a015; HARTMANN C, 1987, J BIOL CHEM, V262, P962; JANES SM, 1991, BIOCHEMISTRY-US, V30, P4599, DOI 10.1021/bi00232a034; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; KNOWLES PF, 1994, AMINE OXIDASES METAL, V30, P361; MANN PJG, 1955, BIOCHEM J, V59, P609, DOI 10.1042/bj0590609; McIntire W. S., 1993, COPPER CONTAINING AM, P97; MOENNELOCCOZ P, 1995, BIOCHEMISTRY-US, V34, P7020, DOI 10.1021/bi00021a013; MURE M, 1993, J AM CHEM SOC, V115, P7117, DOI 10.1021/ja00069a008; SUMMERS MC, 1979, BIOCHEMISTRY-US, V18, P1969, DOI 10.1021/bi00577a019; WARNCKE K, 1994, J AM CHEM SOC, V116, P4028, DOI 10.1021/ja00088a042; YU PH, 1988, BIOCHEM CELL BIOL, V66, P853, DOI 10.1139/o88-097	21	28	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5580	5588		10.1074/jbc.271.10.5580	http://dx.doi.org/10.1074/jbc.271.10.5580			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621418	hybrid			2022-12-25	WOS:A1996TZ28600044
J	Rajput, B; Shaper, NL; Shaper, JH				Rajput, B; Shaper, NL; Shaper, JH			Transcriptional regulation of murine beta 1,4-galactosyltransferase in somatic cells - Analysis of a gene that serves both a housekeeping and a mammary gland-specific function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; NUCLEAR PROTEINS; DNA-REPLICATION; MESSENGER-RNA; PROMOTER; MOUSE; SP1; EXPRESSION; CLONING; RAT	beta 1,4-Gralactosyltransferase (beta 4-GT) is a constitutively expressed enzyme that synthesizes the beta 4-N-acetyllactosamine structure in glycoconjugates. In mammals, beta 4-GT has been recruited for a second biosynthetic function, the production of lactose which occurs exclusively in the lactating mammary gland. In somatic tissues, the murine beta 4-GT gene specifies two mRNAs of 4.1 and 3.9 kilobases (kb), as a consequence of initiation at two different start sites similar to 200 base pairs apart. We have proposed that the region upstream of the 4.1-kb start site functions as a housekeeping promoter, while the region adjacent to the 3.9-kb start site functions primarily as a mammary gland-specific promoter (Harduin-Lepers, A., Shaper, J. H., and Shaper, N. L (1993) J. Biol. Chem. 268, 14348-14359). Using DNase I footprinting and electrophoretic mobility shift assays, we show that the region immediately upstream of the 4.1-kb start site is occupied mainly by the ubiquitous factor Sp1. In contrast, the region adjacent to the 3.9-kb start site is bound by multiple proteins which include the tissue-restricted factor AP2, a mammary gland-specific form of CTF/NF1, Sp1, as well as a candidate negative regulatory factor that represses transcription from the 3.9-kb start site. These data experimentally support our conclusion that the 3.9-kb start site has been introduced into the mammalian beta 4-GT gene to accommodate the recruited role of beta 4-GT in lactose biosynthesis.	JOHNS HOPKINS UNIV,SCH MED,CTR ONCOL,CELL STRUCT & FUNCT LAB,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University					NATIONAL CANCER INSTITUTE [R01CA045799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038310] Funding Source: NIH RePORTER; NCI NIH HHS [CA45799] Funding Source: Medline; NIGMS NIH HHS [GM38310] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODBECK U, 1967, J BIOL CHEM, V242, P1391; BURDON TG, 1994, MOL ENDOCRINOL, V8, P1528, DOI 10.1210/me.8.11.1528; CARDINAUX JR, 1994, J BIOL CHEM, V269, P32947; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; GIL G, 1988, P NATL ACAD SCI USA, V85, P8963, DOI 10.1073/pnas.85.23.8963; GRAVES RA, 1991, GENE DEV, V5, P428, DOI 10.1101/gad.5.3.428; GROBLER JA, 1994, ARCH BIOCHEM BIOPHYS, V313, P360, DOI 10.1006/abbi.1994.1399; GROENEN MAM, 1994, LIVEST PROD SCI, V38, P61, DOI 10.1016/0301-6226(94)90051-5; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HARDUINLEPERS A, 1992, GLYCOBIOLOGY, V2, P361, DOI 10.1093/glycob/2.4.361; Hill R L, 1968, Brookhaven Symp Biol, V21, P139; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; INOUE T, 1990, J BIOL CHEM, V265, P19065; IVANOV V I, 1990, Molekulyarnaya Biologiya (Moscow), V24, P1605; JACKSON SM, 1992, MOL CELL BIOL, V12, P2708, DOI 10.1128/MCB.12.6.2708; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LALLI E, 1994, J BIOL CHEM, V269, P17359; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LI S, 1995, MOL CELL BIOL, V15, P2063; LI S, 1994, J BIOL CHEM, V269, P14235; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LUBON H, 1988, BIOCHEM J, V256, P391, DOI 10.1042/bj2560391; Maxam A M, 1980, Methods Enzymol, V65, P499; MELLENTINMICHELOTTI J, 1994, J BIOL CHEM, V269, P31983; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; Moore DD, 1995, GLOB MOB SURV; Ohtsuki Mamitaro, 1993, Gene Expression, V3, P201; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; RAHUEL C, 1992, EMBO J, V11, P4095, DOI 10.1002/j.1460-2075.1992.tb05502.x; ROBIDOUX S, 1992, MOL CELL BIOL, V12, P3796, DOI 10.1128/MCB.12.9.3796; ROY RJ, 1991, BIOTECHNIQUES, V11, P770; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; SHAPER JH, 1992, CURR OPIN STRUC BIOL, V2, P701; SHAPER NL, 1994, J BIOL CHEM, V269, P25165; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1990, P NATL ACAD SCI USA, V87, P791, DOI 10.1073/pnas.87.2.791; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; TAMURA T, 1988, NUCLEIC ACIDS RES, V16, P11441, DOI 10.1093/nar/16.24.11441; TUGORES A, 1994, J BIOL CHEM, V269, P30789; TURKINGTON RW, 1968, J BIOL CHEM, V2423, P3382; VONDERAHE D, 1988, NUCLEIC ACIDS RES, V16, P7527, DOI 10.1093/nar/16.15.7527; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WATSON CJ, 1991, NUCLEIC ACIDS RES, V19, P6603, DOI 10.1093/nar/19.23.6603; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; YAVUZER U, 1994, MOL CELL BIOL, V14, P3494, DOI 10.1128/MCB.14.5.3494	61	79	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5131	5142						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617793	hybrid			2022-12-25	WOS:A1996TX69700083
J	Zhao, Y; Young, SL				Zhao, Y; Young, SL			Requirement of transforming growth factor-beta (TGF-beta) type II receptor for TGF-beta-induced proliferation and growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; COMPLEX; FACTOR-BETA-1; CELLS; DIFFERENTIATION; TGF-BETA-1; PROTEIN; CLONING; SYSTEM; LUNG	Growth regulation of fibroblasts is important for lung development and repair of lung injury. In this study, we investigated the role of transforming growth factor-beta (TGF-beta) type II receptor in the TGF-beta-dependent proliferative response of lung fibroblasts. TGF-beta stimulated the proliferation of adult lung fibroblasts at a low concentration (1 ng/ml), but inhibited the growth of fetal lung fibroblasts in a dose-dependent fashion (0.1-10 ng/ml). Cross-linking and Northern analysis demonstrated that the two lung fibroblast cell lines expressed the TGF-beta type I receptor (T beta RI) and type II receptor (T beta RII). We overexpressed in lung fibroblasts a truncated derivative of T beta RII that lacked the cytoplasmic serine/threonine kinase domain (T beta RII Delta K). T beta RII Delta K was a dominant-negative inhibitor of TGF-beta signal transduction blocking not only TGF-beta-induced mitogenic action upon adult lung fibroblasts but also TGF-beta-induced growth inhibition of fetal lung fibroblasts. The results indicate that the type II receptor is indispensable for mediating both the mitogenic and antiproliferative effects of TGF-beta upon lung fibroblasts.	VET ADM MED CTR,RES SERV,DURHAM,NC 27710	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Zhao, Y (corresponding author), DUKE UNIV,MED CTR,DEPT MED,POB 3177,DURHAM,NC 27710, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032188] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32188] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; CHEIFETZ S, 1987, CELL, V48, P409, DOI 10.1016/0092-8674(87)90192-9; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; HAFEZ MM, 1990, CELL GROWTH DIFFER, V1, P617; HEINE UI, 1990, DEVELOPMENT, V109, P29; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LIN HY, 1992, CELL, V68, P7775; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1992, CANCER SURV, V12, P81; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; PELTON RW, 1991, AM J RESP CELL MOL, V5, P522, DOI 10.1165/ajrcmb/5.6.522; PELTON RW, 1990, AM REV RESPIR DIS, V142, P531; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAN ZF, 1992, ONCOGENE, V7, P801; ZHAO Y, 1995, AM J PHYSIOL-LUNG C, V269, pL482, DOI 10.1152/ajplung.1995.269.4.L482; ZHAO Y, 1995, AM J PHYSIOL-LUNG C, V269, pL419, DOI 10.1152/ajplung.1995.269.3.L419	26	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2369	2372		10.1074/jbc.271.5.2369	http://dx.doi.org/10.1074/jbc.271.5.2369			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576191	hybrid			2022-12-25	WOS:A1996TT48800005
J	Mauxion, F; LeBorgne, R; MunierLehmann, H; Hoflack, B				Mauxion, F; LeBorgne, R; MunierLehmann, H; Hoflack, B			A casein kinase II phosphorylation site in the cytoplasmic domain of the cation-dependent mannose 6-phosphate receptor determines the high affinity interaction of the AP-1 Golgi assembly proteins with membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-II; RAPID INTERNALIZATION; CARBOXYL-TERMINUS; LYSOSOMAL-ENZYMES; BINDING-PROTEIN; SEQUENCE; CLATHRIN; SIGNAL; LOCALIZATION; ENDOCYTOSIS	The transport of proteins from the secretory to the endocytic pathway is mediated by carrier vesicles coated with the AP-1 Golgi assembly proteins and clathrin. The mannose 6-phosphate receptors (MPRs) are two major transmembrane proteins segregated into these transport vesicles, Together with the GTPase ARF-1, these cargo proteins are essential components for the efficient translocation of the cytosolic AP-1 onto membranes of the trans-Golgi network, the first step of clathrin coat assembly. MPR-negative fibroblasts have a low capacity of recruiting AP-1 which can be restored by re-expressing the MPRs in these cells. This property was used to identify the protein motif of the cation-dependent mannose 6-phosphate receptor (CD-MPR) cytoplasmic domain that is essential for these interactions. Thus, the affinity of AP-1 for membranes and in vivo transport of cathepsin D were measured for MPR-negative cells re-expressing various CD-MPR mutants. The results indicate that the targeting of lysosomal enzymes requires two distinct determinants at the carboxyl terminus of the CD-MPR cytoplasmic domain that are different from tyrosine-based endocytosis motifs, The first is a casein kinase II phosphorylation site (ESEER) that is essential for high affinity binding of AP-1 and therefore probably acts as a dominant determinant controlling CD-MPR sorting in the trans Golgi network. The second is the adjacent di-leucine motif (RLLPM), which, by itself, is not critical for AP-1 binding, but is absolutely required for a downstream sorting event.	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			HOFLACK, Bernard/AAZ-6668-2020; Munier-Lehmann, Hélène/Q-1867-2019; Munier-Lehmann, Helene/N-9889-2017; MAUXION, Fabienne/ABE-3546-2021	Munier-Lehmann, Hélène/0000-0001-7579-8561; Munier-Lehmann, Helene/0000-0001-7579-8561; MAUXION, Fabienne/0000-0003-0554-8211; LE BORGNE, Roland/0000-0001-6892-278X				BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; GEUZE HJ, 1985, J CELL BIOL, V101, P2253, DOI 10.1083/jcb.101.6.2253; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HEMER F, 1993, J BIOL CHEM, V268, P17108; HOFLACK B, 1993, ADV CELL MOL BIOL M, V1, P51; JADOT M, 1992, J BIOL CHEM, V267, P11069; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LeBorgne R, 1996, J BIOL CHEM, V271, P2162; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LUDWIG T, 1992, J BIOL CHEM, V267, P12211; LUDWIG T, 1994, EMBO J, V13, P3430, DOI 10.1002/j.1460-2075.1994.tb06648.x; MACDONALD RG, 1988, SCIENCE, V239, P1134, DOI 10.1126/science.2964083; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WAHEED A, 1990, BIOCHEMISTRY-US, V29, P2449, DOI 10.1021/bi00462a003; WAHEED A, 1990, EUR J BIOCHEM, V193, P47, DOI 10.1111/j.1432-1033.1990.tb19302.x	39	137	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2171	2178		10.1074/jbc.271.4.2171	http://dx.doi.org/10.1074/jbc.271.4.2171			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567675	hybrid			2022-12-25	WOS:A1996TR32000057
J	Byeon, MK; Westerman, MA; Maroulakou, IG; Henderson, KW; Suster, S; Zhang, XK; Papas, TS; Vesely, J; Willingham, MC; Green, JE; Schweinfest, CW				Byeon, MK; Westerman, MA; Maroulakou, IG; Henderson, KW; Suster, S; Zhang, XK; Papas, TS; Vesely, J; Willingham, MC; Green, JE; Schweinfest, CW			The down-regulated in adenoma (DRA) gene encodes an intestine-specific membrane glycoprotein	ONCOGENE			English	Article						colon; tumorigenesis; sulfate transporter; mucosa; differentiation	HUMAN COLORECTAL-CANCER; HUMAN-COLON CARCINOMA; HEPARAN-SULFATE; P-GLYCOPROTEIN; APC GENE; GASTRIC-CANCER; FREQUENT LOSS; EXPRESSION; MUTATIONS; IDENTIFICATION	The protein product of the DRA gene, a gene whose expression is down-regulated in colon adenomas and adenocarcinomas, is a membrane glycoprotein and a member of a family of sulfate transporters. It is expressed in the intestinal tract (duodenum, ileum, cecum, distal colon), but not in the esophagus or stomach, DRA mRNA expression is restricted to the mucosal epithelium, and DRA protein expression is further limited to the columnar epithelial cells, particularly to the brush border, Consistent with its expression in the differentiated columnar epithelium of the adult human colon, DRA is first expressed in the midgut of developing mouse embryos at day 16.5, corresponding with the time of differentiation of the epithelium of the small intestine, A model for the structure of the DRA protein is proposed and its possible role in colon tumorigenesis is discussed.	MED UNIV S CAROLINA,CTR MOLEC & STRUCT BIOL,HOLLINGS CANC CTR,CHARLESTON,SC 29425; NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702; MT SINAI MED CTR,DEPT PATHOL & LAB MED,MIAMI BEACH,FL 33140; UNIV MIAMI,SCH MED,MIAMI,FL 33140; MED UNIV S CAROLINA,DEPT PATHOL & LAB MED,CHARLESTON,SC 29425	Medical University of South Carolina; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mount Sinai Medical Center; University of Miami; Medical University of South Carolina								ABBASI AM, 1993, EUR J CANCER, V29A, P1995, DOI 10.1016/0959-8049(93)90461-N; AUGENLICHT LH, 1991, P NATL ACAD SCI USA, V88, P3286, DOI 10.1073/pnas.88.8.3286; BISSIG M, 1994, J BIOL CHEM, V269, P3017; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; DAMICO D, 1992, CANCER RES, V52, P1996; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; ELDEIRY WS, 1991, P NATL ACAD SCI USA, V88, P3470, DOI 10.1073/pnas.88.8.3470; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ERISMAN MD, 1985, MOL CELL BIOL, V5, P1969, DOI 10.1128/MCB.5.8.1969; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLEY GG, 1989, ONCOGENE, V4, P963; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; FRANSSON LA, 1981, J BIOL CHEM, V256, P3044; HARLOW E, 1988, ANTIBODIES LABORATOR; HARPER JW, 1993, CELL, V75, P805; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; HORII A, 1992, CANCER RES, V52, P3231; HORII A, 1992, CANCER RES, V52, P6696; JACOBY RF, 1994, GENOMICS, V22, P381, DOI 10.1006/geno.1994.1399; KARTNER N, 1985, NATURE, V316, P820, DOI 10.1038/316820a0; KAWAKAMI H, 1981, BIOCHIM BIOPHYS ACTA, V646, P161, DOI 10.1016/0005-2736(81)90283-2; KOI M, 1994, CANCER RES, V54, P4308; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; MULDER JWR, 1994, LANCET, V344, P1470, DOI 10.1016/S0140-6736(94)90290-9; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PROLLA TA, 1994, SCIENCE, V265, P1092; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROBINSON J, 1984, J CELL BIOL, V98, P946, DOI 10.1083/jcb.98.3.946; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SCHWEINFEST CW, 1993, P NATL ACAD SCI USA, V90, P4166, DOI 10.1073/pnas.90.9.4166; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SIKORA K, 1987, CANCER-AM CANCER SOC, V59, P1289, DOI 10.1002/1097-0142(19870401)59:7<1289::AID-CNCR2820590710>3.0.CO;2-O; SILBERG DG, 1995, J BIOL CHEM, V270, P11897, DOI 10.1074/jbc.270.20.11897; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAGUCHI T, 1994, GENOMICS, V20, P147; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; THOMPSON AM, 1993, BRIT J CANCER, V68, P64, DOI 10.1038/bjc.1993.287; UCHINO S, 1992, CANCER RES, V52, P3099; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WIELENGA VJM, 1993, CANCER RES, V53, P4754; WINTERBOURNE DJ, 1981, J BIOL CHEM, V256, P4310; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; ZHANG JT, 1991, J BIOL CHEM, V266, P18224	50	80	80	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					387	396						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570216				2022-12-25	WOS:A1996TR53800018
J	Cowell, JK; Bia, B; Akoulitchev, A				Cowell, JK; Bia, B; Akoulitchev, A			A novel mutation in the promotor region in a family with a mild form of retinoblastoma indicates the location of a new regulatory domain for the RB1 gene	ONCOGENE			English	Article						RB1 gene; promoter; mutation	ONCOGENIC POINT MUTATIONS; HEREDITARY RETINOBLASTOMA; PENETRANCE; IDENTIFICATION; TRANSCRIPTION; CHROMOSOME-13; GERMLINE; LINKAGE	We describe a family segregating the retinoblastoma phenotype where the affected individuals have only unifocal tumours and where linkage analysis has identified unaffected mutant gene carriers. DNA from members of this 'low penetrance' pedigree was subjected to an exon-by-exon SSCP analysis of the RB1 gene, No mutations were found in the 27 exons of the coding region but an SSCP band shift was seen for PCR products covering the RB1 promotor region. Sequencing identified a G-->C change within a GGGCGG motif which is the core of the recognition sequence of the SP1 transcription factor. Electromobility shift assays demonstrated that SP1 does not bind to oligomers from this region of the RB1 promotor but bandshifts were seen for an, as yet, unidentified protein(s) which was not seen using an oligomer containing the G-->C mutation. Thus, identification of a naturally occurring mutation in a family with only 'mild' phenotypes has identified another regulatory sequence in the RB1 promotor which binds an endogenous cellular protein(s). Identification of this protein should allow a better understanding of the control of expression of the RB1 gene.	INST CHILD HLTH,IMPERIAL CANC RES FUND,ONCOL GRP,LONDON WC1N 1EH,ENGLAND; ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,RES LABS,HOWARD HUGHES MED INST,PISCATAWAY,NJ 08854	Cancer Research UK; University of London; University College London; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Cowell, JK (corresponding author), CLEVELAND CLIN FDN,RES INST,DEPT NEUROSCI,9500 EUCLID AVE,NC30,CLEVELAND,OH 44195, USA.			Cowell, John/0000-0002-2079-5950				BLANQUET V, 1993, HUM MOL GENET, V2, P975, DOI 10.1093/hmg/2.7.975; CAVANEE WK, 1983, NATURE, V305, P779; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; CONNOLLY MJ, 1983, HUM GENET, V65, P122, DOI 10.1007/BF00286647; Cowell John K., 1994, European Journal of Human Genetics, V2, P281; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAPER GJ, 1992, BRIT J CANCER, V66, P211, DOI 10.1038/bjc.1992.244; DRYJA TP, 1993, AM J HUM GENET, V52, P1122; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; HOGG A, 1992, ONCOGENE, V7, P1445; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KRATZKE RA, 1994, ONCOGENE, V9, P1321; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; OHTANIFUJITA N, 1994, ONCOGENE, V9, P1703; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; ONADIM Z, 1991, BRIT J OPHTHALMOL, V75, P147, DOI 10.1136/bjo.75.3.147; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; SHIMIZU T, 1994, AM J HUM GENET, V54, P793; SPARKES RS, 1983, SCIENCE, V219, P971, DOI 10.1126/science.6823558; VOGEL F, 1979, HUM GENET, V52, P1; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; YUNIS JJ, 1978, AM J DIS CHILD, V132, P161, DOI 10.1001/archpedi.1978.02120270059012	27	43	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					431	436						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570221				2022-12-25	WOS:A1996TR53800023
J	Loughney, K; Martins, TJ; Harris, EAS; Sadhu, K; Hicks, JB; Sonnenburg, WK; Beavo, JA; Ferguson, K				Loughney, K; Martins, TJ; Harris, EAS; Sadhu, K; Hicks, JB; Sonnenburg, WK; Beavo, JA; Ferguson, K			Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; DEPENDENT PHOSPHODIESTERASE; BOVINE BRAIN; CAMP-PHOSPHODIESTERASE; AMP PHOSPHODIESTERASE; SMOOTH-MUSCLE; PROTEINASE-A; GENE	cDNAs corresponding to two human calcium, calmodulin (CaM)-regulated 3',5'-cyclic nucleotide phosphodiesterases (PDEs) were isolated, One, Hcam1 (PDE1A3), corresponds to the bovine 61-kDa CaM PDE (PDE1A2), The second, Hcam3 (PDE1C), represents a novel phosphodiesterase gene, Hcam1 encodes a 535-amino acid protein that differs most notably from the bovine 61-kDa CaM PDE by the presence of a 14-amino acid insertion and a divergent carboxyl terminus, RNase protection studies indicated that Hcam1 is represented in human RNA from several tissues, including brain, kidney, testes, and heart, Two carboxyl-terminal splice variants for Hcam3 were isolated, One, Hcam3b (PDE1C1), encodes a protein 634 amino acids (72 kDa) in length, The other, Hcam3a (PDE1C3), diverges from Hcam3b 4 amino acids from the carboxyl terminus of Hcam3b, and extends an additional 79 amino acids, All the cDNAs isolated for Hcam3a are incomplete; they do not include the 5'-end of the open reading frame, Northern analysis revealed that both splice variants were expressed in several tissues, including brain and heart, and that there may be additional splice variants, Amino-truncated recombinant proteins were expressed in yeast and characterized biochemically, Hcam3a has a high affinity for both cAMP and cGMP and thus has distinctly different kinetic parameters from Hcam1, which has a higher affinity for cGMP than for cAMP. Both PDE1C enzymes were inhibited by isobutylmethylxanthine, 8-methoxymethyl isobutylmethylxanthine, zaprinast, and vinpocetine.	UNIV WASHINGTON, SCH MED, DEPT PHARMACOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	Loughney, K (corresponding author), ICOS CORP, 22021 20TH AVE SE, BOTHELL, WA 98021 USA.				NHLBI NIH HHS [HL44948] Funding Source: Medline; NIDDK NIH HHS [DK21723] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021723] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN HS, 1992, ADV SEC MESS PHOSPH, V25, P271; AMMERER G, 1986, MOL CELL BIOL, V6, P2490, DOI 10.1128/MCB.6.7.2490; ANDRENYAK DM, 1982, FED PROC, V41, P1728; BEAVO JA, 1990, TRENDS PHARMACOL SCI, V11, P150, DOI 10.1016/0165-6147(90)90066-H; BENTLEY JK, 1992, J BIOL CHEM, V267, P18676; BOLGER G, 1993, MOL CELL BIOL, V13, P6558, DOI 10.1128/MCB.13.10.6558; BORISY FF, 1992, J NEUROSCI, V12, P915; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARBONNEAU H, 1991, BIOCHEMISTRY-US, V30, P7931, DOI 10.1021/bi00246a009; CHARBONNEAU H, 1990, CYCLIC NUCLEOTIDE PH, V2, P267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; ERICKSONVIITANEN S, 1987, METHOD ENZYMOL, V139, P455; FLORIO VA, 1994, BIOCHEMISTRY-US, V33, P8948, DOI 10.1021/bi00196a012; GEREMIA R, 1984, BIOCHEM J, V217, P693, DOI 10.1042/bj2170693; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HAGIWARA M, 1984, BIOCHEM PHARMACOL, V33, P453, DOI 10.1016/0006-2952(84)90240-5; IVY JM, 1986, MOL CELL BIOL, V6, P688, DOI 10.1128/MCB.6.2.688; Johnson R A, 1979, Adv Cyclic Nucleotide Res, V10, P135; JONES EW, 1977, GENETICS, V85, P23; KINCAID RL, 1985, J BIOL CHEM, V260, P9009; KRINKS MH, 1984, ADV CYCLIC NUCL PROT, V16, P31; LOUGHNEY K, 1989, CELL, V58, P1143, DOI 10.1016/0092-8674(89)90512-6; LUGNIER C, 1985, EUR J MED CHEM, V20, P121; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MICHAELI T, 1993, J BIOL CHEM, V268, P12925; NIKAWA JI, 1987, MOL CELL BIOL, V7, P3629, DOI 10.1128/MCB.7.10.3629; NOVACK JP, 1991, BIOCHEMISTRY-US, V30, P7940, DOI 10.1021/bi00246a010; ORRWEAVER TL, 1981, P NATL ACAD SCI-BIOL, V78, P6354, DOI 10.1073/pnas.78.10.6354; POLLI JW, 1992, P NATL ACAD SCI USA, V89, P11079, DOI 10.1073/pnas.89.22.11079; PRPIC V, 1993, ANAL BIOCHEM, V208, P155, DOI 10.1006/abio.1993.1022; PURVIS K, 1981, J BIOL CHEM, V256, P1434; REEVES ML, 1987, BIOCHEM J, V241, P535, DOI 10.1042/bj2410535; REPASKE DR, 1992, J BIOL CHEM, V267, P18683; ROSSI P, 1988, J BIOL CHEM, V263, P15521; Sambrook J, 1989, MOL CLONING LABORATO; SASS P, 1986, P NATL ACAD SCI USA, V83, P9303, DOI 10.1073/pnas.83.24.9303; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHARMA RK, 1994, BIOCHEM J, V299, P97, DOI 10.1042/bj2990097; SHENOLIKAR S, 1985, BIOCHEMISTRY-US, V24, P672, DOI 10.1021/bi00324a020; SKOOG B, 1986, TRAC-TREND ANAL CHEM, V5, P82, DOI 10.1016/0165-9936(86)80045-0; SONNENBURG WK, 1993, J BIOL CHEM, V268, P645; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; TSCHUMPER G, 1980, GENE, V10, P157, DOI 10.1016/0378-1119(80)90133-X; VANDERMEERS A, 1983, BIOCHEM J, V211, P341, DOI 10.1042/bj2110341; WANG JH, 1990, MOL PHARM CELL REGUL, V2, P19; WEISHAAR RE, 1986, BIOCHEM PHARMACOL, V35, P787, DOI 10.1016/0006-2952(86)90247-9; WELLS JN, 1988, METHOD ENZYMOL, V159, P489; WOOLFORD CA, 1993, J BIOL CHEM, V268, P8990; YAN C, 1995, P NATL ACAD SCI USA, V92, P9677, DOI 10.1073/pnas.92.21.9677	52	104	123	3	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					796	806		10.1074/jbc.271.2.796	http://dx.doi.org/10.1074/jbc.271.2.796			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557689	hybrid			2022-12-25	WOS:A1996TP88900032
J	Surette, MG; Levit, M; Liu, Y; Lukat, G; Ninfa, EG; Ninfa, A; Stock, JB				Surette, MG; Levit, M; Liu, Y; Lukat, G; Ninfa, EG; Ninfa, A; Stock, JB			Dimerization is required for the activity of the protein histidine kinase CheA that mediates signal transduction in bacterial chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PHOSPHOTRANSFERASE SYSTEM; SALMONELLA-TYPHIMURIUM; SENSORY TRANSDUCTION; PHOSPHATE REGULON; PHOSPHORYLATION; REGULATOR; COMPLEX; BINDING; AUTOPHOSPHORYLATION	The histidine protein kinase CheA plays an essential role in stimulus response coupling during bacterial chemotaxis. The kinase is a homodimer that catalyzes the reversible transfer of a gamma-phosphoryl group from ATP to the N-3 position of one of its own histidine residues. Kinetic studies of rates of autophosphorylation show a second order dependence on CheA concentrations at submicromolar levels that is consistent with dissociation of the homodimer into inactive monomers. The dissociation was confirmed by chemical cross-linking studies. The dissociation constant (CheA(2) <-> 2cheA; K-D = 0.2-0.4 mu M) was not affected by nucleotide binding, histidine phosphorylation, or binding of the response regulator, CheY. The turnover number per active site within a dimer (assuming 2 independent sites/dimer) at saturating ATP was approximately 10/min. The kinetics of autophosphorylation and ATP/ADP exchange indicated that the dissociation constants of ATP and ADP bound to CheA were similar (K-D values approximate to 0.2-0.3 mM), whereas ATP had a reduced affinity for CheA similar to P (K-D approximate to 0.8 mM) compared with ADP (K-D approximate to 0.3 mM). The rates of phosphotransfer from bound ATP to the phosphoaccepting histidine and from the phosphohistidine back to ADP seem to be essentially equal (k(cat) approximate to 10 min(-1)).	PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544; N DAKOTA STATE UNIV,DEPT CHEM,FARGO,ND 58105; UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	Princeton University; North Dakota State University Fargo; University of Michigan System; University of Michigan				Gottlin, Elizabeth/0000-0003-0886-0024	NIAID NIH HHS [AI20980] Funding Source: Medline; NIGMS NIH HHS [GM47460] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020980] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047460] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMEMURA M, 1990, J BACTERIOL, V172, P6300, DOI 10.1128/jb.172.11.6300-6307.1990; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1993, J BACTERIOL, V175, P2097, DOI 10.1128/JB.175.7.2097-2101.1993; CHAUVIN F, 1994, J BIOL CHEM, V269, P20263; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; CHERVITZ SA, 1995, BIOCHEMISTRY-US, V34, P9722, DOI 10.1021/bi00030a010; CONLEY MP, 1994, J BACTERIOL, V176, P3870, DOI 10.1128/JB.176.13.3870-3877.1994; GASSNER M, 1977, EUR J BIOCHEM, V75, P287, DOI 10.1111/j.1432-1033.1977.tb11528.x; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; KOFOID EC, 1991, J BACTERIOL, V173, P2116, DOI 10.1128/jb.173.6.2116-2119.1991; LICALSI C, 1991, J BIOL CHEM, V266, P19519; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MAKINO K, 1989, J MOL BIOL, V210, P551, DOI 10.1016/0022-2836(89)90131-9; MATHEIS G, 1984, INT J BIOCHEM, V16, P867, DOI 10.1016/0020-711X(84)90145-9; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; NINFA AJ, 1988, P NATL ACAD SCI USA, V85, P5492, DOI 10.1073/pnas.85.15.5492; NINFA EG, 1993, J BACTERIOL, V175, P7024, DOI 10.1128/jb.175.21.7024-7032.1993; NINFA EG, 1991, J BIOL CHEM, V266, P9764; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SCHUSTER SC, 1993, NATURE, V365, P343, DOI 10.1038/365343a0; SEGEL IH, 1975, ENZYME KINETICS BEHA, P847; SMITH RA, 1980, P NATL ACAD SCI-BIOL, V77, P5370, DOI 10.1073/pnas.77.9.5370; STOCK A, 1988, P NATL ACAD SCI USA, V85, P1403, DOI 10.1073/pnas.85.5.1403; STOCK A, 1985, P NATL ACAD SCI USA, V82, P7989, DOI 10.1073/pnas.82.23.7989; STOCK A, 1987, J BIOL CHEM, V262, P535; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; Stock JB, 1996, ESCHERICHIA COLI SAL; SWANSON RV, 1993, MOL MICROBIOL, V8, P435, DOI 10.1111/j.1365-2958.1993.tb01588.x; SWANSON RV, 1993, BIOCHEMISTRY-US, V32, P7623, DOI 10.1021/bi00081a004; TAWA P, 1994, BIOCHEMISTRY-US, V33, P7917, DOI 10.1021/bi00191a019; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; WILLIAMS RL, 1993, J MOL BIOL, V234, P1230, DOI 10.1006/jmbi.1993.1673; WOLFE AJ, 1993, P NATL ACAD SCI USA, V90, P1518, DOI 10.1073/pnas.90.4.1518; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057	41	127	128	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					939	945		10.1074/jbc.271.2.939	http://dx.doi.org/10.1074/jbc.271.2.939			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557708	hybrid			2022-12-25	WOS:A1996TP88900051
J	Cenciarelli, C; Wilhelm, KG; Guo, A; Weissman, AM				Cenciarelli, C; Wilhelm, KG; Guo, A; Weissman, AM			T cell antigen receptor ubiquitination is a consequence of receptor-mediated tyrosine kinase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR BETA-RECEPTOR; SIGNAL TRANSDUCTION; ZETA-CHAIN; LYMPHOCYTES-T; PHOSPHORYLATION; COMPLEX; PATHWAY; CD45; INHIBITOR; INVITRO	Engagement of the T cell antigen receptor results in both its phosphorylation and its ubiquitination. T cell antigen receptor ubiquitination was evaluated in Jurkat, a well characterized human T leukemia cell line. Treatment of cells with the tyrosine kinase inhibitor herbimycin A resulted in an inhibition of receptor ubiquitination, Consistent with this, pervanadate, which increases cellular tyrosine phosphorylation, enhanced receptor ubiquitination, A requirement for receptor-mediated tyrosine kinase activity for ubiquitination was confirmed in cells lacking the tyrosine kinase p56(lck) and also in cells that are defective in expression of CD45, a tyrosine phosphatase that regulates the activity of p56(lck). The need for tyrosine kinase activation for ubiquitination was not bypassed by directly activating protein kinase C and stimulating endocytosis of receptors. These observations establish ubiquitination of the T cell antigen receptor as a tyrosine kinase-dependent manifestation of transmembrane signaling and suggest a role for tyrosine phosphorylation in the ligand-dependent ubiquitination of mammalian transmembrane receptors.	NCI, NIH, DIV BASIC SCI, LAB IMMUNE CELL BIOL, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ABASTADO JP, 1995, J EXP MED, V182, P439, DOI 10.1084/jem.182.2.439; ALARCON B, 1988, NEW ENGL J MED, V319, P1203, DOI 10.1056/NEJM198811033191806; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; CAMBIER JC, 1995, IMMUNOL TODAY, V16, P110, DOI 10.1016/0167-5699(95)80105-7; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DAVIES AA, 1987, J BIOL CHEM, V262, P10918; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; EVANS GA, 1994, J BIOL CHEM, V269, P23407; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FRANK SJ, 1992, J BIOL CHEM, V267, P13656; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRABER M, 1992, INT IMMUNOL, V4, P1201, DOI 10.1093/intimm/4.11.1201; HOU D, 1994, J BIOL CHEM, V269, P14244; IMBERT V, 1994, BIOCHEM J, V297, P163, DOI 10.1042/bj2970163; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KONG SK, 1992, J BIOL CHEM, V267, P14189; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KOYASU S, 1992, J BIOL CHEM, V267, P3375; KRANGEL MS, 1987, J EXP MED, V165, P1141, DOI 10.1084/jem.165.4.1141; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; METZGER H, 1992, J IMMUNOL, V149, P1477; MEUER SC, 1983, J EXP MED, V157, P705, DOI 10.1084/jem.157.2.705; MINAMI Y, 1987, J BIOL CHEM, V262, P13342; MIYAZAWA K, 1994, BLOOD, V83, P137; MORI S, 1992, J BIOL CHEM, V267, P6429; MORI S, 1995, BIOCHEM BIOPH RES CO, V213, P32, DOI 10.1006/bbrc.1995.2094; MORI S, 1993, J BIOL CHEM, V268, P577; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PERI KG, 1994, CHEM IMMUNOL, V59, P19; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RELLAHAN BL, 1994, J EXP MED, V180, P1529, DOI 10.1084/jem.180.4.1529; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WEISSMAN AM, 1994, CHEM IMMUNOL, V59, P1; WEISSMAN AM, 1986, NATURE, V324, P480, DOI 10.1038/324480a0	54	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8709	8713		10.1074/jbc.271.15.8709	http://dx.doi.org/10.1074/jbc.271.15.8709			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621503	hybrid			2022-12-25	WOS:A1996UE73000034
J	Chung, U; Igarashi, T; Nishishita, T; Iwanari, H; Iwamatsu, A; Suwa, A; Mimori, T; Hata, K; Ebisu, S; Ogata, E; Fujita, T; Okazaki, T				Chung, U; Igarashi, T; Nishishita, T; Iwanari, H; Iwamatsu, A; Suwa, A; Mimori, T; Hata, K; Ebisu, S; Ogata, E; Fujita, T; Okazaki, T			The interaction between Ku antigen and REF1 protein mediates negative gene regulation by extracellular calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARATHYROID-HORMONE GENE; DNA-BINDING ACTIVITY; ESCHERICHIA-COLI; PURIFICATION; POLYPEPTIDES; MECHANISM; KINASE; REPAIR; ENDS	Through the specific binding of a negative calcium-responsive element to its binding protein in response to extracellular Ca (Ca-e(2+)), negative calcium-responsive element-bearing genes, such as the human parathyroid hormone gene, are negatively regulated by Ca-e(2+). The Ku antigen mediated negative gene regulation by Ca-e(2+) by interacting with a redox factor protein, REF1. Although sequence-nonspecific DNA binding activity of the Ku antigen has been well characterized, the mechanism of its sequence-specific DNA binding remained obscure. Here, we report that the specific binding of the Ku antigen to another protein, REF1, leads to DNA-protein complex formation with a novel sequence specificity and thereby regulates gene expression.	UNIV TOKYO,SCH MED,DEPT INTERNAL MED 4,ENDOCRINE GENET & HYPERTENS UNIT,BUNKYO KU,TOKYO 112,JAPAN; INST IMMUNOL,BUNKYO KU,TOKYO 112,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,YOKOHAMA,KANAGAWA 236,JAPAN; TOKYO METROPOLITAN OHTSUKA HOSP,TOSHIMA KU,TOKYO 170,JAPAN; KEIO UNIV,SCH MED,DEPT INTERNAL MED,SHINJUKU KU,TOKYO 160,JAPAN; MITSUBISHI KAGAKU BIOCLIN LAB INC,ITABASHI KU,TOKYO 174,JAPAN; HIGETA SHOYU CO LTD,RES LAB,CHOSHI,CHIBA 288,JAPAN; CANC INST HOSP,TOSHIMA KU,TOKYO 170,JAPAN; UNIV TOKYO,SCH MED,HLTH SERV CTR,BUNKYO KU,TOKYO 112,JAPAN	University of Tokyo; Kirin Brewery Company Limited; Keio University; Mitsubishi Kagaku Bio-Clinical Laboratories; Japanese Foundation for Cancer Research; University of Tokyo								BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; DVIR A, 1993, J BIOL CHEM, V268, P10440; GENERSCH E, 1995, EMBO J, V14, P791, DOI 10.1002/j.1460-2075.1995.tb07057.x; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; GRIFFITH AJ, 1992, J BIOL CHEM, V267, P331; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HOFF CM, 1994, P NATL ACAD SCI USA, V91, P762, DOI 10.1073/pnas.91.2.762; INOMATA Y, 1992, ANAL BIOCHEM, V206, P109, DOI 10.1016/S0003-2697(05)80018-1; KIM D, 1995, J BIOL CHEM, V270, P15277, DOI 10.1074/jbc.270.25.15277; KNUTH MW, 1990, J BIOL CHEM, V265, P17911; LI GC, 1995, P NATL ACAD SCI USA, V92, P4512, DOI 10.1073/pnas.92.10.4512; MESSIER H, 1993, P NATL ACAD SCI USA, V90, P2685, DOI 10.1073/pnas.90.7.2685; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P375; NIU H, 1994, P NATL ACAD SCI USA, V91, P9101, DOI 10.1073/pnas.91.19.9101; OKAZAKI T, 1991, J BIOL CHEM, V266, P21903; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; OKAZAKI T, 1992, J CLIN INVEST, V89, P1268, DOI 10.1172/JCI115711; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; REEVES WH, 1989, J BIOL CHEM, V264, P5047; ROBERTS MR, 1994, P NATL ACAD SCI USA, V91, P6354, DOI 10.1073/pnas.91.14.6354; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P5519, DOI 10.1093/nar/19.20.5519; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	29	65	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8593	8598		10.1074/jbc.271.15.8593	http://dx.doi.org/10.1074/jbc.271.15.8593			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621488	hybrid			2022-12-25	WOS:A1996UE73000019
J	Gretch, DG; Sturley, SL; Wang, L; Lipton, BA; Dunning, A; Grunwald, KAA; Wetterau, JR; Yao, ZM; Talmud, P; Attie, AD				Gretch, DG; Sturley, SL; Wang, L; Lipton, BA; Dunning, A; Grunwald, KAA; Wetterau, JR; Yao, ZM; Talmud, P; Attie, AD			The amino terminus of apolipoprotein B is necessary but not sufficient for Microsomal triglyceride transfer protein responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; LIPID TRANSFER PARTICLE; HEP G2 CELLS; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODIES; PHOSPHOLIPID-BILAYERS; TRANSLOCATION; SECRETION; SEQUENCE; B-100	Human apolipoprotein (apo) B mediates the formation of neutral Lipid-containing lipoproteins in the liver and intestine. The association of apoB with lipid is thought to be promoted by the microsomal triglyceride transfer protein complex. We have reconstituted lipoprotein assembly in an insect cell line that normally does not support this process. Expression of human microsomal triglyceride transfer protein (MTP) and apolipoprotein B48 (apoB48) together enabled Sf-21 insect cells to secrete similar to 60-fold more lipoprotein-associated triacylglycerol than control cells. This dramatic effect demonstrates that effective partitioning of triacylglycerol into the secretory pathway requires an endoplasmic reticulum-associated neutral lipid transporter (provided by MTP) and an apolipoprotein to shuttle the lipid through the pathway. Expression of the human apoB48 gene in insect cells resulted in secretion of the protein product, Including both MTP subunits with apoB48 and oleic acid specifically increased apoB48 secretion 8-fold over individual subunits alone. To assess whether specific regions of apoB are necessary for MTP responsiveness, nine apoB segments were expressed. These included NH2-terminal segments as well as internal and COOH-terminal regions of apoB fused with a heterologous signal sequence, ApoB segments containing the NH2-terminal 17% of the protein mere secreted and responded to NTP activity; however, a segment containing only the NH2-terminal 17% of the protein was not significantly responsive to MTP. Segments lacking the NH2 terminus were not MTP-responsive, and five of six of these proteins were trapped intracellularly but, in certain cases, could be rescued by fusion to apoB17. These results suggest that the NH2 terminus of apoB is necessary but not sufficient for MTP responsiveness.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT COMPARAT BIOSCI,MADISON,WI 53706; UNIV LONDON UNIV COLL,DEPT MED,LONDON WC1E 6BT,ENGLAND; BRISTOL MYERS SQUIBB,DEPT METAB DIS,PRINCETON,NJ 08543; UNIV OTTAWA,INST HEART,OTTAWA,ON K1Y 4E9,CANADA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of London; University College London; Bristol-Myers Squibb; University of Ottawa; University of Ottawa Heart Institute			Talmud, Philippa J/C-4402-2008	Talmud, Philippa/0000-0002-5560-1933	NHLBI NIH HHS [HL37251] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037251] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDO S, 1990, BIOCHIM BIOPHYS ACTA, V1043, P289, DOI 10.1016/0005-2760(90)90029-W; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BONNARDEL JA, 1995, J BIOL CHEM, V270, P28892, DOI 10.1074/jbc.270.48.28892; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1992, J BIOL CHEM, V267, P9858; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHEN GC, 1989, BIOCHEMISTRY-US, V28, P2477, DOI 10.1021/bi00432a019; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; CHOI SY, 1995, J BIOL CHEM, V270, P8081, DOI 10.1074/jbc.270.14.8081; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; DAVIS RA, 1982, J BIOL CHEM, V257, P2634; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DU EZ, 1994, J BIOL CHEM, V269, P24169; FOLCH J, 1957, J BIOL CHEM, V226, P497; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; HAMILTON JA, 1991, J BIOL CHEM, V266, P1177; HEINEMANN T, 1994, J LIPID RES, V35, P2200; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; JAMIL H, 1995, J BIOL CHEM, V270, P6549, DOI 10.1074/jbc.270.12.6549; KELLEY JL, 1986, METHOD ENZYMOL, V128, P170; KIM JS, 1993, PROTEIN SCI, V2, P348; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KRUL ES, 1988, J LIPID RES, V29, P937; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; MARCEL YL, 1982, J BIOL CHEM, V257, P13165; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MARSH JB, 1966, J LIPID RES, V7, P574; MILLER DW, 1986, GENETIC ENG PRINCIPL, V8, P277; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; PEASE RJ, 1990, J BIOL CHEM, V265, P553; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; PRASAD SV, 1986, J BIOL CHEM, V266, P17174; RICCI B, 1995, J BIOL CHEM, V270, P14281, DOI 10.1074/jbc.270.24.14281; RYAN RO, 1990, J LIPID RES, V31, P1725; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SPOONER PJR, 1987, BIOCHEMISTRY-US, V26, P5820, DOI 10.1021/bi00392a036; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TESSIER DC, 1991, GENE, V98, P177, DOI 10.1016/0378-1119(91)90171-7; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; TSUCHIDA K, 1988, INSECT BIOCHEM, V18, P263, DOI 10.1016/0020-1790(88)90090-X; VANCE DE, 1984, BIOCHIM BIOPHYS ACTA, V792, P39, DOI 10.1016/0005-2760(84)90280-7; VANHEUSDEN MC, 1989, J BIOL CHEM, V264, P17287; VENKATESAN S, 1993, ARTERIOSCLER THROMB, V13, P1110, DOI 10.1161/01.ATV.13.7.1110; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; WETTERAU JR, 1986, BIOCHIM BIOPHYS ACTA, V875, P610, DOI 10.1016/0005-2760(86)90084-6; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YANG CY, 1990, P NATL ACAD SCI USA, V87, P5523, DOI 10.1073/pnas.87.14.5523; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; YANG CY, 1989, J PROTEIN CHEM, V8, P689, DOI 10.1007/BF01024895; YANG LY, 1995, J LIPID RES, V36, P125; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	63	75	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8682	8691		10.1074/jbc.271.15.8682	http://dx.doi.org/10.1074/jbc.271.15.8682			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621500	hybrid			2022-12-25	WOS:A1996UE73000031
J	Nare, B; Lubega, G; Prichard, RK; Georges, E				Nare, B; Lubega, G; Prichard, RK; Georges, E			p-Azidosalicyl-5-amino-6-phenoxybenzimidazole photolabels the N-terminal 63-103 amino acids of Haemonchus contortus beta-tubulin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BENZIMIDAZOLE ANTHELMINTICS; ASPERGILLUS-NIDULANS; GEL-ELECTROPHORESIS; MAMMALIAN BRAIN; P-GLYCOPROTEIN; RESISTANCE; GENE; BINDING; THIABENDAZOLE; MECHANISM	Benzimidazoles (BZ) are broad spectrum anthelmintics thought to exert their effects by interacting with and disrupting the functions of microtubules. However, direct biochemical evidence for binding between BZ and tubulin has not been shown nor is it known what sequences in tubulin interact with BZ. In this study, a photoactive analogue of 2-acetamido-5-(3-aminophenoxy)benzimidazole that has biological activity similar to other benzimidazoles was synthesized and used to photoaffinity label cell lysates from the parasitic nematode of sheep Haemonchus contortus. The photoactive analogue, 2-acetamido-5-[3-(4-azido-3-I-125-salicylamido)- phenoxy]benzimidazole or I-125-ASA-BZ, was shown to photolabel a 54-kDa protein that was specifically immunoprecipitated with anti-tubulin monoclonal antibodies. Tubulin photoaffinity labeling by I-125-ASA-BZ was also inhibited with molar excess of various BZ analogues and colchicine, Interestingly, I-125-ASA-BZ photoaffinity-labeled the beta- and not the alpha-subunits of tubulin, Proteolytic digestion of I-125-ASA-BZ-labeled tubulin with Staphylococcus aureus V8 proteinase revealed one major peptide with an apparent molecular mass of 3.5 kDa. Exhaustive digestion of I-125-ASA-BZ-labeled beta-tubulin with trypsin resulted in two fractions containing radioactive peptides. Protein sequencing of the high performance liquid chromatography-purified tryptic ASA-BZ-photolabeled peptides identified the N-terminal 63-77 and 78-103 sequences as the BZ binding domain.	MCGILL UNIV,INST PARASITOL,ST ANNE BELLEVUE,PQ H9X 3V9,CANADA	McGill University								BORST P, 1992, DRUG RESISTANCE BIOC, V13, P11; Campbell WW, 1989, IVERMECTIN ABAMECTIN; CLAYTON L, 1980, FEBS LETT, V115, P301, DOI 10.1016/0014-5793(80)81192-6; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAVIDSE LC, 1986, ANNU REV PHYTOPATHOL, V24, P43, DOI 10.1146/annurev.py.24.090186.000355; DAVIDSE LC, 1978, BIOCHIM BIOPHYS ACTA, V543, P82, DOI 10.1016/0304-4165(78)90456-7; DAWSON PJ, 1984, BIOCHEM PHARMACOL, V33, P1069, DOI 10.1016/0006-2952(84)90515-X; Duwel D., 1987, Helminthologia, V24, P141; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; FLYNN TG, 1983, BIOCHEM BIOPH RES CO, V117, P859, DOI 10.1016/0006-291X(83)91675-3; FRIEDMAN PA, 1980, BIOCHIM BIOPHYS ACTA, V630, P271, DOI 10.1016/0304-4165(80)90431-6; FRIEDMAN PA, 1978, BIOCHIM BIOPHYS ACTA, V544, P605, DOI 10.1016/0304-4165(78)90334-3; FUJIMURA M, 1992, CURR GENET, V21, P4; GEARY TG, 1992, MOL BIOCHEM PARASIT, V50, P295, DOI 10.1016/0166-6851(92)90227-B; GEORGES E, 1990, P NATL ACAD SCI USA, V87, P152, DOI 10.1073/pnas.87.1.152; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GOTTSCHALL DW, 1990, PARASITOL TODAY, V6, P115, DOI 10.1016/0169-4758(90)90228-V; HIRAOKA Y, 1984, CELL, V39, P349, DOI 10.1016/0092-8674(84)90013-8; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; JUNG MK, 1992, CELL MOTIL CYTOSKEL, V22, P170, DOI 10.1002/cm.970220304; JUNG MK, 1990, CELL MOTIL CYTOSKEL, V17, P87, DOI 10.1002/cm.970170204; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KOHLER P, 1981, MOL BIOCHEM PARASIT, V4, P325, DOI 10.1016/0166-6851(81)90064-5; KWA MSG, 1993, MOL BIOCHEM PARASIT, V60, P133, DOI 10.1016/0166-6851(93)90036-W; KWA MSG, 1994, MOL BIOCHEM PARASIT, V63, P299, DOI 10.1016/0166-6851(94)90066-3; LACEY E, 1985, BIOCHEM PHARMACOL, V34, P1073, DOI 10.1016/0006-2952(85)90611-2; LACEY E, 1986, MOL BIOCHEM PARASIT, V19, P171, DOI 10.1016/0166-6851(86)90122-2; LACEY E, 1985, BIOCHEM PHARMACOL, V34, P3603, DOI 10.1016/0006-2952(85)90742-7; LACEY E, 1988, INT J PARASITOL, V18, P885, DOI 10.1016/0020-7519(88)90175-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANUSSE CE, 1993, XENOBIOTICA, V23, P285, DOI 10.3109/00498259309059382; LANUSSE CE, 1992, XENOBIOTICA, V22, P419, DOI 10.3109/00498259209046653; LOEWE H, 1977, PESTIC SCI, V8, P544, DOI 10.1002/ps.2780080519; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUBEGA GW, 1993, MOL BIOCHEM PARASIT, V62, P281, DOI 10.1016/0166-6851(93)90117-G; LUBEGA GW, 1991, EXP PARASITOL, V73, P203, DOI 10.1016/0014-4894(91)90023-P; LUBEGA GW, 1991, BIOCHEM PHARMACOL, V41, P93, DOI 10.1016/0006-2952(91)90015-W; LUBEGA GW, 1990, MOL BIOCHEM PARASIT, V38, P221, DOI 10.1016/0166-6851(90)90025-H; LUBEGA GW, 1994, BIOCHEM PHARMACOL, V47, P1705, DOI 10.1016/0006-2952(94)90551-7; NARE B, 1994, BIOCHEM PHARMACOL, V48, P2215, DOI 10.1016/0006-2952(94)00427-7; NARE B, 1994, MOL PHARMACOL, V45, P1145; NEFF NF, 1983, CELL, V33, P211, DOI 10.1016/0092-8674(83)90350-1; NOGALES E, 1995, NATURE, V375, P424, DOI 10.1038/375424a0; ORBACH MJ, 1986, MOL CELL BIOL, V6, P2452, DOI 10.1128/MCB.6.7.2452; PRICHARD RK, 1990, INT J PARASITOL, V20, P515, DOI 10.1016/0020-7519(90)90199-W; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; REYNOLDSON JA, 1991, BIOCH PROTOZOL, V52, P587; ROOS MH, 1990, MOL BIOCHEM PARASIT, V43, P77, DOI 10.1016/0166-6851(90)90132-6; ROOS MH, 1990, PARASITOL TODAY, V6, P125, DOI 10.1016/0169-4758(90)90229-W; RUSSELL GJ, 1992, BIOCHEM PHARMACOL, V43, P1095, DOI 10.1016/0006-2952(92)90617-R; SAFA AR, 1987, J BIOL CHEM, V262, P1261; SAWADA T, 1993, BIOCHEM PHARMACOL, V45, P1387; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; SHEIRNEISS G, 1978, CELL, V5, P639; STEARNS ME, 1993, CANCER RES, V53, P3073; TOWBIN H, 1979, P NATL ACAD SCI USA, V84, P3004; UPPULURI S, 1993, P NATL ACAD SCI USA, V90, P11598, DOI 10.1073/pnas.90.24.11598; van de Bossche M., 1985, CHEMOTHERAPY GASTROI; WEINSTEIN RS, 1991, ADV PATHOLOGY LABORA, P207	61	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8575	8581		10.1074/jbc.271.15.8575	http://dx.doi.org/10.1074/jbc.271.15.8575			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621485	hybrid			2022-12-25	WOS:A1996UE73000016
J	Yao, R; Nimec, Z; Ryan, TJ; Galivan, J				Yao, R; Nimec, Z; Ryan, TJ; Galivan, J			Identification, cloning, and sequencing of a cDNA coding for rat gamma-glutamyl hydrolase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PTEROYLPOLYGLUTAMATE HYDROLASE; CONJUGASE; PURIFICATION; MUCOSA; KIDNEY; MOUSE; CELLS	Purified gamma-glutamyl hydrolase secreted from rat H35 hepatoma cells has been characterized as a diffuse band of 55 kDa on SDS-polyacrylamide gel electrophoresis that is converted to bands of 35 and 33 kDa after enzymatic removal of N-linked carbohydrate. Polyclonal antibodies against 55-kDa gamma-glutamyl hydrolase captured the enzyme activity and recognized the glycosylated and both deglycosylated forms of gamma-glutamyl hydrolase, A complete cDNA sequence of gamma-glutamyl hydrolase was obtained using degenerate oligonucleotides derived from peptide sequences, screening of a rat hepatoma cDNA library, and reverse transcription polymerase chain reaction. Based upon the deduced amino acid sequence the peptide component of gamma-glutamyl hydrolase had a molecular weight of 33,400. The results of amino acid analysis of the purified protein agreed with the deduced amino acid sequence in which there are seven potential asparagine-containing glycosylation sites.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR LABS & RES, DIV MOLEC MED, ALBANY, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center					NATIONAL CANCER INSTITUTE [R01CA025933] Funding Source: NIH RePORTER; NCI NIH HHS [CA 25933] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAGGOTT JE, 1987, AM J CLIN NUTR, V46, P295, DOI 10.1093/ajcn/46.2.295; BHANDARI SD, 1990, J NUTR, V120, P467, DOI 10.1093/jn/120.5.467; CHANDLER CJ, 1986, J BIOL CHEM, V261, P928; ELSENHANS B, 1984, J BIOL CHEM, V259, P6364; GALIVAN J, 1995, BIOCHEM PHARMACOL, V50, P1659, DOI 10.1016/0006-2952(95)02064-0; HORNE DW, 1981, J NUTR, V111, P442, DOI 10.1093/jn/111.3.442; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUMDIECK CL, 1975, AM J CLIN NUTR, V28, P530, DOI 10.1093/ajcn/28.5.530; LIN S, 1993, PHYTOCHEMISTRY, V32, P1109, DOI 10.1016/S0031-9422(00)95074-X; MCGUIRE JJ, 1984, FOLATES PTERINS, V1, P135; OCONNOR BM, 1991, CANCER RES, V51, P3874; OHTSUKA E, 1985, J BIOL CHEM, V260, P2605; PIZZORNO G, 1995, CANCER RES, V55, P566; PRIEST DG, 1982, MOL CELL BIOCHEM, V43, P81, DOI 10.1007/BF00423095; RAO KN, 1977, BIOCHIM BIOPHYS ACTA, V481, P594; REISENAUER AM, 1977, SCIENCE, V198, P196, DOI 10.1126/science.20663; Rhee M. S., 1995, Cellular Pharmacology, V2, P289; RHEE MS, 1993, CANCER RES, V53, P2227; ROSENBERG IH, 1974, J BIOL CHEM, V249, P5126; SAINI PK, 1974, J BIOL CHEM, V249, P5131; SAMUELS LL, 1986, CANCER RES, V46, P2230; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIN YS, 1974, ARCH BIOCHEM BIOPHYS, V163, P211, DOI 10.1016/0003-9861(74)90471-8; SILINK M, 1975, J BIOL CHEM, V250, P5982; STOKSTAD EL, 1967, PHYSIOL REV, V47, P83, DOI 10.1152/physrev.1967.47.1.83; TARENTINO AL, 1994, METHOD ENZYMOL, V230, P44; WANG TTY, 1986, J BIOL CHEM, V261, P3551; WANG Y, 1993, BIOCHIM BIOPHYS ACTA, V1164, P227, DOI 10.1016/0167-4838(93)90253-N; WINZLER RJ, 1973, HORMONAL PROTEINS PE, P1; YAO R, 1995, MOL PHARMACOL, V48, P505	30	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8525	8528		10.1074/jbc.271.15.8525	http://dx.doi.org/10.1074/jbc.271.15.8525			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621474	hybrid			2022-12-25	WOS:A1996UE73000005
J	Goh, KC; Lim, YP; Ong, SH; Siak, CB; Cao, XM; Tan, YH; Guy, GR				Goh, KC; Lim, YP; Ong, SH; Siak, CB; Cao, XM; Tan, YH; Guy, GR			Identification of p90, a prominent tyrosine-phosphorylated protein in fibroblast growth factor-stimulated cells, as 80K-H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; MOLECULAR-CLONING; FACTOR RECEPTORS; FACTOR-I; SUBSTRATE; FAMILY; SIGNAL; SHC	Tyrosine phosphorylation of cellular proteins occurs rapidly upon treatment of fibroblasts with acidic or basic fibroblast growth factors (aFGF, bFGF), suggesting a role for protein phosphorylation in the FGF signaling pathway. Stimulation of Swiss 3T3 cells and MRC-5 fibroblasts with bFGF results in the tyrosine phosphorylation of several proteins, of which the most prominent has been designated as p90. The phosphorylation of p90 is observed within 30 s of treating the cells with FGF but not with other growth factors. Microsequencing of p90 resolved on two-dimensional polyacrylamide gel electrophoresis indicated an N-terminal amino acid sequence which corresponded to a protein previously named as 80K-H. Polyclonal antibodies raised against the predicted C terminus of 80K-H recognized p90 on all Western blots. p90 was found to bind specifically to GRB-2-glutathione S-transferase fusion protein and to be immunoreactive with 80K-H antibody. In addition, anti-phosphotyrosine antibodies immunoprecipitated 80K-H from cell lysates of FGF-stimulated but not from control fibroblasts. The biological function of 80K-H is yet unknown, However, from this study and a previous observation of the obligatory dependence of p90 phosphorylation on FGF receptor occupation, it appears that 80K-H is involved in FGF signaling.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,SIGNAL TRANSDUCT LAB,SINGAPORE 119260,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore								BOGOYEVITCH MA, 1994, J BIOL CHEM, V269, P110; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAIRNS J, 1994, J BIOL CHEM, V269, P9176; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; CRUEZET C, 1995, J NEUROCHEM, V64, P1541; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; FUKUZAWA T, 1995, J BIOL CHEM, V270, P19141; GUY GR, 1994, ELECTROPHORESIS, V15, P417, DOI 10.1002/elps.1150150160; HIRAI M, 1990, BIOCHEM J, V270, P583, DOI 10.1042/bj2700583; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; LANDGREN E, 1995, ONCOGENE, V10, P2027; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; MIGITA K, 1995, BIOCHEM BIOPH RES CO, V210, P1066, DOI 10.1006/bbrc.1995.1765; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAI K, 1992, GENOMICS, V14, P175, DOI 10.1016/S0888-7543(05)80301-5; SAKAI K, 1989, GENOMICS, V5, P309, DOI 10.1016/0888-7543(89)90063-3; SHAOUL E, 1995, ONCOGENE, V10, P1553; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILKIE AOM, 1995, CURR BIOL, V5, P500; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHAN X, 1994, J BIOL CHEM, V269, P20221	38	59	59	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5832	5838		10.1074/jbc.271.10.5832	http://dx.doi.org/10.1074/jbc.271.10.5832			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621453	hybrid			2022-12-25	WOS:A1996TZ28600079
J	Li, XX; Leung, S; Qureshi, S; Darnell, JE; Stark, GR				Li, XX; Leung, S; Qureshi, S; Darnell, JE; Stark, GR			Formation of STAT1-STAT2 heterodimers and their role in the activation of IRF-1 gene transcription by interferon-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY FACTOR-I; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; RESPONSE ELEMENT; BINDING PROTEIN; PROMOTER; ISGF-3; GAMMA	An upstream inverted repeat (IR) element mediates transcriptional activation of the interferon response factor-1 gene (IRF-1) by interferon (IFN)-alpha and IFN-gamma. IFN-alpha and IFN-gamma fail to induce IRF-1 in cells that lack signal transducer and activator of transcription 1 (STAT1), and STAT1 homodimers bind to IR elements in extracts of IFN-alpha-treated cells. We now report that STATE also plays an important role in the IFN-alpha-mediated transcriptional activation of the IRF-1 gene. A new factor, most likely a STAT1-STAT2 heterodimer, was de tected with an IR probe in extracts of IFN-alpha-treated cells. STAT1 and STAT2 are already known to combine with p48, a DNA-binding protein, to form IFN-stimulated gene factor 3 (ISGF3), which binds to IFN-stimulated response elements (ISREs) distinct from the IR of the IRF-1 gene. In extracts of U2A cells, which lack p48, STAT1-STAT2 heterodimers were still formed, indicating that they do not contain p48. We manipulated the intracellular levels of STAT1-STAT2 heterodimers and STAT1 homodimers to examine their roles in the induction of IRF-1 by IFN-alpha. Although both dimers can induce IRF-1 transcription, the heterodimers are more potent and thus may be the major activators in vivo. Deletion analysis reveals that the C-terminal domain of STAT2 is important for transcriptional activation mediated by both STAT1-STAT2 heterodimers and ISGF3.	CLEVELAND CLIN FDN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195; ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021	Cleveland Clinic Foundation; Rockefeller University					NCI NIH HHS [P01 CA 62220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DECKER T, 1991, MOL CELL BIOL, V11, P5147, DOI 10.1128/MCB.11.10.5147; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; HAQUE SJ, 1994, J BIOL CHEM, V269, P19523; HARADA H, 1993, SCIENCE, V259, P971, DOI 10.1126/science.8438157; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; Qureshi SA, 1996, MOL CELL BIOL, V16, P288; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806	34	158	161	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5790	5794		10.1074/jbc.271.10.5790	http://dx.doi.org/10.1074/jbc.271.10.5790			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621447	hybrid			2022-12-25	WOS:A1996TZ28600073
J	Shi, MM; Godleski, JJ; Paulauskis, JD				Shi, MM; Godleski, JJ; Paulauskis, JD			Regulation of macrophage inflammatory protein-1 alpha mRNA by oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MESSENGER-RNA; TRANSCRIPTION FACTOR; INDUCIBLE GENES; BINDING-FACTOR; EXPRESSION; PROTEIN; IDENTIFICATION; ACTIVATION; FAMILY	Accumulation of inflammatory cells within the lung has been implicated in oxidative injury, Recruitment of these cells to a tissue site is a complex process that depends in part upon the local expression of appropriate proinflammatory chemokines, Macrophage inflammatory protein-1 alpha (MIP-1 alpha), a member of the CC subfamily of chemokines, has been shown to contribute to monocyte/macrophage and neutrophil chemotaxis and activation, Our previous work demonstrated that MIP-1 alpha mRNA expression in macrophages is induced by bacterial endotoxin, The objective of this study was to test the hypothesis that an oxidative stress alone may trigger expression of MIP-1 alpha mRNA in macrophages and to determine the mechanism leading to increased expression, A rat alveolar macrophage cell line (NR8383) was exposed to H2O2 or menadione (2-methyl-1,4-naphthoquinone (MQ)), a quinone compound that undergoes redox cycling and generates reactive oxygen species continuously, Steady-state mRNA levels encoding MIP-1 alpha were markedly increased (3-fold) in these cells after 1 h of exposure to 0.5 mw H2O2, remained higher than control levels after 4 h, and decreased after 6 h, Similarly, MQ (25 or 50 mu M) caused a significant increase of MIP-1 alpha mRNA with a maximal induction after 4 h of exposure (5-fold), Both H2O2 and MQ-induced up-regulation of MIP-1 alpha mRNA was suppressed by co-treatment with N-acetylcysteine, a synthetic antioxidant. Co-treatment with actinomycin D reduced the MQ induction of MIP-1 alpha mRNA to a greater extent than the H2O2-induced increase, Transcription of the MIP-1 alpha gene was increased by exposure to both H2O2 and MQ. H2O2 treatment also induced a marked increase of the MIP-1 alpha mRNA half-life, indicating post-transcriptional stabilization, These observations indicate that an oxidative stress can regulate MIP-1 alpha mRNA expression by two distinct mechanisms: transcriptional activation of the MIP-1 alpha gene and post-transcriptional stabilization of MIP-1 alpha mRNA.	HARVARD UNIV,SCH PUBL HLTH,DIV ENVIRONM HLTH,PHYSIOL PROGRAM,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health					NHLBI NIH HHS [HL07118, HL19170] Funding Source: Medline; NIEHS NIH HHS [ES00002] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007118, P50HL019170] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ADAMSON GM, 1992, ARCH BIOCHEM BIOPHYS, V294, P223, DOI 10.1016/0003-9861(92)90161-O; AUSBEL FM, 1990, CURRENT PROTOCOLS MO; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BRUNMARK A, 1989, FREE RADICAL BIO MED, V7, P435, DOI 10.1016/0891-5849(89)90126-3; CHANG M, 1992, AM J PHYSIOL, V6, pL637; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; CHURCH GM, 1984, P NATL ACAD SCI USA, V74, P5463; CLERCH LB, 1991, AM J PHYSIOL, V260, pL428, DOI 10.1152/ajplung.1991.260.6.L428; CLERCH LB, 1992, J BIOL CHEM, V267, P2853; DAVATELIS G, 1988, J EXP MED, V167, P1939, DOI 10.1084/jem.167.6.1939; DEFORGE LE, 1992, J CLIN INVEST, V90, P2123, DOI 10.1172/JCI116097; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; DRISCOLL KE, 1993, TOXICOL APPL PHARM, V119, P306, DOI 10.1006/taap.1993.1074; DUNLOP DJ, 1992, BLOOD, V79, P2221; FARONE A, 1995, AM J RESP CELL MOL, V12, P345, DOI 10.1165/ajrcmb.12.3.7873201; FAVREAU LV, 1993, J BIOL CHEM, V268, P19875; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Fridovich, 1981, OXYGEN LIVING PROCES, P250, DOI 10.1007/978-1-4612-5890-2_13; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HELMKE RJ, 1987, IN VITRO CELL DEV B, V23, P567; HUANG S, 1992, AM J PATHOL, V141, P981; HUANG SL, 1992, BIOCHEM BIOPH RES CO, V184, P922, DOI 10.1016/0006-291X(92)90679-F; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SHANLEY TP, 1995, J IMMUNOL, V154, P4793; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHI M, 1993, FREE RADICAL BIO MED, V15, P57, DOI 10.1016/0891-5849(93)90125-E; SHI MM, 1994, J BIOL CHEM, V269, P26512; SHI MM, 1994, AM J PHYSIOL-LUNG C, V267, pL414, DOI 10.1152/ajplung.1994.267.4.L414; SHI MM, 1995, BIOCHEM BIOPH RES CO, V211, P289, DOI 10.1006/bbrc.1995.1809; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P390, DOI 10.1016/S0025-6196(12)64862-9; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; VANOTTEREN GM, 1994, AM J RESP CELL MOL, V10, P8, DOI 10.1165/ajrcmb.10.1.8292385; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; YOSHIKAWA T, 1990, METHOD ENZYMOL, V186, P660	46	91	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5878	5883		10.1074/jbc.271.10.5878	http://dx.doi.org/10.1074/jbc.271.10.5878			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621460	hybrid			2022-12-25	WOS:A1996TZ28600086
J	Slieker, LJ; Sloop, KW; Surface, PL; Kriauciunas, A; LaQuier, F; Manetta, J; BueValleskey, J; Stephens, TW				Slieker, LJ; Sloop, KW; Surface, PL; Kriauciunas, A; LaQuier, F; Manetta, J; BueValleskey, J; Stephens, TW			Regulation of expression of ob mRNA and protein by glucocorticoids and cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPEPTIDE-Y; ADIPOCYTES; INHIBITION; INSULIN; MICE	Regulation of obese gene (ob) expression in ob/ob and db/db mice and in cultured rat adipocytes was examined. It has been demonstrated that exogenous human OB protein (leptin) treatment reduces food intake and weight gain, as web as insulin, glucose, and corticosterone levels in ob/ob mice. In the present report we show that leptin treatment down-regulates endogenous adipose ob mRNA. However, treatment of isolated rat adipocytes with 100 ng/ml human or murine leptin had no direct effect on expression of endogenous ob mRNA, suggesting that leptin may be able to down-regulate its own expression by an indirect, non-autocrine mechanism, Glucocorticoids increased both ob mRNA levels and secreted leptin levels in vitro. Conversely, agents that increase intracellular cAMP, such as beta-adrenergic agonists or Bt(2)cAMP itself, decreased ob mRNA expression and leptin secretion. Therefore, increased glucocorticoid levels and decreased sympathetic neural activity may contribute to the elevated ob mRNA expression observed in genetically obese, hyperglucocorticoid rodents. Furthermore, leptin might regulate its own expression through a feedback mechanism involving the hypothalamic pituitary axis.	ELI LILLY & CO, LILLY RES LABS, ENDOCRINE RES DIV, INDIANAPOLIS, IN 46285 USA; ELI LILLY & CO, LILLY RES LABS, TECHNOL CORE DIV, INDIANAPOLIS, IN 46285 USA	Eli Lilly; Eli Lilly								CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CAWTHORNE M A, 1992, American Journal of Clinical Nutrition, V55, p252S, DOI 10.1093/ajcn/55.1.252s; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2986, DOI 10.1172/JCI118007; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; FUNAHASHI T, 1995, BIOCHEM BIOPH RES CO, V211, P469, DOI 10.1006/bbrc.1995.1837; GREGOIRE F, 1991, EXP CELL RES, V196, P270, DOI 10.1016/0014-4827(91)90261-R; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HOLLENGA C, 1991, BRIT J PHARMACOL, V102, P577, DOI 10.1111/j.1476-5381.1991.tb12215.x; HOLLOWAY B, 1989, HORMONES THERMOGENES, V4, P477; JEANRENAUD B, 1992, INT J OBESITY, V16, pS9; KITAGAWA K, 1989, BIOCHIM BIOPHYS ACTA, V1014, P83, DOI 10.1016/0167-4889(89)90244-9; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MAFFEI M, 1995, GENETICS, V92, P6957; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MIZUNO T, 1995, ENDOCRINOLOGY S, V136, P174; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V214, P1260, DOI 10.1006/bbrc.1995.2422; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PRALONG FP, 1993, NEUROPEPTIDES, V25, P223, DOI 10.1016/0143-4179(93)90107-L; RODBELL M, 1964, J BIOL CHEM, V239, P375; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWARTZ MW, 1992, ENDOCRINOLOGY, V130, P3608, DOI 10.1210/en.130.6.3608; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; STIRLING B, 1995, DIABETES, V44, P999, DOI 10.2337/diabetes.44.8.999; STRACK AM, 1995, AM J PHYSIOL-REG I, V268, pR142, DOI 10.1152/ajpregu.1995.268.1.R142; TRAYHURN P, 1995, FEBS LETT, V368, P488, DOI 10.1016/0014-5793(95)00719-P; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	30	461	469	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5301	5304		10.1074/jbc.271.10.5301	http://dx.doi.org/10.1074/jbc.271.10.5301			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621378	hybrid			2022-12-25	WOS:A1996TZ28600004
J	Bryant, SS; Mitchell, AL; Collins, F; Miao, WY; Marshall, M; Jove, R				Bryant, SS; Mitchell, AL; Collins, F; Miao, WY; Marshall, M; Jove, R			N-terminal sequences contained in the Src homology 2 and 3 domains of p120 GTPase-activating protein are required for full catalytic activity toward Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROFIBROMATOSIS TYPE-1 GENE; TYROSINE KINASES; SACCHAROMYCES-CEREVISIAE; SH3 DOMAINS; P21 GTPASE; GAP; BINDING; TRANSFORMATION; IDENTIFICATION; CLONING	The p120 GTPase-activating protein (GAP) is a negative regulator of Ras, which has a central role in signal transduction pathways that control cell proliferation. p120 GAP accelerates the conversion of activated Ras-GTP to its inactive form, Ras-GDP, thereby inhibiting mitogenic signaling. To examine potential contributions of p120 N-terminal sequences to regulation of its C-terminal catalytic domain, we constructed deletion mutants lacking defined regions, including the variable hydrophobic region as well as the Src homology 2 (SH2) and 3 (SH3) domains. These mutant proteins were expressed in infected Sf9 insect cells from recombinant baculoviruses and assayed in vitro for their ability to stimulate the intrinsic GTPase activity of purified Ras. While deletion of the variable hydrophobic region had no effect on p120 GAP activity, deletion of the entire SH2/SH3/SH2 region severely impaired catalytic activity toward Ras. Deletion of individual SH2 and SH3 domains within this region partially inhibited p120 GAP activity. Moreover, p120 N-terminal sequences enhanced the Ras GTPase-stimulating activity of the neurofibromin GAP-related domain. These results demonstrate that sequences in the SH2/SH3/SH2 region of p120 GAP are required for full catalytic activity toward Ras. Together with earlier findings that the p120 GAP SH2 domains mediate interactions with several GAP-associated proteins, our results suggest multiple roles for the N-terminal sequences in regulating p120 GAP catalytic activity and mitogenic signaling pathways. In addition, our results raise the possibility that SH2 domain point mutations in p120 GAP detected in some basal cell carcinomas reduce catalytic activity toward Ras and thereby contribute to oncogenesis.	UNIV MICHIGAN,SCH MED,MOLEC & CELLULAR BIOL PROGRAM,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT MICROBIOL & IMMUNOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR COMPREHENS CANC,ANN ARBOR,MI 48109; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892; INDIANA UNIV,MED CTR,DEPT MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute					NATIONAL CANCER INSTITUTE [R01CA055652] Funding Source: NIH RePORTER; NCI NIH HHS [CA55652] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; BROTT BK, 1991, MOL CELL BIOL, V11, P5059, DOI 10.1128/MCB.11.10.5059; BRYANT SS, 1995, J BIOL CHEM, V270, P17947, DOI 10.1074/jbc.270.30.17947; CHANG JH, 1995, METHOD ENZYMOL, V254, P490; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FILVAROFF E, 1992, MOL CELL BIOL, V12, P5319, DOI 10.1128/MCB.12.12.5319; FRIEDMAN E, 1993, NAT GENET, V5, P242, DOI 10.1038/ng1193-242; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P348; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; GOLUBIC M, 1992, ONCOGENE, V7, P2151; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; HETTICH L, 1994, CANCER RES, V54, P5438; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PARK S, 1992, J BIOL CHEM, V267, P11612; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; VISKOCHIL D, 1993, ANNU REV NEUROSCI, V16, P183, DOI 10.1146/annurev.ne.16.030193.001151; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; XU J, 1994, ONCOGENE, V9, P597	48	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5195	5199						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617802				2022-12-25	WOS:A1996TX69700092
J	Nakamura, N; Matsuzaki, R; Choi, YH; Tanizawa, K; SandersLoehr, J				Nakamura, N; Matsuzaki, R; Choi, YH; Tanizawa, K; SandersLoehr, J			Biosynthesis of topa quinone cofactor in bacterial amine oxidases - Solvent origin of C-2 oxygen determined by Raman spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; 6-HYDROXYDOPA; SPECTRA	Resonance Raman spectroscopy is an excellent technique for providing structural information on the 2,4,5-trihydroxyphenylalanine quinone (TPQ) cofactor in copper-containing amine oxidases. This technique has been used to investigate the copper- and O-2-dependent biosynthesis of the TPQ cofactor in phenylethylamine oxidase (PEAO) and histamine oxidase from Arthrobacter globiformis. Incubation of the holoenzyme in (H2O)-O-18 causes frequency shifts at 1684 (-26) cm(-1) in PEAO and at 1679 (-28) cm(-1) in histamine oxidase, allowing this feature to be assigned to the C=O stretch of a single carbonyl group at the C-5 position. When apoprotein is reacted with Cu(II) and O-2 in the presence of (HO)-O-218, the resultant holoproteins show increased shifts of -3 to -6 cm(-1) in a number of other vibrational modes, particularly at 411 and 1397 cm(-1). Because these small shifts persist when the (HO)-O-218-regenerated protein is back-exchanged into (HO)-O-216, they can be assigned to oxygen isotope substitution at the C-2 postion. No isotope shifts are observed when apoprotein is regenerated with Cu(II) in the presence of O-18(2). Thus, it is concluded that the C-2 oxygen atom of TPQ originates from H2O rather than O-2. The isotope dependence of the 1397-cm(-1) mode allows it to be assigned to the C-O moiety at the C-2 position, with its low frequency being indicative of only partial double bond character, Similar frequency shifts due to O-18 at C-2 are observed in the resonance Raman spectra of (H2O)-O-18-regenerated PEAO after derivatization of the C-5 carbonyl with either p-nitrophenylhydrazine (-5 cm(-1) at 480 cm(-1)) or methylamine (-5 cm(-1) at 1301 cm(-1)). Taken together, these results indica cate that the TPQ cofactor in the native enzyme has substantial electron delocalization between the C-2 and C-4 oxygens and that only the C-5 oxygen has predominantly C=O character.	OREGON GRAD INST SCI & TECHNOL,DEPT CHEM BIOCHEM & MOL BIOL,PORTLAND,OR 97291; OSAKA UNIV,INST SCI & IND RES,IBARAKI,OSAKA 567,JAPAN	Osaka University			Nakamura, Nobuhumi/C-1972-2013	Nakamura, Nobuhumi/0000-0002-5373-2972	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034468] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-34468] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BECKER ED, 1991, J PHYS CHEM-US, V95, P2818, DOI 10.1021/j100160a035; BECKER ED, 1965, J CHEM PHYS, V42, P942, DOI 10.1063/1.1696085; BERGER S, 1974, CHEM QUINOID COMPO 1, P186; BROWN DE, 1991, J BIOL CHEM, V266, P4049; CAI DY, 1994, J BIOL CHEM, V269, P32039; CAI DY, 1994, BIOCHEMISTRY-US, V33, P7647, DOI 10.1021/bi00190a019; CAREY PR, 1982, BIOCH APPLICATIONS R; CHOI YH, 1995, J BIOL CHEM, V270, P4712, DOI 10.1074/jbc.270.9.4712; DOOLEY DM, 1993, PRINCIPLES APPLICATI, P275; Frushour B.G., 1975, ADV INFRARED RAMAN S, V1, P35; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; LING JS, 1994, J BIOL CHEM, V269, P5595; LOEHR TM, 1993, METHOD ENZYMOL, V226, P431; LORD RC, 1970, J MOL BIOL, V50, P509, DOI 10.1016/0022-2836(70)90208-1; MATSUZAKI R, 1994, FEBS LETT, V351, P360, DOI 10.1016/0014-5793(94)00884-1; MATSUZAKI R, 1995, BIOCHEMISTRY-US, V34, P4524, DOI 10.1021/bi00014a004; MICHAUDSORET I, 1995, BIOCHEMISTRY-US, V34, P5504, DOI 10.1021/bi00016a022; MOENNELOCCOZ P, 1995, BIOCHEMISTRY-US, V34, P7020, DOI 10.1021/bi00021a013; MU D, 1992, J BIOL CHEM, V267, P7979; MURE M, 1995, J AM CHEM SOC, V117, P8698, DOI 10.1021/ja00139a002; MURE M, 1993, J AM CHEM SOC, V115, P7117, DOI 10.1021/ja00069a008; MURE M, 1995, J AM CHEM SOC, V117, P8707, DOI 10.1021/ja00139a003; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; YAMADA H, 1962, J BIOL CHEM, V237, P1511	26	63	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4718	4724						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617737				2022-12-25	WOS:A1996TX69700027
J	Dember, LM; Kim, ND; Liu, KQ; Anderson, P				Dember, LM; Kim, ND; Liu, KQ; Anderson, P			Individual RNA recognition motifs of TIA-1 and TIAR have different RNA binding specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; U1 RNA; SPLICE SITE; A-PROTEIN; GENE; IDENTIFICATION; DOMAIN; DETERMINANTS; SEGMENT	TIA-1 and TIAR are two closely related RNA recognition motif (RRM) proteins which possess three RRM-type RNA binding domains (RRMs 1, 2, and 3). Although both proteins have been implicated as effecters of apoptotic cell death, the specific functions of TIA-1 and TIAR are not known, We have performed in vitro selection/amplification from pools of random RNA sequences to identify RNAs to which TIA-1 and TIAR bind with high affinity. Both proteins selected RNAs containing one or several short stretches of uridylate residues suggesting that the two proteins have similar RNA binding specificities. Replacement of the uridylate stretch with an equal number of cytidine residues eliminates the protein-RNA interaction. Mutational analysis indicates that, for both TIA-1 and TIAR, it is the second RNA binding domain (RRM 2) which mediates the specific binding to uridylate-rich RNAs. Although RRM 2 is both necessary and sufficient for this interaction, the affinity for the selected RNA (as determined by filter binding assays) does increase when the second domain of TIAR is expressed together with the first and third domains (K-d = 2 x 10(-8) M) rather than alone (K-d = 5 x 10(-8) M). Although RRM 3 (of either TIA-1 or TIAR) does not interact with the uridylate-rich sequences selected by the full-length proteins, it is a bona fide RNA binding domain capable of affinity-precipitating a population of cellular RNAs ranging in size from 0.5 to 5 kilobases. In contrast, RRM 1 does not affinity-precipitate cellular RNA. The inability of RRM 1 to interact with RNA may be due to the presence of negatively charged amino acids within the RNP 1 octamer.	HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT RHEUMATOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dember, LM (corresponding author), HARVARD UNIV, SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL, MAYER 747, 44 BINNEY ST, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033600, R56AI033600] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33600] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; BENTLEY RC, 1991, MOL CELL BIOL, V11, P1829, DOI 10.1128/MCB.11.4.1829; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRAND S, 1993, NUCLEIC ACIDS RES, V21, P3699, DOI 10.1093/nar/21.16.3699; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CAREY J, 1983, BIOCHEMISTRY-US, V22, P2601, DOI 10.1021/bi00280a002; DEMBER IM, UNPUB; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; GORLACH M, 1994, J BIOL CHEM, V269, P23074; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; JACKSON RJ, 1993, CELL, V74, P9, DOI 10.1016/0092-8674(93)90290-7; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KAWAKAMI A, 1992, P NATL ACAD SCI USA, V89, P8681, DOI 10.1073/pnas.89.18.8681; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIM YJ, 1993, MOL CELL BIOL, V13, P174, DOI 10.1128/MCB.13.1.174; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; PINOLROMA S, 1989, METHOD ENZYMOL, V180, P410; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; Sambrook J, 1989, MOL CLONING LABORATO; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; SCHERLY D, 1989, EMBO J, V8, P4163, DOI 10.1002/j.1460-2075.1989.tb08601.x; SCHERLY D, 1991, J MOL BIOL, V219, P577, DOI 10.1016/0022-2836(91)90651-L; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; TAUPIN JL, 1995, P NATL ACAD SCI USA, V92, P1629, DOI 10.1073/pnas.92.5.1629; TIAN QS, 1995, J EXP MED, V182, P865, DOI 10.1084/jem.182.3.865; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WANG JW, 1994, GENE DEV, V8, P2072, DOI 10.1101/gad.8.17.2072; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	41	170	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2783	2788		10.1074/jbc.271.5.2783	http://dx.doi.org/10.1074/jbc.271.5.2783			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576255	hybrid			2022-12-25	WOS:A1996TT48800069
J	Proudfoot, AEI; Power, CA; Hoogewerf, AJ; Montjovent, MO; Borlat, F; Offord, RE; Wells, TNC				Proudfoot, AEI; Power, CA; Hoogewerf, AJ; Montjovent, MO; Borlat, F; Offord, RE; Wells, TNC			Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; HUMAN INTERLEUKIN-8 RECEPTOR; ESCHERICHIA-COLI; FUNCTIONAL EXPRESSION; COUPLED RECEPTORS; HUMAN EOSINOPHILS; CYTOKINE RANTES; AMINO-ACID; AFFINITY; GRANULOCYTES	Extension of recombinant human RANTES by a single residue at the amino terminus is sufficient to produce a potent and selective antagonist. RANTES is a proinflammatory cytokine that promotes cell accumulation and activation in chronic inflammatory diseases, When mature RANTES was expressed heterologously in Escherichia coli, the amino-terminal initiating methionine was not removed by the endogenous amino peptidases. This methionylated protein was fully folded but completely inactive in RANTES bioassays of calcium mobilization and chemotaxis of the promonocytic cell line THP-1. However, when assayed as an antagonist of both RANTES and macrophage inflammatory polypeptide-1 alpha (MIP-1 alpha) in these assays, the methionylated RANTES (Met-RANTES) inhibited the actions of both chemokines, T cell chemotaxis was similarly inhibited, The antagonistic effect was selective since Met-RANTES had no effect on interleukin-8- or monocyte chemotractant protein-1-induced responses in these cells, Met-RANTES can compete with both [I-125]RANTES and [I-125]MIP-1 alpha binding to THP-1 cells or to stably transfected HEK cells recombinantly expressing their common receptor, CC-CKR-1, These data show that the integrity of the amino terminus of RANTES is crucial to receptor binding and cellular activation.	CTR MED UNIV,DEPT BIOCHIM MED,CH-1224 CHAMPEL,GENEVA,SWITZERLAND		Proudfoot, AEI (corresponding author), GLAXO INST MOLEC BIOL SA,14 CHEM AULX,CH-1228 PLAN LES OUATES,GENEVA,SWITZERLAND.			Wells, Timothy/0000-0001-9796-847X				ALAM R, 1993, J IMMUNOL, V150, P3442; BECK LA, 1994, J ALLERGY CLIN IMMUN, V93, P234; BISCHOFF SC, 1993, EUR J IMMUNOL, V23, P761, DOI 10.1002/eji.1830230329; BRAKENHOFF JPJ, 1994, J BIOL CHEM, V269, P86; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHUNG C, IN PRESS BIOCHEMISTR; DELAMARTER JF, 1985, EMBO J, V4, P2575, DOI 10.1002/j.1460-2075.1985.tb03973.x; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; FINCHAM NJ, 1988, J IMMUNOL, V140, P4294; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HERCUS TR, 1994, P NATL ACAD SCI USA, V91, P5838, DOI 10.1073/pnas.91.13.5838; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; KAMEYOSHI Y, 1992, J EXP MED, V176, P587, DOI 10.1084/jem.176.2.587; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; LEATHERBARROW RJ, 1993, GRAFIT VERSION 3 01; LIANG SM, 1995, BIOCHEM J, V229, P429; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; LOISON G, 1988, BIO-TECHNOL, V6, P72, DOI 10.1038/nbt0188-72; LUSTINARASIMHAN M, 1995, J BIOL CHEM, V270, P2716, DOI 10.1074/jbc.270.6.2716; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; MOSER B, 1993, J BIOL CHEM, V268, P7125; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; MURPHY WJ, 1994, EUR J IMMUNOL, V24, P1823, DOI 10.1002/eji.1830240815; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PROUDFOOT AEI, 1995, FEBS LETT, V376, P19, DOI 10.1016/0014-5793(95)01235-X; PROUDFOOT AEI, 1990, BIOCHEM J, V270, P357, DOI 10.1042/bj2700357; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851; WINGFIELD P, 1987, FEBS LETT, V215, P160, DOI 10.1016/0014-5793(87)80133-3; ZHANG YJ, 1995, MOL CELL BIOL, V15, P4851; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	39	368	410	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2599	2603		10.1074/jbc.271.5.2599	http://dx.doi.org/10.1074/jbc.271.5.2599			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576227	hybrid			2022-12-25	WOS:A1996TT48800041
J	Uebele, VN; England, SK; Chaudhary, A; Tamkun, MM; Snyders, DJ				Uebele, VN; England, SK; Chaudhary, A; Tamkun, MM; Snyders, DJ			Functional differences in Kv1.5 currents expressed in mammalian cell lines are due to the presence of endogenous Kv beta 2.1 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+ CHANNEL; POTASSIUM-CHANNEL; XENOPUS-OOCYTES; HUMAN HEART; ACTIVATION; CLONING; CDNAS	The voltage-sensitive currents observed following hKv1.5 alpha subunit expression in HEK 293 and mouse L-cells differ in the kinetics and voltage dependence of activation and slow inactivation. Molecular cloning, immunopurification, and Western blot analysis demonstrated that an endogenous L-cell Kv beta 2.1 subunit assembled with transfected hKv1.5 protein. In contrast, both mRNA and protein analysis failed to detect a beta subunit in the HEK 293 cells, suggesting that functional differences observed between these two systems are due to endogenous L-cell Kv beta 2.1 expression. In the absence of Kv beta 2.1, midpoints for activation and inactivation of hKv1.5 in HEK 293 cells were -0.2 +/- 2.0 and -9.6 +/- 1.8 mV, respectively. In the presence of Kv beta 2.1 these values were -14.1 +/- 1.8 and -22.1 +/- 3.7 mV, respectively. The beta subunit also caused a 1.5-fold increase in the extent of slow inactivation at 50 mV, thus completely reconstituting the L-cell current phenotype in the HEK 293 cells. These results indicate that 1) the Kv beta 2.1 subunit can alter Kv1.5 alpha subunit function, 2) beta subunits are not required for alpha subunit expression, and 3) endogenous beta subunits are expressed in heterologous expression systems used to study K+ channel function.	VANDERBILT UNIV,SCH MED,DEPT MED,DIV CLIN PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHYSIOL & MOLEC BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University			Snyders, Dirk/A-2713-2013	Snyders, Dirk/0000-0001-7142-6672	NHLBI NIH HHS [HL 46681, HL 49330, HL 47594] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046681, R01HL049330] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTALI B, 1993, J BIOL CHEM, V268, P24283; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BOYD AE, 1990, AM J MED, V89, P3; CATTERALL W, 1992, DIABETOLOGIA, V35, P23; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHANDY KG, 1995, HDB RECEPTORS CHANNE, P1; CHOUINARD SW, 1995, P NATL ACAD SCI USA, V92, P6763, DOI 10.1073/pnas.92.15.6763; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; CRUMB WJ, 1995, MOL PHARMACOL, V47, P181; DEAL KK, 1994, J NEUROSCI, V14, P1666, DOI 10.1523/JNEUROSCI.14-03-01666.1994; ENGLAND SK, 1995, J BIOL CHEM, V270, P28531, DOI 10.1074/jbc.270.48.28531; ENGLAND SK, 1995, P NATL ACAD SCI USA, V92, P6309, DOI 10.1073/pnas.92.14.6309; FAMBROUGH DM, 1983, J BIOL CHEM, V258, P3926; FEDIDA D, 1993, CIRC RES, V73, P210, DOI 10.1161/01.RES.73.1.210; FELIPE A, 1993, AM J PHYSIOL, V265, pC1230, DOI 10.1152/ajpcell.1993.265.5.C1230; Hille B., 1992, IONIC CHANNELS EXCIT, V2 ed, P115; HOFFMANN EK, 1992, CAN J PHYSIOL PHARM, V70, P310; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; MAJUMDER K, 1995, FEBS LETT, V361, P13, DOI 10.1016/0014-5793(95)00120-X; MALAYEV AA, 1995, MOL PHARMACOL, V47, P198; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; MAYS DJ, 1995, J CLIN INVEST, V96, P282, DOI 10.1172/JCI118032; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; MORALES MJ, 1995, J BIOL CHEM, V270, P6272, DOI 10.1074/jbc.270.11.6272; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; OVERTURF KE, 1994, AM J PHYSIOL-CELL PH, V267, pC1231, DOI 10.1152/ajpcell.1994.267.5.C1231; PHILIPSON LH, 1991, P NATL ACAD SCI USA, V88, P53, DOI 10.1073/pnas.88.1.53; PHILIPSON LH, 1993, BIOCHIM BIOPHYS ACTA, V1153, P111, DOI 10.1016/0005-2736(93)90282-5; PO S, 1993, CIRC RES, V72, P1326, DOI 10.1161/01.RES.72.6.1326; RAMPE D, 1993, MOL PHARMACOL, V44, P642; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P641, DOI 10.1113/jphysiol.1984.sp015088; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; SNYDERS DJ, 1995, CIRC RES, V77, P575, DOI 10.1161/01.RES.77.3.575; SNYDERS DJ, 1993, J GEN PHYSIOL, V101, P513, DOI 10.1085/jgp.101.4.513; SPIRES S, 1989, J GEN PHYSIOL, V93, P263, DOI 10.1085/jgp.93.2.263; TAMKUN MM, 1991, FASEB J, V5, P331, DOI 10.1096/fasebj.5.3.2001794; UEBELE VN, 1994, FEBS LETT, V340, P104, DOI 10.1016/0014-5793(94)80181-9; WHITE MM, 1985, J GEN PHYSIOL, V85, P539, DOI 10.1085/jgp.85.4.539; YANG T, 1995, BRIT J PHARMACOL, V115, P267, DOI 10.1111/j.1476-5381.1995.tb15873.x	46	115	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2406	2412		10.1074/jbc.271.5.2406	http://dx.doi.org/10.1074/jbc.271.5.2406			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576199	hybrid			2022-12-25	WOS:A1996TT48800013
J	Bromme, D; Okamoto, K; Wang, BB; Biroc, S				Bromme, D; Okamoto, K; Wang, BB; Biroc, S			Human cathepsin O-2, a matrix protein-degrading cysteine protease expressed in osteoclasts - Functional expression of human cathepsin O-2 in Spodoptera frugiperda and characterization of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE-RESORPTION; RABBIT SPLEEN; DEGRADATION; SPECIFICITY; PAPAIN; INHIBITORS; COLLAGEN; CELLS	Cathepsin O2, a human cysteine protease predominantly present in osteoclasts, has been functionally expressed in Spodoptera frugiperda Sf9 cells using the Autographa californica nuclear polyhedrosis virus. Following in vitro activation at pH 4.0 with pepsin, active enzyme with an apparent molecular weight of 29,000 was obtained. N-terminal sequencing revealed the typical processing site for cysteine proteases of the papain family with a proline in the position adjacent to the N-terminal alanine residue. The S2P2 subsite specificity of human cathepsin O2 is similar to cathepsin S but distinguished from cathepsins L and B. Similar to cathepsin S, cathepsin O2 is characterized by a bell-shaped pH activity profile and is stable at pH 6.5 for 30 min at 37 degrees C. Cathepsin O2 is further distinguished by its potent collagenolytic activity against Type I collagen between pH 5 and 6, and elastinolytic activity against insoluble elastin at pH 7.0. Its capacity to efficiently degrade Type I collagen and its high expression in osteoclasts suggest that cathepsin O2 may play a major role in human osteoclastic bone resorption.			Bromme, D (corresponding author), KHEPRI PHARMACEUT INC, 260 LITTLEFIELD AVE, S SAN FRANCISCO, CA 94080 USA.							BANDA MJ, 1987, METHOD ENZYMOL, V144, P288; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BROMME D, 1993, J BIOL CHEM, V268, P4832; BROMME D, 1995, BIOL CHEM H-S, V376, P379, DOI 10.1515/bchm3.1995.376.6.379; BROMME D, 1989, BIOCHEM J, V264, P475; CATTORETTI G, 1992, J PATHOL, V168, P357, DOI 10.1002/path.1711680404; DEBARI K, 1995, CALCIFIED TISSUE INT, V56, P566, DOI 10.1007/BF00298591; Delaisse Jean-Marie, 1992, P289; DELAISSE JM, 1987, BONE, V8, P305, DOI 10.1016/8756-3282(87)90007-X; DELAISSE JM, 1991, BIOCHEM J, V279, P167, DOI 10.1042/bj2790167; EVERTS V, 1988, CALCIFIED TISSUE INT, V43, P172, DOI 10.1007/BF02571316; EVERTS V, 1992, J CELL PHYSIOL, V150, P221, DOI 10.1002/jcp.1041500202; FALLON MD, 1984, ENDOCRINE CONTROL BO, P144; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; GOTO T, 1993, HISTOCHEMISTRY, V99, P411, DOI 10.1007/BF00717054; GROSS J, 1965, P NATL ACAD SCI USA, V54, P1197, DOI 10.1073/pnas.54.4.1197; INAOKA T, 1995, BIOCHEM BIOPH RES CO, V206, P89, DOI 10.1006/bbrc.1995.1013; KAKEGAWA H, 1993, FEBS LETT, V321, P247, DOI 10.1016/0014-5793(93)80118-E; KHOURI HE, 1991, BIOCHEMISTRY-US, V30, P8929, DOI 10.1021/bi00101a003; KIRSCHKE H, 1993, PORTL PR P, P33; KIRSCHKE H, 1994, METHOD ENZYMOL, V244, P500; KRANE SM, 1994, SCI AM MED, V3, P1; MACIEWICZ RA, 1987, COLLAGEN REL RES, V7, P295; MACIEWICZ RA, 1988, BIOCHEM J, V256, P433, DOI 10.1042/bj2560433; MENARD R, 1991, BIOCHEMISTRY-US, V30, P5531, DOI 10.1021/bi00236a028; PAGE AE, 1992, BIOCHIM BIOPHYS ACTA, V1116, P57, DOI 10.1016/0304-4165(92)90128-H; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; ROWAN AD, 1992, J BIOL CHEM, V267, P15993; SANESHIGE S, 1995, BIOCHEM J, V309, P721, DOI 10.1042/bj3090721; SHI GP, 1995, FEBS LETT, V357, P129, DOI 10.1016/0014-5793(94)01349-6; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; TEZUKA K, 1994, J BIOL CHEM, V269, P1106; TURK B, 1993, BIOCHEMISTRY-US, V32, P375, DOI 10.1021/bi00052a046; VERNET T, 1990, J BIOL CHEM, V265, P16661; XIN XQ, 1992, ARCH BIOCHEM BIOPHYS, V299, P334, DOI 10.1016/0003-9861(92)90283-3; [No title captured]	36	367	380	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2126	2132		10.1074/jbc.271.4.2126	http://dx.doi.org/10.1074/jbc.271.4.2126			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567669	hybrid			2022-12-25	WOS:A1996TR32000051
J	Fuentes, GM; RodriguezRodriguez, L; Palaniappan, C; Fay, PJ; Bambara, RA				Fuentes, GM; RodriguezRodriguez, L; Palaniappan, C; Fay, PJ; Bambara, RA			Strand displacement synthesis of the long terminal repeats by HIV reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA TEMPLATES; VIRUS; RNA; RETROVIRUS; EXPRESSION; PROTEIN; INVITRO	According to the current model for retroviral replication, strand displacement of the long terminal. repeat (LTR) is a necessary step during plus strand DNA synthesis in vivo. We have investigated the ability of human immunodeficiency virus reverse transcriptase (HIV-RT) to synthesize in vitro over a 634-nucleotide HIV LTR DNA template, having or lacking a single full-length DNA downstream primer, The presence of the down-stream primer resulted in an approximately 12-fold reduction in the rate of upstream primer elongation. Addition of Escherichia coli single-stranded binding protein (SSB) or human replication protein A (RP-A) enhanced strand displacement synthesis; however, addition of HIV nucleocapsid protein (NC) did not, The presence of excess single-stranded DNA complementary to the downstream primer did not stimulate displacement synthesis, Interestingly, we observed that the elongating upstream primer could readily transfer to this DNA. This observation suggests that recombination is favored during strand displacement synthesis in vivo.	UNIV ROCHESTER,SCH MED & DENT,DEPT MICROBIOL & IMMUNOL,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester; University of Rochester					NCI NIH HHS [CA11198] Funding Source: Medline; NIGMS NIH HHS [GM 49573, 1F 31 GM 17200-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573, F31GM017200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLLETT MS, 1978, J VIROL, V26, P498, DOI 10.1128/JVI.26.2.498-509.1978; DESTEFANO JJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P270, DOI 10.1016/0167-4781(92)90025-U; DIMARZO VF, 1986, SCIENCE, V231, P1281; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; HOTTIGER M, 1994, J BIOL CHEM, V269, P986; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JUNGHANS RP, 1982, J VIROL, V43, P544, DOI 10.1128/JVI.43.2.544-554.1982; KENNY M K, 1990, Journal of Biological Chemistry, V265, P7693; KHAN R, 1992, J BIOL CHEM, V267, P6689; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; Kornberg A., 1992, DNA REPLICATION; LI P, 1993, VIROLOGY, V194, P82, DOI 10.1006/viro.1993.1237; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; MATSON SW, 1980, BIOCHEMISTRY-US, V19, P2089, DOI 10.1021/bi00551a014; MILLER MD, 1995, J VIROL, V69, P3938, DOI 10.1128/JVI.69.6.3938-3944.1995; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; Sambrook J, 1989, MOL CLONING LABORATO; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WHITCOMB JM, 1992, ANNU REV CELL BIOL, V8, P275, DOI 10.1146/annurev.cb.08.110192.001423; WHITING SH, 1994, J VIROL, V68, P4747, DOI 10.1128/JVI.68.8.4747-4758.1994; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; YOU JC, 1993, J BIOL CHEM, V268, P16519; YU H, 1992, J BIOL CHEM, V267, P10888	25	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1966	1971		10.1074/jbc.271.4.1966	http://dx.doi.org/10.1074/jbc.271.4.1966			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567645	hybrid			2022-12-25	WOS:A1996TR32000027
J	Marchfelder, A; Brennicke, A; Binder, S				Marchfelder, A; Brennicke, A; Binder, S			RNA editing is required for efficient excision of tRNA (Phe) from precursors in plant mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; CONSERVATION; SEQUENCES	RNA editing corrects a C-4 . A(69) mismatch to a conventional T-4-A(69) Watson-Crick base pair in the acceptor stem of the mitochondrially encoded tRNA(Phe) in plants. in vitro processing of edited and unedited Oenothera tRNA(Phe) precursor RNAs with pea mitochondrial protein extracts shows a significant effect of this RNA-editing event on the efficiency of 5' and 3' processing. While mature tRNA molecules are rapidly generated by in vitro processing from edited precursors, the formation of mature tRNAs from unedited pre-tRNAs is considerably reduced. Primer extension analyses of in vitro processing products show that processing at both 5' and 3' termini is governed by the RNA-editing event. Investigation of edited and unedited precursor RNAs by lead cleavage experiments reveals differences in the higher order structures of the pre-tRNAs. The differing conformations are most likely responsible for the altered processing efficiencies of edited and unedited precursor molecules. RNA editing of the tRNA(Phe) precursors is thus a prerequisite for efficient excision of the mature tRNA(Phe) in vitro. Hence RNA editing might be involved in regulating the amount of mature tRNA(Phe) in the steady state RNA pool of mitochondria in higher plants.	INST GENBIOL FORSCH, D-14195 BERLIN, GERMANY; UNIV ULM, ABT ALLGEMEINE BOT, D-89069 ULM, GERMANY	Ulm University				Marchfelder, Anita/0000-0002-1382-1794				BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; BINDER S, 1993, NUCLEIC ACIDS RES, V21, P5012, DOI 10.1093/nar/21.22.5012; BINDER S, 1992, J BIOL CHEM, V267, P7615; BINDER S, 1994, MOL GEN GENET, V244, P67, DOI 10.1007/BF00280188; BONNARD G, 1992, CRIT REV PLANT SCI, V10, P503, DOI 10.1080/07352689209382325; BORNER GV, 1995, MOL GEN GENET, V246, P739, DOI 10.1007/BF00290721; CHEN JY, 1988, J BIOL CHEM, V263, P13677; COVELLO PS, 1989, NATURE, V341, P662, DOI 10.1038/341662a0; GRAY MW, 1992, ANNU REV PLANT PHYS, V43, P145, DOI 10.1146/annurev.pp.43.060192.001045; GUALBERTO JM, 1989, NATURE, V341, P660, DOI 10.1038/341660a0; HANICJOYCE PJ, 1990, J BIOL CHEM, V265, P13782; HIESEL R, 1989, SCIENCE, V246, P1632, DOI 10.1126/science.2480644; HIESEL R, 1994, P NATL ACAD SCI USA, V91, P629, DOI 10.1073/pnas.91.2.629; KAHLE D, 1990, EMBO J, V9, P1929, DOI 10.1002/j.1460-2075.1990.tb08320.x; KING MP, 1993, J BIOL CHEM, V268, P10228; KNOOP V, 1995, CURR GENET, V27, P559, DOI 10.1007/BF00314448; MANAM S, 1987, J BIOL CHEM, V262, P10272; MARCHFELDER A, 1990, NUCLEIC ACIDS RES, V18, P1401, DOI 10.1093/nar/18.6.1401; MARCHFELDER A, 1993, BIOCHEM MOL BIOL INT, V29, P621; MARECHALDROUARD L, 1993, NUCLEIC ACIDS RES, V21, P4909, DOI 10.1093/nar/21.21.4909; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1983, EMBO J, V2, P33, DOI 10.1002/j.1460-2075.1983.tb01376.x; RAJASEKHAR VK, 1993, PLANT CELL, V5, P1843, DOI 10.2307/3869699; Sambrook J, 1989, MOL CLONING LABORATO; SCHUSTER W, 1991, CURR GENET, V20, P397, DOI 10.1007/BF00317068; STEINBERG S, 1993, PROG NUCLEIC ACIDS R, V23, P227; THURLOW DL, 1991, NUCLEIC ACIDS RES, V19, P885, DOI 10.1093/nar/19.4.885; WISSINGER B, 1992, TRENDS GENET, V8, P322, DOI 10.1016/0168-9525(92)90265-6; ZITO K, 1993, NUCLEIC ACIDS RES, V21, P5916, DOI 10.1093/nar/21.25.5916	29	48	51	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1898	1903		10.1074/jbc.271.4.1898	http://dx.doi.org/10.1074/jbc.271.4.1898			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567636	hybrid			2022-12-25	WOS:A1996TR32000018
J	Nakayama, J; Fukuda, M				Nakayama, J; Fukuda, M			A human polysialyltransferase directs in vitro synthesis of polysialic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULES; LONG OLIGOSACCHARIDE SEGMENT; CARBOHYDRATE UNITS; MONOCLONAL-ANTIBODY; GLYCOPROTEINS; EXPRESSION; BINDING; ADULT; SIALYLTRANSFERASE; CLEAVAGE	Polysialic acid (PSA) is a linear homopolymer of alpha-2,8-linked sialic acid residues whose expression is developmentally regulated and modulates the adhesive property of the neural adhesion molecule, N-CAM. Recently, hamster and human cDNAs encoding polysialyltransferase (PST-1 for the hamster enzyme and PST for the human enzyme) were cloned, and by using the human cDNA it was demonstrated that the expression of PSA in N-CAM facilitates neurite outgrowth (Nakayama, J., Fukuda, M.N., Fredette, B., Ranscht, B., and Fukuda, M. (1995) Proc. Natl. Acad. Sci. U.S.A., 92, 7031-7035; Eckhardt, M.A., Muhlenhoff, M., Bethe, A., Koopman, J., Frosch, M., and Gerardy-Schahn, R. (1995) Nature 373, 715-718.) Although these studies demonstrated that PST-1 and PST synthesize PSA in cultured cells, it was not shown that they could catalyze the polycondensation of alpha-2,8-linked sialic acid on a glycoconjugate template containing alpha-2,3-linked sialic acid. Here we demonstrate that PSA formation by PST is independent from the presence of N-CAM in vivo. We then develop an in vitro assay of PSA synthesis using glycoproteins other than N-CAM as accepters and a soluble PST as an enzyme source. The soluble PST, produced as a chimeric protein fused with protein A, was incubated with rat alpha(1)-acid glycoprotein, fetuin or human alpha(1)-acid glycoprotein as accepters together with the donor substrate CMP-[C-14]NeuNAc. Incubation of fetuin with the soluble PST, in particular, resulted in a high molecular weight product that was susceptible to PSA-specific endoneuraminidase. Polysialylated products were not formed when alpha-2,3-linked sialic acid was removed from the acceptor fetuin before incubation. These results establish that a single enzyme, PST, alone can catalyze both the addition of the first alpha-2,8-linked sialic acid to alpha-2,3-linked sialic acid and the polycondensation of all alpha-2,8-linked sialic acids, yielding PSA.	LA JOLLA CANC RES FDN, CANC RES CTR, GLYCOBIOL PROGRAM, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [R01CA033895] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA33895] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIXBY JL, 1987, P NATL ACAD SCI USA, V84, P2555, DOI 10.1073/pnas.84.8.2555; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; EDELMAN GM, 1985, ANNU REV BIOCHEM, V54, P135, DOI 10.1146/annurev.bi.54.070185.001031; FINNE J, 1985, J BIOL CHEM, V260, P1265; FINNE J, 1982, J BIOL CHEM, V257, P1966; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; GREEN ED, 1988, J BIOL CHEM, V263, P18253; HALLENBECK PC, 1987, J BIOL CHEM, V262, P3553; HAYRINEN J, 1989, MOL IMMUNOL, V26, P523, DOI 10.1016/0161-5890(89)90003-5; HOFFMAN S, 1983, P NATL ACAD SCI-BIOL, V80, P5762, DOI 10.1073/pnas.80.18.5762; KADMON G, 1990, J CELL BIOL, V110, P209, DOI 10.1083/jcb.110.1.209; KITAZUME S, 1994, J BIOL CHEM, V269, P10330; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MCCOY RD, 1985, J BIOL CHEM, V260, P2695; NAKAYAMA J, 1995, P NATL ACAD SCI USA, V92, P7031, DOI 10.1073/pnas.92.15.7031; NAKAYAMA J, 1993, J HISTOCHEM CYTOCHEM, V41, P1563, DOI 10.1177/41.10.8245415; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SADOUL R, 1983, NATURE, V304, P347, DOI 10.1038/304347a0; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SATO C, 1995, J BIOL CHEM, V270, P18923, DOI 10.1074/jbc.270.32.18923; SCHEIDEGGER EP, 1995, J BIOL CHEM, V270, P22685, DOI 10.1074/jbc.270.39.22685; SEKI T, 1991, ANAT EMBRYOL, V184, P395, DOI 10.1007/BF00957900; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; SUZUKI T, 1995, GLYCOCONJUGATE J, V12, P183, DOI 10.1007/BF00731318; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	32	67	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1829	1832		10.1074/jbc.271.4.1829	http://dx.doi.org/10.1074/jbc.271.4.1829			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567623	hybrid			2022-12-25	WOS:A1996TR32000005
J	Palaniappan, C; Fuentes, GM; RodriguezRodriguez, L; Fay, PJ; Bambara, RA				Palaniappan, C; Fuentes, GM; RodriguezRodriguez, L; Fay, PJ; Bambara, RA			Helix structure and ends of RNA/DNA hybrids direct the cleavage specificity of HIV-1 reverse transcriptase RNase H	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SITE-SPECIFIC MUTAGENESIS; RIBONUCLEASE-H; DNA-POLYMERASE; PHENOTYPIC SELECTION; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; STRAND TRANSFER; ENDONUCLEASE; MECHANISM	RNA/DNA hybrids in human immunodeficiency virus (HIV) replication are cleaved by HIV-1 reverse transcriptase (RT) RNase H in locations determined by hybrid structure, Minus strand DNA synthesis is accompanied by cleavage of template viral RNA directed by RT positioned at the growing 3' DNA end. Some RNA remains as oligomers annealed to the new DNA strand and is cut by RTs positioned at the 5' RNA ends. We constructed substrates to test the hypothesis that internal helix structure, rather than strand end structure, drives the RT to position at 3' DNA and 5' RNA ends. On substrates with an RNA primer recessed on a DNA template, the 5' end of the RNA had a dominant role in the determination of RNase H cleavage positions. If the 5' end region of the RNA could not anneal, cleavage would not occur. Nevertheless, we obtained evidence that helix structure promotes the binding of RT to the end of the helical region closest to the 5' RNA/3' DNA end. When a DNA primer recessed on an RNA template had a 3' unannealed region, cleavage occurred, with RT positioned solely by helical structure at the 5' RNA/3' DNA end of the annealed region of the hybrid. Using substrates having RNA primers annealed to circular DNA templates, we showed that cleavage can be independent of the presence of a DNA 3' end and is directed by the 5' RNA end, Overall, the results suggest that the RT initially binds an internal region of the hybrid and then is driven in the direction to encounter a 3' DNA or 5' RNA end, where it is positioned for catalysis by the strand end. The requirement for two modes of RNA cleavage in viral replication and the unexpected requirement for the 5' RNA end structure are discussed.	UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,CTR CANC,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester					NATIONAL CANCER INSTITUTE [P30CA011198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573] Funding Source: NIH RePORTER; NCI NIH HHS [CA 11198] Funding Source: Medline; NIGMS NIH HHS [GM 49573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; CIRINO NM, 1995, BIOCHEMISTRY-US, V34, P9936, DOI 10.1021/bi00031a016; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P7423; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1993, NUCLEIC ACIDS RES, V21, P4330, DOI 10.1093/nar/21.18.4330; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; DESTEFANO JJ, 1994, BBA-GENE STRUCT EXPR, V1219, P380, DOI 10.1016/0167-4781(94)90062-0; DUDDING LR, 1991, BIOCHEMISTRY-US, V30, P10498, DOI 10.1021/bi00107a019; FU T, 1992, J VIROL, V66, P406; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GHOSH M, 1995, J BIOL CHEM, V270, P7068, DOI 10.1074/jbc.270.13.7068; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JOHNSON MS, 1986, P NATL ACAD SCI USA, V83, P7648, DOI 10.1073/pnas.83.20.7648; KATI WM, 1992, J BIOL CHEM, V267, P25988; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRUG MS, 1989, P NATL ACAD SCI USA, V86, P3539, DOI 10.1073/pnas.86.10.3539; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIGHTFOOTE MM, 1986, J VIROL, V60, P771, DOI 10.1128/JVI.60.2.771-775.1986; PALANIAPPAN C, 1995, J BIOL CHEM, V270, P4861, DOI 10.1074/jbc.270.9.4861; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P3890, DOI 10.1021/bi00179a014; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; REPASKE R, 1989, J VIROL, V63, P1460, DOI 10.1128/JVI.63.3.1460-1464.1989; Sambrook J, 1989, MOL CLONING LABORATO; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; TANESE N, 1988, P NATL ACAD SCI USA, V85, P1777, DOI 10.1073/pnas.85.6.1777; Telesnitsky A, 1993, REVERSE TRANSCRIPTAS; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; ZHAN XY, 1994, BIOCHEMISTRY-US, V33, P1366, DOI 10.1021/bi00172a012	34	76	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2063	2070		10.1074/jbc.271.4.2063	http://dx.doi.org/10.1074/jbc.271.4.2063			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567660	hybrid			2022-12-25	WOS:A1996TR32000042
J	Post, SR; Jacobson, JP; Insel, PA				Post, SR; Jacobson, JP; Insel, PA			P-2 purinergic receptor agonists enhance cAMP production in Madin-Darby canine kidney epithelial cells via an autocrine paracrine mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL TRANSDUCTION SYSTEMS; ATP-STIMULATED MITOGENESIS; ARACHIDONIC-ACID RELEASE; EXTRACELLULAR ATP; P2-PURINERGIC RECEPTORS; ADENYLYL CYCLASE; PROSTAGLANDIN SYNTHESIS; MAMMALIAN-CELLS; PHORBOL ESTER	Mechanisms of cross-talk between different classes of signaling molecules are inadequately understood, We have used clonal Madin-Darby canine kidney (MDCK-D-1) epithelial cells as a model system to investigate the effects of extracellular nucleotides (e.g. ATP, UTP), which promote increase in activity of several phospholipases, on cAMP production, In contrast to observations in some other cell systems, ATP and UTP, acting via P-2 purinergic receptors, stimulated cAMP production in MDCK-D-1 cells, At maximally effective concentrations, ATP and UTP were not additive with the beta-adrenergic receptor agonist isoproterenol, but were synergistic with forskolin in increasing cAMP production, indicating that G(alpha s) is activated by these nucleotides, Additionally, we found that (a) nucleotide-induced increases in cAMP were blocked by indomethacin, a cyclooxygenase inhibitor, (b) arachidonic acid increased cellular cAMP levels in an indomethacin sensitive fashion, and (c) PGE(2), the major metabolite of arachidonic acid, stimulated cAMP formation, Overall, our results suggest a mechanism by which extracellular nucleotides stimulate release of arachidonic acid which is metabolized to PGE(2) which, in turn, acts in an autocrine/paracrine fashion via prostaglandin receptors to activate G(alpha s) and increase cAMP, Based on the ability of extracellular nucleotides to stimulate the formation and release of prostaglandins in MDCK-D-1 epithelial and other cells, we hypothesize that receptor-mediated prostaglandin release may be a general mechanism that regulates cAMP formation in many types of cells.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego				Post, Steven/0000-0002-4711-1723; Jacobson, Jon/0000-0002-7535-8539	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL053773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031987, R01GM040781] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 53773] Funding Source: Medline; NIGMS NIH HHS [GM 40781, GM 31987] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSUP DJ, 1990, MOL PHARMACOL, V38, P84; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BOARDER MR, 1995, TRENDS PHARMACOL SCI, V16, P133, DOI 10.1016/S0165-6147(00)89001-X; BOYER JL, 1993, J PHARMACOL EXP THER, V267, P1140; BOYER JL, 1989, J BIOL CHEM, V264, P884; BURNSTOCK G, 1985, GEN PHARMACOL, V16, P433, DOI 10.1016/0306-3623(85)90001-1; CHOI EJ, 1993, BIOCHEMISTRY-US, V32, P1891, DOI 10.1021/bi00059a001; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; COTE S, 1993, AM J PHYSIOL, V264, pH1498; DARFLER FJ, 1982, J BIOL CHEM, V257, P1901; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; DUBYAK GR, 1986, ARCH BIOCHEM BIOPHYS, V245, P84, DOI 10.1016/0003-9861(86)90192-X; FIRESTEIN BL, 1995, FASEB J, V9, pA553; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; HARDEN TK, 1995, ANNU REV PHARMACOL, V35, P541, DOI 10.1146/annurev.pharmtox.35.1.541; HUANG N, 1994, J BIOL CHEM, V269, P548; HUANG NN, 1991, J CELL PHYSIOL, V146, P483, DOI 10.1002/jcp.1041460320; INSEL PA, 1991, BIOCHEM SOC T, V19, P329, DOI 10.1042/bst0190329; JASPER JR, 1990, MOL PHARMACOL, V37, P44; JOHNSON JA, 1991, MOL PHARMACOL, V40, P539; KEPPENS S, 1992, BRIT J PHARMACOL, V105, P475, DOI 10.1111/j.1476-5381.1992.tb14278.x; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; LAURENZA A, 1991, METHOD ENZYMOL, V195, P52; LAZAROWSKI ER, 1994, AM J PHYSIOL, V266, pC406, DOI 10.1152/ajpcell.1994.266.2.C406; MEIER KE, 1985, AM J PHYSIOL, V249, pC69, DOI 10.1152/ajpcell.1985.249.1.C69; MEIER KE, 1983, J CELL BIOL, V97, P405, DOI 10.1083/jcb.97.2.405; MORIMOTO BH, 1994, J BIOL CHEM, V269, P4065; MUNSHI R, 1993, MOL PHARMACOL, V44, P1185; OKAJIMA F, 1989, J BIOL CHEM, V264, P13029; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; PFEILSCHIFTER J, 1993, BRIT J PHARMACOL, V110, P847, DOI 10.1111/j.1476-5381.1993.tb13890.x; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; SIMMONS NL, 1982, GEN PHARMACOL, V13, P287, DOI 10.1016/0306-3623(82)90047-7; SIMMONS NL, 1991, J PHYSIOL-LONDON, V432, P459, DOI 10.1113/jphysiol.1991.sp018394; SIMMONS NL, 1984, FED PROC, V43, P2225; SLIVKA SR, 1988, J BIOL CHEM, V263, P14640; SUTKOWSKI EM, 1994, BIOCHEMISTRY-US, V33, P12852, DOI 10.1021/bi00209a017; TAKEMOTO F, 1992, PFLUG ARCH EUR J PHY, V421, P302, DOI 10.1007/BF00374216; TAUB ML, 1992, J CELL PHYSIOL, V151, P337, DOI 10.1002/jcp.1041510215; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; VALEINS H, 1992, MOL PHARMACOL, V42, P1033; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WANG DJ, 1991, J CELL PHYSIOL, V146, P473, DOI 10.1002/jcp.1041460319; WATSON PA, 1994, J BIOL CHEM, V269, P28893; WAYMAN GA, 1994, J BIOL CHEM, V269, P25400; XIA ZG, 1993, J NEUROCHEM, V60, P305, DOI 10.1111/j.1471-4159.1993.tb05852.x; YAMADA M, 1992, CIRC RES, V70, P477, DOI 10.1161/01.RES.70.3.477; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	49	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2029	2032		10.1074/jbc.271.4.2029	http://dx.doi.org/10.1074/jbc.271.4.2029			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567655	hybrid			2022-12-25	WOS:A1996TR32000037
J	Shin, JM; Sachs, G				Shin, JM; Sachs, G			Dimerization of the gastric H+,K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION INACTIVATION ANALYSIS; H+/K+-ATPASE; BETA-SUBUNIT; MOLECULAR-SIZE; ALPHA-SUBUNIT; CROSS-LINKING; CDNA CLONING; ELECTROPHORESIS; IDENTIFICATION; H,K-ATPASE	When the gastric H+,K+-ATPase was solubilized by n-dodecyl beta-D-maltoside and electrophoresed in blue native-polyacrylamide gels (BN-PAGE), one major band at about 360 kDa was observed. Since this band was recognized by both monoclonal antibodies 1218 (anti-alpha) and wheat germ agglutinin (anti-beta), the H+,K+-ATPase in its native state exists in a dimeric (alpha beta)(2) form. The site of interaction between the heterodimers was determined using Cu2+-phenanthroline cross-linking. The Cu2+-phenanthroline reagent reacted with the H+,K+-ATPase to produce an alpha,alpha-dimer and inhibited H+,K+-ATPase activity. This cross-linking and enzyme inhibition were prevented by ATP. Cross-linking followed by N-ethylmaleimide blockade of maleimide-reactive SH groups, then reduction and fluorescein 5-maleimide labeling, defined a single fluorescent tryptic peptide of about 6.5 kDa that had been cross-linked. Since its N-terminal amino acid is Val(561), the peptide probably ends at Arg(616) or Arg(621) and Cys(565) and/or Cys(615) are probably within the region of closest contact between the two alpha-subunits.	VET ADM WADSWORTH MED CTR,LOS ANGELES,CA 90073; UNIV CALIF LOS ANGELES,DEPT PHYSIOL & MED,LOS ANGELES,CA 90073	University of California System; University of California Los Angeles					NCRR NIH HHS [1S10RRO554-01] Funding Source: Medline; NIDDK NIH HHS [DK40615, DK41301] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK041301, R01DK040615] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASKARI A, 1980, BIOCHEMISTRY-US, V19, P1132, DOI 10.1021/bi00547a015; BAMBERG K, 1992, BIOCHIM BIOPHYS ACTA, V1131, P69, DOI 10.1016/0167-4781(92)90100-E; CALLAGHAN JM, 1990, J CELL SCI, V95, P563; GANJEIZADEH M, 1995, J BIOL CHEM, V270, P15707, DOI 10.1074/jbc.270.26.15707; HALL K, 1990, BIOCHEMISTRY-US, V29, P701, DOI 10.1021/bi00455a016; HALL K, 1991, BIOCHIM BIOPHYS ACTA, V1077, P173, DOI 10.1016/0167-4838(91)90055-5; HEBERT H, 1992, FEBS LETT, V299, P159, DOI 10.1016/0014-5793(92)80237-B; HUANG WH, 1981, BIOCHIM BIOPHYS ACTA, V645, P54, DOI 10.1016/0005-2736(81)90511-3; JI TH, 1983, METHOD ENZYMOL, V91, P580; KOSTER JC, 1995, J BIOL CHEM, V270, P14332, DOI 10.1074/jbc.270.24.14332; LANE LK, 1986, BIOCHEM BIOPH RES CO, V138, P185, DOI 10.1016/0006-291X(86)90264-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAEDA M, 1988, BIOCHEM BIOPH RES CO, V157, P203, DOI 10.1016/S0006-291X(88)80033-0; MARTIN DW, 1992, J BIOL CHEM, V267, P23922; MERCIER F, 1993, BIOCHIM BIOPHYS ACTA, V1149, P151, DOI 10.1016/0005-2736(93)90036-Y; OKAMOTO CT, 1990, BIOCHIM BIOPHYS ACTA, V1037, P360, DOI 10.1016/0167-4838(90)90038-H; PERIYASAMY SM, 1983, J BIOL CHEM, V258, P9878; RABON EC, 1988, J BIOL CHEM, V263, P16189; REUBEN MA, 1990, P NATL ACAD SCI USA, V87, P6767, DOI 10.1073/pnas.87.17.6767; SACCOMANI G, 1979, J BIOL CHEM, V254, P2821; SACCOMANI G, 1981, J BIOL CHEM, V256, P7727; SACHS G, 1976, J BIOL CHEM, V251, P7690; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; SCHRIJEN JJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P329, DOI 10.1016/0005-2736(83)90025-1; SHIN JM, 1994, J BIOL CHEM, V269, P8642; SHULL GE, 1986, J BIOL CHEM, V261, P6788; TOH BH, 1990, P NATL ACAD SCI USA, V87, P6418, DOI 10.1073/pnas.87.16.6418; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	30	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1904	1908		10.1074/jbc.271.4.1904	http://dx.doi.org/10.1074/jbc.271.4.1904			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567637	hybrid			2022-12-25	WOS:A1996TR32000019
J	Dutta, R; Inouye, M				Dutta, R; Inouye, M			Reverse phosphotransfer from OmpR to EnvZ in a kinase(-)/phosphatase(+) mutant of EnvZ (EnvZ center dot N347D), a bifunctional signal transducer of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORIN GENE-EXPRESSION; PHOSPHATASE-ACTIVITIES; MEMBRANE-PROTEINS; 2-COMPONENT REGULATORS; TRANSMEMBRANE RECEPTOR; KINASE; K-12; PHOSPHORYLATION; OSMOREGULATION; TRANSCRIPTION	EnvZ of Escherichia coli is a transmembrane histidine kinase belonging to the family of two-component signal transducing systems prevalent in prokaryotes and recently discovered in eukaryotes. In response to changes in medium osmolarity EnvZ regulates the level of phosphorylated OmpR, its conjugate response regulating transcription factor for ompF and ompC genes. EnvZ has dual opposing enzymatic activities; OmpR-phosphorylase (kinase) and phospho-OmpR-dephosphorylase (phosphatase). The osmotic signal is proposed to regulate the ratio of the kinase to the phosphatase activities of EnvZ to modulate the level of OmpR phosphorylation. In this work we used a COOH terminal fragment of a previously identified kinase(-)/phosphatase(+) EnvZ mutant (EnvZ . N347D) to demonstrate that the phosphoryl group on phospho-Ompr is transferred back to EnvZ to the same histidine residue (His(243)) that is utilized for the autokinase reaction by the wild type protein. Phospho-EnvZ . N347D thus formed could also transfer its phosphoryl group back to OmpR. The phosphotransfer reaction from phospho-OmpR to EnvZ . N347D was inhibited by ADP while Mg2+ ions stimulated the dephosphorylation reaction, resulting in release of inorganic phosphate. These results indicate that the energy levels of phosphoryl groups on OmpR and EnvZ are very similar and that the phosphatase reaction in the EnvZ . N347D mutant involves a reversal of the phosphotransfer reaction from EnvZ to OmpR using the identical His(243) residue.			Dutta, R (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854, USA.				NIGMS NIH HHS [GM19043] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019043, R37GM019043] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA H, 1989, J BIOL CHEM, V264, P8563; AIBA H, 1990, FEBS LETT, V261, P19, DOI 10.1016/0014-5793(90)80626-T; ALEA LA, 1994, TRENDS GENET, V10, P133; ATKINSON MR, 1993, J BACTERIOL, V175, P7016, DOI 10.1128/jb.175.21.7016-7023.1993; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CROVELLO CS, 1995, CELL, V82, P279, DOI 10.1016/0092-8674(95)90315-1; CSONKA LN, 1991, ANNU REV MICROBIOL, V45, P569, DOI 10.1146/annurev.mi.45.100191.003033; CSONKA LN, 1989, MICROBIOL REV, V53, P121, DOI 10.1128/MMBR.53.1.121-147.1989; DELGADO J, 1993, MOL MICROBIOL, V10, P1037, DOI 10.1111/j.1365-2958.1993.tb00974.x; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; FORST S, 1988, ANNU REV CELL BIOL, V4, P21, DOI 10.1146/annurev.cb.04.110188.000321; HALL MN, 1981, J MOL BIOL, V151, P1, DOI 10.1016/0022-2836(81)90218-7; IGO MM, 1988, J BACTERIOL, V170, P5971, DOI 10.1128/jb.170.12.5971-5973.1988; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; JIN T, 1993, J MOL BIOL, V232, P484, DOI 10.1006/jmbi.1993.1404; KAMBEROV ES, 1994, J BIOL CHEM, V269, P28294; KAWAJI H, 1979, J BACTERIOL, V140, P843, DOI 10.1128/JB.140.3.843-847.1979; KEENER J, 1988, P NATL ACAD SCI USA, V85, P4976, DOI 10.1073/pnas.85.14.4976; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MIZUNO T, 1987, J BIOCHEM-TOKYO, V101, P387, DOI 10.1093/oxfordjournals.jbchem.a121923; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; NINFA AJ, 1986, P NATL ACAD SCI USA, V83, P5909, DOI 10.1073/pnas.83.16.5909; OTA IM, 1993, SCIENCE, V262, P566, DOI 10.1126/science.8211183; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; RUSSO FD, 1991, J MOL BIOL, V222, P567, DOI 10.1016/0022-2836(91)90497-T; SARMA V, 1977, J BACTERIOL, V132, P23, DOI 10.1128/JB.132.1.23-27.1977; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SLAUCH JM, 1989, J MOL BIOL, V210, P281, DOI 10.1016/0022-2836(89)90330-6; SWANSON RV, 1994, CURR BIOL, V4, P234, DOI 10.1016/S0960-9822(00)00052-X; TOKISHITA S, 1994, MOL MICROBIOL, V13, P435, DOI 10.1111/j.1365-2958.1994.tb00438.x; UTSUMI R, 1989, SCIENCE, V245, P1246, DOI 10.1126/science.2476847; WEISS V, 1988, P NATL ACAD SCI USA, V85, P8919, DOI 10.1073/pnas.85.23.8919; YANG Y, 1993, J MOL BIOL, V231, P335, DOI 10.1006/jmbi.1993.1286; YANG Y, 1991, P NATL ACAD SCI USA, V88, P11057, DOI 10.1073/pnas.88.24.11057	34	63	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1424	1429		10.1074/jbc.271.3.1424	http://dx.doi.org/10.1074/jbc.271.3.1424			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576133	hybrid			2022-12-25	WOS:A1996TQ52500029
J	Franco, M; Chardin, P; Chabre, M; Paris, S				Franco, M; Chardin, P; Chabre, M; Paris, S			Myristoylation-facilitated binding of the G protein ARF1(GDP) to membrane phospholipids is required for its activation by a soluble nucleotide exchange factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; BREFELDIN-A; GOLGI MEMBRANES; GUANINE-NUCLEOTIDE; RAS PROTEINS; ARF; DOMAIN	We have investigated the role of N-myristoylation in the activation of bovine ADP-ribosylation factor 1 (ARF1). We previously showed that myristoylation allows some spontaneous GDP-to-GTP exchange to occur on ARF1 at physiological Mg2+ levels in the presence of phospholipid vesicles (France, M., Chardin, P., Chabre, M., and Paris, S, (1995) J, Biol, Chem, 270, 1337-1341), Here, we report that this basal nucleotide exchange can be accelerated (by up to 5-fold) by addition of a soluble fraction obtained from bovine retinas, This acceleration is totally abolished by brefeldin A (IC50 = 2 mu M) and by trypsin treatment of the retinal extract, as expected for an ARF-specific guanine nucleotide exchange factor, To accelerate GDP release from ARF1, this soluble exchange factor absolutely requires myristoylation of ARF1 and the presence of phospholipid vesicles, The retinal extract also stimulates guanosine 5'-3-0-(thio)-triphosphate (GTP?IS) release from ARF1 in the presence of phospholipids, but in this case myristoylation of ARF is not required, These observations, together with our previous findings that both myristoylated and nonmyristoylated forms of ARF(GTP gamma s) but only the myristoylated form of ARF(GDP) bind to membrane phospholipids, suggest that (i) the retinal exchange factor acts only on membrane-bound ARF, (ii) the myristate is not involved in the protein-protein interaction between ARF1 and the exchange factor, and (iii) N-myristoylation facilitates both spontaneous and catalyzed GDP-to-GTP exchange on ARF1 simply by facilitating the binding of ARF(GDP) to membrane phospholipids.	CNRS,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			Franco, Michel/ABH-4993-2020; FRANCO, michel/AAA-9735-2021	Franco, Michel/0000-0003-1853-8661; 				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BIGAY J, 1994, METHOD ENZYMOL, V237, P139; BIGAY J, 1994, BIOCHEMISTRY-US, V33, P14081, DOI 10.1021/bi00251a017; BIGAY J, 1994, NATURE, V372, P704; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DERETIC D, 1991, J CELL BIOL, V113, P1281, DOI 10.1083/jcb.113.6.1281; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FRANCO M, 1995, FEBS LETT, V362, P286, DOI 10.1016/0014-5793(95)00258-B; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; FRANCO M, 1993, J BIOL CHEM, V268, P24531; GLOMSET JA, ANN REV CELL BIOL, V10, P18194; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LIU BX, 1993, ONCOGENE, V8, P3081; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; RANDAZZO PA, 1993, J BIOL CHEM, V268, P9555; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TERUI T, 1994, J BIOL CHEM, V269, P28130; TONER M, 1988, BIOCHEMISTRY-US, V27, P7435, DOI 10.1021/bi00419a039; TSAI SC, 1993, J BIOL CHEM, V268, P10820; TSAI SC, 1994, P NATL ACAD SCI USA, V91, P3068; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	35	109	111	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1573	1578		10.1074/jbc.271.3.1573	http://dx.doi.org/10.1074/jbc.271.3.1573			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576155	hybrid			2022-12-25	WOS:A1996TQ52500051
J	Lee, KY; Rosales, JL; Tang, D; Wang, JH				Lee, KY; Rosales, JL; Tang, D; Wang, JH			Interaction of cyclin-dependent kinase 5 (Cdk5) and neuronal Cdk5 activator in bovine brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED PROTEIN-KINASE; TRANSCRIPTION FACTOR E2F; BINDING; PHASE; ASSOCIATION; INHIBITION; P34(CDC2); SUBUNIT; COMPLEX; FAMILY	Neuronal cdc2-like kinase (Nclk) purified from bovine brain is a heterodimer of Cdk5 and an essential 25-kDa regulatory subunit (Lew, J,, and Wang, J, H, (1995) Trends Biochem, Sci, 20, 33-37), The regulatory subunit is an N-terminal truncated derivative of a 35-kDa protein expressed specifically in brain, hence the name neuronal Cdk5 activator, p25/p35(nck5a), In this study, we probe the relationship between the two different forms of Nck5a and their interaction with and activation of Cdk5 in bovine brain extract, Using protein fraction ation procedures in combination with Western blot analysis and protein kinase assay, three forms of Cdk5 have been detected in bovine brain: a monomeric Cdk5 that can be activated by bacterially expressed GST-p21(nck5a), a heterodimer of Cdk5 and p25(nck5a) that displays high kinase activity, and a Cdk5 . p35(nck5a) complex that is inactive and refractory to GST-p21(nck5a) activation, Analysis of the Cdk5 . p35(nck5a) complex by gel filtration chromatography indicated that the complex was part of a macromolecular structure with a molecular mass of similar to 670 kDa, When the macromolecular complex was subjected to gel filtration chromatography in the presences of 10% ethylene glycol, the fractions containing both p35(nck5a) and Cdk5, although eluting at the same position as control, displayed high kinase activity, The result is compatible with the suggestion that the macromolecular complex contained a kinase inhibitory factor that dissociated from the complex in 10% ethylene glycol.	HONG KONG UNIV SCI & TECHNOL,DEPT BIOCHEM,KOWLOON,HONG KONG; UNIV CALGARY,DEPT MED BIOCHEM,MRC,GRP SIGNAL TRANSDUCT,CALGARY,AB T2N 4N1,CANADA	Hong Kong University of Science & Technology; University of Calgary			Tang, Damu/AAQ-1786-2021	Tang, Damu/0000-0002-3282-9521; Rosales, Jesusa/0000-0002-2543-3801				AZZI L, 1994, J BIOL CHEM, V269, P13279; BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; PINES J, 1990, New Biologist, V2, P389; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG H, 1993, MOL BIOL CELL, V4, P894	45	69	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1538	1543		10.1074/jbc.271.3.1538	http://dx.doi.org/10.1074/jbc.271.3.1538			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576150	hybrid			2022-12-25	WOS:A1996TQ52500046
J	Clark, J; Benjamin, H; Gill, S; Sidhar, S; Goodwin, G; Crew, J; Gusterson, BA; Shipley, J; Cooper, CS				Clark, J; Benjamin, H; Gill, S; Sidhar, S; Goodwin, G; Crew, J; Gusterson, BA; Shipley, J; Cooper, CS			Fusion of the EWS gene to CHN, a member of the steroid thyroid receptor gene superfamily, in a human myxoid chondrosarcoma	ONCOGENE			English	Article						CHN oncogene; chondrosarcoma; steroid thyroid receptor	ACUTE PROMYELOCYTIC LEUKEMIA; ALPHA LOCUS; DNA-BINDING; TRANSLOCATION; BREAKPOINT; REGION; TUMORS; FAMILY	The specific chromosomal translocation t(9;22)(q22-31;q11-12) has been observed in the myxoid variant of human chondrosarcoma. In agreement with this observation we report that the EWS gene located at chromosome band 22q12 becomes fused to CHN, a member of the steroid/thyroid receptor gene superfamily located at 9q22-31, in a skeletal myxoid chondrosarcoma. CHN appears to be the human homologue of the rat gene NOR1, which was recently identified as a sequence overexpressed in rat brain cells undergoing apoptosis. Our results also indicate that the chimaeric EWS-CHN gene encodes a EWS-CHN fusion protein in which the C-terminal RNA-binding domain of EWS is replaced by the entire CHN protein, comprising a long N-terminal domain, a central DNA binding domain and a C-terminal ligand-binding/dimerisation domain.	INST CANC RES,HADDOW LABS,SECT MOLEC CARCINOGENESIS,SUTTON SM2 5NG,SURREY,ENGLAND; INST CANC RES,HADDOW LABS,SECT CELL BIOL & EXPTL PATHOL,SUTTON SM2 5NG,SURREY,ENGLAND; CHESTER BEATTY LABS,SECT CELL & MOLEC BIOL,LONDON SW3 6JB,ENGLAND	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK			gusterson, barry a/D-3752-2009	Shipley, Janet/0000-0001-6748-8678				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DEGOS L, 1992, Current Opinion in Oncology, V4, P45, DOI 10.1097/00001622-199202000-00007; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GILL S, 1995, CANCER, V12, P307; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HINRICHS SH, 1985, CANCER GENET CYTOGEN, V14, P219, DOI 10.1016/0165-4608(85)90187-6; JEON IS, 1995, ONCOGENE, V10, P1229; LADANYI M, 1994, CANCER RES, V54, P2837; MAGES HW, 1994, MOL ENDOCRINOL, V8, P1583, DOI 10.1210/me.8.11.1583; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MITELMAN F, 1991, CATALOG CHROMOSOME A; OHKURA N, 1994, BIOCHEM BIOPH RES CO, V205, P1959, DOI 10.1006/bbrc.1994.2900; ORNDAL C, 1991, CYTOPATHOLOGY, V2, P261, DOI 10.1111/j.1365-2303.1991.tb00497.x; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SAINATI L, 1993, CANCER GENET CYTOGEN, V71, P144, DOI 10.1016/0165-4608(93)90020-M; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; TARKKANEN M, 1994, GENE CHROMOSOME CANC, V9, P136, DOI 10.1002/gcc.2870090210; TSAI MJ, 1994, ANN REV BIOCH, V63, P431; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V30, P145, DOI 10.1016/0165-4608(88)90103-3; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WILSON TE, 1991, SCIENCE, V252, P1297; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	35	146	149	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					229	235						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570200				2022-12-25	WOS:A1996TR53800002
J	DAmbrosio, C; Hongo, A; Li, S; Baserga, R				DAmbrosio, C; Hongo, A; Li, S; Baserga, R			The role of Grb2 in the growth and transformation of mouse embryo cells	ONCOGENE			English	Article						Grb2; IGF-I receptor; transformation; T-antigen	INSULIN-RECEPTOR SUBSTRATE-1; MITOGENIC SIGNAL TRANSDUCTION; FACTOR-I; TYROSINE KINASES; SH3 DOMAIN; RAS; PROTEIN; EXPRESSION; IRS-1; GENE	An overexpressed insulin-like growth factor I receptor (IGF-IR) allows cells to grow in IGF-I only and to form colonies in soft agar. Conversely, cells with a targeted disruption of the IGF-IR genes, R(-) cells, are refractory to transformation by several oncoproteins and growth factor receptors, that readily transform their wild type counterparts, W cells. Grb2 is an SH2-SH3 domains protein that links tyrosine kinase receptors to ras signalling. In order to determine its role in mitogenesis and transformation, we have transfected a plasmid expressing Grb2 into R(-) and W cells, and their derivatives already expressing the SV40 large T antigen. In addition, we have used loss-of-function mutants of Grb2 to inquire whether they would act as dominant negatives. Our results show that: (1) an overexpressed Grb2 cannot replace the IGF-IR in IGF-I-mediated mitogenesis; (2) Grb2 also fails to transform either W or R(-) cells; (3) Grb2 and SV40 T antigen, singly transfected, cannot transform R(-) cells, but can do so when combined; and (4) SH3 domain mutants of Grb2 act as dominant negatives, causing reversion of the transformed phenotype. We conclude that Grb2 is necessary but not sufficient for transformation.	THOMAS JEFFERSON UNIV,JEFFERSON CANC CTR,PHILADELPHIA,PA 19107	Jefferson University					NIA NIH HHS [AG 00378] Funding Source: Medline; NIGMS NIH HHS [GM 33694] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG000378] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BASERGA R, 1995, CANCER RES, V55, P249; BASERGA R, 1985, BIOL CELL REPRODUCTI; BASU T, 1994, ONCOGENE, V9, P3483; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COOK JR, 1993, LIFE SCI, V53, P803, DOI 10.1016/0024-3205(93)90502-T; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DEANGELIS T, 1995, IN PRESS J CELL PHYS; DELALUNA S, 1988, GENE, V62, P121; FALCO JP, 1988, ONCOGENE, V2, P573; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KALEBIC T, 1994, CANCER RES, V54, P5531; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; LI FZ, 1995, MOL CELL BIOL, V15, P4232; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI SW, 1994, J BIOL CHEM, V269, P32558; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LU KH, 1989, MOL CELL BIOL, V9, P3411, DOI 10.1128/MCB.9.8.3411; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; RESNICOFF M, 1995, CANCER RES, V55, P2463; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; TOBE K, 1993, J BIOL CHEM, V268, P11167; TORJAN J, 1993, SCIENCE, V256, P94; ULLRICH A, 1986, EMBO J, V5, P503; VALENTINIS B, 1994, ONCOGENE, V9, P825; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427	71	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					371	378						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570214				2022-12-25	WOS:A1996TR53800016
J	Huff, JL; Jelinek, MA; Jamieson, TA; Parsons, JT				Huff, JL; Jelinek, MA; Jamieson, TA; Parsons, JT			Expression and maturation of the cellular sea receptor, a member of the hepatocyte growth factor (HGF) receptor family of protein tyrosine kinases	ONCOGENE			English	Article						c-sea; receptor; protein tyrosine kinase; hepatocyte growth factor	MACROPHAGE STIMULATING PROTEIN; CHICKEN-EMBRYO FIBROBLASTS; SCATTER FACTOR-RECEPTOR; C-MET; AVIAN RETROVIRUS; EPITHELIAL-CELLS; SRC GENE; MYC GENE; PROTOONCOGENE; ONCOGENE	The c-sea proto-oncogene is a member of the Met/hepatocyte growth factor/scatter factor family of receptor protein tyrosine kinases. A distinguishing feature of this family, whose other member is the Ron/Stk receptor, is a novel heterodimeric structure. We have previously described cDNA clones encoding the avian Sea receptor. In this report we show that a fun length c-sea cDNA directed the synthesis of a single 155 kDa polypeptide chain in vitro, while irt vivo two polypeptides of 160 and 180 kDa were observed. We analysed the structure of the Sea receptor using a soluble chimeric protein consisting of the Sea extracellular domain linked to the hinge and constant regions of human IgG gamma 1. These studies indicated that the receptor undergoes proteolytic processing in the extracellular domain yielding an approximate 35 kDa alpha and a 160 kDa beta chain, and thus the Sea receptor appears to display a structure similar to that of the Met and Ron proteins. An examination of embryonic avian tissues using Sea extracellular domain-specific monoclonal antibodies revealed low levels of Sea receptor in a variety of tissues including kidney, intestine, liver, stomach, white blood cells and allantochorion. Elevated levels of expression were observed upon transformation of chicken embryo cells by the Src oncoprotein.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia				Huff, Janice/0000-0003-4236-7698	NCI NIH HHS [CA 27578] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA027578] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRYANT DL, 1984, MOL CELL BIOL, V4, P862, DOI 10.1128/MCB.4.5.862; CHAN AML, 1988, ONCOGENE, V2, P593; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; CREPALDI T, 1994, J BIOL CHEM, V269, P1750; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; DIRENZO MF, 1991, ONCOGENE, V6, P1997; FARINA SF, 1992, J VIROL, V66, P2698, DOI 10.1128/JVI.66.5.2698-2708.1992; FRIEZNER DSJ, 1991, BIOCHEMISTRY-US, V30, P9781; FURLONG RA, 1991, J CELL SCI, V100, P173; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLOW E, 1988, ANTIBODIES; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAEMMLI UK, 1994, NATURE, V269, P19457; LEE CC, 1994, J BIOL CHEM, V269, P19457; LINIAL M, 1982, VIROLOGY, V119, P382, DOI 10.1016/0042-6822(82)90097-6; MARK MR, 1992, J BIOL CHEM, V267, P26166; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; RONSIN C, 1993, ONCOGENE, V8, P1195; SHIMAMOTO A, 1993, FEBS LETT, V333, P61, DOI 10.1016/0014-5793(93)80375-5; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; STOKER M, 1985, J CELL SCI, V77, P209; Stubbs EL, 1935, J EXP MED, V61, P593, DOI 10.1084/jem.61.5.593; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; WANG MH, 1994, SCIENCE, V266, P177; WEIDNER KM, 1993, AM J RESP CELL MOL, V8, P229, DOI 10.1165/ajrcmb/8.3.229; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097	58	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					299	307						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570207				2022-12-25	WOS:A1996TR53800009
J	Riese, DJ; Bermingham, Y; vanRaaij, TM; Buckley, S; Plowman, GD; Stern, DF				Riese, DJ; Bermingham, Y; vanRaaij, TM; Buckley, S; Plowman, GD; Stern, DF			Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta	ONCOGENE			English	Article						betacellulin; EGF; neuregulin; EGF receptor; ErbB receptors; signaling	TYROSINE PHOSPHORYLATION; EGF RECEPTOR; PROTEIN; CELLS; EXPRESSION; BINDING; KINASE; LINE; HETERODIMERIZATION; ANTIBODIES	Betacellulin is a member of the epidermal growth factor (EGF) family. These soluble proteins are ligands for one or more of the four receptor tyrosine kinases encoded by the erbB gene family (erbB-1/epidermal growth factor receptor (EGFR), neu/erbB-2/HER2, erbB-3/HER3 and erbB-4/HER4). While evidence suggests that betacellulin is a ligand for the EGFR, the ability of betacellulin to regulate other erbB family receptors has not been analysed. Previously we engineered derivatives of the mouse Ba/F3 hematopoietic cell line to ectopically express erbB family receptors, singly and in pairwise combinations. We have stimulated this panel of cell lines with betacellulin and two other EGF family members, EGF itself and neuregulin-beta (NRG-beta). In the cell lines expressing a single erbB family receptor, betacellulin not only stimulated EGFR tyrosine phosphorylation, but it activated erbB-4 as well. Furthermore, in the double recombinant Ba/F3 derivatives, betacellulin stimulated a complex pattern of receptor phosphorylation distinct from the patterns activated by NRG-beta and EGF. Moreover, betacellulin stimulated a complex pattern of interleukin-3 independence in the Ba/F3 derivatives distinct from those activated by NRG-beta and EGF. These data identify a novel receptor for betacellulin and establish that different EGF family ligands activate distinct patterns of receptor phosphorylation and coupling to cellular signaling pathways.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06520; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; SUGEN INC,REDWOOD CITY,CA 94063	Yale University; Bristol-Myers Squibb			Riese, David/AAF-3581-2020; PLOWMAN, Greg D/E-2012-2011	Riese, David/0000-0002-8823-5802	NATIONAL CANCER INSTITUTE [R01CA045708] Funding Source: NIH RePORTER; NCI NIH HHS [CA-45708] Funding Source: Medline; NICHD NIH HHS [HD-07149] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; AVIEZER D, 1994, P NATL ACAD SCI USA, V91, P12173, DOI 10.1073/pnas.91.25.12173; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; CARRAWAY KL, 1995, J BIOL CHEM, V270, P7111, DOI 10.1074/jbc.270.13.7111; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CONNELLY PA, 1990, P NATL ACAD SCI USA, V87, P6054, DOI 10.1073/pnas.87.16.6054; COOK PW, 1995, J CELL PHYSIOL, V163, P407, DOI 10.1002/jcp.1041630221; COOK PW, 1995, J CELL PHYSIOL, V163, P418, DOI 10.1002/jcp.1041630222; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; ECKENSTEIN FP, 1994, J NEUROBIOL, V25, P1467; FAZIOLI F, 1992, J BIOL CHEM, V267, P5155; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GILL GN, 1984, J BIOL CHEM, V259, P7755; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HARWERTH IM, 1992, J BIOL CHEM, V267, P15160; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IBANEZ CF, 1994, J NEUROBIOL, V25, P1349, DOI 10.1002/neu.480251104; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON GR, 1994, J BIOL CHEM, V269, P27149; JOHNSON GR, 1993, J BIOL CHEM, V268, P2924; KARUNAGARAN D, 1995, J BIOL CHEM, V270, P9982, DOI 10.1074/jbc.270.17.9982; KIM HH, 1994, J BIOL CHEM, V269, P24747; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KITA YA, 1994, FEBS LETT, V349, P139, DOI 10.1016/0014-5793(94)00644-X; LANGTON BC, 1991, CANCER RES, V51, P2593; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; QIAN XL, 1992, P NATL ACAD SCI USA, V89, P1330, DOI 10.1073/pnas.89.4.1330; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; SASADA R, 1993, BIOCHEM BIOPH RES CO, V190, P1173, DOI 10.1006/bbrc.1993.1173; SEFTON B, 1979, J VIROL, V28, P957; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; THORNE BA, 1994, MOL CELL BIOL, V14, P1635, DOI 10.1128/MCB.14.3.1635; UENO H, 1992, J BIOL CHEM, V267, P1470; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WATANABE T, 1994, J BIOL CHEM, V269, P9966; Zar JH., 1999, BIOSTAT ANAL	54	225	231	0	9	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					345	353						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570211				2022-12-25	WOS:A1996TR53800013
J	Hanke, JH; Gardner, JP; Dow, RL; Changelian, PS; Brissette, WH; Weringer, EJ; Pollok, K; Connelly, PA				Hanke, JH; Gardner, JP; Dow, RL; Changelian, PS; Brissette, WH; Weringer, EJ; Pollok, K; Connelly, PA			Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor - Study of Lck- and FynT-dependent T cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROVIRUS PROMOTER INSERTION; AMINO-TERMINAL DOMAIN; SIGNAL TRANSDUCTION; PROTEIN-KINASE; ANTIGEN RECEPTOR; CYTOPLASMIC DOMAINS; MICE LACKING; P56LCK; CD4; EXPRESSION	Here, we have studied the activity of a novel protein-tyrosine kinase inhibitor that is selective for the Src family of tyrosine kinases, We have focused our study on the effects of this compound on T cell receptor-induced T cell activation, a process dependent on the activity of the Src kinases Lck and FynT. This compound is a nanomolar inhibitor of Lck and FynT, inhibits anti-CDS-induced protein-tyrosine kinase activity in T cells, demonstrates selectivity for Lck and FynT over ZAP-70, and preferentially inhibits T cell receptor-dependent anti-CD3-induced T cell proliferation over non-T cell receptor-dependent phorbol 12-myristate 13-acetate/interleukin-2 (IL-S) induced T cell proliferation, Interestingly, this compound selectively inhibits the induction of the IL-2 gene, but not the granulocyte macrophage colony-stimulating factor or IL-2 receptor genes, This compound offers a useful new tool for examining the role of the Lck and FynT tyrosine kinases versus ZAP-70 in T cell. activation as well as the role of other Src family kinases in receptor function.			Hanke, JH (corresponding author), PFIZER INC,PFIZER CENT RES,EASTERN POINT RD,GROTON,CT 06340, USA.			Dow, Robert/0000-0002-3045-5503				ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BARRET JM, 1993, BIOCHEM PHARMACOL, V46, P439, DOI 10.1016/0006-2952(93)90520-7; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BURKE T R JR, 1992, Drugs of the Future, V17, P119; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DAVE CG, 1988, INDIAN J CHEM B, V27, P778; FALTYNEK CR, 1995, J ENZYM INHIB, V9, P111, DOI 10.3109/14756369509042811; FEDER D, 1990, J BIOL CHEM, V265, P8205; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GMETIGMEYLING FA, 1980, J IMMUNOL METHODS, V33, P1; HANKE JH, 1992, LYMPHOKINE CYTOK RES, V11, P221; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HSI ED, 1989, J BIOL CHEM, V264, P10836; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KAMPS MP, 1988, ONCOGENE, V2, P305; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LI ZH, 1991, BIOCHEM BIOPH RES CO, V180, P1048; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Maniatis T., 1982, MOL CLONING; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PERLMUTTER R M, 1988, Biochimica et Biophysica Acta, V948, P245; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; TREVILLYAN JM, 1990, J IMMUNOL, V145, P3223; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	50	1764	1830	1	43	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					695	701		10.1074/jbc.271.2.695	http://dx.doi.org/10.1074/jbc.271.2.695			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557675	hybrid			2022-12-25	WOS:A1996TP88900018
J	Izuhara, K; Heike, T; Otsuka, T; Yamaoka, K; Mayumi, M; Imamura, T; Niho, Y; Harada, N				Izuhara, K; Heike, T; Otsuka, T; Yamaoka, K; Mayumi, M; Imamura, T; Niho, Y; Harada, N			Signal transduction pathway of interleukin-4 and interleukin-13 in human B cells derived from X-linked severe combined immunodeficiency patients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GAMMA-CHAIN; TYROSINE PHOSPHORYLATION; FUNCTIONAL COMPONENT; IL-2 RECEPTOR	Interleukin-4 (IL-4) and IL-13 are functionally similar cytokines. The functional IL-4 receptor (IL CR) consists of the IL-4R alpha chain (IL-4R alpha) and the IL-2R gamma chain (gamma(c)), which is shared by the IL-2, IL-7, IL-9, and IL-15 recep tors. The functional IL-13R is thought to involve the IL-4R alpha but not gamma(c). In this study, we have analyzed activation of members of the Janus tyrosine kinase (Jak) family and signal transducers and activators of transcription (STAT) 6 induced by IL-4 and IL-13 in Epstein-Barr virus-transformed B cells derived from two patients of X-linked severe combined immunodeficiency, who have mutations of the gamma(c) gene in the extracellular and intracellular domains. In these B cells, IL-4 failed to induce tyrosine phosphorylation of Jak3 and activation of STAT6, or activation of these molecules was significantly decreased compared with Epstein-Barr virus-transformed normal B cells. In contrast, IL-13 activated STAT6 in these cells as well as normal B cells. However, Jak3 was not activated by IL-13, even in normal B cells. These results clearly indicated that gamma(c) is essential for activation of Jak3 and STAT6 in the signal transduction pathway of IL-4 in human B cells and that IL-13 does not utilize gamma(c) but activates STAT6 through an alternative pathway, which is not impaired in B cells of X-linked severe combined immunodeficiency patients.	KYUSHU UNIV,DEPT INTERNAL MED 1,HIGASHI KU,FUKUOKA 812,JAPAN; KYOTO UNIV,DEPT PEDIAT,SAKYO KU,KYOTO 606,JAPAN; RES INST TB,RES DEPT 1,BIOCHEM SECT,TOKYO 204,JAPAN	Kyushu University; Kyoto University	Izuhara, K (corresponding author), NATL INST GENET,DEPT HUMAN GENET,1111 YATA,MISHIMA,SHIZUOKA 411,JAPAN.							ASAO H, 1994, FEBS LETT, V351, P201, DOI 10.1016/0014-5793(94)00831-0; CONLEY ME, 1991, CLIN IMMUNOL IMMUNOP, V61, pS94, DOI 10.1016/S0090-1229(05)80043-1; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; DISANTO JP, 1994, EUR J IMMUNOL, V24, P475, DOI 10.1002/eji.1830240232; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HARADA N, 1992, J BIOL CHEM, V267, P22752; HE YW, 1995, J IMMUNOL, V155, P9; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOHLER I, 1994, FEBS LETT, V345, P187, DOI 10.1016/0014-5793(94)00438-2; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; LEONARD WJ, 1994, IMMUNOL REV, V138, P61, DOI 10.1111/j.1600-065X.1994.tb00847.x; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MALABARBA MG, 1995, J BIOL CHEM, V270, P9630, DOI 10.1074/jbc.270.16.9630; MATTHEWS DJ, 1995, BLOOD, V85, P38, DOI 10.1182/blood.V85.1.38.bloodjournal85138; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; ROLLING C, 1995, ONCOGENE, V10, P1757; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHULTZ C, 1995, IMMUNOL LETT, V46, P215, DOI 10.1016/0165-2478(95)00050-F; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966, DOI 10.1074/jbc.270.2.966; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; VOSS SD, 1994, BLOOD, V83, P626; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YIN TG, 1994, J BIOL CHEM, V269, P26614; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	40	97	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					619	622		10.1074/jbc.271.2.619	http://dx.doi.org/10.1074/jbc.271.2.619			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557662	hybrid			2022-12-25	WOS:A1996TP88900005
J	Ravindran, S; Radke, GA; Guest, JR; Roche, TE				Ravindran, S; Radke, GA; Guest, JR; Roche, TE			Lipoyl domain-based mechanism for the integrated feedback control of the pyruvate dehydrogenase complex by enhancement of pyruvate dehydrogenase kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ACETYL-COENZYME-A; BOVINE KIDNEY; FATTY-ACIDS; PROTEIN-X; DIHYDROLIPOYL TRANSACETYLASE; HEART-MITOCHONDRIA; KETONE-BODIES; STIMULATION; COMPONENT	To conserve carbohydrate reserves, the reaction of the pyruvate dehydrogenase complex (PDC) must be down-regulated when the citric acid cycle is provided sufficient acetyl-CoA., PDC activity is reduced primarily through increased phosphorylation of its pyruvate dehydrogenase (El) component due to El kinase activity being markedly enhanced by elevated intramitochondrial NADH:NAD(+) and acetyl-CoA:CoA ratios, A mechanism is evaluated in which enhanced kinase activity is facilitated by the build up of the reduced and acetylated forms of the lipoyl moieties of the dihydrolipoyl acetyltransferase (E2) component through using NADH and acetyl-CoA in the reverse of the downstream reactions of the complex, Using a peptide substrate, kinase activity was stimulated by these products, ruling out the possibility kinase activity is increased due to changes in the reaction state of its substrate, El (thiamin pyrophosphate), Each E2 subunit contains two lipoyl domains, an NH2-terminal (L1) and the inward lipoyl domain (L2), which were individually produced in fully lipoylated forms by recombinant techniques, Although reduction and acetylation of the L1 domain or free lipoamide increased kinase activity, those modifications of the lipoate of the kinase-binding L2 domain gave much greater enhancements of kinase activity, The large stimulation of the kinase generated by acetyl-CoA only occurred upon addition of the transacetylase-catalyzing (lipoyl domain-free) inner core portion of E2 plus a reduced lipoate source, affirming that acetylation of this prosthetic group is an essential mechanistic step for acetyl-CoA enhancing kinase activity. Similarly, the lesser stimulation of kinase activity by just NADH required a lipoate source, supporting the need for lipoate reduction by E3 catalysis. Complete enzymatic delipoylation of PDC, the E2-kinase subcomplex, or recombinant L2 abolished the stimulatory effects of NADH and acetyl-CoA. Retention of a small portion of PDC lipoates lowered kinase activity but allowed stimulation of this residual kinase activity by these products, Reintroduction of lipoyl moieties, using lipoyl protein ligase, restored the capacity of the E2 core to support high kinase activity along with stimulation of that activity up to 3-fold by NADH and acetyl-CoA. As suggested by those results, the enhancement of kinase activity is very responsive to reductive acetylation with a half-maximal stimulation achieved with similar to 20% of free L2 acetylated and, from an analysis of previous results, with acetylation of only 3-6 of the 60 L2 domains in intact PDC. Based on these findings, we suggest that kinase stimulation results from modification of the lipoate of an L2 domain that becomes specifically engaged in binding the kinase, In conclusion, kinase activity is attenuated through a substantial range in response to modest changes in the proportion of oxidized, reduced, and acetylated lipoyl moieties of the L2 domain of E2 produced by fluctuations in the NADH: NAD(+) and acetyl-CoA:CoA ratios as translated by the rapid and reversible E3 and E2 reactions.	KANSAS STATE UNIV,DEPT BIOCHEM,MANHATTAN,KS 66506; UNIV SHEFFIELD,DEPT MOLEC BIOL & BIOTECHNOL,SHEFFIELD S10 2UH,S YORKSHIRE,ENGLAND	Kansas State University; University of Sheffield					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018320, R55DK018320] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18320] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Wellcome Trust(Wellcome TrustEuropean Commission)		BATENBURG JJ, 1976, J BIOL CHEM, V251, P1364; BATENBURG JJ, 1975, BIOCHEM BIOPH RES CO, V66, P533, DOI 10.1016/0006-291X(75)90543-4; CARY M, 1984, THESIS KANSAS STATE; CATE RL, 1978, J BIOL CHEM, V253, P496; CATE RL, 1979, J BIOL CHEM, V254, P1659; CATE RL, 1980, J BIOL CHEM, V255, P7556; COOPER RH, 1975, NATURE, V257, P808, DOI 10.1038/257808a0; DENTON RM, 1975, MOL CELL BIOCHEM, V9, P27, DOI 10.1007/BF01731731; GARLAND PB, 1964, BIOCHEM J, V93, P665, DOI 10.1042/bj0930665; GARLAND PB, 1964, BIOCHEM J, V91, P60; GREEN DE, 1995, BIOCHEM J, V309, P853, DOI 10.1042/bj3090853; HANSFORD RG, 1978, ARCH BIOCHEM BIOPHYS, V191, P65, DOI 10.1016/0003-9861(78)90068-1; HANSFORD RG, 1976, J BIOL CHEM, V251, P5483; HUCHO F, 1972, Archives of Biochemistry and Biophysics, V151, P328, DOI 10.1016/0003-9861(72)90504-8; JILKA JM, 1986, J BIOL CHEM, V261, P1858; KERBEY AL, 1976, BIOCHEM J, V154, P327, DOI 10.1042/bj1540327; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; LINN TC, 1972, ARCH BIOCHEM BIOPHYS, V148, P327, DOI 10.1016/0003-9861(72)90151-8; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; LIU SJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P926, DOI 10.1006/abbi.1995.1124; MAENG CY, 1994, BIOCHEMISTRY-US, V33, P13801, DOI 10.1021/bi00250a034; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; MATTEVI A, 1993, BIOCHEMISTRY-US, V32, P3887, DOI 10.1021/bi00066a007; OLSON MS, 1978, ARCH BIOCHEM BIOPHYS, V187, P121, DOI 10.1016/0003-9861(78)90014-0; ONO K, 1993, J BIOL CHEM, V268, P26135; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; PAWELCZYK T, 1992, ARCH BIOCHEM BIOPHYS, V294, P44, DOI 10.1016/0003-9861(92)90134-I; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; PETTIT FH, 1975, BIOCHEM BIOPH RES CO, V65, P575, DOI 10.1016/S0006-291X(75)80185-9; PETTIT FH, 1982, P NATL ACAD SCI-BIOL, V79, P3945, DOI 10.1073/pnas.79.13.3945; POPOV KM, 1993, J BIOL CHEM, V268, P26602; POPOV KM, 1994, J BIOL CHEM, V269, P29720; POPOV KM, 1992, J BIOL CHEM, V267, P13129; PRATT ML, 1979, J BIOL CHEM, V254, P7191; RADKE GA, 1993, BIOCHEM BIOPH RES CO, V190, P982, DOI 10.1006/bbrc.1993.1146; RAHMATULLAH M, 1990, J BIOL CHEM, V265, P14512; RAHMATULLAH M, 1989, J BIOL CHEM, V264, P1245; RAHMATULLAH M, 1985, J BIOL CHEM, V260, P146; RAHMATULLAH M, 1987, J BIOL CHEM, V262, P10265; RANDLE PJ, 1986, BIOCHEM SOC T, V14, P799, DOI 10.1042/bst0140799; REED LJ, 1990, J BIOL CHEM, V265, P8971; REED LJ, 1980, ENZYME REGULATION ME, P47; ROBERTSON JG, 1989, J BIOL CHEM, V264, P11626; ROBERTSON JG, 1990, J BIOL CHEM, V265, P16814; ROCHE TE, 1974, BIOCHEM BIOPH RES CO, V59, P1341, DOI 10.1016/0006-291X(74)90461-6; ROCHE TE, 1976, BIOCHEM BIOPH RES CO, V72, P1375, DOI 10.1016/S0006-291X(76)80166-0; ROCHE TE, 1972, BIOCHEM BIOPH RES CO, V48, P840, DOI 10.1016/0006-291X(72)90684-5; ROCHE TE, 1977, ARCH BIOCHEM BIOPHYS, V183, P664, DOI 10.1016/0003-9861(77)90400-3; SUMEGI B, 1983, EUR J BIOCHEM, V136, P347, DOI 10.1111/j.1432-1033.1983.tb07748.x; SUZUKI K, 1963, J BIOL CHEM, V238, P4021; TAYLOR SI, 1975, J BIOL CHEM, V250, P2028; TAYLOR SI, 1973, J BIOL CHEM, V248, P73; TSAI CS, 1973, J BIOL CHEM, V248, P8348; WIELAND O, 1971, FEBS LETT, V15, P295, DOI 10.1016/0014-5793(71)80641-5; WIELAND OH, 1974, EUR J BIOCHEM, V45, P577, DOI 10.1111/j.1432-1033.1974.tb03584.x	55	67	74	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					653	662		10.1074/jbc.271.2.653	http://dx.doi.org/10.1074/jbc.271.2.653			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557670	hybrid			2022-12-25	WOS:A1996TP88900013
J	Tan, SH; Sim, TS				Tan, SH; Sim, TS			Functional analysis of conserved histidine residues in Cephalosporium acremonium isopenicillin N synthase by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-ABSORPTION; SYNTHETASE GENE; ACTIVE-SITE; STREPTOMYCES-CLAVULIGERUS; PENICILLIUM-CHRYSOGENUM; SEQUENCE DETERMINATION; NUCLEOTIDE-SEQUENCE; BIOSYNTHETIC GENES; CLONING; EXPRESSION	The isopenicillin N synthase of Cephalosporium acremonium (cIPNS) involves a catalytically important non-heme iron which is coordinated credibly to histidine residues, A comparison of the IPNS genes from various microbial sources indicated that there are seven conserved histidine residues, These were individually replaced by leucine residues through site-directed mutagenesis, and the sites of mutation were confirmed by DNA sequencing, The seven mutant genes were cloned separately into the vector pET24d for expression in Escherichia coli BL21(DE3), and the proteins were expressed as soluble enzymes, All the resulting mutant enzymes obtained have mobilities of similar to 38 kDa, identical with the wild-type enzyme on SDS-polyacrylamide gel electrophoresis, and were also reactive to cIPNS antibodies, The enzymes were purified by ammonium sulfate precipitation and DEAE-Sephadex A-50 ion exchange chromatography, and these were analyzed for enzyme activity, A group of mutant enzymes, H49L, H64L, H116L, H126L, and H137L, were found to be enzymatically active with reduced activities of 16-93.7%, indicating that they are not essential for catalysis, Two of the mutant enzymes, H216L and H272L, were found to have lost their enzymatic activity completely, indicating that both His-216 and His-272 are crucial for catalysis, It is suggested that these histidines are likely to serve as ligands for binding to the non-heme iron in the IPNS active site, Alignment of the amino acid sequence of IPNS to related non-heme Fe2+-requiring enzymes indicated that the two essential histidine residues correspond to two invariant residues located in highly homologous regions, The conservation of the two closely located histidine residues indicates the possible conservation of similar iron binding sites in these enzymes.	NATL UNIV SINGAPORE, FAC MED, DEPT MICROBIOL, SINGAPORE 117548, SINGAPORE	National University of Singapore								AHARONOWITZ Y, 1992, ANNU REV MICROBIOL, V46, P461, DOI 10.1146/annurev.mi.46.100192.002333; BALDWIN JE, 1990, BIOCHEM J, V266, P561; BALDWIN JE, 1988, NAT PROD REP, V5, P129, DOI 10.1039/np9880500129; BALDWIN JE, 1987, J ANTIBIOT, V40, P652, DOI 10.7164/antibiotics.40.652; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRITSCH L, 1993, EUR J BIOCHEM, V217, P745, DOI 10.1111/j.1432-1033.1993.tb18301.x; CARR LG, 1986, GENE, V48, P257, DOI 10.1016/0378-1119(86)90084-3; CHEN VJ, 1989, J BIOL CHEM, V264, P21677; Cooper R D, 1993, Bioorg Med Chem, V1, P1, DOI 10.1016/S0968-0896(00)82098-2; COQUE JJR, 1991, MOL MICROBIOL, V5, P1125, DOI 10.1111/j.1365-2958.1991.tb01885.x; GARCIADOMINGUEZ M, 1991, ANTIMICROB AGENTS CH, V35, P44, DOI 10.1128/AAC.35.1.44; GIBBS BS, 1993, J BIOL CHEM, V268, P8046; JENSEN SE, 1982, J ANTIBIOT, V35, P1026, DOI 10.7164/antibiotics.35.1026; JIANG F, 1991, BIOCHEMISTRY-US, V30, P11437, DOI 10.1021/bi00112a010; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; LESKIW BK, 1988, GENE, V62, P187, DOI 10.1016/0378-1119(88)90557-4; MATSUDA J, 1991, J BIOL CHEM, V266, P9460; MING LJ, 1991, BIOCHEMISTRY-US, V30, P11653, DOI 10.1021/bi00114a007; MING LJ, 1990, INORG CHEM, V29, P1111, DOI 10.1021/ic00331a001; MYLLYLA R, 1992, BIOCHEM J, V286, P923, DOI 10.1042/bj2860923; ORVILLE AM, 1992, BIOCHEMISTRY-US, V31, P4602, DOI 10.1021/bi00134a010; PERRY D, 1988, BIOCHEM J, V255, P345; RAMON D, 1987, GENE, V57, P171, DOI 10.1016/0378-1119(87)90120-X; RANDALL CR, 1993, BIOCHEMISTRY-US, V32, P6664, DOI 10.1021/bi00077a020; ROACH PL, 1995, NATURE, V375, P700, DOI 10.1038/375700a0; Sambrook J, 1989, MOL CLONING LABORATO; SAMSON SM, 1985, NATURE, V318, P191, DOI 10.1038/318191a0; SAMSON SM, 1987, P NATL ACAD SCI USA, V84, P5705, DOI 10.1073/pnas.84.16.5705; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT RA, 1992, BIOCHEMISTRY-US, V31, P4596, DOI 10.1021/bi00134a009; SHIFFMAN D, 1988, MOL GEN GENET, V214, P562, DOI 10.1007/BF00330495; SHIFFMAN D, 1990, NUCLEIC ACIDS RES, V18, P660, DOI 10.1093/nar/18.3.660; SIM TS, 1994, FEMS MICROBIOL LETT, V120, P241; SIM TS, 1995, BIOCHEM MOL BIOL INT, V35, P1069; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ZHANG YY, 1992, P NATL ACAD SCI USA, V89, P485, DOI 10.1073/pnas.89.2.485	38	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					889	894		10.1074/jbc.271.2.889	http://dx.doi.org/10.1074/jbc.271.2.889			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557701				2022-12-25	WOS:A1996TP88900044
J	ZeilstraRyalls, J; Fayet, O; Georgopoulos, C				ZeilstraRyalls, J; Fayet, O; Georgopoulos, C			In vivo protein folding: Suppressor analysis of mutations in the groES cochaperone gene of Escherichia coli	FASEB JOURNAL			English	Article						multicopy suppression; GroES; GroEL; dnaA46; heat shock; groES; intra- and extragenic suppression	BACTERIOPHAGE MORPHOGENESIS; HOST-CELL; PRODUCTS; MUTANTS; LAMBDA; GROWTH; DNA	Our previous work has shown that the Escherichia coli groES14 and groES15 mutations result in reduced GroE chaperone machine function. By selecting for restoration of the ability of those mutant groES alleles to suppress the thermosensitivity of bacteria bearing the dnaA46 mutation, we isolated a number of intra- and extragenic suppressors that increase in vivo GroE chaperone function. One of the intragenic suppressors has been mapped to a segment that codes for the GroES mobile loop, previously shown to be indispensable for proper GroES/GroEL interaction, Two extragenic suppressors have been mapped to a groEL segment, previously identified by mutational analysis as coding for an important functional region of the GroEL protein. Our results should contribute to our eventual understanding of the structure-function relationships of the universally conserved GroE chaperone machine.	CNRS,F-31062 TOULOUSE,FRANCE; CTR MED UNIV GENEVA,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND	Centre National de la Recherche Scientifique (CNRS); University of Geneva	ZeilstraRyalls, J (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT MICROBIOL & MOLEC GENET,POB 20708,HOUSTON,TX 77225, USA.				NIAID NIH HHS [AI121029] Funding Source: Medline; NIGMS NIH HHS [GM23917] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023917, R01GM023917] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; COPPO A, 1973, J MOL BIOL, V76, P61, DOI 10.1016/0022-2836(73)90081-8; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GEORGOPOULOS CP, 1972, NATURE-NEW BIOL, V239, P38, DOI 10.1038/newbio239038a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HUMPHREYS GO, 1976, MOL GEN GENET, V145, P101, DOI 10.1007/BF00331564; ISHHOROWICZ D, 1981, NUCLEIC ACIDS RES, V9, P2989, DOI 10.1093/nar/9.13.2989; JENKINS AJ, 1986, MOL GEN GENET, V202, P446, DOI 10.1007/BF00333275; Jessee J., 1986, FOCUS, V8, P9; KEPPEL F, 1990, GENE, V86, P19, DOI 10.1016/0378-1119(90)90109-5; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; Miller J.H., 1972, EXPT MOL GENETICS; REVEL HR, 1980, J VIROL, V33, P366, DOI 10.1128/JVI.33.1.366-376.1980; STERNBERG N, 1973, J MOL BIOL, V76, P1, DOI 10.1016/0022-2836(73)90078-8; TAKANO T, 1972, NATURE-NEW BIOL, V239, P34, DOI 10.1038/newbio239034a0; TILLY K, 1982, J BACTERIOL, V149, P1082, DOI 10.1128/JB.149.3.1082-1088.1982; TILLY K, 1981, P NATL ACAD SCI-BIOL, V78, P1629, DOI 10.1073/pnas.78.3.1629; VANDERVIES SM, 1994, NATURE, V368, P654, DOI 10.1038/368654a0; VANDYK TK, 1989, NATURE, V342, P451, DOI 10.1038/342451a0; ZAHN R, 1993, J MOL BIOL, V229, P579, DOI 10.1006/jmbi.1993.1062; ZEILSTRARYALLS J, 1991, ANNU REV MICROBIOL, V45, P301, DOI 10.1146/annurev.mi.45.100191.001505; ZEILSTRARYALLS J, 1993, J BACTERIOL, V175, P1134, DOI 10.1128/JB.175.4.1134-1143.1993; ZEILSTRARYALLS J, 1994, J BACTERIOL, V176, P6558, DOI 10.1128/JB.176.21.6558-6565.1994	32	6	6	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					148	152		10.1096/fasebj.10.1.8566535	http://dx.doi.org/10.1096/fasebj.10.1.8566535			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566535				2022-12-25	WOS:A1996TR32800019
J	Innocenti, B; Pozzan, T; Fasolato, C				Innocenti, B; Pozzan, T; Fasolato, C			Intracellular ADP modulates the Ca2+ release-activated Ca2+ current in a temperature- and Ca2+-dependent way	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MAST-CELLS; CAPACITATIVE CALCIUM-ENTRY; T-CELLS; STORES; DEPLETION; INFLUX; CA-2+; THAPSIGARGIN; FLUORESCENCE; INHIBITION	The rat basophilic cell line RBL-1 is known to express high levels of the Ca2+ current activated by store depletion, known as Ca2+ release-activated Ca2+ current (I-CRAC), the main Ca2+ influx pathway so far identified in nonexcitable cells. We show here that, as reported in other cell types, metabolic drugs strongly inhibit the Ca2+ influx operated by store depletion in RBL-1 cells also. We have tested the hypothesis that intracellular adenine and/or guanine nucleotide levels act as coupling factors between I-CRAC and eel metabolism. Using the whole cell configuration of the patch-clamp technique, we demonstrate that addition of ADP to the intracellular solution significantly reduces I-CRAC induced by inositol 1,4,5-trisphosphate. This phenomenon differs from other regulatory pathways of I-CRAC since it is highly temperature-dependent, is observable only in the presence of low intracellular Ca2+ buffering capacity, and requires a cytosolic factor(s) which is rapidly lost during cell dialysis, Moreover, the inhibition is specific for ADP and is partially mimicked by ADP beta S and AMP, but not by GDP or GTP.	UNIV PADUA,CNR,CTR STUDY BIOMEMBRANES,DEPT BIOMED SCI,I-35131 PADUA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Padua			Fasolato, Cristina/AAE-6024-2019	Fasolato, Cristina/0000-0002-9816-7751	Telethon [495] Funding Source: Medline	Telethon(Fondazione Telethon)		BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIRD GS, 1995, NATURE, V373, P481, DOI 10.1038/373481b0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; CASTEELS R, 1981, J PHYSIOL-LONDON, V317, P263, DOI 10.1113/jphysiol.1981.sp013824; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0; DUSZYNSKI J, 1995, CELL CALCIUM, V18, P19, DOI 10.1016/0143-4160(95)90042-X; EDWARDS G, 1993, ANNU REV PHARMACOL, V33, P597, DOI 10.1146/annurev.pa.33.040193.003121; FASOLATO C, 1993, PFLUG ARCH EUR J PHY, V423, P225, DOI 10.1007/BF00374399; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; GAMBERUCCI A, 1994, J BIOL CHEM, V269, P23597; GRAIER WF, 1995, J PHYSIOL-LONDON, V482, P259, DOI 10.1113/jphysiol.1995.sp020515; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HOTH M, 1993, ANN NY ACAD SCI, V707, P198, DOI 10.1111/j.1749-6632.1993.tb38053.x; HOTH M, 1995, PFLUG ARCH EUR J PHY, V430, P315, DOI 10.1007/BF00373905; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; JACONI MEE, 1993, J BIOL CHEM, V268, P26075; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; MILBOURNE EA, 1995, CELL CALCIUM, V18, P207, DOI 10.1016/0143-4160(95)90065-9; MOHR FC, 1990, AM J PHYSIOL, V258, pC217, DOI 10.1152/ajpcell.1990.258.2.C217; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; PARTISETI M, 1994, J BIOL CHEM, V269, P32327; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; PETERSEN CCH, 1995, BIOCHEM J, V307, P663, DOI 10.1042/bj3070663; POZZAN T, 1994, PHYSIOL REV, V74, P596; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMAS D, 1995, J BIOL CHEM, V270, P6429, DOI 10.1074/jbc.270.12.6429; VACA L, 1993, AM J PHYSIOL, V264, pH1319, DOI 10.1152/ajpheart.1993.264.4.H1319; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; XU X, 1994, J BIOL CHEM, V269, P12645; ZHANG L, 1995, J PHYSIOL-LONDON, V483, P59, DOI 10.1113/jphysiol.1995.sp020567; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	47	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8582	8587		10.1074/jbc.271.15.8582	http://dx.doi.org/10.1074/jbc.271.15.8582			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621486	hybrid			2022-12-25	WOS:A1996UE73000017
J	Rooney, MM; Parise, LV; Lord, ST				Rooney, MM; Parise, LV; Lord, ST			Dissecting clot retraction and platelet aggregation - Clot retraction does not require an intact fibrinogen gamma chain C terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB; MONOCLONAL-ANTIBODIES; SEQUENCE; PEPTIDES; PROTEINS; DOMAINS; COMPLEX	Fibrinogen mediates the processes of platelet aggregation and clot retraction. Previous studies have demonstrated that fibrinogen binding to the platelet receptor alpha(IIb)beta(3) requires the C-terminal residues of the fibrinogen gamma chain. We made a recombinant human fibrinogen that lacks the gamma chain C-terminal four residues (AGDV). As expected this fibrinogen did not support platelet aggregation. Unexpectedly, this variant did support clot retraction that was indistinguishable from re traction with normal recombinant or plasma fibrinogen. These results suggest that the site on fibrinogen that is required for platelet aggregation differs from the site on fibrin that is required for clot retraction.	UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT CHEM, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL045100] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL45100] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BINNIE CG, 1993, BIOCHEMISTRY-US, V32, P107, DOI 10.1021/bi00052a015; BORN GVR, 1962, NATURE, V194, P927, DOI 10.1038/194927b0; CHEN YP, 1995, BLOOD, V86, P2606, DOI 10.1182/blood.V86.7.2606.bloodjournal8672606; FARRELL DH, 1992, P NATL ACAD SCI USA, V89, P10729, DOI 10.1073/pnas.89.22.10729; GARTNER TK, 1988, THROMB RES, V49, P43; HANTGAN RR, 1988, BIOCHIM BIOPHYS ACTA, V968, P36, DOI 10.1016/0167-4889(88)90041-9; HEILMANN E, 1991, ARTERIOSCLER THROMB, V11, P704, DOI 10.1161/01.ATV.11.3.704; HETTASCH JM, 1992, THROMB HAEMOSTASIS, V68, P701; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lord ST, 1996, BIOCHEMISTRY-US, V35, P2342, DOI 10.1021/bi952353u; OBRIEN JR, 1966, J CLIN PATHOL, V19, P148, DOI 10.1136/jcp.19.2.148; PHILLIPS DR, 1987, ANN NY ACAD SCI, V509, P177, DOI 10.1111/j.1749-6632.1987.tb30994.x; SCHIELEN WJG, 1989, P NATL ACAD SCI USA, V86, P8951, DOI 10.1073/pnas.86.22.8951; SHIBA E, 1991, AM J PHYSIOL, V260, pC965, DOI 10.1152/ajpcell.1991.260.5.C965; TUSZYNSKI GP, 1984, J BIOL CHEM, V259, P5247; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WEISEL JW, 1985, SCIENCE, V230, P1388, DOI 10.1126/science.4071058	18	96	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8553	8555		10.1074/jbc.271.15.8553	http://dx.doi.org/10.1074/jbc.271.15.8553			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621481	hybrid			2022-12-25	WOS:A1996UE73000012
J	Wilson, M; Burt, AR; Milligan, G; Anderson, NG				Wilson, M; Burt, AR; Milligan, G; Anderson, NG			Wortmannin-sensitive activation of p70(s6k) by endogenous and heterologously expressed G(i)-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-1 FIBROBLASTS; PROTEIN-KINASE; DEPENDENT ACTIVATION; S6 KINASE; RAPAMYCIN; PHOSPHORYLATION; ADENYLYLCYCLASE; INHIBITION; RAS	In order to study the regulation of the ribosomal protein S6 kinase, p70(s6k), by G protein-coupled receptors, Rat-1 fibroblasts were stably transfected with two versions of the alpha(2) adrenergic receptor, Stimulation of clone 1C cells, which express 3.5 pmol/mg of protein of the human alpha(2C10) receptor, with the alpha(2) agonist UK 14304 led to a transient increase in p70(s6k) activity, UK 14304 also activated p70(s6k) in a clone expressing the porcine alpha(2A) receptor (400 fmol/mg of protein). Lysophosphatidic acid (LPA), acting through endogenous G protein-coupled receptors, also activated p70(s6k) in alpha(2) receptor-transfected and in nontransfected cells. Activation of p70(s6k) by both UK 14304 and LPA was accompanied by increased phosphorylation of the protein, Rapamycin completely blocked the activation of p70(s6k) by both agents, Activation of p70(s6k) by UK 14304 and by LPA, but not by platelet-derived growth factor (PDGF), was blocked by preincubation of cells with pertussis toxin, Wortmannin, a selective inhibitor of phosphoinositide (PI) 3-OH kinase, prevented activation of p70(s6k) by UK 14304, LPA, and PDGF, These data indicate that p70(s6k) is regulatable by G(i)-coupled receptor agonists in a pertussis toxin-sensitive fashion in Rat-1 fibroblasts and that activation of p70(s6k) by such agents appears to involve an isoform of PI 3-kinase.	HANNAH RES INST,AYR KA6 5HL,SCOTLAND; UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV BIOCHEM & MOLEC BIOL,MOLEC PHARMACOL GRP,GLASGOW G12 8QQ,LANARK,SCOTLAND	University of Glasgow			Milligan, Graeme/F-9426-2011	Milligan, Graeme/0000-0002-6946-3519				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ANDERSON NG, 1994, BIOCHEM BIOPH RES CO, V200, P1529, DOI 10.1006/bbrc.1994.1624; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANDI HR, 1993, J BIOL CHEM, V268, P11473; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; CERESA BP, 1994, J BIOL CHEM, V269, P29557; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; FAURE M, 1994, J BIOL CHEM, V269, P7851; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HORSTMAN DA, 1990, J BIOL CHEM, V265, P21590; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KIDO Y, 1995, BIOCHEM BIOPH RES CO, V209, P131, DOI 10.1006/bbrc.1995.1480; KILGOUR E, 1996, IN PRESS BIOCH J; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOZMA SC, 1994, SEMIN CANCER BIOL, V5, P255; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; MILLIGAN G, 1991, J BIOL CHEM, V266, P6447; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TERADA N, 1994, P NATL ACAD SCI USA, V91, P11477, DOI 10.1073/pnas.91.24.11477; TERADA N, 1993, J BIOL CHEM, V268, P12062; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; WINITZ S, 1993, J BIOL CHEM, V268, P19196; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589	41	42	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8537	8540		10.1074/jbc.271.15.8537	http://dx.doi.org/10.1074/jbc.271.15.8537			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621477	hybrid			2022-12-25	WOS:A1996UE73000008
J	Baker, DL; Dave, V; Reed, T; Periasamy, M				Baker, DL; Dave, V; Reed, T; Periasamy, M			Multiple Sp1 binding sites in the cardiac slow twitch muscle sarcoplamsic reticulum Ca2+-ATPase gene promoter are required for expression in Sol8 muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CA-2+-ATPASE GENE; ACTIVATION; ATPASE; ELEMENTS; ISOFORMS; SKELETAL; RECEPTOR; DOMAINS; HORMONE	The rabbit cardiac/slow twitch muscle sarcoplasmic reticulum Ca2+-ATPase (SERCA2) gene encodes a Ca2+ transport pump whose expression is regulated during skeletal and cardiac muscle development and in response to various pathophysiological and hormonal states. Employing transient transfection analyses in Sol8 muscle cells, we have identified two positive regulatory regions, one distal (-1810 base pair (bp) to -1110 bp) and one proximal (-284 bp to -72 bp), within the SERCA2 promoter. The proximal promoter region hom -284 bp to -80 bp was shown to confer muscle-specific expression to a heterologous promoter in So18 cells. This region is highly CC-rich containing the consensus sequence for four Spl elements (GGGCGG) and three Sp1-like elements (GGGAGG). DNase I footprint analysis with Sol8 nuclear extracts and purified Sp1 protein showed the protection of the seven Sp1 binding sites. In addition, site-directed mutagenesis of the Sp1 consensus sites demonstrated that Sp1 sites are essential for the muscle-specific expression of the SERCA2 promoter. Furthermore, we demonstrate that cotransfection of an Sp1 expression vector together with SERCA2-CAT constructs can up-regulate SERCA2 promoter activity. These results imply that the Sp1 transcription factor plays an important role in the transcriptional regulation of SERCA2 within muscle cells.	UNIV CINCINNATI,COLL MED,DIV CARDIOL,SECT MOLEC CARDIOL,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,CARDIOVASC RES CTR,CINCINNATI,OH 45267	University of Cincinnati; University of Cincinnati			Dave, Vrushank/K-5262-2012	Dave, Vrushank/0000-0003-4044-2658; Periasamy, Muthu/0000-0001-8834-5975	NHLBI NIH HHS [NIH-HL52318-01, F32 HL09409-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009409, P50HL052318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; ANGER M, 1994, J MOL CELL CARDIOL, V26, P539, DOI 10.1006/jmcc.1994.1064; ARAI M, 1994, CIRC RES, V74, P555, DOI 10.1161/01.RES.74.4.555; ARAI M, 1992, AM J PHYSIOL, V262, pC614, DOI 10.1152/ajpcell.1992.262.3.C614; ARDATI A, 1993, EMBO J, V12, P5131, DOI 10.1002/j.1460-2075.1993.tb06208.x; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DELABASTIE D, 1988, FEBS LETT, V229, P45, DOI 10.1016/0014-5793(88)80794-4; FISHER SA, 1993, CIRC RES, V73, P622, DOI 10.1161/01.RES.73.4.622; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GROVER AK, 1992, CELL CALCIUM, V13, P9, DOI 10.1016/0143-4160(92)90025-N; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HARTONG R, 1994, J BIOL CHEM, V269, P13021; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; IKEDA K, 1993, GENE, V136, P341; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; LOMPRE AM, 1991, CIRC RES, V69, P1380, DOI 10.1161/01.RES.69.5.1380; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1989, J BIOL CHEM, V264, P7059; LYTTON J, 1992, HEART CARDIOVASCULAR, P1203; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MOORMAN AFM, 1995, CIRC RES, V76, P616, DOI 10.1161/01.RES.76.4.616; MULLE C, 1988, P NATL ACAD SCI USA, V85, P5728, DOI 10.1073/pnas.85.15.5728; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; NAGAI R, 1989, P NATL ACAD SCI USA, V86, P2966, DOI 10.1073/pnas.86.8.2966; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Sambrook J., 2002, MOL CLONING LAB MANU; SARTORELLI V, 1992, P NATL ACAD SCI USA, V89, P4047, DOI 10.1073/pnas.89.9.4047; SCHAUFELE F, 1990, J BIOL CHEM, V265, P17189; SOMMER JR, 1992, HEART CARDIOVASCULAR, P3; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SUKOVICH DA, 1993, NUCLEIC ACIDS RES, V21, P2723, DOI 10.1093/nar/21.11.2723; THOMPSON WR, 1991, J BIOL CHEM, V266, P22678; VERBOOMEN H, 1992, BIOCHEM J, V286, P591, DOI 10.1042/bj2860591; VERBOOMEN H, 1994, BIOCHEM J, V303, P979, DOI 10.1042/bj3030979; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; WUYTACK F, 1992, ANN NY ACAD SCI, V671, P82, DOI 10.1111/j.1749-6632.1992.tb43786.x; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670; ZARAINHERZBERG A, 1994, J BIOL CHEM, V269, P1460	46	62	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5921	5928		10.1074/jbc.271.10.5921	http://dx.doi.org/10.1074/jbc.271.10.5921			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621466	hybrid			2022-12-25	WOS:A1996TZ28600092
J	Bedale, WA; Cox, MM				Bedale, WA; Cox, MM			Evidence for the coupling of ATP hydrolysis to the final (extension) phase of RecA protein-mediated DNA strand exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOPROTEIN FILAMENTS; NUCLEOSIDE TRIPHOSPHATE; BINDING-PROTEIN; COMPLEXES; PURIFICATION	RecA protein promotes a limited DNA strand exchange reaction, without ATP hydrolysis, that typically results in formation of short (1-2 kilobase pairs) regions of hybrid DNA. This nascent hybrid DNA is extended in a reaction that can be coupled to ATP hydrolysis. When ATP is hydrolyzed, the extension phase is progressive and its rate is 380 +/- 20 bp min(-1) at 37 degrees C. A single RecA nucleoprotein filament can participate in multiple DNA strand exchange reactions concurrently (involving duplex DNA fragments that are homologous to different segments of the DNA within a nucleoprotein filament), with no effect on the observed rate of ATP hydrolysis. The ATP hydrolytic and hybrid DNA extension activities exhibit a dependence on temperature between 25 and 45 degrees C that is, within experimental error, identical. This provides new evidence that the two processes are coupled. Arrhenius activation energies derived from the work are 13.3 +/- 1.1 kcal mole(-1) for DNA strand exchange, and 14.4 +/- 1.4 kcal mole(-1) for ATP hydrolysis during strand exchange. The rate of branch movement in the extension phase (base pair min(-1)) is related to the k(cat) for ATP hydrolysis during strand exchange (min(-1)) by a factor equivalent to 18 bp throughout the temperature range examined. The 18-base pair factor conforms to a quantitative prediction derived from a model in which ATP hydrolysis is coupled to a facilitated rotation of the DNA substrates. RecA filaments possess an intrinsic capacity for DNA strand exchange, mediated by binding energy rather than ATP hydrolysis, that is augmented by an ATP-dependent molecular motor.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison				Bedale, Wendy/0000-0002-0122-4255	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032335, U01GM032335] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32335] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1992, CELL, V68, P415, DOI 10.1016/0092-8674(92)90179-G; ANSON M, 1992, J MOL BIOL, V224, P1029, DOI 10.1016/0022-2836(92)90467-X; BRENNER SL, 1987, J BIOL CHEM, V262, P4011; BURNETT B, 1994, J MOL BIOL, V238, P540, DOI 10.1006/jmbi.1994.1313; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Davis R., 1980, ADV BACTERIAL GENETI; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; IYPE LE, 1994, J BIOL CHEM, V269, P24967; JAIN SK, 1994, J BIOL CHEM, V269, P20653; KIM JI, 1992, J BIOL CHEM, V267, P16444; KIM JI, 1992, J BIOL CHEM, V267, P16438; KORNBERG A, 1978, J BIOL CHEM, V253, P3298; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; LEVY HM, 1959, P NATL ACAD SCI USA, V45, P785, DOI 10.1073/pnas.45.6.785; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; ROSSELLI W, 1991, EMBO J, V10, P4391, DOI 10.1002/j.1460-2075.1991.tb05017.x; SCHUTTE BC, 1987, BIOCHEMISTRY-US, V26, P5616, DOI 10.1021/bi00392a006; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	40	72	73	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5725	5732		10.1074/jbc.271.10.5725	http://dx.doi.org/10.1074/jbc.271.10.5725			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621438	hybrid			2022-12-25	WOS:A1996TZ28600064
J	Diviani, D; Lattion, AL; Larbi, N; Kunapuli, P; Pronin, A; Benovic, JL; Cotecchia, S				Diviani, D; Lattion, AL; Larbi, N; Kunapuli, P; Pronin, A; Benovic, JL; Cotecchia, S			Effect of different G protein-coupled receptor kinases on phosphorylation and desensitization of the alpha(1B)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HOMOLOGOUS DESENSITIZATION; DEPENDENT PHOSPHORYLATION; MOLECULAR-CLONING; 48-KDA PROTEIN; EXPRESSION; FAMILY; RHODOPSIN; ARRESTIN; MEMBER	The alpha(1B)-adrenergic receptor (alpha(1B)AR), its truncated mutant T368, different G protein-coupled receptor kinases (GRK) and arrestin proteins were transiently expressed in COS-7 or HEK293 cells alone and/or in various combinations, Coexpression of beta-adrenergic receptor kinase (beta ARK) 1 (GRK2) or 2 (GRK3) could increase epinephrine-induced phosphorylation of the wild type alpha(1B)AR above basal as compared to that of the receptor expressed alone, On the other hand, overexpression of the dominant negative beta ARK (K220R) mutant impaired agonist-induced phosphorylation of the receptor, Overexpression of GRK6 could also increase epinephrine-induced phosphorylation of the receptor, whereas GRK5 enhanced basal but not agonist-induced phosphorylation of the alpha(1B)AR. Increasing coexpression of beta ARK1 or beta ARK2 resulted in the progressive attenuation of the alpha(1B)AR-mediated response on polyphosphoinositide (PI) hydrolysis, However, coexpression of beta ARK1 or 2 at low levels did not significantly impair the PI response mediated by the truncated alpha(1B)AR mutant T368, lacking the C terminus, which is involved in agonist-induced desensitization and phosphorylation of the receptor, Similar attenuation of the receptor-mediated PI response was also observed for the wild type alpha(1B)AR, but not for its truncated mutant, when the receptor was coexpressed with beta-arrestin 1 or beta-arrestin 2, Despite their pronounced effect on phosphorylation of the alpha(1B)AR, overexpression of GRK5 or GRK6 did not affect the receptor-mediated response, In conclusion, our results provide the first evidence that beta ARK1 and 2 as well as arrestin proteins might be involved in agonist-induced regulation of the alpha(1B)AR. They also identify the alpha(1B)AR as a potential phosphorylation substrate of GRK5 and GRK6. However, the physiological implications of GRK5- and GRK6-mediated phosphorylation of the alpha(1B)AR remain to be elucidated.	FAC MED,INST PHARMACOL & TOXICOL,CH-1005 LAUSANNE,SWITZERLAND; THOMAS JEFFERSON UNIV,DEPT PHARMACOL,PHILADELPHIA,PA 19107	University of Geneva; Jefferson University				Diviani, Dario/0000-0003-4375-3718				ABRAMS CS, 1995, J BIOL CHEM, V270, P14485, DOI 10.1074/jbc.270.24.14485; Ambrose Christine, 1992, Human Molecular Genetics, V1, P697, DOI 10.1093/hmg/1.9.697; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARRIZA JL, 1992, J NEUROSCI, V12, P4045; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1993, J BIOL CHEM, V268, P19521; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; DELEAN A, 1982, MOL PHARMACOL, V21, P5; DICKENSON JM, 1993, BRIT J PHARMACOL, V110, P1449, DOI 10.1111/j.1476-5381.1993.tb13984.x; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; INGLESE J, 1993, J BIOL CHEM, V268, P23735; ISHII K, 1994, J BIOL CHEM, V269, P1125; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KONG GH, 1994, J BIOL CHEM, V269, P13084; KUHN H, 1982, FEBS LETT, V20, P1; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LATTION AL, 1994, J BIOL CHEM, V269, P22887; LONDON RP, 1994, J BIOL CHEM, V269, P22691; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; PARIS S, 1988, J BIOL CHEM, V263, P11250; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; WALSH JH, 1993, J CELL PHYSIOL, V156, P333, DOI 10.1002/jcp.1041560216; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	41	162	168	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5049	5058						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617782				2022-12-25	WOS:A1996TX69700072
J	Lachaal, M; Rampal, AL; Lee, W; Shi, YW; Jung, CY				Lachaal, M; Rampal, AL; Lee, W; Shi, YW; Jung, CY			GLUT1 transmembrane glucose pathway - Affinity labeling with a transportable D-glucose diazirine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; PROTEINS; MEMBRANE; ELECTROPHORESIS; LOCALIZATION; SEQUENCE; VESICLES; CARRIER; FAMILY	We synthesized a transportable diazirine derivative of D-glucose, 3-deoxy-3,3-azi-D-glucopyranose (3-DAG), and studied its interaction with purified human erythrocyte facilitative glucose transporter, GLUT1. 3-DAG was rapidly transported into human erythrocytes and their resealed ghosts in the dark via a mercuric chloride-inhibitable mechanism and with a speed comparable with that of 3-O-methyl-D-glucose (S-OMG). The rate of 3-DAG transport in resealed ghosts was a saturable function of 3-DAG concentration with an apparent K-m of 3.2 mM and the V-max of 3.2 mu mol/s/ml. D-Glucose inhibited the 3-DAG flux competitively with an apparent K-I of 11 mM. Cytochalasin B inhibited this S-DAG flux in a dose-dependent manner with an estimated K-I of 2.4 x 10(-7) M. Cytochalasin E had no effect. These findings clearly establish that 3-DAG is a good substrate of GLUT1. UV irradiation of purified GLUT1 in liposomes in the presence of 3-DAG produced a significant covalent incorporation of 3-DAG into GLUT1, and 200 mM D-glucose abolished this 3-DAG incorporation. Analyses of trypsin and endoproteinase Lys-C digestion of 3-DAG-photolabeled GLUT1 revealed that the cleavage products corresponding to the residues 115-183, 256-300, and 301-451 of the GLUT1 sequence were labeled by 3-DAG, demonstrating that not only the C-terminal half but also the N-terminal half of the transmembrane domain participate in the putative substrate channel formation. 3-DAG may be useful in further identification of the amino acid residues that form the substrate channel of this and other members of the facilitative glucose transporter family.	VET ADM MED CTR,BIOPHYS LAB,BUFFALO,NY 14215; SUNY BUFFALO,SCH MED,DEPT BIOPHYS SCI,BUFFALO,NY 14215	US Department of Veterans Affairs; Veterans Health Administration (VHA); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Lee, Wan/B-6252-2013	Lee, Wan/0000-0002-5181-2135	NIDDK NIH HHS [DK17736] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAKER DC, 1972, CARBOHYD RES, V24, P192, DOI 10.1016/S0008-6215(00)82279-X; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BELL GI, 1993, J BIOL CHEM, V268, P19161; CAIRNS MT, 1984, BIOCHEM J, V221, P179, DOI 10.1042/bj2210179; CHIN JJ, 1986, J BIOL CHEM, V261, P7101; CHIN JJ, 1987, P NATL ACAD SCI USA, V84, P4113, DOI 10.1073/pnas.84.12.4113; CLANCY BM, 1991, J BIOL CHEM, V266, P10122; CLARK AE, 1990, BIOCHEM J, V269, P615, DOI 10.1042/bj2690615; DEZIEL MR, 1985, BIOCHIM BIOPHYS ACTA, V819, P83, DOI 10.1016/0005-2736(85)90198-1; ERNI B, 1980, J AM CHEM SOC, V102, P3888, DOI 10.1021/ja00531a034; FUKUMOTO H, 1988, P NATL ACAD SCI USA, V85, P5434, DOI 10.1073/pnas.85.15.5434; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; HONDA S, 1991, CARBOHYD RES, V215, P193, DOI 10.1016/0008-6215(91)84018-A; ISMAILBEIGI F, 1993, J MEMBRANE BIOL, V135, P1; JAMES DE, 1989, NATURE, V338, P83, DOI 10.1038/338083a0; JHUN E, 1991, J BIOL CHEM, V266, P9403; JUNG CY, 1977, J BIOL CHEM, V252, P5456; JUNG EKY, 1986, J BIOL CHEM, V261, P9155; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MIDGLEY PJW, 1985, BIOCHIM BIOPHYS ACTA, V812, P27, DOI 10.1016/0005-2736(85)90517-6; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; PARK JT, 1949, J BIOL CHEM, V181, P149; RAMPAL AL, 1986, BIOCHIM BIOPHYS ACTA, V859, P135, DOI 10.1016/0005-2736(86)90208-7; REUSCH JEB, 1993, J BIOL CHEM, V268, P3348; RIVIERE LR, 1991, TECHNIQUES PROTEIN C, V2, P171; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Takasaki S, 1978, Methods Enzymol, V50, P50; WADZINSKI BE, 1990, BIOCHEM J, V272, P151, DOI 10.1042/bj2720151; WRIGHT EM, 1984, J BIOL CHEM, V259, P4993; Zeng H, 1996, BIOPHYS J, V70, P14, DOI 10.1016/S0006-3495(96)79560-7	32	21	21	6	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5225	5230						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617806				2022-12-25	WOS:A1996TX69700096
J	Siegfried, G; Amiel, C; Friedlander, G				Siegfried, G; Amiel, C; Friedlander, G			Inhibition of ecto-5'-nucleotidase by nitric oxide donors - Implications in renal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED MESANGIAL CELLS; BRUSH-BORDER MEMBRANES; OPOSSUM KIDNEY-CELLS; BULL SEMINAL PLASMA; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; RAT-KIDNEY; ADP-RIBOSYLATION; ADENINE-NUCLEOTIDES; ADENOSINE TRANSPORT; S-NITROSYLATION	We evaluated, in renal epithelial cells with a proximal tubule phenotype, the effect of nitric oxide (NO) on ecto-5'-nucleotidase (5'-NU), the underlying mechanism and its functional consequence. Sodium nitroprusside (SNP, 1-1000 mu M), a NO donor, inhibited 5'-NU activity in a time- and concentration-dependent manner. Consequently, NO blunted the inhibition by extracellular cyclic AMP (cAMP, 10-1000 mu M) of sodium-phosphate co-transport, a pathway which involves degradation of adenosine monophosphate (AMP) by 5'-NU. SNP-induced inhibition of 5'-NU was not mediated by cyclic GMP, since it was not mimicked by atrial natriuretic peptide, and was reproduced by isosorbide dinitrate and sodium nitrate, two NO donors. SNP and genuine NO decreased the activity of 5'-NU in renal homogenates, and the effect of SNP was potentiated by dithiothreitol and glutathione, but not by nicotinamide adenine dinucleotide. In vivo in rats, kidney ischemia/reperfusion, which activates inducible NO-synthase, inhibited renal 5'-NU. This inhibition was prevented by N omega-nitro-L-arginine methyl ester, a NO-synthase inhibitor. These results indicate that: (i) NO-related activity inhibited the activity of an ecto-enzyme, 5'-NU, most likely through S-nitrosylation of the enzyme; (ii) inhibition of 5'-NU activity by NOx, which can occur in vivo under pathophysiological conditions, affected the extent to which extracellular cAMP inhibited sodium-P-i cotransport.	UNIV DENIS DIDEDROT,INSERM,U426,FAC MED XAVIER BICHAT,F-75018 PARIS 7,FRANCE; UNIV DENIS DIDEDROT,DEPT PHYSIOL,PARIS 7,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Siegfried, Géraldine/N-6017-2018	Friedlander, Gerard/0000-0002-6854-4261; siegfried, geraldine/0000-0002-6346-5206				AMIEL C, 1976, J CLIN INVEST, V57, P256, DOI 10.1172/JCI108276; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; BOUMENDILPODEVIN EF, 1977, J BIOL CHEM, V252, P6675; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNE B, 1990, ARCH BIOCHEM BIOPHYS, V279, P286, DOI 10.1016/0003-9861(90)90493-I; CLANCY RM, 1990, ANAL BIOCHEM, V191, P138, DOI 10.1016/0003-2697(90)90400-4; CULIC O, 1990, BIOCHIM BIOPHYS ACTA, V1030, P143, DOI 10.1016/0005-2736(90)90249-N; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; FINI C, 1990, BIOCHIM BIOPHYS ACTA, V1038, P18, DOI 10.1016/0167-4838(90)90004-Y; FINI C, 1985, BIOCHIM BIOPHYS ACTA, V827, P403, DOI 10.1016/0167-4838(85)90225-0; FRANCO R, 1990, BIOCHIM BIOPHYS ACTA, V1024, P241, DOI 10.1016/0005-2736(90)90350-W; FRIEDLANDER G, 1992, J CLIN INVEST, V90, P848, DOI 10.1172/JCI115960; GENTRY MK, 1975, ANAL BIOCHEM, V64, P624, DOI 10.1016/0003-2697(75)90478-9; KETTELER M, 1994, AM J PHYSIOL, V267, pF197, DOI 10.1152/ajprenal.1994.267.2.F197; KUNTZIGER H, 1974, AM J PHYSIOL, V227, P905, DOI 10.1152/ajplegacy.1974.227.4.905; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANDER HM, 1993, J IMMUNOL, V151, P7182; LEGOAS F, 1991, AM J PHYSIOL, V261, pF587, DOI 10.1152/ajprenal.1991.261.4.F587; LEHIR M, 1985, EUR J CLIN INVEST, V15, P121; LEHIR M, 1993, AM J PHYSIOL, V264, pF377, DOI 10.1152/ajprenal.1993.264.3.F377; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LUSCHER TF, 1991, KIDNEY INT, V39, P575, DOI 10.1038/ki.1991.68; MANDEL LJ, 1988, J CLIN INVEST, V81, P1255, DOI 10.1172/JCI113443; MARKEWITZ BA, 1993, J CLIN INVEST, V91, P2138, DOI 10.1172/JCI116439; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MCLAY JS, 1994, KIDNEY INT, V46, P1043, DOI 10.1038/ki.1994.365; MONCADA S, 1991, EUR J CLIN INVEST, V21, P361, DOI 10.1111/j.1365-2362.1991.tb01383.x; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; NAKAI M, 1988, BIOCHEM BIOPH RES CO, V152, P1416, DOI 10.1016/S0006-291X(88)80443-1; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; PLAGEMANN PGW, 1990, BIOCHIM BIOPHYS ACTA, V1028, P289, DOI 10.1016/0005-2736(90)90178-Q; RAIJ L, 1993, CIRCULATION, V87, P26; SAVIC V, 1990, IMMUNOLOGY, V70, P321; SAVIC V, 1991, ARCH BIOCHEM BIOPHYS, V290, P202, DOI 10.1016/0003-9861(91)90609-M; SIEGFRIED G, 1995, ENDOCRINOLOGY, V136, P1267, DOI 10.1210/en.136.3.1267; Snedecor G W, 1972, STAT METHODS, P593; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TRIMBLE ME, 1984, AM J PHYSIOL, V246, pF794, DOI 10.1152/ajprenal.1984.246.6.F794; VANWAARDE A, 1989, AM J PHYSIOL, V256, pF298, DOI 10.1152/ajprenal.1989.256.2.F298; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; VLAHOVIC P, 1994, ARCH INT PHYSIOL BIO, V102, P171, DOI 10.3109/13813459409007533; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862; YU L, 1994, P NATL ACAD SCI USA, V91, P1691, DOI 10.1073/pnas.91.5.1691; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	50	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4659	4664						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617729				2022-12-25	WOS:A1996TX69700019
J	Alla, SA; Quitterer, U; Grigoriev, S; Maidhof, A; Haasemann, M; Jarnagin, K; MullerEsterl, W				Alla, SA; Quitterer, U; Grigoriev, S; Maidhof, A; Haasemann, M; Jarnagin, K; MullerEsterl, W			Extracellular domains of the bradykinin B2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; FIBROBLASTS; CLONING; EPITOPE	Many of the physiological functions of bradykinin are mediated via the B2 receptor, Little is known about binding sites for bradykinin on the receptor, Therefore, antisera against peptides derived from the putative extracellular domains of the B2 receptor were raised, The antibodies strongly reacted with their corresponding antigens and cross-reacted both with the denatured and the native B2 receptor, Affinity-purified antibodies to the various extracellular domains were used to probe the contact sites between the receptor and its agonist, bradykinin or its antagonist HOE140, Antibodies to extracellular domain 3 (second loop) efficiently interfered, in a concentration-dependent manner, with agonist and antagonist binding and vice versa, Antibodies to extracellular domain 4 (third loop) blocked binding of the agonist but not of the antagonist, whereas antibodies to extracellular domains 1 and 2 or to intracellular domains failed to block ligand binding, Antibodies to ectodomain 3 competed with agonistic anti-idiotypic antibodies for B2 receptor binding, Further, affinity-purified antibodies to the amino-terminal portion of extracellular domain 3 transiently increased intracellular free Ca2+ concentration and thus are agonists, The Ca2+ signal was specifically blocked by the B2 antagonist HOE140, By contrast, antibodies to the carboxyl-terminal segment of extracellular domain 4 failed to trigger Ca2+ release, The specific effects of antibodies to the amino-terminal portion of extracellular domain 3 suggest that this portion of the B2 receptor may be involved in ligand binding and in agonist function.	UNIV MAINZ, INST PHYSIOL CHEM & PATHOBIOCHEM, D-55099 MAINZ, GERMANY; UNIV PARIS 07, INST JACQUES MONOD, F-75005 PARIS, FRANCE; SYNTEX INC, BIOTECHNOL UNIT, PALO ALTO, CA 94304 USA	Johannes Gutenberg University of Mainz; UDICE-French Research Universities; Universite Paris Cite; Syntex Corporation								ABDALLA S, 1993, J BIOL CHEM, V268, P17277; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; FIGUEROA CD, 1995, J HISTOCHEM CYTOCHEM, V43, P137, DOI 10.1177/43.2.7822771; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FREEDMAN R, 1992, RECENT PROGR KININS, P467; FU LX, 1993, J CLIN INVEST, V91, P1964, DOI 10.1172/JCI116416; FU MLX, 1994, LANCET, V344, P1660, DOI 10.1016/S0140-6736(94)90456-1; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HAASEMANN M, 1991, J IMMUNOL, V147, P3882; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HUDGIN RL, 1974, J BIOL CHEM, V249, P5536; KLEYMANN G, 1993, EUR J BIOCHEM, V213, P797, DOI 10.1111/j.1432-1033.1993.tb17822.x; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; KYLE DJ, 1994, J MED CHEM, V37, P1347, DOI 10.1021/jm00035a015; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KM, 1993, J BIOL CHEM, V268, P9945; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MAGNUSSON Y, 1994, CIRCULATION, V89, P2760, DOI 10.1161/01.CIR.89.6.2760; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MENKE JG, 1994, J BIOL CHEM, V269, P21583; Muller-Esterl W., 1993, BIOMED PROG, V6, P49; NARDONE J, 1994, P NATL ACAD SCI USA, V91, P4417, DOI 10.1073/pnas.91.10.4417; NOVOTNY EA, 1994, BIOCHEM BIOPH RES CO, V201, P523, DOI 10.1006/bbrc.1994.1733; QUITTERER U, 1995, J BIOL CHEM, V270, P1992, DOI 10.1074/jbc.270.5.1992; REGOLI D, 1988, METHOD ENZYMOL, V163, P210; ROSCHER AA, 1983, J CLIN INVEST, V72, P626, DOI 10.1172/JCI111012; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SHARIF M, 1992, NATURE, V357, P279, DOI 10.1038/357279a0; TIPPMER S, 1994, EUR J BIOCHEM, V225, P297, DOI 10.1111/j.1432-1033.1994.00297.x; WEBB N R, 1990, Technique (Philadelphia), V2, P173; WIRTH K, 1991, BRIT J PHARMACOL, V102, P774, DOI 10.1111/j.1476-5381.1991.tb12249.x	36	63	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1748	1755		10.1074/jbc.271.3.1748	http://dx.doi.org/10.1074/jbc.271.3.1748			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576178	hybrid			2022-12-25	WOS:A1996TQ52500074
J	Auerbach, BJ; Bisgaier, CL; Wolle, J; Saxena, U				Auerbach, BJ; Bisgaier, CL; Wolle, J; Saxena, U			Oxidation of low density lipoproteins greatly enhances their association with lipoprotein lipase anchored to endothelial cell matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-B; ATHEROSCLEROSIS; MACROPHAGE; PATHOGENESIS; EXPRESSION; METABOLISM; RETENTION; RECEPTOR; ADDUCTS; BINDING	Native and oxidized low density lipoprotein retention within arterial wall endothelial cell matrix (ECM) is an early event in the pathogenesis of atherosclerosis. Previously we showed lipoprotein lipase (LPL) addition to ECM enhanced the retention of apoB-containing lipoproteins. In the present studies we examined whether the oxidation of low density lipoprotein (LDL) increases its retention by LPL-containing ECM, Except where noted, I-125-labeled moderately oxidized LDL (ModOx-LDL) was prepared by long term storage of I-125-LDL. Without LPL, I-125-ModOxLDL matrix binding was low and nonsaturable, LPL preanchored to ECM resulted in I-125-ModOxLDL binding that was saturable and 20-fold greater than in the absence of LPL, with an association constant equal to 2.6 nM, Copper-oxidized LDL (Cu-Ox-LDL) was able to compete with I-125-ModOxLDL, whereas a 60-fold native LDL excess had no effect, Reconstituted apolipoprotein B from Cu-OxLDL also reduced I-125-ModOxLDL to LPL, whereas liposomes derived from the lipid extract of Cu-OxLDL had no effect on binding, These data suggest that the increased binding of oxidized LDL to LPL ECM may be due to the exposure of novel apoB binding sites and not an oxidized lipid moiety, I-125-ModOxLDL binding was also not affected by either preincubation with a 300-fold molar excess of apoE-poor HDL or an 340 fold molar excess of Cu-Ox-HDL, In contrast, a I-fold apoE-rich HDL excess (based on protein) totally inhibited I-125-ModOxLDL matrix retention, Positively charged peptides of polyarginine mimicked the effect of apoE-rich HDL in reducing the I-125-ModOxLDL retention; however, polylysine had no effect, We postulate that the oxidation of LDL may be a mechanism that enhances LDL retention by the ECM-bound LPE and that the protective effects of apoE-containing HDL may in part be due to its ability to block the retention of oxidized LDL in vivo.			Auerbach, BJ (corresponding author), WARNER LAMBERT CO,PHARMACEUT RES,ATHEROSCLEROSIS THERAPEUT,2800 PLYMOUTH RD,ANN ARBOR,MI 48105, USA.							ABDALLA DSP, 1994, ATHEROSCLEROSIS, V107, P157, DOI 10.1016/0021-9150(94)90017-5; AVOGARO P, 1988, ARTERIOSCLEROSIS, V8, P79, DOI 10.1161/01.ATV.8.1.79; BELKNER J, 1993, EUR J BIOCHEM, V213, P251, DOI 10.1111/j.1432-1033.1993.tb17755.x; BELLOMO G, 1995, DIABETES, V44, P60, DOI 10.2337/diabetes.44.1.60; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BONNEFONTROUSSELOT D, 1995, BBA-LIPID LIPID MET, V1255, P23, DOI 10.1016/0005-2760(94)00211-G; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CAMEJO EH, 1992, ARTERIOSCLER THROMB, V12, P569; CHANG GJ, 1994, ARTERIOSCLER THROMB, V14, P1808, DOI 10.1161/01.ATV.14.11.1808; CHANG MY, 1993, BIOCHEMISTRY-US, V32, P8518, DOI 10.1021/bi00084a018; CHISOLM GM, 1994, P NATL ACAD SCI USA, V91, P11452, DOI 10.1073/pnas.91.24.11452; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; DUPLAA C, 1993, EUR J CLIN INVEST, V23, P474, DOI 10.1111/j.1365-2362.1993.tb00793.x; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HEINECKE JW, 1993, J LIPID RES, V34, P2051; HERTTUALA SY, 1991, P NATL ACAD SCI USA, V88, P10143; HODIS HN, 1994, J LIPID RES, V35, P669; HOLVOET P, 1994, FASEB J, V8, P1279, DOI 10.1096/fasebj.8.15.8001740; HUNT JV, 1994, FEBS LETT, V349, P375, DOI 10.1016/0014-5793(94)00706-3; JURGENS G, 1993, ARTERIOSCLER THROMB, V13, P1689, DOI 10.1161/01.ATV.13.11.1689; Kahn BV, 1995, J CLIN INVEST, V95, P1262; KATSURA M, 1994, BBA-LIPID LIPID MET, V1213, P231, DOI 10.1016/0005-2760(94)90031-0; KUME N, 1992, J CLIN INVEST, V90, P1138, DOI 10.1172/JCI115932; LECOMTE E, 1993, CLIN CHIM ACTA, V218, P39, DOI 10.1016/0009-8981(93)90220-X; LEHR HA, 1995, CIRCULATION, V91, P1525, DOI 10.1161/01.CIR.91.5.1525; LIAO F, 1991, J CLIN INVEST, V87, P2253, DOI 10.1172/JCI115261; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSIS AJ, 1993, BIOCHEM PHARMACOL, V46, P2119, DOI 10.1016/0006-2952(93)90599-R; LYONS TJ, 1994, DIABETES, V43, P1090, DOI 10.2337/diabetes.43.9.1090; MAEBA R, 1994, BBA-LIPID LIPID MET, V1215, P79, DOI 10.1016/0005-2760(94)90094-9; MAGGI E, 1994, ARTERIOSCLER THROMB, V14, P1892, DOI 10.1161/01.ATV.14.12.1892; MAGGI E, 1994, PRESSE MED, V23, P1158; Mahley R W, 1980, Ann N Y Acad Sci, V348, P265, DOI 10.1111/j.1749-6632.1980.tb21306.x; MARCHANT CE, 1995, FEBS LETT, V358, P175, DOI 10.1016/0014-5793(94)01393-F; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MCMURRAY HF, 1993, J CLIN INVEST, V92, P1004, DOI 10.1172/JCI116605; NEGRESALVAYRE A, 1995, TRACE ELEM RES, V47, P81; OBRIEN K, 1994, MED CLIN N AM, V78, P41, DOI 10.1016/S0025-7125(16)30176-6; OBRIEN KD, 1992, J CLIN INVEST, V89, P1544, DOI 10.1172/JCI115747; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; PARTHASARATHY S, 1987, P NATL ACAD SCI USA, V84, P537, DOI 10.1073/pnas.84.2.537; PARTHASARATHY S, 1992, ANNU REV MED, V43, P219, DOI 10.1146/annurev.me.43.020192.001251; PENN MS, 1994, ATHEROSCLEROSIS, V108, pS21, DOI 10.1016/0021-9150(94)90150-3; RADHAKRISHNAMURTHY B, 1990, EUR HEART J, V11, P148, DOI 10.1093/eurheartj/11.suppl_E.148; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; RIFICI VA, 1985, BIOCHIM BIOPHYS ACTA, V834, P205, DOI 10.1016/0005-2760(85)90157-2; SAXENA U, 1995, ARTERIOSCL THROM VAS, V15, P1240, DOI 10.1161/01.ATV.15.8.1240; SAXENA U, 1989, J BIOL CHEM, V264, P4349; SAXENA U, 1993, BIOCHEM BIOPH RES CO, V194, P769, DOI 10.1006/bbrc.1993.1888; SAXENA U, 1993, J BIOL CHEM, V268, P14812; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SAXENA U, 1991, P NATL ACAD SCI USA, V88, P2254, DOI 10.1073/pnas.88.6.2254; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; UEDA A, 1994, J IMMUNOL, V153, P2052; VANREE JH, 1995, ATHEROSCLEROSIS, V112, P237, DOI 10.1016/0021-9150(94)05419-J; VANREE JH, 1994, ATHEROSCLEROSIS, V111, P25, DOI 10.1016/0021-9150(94)90188-0; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111	63	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1329	1335		10.1074/jbc.271.3.1329	http://dx.doi.org/10.1074/jbc.271.3.1329			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576120	hybrid			2022-12-25	WOS:A1996TQ52500016
J	Chapin, SJ; Enrich, C; Aroeti, B; Havel, RJ; Mostov, KE				Chapin, SJ; Enrich, C; Aroeti, B; Havel, RJ; Mostov, KE			Calmodulin binds to the basolateral targeting signal of the polymeric immunoglobulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; RAT INTESTINE; MDCK CELLS; SORTING SIGNAL; PROTEIN; INTERNALIZATION; PHOSPHORYLATION; TRANSCYTOSIS; ANTIBODY; IGA	We have identified a major calmodulin (CaM)-binding protein in rat liver endosomes using I-125-CaM overlays from two dimensional protein blots, Immunostaining of blots demonstrates that this protein is the polymeric immunoglobulin receptor (pIgR). We further investigated the interaction between pIgR and CaM using Madin-Darby canine kidney cells stably expressing cloned wild-type and mutant pIgR, We found that detergent-solubilized pIgR binds to CaM-agarose in a Ca2+-dependent fashion, and binding is inhibited by the addition of excess free CaM: or the CaM. antagonist W-13 (N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide), suggesting that pIgR binding to CaM is specific, Furthermore, pIgR is the most prominent S-35-labeled CaM-binding protein in the detergent phase of Triton X-114-solubilized, metabolically labeled pIgR-expressing Madin-Darby canine kidney cells. CaM can be chemically cross-linked to both solubilized and membrane-associated pIgR, suggesting that binding can occur while the pIgR is in intact membranes, The CaM binding site is located in the membrane-proximal 17-amino acid segment of the pIgR cytoplasmic tail. This region of pIgR constitutes an autonomous basolateral targeting signal. However, binding of CaM to various pIgR mutants suggests that CaM binding is not necessary for basolateral targeting, We suggest that CaM may be involved in regulation of pIgR transcytosis and/or signaling by pIgR.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV BARCELONA, FAC MED, DEPT BIOL CELULAR, E-08028 BARCELONA, SPAIN	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Barcelona	Chapin, SJ (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT ANAT, BOX 0452, SAN FRANCISCO, CA 94143 USA.			Enrich, Carlos/0000-0003-0382-2993; mostov, keith/0000-0002-8123-6247	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036953, R01AI025144] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-14237] Funding Source: Medline; NIAID NIH HHS [R01 AI 25144, R01 AI36953] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APODACA G, 1993, J BIOL CHEM, V268, P20380; APODACA G, 1994, J BIOL CHEM, V269, P19005; APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; AROETI B, 1994, EMBO J, V13, P2297, DOI 10.1002/j.1460-2075.1994.tb06513.x; BACHS O, 1987, J BIOL CHEM, V262, P10786; BANSAL A, 1991, CELL, V67, P1195, DOI 10.1016/0092-8674(91)90295-A; BARROSO M, 1994, J CELL BIOL, V124, P83, DOI 10.1083/jcb.124.1.83; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BELCHER JD, 1987, P NATL ACAD SCI USA, V84, P6785, DOI 10.1073/pnas.84.19.6785; BOMSEL M, 1993, J BIOL CHEM, V268, P25824; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BURGOYNE RD, 1993, J ANAT, V183, P309; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARDONE MH, 1994, J CELL BIOL, V124, P717, DOI 10.1083/jcb.124.5.717; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; ENRICH C, 1988, BIOCHEM J, V255, P999, DOI 10.1042/bj2550999; FREIER S, 1987, GASTROENTEROLOGY, V93, P1242, DOI 10.1016/0016-5085(87)90251-4; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GROBLEWSKI GE, 1994, J BIOL CHEM, V269, P15111; GUERINI D, 1984, J BIOL CHEM, V259, P5172; HANSEN SH, 1994, J CELL BIOL, V126, P677, DOI 10.1083/jcb.126.3.677; HIRT RP, 1993, CELL, V74, P245, DOI 10.1016/0092-8674(93)90416-N; HUNZIKER W, 1994, J BIOL CHEM, V269, P29003; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JIN GF, 1989, DIGEST DIS SCI, V34, P1708, DOI 10.1007/BF01540048; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; LIU JP, 1992, DIGESTION, V53, P162; MATTER K, 1993, CELL, V74, P1053, DOI 10.1016/0092-8674(93)90727-8; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; NATHANSON MH, 1994, SCIENCE, V265, P970; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; OKAMOTO CT, 1994, J BIOL CHEM, V269, P15676; PIMPLIKAR SW, 1994, J CELL BIOL, V125, P1025, DOI 10.1083/jcb.125.5.1025; PIMPLIKAR SW, 1994, J BIOL CHEM, V269, P19054; PIMPLIKAR SW, 1993, NATURE, V362, P456, DOI 10.1038/362456a0; RAPHAEL GD, 1988, AM REV RESPIR DIS, V138, P413, DOI 10.1164/ajrccm/138.2.413; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SOLARI R, 1984, CELL, V36, P61, DOI 10.1016/0092-8674(84)90074-6; SONG WX, 1994, P NATL ACAD SCI USA, V91, P163, DOI 10.1073/pnas.91.1.163; SONG WX, 1994, J BIOL CHEM, V269, P29474; SULLIVAN KMC, 1993, CELL, V73, P1411, DOI 10.1016/0092-8674(93)90366-X; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; WILSON ID, 1982, GASTROENTEROLOGY, V83, P881	54	33	34	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1336	1342		10.1074/jbc.271.3.1336	http://dx.doi.org/10.1074/jbc.271.3.1336			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576121	hybrid			2022-12-25	WOS:A1996TQ52500017
J	Kovacs, A; Kandala, JC; Weber, KT; Guntaka, RV				Kovacs, A; Kandala, JC; Weber, KT; Guntaka, RV			Triple helix-forming oligonucleotide corresponding to the polypyrimidine sequence in the rat alpha 1(I) collagen promoter specifically inhibits factor binding and transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-BETA; I COLLAGEN; GENE-EXPRESSION; MESSENGER-RNA; SENSITIVE METHOD; MAMMALIAN-CELLS; FIBROSIS; DNA; PROTEINS; FIBROBLASTS	Type I and III fibrillar collagens are the major structural proteins of the extracellular matrix found in various organs including the myocardium. Abnormal and progressive accumulation of fibrillar type I collagen in the interstitial spaces compromises organ function and therefore, the study of transcriptional regulation of this gene and specific targeting of its expression is of major interest. Transient transfection of adult cardiac fibroblasts indicate that the polypurine-polypyrimidine sequence of a1(I) collagen promoter between nucleotides -200 and -140 represents an overall positive regulatory element. DNase I footprinting and electrophoretic mobility shift assays suggest that multiple factors bind to different elements of this promoter region. We further demonstrate that the unique polypyrimidine sequence between -172 and -138 of the promoter represents a suitable target for a single-stranded polypurine oligonucleotide (TFO) to form a triple helix DNA structure. Modified electrophoretic mobility shift assays show that this TFO specifically inhibits the protein-DNA interaction within the target region. In vitro transcription assays and transient transfection experiments demonstrate that the transcriptional activity of the promoter is inhibited by this oligonucleotide. We propose that TFOs represent a therapeutic potential to specifically influence the expression of alpha 1(I) collagen gene in various disease states where abnormal type I collagen accumulation is known to occur.	UNIV MISSOURI, SCH MED, DEPT MOLEC MICROBIOL & IMMUNOL, COLUMBIA, MO 65212 USA; UNIV MISSOURI, SCH MED, DEPT INTERNAL MED, DIV CARDIOL, COLUMBIA, MO 65212 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031701] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-31701] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABERGEL RP, 1987, J INVEST DERMATOL, V88, P727, DOI 10.1111/1523-1747.ep12470397; BISHOP JE, 1990, J MOL CELL CARDIOL, V22, P1157, DOI 10.1016/0022-2828(90)90079-H; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER DA, 1993, HEPATOLOGY, V17, P287, DOI 10.1016/0270-9139(93)90090-A; BRENNER DA, 1989, NUCLEIC ACIDS RES, V17, P6055, DOI 10.1093/nar/17.15.6055; BRENNER DA, 1993, AM J PHYSIOL, V264, pG589, DOI 10.1152/ajpgi.1993.264.4.G589; BRILLA CG, 1994, J MOL CELL CARDIOL, V26, P809, DOI 10.1006/jmcc.1994.1098; CHAPMAN D, 1990, CIRC RES, V67, P787, DOI 10.1161/01.RES.67.4.787; CHUA CC, 1991, CONNECT TISSUE RES, V26, P271, DOI 10.3109/03008209109152444; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; DECROMBRUGGHE B, 1991, ANN RHEUM DIS, V50, P872, DOI 10.1136/ard.50.Suppl_4.872; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOWNER G, 1988, J CLIN INVEST, V82, P998, DOI 10.1172/JCI113710; DURLAND RH, 1991, BIOCHEMISTRY-US, V30, P9246, DOI 10.1021/bi00102a017; DURLAND RH, 1990, JERUS SYM Q, V23, P565; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FRANKKAMENETSKI MD, 1995, ANNU REV BIOCHEM, V64, P95; FURTH JJ, 1991, EXP CELL RES, V192, P118, DOI 10.1016/0014-4827(91)90165-Q; GLICK AD, 1992, HUM PATHOL, V23, P1373, DOI 10.1016/0046-8177(92)90057-A; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; ING NH, 1993, NUCLEIC ACIDS RES, V21, P2789, DOI 10.1093/nar/21.12.2789; JIMENEZ SA, 1984, J CLIN INVEST, V74, P1112, DOI 10.1172/JCI111480; KARSENTY G, 1990, J BIOL CHEM, V265, P9934; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LAPTEV AV, 1994, BIOCHEMISTRY-US, V33, P11033, DOI 10.1021/bi00202a024; LAWRENCE WT, 1994, CLIN DERMATOL, V12, P157, DOI 10.1016/0738-081X(94)90266-6; LIAU G, 1986, J BIOL CHEM, V261, P1362; LICHTLER A, 1989, J BIOL CHEM, V264, P3072; MADRI JA, 1980, HUM PATHOL, V11, P353, DOI 10.1016/S0046-8177(80)80031-1; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P70, DOI 10.1021/bi00116a012; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; RAVAZZOLO R, 1991, J BIOL CHEM, V266, P7382; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPPINO AP, 1990, LAB INVEST, V63, P144; SCHMIDT A, 1985, NATURE, V314, P286, DOI 10.1038/314286a0; SLACK JL, 1993, AM J MED GENET, V45, P140, DOI 10.1002/ajmg.1320450203; SOLISHERRUZO JA, 1988, J BIOL CHEM, V263, P5841; WEBER KT, 1994, NEWS PHYSIOL SCI, V9, P123; WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849; WEBER KT, 1988, CIRC RES, V62, P757, DOI 10.1161/01.RES.62.4.757; WEBER KT, 1992, J LAB CLIN MED, V120, P22	46	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1805	1812		10.1074/jbc.271.3.1805	http://dx.doi.org/10.1074/jbc.271.3.1805			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576186	hybrid			2022-12-25	WOS:A1996TQ52500082
J	Lehmann, S; Harris, DA				Lehmann, S; Harris, DA			Mutant and infectious prion proteins display common biochemical properties in cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB DISEASE; SCRAPIE-ASSOCIATED FORM; NEURO-BLASTOMA CELLS; PHOSPHOLIPASE-C; PRP 27-30; RESISTANT; AGENT; GENE; PURIFICATION; BIOSYNTHESIS	Prion diseases are unusual neurodegenerative disorders that can be both infectious and inherited. Both forms are hypothesized to result from a posttranslational structural alteration in the cell surface glycoprotein PrPC (cellular isoform of the prion protein) that converts it into the protease-resistant isoform PrPSc (scrapie isoform of the prion protein). However, a direct comparison of molecular events underlying these two manifestations of prion diseases has not been possible, because there has been no cell culture model for the familial forms. We report here that when mutant prion proteins associated with three different inherited prion disorders of humans are expressed as their murine homologues in cultured Chinese hamster ovary cells, the proteins are protease-resistant and detergent-insoluble, two biochemical properties characteristic of infectious PrPSc. In addition, each mutant protein remains tightly associated with the plasma membrane after enzymatic cleavage of its glycosylphosphatidylinositol anchor, a property that we now show is also typical of infectious PrPSc. The cell culture system described here is the first in vitro model for familial prion diseases and provides compelling evidence that infectious and genetic cases share common molecular features.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Lehmann, Sylvain/P-1301-2017	Lehmann, Sylvain/0000-0001-6117-562X; Harris, David/0000-0002-6985-5790				BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; DICKINSON AG, 1968, J COMP PATHOL, V78, P293, DOI 10.1016/0021-9975(68)90005-4; GAJDUSEK DC, 1990, VIROLOGY, P2289; GIBBONS RA, 1967, NATURE, V215, P1041, DOI 10.1038/2151041a0; GOLDFARB LG, 1991, EUR J EPIDEMIOL, V7, P477, DOI 10.1007/BF00143125; GOLDFARB LG, 1992, SCIENCE, V258, P806, DOI 10.1126/science.1439789; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; HARRIS DA, 1993, BIOCHEMISTRY-US, V32, P1009, DOI 10.1021/bi00055a003; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; HIGUCHI R, 1989, PCR TECHNOLOGY; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO K, 1991, NEW ENGL J MED, V324, P1091, DOI 10.1056/NEJM199104183241604; HUNTER GD, 1964, J GEN MICROBIOL, V34, P319, DOI 10.1099/00221287-34-2-319; KIMBERLIN RH, 1978, J GEN VIROL, V39, P487, DOI 10.1099/0022-1317-39-3-487; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OWEN F, 1990, AM J HUM GENET, V46, P1215; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; POULTER M, 1992, BRAIN, V115, P675, DOI 10.1093/brain/115.3.675; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; PRUSINER SB, 1978, BIOCHEMISTRY-US, V17, P4993, DOI 10.1021/bi00616a021; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1994, ANNU REV NEUROSCI, V17, P311, DOI 10.1146/annurev.ne.17.030194.001523; PRUSINER SB, 1993, PHILOS T R SOC B, V339, P239, DOI 10.1098/rstb.1993.0022; PRUSINER SB, 1994, ANN NEUROL, V35, P385, DOI 10.1002/ana.410350404; RACE RE, 1988, J VIROL, V62, P2845, DOI 10.1128/JVI.62.8.2845-2849.1988; ROSENBERRY TL, 1991, CELL BIOL INT REP, V15, P1133, DOI 10.1016/0309-1651(91)90060-V; RUBENSTEIN R, 1994, MOL NEUROBIOL, V8, P129, DOI 10.1007/BF02780663; SAFAR J, 1993, J BIOL CHEM, V268, P20276; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; STAHL N, 1990, BIOCHEMISTRY-US, V29, P5405, DOI 10.1021/bi00474a028; STAHL N, 1990, MOL CELL BIOL MEMBRA, P189; TARABOULOS A, 1990, J CELL BIOL, V110, P2117, DOI 10.1083/jcb.110.6.2117; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6; YOUNG K, 1995, NEUROLOGY, V45, P1127, DOI 10.1212/WNL.45.6.1127	49	124	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1633	1637		10.1074/jbc.271.3.1633	http://dx.doi.org/10.1074/jbc.271.3.1633			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576163	hybrid			2022-12-25	WOS:A1996TQ52500059
J	Pelletier, AJ; Kunicki, T; Quaranta, V				Pelletier, AJ; Kunicki, T; Quaranta, V			Activation of the integrin alpha(v)beta(3) involves a discrete cation-binding site that regulates conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; CELL-ADHESION; SIGNAL TRANSDUCTION; GLYCOPROTEIN-IIIA; ALPHA-IIB-BETA-3; RECEPTOR; MODULATION; FIBRINOGEN; AFFINITY; PP125(FAK)	''Activation'' of integrins is involved in the dramatic transition of leukocytes and platelets from suspension to adhesion, The integrin alpha(v) beta(3), is not known to take part in this sort of transition, even though it shares its beta subunit with alpha(IIb)beta(3), the activable integrin on platelets, In the context of a constitutively adhered cell, changes in activation state may be more subtle in their effects, but nonetheless important in regulating cell behavior, We hypothesized that alpha(v) beta(3) can undergo conformational changes analogous to those associated with alpha(IIb)beta(3) activation, Accordingly, we examined alpha(v) beta(3) on the surface of M21 cells (a human melanoma cell line) and found that, like alpha(IIb)beta(3), it can undergo conformational changes upon binding of a ligand analog and can be activated for ligand binding and migration by a monoclonal antibody directed against beta(3). Modulation of the binding of this activating antibody, AP5, ligand binding, and antibody mediated activation all are associated with a discrete cation-binding site shared in both alpha(IIb)beta(3) and alpha(v) beta(3). Based on a measured K-i, this site has an apparent K-d for calcium of approximately 20 mu M. At physiological levels of calcium, about 40% of the total alpha(v) beta(3) on a cell's surface is in a conformation detected by AP5, The data suggest a model for both alpha(v) beta(3) and alpha(IIb)beta(3) function in which the molecule can exist in either of (at least) two conformational states, one stabilized either by AP5 or ligand binding, refractory to calcium binding, and enhanced for ligand recognition, the other stabilized by calcium binding and refractory to AP5 and ligand binding, Functional analysis suggests that AP5 activates alpha(v) beta(3) by preventing occupation of this calcium site, and that the activated form of alpha(v) beta(3) differs functionally from the basal form, The active form is more conducive to migration and the basal to tight adhesion.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	Scripps Research Institute	Pelletier, AJ (corresponding author), Scripps Res Inst, DEPT CELL BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Quaranta, Vito/G-6512-2016	Quaranta, Vito/0000-0001-7491-8672	NHLBI NIH HHS [HL 46979] Funding Source: Medline; NIAID NIH HHS [AI 07244] Funding Source: Medline; NIDCR NIH HHS [DE 10063] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010063] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALTIERI DC, 1990, J IMMUNOL, V145, P662; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BARKER PL, 1992, J MED CHEM, V35, P2040, DOI 10.1021/jm00089a014; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CAI TQ, 1995, J BIOL CHEM, V270, P14358, DOI 10.1074/jbc.270.24.14358; CALOF AL, 1991, J CELL BIOL, V115, P779, DOI 10.1083/jcb.115.3.779; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CIERNIEWSKI CS, 1994, BIOCHEMISTRY-US, V33, P12238, DOI 10.1021/bi00206a029; CROWE DT, 1994, J BIOL CHEM, V269, P14411; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DU XP, 1993, J BIOL CHEM, V268, P23087; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; Habermann BF, 1993, CURR OPIN CELL BIOL, V5, P864, DOI 10.1016/0955-0674(93)90036-P; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HILLERY CA, 1991, J BIOL CHEM, V266, P14663; HOGG N, 1993, AM REV RESPIR DIS, V148, pS55, DOI 10.1164/ajrccm/148.6_Pt_2.S55; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PELLETIER AJ, 1995, J BIOL CHEM, V270, P18133, DOI 10.1074/jbc.270.30.18133; PELLETIER AJ, 1992, MOL BIOL CELL, V3, P989, DOI 10.1091/mbc.3.9.989; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; SHATTIL SJ, 1993, THROMB HAEMOSTASIS, V70, P224; SHAW LM, 1993, J BIOL CHEM, V268, P11401; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SMITH JW, 1994, J BIOL CHEM, V269, P960; ZOLKIEWSKA A, 1993, J BIOL CHEM, V268, P25273	35	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1364	1370		10.1074/jbc.271.3.1364	http://dx.doi.org/10.1074/jbc.271.3.1364			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576125	hybrid			2022-12-25	WOS:A1996TQ52500021
J	Viollet, B; LefrancoisMartinez, AM; Henrion, A; Kahn, A; Raymondjean, M; Martinez, A				Viollet, B; LefrancoisMartinez, AM; Henrion, A; Kahn, A; Raymondjean, M; Martinez, A			Immunochemical characterization and transacting properties of upstream stimulatory factor isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; HELIX-ZIPPER PROTEIN; PYRUVATE-KINASE GENE; BOX-BINDING-PROTEINS; MAJOR LATE PROMOTER; DNA-BINDING; MESSENGER-RNA; DIMERIZATION SPECIFICITY; MULTIPLE FORMS; LEUCINE ZIPPER	The ubiquitous upstream stimulatory factor (USF) transcription factors encoded by two distinct genes (USF1 and USF2) exist under the form of various dimers able to bind E-boxes, We report the molecular cloning and functional characterization of USF2 isoforms, corresponding to a 44-kDa subunit, USF2a, and a new 38-kDa subunit, USF2b, generated by differential splicing. Using specific anti USF antibodies, we define the different binding complexes in various nuclear extracts, In vivo, the USF1/USF2a heterodimer represents over 66% of the USF binding activity whereas the USF1 and USF2a homodimers represent less than 10%, which strongly suggests an in vivo preferential association in heterodimers. In particular, an USF1/USF2b heterodimer accounted for almost 15% of the USF species in some cells. The preferential heterodimerization of USF subunits was reproduced ex vivo, while the in vitro association of cotranslated subunits, or recombinant USF proteins, appeared to be random. In transiently transfected HeLa or hepatoma cells, USF2a and USF1 homodimers transactivated a minimal promoter with similar efficiency, whereas USF2b, which lacks an internal 67-amino acid domain, was a poor transactivator. Additionally, USF2b was as efficient as USF1 and USF2a homodimers in transactivating the liver-specific pyruvate kinase gene promoter.	UNIV PARIS 05, U129 INSERM, INST COCHIN GENET MOLEC, F-75014 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Caude, Alexandra A Henrion/I-2778-2016; Viollet, Benoit/N-2397-2019; Viollet, Benoit/O-6927-2017	Caude, Alexandra A Henrion/0000-0002-8170-2260; Viollet, Benoit/0000-0002-0121-0224; Viollet, Benoit/0000-0002-0121-0224				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BRESNICK EH, 1993, J BIOL CHEM, V268, P18824; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; CHELLY J, 1990, EUR J BIOCHEM, V187, P691, DOI 10.1111/j.1432-1033.1990.tb15355.x; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHODOSH LA, 1987, SCIENCE, V238, P684, DOI 10.1126/science.3672119; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; COGNET M, 1991, J BIOL CHEM, V266, P7368; CVEKL A, 1994, MOL CELL BIOL, V14, P7363, DOI 10.1128/MCB.14.11.7363; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; FERREDAMARE AR, 1994, EMBO J, V13, P180, DOI 10.1002/j.1460-2075.1994.tb06247.x; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HENRION AA, 1995, GENOMICS, V25, P36, DOI 10.1016/0888-7543(95)80107-W; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KAULEN H, 1991, MOL CELL BIOL, V11, P412, DOI 10.1128/MCB.11.1.412; KIRSCHBAUM BJ, 1992, MOL CELL BIOL, V12, P5094, DOI 10.1128/MCB.12.11.5094; KOZLOWSKI MT, 1991, DEV BIOL, V148, P625, DOI 10.1016/0012-1606(91)90280-G; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LEVRAT F, 1993, EXP CELL RES, V209, P307, DOI 10.1006/excr.1993.1315; LIN Q, 1994, J BIOL CHEM, V269, P23894; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MIYAMOTO NG, 1985, EMBO J, V4, P3563, DOI 10.1002/j.1460-2075.1985.tb04118.x; NAVANKASATTUSAS S, 1994, MOL CELL BIOL, V14, P7331, DOI 10.1128/MCB.14.11.7331; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PERITZ LN, 1988, J BIOL CHEM, V263, P5005; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; POGNONEC P, 1991, NUCLEIC ACIDS RES, V19, P6650, DOI 10.1093/nar/19.23.6650; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHIH HM, 1994, J BIOL CHEM, V269, P9380; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Sirito Mario, 1992, Gene Expression, V2, P231; TACHIBANA M, 1994, HUM MOL GENET, V3, P553, DOI 10.1093/hmg/3.4.553; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; WATT F, 1993, NUCLEIC ACIDS RES, V21, P5092, DOI 10.1093/nar/21.22.5092; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	67	179	185	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1405	1415		10.1074/jbc.271.3.1405	http://dx.doi.org/10.1074/jbc.271.3.1405			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576131	hybrid			2022-12-25	WOS:A1996TQ52500027
J	Gan, WN; Rhoads, RE				Gan, WN; Rhoads, RE			Internal initiation of translation directed by the 5'-untranslated region of the mRNA for eIF4G, a factor involved in the picornavirus-induced switch from cap-dependent to internal initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN COMPLEX; 5' NONCODING REGION; MESSENGER-RNA; VIRUS-RNA; 5'-NONCODING SEQUENCES; INVITRO TRANSLATION; HEAT-SHOCK; RIBOSOMES; ENTRY; CELLS	The eIF4 group initiation factors carry out recognition of the mRNA cap, unwinding of mRNA secondary structure, and binding of mRNA to the 43 S preinitiation complex, Infection by picornaviruses results in proteolytic cleavage of one of these factors, eIF4G, an event that severely restricts cap-dependent translation but permits cap independent initiation to proceed from internal ribosome entry sequences in picornaviral RNAs. The 5'-untranslated region (5'-UTR) of eIF4G mRNA resembles such picornaviral sequences in being unusually long and containing multiple open reading frames and a polypyrimidine tract. When inserted upstream of a luciferase reporter gene, this 5'-UTR served as a translational enhancer in four different cell lines. Mutation of all four upstream ATG codons to AAG did not alter the translational enhancement. The presence of the eIF4G 5'-UTR between an RNA hairpin and the luciferase cistron stimulated expression 119-fold. Similarly, the presence of the 5'-UTR between the two cistrons of a bicistronic mRNA stimulated expression of the downstream cistron 42-fold. These results indicate that the eIF4G 5'-UTR directs internal initiation. The ability to continue synthesis of eIF4G when the cell is unable to carry out normal cap dependent translation may represent an autoregulatory mechanism or be part of the cellular response to stresses that interrupt cap-dependent translation.	LOUISIANA STATE UNIV,MED CTR,DEPT BIOCHEM & MOLEC BIOL,SHREVEPORT,LA 71130	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport					PHS HHS [20818] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BANDYOPADHYAY PK, 1992, J VIROL, V66, P6249, DOI 10.1128/JVI.66.11.6249-6256.1992; BELSHAM GJ, 1990, J VIROL, V64, P5389, DOI 10.1128/JVI.64.11.5389-5395.1990; BERLIOZ C, 1995, J VIROL, V69, P2214, DOI 10.1128/JVI.69.4.2214-2222.1995; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CORMACK B, 1994, CURRENT PROTOCOLS MO; GILMAN M, 1994, CURRENT PROTOCOLS MO; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; HAMBIDGE SJ, 1992, P NATL ACAD SCI USA, V89, P10272, DOI 10.1073/pnas.89.21.10272; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; JACKSON RJ, 1995, CAP INDEPENDENT TRAN, P1; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; Kaminski A, 1994, Genet Eng (N Y), V16, P115; KINGSTON RE, 1994, CURRENT PROTOCOLS MO; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; LIU DX, 1992, J VIROL, V66, P6143, DOI 10.1128/JVI.66.10.6143-6154.1992; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MADER S, 1995, MOL CELL BIOL, V15, P4490; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Rhoads RE, 1995, CURR TOP MICROBIOL, V203, P131; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; SARNOW P, 1995, CAP INDEPENDENT TRAN; THOMAS AAM, 1992, EUR J BIOCHEM, V207, P471, DOI 10.1111/j.1432-1033.1992.tb17073.x; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; YAN RQ, 1992, J BIOL CHEM, V267, P23226; ZAPATA JM, 1991, J BIOL CHEM, V266, P16007; ZIEGLER E, 1995, J VIROL, V69, P3465, DOI 10.1128/JVI.69.6.3465-3474.1995	37	94	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					623	626		10.1074/jbc.271.2.623	http://dx.doi.org/10.1074/jbc.271.2.623			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557663	hybrid			2022-12-25	WOS:A1996TP88900006
J	Lee, SY; Nagy, BP; Brooks, AR; Wang, DM; Paulweber, B; LevyWilson, B				Lee, SY; Nagy, BP; Brooks, AR; Wang, DM; Paulweber, B; LevyWilson, B			Members of the caudal family of homeodomain proteins repress transcription from the human apolipoprotein B promoter in intestinal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCRASE-ISOMALTASE GENE; HOMEOBOX GENE; LINE CACO-2; INVITRO TRANSCRIPTION; EPITHELIAL-CELLS; TRANSGENIC MICE; EXPRESSION; DIFFERENTIATION; ACTIVATION; ENHANCER	Apolipoprotein B (apoB) is the major protein component of low density lipoproteins, and plays a central role in cholesterol transport and metabolism, The apoB gene is transcribed in the liver and in the intestine in humans. Although much is known about the DNA sequence elements and protein factors that are important for transcription of the human apolipoprotein B gene in the liver, less is known about the mechanisms that control transcription of this gene in the intestine, The sucrose isomaltase gene (SI), is expressed exclusively in the intestine, Two sequences from the promoter region of the SI gene, namely SIF-1 and SIF-3, are essential for promoter activity of the SI gene in intestinal cells, Sequences displaying a high degree of similarity to those of SIF-1 and SIF-3 are present in the third intron of the apoB gene, Rather than stimulating apoB promoter activity, the BSIF-1 and BSIF-3 sequences repressed transcription in CaCo-2 cells, Gel retardation studies demonstrated that BSIF-1, like SIF-1, binds to proteins related to the caudal family of proteins such as mCdx-4 and mCdx-2. These proteins appear to repress transcription from the apoB promoter by a mechanism that involves an interaction with members of the C/EBP family of proteins, that bind to a target sequence for the repressor in the segment from -139 to -111 of the apoB pro meter, On the other hand, BSIF-3, like SIF-S, binds to HNF-1 and also represses transcription from the apoB promoter.	PALO ALTO MED FDN,RES INST,PALO ALTO,CA 94301; LANDESKRANKENANTALTEN,DEPT INTERNAL MED 1,SALZBURG,AUSTRIA; GLADSTONE INST CARDIOVASC DIS,SALZBURG,AUSTRIA	Palo Alto Medical Foundation Research Institute					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL41633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLACKHART BD, 1986, J BIOL CHEM, V261, P5364; BLUMBERG B, 1991, SCIENCE, V253, P194, DOI 10.1126/science.1677215; BROOKS AR, 1994, MOL CELL BIOL, V14, P2243, DOI 10.1128/MCB.14.4.2243; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; BROOKS AR, 1992, MOL CELL BIOL, V12, P1134, DOI 10.1128/MCB.12.3.1134; BURGLIN TR, 1989, NATURE, V341, P239, DOI 10.1038/341239a0; CHUNG YS, 1985, CANCER RES, V45, P2976; DEAROLF CR, 1989, NATURE, V341, P340, DOI 10.1038/341340a0; DEMMER LA, 1986, P NATL ACAD SCI USA, V83, P8102, DOI 10.1073/pnas.83.21.8102; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOLL U, 1993, DEV BIOL, V156, P155, DOI 10.1006/dbio.1993.1066; DUPREY P, 1988, GENE DEV, V2, P1647, DOI 10.1101/gad.2.12a.1647; FREUND JN, 1992, FEBS LETT, V314, P163, DOI 10.1016/0014-5793(92)80965-J; FROST SC, 1983, J LIPID RES, V24, P899; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GAMER LW, 1993, MECH DEVELOP, V43, P71, DOI 10.1016/0925-4773(93)90024-R; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GORDON JI, 1993, GASTROENTEROLOGY, V104, P315; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRASSET E, 1985, AM J PHYSIOL, V248, pC410, DOI 10.1152/ajpcell.1985.248.5.C410; HAFFEN K, 1987, J PEDIATR GASTR NUTR, V6, P14, DOI 10.1097/00005176-198701000-00005; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HERMISTON ML, 1993, SEMIN DEV BIOL, V4, P275; HUGHES TE, 1987, J BIOL CHEM, V262, P3762; JAMES R, 1991, J BIOL CHEM, V266, P3246; JAMES R, 1994, J BIOL CHEM, V269, P15229; JOLY JS, 1992, DIFFERENTIATION, V50, P75, DOI 10.1111/j.1432-0436.1992.tb00488.x; KARDASSIS D, 1992, J BIOL CHEM, V267, P2622; Klein R.M., 1989, HUMAN GASTROINTESTIN, P393; KLEIN RM, 1989, HUMAN GASTROINTESTIN, P367; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEVYWILSON B, 1995, PROG NUCLEIC ACID RE, V50, P161, DOI 10.1016/S0079-6603(08)60814-4; MARGALIT Y, 1993, NUCLEIC ACIDS RES, V21, P4915, DOI 10.1093/nar/21.21.4915; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; MENDEL DB, 1991, J BIOL CHEM, V266, P677; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MEYER BI, 1993, DEVELOPMENT, V117, P191; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; OHKUMA Y, 1990, CELL, V61, P475, DOI 10.1016/0092-8674(90)90529-N; PAULWEBER B, 1993, MOL CELL BIOL, V13, P1534, DOI 10.1128/MCB.13.3.1534; PAULWEBER B, 1991, J BIOL CHEM, V266, P21956; PAULWEBER B, 1991, J BIOL CHEM, V266, P24161; PINTO M, 1983, BIOL CELL, V47, P323; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; ROUET P, 1995, NUCLEIC ACIDS RES, V23, P395, DOI 10.1093/nar/23.3.395; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; VINCENT ML, 1985, HUM NUTR-CLIN NUTR, V39C, P355; WU GD, 1994, J BIOL CHEM, V269, P17080; XANTOPOULOS KG, 1996, EUR J BIOCHEM, V216, P353; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574; ZAWEL L, 1995, ANNU REV BIOCHEM, V64, P533	57	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					707	718		10.1074/jbc.271.2.707	http://dx.doi.org/10.1074/jbc.271.2.707			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557677	hybrid			2022-12-25	WOS:A1996TP88900020
J	Mikulits, W; Hengstschlager, M; Sauer, T; Wintersberger, E; Mullner, EW				Mikulits, W; Hengstschlager, M; Sauer, T; Wintersberger, E; Mullner, EW			Overexpression of thymidine kinase mRNA eliminates cell cycle regulation of thymidine kinase enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYMIDYLATE SYNTHASE; MESSENGER-RNA; BINDING-SITE; MAMMALIAN-CELLS; GENE; PROTEIN; EXPRESSION; SEQUENCE; PROMOTER; GROWTH	Expression of thymidine kinase (TK) enzyme activity and mRNA is strictly S phase-specific in primary cells. In contrast, DNA tumor virus-transformed cells have enhanced and constitutive levels of TK mRNA during the whole cell cycle. Their TK protein abundance, however, still increases at the G(1)-S transition and stays high throughout G(2) until mitosis. Therefore, post-transcriptional control must account for the decoupling of TK mRNA from protein synthesis in G(1). To characterize the underlying mechanism, we studied the consequences of TK mRNA abundance on the cell cycle-dependent regulation of TK activity in nontransformed cells. Constitutive as well as conditional human and mouse TK cDNA vectors were stably transfected into mouse fibroblasts, which were subsequently synchronized by centrifugal elutriation. Low constitutive TK mRNA expression still resulted in a fluctuation of TK activity with a pronounced maximum in S phase. This pattern of cell cycle-dependent TK activity variation reflected the one in primary cells but is caused by post-transcriptional control. Increasing overexpression of TK transcripts after hormonal induction compromised this regulation. At the highest constant mRNA levels, regulation of enzyme activity was totally abolished in each phase of the cell cycle. These data indicate that post-transcriptional regulation of TK is tightly coupled to the amount of mRNA; high concentrations apparently titrate a factor(s) required for repressing TK production during G(1) and presumably also G(2).	UNIV VIENNA, BIOCTR, INST MOLEC BIOL, A-1030 VIENNA, AUSTRIA; UNIV VIENNA, DEPT PRENATAL DIAG & THERAPY, A-1090 VIENNA, AUSTRIA	University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); University of Vienna			Mikulits, Wolfgang/AAH-4043-2021	Mikulits, Wolfgang/0000-0003-4612-7106				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; BUETTI E, 1994, MOL CELL BIOL, V14, P1191, DOI 10.1128/MCB.14.2.1191; BUETTI E, 1986, J MOL BIOL, V190, P379, DOI 10.1016/0022-2836(86)90009-4; CAROZZA MA, 1994, CELL GROWTH DIFFER, V5, P901; CHANG ZF, 1994, J BIOL CHEM, V269, P21249; CHANG ZF, 1993, J BIOL CHEM, V268, P1266; CHU E, 1993, BIOCHEMISTRY-US, V32, P4756, DOI 10.1021/bi00069a009; CHU E, 1993, P NATL ACAD SCI USA, V90, P517, DOI 10.1073/pnas.90.2.517; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; DANIEL F, 1983, EMBO J, V2, P1061, DOI 10.1002/j.1460-2075.1983.tb01546.x; Favaloro J, 1980, Methods Enzymol, V65, P718; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GROSS MK, 1988, NUCLEIC ACIDS RES, V16, P11625, DOI 10.1093/nar/16.24.11625; GROSS MK, 1989, P NATL ACAD SCI USA, V86, P4987, DOI 10.1073/pnas.86.13.4987; HENGSTSCHLAGER M, 1994, INT J ONCOL, V4, P207; HENGSTSCHLAGER M, 1994, J BIOL CHEM, V269, P13836; HENGSTSCHLAGER M, 1994, CELL GROWTH DIFFER, V5, P1389; HOFBAUER R, 1987, NUCLEIC ACIDS RES, V15, P741, DOI 10.1093/nar/15.2.741; ITO M, 1990, J BIOL CHEM, V265, P6954; KAUFFMAN MG, 1991, MOL CELL BIOL, V11, P2538, DOI 10.1128/MCB.11.5.2538; KAUFFMAN MG, 1991, ONCOGENE, V6, P1427; KIM YK, 1992, J BIOL CHEM, V267, P2723; KNOFLER M, 1993, J BIOL CHEM, V268, P11409; KUHNEL B, 1986, J MOL BIOL, V190, P367, DOI 10.1016/0022-2836(86)90008-2; LI LJ, 1993, P NATL ACAD SCI USA, V90, P3554, DOI 10.1073/pnas.90.8.3554; LITTLEFIELD JW, 1964, SCIENCE, V145, P709, DOI 10.1126/science.145.3633.709; MIKULITS W, 1994, FEBS LETT, V345, P172, DOI 10.1016/0014-5793(94)00451-X; MIKULITS W, 1995, NUCLEIC ACIDS RES, V23, P2342, DOI 10.1093/nar/23.12.2342; MUDRAK I, 1994, MOL CELL BIOL, V14, P1886, DOI 10.1128/MCB.14.3.1886; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RAAKA BM, 1989, MOL ENDOCRINOL, V3, P332, DOI 10.1210/mend-3-2-332; SAMUELS HH, 1979, BIOCHEMISTRY-US, V18, P715, DOI 10.1021/bi00571a025; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; STUART P, 1985, MOL CELL BIOL, V5, P1490, DOI 10.1128/MCB.5.6.1490; WAWRA E, 1981, J VIROL, V38, P973, DOI 10.1128/JVI.38.3.973-981.1981; WHITE JH, 1991, P NATL ACAD SCI USA, V88, P7674, DOI 10.1073/pnas.88.17.7674; [No title captured]	44	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					853	860		10.1074/jbc.271.2.853	http://dx.doi.org/10.1074/jbc.271.2.853			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557696	hybrid			2022-12-25	WOS:A1996TP88900039
J	Nowatzke, WL; Richardson, JP				Nowatzke, WL; Richardson, JP			Characterization of an unusual Rho factor from the high G+C Gram-positive bacterium Micrococcus luteus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATION FACTOR-RHO; PHOSPHOHYDROLASE ATPASE ACTIVITY; ESCHERICHIA-COLI; MESSENGER-RNA; TRANSCRIPTION; DNA; GENE; INHIBITORS; FRAGMENTS; PROTEINS	A transcription termination factor (Rho) was purified from the Gram-positive bacterium Micrococcus luteus, and the complete gene sequence was determined, The M. luteus Rho polypeptide has 690 residues, which is 271 residues more than its homolog from Escherichia coli, Most of the additional residues compose a highly charged, hydrophilic segment that is inserted in a nonconserved region between two conserved regions of the RNA binding domain of the known Rho homolog proteins, This segment extends from residues 49 to 311 and includes a stretch of 238 residues that contain no hydrophobic side chains, Biochemical studies indicate that the M. luteus protein is very similar to E. coli Rho in terms of its RNA-dependent NTPase activity and its sensitivity to the Rho-specific inhibitor bicyclomycin. However, the M. luteus protein has a less stringent RNA cofactor specificity, It also acts to terminate RNA transcription with E. coli RNA polymerase on the A cro DNA template, but at much earlier termination stop points than those recognized by E. coli Rho, Thus, the M. luteus protein functions as a true Rho factor, but with a different specificity than that of E. coli Rho, We propose that this altered specificity is consistent with its need to function on transcripts that have a high content of G + C residues.	INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington					NIAID NIH HHS [AI 10142] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI010142, R01AI010142] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALIFANO P, 1991, CELL, V64, P553; BARR PJ, 1986, BIOTECHNIQUES, V4, P428; BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; BURNS CM, 1995, P NATL ACAD SCI USA, V92, P4738, DOI 10.1073/pnas.92.11.4738; FAUS I, 1990, J MOL BIOL, V212, P53, DOI 10.1016/0022-2836(90)90304-5; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINGER LR, 1982, J MOL BIOL, V156, P208; HUGLI TE, 1989, TECHNIQUES PROTEIN C, P28; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LAU LF, 1982, P NATL ACAD SCI-BIOL, V79, P6171, DOI 10.1073/pnas.79.20.6171; LI J, 1993, GENE DEV, V7, P161, DOI 10.1101/gad.7.1.161; LOWERY C, 1977, J BIOL CHEM, V252, P1375; LOWERY C, 1977, J BIOL CHEM, V252, P1381; MILOSO M, 1993, J BACTERIOL, V175, P8030, DOI 10.1128/JB.175.24.8030-8037.1993; MORGAN WD, 1984, J BIOL CHEM, V259, P8664; NOWATZKE WL, 1996, IN PRESS METHODS ENZ; OHAMA T, 1989, J MOL EVOL, V29, P381, DOI 10.1007/BF02602908; OPPERMAN T, 1994, J BACTERIOL, V176, P5033, DOI 10.1128/jb.176.16.5033-5043.1994; OPPERMAN T, 1993, THESIS INDIANA U; PINKHAM JL, 1983, NUCLEIC ACIDS RES, V11, P3531, DOI 10.1093/nar/11.11.3531; PLATT T, 1992, TRANSCRIPTIONAL REGU, P365; QUIRK PG, 1993, J BACTERIOL, V175, P647, DOI 10.1128/JB.175.3.647-654.1993; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TILLY K, 1993, NUCLEIC ACIDS RES, V21, P1040, DOI 10.1093/nar/21.4.1040; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; Wilson K, 1989, CURRENT PROTOCOLS MO; ZWIEFKA A, 1993, BIOCHEMISTRY-US, V32, P3564, DOI 10.1021/bi00065a007	36	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					742	747		10.1074/jbc.271.2.742	http://dx.doi.org/10.1074/jbc.271.2.742			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557681	hybrid			2022-12-25	WOS:A1996TP88900024
J	Rodnina, MV; Pape, T; Fricke, R; Kuhn, L; Wintermeyer, W				Rodnina, MV; Pape, T; Fricke, R; Kuhn, L; Wintermeyer, W			Initial binding of the elongation factor Tu center dot GTP center dot aminoacyl-tRNA complex preceding codon recognition on the ribosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-BINDING; PROTEIN-SYNTHESIS; TERNARY COMPLEX; CONFORMATION; SITES; FLUORESCENCE; TOPOLOGY; CYCLE	The first step in the sequence of interactions between the ribosome and the complex of elongation factor Tu (EF-Tu), GTP, and aminoacyl-tRNA, which eventually leads to A site-bound aminoacyl-tRNA, is the codon-independent formation of an initial complex. We have characterized the initial binding and the resulting complex by time resolved (stopped-flow) and steady-state fluorescence measurements using several fluorescent tRNA derivatives. The complex is labile, with rate constants of 6 x 10(7) M(-1) s(-1) and 24 s(-1) (20 degrees C, 10 mM Mg2+) for binding and dissociation, respectively. Both thermodynamic and activation parameters of initial binding were determined, and five Mg2+ ions were estimated to participate in the interaction. While a cognate ternary complex proceeds from initial binding through codon recognition to rapid GTP hydrolysis, the rate constant of GTP hydrolysis in the non-cognate complex is 4 orders of magnitude lower, despite the rapid formation of the initial complex in both cases, Hence, the ribosome-induced GTP hydrolysis by EF-Tu is strongly affected by the presence of the tRNA. This suggests that codon-anticodon recognition, which takes place after the formation of the initial binding complex, provides a specific signal that triggers fast GTP hydrolysis by EF-Tu on the ribosome.	UNIV WITTEN HERDECKE,INST MOLEK BIOL,D-58448 WITTEN,GERMANY	Witten Herdecke University			Rodnina, Marina V./AAD-4667-2019	Rodnina, Marina V./0000-0003-0105-3879; Pape, Tillmann/0000-0002-0612-3568				ADKINS HJ, 1983, BIOCHEMISTRY-US, V22, P1208, DOI 10.1021/bi00274a034; ALBERTY RA, 1969, J BIOL CHEM, V244, P3290; Bernasconi C. F., 1976, RELAXATION KINETICS; BILGIN N, 1988, FEBS LETT, V233, P95, DOI 10.1016/0014-5793(88)81362-0; BILGIN N, 1992, J MOL BIOL, V224, P1011, DOI 10.1016/0022-2836(92)90466-W; Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; Ehrenberg M, 1990, RIBOSOMES PROTEIN SY, P101; FASANO O, 1982, J BIOL CHEM, V257, P3145; GIRSHOVICH AS, 1986, FEBS LETT, V197, P192, DOI 10.1016/0014-5793(86)80325-8; HARDESTY B, 1969, COLD SPRING HARB SYM, V39, P331; HARUKI M, 1990, FEBS LETT, V263, P361, DOI 10.1016/0014-5793(90)81414-J; HAUSNER TP, 1987, BIOCHIMIE, V69, P911, DOI 10.1016/0300-9084(87)90225-2; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; IKEMURA T, 1981, J MOL BIOL, V146, P1, DOI 10.1016/0022-2836(81)90363-6; JANIAK F, 1990, BIOCHEMISTRY-US, V29, P4268, DOI 10.1021/bi00470a002; KRUSE TA, 1978, NUCLEIC ACIDS RES, V5, P879, DOI 10.1093/nar/5.3.879; LAKE JA, 1977, P NATL ACAD SCI USA, V74, P1903, DOI 10.1073/pnas.74.5.1903; LANGER JA, 1986, J MOL BIOL, V187, P617, DOI 10.1016/0022-2836(86)90339-6; LEBERMAN R, 1980, ANAL BIOCHEM, V104, P99; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; NINIO J, 1975, BIOCHIMIE, V57, P587, DOI 10.1016/S0300-9084(75)80139-8; POWERS T, 1993, P NATL ACAD SCI USA, V90, P1364, DOI 10.1073/pnas.90.4.1364; RAPPOPORT S, 1974, METHOD ENZYMOL, V24, P685; RIEHL N, 1983, FEBS LETT, V154, P42, DOI 10.1016/0014-5793(83)80871-0; ROBERTSON JM, 1981, J MOL BIOL, V151, P57, DOI 10.1016/0022-2836(81)90221-7; RODNINA MV, 1992, J MOL BIOL, V228, P450, DOI 10.1016/0022-2836(92)90834-7; RODNINA MV, 1995, EMBO J, V14, P2613, DOI 10.1002/j.1460-2075.1995.tb07259.x; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; RODNINA MV, 1994, BIOCHEMISTRY-US, V33, P12267, DOI 10.1021/bi00206a033; RODNINA MV, 1993, TRANSLATIONAL APPARATUS, P317; TAPPRICH WE, 1990, EMBO J, V9, P2649, DOI 10.1002/j.1460-2075.1990.tb07447.x; THOMPSON RC, 1986, J BIOL CHEM, V261, P4868; THOMPSON RC, 1988, TRENDS BIOCHEM SCI, V13, P91, DOI 10.1016/0968-0004(88)90047-3; THOMPSON RC, 1982, J BIOL CHEM, V257, P6677; WEYGANDDURASEVIC I, 1981, EUR J BIOCHEM, V116, P59, DOI 10.1111/j.1432-1033.1981.tb05300.x; WIKMAN FP, 1982, EMBO J, V1, P1095, DOI 10.1002/j.1460-2075.1982.tb01302.x; WINTERMEYER W, 1979, EUR J BIOCHEM, V98, P465	38	128	129	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					646	652		10.1074/jbc.271.2.646	http://dx.doi.org/10.1074/jbc.271.2.646			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557669	Green Published, hybrid			2022-12-25	WOS:A1996TP88900012
J	Svejstrup, JQ; Feaver, WJ; Kornberg, RD				Svejstrup, JQ; Feaver, WJ; Kornberg, RD			Subunits of yeast RNA polymerase II transcription factor TFIIH encoded by the CCL1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; SEQUENCES; P40(MO15); P34(CDC2); CYCLIN; KIN28	Both 45- and 47-kDa subunits of TFIIK, a subcomplex of RNA polymerase II general transcription factor TFIIH, are encoded by the yeast cyclin gene CCL1. In all likelihood, these two subunits individually form cyclin-dependent kinase/cyclin dimers with Kin28 protein, a key enzyme in phosphorylation of the C-terminal domain of RNA polymerase II concomitant with transcription.	STANFORD UNIV,SCH MED,DEPT BIOL STRUCT,STANFORD,CA 94305	Stanford University				Svejstrup, Jesper/0000-0003-4964-6147	NIGMS NIH HHS [GM36659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036659, R01GM036659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CIGAN AM, 1988, MOL CELL BIOL, V8, P2964, DOI 10.1128/MCB.8.7.2964; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; SVEJSTRUP JQ, 1995, CELL, V80, P21, DOI 10.1016/0092-8674(95)90447-6; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0	22	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					643	645		10.1074/jbc.271.2.643	http://dx.doi.org/10.1074/jbc.271.2.643			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557668	hybrid			2022-12-25	WOS:A1996TP88900011
J	Vasavada, RC; Cavaliere, C; DErcole, AJ; Dann, P; Burtis, WJ; Madlener, AL; Zawalich, K; Zawalich, W; Philbrick, W; Stewart, AF				Vasavada, RC; Cavaliere, C; DErcole, AJ; Dann, P; Burtis, WJ; Madlener, AL; Zawalich, K; Zawalich, W; Philbrick, W; Stewart, AF			Overexpression of parathyroid hormone-related protein in the pancreatic islets of transgenic mice causes islet hyperplasia, hyperinsulinemia, and hypoglycemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLASE-STIMULATING ACTIVITY; HUMORAL HYPERCALCEMIA; PEPTIDE GENE; INSULIN-SECRETION; CELL-LINE; EXPRESSION; MALIGNANCY; TUMORS; GLUCOSE; GROWTH	Parathyroid hormone-related protein (PTHrP) is produced by the pancreatic islet. It also has receptors on islet cells, suggesting that it may serve a paracrine or autocrine role within the islet. We have developed transgenic mice, which overexpress PTHrP in the islet through the use of the rat insulin II promoter (RIP). Glucose homeostasis in these mice is markedly abnormal; RIP-PTHrP mice are hypoglycemic in the postprandial and fasting states and display inappropriate hyperinsulinemia. At the end of a 24-hour fast, blood glucose values are 49 mg/dl in RIP-PTHrP mice, as compared to 77 mg/dl in normal littermates; insulin concentrations at this time are 6.3 and 3.9 ng/ml, respectively, Islet perifusion studies failed to demonstrate abnormalities in insulin secretion. In contrast, quantitative islet histomorphometry demonstrates that the total islet number and total islet mass are 2-fold higher in RIP-PTHrP mice than in their normal littermates. PTHrP very likely plays a normal physiologic role within the pancreatic islet. This role is most likely paracrine or autocrine. PTHrP appears to regulate insulin secretion either directly or indirectly, through developmental or growth effects on islet mass. PTHrP may have a role as an agent that enhances islet mass and/or enhances insulin secretion.	YALE UNIV,SCH MED,ENDOCRINOL SECT,NEW HAVEN,CT 06510; YALE UNIV,SCH NURSING,NEW HAVEN,CT 06510; UNIV N CAROLINA,SCH MED,DIV PEDIAT ENDOCRINOL,CHAPEL HILL,NC 27599	Yale University; Yale University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Vasavada, RC (corresponding author), W HAVEN VET AFFAIRS MED CTR,DIV ENDOCRINOL,950 CAMPBELL AVE,W HAVEN,CT 06516, USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030102, R37AR030102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041230, P30DK045735] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 30102] Funding Source: Medline; NIDDK NIH HHS [DK 41230, DK 45735] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASA SL, 1990, J CLIN ENDOCR METAB, V71, P1112, DOI 10.1210/jcem-71-5-1112; BEHRINGER RR, 1990, ENDOCRINOLOGY, V127, P1033, DOI 10.1210/endo-127-3-1033; BODEN G, 1994, ANN INTERN MED, V121, P109, DOI 10.7326/0003-4819-121-2-199407150-00005; Broadus Arthur E., 1994, P259; BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEPAPP AE, 1993, TRENDS ENDOCRIN MET, V4, P181, DOI 10.1016/1043-2760(93)90114-T; DRUCKER DJ, 1989, MOL ENDOCRINOL, V3, P1589, DOI 10.1210/mend-3-10-1589; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EPSTEIN PN, 1992, P NATL ACAD SCI USA, V89, P12038, DOI 10.1073/pnas.89.24.12038; GAICH G, 1990, ENDOCRINOLOGY, V127, P1444, DOI 10.1210/endo-127-3-1444; GAICH G, 1993, ENDOCRINOLOGY, V132, P1402, DOI 10.1210/en.132.3.1402; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; KAISER SM, 1992, J BIOL CHEM, V267, P13623; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KARAPLIS AC, 1994, J BONE MINER RES  S1, V9, pS121; KATO I, 1994, J BIOL CHEM, V269, P21223; LANSKE B, 1994, J BONE MINER RES  S1, V9, pS121; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; MA YH, 1994, ENDOCRINOLOGY, V134, P42, DOI 10.1210/en.134.1.42; NISSENSON RA, 1992, PARATHYROID HORMONE; ORLOFF JJ, 1994, ENDOCR REV, V15, P40, DOI 10.1210/er.15.1.40; PARSONS JA, 1995, ENDOCRINOLOGY, V136, P2013, DOI 10.1210/en.136.5.2013; PHILBRICK WM, 1996, IN PRESS PHYSL REV; PICARELLA DE, 1992, P NATL ACAD SCI USA, V89, P10036, DOI 10.1073/pnas.89.21.10036; SOIFER NE, 1993, J CLIN INVEST, V92, P2850, DOI 10.1172/JCI116905; STEWART AF, 1986, J BONE MINER RES, V1, P267; STEWART AF, 1983, P NATL ACAD SCI-BIOL, V80, P1454, DOI 10.1073/pnas.80.5.1454; STEWART AF, 1982, J CLIN ENDOCR METAB, V55, P219, DOI 10.1210/jcem-55-2-219; STEWART AF, 1995, ENDOCRINOLOGY, P1061; STEWART AF, 1993, AM SOC BONE MINERAL, P169; STREUTKER C, 1991, MOL ENDOCRINOL, V5, P703, DOI 10.1210/mend-5-5-703; THIEDE MA, 1990, P NATL ACAD SCI USA, V87, P6969, DOI 10.1073/pnas.87.18.6969; WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133; WYSOLMERSKI JJ, 1994, J BONE MINER RES, V9, pS121; ZAWALICH WS, 1991, BIOCHEM J, V278, P49, DOI 10.1042/bj2780049; ZAWALICH WS, 1993, DIABETES, V42, P843, DOI 10.2337/diabetes.42.6.843	38	114	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1200	1208		10.1074/jbc.271.2.1200	http://dx.doi.org/10.1074/jbc.271.2.1200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557651	hybrid, Green Published			2022-12-25	WOS:A1996TP88900088
J	DubsPoterszman, MC; Tocque, B; Wasylyk, B				DubsPoterszman, MC; Tocque, B; Wasylyk, B			MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest	ONCOGENE			English	Article						E2F; transcription; Rb; inhibition; anchorage-independent growth	AUTOREGULATORY FEEDBACK LOOP; WILD-TYPE P53; GENE; EXPRESSION; PROTEIN; OVEREXPRESSION; AMPLIFICATION; SUPPRESSION; MUTATIONS; ONCOGENE	The p53 tumour-suppressor guards the genome in response to genotoxic stress by transcriptional regulation of genes involved in cell-cycle control, DNA replication, repair and apoptosis such as p21, GADD45, bar and mdm2 (Cox and Lane, 1995), Mdm2 is classically considered to be an inhibitor of p53, that forms an auto-regulatory loop (Momand et al., 1992; Oliner et al., 1993; Wu el al., 1993; Chen et al., 1994; Chen and Levine, 1995). It immortalises cells containing wild type p53 and transforms them together with Ras (Finlay, 1993). We show that, in the absence of p53, mdm2 confers a growth advantage to cells (ie ''transforms'' them) and can overcome a G1 cell-cycle arrest induced by p107, a member of the pRb tumour-suppressor family (Adams and Kaelin, 1995), The minimum ''transforming'' and p107 inhibiting region of Mdm2 corresponds to its p53 binding domain, p53 inhibits transformation by Mdm2, apparently without requiring transcription, p53 can be considered to be a suppressor of Mdm2, a positive effector of the cell cycle, Mdm2 over-expression in tumours is reminiscent of p53 mutations with gain of function, in that Mdm2 both transforms cells and inhibits p53 activity.	INST GENET & BIOL MOLEC & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,F-94403 VITRY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Sanofi-Aventis				WASYLYK, Bohdan/0000-0002-1718-1237				ADAMS PD, 1995, CANC BIOL, V6, P99; BATES S, 1995, CANCER BIOL, V6, P73; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CORDONCARDO C, 1994, CANCER RES, V54, P794; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; HAHN BC, 1995, NAT GENET, V9, P221; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEACH FS, 1993, CANCER RES, V53, P2231; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTTO A, 1993, ONCOGENE, V8, P2591; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; QUESNEL B, 1994, BRIT J HAEMATOL, V88, P415, DOI 10.1111/j.1365-2141.1994.tb05044.x; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SHAULSKY G, 1991, CANCER RES, V51, P5232; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; WATANABE T, 1994, BLOOD, V84, P3158; WHARTON W, 1989, CELL GROWTH DIVISION, P139; WHYTE P, 1995, CANCER BIOL, V6, P83; WOLF D, 1984, MOL CELL BIOL, V4, P552, DOI 10.1128/MCB.4.3.552; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	37	87	90	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2445	2449						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570197				2022-12-25	WOS:A1995TK70200030
J	Canossa, M; Rovelli, G; Shooter, EM				Canossa, M; Rovelli, G; Shooter, EM			Transphosphorylation of the neurotrophin Trk receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; SYMPATHETIC NEURONS; SIGNAL TRANSDUCTION; INSULIN-RECEPTOR; RAT TRKC; CELLS; EGF; ACTIVATION; PROTEIN	The potential for the activation of one Trk receptor by ligand binding to another Trk receptor was explored by determining if transphosphorylation on tyrosine residues can occur between receptors. For most of these experiments, functional chimeric receptors were used that contained the extracellular domain of the human type 2 tumor necrosis factor receptor and the transmembrane and cytoplasmic domains of rat TrkA, TrkB, or TrkC and that, when activated by the tumor necrosis factor, mediated the nerve growth factor-like biological activities in PC12 cells. Cotransfection experiments in COS-7 cells and fibroblasts showed that despite the presence of different extracellular regions, intermolecular transphosphorylation of homologous cytoplasmic domains occurred between TrkA or TrkB and their cognate chimeras, Heterologous transphosphorylation between TrkB and TrkC kinase domains was also observed when one partner was a chimeric receptor; however, TrkA did not transphosphorylate the TrkB or TrkC kinase domains of chimeric receptors or act as a transphosphorylation substrate for these two receptors. The failure of TrkA to take part in transphosphorylation reactions with TrkB and TrkC was confirmed using the natural receptors. Trk receptor transphosphorylation occurs in the two non-neuronal cell types, but TrkA is excluded from these reactions.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University			Canossa, Marco/R-7425-2016	Canossa, Marco/0000-0003-3898-2030	NINDS NIH HHS [NS04270] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS004270] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Barbacid Mariano, 1993, P123; BARKER PA, 1993, J BIOL CHEM, V268, P1; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; CHUN LLY, 1977, J CELL BIOL, V75, P705, DOI 10.1083/jcb.75.3.705; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GREENE LA, 1977, DEV BIOL, V58, P96, DOI 10.1016/0012-1606(77)90076-8; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HACK N, 1993, J BIOL CHEM, V268, P26441; HERBST R, 1991, J BIOL CHEM, V266, P19908; HEYMACH JV, 1995, J BIOL CHEM, V270, P12297, DOI 10.1074/jbc.270.20.12297; HOHMANN HP, 1989, J BIOL CHEM, V264, P14927; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HONEGGER A, 1988, EMBO J, V7, P3045, DOI 10.1002/j.1460-2075.1988.tb03169.x; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JUNGBLUTH S, 1994, EUR J BIOCHEM, V221, P677, DOI 10.1111/j.1432-1033.1994.tb18780.x; KHAZAIE K, 1988, EMBO J, V7, P3061, DOI 10.1002/j.1460-2075.1988.tb03171.x; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; LUTHMAN H, 1983, NUCLEIC ACIDS RES, V11, P1295, DOI 10.1093/nar/11.5.1295; MCMAHON SB, 1994, NEURON, V12, P1161, DOI 10.1016/0896-6273(94)90323-9; MEAKIN SO, 1992, TRENDS NEUROSCI, V15, P323, DOI 10.1016/0166-2236(92)90047-C; OBERMEIER A, 1993, EMBO J, V12, P933, DOI 10.1002/j.1460-2075.1993.tb05734.x; RADZIEWJEWSKI C, 1993, BIOCHEMISTRY-US, V32, P13350, DOI 10.1021/bi00211a049; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; ROVELLI G, 1993, P NATL ACAD SCI USA, V90, P8717, DOI 10.1073/pnas.90.18.8717; RUSSELL DS, 1987, J BIOL CHEM, V262, P11833; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; Verge V. M. K., 1993, Society for Neuroscience Abstracts, V19, P1477	39	16	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5812	5818		10.1074/jbc.271.10.5812	http://dx.doi.org/10.1074/jbc.271.10.5812			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621450	hybrid			2022-12-25	WOS:A1996TZ28600076
J	Chen, CY; Faller, DV				Chen, CY; Faller, DV			Phosphorylation of Bcl-2 protein and association with p21(Ras) in Ras-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROGRAMMED CELL-DEATH; KINASE-C; GUANINE-NUCLEOTIDES; ACTIVATION; EXCHANGE; P21RAS; PROTOONCOGENE; STIMULATION; NEURONS	p21(Ras) mediates mitogenic responses and also renders cells susceptible to apoptosis after inhibition of protein kinase C (PKC) activity. Ras-induced apoptosis can be blocked by the proto-oncogene bcl-2, but the biochemical or functional nature of Bcl-2 regulation of Ras-induced apoptosis is not understood. We demonstrate that Bcl-2 and p21(Ras) molecules can be co-immunoprecipitated in Jurkat cells. The level of this association is enhanced when an apoptotic stimulus (inhibition of PKC activity) is delivered. Bcl-2/p21(Ras) association is coincident with new phosphorylation of the Bcl-2 protein. Inhibition of this phosphorylation prevents protection from apoptosis by Bcl-2, providing a functional cor relation to the phosphorylation event. The Bcl-2/p21(Ras) association cannot be competed by exogenous glutathione S-transferase-Ras fusion protein, suggesting that the endogenous complex may be formed before cell lysis. These results provide a possible mechanism of regulation of has-induced apoptosis by Bcl-2.	BOSTON UNIV,SCH MED,CTR CANC RES,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PATHOL & LAB MED,BOSTON,MA 02118	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University					NCI NIH HHS [CA50459] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050459] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; CHEN CY, 1995, ONCOGENE, V11, P1487; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CONNOLLY TM, 1986, CELL, V46, P951, DOI 10.1016/0092-8674(86)90077-2; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FERNANDEZ A, 1995, ONCOGENE, V10, P769; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HALBERG B, 1994, J BIOL CHEM, V269, P3913; HATTORI S, 1992, J BIOL CHEM, V267, P20436; HIRAKAWA T, 1988, P NATL ACAD SCI USA, V85, P1519, DOI 10.1073/pnas.85.5.1519; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOWE PH, 1993, J BIOL CHEM, V268, P21448; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JAIN J, 1992, J EXP MED, V175, P853, DOI 10.1084/jem.175.3.853; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOKA P, 1991, J IMMUNOL, V146, P2417; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MIYASHITA T, 1993, BLOOD, V81, P151; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; RAKE JB, 1991, J BIOL CHEM, V266, P5348; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TILBROOK PA, 1995, ONCOGENE, V10, P805; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALTON MI, 1993, CANCER RES, V53, P1853; WANG HG, 1994, ONCOGENE, V9, P2751; WOODS NM, 1987, BIOCHEM J, V246, P619, DOI 10.1042/bj2460619; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380	40	123	129	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2376	2379		10.1074/jbc.271.5.2376	http://dx.doi.org/10.1074/jbc.271.5.2376			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576193	hybrid			2022-12-25	WOS:A1996TT48800007
J	Gencheva, M; Anachkova, B; Russev, G				Gencheva, M; Anachkova, B; Russev, G			Mapping the sites of initiation of DNA replication in rat and human rRNA genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA GENES; MAMMALIAN-CELLS; ORIGIN; SEQUENCE; IDENTIFICATION; LOCALIZATION; ELEMENTS; UPSTREAM; REGIONS; PROTEIN	To study the organization of DNA replication in mammalian rRNA genes, the sites of initiation of DNA synthesis in rat and human rRNA genes were mapped by two independent techniques. In rat cells the growth of the nascent DNA chains was blocked by Trioxsalen cross-links introduced in vivo, The fraction of ''restricted'' nascent DNA chains labeled in vivo was isolated, and the abundance in this fraction of cloned ribosomal DNA sequences was determined by hybridization. In the experiments with human cells, the nascent DNA chains were allowed to grow unrestricted for a certain period of time and the movement of the replication forks along the rRNA genes was followed by hybridization of cloned ribosomal DNA sequences to the ''unrestricted'' nascent DNA fragments fractionated according to size, The results show that in both rRNA genes there are two well defined regions of initiation of DNA synthesis. The first one is located upstream of the transcription units and the second one is located at the 3'-end of the coding regions of the ribosomal DNA repeats.	BULGARIAN ACAD SCI,INST MOLEC BIOL,BU-1113 SOFIA,BULGARIA	Bulgarian Academy of Sciences								ANACHKOVA B, 1984, EUR J BIOCHEM, V141, P105, DOI 10.1111/j.1432-1033.1984.tb08163.x; ANACHKOVA B, 1985, BIOCHEM BIOPH RES CO, V128, P101, DOI 10.1016/0006-291X(85)91650-X; ANACHKOVA B, 1989, MOL CELL BIOL, V9, P532, DOI 10.1128/MCB.9.2.532; ANACHKOVA BB, 1986, DOKL BOLG AKAD NAUK, V39, P113; BENBOW RM, 1992, BIOESSAYS, V14, P661, DOI 10.1002/bies.950141004; BRAGA EA, 1982, GENE, V20, P145, DOI 10.1016/0378-1119(82)90033-6; COFFMAN FD, 1993, EXP CELL RES, V209, P123, DOI 10.1006/excr.1993.1292; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DIMITROVA D, 1993, NUCLEIC ACIDS RES, V21, P5554, DOI 10.1093/nar/21.24.5554; DOBBS DL, 1994, NUCLEIC ACIDS RES, V22, P2479, DOI 10.1093/nar/22.13.2479; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FINANCSEK I, 1986, NUCLEIC ACIDS RES, V14, P3263, DOI 10.1093/nar/14.8.3263; GALE JM, 1992, J MOL BIOL, V224, P343, DOI 10.1016/0022-2836(92)90999-Z; GASSER SM, 1986, CELL, V46, P521, DOI 10.1016/0092-8674(86)90877-9; HAMLIN JL, 1994, BBA-REV CANCER, V1198, P85, DOI 10.1016/0304-419X(94)90008-6; IGUCHIARIGA SMM, 1993, BIOCHIM BIOPHYS ACTA, V1172, P73, DOI 10.1016/0167-4781(93)90271-E; KAISERMAN HB, 1990, EUKARYOTIC NUCLEUS M, V2, P783; KAYE J, 1980, CANCER RES, V40, P696; LIN S, 1994, J MOL BIOL, V235, P496, DOI 10.1006/jmbi.1994.1009; LITTLE RD, 1993, MOL CELL BIOL, V13, P6600, DOI 10.1128/MCB.13.10.6600; MULLER F, 1991, DNA CELL BIOL, V10, P149, DOI 10.1089/dna.1991.10.149; NATALE DA, 1993, NUCLEIC ACIDS RES, V21, P555, DOI 10.1093/nar/21.3.555; NATALE DA, 1992, P NATL ACAD SCI USA, V89, P2654, DOI 10.1073/pnas.89.7.2654; ONEILL EA, 1988, J BIOL CHEM, V263, P931; PALZKILL TG, 1988, CELL, V53, P441, DOI 10.1016/0092-8674(88)90164-X; RAO BS, 1990, GENE, V87, P233; RUSSEV G, 1992, EUR J BIOCHEM, V204, P267, DOI 10.1111/j.1432-1033.1992.tb16633.x; RUSSEV G, 1982, J MOL BIOL, V161, P77, DOI 10.1016/0022-2836(82)90279-0; SYLVESTER JE, 1989, GENE, V84, P193, DOI 10.1016/0378-1119(89)90155-8; TAIRA T, 1994, MOL CELL BIOL, V14, P6386, DOI 10.1128/MCB.14.9.6386; TASHEVA ES, 1994, MOL CELL BIOL, V14, P5628, DOI 10.1128/MCB.14.9.5628; VASSILEV L, 1990, MOL CELL BIOL, V10, P4899, DOI 10.1128/MCB.10.9.4899; VASSILEV L, 1989, NUCLEIC ACIDS RES, V17, P7693, DOI 10.1093/nar/17.19.7693; VASSILEV LT, 1992, CRIT REV BIOCHEM MOL, V27, P445, DOI 10.3109/10409239209082569; VASSILEV LT, 1990, MOL CELL BIOL, V10, P4685, DOI 10.1128/MCB.10.9.4685; VIRTAPEARLMAN VJ, 1993, MOL CELL BIOL, V13, P5931, DOI 10.1128/MCB.13.10.5931; YAVACHEV LP, 1986, NUCLEIC ACIDS RES, V14, P2799, DOI 10.1093/nar/14.6.2799; YOON Y, 1995, MOL CELL BIOL, V15, P2482	39	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2608	2614		10.1074/jbc.271.5.2608	http://dx.doi.org/10.1074/jbc.271.5.2608			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576229	hybrid			2022-12-25	WOS:A1996TT48800043
J	Galli, T; McPherson, PS; DeCamilli, P				Galli, T; McPherson, PS; DeCamilli, P			The V-o sector of the V-ATPase, synaptobrevin, and synaptophysin are associated on synaptic vesicles in a triton X-100-resistant, freeze-thawing sensitive, complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL-SPECIFIC PHOSPHOPROTEIN; CULTURED HIPPOCAMPAL-NEURONS; I PROTEIN-I; MEMBRANE-PROTEIN; MEDIATOPHORE; CHANNEL; TORPEDO; FUSION	Anti-synaptobrevin 2 immunoprecipitates obtained from freshly prepared Triton X-100 extracts of rat synaptosomes contained, in addition to synaptophysin, a 10-kDa band, which we identified by peptide sequencing and Western blotting as the c subunit of the vacuolar proton pump (V-ATPase) also called ductin or mediatophore, Ac39 and Ac116, two other transmembrane subunits of the V-0 sector of the V-ATPase, were also found by Western blotting to be enriched in the immunoprecipitates. None of these V-ATPase subunits, or synaptophysin, was present in anti-synaptobrevin 2 immuno-precipitates obtained from frozen-thawed Triton X-100 extracts, which were greatly enriched, instead, in SNAP-25 and syntaxin 1. Accordingly, V-ATPase subunit c was found in anti-synaptophysin immunoprecipitates generated from fresh, but not frozen-thawed extracts, and was not found in anti syntaxin 1 immunoprecipitates. Thus, the two complexes appear to be mutually exclusive. Subcellular fractionation of rat brain demonstrated that V-ATPase subunit c is localized with synaptobrevin 2 and synaptophysin in synaptic vesicles. The coprecipitation of V-ATPase subunit c with the synaptobrevin-synaptophysin complex suggests that this interaction may play a role in recruiting the proton pump into synaptic vesicles. Freeze-thawing, which involves a mild denaturing step, may produce a conformational change which dissociates the complex and mimics a change which occurs in, vivo as a prerequisite to SNARE complex formation.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510	Yale University; Howard Hughes Medical Institute; Yale University			Galli, Thierry/G-8842-2011; Galli, Thierry/Q-2249-2019	Galli, Thierry/0000-0001-8514-7455; Galli, Thierry/0000-0001-8514-7455	NCI NIH HHS [CA46128] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BROCHIER G, 1993, BIOL CELL, V78, P145, DOI 10.1016/0248-4900(93)90125-X; BROCHIER G, 1993, NEUROCHEM INT, V23, P525, DOI 10.1016/0197-0186(93)90100-J; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; CHILCOTE TJ, 1995, J CELL BIOL, V129, P219, DOI 10.1083/jcb.129.1.219; DECAMILLI P, 1995, FEBS LETT, V369, P3, DOI 10.1016/0014-5793(95)00739-V; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; DEFERRA F, 1985, CELL, V43, P721, DOI 10.1016/0092-8674(85)90245-4; DUNLOP M, 1995, EMBO J, V14, P3609; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FINBOW ME, 1992, PROTEIN ENG, V5, P7, DOI 10.1093/protein/5.1.7; FINBOW ME, 1995, BIOESSAYS, V17, P247, DOI 10.1002/bies.950170311; FLOOR E, 1995, J NEUROCHEM, V64, P689; GACIA EP, 1995, J CELL BIOL, V129, P105; GALLI T, 1995, NEUROPHARMACOLOGY, V34, P1351, DOI 10.1016/0028-3908(95)00113-K; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HANSONPI, 1995, J BIOL CHEM, V270, P16955; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JOHNSTON PA, 1990, J BIOL CHEM, V265, P8869; MATTEOLI M, 1992, J CELL BIOL, V117, P849, DOI 10.1083/jcb.117.4.849; MCMAHON HT, 1995, J BIOL CHEM, V270, P213; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; MUNDIGL O, 1993, J CELL BIOL, V122, P1207, DOI 10.1083/jcb.122.6.1207; MYERS M, 1993, J CELL PHYSIOL, V156, P35, DOI 10.1002/jcp.1041560106; NELSON N, 1992, J BIOENERG BIOMEMBR, V24, P407, DOI 10.1007/BF00762533; NELSON N, 1993, J PHYSIOLOGY-PARIS, V87, P171, DOI 10.1016/0928-4257(93)90028-R; PERIN MS, 1991, J BIOL CHEM, V266, P3877; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIEBERT A, 1994, J BIOL CHEM, V269, P28329; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TAKEI K, 1992, J NEUROSCI, V12, P489; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; THOMAS L, 1990, J CELL BIOL, V111, P2041, DOI 10.1083/jcb.111.5.2041; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WASHBOURNE P, 1995, BIOCHEM J, V305, P721, DOI 10.1042/bj3050721; WILLIAMS KR, 1995, TECHNIQUES PROTEIN C, V6	48	117	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2193	2198		10.1074/jbc.271.4.2193	http://dx.doi.org/10.1074/jbc.271.4.2193			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567678	hybrid			2022-12-25	WOS:A1996TR32000060
J	Turk, E; Kerner, CJ; Lostao, MP; Wright, EM				Turk, E; Kerner, CJ; Lostao, MP; Wright, EM			Membrane topology of the human Na+/glucose cotransporter SGLT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ GLUCOSE COTRANSPORTER; ESCHERICHIA-COLI; TRANSBILAYER HELICES; MEGAPRIMER METHOD; PROTEINS; EXPRESSION; CLONING; MUTAGENESIS; ORIENTATION; SEQUENCES	The membrane topology of the human Na+/glucose cotransporter SGLT1 has been probed using N-glycosylation scanning mutants and nested truncations. Functional analysis proved essential for establishment of signal-anchor topology. The resultant model diverges significantly from previously held suppositions of structure based primarily on hydropathy analysis, SGLT1 incorporates 14 membrane spans. The N terminus resides extracellularly, and two hydrophobic regions form newly recognized membrane spans 4 and 12; the large charged domain near the C terminus is cytoplasmic. This model was evaluated further using two advanced empirically-based algorithms predictive of transmembrane helices. Helix ends were predicted using thermodynamically-based algorithms known to predict x-ray crystallographically determined transmembrane helix ends. Several considerations suggest the hydrophobic C terminus forms a 14th transmembrane helix, differentiating the eukaryotic members of the SGLT1 family from bacterial homologues. Our data inferentially indicate that these bacterial homologues incorporate 13 spans, with an extracellular N terminus. The model of SGLT1 secondary structure and the predicted helix ends signify information prerequisite for the rational design of further experiments on structure/function relationships.			Turk, E (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,BOX 951751,LOS ANGELES,CA 90095, USA.		Lostao, M. Pilar/ABH-4714-2020; Lostao, M. Pilar/AAW-4238-2021	Lostao, M. Pilar/0000-0002-7319-3451; Lostao, M. Pilar/0000-0002-7319-3451	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044582, R01DK044602] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-44582, DK-44602] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AIYAR A, 1993, BIOTECHNIQUES, V14, P366; AUBERT JP, 1976, ARCH BIOCHEM BIOPHYS, V175, P410, DOI 10.1016/0003-9861(76)90528-2; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BERRY GT, 1995, GENOMICS, V25, P507, DOI 10.1016/0888-7543(95)80052-N; CHANG XB, 1994, J BIOL CHEM, V269, P18572; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Geli V, 1994, Subcell Biochem, V22, P21; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HAYCOCK JW, 1993, ANAL BIOCHEM, V208, P397, DOI 10.1006/abio.1993.1068; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1991, BIOCHIM BIOPHYS ACTA, V1064, P360, DOI 10.1016/0005-2736(91)90323-Z; HIRAYAMA BA, 1991, AM J PHYSIOL, V261, pC296, DOI 10.1152/ajpcell.1991.261.2.C296; HITOMI K, 1994, BBA-BIOMEMBRANES, V1190, P469, DOI 10.1016/0005-2736(94)90110-4; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; JACKOWSKI S, 1990, J BACTERIOL, V172, P3842, DOI 10.1128/jb.172.7.3842-3848.1990; JACOBS RE, 1989, BIOCHEMISTRY-US, V28, P3421, DOI 10.1021/bi00434a042; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; KOMEIJI Y, 1989, FEBS LETT, V256, P135, DOI 10.1016/0014-5793(89)81733-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOLTMARTICORENA C, 1994, BIOCHEM J, V302, P253, DOI 10.1042/bj3020253; LEE WS, 1994, J BIOL CHEM, V269, P12032; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; LOSTAO MP, 1994, J MEMBRANE BIOL, V142, P161; MACKENZIE B, 1994, J BIOL CHEM, V269, P22488; MARTIN MG, 1995, IN PRESS NATURE GENE; NAKAO T, 1987, MOL GEN GENET, V208, P70, DOI 10.1007/BF00330424; OLENDER EH, 1992, J BIOL CHEM, V267, P4223; PAJOR AM, 1994, BBA-BIOMEMBRANES, V1194, P349, DOI 10.1016/0005-2736(94)90319-0; PAJOR AM, 1992, J BIOL CHEM, V267, P3557; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PARKS GD, 1993, J BIOL CHEM, V268, P19101; REIZER J, 1994, BBA-REV BIOMEMBRANES, V1197, P133, DOI 10.1016/0304-4157(94)90003-5; ROST B, 1995, PROTEIN SCI, V4, P521; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; TAKATA K, 1991, J HISTOCHEM CYTOCHEM, V39, P287, DOI 10.1177/39.3.1993828; TURK E, 1994, J BIOL CHEM, V269, P15204; WHITE SH, 1990, J MEMBRANE BIOL, V115, P145, DOI 10.1007/BF01869453; White SH., 1994, MEMBRANE PROTEIN STR, P97, DOI [10.1007/978-1-4614-7515-6_4, DOI 10.1007/978-1-4614-7515-6_4]; WRIGHT E M, 1992, Current Opinion in Cell Biology, V4, P696, DOI 10.1016/0955-0674(92)90091-P	44	140	143	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1925	1934		10.1074/jbc.271.4.1925	http://dx.doi.org/10.1074/jbc.271.4.1925			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567640	hybrid			2022-12-25	WOS:A1996TR32000022
J	Bies, J; Hoffman, B; Amanullah, A; Giese, T; Wolff, L				Bies, J; Hoffman, B; Amanullah, A; Giese, T; Wolff, L			B-Myb prevents growth arrest associated with terminal differentiation of monocytic cells	ONCOGENE			English	Article						B-myb; differentiation; monocytic cells; growth arrest; apoptosis	MYELOID-LEUKEMIA CELLS; C-MYB; V-MYB; TRANSCRIPTIONAL ACTIVATION; REGULATED EXPRESSION; HEMATOPOIETIC-CELLS; MESSENGER-RNA; MIM-1 GENE; A-MYB; PROLIFERATION	B-Myb is a transcriptional regulator of gene expression and is highly homologous to c-Myb in its N-terminal DNA binding domain. However, unlike c-myb, whose expression is restricted largely to immature hematopoietic cells, B-myb mRNA has been found to be expressed in all proliferating mammalian cell lines and is clearly regulated in a cell cycle dependent manner. That c-Myb and B-Myb proteins perform different roles in proliferation and/or differentiation is suggested by the redundancy of their expression. It was previously shown that deregulated c-Myb expression can inhibit IL-6 induced terminal differentiation of the leukemia cell line M1. We found that, unlike the downregulation of c-Myb protein which is an early response of progenitor M1 cells to IL-6 treatment, the downregulation of B-Myb occurs late, just prior to terminal differentiation and growth arrest. It was, therefore, of interest to examine the role of the murine B-Myb protein in the proliferation and differentiation of the M1 cells and to compare these effects to those of c-Myb in the same system. Clones ectopically producing B-Myb, like those ectopically expressing c-Myb, proliferated in the presence of the differentiation-inducing agent and did not undergo the programmed cell death which normally follows terminal macrophage differentiation. In addition, the cell-cycle distribution of M1/B-Myb cells was comparable to untreated cells. Although M1/B-Myb and M1/c-Myb clones treated with IL-6 appeared quite immature, differentiation markers were demonstrated to be maintained at near normal levels (e.g. MyD88, Mac-2), or be partially reduced in expression (C3, Fc and Mac-1 receptors) suggesting that the cells had undergone commitment to maturation, but were unable to terminally differentiate.	NCI,GENET LAB,BETHESDA,MD 20892; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NCI NIH HHS [1RO1CA51162] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA051162] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARSURA M, 1994, BLOOD, V83, P1778, DOI 10.1182/blood.V83.7.1778.bloodjournal8371778; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIES J, 1995, CANCER RES, V55, P501; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GOLAY J, 1992, J IMMUNOL, V149, P300; GOLAY J, 1991, BLOOD, V77, P149; GONDA TJ, 1991, SEMINARS VIROLOGY, V2, P351; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; KU DH, 1993, J BIOL CHEM, V268, P2255; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LORD KA, 1990, ONCOGENE, V5, P1095; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sambrook J, 1989, MOL CLONING LABORATO; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHAPIRO LH, 1995, J BIOL CHEM, V270, P8763, DOI 10.1074/jbc.270.15.8763; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; TASHIRO S, 1995, ONCOGENE, V10, P1699; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267	48	55	55	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					355	363						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570212				2022-12-25	WOS:A1996TR53800014
J	Blat, Y; Eisenbach, M				Blat, Y; Eisenbach, M			Mutants with defective phosphatase activity show no phosphorylation-dependent oligomerization of CheZ - The phosphatase of bacterial chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SIGNAL TRANSDUCTION; PROTEIN-PHOSPHORYLATION; SALMONELLA-TYPHIMURIUM; FLAGELLAR ROTATION; RESPONSE REGULATOR; CELL ENVELOPES; GENES; DIRECTION; COMPLEX	CheZ is the phosphatase of CheY, the response regulater in bacterial chemotaxis. The mechanism by which the activity of CheZ is regulated is not known. We used cheZ mutants of Salmonella typhimurium, which had been isolated by Sockett et al. (Sockett, H., Yamaguchi, S., Kihara, M., Irikura, V. M., and Macnab, R. M. (1992) J. Bacteriol. 174, 793-806), for cloning the mutant cheZ genes, overexpressing and purifying their products. We then measured the phosphatase activity, binding to CheY and to phosphorylated CheY (CheY similar to P), and CheY similar to P-dependent oligomerization of the mutant CheZ proteins. While all the mutant proteins were defective in their phosphatase activity, they bound to CheY and CheY similar to P as well as wild-type CheZ. However, unlike wild-type CheZ, all the four mutant proteins failed to oligomerize upon interaction with CheY similar to P. On the basis of these and earlier results it is suggested that (i) oligomerization is required for the phosphatase activity of CheZ, (ii) the region defined by residues 141-145 plays an important role in mediating CheZ oligomerization and CheY similar to P dephosphorylation but is not necessary for the binding to CheY similar to P, (iii) the oligomerization and hence the phosphatase activity are regulated by the level of CheY similar to P, and (iv) this regulation plays a role in the adaptation to chemotactic stimuli.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Eisenbach, Michael/0000-0001-9048-4720				ASWAD D, 1975, J MOL BIOL, V97, P225, DOI 10.1016/S0022-2836(75)80036-2; Barak R, 1996, CURR TOP CELL REGUL, V34, P137, DOI 10.1016/S0070-2137(96)80005-7; BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; BLAT Y, 1994, BIOCHEMISTRY-US, V33, P902, DOI 10.1021/bi00170a008; Blat Y, 1996, J BIOL CHEM, V271, P1226, DOI 10.1074/jbc.271.2.1226; BLOCK SM, 1982, CELL, V31, P215, DOI 10.1016/0092-8674(82)90421-4; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRAY D, 1993, MOL BIOL CELL, V4, P469, DOI 10.1091/mbc.4.5.469; CLEGG DO, 1984, P NATL ACAD SCI USA, V81, P2056; EISENBACH M, 1981, J BIOL CHEM, V256, P8807; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; HUANG CX, 1993, BIOCHIM BIOPHYS ACTA, V1202, P297, DOI 10.1016/0167-4838(93)90019-N; KHAN S, 1993, BIOPHYS J, V65, P2368, DOI 10.1016/S0006-3495(93)81317-1; LARSEN SH, 1974, NATURE, V249, P74, DOI 10.1038/249074a0; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MACNAB RM, 1995, 2 COMPONENT SIGNAL T, P181; MANSON MD, 1992, ADV MICROB PHYSIOL, V33, P277, DOI 10.1016/S0065-2911(08)60219-2; MASDUKI A, 1995, J BACTERIOL, V177, P948, DOI 10.1128/jb.177.4.948-952.1995; MCNALLY DF, 1991, P NATL ACAD SCI USA, V88, P6269, DOI 10.1073/pnas.88.14.6269; MUTOH N, 1986, J BACTERIOL, V165, P161, DOI 10.1128/jb.165.1.161-166.1986; NINFA EG, 1991, J BIOL CHEM, V266, P9764; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; PARKINSON JS, 1983, J BACTERIOL, V155, P265, DOI 10.1128/JB.155.1.265-274.1983; RAVID S, 1984, J BACTERIOL, V159, P433; RAVID S, 1984, J BACTERIOL, V158, P222, DOI 10.1128/JB.158.1.222-230.1984; RAVID S, 1986, P NATL ACAD SCI USA, V83, P7157, DOI 10.1073/pnas.83.19.7157; Satir B.H., 1991, MODERN CELL BIOL, P137; SEGALL JE, 1982, NATURE, V296, P855, DOI 10.1038/296855a0; SEGALL JE, 1986, P NATL ACAD SCI USA, V83, P8987, DOI 10.1073/pnas.83.23.8987; SMITH RA, 1980, P NATL ACAD SCI-BIOL, V77, P5370, DOI 10.1073/pnas.77.9.5370; SOCKETT H, 1992, J BACTERIOL, V174, P793, DOI 10.1128/jb.174.3.793-806.1992; STOCK AM, 1987, J BACTERIOL, V169, P3301, DOI 10.1128/jb.169.7.3301-3311.1987; STOCK J, 1985, CELL, V42, P683, DOI 10.1016/0092-8674(85)90125-4; STOCK J, 1990, PROTEIN METHYLATION, P275; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; WEIS RM, 1988, P NATL ACAD SCI USA, V85, P83, DOI 10.1073/pnas.85.1.83; WELCH M, 1994, BIOCHEMISTRY-US, V33, P10470, DOI 10.1021/bi00200a031; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8887; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6; YAMAGUCHI S, 1986, J BACTERIOL, V168, P1172, DOI 10.1128/jb.168.3.1172-1179.1986	43	40	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1232	1236		10.1074/jbc.271.2.1232	http://dx.doi.org/10.1074/jbc.271.2.1232			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557655	hybrid			2022-12-25	WOS:A1996TP88900092
J	Kulas, DT; Goldstein, BJ; Mooney, RA				Kulas, DT; Goldstein, BJ; Mooney, RA			The transmembrane protein-tyrosine phosphatase LAR modulates signaling by multiple receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; INSULIN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOTYROSINE PHOSPHATASE; PHOSPHORYLATED PROTEIN; INTACT-CELLS; MAP KINASE; FACTOR-I; ASSOCIATION; SUBSTRATE	Antisense-mediated suppression of the transmembrane protein-tyrosine phosphatase (PTPase) LAR has been shown previously to increase insulin-dependent phosphatidylinositol 3-kinase (PI 3-kinase) activation by greater than 300% in the rat hepatoma cell line McA-RH7777, Here, insulin-dependent insulin receptor tyrosine kinase activation was examined with recombinant insulin receptor substrate 1 (IRS-1) as the substrate and shown to be 3-fold greater in cells with suppressed LAR levels, Consistent with a receptor level effect, in vivo insulin-dependent tyrosine phosphorylation of both IRS-1 and She was increased by a similar 3-fold with LAR suppression, These increases in IRS-1 and She phosphorylation were paralleled by increases in insulin-dependent PI 3-kinase association with IRS-1 and activation of the MAP kinase pathway, Reduced LAR levels also resulted in increases of over 300% and 250% in epidermal growth factor (EGF)- and hepatocyte growth factor (HGF)-dependent receptor autophosphorylation, respectively, as well as a severalfold increase in substrate tyrosine phosphorylation, In a post-receptor response, EGF- and HGF- dependent MAP kinase activation was increased by 300% and 350%, respectively, with LAR suppression, Similarly, growth factor dependent PI 3-kinase activation was increased in LAR antisense expressing cells when compared to null vector expressing cells, These results demonstrate that the transmembrane PTPase LAR modulates ligand dependent activation of at least three receptor tyrosine kinases.	UNIV ROCHESTER, SCH MED & DENT, DEPT PATHOL & LAB MED, ROCHESTER, NY 14642 USA; JEFFERSON MED COLL, DEPT MED, DIV ENDOCRINOL & METAB DIS, DORRANCE H HAMILTON RES LABS, PHILADELPHIA, PA 19107 USA	University of Rochester; Jefferson University					NIDDK NIH HHS [R01-DK43396, R01-DK38138] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038138, R01DK043396] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMAD F, 1995, J CLIN INVEST, V95, P2806, DOI 10.1172/JCI117985; AHN NG, 1992, CIBA F SYMP, V164, P113; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BARDELLI A, 1992, ONCOGENE, V7, P1973; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOYLAN JM, 1994, AM J PHYSIOL-GASTR L, V267, pG1078, DOI 10.1152/ajpgi.1994.267.6.G1078; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BUCHER NLR, 1991, J GASTROEN HEPATOL, V6, P615, DOI 10.1111/j.1440-1746.1991.tb00921.x; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DONALDSON RW, 1992, P NATL ACAD SCI USA, V89, P8477, DOI 10.1073/pnas.89.18.8477; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FOLLI F, 1992, J BIOL CHEM, V267, P22171; GALIMI F, 1993, STEM CELLS, V11, P22; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GOLDSTEIN BJ, 1993, RECEPTOR, V3, P1; HASHIMOTO N, 1992, BIOCHEM J, V284, P569, DOI 10.1042/bj2840569; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; HERNANDEZSOTOMAYOR SMT, 1992, J MEMBRANE BIOL, V128, P81; HERNANDEZSOTOMAYOR SMT, 1993, P NATL ACAD SCI USA, V90, P7691, DOI 10.1073/pnas.90.16.7691; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KOMADA M, 1994, J BIOL CHEM, V269, P16131; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; KUBLAOUI B, 1995, J BIOL CHEM, V270, P59, DOI 10.1074/jbc.270.1.59; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; MOONEY RA, 1992, J BIOL CHEM, V267, P23443; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; PALLEN CJ, 1991, P NATL ACAD SCI USA, V88, P6996, DOI 10.1073/pnas.88.16.6996; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROTHENBERG PL, 1991, J BIOL CHEM, V266, P8302; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; SAP J, 1994, MOL CELL BIOL, V14, P1; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SERRAPAGES C, 1994, J BIOL CHEM, V269, P23632; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STREULI M, 1988, J EXP MED, V168, P1523, DOI 10.1084/jem.168.5.1523; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WADA I, 1992, J CELL BIOL, V116, P321, DOI 10.1083/jcb.116.2.321; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WAY BA, 1993, J BIOL CHEM, V268, P26409; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	64	114	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					748	754		10.1074/jbc.271.2.748	http://dx.doi.org/10.1074/jbc.271.2.748			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557682	hybrid			2022-12-25	WOS:A1996TP88900025
J	Kulas, DT; Freund, GG; Mooney, RA				Kulas, DT; Freund, GG; Mooney, RA			The transmembrane protein-tyrosine phosphatase CD45 is associated with decreased insulin receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; PHOSPHOTYROSINE PHOSPHATASE; HEMATOPOIETIC-CELLS; CROSS-LINKING; EXPRESSION; PHOSPHORYLATION; PROLIFERATION; MITOGENESIS; ACTIVATION; INCREASE	Overexpression of the transmembrane protein-tyrosine phosphatase (PTPase) CD45 in nonhematopoietic cells results in decreased signaling through growth factor receptor tyrosine kinases, Consistent with these data, insulin receptor signaling is increased when the CD45-related PTPase LAR is reduced by antisense suppression in a rat hepatoma cell line, To test whether the hematopoietic cell specific PTPase CD45 functions in a manner similar to LAR by negatively modulating insulin receptor signaling in hematopoietic cells, the insulin-responsive human multiple myeloma cell line U266 was isolated into two subpopulations that differed in CD45 expression, In CD45 nonexpressing (CD45-) cells, insulin receptor autophosphorylation was increased by 3-fold after insulin treatment when compared to CD45 expressing (CD45+) cells, This increase in receptor autophosphorylation was associated with similar increases in insulin-dependent tyrosine kinase activation. These receptor level effects were paralleled by postreceptor responses, Insulin-dependent tyrosine phosphorylation of insulin receptor substrate 1 (IRS-1) and She was 3-fold greater in CD45- cells. In addition, insulin-dependent IRS-1/phosphatidylinositol 3-kinase association and MAP kinase activation in CD45- cells were also 3-fold larger. While expression of CD45 was associated with a decrease in the responsiveness of early insulin receptor signaling, interleukin 6-dependent activation of mitogen-activated protein kinase kinase and mitogen-activated protein kinase was equivalent between CD45 and CD45+ cells. These observations indicate that CD45 can function as a negative modulator of growth factor receptor tyrosine kinases in addition to its well-established role as an activator of src family tyrosine kinases.	UNIV ROCHESTER,SCH MED & DENT,DEPT PATHOL & LAB MED,ROCHESTER,NY 14642	University of Rochester					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038138, T32DK007092] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK07092, R01-DK38138] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI M, 1992, CANCER RES, V52, P737; DAEIPOUR M, 1993, J IMMUNOL, V150, P4743; DANIELIAN S, 1992, EUR J IMMUNOL, V22, P2915, DOI 10.1002/eji.1830221124; DENTON RM, 1995, EUR J BIOCHEM, V227, P597, DOI 10.1111/j.1432-1033.1995.tb20179.x; FREUND GG, 1993, J IMMUNOL, V151, P1811; FREUND GG, 1994, CANCER RES, V54, P3179; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; HASEGAWA K, 1990, INT IMMUNOL, V2, P367, DOI 10.1093/intimm/2.4.367; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JUSTEMENT LB, 1994, IMMUNOL TODAY, V15, P399, DOI 10.1016/0167-5699(94)90268-2; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; KUMAR G, 1994, J IMMUNOL, V153, P4436; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; MOONEY RA, 1992, J BIOL CHEM, V267, P23443; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NILSSON K, 1970, CLIN EXP IMMUNOL, V7, P477; PFEFFER LM, 1987, J BIOL CHEM, V262, P3665; RANKIN BM, 1993, J IMMUNOL, V150, P605; STAHL N, 1993, J BIOL CHEM, V268, P7628; STREULI M, 1988, J EXP MED, V168, P1553; UDDIN S, 1995, J BIOL CHEM, V270, P7712, DOI 10.1074/jbc.270.13.7712; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WAY BA, 1993, J BIOL CHEM, V268, P26409; WAY BA, 1994, MOL CELL BIOCHEM, V139, P167, DOI 10.1007/BF01081740; WHITE MF, 1994, J BIOL CHEM, V269, P1	28	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					755	760		10.1074/jbc.271.2.755	http://dx.doi.org/10.1074/jbc.271.2.755			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557683	hybrid			2022-12-25	WOS:A1996TP88900026
J	Shapiro, PS; Evans, JN; Davis, RJ; Posada, JA				Shapiro, PS; Evans, JN; Davis, RJ; Posada, JA			The seven-transmembrane-spanning receptors for endothelin and thrombin cause proliferation of airway smooth muscle cells and activation of the extracellular regulated kinase and c-Jun NH2-terminal kinase groups of mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; TYROSINE PHOSPHORYLATION; 3T3 CELLS; GROWTH; IDENTIFICATION; FIBROBLASTS; INHIBITION; SIGNALS; INVITRO; RAF-1	In airway smooth muscle cells ligand binding to the seven-transmembrane endothelin and thrombin receptors stimulates cell growth. Rapid activation of the extracellular regulated kinase 2 and c-Jun NH2-terminal kinase groups of mitogen-activated protein kinases was also observed. The results demonstrate a novel mechanism of seven-transmembrane receptor signaling involving activation of the Jun kinase pathway. Receptor coupling to Jun kinase activation may involve heterotrimeric G proteins since the kinase was enzymatically activated in cells treated with aluminum fluoride. The activity of Raf-1, measured by immune complex kinase assay, revealed that platelet-derived growth factor and phorbol 12-myristate 13-acetate both stimulated Raf-1 activity, while thrombin and endothelin did not appreciably stimulate Raf-1. The data suggest that endothelin and thrombin stimulate Raf-1-independent mechanisms of mitogen-activated protein kinase activation. Endothelin- or thrombin-induced activation of mitogen-activated protein kinases was significantly inhibited by ac tivation of cyclic AMP-dependent protein kinase by forskolin. Proliferation of airway smooth muscle cells, measured by incorporation of [H-3]thymidine into DNA, was also greatly attenuated by forskolin.	UNIV VERMONT,COLL MED,DEPT MOLEC PHYSIOL & BIOPHYS,BURLINGTON,VT 05405; UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Vermont; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester				Posada, James/0000-0003-3582-9612	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049570] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 49570] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABSHER M, 1994, AM J PHYSIOL, V267, pL101, DOI 10.1152/ajplung.1994.267.2.L101; AHN NG, 1991, J BIOL CHEM, V266, P4220; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSON NG, 1991, J BIOL CHEM, V266, P10131; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BALDI E, 1994, AM J PHYSIOL, V266, pF957, DOI 10.1152/ajprenal.1994.266.6.F957; BLACKMORE PF, 1985, J BIOL CHEM, V260, P4477; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; HERGET T, 1994, EUR J BIOCHEM, V225, P539, DOI 10.1111/j.1432-1033.1994.00539.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MANSOUR SJ, 1994, J BIOCHEM-TOKYO, V116, P304, DOI 10.1093/oxfordjournals.jbchem.a124524; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, NATURE, V367, P686, DOI 10.1038/367686a0; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MULDOON LL, 1990, CELL REGUL, V1, P379, DOI 10.1091/mbc.1.4.379; Panettieri Jr RA, 1994, AIRWAYS SMOOTH MUSCL, P41; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1992, J BIOL CHEM, V267, P14373; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; STEWART AG, 1994, CLIN EXP PHARMACOL P, V21, P277, DOI 10.1111/j.1440-1681.1994.tb02513.x; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	47	100	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5750	5754		10.1074/jbc.271.10.5750	http://dx.doi.org/10.1074/jbc.271.10.5750			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621441	hybrid			2022-12-25	WOS:A1996TZ28600067
J	Kuwabara, K; Matsumoto, M; Ikeda, J; Hori, O; Ogawa, S; Maeda, Y; Kitagawa, K; Imuta, N; Kinoshita, T; Stern, DM; Yanagi, H; Kamada, T				Kuwabara, K; Matsumoto, M; Ikeda, J; Hori, O; Ogawa, S; Maeda, Y; Kitagawa, K; Imuta, N; Kinoshita, T; Stern, DM; Yanagi, H; Kamada, T			Purification and characterization of a novel stress protein, the 150-kDa oxygen-regulated protein (ORP150), from cultured rat astrocytes and its expression in ischemic mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; GENE	As the most abundant cell type in the central nervous system, astrocytes are positioned to nurture and sustain neurons, especially in response to cellular stresses, which occur in ischemic cerebrovascular disease. In a previous study (Hori, O., Matsumoto, M., Kuwabara, K., Maeda, M., Ueda, H., Ohtsuki, T., Kinoshita, T., Ogawa, S., Kamada, T., and Stern, D. (1996) J. Neurochem., in press), we identified five polypeptide bands on SDS-polyacrylamide gel electrophoresis, corresponding to molecular masses of about 28, 33, 78, 94, and 150 kDa, whose expression was induced/enhanced in astrocytes exposed to hypoxia or hypoxia followed by replacement into the ambient atmosphere (reoxygenation). In the current study, the approximate to 150-kDa polypeptide has been characterized. Chromatography of lysates from cultured rat astrocytes on fast protein liquid chromatography Mono Q followed by preparative SDS-polyacrylamide gel electrophoresis led to isolation of a approximate to 150-kDa band only observed in hypoxic cells and which had a unique N-terminal sequence of 15 amino acids. Antisera raised to either the purified approximate to 150-kDa band in polyacrylamide gels or to a synthetic peptide comprising the N-terminal sequence detected the same polypeptide in extracts of cultured rat astrocytes exposed to hypoxia; expression was not observed in normoxia but was induced by hypoxia within 24 h, augmented further during early reoxygenation, and thereafter decreased to the base line by 24 h in normoxia. ORP150 expression in hypoxic astrocytes resulted from de novo protein synthesis, as shown by inhibition in the presence of cycloheximide. In contrast to hypoxia-mediated induction of the approximate to 150-kDa polypeptide, neither heat shock nor a range of other stimuli, including hydrogen peroxide, cobalt chloride, 2-deoxyglucose, or tunicamycin, led to its expression, suggesting selectivity for production of ORP150 in response to oxygen deprivation, i.e. it was an oxygen-regulated protein (ORP150). Northern and nuclear run-off analysis confirmed the apparent selectivity for ORP150 mRNA induction in hypoxia. Subcellular localization studies showed ORP150 to be present intracellularly within endoplasmic reticulum and only in hypoxic astrocytes, not cultured microglia, endothelial cells, or neurons subject to hypoxia. Consistent with these in vitro results, induction of cerebral ischemia in mice resulted in expression of ORP150 (the latter was not observed in normoxic brain). These data suggest that astroglia respond to oxygen deprivation by redirection of protein synthesis with the appearance of a novel stress protein, ORP150. This polypeptide, selectively expressed by astrocytes, may contribute to their adaptive response to ischemic stress, thereby ultimately contributing to enhanced survival of neurons.	OSAKA UNIV,SCH MED,DEPT MED 1,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT NEUROL,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,DEPT IMMUNOREGULAT,SUITA,OSAKA 565,JAPAN; HSP RES INST,SHIMOKYO KU,KYOTO 600,JAPAN; COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT SURG,NEW YORK,NY 10032	Osaka University; Osaka University; Osaka University; Columbia University; Columbia University			Kinoshita, Taroh/C-7353-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042507] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52609, HL42507] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALAM J, 1995, J BIOL CHEM, V270, P11977, DOI 10.1074/jbc.270.20.11977; BOYD FT, 1985, J BIOL CHEM, V260, P5880; COOPER HN, 1991, CURRENT PROTOCOLS IM; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GORDON EL, 1991, IN VITRO CELL DEV B, V27, P312; HENN FA, 1972, BRAIN RES, V43, P437, DOI 10.1016/0006-8993(72)90399-X; HERTZ L, 1981, HDB NEUROCHEMISTRY, V1, P603; HORI O, 1994, J NEUROCHEM, V62, P1489; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; HORI O, 1996, IN PRESS J NEUROCHEM; KARAKURUM M, 1994, J CLIN INVEST, V93, P1564, DOI 10.1172/JCI117135; KITAGAWA K, 1991, J CEREBR BLOOD F MET, V11, P449, DOI 10.1038/jcbfm.1991.86; KOGA S, 1992, J CLIN INVEST, V90, P1007, DOI 10.1172/JCI115913; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; KUWABARA K, 1995, P NATL ACAD SCI USA, V92, P4606, DOI 10.1073/pnas.92.10.4606; LOIKE JD, 1992, AM J PHYSIOL, V263, pC326, DOI 10.1152/ajpcell.1992.263.2.C326; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; MATSUMOTO K, 1994, NEUROL RES, V16, P460; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; PECHAN PA, 1992, NEUROREPORT, V3, P469, DOI 10.1097/00001756-199206000-00003; PETITO CK, 1990, J CEREBR BLOOD F MET, V10, P850, DOI 10.1038/jcbfm.1990.141; SCHOUSBOE A, 1977, NEUROCHEM RES, V2, P217, DOI 10.1007/BF00964098; SHCREENIWAS R, 1991, J CELL PHYSL, V146, P8; SHUI RPB, 1977, P NATL ACAD SCI USA, V74, P3840; SWANSON RA, 1993, J CEREBR BLOOD F MET, V13, P162, DOI 10.1038/jcbfm.1993.19; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TAMURA A, 1981, J CEREBR BLOOD FLOW, V1, P449; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WILSON RE, 1989, INT J RADIAT ONCOL, V6, P9561	32	170	181	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5025	5032						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617779				2022-12-25	WOS:A1996TX69700069
J	Schnurr, K; Belkner, J; Ursini, F; Schewe, T; Kuhn, H				Schnurr, K; Belkner, J; Ursini, F; Schewe, T; Kuhn, H			The selenoenzyme phospholipid hydroperoxide glutathione peroxidase controls the activity of the 15-lipoxygenase with complex substrates and preserves the specificity of the oxygenation products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; LOW-DENSITY-LIPOPROTEIN; RETICULOCYTE LIPOXYGENASE; SOYBEAN LIPOXYGENASE-1; LIPID-PEROXIDATION; MESSENGER-RNA; FREE-RADICALS; PROTEIN; MEMBRANES; 5-LIPOXYGENASE	Mammalian 15-lipoxygenases have been suggested to be involved in cell differentiation and atherogenesis because of their capability of oxygenating polyenoic fatty acids esterified to biomembranes and lipoproteins. We investigated the interaction of the lipid-peroxidizing 15-lipoxygenase and the hydroperoxy lipid-reducing phospholipid hydroperoxide glutathione peroxidase during their reaction with biomembranes and lipoproteins and obtained the following results. 1) Lipoxygenase treatment of submitochondrial membranes led to the formation of hydroperoxyphosphatidylethanolamine and hydroperoxyphosphatidylcholine as indicated by high performance liquid chromatography with chemiluminescence detection. In 15-lipoxygenase-treated low density lipoprotein cholesteryl hydroperoxylinoleate was the major oxygenation product. 2) Phospholipid hydroperoxide glutathione peroxidase was capable of reducing the hydroperoxy lipids formed by the 15-lipoxygenase to their corresponding alcohols. 3) Preincubation of low density lipoprotein and submitochondrial membranes with the phospholipid hydroperoxide glutathione peroxidase completely prevented the lipoxygenase reaction. However, addition of exogenous hydroperoxy lipids restored the oxygenase activity. 4) Short-term incubations of the complex substrates with the 15-lipoxygenase led to a specific pattern of oxidation products which was rendered more unspecific at long-term incubation or at high substrate concentrations. If the phosholipid hydroperoxide glutathione peroxidase was present during the reaction, the specific product pattern was preserved. These data indicate that the phospholipid hydroperoxide glutathione peroxidase is capable of reducing hydroperoxy ester lipids formed by a 15-lipoxygenase, and that it may down-regulate the 15-lipoxygenase pathways in mammalian cells. The specificity of 15-lipoxygenase-derived hydroperoxy lipids depends on their immediate reduction to the corresponding alcohols preventing postcatalytic isomerization.	HUMBOLDT UNIV BERLIN, UNIV CLIN CHARITE, INST BIOCHEM, D-10115 BERLIN, GERMANY; UNIV UDINE, DEPT CHEM SCI & TECHNOL, I-33100 UDINE, ITALY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Udine								ANTUNES F, 1995, FREE RADICAL BIO MED, V19, P669, DOI 10.1016/0891-5849(95)00040-5; BELKNER J, 1993, EUR J BIOCHEM, V213, P251, DOI 10.1111/j.1432-1033.1993.tb17755.x; BINDOLI A, 1988, FREE RADICAL BIO MED, V5, P247, DOI 10.1016/0891-5849(88)90018-4; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORGEAT P, 1989, CAN J PHYSIOL PHARM, V67, P936, DOI 10.1139/y89-147; BROCK TG, 1995, J BIOL CHEM, V270, P21652, DOI 10.1074/jbc.270.37.21652; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; CHEESBROUGH TM, 1983, BIOCHEMISTRY-US, V22, P3837, DOI 10.1021/bi00285a019; CRANE FL, 1956, BIOCHIM BIOPHYS ACTA, V22, P475, DOI 10.1016/0006-3002(56)90058-0; DEGROOT JJM, 1975, BIOCHIM BIOPHYS ACTA, V377, P71, DOI 10.1016/0005-2744(75)90287-9; ERNSTER L, 1993, OXYGEN RADICALS, P1; FISKUM G, 1985, PROSTAGLANDINS LEUKO, P87; Flohe L., 1989, GLUTATHIONE CHEM BIO, P643; FOLCIK VA, 1995, J CLIN INVEST, V96, P504, DOI 10.1172/JCI118062; FUNK MO, 1981, BIOCHEM BIOPH RES CO, V98, P922, DOI 10.1016/0006-291X(81)91199-2; GUTTERIDGE JMC, 1993, FREE RADICAL RES COM, V19, P141, DOI 10.3109/10715769309111598; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HARLAND WA, 1971, ATHEROSCLEROSIS, V13, P239, DOI 10.1016/0021-9150(71)90026-8; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; ISAACSON Y, 1990, CHEM PHYS LIPIDS, V52, P217, DOI 10.1016/0009-3084(90)90117-A; KUHN H, 1985, PROSTA LEUKOTR MED, V17, P291, DOI 10.1016/0262-1746(85)90118-0; KUHN H, 1990, J BIOL CHEM, V265, P18351; KUHN H, 1992, EICOSANOIDS, V5, P17; KUHN H, 1994, J LIPID RES, V35, P1749; KUHN H, 1994, J EXP MED, V179, P1903, DOI 10.1084/jem.179.6.1903; KUHN H, 1990, J BIOL CHEM, V265, P1454; LUDWIG P, 1987, EUR J BIOCHEM, V168, P325, DOI 10.1111/j.1432-1033.1987.tb13424.x; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MCGUIRE J, 1985, J BIOL CHEM, V260, P8316; MURRAY JJ, 1988, ARCH BIOCHEM BIOPHYS, V265, P514, DOI 10.1016/0003-9861(88)90156-7; NELSON MJ, 1995, BIOCHEMISTRY-US, V34, P6159, DOI 10.1021/bi00018a019; PATTON GM, 1982, J LIPID RES, V23, P190; PORTER N, 1985, J CHEM SOC CHEM COMM, P1472, DOI 10.1039/c39850001472; PRADHAN D, 1990, BIOCHIM BIOPHYS ACTA, V1023, P398, DOI 10.1016/0005-2736(90)90132-8; ROVERI A, 1994, METHOD ENZYMOL, V233, P202; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SATTLER W, 1994, ARCH BIOCHEM BIOPHYS, V309, P214, DOI 10.1006/abbi.1994.1105; SATTLER W, 1994, METHOD ENZYMOL, V233, P469; SCHEWE T, 1991, TRENDS BIOCHEM SCI, V16, P369, DOI 10.1016/0968-0004(91)90153-M; SCHILSTRA MJ, 1993, BIOCHEMISTRY-US, V32, P7686, DOI 10.1021/bi00081a012; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Sies H., 1991, OXIDATIVE STRESS OXI; STEINBERG D, 1990, JAMA-J AM MED ASSOC, V264, P3047, DOI 10.1001/jama.264.23.3047; TAKAHASHI K, 1986, BLOOD, V68, P640; TAKAHASHI Y, 1993, EUR J BIOCHEM, V218, P165, DOI 10.1111/j.1432-1033.1993.tb18362.x; THOMAS JP, 1990, J BIOL CHEM, V265, P454; URSINI F, 1995, METHOD ENZYMOL, V252, P38; URSINI F, 1987, CHEM PHYS LIPIDS, V44, P255, DOI 10.1016/0009-3084(87)90053-3; Ursini F., 1991, OXIDANTS ANTIOXIDANT, P319; WEITZEL F, 1993, J BIOL CHEM, V268, P6288; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111; YLAHERTTUALA S, 1990, P NATL ACAD SCI USA, V87, P6959, DOI 10.1073/pnas.87.18.6959	53	156	159	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4653	4658						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617728				2022-12-25	WOS:A1996TX69700018
J	Csortos, C; Zolnierowicz, S; Bako, E; Durbin, SD; DePaoliRoach, AA				Csortos, C; Zolnierowicz, S; Bako, E; Durbin, SD; DePaoliRoach, AA			High complexity in the expression of the B' subunit of protein phosphatase 2A(0) - Evidence for the existence of at least seven novel isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; MEDIUM TUMOR-ANTIGEN; MOLECULAR-CLONING; CATALYTIC SUBUNIT; REGULATORY SUBUNIT; GEL-ELECTROPHORESIS; SEQUENCE-ANALYSIS; TYPE-2A; FORMS; IDENTIFICATION	Association of the catalytic subunit (C2) with a variety of regulatory subunits is believed to modulate the activity and specificity of protein phosphatase 2A (PP2A). In this study we report the cloning and expression of a new family of B-subunit, the B', associated with the PP2A(0) form. Polymerase chain reactions and cDNA library screening have identified at least seven cDNA isotypes, designated alpha, beta 1, beta 2, beta 3, beta 4, gamma, and delta. The different beta subtypes appear to be generated by alternative splicing. The deduced amino acid sequences of the alpha, beta 2, beta 3, beta 4 and gamma isoforms predict molecular weights of 57,600, 56,500, 60,900, 52,500, and 68,000, respectively. The proteins are 60-80% identical and differ mostly at their termini. Two of the isoforms, B'beta 3 and B'gamma, contain a bipartite nuclear localization signal in their COOH terminus. No homology; was found with other B- or B-related subunits. Northern analyses indicate a tissue-specific expression of the isoforms. Expression of B'alpha protein in Escherichia coli generated a polypeptide of similar to 53 kDa, similar to the size of the B' subunit present in the purified PP2A(0). The recombinant protein was recognized by antibody raised against native B' and interacted with the dimeric PP2A (A . C2) to generate a trimeric phosphatase. The deduced aminoacid sequences of the B' isoforms show significant homology to mammalian, fungal, and plant nucleotide sequences of unknown function present in the data bases. Notably, a high degree of homology (55-66%) was found with a yeast gene, RTS1, encoding a multicopy suppressor of a rox3 mutant. Our data indicate that at least seven B' subunit isoforms may participate in the generation of a large number of PP2A(0) holoenzymes that may be spatially and/or functionally targeted to different cellular processes.	INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis					NHLBI NIH HHS [P01 HL6308] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006308] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; BERNDT N, 1990, EUR J BIOCHEM, V190, P291, DOI 10.1111/j.1432-1033.1990.tb15575.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; DACRUZ ESOB, 1987, FEBS LETT, V226, P176, DOI 10.1016/0014-5793(87)80574-4; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRIGNO P, 1993, MOL BIOL CELL, V4, P669, DOI 10.1091/mbc.4.7.669; GREEN DD, 1987, P NATL ACAD SCI USA, V84, P4880, DOI 10.1073/pnas.84.14.4880; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HENDRIX P, 1993, J BIOL CHEM, V268, P15267; IMAOKA T, 1983, J BIOL CHEM, V258, P1526; JAKES S, 1986, BIOCHIM BIOPHYS ACTA, V888, P135, DOI 10.1016/0167-4889(86)90079-0; KAMIBAYASHI C, 1994, J BIOL CHEM, V269, P20139; KAMIBAYASHI C, 1992, J BIOL CHEM, V267, P21864; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE J, 1993, J BIOL CHEM, V268, P19192; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; Mayer-Jaekel Regina E., 1994, Trends in Cell Biology, V4, P287, DOI 10.1016/0962-8924(94)90219-4; MAYERJAEKEL RE, 1994, J CELL SCI, V107, P2609; MAYERJAEKEL RE, 1993, CELL, V72, P621, DOI 10.1016/0092-8674(93)90080-A; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; SHU YM, 1995, MOL CELL BIOL, V15, P5618; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; TANG PM, 1991, J BIOL CHEM, V266, P15782; TUNG HYL, 1985, EUR J BIOCHEM, V148, P253, DOI 10.1111/j.1432-1033.1985.tb08833.x; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; UEMURA T, 1993, GENE DEV, V7, P429, DOI 10.1101/gad.7.3.429; USUI H, 1988, J BIOL CHEM, V263, P3752; WAELKENS E, 1987, J BIOL CHEM, V262, P1049; WALTER G, 1989, P NATL ACAD SCI USA, V86, P8669, DOI 10.1073/pnas.86.22.8669; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; XIE HY, 1993, J BIOL CHEM, V268, P13364; ZHANG WM, 1989, FASEB J, V3, P2532, DOI 10.1096/fasebj.3.13.2509275; ZOLNIEROWICZ S, 1994, BIOCHEMISTRY-US, V33, P11858, DOI 10.1021/bi00205a023	51	154	163	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2578	2588		10.1074/jbc.271.5.2578	http://dx.doi.org/10.1074/jbc.271.5.2578			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576224	hybrid			2022-12-25	WOS:A1996TT48800038
J	Goldfarb, AN; Lewandowska, K; Shoham, M				Goldfarb, AN; Lewandowska, K; Shoham, M			Determinants of helix-loop-helix dimerization affinity - Random mutational analysis of SCL/tal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; HLH PROTEINS; GENE; PROGRAM; INVIVO	Dimerization represents a key regulatory step in the function of basic helix-loop-helix transcriptional factors. In many instances tissue-specific basic helix-loop-helix proteins, such as the hematopoietic factor SCL/tal or the myogenic factor MyoD, interact with ubiquitously expressed basic helix-loop-helix proteins, such as E2A or E2-2. Such dimerization is necessary for high affinity, sequence-specific DNA binding. Previous biochemical and structural studies have shown the helix-loop-helix region to be necessary and sufficient for this interaction, In the present study, we analyzed the relative affinities of various helix-loop-helix interactions using the yeast two-hybrid system. The relative affinities of selected helix-loop-helix species for the partner protein E2-2 were as follows: Id2 > MyoD > SCL/tal. Mutants of SCL/tal with increased affinity for E2-2 were selected from a library of randomly mutated basic helix-loop-helix domains, The amino acid changes in these high affinity versions of SCL/tal introduced residues that resembled those in the corresponding positions of the Id proteins and MyoD. One of the mutants, SCL 12, also contained mutations in highly conserved residues previously thought to be necessary for dimerization. This mutant of SCL demonstrated diminished temperature sensitivity in in vitro interaction assays as compared with the wild type protein. Computational modeling of helix-loop-helix dimers provides an explanation for the increased dimerization affinity of SCL mutant 12.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106	Case Western Reserve University	Goldfarb, AN (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT PATHOL,BIOMED RES BLDG,RM 936,10900 EUCLID AVE,CLEVELAND,OH 44106, USA.							BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; ELLENBERGER T, 1994, GENE DEV, V8, P970, DOI 10.1101/gad.8.8.970; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOLDFARB AN, 1995, BLOOD, V85, P465; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Leung DW, 1989, TECHNIQUE, V1, P11; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; SHIRAKATA M, 1993, GENE DEV, V7, P2456, DOI 10.1101/gad.7.12a.2456; SHIRAKATA M, 1995, EMBO J, V14, P1766, DOI 10.1002/j.1460-2075.1995.tb07165.x; SHOJI W, 1994, J BIOL CHEM, V269, P5078; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152, DOI 10.1093/nar/23.7.1152; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; 1993, YEAST 2 HYBRID PROCE	30	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2683	2688		10.1074/jbc.271.5.2683	http://dx.doi.org/10.1074/jbc.271.5.2683			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576241	hybrid			2022-12-25	WOS:A1996TT48800055
J	Guthapfel, R; Gueguen, P; Quemeneur, E				Guthapfel, R; Gueguen, P; Quemeneur, E			ATP binding and hydrolysis by the multifunctional protein disulfide isomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; TRANSLOCATION; LUMEN	We previously reported the ability of protein disulfide isomerase (PDI) to undergo an ATP-dependent autophosphorylation. Our efforts to map the modification site have been hindered by the low abundance and instability of the labeling. Results are presented in this paper on the nature of phospho-PDI, which appears as an intermediate with a half-life of 2.5-8.8 min in an ATPase reaction. ATP binds to PDI with high affinity, K-d 9.66 mu M, and the kinetic parameters K-m ATP and k(cat) of the ATPase reaction were measured by using a pyruvate kinase-lactate dehydrogenase-coupled assay under various conditions. Strikingly, the ATPase reaction is stimulated in the presence of denatured polypeptides, while the disulfide oxidization activity of PDI is not affected by ATP. However, PDI is known to participate in various unrelated functions in the endoplasmic reticulum, and ATP could be involved in the regulation of one of these. The results are discussed in light of recent findings on ATP-chaperone relationships.	CEA SACLAY,CEA,DEPT INGN & ETUD PROT,F-91191 GIF SUR YVETTE,FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay								BELIN P, 1994, MOL GEN GENET, V242, P23, DOI 10.1007/BF00277344; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; CAI H, 1994, J BIOL CHEM, V269, P24550; CLAIRMONT CA, 1992, J BIOL CHEM, V267, P3983; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HANSEN JE, 1994, J BIOL CHEM, V269, P6286; JAENICKE R, 1993, CURR OPIN STRUC BIOL, V3, P104, DOI 10.1016/0959-440X(93)90209-4; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LAMBERT N, 1983, BIOCHEM J, V213, P235, DOI 10.1042/bj2130235; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MAYINGER P, 1993, EMBO J, V12, P659, DOI 10.1002/j.1460-2075.1993.tb05699.x; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1994, PROTEIN EXPRES PURIF, V5, P1, DOI 10.1006/prep.1994.1001; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PUIG A, 1994, J BIOL CHEM, V269, P7764; QUEMENEUR E, 1994, J BIOL CHEM, V269, P5485; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHWALLER MD, 1994, FASEB J, V8, pA1386; SHERMAN MY, 1992, NATURE, V357, P167, DOI 10.1038/357167a0; VUORI K, 1992, J BIOL CHEM, V267, P7211; YU XC, 1994, BBA-PROTEIN STRUCT M, V1207, P109, DOI 10.1016/0167-4838(94)90058-2; ZAPUN A, 1992, PROTEINS, V14, P10, DOI 10.1002/prot.340140104	28	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2663	2666		10.1074/jbc.271.5.2663	http://dx.doi.org/10.1074/jbc.271.5.2663			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576238	hybrid			2022-12-25	WOS:A1996TT48800052
J	Lazazzera, BA; Beinert, H; Khoroshilova, N; Kennedy, MC; Kiley, PJ				Lazazzera, BA; Beinert, H; Khoroshilova, N; Kennedy, MC; Kiley, PJ			DNA binding and dimerization of the Fe-S-containing FNR protein from Escherichia coli are regulated by oxygen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON SULFUR PROTEINS; TRANSCRIPTIONAL REGULATOR; ANAEROBIC RESPIRATION; ELECTRON-TRANSPORT; RHIZOBIUM-MELILOTI; CYSTEINE RESIDUES; GENE-EXPRESSION; INACTIVATION; CLUSTER; ACTIVATION	The transcription factor FNR from Escherichia coli regulates transcription of genes in response to oxygen deprivation. To determine how the activity of FNR is regulated by oxygen, a form of FNR had to be isolated that had properties similar to those observed in vivo, This was accomplished by purification of an FNR fraction which exhibited enhanced DNA binding in the absence of oxygen, Iron and sulfide analyses of this FNR fraction indicated the presence of an Fe-S cluster, To determine the type of Fe-S cluster present, an oxygen-stable mutant protein LH28-DA154 was also analyzed since FNR LH28-DA154 purified anoxically contained almost 3-fold more iron and sulfide than the wild-type protein, Based on the sulfide analysis, the stoichiometry (3.3 mol of S2-/FNR monomer) was consistent with either one [4Fe-4S] or two [2Fe-2S] clusters per mutant FNR monomer, However, since FNR has only four Cys residues as potential cluster ligands and an EPR signal typical of a 3Fe-4S cluster was detected on oxidation, we conclude that there is one [4Fe-4S] cluster present per monomer of FNR LH28-DA154. We assume that the wild type also contains one [4Fe-4S] cluster per monomer and that the lower amounts of iron and sulfide observed per monomer were due to partial occupancy, Consistent with this, the Fe-S cluster in the wild-type protein was found to be extremely oxygen-labile. In addition, molecular-sieve chromatographic analysis showed that the majority of the anoxically purified protein was a dimer as compared to aerobically purified FNR which is a monomer, The loss of the Fe-S cluster by exposure to oxygen was associated with a conversion to the monomeric form and decreased DNA binding, Taken together, these observations suggest that oxygen regulates the activity of wild-type FNR through the lability of the Fe-S cluster to oxygen.	UNIV WISCONSIN,DEPT BIOMOLEC CHEM,MADISON,WI 53706; UNIV WISCONSIN,INST ENZYME RES,MADISON,WI 53706; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226; MED COLL WISCONSIN,BIOPHYS RES INST,MILWAUKEE,WI 53226	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Medical College of Wisconsin; Medical College of Wisconsin				Kiley, Patricia/0000-0002-8771-1782	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008349, R01GM045844] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45844, GM08349] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATES DM, 1995, J BACTERIOL, V177, P3972, DOI 10.1128/jb.177.14.3972-3978.1995; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BEINERT H, 1983, ARCH BIOCHEM BIOPHYS, V222, P333, DOI 10.1016/0003-9861(83)90531-3; Bollag D.M., 1991, PROTEIN METHODS; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN OR, 1995, ARCH BIOCHEM BIOPHYS, V319, P10, DOI 10.1006/abbi.1995.1262; FLINT DH, 1993, J BIOL CHEM, V268, P25547; FLINT DH, 1993, J BIOL CHEM, V268, P22369; GARDNER PR, 1992, J BIOL CHEM, V267, P8757; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; GRANDONI JA, 1989, J BIOL CHEM, V264, P6058; GREEN J, 1993, FEMS MICROBIOL LETT, V113, P219, DOI 10.1111/j.1574-6968.1993.tb06517.x; GREEN J, 1993, FEBS LETT, V329, P55, DOI 10.1016/0014-5793(93)80192-W; GREEN J, 1993, MOL MICROBIOL, V8, P61, DOI 10.1111/j.1365-2958.1993.tb01203.x; GREEN J, 1991, P ROY SOC B-BIOL SCI, V244, P137, DOI 10.1098/rspb.1991.0062; HIDALGO E, 1994, EMBO J, V13, P138, DOI 10.1002/j.1460-2075.1994.tb06243.x; JOHNSON MK, 1994, ENCY INORGANIC CHEM, V4, P1896; KENNEDY MC, 1984, J BIOL CHEM, V259, P4463; KHOROSHILOVA N, 1995, P NATL ACAD SCI USA, V92, P2499, DOI 10.1073/pnas.92.7.2499; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; LAZAZZERA BA, 1993, GENE DEV, V7, P1993, DOI 10.1101/gad.7.10.1993; MELVILLE SB, 1990, J BIOL CHEM, V265, P18733; Miller J. H., 1972, EXPT MOL GENETICS, P431; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; PALMER C, 1973, IRON SULFUR PROTEINS, V2, P2285; Sambrook J, 1989, MOL CLONING LABORATO; SHAW DJ, 1983, J MOL BIOL, V166, P241, DOI 10.1016/S0022-2836(83)80011-4; SPIRO S, 1988, MOL MICROBIOL, V2, P701, DOI 10.1111/j.1365-2958.1988.tb00080.x; SPIRO S, 1989, MOL MICROBIOL, V3, P601, DOI 10.1111/j.1365-2958.1989.tb00207.x; SPIRO S, 1990, FEMS MICROBIOL LETT, V75, P399, DOI 10.1016/0378-1097(90)90690-R; SWITZER R L, 1989, Biofactors, V2, P77; TRAGESER M, 1990, MOL MICROBIOL, V4, P21, DOI 10.1111/j.1365-2958.1990.tb02011.x; TRAGESER M, 1989, MOL MICROBIOL, V3, P593, DOI 10.1111/j.1365-2958.1989.tb00206.x; UNDEN G, 1985, EUR J BIOCHEM, V146, P193, DOI 10.1111/j.1432-1033.1985.tb08638.x; WEBER IT, 1988, METHOD ENZYMOL, V159, P278; WU J, 1995, J BIOL CHEM, V270, P10323, DOI 10.1074/jbc.270.17.10323; ZIEGELHOFFER EC, 1995, J MOL BIOL, V245, P351, DOI 10.1006/jmbi.1994.0029	37	252	254	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2762	2768		10.1074/jbc.271.5.2762	http://dx.doi.org/10.1074/jbc.271.5.2762			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576252	hybrid			2022-12-25	WOS:A1996TT48800066
J	Or, E; Goldshleger, R; Karlish, SJD				Or, E; Goldshleger, R; Karlish, SJD			An effect of voltage on binding of Na+ at the cytoplasmic surface of the Na+-K+ pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-POTASSIUM PUMP; PHOSPHOLIPID-VESICLES; CHARGE TRANSLOCATION; XENOPUS OOCYTES; NA/K PUMP; CONFORMATIONAL TRANSITIONS; CATION OCCLUSION; EXTERNAL K+; NA,K PUMP; NA,K-PUMP	This work utilizes proteoliposomes reconstituted with renal Na+-K+-ATPase to study effects of electrical potential (40-80 mV) on activation of pump-mediated fluxes of Na+ or Rb+ (K+) ions and on inhibitory effects of Rb+ ions or organic cations. The latter include guanidinium derivatives that are competitive Na+-like antagonists (David, P., Mayan, H., Cohen. H., Tal, D. M., and Karlish, S. J. D. (1992) J. Biol. Chem. 267, 1141-1149). Cytoplasmic side positive diffusion potentials significantly decreased the K-0.5 of Na+ at the cytoplasmic surface for activation of ATP-dependent Na+-K+ exchange but did not affect the inhibitory potency of Rb+ (K+) or any Na+-like antagonist. Diffusion potentials did not affect activation of Rb+-Rb+ exchange by Rb+ ions at the cytoplasmic surface and had only a minor effect on Rb+ activation at the extracellular surface. Previously, we proposed that the cation binding domain consists of two negatively charged sites, to which two K+ or two Na+ ions bind, and one neutral site for the third Na+ (Glynn, I. M., and Karlish, S. J. D. (1990) Annu. Rev. Biochem. 59, 171-205). The present experiments suggest that binding of a Na+ ion in the neutral site at the cytoplasmic surface is sensitive to voltage. By contrast, binding of Rb+ ions at the extracellular surface of renal pumps appears to be only weakly or insignificantly affected by voltage. Inferences on the identity of the charge-carrying steps, based on experiments using proteoliposomes, are discussed in relation to recent evidence that dissociation of Na+ or association of K+ ions, at the extracellular surface, represent the major charge-carrying steps.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								APELL HJ, 1987, J MEMBRANE BIOL, V97, P179, DOI 10.1007/BF01869221; BAHINSKI A, 1988, P NATL ACAD SCI USA, V85, P3412, DOI 10.1073/pnas.85.10.3412; BORLINGHAUS R, 1987, J MEMBRANE BIOL, V97, P161, DOI 10.1007/BF01869220; BUHLER R, 1991, J MEMBRANE BIOL, V121, P141, DOI 10.1007/BF01870529; CAPASSO JM, 1992, J BIOL CHEM, V267, P1150; CHA S, 1968, J BIOL CHEM, V243, P820; DAVID P, 1992, J BIOL CHEM, V267, P1141; FENDLER K, 1985, EMBO J, V4, P3079, DOI 10.1002/j.1460-2075.1985.tb04048.x; FORBUSH B, 1984, P NATL ACAD SCI-BIOL, V81, P5310, DOI 10.1073/pnas.81.17.5310; FORBUSH B, 1991, SODIUM PUMP STRUCTUR, P212; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; GLYNN IM, 1990, ANNU REV BIOCHEM, V59, P171, DOI 10.1146/annurev.bi.59.070190.001131; GOLDSHLEGER R, 1990, J MEMBRANE BIOL, V113, P139, DOI 10.1007/BF01872888; GOLDSHLEGGER R, 1987, J PHYSIOL-LONDON, V387, P331, DOI 10.1113/jphysiol.1987.sp016576; HEYSE S, 1994, J GEN PHYSIOL, V104, P197, DOI 10.1085/jgp.104.2.197; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; JAISSER F, 1994, J GEN PHYSIOL, V103, P605, DOI 10.1085/jgp.103.4.605; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; KARLISH SJD, 1981, J PHYSIOL-LONDON, V312, P505, DOI 10.1113/jphysiol.1981.sp013641; KARLISH SJD, 1985, J PHYSIOL-LONDON, V359, P119, DOI 10.1113/jphysiol.1985.sp015578; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KARLISH SJD, 1982, J PHYSIOL-LONDON, V328, P333, DOI 10.1113/jphysiol.1982.sp014267; KARLISH SJD, 1988, METHOD ENZYMOL, V156, P179; KARLISH SJD, 1985, SODIUM PUMP, P487; KLODOS I, 1988, J GEN PHYSIOL, V92, P46; LAFAIRE AV, 1986, J MEMBRANE BIOL, V91, P43, DOI 10.1007/BF01870213; LAUGER P, 1986, EUR BIOPHYS J BIOPHY, V13, P309, DOI 10.1007/BF00254213; LAUGER P, 1991, ELECTROGENIC ION PUM, P212; LAUGER P, 1991, ELECTROGENIC ION PUM, P68; NAKAO M, 1989, J GEN PHYSIOL, V94, P539, DOI 10.1085/jgp.94.3.539; NAKAO M, 1986, NATURE, V323, P628, DOI 10.1038/323628a0; OR E, 1993, J BIOL CHEM, V268, P16929; POLVANI C, 1989, J BIOL CHEM, V264, P15182; RAKOWSKI RF, 1991, J MEMBRANE BIOL, V121, P177, DOI 10.1007/BF01870531; RAKOWSKI RF, 1993, J GEN PHYSIOL, V101, P117, DOI 10.1085/jgp.101.1.117; REPHAELI A, 1986, J BIOL CHEM, V261, P2437; REPHAELI A, 1986, J BIOL CHEM, V261, P6248; SHANZER A, 1983, J AM CHEM SOC, V105, P3815, DOI 10.1021/ja00350a012; STEINBERG M, 1989, J BIOL CHEM, V264, P2726; STURMER W, 1991, J MEMBRANE BIOL, V121, P163, DOI 10.1007/BF01870530; STURMER W, 1992, FEBS LETT, V300, P1, DOI 10.1016/0014-5793(92)80151-6; STURMER W, 1989, J MEMBRANE BIOL, V110, P67, DOI 10.1007/BF01870994; VASILETS LA, 1992, J MEMBRANE BIOL, V125, P119; VASILETS LA, 1991, J BIOL CHEM, V266, P16285; WUDDEL I, 1995, BIOPHYS J, V69, P909, DOI 10.1016/S0006-3495(95)79965-9	45	33	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2470	2477		10.1074/jbc.271.5.2470	http://dx.doi.org/10.1074/jbc.271.5.2470			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576209	hybrid			2022-12-25	WOS:A1996TT48800023
J	Wang, YF; Liu, JW; Mamidi, M; Walker, AM				Wang, YF; Liu, JW; Mamidi, M; Walker, AM			Identification of the major site of rat prolactin phosphorylation as serine 177	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; BOVINE PROLACTIN; ANTERIOR-PITUITARY; ISOFORMS; GRANULES; GLAND; CLEAVAGE; RESIDUES	Phosphorylation of prolactin by endogenous protein kinases within isolated secretory granules was shown to result in the production of both phosphoserine and phosphothreonine residues. The majority of the radiolabel was determined to be present in the C terminus of the molecule after specific cleavage with glandular kallikrein, Glandular kallikrein cleaves in three places at the C terminus, liberating three small peptides, only one of which contains a phosphorylatable residue. Sequencing of this phosphopeptide showed it to be Arg(175)-Lys(185). Thus the major site of prolactin phosphorylation was determined to be serine 177. Using a synthetic peptide equivalent to this region of the molecule (Ser(161)-Val(180)), serine 177 was demonstrated to be a substrate for protein kinase A as well as for one of the endogenous granule kinases. Inclusion of the synthetic peptide in an endogenous granule phosphorylation reaction resulted in competition for the kinase and reduced phosphorylation of prolactin, Protein kinase A phosphorylation of purified prolactin resulted in the production of only phosphoserine and primarily the most abundant (monophosphorylated) variant, We conclude that serine 177 is the major in vivo phosphorylation site of rat prolactin and that phosphorylation of this site can be reproduced by protein kinase A in vitro, The minor threonine phosphorylation site was demonstrated by two-dimensional tryptic peptide mapping and mass analysis to be either threonine 58 or 63, both of which are contained within a single peptide.	UNIV CALIF RIVERSIDE, DIV BIOMED SCI, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside					NICHD NIH HHS [HD 28726] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD028726] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALI S, 1991, J BIOL CHEM, V266, P20110; ARAMBURO C, 1992, J MOL ENDOCRINOL, V8, P183, DOI 10.1677/jme.0.0080183; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BROOKS CL, 1990, MOL CELL ENDOCRINOL, V71, P117, DOI 10.1016/0303-7207(90)90248-7; BYFORD MF, 1991, BIOCHEM J, V280, P261, DOI 10.1042/bj2800261; CARTY SE, 1982, J BIOL CHEM, V257, P7269; CLAPP C, 1987, ENDOCRINOLOGY, V121, P2055, DOI 10.1210/endo-121-6-2055; FARQUHAR MG, 1978, ENDOCRINOLOGY, V102, P296, DOI 10.1210/endo-102-1-296; GLASS DB, 1992, BIOCHEMISTRY-US, V31, P1728, DOI 10.1021/bi00121a021; GREENAN JR, 1989, ENDOCRINOLOGY, V125, P2041, DOI 10.1210/endo-125-4-2041; HO TWC, 1989, ENDOCRINOLOGY, V124, P1507, DOI 10.1210/endo-124-3-1507; HO TWC, 1993, NEUROENDOCRINOLOGY, V58, P160, DOI 10.1159/000126528; HO TWC, 1993, ENDOCR J, V1, P435; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; LABRIE F, 1971, J BIOL CHEM, V246, P7293; LEWIS UJ, 1984, P NATL ACAD SCI-BIOL, V81, P385, DOI 10.1073/pnas.81.2.385; LORENSON MY, 1981, LIFE SCI, V28, P2309, DOI 10.1016/0024-3205(81)90584-1; LUCK DN, 1991, MOL ENDOCRINOL, V5, P1880, DOI 10.1210/mend-5-12-1880; LUCK DN, 1989, MOL ENDOCRINOL, V3, P822, DOI 10.1210/mend-3-5-822; MEGA T, 1990, J BIOCHEM-TOKYO, V107, P68, DOI 10.1093/oxfordjournals.jbchem.a123013; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; OETTING WS, 1986, J BIOL CHEM, V261, P1649; OETTING WS, 1985, ENDOCRINOLOGY, V117, P1565, DOI 10.1210/endo-117-4-1565; OETTING WS, 1986, ENDOCRINOLOGY, V119, P1377, DOI 10.1210/endo-119-3-1377; POWERS CA, 1990, ENDOCRINOLOGY, V127, P1916, DOI 10.1210/endo-127-4-1916; SINHA YN, 1985, J CLIN ENDOCR METAB, V60, P239, DOI 10.1210/jcem-60-2-239; TURGEON JL, 1986, BIOCHEM J, V237, P53, DOI 10.1042/bj2370053; WANG YF, 1993, ENDOCRINOLOGY, V133, P2156, DOI 10.1210/en.133.5.2156; ZANINI A, 1973, ENDOCRINOLOGY, V92, P349, DOI 10.1210/endo-92-2-349	29	37	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2462	2469		10.1074/jbc.271.5.2462	http://dx.doi.org/10.1074/jbc.271.5.2462			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576208	hybrid			2022-12-25	WOS:A1996TT48800022
J	Brand, IA; Kleineke, J				Brand, IA; Kleineke, J			Intracellular zinc movement and its effect on the carbohydrate metabolism of isolated rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FRUCTOSE 2,6-BISPHOSPHATE; HORMONAL-REGULATION; INSULIN-RECEPTOR; LIVER; METALLOTHIONEIN; GLYCOLYSIS; ADIPOCYTES; VANADATE; PHOSPHORYLATION	The effect of zinc ions on carbohydrate metabolism and intracellular Zn2+ was studied in hepatocytes from fed rats. The addition of ZnCl2 to the medium led to an almost 3-fold increase in lactate production and an increase in net glucose production of about 50%. Half-maximal rates occurred at about 40 mu M ZnCl2,. These effects were not seen with Mn2+, Co2+, up Ni2+ up to 80 mu M, whereas Cu2+ at 80 mu M and Cd2+ or Pb2+ at 8 mu M exhibited similar effects as 80 mu M ZnCl2. Changes in intracellular Zn2+ were followed by single cell epifluorescence using zinquin as a specific probe. Intracellular free Zn2+ in isolated hepatocytes was 1.26 a 0.27 mu M, and the addition of ZnCl2 led to a concentration-dependent increase in epifluorescence. CdCl2 or PbCl2 at 8 mu M was as potent as ZnCl2 at 20-80 mu M, whereas NiCl2 at 80 mu M was without effect. ZnCl2 completely abolished the inhibition of glycolysis by glucagon (cAMP). Glucagon led to a pronounced drop in cytosolic Zn2+. Both glucagon and zinc stimulated glycogenolysis by increasing the phosphorylation of glycogen phosphorylase but acted oppositely on glycolysis. Zinc overcame the inactivation of pyruvate kinase by glucagon without changing the hormone-induced protein phosphorylation. The antagonistic action of zinc and cAMP on glycolysis together with the rapid and marked decrease in free zinc concentration induced by glucagon (cAMP) may indicate an as yet unknown role of zinc as an important mediator of regulation of carbohydrate metabolism.			Brand, IA (corresponding author), UNIV GOTTINGEN,ZENTRUM INNERE MED,ABT KLIN BIOCHEM,ROBERT KOCH STR 40,D-37075 GOTTINGEN,GERMANY.							BAUDIER J, 1983, BIOCHEM BIOPH RES CO, V114, P1138, DOI 10.1016/0006-291X(83)90681-2; Bergmeyer HU., 1970, METHODEN ENZYMATISCH, V2; BERRY MN, 1991, LABORATORY TECHNIQUE, V21, P15; BOSCH F, 1987, J BIOL CHEM, V262, P218; BRAND IA, 1986, J BIOL CHEM, V261, P5892; BRAND IA, 1991, EUR J CELL BIOL, V54, P157; BRAND IA, 1991, J BIOL CHEM, V266, P20984; BRAND IA, 1982, EUR J BIOCHEM, V122, P175, DOI 10.1111/j.1432-1033.1982.tb05864.x; CHIN JE, 1993, J BIOL CHEM, V268, P6338; COSTAS MJ, 1988, BIOCHEM INT, V16, P747; COULSTON L, 1980, DIABETES, V29, P665, DOI 10.2337/diabetes.29.8.665; COYLE P, 1993, BIOL TRACE ELEM RES, V36, P35, DOI 10.1007/BF02783778; COYLE P, 1994, BIOCHEM J, V303, P781, DOI 10.1042/bj3030781; EKMAN P, 1976, BIOCHIM BIOPHYS ACTA, V429, P374, DOI 10.1016/0005-2744(76)90285-0; ETZEL KR, 1981, P SOC EXP BIOL MED, V167, P233; EZAKI O, 1989, J BIOL CHEM, V264, P16118; FORBES IJ, 1990, BIOCHIM BIOPHYS ACTA, V1053, P113, DOI 10.1016/0167-4889(90)90001-T; GOMEZFOIX AM, 1988, BIOCHEM J, V255, P507; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAGENMULLER P, 1950, CR HEBD ACAD SCI, V230, P2190; HIDER RC, 1990, BIOCHEM PHARMACOL, V39, P1005, DOI 10.1016/0006-2952(90)90278-S; HUE L, 1975, BIOCHEM J, V152, P105, DOI 10.1042/bj1520105; KINGSLEY BS, 1979, AM J PHYSIOL, V236, pC139, DOI 10.1152/ajpcell.1979.236.3.C139; MAGNESON GR, 1987, J BIOL CHEM, V262, P11140; MAY JM, 1982, J BIOL CHEM, V257, P4362; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; RIDER MH, 1990, EUR J BIOCHEM, V190, P53, DOI 10.1111/j.1432-1033.1990.tb15544.x; ROGNSTAD R, 1984, BIOCHEM BIOPH RES CO, V122, P726, DOI 10.1016/S0006-291X(84)80094-7; SEGLEN PO, 1972, BIOCHIM BIOPHYS ACTA, V264, P398, DOI 10.1016/0304-4165(72)90002-5; SHISHEVA A, 1992, DIABETES, V41, P982, DOI 10.2337/diabetes.41.8.982; TAMAKI N, 1983, J NUTR SCI VITAMINOL, V29, P655; TEJWANI GA, 1976, P NATL ACAD SCI USA, V73, P2692, DOI 10.1073/pnas.73.8.2692; THIERS RE, 1957, J BIOL CHEM, V235, P911; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; VANBERKEL TJC, 1976, BIOCHEM BIOPH RES CO, V72, P917, DOI 10.1016/S0006-291X(76)80219-7; VANSCHAFTINGEN E, 1982, EUR J BIOCHEM, V129, P191; WAALKES MP, 1984, TOXICOL LETT, V20, P33, DOI 10.1016/0378-4274(84)90179-6; ZALEWSKI PD, 1993, BIOCHEM J, V296, P403, DOI 10.1042/bj2960403	40	80	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1941	1949		10.1074/jbc.271.4.1941	http://dx.doi.org/10.1074/jbc.271.4.1941			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567642	hybrid			2022-12-25	WOS:A1996TR32000024
J	Pollak, ES; Hung, HL; Godin, W; Overton, GC; High, KA				Pollak, ES; Hung, HL; Godin, W; Overton, GC; High, KA			Functional characterization of the human Factor VII 5'-flanking region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-VII; RNA POLYMERASE-II; BLOOD-COAGULATION; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; REPORTER GENE; PROMOTER; PROTEIN; BINDING; DNA	Factor VII is a vitamin K-dependent coagulation protein essential for proper hemostasis, The human Factor VII gene spans 13 kilobase pairs and is located on chromosome 13 just 2.8 kilobase pairs 5' to the Factor X gene, In this report, we show that Factor VII transcripts are restricted to the liver and that steady state levels of mRNA are much lower than those of Factor X, The major transcription start site is mapped at -51 by RNase protection assay and primer extension experiments, The first 185 base pairs 5' of the translation start site are sufficient to confer maximal promoter activity in HepGa cells, Protein binding sites are identified at nucleotides -51 to -32, -63 to -58, -108 to -84, and -233 to -215 by DNase I footprint analysis and gel mobility shift assays, A liver enriched transcription factor, hepatocyte nuclear factor-4 (HNF-4), and a ubiquitous transcription factor, Sp1, are shown to bind within the first 108 base pairs of the promoter region at nucleotide sequences ACTTTG and CCCCTCCCCC, respectively, The importance of these binding sites in promoter activity is demonstrated through independent functional mutagenesis experiments, which show dramatically reduced promoter activity, Transactivation studies with an HNF-4 expression plasmid in HeLa cells also demonstrate the importance of HNF-4 in promoting transcription in nonhepatocyte derived cells, Additionally, the sequence of a naturally occurring allele containing a previously described decanucleotide insert polymorphism at -323 is shown to reduce promoter activity by 33% compared with the more common allelic sequence.	UNIV PENN, DEPT PEDIAT, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP PHILADELPHIA, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT GENET, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania			High, Katherine A./AAB-9322-2020		NHLBI NIH HHS [HL48322] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048322] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BALLEISEN L, 1985, THROMB HAEMOSTASIS, V54, P475; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BONITHONKOPP C, 1988, ATHEROSCLEROSIS, V71, P71, DOI 10.1016/0021-9150(88)90303-6; BONNAR J, 1987, AM J OBSTET GYNECOL, V157, P1042, DOI 10.1016/S0002-9378(87)80129-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAIR DS, 1986, BLOOD, V67, P64; FAIR DS, 1983, BLOOD, V62, P784; FOLSOM AR, 1991, ATHEROSCLEROSIS, V91, P191, DOI 10.1016/0021-9150(91)90167-2; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GREEN F, 1991, ARTERIOSCLER THROMB, V11, P540, DOI 10.1161/01.ATV.11.3.540; GUSTAFSON TA, 1989, MOL CELL BIOL, V9, P3269, DOI 10.1128/MCB.9.8.3269; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOFFMAN CJ, 1992, ARTERIOSCLER THROMB, V12, P267, DOI 10.1161/01.ATV.12.3.267; HUANG MN, 1992, J BIOL CHEM, V267, P15440; JAMISON CS, 1991, BIOCHIM BIOPHYS ACTA, V1088, P208; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KARIO K, 1994, ARTERIOSCLER THROMB, V14, P265, DOI 10.1161/01.ATV.14.2.265; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LANS MS, 1994, J BIOL CHEM, V269, P14170; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MADER S, 1993, J BIOL CHEM, V268, P591; MARCHETTI G, 1993, HUM GENET, V90, P575; Maxam A M, 1980, Methods Enzymol, V65, P499; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIAO CH, 1992, J BIOL CHEM, V267, P7395; MITROPOULOS KA, 1994, ARTERIOSCLER THROMB, V14, P214, DOI 10.1161/01.ATV.14.2.214; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P5648; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OHARA PJ, 1987, P NATL ACAD SCI USA, V84, P5158, DOI 10.1073/pnas.84.15.5158; PETERSON LC, 1995, MOL BASIS THROMBOSIS, P147; PFEIFFER RA, 1982, HUM GENET, V62, P358, DOI 10.1007/BF00304557; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAMACHANDRAN B, 1995, EXP HEMATOL, V23, P49; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; ROBERTS HR, 1992, HOSP PRACT, V27, P97; SACCHI E, 1995, THROMB HAEMOSTASIS, V73, P950; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARABIN PY, 1990, THROMB RES, V57, P227, DOI 10.1016/0049-3848(90)90322-4; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SELIGSOHN U, 1979, BLOOD, V53, P828; SHEN L, 1995, THROMB HAEMOSTASIS, V73, P937; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; SUTTIE JW, 1976, J BIOL CHEM, V251, P5827; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	56	117	120	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1738	1747		10.1074/jbc.271.3.1738	http://dx.doi.org/10.1074/jbc.271.3.1738			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576177	hybrid			2022-12-25	WOS:A1996TQ52500073
J	Jackson, VN; Halestrap, AP				Jackson, VN; Halestrap, AP			The kinetics, substrate, and inhibitor specificity of the monocarboxylate (lactate) transporter of rat liver cells determined using the fluorescent intracellular pH indicator, 2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARRIER-MEDIATED UPTAKE; PLASMA-MEMBRANE; ISOLATED HEPATOCYTES; DISTINCT CARRIERS; CARDIAC MYOCYTES; HEART-CELLS; GUINEA-PIG; ERYTHROCYTES; PYRUVATE; GLUCONEOGENESIS	The kinetics of transport of L lactate, pyruvate, ketone bodies, and other monocarboxylates into isolated hepatocytes from starved rats were measured at 25 degrees C using the intracellular pH-sensitive dye, 2',7'-bis(carboxyethyl) 5(6)-carboxyfluorescein, to detect the associated proton influx. Transport kinetics were similar, but not identical, to those determined using the same technique for the monocarboxylate transporter (MCT) of Ehrlich Lettre tumor cells (MCT1) (Carpenter, L., and Halestrap, A. P. (1994) Biochem. J. 304, 751-760). K-m values for L-lactate (4.7 mM), D-lactate (27 mM), D,L-2-hydroxybutyrate (3.3 mM), L-3-hydroxybutyrate (12.7 mM), and acetoacetate (6.1 mM) were very similar in both cell types, whereas in hepatocytes the K-m values were higher than MCT1 for pyruvate (1.3 mM, cf. 0.72 mM), D-3-hydroxybutyrate (24.7 mM, cf. 10.1 mM), L-2-chloropropionate (1.3 mM, cf. 0.8 mM), 4-hydroxybutyrate (18.1 mM, cf. 7.7 mM), and acetate (5.4 mM, cf. 3.7 mM). In contrast, the hepatocyte carrier had lower K-m values than MCT1 for glycolate, chloroacetate, dichloroacetate, and 2-hydroxy-2-methylpropionate. Differences in stereoselectivity were also detected; both carriers showed a lower K-m for L-actate than D-lactate, while hepatocyte MCT exhibited a lower K-m for D- than L-2-chloropropionate and for L- than D-3-hydroxybutyrate; this is not the case for MCT1. A range of inhibitors of MCT1, including alpha-cyanocinnamate derivatives, phloretin, and niflumic acid, inhibited hepatocyte MCT with K-0.5 values significantly higher than for tumor cell MCT1, while stilbene disulfonate derivatives and p-chloromercuribenzene sulfonate had similar K-0.5 values in both cell types. The branched chain ketoacids alpha-ketoisocaproate and alpha-ketoisovalerate were also potent inhibitors of hepatocyte MCT with K-0.5 values of 270 and 340 mu M, respectively. The activation energy of L-lactate transport into hepatocytes was 58 kJ mol(-1), and measured rates of transport at 37 degrees C were considerably greater than those required for maximal rates of gluconeogenesis. The properties of the hepatocyte monocarboxylate transporter are consistent with the presence of a distinct isoform of MCT in liver cells as suggested by the cloning and sequencing of MCT2 from hamster liver (Garcia, C. K., Brown, M. S., Pathak, R. K., and Goldstein, J. L. (1995) J. Biol. Chem. 270, 1843-1849).	UNIV BRISTOL, SCH MED SCI, DEPT BIOCHEM, BRISTOL BS8 1TD, AVON, ENGLAND	University of Bristol			Halestrap, Andrew P/G-7275-2011	Halestrap, Andrew/0000-0001-5374-2778	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BRACHT A, 1981, EUR J BIOCHEM, V114, P471, DOI 10.1111/j.1432-1033.1981.tb05169.x; CARPENTER L, 1994, BIOCHEM J, V304, P751, DOI 10.1042/bj3040751; DEUTICKE B, 1982, J MEMBRANE BIOL, V70, P89, DOI 10.1007/BF01870219; EDLUND GL, 1988, BIOCHEM J, V249, P117, DOI 10.1042/bj2490117; EISNER DA, 1989, PFLUG ARCH EUR J PHY, V413, P553, DOI 10.1007/BF00594188; FAFOURNOUX P, 1985, J BIOL CHEM, V260, P292; FAFOURNOUX P, 1985, BIOCHIM BIOPHYS ACTA, V818, P73, DOI 10.1016/0005-2736(85)90140-3; FRELIN C, 1988, EUR J BIOCHEM, V174, P3, DOI 10.1111/j.1432-1033.1988.tb14055.x; GARCIA CK, 1994, CELL, V76, P865, DOI 10.1016/0092-8674(94)90361-1; GARCIA CK, 1995, J BIOL CHEM, V270, P1843, DOI 10.1074/jbc.270.4.1843; GROEN AK, 1983, J BIOL CHEM, V258, P4346; KILBERG MS, 1983, J BIOL CHEM, V258, P1524; LUPO MA, 1990, METABOLISM, V39, P374, DOI 10.1016/0026-0495(90)90251-7; MCGIVAN JD, 1979, BIOCHEM J, V182, P697, DOI 10.1042/bj1820697; METCALFE HK, 1986, J CLIN INVEST, V78, P743, DOI 10.1172/JCI112635; MONSON JP, 1982, CLIN SCI, V62, P411, DOI 10.1042/cs0620411; NALECZ KA, 1984, BIOCHIM BIOPHYS ACTA, V805, P1; POOLE RC, 1991, BIOCHEM J, V275, P307, DOI 10.1042/bj2750307; POOLE RC, 1992, BIOCHEM J, V283, P855, DOI 10.1042/bj2830855; POOLE RC, 1994, BIOCHEM J, V303, P755, DOI 10.1042/bj3030755; POOLE RC, 1993, AM J PHYSIOL, V264, pC761, DOI 10.1152/ajpcell.1993.264.4.C761; POOLE RC, 1990, BIOCHEM J, V269, P827, DOI 10.1042/bj2690827; POOLE RC, 1988, BIOCHEM SOC T, V16, P602, DOI 10.1042/bst0160602; POOLE RC, 1989, BIOCHEM J, V264, P409, DOI 10.1042/bj2640409; QUINLAN PT, 1986, BIOCHEM J, V236, P789, DOI 10.1042/bj2360789; QUINTANA I, 1988, FEBS LETT, V235, P224, DOI 10.1016/0014-5793(88)81267-5; ROTH DA, 1991, MED SCI SPORT EXER, V23, P925; SCHWAB AJ, 1979, EUR J BIOCHEM, V102, P537, DOI 10.1111/j.1432-1033.1979.tb04270.x; TISCHLER ME, 1977, ARCH BIOCHEM BIOPHYS, V184, P222, DOI 10.1016/0003-9861(77)90346-0; WANG XM, 1993, BIOCHEM J, V290, P249, DOI 10.1042/bj2900249; WANG XM, 1966, IN PRESS AM J PHYSL; WANG XM, 1994, AM J PHYSIOL-HEART C, V36, pH1759	32	159	168	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					861	868		10.1074/jbc.271.2.861	http://dx.doi.org/10.1074/jbc.271.2.861			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557697	hybrid			2022-12-25	WOS:A1996TP88900040
J	Jones, RT; Shih, DT; Fujita, TS; Song, YH; Xiao, H; Head, C; Kluger, R				Jones, RT; Shih, DT; Fujita, TS; Song, YH; Xiao, H; Head, C; Kluger, R			A doubly cross-linked human hemoglobin - Effects of cross-links between different subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTITUTES; CHAINS	Human deoxyhemoglobin cross linked with trimesyl tris(3,5-dibromosalicylate) produces the previously reported cross-linked hemoglobin in which the epsilon amino groups of the two beta chain 82 lysyl residues are joined by a trimesyl bridge. Further specific modification of this protein directed to the alpha subunits with bis(3,5-dibromosalicyl)fumarate gives a doubly cross-linked material in which the epsilon-amino groups of the two alpha chain 99 lysyl residues are now joined by a fumaryl bridge. The singly cross-linked beta chain species binds oxygen cooperatively with a high oxygen affinity (P-50 = 4.8 torr at pH 7.4). The addition of the second cross-linking reduces the oxygen affinity to 15.9 torr, which compares with 13.0 torr for the singly cross-linked alpha chain species. The doubly cross-linked hemoglobin retains significant cooperativity with a Hill coefficient of 2.3 compared with 3.0 for unmodified hemoglobin. Because some of the groups responsible for the Bohr effect are acylated, this doubly cross-linked hemoglobin exhibits 25% of the normal Bohr effect and less than 20% of the normal chloride effect. The use of two distinct cross-links within the same tetramer provides a material for physical and structural analysis as well as for further modifications for specific applications. The results indicate that the cross-link introducing the lowest oxygen affinity in the two singly cross-linked species appears to control the overall affinity in this doubly cross-linked species.	UNIV TORONTO,DEPT CHEM,LASH MILLER CHEM LABS,TORONTO,ON M5S 1A1,CANADA	University of Toronto	Jones, RT (corresponding author), OREGON HLTH SCI UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201, USA.			Kluger, Ronald/0000-0002-1749-2094	NHLBI NIH HHS [HL20142] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL020142] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BUCCI E, 1989, J BIOL CHEM, V264, P6191; CHATTERJEE R, 1986, J BIOL CHEM, V261, P9929; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; IMAI K, 1970, Biochimica et Biophysica Acta, V200, P189, DOI 10.1016/0005-2795(70)90163-7; JONES RT, 1994, METHOD ENZYMOL, V231, P322; JONES RT, 1993, BIOCHEMISTRY-US, V32, P215, DOI 10.1021/bi00052a028; KEIPERT PE, 1989, TRANSFUSION, V29, P768, DOI 10.1046/j.1537-2995.1989.29990070179.x; KILMARTIN JV, 1980, BIOCHEMISTRY-US, V19, P3189, DOI 10.1021/bi00555a013; KLUGER R, 1992, BIOCHEMISTRY-US, V31, P7551, DOI 10.1021/bi00148a016; KLUGER R, 1994, ARTIF CELL BLOOD SUB, V22, P415, DOI 10.3109/10731199409117871; KLUGER R, 1994, J ORG CHEM, V59, P733, DOI 10.1021/jo00083a012; KLUGER R, 1992, J AM CHEM SOC, V114, P9275, DOI 10.1021/ja00050a005; OLSEN K W, 1991, Biomaterials Artificial Cells and Immobilization Biotechnology, V19, P460; PERUTZ MF, 1994, J MOL BIOL, V239, P555, DOI 10.1006/jmbi.1994.1394; SCHUMACHER MA, 1995, NATURE, V375, P84, DOI 10.1038/375084a0; SEYMOUR LW, 1992, CRIT REV THER DRUG, V9, P135; SHIH DTB, 1993, J MOL BIOL, V230, P1291; SHIH DTB, 1986, METHODS HEMATOL, V15, P124; SHIH TB, 1982, HEMOGLOBIN, V6, P153, DOI 10.3109/03630268209002291; SNYDER SR, 1987, P NATL ACAD SCI USA, V84, P7280, DOI 10.1073/pnas.84.20.7280; VANDEGRIFF KD, 1991, CHEM IND-LONDON, P497; WALDER JA, 1979, BIOCHEMISTRY-US, V18, P4265, DOI 10.1021/bi00587a001; WALDER RY, 1994, METHOD ENZYMOL, V2331, P274	23	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					675	680		10.1074/jbc.271.2.675	http://dx.doi.org/10.1074/jbc.271.2.675			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557672	hybrid			2022-12-25	WOS:A1996TP88900015
J	Post, SR; AguilaBuhain, O; Insel, PA				Post, SR; AguilaBuhain, O; Insel, PA			A key role for protein kinase A in homologous desensitization of the beta(2)-adrenergic receptor pathway in S49 lymphoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; G(S)-STIMULATED ADENYLYL CYCLASES; HETEROLOGOUS DESENSITIZATION; WILD-TYPE; BETA-2-ADRENERGIC RECEPTORS; PHOSPHORYLATION SITES; BINDING; SIGNAL; IDENTIFICATION; STIMULATION	We have used a [H-3]forskolin binding assay to assess G(s)-adenylyl cyclase interactions in intact wild-type (WT) and kin(-) S49 cells under conditions that desensitize the beta(2)-adrenergic receptor (beta(2)-AR) system, This assay provides a measurement of G alpha(s)-adenylyl cyclase interaction that does not rely on the determination of second messenger accumulation or enzyme activity in broken cells, Kin(-) S49 cells lack protein kinase A (PKA) activity and provide a unique system in which to study the relative importance of this enzyme in beta(2)-AR desensitization, Although both WT and kin(-) S49 cells display similar kinetics of cAMP accumulation and agonist-induced cell-surface beta(2)-AR loss, we found that these cell types exhibited very different extents of desensitization of forskolin binding following agonist treatment, Specifically, 10 mu M isoproterenol (37 degrees C, 30 min) induced the loss of 70% of [H-3]forskolin binding sites in WT cells but only 30% in kin(-) cells, This loss of sites in WT cells displayed a t(1/2) of approximate to 7 min, was agonist concentration-dependent (EC(50) approximate to 60 nM), was not mimicked by 8-Br-cAMP, and could be blocked by the PHA inhibitor, H89, The difference between WT and kin(-) cells in agonist-induced desensitization of the beta(2)-AR pathway was also noted in studies of cAMP accumulation in cells, In addition, preincubation of intact cells with isoproterenol did not inhibit guanine nucleotide-dependent [H-3]forskolin binding in permeabilized cells, Overall, data obtained from [H-3]forskolin binding assays demonstrate the involvement of PKA in the agonist-dependent uncoupling of beta(2)-AR and G(s); thus we conclude that PKA plays an important role in the homologous desensitization of the beta(2)-AR-G(s)-adenylyl cyclase pathway in intact cells.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego				Post, Steven/0000-0002-4711-1723	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017682, P50HL053773] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040781] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53773, HL17682] Funding Source: Medline; NIGMS NIH HHS [GM40781] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALOUSI AA, 1991, FASEB J, V5, P2300, DOI 10.1096/fasebj.5.9.1650314; BARBER R, 1988, SEC MESS PHOSPHOPROT, V12, P59; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; CLARK RB, 1989, MOL PHARMACOL, V36, P343; CLARK RB, 1988, P NATL ACAD SCI USA, V85, P1442, DOI 10.1073/pnas.85.5.1442; CLARK RB, 1987, FASEB J, V1, P289, DOI 10.1096/fasebj.1.4.2820824; DARFLER FJ, 1982, J BIOL CHEM, V257, P1901; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; FELDMAN RD, 1989, MOL PHARMACOL, V35, P304; GILMAN AG, 1990, ADV SEC MESS PHOSPH, V24, P51; HAUSDORFF WP, 1990, SYM SOC EXP BIOL, V44, P225; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HOCHMAN J, 1975, P NATL ACAD SCI USA, V72, P5051, DOI 10.1073/pnas.72.12.5051; INSEL PA, 1975, SCIENCE, V190, P896, DOI 10.1126/science.171770; INSEL PA, 1983, J BIOL CHEM, V258, P3597; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JASPER JR, 1990, MOL PHARMACOL, V37, P44; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; KUNKEL MW, 1989, FASEB J, V3, P2067, DOI 10.1096/fasebj.3.9.2545497; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LEFKOWITZ RJ, 1993, ADV SEC MESS PHOSPH, V28, P1; LEFKOWITZ RJ, 1992, COLD SPRING HARB SYM, V57, P127, DOI 10.1101/SQB.1992.057.01.016; LEIBER D, 1993, J BIOL CHEM, V268, P3833; LIGGETT SB, 1989, MOL PHARMACOL, V36, P641; LOHSE MJ, 1989, P NATL ACAD SCI USA, V86, P3011, DOI 10.1073/pnas.86.9.3011; MAHAN LC, 1986, MOL PHARMACOL, V29, P16; MAHAN LC, 1985, P NATL ACAD SCI USA, V82, P129, DOI 10.1073/pnas.82.1.129; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; Pieroni J P, 1993, Curr Opin Neurobiol, V3, P345, DOI 10.1016/0959-4388(93)90127-K; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; POST SR, 1995, BIOCHEM J, V311, P75, DOI 10.1042/bj3110075; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; SHEAR M, 1976, J BIOL CHEM, V251, P7572; SHIH ML, 1994, P NATL ACAD SCI USA, V91, P12193, DOI 10.1073/pnas.91.25.12193; Sibley D R, 1987, Adv Exp Med Biol, V221, P253; STICKLE D, 1989, MOL PHARMACOL, V36, P437; STRASSER RH, 1986, BIOCHEMISTRY-US, V25, P1371, DOI 10.1021/bi00354a027; SUTKOWSKI EM, 1994, BIOCHEMISTRY-US, V33, P12852, DOI 10.1021/bi00209a017; TANG WJ, 1992, CELL, V70, P869, DOI 10.1016/0092-8674(92)90236-6; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; WARD WHJ, 1990, TRENDS PHARMACOL SCI, V11, P280, DOI 10.1016/0165-6147(90)90009-W; WATSON PA, 1994, J BIOL CHEM, V269, P28893; YUAN NY, 1994, J BIOL CHEM, V269, P23032	49	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					895	900		10.1074/jbc.271.2.895	http://dx.doi.org/10.1074/jbc.271.2.895			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557702	hybrid			2022-12-25	WOS:A1996TP88900045
J	Uetsuki, T; Takagi, K; Sugiura, H; Yoshikawa, K				Uetsuki, T; Takagi, K; Sugiura, H; Yoshikawa, K			Structure and expression of the mouse necdin gene - Identification of a postmitotic neuron-restrictive core promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOBIOTIC RESPONSIVE ELEMENTS; SILENCER ELEMENT; NUCLEAR-PROTEIN; NERVOUS-SYSTEM; CELLS; DIFFERENTIATION; SIMILARITY; ENCODES; COMMON; INVIVO	Necdin is a 325 amino acid residue protein encoded by a cDNA clone isolated from neurally differentiated embryonal carcinoma cells, In situ hybridization histochemistry revealed that necdin mRNA-containing cells in vivo coincided with postmitotic neurons in the mouse brain from early periods of neurogenesis until adulthood, To study the regulation of necdin gene expression, we have isolated and characterized the necdin gene from a mouse genomic DNA library, The necdin gene contains no intron, and its upstream region lacks canonical TATA and CAAT boxes, To assess promoter activity, the 5'-flanking sequence (844 base pairs) of the necdin gene was fused to the LacZ reporter gene and transiently transfected into retinoic acid-treated P19 embryonal carcinoma cells, Most of the transfectants expressing high levels of LacZ immunoreactivity were postmitotic neurons differentiated from P19 cells, Deletion analysis using luciferase reporter genes demonstrated that a neuron restrictive core promoter is localized to positions -80 to -35, in which a G+C-rich domain and a putative binding site for transcription factors with PAS (per, arnt, and single-minded) dimerization domain are comprised, These results suggest that postmitotic neuron-restrictive expression of the necdin gene is mediated by the specific cis acting elements and that this promoter is applicable to postmitotic neuron-targeted expression of various transgenic systems.	OSAKA UNIV,INST PROT RES,DIV REGULAT MACROMOLEC FUNCT,SUITA,OSAKA 565,JAPAN; TOKYO METROPOLITAN INST NEUROSCI,DEPT MOLEC NEUROBIOL,TOKYO 183,JAPAN	Osaka University; Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science								AIZAWA T, 1992, DEV BRAIN RES, V63, P265; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; COCHARD P, 1984, J NEUROSCI, V4, P2080; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; HAYASHI Y, 1995, BIOCHEM BIOPH RES CO, V213, P317, DOI 10.1006/bbrc.1995.2132; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; KUO XH, 1995, BIOCHEM BIOPH RES CO, V211, P438; LEWIS SA, 1985, J CELL BIOL, V100, P843, DOI 10.1083/jcb.100.3.843; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; MCBURNEY MW, 1988, J NEUROSCI, V8, P1063; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SOGAWA K, 1995, P NATL ACAD SCI USA, V92, P1936, DOI 10.1073/pnas.92.6.1936; THOMAS JB, 1988, CELL, V52, P133, DOI 10.1016/0092-8674(88)90537-5; WATSON AJ, 1992, J BIOL CHEM, V266, P6874; WHARTON KA, 1994, DEVELOPMENT, V120, P3563	23	87	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					918	924		10.1074/jbc.271.2.918	http://dx.doi.org/10.1074/jbc.271.2.918			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557705	hybrid			2022-12-25	WOS:A1996TP88900048
J	Koegl, M; Courtneidge, SA; SupertiFurga, G				Koegl, M; Courtneidge, SA; SupertiFurga, G			Structural requirements for the efficient regulation of the Src protein tyrosine kinase by Csk	ONCOGENE			English	Article						Src protein tyrosine kinase; Csk protein tyrosine kinase; SH2 domain; SH3 domain; autophosphorylation site; schizosaccharomyces pomte	C-SRC; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; AUTOPHOSPHORYLATION SITE; TRANSFORMING PROTEIN; CELL-TRANSFORMATION; FAMILY KINASES; SARCOMA-VIRUS; PP60C-SRC; PHOSPHORYLATION	Protein tyrosine kinases of the Src family are negatively regulated by phosphorylation in the C-terminal tail of the molecule, A different protein tyrosine kinase, Csk, is largely responsible for this regulation, The phosphorylated tail of c-Src engages with the SH2 domain in a conformation that is associated with low kinase activity and which involves stabilization by the SH3 domain, Inducible expression of c-Src in fission yeast is lethal unless Csk is coexpressed, Using this assay we present evidence that Src regulation by C-terminal phosphorylation does not require the myristylation signal or the unique domain at the N-terminus of the Src protein, Mutagenesis of the SH3 and SH2 domains of Csk show that neither are necessary in yeast or in vitro for efficient regulation of Src, Mutation of Tyr416 of Src, a site of autophosphorylation common to most protein tyrosine kinases, abolished the ability of Src to arrest growth of S. pombe and dramatically reduces the ability to phosphorylate endogenous proteins, Tyr416 had the same effect on a shorter form of Src consisting of the kinase domain only, indicating that the mutation affects a property intrinsic to the catalytic domain, The residual activity of full-length Src mutated at Tyr416 is efficiently repressed by Csk action, suggesting that regulation by C-terminal phosphorylation does not act by preventing phosphorylation at Tyr416.	EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, D-69012 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)			Superti-Furga, Giulio/F-4755-2015; Superti-Furga, Giulio/AAE-5681-2019	Superti-Furga, Giulio/0000-0002-0570-1768; 				BAGRODIA S, 1993, MOL CELL BIOL, V13, P1464, DOI 10.1128/MCB.13.3.1464; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BORCHERT TV, 1994, FEBS LETT, V341, P79, DOI 10.1016/0014-5793(94)80244-0; BRAUNINGER A, 1992, GENE, V110, P205, DOI 10.1016/0378-1119(92)90649-A; BRUGGE JS, 1987, MOL CELL BIOL, V7, P2180, DOI 10.1128/MCB.7.6.2180; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FLORIO M, 1994, MOL BIOL CELL, V5, P283, DOI 10.1091/mbc.5.3.283; HARVEY R, 1989, MOL CELL BIOL, V9, P3647, DOI 10.1128/MCB.9.9.3647; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KMIECIK TE, 1988, MOL CELL BIOL, V8, P4541, DOI 10.1128/MCB.8.10.4541; KNIGHTON DR, 1993, P NATL ACAD SCI USA, V90, P5001, DOI 10.1073/pnas.90.11.5001; KOEGL M, 1994, BIOCHEM J, V302, P737, DOI 10.1042/bj3020737; KOEGL M, 1992, SEMIN VIROL, V2, P375; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIU XQ, 1993, ONCOGENE, V8, P1119; MARIN O, 1991, J BIOL CHEM, V266, P17798; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1988, J BIOCHEM-TOKYO, V104, P297, DOI 10.1093/oxfordjournals.jbchem.a122461; OKADA M, 1993, J BIOL CHEM, V268, P18070; OKADA M, 1988, BIOCHEM BIOPH RES CO, V154, P796, DOI 10.1016/0006-291X(88)90210-0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PARTANEN J, 1991, ONCOGENE, V6, P2013; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; RUZZENE M, 1994, J BIOL CHEM, V269, P15885; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SNYDER MA, 1983, CELL, V32, P891, DOI 10.1016/0092-8674(83)90074-0; SNYDER MA, 1984, VIROLOGY, V136, P375, DOI 10.1016/0042-6822(84)90174-0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STOVER DR, 1994, J BIOL CHEM, V269, P26885; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P321, DOI 10.1002/bies.950170408; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; XU Y, 1993, P NATL ACAD SCI USA, V90, P7074, DOI 10.1073/pnas.90.15.7074	72	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2317	2329						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570183				2022-12-25	WOS:A1995TK70200016
J	Lee, GH; Ogawa, K; Nishimori, H; Drinkwater, NR				Lee, GH; Ogawa, K; Nishimori, H; Drinkwater, NR			Most liver epithelial cell lines from C3B6F(1) mice exhibit parentally-biased loss of heterozygosity at the Lci (Liver cell immortalization) locus on chromosome 4	ONCOGENE			English	Article						hepatocyte; immortalization; tumor suppressor	TUMOR PROGRESSION; MOUSE-LIVER; SHORT ARM; HEPATOCELLULAR CARCINOMAS; GENETIC SUSCEPTIBILITY; B6C3F1 MOUSE; CANCER; NEOPLASIA; BREAST; EXPRESSION	Liver epithelial cell lines established from F-1 animals generated from hepatocarcinogen-sensitive C3H/HeJ and -resistant C57BL/6J mice were analysed for loss of heterozygosity at more than 60 simple sequence repeat marker loci distributed over all of the autosomal chromosomes, Nineteen of 20 clonal cell lines showed loss of heterozygosity at a chromosome 4 locus, designated Lci (Liver cell immortalization) and in most of the cases (18 of 19), alleles from the hepatocarcinogen-resistant parental strain, C57BL/6J, were lost, Detailed deletion mapping localized the putative suppressor gene for immortalization to within a 2 cM interval which includes a cluster of genes for gap junctional proteins. We also observed a loss of heterozygosity on chromosomes 7, 14, or 17 in more than 50% of the cell lines.	ASAHIKAWA MED COLL, DEPT PATHOL, ASAHIKAWA, HOKKAIDO 078, JAPAN; UNIV WISCONSIN, SCH MED, MCARDLE LAB CANC RES, MADISON, WI 53076 USA	Asahikawa Medical College; University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [P30CA007175, P01CA022484] Funding Source: NIH RePORTER; NCI NIH HHS [CA07175, CA22484] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALE SJ, 1989, NEW ENGL J MED, V320, P1367, DOI 10.1056/NEJM198905253202102; BEER DG, 1988, CANCER RES, V48, P1610; Bennett L. M., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P144; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; CHO KR, 1992, J CELL BIOCHEM, P137; DAVIS LM, 1994, CARCINOGENESIS, V15, P1637; DEVILEE P, 1994, CANCER RES, V51, P1637; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DOULL J, 1987, ARCH TOXICOL, P3; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; DRAGANI TA, 1987, J CANCER RES CLIN, V113, P223, DOI 10.1007/BF00396377; DRAGANI TA, 1991, CANCER RES, V51, P6299; DRINKWATER NR, 1986, CARCINOGENESIS, V7, P1701, DOI 10.1093/carcin/7.10.1701; DRINKWATER NR, 1991, PROG EXP TUMOR RES, V33, P1; ELICEIRI B, 1991, P NATL ACAD SCI USA, V88, P2179, DOI 10.1073/pnas.88.6.2179; FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FUJIMORI M, 1991, CANCER RES, V51, P89; GARIBOLDI M, 1993, CANCER RES, V53, P209; GENUARDI M, 1989, AM J HUM GENET, V45, P73; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GRASSO P, 1975, MOUSE HEPATIC NEOPLA, P111; HANIGAN MH, 1988, CARCINOGENESIS, V9, P885, DOI 10.1093/carcin/9.6.885; HEGI ME, 1994, CANCER RES, V54, P6257; Hillyard A. L., 1993, Mouse Genome, V91, P15; HOLDER JW, 1993, CANCER RES, V53, P3475; JANSSENTIMMEN U, 1986, CARCINOGENESIS, V7, P1475, DOI 10.1093/carcin/7.9.1475; JONES G, 1974, MOUSE HEPATIC NEOPLA, P21; KADOHAMA T, 1994, ONCOGENE, V9, P2845; KRESS S, 1992, MOL CARCINOGEN, V6, P148, DOI 10.1002/mc.2940060210; LEE GH, 1989, CANCER RES, V49, P403; LEE GH, 1990, CARCINOGENESIS, V11, P1145, DOI 10.1093/carcin/11.7.1145; LEE GH, 1995, GENETICS, V139, P387; LEE GH, 1991, INT J CANCER, V47, P60, DOI 10.1002/ijc.2910470112; LEISTER I, 1990, CANCER RES, V50, P7232; MANENTI G, 1994, GENOMICS, V23, P118, DOI 10.1006/geno.1994.1466; MANENTI G, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P119; MITAKA T, 1991, HEPATOLOGY, V13, P21, DOI 10.1016/0270-9139(91)90211-D; MOLEY JF, 1992, CANCER RES, V52, P770; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; NISHIMORI H, 1994, INT J CANCER, V59, P108, DOI 10.1002/ijc.2910590120; NORDENSKJOLD M, 1988, IMPORTANT ADV ONCOLO, V4, P83; OYAMADA M, 1990, MOL CARCINOGEN, V3, P273, DOI 10.1002/mc.2940030507; Poole T. M., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P255; POTTER M, 1994, CANCER RES, V54, P969; REYNOLDS SH, 1987, SCIENCE, V237, P1309, DOI 10.1126/science.3629242; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SATO T, 1990, CANCER RES, V50, P7184; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; SIMON D, 1991, ONCOGENE, V6, P765; THEILLET C, 1986, CANCER RES, V46, P4776; VANDAMME B, 1992, CANCER RES, V52, P6646; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WISEMAN RW, 1994, P NATL ACAD SCI USA, V91, P3759, DOI 10.1073/pnas.91.9.3759; WISEMAN RW, 1986, P NATL ACAD SCI USA, V83, P5825, DOI 10.1073/pnas.83.16.5825; YEH SH, 1994, CANCER RES, V54, P4188; YOSHIE M, 1994, TR SOC PATHOL JPN, V88, P157; YOSHIMOTO K, 1989, CANCER RES, V49, P2716	60	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2281	2287						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570178				2022-12-25	WOS:A1995TK70200011
J	YonishRouach, E; Deguin, V; Zaitchouk, T; Breugnot, C; Mishal, Z; Jenkins, JR; May, E				YonishRouach, E; Deguin, V; Zaitchouk, T; Breugnot, C; Mishal, Z; Jenkins, JR; May, E			Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53	ONCOGENE			English	Article						p53, apoptosis; transcriptional-activation	CELL-CYCLE CONTROL; DNA-BINDING; MONOCLONAL-ANTIBODIES; T-ANTIGEN; PROTEIN; MUTANT; TRANSFORMATION; IDENTIFICATION; INHIBITION; MUTATIONS	The p53 tumor suppressor gene has been implicated in the induction of apoptosis in several cell systems, We have recently reported that transiently-transfected wt p53 is capable of inducing apoptosis in certain transformed cell lines, We demonstrated by quantitative analysis using flow cytometry that apoptosis was restricted to the population expressing wt, but not mutant, p53, In the present study we use this model system to analyse the functional domains of p53 in the induction of apoptosis, Several constructs expressing mutations or deletions in the C-terminal oligomerization domain, the N-terminal transactivation domain or the central DNA-binding domain were introduced into HeLa cells, and the ability of the expressed proteins to induce apoptosis was evaluated, All the functional domains were found to be necessary for the induction of apoptosis, In addition, cycloheximide and actinomycin D inhibited wt p53-induced apoptosis, We therefore conclude that p53 acts in this cell system, at least in part, as a transcriptional activator in the induction of apoptosis.	INST RECH SCI CANC, CNRS, CYTOMETRIE LAB, F-94801 VILLEJUIF, FRANCE; MARIE CURIE RES INST, SURREY RH8 0TL, ENGLAND	Centre National de la Recherche Scientifique (CNRS)	YonishRouach, E (corresponding author), INST RECH SCI CANC, CNRS, ONCOL MOLEC LAB, 7 RUE GUY MOQUET, F-94801 VILLEJUIF, FRANCE.							ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HADLAR S, 1994, CANCER RES, V54, P2095; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HEBEL M, 1986, Z NATURFORSCH C, V41, P94; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEGROS Y, 1994, ONCOGENE, V9, P2071; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MAY E, 1991, ONCOGENE, V6, P1363; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OMILLI F, 1986, MOL CELL BIOL, V6, P1875, DOI 10.1128/MCB.6.6.1875; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROMANO JW, 1989, ONCOGENE, V4, P1483; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TARUNINA M, 1993, ONCOGENE, V8, P3165; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG YS, 1993, ONCOGENE, V8, P3427; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHANG W, 1994, ONCOGENE, V9, P2513	61	61	63	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2197	2205						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570169				2022-12-25	WOS:A1995TK70200002
J	Holloway, MP; Bram, RJ				Holloway, MP; Bram, RJ			A hydrophobic domain of Ca2+-modulating cyclophilin ligand modulates calcium influx signaling in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; PLASMA-MEMBRANE; CALCINEURIN; THAPSIGARGIN; ACTIVATION; PROMOTER; POOL; IDENTIFICATION; ENTRY	Ca2+-modulating cyclophilin ligand (CAML) was originally described as a cyclophilin B-binding protein whose overexpression in T cells causes a rise in intracellular calcium, thus activating transcription factors responsible for the early immune response. As reported here, structure-function analysis of the CAML gene in Jurkat T cells indicates that two of CAML's putative membrane-spanning domains are necessary and sufficient for the modulation of intracellular calcium, We propose that the hydrophobic C-terminal tail of CAML forms its effector domain, thus implicating the N-terminal hydrophilic domain in a regulatory role, These findings define a novel protein motif that functions in intracellular calcium signaling.	ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, DEPT PEDIAT, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center					NCI NIH HHS [CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRAM R, 1996, IN PRESS GENE AMST; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; CARDENAS ME, 1994, EMBO J, V13, P5944, DOI 10.1002/j.1460-2075.1994.tb06940.x; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEMURA H, 1991, BIOCHEM BIOPH RES CO, V180, P1518, DOI 10.1016/S0006-291X(05)81368-3; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266	20	31	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8549	8552		10.1074/jbc.271.15.8549	http://dx.doi.org/10.1074/jbc.271.15.8549			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621480	hybrid			2022-12-25	WOS:A1996UE73000011
J	Ma, JH; Spremulli, LL				Ma, JH; Spremulli, LL			Expression, purification, and mechanistic studies of bovine mitochondrial translational initiation factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FUNCTIONAL DOMAINS; FACTOR-II; POLYMERASE; PROTEINS; PROTEASE	A complete cDNA clone encoding bovine mitochondrial translational initiation factor 2 (IF-2(mt)) has been obtained. The regions of the cDNA corresponding to mature IF-2(mt) and several of its functional domains have been expressed in Escherichia coli as histidine-tagged proteins. The precursor (similar to 90 kDa) and mature (similar to 85 kDa) forms of IF-2(mt) are toxic to E. coli and can only be expressed at low levels. Shorter forms of this factor (similar to 80 and similar to 72 kDa) are also found during the expression of mature IF-2(mt). The various forms of IF-2(mt) can be separated by high performance liquid chromatography. All of these forms are active in promoting the GTP-dependent binding of formyl-Met-tRNA to the small subunit of either E. coli or bovine mitochondrial ribosomes. IF-2(mt) can bind to mitochondrial ribosomes in the absence of GTP, initiator tRNA, or messenger RNA. The presence of GTP stimulates IF-2(mt) binding to ribosomes about 3-fold. IF-2(mt) interacts only weakly with GTP or with the initiator tRNA in the absence of ribosomes. Molecular dissection of IF-2(mt) shows that a long deletion (similar to 150 amino acid residues) from the NH2-terminal region does not affect its activity in vitro. The COOH domain of IF-2(mt) (amino acid residues 332-727) can bind to ribosomes even though it does not promote initiator-tRNA binding.	UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC RES CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32734] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; DESMIT MH, 1994, J MOL BIOL, V235, P173, DOI 10.1016/S0022-2836(05)80024-5; DUBNOFF J S, 1972, Journal of Biological Chemistry, V247, P2876; EBERLY SL, 1985, J BIOL CHEM, V260, P8721; GRAVES MC, 1993, ARCH BIOCHEM BIOPHYS, V222, P192; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; GUALERZI CO, 1991, J BIOL CHEM, V266, P16356; HARALSON MA, 1974, ARCH BIOCHEM BIOPHYS, V165, P247, DOI 10.1016/0003-9861(74)90161-1; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; LAALAMI S, 1991, BIOCHIMIE, V73, P1557, DOI 10.1016/0300-9084(91)90191-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAO HX, 1991, J BIOL CHEM, V266, P20714; LIAO HX, 1990, J BIOL CHEM, V265, P13618; MA JH, 1995, BBA-GENE STRUCT EXPR, V1261, P321, DOI 10.1016/0167-4781(95)00041-E; MA L, 1995, J BIOL CHEM, V270, P1859, DOI 10.1074/jbc.270.4.1859; MATTHEWS DE, 1982, J BIOL CHEM, V257, P8788; PERRIN S, 1990, NUCLEIC ACIDS RES, V18, P7433, DOI 10.1093/nar/18.24.7433; PON CL, 1985, J BIOL CHEM, V260, P8918; SEVERINI M, 1990, FEBS LETT, V276, P14, DOI 10.1016/0014-5793(90)80495-5; STEFFENSEN S, 1994, BIOCHEM MOL BIOL INT, V34, P1245; SUGIMURA K, 1988, J BACTERIOL, V170, P3650, DOI 10.1128/jb.170.8.3650-3654.1988; VACHON G, 1990, BIOCHEMISTRY-US, V29, P9728, DOI 10.1021/bi00493a031; VAMBUTAS A, 1991, EUR J BIOCHEM, V201, P643, DOI 10.1111/j.1432-1033.1991.tb16325.x	23	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5805	5811		10.1074/jbc.271.10.5805	http://dx.doi.org/10.1074/jbc.271.10.5805			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621449	Green Published, hybrid			2022-12-25	WOS:A1996TZ28600075
J	Chavany, C; Mimnaugh, E; Miller, P; Bitton, R; Nguyen, P; Trepel, J; Whitesell, L; Schnur, R; Moyer, JD; Neckers, L				Chavany, C; Mimnaugh, E; Miller, P; Bitton, R; Nguyen, P; Trepel, J; Whitesell, L; Schnur, R; Moyer, JD; Neckers, L			p185(erbB2) binds to GRP94 in vivo - Dissociation of the p185(erbB2)/GRP94 heterocomplex by benzoauinone ansamycins precedes depletion of p185(erbB2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ENDOPLASMIC-RETICULUM; KINASE-ACTIVITY; HSP90; GLYCOPROTEIN	Treatment of SKBr3 cells with benzoquinone ansamycins, such as geldanamycin (GA), depletes p185(erbB2), the receptor tyrosine kinase encoded by the erbB2 gene. In the same cells, a biologically active benzoquinone photoaffinity label specifically binds a protein of about 100 kDa, and the ability of various GA derivatives to reduce the intracellular level of p185(erbB2) correlates with their ability to compete with the photoaffinity label for binding to this protein. In this report, we present evidence that the similar to 100-kDa ansamycin-binding protein is GRP94. Membrane-associated p185(erbB2) exists in a stable complex with GRP94. GA binding to GRP94 disrupts this complex, leading to degradation of pre-existing p185(erbB2) protein, and resulting in an altered subcellular distribution of newly synthesized p185(erbB2).	NCI, NIH, CLIN PHARMACOL BRANCH, BETHESDA, MD 20892 USA; NCI, NIH, MED BRANCH, BETHESDA, MD 20892 USA; PFIZER INC, CENT RES, GROTON, CT 06340 USA; UNIV ARIZONA, HLTH SCI CTR, STEELE MEM RES CTR, DEPT PEDIAT, TUCSON, AZ 85724 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pfizer; University of Arizona; University of Arizona Health Sciences								ALIGUE R, 1994, EMBO J, V13, P6099, DOI 10.1002/j.1460-2075.1994.tb06956.x; BITTON RJ, 1995, P AM ASSOC CANC RES, V36, P355; Black A R, 1991, Methods Achiev Exp Pathol, V15, P126; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CALA SE, 1994, J BIOL CHEM, V269, P5926; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; LEE AS, 1984, J BIOL CHEM, V259, P4616; LI ZH, 1993, EMBO J, V12, P3143, DOI 10.1002/j.1460-2075.1993.tb05983.x; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MILLER P, 1994, CANCER RES, V54, P2724; MILLER P, 1994, BIOCHEM BIOPH RES CO, V201, P1313, DOI 10.1006/bbrc.1994.1847; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MURAKAMI Y, 1994, BIOCHEM J, V301, P57, DOI 10.1042/bj3010057; MURAKAMI Y, 1994, BIOCHEM J, V301, P63, DOI 10.1042/bj3010063; NAVARRO D, 1991, VIROLOGY, V184, P253, DOI 10.1016/0042-6822(91)90842-Y; Pratt William B., 1994, Seminars in Cell Biology, V5, P83; SARGAN DR, 1986, BIOCHEMISTRY-US, V25, P6252, DOI 10.1021/bi00368a062; SCHNUR RC, 1995, J MED CHEM, V38, P3813, DOI 10.1021/jm00019a011; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; UEHARA Y, 1989, CANCER RES, V49, P780; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324	28	201	214	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4974	4977						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617772				2022-12-25	WOS:A1996TX69700062
J	Raffel, GD; Parmar, K; Rosenberg, N				Raffel, GD; Parmar, K; Rosenberg, N			In vivo association of v-Abl with Shc mediated by a non-phosphotyrosine-dependent SH2 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LEUKEMIA-VIRUS; TYROSINE KINASE; ADAPTER PROTEIN; ONCOGENE; DOMAIN; BCR; TRANSFORMATION; CELLS; RECEPTOR; COMPLEX	A necessary downstream element of Abelson murine leukemia virus (Ab-MLV)-mediated transformation is Ras, which can be activated by the phosphotyrosine-dependent association of Shc with the Grb2-mSos complex. Here we show that Shc is tyrosine phosphorylated and associates with Grb2 in v-Abl-transformed cells, whereas Shc in NIH3T3 cells is phosphorylated solely on serine and is not Grb2 associated. In addition, Shc co-precipitates with P120 v-Abl and P70 v-Abl, which lacks the carboxyl terminus. Surprisingly, a kinase defective mutant of P120 also binds Shc, demonstrating that Shc/v-Abl association is a phosphotyrosine-independent interaction. Glutathione S-transferase fusion proteins were used to map the interacting domains and showed that Shc from both NIH3T3 and v-Abl-transformed cells binds to the Abl SH2 domain and that P120 v-Abl binds to a region in the amino terminus of Shc. Consistent with these data, a v-Abl mutant encoding only the Gag and SH2 regions was able to bind Shc in vivo. The unique non-phosphotyrosine-mediated binding of Shc may allow direct tyrosine phosphorylation of Shc by v-Abl and subsequent activation of the Ras pathway through assembly of a signaling complex with Grb2-mSos.	TUFTS UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02111 USA	Tufts University; Tufts University					NATIONAL CANCER INSTITUTE [R01CA024220] Funding Source: NIH RePORTER; NCI NIH HHS [CA24220] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CHESEBRO B, 1981, VIROLOGY, V112, P131, DOI 10.1016/0042-6822(81)90619-X; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; ENGELMAN A, 1987, P NATL ACAD SCI USA, V84, P8021, DOI 10.1073/pnas.84.22.8021; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HABIB T, 1994, J BIOL CHEM, V269, P25243; HEVEZI P, 1993, ONCOGENE, V8, P2413; HU QJ, 1995, MOL CELL BIOL, V15, P1169; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KELLIHER M, 1991, THESIS TUFTS U BOSTO; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KLINE MJ, 1994, NEW ENGL J MED, V330, P328; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MURTAGH K, 1986, J VIROL, V60, P599, DOI 10.1128/JVI.60.2.599-606.1986; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OUWENS DM, 1994, J BIOL CHEM, V269, P33116; OWENLYNCH PJ, 1995, J BIOL CHEM, V270, P5956, DOI 10.1074/jbc.270.11.5956; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SCHLAEPFER DD, 1994, NATURE, V372, P786; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; VANBEVERN C, 1985, RNA TUMOR VIRUSES, P850; WANG JYJ, 1985, J BIOL CHEM, V260, P64; WANG JYJ, 1988, ONCOGENE RES, V3, P293; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	59	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4640	4645						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617726				2022-12-25	WOS:A1996TX69700016
J	Baque, S; Guinovart, JJ; GomezFoix, AM				Baque, S; Guinovart, JJ; GomezFoix, AM			Overexpression of muscle glycogen phosphorylase in cultured human muscle fibers causes increased glucose consumption and nonoxidative disposal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRUS-MEDIATED TRANSFER; HUMAN SKELETAL-MUSCLE; SYNTHASE ACTIVITY; LIVER-GLYCOGEN; NO NEED; EXERCISE; INSULIN; RAT; METABOLISM; TRANSPORT	The effect of increased expression of glycogen phosphorylase on glucose metabolism inhuman muscle was examined in primary cultured fibers transduced with recombinant adenovirus AdCMV-MGP encoding muscle glycogen phosphorylase, Increments of 20-fold in total enzyme activity and of 14-fold of the active form of the enzyme were associated with a 30% reduction in basal glycogen levels, Total glycogen synthase activity was doubled in AdCMV-MGP-transduced cells even though the activity ratio was decreased, Incubation with forskolin, which inactivated glycogen synthase and activated glycogen phosphorylase, induced greater net glycogenolysis in engineered cells, In unstimulated fibers, lactate production was three times higher in AdCMV-MGP fibers as compared with controls, despite similar rates of glycogenolysis. In transduced fibers incubated with 2-deoxyglucose, the level: of 2-deoxyglucose 6-phosphate was about 8-fold elevated over the control even though hexokinase activity was unmodified in AdCMV-MGP fibers, Overexpression of glycogen phosphorylase also led to enhancement of [U-C-14]glucose incorporation into glycogen, lactate, and lipid. Accordingly, determination of lipid cell content revealed that engineered cells were accumulating lipids, Furthermore, (CO2)-C-14 formation from [U-C-14]glucose was 1.6-fold higher, whereas (CO2)-C-14 formation from [6-C-14]glucose was unmodified, in AdCMV-MGP fibers, Our data show that in human skeletal muscle cells in culture, the increase in glycogen phosphorylase activity is able to up-regulate glycogen synthase activity indicating the enhancement of glycogen turnover, We suggest that the increase in glycogen phosphorylase and, thereby, in glycogen metabolism, is sufficient to enhance glucose uptake in the muscle cell, Glucose taken up by engineered muscle cells is essentially disposed of through nonoxidative metabolism and converted into lactate and lipid.	UNIV BARCELONA,FAC QUIM,DEPT BIOQUIM & BIOL MOLEC,E-08028 BARCELONA,SPAIN	University of Barcelona								ASKANAS V, 1985, ARCH NEUROL-CHICAGO, V42, P749, DOI 10.1001/archneur.1985.04210090013004; ASKANAS V, 1975, NEUROLOGY, V25, P58, DOI 10.1212/WNL.25.1.58; BAK JF, 1990, AM J PHYSIOL, V258, pE957, DOI 10.1152/ajpendo.1990.258.6.E957; BAK JF, 1989, J CLIN ENDOCR METAB, V69, P158, DOI 10.1210/jcem-69-1-158; BAQUE S, 1994, BIOCHEM J, V304, P1009, DOI 10.1042/bj3041009; BECKER TC, 1994, METHOD CELL BIOL, V43, P191; BJORNTORP P, 1970, ACTA PHYSIOL SCAND, V80, P29, DOI 10.1111/j.1748-1716.1970.tb04766.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CADEFAU J, 1990, ACTA PHYSIOL SCAND, V140, P341, DOI 10.1111/j.1748-1716.1990.tb09008.x; DAVID M, 1990, J CLIN INVEST, V86, P612, DOI 10.1172/JCI114752; FELL RD, 1982, J APPL PHYSIOL, V52, P434, DOI 10.1152/jappl.1982.52.2.434; FOLCH J, 1951, J BIOL CHEM, V191, P833; GILBOE DP, 1972, ANAL BIOCHEM, V47, P20, DOI 10.1016/0003-2697(72)90274-6; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Gutmann I., 1974, METHODS ENZYMATIC AN, P1464; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; KONO N, 1984, NEUROLOGY, V34, P1471, DOI 10.1212/WNL.34.11.1471; LANG G, 1974, METHOD ENZYMAT AN, V3, P1238; MAGNUSSON I, 1994, AM J PHYSIOL, V266, pE796, DOI 10.1152/ajpendo.1994.266.5.E796; NAKANO K, 1986, FEBS LETT, V204, P283, DOI 10.1016/0014-5793(86)80829-8; NESHER R, 1985, AM J PHYSIOL, V249, pC226, DOI 10.1152/ajpcell.1985.249.3.C226; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; NEWGARD CB, 1983, J BIOL CHEM, V258, P8046; NOLTE LA, 1994, J APPL PHYSIOL, V76, P2054, DOI 10.1152/jappl.1994.76.5.2054; PLOUG T, 1984, AM J PHYSIOL, V247, pE726, DOI 10.1152/ajpendo.1984.247.6.E726; REN JM, 1993, J BIOL CHEM, V268, P16113; RICHTER EA, 1985, DIABETES, V34, P1041, DOI 10.2337/diabetes.34.10.1041; RICHTER EA, 1984, AM J PHYSIOL, V246, pE476, DOI 10.1152/ajpendo.1984.246.6.E476; RICHTER EA, 1982, AM J PHYSIOL, V242, pE25, DOI 10.1152/ajpendo.1982.242.1.E25; RICHTER EA, 1982, J CLIN INVEST, V69, P785, DOI 10.1172/JCI110517; RODNICK KJ, 1990, DIABETES, V39, P1425, DOI 10.2337/diabetes.39.11.1425; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; THORBURN AW, 1990, J CLIN INVEST, V85, P522, DOI 10.1172/JCI114468; TREADWAY JL, 1989, AM J PHYSIOL, V256, pE138, DOI 10.1152/ajpendo.1989.256.1.E138; WALLBERGHENRIKSSON H, 1984, J APPL PHYSIOL, V57, P1045, DOI 10.1152/jappl.1984.57.4.1045; WALLBERGHENRIKSSON H, 1985, AM J PHYSIOL, V249, pC233, DOI 10.1152/ajpcell.1985.249.3.C233; WESTERGAARD H, 1994, AM J PHYSIOL, V266, pE92; YAN Z, 1992, ACTA PHYSIOL SCAND, V145, P345, DOI 10.1111/j.1748-1716.1992.tb09374.x	38	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2594	2598		10.1074/jbc.271.5.2594	http://dx.doi.org/10.1074/jbc.271.5.2594			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576226	hybrid			2022-12-25	WOS:A1996TT48800040
J	Kee, BL; Arias, J; Montminy, MR				Kee, BL; Arias, J; Montminy, MR			Adaptor-mediated recruitment of RNA polymerase II to a signal-dependent activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR CREB; TRANSCRIPTION; PHOSPHORYLATION	The second messenger cAMP stimulates the expression of a number of target genes via the protein kinase A-mediated phosphorylation of CREB at Ser-133 (Gonzalez, G. A., and Montminy, M. R. (1989) Cell 59, 675-680). Ser-133 phosphorylation enhances CREB activity by promoting interaction with a 265-kDa CREB binding protein referred to as CBP (Arias, J., Alberts, A., Brindle, P., Claret, F., Smeal, T., Karin, M., Feramisco, J., and Montminy, M. (1994) Nature 370, 226-228; Chrivia, J. C., Kwok, R. P., Lamb, N., Hagiwara, M., Montminy, M. R., and Goodman, R. H. (1993) Nature 365, 855-859). The mechanism by which CBP in turn mediates induction of cAMP-responsive genes is unknown but is thought to involve recruitment of basal transcription factors to the promoter. Here we demonstrate that CBP associates specifically with RNA polymerase II in HeLa nuclear extracts. This association in turn permits RNA polymerase II to be recruited to CREB in a phospho-(Ser-133)-dependent manner. As anti-CBP antiserum, which inhibits recruitment of CBP and RNA polymerase II to phospho-(Ser-133) CREB, attenuates transcriptional induction by protein kinase A in vitro, our results demonstrate that the CBP RNA polymerase II complex is critical for expression of cAMP-responsive genes.	SALK INST BIOL STUDIES,CLAYTON FDN LABS PEPTIDE BIOL,LA JOLLA,CA 92037	Salk Institute					NIGMS NIH HHS [GM 37828] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037828, R01GM037828] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS AS, 1994, J BIOL CHEM, V269, P7623; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BARBERIS A, 1995, CELL, V81, P359, DOI 10.1016/0092-8674(95)90389-5; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0	10	180	185	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2373	2375		10.1074/jbc.271.5.2373	http://dx.doi.org/10.1074/jbc.271.5.2373			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576192	hybrid			2022-12-25	WOS:A1996TT48800006
J	Lounsbury, KM; Richards, SA; Perlungher, RR; Macara, IG				Lounsbury, KM; Richards, SA; Perlungher, RR; Macara, IG			Ran binding domains promote the interaction of Ran with p97/beta-karyopherin, linking the docking and translocation steps of nuclear import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN RAN/TC4; 2 STEPS; ENVELOPE; PORE	Nuclear protein import is accomplished by two sequential events: docking at the nuclear pore complex followed by ATP-dependent translocation across the nuclear envelope. Docking of nuclear targeted proteins requires a 56-kDa nuclear localization signal receptor (alpha-karyopherin, importin-alpha, SRP1 alpha) and a 97-kDa protein (beta-karyopherin, importin-beta). Components necessary for translocation include the Ran/TC4 GTPase and NTF2/B-2. The functions of these factors at a molecular level remain unclear. We have now found that a complex of Ran, in the GTP-bound state, with either the Ran binding protein, RanBP1, or an isolated Ran binding domain binds with high affinity and specificity to beta-karyopherin to form a ternary complex, We find that a C-terminal truncation mutant of Ran, Delta-DE Ran, also binds to beta-karyopherin and that Delta-DE Ran can associate with a cytosolic, multiprotein complex that contains beta-karyopherin and another Delta-DE Ran binding protein of 115/120 kDa. These data suggest a physical link between docking and translocation mediated by a Ran GTPase-Ran binding protein complex.	UNIV VERMONT,CTR COMPREHENS CANC,BURLINGTON,VT 05405	University of Vermont	Lounsbury, KM (corresponding author), UNIV VERMONT,DEPT PATHOL,BURLINGTON,VT 05405, USA.				NATIONAL CANCER INSTITUTE [F32CA063801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050526] Funding Source: NIH RePORTER; NCI NIH HHS [F32 CA63801] Funding Source: Medline; NIEHS NIH HHS [EST 3207122] Funding Source: Medline; NIGMS NIH HHS [R01 GM050526, GM 50526] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEDDOW AL, 1995, P NATL ACAD SCI USA, V92, P3328, DOI 10.1073/pnas.92.8.3328; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MOOORE MS, 1994, P NATL ACAD SCI USA, V91, P10212; MOORE MS, 1992, CELL, V69, P939, DOI 10.1016/0092-8674(92)90613-H; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P2008, DOI 10.1073/pnas.92.6.2008; NEWMEYER DD, 1988, CELL, V52, P641, DOI 10.1016/0092-8674(88)90402-3; PASCHAL BM, 1995, J CELL BIOL, V129, P925, DOI 10.1083/jcb.129.4.925; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; RICHARDS SA, 1995, J BIOL CHEM, V270, P14405, DOI 10.1074/jbc.270.24.14405; RICHARDSON WD, 1988, CELL, V52, P655, DOI 10.1016/0092-8674(88)90403-5; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; WEIS K, 1995, SCIENCE, V268, P1049, DOI 10.1126/science.7754385; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKAYAMA N, 1995, NATURE, V376, P184	26	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2357	2360		10.1074/jbc.271.5.2357	http://dx.doi.org/10.1074/jbc.271.5.2357			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576188	hybrid			2022-12-25	WOS:A1996TT48800002
J	Xu, K; Clark, D; Strauch, MA				Xu, K; Clark, D; Strauch, MA			Analysis of abrB mutations, mutant proteins, and why abrB does not utilize a perfect consensus in the -35 region of its sigma(A) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION REGULATOR ABRB; BACILLUS-SUBTILIS; SPORULATION MUTANTS; PARTIAL REVERTANTS; DNA; HOMEODOMAIN; EXPRESSION; GENE	The Bacillus subtilis global regulator AbrB is a DNA-binding protein composed of six identical monomers of 96 amino acids that shows specificity to the promoter regions of its target genes including its own, We have sequenced thirteen previously uncharacterized abrB mutations, Four mutant AbrB proteins were purified, and their DNA-binding properties and multimeric structures were examined, AbrB23 (R25S) had no appreciable DNA binding activity but retained a hexameric structure, indicating that Arg25 is important in DNA interactions, Three other mutant proteins, AbrB1 (C56Y), AbrB19 (Gln(83) --> termination codon), and AbrB100 (L69P), showed decreased DNA binding and altered multimeric interactions, Analysis of the expression and AbrB binding affinities of mutant abrB promoters demonstrated that a consensus -35 region is incompatible with proper autoregulation of the abrB gene.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV CELLULAR BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute					NATIONAL CENTER FOR RESEARCH RESOURCES [S03RR003010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046700] Funding Source: NIH RePORTER; NCRR NIH HHS [S03RR03010] Funding Source: Medline; NIGMS NIH HHS [GM46700] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANAGNOSTOPOULOS C, 1961, P NATL ACAD SCI USA, V47, P378, DOI 10.1073/pnas.47.3.378; BROSIUS J, 1989, DNA-J MOLEC CELL BIO, V8, P759, DOI 10.1089/dna.1989.8.759; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; FERRARI E, 1988, J BACTERIOL, V170, P289, DOI 10.1128/JB.170.1.289-295.1988; FISHER SH, 1994, J BACTERIOL, V176, P1903, DOI 10.1128/jb.176.7.1903-1912.1994; FURBASS R, 1991, MOL GEN GENET, V225, P347; GALLAGHER SR, 1991, CURRENT PROTOCOLS MO; GUESPINMICHEL JF, 1971, MOL GEN GENET, V112, P243, DOI 10.1007/BF00269177; GUESPINMICHEL JF, 1971, J BACTERIOL, V108, P241, DOI 10.1128/JB.108.1.241-247.1971; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HEDRICK JL, 1968, ARCH BIOCHEM BIOPHYS, V126, P155, DOI 10.1016/0003-9861(68)90569-9; ITO J, 1973, MOL GEN GENET, V124, P97, DOI 10.1007/BF00265143; ITO J, 1971, MOL GEN GENET, V112, P104, DOI 10.1007/BF00267488; KOBAYASHI K, 1995, J BACTERIOL, V177, P176, DOI 10.1128/jb.177.1.176-182.1995; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; Ogasawara N, 1994, DNA Res, V1, P1, DOI 10.1093/dnares/1.1.1; OPOKU J, 1994, J BIOL CHEM, V269, P503; PEREGO M, 1988, MOL MICROBIOL, V2, P689, DOI 10.1111/j.1365-2958.1988.tb00079.x; Perego Marta, 1993, P615; SCOTT MP, 1989, BIOCHIM BIOPHYS ACTA, V989, P25, DOI 10.1016/0304-419X(89)90033-4; SLACK FJ, 1991, MOL MICROBIOL, V5, P1915, DOI 10.1111/j.1365-2958.1991.tb00815.x; STRAUCH M, 1990, P NATL ACAD SCI USA, V87, P1801, DOI 10.1073/pnas.87.5.1801; STRAUCH MA, 1989, MOL MICROBIOL, V3, P1203, DOI 10.1111/j.1365-2958.1989.tb00270.x; STRAUCH MA, 1989, EMBO J, V8, P1615, DOI 10.1002/j.1460-2075.1989.tb03546.x; STRAUCH MA, 1995, J BACTERIOL, V177, P6727, DOI 10.1128/jb.177.23.6727-6731.1995; STRAUCH MA, 1993, PROG NUCLEIC ACID RE, V46, P121, DOI 10.1016/S0079-6603(08)61020-X; STRAUCH MA, 1995, J BACTERIOL, V177, P6999, DOI 10.1128/jb.177.23.6999-7002.1995; STRAUCH MA, 1995, J BACTERIOL, V177, P4532, DOI 10.1128/jb.177.15.4532-4536.1995; Strauch Mark A., 1993, P757; TROWSDALE J, 1979, MOL GEN GENET, V173, P61, DOI 10.1007/BF00267691; TROWSDALE J, 1978, SPORES, V7, P131; XU K, 1996, IN PRESS MOL MICROBI; ZUBER P, 1987, J BACTERIOL, V169, P2223, DOI 10.1128/jb.169.5.2223-2230.1987	34	24	24	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2621	2626		10.1074/jbc.271.5.2621	http://dx.doi.org/10.1074/jbc.271.5.2621			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576231	hybrid			2022-12-25	WOS:A1996TT48800045
J	Ohshima, K; Kang, S; Wells, RD				Ohshima, K; Kang, S; Wells, RD			CTG triplet repeats from human hereditary diseases are dominant genetic expansion products in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAG REPEAT; INSTABILITY; DYSTROPHY; MUTATIONS; MECHANISM; REGION; CANCER	The relative ability of the 10 triplet repeat sequences to be expanded in Escherichia coli was determined. Surprisingly, CTG; tracts are expanded at least 8 times more frequently than any of the other nine triplets. Low levels of expansion were found also for CGG;, GTG, and GTC. Thus, the structure of the CTG repeats and/or their utilization by the DNA synthetic systems in vivo must be quite different from the other triplets. These data further validate this genetically defined system for elucidating molecular mechanisms of expansion and may explain why most triplet repeat hereditary neuromuscular and neurodegenerative disease genes contain CTG repeats.	TEXAS A&M UNIV, TEXAS MED CTR, CTR GENOME RES, INST BIOSCI & TECHNOL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Texas A&M University System					NIGMS NIH HHS [GM52982] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BURKE JR, 1994, NAT GENET, V7, P521, DOI 10.1038/ng0894-521; Chastain PD, 1995, BIOCHEMISTRY-US, V34, P16125, DOI 10.1021/bi00049a027; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; EICHLER EE, 1994, NAT GENET, V8, P88, DOI 10.1038/ng0994-88; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; GACY AM, 1995, CELL, V81, P533; HAN J, 1994, NUCLEIC ACIDS RES, V22, P1735, DOI 10.1093/nar/22.9.1735; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; KANG SM, 1995, J BIOL CHEM, V270, P27014, DOI 10.1074/jbc.270.45.27014; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LINDBLAD K, 1994, NAT GENET, V7, P124, DOI 10.1038/ng0694-124; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MITAS M, 1995, NUCLEIC ACIDS RES, V23, P1050, DOI 10.1093/nar/23.6.1050; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NELSON DL, 1993, GENOME ANAL, V7, P1; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Sambrook J, 1989, MOL CLONING LABORATO; SMITH GK, 1995, NUCLEIC ACIDS RES, V23, P4303; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; WEBER JL, 1990, GENOMICS, V7, P524, DOI 10.1016/0888-7543(90)90195-Z; WIERINGA B, 1994, HUM MOL GENET, V3, P1, DOI 10.1093/hmg/3.1.1-a; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; YU AD, 1995, NUCLEIC ACIDS RES, V23, P2706, DOI 10.1093/nar/23.14.2706; 1993, CELL, V72, P971	34	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1853	1856		10.1074/jbc.271.4.1853	http://dx.doi.org/10.1074/jbc.271.4.1853			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567629	hybrid			2022-12-25	WOS:A1996TR32000011
J	Athanasiou, M; Mavrothalassitis, GJ; Yuan, CC; Blair, DG				Athanasiou, M; Mavrothalassitis, GJ; Yuan, CC; Blair, DG			The Gag-Myb-Ets fusion oncogene alters the apoptotic response and growth factor dependence of interleukin-3 dependent murine cells	ONCOGENE			English	Article						v-ets; ETS oncogene; apoptosis; IT-3 dependent; erythropoietin; erythroid differentiation	TRANSCRIPTION FACTOR GATA-1; AVIAN LEUKEMIA-VIRUS; HEMATOPOIETIC-CELLS; ERYTHROPOIETIN RECEPTOR; NEURORETINA CELLS; GENE-EXPRESSION; LINE; E26; TRANSACTIVATION; DIFFERENTIATION	Expression of the avian E26-derived Gag-Myb-Ets fusion oncogene in interleukin-3(IL3)-dependent murine hematopoietic cell lines results in a pattern of cell line dependent changes in growth factor-induced proliferation and apoptosis. A drug-selectable retrovirus expressing p135(Gag-Myb-Ets) induced an erythropoietin(Epo)-responsive phenotype in the cell lines FDC-P2, BaF3 and 32Dc123. Gag-Myb-Ets expression alone did not increase expression of GATA-1 or the Epo receptor(EpoR) in the presence of IL3, and infected cell lines express increased GATA-1 and EpoR only when IL3 was replaced by Epo in the culture media. Indicative of Epo-induced erythroid differentiation, these cells also began to express beta-globin after 3-5 days growth in Epo. Unlike control cells, infected FDC-P2 cells failed to undergo programmed cell death (apoptosis) when transferred from IL3- to Epo-containing media, although a fraction of the cells failed to proliferate following the media shift. Three other IL3-dependent cell Lines showed no changes in growth behavior when induced to express the fusion oncogene. Our data shows that Gag-Myb-Ets can have different affects on growth factor pathways depending on the cell background, suggesting a model in which the p135(gag-myb-ets) fusion oncogene promotes these different responses through its affect on apoptosis.	SAIC,LAB CELLULAR BIOCHEM,FREDERICK,MD 21702; NCI,MOLEC ONCOL LAB,FREDERICK,MD	Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AMOUYEL P, 1989, J VIROL, V63, P3382, DOI 10.1128/JVI.63.8.3382-3388.1989; Ascione R., 1993, Genome research in molecular medicine and virology., P199; AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; BERRIDGE MV, 1993, EXP HEMATOL, V21, P269; BISTER K, 1982, P NATL ACAD SCI-BIOL, V79, P3677, DOI 10.1073/pnas.79.12.3677; CALABRETTA B, 1991, Critical Reviews in Oncogenesis, V2, P187; CHIBA T, 1993, P NATL ACAD SCI USA, V90, P11593, DOI 10.1073/pnas.90.24.11593; CHIBA T, 1991, NUCLEIC ACIDS RES, V19, P3843, DOI 10.1093/nar/19.14.3843; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANDREA AD, 1994, CURR OPIN CELL BIOL, V6, P804, DOI 10.1016/0955-0674(94)90048-5; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DUBART A, 1994, MOL CELL BIOL, V14, P4834, DOI 10.1128/MCB.14.7.4834; EVANS T, 1991, MOL CELL BIOL, V11, P843, DOI 10.1128/MCB.11.2.843; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; GARRIDO C, 1992, J VIROL, V66, P160, DOI 10.1128/JVI.66.1.160-166.1992; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; ICHIKAWA H, 1994, CANCER RES, V54, P2865; ISFORT RJ, 1990, SOMAT CELL MOLEC GEN, V16, P109, DOI 10.1007/BF01233041; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; JURDIC P, 1987, J VIROL, V61, P3058, DOI 10.1128/JVI.61.10.3058-3065.1987; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRAUT N, 1995, ONCOGENE, V10, P1027; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MCCUBREY JA, 1993, ONCOGENE, V8, P2905; MIGLIACCIO AR, 1991, P NATL ACAD SCI USA, V88, P11086, DOI 10.1073/pnas.88.24.11086; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NUNN M, 1984, VIROLOGY, V133, P330; ORKIN SH, 1992, BLOOD, V80, P575; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAVELCHAPUIS P, 1991, J VIROL, V65, P3928, DOI 10.1128/JVI.65.7.3928-3931.1991; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; SETH A, 1993, ONCOGENE, V8, P1783; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VARIO G, 1990, J BIOL CHEM, V265, P2692; WANG LG, 1994, CELL GROWTH DIFFER, V5, P1243; WATSON DK, 1988, VIROLOGY, V164, P99, DOI 10.1016/0042-6822(88)90624-1; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	51	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					337	344						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570210				2022-12-25	WOS:A1996TR53800012
J	Whittaker, MM; Kersten, PJ; Nakamura, N; SandersLoehr, J; Schweizer, ES; Whittaker, JW				Whittaker, MM; Kersten, PJ; Nakamura, N; SandersLoehr, J; Schweizer, ES; Whittaker, JW			Glyoxal oxidase from Phanerochaete chrysosporium is a new radical-copper oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGNIN-DEGRADING ENZYME; GALACTOSE-OXIDASE; DACTYLIUM-DENDROIDES; SUPEROXIDE DISMUTASE; ACTIVE-SITE; RESONANCE; IDENTIFICATION; DEGRADATION; INVOLVEMENT; ACTIVATION	A free radical-coupled copper complex has been identified as the catalytic structure in the active site of glyoxal oxidase from Phanerochaete chrysosporium based on a combination of spectroscopic and biochemical studies, The native (inactive) enzyme is activated by oxidants leading to the elimination of the cupric EPR signal consistent with formation of an antiferromagnetically coupled radical-copper complex, Oxidation also leads to the appearance of a substoichiometric free radical EPR signal with an average g value (g(av) = 2.0055) characteristic of phenoxyl pi-radicals arising from a minority apoenzyme fraction, Optical absorption, CD, and spectroelectrochemical measurements on the active enzyme reveal complex spectra extending into the near IR and define the redox potential for radical formation (E(1/2) = 0.64 V versus NHE, pH 7.0), Resonance Raman spectra have identified the signature of a modified (cysteinyl-tyrosine) phenoxyl in the vibrational spectra of the active complex, This radical-copper motif has previously been found only in galactose oxidase, with which glyoxal oxidase shares many properties despite lacking obvious sequence identity, and catalyzing a distinct reaction, The enzymes thus represent members of a growing class of free radical metalloenzymes based on the radical-copper catalytic motif and appear to represent functional variants that have evolved to distinct catalytic roles.	CARNEGIE MELLON UNIV,DEPT CHEM,PITTSBURGH,PA 15213; USDA,FOREST PROD LAB,MADISON,WI 53705; OREGON GRAD INST SCI & TECHNOL,DEPT CHEM BIOCHEM & MOLEC BIOL,PORTLAND,OR 97291	Carnegie Mellon University; United States Department of Agriculture (USDA); United States Forest Service			Nakamura, Nobuhumi/C-1972-2013	Nakamura, Nobuhumi/0000-0002-5373-2972	NIGMS NIH HHS [GM 46749, GM 18865] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018865, R01GM046749] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGNUS Y, 1979, J AM CHEM SOC, V101, P3381, DOI 10.1021/ja00506a045; BABCOCK GT, 1992, J AM CHEM SOC, V114, P3727, DOI 10.1021/ja00036a023; Barker R., 1971, ORGANIC CHEM BIOL CO; BEREMAN RD, 1977, J AM CHEM SOC, V99, P7322, DOI 10.1021/ja00464a036; BULLOCK JP, 1987, INORG CHEM, V26, P3084, DOI 10.1021/ic00266a004; BUSCHMANN HJ, 1980, BER BUNSEN PHYS CHEM, V84, P41, DOI 10.1002/bbpc.19800840109; COVE DJ, 1966, BIOCHIM BIOPHYS ACTA, V113, P51, DOI 10.1016/S0926-6593(66)80120-0; DOOLEY DM, 1983, J BIOL CHEM, V258, P4245; FAISON BD, 1983, APPL ENVIRON MICROB, V46, P1140, DOI 10.1128/AEM.46.5.1140-1145.1983; FEE JA, 1972, J BIOL CHEM, V247, P60; GLENN JK, 1983, BIOCHEM BIOPH RES CO, V114, P1077, DOI 10.1016/0006-291X(83)90672-1; HAMILTON GA, 1978, J AM CHEM SOC, V100, P1899, DOI 10.1021/ja00474a042; HAMMEL KE, 1994, BIOCHEMISTRY-US, V33, P13349, DOI 10.1021/bi00249a022; HAWKRIDGE FM, 1973, ANAL CHEM, V45, P1021, DOI 10.1021/ac60329a038; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; ITOH S, 1993, CHEM LETT, P2099, DOI 10.1246/cl.1993.2099; JOHNSON JM, 1985, BIOCHEMISTRY-US, V24, P1579, DOI 10.1021/bi00328a001; KELLEHER FM, 1986, J BIOL CHEM, V261, P1045; KERSTEN PJ, 1990, P NATL ACAD SCI USA, V87, P2936, DOI 10.1073/pnas.87.8.2936; KERSTEN PJ, 1987, J BACTERIOL, V169, P2195, DOI 10.1128/jb.169.5.2195-2201.1987; KERSTEN PJ, 1995, P NATL ACAD SCI USA, V177, P6106; KIRK TK, 1987, ANNU REV MICROBIOL, V41, P465, DOI 10.1146/annurev.mi.41.100187.002341; Kolthoff IM, 1936, J PHYS CHEM-US, V40, P247, DOI 10.1021/j150371a011; Kosman D. J., 1984, COPPER PROTEINS COPP, V2, P1; KUREK B, 1995, ENZYME MICROB TECH, V17, P751, DOI 10.1016/0141-0229(95)00003-N; LANDRUM GA, 1995, BIOPHYS J, V69, P674, DOI 10.1016/S0006-3495(95)79943-X; LATIMER WM, 1952, OXIDATION POTENTIALS, P342; LEISOLA M, 1985, J BIOTECHNOL, V2, P379, DOI 10.1016/0168-1656(85)90024-0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGERUM DW, 1975, J AM CHEM SOC, V97, P6894, DOI 10.1021/ja00856a065; MCGLASHEN ML, 1995, J PHYS CHEM-US, V99, P4918, DOI 10.1021/j100014a008; MCPHERSON MJ, 1992, J BIOL CHEM, V267, P8146; MORPURGO L, 1973, BIOCHIM BIOPHYS ACTA, V322, P204, DOI 10.1016/0005-2795(73)90294-8; MUKHERJEE A, 1995, J PHYS CHEM-US, V99, P4912, DOI 10.1021/j100014a007; QUE L, 1989, BIOL APPLICATIONS RA, V3, P492; RENGANATHAN V, 1985, ARCH BIOCHEM BIOPHYS, V241, P304, DOI 10.1016/0003-9861(85)90387-X; TIEN M, 1983, SCIENCE, V221, P661, DOI 10.1126/science.221.4611.661; TIEN M, 1984, P NATL ACAD SCI-BIOL, V81, P2280, DOI 10.1073/pnas.81.8.2280; TRESSEL PS, 1982, METHOD ENZYMOL, V89, P163; WHITTAKER JW, 1994, MET IONS BIOL SYST, V30, P315; WHITTAKER JW, 1991, J AM CHEM SOC, V113, P5528, DOI 10.1021/ja00015a003; WHITTAKER JW, 1995, METHOD ENZYMOL, V258, P262; WHITTAKER MM, 1988, J BIOL CHEM, V263, P6074; WHITTAKER MM, 1993, J AM CHEM SOC, V115, P10029, DOI 10.1021/ja00075a019; WHITTAKER MM, 1993, BIOPHYS J, V64, P762, DOI 10.1016/S0006-3495(93)81437-1; WHITTAKER MM, 1989, J BIOL CHEM, V264, P7104; WHITTAKER MM, 1990, J BIOL CHEM, V265, P9610; WHITTAKER MM, 1995, IN PRESS INORG CHEM; WIBERG KB, 1994, J AM CHEM SOC, V116, P11067, DOI 10.1021/ja00103a024; [No title captured]	50	180	181	4	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					681	687		10.1074/jbc.271.2.681	http://dx.doi.org/10.1074/jbc.271.2.681			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557673	hybrid			2022-12-25	WOS:A1996TP88900016
J	Wiese, N; Tsygankov, AY; Klauenberg, U; Bolen, JB; Fleischer, B; Broker, BM				Wiese, N; Tsygankov, AY; Klauenberg, U; Bolen, JB; Fleischer, B; Broker, BM			Selective activation of T cell kinase p56(lck) by Herpesvirus saimiri protein tip	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LYMPHOCYTES-T; VIRUS TYPE-I; TYROSINE KINASE; SIGNAL-TRANSDUCTION; SRC FAMILY; P56LCK; TRANSFORMATION; CLONES; IMMORTALIZATION; PHENOTYPE	Infection with Herpesvirus saimiri, a T lymphotropic virus of non-human primates, immortalizes human T cells in vitro, The cells show a mature activated phenotype and retain their antigen specificity. We have previously shown that in H. saimiri transformed cells a viral gene product termed tyrosine kinase interacting protein (Tip) associates with the T cell-specific tyrosine kinase p56(lck) and becomes phosphorylated by the enzyme on tyrosine residues. Here we show that p56(lck) is activated by recombinant and native Tip in cell-free systems. A dramatic increase of Lck activity was also observed in T cell lines transfected with Tip. p60(fyn) and p53/56(lyn), the other Src-related kinases expressed in H. saimiri transformed T cells, did not phosphorylate Tip, and they were not activated by the protein. The selective activation of p56(lck) by Tip could contribute to the transformed phenotype of H. saimiri infected cells, and it might explain the T cell selectivity of the transformation event.	BERNHARD NOCHT INST TROP MED,D-20359 HAMBURG,GERMANY; TEMPLE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304	Bernhard Nocht Institut fur Tropenmedizin; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Bröker, Barbara M/O-4850-2015; Tsygankov, Alexander Y/K-6205-2017	Bröker, Barbara M/0000-0002-5020-8542; 				ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ADLER HT, 1992, ONCOGENE, V7, P1191; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BIESINGER B, 1990, VIROLOGY, V176, P505, DOI 10.1016/0042-6822(90)90020-R; BIESINGER B, 1995, J BIOL CHEM, V270, P4729, DOI 10.1074/jbc.270.9.4729; BIESINGER B, 1992, P NATL ACAD SCI USA, V89, P3116, DOI 10.1073/pnas.89.7.3116; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BROKER BM, 1993, J IMMUNOL, V151, P1184; DANIELIAN S, 1991, EUR J IMMUNOL, V21, P1967, DOI 10.1002/eji.1830210828; DECARLI M, 1993, J IMMUNOL, V151, P5022; Dilworth Stephen M., 1995, Trends in Microbiology, V3, P31, DOI 10.1016/S0966-842X(00)88866-6; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; JUNG JU, 1995, J BIOL CHEM, V270, P20660, DOI 10.1074/jbc.270.35.20660; JUNG JU, 1991, P NATL ACAD SCI USA, V88, P7051, DOI 10.1073/pnas.88.16.7051; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; LI ZH, 1992, BIOCHEM BIOPH RES CO, V187, P1536, DOI 10.1016/0006-291X(92)90477-3; LUND T, 1995, J VIROL, V69, P4495, DOI 10.1128/JVI.69.7.4495-4499.1995; MARIECARDINE A, 1992, J IMMUNOL, V148, P3879; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MITTRUCKER HW, 1993, INT IMMUNOL, V5, P985, DOI 10.1093/intimm/5.8.985; MITTRUCKER HW, 1992, J EXP MED, V176, P909, DOI 10.1084/jem.176.3.909; MURPHY C, 1994, ONCOGENE, V9, P221; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505; SPANA C, 1993, PROTEIN EXPRES PURIF, V4, P390, DOI 10.1006/prep.1993.1051; UCHIUMI F, 1992, MOL CELL BIOL, V12, P3784, DOI 10.1128/MCB.12.9.3784; WEBER F, 1993, P NATL ACAD SCI USA, V90, P11049, DOI 10.1073/pnas.90.23.11049; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538	30	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					847	852		10.1074/jbc.271.2.847	http://dx.doi.org/10.1074/jbc.271.2.847			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557695	hybrid			2022-12-25	WOS:A1996TP88900038
J	Hynes, G; Sutton, CW; U, S; Willison, KR				Hynes, G; Sutton, CW; U, S; Willison, KR			Peptide mass fingerprinting of chaperonin-containing TCP-1 (CCT) and copurifying proteins	FASEB JOURNAL			English	Article						peptide mass fingerprinting; CCT theta; adenylylation	T-COMPLEX POLYPEPTIDE-1; MOLECULAR CHAPERONE; THERMOPHILIC ARCHAEBACTERIUM; CYTOPLASMIC CHAPERONIN; GLUTAMINE-SYNTHETASE; TUBULIN; IDENTIFICATION; EXPRESSION; PARTICLE; SUBUNITS	The chaperonin-containing TCP-1 (CCT), found in the eukaryotic cytosol, is currently the focus of extensive research, CCT isolated from mouse testis lysate sediments at 20S in a sucrose gradient and accounts for about 70% of the total protein in this fraction. We intend to identify all the other proteins that copurify with CCT and to compile a reference profile for future studies. Their identification can be accelerated by a combination of protease digestion, matrix-assisted laser desorption-mass spectrometry, and database matching known as peptide mass fingerprinting, We applied this strategy to 32 polypeptides resolved by 2-dimensional gel electrophoresis, and 23 known proteins and 6 novel proteins were identified, We analyzed isoelectric variants of the CCT subunits and differences in the peptide mass spectra of two CCT theta isoforms indicated a novel posttranslational modification of this subunit.	INST CANC RES,CHESTER BEATTY LABS,CRC CTR CELL & MOLEC BIOL,LONDON SW3 6JB,ENGLAND; FINNIGAN MAT LTD,HEMMEL HEMPSTEAD HP2 4TG,HERTS,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK				Sutton, Chris/0000-0002-1548-5093				CORBETT J, 1992, METHOD MOL BIOL, V19, P219; COTTRELL JS, 1994, PEPTIDE RES, V7, P115; CREUTZ CE, 1994, J BIOL CHEM, V269, P32035; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GAO YI, 1993, MOL CELL BIOL, V13, P2478, DOI 10.1128/MCB.13.4.2478; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GOA Y, 1994, J CELL BIOL, V125, P989; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847, DOI 10.1002/j.1460-2075.1993.tb05946.x; HYNES G, 1995, FEBS LETT, V358, P129, DOI 10.1016/0014-5793(94)01408-S; KIM S, 1994, TRENDS BIOCHEM SCI, V19, P543, DOI 10.1016/0968-0004(94)90058-2; KUBOTA H, 1995, EUR J BIOCHEM, V230, P3, DOI 10.1111/j.1432-1033.1995.0003i.x; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; KUBOTA H, 1995, GENE, V154, P231, DOI 10.1016/0378-1119(94)00880-2; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LINGAPPA JR, 1994, J CELL BIOL, V125, P99, DOI 10.1083/jcb.125.1.99; MAREO S, 1994, BIOPHYS J, V67, P364; MARTIN WH, 1990, J NEUROCHEM, V54, P612, DOI 10.1111/j.1471-4159.1990.tb01915.x; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; PATTERSON SD, 1994, ANAL BIOCHEM, V221, P1, DOI 10.1006/abio.1994.1371; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PHIPPS BM, 1993, NATURE, V361, P475, DOI 10.1038/361475a0; RHEE SG, 1984, METHOD ENZYMOL, V107, P183; SHAPIRO BM, 1967, P NATL ACAD SCI USA, V58, P642, DOI 10.1073/pnas.58.2.642; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; STREICHER SL, 1981, P NATL ACAD SCI-BIOL, V78, P229, DOI 10.1073/pnas.78.1.229; SUTTON CW, 1995, ELECTROPHORESIS, V16, P308, DOI 10.1002/elps.1150160151; SUTTON CW, 1994, ANAL BIOCHEM, V218, P34, DOI 10.1006/abio.1994.1138; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; WILLISON KR, 1990, GENET RES, V56, P193, DOI 10.1017/S0016672300035291; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0; ZAKERI ZF, 1988, MOL CELL BIOL, V8, P2925, DOI 10.1128/MCB.8.7.2925; ZHANG WZ, 1994, PROTEIN SCI, V3, P677	37	29	30	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					137	147		10.1096/fasebj.10.1.8566534	http://dx.doi.org/10.1096/fasebj.10.1.8566534			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566534				2022-12-25	WOS:A1996TR32800018
J	Kobayashi, T; Consoli, U; Andreeff, M; Shiku, H; Deisseroth, AB; Zhang, W				Kobayashi, T; Consoli, U; Andreeff, M; Shiku, H; Deisseroth, AB; Zhang, W			Activation of p21(WAF1/Cip1) expression by a temperature-sensitive mutant of human p53 does not lead to apoptosis	ONCOGENE			English	Article						p21; temperature-sensitive p53; K562 cells; apoptosis	WILD-TYPE P53; CELL-LINE; INHIBITION; GROWTH; TRANSFORMATION; SUPPRESSION; KINASES; P21	The cyclin-dependent kinase inhibitor p21(WAF1/Cip1) (p21) inhibits cellular proliferation and has been implicated in p53-dependent apoptosis. In this study, we examined the regulation of p21 in the K562 erythroleukemia cell line using a human temperature-sensitive mutant of p53, 143Ala. We showed that 143Ala at the permissive temperature (32 degrees C) activated the expression of p21. Stable cell lines expressing 143Ala or other p53 mutants were established. We then examined whether elevation of p21 promotes apoptosis and sensitizes cells to radiation-induced apoptosis. Our results showed that p21 elevation did not promote or sensitize K562 cells to apoptosis.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT NEUROONCOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT HEMATOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA; MIE UNIV, SCH MED, DEPT INTERNAL MED 2, TSU, MIE 514, JAPAN	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Mie University			Consoli, Ugo/ADT-6954-2022		NATIONAL CANCER INSTITUTE [R01CA057639, P30CA016672, P01CA055164] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA55164, CA57639, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; GORCZYCA W, 1993, CANCER RES, V53, P1945; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; JUNG JM, 1995, CELL GROWTH DIFFER, V6, P909; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LINDENBOIM L, 1995, CANCER RES, V55, P1242; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; PROSSER J, 1990, ONCOGENE, V5, P1573; RADINSKY R, 1994, ONCOGENE, V9, P1877; RAMQVIST T, 1993, ONCOGENE, V8, P1495; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHANG W, 1995, CANCER RES, V55, P668	43	53	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2311	2316						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570182				2022-12-25	WOS:A1995TK70200015
J	Aarhus, R; Dickey, DM; Graeff, RM; Gee, KR; Walseth, TF; Lee, HC				Aarhus, R; Dickey, DM; Graeff, RM; Gee, KR; Walseth, TF; Lee, HC			Activation and inactivation of Ca2+ release by NAADP(+)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URCHIN	Nicotinic acid adenine dinucleotide phosphate (NAADP(+)) is a recently identified metabolite of NADP(+) that is as potent as inositol trisphosphate (IP3) and cyclic ADP-ribose (cADPR) in mobilizing intracellular Ca2+ in sea urchin eggs and microsomes (Clapper, D. L., Walseth, T. F., Dargie, P. J., and Lee, H. C. (1987) J. Biol. Chem. 262, 9561-9568; Lee, H. C., and Aarhus, R. (1995) J. Biol, Chem, 270, 2152-2157). The mechanism of Ca2+ release activated by NAADP(+) and the Ca2+ stores it acts on are different from those of IP3 and cADPR. In this study we show that photolyzing caged NAADP(+) in intact sea urchin eggs elicits long term Ca2+ oscillations, On the other hand, uncaging threshold amounts of NAADP(+) produces desensitization. In microsomes, this self-inac tivation mechanism exhibits concentration and time dependence, Binding studies show that the NAADP(+) receptor is distinct from that of cADPR, and at subthreshold concentrations, NAADP(+) can fully inactivate subsequent binding to the receptor in a time-dependent manner, Thus, the NAADP(+)-sensitive Ca2+ release process has novel regulatory characteristics, which are distinguishable from Ca2+ release mediated by either IP3 or cADPR. This battery of release mechanisms may provide the necessary versatility for cells to respond to diverse signals that lead to Ca2+ mobilization.	UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,DEPT PHARMACOL,MINNEAPOLIS,MN 55455; MOLEC PROBES INC,EUGENE,OR 97402	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Graeff, Richard Milton/B-3425-2011; Lee, Hon Cheung/C-4329-2009; Walseth, Timothy F/F-9518-2010	Walseth, Timothy F/0000-0003-2558-7859	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032040] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA008131] Funding Source: NIH RePORTER; NICHD NIH HHS [HD32040] Funding Source: Medline; NIDA NIH HHS [DA08131] Funding Source: Medline; NIGMS NIH HHS [T32GM07994] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; AARHUS R, 1995, J BIOL CHEM, V270, P7745, DOI 10.1074/jbc.270.13.7745; ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; EPEL D, 1981, CELL, V23, P543, DOI 10.1016/0092-8674(81)90150-1; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GRAEFF RM, 1995, BIOCHEM BIOPH RES CO, V206, P786, DOI 10.1006/bbrc.1995.1111; HUA SY, 1994, NEURON, V12, P1073, DOI 10.1016/0896-6273(94)90315-8; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1995, J BIOL CHEM, V270, P9060, DOI 10.1074/jbc.270.16.9060; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; LEE HC, 1995, RYANODINE RECEPTORS, P31; PerezTerzic CM, 1995, BIOCHEM J, V312, P955, DOI 10.1042/bj3120955; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y	18	151	152	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8513	8516		10.1074/jbc.271.15.8513	http://dx.doi.org/10.1074/jbc.271.15.8513			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621471	hybrid			2022-12-25	WOS:A1996UE73000002
J	Tang, JX; Janmey, PA				Tang, JX; Janmey, PA			The polyelectrolyte nature of F-actin and the mechanism of actin bundle formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYLINDRICAL POLY-ELECTROLYTE; CROSS-LINKING; CONDENSATION; FILAMENTS; BINDING; PROTEIN; DNA; CALPONIN; PHOSPHORYLATION; PARACRYSTALS	Polymerized (F-)actin is induced to form bundles by a number of polycations including divalent metal ions, Co(NH3)(6)(3+), and basic polypeptides. The general features of bundle formation are largely independent of the specific structure of the bundling agent used. A threshold concentration of polycation is required to form lateral aggregates of actin filaments. The threshold concentration varies strongly with the valence of the cation and increases with the ionic strength of the solution. Polyanions such as nucleoside phosphates or oligomers of acidic amino acids disaggregate actin bundles in-to single filaments. These features are similar to the phenomenon of DNA condensation and can be explained analogously by polyelectrolyte theories. Similar results were found when F-actin was bundled by the peptide corresponding to the actin binding site of myristoylated alanine-rich protein kinase C substrate protein (MARCKS) or by smooth muscle calponin, suggesting that a broad class of actin bundling factors may function in a common manner. Physiologic concentrations of both small ions and large proteins can induce actin interfilament association independent of a requirement for specific binding sites.			Tang, JX (corresponding author), BRIGHAM & WOMENS HOSP,DIV EXPTL MED,LMRC 301,BOSTON,MA 02115, USA.				NHLBI NIH HHS [HL19429] Funding Source: Medline; NIAMS NIH HHS [AR38910] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL019429, R01HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038910, R29AR038910] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBANESI JP, 1987, J BIOL CHEM, V262, P3404; BAEZA I, 1987, BIOCHEMISTRY-US, V26, P6387, DOI 10.1021/bi00394a012; BLOOMFIELD VA, 1991, BIOPOLYMERS, V31, P1471, DOI 10.1002/bip.360311305; CLARKE FM, 1976, BIOCHEM J, V159, P797, DOI 10.1042/bj1590797; COOK RK, 1992, J BIOL CHEM, V267, P9430; CURMI PMG, 1984, J MUSCLE RES CELL M, V5, P423, DOI 10.1007/BF00818260; DELVILLE A, 1982, J CHEM PHYS, V77, P2045, DOI 10.1063/1.444007; DELVILLE A, 1983, BIOPHYS CHEM, V17, P119, DOI 10.1016/0301-4622(83)80005-2; DEWEY TG, 1990, BIOPOLYMERS, V29, P1793, DOI 10.1002/bip.360291410; DRABIKOWSKI W, 1977, ARCH BIOCHEM BIOPHYS, V181, P359, DOI 10.1016/0003-9861(77)90515-X; FOWLER WE, 1982, J CELL BIOL, V93, P452, DOI 10.1083/jcb.93.2.452; GONG BJ, 1993, J BIOCHEM-TOKYO, V114, P453, DOI 10.1093/oxfordjournals.jbchem.a124197; GRANT NJ, 1983, EUR J CELL BIOL, V30, P67; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; ITANO N, 1991, CELL MOTIL CYTOSKEL, V19, P244, DOI 10.1002/cm.970190403; JANMEY PA, 1994, ANN T NORDIC RHEOLOG, P8; JOHARA M, 1993, P NATL ACAD SCI USA, V90, P2127, DOI 10.1073/pnas.90.6.2127; KAWAMURA M, 1970, J BIOCHEM-TOKYO, V68, P885, DOI 10.1093/oxfordjournals.jbchem.a129428; KOLAKOWSKI J, 1995, BIOCHEM J, V306, P199; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; LEBRET M, 1984, BIOPOLYMERS, V23, P287; LEBRET M, 1984, BIOPOLYMERS, V23, P271; LEHRER SS, 1972, ARCH BIOCHEM BIOPHYS, V150, P164, DOI 10.1016/0003-9861(72)90023-9; LIN EC, 1993, BIOPHYS J, V65, P1371, DOI 10.1016/S0006-3495(93)81188-3; LU FWM, 1995, BIOCHEMISTRY-US, V34, P11864, DOI 10.1021/bi00037a026; MA CL, 1994, BIOPHYS J, V67, P1678, DOI 10.1016/S0006-3495(94)80641-1; MAKUCH R, 1991, BIOCHEM J, V280, P33, DOI 10.1042/bj2800033; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MARQUET R, 1991, J BIOMOL STRUCT DYN, V9, P159, DOI 10.1080/07391102.1991.10507900; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; OKAGAKI T, 1987, J BIOCHEM-TOKYO, V101, P189, DOI 10.1093/oxfordjournals.jbchem.a121890; OOSAWA F, 1971, POLYELECTROLYTES, P120; ORIOLAUDIT C, 1985, EUR J BIOCHEM, V151, P557, DOI 10.1111/j.1432-1033.1985.tb09139.x; OTTO JJ, 1994, CURR OPIN CELL BIOL, V6, P105, DOI 10.1016/0955-0674(94)90123-6; OWEN CH, 1992, J STRUCT BIOL, V109, P248, DOI 10.1016/1047-8477(92)90037-B; PEDROTTI B, 1994, BIOCHEMISTRY-US, V33, P12463, DOI 10.1021/bi00207a013; PEDROTTI B, 1994, BIOCHEMISTRY-US, V33, P8798, DOI 10.1021/bi00195a023; RAU DC, 1984, P NATL ACAD SCI-BIOL, V81, P2621, DOI 10.1073/pnas.81.9.2621; RAY J, 1994, LANGMUIR, V10, P2450, DOI 10.1021/la00019a071; SANCHEZSANCHEZ JE, 1992, CHEM PHYS LETT, V190, P202, DOI 10.1016/0009-2614(92)85327-7; SCHMITZ KS, 1993, MACROIONS SOLUTION C, P213; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; SHARP KA, 1995, BIOPOLYMERS, V36, P245, DOI 10.1002/bip.360360211; SHETERLINE P, 1994, PROTEIN PROFILE, V1, P1; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STAFFORD WF, 1995, J BIOL CHEM, V270, P10576, DOI 10.1074/jbc.270.18.10576; STOKES DL, 1991, BIOPHYS J, V59, P456, DOI 10.1016/S0006-3495(91)82239-1; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; TANG JX, 1996, P POL POTSD GERM SEP; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; YAMAUCHI PS, 1993, BIOCHEM BIOPH RES CO, V190, P710, DOI 10.1006/bbrc.1993.1107	51	349	354	0	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8556	8563		10.1074/jbc.271.15.8556	http://dx.doi.org/10.1074/jbc.271.15.8556			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621482	hybrid			2022-12-25	WOS:A1996UE73000013
J	Villalobos, C; Nunez, L; GarciaSancho, J				Villalobos, C; Nunez, L; GarciaSancho, J			Functional glutamate receptors in a subpopulation of anterior pituitary cells	FASEB JOURNAL			English	Article						hypothalamic releasing hormones; thyrotropin-releasing hormone; NMDA	AMINO-ACID RECEPTORS; PROLACTIN SECRETION; GROWTH-HORMONE; RAT; ANTAGONISTS; STIMULATION	We have studied the effects of glutamate receptor agonists on the cytosolic Ca2+ concentration ([Ca2+](i)) of single rat anterior pituitary (AP) cells, Ionotropic (NMDA and kainate/AMPA) and, to a smaller extent, metabotropic glutamate receptors were both present in all the five AP cell types, defined by the hormone they store, Cells within all the types responded also to thyrotropin-releasing hormone (TRH). Alternative typing by the response to four well-established hypothalamic releasing hormones (HRHs), GHRH, GnRH, CRH, and TRH, was performed, One-third of the cells were not sensitive to any HRH, another third were sensitive to only one HRH, and the last third were sensitive to more than one HRH, frequently to all four, Only the cells responding to TRH showed functional glutamate receptors, Superimposed to the above association, the strongest responses to glutamate were found in the cells responsive to multiple HRHs, These results suggest that glutamate may act, by a nonsynaptic mechanism, as a new releasing factor for one or, like TRH, several AIP hormones, Coexpression of glutamate and TRH receptors in the subpopulation of cells responsive to multiple HRHs might have a functional meaning, perhaps related to phenotypic plasticity and long-term regulation of hormone secretion by the anterior pituitary.	CSIC,DEPT BIOQUIM & BIOL MOLEC & FISIOL,FAC MED,E-47005 VALLADOLID,SPAIN; UNIV VALLADOLID,INST BIOL & GENET MOLEC,E-47005 VALLADOLID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid			nunez, lucia/AAG-8018-2019; Villalobos, Carlos/M-9839-2017; Garcia-Sancho, Javier/K-2975-2014	Villalobos, Carlos/0000-0002-0429-3846; Nunez, Lucia/0000-0002-9638-5747; Garcia-Sancho, Javier/0000-0003-4573-7930				BRANN DW, 1995, NEUROENDOCRINOLOGY, V61, P213, DOI 10.1159/000126843; CRONIN MJ, 1980, ENDOCRINOLOGY, V106, P718, DOI 10.1210/endo-106-3-718; DOBSON PRM, 1985, METHOD ENZYMOL, V109, P293; DONOSO AO, 1994, BRAZ J MED BIOL RES, V27, P921; FRAWLEY LS, 1991, ENDOCR REV, V12, P337, DOI 10.1210/edrv-12-4-337; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; GERSHENGORN MC, 1986, ANNU REV PHYSIOL, V48, P515; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HERITIER AG, 1993, ENDOCRINOLOGY, V132, P634, DOI 10.1210/en.132.2.634; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; INAGAKI N, 1995, FASEB J, V9, P686, DOI 10.1096/fasebj.9.8.7768362; KASAHARA K, 1994, BIOCHEM BIOPH RES CO, V199, P1436, DOI 10.1006/bbrc.1994.1391; KATO M, 1992, J PHYSIOL-LONDON, V447, P171, DOI 10.1113/jphysiol.1992.sp018997; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; KIYAMA H, 1993, MOL BRAIN RES, V19, P262, DOI 10.1016/0169-328X(93)90039-R; LAMBERTS SWJ, 1990, PHYSIOL REV, V70, P279, DOI 10.1152/physrev.1990.70.2.279; LAUDER JM, 1993, TRENDS NEUROSCI, V16, P233, DOI 10.1016/0166-2236(93)90162-F; LINDSTROM P, 1992, ENDOCRINOLOGY, V131, P1903, DOI 10.1210/en.131.4.1903; LOGIN IS, 1990, LIFE SCI, V47, P2269, DOI 10.1016/0024-3205(90)90158-N; LOPEZ MG, 1995, J PHYSIOL-LONDON, V482, P15, DOI 10.1113/jphysiol.1995.sp020496; MASON GA, 1983, BRAIN RES, V289, P366, DOI 10.1016/0006-8993(83)90044-6; MEEKER RB, 1994, ENDOCRINOLOGY, V134, P621, DOI 10.1210/en.134.2.621; NIIMI M, 1994, NEUROENDOCRINOLOGY, V60, P173, DOI 10.1159/000126748; NUNEZ L, 1995, IN PRESS AM J PHYSL; OLEARY R, 1995, J NEUROCHEM, V65, P953; PALMER E, 1989, EUR J PHARMACOL, V166, P585, DOI 10.1016/0014-2999(89)90383-X; PREVARSKAYA N, 1994, MOL CELL NEUROSCI, V5, P699, DOI 10.1006/mcne.1994.1084; SCHALLY AV, 1978, ANNU REV BIOCHEM, V47, P89, DOI 10.1146/annurev.bi.47.070178.000513; SCHOEPP D, 1990, TRENDS PHARMACOL SCI, V11, P508, DOI 10.1016/0165-6147(90)90052-A; TERRY LC, 1981, BRAIN RES, V217, P129; VANDENPOL AN, 1990, SCIENCE, V250, P1276, DOI 10.1126/science.1978759; VILLALOBOS C, 1995, FASEB J, V9, P815, DOI 10.1096/fasebj.9.9.7601345; WATKINS JC, 1987, TRENDS NEUROSCI, V10, P265, DOI 10.1016/0166-2236(87)90171-8; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; ZANISI M, 1994, P SOC EXP BIOL MED, V206, P431	35	64	65	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1996	10	5					654	660		10.1096/fasebj.10.5.8621065	http://dx.doi.org/10.1096/fasebj.10.5.8621065			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ055	8621065				2022-12-25	WOS:A1996UJ05500014
J	Englander, EW; Howard, BH				Englander, EW; Howard, BH			A naturally occurring T(14)A(11) tract blocks nucleosome formation over the human neurofibromatosis type 1 (NF1)-Alu element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-III; ALU REPEATED SEQUENCES; TRANSCRIPTION COMPLEXES; FAMILY MEMBERS; DNA; CHROMATIN; GENES; HISTONES; POLY(DA).POLY(DT); ORGANIZATION	The nature of chromatin organization over Alu repetitive elements is of interest with respect to the maintenance of their transcriptional silencing as well as their potential to influence local chromatin structure. We previously demonstrated that the pattern of nucleosomal organization over Alu elements in native chromatin is specific and similar to the pattern observed with an in vitro reconstituted Alu template. This pattern, distinguished by a nucleosome centered over the 5'-end of the Alu element, is associated with repression of polymerase m-dependent transcription in vitro (Englander, E. W., Wolffe, A. P., and Howard, B. H. (1993) J. Biol. Chem. 268, 19565-19573; Englander, E. W., and Howard, B. H. (1995) J. Biol. Chem. 270, 10091-10096). In the current study, additional templates representing both evolutionarily old and young Alu subfamilies were found to direct a similar pattern of nucleosome assembly, consistent with the view that nucleosome positioning in vitro is shared by a majority of Alus. We discovered however, that the specific nucleosome positioning pattern was disrupted over one member of a young Alu subfamily, which recently transposed immediately downstream to a T(14)A(11) sequence in the neurofibromatosis type 1 locus (Wallace, M. R., Andersen, L. B., Saulino, A. M., Gregory, P. E., Glover, T. W., and Collins, F. S. (1991) Nature 353, 864-866). Upon removal of this sequence motif, the expected pattern of assembly was restored to the neurofibromatosis type 1-Alu template. This finding indicates that, at least in vitro, certain sequences can override the propensity for positioning nucleosomes that is inherent to Alu elements. The finding also raises the possibility that a similar situation may occur in vivo, with potential implications for understanding mechanisms by which certain Alu elements may evade chromatin-mediated transcriptional silencing.			Englander, EW (corresponding author), NICHHD,NIH,LAB MOLEC GROWTH REGULAT,BETHESDA,MD 20892, USA.							ARCOT SS, 1995, GENE, V163, P273, DOI 10.1016/0378-1119(95)00317-Y; BATZER MA, 1990, NUCLEIC ACIDS RES, V18, P6793, DOI 10.1093/nar/18.23.6793; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; CAREY MF, 1988, P NATL ACAD SCI USA, V85, P7059, DOI 10.1073/pnas.85.19.7059; CHIPEV CC, 1992, MOL CELL BIOL, V12, P45, DOI 10.1128/MCB.12.1.45; CHU WM, 1995, NUCLEIC ACIDS RES, V23, P1750, DOI 10.1093/nar/23.10.1750; DANIELS GR, 1985, NATURE, V317, P819, DOI 10.1038/317819a0; DEININGER P, 1989, MOBILE DNA, V10, P619; DEININGER PL, 1988, MOL CELL BIOL, V8, P4566, DOI 10.1128/MCB.8.10.4566; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; ELDER JT, 1981, NUCLEIC ACIDS RES, V9, P1171, DOI 10.1093/nar/9.5.1171; ENGLANDER EW, 1993, J BIOL CHEM, V268, P19565; ENGLANDER EW, 1995, J BIOL CHEM, V270, P10091, DOI 10.1074/jbc.270.17.10091; FUHRMAN SA, 1981, NUCLEIC ACIDS RES, V9, P6439, DOI 10.1093/nar/9.23.6439; GIBBS PEM, 1987, BIOCHEMISTRY-US, V26, P1332, DOI 10.1021/bi00379a020; GOODSELL DS, 1993, P NATL ACAD SCI USA, V90, P2930, DOI 10.1073/pnas.90.7.2930; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; JANG KL, 1992, BIOCHEM J, V284, P667, DOI 10.1042/bj2840667; JANG KL, 1992, J ACQ IMMUN DEF SYND, V5, P1142; JURKA J, 1988, P NATL ACAD SCI USA, V85, P4775, DOI 10.1073/pnas.85.13.4775; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KUNKEL GR, 1981, NUCLEIC ACIDS RES, V9, P6869, DOI 10.1093/nar/9.24.6869; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LIU WM, 1994, NUCLEIC ACIDS RES, V22, P1087, DOI 10.1093/nar/22.6.1087; LIU WM, 1995, NUCLEIC ACIDS RES, V23, P1758, DOI 10.1093/nar/23.10.1758; LOSA R, 1987, CELL, V50, P601; MARAIA RJ, 1992, MOL CELL BIOL, V12, P1500, DOI 10.1128/MCB.12.4.1500; MATERA AG, 1990, MOL CELL BIOL, V10, P5424, DOI 10.1128/MCB.10.10.5424; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; PAN J, 1981, NUCLEIC ACIDS RES, V9, P1151; PANNING B, 1995, J MOL BIOL, V248, P513, DOI 10.1006/jmbi.1995.0239; PANNING B, 1993, MOL CELL BIOL, V13, P3231, DOI 10.1128/MCB.13.6.3231; PANNING B, 1994, VIROLOGY, V202, P408, DOI 10.1006/viro.1994.1357; PRUNELL A, 1982, EMBO J, V1, P173, DOI 10.1002/j.1460-2075.1982.tb01143.x; PUHL HL, 1991, J MOL BIOL, V222, P1149, DOI 10.1016/0022-2836(91)90598-Z; RHODES D, 1979, NUCLEIC ACIDS RES, V6, P1805, DOI 10.1093/nar/6.5.1805; RUSSANOVA VR, 1995, MOL CELL BIOL, V15, P4282; SAKAMOTO K, 1991, J BIOL CHEM, V266, P3031; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SCHLISSEL MS, 1984, CELL, V37, P903, DOI 10.1016/0092-8674(84)90425-2; Schmid C, 1992, CURR OPIN GENET DEV, V2, P874, DOI 10.1016/S0959-437X(05)80110-8; SCHMID CW, 1985, MOL EVOLUTIONARY GEN, V10, P323; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1979, NUCLEIC ACIDS RES, V6, P1387, DOI 10.1093/nar/6.4.1387; SINNETT D, 1992, J MOL BIOL, V226, P689, DOI 10.1016/0022-2836(92)90626-U; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; ULLU E, 1985, NATURE, V318, P371, DOI 10.1038/318371a0; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817; [No title captured]	53	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5819	5823		10.1074/jbc.271.10.5819	http://dx.doi.org/10.1074/jbc.271.10.5819			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621451	hybrid			2022-12-25	WOS:A1996TZ28600077
J	Allen, PG; Laham, LE; Way, M; Janmey, PA				Allen, PG; Laham, LE; Way, M; Janmey, PA			Binding of phosphate, aluminum fluoride, or beryllium fluoride to F-actin inhibits severing by gelsolin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA GELSOLIN; ATP HYDROLYSIS; ADP-ACTIN; INORGANIC-PHOSPHATE; POLYMERIZATION; FILAMENTS; NUCLEOTIDE; MODULATION; MICROTUBULES; MECHANISM	Actin exhibits ATPase activity of unknown function that increases when monomers polymerize into filaments. Differences in the kinetics of ATP hydrolysis and the release of the hydrolysis products ADP and inorganic phosphate suggest that phosphate-rich domains exist in newly polymerized filaments. We examined whether the enrichment of phosphate on filamentous ADP-actin might modulate the severing activity of gel-solin, a protein previously shown to bind differently to ATP and ADP actin monomers. Binding of phosphate, or the phosphate analogs aluminum fluoride and beryllium fluoride, to actin filaments reduces their susceptibility to severing by gelsolin. The concentration and pH dependence of inhibition suggest that HPO42- binding to actin filaments generates this resistant state. We also provide evidence for two different binding sites for beryllium fluoride on actin. Actin has been postulated to contain two P-i binding sites. Our data suggest that they are sequentially occupied following ATP hydrolysis by HPO42- which is subsequently titrated to H2PO4-. We speculate that beryllium fluoride and aluminum fluoride bind to the HPO42- binding site. The cellular consequences of this model of phosphate release are discussed.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; CHILDRENS HOSP,DANA FARBER CANC INST,BOSTON,MA 02115; EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; European Molecular Biology Laboratory (EMBL)	Allen, PG (corresponding author), BRIGHAM & WOMENS HOSP,DIV EXPT MED,LMRC 301,221 LONGWOOD AVE,BOSTON,MA 02115, USA.			Way, Michael/0000-0001-7207-2722	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038910, R29AR038910] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 07680] Funding Source: Medline; NIAMS NIH HHS [AR 38910] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLEN PG, 1994, J BIOL CHEM, V269, P32916; Carlier M F, 1990, Adv Biophys, V26, P51, DOI 10.1016/0065-227X(90)90007-G; CARLIER MF, 1986, J BIOL CHEM, V261, P785; CARLIER MF, 1987, BIOCHEM BIOPH RES CO, V143, P1069, DOI 10.1016/0006-291X(87)90361-5; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; CARLIER MF, 1985, J BIOL CHEM, V260, P6565; CARLIER MF, 1992, PHILOS T R SOC B, V336, P93, DOI 10.1098/rstb.1992.0048; CARLIER MF, 1988, J BIOL CHEM, V263, P817; COMBEAU C, 1988, J BIOL CHEM, V263, P17429; COMBEAU C, 1989, J BIOL CHEM, V264, P19017; COOKE R, 1975, BIOCHEMISTRY-US, V14, P3250, DOI 10.1021/bi00685a035; DANCKER P, 1989, Z NATURFORSCH C, V44, P698; DUFORT PA, 1993, BIOPHYS J, V65, P1757, DOI 10.1016/S0006-3495(93)81271-2; HUANG ZJ, 1992, ANAL BIOCHEM, V200, P199, DOI 10.1016/0003-2697(92)90299-M; IKEUCHI Y, 1992, J BIOCHEM, V111, P606, DOI 10.1093/oxfordjournals.jbchem.a123805; JANMEY PA, 1990, NATURE, V347, P95, DOI 10.1038/347095a0; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; KORN ED, 1987, SCIENCE, V238, P638, DOI 10.1126/science.3672117; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; LAHAM LE, 1993, J BIOL CHEM, V268, P14202; LAMB JA, 1993, J BIOL CHEM, V268, P8999; LEPAULT J, 1994, J STRUCT BIOL, V112, P79, DOI 10.1006/jsbi.1994.1009; MACIVER SK, 1994, FEBS LETT, V347, P251, DOI 10.1016/0014-5793(94)00552-4; MACIVER SK, 1991, J CELL BIOL, V115, P1611, DOI 10.1083/jcb.115.6.1611; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MUHLRAD A, 1994, J BIOL CHEM, V269, P11852; NIKOLAEVA OP, 1994, FEBS LETT, V351, P15, DOI 10.1016/0014-5793(94)00801-9; NONOMURA Y, 1975, J BIOCHEM, V78, P1101, DOI 10.1093/oxfordjournals.jbchem.a130988; ORLOVA A, 1992, J MOL BIOL, V227, P1043, DOI 10.1016/0022-2836(92)90520-T; PANTALONI D, 1984, J BIOL CHEM, V259, P6274; PERELROIZEN I, 1995, J BIOL CHEM, V270, P1501, DOI 10.1074/jbc.270.4.1501; POLLARD TD, 1992, J BIOL CHEM, V267, P20339; RICKARD JE, 1986, J MOL BIOL, V191, P273, DOI 10.1016/0022-2836(86)90264-0; SMALL JV, 1995, J CELL BIOL, V129, P1275, DOI 10.1083/jcb.129.5.1275; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STRAUB FB, 1950, BIOCHIM BIOPHYS ACTA, V4, P455, DOI 10.1016/0006-3002(50)90052-7; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; VERHOEVEN AJM, 1988, ANAL BIOCHEM, V174, P672, DOI 10.1016/0003-2697(88)90072-3; WANGER M, 1987, BIOCHIM BIOPHYS ACTA, V914, P105, DOI 10.1016/0167-4838(87)90052-5; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WENDEL H, 1986, BIOCHIM BIOPHYS ACTA, V873, P387, DOI 10.1016/0167-4838(86)90088-9; YAMAMOTO H, 1990, J BIOCHEM-TOKYO, V108, P505, DOI 10.1093/oxfordjournals.jbchem.a123229	42	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4665	4670						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617730				2022-12-25	WOS:A1996TX69700020
J	Hopf, C; Hoch, W				Hopf, C; Hoch, W			Agrin binding to alpha-dystroglycan - Domains of agrin necessary to induce acetylcholine receptor clustering are overlapping but not identical to the alpha-dystroglycan-binding region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-RELATED PROTEIN; SKELETAL-MUSCLE; NEUROMUSCULAR-JUNCTIONS; GLYCOPROTEIN COMPLEX; MEMBRANE-PROTEINS; LOCALIZATION; PURIFICATION; AGGREGATION; SARCOLEMMA; LAMININ	The synaptic basal membrane protein agrin initiates the aggregation of acetylcholine receptors at the postsynaptic membrane of the developing neuromuscular junction. Recently, alpha-dystroglycan was found to be a major agrin-binding protein on the muscle cell surface and was therefore considered a candidate agrin receptor, Employing different truncation fragments of agrin, we determined regions of the protein involved in binding to alpha-dystroglycan and to heparin, an inhibitor of alpha-dystroglycan binding. Deletion of a 15-kDa fragment from the C terminus of agrin had no effect on its binding tb alpha-dystroglycan from rabbit muscle membranes, even though this deletion completely abolishes its acetylcholine receptor aggregating activity. Conversely, deletion of a central region does not affect agrin's clustering activity, but reduced its affinity for alpha-dystroglycan. Combination of these two deletions resulted in a fragment of similar to 35 kDa that weakly bound to alpha-dystroglycan, but displayed no clustering activity. All of these fragments bound to heparin with high affinity. Thus, alpha-dystroglycan does not show the binding specificity expected for an agrin receptor. Our data suggest the existence of an additional component on the muscle cell surface that generates the observed ligand specificity.	MAX PLANCK INST ENTWICKLUNGSBIOL,BIOCHEM ABT,D-72076 TUBINGEN,GERMANY	Max Planck Society			Hopf, Carsten/A-3275-2015	Hopf, Carsten/0000-0003-0802-6451				ADAMS ME, 1993, NEURON, V11, P531, DOI 10.1016/0896-6273(93)90157-M; BECKER CM, 1989, J NEUROCHEM, V53, P124, DOI 10.1111/j.1471-4159.1989.tb07303.x; BOW MA, 1995, ANN REV NEUROSCI, V18, P443; BOWE MA, 1994, NEURON, V12, P1173, DOI 10.1016/0896-6273(94)90324-7; CAMPANELLI JT, 1991, CELL, V67, P909, DOI 10.1016/0092-8674(91)90364-5; CAMPANELLI JT, 1994, CELL, V77, P663, DOI 10.1016/0092-8674(94)90051-5; COHEN MW, 1995, J CELL BIOL, V129, P1093, DOI 10.1083/jcb.129.4.1093; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FALLON JR, 1994, TRENDS NEUROSCI, V17, P469, DOI 10.1016/0166-2236(94)90135-X; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FERNS MJ, 1993, NEURON, V11, P491, DOI 10.1016/0896-6273(93)90153-I; FROEHNER SC, 1991, J CELL BIOL, V114, P1, DOI 10.1083/jcb.114.1.1; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GEE SH, 1993, J BIOL CHEM, V268, P14972; GESEMANN M, 1995, J CELL BIOL, V128, P625, DOI 10.1083/jcb.128.4.625; HALL RF, 1993, IEEE SOFTWARE, V10, P9; HOCH W, 1994, EMBO J, V13, P2814, DOI 10.1002/j.1460-2075.1994.tb06575.x; HOCH W, 1994, J CELL BIOL, V126, P1, DOI 10.1083/jcb.126.1.1; HOCH W, 1993, NEURON, V11, P479, DOI 10.1016/0896-6273(93)90152-H; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MA JY, 1993, J BIOL CHEM, V268, P25108; MAN NT, 1991, J CELL BIOL, V115, P1695; MARTIN PT, 1995, NEURON, V14, P743, DOI 10.1016/0896-6273(95)90218-X; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; NASTUK MA, 1991, NEURON, V7, P807, DOI 10.1016/0896-6273(91)90283-6; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; OCONNOR LT, 1994, J NEUROSCI, V14, P1141, DOI 10.1523/JNEUROSCI.14-03-01141.1994; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; PHILLIPS WD, 1993, J CELL BIOL, V123, P729, DOI 10.1083/jcb.123.3.729; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; RUEGG MA, 1992, NEURON, V8, P691, DOI 10.1016/0896-6273(92)90090-Z; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SEALOCK R, 1991, J CELL BIOL, V113, P1133, DOI 10.1083/jcb.113.5.1133; SMITH MA, 1994, NEURON, V12, P795, DOI 10.1016/0896-6273(94)90332-8; STEINBACH JH, 1981, DEV BIOL, V84, P267, DOI 10.1016/0012-1606(81)90394-8; SUGIYAMA J, 1994, NEURON, V13, P103, DOI 10.1016/0896-6273(94)90462-6; TSIM KWK, 1992, NEURON, V8, P677, DOI 10.1016/0896-6273(92)90089-V; WALLACE BG, 1992, J NEUROBIOL, V23, P592, DOI 10.1002/neu.480230512	44	80	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5231	5236						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617807				2022-12-25	WOS:A1996TX69700097
J	Schimmer, BP; Tsao, J; Czerwinski, W				Schimmer, BP; Tsao, J; Czerwinski, W			Amplification of the transketolase gene in desensitization-resistant mutant Y1 mouse adrenocortical tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE ACTIVITY; STREPTOCOCCUS-PNEUMONIAE; 68,000-DALTON PROTEIN; NUCLEOTIDE-SEQUENCE; WERNICKE-KORSAKOFF; TRANSFORMATION; PURIFICATION; ASSOCIATION; ABNORMALITY; KINASE	As shown previously, mutants of the Y1 mouse adrenocortical tumor cell line that resist agonist-induced desensitization of adenylyl cyclase have elevated levels of a 68-kDa protein (designated p68), suggesting a possible relationship between p68 and the regulation of adenylyl cyclase activity. In the present study, cDNA cloning and sequencing were used to identify p68 as mouse transketolase. Cells overexpressing p68 exhibited a 17.4-fold increase in transketolase enzymatic activity relative to parental Y1 cells and a 28-fold amplification of the transketolase gene as determined by Southern blot hybridization analysis, Using fluorescent in situ hybridization analysis, the transketolase gene was mapped to mouse chromosome 16B1 and to human chromosome 3p21.2, Transketolase gene amplification was associated with telomeric fusion of the chromosome 16 pair together with the appearance of multiple copies of the transketolase gene throughout a different chromosome, The relationship between overexpression of transketolase and desensitization resistance was evaluated in somatic cell hybrids formed between a desensitization-resistant adrenal cell line and a desensitization-sensitive rat glial cell line. In these hybrids, transketolase overexpression behaved dominantly, whereas desensitization resistance behaved recessively, These results dissociate the desensitization resistance phenotype from overexpression of transketolase and suggest that desensitization resistance may have resulted from disruption of an essential regulatory gene in conjunction with the amplification event.			Schimmer, BP (corresponding author), UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA.							BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; BLASS JP, 1977, NEW ENGL J MED, V297, P1367, DOI 10.1056/NEJM197712222972503; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAQUILA RT, 1991, NUCLEIC ACIDS RES, V19, P3749, DOI 10.1093/nar/19.13.3749; FENG GS, 1994, ONCOGENE, V9, P1545; FRANKLIN TJ, 1976, FEBS LETT, V66, P225, DOI 10.1016/0014-5793(76)80509-1; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1994, HUM MOL GENET, V3, P61, DOI 10.1093/hmg/3.1.61; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; LAPSYS NM, 1992, CYTOGENET CELL GENET, V61, P274, DOI 10.1159/000133421; Lehninger A.L, 1975, BIOCHEMISTRY-US; Maniatis T., 1982, MOL CLONING; MARTIN PR, 1995, METAB BRAIN DIS, V19, P45; MCCOOL BA, 1993, J BIOL CHEM, V268, P1397; OBRIEN SJ, 1993, NAT GENET, V3, P103, DOI 10.1038/ng0293-103; OLSON MF, 1994, ENDOCRINOLOGY, V134, P7, DOI 10.1210/en.134.1.7; OLSON MF, 1991, ENDOCR RES, V17, P19, DOI 10.1080/07435809109027187; OLSON MF, 1991, MOL ENDOCRINOL, V5, P34, DOI 10.1210/mend-5-1-34; OLSON MF, 1992, MOL ENDOCRINOL, V6, P1095, DOI 10.1210/me.6.7.1095; OLSON MF, 1993, MOL ENDOCRINOL, V7, P477, DOI 10.1210/me.7.4.477; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RADNIS BA, 1990, J BACTERIOL, V172, P3669, DOI 10.1128/jb.172.7.3669-3674.1990; RAE PA, 1979, P NATL ACAD SCI USA, V76, P1896, DOI 10.1073/pnas.76.4.1896; REEVES RH, 1993, MAMM GENOME, V4, pS223, DOI 10.1007/BF00360842; REIZER J, 1993, RES MICROBIOL, V144, P341, DOI 10.1016/0923-2508(93)90191-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYER JR, 1986, SCIENCE, V232, P1632; SCHIMKE RT, 1992, MUTAT RES, V276, P145, DOI 10.1016/0165-1110(92)90004-S; Schimmer B P, 1979, Methods Enzymol, V58, P570; SCHIMMER BP, 1995, J CELL PHYSIOL, V163, P164, DOI 10.1002/jcp.1041630119; SCHIMMER BP, 1990, MOL ENDOCRINOL, V4, P1698, DOI 10.1210/mend-4-11-1698; SCHIMMER BP, 1984, J CELL PHYSIOL, V121, P483, DOI 10.1002/jcp.1041210306; SCHIMMER BP, 1984, CAN J BIOCHEM CELL B, V62, P601, DOI 10.1139/o84-080; SCHIMMER BP, 1979, HORMONES CELL CULTUR, V6, P281; SHEU KFR, 1988, ARCH NEUROL-CHICAGO, V45, P841, DOI 10.1001/archneur.1988.00520320027010; SNYDER M, 1987, METHOD ENZYMOL, V154, P107; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; WATT VM, 1981, J BIOL CHEM, V256, P1365; WATT VM, 1982, J BIOL CHEM, V257, P1684; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X	42	9	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4993	4998						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617775				2022-12-25	WOS:A1996TX69700065
J	vandePut, FHMM; Elliott, AC				vandePut, FHMM; Elliott, AC			Imaging of intracellular calcium stores in individual permeabilized pancreatic acinar cells - Apparent homogeneous cellular distribution of inositol 1,4,5-trisphosphate-sensitive stores in permeabilized pancreatic acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE; EXOCRINE PANCREAS; FLUORESCENT INDICATOR; OSCILLATIONS; AGONIST; CA-2+; TRISPHOSPHATE; INHIBITION; GRADIENTS; SECRETION	Several lines of evidence suggest that the existence of a heterogeneous population of inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3)-sensitive Ca2+ stores underlies the polarized agonist-induced rise in cytosolic Ca2+ concentration ([Ca2+](i)) in pancreatic acinar cells (Kasai, H., Li, Y. X., and Miyashita, Y. (1993) Cell 74, 669-677; Thorn, P., Lawrie, A. M., Smith, P. M., Gallacher, D. V., and Petersen, O. H. (1993) Cell 74, 661-668). To investigate whether the apical pole of acinar cells contains Ca2+ stores which are relatively more sensitive to Ins(1,4,5)P-3 than those in basolateral areas, we studied Ca2+ handling by Ca2+ stores in individual streptolysin O (SLO) permeabilized cells using the low affinity Ca2+ indicator Magfura-2 and an in situ imaging technique. The uptake of Ca2+ by intracellular Ca2+ stores was ATP-dependent. A steady-state level was reached within 10 min, and the free Ca2+ concentration inside loaded Ca2+ stores was estimated to be 70 mu M. Ins(1,4,5)P-3 induced Ca2+ release in a dose-dependent, ''quantal'' fashion. The kinetics of this release were similar to those reported for suspensions of permeabilized pancreatic acinar cells. Interestingly, the permeabilized acinar cells showed no intercellular variation in Ins(1,4,5)P-3 sensitivity. Although SLO treatment is known to result in a considerable loss of cytosolic factors, permeabilization did not result in a redistribution of zymogen granules, as judged by electron microscope analysis. These results suggest that Ins(1,4,5)P-3-sensitive Ca2+ stores are unlikely to be redistributed as a result of SLO treatment. The effects of Ins(1,4,5)P-3 were therefore subsequently studied at the subcellular level. Detailed analysis demonstrated that no regional differences in Ins(1,4,5)P-3 sensitivity exist in this permeabilized cell system. Therefore, we propose that additional cytosolic factors and/or the involvement of ryanodine receptors underlie the polarized pattern of agonist-induced Ca2+ signaling in intact pancreatic acinar cells.			vandePut, FHMM (corresponding author), UNIV MANCHESTER,SCH BIOL SCI,G 38 STOPFORD BLDG,OXFORD BLDG,MANCHESTER M13 9PT,LANCS,ENGLAND.			Elliott, Austin/0000-0003-3569-9002	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1995, J MEMBRANE BIOL, V145, P205; BOOTMAN MD, 1994, MOL CELL ENDOCRINOL, V98, P157, DOI 10.1016/0303-7207(94)90134-1; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; EAGLE H, 1959, SCIENCE, V130, P432, DOI 10.1126/science.130.3373.432; ELLIOTT AC, 1992, PFLUG ARCH EUR J PHY, V422, P245, DOI 10.1007/BF00376209; FUJINO I, 1995, CELL TISSUE RES, V280, P201, DOI 10.1007/s004410050345; GLENNON MC, 1992, J BIOL CHEM, V267, P25568; GROMADA J, 1993, CELL CALCIUM, V14, P711, DOI 10.1016/0143-4160(93)90097-P; GROMADA J, 1995, FEBS LETT, V360, P303, DOI 10.1016/0014-5793(95)00131-R; HOFER AM, 1994, AM J PHYSIOL, V267, pG442, DOI 10.1152/ajpgi.1994.267.3.G442; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KENDALL JM, 1992, BIOCHEM BIOPH RES CO, V189, P1008, DOI 10.1016/0006-291X(92)92304-G; KENDALL JM, 1994, ANAL BIOCHEM, V221, P173, DOI 10.1006/abio.1994.1394; LAWRIE AM, 1993, CELL CALCIUM, V14, P698, DOI 10.1016/0143-4160(93)90096-O; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; RAJU B, 1989, AM J PHYSIOL, V256, pC540, DOI 10.1152/ajpcell.1989.256.3.C540; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; ROBERTS RA, 1965, ELECTROLYUTE SOLUTIO; SASAKI T, 1994, AM J PHYSIOL, V267, pL152, DOI 10.1152/ajplung.1994.267.2.L152; SCHOENMAKERS TJM, 1992, BIOTECHNIQUES, V12, P870; SCHULZ I, 1990, METHOD ENZYMOL, V192, P280; SERVANT M, 1994, PANCREAS, V9, P591, DOI 10.1097/00006676-199409000-00009; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SMITH GL, 1985, BIOCHIM BIOPHYS ACTA, V839, P287, DOI 10.1016/0304-4165(85)90011-X; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; TAN YP, 1992, P NATL ACAD SCI USA, V89, P11229, DOI 10.1073/pnas.89.23.11229; TAYLOR CW, 1995, J MEMBRANE BIOL, V145, P109; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; VANDEPUT FHMM, 1993, J MEMBRANE BIOL, V135, P153, DOI 10.1007/BF00231441; VANDEPUT FHMM, 1994, J BIOL CHEM, V269, P12438; WILLEMS PHGM, 1989, J BIOL CHEM, V264, P9762; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHANG BX, 1993, J BIOL CHEM, V268, P10997	43	32	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4999	5006						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617776				2022-12-25	WOS:A1996TX69700066
J	Wei, LN; Chang, LM				Wei, LN; Chang, LM			Promoter and upstream regulatory activities of the mouse cellular retinoic acid-binding protein-I gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC MICE; MOLECULAR-CLONING; LACZ EXPRESSION; NERVOUS-SYSTEM; SEQUENCE; REGION	The promoter and its upstream regulatory region of the mouse cellular retinoic acid-binding protein I (crabp-I) gene were examined in transgenic mouse embryos, a mouse embryonal carcinoma cell line P19, and a mouse embryonic fibroblast cell line 3T6. In transgenic mouse embryos, a beta-galactosidase reporter gene under the control of crabp-I promoter and its upstream regulatory region displayed a very specific pattern of expression characteristic of crabp-I gene expression during developmental stages. In tissue culture systems, the minimal promoter of this gene was identified, and regions containing positive and negative regulatory activities were dissected from the upstream 3-kilobase sequence using assays for transient reporter activity. It is concluded that the minimal promoter of the mouse crabp-I gene is located between 120 and 150 base pairs upstream from the transcription initiation site. Several cell type-specific positive and negative regulatory regions for this promoter have been identified. A region encoding a common negative regulatory activity in both P19 and 3T6 cells is also inhibitory to two heterologous promoters, and specific protein-DNA interactions between this DNA fragment and nuclear extracts of P19 and 3T6 are demonstrated by gel retardation experiments.			Wei, LN (corresponding author), UNIV MINNESOTA,SCH MED,DEPT PHARMACOL,3-249 MILLARD HALL,435 DELAWARE ST SE,MINNEAPOLIS,MN 55455, USA.				NIDDK NIH HHS [DK46866-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046866] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASS NM, 1993, MOL CELL BIOCHEM, V123, P191, DOI 10.1007/BF01076492; BOYLAN JF, 1991, J CELL BIOL, V112, P1965; DEBRUIJN DRH, 1994, DIFFERENTIATION, V58, P141; FIORELLA PD, 1994, J BIOL CHEM, V269, P10538; GORRY P, 1994, P NATL ACAD SCI USA, V91, P9032, DOI 10.1073/pnas.91.19.9032; HOGAN B, 1986, MANIPULATING MOUSE E; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; KATO M, 1985, J BIOL CHEM, V260, P4832; KRESS C, 1990, DEVELOPMENT, V109, P775; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LYN S, 1994, DEV DYNAM, V199, P280, DOI 10.1002/aja.1001990404; MANGELSDORF DJ, 1993, RETINOIDS, V2, P319; NUGENT P, 1995, IN VITRO CELL DEV-AN, V31, P553; ONG DE, 1993, RETINOIDS, P283; PEREZCASTRO AV, 1989, P NATL ACAD SCI USA, V86, P8813, DOI 10.1073/pnas.86.22.8813; RUBERTE E, 1993, DEVELOPMENT, V118, P267; SHUBEITA HE, 1987, P NATL ACAD SCI USA, V84, P5645, DOI 10.1073/pnas.84.16.5645; STANDKE GJR, 1994, MOL ENDOCRINOL, V8, P469, DOI 10.1210/me.8.4.469; SU Y, 1994, J BIOL CHEM, V269, P16512; SUCOV HM, 1995, MOL NEUROBIOL, V10, P169, DOI 10.1007/BF02740674; VAESSEN MJ, 1989, DIFFERENTIATION, V40, P99, DOI 10.1111/j.1432-0436.1989.tb00819.x; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441; WEI LN, 1989, MOL ENDOCRINOL, V3, P454, DOI 10.1210/mend-3-3-454; WEI LN, 1992, DEV GROWTH DIFFER, V34, P479; WEI LN, 1994, DEV DYNAM, V201, P1, DOI 10.1002/aja.1002010102; WEI LN, 1990, DNA CELL BIOL, V9, P471, DOI 10.1089/dna.1990.9.471; WEI LN, 1991, DEVELOPMENT, V112, P847; WEI LN, 1995, MOL CELL ENDOCRINOL, V111, P207, DOI 10.1016/0303-7207(95)03570-W; WEI LN, 1987, MOL ENDOCRINOL, V2, P526; ZAKANY J, 1988, NEURON, V1, P679, DOI 10.1016/0896-6273(88)90167-5	30	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5073	5078						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617785				2022-12-25	WOS:A1996TX69700075
J	Keiler, KC; Sauer, RT				Keiler, KC; Sauer, RT			Sequence determinants of C-terminal substrate recognition by the Tsp protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; PROTEOLYSIS; CYTOCHROME-B562; DEGRADATION	Cytochrome b(562) is not cleaved by the tail-specific protease Tsp in vitro or in the periplasm of Escherichia coli but becomes a good substrate when the C-terminal sequence WVAAA is added, Following randomization of the final three residue positions of this substrate, 54 different mutants with single residue substitutions were recovered, The steady-state expression levels of cytochrome variants bearing these mutant tails were similar in an E. coli strain deleted for the tsp gene but differed markedly in a strain containing Tsp. Wild-type cytochrome b(562) and seven variants, displaying a range of intracellular expression levels, were purified. These proteins were found to have the same T-m values in thermal denaturation experiments but to be cleaved by Tsp at rates differing by as much as 30-fold. Overall, the rates of Tsp cleavage of these proteins in vitro correlate with their rates of cleavage in vivo as determined by pulse-chase experiments, These results indicate that the C-terminal sequence of the cytochrome-b(562) variants is important in determining their proteolytic fate in the cell and show that this degradation is mediated predominantly by Tsp, There are different selectivity rules at each of the three C-terminal positions. The identity of the C-terminal residue of the substrate, where small, uncharged residues (Ala, Cys, Ser, Thr, Val) are preferred, is most important in determining the rate of substrate cleavage by Tsp. Non-polar residues are also preferred at the second and third positions, but larger and more hydrophobic side chains are also acceptable at these positions in good substrates.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)				Sauer, Robert/0000-0002-1719-5399; Keiler, Kenneth/0000-0001-8753-335X	NIAID NIH HHS [AI-16892, AI-15706] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015706, R37AI015706, R01AI016892] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES GF, 1984, J BACTERIOL, V160, P1181, DOI 10.1128/JB.160.3.1181-1183.1984; BOWIE JU, 1989, J BIOL CHEM, V264, P7596; BRENSTEIN RJ, 1989, NONLIN MACINTOSH; BRUNET AP, 1993, NATURE, V364, P355, DOI 10.1038/364355a0; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; GOLDBERG AL, 1976, ANNU REV BIOCHEM, V45, P747, DOI 10.1146/annurev.bi.45.070176.003531; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; ITAGAKI E, 1966, J BIOL CHEM, V241, P3687; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; KEILER KC, 1995, PROTEIN SCI, V4, P1507, DOI 10.1002/pro.5560040808; LEDERER F, 1981, J MOL BIOL, V148, P427, DOI 10.1016/0022-2836(81)90185-6; MATHEWS FS, 1979, J BIOL CHEM, V254, P1699; PARSELL DA, 1990, GENE DEV, V4, P277, DOI 10.1101/gad.4.2.277; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; SILBER KR, 1994, MOL GEN GENET, V242, P237, DOI 10.1007/BF00391018; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322	18	89	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2589	2593		10.1074/jbc.271.5.2589	http://dx.doi.org/10.1074/jbc.271.5.2589			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576225	hybrid			2022-12-25	WOS:A1996TT48800039
J	Nie, ZQ; Chen, SM; Kumar, R; Zack, DJ				Nie, ZQ; Chen, SM; Kumar, R; Zack, DJ			RER, an evolutionarily conserved sequence upstream of the rhodopsin gene, has enhancer activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT RETINITIS-PIGMENTOSA; NUCLEAR-PROTEIN BINDING; RAT OPSIN GENE; TRANSGENIC MICE; INVITRO TRANSCRIPTION; MOLECULAR-GENETICS; MOUSE RETINA; PINEAL-GLAND; S-ANTIGEN; EXPRESSION	Previous transgenic mouse experiments localized the mammalian rhodopsin gene promoter to a region just upstream of the mRNA start site, and also suggested the existence of a second more distal regulatory region. A highly conserved 100-base pair (bp) sequence which is homologous to the red and green opsin locus control region is located 1.5-2 kilobases upstream of the rhodopsin gene (depending on the species). In order to test the activity of this 100-bp region, transgenic mice were generated with bovine rhodopsin promoter/lacZ constructs which differed only by the presence or absence of the sequence. Of 11 lines generated, all demonstrated photoreceptor-specific expression of the transgene, but the lines with the putative regulatory region showed significantly higher expression. Additional transgenic lines in which the region was fused to a minimal heterologous promoter did not show transgene expression in the retina. Gel mobility shift and DNase I footprint assays demonstrated that bovine retinal nuclear extracts contain retina specific as well as ubiquitously expressed factors that interact with the putative regulatory region in a sequence-specific manner. These results indicate that the 100-bp sequence can indeed function in vivo as a rhodopsin enhancer region.	JOHNS HOPKINS UNIV,SCH MED,DEPT OPHTHALMOL,WILMER INST,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21287; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21287	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University				Zack, Don/0000-0002-7966-1973	NATIONAL EYE INSTITUTE [F32EY006434, R01EY009769, F32EY006614] Funding Source: NIH RePORTER; NEI NIH HHS [EY06434, EY06614, F32 EY006614, EY09769] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADLER R, 1993, INT REV CYTOL, V146, P145, DOI 10.1016/S0074-7696(08)60382-4; AHMAD I, 1994, J NEUROCHEM, V62, P396; BLAU HM, 1992, NATURE, V358, P284, DOI 10.1038/358284a0; BORST DE, 1991, J CELL BIOL, V115, P312; BREITMAN ML, 1991, J BIOL CHEM, V266, P15505; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P263, DOI 10.1002/cne.901880205; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; CHEN J, 1994, P NATL ACAD SCI USA, V91, P2611, DOI 10.1073/pnas.91.7.2611; CHIU MI, 1994, J NEUROSCI, V14, P3426; CHIU MI, 1994, VISUAL NEUROSCI, V11, P773, DOI 10.1017/S0952523800003072; CHODOSH LA, 1988, CURRENT PROTOCOLS MO; CONSTANTINEPATON M, 1986, NATURE, V324, P459, DOI 10.1038/324459a0; DAVIDSON EH, 1990, DEVELOPMENT, V108, P365; DESJARDIN LE, 1993, J BIOL CHEM, V268, P6953; DONOGHUE MJ, 1992, CELL, V69, P67, DOI 10.1016/0092-8674(92)90119-W; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; FARBER DB, 1991, EXP EYE RES, V53, P781, DOI 10.1016/0014-4835(91)90114-T; GARABEDIAN MJ, 1993, GENE TRANSCRIPTION P, P243; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOURAS P, 1994, VISUAL NEUROSCI, V11, P1227, DOI 10.1017/S0952523800007021; GRIESHAMMER U, 1992, CELL, V69, P79, DOI 10.1016/0092-8674(92)90120-2; GROSVELD F, 1993, PHILOS T ROY SOC B, V339, P183, DOI 10.1098/rstb.1993.0015; HOGAN B, 1986, MANIPULATING MOUSE G; KIKUCHI T, 1993, MOL CELL BIOL, V13, P4400, DOI 10.1128/MCB.13.7.4400; KRUMMEL B, 1990, PCR PROTOCOLS GUIDE, P184; KUMAR R, 1994, MOL GENETICS OCULAR, P139; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; LI HS, 1994, DEV BIOL, V162, P181, DOI 10.1006/dbio.1994.1077; LIOU GI, 1991, BIOCHEM BIOPH RES CO, V181, P159, DOI 10.1016/S0006-291X(05)81395-6; MCCAFFERY P, 1993, DEV BIOL, V158, P390, DOI 10.1006/dbio.1993.1197; MCLOON SC, 1991, J NEUROSCI, V11, P1470; MISMER D, 1987, GENETICS, V116, P565; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; NATHANS J, 1989, SCIENCE, V245, P831, DOI 10.1126/science.2788922; NATHANS J, 1994, CELL, V78, P357, DOI 10.1016/0092-8674(94)90414-6; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; NATHANS J, 1987, ANNU REV NEUROSCI, V10, P163; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; PERRY MD, 1994, GENE, V146, P273, DOI 10.1016/0378-1119(94)90305-0; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; SHESHBERADARAN H, 1994, MOL CELL NEUROSCI, V5, P309, DOI 10.1006/mcne.1994.1037; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; SUN DX, 1993, EXP EYE RES, V57, P177, DOI 10.1006/exer.1993.1113; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1994, J NEUROSCI, V14, P5818; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TIMMERS AM, 1993, EXP EYE RES, V56, P257, DOI 10.1006/exer.1993.1034; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; TREISMAN JE, 1988, MOL CELL BIOL, V8, P1570, DOI 10.1128/MCB.8.4.1570; TRISLER GD, 1981, P NATL ACAD SCI-BIOL, V78, P2145, DOI 10.1073/pnas.78.4.2145; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; WEINTRAUB H, 1993, CELL, V75, P1; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; WOODFORD BJ, 1994, EXP EYE RES, V58, P631, DOI 10.1006/exer.1994.1058; YAMAKI K, 1990, J BIOL CHEM, V265, P20757; YU X, 1993, BIOCHEM BIOPH RES CO, V191, P76, DOI 10.1006/bbrc.1993.1186; ZACK DJ, 1991, NEURON, V6, P187, DOI 10.1016/0896-6273(91)90355-4; ZACK DJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P1477, DOI 10.1001/archopht.1993.01090110043019; ZACK DJ, 1993, METH NEUROSCI, V15, P331	63	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2667	2675		10.1074/jbc.271.5.2667	http://dx.doi.org/10.1074/jbc.271.5.2667			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576239	hybrid			2022-12-25	WOS:A1996TT48800053
J	Skaliter, R; Bergstein, M; Livneh, Z				Skaliter, R; Bergstein, M; Livneh, Z			beta*, a UV-inducible shorter form of the beta subunit of DNA polymerase III of Escherichia coli .2. Overproduction, purification, and activity as a polymerase processivity clamp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-NUCLEAR ANTIGEN; SINGLE-STRANDED-DNA; REPLICATION FACTOR-C; INVITRO REPLICATION; ACCESSORY PROTEINS; HOLOENZYME; MUTAGENESIS; MECHANISM; BYPASS; TERMINATION	Control elements located inside the coding sequence of dnaN, the gene encoding the beta subunit of DNA polymerase III holoenzyme, direct the synthesis of a shorter and UV-inducible form of the beta subunit (Skaliter, R., Paz-Elizur, T., and Livneh, Z. (1996) J. Biol. Chem. 271, 2278-2281, and Paz-Elizur, T., Skaliter, R., Blumenstein, S., and Livneh, Z. (1996) J. Biol. Chem. 271, 2282-2290), The protein, termed beta*, was overproduced using the phage T7 expression system, leading to its accumulation as inclusion bodies at 5-10% of the total cellular proteins, beta* was purified in denatured form, followed by refolding to yield a preparation >95% pure, Denatured beta* had a molecular mass of 26 kDa and contained two isoforms when analyzed by two-dimensional gel electrophoresis. The major isoform had a pI of 5.45, and comigrated with cellular beta*, Size exclusion high performance liquid chromatography under nondenaturing conditions and chemical cross-linking experiments indicate that beta* is a homotrimer, DNA synthesis by DNA polymerase III* was stimulated up to 10-fold by beta*, primarily due to an increase in the processivity of polymerization. It is suggested that beta* functions as an alternative sliding DNA clamp in a process associated with DNA synthesis in UV-irradiated cells.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; BURTERS PMJ, 1982, J BIOL CHEM, V257, P11468; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FRIEDBERG EC, 1995, DNA REPAIR; GOGOL EP, 1992, J MOL BIOL, V224, P395, DOI 10.1016/0022-2836(92)91003-8; HATA S, 1992, EUR J BIOCHEM, V203, P367, DOI 10.1111/j.1432-1033.1992.tb16559.x; HEVRONI D, 1988, P NATL ACAD SCI USA, V85, P5046, DOI 10.1073/pnas.85.14.5046; JARVIS TC, 1989, J BIOL CHEM, V264, P12709; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KHIDHIR MA, 1985, MOL GEN GENET, V199, P133, DOI 10.1007/BF00327522; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1991, DNA REPLICATION; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KRUEGER JH, 1984, P NATL ACAD SCI-BIOL, V81, P1499, DOI 10.1073/pnas.81.5.1499; LASKEN RS, 1987, J BIOL CHEM, V262, P1720; LEE SH, 1991, J BIOL CHEM, V266, P594; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LIVNEH Z, 1986, J BIOL CHEM, V261, P9526; LIVNEH Z, 1993, CRIT REV BIOCHEM MOL, V28, P465, DOI 10.3109/10409239309085136; LIVNEH Z, 1986, P NATL ACAD SCI USA, V83, P4599, DOI 10.1073/pnas.83.13.4599; MAKI S, 1988, J BIOL CHEM, V263, P6555; MOK M, 1987, J BIOL CHEM, V262, P16644; Nossal N.G., 1983, BACTERIOPHAGE T4, P71; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PazElizur T, 1996, J BIOL CHEM, V271, P2482, DOI 10.1074/jbc.271.5.2482; SHAVITT O, 1989, J BIOL CHEM, V264, P11275; SHWARTZ H, 1987, J BIOL CHEM, V262, P10518; SHWARTZ H, 1988, J BIOL CHEM, V263, P18277; Skaliter R, 1996, J BIOL CHEM, V271, P2478, DOI 10.1074/jbc.271.5.2478; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TADMOR Y, 1992, J BACTERIOL, V174, P2517, DOI 10.1128/jb.174.8.2517-2524.1992; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; WEINER JH, 1975, J BIOL CHEM, V250, P1972; WITKIN EM, 1987, P NATL ACAD SCI USA, V84, P6805, DOI 10.1073/pnas.84.19.6805	40	10	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2491	2496		10.1074/jbc.271.5.2491	http://dx.doi.org/10.1074/jbc.271.5.2491			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576212	hybrid			2022-12-25	WOS:A1996TT48800026
J	Taher, TEI; Smit, L; Griffioen, AW; SchilderTol, EJM; Borst, J; Pals, ST				Taher, TEI; Smit, L; Griffioen, AW; SchilderTol, EJM; Borst, J; Pals, ST			Signaling through CD44 is mediated by tyrosine kinases - Association with p56(lck) in T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METASTASIS-ASSOCIATED VARIANT; CELL ANTIGEN RECEPTOR; NON-HODGKINS-LYMPHOMA; HOMING RECEPTOR; ACTIVATION; GLYCOPROTEIN; MOLECULE; EXPRESSION; ANTIBODIES; ADHESION	Evidence from a large body of studies indicates that CD44 is involved in a number of important biological processes, including lymphocyte activation and homing, hematopoiesis, and tumor progression and metastasis. A proper understanding of the role of CD44 in these processes has been severely hampered by a lack of insight into the mode in which CD44 communicates with intracellular signal transduction pathways. In this report, we have addressed this aspect of CD44 functioning by studying CD44 signaling in T lymphocytes. We show that ligation of CD44 by monoclonal antibodies (mAbs) transduces signals to T cells which lead to tyrosine phosphorylation of ZAP-70 and other intracellular proteins. In vitro kinase assays demonstrate that cross linking of CD44 induces an increase in the intrinsic activity of p56(lck). Furthermore, immunoprecipitations show that CD44 is physically associated with p56(lck). Our findings suggest that tyrosine kinases, particularly p56(lck), play a central role in CD44 mediated signaling.	UNIV AMSTERDAM,ACAD MED CTR,DEPT PATHOL,1105 AZ AMSTERDAM,NETHERLANDS; NETHERLANDS CANC INST,DEPT CELLULAR BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Netherlands Cancer Institute				Pals, Steven/0000-0002-1419-0939; Smit, Linda/0000-0003-0025-269X; Borst, Jannie/0000-0002-8043-5009				ANDERSON SJ, 1994, ADV IMMUNOL, V56, P151, DOI 10.1016/S0065-2776(08)60451-4; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; BROUNS GS, 1993, EUR J IMMUNOL, V23, P1088, DOI 10.1002/eji.1830230517; CARMO AM, 1993, EUR J IMMUNOL, V23, P2196, DOI 10.1002/eji.1830230922; CARTER WG, 1988, J BIOL CHEM, V263, P4193; DENNING SM, 1990, J IMMUNOL, V144, P7; FOX SB, 1994, CANCER RES, V54, P4539; FUNG MR, 1991, J IMMUNOL, V147, P1253; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HORST E, 1990, LEUKEMIA, V4, P383; HUET S, 1989, J IMMUNOL, V143, P798; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JALKANEN S, 1991, J CLIN INVEST, V87, P1835, DOI 10.1172/JCI115205; JALKANEN S, 1987, J CELL BIOL, V105, P983, DOI 10.1083/jcb.105.2.983; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; JUAN M, 1994, J EXP MED, V179, P1747, DOI 10.1084/jem.179.6.1747; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOOPMAN G, 1990, J IMMUNOL, V145, P3589; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; PALS ST, 1989, J IMMUNOL, V143, P851; PALS ST, 1989, BLOOD, V73, P885; PIERRES A, 1992, EUR J IMMUNOL, V22, P413, DOI 10.1002/eji.1830220219; RAAB M, 1994, MOL CELL BIOL, V14, P2862, DOI 10.1128/MCB.14.5.2862; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WIELENGA VJM, 1993, CANCER RES, V53, P4754; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	41	147	150	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2863	2867		10.1074/jbc.271.5.2863	http://dx.doi.org/10.1074/jbc.271.5.2863			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576267	hybrid			2022-12-25	WOS:A1996TT48800081
J	Bakovic, M; Dunford, HB				Bakovic, M; Dunford, HB			Reactions of prostaglandin endoperoxide synthase and its compound I with hydroperoxides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER OXIDATION-STATES; H SYNTHASE; TYROSYL RADICALS; GRANULOSA-CELLS; HORSERADISH-PEROXIDASE; GENE; KINETICS; MECHANISM; CATALYSIS; PROMOTER	The reactions of native prostaglandin endoperoxide synthase with structurally different hydroperoxides have been investigated by using kinetic spectrophotometric scan and conventional and sequential mixing stopped-flow experiments. The second order rate constants for compound I formation are (5.9 +/- 0.1) x 10(4) M(-1) s(-1) using t-butyl hydroperoxide as the oxidant, (2.5 +/- 0.1) x 10(6) M(-1) s(-1) for ethyl hydroperoxide and (5.1 +/- 0.6) x 10(7) M(-1) s(-1) for m-chloroperoxybenzoic acid at pH 7.0, 6.7 +/- 0.2 degrees C, and ionic strength 0.1 M. Sequential mixing, transient state experiments show for the first time that all hydroperoxides reduce compound I in a bimolecular reaction. Ethyl hydroperoxide, t-butyl hydroperoxide, and m-chloroperoxybenzoic acid react directly with compound I. The natural substrate prostaglandin G(2) forms a transient complex with compound I before the reduction step occurs. Therefore, compound I initially transforms to compound II, not to the compound I-tyrosyl radical. Second order rate constants for the reactions of compound I are (2.9 +/- 0.2) x 10(4) for t-butyl hydroperoxide, (3.5 +/- 0.5) x 10(4) for hydrogen peroxide, (4.2 +/- 0.2) x 10(4) for ethyl hydroperoxide, and (4.2 +/- 0.3) x 10(5) for m-chloroperoxybenzoic acid, all in units of M(-1) s(-1) and same conditions as for compound I formation. The rate of reaction of prostaglandin G(2) with compound I, calculated from the ratio of k(cat) to K-m obtained from the saturation curve, is (1.0 +/- 0.2) x 10(6) M(-1) s(-1) at 3.0 +/- 0.2 degrees C. Results are discussed in the contest of the current state of knowledge of the mechanisms of the cyclooxygenase and peroxidase reactions of prostaglandin endoperoxide synthase.	UNIV ALBERTA,DEPT CHEM,EDMONTON,AB T6G 2G2,CANADA	University of Alberta								BAKOVIC M, 1994, BIOCHEMISTRY-US, V33, P6475, DOI 10.1021/bi00187a013; BAKOVIC M, 1995, BIOPHYS CHEM, V54, P237, DOI 10.1016/0301-4622(94)00135-7; BAKOVIC M, 1996, IN PRESS PROSTAGLAND; COOK HW, 1979, ANAL BIOCHEM, V96, P341, DOI 10.1016/0003-2697(79)90591-8; COTTON ML, 1973, CAN J CHEM, V51, P582, DOI 10.1139/v73-088; DEGRAY JA, 1992, J BIOL CHEM, V267, P23583; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; DOLMAN D, 1975, CAN J BIOCHEM CELL B, V53, P495, DOI 10.1139/o75-069; DUNFORD HB, 1976, COORDIN CHEM REV, V19, P187, DOI 10.1016/S0010-8545(00)80316-1; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; HSI LC, 1995, BIOCHEM BIOPH RES CO, V207, P652, DOI 10.1006/bbrc.1995.1237; HSUANYU Y, 1989, BIOCH CELL BIOL, V68, P965; HSUANYU YC, 1992, J BIOL CHEM, V267, P17649; HSUANYU YC, 1992, ARCH BIOCHEM BIOPHYS, V292, P213, DOI 10.1016/0003-9861(92)90070-D; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; KRYLOV SN, 1996, IN PRESS J PHYS CHEM; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1984, J BIOL CHEM, V259, P6358; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; MACDONALD ID, 1989, J INORG BIOCHEM, V37, P35, DOI 10.1016/0162-0134(89)80027-3; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; MARNETT LJ, 1984, MOL PHARMACOL, V26, P328; MARQUEZ LA, 1994, BIOCHEMISTRY-US, V33, P1447, DOI 10.1021/bi00172a022; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REGIER MK, 1993, ARCH BIOCHEM BIOPHYS, V301, P439, DOI 10.1006/abbi.1993.1168; RUF HH, 1993, BIOCHEM SOC T, V21, P739, DOI 10.1042/bst0210739; SCHONBAUM GR, 1972, J BIOL CHEM, V247, P3353; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SIROIS J, 1992, J BIOL CHEM, V267, P6382; SIROIS J, 1993, J BIOL CHEM, V268, P21931; SIROIS J, 1993, J BIOL CHEM, V268, P12199; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; TAZAWA R, 1994, BIOCHEM BIOPH RES CO, V203, P190, DOI 10.1006/bbrc.1994.2167; TSAI AL, 1994, J BIOL CHEM, V269, P5085; TSAI AL, 1992, J BIOL CHEM, V267, P17753; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; WEI CH, 1995, BIOCHEMISTRY-US, V34, P8499, DOI 10.1021/bi00026a034; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; Yonetani T., 1976, ENZYMES, P345	44	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2048	2056		10.1074/jbc.271.4.2048	http://dx.doi.org/10.1074/jbc.271.4.2048			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567658	hybrid			2022-12-25	WOS:A1996TR32000040
J	Busca, R; Martinez, M; Vilella, E; Pognonec, P; Deeb, S; Auwerx, J; Reina, M; Vilaro, S				Busca, R; Martinez, M; Vilella, E; Pognonec, P; Deeb, S; Auwerx, J; Reina, M; Vilaro, S			The mutation Gly(142)->Glu in human lipoprotein lipase produces a missorted protein that is diverted to lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED MOUSE ADIPOCYTES; SITE-SPECIFIC MUTAGENESIS; GOLGI COMPARTMENT; HUMAN-PLASMA; EXPRESSION; ENZYME; SECRETION; CELLS; GENE; GLYCOSYLATION	While the molecular characterization of lipoprotein lipase (LPL) activation is progressing, the intracellular processing, transport, and secretion signals of LPL are still poorly known, The aim of this paper is to study the involvement of glycine 142 in LPL secretion and to elucidate the intracellular destination of the altered protein that remains inside the cell. We mutated the human LPL cDNA by site-directed mutagenesis in order to produce the G142E hLPL in which the glycine 142 was replaced by a glutamic acid. The wild type human LPL (WT hLPL) and the mutant G142E hLPL were expressed by transient transfection in COS1 cells, Using Western blot assays we identified a single band that had the same molecular weight for both proteins, However, Western blots of culture media did not reveal any specific band for the mutant protein, and ELISA experiments showed that the extracellular mass of the mutant LPL was only 25% of the WT protein, indicating defective secretion of the altered enzyme. Heparin increased LPL secretion in the case of the WT hLPL but did not have any stimulatory effect when acting on G142E hLPL-transfected cells. However, heparin-Sepharose chromatography revealed that both proteins presented the same heparin affinity, Metabolic labeling and radioimmunoprecipitation studies showed that both the WT and the mutant hLPL intracellular levels decreased upon chase time. Furthermore, leupeptin had a greater effect on the intracellular level of the mutant enzyme, thus indicating its higher intracellular degradation. Immunofluorescent studies using confocal microscopy indicated high colocalization of the LPL labeling and the Lamp1 lysosomal labeling in G142E hLPL-expressing cells. This result was confirmed using immunoelectron microscopy, which in addition showed gold labeling in Golgi stacks. This finding, together with experiments performed with endoglycosidase H digestion of immunoprecipitated radiolabeled LPL, indicated that the mutant enzyme entered the Golgi compartment. The results reported in this paper show that the G142E hLPL is not efficiently secreted to the extracellular medium, but it is missorted to lysosomes for intracellular degradation. This finding suggests that lysosomal missorting might be a mechanism of cell quality control of secreted LPL.	UNIV BARCELONA,DEPT CELL BIOL,E-08028 BARCELONA,SPAIN; HOSP ST JOAN,BIOMED RES CTR,E-43201 REUS,TARRAGONA,SPAIN; UNIV NICE,CTR BIOCHIM,F-06108 NICE 2,FRANCE; UNIV WASHINGTON,DEPT GENET & MED,SEATTLE,WA 98195; INST PASTEUR,DEPT ATHEROSCLEROSE,BIOL REGULAT CHEZ EUCARYOTES LAB,F-59019 LILLE,FRANCE	University of Barcelona; UDICE-French Research Universities; Universite Cote d'Azur; University of Washington; University of Washington Seattle; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Reina, Manuel/D-4655-2014	Reina, Manuel/0000-0002-0701-200X; Auwerx, Johan/0000-0002-5065-5393	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL047151] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47151] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AILHAUD G, 1990, CLIN BIOCHEM, V23, P343, DOI 10.1016/0009-9120(90)90034-R; AMEIS D, 1991, J CLIN INVEST, V87, P1165, DOI 10.1172/JCI115114; AUWERX JH, 1989, BIOCHEMISTRY-US, V28, P4563, DOI 10.1021/bi00437a009; BENZEEV O, 1992, J BIOL CHEM, V267, P6219; BRAUN JEA, 1992, BIOCHEM J, V287, P337, DOI 10.1042/bj2870337; BRUNZELL JD, 1983, METABOLIC BASIS INHE, P1165; BUSCA R, 1995, J LIPID RES, V36, P939; CAMPS L, 1990, AM J PHYSIOL, V258, P673; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; CISAR LA, 1989, J BIOL CHEM, V264, P1767; CUPP M, 1987, J BIOL CHEM, V262, P6383; DAMHS N, 1989, J BIOL CHEM, V264, P12115; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; HALBAN PA, BIOCHEM J, V299, P1; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; JACKSON RL, 1977, P NATL ACAD SCI USA, V74, P1942, DOI 10.1073/pnas.74.5.1942; KRIEGLER M, 1990, GENE TRANSFER EXPRES, P99; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MASUNO H, 1991, BIOCHEM J, V277, P801, DOI 10.1042/bj2770801; MIYAZAKI J, 1989, GENE, V79, P269; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; Olivecrona Thomas, 1993, Current Opinion in Lipidology, V4, P187, DOI 10.1097/00041433-199306000-00003; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; OSTLUNDLINDQVIST AM, 1977, FEBS LETT, V83, P231, DOI 10.1016/0014-5793(77)81011-9; PRADINESFIGUERES A, 1990, J LIPID RES, V31, P1467; RAMIREZ I, 1985, BIOCHEM J, V232, P229, DOI 10.1042/bj2320229; SANNTAMARINAFOJ.S, 1992, CURR OPIN LIPIDOL, V3, P86; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; SHAMU CE, 1994, TRENDS CELL BIOL, V4, P55; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; VANNIER C, 1989, J BIOL CHEM, V264, P13206; VANNIER C, 1989, J BIOL CHEM, V264, P13199; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VILELLA E, 1993, J LIPID RES, V34, P1555; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	40	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2139	2146		10.1074/jbc.271.4.2139	http://dx.doi.org/10.1074/jbc.271.4.2139			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567671	hybrid			2022-12-25	WOS:A1996TR32000053
J	Gabbay, RA; Sutherland, C; Gnudi, L; Kahn, BB; OBrien, RM; Granner, DK; Flier, JS				Gabbay, RA; Sutherland, C; Gnudi, L; Kahn, BB; OBrien, RM; Granner, DK; Flier, JS			Insulin regulation of phosphoenolpyruvate carboxykinase gene expression does not require activation of the Ras mitogen-activated protein kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION; GLUCONEOGENESIS; PHOSPHORYLATION; STIMULATION; INHIBITION; SEQUENCE; NIDDM	Expression of phosphoenolpyruvate carboxykinase (PEPCK), the rate-limiting step in hepatic gluconeogenesis, is primarily regulated at the level of gene transcription, Insulin and phorbol esters inhibit basal PEPCK transcription and antagonize the induction of PEPCK gene expression by glucocorticoids and glucagon (or its second messenger cAMP). Insulin activates a signaling cascade involving Ras --> Raf --> p42/p44 mitogen-activated protein (MAP) kinase kinase (MEK) --> p42/p44 MAP kinase (ERR 1 and 2). Recent reports suggest that activation of this Ras/MAP kinase pathway is critical for the effects of insulin on mitogenesis and c-fos transcription but is not required for insulin action on metabolic processes such as glycogen synthesis, lipogenesis, and Glut-4-mediated glucose transport. We have used three distinct approaches to examine the role of the Ras/MAP kinase pathway in the regulation of PEPCK transcription by insulin in H4IIE-derived liver cells: (i) chemical inhibition of Ras farnesylation, (ii) infection of cells with an adenovirus vector encoding a dominant-negative mutant of Ras, and (iii) use of a chemical inhibitor of MEK. Although each of these methods blocks insulin activation of MAP kinase, none alters insulin antagonism of cAMP- and glucocorticoid-stimulated PEPCK transcription. Although phorbol esters activate MAP kinase and mimic the effects of insulin on PEPCK gene transcription, inhibition of MEK has no effect on phorbol ester inhibition of PEPCK gene transcription. Using the structurally and mechanistically distinct phosphatidylinositol 3-kinase (PI 3-kinase) inhibitors, wortmannin and LY 294002, we provide further evidence supporting a role for PI 3-kinase activation in the regulation of PEPCK gene transcription by insulin. We conclude that neither insulin nor phorbol ester regulation of PEPCK gene transcription requires activation of the Ras/MAP kinase pathway and that insulin signaling to the PEPCK promoter is dependent on PI 3-kinase activation.	VANDERBILT UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University	Gabbay, RA (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV ENDOCRINOL,HARVARD THORNDIKE DEPT MED,BOSTON,MA 02215, USA.		Flier, jeffrey/AAG-6223-2019	Sutherland, Calum/0000-0003-4398-7434; gnudi, luigi/0000-0002-6353-630X	NIDDK NIH HHS [R01 DK043051] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043051] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BEGUM N, 1995, J BIOL CHEM, V270, P709, DOI 10.1074/jbc.270.2.709; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CONSOLI A, 1989, DIABETES, V38, P550, DOI 10.2337/diabetes.38.5.550; CONSOLI A, 1992, DIABETES CARE, V15, P430, DOI 10.2337/diacare.15.3.430; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COX AD, 1994, J BIOL CHEM, V269, P19203; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DECLUE JE, 1991, CANCER RES, V51, P712; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FINGAR DC, 1994, J BIOL CHEM, V269, P10127; FOREST CD, 1990, MOL ENDOCRINOL, V4, P1302, DOI 10.1210/mend-4-9-1302; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GLUZMAN Y, 1982, EUKARYOTIC VIRAL VEC; Hanson R W, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P203; HAUSDORFF SF, 1994, J BIOL CHEM, V269, P21391; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JHUN BH, 1994, J BIOL CHEM, V269, P5699; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KYRIAKIS JM, 1993, PROTEIN KINASES FRON; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; MANCHESTER J, 1994, P NATL ACAD SCI USA, V91, P4644, DOI 10.1073/pnas.91.11.4644; MCGUIRE TF, 1994, BIOCHEM BIOPH RES CO, V204, P399, DOI 10.1006/bbrc.1994.2472; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OBRIEN RM, 1991, BIOCHEM J, V278, P609, DOI 10.1042/bj2780609; OBRIEN RM, 1991, P NATL ACAD SCI USA, V88, P6580, DOI 10.1073/pnas.88.15.6580; OBRIEN RM, 1996, IN PRESS PHYSL REV; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OKADA T, 1994, J BIOL CHEM, V269, P3568; RAHN T, 1994, FEBS LETT, V350, P314, DOI 10.1016/0014-5793(94)00797-7; REUSCH JEB, 1995, J BIOL CHEM, V270, P2036, DOI 10.1074/jbc.270.5.2036; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; SASAKI K, 1984, J BIOL CHEM, V259, P5242; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SEBOLTLEOPOLD JS, 1995, CANCER DRUG DISCOVER; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SOZERI O, 1992, ONCOGENE, V7, P2259; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; TOKER A, 1994, J BIOL CHEM, V269, P32358; TORNKVIST A, 1994, J BIOL CHEM, V269, P13919; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; VANDENBERGHE N, 1994, MOL CELL BIOL, V14, P2372, DOI 10.1128/MCB.14.4.2372; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; WILDEN PA, 1994, MOL ENDOCRINOL, V8, P558, DOI 10.1210/me.8.5.558; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YANO H, 1993, J BIOL CHEM, V268, P25846	72	120	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1890	1897		10.1074/jbc.271.4.1890	http://dx.doi.org/10.1074/jbc.271.4.1890			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567635	hybrid			2022-12-25	WOS:A1996TR32000017
J	Sekiguchi, JA; Stivers, JT; Mildvan, AS; Shuman, S				Sekiguchi, JA; Stivers, JT; Mildvan, AS; Shuman, S			Mechanism of inhibition of vaccinia DNA topoisomerase by novobiocin and coumermycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC INTERACTION; CAMPTOTHECIN RESISTANCE; ESCHERICHIA-COLI; ANTITUMOR DRUGS; DUPLEX DNA; PURIFICATION; GYRASE; IDENTIFICATION; CLEAVAGE; PROTEIN	Vaccinia DNA topoisomerase, a eukaryotic type I enzyme, has unique pharmacological properties, including sensitivity to the coumarin drugs novobiocin and coumermycin, which are classical inhibitors of DNA gyrase, a type II enzyme. Whereas coumarins inhibit gyrase by binding the GyrB subunit and thereby blocking the ATP-binding site, they inhibit vaccinia topoisomerase by binding to the protein and blocking the interaction of enzyme with DNA. Noncovalent DNA binding and single-turnover DNA cleavage by topoisomerase are inhibited with K-I values of 10-25 mu M for coumermycin and 350 mu M for novobiocin. Spectroscopic and fluorescence measurements of drug binding to enzyme indicate a single binding site on vaccinia topoisomerase for coumermycin (K-D = 27 +/- 5 mu M) and two classes of binding sites for novobiocin, one tight site (K-D1 = 20 +/- 5 mu M) and several weak sites (K-D2 = 513 +/- 125 mu M; n = 4.9 +/- 0.7). Addition of a stoichiometric amount of DNA to a preformed coumermycin-topoisomerase complex quantitatively displaces the drug, indicating that coumermycin binding and DNA binding to topoisomerase are mutually exclusive. A simple interpretation is that the site of drug binding coincides or overlaps with the DNA-binding site on the topoisomerase. Both novobiocin and coumermycin alter the susceptibility of vaccinia topoisomerase to proteolysis with either chymotrypsin or trypsin; similar effects occur when topoisomerase binds to duplex DNA.	SLOAN KETTERING INST,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205	Memorial Sloan Kettering Cancer Center; Johns Hopkins University				Sekiguchi, JoAnn/0000-0002-7178-4258	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028616, R01DK028616] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046330, R37GM046330] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK28616] Funding Source: Medline; NIGMS NIH HHS [GM46330] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENEDETTI P, 1993, CANCER RES, V53, P4343; BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; CONTRERAS A, 1992, MOL MICROBIOL, V6, P1617; ELSEA SH, 1995, J BIOL CHEM, V270, P1913, DOI 10.1074/jbc.270.4.1913; FOGELSONG PD, 1984, J VIROL, V49, P1; GILBERT EJ, 1994, MOL MICROBIOL, V12, P365, DOI 10.1111/j.1365-2958.1994.tb01026.x; GOTO T, 1984, J BIOL CHEM, V259, P422; LEWIS RJ, 1994, J MOL BIOL, V241, P128, DOI 10.1006/jmbi.1994.1480; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MAXWELL A, 1993, MOL MICROBIOL, V9, P681, DOI 10.1111/j.1365-2958.1993.tb01728.x; MELENDY T, 1989, J BIOL CHEM, V264, P1870; MILLER KG, 1981, J BIOL CHEM, V256, P9334; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; REECE RJ, 1991, CRIT REV BIOCHEM MOL, V26, P335, DOI 10.3109/10409239109114072; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; RUBIN E, 1994, J BIOL CHEM, V269, P2433; SAIJO M, 1990, BIOCHEMISTRY-US, V29, P583, DOI 10.1021/bi00454a036; SEKIGUCHI J, 1994, NUCLEIC ACIDS RES, V22, P5360, DOI 10.1093/nar/22.24.5360; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P29760; SHAFFER R, 1987, J BIOL CHEM, V262, P9309; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1992, J BIOL CHEM, V267, P16755; SHUMAN S, 1992, J BIOL CHEM, V267, P8620; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; SOPHIANOPOULOS JA, 1978, ARCH BIOCHEM BIOPHYS, V187, P132, DOI 10.1016/0003-9861(78)90015-2; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P15449, DOI 10.1021/bi00255a027; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; SULLIVAN DM, 1989, BIOCHEMISTRY-US, V28, P5680, DOI 10.1021/bi00439a051; TAMURA H, 1991, NUCLEIC ACIDS RES, V19, P69, DOI 10.1093/nar/19.1.69; TANIZAWA A, 1993, J BIOL CHEM, V268, P25463; WASSERMAN RA, 1994, J BIOL CHEM, V269, P20943; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; ZWELLING LA, 1989, J BIOL CHEM, V264, P16411	39	20	28	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2313	2322		10.1074/jbc.271.4.2313	http://dx.doi.org/10.1074/jbc.271.4.2313			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567695	hybrid			2022-12-25	WOS:A1996TR32000077
J	Kontani, K; Kukimoto, I; Nishina, H; Hoshino, S; Hazeki, O; Kanaho, Y; Katada, T				Kontani, K; Kukimoto, I; Nishina, H; Hoshino, S; Hazeki, O; Kanaho, Y; Katada, T			Tyrosine phosphorylation of the c-cbl proto-oncogene product mediated by cell surface antigen CD38 in HL-60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; ACTIVATION; DIFFERENTIATION; EXPRESSION; MOLECULE; RECEPTOR; HYDROLYSIS; LINEAGE; KINASES	The human cell surface antigen CD38 is a 46-kDa type II transmembrane glycoprotein with a short N-terminal cytoplasmic domain and a long Cys rich C-terminal extracellular one. We demonstrated previously that the extracellular domain of CD38 has NAD(+) glycohydrolase (NADase) activity and that the ecto-form NADase activity induced in HL-60 cells during cell differentiation by retinoic acid is due to CD38. In the present study, we investigated the intracellular signaling mediated by CD38 in retinoic acid differentiated HL-60 cells with an anti-CD38 monoclonal antibody, The addition of anti-CD38 monoclonal antibody to the cells induced rapid tyrosine phosphorylation of the cellular proteins with molecular weights of 120,000, 87,000, and 77,000, An increase in tyrosine kinase activity in the anti-phosphotyrosine immunoprecipitates of the cells was also observed after the addition of anti-CD38 monoclonal antibody, Moreover, one of the prominent tyrosine-phosphorylated proteins stimulated by the anti-CD38 monoclonal antibody was identified as the c-cbl protooncogene product, p120(c-cbl). These results indicated that tyrosine phosphorylation of cellular proteins, including p120(c-cbl), is possibly involved in transmembrane signaling mediated by CD38.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,TOKYO 113,JAPAN; TOKYO INST TECHNOL,DEPT LIFE SCI,YOKOHAMA,KANAGAWA 227,JAPAN	University of Tokyo; Tokyo Institute of Technology			Kukimoto, I/I-3995-2019	Kukimoto, I/0000-0001-9080-1642; Hoshino, Shinichi/0000-0001-6135-7896				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; DIANZANI U, 1994, J IMMUNOL, V153, P952; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FUNARO A, 1990, J IMMUNOL, V145, P2390; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; IIRI T, 1989, J BIOL CHEM, V264, P21394; INAGEDA K, 1995, J BIOCHEM-TOKYO, V117, P125, DOI 10.1093/oxfordjournals.jbchem.a124698; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KIRKHAM PA, 1994, IMMUNOLOGY, V83, P513; KONTANI K, 1993, J BIOL CHEM, V268, P16895; KUMAGAI MA, 1995, J EXP MED, V181, P1101, DOI 10.1084/jem.181.3.1101; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; LEE HC, 1994, MOL CELL BIOCHEM, V138, P229, DOI 10.1007/BF00928466; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; NISHINA H, 1994, BIOCHEM BIOPH RES CO, V203, P1318, DOI 10.1006/bbrc.1994.2326; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SANTOSARGUMEDO L, 1995, INT IMMUNOL, V7, P163, DOI 10.1093/intimm/7.2.163; SANTOSARGUMEDO L, 1993, J IMMUNOL, V151, P3119; SIEFF C, 1982, BLOOD, V60, P703; SMITH CIE, 1994, J IMMUNOL, V152, P557; STASHENKO P, 1981, P NATL ACAD SCI-BIOL, V78, P3848, DOI 10.1073/pnas.78.6.3848; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TSUKADA S, 1994, CURR OPIN IMMUNOL, V6, P623, DOI 10.1016/0952-7915(94)90151-1; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZUPO S, 1994, EUR J IMMUNOL, V24, P1218, DOI 10.1002/eji.1830240532	35	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1534	1537						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576149				2022-12-25	WOS:A1996TQ52500045
J	Rigacci, S; Degl'Innocenti, D; Bucciantini, M; Cirri, P; Berti, A; Ramponi, G				Rigacci, S; Degl'Innocenti, D; Bucciantini, M; Cirri, P; Berti, A; Ramponi, G			pp60(v-src) phosphorylates and activates low molecular weight phosphotyrosine-protein phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LIVER; GROWTH; OVEREXPRESSION; EXPRESSION; RECEPTOR; TYROSINE; CELLS	Low M(r) phosphotyrosine-protein phosphatase belongs to the non-receptor cytosolic phosphotyrosine-protein phosphatase subfamily. It has been demonstrated that this enzyme dephosphorylates receptor tyrosine kinases, namely the epidermal growth factor receptor in vitro and the platelet-derived growth factor receptor in vivo. Low M(r) phosphotyrosine-protein phosphatase is constitutively tyrosine-phosphorylated in NIH/3T3 cells transformed by pp60(v-src). The same tyrosine kinase, previously immunoprecipitated, phosphorylates this enzyme in vitro as well. Phosphorylation is enhanced using phosphatase inhibitors and phenylarsine oxide-inactivated phosphatase, consistently with the existence of an auto-dephosphorylation process. Intermolecular dephosphorylation is demonstrated adding the active enzyme in a solution containing the inactivated and previously phosphorylated one. This tyrosine phosphorylation correlates with an increase in catalytic activity. Our results provide evidence of a physiological mechanism of low M(r) phosphotyrosine-protein phosphatase activity regulation.	UNIV FLORENCE, DEPT BIOCHEM SCI, I-50134 FLORENCE, ITALY	University of Florence			Degl'Innocenti, Donatella/O-8813-2014	Degl'Innocenti, Donatella/0000-0002-3342-5537; bucciantini, monica/0000-0002-5243-9301				BERTI A, 1994, FEBS LETT, V349, P7, DOI 10.1016/0014-5793(94)00620-2; CHIARUGI P, 1992, FEBS LETT, V310, P9, DOI 10.1016/0014-5793(92)81134-8; CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; de Araujo P S, 1976, Biochim Biophys Acta, V452, P121, DOI 10.1016/0005-2744(76)90063-2; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; LAU KHW, 1993, CRIT REV ONCOGENESIS, V4, P451; MATOZAKI T, 1994, BIOCHEM BIOPH RES CO, V204, P874, DOI 10.1006/bbrc.1994.2541; RAMPONI G, 1992, INT J CANCER, V51, P652, DOI 10.1002/ijc.2910510424; RAMPONI G, 1989, FEBS LETT, V250, P469, DOI 10.1016/0014-5793(89)80778-1; RAUGEI G, 1991, BIOCHEM INT, V23, P317; RUGGIERO M, 1993, FEBS LETT, V326, P294, DOI 10.1016/0014-5793(93)81811-D; RUGGIERO M, 1989, ONCOGENE, V4, P767; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; SUPERTIFURGA G, 1995, BIOESSAYS, V17, P1; TADDEI N, 1994, FEBS LETT, V350, P328, DOI 10.1016/0014-5793(94)00805-1; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TAWMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696; UCHIDA T, 1994, J BIOL CHEM, V269, P12220; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; YEUNG YG, 1992, J BIOL CHEM, V267, P23447	26	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1278	1281		10.1074/jbc.271.3.1278	http://dx.doi.org/10.1074/jbc.271.3.1278			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576112	hybrid			2022-12-25	WOS:A1996TQ52500008
J	Yoo, SH				Yoo, SH			pH- and Ca2+-dependent aggregation property of secretory vesicle matrix proteins and the potential role of chromogranins A and B in secretory vesicle biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED CHROMAFFIN VESICLES; CONFORMATIONAL CHANGE; SECRETOGRANIN-II; NERVOUS-TISSUE; MESSENGER-RNA; SEQUENCE; MEMBRANE; CALCIUM; BINDING; CELLS	Chromogranins A and B (CGA and CGB), the major proteins of the secretory vesicles of the regulated secretory pathway, have been shown to aggregate in a low pH and high calcium environment, the condition found in the trans-Golgi network where secretory vesicles are formed. Moreover, CGA and CGB, as well as several other secretory vesicle matrix proteins, have recently been shown to bind to the vesicle membrane at the intravesicular pH of 5.5 and to be released from it at a near physiological pH of 7.5. The pH- and Ca2(+)-dependent aggregation and interaction of chromogranins, as well as several other matrix proteins, with the vesicle membrane are considered essential in vesicle biogenesis. Therefore, to gain further insight into how vesicle matrix proteins find their way into the secretory vesicles, the pH- and Ca2+-dependent aggregation and vesicle membrane binding properties of the vesicle matrix proteins were studied, and it was found that most of the vesicle matrix proteins aggregated in the presence of Ca2+ at the intravesicular pH of 5.5. Furthermore, most of the vesicle matrix proteins bound not only to the vesicle membrane but also to CGA at pH 5.5, with the exception of a few matrix proteins that appeared to bind only to CGA or to vesicle membrane. Purified CGB was also shown to interact with CGA at pH 5.5. The extent and Ca2+-sensitivity of the aggregation of vesicle matrix proteins lay between those of purified CGB and CGA, CGE aggregation showing the highest degree of aggregation and being the most Ca2+ sensitive at a given protein concentration. Hence, in view of the abundance of chromogranins in secretory vesicles and their low pH and high calcium-dependent aggregation property, combined with their ability to interact with both the vesicle matrix proteins and the vesicle membrane, CGA and CGB are proposed to play essential roles in the selective aggregation and sorting of potential vesicle matrix proteins to the immature secretory vesicles of the regulated secretory pathway.			Yoo, SH (corresponding author), NIDCD, NEUROCHEM LAB, 5 RES COURT, 2A37, BETHESDA, MD 20892 USA.							ANDERSON RGW, 1985, CELL, V40, P635, DOI 10.1016/0092-8674(85)90212-0; BAUER JW, 1991, BIOCHIM BIOPHYS ACTA, V1089, P124, DOI 10.1016/0167-4781(91)90094-3; BENEDUM UM, 1986, EMBO J, V5, P1495, DOI 10.1002/j.1460-2075.1986.tb04388.x; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P7760, DOI 10.1021/bi00347a039; CASEY RP, 1977, BIOCHEMISTRY-US, V16, P972, DOI 10.1021/bi00624a025; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; FISCHERCOLBRIE R, 1990, J BIOL CHEM, V265, P9208; GERDES HH, 1989, J BIOL CHEM, V264, P12009; GORR SU, 1989, AM J PHYSIOL, V257, pE247, DOI 10.1152/ajpendo.1989.257.2.E247; HUTTNER WB, 1988, INT CONGR SER, V799, P325; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; HUTTNER WB, 1991, MARKERS NEURAL ENDOC, P93; HUTTON JC, 1989, DIABETOLOGIA, V32, P271, DOI 10.1007/BF00265542; IACANGELO A, 1986, NATURE, V323, P82, DOI 10.1038/323082a0; JOHNSON RG, 1976, J BIOL CHEM, V251, P2189; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATA M, 1989, J HISTOCHEM CYTOCHEM, V37, P971, DOI 10.1177/37.7.2525142; OCONNOR DT, 1984, J BIOL CHEM, V259, P3237; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; PIMPLIKAR SW, 1992, J BIOL CHEM, V267, P4110; REIFFEN FU, 1986, FEBS LETT, V195, P327, DOI 10.1016/0014-5793(86)80187-9; ROOS N, 1988, SCANNING MICROSCOPY, V2, P323; SIMON JP, 1989, BIOCHEM J, V262, P1; SONG LX, 1995, J BIOL CHEM, V270, P7963, DOI 10.1074/jbc.270.14.7963; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; YOO SH, 1995, BIOCHEMISTRY-US, V34, P8680, DOI 10.1021/bi00027a017; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1994, J BIOL CHEM, V269, P12001; YOO SH, 1990, J BIOL CHEM, V265, P14414; YOO SH, 1995, J BIOL CHEM, V270, P12578, DOI 10.1074/jbc.270.21.12578; YOO SH, 1993, FEBS LETT, V334, P373, DOI 10.1016/0014-5793(93)80715-7; YOO SH, 1991, J BIOL CHEM, V266, P7740; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8213, DOI 10.1021/bi00083a023; YOO SH, 1995, BIOCHEMISTRY-US, V34, P632, DOI 10.1021/bi00002a030; YOO SH, 1993, BIOCHIM BIOPHYS ACTA, V1179, P239, DOI 10.1016/0167-4889(93)90078-4	36	81	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1558	1565						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576153				2022-12-25	WOS:A1996TQ52500049
J	Kaya, M; Yoshida, K; Higashino, F; Mitaka, T; Ishii, S; Fujinaga, K				Kaya, M; Yoshida, K; Higashino, F; Mitaka, T; Ishii, S; Fujinaga, K			A single ets-related transcription factor, E1AF, confers invasive phenotype on human cancer cells	ONCOGENE			English	Article						ets-related E1AF; MMPs; invasion; motility	TUMOR-CELLS; NEGATIVE REGULATION; BASEMENT-MEMBRANE; IV COLLAGEN; EXPRESSION; METASTASIS; ONCOGENE; GENE; PEA3; METALLOPROTEINASES	Invasion of cancer cells is the first step of metastasis. The invasive activity is thought to be dependent on the production of matrix metalloproteinases (MMPs), The transcription regulatory regions of MMP genes often contain binding sites for Ets and AP-1 transcription factors and they mediate oncogene- and growth factor-induced transcription of the genes, We recently isolated the cDNA encoding human E1AF, a new member of ets oncogene family, E1AF highly stimulated transcription from three different subclasses of MMP genes in transient expression assays, Here we show that transfection of the non-invasive human breast cancer cell line MCF-7 with the E1AF expression plasmid results in induction of invasive and motile activities, accompanied by an increase of 92 kD type IV collagenase (MMP-9) gene expression, Tumors derived from the E1AF transfectant were highly invasive and produced MMP-9, Expression of E1AF and MMP-9 genes was elevated in several invasive tumor cell lines. These results provide evidence for an important role of ets-related E1AF in tumor cell invasion.	SAPPORO MED UNIV, SCH MED, CANC RES INST, DEPT MOLEC BIOL, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN; SAPPORO MED UNIV, SCH MED, CANC RES INST, DEPT PATHOL, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN; SAPPORO MED UNIV, SCH MED, DEPT ORTHOPED SURG, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN	Sapporo Medical University; Sapporo Medical University; Sapporo Medical University			Higashino, Fumihiro/F-8510-2012; Mitaka, Toshihiro/K-9424-2013	Mitaka, Toshihiro/0000-0001-9467-4871				ALBINI A, 1987, CANCER RES, V47, P3239; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; GAIRE M, 1994, J BIOL CHEM, V269, P2032; GREVIN D, 1993, INT J DEV BIOL, V37, P519; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LIOTTA LA, 1991, CANCER RES, V51, pS5054; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MOHLER JL, 1988, CANCER RES, V48, P4312; NAKAJIMA M, 1987, CANCER RES, V47, P4869; NAKAJIMA M, 1990, SEMIN CANCER BIOL, V1, P99; NERLOV C, 1991, ONCOGENE, V6, P1583; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PARTIN AW, 1989, P NATL ACAD SCI USA, V86, P1254, DOI 10.1073/pnas.86.4.1254; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; POWELL WC, 1993, CANCER RES, V53, P417; SATO H, 1992, ONCOGENE, V7, P77; SATO H, 1993, ONCOGENE, V8, P395; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETH A, 1990, ADV AP BIOT, V6, P297; SHINDOH M, 1995, OBSTET GYNECOL, V85, P721, DOI 10.1016/0029-7844(95)00043-Q; TAKAHASHI K, 1990, IN VITRO CELL DEV B, V26, P265; TANIGUCHI S, 1989, CANCER RES, V49, P6738; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; YOSHIDA K, 1995, CURR TOP MICROBIOL, V199, P113	41	118	119	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					221	227						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570199				2022-12-25	WOS:A1996TR53800001
J	Biggs, JR; Kudlow, JE; Kraft, AS				Biggs, JR; Kudlow, JE; Kraft, AS			The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEINS; DIFFERENTIATION; ENHANCER; KINASE; HL-60	The Waf1/Cip1 protein induces cell cycle arrest through inhibition of the activity of cyclin-dependent kinases and proliferating cell nuclear antigen, Expression of the WAF1/CIP1 gene is induced in a p53-dependent manner in response to DNA damage but can also be induced in the absence of p53 by agents such as growth factors, phorbol esters, and okadaic acid, WAF1/CIP1 expression in U937 human leukemic cells is induced by both phorbol ester, a protein kinase C activator, and by okadaic acid, an inhibitor of phosphatases 1 and 2A, Both of these agents induce the differentiation of these leukemic cells toward macrophages. We demonstrate that phorbol esters and okadaic acid stimulate transcription from the WAF1/CIP1 promoter in U937 cells, This transcription is mediated by a region of the promoter between -154 and +16, which contains two binding sites for the transcription factor Sp1, Deletion or mutation of these Sp1 sites reduces WAF1/CIP1 promoter response to phorbol ester and okadaic acid, while a reporter gene under the control of a promoter containing only multiple Sp1 binding sites and a TATA box is induced by phorbol ester and okadaic acid, The WAF1/CIP1 promoter is also highly induced by exogenous Sp1 in the Sp1-deficient Drosophila Schnieder SL 2 cell line, These results suggest that phorbol ester and okadaic acid activate transcription of the WAF1/CIP1 promoter through a complex of proteins that includes Spl and basal transcription factors.	UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DIV ENDOCRINOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NCI NIH HHS [CA42533] Funding Source: Medline; NIDDK NIH HHS [DK 43652] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043652] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADUYAH SE, 1991, J CELL PHYSL, V151, P415; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; CAO XM, 1993, J BIOL CHEM, V268, P16949; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDIERY W, 1994, CELL, V75, P817; FRIDOVICHKEIL JL, 1991, BIOTECHNIQUES, V11, P572; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P401; HASS R, 1989, EUR J CELL BIOL, V48, P282; ISHIDA Y, 1992, J CELL PHYSIOL, V150, P484, DOI 10.1002/jcp.1041500308; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JIANG HP, 1994, ONCOGENE, V9, P3397; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KRAFT AS, 1987, ONCOGENE, V1, P111; LEVIN DE, 1993, J NIH RES, V5, P49; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; MURATA Y, 1994, J BIOL CHEM, V269, P20674; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; YEN A, 1987, CANCER RES, V47, P129; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	35	203	203	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					901	906		10.1074/jbc.271.2.901	http://dx.doi.org/10.1074/jbc.271.2.901			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557703	hybrid			2022-12-25	WOS:A1996TP88900046
J	Guo, DQ; Donner, DB				Guo, DQ; Donner, DB			Tumor necrosis factor promotes phosphorylation and binding of insulin receptor substrate 1 to phosphatidylinositol 3-kinase in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; HEMATOPOIETIC-CELLS; GENE-EXPRESSION; FACTOR-ALPHA; FACTOR TNF; IRS-1; STIMULATION; ELEMENTS; OBESITY; DOMAINS	Chronic incubation of 3T3-L1 adipocytes with tumor necrosis factor (TNF) induces a state of insulin resistance characterized by a diminished ability of insulin to induce phosphorylation of the beta subunit of its own receptor and insulin receptor substrate 1 (IRS-1), When adipocytes are briefly pretreated with TNF and then stimulated with insulin, tyrosine phosphorylation of IRS-1 increases above the level induced by insulin alone, By itself, TNF induces the time-dependent tyrosine phosphorylation of proteins in 3T3-L1 adipocytes, Among these is IRS-1, a docking protein with tyrosine phosphorylation sites that bind cytoplasmic signaling molecules that contain Src homology 2 (SH2) domains, TNF stimulation of 3T3-L1 adipocytes also promotes the association of the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI 3-kinase) with IRS-1 and also its tyrosine phosphorylation, In murine 3T3-L1 adipocytes, IRS-1 and PI S-kinase phosphorylation and the association of these proteins are promoted by murine TNF, which interacts with the type 1 and type 2 TNF receptors. Human TNF, which binds to the murine type 1 TNF receptor selectively, also promotes IRS-1 phosphorylation and binding of IRS-1 to PI 3-kinase. This is the first demonstration that a member of the TNF/nerve growth factor receptor superfamily can use an IRS-1 signaling system as a component of its cellular response and provides a mechanism through which TNF receptors may engage downstream elements in signaling pathways.	INDIANA UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute								ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; FRY MJ, 1993, PHILOS T ROY SOC B, V340, P337, DOI 10.1098/rstb.1993.0076; GEHR G, 1992, J IMMUNOL, V149, P911; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; JACOBSEN FW, 1994, P NATL ACAD SCI USA, V91, P10695, DOI 10.1073/pnas.91.22.10695; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; LAM K, 1994, J BIOL CHEM, V269, P20648; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; MANCHESTER KM, 1993, BIOCHEM J, V290, P185, DOI 10.1042/bj2900185; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; OKADA T, 1994, J BIOL CHEM, V269, P3568; Panayotou George, 1992, Trends in Cell Biology, V2, P358, DOI 10.1016/0962-8924(92)90042-L; PAWSON T, 1988, ONCOGENE, V3, P491; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RIDDERSTRALE M, 1995, J BIOL CHEM, V270, P3471, DOI 10.1074/jbc.270.8.3471; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; SIDHU RS, 1993, PHARMACOL THERAPEUT, V57, P79, DOI 10.1016/0163-7258(93)90037-E; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SOUZA SC, 1994, J BIOL CHEM, V269, P30085; SPIEGELMAN BM, 1993, CELL, V73, P625, DOI 10.1016/0092-8674(93)90243-J; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WONG GHW, 1992, J IMMUNOL, V149, P3350	42	95	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					615	618		10.1074/jbc.271.2.615	http://dx.doi.org/10.1074/jbc.271.2.615			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557661	hybrid			2022-12-25	WOS:A1996TP88900004
J	Kuriyama, M; Harada, N; Kuroda, S; Yamamoto, T; Nakafuku, M; Iwamatsu, A; Yamamoto, D; Prasad, R; Croce, C; Canaani, E; Kaibuchi, K				Kuriyama, M; Harada, N; Kuroda, S; Yamamoto, T; Nakafuku, M; Iwamatsu, A; Yamamoto, D; Prasad, R; Croce, C; Canaani, E; Kaibuchi, K			Identification of AF-6 and canoe as putative targets for Ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; SIGNAL-TRANSDUCTION; SEPTATE JUNCTIONS; CLONING; HOMOLOG; GENE; ZO-1	Ras (Ha-Ras, Ki-Ras, N-Ras) is implicated in the regulation of various cell functions such as gene expression and cell proliferation downstream from specific extracellular signals. Here, we partially purified a Ras-inter acting protein with molecular mass of about 180 kDa (p180) from bovine brain membrane extract by glutathione S-transferase (GST) Ha-Ras affinity column chromatography. This protein bound to the GTP gamma S (guanosine 5'-(3-O-thio)triphosphate, a nonhydrolyzable GTP analog). GST-Ha-Ras affinity column but not to those containing GDP . GST-Ha-Ras or GTP gamma S . GST-Ha-Ras with a mutation in the effector domain (Ha-Ras(A38)). The amino acid sequences of the peptides derived from p180 were almost identical to those of human AF-6 that is identified as the fusion partner of the ALL-1 protein. The ALL-1/AF-6 chimeric protein is the critical product of the t (6:11) abnormality associated with some human leukemia. AF-6 has a GLGF/Dlg homology repeat (DHR) motif and shows a high degree of sequence similarity with Drosophila Canoe, which is assumed to function downstream from Notch in a common developmental pathway. The recombinant N-terminal domain of AF-6 and Canoe specifically interacted with GTP gamma S . GST-Ha-Ras. The known Ras target c-Raf-1 inhibited the interaction of AF 6 with GTP gamma S . GST-Ha-Ras. These results indicate that AF-6 and Canoe are putative targets for Ras.	NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,IKOMA 63001,JAPAN; KIRIN BREWERY CO LTD,CENT LABS KEY TECHNOL,YOKOHAMA,KANAGAWA 236,JAPAN; MITSUBISHI KASEI INST LIFE SCI,MACHIDA 194,TOKYO,JAPAN; ERATO YAMAMOTO BEHAV GENES PROJECT,MACHIDA,TOKYO 194,JAPAN; THOMAS JEFFERSON UNIV,PHILADELPHIA,PA 19107; WEIZMANN INST SCI,IL-76100 REHOVOT,ISRAEL	Nara Institute of Science & Technology; Kirin Brewery Company Limited; Japan Science & Technology Agency (JST); Jefferson University; Weizmann Institute of Science			Young, Richard A/F-6495-2012; KURODA, SHINYA/G-4961-2014; Nakafuku, Masato/J-3068-2013	Young, Richard A/0000-0001-8855-8647; , Daisuke/0000-0002-4623-0106; Nakafuku, Masato/0000-0001-7783-9005				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CATLING AD, 1994, J BIOL CHEM, V269, P30014; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HARLOW E, 1988, ANTIBODIES LABORATOR; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MIYAMOTO H, 1995, GENE DEV, V9, P612, DOI 10.1101/gad.9.5.612; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; PRASAD R, 1993, CANCER RES, V53, P5624; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; THEISEN H, 1994, DEVELOPMENT, V120, P347; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557	31	180	184	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					607	610		10.1074/jbc.271.2.607	http://dx.doi.org/10.1074/jbc.271.2.607			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557659	hybrid			2022-12-25	WOS:A1996TP88900002
J	Zwart, DE; Brewer, CB; Lazarovits, J; Henis, YI; Roth, MG				Zwart, DE; Brewer, CB; Lazarovits, J; Henis, YI; Roth, MG			Degradation of mutant influenza virus hemagglutinins is influenced by cytoplasmic sequences independent of internalization signals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; MEMBRANE-PROTEIN TRAFFICKING; FLUID-PHASE ENDOCYTOSIS; HAMSTER OVARY CELLS; AMINO-ACID CHANGE; PLASMA-MEMBRANE; INTRACELLULAR-TRANSPORT; TRANSFERRIN RECEPTOR; SURFACE GLYCOPROTEINS; COATED PITS	A mutant influenza virus hemagglutinin, HA+8, having a carboxyl-terminal extension of 8 amino acids that included 4 aromatic residues, was internalized within 2 min of arriving at the cell surface and was degraded quickly by a process that was inhibited by ammonium chloride, Through second site mutagenesis, the internalization sequence of HA+8 was found to closely resemble the internalization signals of the transferrin receptor or large mannose 6-phosphate receptor, Comparison of the intracellular traffic of HA+8 and a series of other HA mutants that differed in their rates of internalization revealed a relation between the amount of the protein on the plasma membrane at steady state and the internalization rate that would be predicted if most of each protein recycled to the cell surface. However, there was no simple correlation between the internalization rate and the rate of degradation, indicating that transport to the compartment where degradation occurred was not simply a function of the concentration of the proteins in early endosomes, The internal populations of both HA+8, which was degraded with a t(1/2) of 1.9 h, and HA-Y543, which was degraded with a t(1/2) of 2.9 h, were found by cell fractionation and density-shift experiments to reside in early endosomes with little accumulation in lysosomes, A fluid-phase marker reached lysosomes 3-4-fold faster than these proteins were degraded, Degradation of these mutant HAs involved a rate-determining step in early endosomes that was sensitive to some feature of the protein that depended upon sequence differences in the cytoplasmic domain unrelated to the internalization signal.	UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT BIOCHEM, IL-69978 TEL AVIV, ISRAEL	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tel Aviv University				Roth, Michael/0000-0002-9056-332X; Henis, Yoav/0000-0002-1408-3877	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037547] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37547] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AJIOKA RS, 1987, J CELL BIOL, V104, P77, DOI 10.1083/jcb.104.1.77; ANDERSON RGW, 1982, J CELL BIOL, V93, P523, DOI 10.1083/jcb.93.3.523; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; BURGERT HG, 1983, EXP CELL RES, V144, P127, DOI 10.1016/0014-4827(83)90447-0; COPELAND CS, 1986, J CELL BIOL, V103, P1179, DOI 10.1083/jcb.103.4.1179; COURTOY PJ, 1984, J CELL BIOL, V98, P870, DOI 10.1083/jcb.98.3.870; DAUKAS G, 1985, J CELL BIOL, V101, P1673, DOI 10.1083/jcb.101.5.1673; DOXSEY SJ, 1987, CELL, V50, P453, DOI 10.1016/0092-8674(87)90499-5; DOYLE C, 1985, J CELL BIOL, V100, P704, DOI 10.1083/jcb.100.3.704; DUNN KW, 1989, J CELL BIOL, V109, P3303, DOI 10.1083/jcb.109.6.3303; FIRE E, 1995, J BIOL CHEM, V270, P21075, DOI 10.1074/jbc.270.36.21075; FIRE E, 1991, J CELL BIOL, V115, P1585, DOI 10.1083/jcb.115.6.1585; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; GETHING MJ, 1980, NATURE, V287, P301, DOI 10.1038/287301a0; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GEUZE HJ, 1983, CELL, V32, P277, DOI 10.1016/0092-8674(83)90518-4; GREEN SA, 1994, J CELL BIOL, V124, P435, DOI 10.1083/jcb.124.4.435; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; HANSEN SH, 1992, EXP CELL RES, V199, P19, DOI 10.1016/0014-4827(92)90457-J; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HARTER C, 1992, J CELL BIOL, V117, P311, DOI 10.1083/jcb.117.2.311; HERBST JJ, 1994, J BIOL CHEM, V269, P12865; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HONING S, 1991, EUR J CELL BIOL, V55, P48; HOPKINS CR, 1992, TRENDS BIOCHEM SCI, V17, P27, DOI 10.1016/0968-0004(92)90423-7; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; HOPKINS CR, 1990, NATURE, V346, P335, DOI 10.1038/346335a0; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURZ JB, 1992, MOL PHARMACOL, V41, P375; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LAZAROVITS J, 1990, J BIOL CHEM, V265, P4760; LINDERMAN JJ, 1988, J THEOR BIOL, V132, P203, DOI 10.1016/S0022-5193(88)80157-7; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MATHEWS PM, 1992, J CELL BIOL, V118, P1027, DOI 10.1083/jcb.118.5.1027; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; MCGRAW TE, 1991, J CELL BIOL, V112, P853, DOI 10.1083/jcb.112.5.853; MELLMAN I, 1984, J CELL BIOL, V98, P1170, DOI 10.1083/jcb.98.4.1170; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; MIETTINEN HM, 1992, J CELL BIOL, V116, P875, DOI 10.1083/jcb.116.4.875; NAIM HY, 1994, METHOD CELL BIOL, V43, P113; NAIM HY, 1994, J BIOL CHEM, V269, P3928; NOLAN CM, 1987, J CELL BIOCHEM, V35, P137, DOI 10.1002/jcb.240350207; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; RAUB TJ, 1986, EXP CELL RES, V165, P73, DOI 10.1016/0014-4827(86)90534-3; ROBBINS AR, 1979, P NATL ACAD SCI USA, V76, P1911, DOI 10.1073/pnas.76.4.1911; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; SANDVIG K, 1990, J BIOL CHEM, V265, P6382; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; STEINMAN RM, 1976, J CELL BIOL, V68, P665, DOI 10.1083/jcb.68.3.665; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; STOORVOGEL W, 1987, J CELL BIOL, V104, P1261, DOI 10.1083/jcb.104.5.1261; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; TOOZE J, 1991, J CELL BIOL, V115, P635, DOI 10.1083/jcb.115.3.635; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WANG RH, 1990, J BIOL CHEM, V265, P20179; WARD DM, 1989, J BIOL CHEM, V264, P8164; WATTS C, 1988, EMBO J, V7, P1937, DOI 10.1002/j.1460-2075.1988.tb03031.x; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	63	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					907	917		10.1074/jbc.271.2.907	http://dx.doi.org/10.1074/jbc.271.2.907			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557704	hybrid			2022-12-25	WOS:A1996TP88900047
J	Franklin, CC; Kraft, AS				Franklin, CC; Kraft, AS			Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-Jun transcriptional activity in U937 human leukemic cells	ONCOGENE			English	Article						SAPK(JNK); MAPK(ERK); MEK; MPK-1; c-Jun	SERUM RESPONSE ELEMENT; PROTEIN-KINASE; ACTIVATION DOMAIN; SIGNAL-TRANSDUCTION; TERNARY COMPLEX; GENE-PRODUCT; FOS PROMOTER; PHOSPHORYLATION; DIFFERENTIATION; PROLIFERATION	Treatment of U937 human leukemic cells with the phorbol ester PMA, activates both mitogen-activated kinase (MAPK) and stress-activated protein kinase (SAPK), stimulates c-Jun phosphorylation and transcriptional activity, and induces a macrophage-like differentiation of U937 cells, The involvement of the MAPK pathway in mediating both the early phosphorylation and transcriptional activation events and the chronic differentiation of U937 cells was examined utilizing constitutively active MAPK kinase (MEK1) mutants, Transient expression of an activated MEK1 construct in U937 cells was found to stimulate MAPK and SAPK activity, as well as enhancing AP1-, SRE- and c-Jun-mediated transcriptional activity, Transient transfection of MAPK phosphatase-l (MKP-1), a protein phosphatase which preferentially dephosphorylates and inactivates MAPK, inhibited the functional effects of both PMA and the constitutively active MEK1 mutants, To determine whether specific activation of the MEK/MAPK pathway was sufficient to induce hematopoietic differentiation, U937 cell lines were established that conditionally expressed the activataed MEK1 mutant under the control of the human IIa metallothionein promoter, The induction of constitutively active MEK1 protein expression resulted in an increase in MEK1 activity, c-Jun and AP-1 transcriptional activity and an inhibition of U937 cell growth, However, this growth inhibition was not accompanied by U937 cell differentiation, These results suggest that a cross-talk mechanism exists between the MAPK and SAPK signal transduction pathways in U937 cells and that PMA-mediated SAPK activation may involve the MAPK pathway, Furthermore, selective activation of the MEK/MAPK pathway utilizing a constitutively active MEK1 mutant, while growth inhibitory, was not sufficient to induce the macrophage-like differentiation of U937 cells.	UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NCI NIH HHS [CA42533] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADUNYAH SE, 1992, J CELL PHYSIOL, V151, P415, DOI 10.1002/jcp.1041510223; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRUNET A, 1994, ONCOGENE, V9, P3379; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FRANKLIN CC, 1993, CELL GROWTH DIFFER, V4, P377; FRANKLIN CC, 1992, P NATL ACAD SCI USA, V89, P7247, DOI 10.1073/pnas.89.15.7247; FROST JA, 1994, P NATL ACAD SCI USA, V91, P3844, DOI 10.1073/pnas.91.9.3844; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU A, 1995, J BIOL CHEM, V270, P8377; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PERALDI P, 1994, P NATL ACAD SCI USA, V91, P5002, DOI 10.1073/pnas.91.11.5002; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; WAYS DK, 1994, CELL GROWTH DIFFER, V5, P1195; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; YAN MH, 1994, NATURE, V372, P798; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x	55	55	56	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2365	2374						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570188				2022-12-25	WOS:A1995TK70200021
J	Stoesz, SP; Gould, MN				Stoesz, SP; Gould, MN			Overexpression of neu-related lipocalin (NRL) in neu-initiated but not ras or chemically initiated rat mammary carcinomas	ONCOGENE			English	Article						lipocalin; neu; ras; mammary cancer	HUMAN-BREAST-CANCER; EPITHELIAL-CELLS; CLASS-I; GENE-EXPRESSION; PROTEIN FAMILY; ONCOGENE; SEQUENCE; GELATINASE; ANTIGENS; AMPLIFICATION	The activated neu (HER2/c-erbB-2) oncogene is extremely potent in inducing mammary cancer, For example, neu induces greater than 200 times as many tumors as the activated ras oncogene when directly introduced into in situ rat mammary epithelial cells using replication-defective retroviral vectors. In order to characterize mechanisms underlying this potency, we sought to identify uniquely overexpressed genes in neu-initiated tumors that were not overexpressed in tumors induced by weaker initiating agents, including activated ras and the chemical carcinogens dimethylbenz[a]anthracene and N-nitroso-N-methylurea. Several genes, including those encoding keratin K7 and the u haplotype of MHC class I RT1-A, were found to be overexpressed in neu-initiated carcinomas as well as in mammary carcinomas induced by other agents, when compared to their expression in normal mammary tissue, One gene, however, encoding a member of the lipocalin and calycin protein families, was 12-fold overexpressed in neu mammary tumors and was not overexpressed in ras or chemically induced carcinomas, This uniquely overexpressed gene was termed neu-related lipocalin (NRL). NRL protein was produced in a baculovirus system, purified and used to generate polyclonal antibodies, Western blot analysis indicated that neu-initiated mammary carcinomas express abundant NRL protein when compared to other mammary tumors.	UNIV WISCONSIN, DEPT HUMAN ONCOL, MADISON, WI 53792 USA; UNIV WISCONSIN, CELLULAR & MOLEC BIOL PROGRAM, MADISON, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Gould, Michael N/C-7414-2014		NCI NIH HHS [CA58328] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058328] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKERSTROM B, 1990, TRENDS BIOCHEM SCI, V15, P240, DOI 10.1016/0968-0004(90)90037-C; ANDERSSON LM, 1994, EXP CELL RES, V212, P389, DOI 10.1006/excr.1994.1159; BEDARD PA, 1989, MOL CELL BIOL, V9, P1371, DOI 10.1128/MCB.9.3.1371; BERGER MS, 1988, CANCER RES, V48, P1238; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BIFLOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BUNDGAARD JR, 1994, BIOCHEM BIOPH RES CO, V202, P1468, DOI 10.1006/bbrc.1994.2096; CANCEDDA FD, 1988, J CELL BIOL, V107, P2455, DOI 10.1083/jcb.107.6.2455; CHAN YL, 1988, NUCLEIC ACIDS RES, V16, P11368, DOI 10.1093/nar/16.23.11368; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DICKSON SR, 1992, J HISTOCHEM CYTOCHEM, V40, P697, DOI 10.1177/40.5.1315355; FLOWER DR, 1991, BIOCHEM BIOPH RES CO, V180, P69, DOI 10.1016/S0006-291X(05)81256-2; FLOWER DR, 1993, PROTEIN SCI, V2, P753, DOI 10.1002/pro.5560020507; GLASS C, 1985, J CELL BIOL, V101, P2366, DOI 10.1083/jcb.101.6.2366; GLASS C, 1988, J CELL BIOL, V107, P1337, DOI 10.1083/jcb.107.4.1337; GOULD MN, 1993, J CELL BIOCHEM, P66; GRAND RJA, 1987, INT J CANCER, V40, P213, DOI 10.1002/ijc.2910400215; HAAG JD, 1992, CANCER RES, V52, P4021; HRABARENEVEY S, 1989, ONCOGENE, V4, P601; KJELDSEN L, 1993, J BIOL CHEM, V268, P10425; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; MAUXION F, 1989, IMMUNOGENETICS, V29, P397, DOI 10.1007/BF00375868; MCCANN AH, 1991, CANCER RES, V51, P3296; MERUELO D, 1978, J EXP MED, V147, P470, DOI 10.1084/jem.147.2.470; MORRISON BW, 1994, ONCOGENE, V9, P3417; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH GH, 1990, CELL GROWTH DIFFER, V1, P161; STRANGE R, 1992, DEVELOPMENT, V115, P49; SWEETSER MT, 1989, NATURE, V342, P180, DOI 10.1038/342180a0; TETU B, 1994, CANCER, V73, P2359, DOI 10.1002/1097-0142(19940501)73:9<2359::AID-CNCR2820730919>3.0.CO;2-9; TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319; WANG BC, 1991, CANCER RES, V51, P2642; WANG BC, 1991, CANCER RES, V51, P5649; YANG YM, 1994, J CELL BIOL, V127, P1097, DOI 10.1083/jcb.127.4.1097	43	55	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2233	2241						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570173				2022-12-25	WOS:A1995TK70200006
J	vanLeeuwen, FN; vanderKammen, RA; Habets, GGM; Collard, JG				vanLeeuwen, FN; vanderKammen, RA; Habets, GGM; Collard, JG			Oncogenic activity of Tiam1 and Rac1 in NIH3T3 cells	ONCOGENE			English	Article						Tiam1; oncogene; GDP dissociation stimulator	PROTEINS	We have recently identified the invasion-inducing Tiam1 gene by proviral insertional mutagenesis. The Tiam1 protein shares a Dbl homology (DH) domain with an increasing number of oncoproteins, some of which have been shown to function as GDP dissociation stimulators (GDS) for small GTPases of the Rho family. In vitro and in vivo analyses indicate that Tiam1 activates the Rho like GTPase Rad. Here we have analysed the consequences of overexpression of several mutant Tiam1 proteins in NIH3T3 fibroblasts. Similar to other proteins containing a DH domain, N-terminal truncation of the Tiam1 protein activates its oncogenic potential, establishing Tiam1 as a proto-oncogene. In addition, we show that sequences N-terminal of the catalytic DH domain are required for morphological transformation accompanied by the formation of membrane ruffling, but not for the induction of an oncogenic phenotype. Overexpression of constitutively active Rac1 (V12Rac1) in NIH3T3 cells produces a similar oncogenic phenotype, suggesting that the oncogenic effects of Tiam1 are a consequence of Rac activation.	NETHERLANDS CANC INST,DIV CELL BIOL,ANTONI VAN LEEUWENHOEKHUIS,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute			van Leeuwen, Frank/AAQ-6799-2020	van Leeuwen, Frank/0000-0003-1107-6513				CHAN AML, 1994, ONCOGENE, V9, P1057; COLLARD JG, 1985, INT J CANCER, V35, P207, DOI 10.1002/ijc.2910350211; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PERONA R, 1993, ONCOGENE, V8, P1285; PONTING CP, 1995, TRENDS BIOCHEM SCI, V20, P102, DOI 10.1016/S0968-0004(00)88973-2; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RON D, 1989, ONCOGENE, V4, P1067; SELF AJ, 1993, ONCOGENE, V8, P655; TOKSOZ D, 1994, ONCOGENE, V9, P621; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	29	110	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2215	2221						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570171				2022-12-25	WOS:A1995TK70200004
J	FeldingHabermann, B; Habermann, R; Saldivar, E; Ruggeri, ZM				FeldingHabermann, B; Habermann, R; Saldivar, E; Ruggeri, ZM			Role of beta 3 integrins in melanoma cell adhesion to activated platelets under flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE PROTEINS; TUMOR-CELLS; EXPERIMENTAL METASTASIS; MURAL THROMBOGENESIS; VONWILLEBRAND-FACTOR; CANCER METASTASIS; IIB-IIIA; GLYCOPROTEIN-IIB/IIIA; VITRONECTIN RECEPTOR; ENDOTHELIAL-CELLS	Mechanisms mediating tumor cell attachment to the vessel wall under flow conditions are largely unknown, Therefore we analyzed the ability of human melanoma cells to adhere to an immobilized matrix during blood flow and determined the role of platelets in this process, In a parallel plate flow chamber, M21 melanoma cells were suspended in human blood and perfused over a collagen I matrix at a wall shear rate of 50 s(-1) (2 dynes/cm(2)) to simulate venous flow over a thrombogenic surface, Melanoma cell interaction with the matrix or blood cells and platelets was monitored and quantified by fluorescence and confocal laser microscopy, Despite their ability to adhere to collagen I under static conditions, M21 cells failed to attach directly to this matrix during blood flow, However, they associated with adherent thrombi, and this resulted in stable melanoma cell arrest, Inhibition of platelet activation or platelet integrin alpha IIb beta 3 function abolished M21 cell attachment, Melanoma cell interaction with thrombi was specific and required beta 3 integrin expression, M21-L cells which lack integrin alpha v beta 3 failed to associate with thrombi and to arrest during blood flow, Transfection of these cells with the integrin subunits alpha v or alpha IIb resulted in variants expressing alpha v beta 3, as in the wild type, or alpha IIb beta 3. Both variants were able to associate with thrombi and to arrest during blood flow, Therefore, beta 3 integrin-mediated binding to activated platelets represents an efficient mechanism for melanoma cell arrest under flow, and this may contribute to the role of platelets in hematogenous metastasis.			FeldingHabermann, B (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, MAILDROP SBR 8, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R29CA067988] Funding Source: NIH RePORTER; NCI NIH HHS [CA67988-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBELDA SM, 1990, CANCER RES, V50, P6757; ALEVRIADOU BR, 1993, BLOOD, V81, P1263; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; ASAKO H, 1994, J CLIN INVEST, V93, P1508, DOI 10.1172/JCI117129; BARNES MJ, 1985, COLLAGEN REL RES, V5, P65; BASTIDA E, 1988, HAEMOSTASIS, V18, P29; BASTIDA E, 1984, BLOOD, V64, P177; BAUMGARTNER HR, 1976, THROMB HAEMOSTASIS, V35, P124, DOI 10.1055/s-0038-1647919; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BIRCH M, 1991, CANCER RES, V51, P6660; BOUKERCHE H, 1989, BLOOD, V74, P658; BRASS LF, 1974, J CLIN INVEST, V54, P1480, DOI 10.1172/JCI107896; CAVANAUGH PG, 1988, HAEMOSTASIS, V18, P37; CHEN YQ, 1992, J BIOL CHEM, V267, P17314; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; COSTANTINI V, 1990, PROSTAGLANDINS, V39, P581, DOI 10.1016/0090-6980(90)90020-V; CRISSMAN JD, 1988, CANCER RES, V48, P4065; ESUMI N, 1991, CANCER RES, V51, P4549; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; FIDLER IJ, 1990, CANCER RES, V50, P6130; FOLIE BJ, 1989, BIOPHYS J, V56, P1121, DOI 10.1016/S0006-3495(89)82760-2; FOLIE BJ, 1988, BLOOD, V72, P1393; GASIC GJ, 1984, CANCER METAST REV, V3, P99, DOI 10.1007/BF00047657; GASIC GJ, 1973, INT J CANCER, V11, P704, DOI 10.1002/ijc.2910110322; GIAVAZZI R, 1993, J CLIN INVEST, V92, P3038, DOI 10.1172/JCI116928; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; GRIGNANI G, 1989, INVAS METAST, V9, P298; GRIGNANI G, 1988, BLOOD, V71, P844; GROSSI IM, 1988, FASEB J, V2, P2385, DOI 10.1096/fasebj.2.8.2452113; HOLME R, 1978, THROMB HAEMOSTASIS, V40, P89; HONN KV, 1992, CANCER METAST REV, V11, P325, DOI 10.1007/BF01307186; HONN KV, 1992, SEMIN THROMB HEMOST, V18, P392, DOI 10.1055/s-2007-1002578; HUBBELL JA, 1986, BIOMATERIALS, V7, P354, DOI 10.1016/0142-9612(86)90006-2; HUMPHRIES MJ, 1988, J CLIN INVEST, V81, P782, DOI 10.1172/JCI113384; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; JAMIESON GA, 1987, PLATELETS BIOL PATHO, V3, P161; KARPATKIN S, 1988, J CLIN INVEST, V81, P1012, DOI 10.1172/JCI113411; KIEFFER N, 1991, J CELL BIOL, V113, P451, DOI 10.1083/jcb.113.2.451; KIMOTO M, 1993, CLIN EXP METASTAS, V11, P285, DOI 10.1007/BF00121171; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; LONGENECKER GL, 1989, CANCER RES, V49, P16; MCGREGOR BC, 1989, AM J CLIN PATHOL, V92, P495, DOI 10.1093/ajcp/92.4.495; MENTER DG, 1991, CELL BIOPHYS, V18, P123, DOI 10.1007/BF02989810; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; NIERODZIK ML, 1991, J CLIN INVEST, V87, P229, DOI 10.1172/JCI114976; NIIYA K, 1987, BLOOD, V70, P475; PATTON JT, 1993, CELL MOTIL CYTOSKEL, V26, P88, DOI 10.1002/cm.970260109; PATTON JT, 1994, MATER RES SOC S P, V133, P147; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; PEARLSTEIN E, 1984, CANCER RES, V44, P3884; PISCHEL KD, 1988, J CLIN INVEST, V81, P505, DOI 10.1172/JCI113348; RICE GE, 1989, SCIENCE, V246, P1303, DOI 10.1126/science.2588007; RICKLES FR, 1988, SEMIN THROMB HEMOST, V14, P126, DOI 10.1055/s-2007-1002765; RUGGERI ZM, 1993, FASEB J, V7, P308, DOI 10.1096/fasebj.7.2.8440408; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; SAELMAN EUM, 1994, BLOOD, V83, P1244; SAIKI I, 1989, BRIT J CANCER, V60, P722, DOI 10.1038/bjc.1989.347; SMITH CW, 1993, SEMIN HEMATOL, V30, P45; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SOSZKA T, 1991, EXP CELL RES, V196, P6, DOI 10.1016/0014-4827(91)90449-5; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STONE JP, 1993, J CLIN INVEST, V92, P804, DOI 10.1172/JCI116654; TANG DG, 1993, INT J CANCER, V54, P338, DOI 10.1002/ijc.2910540229; TIMPL R, 1993, EXPERIENTIA, V49, P417, DOI 10.1007/BF01923586; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TOHGO A, 1985, INVAS METAST, V5, P96; TZANAKAKIS GN, 1993, CANCER, V71, P2466, DOI 10.1002/1097-0142(19930415)71:8<2466::AID-CNCR2820710807>3.0.CO;2-Q; UGEN KE, 1988, J NATL CANCER I, V80, P1461, DOI 10.1093/jnci/80.18.1461; WEISS L, 1989, CELL BIOPHYS, V14, P187, DOI 10.1007/BF02797133; WHITMORE RL, 1968, RHEOLOGY CIRCULATION, P90; WOJTUKIEWICZ MZ, 1993, INT J CANCER, V54, P793, DOI 10.1002/ijc.2910540514	73	132	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5892	5900		10.1074/jbc.271.10.5892	http://dx.doi.org/10.1074/jbc.271.10.5892			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621462	hybrid			2022-12-25	WOS:A1996TZ28600088
J	Ram, PA; Park, SH; Choi, HK; Waxman, DJ				Ram, PA; Park, SH; Choi, HK; Waxman, DJ			Growth hormone activation of Stat 1, Stat 3, and Stat 5 in rat liver - Differential kinetics of hormone desensitization and growth hormone stimulation of both tyrosine phosphorylation and serine/threonine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS; FACTOR-I; GENE-EXPRESSION; BINDING PROTEIN; MOUSE-LIVER; RECEPTOR; TRANSCRIPTION; INDUCTION; KINASE; GH	Intermittent plasma growth hormone (GH) pulses, which occur in male but not female rats, activate liver Stat 5 by a mechanism that involves tyrosine phosphorylation and nuclear translocation of this latent cytoplasmic transcription factor (Waxman, D. J., Ram, P. A., Park, S. H., and Choi, H. K. (1995) J. Biol. Chem. 270, 13262-13270). We demonstrate that physiological levels of GH can also activate Stat 1 and Stat 3 in liver tissue, but with a dependence on the dose of GH and its temporal plasma profile that is distinct from Stat 5 and with a striking desensitization following a single hormone pulse that is not observed with liver Stat 5. GH activation of the two groups of Stats leads to their selective binding to DNA response elements upstream of the c-fos gene (c-sis-inducible enhancer element; Stat 1 and Stat 3 binding) and the beta-casein gene (mammary gland factor element; Liver Stat 5 binding). In addition to tyrosine phosphorylation, GH is shown to stimulate phosphorylation of these Stats on serine or threonine in a manner that either enhances (Stat 1 and Stat 3) or substantially alters (Liver Stat 5) the binding of each Stat to its cognate DNA response element. These findings establish the occurrence of multiple, Stat-dependent GH signaling pathways in liver cells that can target distinct genes and thereby contribute to the diverse effects that GH and its sexually dimorphic plasma profile have on liver gene expression.	BOSTON UNIV,DEPT BIOL,DIV CELL & MOLEC BIOL,BOSTON,MA 02215	Boston University				Waxman, David/0000-0001-7982-9206	NIDDK NIH HHS [DK33765] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033765, R56DK033765] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1995, J BIOL CHEM, V270, P14685, DOI 10.1074/jbc.270.24.14685; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; BAUMBACH WR, 1995, ENDOCRINOLOGY, V136, P749, DOI 10.1210/en.136.2.749; BICK T, 1992, ENDOCRINOLOGY, V131, P423, DOI 10.1210/en.131.1.423; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; COHEN P, 1989, J BIOL CHEM, V264, P21435; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DOGLIO A, 1989, P NATL ACAD SCI USA, V86, P1148, DOI 10.1073/pnas.86.4.1148; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; GRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171, DOI 10.1210/me.9.2.171; GURLAND G, 1990, ENDOCRINOLOGY, V127, P3187, DOI 10.1210/endo-127-6-3187; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; ISGAARD J, 1988, ENDOCRINOLOGY, V123, P2605, DOI 10.1210/endo-123-6-2605; JANSSON JO, 1988, J CLIN INVEST, V82, P1871, DOI 10.1172/JCI113804; JOHNSON D, 1995, J MOL ENDOCRINOL, V14, P21, DOI 10.1677/jme.0.0140021; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LEBRUN JJ, 1995, J BIOL CHEM, V270, P10664, DOI 10.1074/jbc.270.18.10664; LECAM A, 1994, J BIOL CHEM, V269, P21532; LEGRAVEREND C, 1992, MOL ENDOCRINOL, V6, P259, DOI 10.1210/me.6.2.259; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; LUTTICKEN C, 1995, FEBS LETT, V360, P137, DOI 10.1016/0014-5793(95)00076-L; MAITER D, 1992, ENDOCRINOLOGY, V130, P3257, DOI 10.1210/en.130.6.3257; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MEYER DJ, 1993, P NATL ACAD SCI USA, V90, P6721, DOI 10.1073/pnas.90.14.6721; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NAGANO M, 1994, J BIOL CHEM, V269, P13337; NORSTEDT G, 1984, CELL, V36, P805, DOI 10.1016/0092-8674(84)90030-8; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; POSTELVINAY MC, 1976, FEBS LETT, V69, P137, DOI 10.1016/0014-5793(76)80670-9; RUDLING M, 1992, P NATL ACAD SCI USA, V89, P6983, DOI 10.1073/pnas.89.15.6983; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; RUFFJAMISON S, 1995, P NATL ACAD SCI USA, V92, P4215, DOI 10.1073/pnas.92.10.4215; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SILVA CM, 1994, J BIOL CHEM, V269, P27532; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SRIVASTAVA PK, 1993, BIOCHEM J, V294, P159, DOI 10.1042/bj2940159; SUNDSETH SS, 1992, J BIOL CHEM, V267, P3907; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WANG XZ, 1995, J BIOL CHEM, V270, P6261, DOI 10.1074/jbc.270.11.6261; WANG YD, 1995, MOL ENDOCRINOL, V9, P303, DOI 10.1210/me.9.3.303; WAXMAN DJ, 1992, J STEROID BIOCHEM, V43, P1055, DOI 10.1016/0960-0760(92)90333-E; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; WAXMAN DJ, 1991, P NATL ACAD SCI USA, V88, P6868, DOI 10.1073/pnas.88.15.6868; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WESTIN S, 1992, J STEROID BIOCHEM, V43, P1045, DOI 10.1016/0960-0760(92)90332-D; WINSTON LA, 1992, J BIOL CHEM, V267, P4747; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; YAMADA K, 1984, BIOCHEM J, V220, P361, DOI 10.1042/bj2200361; YAMAZOE Y, 1989, MOL PHARMACOL, V35, P707; YOON JB, 1990, J BIOL CHEM, V265, P19947; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	71	201	203	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5929	5940		10.1074/jbc.271.10.5929	http://dx.doi.org/10.1074/jbc.271.10.5929			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621467	hybrid			2022-12-25	WOS:A1996TZ28600093
J	Zhang, R; Buczko, E; Dufau, ML				Zhang, R; Buczko, E; Dufau, ML			Requirement of cysteine residues in exons 1-6 of the extracellular domain of the luteinizing hormone receptor for gonadotropin binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THYROTROPIN RECEPTOR; SITE-DIRECTED MUTAGENESIS; FUNCTIONAL EXPRESSION; HIGH-AFFINITY; RAT; CELLS; MUTATION; GENE; CDNA; TSH	The functional importance of cysteine residues in the extracellular domain and the extracellular loops (EL1 and EL2) to hormone binding of the rat luteinizing hormone receptor (LHR) was investigated. For this purpose, cysteines in the seven-transmembrane holoreceptor (Form A) and its hormone-binding splice variant (Form B) were replaced by serine residues, and mutant receptors were expressed in COS1 and/or insect cells. Within the extracellular domain, individual replacement of all four cysteines from Exon 1 abolished hormone binding activity, and replacement of Cys-109 and Cys-134 from exons 5 and 6 caused a 75% decrease in both cell surface and total cellular solubilized LHR hormone binding activity. Mutations of Cys-257 and -258 (Exon 9), Cys-321 and -331, and Cys-417 and -492 of EL1 and EL2, respectively (Exon 11), showed no surface hormone binding activity on intact cells, but exhibited wild type levels of total hormone binding activity when recovered from detergent-solubilized cellular extracts. This finding indicated that expression of high affinity LHR binding activity at the cell surface is independent of the acquisition of the high affinity binding conformation. Other cysteine residues, including Cys-282 (exon 10), and Cys-314 (exon 11) were not essential for hormone binding activity or plasma membrane insertion. This study demonstrates that the functional hormone binding domain utilizes all cysteines N-terminal to exon 7 and localizes the binding site to this N-terminal region of the extracellular domain.	NICHHD,NIH,SECT MOLEC ENDOCRINOL,ENDOCRINOL & REPROD RES BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								CATT KJ, 1976, METHODS RECEPTOR RES, V1, P175; DUFAU ML, 1977, P NATL ACAD SCI USA, V74, P3419, DOI 10.1073/pnas.74.8.3419; DUFAU ML, 1990, RECEPTOR PURIFICATIO, P147; FRASER CM, 1989, J BIOL CHEM, V264, P9266; JI I, 1991, ENDOCRINOLOGY, V126, P2648; JONES DH, 1990, BIOTECHNIQUES, V8, P178; KARNIK SS, 1993, P NATL ACAD SCI USA, V90, P40, DOI 10.1073/pnas.90.1.40; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KAWATE N, 1994, J BIOL CHEM, V269, P30651; KETELSLEGERS JM, 1975, BIOCHEMISTRY-US, V14, P3075, DOI 10.1021/bi00685a006; KOH YC, 1993, J BIOL CHEM, V268, P18267; KOSUGI S, 1992, BIOCHEM BIOPH RES CO, V189, P1754, DOI 10.1016/0006-291X(92)90281-O; KUHL PW, 1985, EXPERIENTIA, V41, P1118; KUSUDA S, 1986, J BIOL CHEM, V261, P6161; LOOSFELT H, 1992, P NATL ACAD SCI USA, V89, P3765, DOI 10.1073/pnas.89.9.3765; MCFARLAND K, 1969, SCIENCE, V245, P494; NAGAYAMA Y, 1990, BIOCHEM BIOPH RES CO, V173, P1150, DOI 10.1016/S0006-291X(05)80906-4; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; ROBILLARD GT, 1982, EUR J BIOCHEM, V127, P597; SAVARESE TM, 1992, J BIOL CHEM, V267, P11439; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; WANG Z, 1993, MOL ENDOCRINOL, V7, P85, DOI 10.1210/me.7.1.85; XIE YB, 1990, J BIOL CHEM, V265, P21411; ZHANG R, 1995, J BIOL CHEM, V270, P21722, DOI 10.1074/jbc.270.37.21722; ZHU HY, 1995, MOL ENDOCRINOL, V9, P141, DOI 10.1210/me.9.2.141	27	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5755	5760		10.1074/jbc.271.10.5755	http://dx.doi.org/10.1074/jbc.271.10.5755			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621442	hybrid			2022-12-25	WOS:A1996TZ28600068
J	Groisman, R; Masutani, H; Leibovitch, MP; Robin, P; Soudant, I; Trouche, D; HarelBellan, A				Groisman, R; Masutani, H; Leibovitch, MP; Robin, P; Soudant, I; Trouche, D; HarelBellan, A			Physical interaction between the mitogen-responsive serum response factor and myogenic basic-helix-loop-helix proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-FACTOR; MUSCLE-SPECIFIC GENES; CREATINE-KINASE ENHANCER; CARDIAC ACTIN GENE; C-FOS; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; PROMOTER ELEMENTS; SPLICING FACTORS; XENOPUS EMBRYOS	Terminal differentiation of muscle cells results in opposite effects on gene promoters: muscle-specific promoters, which are repressed during active proliferation of myoblasts, are turned on, whereas at least some proliferation-associated promoters, such as c-fos, which are active during cell division, are turned off. MyoD and myogenin, transcription factors from the basic-helix-loop-helix (bHLH) family, are involved in both processes, up-regulating muscle genes and down-regulating c-fos. On the other hand, the serum response factor (SRF) is involved in the activation of muscle-specific genes, such as c-fos, as well as in the up-regulation of a subset of genes that are responsive to mitogens. Upon terminal differentiation, the activity of these various transcription factors could be modulated by the formation of distinct protein-protein complexes. Here, we have investigated the hypothesis that the function of SRF and/or MyoD and myogenin could be modulated by a physical association between these transcription factors. We show that myogenin from differentiating myoblasts specifically binds to SRF. In, vitro analysis, using the glutathione S-transferase pull-down assay, indicates that SRF-myogenin interactions occur only with myogenin-E12 heterodimers and not with isolated myogenin. A physical interaction between myogenin, E12, and SRF could also be demonstrated in vivo using a triple-hybrid approach in yeast. Glutathione S-transferase pull-down analysis of vari ous mutants of the proteins demonstrated that the bHLH domain of myogenin and that of E12 were necessary and sufficient for the interaction to be observed. Specific binding to SRF was also seen with MyoD. In contrast, Id, a natural inhibitor of myogenic bHLH proteins, did not bind SRF in any of the situations tested. These data suggest that SRF, on one hand, and myogenic bHLH, on the other, could modulate each other's activity through the formation of a heterotrimeric complex.	INST GUSTAVE ROUSSY,LAB BIOL TUMEURS HUMAINES,CNRS,URA 1156,F-94805 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA 1967,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy			Trouche, Didier/B-2854-2008; Masutani, Hiroshi/B-5114-2014; Harel-Bellan, Annick/M-9795-2015	Groisman, Regina/0000-0003-3990-7622; Harel-Bellan, Annick/0000-0002-2339-153X; Groisman, Sonia/0000-0003-1153-3841; Trouche, Didier/0000-0003-1398-6481; Masutani, Hiroshi/0000-0001-7633-2827				AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P3822, DOI 10.1073/pnas.88.9.3822; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BRENNAN TJ, 1991, P NATL ACAD SCI USA, V88, P5675, DOI 10.1073/pnas.88.13.5675; CATALA F, 1995, MOL CELL BIOL, V15, P4585; CHAKRABORTY T, 1991, MOL CELL BIOL, V11, P3633, DOI 10.1128/MCB.11.7.3633; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; CSERJESI P, 1991, MOL CELL BIOL, V11, P4854, DOI 10.1128/MCB.11.10.4854; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; EDMONDSON DG, 1991, J BIOL CHEM, V266, P21343; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; FUNK WD, 1992, P NATL ACAD SCI USA, V89, P9484, DOI 10.1073/pnas.89.20.9484; GILGENKRANTZ H, 1992, J BIOL CHEM, V267, P10823; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GROSSI M, 1991, ONCOGENE, V6, P1767; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; LEGRAIN P, 1993, SCIENCE, V262, P108, DOI 10.1126/science.8211114; LEGRAIN P, 1993, GENE DEV, V7, P1390, DOI 10.1101/gad.7.7b.1390; LEIBOVITCH MP, 1987, EXP CELL RES, V170, P80, DOI 10.1016/0014-4827(87)90118-2; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LIN H, 1992, J BIOL CHEM, V267, P4773; MARTIN JF, 1992, J BIOL CHEM, V267, P10956; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MIWA T, 1987, MOL CELL BIOL, V7, P2803, DOI 10.1128/MCB.7.8.2803; MOHUN TJ, 1989, EMBO J, V8, P1153, DOI 10.1002/j.1460-2075.1989.tb03486.x; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MUSCAT GE, 1988, MOL CELL BIOL, V8, P4120, DOI 10.1128/MCB.8.10.4120; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1991, MOL CELL BIOCHEM, V104, P7; PASSMORE S, 1989, GENE DEV, V3, P921, DOI 10.1101/gad.3.7.921; PHANDINHTUY F, 1988, EUR J BIOCHEM, V173, P507, DOI 10.1111/j.1432-1033.1988.tb14027.x; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; QUITSCHKE WW, 1989, MOL CELL BIOL, V9, P3218, DOI 10.1128/MCB.9.8.3218; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHWARZ JJ, 1992, MOL CELL BIOL, V12, P266, DOI 10.1128/MCB.12.1.266; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHARROCKS AD, 1993, MOL CELL BIOL, V13, P123, DOI 10.1128/MCB.13.1.123; SIKORSKI RS, 1989, GENETICS, V122, P19; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; SOULEZ M, 1993, BIOCHEM BIOPH RES CO, V195, P400, DOI 10.1006/bbrc.1993.2057; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TAYLOR M, 1989, DEVELOPMENT, V106, P67; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TROUCHE D, 1993, BIOCHEM BIOPH RES CO, V196, P611, DOI 10.1006/bbrc.1993.2293; TROUCHE D, 1993, NATURE, V363, P79, DOI 10.1038/363079a0; TROUCHE D, 1995, FEBS LETT, V361, P140, DOI 10.1016/0014-5793(95)00140-5; TUIL D, 1990, J MOL BIOL, V213, P677, DOI 10.1016/S0022-2836(05)80255-4; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	80	97	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5258	5264						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617811				2022-12-25	WOS:A1996TX69700101
J	Luisiri, P; Lee, YJ; Eisfelder, BJ; Clark, MR				Luisiri, P; Lee, YJ; Eisfelder, BJ; Clark, MR			Cooperativity and segregation of function within the Ig-alpha/beta heterodimer of the B cell antigen receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; ZETA-CHAIN; SIGNAL-TRANSDUCTION; T-CELLS; IMMUNOGLOBULIN; BETA; ASSOCIATION; STIMULATION; ACTIVATION; PATHWAYS	The B cell antigen receptor complex contains heterodimers of Ig-alpha and Ig-beta. The cytoplasmic tails of each of these chains contain two conserved tyrosines, phosphorylation of which initiates the signal transduction cascades activated by the receptor complex. Although the cytoplasmic domains of Ig-alpha and Ig-beta have been expressed individually and demonstrated to be competent signal transduction units, we postulated that within the context of a heterodimer, Ig-alpha and Ig-beta could have new, complementary or even synergistic functions. Therefore we developed a system to compare the signal transducing capacities of dimers of Ig-alpha/Ig-alpha, Ig-beta/Ig-beta, or Ig-alpha/Ig-beta. This was done by fusing the extracellular and transmembrane domains of either human platelet-derived growth factor receptor (PDGFR) alpha or beta to the cytoplasmic tail of either Ig-alpha or Ig-beta. Three cell lines expressing PDGFR beta/Ig-alpha, PDGFR beta/Ig-beta, or PDGFR alpha/Ig-beta together with PDGFR beta/Ig-alpha were established in the murine B cell line A20 IIA1.6. While aggregation of each dimer by itself could induce the tyrosine phosphorylation of cellular substrates, only aggregation of the heterodimer induced the phosphorylation of substrates similar in range and intensity to that induced by the endogenous B cell antigen receptor complex. Interestingly, Ig-beta remarkably enhanced the rapidity (T-max decreased from 5 to 1 min) and intensity (greater than 10-fold enhancement) of Ig-alpha phosphorylation. Conversely, the phosphorylation of Ig-beta was reduced to undetectable levels when co-aggregated with Ig-alpha. The enhancement of Ig-alpha phosphorylation by Ig-beta correlated with a lowering of the stimulation threshold for tyrosine kinase activation.	UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PATHOL,CHICAGO,IL 60637	University of Chicago; University of Chicago					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052736] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52736] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALARCON B, 1991, EMBO J, V10, P903, DOI 10.1002/j.1460-2075.1991.tb08023.x; BURKHARDT AL, 1994, MOL CELL BIOL, V14, P1095, DOI 10.1128/MCB.14.2.1095; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMBIER JC, 1995, IMMUNOL LETT, V44, P77, DOI 10.1016/0165-2478(94)00196-X; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CAMPBELL KS, 1990, EMBO J, V9, P441, DOI 10.1002/j.1460-2075.1990.tb08129.x; CAMPBELL KS, 1991, P NATL ACAD SCI USA, V88, P3982, DOI 10.1073/pnas.88.9.3982; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHOQUET D, 1994, J BIOL CHEM, V269, P6491; CLARK MR, 1992, J IMMUNOL, V149, P2857; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLD MR, 1994, J IMMUNOL, V153, P2369; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JONES B, 1986, J IMMUNOL, V136, P348; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KIM KM, 1993, EUR J IMMUNOL, V23, P911, DOI 10.1002/eji.1830230422; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; PAPAVASILIOU F, 1995, SCIENCE, V268, P408, DOI 10.1126/science.7716544; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; RETH M, 1991, IMMUNOL TODAY, V12, P196, DOI 10.1016/0167-5699(91)90053-V; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; SAMELSON LE, 1985, P NATL ACAD SCI USA, V82, P1969, DOI 10.1073/pnas.82.7.1969; SANCHEZ M, 1993, J EXP MED, V178, P1049, DOI 10.1084/jem.178.3.1049; SANDERS VM, 1987, J IMMUNOL, V139, P2349; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SONYANG Z, 1993, CELL, V72, P767; TSENG J, 1994, IMMUNOL RES, V13, P299, DOI 10.1007/BF02935621; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	38	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5158	5163						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617796				2022-12-25	WOS:A1996TX69700086
J	Haga, K; Kameyama, K; Haga, T; Kikkawa, U; Shiozaki, K; Uchiyama, H				Haga, K; Kameyama, K; Haga, T; Kikkawa, U; Shiozaki, K; Uchiyama, H			Phosphorylation of human m1 muscarinic acetylcholine receptors by G protein-coupled receptor kinase 2 and protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-DEPENDENT PHOSPHORYLATION; BETA-GAMMA-SUBUNITS; CHOLINERGIC RECEPTORS; RHODOPSIN KINASE; INSECT CELLS; BINDING; ACTIVATION; DESENSITIZATION; DIVERSITY; SUBSTRATE	Human muscarinic acetylcholine receptor m1 subtypes (m1 receptors) were expressed in and purified from insect Sf9 cells and then subjected to phosphorylation by G protein-coupled receptor kinase 2 (GRK2) expressed in and purified from Sf9 cells and by protein kinase C purified from rat brain (a mixture of alpha, beta, and gamma types, PKC). The m1 receptor was phosphorylated by either GRK2 or PKC in an agonist-dependent or independent manner, respectively, G protein beta gamma subunits stimulated the phosphorylation by GRK2 but did not affect the phosphorylation by PKC. The number of incorporated phosphates was 4.6 and 2.8 mol/mol of receptor for phosphorylation by GRK2 and PKC, respectively, The number of incorporated phosphates was 7.5 mol/mol receptor for phosphorylation by GRK2 followed by PKC, but was 5.8 mol/mol of receptor for the phosphorylation by PKC followed by GRK2. Major sites phosphorylated by GRK2 and PKC were located in the third intracellular loop and the carboxyl-terminal tail, respectively, These results indicate that GRK2 and PKC phosphorylate different sites of mi receptors and that the phosphorylation by PKC partially inhibits the phosphorylation by GRK2, probably by affecting activation of GRK2 by agonist-bound receptors.	KOBE UNIV,BIOSIGNAL RES CTR,NADA KU,KOBE 657,JAPAN; NATL DEF MED COLL,DEPT PHARMACOL,TOKOROZAWA,SAITAMA 359,JAPAN; HAMAMATSU RED CROSS HOSP,DEPT NEUROSURG,HAMAMATSU,SHIZUOKA,JAPAN	Kobe University; National Defense Medical College - Japan	Haga, K (corresponding author), UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT BIOCHEM,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.							BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BERSTEIN B, 1990, CURRENT ASPECTS NEUR, P245; BERSTEIN G, 1989, MOL PHARMACOL, V36, P601; BONNER TI, 1989, TRENDS NEUROSCI, V12, P148, DOI 10.1016/0166-2236(89)90054-4; DEBBURMAN SK, 1995, MOL PHARMACOL, V47, P224; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; FOWLES C, 1988, FEBS LETT, V238, P56, DOI 10.1016/0014-5793(88)80224-2; HAGA K, 1994, J BIOL CHEM, V269, P12594; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, J NEUROCHEM, V54, P1639, DOI 10.1111/j.1471-4159.1990.tb01216.x; HAGA K, 1989, BIOMED RES-TOKYO, V10, P293, DOI 10.2220/biomedres.10.293; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAGA K, 1986, J BIOL CHEM, V261, P133; HAGA K, 1985, J BIOL CHEM, V260, P7927; HAGA T, 1993, LIFE SCI, V52, P421, DOI 10.1016/0024-3205(93)90297-G; HAGA T, 1994, J NEUROCHEM, V63, P400; HAGA T, 1995, MOL B INT U, P227; HOSEY MM, 1992, FASEB J, V6, P845, DOI 10.1096/fasebj.6.3.1740234; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KAMEYAMA K, 1994, EUR J BIOCHEM, V226, P267, DOI 10.1111/j.1432-1033.1994.tb20050.x; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kitano T, 1986, Methods Enzymol, V124, P349; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUROSE H, 1994, J BIOL CHEM, V269, P10093; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; KWATRA MM, 1989, BIOCHEMISTRY-US, V28, P4543, DOI 10.1021/bi00437a005; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; MORO O, 1993, J BIOL CHEM, V268, P6862; NAKAMURA F, 1995, J BIOL CHEM, V270, P6246, DOI 10.1074/jbc.270.11.6246; NAKATA H, 1994, EUR J BIOCHEM, V220, P29, DOI 10.1111/j.1432-1033.1994.tb18595.x; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PARKER EM, 1991, J BIOL CHEM, V266, P519; PHILLIPS WJ, 1992, J BIOL CHEM, V267, P17032; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; RICHARDSON RM, 1990, BIOCHEMISTRY-US, V29, P8555, DOI 10.1021/bi00489a008; RICHARDSON RM, 1992, J BIOL CHEM, V267, P22249; TSU TC, 1995, J BIOL CHEM, V270, P18660; TSUGA H, 1994, J BIOL CHEM, V269, P32522; UCHIYAMA H, 1990, J NEUROCHEM, V54, P1870, DOI 10.1111/j.1471-4159.1990.tb04885.x	46	74	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2776	2782		10.1074/jbc.271.5.2776	http://dx.doi.org/10.1074/jbc.271.5.2776			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576254	hybrid			2022-12-25	WOS:A1996TT48800068
J	Ichtchenko, K; Nguyen, T; Sudhof, TC				Ichtchenko, K; Nguyen, T; Sudhof, TC			Structures, alternative splicing, and neurexin binding of multiple neuroligins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO-CALIFORNICA; ACETYLCHOLINESTERASE; SEQUENCE; CLONING; ALPHA	Neuroligin 1 is a neuronal cell surface protein that binds to a subset of neurexins, polymorphic cell surface proteins that are also localized on neurons (Ichtchenko, K., Hata, Y., Nguyen, T., Ullrich, B., Missler, M., Moomaw, C., and Sudhof, T. C. (1995) Cell 81, 435-443), We now describe two novel neuroligins called neuroligins 2 and 3 that are similar in structure and sequence to neuroligin 1. All neuroligins contain an N-terminal hydrophobic sequence with the characteristics of a cleaved signal peptide followed by a large esterase homology domain, a highly conserved single transmembrane region, and a short cytoplasmic domain, The three neuroligins are alternatively spliced at the same position and are ex pressed at high levels only in brain, Binding studies demonstrate that all three neuroligins bind to beta-neurexins both as native brain proteins and as recombinant proteins, Tight binding of the three neuroligins to beta-neurexins is observed only for beta-neurexins lacking an insert in splice site 4. Thus, neuroligins constitute a multigene family of brain-specific proteins with distinct isoforms that may have overlapping functions in mediating recognition processes between neurons.	UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIMH NIH HHS [R01-MH52804] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AULD VJ, 1995, CELL, V81, P757, DOI 10.1016/0092-8674(95)90537-5; DILAURO R, 1985, EUR J BIOCHEM, V148, P7; FOURNIER D, 1988, FEBS LETT, V238, P333, DOI 10.1016/0014-5793(88)80507-6; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; NAGAO T, 1993, J BIOCHEM, V113, P776, DOI 10.1093/oxfordjournals.jbchem.a124117; ROBBI M, 1990, BIOCHEM J, V269, P451, DOI 10.1042/bj2690451; SCHUMACHER M, 1986, NATURE, V319, P407, DOI 10.1038/319407a0; SCHUMACHER M, 1988, J BIOL CHEM, V263, P18979; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; ULLRICH B, 1995, NEURON, V14, P497, DOI 10.1016/0896-6273(95)90306-2; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; USHKARYOV YA, 1994, J BIOL CHEM, V269, P11987; USHKARYOV YA, 1993, P NATL ACAD SCI USA, V90, P6410, DOI 10.1073/pnas.90.14.6410; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	17	349	366	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2676	2682		10.1074/jbc.271.5.2676	http://dx.doi.org/10.1074/jbc.271.5.2676			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576240	hybrid			2022-12-25	WOS:A1996TT48800054
J	WeygandDurasevic, I; Lenhard, D; Filipic, S; Soll, D				WeygandDurasevic, I; Lenhard, D; Filipic, S; Soll, D			The C-terminal extension of yeast seryl-tRNA synthetase affects stability of the enzyme and its substrate affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; LYSYL-TRANSFER RNA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; MULTISYNTHETASE COMPLEX; GENE; CLONING; DOMAIN; FAMILY; CONSTRUCTION	Saccharomyces cerevisiae seryl-tRNA synthetase (SerRS) contains a 20-amino acid C-terminal extension, which is not found in prokaryotic SerRS enzymes. A truncated yeast SES1 gene, lacking the 60 base pairs that encode this C-terminal domain, is able to complement a yeast SES1 null allele strain; thus, the C-terminal extension in SerRS is dispensable for the viability of the cell. However, the removal of the C-terminal peptide affects both stability of the enzyme and its affinity for the substrates. The truncation mutant binds tRNA with 3.6-fold higher affinity, while the K-m for serine is 4-fold increased relative to the wild-type SerRS. This indicates the importance of the C-terminal extension in maintaining the overall structure of SerRS.	YALE UNIV, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA; UNIV ZAGREB, FAC SCI, DEPT BIOCHEM, ZAGREB 10000, CROATIA; RUDJER BOSKOVIC INST, DEPT MOLEC GENET, ZAGREB 10000, CROATIA	Yale University; University of Zagreb; Rudjer Boskovic Institute				Lenhard, Boris/0000-0002-1114-1509				AGOU F, 1995, BIOCHEMISTRY-US, V34, P569, DOI 10.1021/bi00002a023; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BOREL F, 1994, NUCLEIC ACIDS RES, V22, P2963, DOI 10.1093/nar/22.15.2963; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CIRAKOGLU B, 1985, EUR J BIOCHEM, V149, P353; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DELARUE M, 1995, CURR OPIN STRUC BIOL, V5, P48, DOI 10.1016/0959-440X(95)80008-O; DOCKBREGEON AC, 1990, EUR J BIOCHEM, V188, P283, DOI 10.1111/j.1432-1033.1990.tb15401.x; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FLEIG UN, 1986, GENE, V46, P237, DOI 10.1016/0378-1119(86)90408-7; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; Guthrie C, 1991, GUIDE YEAST GENETICS; HADFIELD C, 1994, MOL GENETICS YEAST P, P17; HARTLEIN M, 1987, NUCLEIC ACIDS RES, V15, P1005, DOI 10.1093/nar/15.3.1005; HEIDER H, 1971, EUR J BIOCHEM, V20, P144, DOI 10.1111/j.1432-1033.1971.tb01372.x; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; LAZARD M, 1993, GENE, V132, P237, DOI 10.1016/0378-1119(93)90201-D; LORBER B, 1988, EUR J BIOCHEM, V174, P155, DOI 10.1111/j.1432-1033.1988.tb14076.x; LUDMERER SW, 1987, J BIOL CHEM, V262, P10807; LUDMERER SW, 1993, J BIOL CHEM, V268, P5519; LUNEL C, 1992, NUCLEIC ACIDS RES, V20, P2597, DOI 10.1093/nar/20.10.2597; MAKMAN MH, 1965, BIOCHEMISTRY-US, V4, P1434, DOI 10.1021/bi00883a031; Meinnel Thierry, 1995, P251; MELKI R, 1991, BIOCHEMISTRY-US, V30, P11536, DOI 10.1021/bi00113a008; MIRANDE M, 1992, EUR J BIOCHEM, V203, P459, DOI 10.1111/j.1432-1033.1992.tb16570.x; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; MIRANDE M, 1988, J BIOL CHEM, V263, P18443; NICHOLS RC, 1995, GENE, V155, P299, DOI 10.1016/0378-1119(94)00634-5; OGASAWARAN, 1994, DNA RES, V1, P1; OSWALD W, 1993, J VET MED B, V40, P366, DOI 10.1111/j.1439-0450.1993.tb00151.x; PRICE S, 1993, FEBS LETT, V324, P167, DOI 10.1016/0014-5793(93)81386-E; REED VS, 1994, J BIOL CHEM, V269, P32937; ROCKMILL B, 1991, METHOD ENZYMOL, V194, P146; ROMANOS MA, 1995, DNA CLONING, V2, P123; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SHIBA K, 1994, P NATL ACAD SCI USA, V91, P7435, DOI 10.1073/pnas.91.16.7435; VELLEKAMP G, 1987, J BIOL CHEM, V262, P9927; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WALTER P, 1989, J BIOL CHEM, V264, P17126; WEYGANDDURASEVIC I, 1994, J BACTERIOL, V176, P232; WEYGANDDURASEVIC I, 1987, NUCLEIC ACIDS RES, V15, P1887, DOI 10.1093/nar/15.5.1887; WEYGANDDURASEVIC I, 1993, EUR J BIOCHEM, V214, P869, DOI 10.1111/j.1432-1033.1993.tb17990.x	44	30	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2455	2461		10.1074/jbc.271.5.2455	http://dx.doi.org/10.1074/jbc.271.5.2455			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576207	hybrid			2022-12-25	WOS:A1996TT48800021
J	Hasegawa, H; Negishi, M; Ichikawa, A				Hasegawa, H; Negishi, M; Ichikawa, A			Two isoforms of the prostaglandin E receptor EP3 subtype different in agonist-independent constitutive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; TERMINAL DOMAINS; 2 ISOFORMS; PROTEIN; CAMP; VASOPRESSIN; INHIBITION; MUTATION; LIGAND; CELLS	We previously identified two isoforms of the mouse prostaglandin E receptor EP3 subtype, EP3 alpha and EP3 beta, with different carboxyl-terminal tails, produced through alternative splicing and showing different efficiency in inhibition of adenylate cyclase (Sugimoto, Y., Nesshi, M., Hayashi, Y., Namba, T., Honda, A., Watabe, A., Hirata, M., Narumiya, S., and Ichikawa, A. (1993) J. Biol. Chem. 268, 2712-2718). To assess the role of the carboxyl-terminal tails in the G protein coupling properties of the EP3 receptor, we examined the G(i) activities of EP3 alpha, EP3 beta, and the mutant receptor, in which the carboxyl-terminal tail was truncated at the splicing site. The EP3 alpha receptor showed marked agonist-independent constitutive inhibition of adenylate cyclase, while EP3 beta receptor had no agonist-independent inhibition. On the other hand, the truncated receptor showed only agonist-independent constitutive inhibition. The constitutive activity of these receptors on the stimulation of GTPase activity of G(i) was also observed. Thus, alternative splicing produced two isoforms with different carboxyl-terminal tails and with different constitutive activity, and the truncation of the carboxyl-terminal tail caused full constitutive activity.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,SAKYO KU,KYOTO 606,JAPAN	Kyoto University								ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; CHEN MCY, 1988, GASTROENTEROLOGY, V94, P1121, DOI 10.1016/0016-5085(88)90002-9; COLEMAN RA, 1994, PROSTAGLANDINS, V47, P151, DOI 10.1016/0090-6980(94)90084-1; COLEMAN RA, 1990, COMPREHENSIVE MED CH, V3, P643; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; COSTA T, 1992, MOL PHARMACOL, V41, P549; GARCIAPEREZ A, 1984, J CLIN INVEST, V74, P63, DOI 10.1172/JCI111419; HALUSHKA PV, 1989, ANN REV PHARM TOXICO, V10, P213; HEDQVIST P, 1972, NEUROPHARMACOLOGY, V11, P177, DOI 10.1016/0028-3908(72)90090-1; IRIE A, 1993, EUR J BIOCHEM, V217, P313, DOI 10.1111/j.1432-1033.1993.tb18248.x; IRIE A, 1994, EUR J BIOCHEM, V224, P161, DOI 10.1111/j.1432-1033.1994.tb20007.x; KRALL JF, 1984, J ENDOCRINOL, V102, P329, DOI 10.1677/joe.0.1020329; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MATUSLEIBOVITCH N, 1995, J BIOL CHEM, V270, P1041, DOI 10.1074/jbc.270.3.1041; MELIEN O, 1988, EUR J BIOCHEM, V172, P293, DOI 10.1111/j.1432-1033.1988.tb13886.x; NAKAO A, 1989, AM J PHYSIOL, V256, pC652, DOI 10.1152/ajpcell.1989.256.3.C652; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; NEGISHI M, 1993, PROG LIPID RES, V32, P417, DOI 10.1016/0163-7827(93)90017-Q; REN Q, 1993, J BIOL CHEM, V268, P16483; RICHELSEN B, 1984, J LIPID RES, V26, P127; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463; SUGIMOTO Y, 1993, J BIOL CHEM, V268, P2712; TORIKAI S, 1983, AM J PHYSIOL, V245, pF58, DOI 10.1152/ajprenal.1983.245.1.F58	24	100	109	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1857	1860		10.1074/jbc.271.4.1857	http://dx.doi.org/10.1074/jbc.271.4.1857			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567630	hybrid			2022-12-25	WOS:A1996TR32000012
J	Zhu, JH; Bilan, PJ; Moyers, JS; Antonetti, DA; Kahn, CR				Zhu, JH; Bilan, PJ; Moyers, JS; Antonetti, DA; Kahn, CR			Rad, a novel ras-related GTPase, interacts with skeletal muscle beta-tropomyosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN; RAN/TC4	Rad, a prototypic member of a subfamily of Ras-related GTPases, is overexpressed in skeletal muscle of type II diabetic humans. By expression screening of mouse embryo and human skeletal muscle cDNA libraries, we found that Rad interacted with skeletal muscle beta-tropomyosin. In the mouse skeletal muscle cell line C2C12, this interaction was significantly increased by the calcium ionophore A23187. A23187 also caused a time and concentration-dependent decrease in total cellular Rad with increased interaction between tropomyosin and Rad in the detergent-soluble fraction and the appearance of Rad in the cytoskeleton. In C2C12 cells stably overexpressing a putative dominant negative mutant of Rad (S105N), there was an increase in the amount of tropomyosin in Rad immunoprecipitates. In cells overexpressing wild type Rad, much of Rad was associated with the cytoskeleton and was no longer responsive to A23187. In far-Western blotting and guanine nucleotide saturation studies, GDP-Rad bound to tropomyosin far better than GTP-Rad. We conclude that Rad interacts with skeletal muscle beta-tropomyosin and the cytoskeleton in a guanine nucleotide-dependent manner. These data suggest that Rad may be involved in skeletal muscle motor function and cytoskeletal organization.	JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021	Kahn, Ronald/0000-0002-7583-9228; antonetti, david/0000-0003-1130-6577	NIDDK NIH HHS [DK 45935, DK 07260] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045935, T32DK007260] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MCMAHON DK, 1994, AM J PHYSIOL, V266, pC1795, DOI 10.1152/ajpcell.1994.266.6.C1795; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MOYERS JS, 1995, DIABETES, V44, pA81; NISHIMURA N, 1994, J BIOL CHEM, V269, P14191; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POLLARD TD, 1994, ANNU REV CELL BIOL, V10, P207, DOI 10.1146/annurev.cellbio.10.1.207; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHEEL AAR, 1995, EMBO J, V14, P697; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TORTI M, 1993, P NATL ACAD SCI USA, V90, P7553, DOI 10.1073/pnas.90.16.7553; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	22	49	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					768	773		10.1074/jbc.271.2.768	http://dx.doi.org/10.1074/jbc.271.2.768			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557685	hybrid			2022-12-25	WOS:A1996TP88900028
J	Conzen, SD; Cole, CN				Conzen, SD; Cole, CN			The three transforming regions of SV40 T antigen are required for immortalization of primary mouse embryo fibroblasts	ONCOGENE			English	Article						SV40 large T antigen; immortalization; senescence; apoptosis	LARGE TUMOR-ANTIGEN; P53 BINDING; GENE; MUTANTS; CELLS; DNA; VIRUS; E1A; IDENTIFICATION; ADENOVIRUS-E1A	Simian virus 40 (SV40) is a small DNA tumor virus whose early region gene product, large T antigen, is sufficient to immortalize primary rodent cells and transform established rodent cell lines, Three functional domains of large T antigen are required for transformation of the rat embryo fibroblast REF 52 cell line: the extreme amino-terminal region, a domain which binds p105(Rb) family members, and the bipartite p53-binding region, Many studies have attempted to define the activities and regions of SV40 large T antigen required for immortalization of mouse embryo fibroblasts (MEFs), In most of these studies, investigators have used survival of T antigen-expressing primary MEF colonies at the time when control MEFs undergo senescence as a measurement of 'immortalization' and concluded that immortalization of MEFs is correlated with large T antigen's ability to sequester the human tumor suppressor gene product p53 and separable from its p105(Rb)-binding or N terminal functions, In order to more rigorously define the regions of SV40 large T antigen required for escape from senescence, individual T antigen-expressing primary MEF colonies were systematically subcultured for >60 population doublings beyond the time of control MEF senescence under conditions known to limit the number of spontaneously immortalized cells, We found that although interaction of T antigen with p53 was sufficient to substantially extend the lifespan of MEFs, all three SV40 large T antigen domains required for REF 52 transformation were necessary to immortalize primary MEFs, These results indicate that p53 inactivation alone is insufficient to immortalize primary MEFs; rather, immortalization requires multiple activities of T antigen which are also required for efficient transformation.	DARTMOUTH COLL SCH MED,DEPT BIOCHEM,HANOVER,NH 03755	Dartmouth College			Cole, Charles/GRR-1551-2022		NCI NIH HHS [CA39259, CA16038] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039259, P01CA016038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASSELIN C, 1985, J VIROL, V56, P958, DOI 10.1128/JVI.56.3.958-968.1985; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; COLBY WW, 1982, P NATL ACAD SCI-BIOL, V79, P5189, DOI 10.1073/pnas.79.17.5189; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOGAN J, 1981, VIROLOGY, V115, P419, DOI 10.1016/0042-6822(81)90126-4; LOWE S, 1994, P NATL ACAD SCI USA, V91, P1026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAULBECKER C, 1992, J VIROL, V4, P2195; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SCHAEFER DI, 1993, CANCER RES, V53, P4946; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SOMPAYRAC L, 1991, VIROLOGY, V181, P412, DOI 10.1016/0042-6822(91)90516-E; SOUTHERN PJ, 1982, J MOL APPL GENET, V1, P324; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TEVETHIA MJ, 1984, VIROLOGY, V137, P414, DOI 10.1016/0042-6822(84)90234-4; TEVETHIA MJ, 1988, VIROLOGY, V162, P76, DOI 10.1016/0042-6822(88)90396-0; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHITE AE, 1994, GENE DEV, V15, P667; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WOODS C, 1994, ONCOGENE, V9, P2943; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; ZHU J, 1992, J VIROL, V65, P6872; ZHU JY, 1989, J VIROL, V63, P4777, DOI 10.1128/JVI.63.11.4777-4786.1989; ZHU JY, 1991, J VIROL, V65, P2778, DOI 10.1128/JVI.65.6.2778-2790.1991; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	40	51	52	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2295	2302						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570180				2022-12-25	WOS:A1995TK70200013
J	Sakamuro, D; Eviner, V; Elliott, KJ; Showe, L; White, E; Prendergast, GC				Sakamuro, D; Eviner, V; Elliott, KJ; Showe, L; White, E; Prendergast, GC			c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms	ONCOGENE			English	Article						Myc; p53; apoptosis; epithelial cells	ORNITHINE DECARBOXYLASE; ADENOVIRUS E1A; P53; BCL-2; GENE; EXPRESSION; PROLIFERATION; MUTATIONS; LYMPHOMA; DEATH	We tested the hypothesis that wild-type p53 activity is required for c-Myc-dependent apoptosis in epithelial cells, Primary baby rat kidney epithelial cell lines were generated by immortalization through the concerted action of c-Myc and a temperature-sensitive (ts) dominant inhibitory mutant allele of p53 (BRK myc/p53ts cells), When shifted to the permissive temperature for wild-type p53 activity, the BRK myc/p53ts cells underwent growth arrest and apoptosis, However, apoptosis also could be induced by serum deprivation at the nonpermissive temperature, when p53 was in the mutant state, Bcl-2 suppressed both modes of cell death, Apoptosis induced by wild-type p53 but not by serum deprivation was accompanied by G1 cell cycle arrest and increased expression of the Bcl-2 antagonist Bar. We concluded that c-Myc could induce apoptosis in epithelial cells by at least two mechanisms that could be distinguished by their p53 requirement, Our results support the possibility that c-Myc-dependent cell death might be exploited for therapeutic ends during carcinoma development, without regard to p53 status of the target cell.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,MOLEC BIOL GRAD GRP,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT GENET,PHILADELPHIA,PA 19104; CTR ADV BIOCHEM & MED,PISCATAWAY,NJ 08854; RUTGERS STATE UNIV,DEPT BIOMED SCI,PISCATAWAY,NJ 08854	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; Rutgers State University New Brunswick			White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065; Eviner, Valerie/0000-0001-5530-9417	NCI NIH HHS [CA-10815-28, CA-53370] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA053370, P30CA010815, R01CA053370] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERT T, 1994, ONCOGENE, V9, P759; ASKEW DS, 1993, BLOOD, V82, P2079; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P8910, DOI 10.1073/pnas.90.19.8910; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRYKBERG L, 1987, ONCOGENE, V1, P415; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; HARPER JW, 1993, CELL, V75, P805; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HERMEKING H, 1994, P NATL ACAD SCI USA, V91, P10412, DOI 10.1073/pnas.91.22.10412; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; RAJCHEL A, 1987, NUCLEIC ACIDS RES, V16, P2347; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; TEODORO JG, 1995, ONCOGENE, V11, P467; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WANG YS, 1993, ONCOGENE, V8, P3427; YANO T, 1993, ONCOGENE, V8, P2741	53	157	160	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2411	2418						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570193				2022-12-25	WOS:A1995TK70200026
J	Hunter, JJ; Parslow, TG				Hunter, JJ; Parslow, TG			A peptide sequence from Bax that converts Bcl-2 into an activator of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; HOMOLOG; GENE	Bcl-2 and Bax are members of a family of cytoplasmic proteins that regulate apoptosis. The two proteins have highly similar amino acid sequences but are functionally opposed: Bcl-2 acts to inhibit apoptosis, whereas Bax counteracts this effect. The antagonism appears to depend upon dimerization between Bcl-2 and Bax, but its mechanism is otherwise unknown. Here we report that overexpressing Bax induces apoptosis in a mammalian fibroblast cell line, and we identify a novel, short ''suicide domain'' in Bax that is required for this effect. Inserting this domain in place of the corresponding, divergent sequence in Bcl-2 converts Bcl-2 from an inhibitor into an activator of cell death. These findings imply that a specific region in Bax confers an active propensity for apoptosis in mammalian cells and support the view that Bcl-2 may block death primarily by suppressing Bax activity.	UNIV CALIF SAN FRANCISCO, DEPT PATHOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco				Hunter, John/0000-0001-8262-4404	NIAID NIH HHS [AI29313, AI36636] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029313, R01AI036636] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BOYD JM, 1995, ONCOGENE, V11, P1921; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HOPE TJ, 1990, J VIROL, V64, P5360, DOI 10.1128/JVI.64.11.5360-5366.1990; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	20	100	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8521	8524		10.1074/jbc.271.15.8521	http://dx.doi.org/10.1074/jbc.271.15.8521			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621473	hybrid			2022-12-25	WOS:A1996UE73000004
J	Amaratunga, A; Abraham, CR; Edwards, RB; Sandell, JH; Schreiber, BM; Fine, RE				Amaratunga, A; Abraham, CR; Edwards, RB; Sandell, JH; Schreiber, BM; Fine, RE			Apolipoprotein E is synthesized in the retina by Muller glial cells, secreted into the vitreous, and rapidly transported into the optic nerve by retinal ganglion cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PROTEIN; LIPOPROTEINS; RECEPTOR; BINDING; REGENERATION; APOPROTEIN; IDENTITY; MEMBRANE; KINESIN	We have investigated the synthesis and transport of apoE, the major apolipoprotein of the central nervous system, in the retina of the living rabbit. Four hours after the injection of [S-35]methionine/cysteine into the vitreous, 44% of [S-35]Met/Cys-labeled apoE is in soluble and membrane-enclosed retinal fractions, while 50% is in the vitreous. A significant amount of intact [S-35]Met/Cys-labeled apoE is rapidly transported into the optic nerve and its terminals in the lateral geniculate and superior colliculus within 3-6 h in two distinguishable vesicular compartments. Muller glia in cell culture also synthesize and secrete apoE. Taken together, these results suggest that apoE is synthesized by Muller glia and secreted into the vitreous. ApoE is also internalized by retinal ganglion cells and/or synthesized by these cells and rapidly transported into the optic nerve and brain as an intact molecule. We discuss the possible roles of retinal apoE in neuronal dynamics.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT OPHTHALMOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT ANAT,BOSTON,MA 02118; ELEANOR NOURSE RODGERS VET ADM HOSP,BEDFORD,MA 01730	Boston University; Boston University; Boston University; Boston University				Sandell, Julie/0000-0002-0528-161X; Schreiber, Barbara/0000-0001-8560-4249; Abraham, Carmela/0000-0002-6649-1960	NEI NIH HHS [R01EY-08535] Funding Source: Medline; NIA NIH HHS [R01AG-09905, R37AG-05894] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008535] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG005894, R01AG009905] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMARATUNGA A, 1993, J BIOL CHEM, V268, P17427; AMARATUNGA A, 1995, J BIOL CHEM, V270, P17268, DOI 10.1074/jbc.270.29.17268; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EDWARDS RB, 1992, EXP EYE RES, V54, P481, DOI 10.1016/0014-4835(92)90126-D; HUI DY, 1981, J BIOL CHEM, V256, P5646; IGNATIUS MJ, 1986, P NATL ACAD SCI USA, V83, P1125, DOI 10.1073/pnas.83.4.1125; IKONEN E, 1994, CURR BIOL, V4, P56; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS GP, 1988, EXP EYE RES, V47, P855, DOI 10.1016/0014-4835(88)90068-1; LORENZ T, 1978, P NATL ACAD SCI USA, V75, P505, DOI 10.1073/pnas.75.1.505; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MASLIAH E, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P405; MORIN PJ, 1991, J NEUROCHEM, V56, P415, DOI 10.1111/j.1471-4159.1991.tb08167.x; MORIN PJ, 1993, BIOCHIM BIOPHYS ACTA, V1146, P275, DOI 10.1016/0005-2736(93)90366-8; MORIN PJ, 1993, J NEUROCHEM, V61, P464; MORIN PJ, 1991, ANN NY ACAD SCI, V632, P442, DOI 10.1111/j.1749-6632.1991.tb33150.x; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; OCHS S, 1975, J PHYSIOL-LONDON, V253, P459, DOI 10.1113/jphysiol.1975.sp011200; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; REBECK GW, 1993, NEURON, V11, P575; REICHENBACH A, 1988, J HIRNFORSCH, V29, P481; SCHREIBER BM, 1994, J LIPID RES, V35, P1177; SHERRILL BC, 1980, J BIOL CHEM, V255, P1804; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SJOSTRAN.J, 1969, J NEUROCHEM, V16, P833, DOI 10.1111/j.1471-4159.1969.tb08971.x; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VANCE JE, 1994, J NEUROCHEM, V62, P329; WILLARD M, 1974, P NATL ACAD SCI USA, V71, P2183, DOI 10.1073/pnas.71.6.2183; WINDLER E, 1980, J BIOL CHEM, V255, P8303; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431	36	81	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5628	5632		10.1074/jbc.271.10.5628	http://dx.doi.org/10.1074/jbc.271.10.5628			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621425	hybrid			2022-12-25	WOS:A1996TZ28600051
J	Bucurenci, N; Sakamoto, H; Briozzo, P; Palibroda, N; Serina, L; Sarfati, RS; Labesse, G; Briand, G; Danchin, A; Barzu, O; Gilles, AM				Bucurenci, N; Sakamoto, H; Briozzo, P; Palibroda, N; Serina, L; Sarfati, RS; Labesse, G; Briand, G; Danchin, A; Barzu, O; Gilles, AM			CMP kinase from Escherichia coli is structurally related to other nucleoside monophosphate kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ADENYLATE KINASE; BINDING; GENE; PROTEIN; EXPRESSION; SEQUENCE; CLONING; RNA	CMP kinase from Escherichia coli is a monomeric protein of 225 amino acid residues. The protein exhibits little overall sequence similarities with other known NMP kinases. However, residues involved in binding of substrates and/or in catalysis were found conserved, and sequence comparison suggested conservation of the global fold found in adenylate kinases or in several CMP/UMP kinases. The enzyme was purified to homogeneity, crystallized, and analyzed for its structural and catalytic properties. The crystals belong to the hexagonal space group P6(3), have unit cell parameters a = b = 82.3 Angstrom and c = 60.7 Angstrom and diffract x-rays to a 1.9 Angstrom resolution. The bacterial enzyme exhibits a fluorescence emission spectrum with maximum at 328 nm upon excitation at 295 nm, which suggests that the single tryptophan residue (Trp(30)) is located in a hydrophobic environment. Substrate specificity studies showed that CMP kinase from E. coli is active with ATP, dATP, or GTP as donors and with CMP, dCMP, and arabinofuranosyl-CMP as accepters. This is in contrast with CMP/UMP kinase from Dictyostelium discoideum, an enzyme active on CMP or UMP but much less active on the corresponding deoxynucleotides. Binding of CMP enhanced the affinity of E. coli CMP kinase for ATP or ADP, a particularity never described in this family of proteins that might explain inhibition of enzyme activity by excess of nucleoside monophosphate.	INST PASTEUR,UNITE BIOCHIM REGULAT CELLULAIRES,F-75724 PARIS 15,FRANCE; INST PASTEUR,UNITE CHIM ORGAN,F-75724 PARIS 15,FRANCE; INST PASTEUR,UNITE REGULAT EXPRESS GENET,F-75724 PARIS 15,FRANCE; UNIV PARIS 06,LAB MINERAL CRISTALLOG,F-75252 PARIS 05,FRANCE; UNIV PARIS 07,F-75252 PARIS 05,FRANCE; CNRS,UMR 9920,LAB BIOL STRUCT,F-91198 GIF SUR YVETTE,FRANCE; UNIV LILLE 2,LAB APPLICAT SPECTROMETRIE MASSE,F-59405 LILLE,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Universite de Lille - ISITE; Universite de Lille				Sakamoto, Hiroshi/0000-0002-8767-2111; Labesse, Gilles/0000-0002-6861-3300; Danchin, Antoine/0000-0002-6350-5001				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anderson E. P., 1973, ENZYMES, V8, P49; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARZU O, 1983, FEBS LETT, V153, P280, DOI 10.1016/0014-5793(83)80624-3; BARZU O, 1993, ANN I PASTEUR ACTUAL, V4, P121; BECK CF, 1974, J BACTERIOL, V120, P1370, DOI 10.1128/JB.120.3.1370-1379.1974; BELL JE, 1988, PROTEINS ENZYMES, P370; BLINKLEY JP, 1986, J BACTERIOL, V168, P1457; BLONDIN C, 1994, ANAL BIOCHEM, V220, P219, DOI 10.1006/abio.1994.1326; Boyer P.D, 1973, ENZYMES, P279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRICKE J, 1995, J BACTERIOL, V177, P517, DOI 10.1128/jb.177.3.517-523.1995; HIRATSUKA T, 1982, J BIOL CHEM, V257, P13354; KONRAD M, 1992, J BIOL CHEM, V267, P25652; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LESLIE AGW, 1986, DARESBURY LAB INF Q, V18, P33; LILJELUND P, 1989, BIOCHEM BIOPH RES CO, V165, P464, DOI 10.1016/0006-291X(89)91093-0; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MULLERDIECKMANN HJ, 1995, J MOL BIOL, V246, P522; MULLERDIECKMANN HJ, 1994, J MOL BIOL, V236, P361, DOI 10.1006/jmbi.1994.1140; Neuhard J, 1987, ESCHERICHIA COLI SAL, P445; OKAJIMA T, 1995, J BIOCHEM-TOKYO, V117, P980, DOI 10.1093/oxfordjournals.jbchem.a124830; OKAJIMA T, 1993, FEBS LETT, V334, P86, DOI 10.1016/0014-5793(93)81687-U; PEDERSEN S, 1984, MOL GEN GENET, V196, P135, DOI 10.1007/BF00334105; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; RALEIGH EA, 1988, NUCLEIC ACIDS RES, V16, P1563, DOI 10.1093/nar/16.4.1563; REGNIER P, 1987, J BIOL CHEM, V262, P63; RICHARDSON JS, 1976, P NATL ACAD SCI USA, V73, P2619, DOI 10.1073/pnas.73.8.2619; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARFATI RS, 1990, J BIOL CHEM, V265, P18902; SERINA L, 1995, BIOCHEMISTRY-US, V34, P5066, DOI 10.1021/bi00015a018; SMALLSHAW JD, 1992, LIFE SCI ADV, V11, P59; SUTCLIFFE MJ, 1987, PROTEIN ENG, V1, P377, DOI 10.1093/protein/1.5.377; TSAI MD, 1991, BIOCHEMISTRY-US, V30, P6806, DOI 10.1021/bi00242a002; VONRHEIN C, 1995, STRUCTURE, V3, P483, DOI 10.1016/S0969-2126(01)00181-2; WIESMULLER L, 1990, J BIOL CHEM, V265, P6339; WIESMULLER L, 1995, FEBS LETT, V363, P22, DOI 10.1016/0014-5793(95)00271-A; YAMANAKA K, 1994, MOL GEN GENET, V243, P9, DOI 10.1007/BF00283870; YAMANAKA K, 1992, J BACTERIOL, V174, P7517, DOI 10.1128/JB.174.23.7517-7526.1992	44	59	63	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2856	2862		10.1074/jbc.271.5.2856	http://dx.doi.org/10.1074/jbc.271.5.2856			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576266	hybrid			2022-12-25	WOS:A1996TT48800080
J	Xie, YH; LanghansRajasekaran, SA; Bellovino, D; Morimoto, T				Xie, YH; LanghansRajasekaran, SA; Bellovino, D; Morimoto, T			Only the first and the last hydrophobic segments in the COOH-terminal third of Na,K-ATPase alpha subunit initiate and halt, respectively, membrane translocation of the newly synthesized polypeptide - Implications for the membrane topology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; OUABAIN BINDING; NA+/K+-ATPASE; NA/K-ATPASE; TRANSPORT; EPITOPE; PROTEIN; SURFACE; CHAIN	We studied the topogenic properties of five hydrophobic segments (H5-H9) in the COOH-terminal third of Na,K-ATPase alpha subunit using in vitro insertion of fusion proteins into endoplasmic reticulum membranes, These fusion proteins consisted of several different lengths of truncated alpha subunit starting at Met(729) and a reporter protein, chloramphenicol acetyltransferase, that was linked in frame after each hydrophobic segment. We found that membrane insertion of the newly synthesized COOH-terminal third was initiated by H5 and terminated by H9, indicating that here only H5 and H9 have topogenic function. The other three, H6-H8, did not have topogenic function in the native context and were translocated into the endoplasmic reticulum lumen. These results were in striking contrast to the previous models in which four or six hydrophobic segments were proposed to cross the membrane. Furthermore, the findings suggest a novel mechanism for achieving the final membrane topology of the COOH-terminal third of the alpha subunit.	NYU, SCH MED, DEPT CELL BIOL, NEW YORK, NY 10016 USA; NYU, SCH MED, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	New York University; New York University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020277] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20277] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTOLOVIC R, 1991, EUR J BIOCHEM, V199, P195, DOI 10.1111/j.1432-1033.1991.tb16109.x; ARYSTARKHOVA E, 1995, J BIOL CHEM, V270, P8785, DOI 10.1074/jbc.270.15.8785; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; BROTHERUS JR, 1983, BIOCHIM BIOPHYS ACTA, V731, P290, DOI 10.1016/0005-2736(83)90021-4; CANFIELD VA, 1993, BIOCHEMISTRY-US, V32, P13782, DOI 10.1021/bi00213a005; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FELSENFELD DP, 1988, J BIOL CHEM, V263, P10932; FISONE G, 1994, J BIOL CHEM, V269, P9368; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARA Y, 1987, J BIOCHEM-TOKYO, V102, P43, DOI 10.1093/oxfordjournals.jbchem.a122039; HOMAREDA H, 1993, BIOCHEM CELL BIOL, V71, P410, DOI 10.1139/o93-060; HOMAREDA H, 1992, SODIUM PUMP RECENT D, P217; KANO I, 1990, BIOCHEM CELL BIOL, V68, P1262, DOI 10.1139/o90-187; KARLISH SJD, 1993, J BIOL CHEM, V268, P3471; KARLISH SJD, 1990, P NATL ACAD SCI USA, V87, P4566, DOI 10.1073/pnas.87.12.4566; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEMAS MV, 1994, J BIOL CHEM, V269, P8255; LIN JL, 1995, J BIOL CHEM, V270, P6942, DOI 10.1074/jbc.270.12.6942; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; Mercer Robert W., 1993, V137C, P139; MODYANOV N, 1991, SOC GEN PHY, V46, P99; MOHRAZ M, 1994, J BIOL CHEM, V269, P2929; NING G, 1993, FEBS LETT, V336, P521, DOI 10.1016/0014-5793(93)80868-U; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SABATINI DD, 1994, METABOLIC MOL BASIS, P459; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SKACH WR, 1994, J CELL BIOL, V125, P803, DOI 10.1083/jcb.125.4.803; SKACH WR, 1993, J BIOL CHEM, V268, P6903; TAKEYASU K, 1994, SODIUM PUMP, P264; VASILETS LA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P201, DOI 10.1016/0304-4157(93)90012-D; VONHEIJNE G, 1994, ANNU REV BIOPH BIOM, V23, P167; WALTER P, 1983, METHOD ENZYMOL, V96, P84; XIE YH, 1995, J BIOL CHEM, V270, P11985, DOI 10.1074/jbc.270.20.11985; YOON KL, 1994, J BIOL CHEM, V269, P28249	38	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2563	2573		10.1074/jbc.271.5.2563	http://dx.doi.org/10.1074/jbc.271.5.2563			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576222	hybrid			2022-12-25	WOS:A1996TT48800036
J	Yonehara, M; Minami, Y; Kawata, Y; Nagai, J; Yahara, I				Yonehara, M; Minami, Y; Kawata, Y; Nagai, J; Yahara, I			Heat-induced chaperone activity of HSP90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHOCK PROTEIN; ESCHERICHIA-COLI; DIHYDROFOLATE-REDUCTASE; CONFORMATIONAL CHANGE; MOLECULAR CHAPERONES; RNA-POLYMERASE; RODENT CELLS; GROEL; GENE; DNAK	The 90-kDa stress protein, HSP90, is a major cytosolic protein ubiquitously distributed in all species. Using two substrate proteins, dihydrofolate reductase (DHFR) and firefly luciferase, we demonstrate here that HSP90 newly acquires a chaperone activity when incubated at temperatures higher than 46 degrees C, which is coupled with self-oligomerization of HSP90. While chemically denatured DHFR refolds spontaneously upon dilution from denaturant, oligomerized HSP90 bound DHFR during the process of refolding and prevented it from renaturation. DHFR was released from the complex with HSP90 by incubating with GroEL/ES complexes in an ATP-dependent manner and refolded into the native form. alpha-Casein inhibited the binding of DHFR to HSP90 and also chased DHFR from the complex with HSP90. These results suggest that HSP90 binds substrates to maintain them in a folding-competent structure. Furthermore, we found that HSP90 prevents luciferase from irreversible thermal denaturation and enables it to refold when postincubated with reticulocyte lysates. This heat-induced chaperone activity of HSP90 associated with its oligomerization may have a pivotal role in protection of cells from thermal damages.	TOKYO METROPOLITAN INST MED SCI,DEPT CELL BIOL,TOKYO 113,JAPAN; TOTTORI UNIV,FAC ENGN,DEPT BIOTECHNOL,TOTTORI 680,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tottori University			Kawata, Yasushi/ABA-9608-2021	Kawata, Yasushi/0000-0002-2744-1506				AOYAMA A, 1993, MOL CELL BIOL, V13, P1842; ASHBURNER M, 1979, CELL, V17, P241, DOI 10.1016/0092-8674(79)90150-8; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3694, DOI 10.1021/bi00065a023; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; HARTMAN DJ, 1993, P NATL ACAD SCI USA, V90, P2276, DOI 10.1073/pnas.90.6.2276; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HUANG SM, 1989, BIOCHEMISTRY-US, V28, P471, DOI 10.1021/bi00428a010; JACOB U, 1994, TRENDS BIOCHEM SCI, V19, P205; JAKOB U, 1995, J BIOL CHEM, V270, P7288, DOI 10.1074/jbc.270.13.7288; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LANKS KW, 1992, BIOCHEM BIOPH RES CO, V184, P394, DOI 10.1016/0006-291X(92)91206-6; LI GC, 1991, P NATL ACAD SCI USA, V88, P1681, DOI 10.1073/pnas.88.5.1681; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1992, SCIENCE, V258, P995, DOI 10.1126/science.1359644; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; MELNICK J, 1994, NATURE, V370, P373, DOI 10.1038/370373a0; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; MINAMI Y, 1993, J BIOL CHEM, V268, P9604; MIYATA Y, 1995, BIOCHEMISTRY-US, V34, P8123, DOI 10.1021/bi00025a019; MIYATA Y, 1992, J BIOL CHEM, V267, P7042; MIZOBATA T, 1992, J BIOL CHEM, V267, P17773; NIMMESGERN E, 1993, FEBS LETT, V331, P25, DOI 10.1016/0014-5793(93)80290-B; OSTOASALOMA P, 1990, BIOCHIM BIOPHYS ACTA, V1041, P146, DOI 10.1016/0167-4838(90)90058-N; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PARSELL DA, 1993, ANNU REV GENET, V27, P467; ROLLET E, 1992, BIOCHEM BIOPH RES CO, V185, P116, DOI 10.1016/S0006-291X(05)80963-5; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; TOUCHETTE NA, 1986, BIOCHEMISTRY-US, V25, P5445, DOI 10.1021/bi00367a015; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; WAXMAN L, 1986, SCIENCE, V232, P500, DOI 10.1126/science.2938257; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; YAHARA I, 1986, CELL STRUCT FUNCT, V11, P65, DOI 10.1247/csf.11.65; YAMAMOTO M, 1991, J BIOCHEM-TOKYO, V110, P141, DOI 10.1093/oxfordjournals.jbchem.a123532; ZIEMIENOWICZ A, 1993, J BIOL CHEM, V268, P25425	47	146	164	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2641	2645		10.1074/jbc.271.5.2641	http://dx.doi.org/10.1074/jbc.271.5.2641			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576234	hybrid			2022-12-25	WOS:A1996TT48800048
J	Berkhout, B; vanWamel, J				Berkhout, B; vanWamel, J			Accurate scanning of the BssHII endonuclease in search for its DNA cleavage site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFUSION-DRIVEN MECHANISMS; PROTEIN TRANSLOCATION; ECORI ENDONUCLEASE; LINEAR DIFFUSION; RNA-POLYMERASE; NUCLEIC-ACIDS; RECOGNITION; ENZYME	A facilitated diffusion mechanism has been proposed to account for the kinetic efficiency with which restriction endonucleases are able to locate DNA recognition sites, Such a mechanism involves the initial formation of a nonspecific complex upon collision of the protein with the DNA, with the subsequent diffusion of the protein along the DNA helix until either a recognition site is located or the protein dissociates into solution. Protein translocation may be facilitated by either sliding along the DNA, hopping to nearby sites, or intersegment transfer over larger distances, Previous analyses of the manner in which restriction enzymes cleave DNA substrates did rule out the latter mechanism, To discriminate between protein sliding or scanning and protein hopping, we designed a unique DNA template with three overlapping, mutually exclusive recognition sites for the BssHII endonuclease. Analysis of the cleavage pattern demonstrated efficient usage of both external sites, whereas the centrally located site was not efficiently cleaved, These results confirm that linear diffusion of the BssHII enzyme occurs by scanning along the DNA, Furthermore, the scanning enzyme was found to stop and cleave at the first site encountered, Thus, a sliding restriction endonuclease recognizes cleavage sites with high fidelity, without skipping of potential sites.			Berkhout, B (corresponding author), UNIV AMSTERDAM,ACAD MED CTR,DEPT VIROL,MEIBERGDREEF 15,1105 AZ AMSTERDAM,NETHERLANDS.							BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; CONRAD M, 1989, P NATL ACAD SCI USA, V86, P9707, DOI 10.1073/pnas.86.24.9707; EHBRECHT HJ, 1985, J BIOL CHEM, V260, P6160; FRIED MG, 1984, J MOL BIOL, V172, P263, DOI 10.1016/S0022-2836(84)80026-1; HAMILTON RW, 1989, J BIOL CHEM, V265, P17422; JACK WE, 1982, P NATL ACAD SCI-BIOL, V79, P4010, DOI 10.1073/pnas.79.13.4010; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; KLAVER B, 1994, J VIROL, V68, P3830, DOI 10.1128/JVI.68.6.3830-3840.1994; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; LANGOWSKI J, 1983, NUCLEIC ACIDS RES, V11, P501, DOI 10.1093/nar/11.2.501; NARDONE G, 1986, J BIOL CHEM, V261, P2128; PEDEN K, 1991, VIROLOGY, V185, P661, DOI 10.1016/0042-6822(91)90537-L; TERRY BJ, 1985, J BIOL CHEM, V260, P3130; VONHIPPEL PH, 1994, SCIENCE, V263, P769, DOI 10.1126/science.8303292; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WHEELER AR, 1987, BIOCHEMISTRY-US, V26, P3322, DOI 10.1021/bi00386a012; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030	17	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1837	1840		10.1074/jbc.271.4.1837	http://dx.doi.org/10.1074/jbc.271.4.1837			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567625	hybrid			2022-12-25	WOS:A1996TR32000007
J	Boege, F; Straub, T; Kehr, A; Boesenberg, C; Christiansen, K; Andersen, A; Jakob, F; Kohrle, J				Boege, F; Straub, T; Kehr, A; Boesenberg, C; Christiansen, K; Andersen, A; Jakob, F; Kohrle, J			Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIPROLIFERATIVE ACTIVITY; INTOPLICINE RP-60475; ANTITUMOR AGENTS; CELL-CYCLE; QUERCETIN; CLEAVAGE; CAMPTOTHECIN; GROWTH; COMPLEX; MODE	Topoisomerases are involved in many aspects of DNA metabolism such as replication and transcription reactions. Camptothecins, which stabilize the covalent intermediate of topoisomerase I and DNA are effective, though toxic, drugs for cancer therapy. In this study, a new class of topoisomerase I inhibitors was identified, and their mode of action was characterized using recombinant human topoisomerase I preparations and human HL-60 leukemic cells. Quercetin and the related natural flavones, acacetin, apigenin, kaempferol, and morin, inhibit topoisomerase I-catalyzed DNA religation. In contrast to camptothecin, these compounds do not act directly on the catalytic intermediate and also do not interfere with DNA cleavage. However, formation of a ternary complex with topoisomerase I and DNA during the cleavage reaction inhibits the following DNA religation step. 3,3',4',7-Tetrahydroxy-substituted flavones stabilize the covalent topoisomerase I-DNA intermediate most efficiently. Enhanced formation of covalent topoisomerase I-DNA complexes was also demonstrated in human HL-60 cells. In contrast, synthetic 3',5'-dibromo-4'-hydroxy-3-methylflavones bind selectively to topoisomerase I in its non-DNA-bound form and block the following DNA binding step. As a consequence, these synthetic flavonoids are capable of counteracting topoisomerase I-directed effects of camptothecin. Inhibition of DNA binding is obtained by voluminous hydrophobic substituents in 6-position of the flavone structure. Our data show that selective inhibitors of both half-reactions of topoisomerase I can be derived from the flavone structure.	UNIV WURZBURG,MED POLIKLIN,KLIN FORSCH GRP,D-97070 WURZBURG,GERMANY; AARHUS UNIV,DEPT MOLEC BIOL,DK-8000 AARHUS,DENMARK	University of Wurzburg; Aarhus University			Jakob, Franz/F-9894-2015; Straub, Tobias/B-2023-2009; Jakob, Franz/D-8526-2015; Köhrle, Josef/AAH-6438-2020; Andersen, Anni/O-1162-2017; Boege, Fritz/H-3261-2019	Straub, Tobias/0000-0002-0547-0453; Köhrle, Josef/0000-0002-9187-9078; Andersen, Anni/0000-0001-7194-3258				AFLALO E, 1994, CANCER RES, V54, P5138; AUSTIN CA, 1992, BIOCHEM J, V282, P883, DOI 10.1042/bj2820883; BIBBY MC, 1993, ANTI-CANCER DRUG, V4, P3, DOI 10.1097/00001813-199302000-00001; BISSERY MC, 1993, INVEST NEW DRUG, V11, P263, DOI 10.1007/BF00874425; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BUSK H, 1987, NATURE, V327, P638, DOI 10.1038/327638a0; CASTILLO MH, 1989, AM J SURG, V158, P351, DOI 10.1016/0002-9610(89)90132-3; CHRISTIANSEN K, 1993, J BIOL CHEM, V268, P9690; CISZAK E, 1992, P NATL ACAD SCI USA, V89, P6644, DOI 10.1073/pnas.89.14.6644; CISZAK E, 1991, J MOL STRUCT, V251, P345; CODY V, 1991, STRUCT CHEM, V2, P601, DOI 10.1007/BF00673444; Cody V, 1988, PROGR CLIN BIOL RES, V280; FERRIOLA PC, 1989, BIOCHEM PHARMACOL, V38, P1617, DOI 10.1016/0006-2952(89)90309-2; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GREENFIELD L, 1975, BIOCHIM BIOPHYS ACTA, V407, P365, DOI 10.1016/0005-2787(75)90104-5; Gumbinger H G, 1988, Prog Clin Biol Res, V280, P345; HECHT SM, 1992, J NAT PROD, V55, P401, DOI 10.1021/np50082a001; HERTOG MGL, 1993, NUTR CANCER, V20, P21, DOI 10.1080/01635589309514267; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; HOFMANN J, 1990, INT J CANCER, V45, P536, DOI 10.1002/ijc.2910450327; LAROCCA LM, 1991, BRIT J HAEMATOL, V79, P562, DOI 10.1111/j.1365-2141.1991.tb08082.x; LI CJ, 1993, J BIOL CHEM, V268, P22463; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; MOREL I, 1993, BIOCHEM PHARMACOL, V45, P13, DOI 10.1016/0006-2952(93)90371-3; NAKAYAMA T, 1993, BIOCHEM PHARMACOL, V45, P265; OKURA A, 1988, BIOCHEM BIOPH RES CO, V157, P183, DOI 10.1016/S0006-291X(88)80030-5; PODDEVIN B, 1993, MOL PHARMACOL, V44, P767; RAHMAN A, 1989, CARCINOGENESIS, V10, P1833, DOI 10.1093/carcin/10.10.1833; RIOU JF, 1993, CANCER RES, V53, P5987; SCAMBIA G, 1990, Anti-Cancer Drugs, V1, P45, DOI 10.1097/00001813-199010000-00008; SLICHENMYER WJ, 1993, JNCI-J NATL CANCER I, V85, P271, DOI 10.1093/jnci/85.4.271; SORENSEN BS, 1992, J MOL BIOL, V228, P778, DOI 10.1016/0022-2836(92)90863-F; SUOLINNA EM, 1975, CANCER RES, V35, P1865; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TAMURA H, 1990, FEBS LETT, V261, P151, DOI 10.1016/0014-5793(90)80658-6; TEOFILI L, 1992, LEUKEMIA RES, V16, P497, DOI 10.1016/0145-2126(92)90176-8; YAMASHITA Y, 1990, BIOCHEM PHARMACOL, V39, P737; YAMASHITA Y, 1991, BIOCHEMISTRY-US, V30, P5838, DOI 10.1021/bi00238a005; YAMASHITA Y, 1990, J ANTIBIOT, V43, P1344, DOI 10.7164/antibiotics.43.1344; YOSHIDA M, 1990, FEBS LETT, V260, P10, DOI 10.1016/0014-5793(90)80053-L; YOSHIDA M, 1992, CANCER RES, V52, P6676	41	204	211	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2262	2270		10.1074/jbc.271.4.2262	http://dx.doi.org/10.1074/jbc.271.4.2262			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567688	hybrid			2022-12-25	WOS:A1996TR32000070
J	Li, HZ; Hsu, P; Sachais, BS; Krause, JE; Leeman, SE; Boyd, ND				Li, HZ; Hsu, P; Sachais, BS; Krause, JE; Leeman, SE; Boyd, ND			Identification of the site in the substance P (NK-1) receptor for modulation of peptide binding by sulfhydryl reagents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; HUMAN NEUROKININ-1 RECEPTOR; LIGAND-BINDING; MOLECULAR-CLONING; N-ETHYLMALEIMIDE; BETA-2-ADRENERGIC RECEPTOR; FUNCTIONAL EXPRESSION; ANTAGONIST BINDING; DISULFIDE BOND; NK1 RECEPTOR	Substance P (SP) is a peptide neurotransmitter that is involved in multiple responses in both the central and the peripheral nervous systems through a G-protein-coupled receptor. The primary structure of the rat SP receptor contains a number of conserved cysteine residues, To localize and identify the cysteine residues that participate in receptor binding, intact Chinese hamster ovary cells expressing the SP receptor were treated with various sulfhydryl reagents and the effect of these reagents on radioiodinated SP binding affinity and dissociation rate was determined. We used a series of amphiphilic maleimide derivatives in which the reactive maleimide group penetrates to different depths within the plane of membrane. Only the maleimide derivatives with intermediate chain lengths modified receptor binding properties, indicating that the reactive sulfhydryl group is located within a transmembrane domain of the receptor close (within 1.7 nm) to the extracellular border. Since peptide binding to a mutant receptor C199S, in which Cys-199 was replaced by a serine, was found to be insensitive to modulation by sulfhydryl reagents, this reactive sulfhydryl group is on Cys-199 of the receptor, Receptor occupancy by SP protects Cys-199 from modification and thus this residue is either located at or conformationally linked to the SP binding site.	BOSTON UNIV, SCH MED, DEPT PHARMACOL, BOSTON, MA 02118 USA; WASHINGTON UNIV, SCH MED, DEPT ANAT & NEUROBIOL, ST LOUIS, MO 63110 USA	Boston University; Washington University (WUSTL)			Sachais, Bruce/D-1236-2009	Leeman, Susan/0000-0002-0951-5364	NINDS NIH HHS [NS31346] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031346] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARONSTAM RS, 1985, NEUROSCI LETT, V54, P289, DOI 10.1016/S0304-3940(85)80093-8; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; BLOUNT P, 1993, J BIOL CHEM, V268, P16388; Boyd ND, 1996, P NATL ACAD SCI USA, V93, P433, DOI 10.1073/pnas.93.1.433; DOHLMAN HG, 1990, BIOCHEMISTRY-US, V29, P2335, DOI 10.1021/bi00461a018; FALCONE RC, 1990, J PHARMACOL EXP THER, V255, P565; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; FONG TM, 1992, MOL PHARMACOL, V41, P24; FOUCHIER F, 1992, EUR J CELL BIOL, V59, P382; FREISSMUTH M, 1991, J BIOL CHEM, V266, P17778; GERARD NP, 1991, BIOCHEMISTRY-US, V30, P10640, DOI 10.1021/bi00108a006; GORBULEV V, 1992, BIOCHIM BIOPHYS ACTA, V1131, P99, DOI 10.1016/0167-4781(92)90105-9; GRIFFITHS DG, 1984, J BIOENERG BIOMEMBR, V16, P465, DOI 10.1007/BF00743239; GRIFFITHS DG, 1990, J BIOENERG BIOMEMBR, V22, P691, DOI 10.1007/BF00809072; GRIFFITHS DG, 1981, FEBS LETT, V134, P261, DOI 10.1016/0014-5793(81)80615-1; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; HOPKINS B, 1991, BIOCHEM BIOPH RES CO, V180, P1110, DOI 10.1016/S0006-291X(05)81181-7; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KRAUSE JE, 1994, TACHYKININ RECEPTORS, P165; KURTENBACH E, 1990, J BIOL CHEM, V265, P13702; LARSEN NE, 1981, MOL PHARMACOL, V20, P255; LI YM, 1995, J BIOL CHEM, V270, P1213, DOI 10.1074/jbc.270.3.1213; LIANG T, 1981, J NEUROSCI, V1, P1133; LIU YF, 1992, J NEUROCHEM, V59, P1024, DOI 10.1111/j.1471-4159.1992.tb08344.x; MCLEAN S, 1991, SCIENCE, V251, P437, DOI 10.1126/science.1703324; MOORE RJ, 1985, BIOCHEM SOC T, V13, P690, DOI 10.1042/bst0130690; NAKANISHI S, 1991, ANNU REV NEUROSCI, V14, P123, DOI 10.1146/annurev.ne.14.030191.001011; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OFRI D, 1992, RECEPTOR, V2, P109; OTSUKA M, 1993, PHYSIOL REV, V73, P229, DOI 10.1152/physrev.1993.73.2.229; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PAVO I, 1990, FEBS LETT, V272, P205, DOI 10.1016/0014-5793(90)80485-2; REGAN JW, 1986, J BIOL CHEM, V261, P3894; SACHAIS BS, 1993, J BIOL CHEM, V268, P2319; SHARMA PM, 1987, EUR J PHARMACOL, V138, P9; SIBLEY DR, 1983, J BIOL CHEM, V258, P4957; SIDHU A, 1986, BIOCHEMISTRY-US, V25, P6695, DOI 10.1021/bi00369a055; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; SUNDELIN JB, 1992, EUR J BIOCHEM, V203, P625, DOI 10.1111/j.1432-1033.1992.tb16592.x; TAKEDA Y, 1992, J NEUROCHEM, V59, P740, DOI 10.1111/j.1471-4159.1992.tb09430.x; TAKEDA Y, 1991, BIOCHEM BIOPH RES CO, V179, P1232, DOI 10.1016/0006-291X(91)91704-G; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	43	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1950	1956		10.1074/jbc.271.4.1950	http://dx.doi.org/10.1074/jbc.271.4.1950			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567643	hybrid			2022-12-25	WOS:A1996TR32000025
J	Tsujita, T; Miyazaki, T; Tabei, R; Okuda, H				Tsujita, T; Miyazaki, T; Tabei, R; Okuda, H			Coenzyme A-independent monoacylglycerol acyltransferase from rat intestinal mucosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC CHOLESTEROL ESTERASES; CARBOXYLESTER LIPASE; PURIFICATION; SYNTHASE; TISSUE; LIVER	Rat intestinal mucosa contains high diacylglycerol-synthesizing activity (monoacylglycerol acyltransferase (MGAT) activity) due to monoacylglycerol and fatty acid, independently of coenzyme A and ATP. MGAT activity was purified from rat intestinal mucosa by successive chromatography separations on DEAE-cellulose, CM- Sephadex, and anti-IgG-Sepharose against rat pancreatic lipase. The enzyme was electrophoretically homogeneous, and its molecular weight was 49,000, which is identical with that of rat pancreatic lipase. Immunoblotting analysis with antibody against rat pancreatic lipase showed one immunoreactive protein with an estimated molecular weight of 49,000. The activity of the purified enzyme was completely inhibited by addition of the antibody. Using immunocytochemical techniques, it was found that immunoreactive protein against rat pancreatic lipase was uniformly distributed within the absorptive cells of the intestine but was absent from the microvillar membrane. The MGAT activity of intestinal mucosal homogenate was inhibited by about 65% by addition of antibody against rat pancreatic lipase. Trioleoylglycerol- and dioleoylglycerol-hydrolyzing activities of the purified enzyme and pancreatic lipase were inhibited by addition of intestinal mucosa extract. These results suggest that pancreatic lipase is present in intestinal absorptive cells and that it may contribute to resynthesis of diacylglycerol from monoacylglycerol and fatty acids in these cells.	EHIME UNIV,SCH MED,DEPT PATHOL,SHIGENOBU,EHIME 79102,JAPAN	Ehime University	Tsujita, T (corresponding author), EHIME UNIV,SCH MED,DEPT MED BIOCHEM,SHIGENOBU,EHIME 79102,JAPAN.							BELFRAGE P, 1969, J LIPID RES, V10, P341; Bell RM, 1983, ENZYMES, V16, P87; BHAT BG, 1993, ARCH BIOCHEM BIOPHYS, V300, P663, DOI 10.1006/abbi.1993.1092; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSNER MS, 1989, J BIOL CHEM, V264, P20261; CARRIERE F, 1993, GASTROENTEROLOGY, V105, P876, DOI 10.1016/0016-5085(93)90908-U; CHEN RF, 1967, J BIOL CHEM, V242, P173; COLEMAN RA, 1986, J LIPID RES, V27, P158; COLEMAN RA, 1986, J BIOL CHEM, V261, P224; FRUTON JS, 1982, ADV ENZYMOL RAMB, V53, P239; GALLO LL, 1980, J LIPID RES, V21, P537; GALLO LL, 1977, P SOC EXP BIOL MED, V114, P69; GIDEZ LI, 1968, J LIPID RES, V9, P794; HYUN J, 1969, J BIOL CHEM, V244, P1937; KISSEL JA, 1989, BIOCHIM BIOPHYS ACTA, V1006, P227, DOI 10.1016/0005-2760(89)90201-4; KYGER EM, 1990, BIOCHEMISTRY-US, V29, P3853, DOI 10.1021/bi00468a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNER R, 1995, J BIOL CHEM, V270, P13630, DOI 10.1074/jbc.270.23.13630; MATTSON FH, 1964, J BIOL CHEM, V239, P2772; MUDERHWA JM, 1992, BIOCHEMISTRY-US, V31, P141, DOI 10.1021/bi00116a021; RAO GA, 1966, BIOCHIM BIOPHYS ACTA, V125, P465, DOI 10.1016/0005-2760(66)90035-X; RILEY DJS, 1990, BIOCHEMISTRY-US, V29, P3848, DOI 10.1021/bi00468a007; TSUJISAKA Y, 1977, BIOCHIM BIOPHYS ACTA, V489, P415; TSUJITA T, 1994, J BIOL CHEM, V269, P5884; TSUJITA T, 1989, J BIOL CHEM, V264, P8612; TSUJITA T, 1994, EUR J BIOCHEM, V224, P57, DOI 10.1111/j.1432-1033.1994.tb19994.x; TSUJITA T, 1992, J BIOL CHEM, V267, P23489; Verger R., 1984, P83; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; ZAKS A, 1984, SCIENCE, V224, P1249, DOI 10.1126/science.6729453	30	13	13	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2156	2161		10.1074/jbc.271.4.2156	http://dx.doi.org/10.1074/jbc.271.4.2156			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567673	hybrid			2022-12-25	WOS:A1996TR32000055
J	Ambrosini, G; Altieri, DC				Ambrosini, G; Altieri, DC			Molecular dissection of effector cell protease receptor-1 recognition of factor Xa - Assignment of critical residues involved in antibody reactivity and ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AORTIC ENDOTHELIAL-CELLS; FACTOR-V; PLASMINOGEN-ACTIVATOR; COAGULATION; THROMBIN; PROTHROMBINASE; EXPRESSION; MONOCYTES; MITOGENS; ADHESION	Receptor-mediated assembly of blood proteases on vascular cells maintains the hemostatic balance and initiates intracellular signal transduction. Effector cell protease receptor-1 (EPR-1) is an similar to 62-kDa vascular cell membrane receptor for the clotting protease factor Xa, participating in thrombin formation and lymphocyte activation. Here, recombinant EPR-1 fragments were engineered in the frame of intercellular adhesion molecule-1, transfected in mammalian cells, and analyzed for antibody recognition and ligand binding. Chimeric transfectants containing the EPR-1 sequence Met(1)-Arg(60) bound the immunosuppressive anti-EPR-l monoclonal antibody (mAb) 2E1. In contrast, transfected cells expressing the EPR-1 sequence pro(120)-Ala(154) mere recognized by the functionally inhibitory anti EPR-1 mAbs 9D4 and B6, bound I-125-factor Xa in a reaction quantitatively indistinguishable from that of wild-type EPR-1 transfectants, and promoted factor Xa concentration-dependent prothrombin activation in the absence of ex ogenous factor V/Va. Chimeric transfectants expressing the COOH terminus end of the EPR-1 extracellular domain (Ala(157)-Glu(221)) did not bind anti-EPR-1 mAbs and did not associate with factor Xa. Mutagenesis of Asn(131) or Lys(133) in the EPR-1 ligand recognition domain abolished factor Xa binding by 80 +/- 5.5 and 96 +/- 4%, respectively, while mutation of Lys(126), Gly(128), Asn(129), and Asn(134) was without effect. A synthetic peptide duplicating the EPR-1 sequence S(123)PGKPGNQNSKNEPP(137) dose dependently inhibited factor V/Va-independent thrombin generation of resting endothelium (IC50 similar to 1 mu M), while the adjacent EPR-1 sequence p(136)PKK- RERERSSHCYP(150) was ineffective. These findings demonstrate that EPR-1 contains two spatially distinct functional domains implicated in lymphocyte activation (Met(1)-Arg(60)) or factor Xa binding and prothrombin activation (pro(120)-Ala(154)). These interacting sequences may provide a novel potential target for inhibition of factor Xa-dependent vascular cell responses.	YALE UNIV,SCH MED,DEPT PATHOL,BOYER CTR MOLEC MED,MOLEC CARDIOBIOL PROGRAM,NEW HAVEN,CT 06536	Yale University					NHLBI NIH HHS [R01 HL54131, HL43773] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043773, R01HL054131] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1994, BIOCHEMISTRY-US, V33, P13848, DOI 10.1021/bi00250a039; ALTIERI DC, 1994, J BIOL CHEM, V269, P3139; ALTIERI DC, 1990, J IMMUNOL, V145, P246; ALTIERI DC, 1989, J BIOL CHEM, V264, P2969; ALTIERI DC, 1995, J LEUKOCYTE BIOL, V58, P120, DOI 10.1002/jlb.58.2.120; ANNAMALAI AE, 1985, ARTERIOSCLEROSIS, V6, P196; COUGHLIN SR, 1993, THROMB HAEMOSTASIS, V70, P184; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; GAJDUSEK C, 1986, J CELL BIOL, V103, P419, DOI 10.1083/jcb.103.2.419; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; LANGUINO LR, 1995, P NATL ACAD SCI USA, V92, P1505, DOI 10.1073/pnas.92.5.1505; NAWROTH PP, 1985, J EXP MED, V162, P559, DOI 10.1084/jem.162.2.559; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NYKJAER A, 1994, J IMMUNOL, V152, P505; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; POLLANEN JJ, 1993, BLOOD, V82, P2719; RAO NK, 1995, J CLIN INVEST, V96, P465, DOI 10.1172/JCI118057; RODGERS GM, 1985, BIOCHIM BIOPHYS ACTA, V844, P320, DOI 10.1016/0167-4889(85)90133-8; RODGERS GM, 1983, P NATL ACAD SCI-BIOL, V80, P7001, DOI 10.1073/pnas.80.22.7001; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHUMAN MA, 1986, ANN NY ACAD SCI, V485, P349; SIMMONS D, 1988, NATURE, V331, P624, DOI 10.1038/331624a0; STERN DM, 1984, J CLIN INVEST, V74, P1910, DOI 10.1172/JCI111611; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; WORFOLK LA, 1992, BLOOD, V80, P1989	32	27	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1243	1248		10.1074/jbc.271.2.1243	http://dx.doi.org/10.1074/jbc.271.2.1243			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557657	hybrid			2022-12-25	WOS:A1996TP88900094
J	Austin, CD; Shields, D				Austin, CD; Shields, D			Prosomatostatin processing in permeabilized cells - Calcium is required for prohormone cleavage but not formation of nascent secretory vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; GH3 PITUITARY-CELLS; INHIBITS ENDOCYTOSIS; PROTEINS; ACIDIFICATION; CLATHRIN; FAMILY; MATRIX; CA-2+; PH	Our laboratory has been using a permeabilized cell system derived from rat anterior pituitary GH(3) cells expressing prosomatostatin (pro SRIF) to study prohormone processing and nascent secretory vesicle formation in vitro. Because calcium is necessary for prohormone processing enzyme activity, secretory granule fusion with the plasma membrane, and possibly sorting to the regulated pathway, we treated permeabilized cells with the calcium ionophore A23187 to determine the role of calcium in pro-SRIF cleavage and nascent vesicle formation from the trans-Golgi network (TGN). Here we demonstrate that pro-SRIF cleavage was markedly inhibited when lumenal free calcium was chelated with EGTA in the presence of A23187. Surprisingly, submillimolar free calcium (similar to 15 mu M) was sufficient to maintain prohormone cleavage efficiency, a value far lower than that estimated for total calcium levels in the TGN and secretory granules. Experiments using both A23187 and the protonophore CCCP revealed that free calcium is absolutely required for efficient pro-SRIF cleavage, even at the optimal pH of 6.1. Secretory vesicle formation by contrast was not inhibited by calcium chelation but rather by millimolar extralumenal free calcium. Together, these observations demonstrate that pro-SRIF processing and budding of nascent secretory vesicles from the TGN can be uncoupled and therefore have distinct biochemical requirements. Interestingly, our data using intact GH(3) cells demonstrate that basal secretion of SRIF-related material is largely calcium-dependent and therefore cannot be equated with constitutive pathway secretion. These results underscore the importance of determining calcium requirements before assigning a secretion event to either the constitutive or regulated secretory pathway.	ALBERT EINSTEIN COLL MED, DEPT DEV & MOLEC BIOL, BRONX, NY 10461 USA; ALBERT EINSTEIN COLL MED, DEPT ANAT & STRUCT BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021860, R01DK021860] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK21860] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; ARDEN SD, 1994, BIOCHEM J, V298, P521, DOI 10.1042/bj2980521; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; BENNETT DL, 1992, J BIOL CHEM, V267, P15229; BENNETT MK, 1988, EMBO J, V7, P4075, DOI 10.1002/j.1460-2075.1988.tb03301.x; BERS DM, 1994, METHOD CELL BIOL, V40, P3; BRAKCH N, 1995, FEBS LETT, V362, P143, DOI 10.1016/0014-5793(95)00229-3; BULENDA D, 1985, BIOCHEMISTRY-US, V24, P7760, DOI 10.1021/bi00347a039; CARNELL L, 1994, J CELL BIOL, V127, P693, DOI 10.1083/jcb.127.3.693; CHANAT E, 1991, J CELL BIOL, V115, P1505, DOI 10.1083/jcb.115.6.1505; CHANDRA S, 1991, J CELL SCI, V100, P747; COLOMER V, 1994, EMBO J, V13, P3711, DOI 10.1002/j.1460-2075.1994.tb06680.x; COSSON P, 1989, J CELL BIOL, V108, P377, DOI 10.1083/jcb.108.2.377; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; ELGORT A, 1994, J BIOL CHEM, V269, P30668; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HEUSER J, 1989, J CELL BIOL, V108, P401, DOI 10.1083/jcb.108.2.401; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; HUANG XF, 1994, J BIOL CHEM, V269, P20838; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; MACKIN RB, 1991, ENDOCRINOLOGY, V129, P2263, DOI 10.1210/endo-129-4-2263; MARTIN TFJ, 1989, J BIOL CHEM, V264, P10299; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; ORCI L, 1987, CELL, V51, P1039, DOI 10.1016/0092-8674(87)90590-3; REIFFEN FU, 1986, BIOCHEMISTRY-US, V25, P4402, DOI 10.1021/bi00363a034; RHODES CJ, 1993, J BIOL CHEM, V268, P4267; RONNING SA, 1986, J BIOL CHEM, V261, P7840; ROSA P, 1992, J HISTOCHEM CYTOCHEM, V40, P523, DOI 10.1177/40.4.1552186; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; SEIDAH N, 1994, BIOCHIMIE, V76, P197, DOI 10.1016/0300-9084(94)90147-3; SEIDAH NG, 1993, BIOCHEM SOC T, V21, P685, DOI 10.1042/bst0210685; SEKSEK O, 1995, J BIOL CHEM, V270, P4967, DOI 10.1074/jbc.270.10.4967; SHENNAN KIJ, 1995, J BIOL CHEM, V270, P1402, DOI 10.1074/jbc.270.3.1402; SHIELDS D, 1993, MECHANISMS INTRACELL, P131; SONG LX, 1995, J BIOL CHEM, V270, P7963, DOI 10.1074/jbc.270.14.7963; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; STEINER DF, 1992, J BIOL CHEM, V267, P23435; STOLLER TJ, 1988, J CELL BIOL, V107, P2087, DOI 10.1083/jcb.107.6.2087; TURNER MD, 1992, J CELL BIOL, V117, P269, DOI 10.1083/jcb.117.2.269; WARREN TG, 1984, BIOCHEMISTRY-US, V23, P2684, DOI 10.1021/bi00307a023; XU HX, 1994, J BIOL CHEM, V269, P22875; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; YI Z, 1993, J BIOL CHEM, V268, P5615; YILLA M, 1993, J BIOL CHEM, V268, P19092	46	34	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1194	1199		10.1074/jbc.271.2.1194	http://dx.doi.org/10.1074/jbc.271.2.1194			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557650	hybrid			2022-12-25	WOS:A1996TP88900087
J	Johnson, JD; Snyder, C; Walsh, M; Flynn, M				Johnson, JD; Snyder, C; Walsh, M; Flynn, M			Effects of myosin light chain kinase and peptides on Ca2+ exchange with the N- and C-terminal Ca2+ binding sites of calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STOPPED-FLOW FLUORESCENCE; DEPENDENT PROTEIN-KINASE; CALCIUM-BINDING; TROPONIN-C; RECOGNITION; DISSOCIATION; FRAGMENTS; KINETICS; COMPLEX; DOMAINS	Myosin light chain kinase and peptides from the calmodulin (CaM) binding domains of myosin light chain kinase (RS-20, M-13), CaM kinase II, and the myristoylated alanine-rich protein kinase C substrate protein slowed Ca2+ dissociation from CaM's N-terminal sites from 405 +/- 75/s to 1.8-2.9/s and from CaM's C-terminal sites from 2.4 +/- 0.2/s to 0.1-0.4/s at 10 degrees C. Since Ca2+ dissociates 5-29 times faster from the N-terminal in these CaM peptide complexes and both lobes are required for activation, Ca2+ dissociation from the N-terminal would control target protein inactivation. Ca2+ binds 70 times faster to the N-terminal (1.6 x 10(8) M(-1) s(-1)) than the C-terminal sites (2.3 x 10(6) M(-1) s(-1)). In a 0.6-ms half-width Ca2+ transient, Ca2+ occupied >70% of the N-terminal but only 20% of the C-terminal sites. RS-20 produced a 9-fold and CaM kinase II a 6.3-fold increase in C-terminal Ca2+ affinity, suggesting that some target proteins may be bound to the C-terminal at resting [Ca2+]. When this is the case, Ca2+ exchange with the faster N-terminal sites may regulate CaM's activation and inactivation of these target proteins during a Ca2+ transient.	UNIV CALGARY,DEPT MED BIOCHEM,CALGARY,AB T2N 4N1,CANADA	University of Calgary	Johnson, JD (corresponding author), OHIO STATE UNIV,MED CTR,DEPT MED BIOCHEM,333 HAMILTON HALL,1645 NEIL AVE,COLUMBUS,OH 43210, USA.				NIDDK NIH HHS [DK 33727] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033727] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAYLEY P, 1984, BIOCHEM BIOPH RES CO, V120, P185, DOI 10.1016/0006-291X(84)91431-1; BLUMENTHAL DK, 1985, P NATL ACAD SCI USA, V82, P3187, DOI 10.1073/pnas.82.10.3187; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; DEDMAN JR, 1977, J BIOL CHEM, V252, P8415; GEORGE SE, 1993, J BIOL CHEM, V268, P25213; GRABAREK Z, 1991, BIOPHYS J, V59, P23; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; JOHNSON JD, 1986, BIOCHEMISTRY-US, V25, P2226, DOI 10.1021/bi00356a056; JOHNSON JD, 1979, J BIOL CHEM, V254, P3497; JOHNSON JD, 1994, J BIOL CHEM, V269, P8919; JOHNSON JD, 1981, J BIOL CHEM, V256, P2194; KASTURI R, 1993, J BIOL CHEM, V268, P7958; KELLER CH, 1982, BIOCHEMISTRY-US, V21, P156, DOI 10.1021/bi00530a027; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; LUKAS TJ, 1986, BIOCHEMISTRY-US, V25, P1458, DOI 10.1021/bi00354a041; MARTIN SR, 1985, EUR J BIOCHEM, V151, P543, DOI 10.1111/j.1432-1033.1985.tb09137.x; MARTIN SR, 1992, EUR J BIOCHEM, V205, P1107, DOI 10.1111/j.1432-1033.1992.tb16879.x; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MILLS JS, 1985, BIOCHEMISTRY-US, V24, P4897, DOI 10.1021/bi00339a026; MINOWA O, 1984, J BIOCH, V56, P1175; NGAI PK, 1984, BIOCHEM J, V218, P863, DOI 10.1042/bj2180863; OLWIN BB, 1984, J BIOL CHEM, V259, P949; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PAYNE ME, 1988, J BIOL CHEM, V263, P7190; PERSECHINI A, 1988, J BIOL CHEM, V263, P12175; POTTER JD, 1981, CALCIUM CELL FUNCTIO, V2, P145; ROBERTSON S, 1984, METHOD PHARMACOL, V5, P63, DOI DOI 10.1007/978-1-4684-4778-1_6; SMITH PD, 1984, ANAL BIOCHEM, V143, P188, DOI 10.1016/0003-2697(84)90575-X; STULL JT, 1986, ENZYMES, V17, P113; SUKO J, 1985, EUR J BIOCHEM, V153, P451, DOI 10.1111/j.1432-1033.1985.tb09323.x; TANAKA T, 1980, J BIOL CHEM, V255, P1078; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; WEINSTEIN H, 1994, ANNU REV PHYSIOL, V56, P213, DOI 10.1146/annurev.ph.56.030194.001241; YAGI K, 1989, CALCIUM PROTEIN SIGN, P147	37	107	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					761	767		10.1074/jbc.271.2.761	http://dx.doi.org/10.1074/jbc.271.2.761			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557684	hybrid			2022-12-25	WOS:A1996TP88900027
J	Kitagawa, H; Mattei, MG; Paulson, JC				Kitagawa, H; Mattei, MG; Paulson, JC			Genomic organization and chromosomal mapping of the Gal beta 1,3GalNAc/Gal beta 1,4GlcNAc alpha 2,3-sialyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; HUMAN ALPHA(1,3)FUCOSYLTRANSFERASE GENE; MOLECULAR-CLONING; GAL-BETA-1,3(4)GLCNAC ALPHA-2,3-SIALYLTRANSFERASE; MURINE BETA-1,4-GALACTOSYLTRANSFERASE; TRANSCRIPTION FACTORS; BINDING PROTEIN; CELL-ADHESION; LEWIS-X; EXPRESSION	In this report we describe the chromosome mapping and genomic organization of the human Gal beta 1,3GalNAc/Gal beta 1,4GlcNAc alpha 2,3-sialyltransferase gene. The gene is localized to human chromosome 11(q23-q24) by in situ hybridization of metaphase chromosomes. It spans more than 25 kilobases of human genomic DNA and is distributed over 14 exons that range in size from 61 to 679 base pairs. Previous characterization of cDNAs encoding the Gal beta 1,3GalNAc/Gal beta 1,4G1cNAc alpha 2,3-sialyltransferase revealed that the gene produces at least three transcripts in human placenta, which code for identical protein sequences except at the 5' ends (Kitagawa, H., and Paulson, J. C. (1994a) J. Biol. Chem. 269, 1394-1401). Repeated screening for clones that contain the 5' end of the cDNA has identified two additional distinct mRNAs that are expressed in human placenta. Comparison of the genomic DNA sequence with that of the five different mRNAs indicates that these transcripts are produced by a combination of alternative splicing and alternative promoter utilization. Northern analysis indicated that one of them is specifically expressed in placenta, testis, and ovary, indicating that its expression is independently regulated from the others.	CYTEL CORP,SAN DIEGO,CA 92121; GRP HOSP TIMONE,INSERM,U242,F-13385 MARSEILLE 5,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille			Kitagawa, Hiroshi/AAJ-1344-2020; Paulson, James/AAG-3565-2019	Kitagawa, Hiroshi/0000-0002-9307-7079; 	NIGMS NIH HHS [GM27904] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027904] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASHEIM HC, 1993, EUR J BIOCHEM, V213, P467, DOI 10.1111/j.1432-1033.1993.tb17783.x; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BRANDLEY BK, 1990, CELL, V63, P861, DOI 10.1016/0092-8674(90)90487-Y; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHANG ML, 1995, GLYCOBIOLOGY, V5, P319, DOI 10.1093/glycob/5.3.319; COX PM, 1988, NUCLEIC ACIDS RES, V16, P11047, DOI 10.1093/nar/16.23.11047; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14348; HOLLIS GF, 1989, BIOCHEM BIOPH RES CO, V162, P1069, DOI 10.1016/0006-291X(89)90782-1; HULL E, 1991, BIOCHEM BIOPH RES CO, V176, P608, DOI 10.1016/S0006-291X(05)80227-X; IHARA Y, 1993, J BIOCHEM-TOKYO, V113, P692, DOI 10.1093/oxfordjournals.jbchem.a124105; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAGEYAMA R, 1989, J BIOL CHEM, V264, P15508; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; KUROSAWA N, 1994, J BIOL CHEM, V269, P19048; KUROSAWA N, 1994, J BIOL CHEM, V269, P1402; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEE YC, 1994, J BIOL CHEM, V269, P10028; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LOWE JB, 1991, J BIOL CHEM, V266, P17467; LOWINGS P, 1992, MOL CELL BIOL, V12, P3653, DOI 10.1128/MCB.12.8.3653; MINK S, 1992, MOL CELL BIOL, V12, P4906, DOI 10.1128/MCB.12.11.4906; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; NATSUKA S, 1994, CURR OPIN STRUC BIOL, V4, P683, DOI 10.1016/S0959-440X(94)90166-X; NGUYEN C, 1986, J CELL BIOL, V102, P711, DOI 10.1083/jcb.102.3.711; OHANLON TP, 1992, GLYCOBIOLOGY, V2, P257, DOI 10.1093/glycob/2.3.257; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PAULSON JC, 1989, TRENDS BIOCHEM SCI, V14, P272, DOI 10.1016/0968-0004(89)90062-5; PAULSON JC, 1989, J BIOL CHEM, V264, P10931; POWELL LD, 1995, J BIOL CHEM, V270, P14243, DOI 10.1074/jbc.270.24.14243; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; REDDY S, 1990, J BIOL CHEM, V265, P1683; RUSSO RN, 1990, J BIOL CHEM, V265, P3324; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; WANG XC, 1993, J BIOL CHEM, V268, P4355; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P21011; WEN DX, 1992, J BIOL CHEM, V267, P2512; WESTON BW, 1992, J BIOL CHEM, V267, P4152; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628	60	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					931	938		10.1074/jbc.271.2.931	http://dx.doi.org/10.1074/jbc.271.2.931			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557707	hybrid			2022-12-25	WOS:A1996TP88900050
J	Nakano, R; Sato, H; Watanabe, A; Ito, O; Shimizu, T				Nakano, R; Sato, H; Watanabe, A; Ito, O; Shimizu, T			Conserved Glu(318) at the cytochrome P450 1A2 distal site is crucial in the nitric oxide complex stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; CATALYTIC FUNCTION; LIGAND-BINDING; HEME; OXYGEN; SYNTHASE; HEMOPROTEIN; PHOTOLYSIS; ACTIVATION; ENZYMES	Nitric oxide synthase (NOS) has a thiolate-coordinated heme active site similar to that of cytochrome P450 (P450). Both NOS and P450 form stable nitric oxide (NO)-ferric heme complexes, whereas an NO-ferric heme complex of methemoglobin, that has an imidazole-coordinated heme active site, is easily reduced, The NO complex stability of the thiolate-coordinated hemoproteins, however, appeared irreconcilable with the strong electron-donating capability of the cysteine thiolate, In the present study, NO bindings to cytochrome P450 1A2 (P450 1A2) distal mutants were studied in the presence of various substrates. We found that a mutation at Glu-318 to Ala in the putative distal site of P450 1A2, suggested to be important in the O-2 activation of P450 reactions, markedly facilitates the reduction of the NO-ferric complex. Addition of 1,2:3,4-dibenzanthracene or phenanthrene almost abolished the mutation effect on the NO complex. Based on these results, together with other spectral and kinetic data, it is suggested that the NO-ferric complex stability of P450, and perhaps of NOS, is largely ascribed to an ionic bridge between NO and the distal carboxyl group.	TOHOKU UNIV,INST CHEM REACT SCI,SENDAI,MIYAGI 98077,JAPAN	Tohoku University								ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; BOHLE DS, 1995, J AM CHEM SOC, V117, P9584, DOI 10.1021/ja00142a035; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; CHEN PF, 1994, J BIOL CHEM, V269, P25062; CHIEN JCW, 1969, J AM CHEM SOC, V91, P2166, DOI 10.1021/ja01036a085; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; DUPRAT AF, 1995, BIOCHEMISTRY-US, V34, P2634, DOI 10.1021/bi00008a030; GARBER NC, 1994, J BIOL CHEM, V269, P4260; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GWOST D, 1973, INORG CHEM, V12, P2095, DOI 10.1021/ic50127a030; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; HORI H, 1992, J BIOL CHEM, V267, P18377; HOSHINO M, 1993, J AM CHEM SOC, V115, P9568, DOI 10.1021/ja00074a023; HU SZ, 1991, J AM CHEM SOC, V113, P9760, DOI 10.1021/ja00026a008; HU SZ, 1991, J AM CHEM SOC, V113, P2843, DOI 10.1021/ja00008a007; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; IKEDASAITO M, 1993, J BIOL CHEM, V268, P6855; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; ISHIGOOKA M, 1992, BIOCHEMISTRY-US, V31, P1528, DOI 10.1021/bi00120a033; ITO O, 1995, J PHYS CHEM-US, V99, P9838, DOI 10.1021/j100024a027; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OKEEFFE DH, 1978, J BIOL CHEM, V253, P3509; PETRICH JW, 1994, J MOL BIOL, V238, P437, DOI 10.1006/jmbi.1994.1302; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; PUFAHL RA, 1995, BIOCHEMISTRY-US, V34, P1930, DOI 10.1021/bi00006a014; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; SHIMIZU T, 1991, BIOCHEMISTRY-US, V30, P4659, DOI 10.1021/bi00233a004; SHIMIZU T, 1991, BIOCHEMISTRY-US, V30, P1490, DOI 10.1021/bi00220a007; SHIMIZU T, 1994, J BIOL CHEM, V269, P13296; SHIRO Y, 1995, J BIOL CHEM, V270, P1617, DOI 10.1074/jbc.270.4.1617; SHRIVER DF, 1994, INORG CHEM, P668; SNYDER SH, 1995, NATURE, V377, P196, DOI 10.1038/377196a0; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; WATANABE A, 1994, J PHYS CHEM-US, V98, P7736, DOI 10.1021/j100082a052; WAYLAND BB, 1973, J CHEM SOC CHEM COMM, P897, DOI 10.1039/c39730000897; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WHITE RE, 1982, J BIOL CHEM, V257, P3073; YEOM H, 1995, BIOCHEMISTRY-US, V34, P14733, DOI 10.1021/bi00045a014; YOSHIMURA T, 1986, BIOCHEMISTRY-US, V25, P2436, DOI 10.1021/bi00357a021	52	38	38	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8570	8574		10.1074/jbc.271.15.8570	http://dx.doi.org/10.1074/jbc.271.15.8570			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621484	hybrid			2022-12-25	WOS:A1996UE73000015
J	Shan, Q; Cox, MM; Inman, RB				Shan, Q; Cox, MM; Inman, RB			DNA strand exchange promoted by RecA K72R - Two reaction phases with different Mg2+ requirements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ATP HYDROLYSIS; NUCLEOSIDE TRIPHOSPHATE; PARTIAL DENATURATION; BINDING-PROTEIN; COMPLEXES; PURIFICATION; MOLECULES; FILAMENTS; SEQUENCES	Replacement of lysine 72 in RecA protein with arginine produces a mutant protein that binds but does not hydrolyze ATP. The protein nevertheless promotes DNA strand exchange (Rehrauer, W. M., and Kowalczykowski, S. C. (1993) J. Biol. Chem. 268, 1292-1297). With RecA K72R protein, the formation of the hybrid DNA product of strand exchange is greatly affected by the concentration of Mg2+ in ways that reflect the concentration of a Mg . dATP complex. When Mg2+ is present at concentrations just sufficient to form the Mg . dATP complex, substantial generation of completed product hybrid DNAs over 7 kilobase pairs in length is observed (albeit slowly). Higher levels of Mg2+ are required for optimal uptake of substrate duplex DNA into the nucleoprotein filament, indicating that the formation of joint molecules is facilitated by Mg2+ levels that inhibit the subsequent migration of a DNA branch. We also show that the strand exchange reaction promoted by RecA K72R, regardless of the Mg2+ concentration, is bidirectional and incapable of bypassing structural barriers in the DNA or accommodating four DNA strands. The reaction exhibits the same limitations as that promoted by wild type RecA protein in the presence of adenosine 5'-O-(3-thio)triphosphate. The Mg2+ effects, the limitations of RecA-mediated DNA strand exchange in the absence of ATP hydrolysis, and unusual DNA structures observed by electron microscopy in some experiments, are interpreted in the context of a model in which a fast phase of DNA strand exchange produces a discontinuous three-stranded DNA pairing intermediate, followed by a slow phase in which the discontinuities are resolved. The mutant protein also facilitates the autocatalytic cleavage of the LexA repressor, but at a reduced rate.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014711, R01GM032335, U01GM032335] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM14711, GM32335] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1992, GENE DEV, V6, P1679, DOI 10.1101/gad.6.9.1679; ALBERTY RA, 1969, J BIOL CHEM, V244, P3290; Bedale WA, 1996, J BIOL CHEM, V271, P5725, DOI 10.1074/jbc.271.10.5725; BRENNER SL, 1987, J BIOL CHEM, V262, P4011; CLARK AJ, 1994, CRIT REV MICROBIOL, V20, P125, DOI 10.3109/10408419409113552; COX MM, 1995, J BIOL CHEM, V270, P26021, DOI 10.1074/jbc.270.44.26021; COX MM, 1981, J BIOL CHEM, V256, P4676; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; COX MM, 1993, BIOESSAYS, V15, P617, DOI 10.1002/bies.950150908; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Davis R., 1980, ADV BACTERIAL GENETI; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; JAIN SK, 1994, J BIOL CHEM, V269, P20653; KAHN R, 1984, J BIOL CHEM, V259, P7495; KIM JI, 1992, J BIOL CHEM, V267, P16444; KIM JI, 1992, J BIOL CHEM, V267, P16438; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; KONFORTI BB, 1992, J MOL BIOL, V227, P38, DOI 10.1016/0022-2836(92)90680-I; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; LINDSLEY JE, 1990, J BIOL CHEM, V265, P10164; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLEWOOD RK, 1982, NUCLEIC ACIDS RES, V10, P1691, DOI 10.1093/nar/10.5.1691; LIVNEH Z, 1993, CRIT REV BIOCHEM MOL, V28, P465, DOI 10.3109/10409239309085136; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MALKOV VA, 1992, NUCLEIC ACIDS RES, V20, P4889, DOI 10.1093/nar/20.18.4889; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; Record Jr M. T., 1990, BIOL NONSPECIFIC DNA, P33; RECORD MT, 1975, BIOPOLYMERS, V14, P2137, DOI 10.1002/bip.1975.360141012; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; ROSSELLI W, 1990, J MOL BIOL, V216, P335, DOI 10.1016/S0022-2836(05)80325-0; ROSSELLI W, 1991, EMBO J, V10, P4391, DOI 10.1002/j.1460-2075.1991.tb05017.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHUTTE BC, 1987, BIOCHEMISTRY-US, V26, P5616, DOI 10.1021/bi00392a006; SENECOFF JF, 1985, P NATL ACAD SCI USA, V82, P7270, DOI 10.1073/pnas.82.21.7270; SHCHYOLKINA AK, 1994, FEBS LETT, V339, P113, DOI 10.1016/0014-5793(94)80396-X; STASIAK A, 1994, EXPERIENTIA, V50, P192, DOI 10.1007/BF01924002; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; ULLSPERGER CJ, 1995, BIOCHEMISTRY-US, V34, P10859, DOI 10.1021/bi00034a019; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; WEISEMANN JM, 1985, J BACTERIOL, V163, P748, DOI 10.1128/JB.163.2.748-755.1985; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	51	115	117	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5712	5724		10.1074/jbc.271.10.5712	http://dx.doi.org/10.1074/jbc.271.10.5712			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621437	hybrid			2022-12-25	WOS:A1996TZ28600063
J	Slater, SJ; Ho, C; Kelly, MB; Larkin, JD; Taddeo, FJ; Yeager, MD; Stubbs, CD				Slater, SJ; Ho, C; Kelly, MB; Larkin, JD; Taddeo, FJ; Yeager, MD; Stubbs, CD			Protein kinase C alpha contains two activator binding sites that bind phorbol esters and diacylglycerols with opposite affinities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-VESICLES; RAT-BRAIN; EXPRESSION; PHARMACOPHORE; BRYOSTATIN-1; ISOENZYMES; INHIBITION; RECEPTOR	Based on marked differences in the enzymatic properties of diacylglycerols compared with phorbol ester-activated protein kinase C (PKC), we recently proposed that activation induced by these compounds may not be equivalent (Slater, S. J., Kelly, M. B., Taddeo, F. J., Rubin, E., and Stubbs, C. D. (1994) J. Biol. Chem. 269, 17160-17165). In the present study, direct evidence is provided showing that phorbol esters and diacylglycerols bind simultaneously to PKC alpha. Using a novel binding assay employing the fluorescent phorbol ester, sapintoxin-D (SAPD), evidence for two sites of high and low affinity was obtained. Thus, both binding and activation dose-response curves for SAPD were double sigmoidal, which was also observed for dose-dependent activation by the commonly used phorbol ester, 4 beta-12-O-tetradecanoylphorbol-13-acetate (TPA). TPA removed high affinity SAPD binding and also competed for the low affinity site. By contrast with TPA, low affinity binding of SAPD was inhibited by sn-1,2-dioleoylglycerol (DAG), while binding to the high affinity site was markedly enhanced. Again contrasting with both TPA and DAG, the potent PKC activator, bryostatin-I (B-I), inhibited SAPD binding to its high affinity site, while low affinity binding was unaffected. Based on these findings, a model for PKC activation is proposed in which binding of one activator to the low affinity site allosterically promotes binding of a second activator to the high affinity site, resulting in an enhanced level of activity. Overall, the results provide direct evidence that PKC alpha contains two distinct binding sites, with affinities that differ for each activator in the order: DAG > phorbol ester > B-I and B-I > phorbol ester > DAG, respectively.	THOMAS JEFFERSON UNIV, DEPT PATHOL & CELL BIOL, PHILADELPHIA, PA 19107 USA	Jefferson University				Larkin, Jonathan/0000-0002-1202-9287	NIAAA NIH HHS [AA08022, AA07186, AA07215] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R29AA008022, R01AA008022, P50AA007186] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BAZZI MD, 1988, BIOCHEM BIOPH RES CO, V152, P336, DOI 10.1016/S0006-291X(88)80719-8; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P3577, DOI 10.1021/bi00434a064; BAZZI MD, 1988, BIOCHEMISTRY-US, V27, P7589, DOI 10.1021/bi00420a003; BELL RM, 1991, J BIOL CHEM, V266, P4661; BLUMBERG PM, 1991, MOL CARCINOGEN, V4, P339, DOI 10.1002/mc.2940040502; BLUMBERG PM, 1992, ALFRED BENZON SYMP S, V33, P273; BONI LT, 1985, J BIOL CHEM, V260, P819; BURNS DJ, 1991, J BIOL CHEM, V266, P18330; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; DEVRIES DJ, 1988, BIOCHEM PHARMACOL, V37, P4069, DOI 10.1016/0006-2952(88)90097-4; DIMITRIJEVIC SM, 1995, MOL PHARMACOL, V48, P259; EPAND RM, 1994, ANAL BIOCHEM, V218, P241, DOI 10.1006/abio.1994.1173; HENNINGS H, 1987, CARCINOGENESIS, V8, P1343, DOI 10.1093/carcin/8.9.1343; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; ICHIKAWA S, 1995, J BIOCHEM-TOKYO, V117, P566, DOI 10.1093/oxfordjournals.jbchem.a124745; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KREUTTER D, 1985, J BIOL CHEM, V260, P5979; LELI U, 1990, MOL PHARMACOL, V37, P286; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MARQUEZ C, 1992, J IMMUNOL, V149, P2560; MORIN MJ, 1995, J BIOL CHEM, V262, P11758; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; QUEST AFG, 1994, J BIOL CHEM, V269, P2953; QUEST AFG, 1994, J BIOL CHEM, V269, P2961; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; RANDO RR, 1992, BIOCHEMISTRY-US, V31, P2211, DOI 10.1021/bi00123a001; SHARKEY NA, 1985, BIOCHEM BIOPH RES CO, V133, P1051, DOI 10.1016/0006-291X(85)91242-2; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; SLATER SJ, 1994, J BIOL CHEM, V269, P17160; SLATER SJ, 1993, NATURE, V364, P82, DOI 10.1038/364082a0; SLATER SJ, 1995, J BIOL CHEM, V270, P6639, DOI 10.1074/jbc.270.12.6639; SLATER SJ, 1994, J BIOL CHEM, V269, P4866; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STABEL S, 1991, METHOD ENZYMOL, V200, P670; TAYLOR SE, 1981, EXPERIENTIA, V37, P681, DOI 10.1007/BF01967918; WANG SM, 1994, J MED CHEM, V37, P4479, DOI 10.1021/jm00052a007; WENDER PA, 1995, P NATL ACAD SCI USA, V92, P239, DOI 10.1073/pnas.92.1.239; WENDER PA, 1988, P NATL ACAD SCI USA, V85, P7197, DOI 10.1073/pnas.85.19.7197; WENDER PA, 1986, P NATL ACAD SCI USA, V83, P4214, DOI 10.1073/pnas.83.12.4214; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	48	120	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4627	4631						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617724				2022-12-25	WOS:A1996TX69700014
J	Levy, AP; Levy, NS; Goldberg, MA				Levy, AP; Levy, NS; Goldberg, MA			Post-transcriptional regulation of vascular endothelial growth factor by hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; BIOLOGY; PROTEIN; INVITRO; CELLS; GENE	The major control point for the hypoxic induction of the vascular endothelial growth factor (VEGF) gene is the regulation of the steady-state level of the mRNA. We previously demonstrated a discrepancy between the transcription rate and the steady-state mRNA level induced by hypoxia. This led us to examine the post-transcriptional regulation of VEGF expression. Actinomycin D experiments revealed that hypoxia increased VEGF mRNA half-life from 43 +/- 6 min to 106 +/- 9 min. Using an in vitro mRNA degradation assay, the half-life of VEGF mRNA 3'-untranslated region (UTR) transcripts were also found to be increased when incubated with hypoxic versus normoxic extracts. Both cis-regulatory elements involved in VEGF mRNA degradation under normoxic conditions and in increased stabilization under hypoxic conditions were mapped using this degradation assay. A hypoxia-induced protein(s) was found that bound to the sequences in the VEGF 3'-UTR which mediated increased stability in the degradation assay. Furthermore, genistein, a tyrosine kinase inhibitor, blocked the hypoxia-induced stabilization of VEGF 3'-UTR transcripts and inhibited hypoxia-induced protein binding to the VEGF 3'-UTR. These findings demonstrate a significant post-transcriptional component to the regulation of VEGF.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV HEMATOL ONCOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV CARDIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NHLBI NIH HHS [IKO8HL03405-01, T32HL07604, 1F32HL08838-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007604, K08HL003405, F32HL008838] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; AURUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279; CZYZYKRZESKA MF, 1994, J BIOL CHEM, V269, P9940; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOLDBERG MA, 1991, BLOOD, V77, P271; GOROSPE M, 1994, J BIOL CHEM, V269, P11845; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; HO V, 1995, J BIOL CHEM, V270, P10084, DOI 10.1074/jbc.270.17.10084; KHALILI K, 1984, J MOL BIOL, V180, P1007, DOI 10.1016/0022-2836(84)90268-7; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Levy AP, 1989, GROWTH FACTORS, V2, P9, DOI 10.3109/08977198909069077; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; RODGERS JR, 1985, METHOD ENZYMOL, V109, P572; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; SABRI MN, 1991, AM HEART J, V121, P876, DOI 10.1016/0002-8703(91)90202-S; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; SHARMA H, 1992, J MOL CELL CARDIO S5, V24; SHARMA HS, 1992, J CARDIOVASC PHARM, V20, pS23, DOI 10.1097/00005344-199206201-00006; SHARMA HS, 1992, J CARDIOVASC PHARM, V61, P255; SHEETS MD, 1990, NUCLEIC ACIDS RES, V18, P5799, DOI 10.1093/nar/18.19.5799; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Skoog D. A., 1980, ANAL CHEM; STOFLET ES, 1988, SCIENCE, V239, P491, DOI 10.1126/science.3340835; WANG XM, 1995, MOL CELL BIOL, V15, P1769; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	33	530	571	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2746	2753		10.1074/jbc.271.5.2746	http://dx.doi.org/10.1074/jbc.271.5.2746			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576250	hybrid			2022-12-25	WOS:A1996TT48800064
J	Sivasubramanian, N; Adhikary, G; Sil, PC; Sen, S				Sivasubramanian, N; Adhikary, G; Sil, PC; Sen, S			Cardiac myotrophin exhibits rel/NF-kappa B interacting activity in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE; EXPRESSION; PROTEINS; BINDING; FAMILY; HEART; CELLS	Myotrophin is a soluble-12 kilodalton protein isolated from hypertrophied spontaneously hypertensive rat and dilated cardiomyopathic human hearts. We have recently cloned the gene coding for myotrophin and expressed it in Escherichia coli. In the present study, the expression of myotrophin gene was analyzed, and at least seven transcripts have been detected in rat heart and in other tissues. We have further analyzed the primary structure of myotrophin protein and identified significant new structural and functional domains, Our analysis revealed that one of the ankyrin repeats of myotrophin is highly homologous specifically to those of I kappa B alpha/rel ankyrin repeats. In addition, putative consensus phosphorylation sites for protein kinase C and casein kinase II, which were observed in I kappa B alpha proteins, were identified in myotrophin. To verify the significance of these homologies, kappa B gel shift assays were performed with Jurkat T cell nuclear extract proteins and the recombinant myotrophin. Results of these assays indicate that the recombinant myotrophin has the ability to interact with NF-kappa B/rel proteins as revealed by the formation of ternary protein-DNA complexes. While myotrophin-specific antibodies inhibited the formation of these complexes, rel-specific p50 and p65 antibodies supershifted these complexes. Thus, these results clearly indicate that the myotrophin protein to be a unique rel/NF-kappa B interacting protein.			Sivasubramanian, N (corresponding author), CLEVELAND CLIN FDN,RES INST,DEPT MOLEC CARDIOL,CLEVELAND,OH 44195, USA.		Sil, Parames C./AAJ-9795-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047794] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47794] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ALUBAIDI MR, 1990, J BIOL CHEM, V265, P20563; BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BHARGAVA AK, 1993, P NATL ACAD SCI USA, V90, P10260, DOI 10.1073/pnas.90.21.10260; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; GRILLI M, 1993, INT REV CYTOL, V143, P1; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HUARTE J, 1992, CELL, V69, P1021, DOI 10.1016/0092-8674(92)90620-R; MUKHERJEE DP, 1993, HYPERTENSION, V21, P142, DOI 10.1161/01.HYP.21.2.142; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; SEN S, 1990, J BIOL CHEM, V265, P16635; SIL P, 1995, CIRC RES, V76, P1020, DOI 10.1161/01.RES.76.6.1020; SIL P, 1993, CIRC RES, V73, P98, DOI 10.1161/01.RES.73.1.98; SIVASUBRAMANIAN N, 1994, CIRCULATION, V90, P637; TAOKA M, 1994, J BIOL CHEM, V269, P9946; TAOKA M, 1992, EUR J BIOCHEM, V207, P615, DOI 10.1111/j.1432-1033.1992.tb17088.x; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898	22	34	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2812	2816		10.1074/jbc.271.5.2812	http://dx.doi.org/10.1074/jbc.271.5.2812			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576259	hybrid			2022-12-25	WOS:A1996TT48800073
J	Gualix, J; Abal, M; Pintor, J; GarciaCarmona, F; MirasPortugal, MT				Gualix, J; Abal, M; Pintor, J; GarciaCarmona, F; MirasPortugal, MT			Nucleotide vesicular transporter of bovine chromaffin granules - Evidence for a mnemonic regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIADENOSINE POLYPHOSPHATES; ADRENAL-MEDULLA; SECRETORY ORGANELLES; INDUCED RELEASE; CELLS; ENZYMES; STORAGE; AP4A; AP5A; SPECIFICITY	The nucleotide vesicular transport has been studied with the fluorescent substrate analogues, the (1,N-6-ethenoadenosine) nucleotides. The transport experiments were carried out with granular preparations from bovine adrenal medulla, and epsilon-ATP, epsilon-ADP, and epsilon-AMP were quantified after separation by high performance liquid chromatography. The granular concentration increase of all three nucleotides was time-dependent. The concentration dependence of epsilon-nucleotide transport to chromaffin granules did not follow the Michaelis-Menten kinetics and presented a similar three-step curve with cooperativity. This shape can be considered to be the result of the addition of three sigmoidal curves with their corresponding kinetic parameters. epsilon-ATP exhibited K values of 0.25, 1, and 3 mM and V-max values of 0.02, 0.04 and 0.19 nmol.min(-1) mg of protein(-1), for the first, second, and third curves for each step, respectively. epsilon-ADP exhibited K values of 0.15, 0.9, and 3.6 mM and V-max values of 0.025, 0.035, and 0.3 nmol.min(-1) mg of protein(-1), respectively for the first, second, and third curves. epsilon-AMP exhibited K values of 0.2, 1.2, and 3.2 mM, and V-max values of 0.01, 0.04, and 0.055 nmol.min(-1) mg of protein(-1), also for the first to third steps. The Hill numbers for epsilon-ATP, epsilon-ADP, and epsilon-AMP were not constant but a function of the transport saturation. The nonhydrolyzable ATP analogues AMPPNP, ATP gamma S, and ADP beta S were activators of epsilon-nucleotide transport at concentrations under 1 mM and inhibitors at higher concentrations. Atractyloside and N-ethylmaleimide partially inhibited the nucleotide granular transport. High extragranular ATP concentrations specifically induced the exit of the previously transported granular epsilon-ATP.	UNIV COMPLUTENSE MADRID,FAC VET,DEPT BIOQUIM,E-28040 MADRID,SPAIN; UNIV MURCIA,FAC BIOL,DEPT BIOQUIM,E-30080 MURCIA,SPAIN	Complutense University of Madrid; University of Murcia			Miras-Portugal, Maria Teresa/L-7137-2014; Gualix, Javier/C-5783-2017; Garcia-Carmona, Francisco/K-6520-2017	Gualix, Javier/0000-0001-7215-6483; Abal Posada, Miguel/0000-0003-3533-7781; Pintor, Jesus/0000-0002-9191-7679				ABERER W, 1978, BIOCHEM J, V172, P353, DOI 10.1042/bj1720353b; APPS DK, 1987, ANN NY ACAD SCI, V493, P179; BANKS RD, 1979, NATURE, V279, P773, DOI 10.1038/279773a0; CASILLAS T, 1993, BIOCHEMISTRY-US, V32, P14203, DOI 10.1021/bi00214a020; CASTRO E, 1990, BRIT J PHARMACOL, V100, P360, DOI 10.1111/j.1476-5381.1990.tb15809.x; CIDON S, 1983, J BIOL CHEM, V258, P1684; DELCASTILLO AR, 1988, J NEUROCHEM, V51, P1696, DOI 10.1111/j.1471-4159.1988.tb01147.x; GRUNINGER HA, 1983, NEUROSCIENCE, V9, P917, DOI 10.1016/0306-4522(83)90280-4; HEBERT DN, 1991, BIOCHEMISTRY-US, V30, P4654, DOI 10.1021/bi00233a003; HENRY JP, 1994, J EXP BIOL, V196, P251; IRVING MG, 1973, BIOCHEM J, V131, P287, DOI 10.1042/bj1310287; IRVING MG, 1973, BIOCHEM J, V131, P303, DOI 10.1042/bj1310303; KAGAN ZS, 1973, BIOCHIM BIOPHYS ACTA, V302, P110, DOI 10.1016/0005-2744(73)90014-4; KLINGENBERG M, 1975, EUR J BIOCHEM, V52, P351, DOI 10.1111/j.1432-1033.1975.tb04003.x; KNOTH J, 1980, BIOCHEMISTRY-US, V19, P2938, DOI 10.1021/bi00554a019; KURGANOV BI, 1982, KINETIC BEHAVIOUR; KWONG FYP, 1992, J BIOL CHEM, V267, P21954; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; LUQMANI YA, 1981, NEUROSCIENCE, V6, P1011, DOI 10.1016/0306-4522(81)90067-1; MILLARUELO AI, 1986, MOL CELL BIOCHEM, V70, P67; MIRASPORTUGAL MT, 1980, MOL CELL BIOCHEM, V33, P25; MORO MA, 1991, J NEUROCHEM, V57, P363, DOI 10.1111/j.1471-4159.1991.tb03761.x; NARI J, 1984, EUR J BIOCHEM, V145, P319, DOI 10.1111/j.1432-1033.1984.tb08555.x; NEET KE, 1976, TRENDS BIOCHEM SCI, V7, P145; NELSON N, 1992, J EXP BIOL, V172, P149; NJUS D, 1978, BIOCHIM BIOPHYS ACTA, V463, P219, DOI 10.1016/0304-4173(78)90001-0; PINTOR J, 1992, NEUROSCI LETT, V136, P141, DOI 10.1016/0304-3940(92)90034-5; PINTOR J, 1992, NEUROSCI RES COMMUN, V10, P9; PINTOR J, 1992, ANAL BIOCHEM, V200, P296, DOI 10.1016/0003-2697(92)90469-N; PINTOR J, 1991, LIFE SCI, V48, P2317, DOI 10.1016/0024-3205(91)90268-G; POLLARD HB, 1976, J BIOL CHEM, V351, P4544; RICARD J, 1987, EUR J BIOCHEM, V166, P255, DOI 10.1111/j.1432-1033.1987.tb13510.x; ROISIN MP, 1982, BIOCHIM BIOPHYS ACTA, V681, P292, DOI 10.1016/0005-2728(82)90034-2; ROTLLAN P, 1991, FEBS LETT, V280, P371; SCHERMAN D, 1983, BIOCHEMISTRY-US, V22, P2805, DOI 10.1021/bi00281a006; SCHLUTER H, 1994, NATURE, V367, P186, DOI 10.1038/367186a0; SCHLUTTER H, 1994, J NEUROCHEM, V63, P1924; SCHULDINER S, 1995, PHYSIOL REV, V75, P369, DOI 10.1152/physrev.1995.75.2.369; SECRIST JA, 1972, BIOCHEMISTRY-US, V11, P3499, DOI 10.1021/bi00769a001; SILONOVA G V, 1969, Molekulyarnaya Biologiya (Moscow), V3, P768; SOMERO GN, 1969, NATURE, V223, P194, DOI 10.1038/223194a0; TAUGNER G, 1988, BIOGENIC AMINES, V5, P409; TERLAND O, 1979, BIOCHIM BIOPHYS ACTA, V553, P460, DOI 10.1016/0005-2736(79)90301-8; TORRES M, 1992, BIOCHIM BIOPHYS ACTA, V1105, P291, DOI 10.1016/0005-2736(92)90207-3; VALERO E, 1992, BIOCHEM J, V286, P623, DOI 10.1042/bj2860623; VORA S, 1985, BIOCHEM J, V229, P333, DOI 10.1042/bj2290333; WEBER A, 1981, NEUROSCIENCE, V6, P2269, DOI 10.1016/0306-4522(81)90016-6; Winkler H, 1982, SECRETORY GRANULE, P3; ZIMMERMANN H, 1994, TRENDS NEUROSCI, V17, P420, DOI 10.1016/0166-2236(94)90016-7	50	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1957	1965		10.1074/jbc.271.4.1957	http://dx.doi.org/10.1074/jbc.271.4.1957			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567644	hybrid			2022-12-25	WOS:A1996TR32000026
J	Hung, HL; High, KA				Hung, HL; High, KA			Liver-enriched transcription factor HNF-4 and ubiquitous factor NF-Y are critical for expression of blood coagulation factor X	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; MESSENGER-RNA; ALBUMIN GENE; HEMOPHILIA-B; PROMOTER; MOUSE; CELLS; SITE; DISRUPTION; CLONING	Blood coagulation Factor X and its activated form Factor Xa play an essential role in the midphase of the clotting cascade, To delineate the mechanisms governing the liver-specific expression of Factor X, we have previously characterized the complete 2.8 kilobase pairs of the 5'-flanking region of Factor X and demonstrated that the first 209 base pairs is sufficient to confer maximal promoter activity in HepG2 cells, a hepatoma cell line that expresses Factor X, We have also shown that mutations at ACTTTG and CCAAT elements located at -56 to -51 and -120 to -116, respectively, significantly reduce the promoter activity, In this report, we demonstrate that Factor X mRNA is primarily but not exclusively expressed in the liver. Using DNase I footprinting analysis, we determine four protein binding sites within the 209-base pair fragment, designated site 1 (-73 to -44), site 2 (-128 to -94), site 3 (-165 to -132), and site 4 (-195 to -169), Using gel mobility shift assays in combination with competition and supershift experiments, we demonstrate that hepatocyte nuclear factor 4 and Sp1 bind at site 1, the site which contains the ACTTTG element, Methylation interference assays reveal that HNF-4 and Sp1 contact adjacent sites with minor overlap. HNF-4 and Sp1 appear to bind site 1 in a mutually exclusive fashion. We also demonstrate that HNF-4 can transactivate the Factor X promoter in HeLa cells; mutation at the adjacent Sp1 site further increases the transactivation. Heteromeric transcription factor NF-Y was identified as the protein that binds the CCAAT box at site 2, We conclude that HNF-4 and NF-Y play crucial roles in modulating the activity of the proximal promoter of Factor X.	UNIV PENN,DEPT PEDIAT,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; CHILDRENS HOSP PHILADELPHIA,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia			High, Katherine A./AAB-9322-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048322] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48322] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI D, 1995, FASEB J, V862, P860; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAHNAK BR, 1987, BLOOD, V69, P224; COUGHLIN SR, 1995, MOL BASIS THROMBOSIS, P639; CROSSLEY M, 1990, NATURE, V345, P444, DOI 10.1038/345444a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HUANG MN, 1992, J BIOL CHEM, V267, P15440; JAMISON CS, 1991, BIOCHIM BIOPHYS ACTA, V1088, P208; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; LI XY, 1992, J BIOL CHEM, V267, P8984; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; Maxam A M, 1980, Methods Enzymol, V65, P499; MIAO CH, 1992, J BIOL CHEM, V267, P7395; MIETUSSNYDER M, 1992, MOL CELL BIOL, V12, P1708, DOI 10.1128/MCB.12.4.1708; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; RAMACHANDRAN B, 1995, EXP HEMATOL, V23, P49; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SALIER JP, 1990, J BIOL CHEM, V265, P7062; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WRIGHT DJ, 1995, MOL BASIS THROMBOSIS, P309	34	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2323	2331		10.1074/jbc.271.4.2323	http://dx.doi.org/10.1074/jbc.271.4.2323			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567696	hybrid			2022-12-25	WOS:A1996TR32000078
J	Mirzabekov, TA; Lin, MC; Kagan, BL				Mirzabekov, TA; Lin, MC; Kagan, BL			Pore formation by the cytotoxic islet amyloid peptide amylin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID BILAYER-MEMBRANES; DIABETES-MELLITUS; POLYPEPTIDE; CHANNELS; GLUCOSE; RESISTANCE; SECRETION; PROTEIN	Amylin is a 37-amino acid cytotoxic constituent of amyloid deposits found in the islets of Langerhans of patients with type II diabetes. Extracellular accumulation of this peptide results in damage to insulin-producting beta cell membranes and cell death. We report here that at cytotoxic concentrations, amylin forms voltage-dependent, relatively nonselective, ion-permeable channels in planar phospholipid bilayer membranes. Channel formation is dependent upon lipid membrane composition, ionic strength, and membrane potential, At 1-10 mu M, cytotoxic human amylin dramatically increases the conductance of lipid bilayer membranes, while noncytotoxic rat amylin does not. We suggest that channel formation may be the mechanism of cytotoxicity of human amylin.	UNIV CALIF LOS ANGELES,INST NEUROPSYCHIAT,BRAIN RES INST,MENTAL RETARDAT RES CTR,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST NEUROPSYCHIAT,BRAIN RES INST,MENTAL RETARDAT RES CTR,LOS ANGELES,CA 90095; VET ADM MED CTR,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Kagan, Bruce/ABD-7389-2020		NIMH NIH HHS [MH 43433, MH 01174] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH001174, R29MH043433] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; ATWATER I, 1978, J PHYSIOL-LONDON, V278, P117, DOI 10.1113/jphysiol.1978.sp012296; BETSHOLTZ C, 1989, FEBS LETT, V251, P261, DOI 10.1016/0014-5793(89)81467-X; CLARK A, 1993, BIOCHEM SOC T, V21, P169, DOI 10.1042/bst0210169; CLARK A, 1987, LANCET, V2, P231; COOPER GJS, 1987, P NATL ACAD SCI USA, V84, P8628, DOI 10.1073/pnas.84.23.8628; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; CRUCIANI RA, 1992, EUR J PHARM-MOLEC PH, V226, P287, DOI 10.1016/0922-4106(92)90045-W; DEKONING EJP, 1994, P NATL ACAD SCI USA, V91, P8467, DOI 10.1073/pnas.91.18.8467; DUCLOHIER H, 1994, TOXICOLOGY, V87, P175, DOI 10.1016/0300-483X(94)90160-0; FARTHROP DJ, 1991, ARCH TOXICOL, V65, P437; HOWARD CF, 1978, DIABETES, V27, P357, DOI 10.2337/diabetes.27.4.357; JOHNSON KH, 1973, DIABETES, V22, P81, DOI 10.2337/diab.22.2.81; JOHNSON KH, 1992, LAB INVEST, V66, P522; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KANATSUKA A, 1989, FEBS LETT, V259, P199, DOI 10.1016/0014-5793(89)81527-3; LEIGHTON B, 1988, NATURE, V335, P632, DOI 10.1038/335632a0; LIN M, 1995, BIOPHYS J, V68, P383; LORENZO A, 1994, NATURE, V368, P756, DOI 10.1038/368756a0; MANNELLA CA, 1992, J BIOENERG BIOMEMBR, V24, P7, DOI 10.1007/BF00769525; MCLEAN LR, 1992, BIOCHIM BIOPHYS ACTA, V1122, P317, DOI 10.1016/0167-4838(92)90411-6; MIRZABEKOV T, 1993, J MEMBRANE BIOL, V133, P129; MIRZABEKOV T, 1994, BIOCHEM BIOPH RES CO, V202, P1142, DOI 10.1006/bbrc.1994.2047; NAKAJIMA Y, 1987, J BIOL CHEM, V262, P1665; ORRENIUS S, 1992, TOXICOL LETT, V64-5, P357, DOI 10.1016/0378-4274(92)90208-2; SCHNEIDER HM, 1980, DEUT MED WOCHENSCHR, V105, P1143, DOI 10.1055/s-2008-1070828; TERZI E, 1994, BIOCHEMISTRY-US, V33, P1345, DOI 10.1021/bi00172a009; URRUTIA R, 1989, FEBS LETT, V247, P7; WAGONER PK, 1993, P NATL ACAD SCI USA, V90, P9145, DOI 10.1073/pnas.90.19.9145; WESTERMARK P, 1978, DIABETOLOGIA, V15, P417, DOI 10.1007/BF01219652; WESTERMARK P, 1973, ACTA PATH MICRO IM A, VA 81, P291; WESTERMARK P, 1973, VIRCHOWS ARCH A, V359, P1, DOI 10.1007/BF00549079; YANO BL, 1981, VET PATHOL, V18, P621, DOI 10.1177/030098588101800507; YOUNG AA, 1994, J CELL BIOCHEM, V55, P12, DOI 10.1002/jcb.240550003	34	369	377	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1988	1992		10.1074/jbc.271.4.1988	http://dx.doi.org/10.1074/jbc.271.4.1988			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567648	hybrid			2022-12-25	WOS:A1996TR32000030
J	Varanasi, U; Chu, RY; Huang, Q; Castellon, R; Yeldandi, AV; Reddy, JK				Varanasi, U; Chu, RY; Huang, Q; Castellon, R; Yeldandi, AV; Reddy, JK			Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; ACTIVATED RECEPTOR; BETA-OXIDATION; COA OXIDASE; RAT-LIVER; HORMONE; ACID; EXPRESSION; INDUCTION; MEMBER	Peroxisome proliferators cause a rapid and coordinated transcriptional activation of genes encoding the enzymes of the peroxisomal beta-oxidation pathway in rats and mice. Cis-acting peroxisome proliferator responsive elements (PPREs) have been identified in the 5'-flanking region of H2O2-producing rat acyl-CoA oxidase (ACOX) gene and in other genes inducible by peroxisome proliferators. To gain more insight into the purported nonresponsiveness of human liver cells to peroxisome proliferator-induced increases in peroxisome volume density and in the activity of the beta-oxidation enzyme system, we have previously cloned the human ACOX gene, the first and rate-limiting enzyme of the peroxisomal beta-oxidation system. We now present information on a regulatory element for the peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor (RXR) heterodimers. The PPRE, consists of AGGTCA C TGGTCA, which is a direct repeat of hexamer half-sites interspaced by a single nucleotide (DR1 motif). It is located at - 1918 to - 1906 base pairs upstream of the transcription initiation site of this human ACOX gene. This PPRE specifically binds to baculovirus-expressed recombinant rat PPAR alpha/RXR alpha heterodimers. In transient transfection experiments, the maximum induction of luciferase expression by ciprofibrate and/or 9-cis-retinoic acid is dependent upon cotransfection of expression plasmids for PPAR alpha and RXR alpha. The functionality of this human ACOX promoter was further demonstrated by linking it to a beta-galactosidase reporter gene or to a rat urate oxidase cDNA and establishing stably transfected African green monkey kidney (CV1) cell lines expressing reporter protein, The human ACOX promoter has been found to be responsive to peroxisome proliferators in CV1 cells stably expressing PPAR alpha, whereas only a basal level of promoter activity is detected in stably transfected cells lacking PPAR alpha. The presence of a PPRE in the promoter of this human peroxisomal ACOX gene and its responsiveness to peroxisome proliferators suggests that factors other than the PPRE in the 5'-flanking sequence of the human ACOX gene may account for differences, if any, in the pleiotropic responses of humans to peroxisome proliferators.	NORTHWESTERN UNIV,SCH MED,DEPT PATHOL,CHICAGO,IL 60611	Northwestern University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023750] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM23750] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDRIDGE TC, 1995, BIOCHEM J, V306, P473, DOI 10.1042/bj3060473; ALVARES K, 1992, P NATL ACAD SCI USA, V89, P4908, DOI 10.1073/pnas.89.11.4908; ASHBY J, 1994, HUM EXP TOXICOL S2, V13, P1; BENTLEY P, 1993, FOOD CHEM TOXICOL, V31, P857, DOI 10.1016/0278-6915(93)90225-N; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; CHU R, 1995, IN PRESS J BIOL CHEM; CHU RY, 1995, J BIOL CHEM, V270, P4908, DOI 10.1074/jbc.270.9.4908; CHU S, 1995, P NATL ACAD SCI USA, V92, P7080, DOI 10.1073/pnas.92.15.7080; DEDUVE C, 1966, PHYSIOL REV, V46, P323, DOI 10.1152/physrev.1966.46.2.323; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; GEARING KL, 1993, P NATL ACAD SCI USA, V90, P1440, DOI 10.1073/pnas.90.4.1440; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; HANEFELD M, 1983, ATHEROSCLEROSIS, V46, P239, DOI 10.1016/0021-9150(83)90115-6; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; ISSEMANN I, 1993, J MOL ENDOCRINOL, V11, P37, DOI 10.1677/jme.0.0110037; JOW L, 1995, J BIOL CHEM, V270, P3836, DOI 10.1074/jbc.270.8.3836; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; LAZAROW PB, 1976, P NATL ACAD SCI USA, V73, P2043, DOI 10.1073/pnas.73.6.2043; LEE SST, 1995, MOL CELL BIOL, V15, P3012; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MIYATA KS, 1993, J BIOL CHEM, V268, P19169; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NAAR AM, 1991, CELL, V65, P1267, DOI 10.1016/0092-8674(91)90021-P; NEMALI MR, 1988, CANCER RES, V48, P5316; NEMALI MR, 1989, TOXICOL APPL PHARM, V97, P72, DOI 10.1016/0041-008X(89)90056-2; OSUMI T, 1991, BIOCHEM BIOPH RES CO, V175, P866, DOI 10.1016/0006-291X(91)91645-S; OSUMI T, 1993, BIOCHIMIE, V75, P243, DOI 10.1016/0300-9084(93)90083-5; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; RAO MS, 1987, CARCINOGENESIS, V8, P631; REDDY JK, 1986, TRENDS PHARMACOL SCI, V7, P438, DOI 10.1016/0165-6147(86)90416-5; REDDY JK, 1975, SCIENCE, V190, P787, DOI 10.1126/science.1198095; REDDY JK, 1980, NATURE, V283, P397, DOI 10.1038/283397a0; REDDY JK, 1986, P NATL ACAD SCI USA, V83, P1747, DOI 10.1073/pnas.83.6.1747; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; REDDY JK, 1992, MECHANISM CARCINOGEN, P225; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; TOLBERT NE, 1981, ANNU REV BIOCHEM, V50, P133, DOI 10.1146/annurev.bi.50.070181.001025; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VARANASI U, 1994, P NATL ACAD SCI USA, V91, P3107, DOI 10.1073/pnas.91.8.3107; Yeldandi AV, 1995, GENE EXPRESSION, V5, P123; ZHANG BW, 1993, J BIOL CHEM, V268, P12939; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	49	145	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2147	2155		10.1074/jbc.271.4.2147	http://dx.doi.org/10.1074/jbc.271.4.2147			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567672	hybrid			2022-12-25	WOS:A1996TR32000054
J	Zannini, M; Acebron, A; DeFelice, M; Arnone, MI; MartinPerez, J; Santisteban, P; DiLauro, R				Zannini, M; Acebron, A; DeFelice, M; Arnone, MI; MartinPerez, J; Santisteban, P; DiLauro, R			Mapping and functional role of phosphorylation sites in the thyroid transcription factor-1 (TTF-1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; CHLORAMPHENICOL ACETYLTRANSFERASE; DIFFERENTIATION EXPRESSION; THYROGLOBULIN PROMOTER; CELL-PROLIFERATION; GENE-EXPRESSION; MAMMALIAN-CELLS; PHORBOL ESTERS; THYROTROPIN; GROWTH	The phosphorylation of thyroid transcription factor-1 (TTF-1), a homeodomain-containing transcription factor that is required for thyroid-specific expression of the thyroglobulin and thyroperoxidase gene promoters, has been studied. Phosphorylation occurs on a maximum of seven serine residues that are distributed in three tryptic peptides. Mutant derivatives of TTF-1, with alanine residues replacing the serines in the phosphorylation sites, have been constructed and used to assess the functional relevance of TTF-1 phosphorylation. The DNA binding activity of TTF-1 appears to be phosphorylation-independent, as indicated also by the performance of TTF-1 purified from an overexpressing Escherichia coli strain. Transcriptional activation by TTF-1 could require phosphorylation only in specific cell types since in a co-transfection assay in heterologous cells both wild-type and mutant proteins show a similar transcriptional activity.	STAZ ZOOL ANTON DOHRN, INST INVEST BIOMED, I-80121 NAPLES, ITALY; CSIC, FAC MED, IST PLURIDISCIPLINARE PATOL GEN, CATTEDRA IMMUNOL, E-28029 MADRID, SPAIN; UNIV MESSINA, MESSINA, ITALY	Stazione Zoologica Anton Dohrn di Napoli; Consejo Superior de Investigaciones Cientificas (CSIC); University of Messina			Di Lauro, Roberto/A-2746-2012; Zannini, Mariastella/I-1735-2012; Martin-Perez, Jorge/A-3522-2008; Santisteban, Pilar/E-7829-2016	Di Lauro, Roberto/0000-0001-9493-3036; Martin-Perez, Jorge/0000-0002-2292-0057; Santisteban, Pilar/0000-0002-2758-796X; ARNONE, Maria Immacolata/0000-0002-9012-7624				Ambesi-Impiombato F S, 1979, Int Rev Cytol Suppl, P163; ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; AVVEDIMENTO VE, 1991, GENE DEV, V5, P22, DOI 10.1101/gad.5.1.22; BACHRACH LK, 1985, ENDOCRINOLOGY, V116, P1603, DOI 10.1210/endo-116-4-1603; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; DAMANTE G, 1994, BBA-GENE STRUCT EXPR, V1218, P255, DOI 10.1016/0167-4781(94)90176-7; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; DUMONT JE, 1995, ENDOCRINOLOGY, V1, P543; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; FUJIMOTO J, 1992, ENDOCRINOLOGY, V130, P1587, DOI 10.1210/en.130.3.1587; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GINSBERG J, 1986, FEBS LETT, V206, P309, DOI 10.1016/0014-5793(86)81002-X; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Jackson S P, 1992, Trends Cell Biol, V2, P104, DOI 10.1016/0962-8924(92)90014-E; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KRAIEM Z, 1995, ENDOCRINOLOGY, V136, P585, DOI 10.1210/en.136.2.585; LACAL JC, 1990, MOL CELL BIOL, V10, P2983, DOI 10.1128/MCB.10.6.2983; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; LEDENT C, 1990, P NATL ACAD SCI USA, V87, P6176, DOI 10.1073/pnas.87.16.6176; LOMBARDI A, 1988, ENDOCRINOLOGY, V123, P1544, DOI 10.1210/endo-123-3-1544; MUSTI AM, 1987, NUCLEIC ACIDS RES, V15, P8149, DOI 10.1093/nar/15.20.8149; POHL V, 1990, J CELL BIOL, V111, P663, DOI 10.1083/jcb.111.2.663; ROGER PP, 1986, CANCER RES, V46, P898; ROSSI DL, 1995, J BIOL CHEM, V270, P23139, DOI 10.1074/jbc.270.39.23139; SHIMURA H, 1994, MOL ENDOCRINOL, V8, P1049, DOI 10.1210/me.8.8.1049; SINCLAIR AJ, 1990, EUR J BIOCHEM, V193, P311, DOI 10.1111/j.1432-1033.1990.tb19339.x; VASSART G, 1992, ENDOCR REV, V13, P596, DOI 10.1210/er.13.3.596; ZANNINI S, 1994, TRANSCRIPTION FACTOR, P79	39	68	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2249	2254		10.1074/jbc.271.4.2249	http://dx.doi.org/10.1074/jbc.271.4.2249			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567686	hybrid, Green Accepted			2022-12-25	WOS:A1996TR32000068
J	Lemberger, T; Saladin, R; Vazquez, M; Assimacopoulos, F; Staels, B; Desvergne, B; Wahli, W; Auwerx, J				Lemberger, T; Saladin, R; Vazquez, M; Assimacopoulos, F; Staels, B; Desvergne, B; Wahli, W; Auwerx, J			Expression of the peroxisome proliferator-activated receptor alpha gene is stimulated by stress and follows a diurnal rhythm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-OXIDATION PATHWAY; FATTY-ACIDS; GLUCOCORTICOID RECEPTOR; RAT-LIVER; MEMBER; IDENTIFICATION; SUPERFAMILY; CLONING; FAMILY; PPAR	Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that can be activated by fatty acids and peroxisome proliferators. The PPAR alpha subtype mediates the pleiotropic effects of these activators in liver and regulates several target genes involved in fatty acid catabolism. In primary hepatocytes cultured in vitro, the PPAR alpha gene is regulated at the transcriptional level by glucocorticoids. We investigated if this hormonal regulation also occurs in the whole animal in physiological situations leading to increased plasma corticosterone levels in rats. We show here that an immobilization stress is a potent and rapid stimulator of PPAR alpha expression in liver but not in hippocampus. The injection of the synthetic glucocorticoid dexamethasone into adult rats produces a similar increase in PPAR alpha expression in liver, whereas the administration of the antiglucocorticoid RU 486 inhibits the stress-dependent stimulation. We conclude that glucocorticoids are major mediators of the stress response. Consistent with this hormonal regulation, hepatic PPAR alpha mRNA and protein levels follow a diurnal rhythm, which parallels that of circulating corticosterone. To test the effects of variations in PPAR alpha expression on PPAR alpha target gene activity, high glucocorticoid-dependent PPAR alpha expression was mimicked in cultured primary hepatocytes. Under these conditions, hormonal stimulation of receptor expression synergizes with receptor activation by WY-14,643 to induce the expression of the PPAR alpha target gene acyl-CoA oxidase. Together, these results show that regulation of the PPAR alpha expression levels efficiently modulates PPAR activator signaling and thus may affect downstream metabolic pathways involved in lipid homeostasis.	UNIV LAUSANNE, INST BIOL ANIM, CH-1015 LAUSANNE, SWITZERLAND; INST PASTEUR, DEPT ATHEROSCLEROSE, INSERM U325, LAB BIOL REGULAT EUCARYOTES, F-59019 LILLE, FRANCE; UNIV GENEVA, CTR MED, DEPT BIOCHIM MED, CH-1211 GENEVA, SWITZERLAND	University of Lausanne; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of Geneva			Wahli, Walter/I-3194-2019; Vázquez-Carrera, Manuel/H-2612-2015; Wahli, Walter/B-1398-2009; Lemberger, Thomas/A-7301-2008; Staels, Bart/N-9497-2016; Desvergne, Beatrice/C-8892-2016	Vázquez-Carrera, Manuel/0000-0001-7138-8207; Wahli, Walter/0000-0002-5966-9089; Lemberger, Thomas/0000-0002-2499-4025; Staels, Bart/0000-0002-3784-1503; Auwerx, Johan/0000-0002-5065-5393; Desvergne, Beatrice/0000-0001-5483-288X				ALEXANDROVA M, 1992, J STEROID BIOCHEM, V42, P493, DOI 10.1016/0960-0760(92)90261-G; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; AXELROD J, 1984, SCIENCE, V224, P452, DOI 10.1126/science.6143403; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BRAISSANT O, 1996, IN PRESS ENDOCRINOLO; CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DESVERGNE B, 1995, INDUCIBLE GENE EXPRE, V1, P142; DHABHAR FS, 1993, BRAIN RES, V616, P89, DOI 10.1016/0006-8993(93)90196-T; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5; GOTTLICHER M, 1992, P NATL ACAD SCI USA, V89, P4653, DOI 10.1073/pnas.89.10.4653; Greene M. E., 1995, Gene Expression, V4, P281; GUILLAUMEGENTIL C, 1990, ENDOCRINOLOGY, V126, P1873, DOI 10.1210/endo-126-4-1873; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; GWOSDOWCOHEN A, 1982, P SOC EXP BIOL MED, V170, P29, DOI 10.3181/00379727-170-41391; HERTZ R, 1995, J BIOL CHEM, V270, P13470, DOI 10.1074/jbc.270.22.13470; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KELLER H, 1993, P NATL ACAD SCI USA, V90, P2160, DOI 10.1073/pnas.90.6.2160; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; LEE SST, 1995, MOL CELL BIOL, V15, P3012; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEMBERGER T, 1994, J BIOL CHEM, V269, P24527; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; MCEWEN BS, 1995, CURR OPIN NEUROBIOL, V5, P205, DOI 10.1016/0959-4388(95)80028-X; MCEWEN BS, 1991, PRESSE MED, V20, P1801; MIYAZAWA S, 1989, MOL CELL BIOL, V9, P83, DOI 10.1128/MCB.9.1.83; MUERHOFF AS, 1992, J BIOL CHEM, V267, P19051; NEWSHOLME EA, 1973, REGULATION METABOLIS, P293; RODRIGUEZ JC, 1994, J BIOL CHEM, V269, P18767; SCHMIDT A, 1992, MOL ENDOCRINOL, V6, P1634, DOI 10.1210/me.6.10.1634; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; STEINEGER HH, 1994, EUR J BIOCHEM, V225, P967, DOI 10.1111/j.1432-1033.1994.0967b.x; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; VUDAC N, 1994, J BIOL CHEM, V269, P31012; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; WAHLI W, 1995, CHEM BIOL, V2, P261, DOI 10.1016/1074-5521(95)90045-4; WEINDENFELD J, 1993, NEUROENDOCRINOLOGY, V58, P49; ZHANG BW, 1992, P NATL ACAD SCI USA, V89, P7541, DOI 10.1073/pnas.89.16.7541; ZHU YJ, 1993, J BIOL CHEM, V268, P26817	42	267	272	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1764	1769		10.1074/jbc.271.3.1764	http://dx.doi.org/10.1074/jbc.271.3.1764			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576180	hybrid			2022-12-25	WOS:A1996TQ52500076
J	Wu, SY; Kaufman, RJ				Wu, SY; Kaufman, RJ			Double-stranded (ds) RNA binding and not dimerization correlates with the activation of the dsRNA-dependent protein kinase (PKR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; MESSENGER-RNAS; TRANSLATIONAL CONTROL; INTERFERON ACTION; MAMMALIAN-CELLS; P68 KINASE; PHOSPHORYLATION; MECHANISM; DAI; IDENTIFICATION	Upon binding to double-stranded (ds) RNA, the dsRNA-dependent protein kinase (PKR) sequentially undergoes autophosphorylation and activation, Activated PKR may exist as a dimer and phosphorylates the eukaryotic translation initiation factor 2 alpha subunit (eIF-2 alpha) to inhibit polypeptide chain initiation, Transfection of COS-1 cells with a plasmid cDNA expression vector encoding a marker gene, activates endogenous PKR, and selectively inhibits translation of the marker mRNA, dihydrofolate reductase (DEER), This system was used to study the dsRNA binding and dimerization requirements for overexpressed PKR mutants and subdomains to affect DHFR translation, DHFR translation was rescued by expression of either an ATP hydrolysis defective mutant PKR K296P, the amino terminal 1-243 fragment containing two dsRNA binding motifs, or the isolated first RNA binding motif (amino acids 1-123), Mutation of K64E within the dsRNA binding motif 1 destroyed dsRNA binding and the ability to rescue DHFR translation, Immunoprecipitation of T7 epitope-tagged PKR derivatives from cell lysates detected interaction between intact PKR and the amino-terminal 1-243 fragment as well as a 1-243 fragment harboring the K64E mutation. Expression of adenovirus VAI RNA, a potent inhibitor of PKR activity, did not disrupt this interaction, In contrast, intact PKR did not interact with fragments containing the first dsRNA binding motif (1-123), the second dsRNA binding motif (98-243), or the isolated PKR kinase catalytic domain (228-551), These results demon strate that the translational stimulation mediated by the dominant negative PKR mutant does not require dimerization, but requires the ability to bind dsRNA and indicate these mutants act by competition for binding to activators.	UNIV MICHIGAN, SCH MED, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Wu, Shiyong/I-3359-2013	Wu, Shiyong/0000-0002-4104-4160				BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; BARBER GN, 1995, J BIOL CHEM, V270, P17423, DOI 10.1074/jbc.270.29.17423; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; CHEN JJ, 1993, TRANSLATIONAL REGULA, V2, P349; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; DERMAN E, 1981, CELL, V23, P731, DOI 10.1016/0092-8674(81)90436-0; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; GALABRU J, 1989, EUR J BIOCHEM, V178, P581, DOI 10.1111/j.1432-1033.1989.tb14485.x; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GREEN SR, 1995, MOL CELL BIOL, V15, P358, DOI 10.1128/MCB.15.1.358; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; KATZE MG, 1993, SEMIN VIROL, V4, P259, DOI 10.1006/smvy.1993.1022; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KAUFMAN RJ, 1987, MOL CELL BIOL, V7, P1568, DOI 10.1128/MCB.7.4.1568; KONIECZNY A, 1983, J BIOL CHEM, V258, P3402; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOSTURA M, 1989, MOL CELL BIOL, V9, P1576, DOI 10.1128/MCB.9.4.1576; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGLAND JO, 1992, J BIOL CHEM, V267, P10729; LASKY SR, 1982, J BIOL CHEM, V257, P1108; LEE SB, 1993, VIROLOGY, V192, P380, DOI 10.1006/viro.1993.1048; LEE SB, 1994, P NATL ACAD SCI USA, V91, P10551, DOI 10.1073/pnas.91.22.10551; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; MATHEWS MB, 1993, SEMIN VIROL, V4, P247, DOI 10.1006/smvy.1993.1021; MCCORMACK SJ, 1994, VIROLOGY, V198, P92, DOI 10.1006/viro.1994.1011; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MCMILLAN NAJ, 1995, J BIOL CHEM, V270, P2601, DOI 10.1074/jbc.270.6.2601; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MINKS MA, 1979, J BIOL CHEM, V254, P180; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; PATEL RC, 1994, J BIOL CHEM, V269, P18592; PROUD CG, 1986, TRENDS BIOCHEM SCI, V11, P73, DOI 10.1016/0968-0004(86)90269-0; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARP TV, 1993, EUR J BIOCHEM, V214, P945, DOI 10.1111/j.1432-1033.1993.tb17998.x; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THOMIS DC, 1992, P NATL ACAD SCI USA, V89, P10837, DOI 10.1073/pnas.89.22.10837; THOMIS DC, 1993, J VIROL, V67, P7695, DOI 10.1128/JVI.67.12.7695-7700.1993	51	73	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1756	1763		10.1074/jbc.271.3.1756	http://dx.doi.org/10.1074/jbc.271.3.1756			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576179	hybrid			2022-12-25	WOS:A1996TQ52500075
J	Tanaka, K; KikuchiYanoshita, R; Muraoka, M; Konishi, M; Oshimura, M; Miyaki, M				Tanaka, K; KikuchiYanoshita, R; Muraoka, M; Konishi, M; Oshimura, M; Miyaki, M			Suppression of tumorigenicity and invasiveness of colon carcinoma cells by introduction of normal chromosome 8p12-pter	ONCOGENE			English	Article						tumor suppressor gene; colon carcinoma; chromosome 8	FAMILIAL ADENOMATOUS POLYPOSIS; COLORECTAL CARCINOMAS; WILMS-TUMOR; SHORT ARM; GENE; IDENTIFICATION; EXPRESSION; CANCER; LINES; DELETIONS	The development of human colon carcinomas is associated with a number of genetic alterations, A high frequency of deletion of the short arm of chromosome 8 at a late stage of colon carcinogenesis was detected by DNA analysis of colon carcinomas, which suggests the presence of a tumor suppressor gene, We therefore, introduced normal human chromosome 8 into colon carcinoma cells that showed allele loss on 8p21, through microcell hybridization, Five clones of hybrid cells were obtained from independent experiments. Three hybrids exhibited morphological alteration and suppressed tumorigenicity in the subcutis of nude mice, but the other two did not, The difference between the two types of hybrids was the region of the introduced normal chromosome 8: Three hybrids exhibiting morphological alteration and suppressed tumorigenicity had the entire region of the introduced chromosome 8, whereas the other two, exhibiting no change, lacked 8p12-pter from the introduced chromosome, Furthermore, the invasiveness of the hybrids with suppressed tumorigenicity was reduced to one-fifth of that of the parental cells, These results indicate that 8p12-pter carries a gene that contributes to suppression of both tumorigenicity and invasiveness of colon carcinomas.	TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOTTORI UNIV,FAC MED,DEPT MOLEC & CELL GENET,YONAGO,TOTTORI 683,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tottori University								ALBINI A, 1987, CANCER RES, V47, P3239; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BROWN PD, 1990, CANCER RES, V50, P6184; CHEN JM, 1991, J BIOL CHEM, V266, P5113; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; EMI M, 1992, CANCER RES, V52, P5368; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; ICHIKAWA T, 1994, CANCER RES, V54, P2299; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KIKUCHIYANOSHIT.R, 1992, CANCER RES, V53, P3965; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNOWLES MA, 1993, ONCOGENE, V8, P1357; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; Liotta L A, 1982, Cancer Metastasis Rev, V1, P277, DOI 10.1007/BF00124213; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; MCGOWAN JI, 1994, CANCER RES, V54, P2568; MIYAKI M, 1990, CANCER RES, V50, P7166; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; MULERIS M, 1990, CANCER GENET CYTOGEN, V46, P143, DOI 10.1016/0165-4608(90)90100-O; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SHIMIZU M, 1990, ONCOGENE, V5, P185; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; TANAKA K, 1993, ONCOGENE, V8, P2253; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VANDERBOSCH K, 1992, GENE CHROMOSOME CANC, V5, P91, DOI 10.1002/gcc.2870050114; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WELCH DR, 1994, ONCOGENE, V9, P255; YAMADA H, 1990, ONCOGENE, V5, P1141; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817	41	27	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					405	410						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570218				2022-12-25	WOS:A1996TR53800020
J	Cohen, T; Nahari, D; Cerem, LW; Neufeld, G; Levi, BZ				Cohen, T; Nahari, D; Cerem, LW; Neufeld, G; Levi, BZ			Interleukin 6 induces the expression of vascular endothelial growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; 5' UNTRANSLATED REGION; PERMEABILITY FACTOR; RESPONSE ELEMENT; GENE-EXPRESSION; FACTOR VEGF; ANGIOGENESIS; INVIVO; CELLS; MITOGEN	Angiogenesis, the formation of new blood vessels, is induced by various growth factors and cytokines that act either directly or indirectly. Vascular endothelial growth factor (VEGF) is a specific mitogen for vascular endothelial cells and therefore has a central role in physiological events of angiogenesis. Interleukin-6 (IL-6) expression on the other hand is elevated in tissues that undergo active angiogenesis but does not induce proliferation of endothelial cells. We demonstrate using Northern analysis that treatment of various cell lines with IL-6 for 6-48 h results in a significant induction of VEGF mRNA. The level of induction is comparable to the documented induction of VEGF mRNA by hypoxia or cobalt chloride, an activator of hypoxia-induced genes. In addition, it is demonstrated by transient transfection assays that the effect of IL-6 is mediated not only by DNA elements at the promoter region but also through specific motif(s) located in the 5'-untranslated region (5'-UTR) of VEGF mRNA. Our results imply that IL-6 may induce angiogenesis indirectly by inducing VEGF expression. It is also shown that the 5'-UTR is important for the expression of VEGF. The 5'-UTR of VEGF is exceptionally long (1038 base pairs) and very rich in G + C. This suggests that secondary structures in the 5'-UTR might be essential for VEGF expression through transcriptional and post-transcriptional control mechanisms.	TECHNION ISRAEL INST TECHNOL, DEPT FOOD ENGN & BIOTECHNOL, IL-32000 HAIFA, ISRAEL	Technion Israel Institute of Technology			Neufeld, Gera/F-1524-2019					AKIRA S, 1992, CHEM IMMUNOL, V51, P299; ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; BARKER JNWN, 1991, LANCET, V337, P211, DOI 10.1016/0140-6736(91)92168-2; BERNSTEIN J, 1995, J BIOL CHEM, V270, P10559, DOI 10.1074/jbc.270.18.10559; BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; BROGI E, 1994, CIRCULATION, V90, P649, DOI 10.1161/01.CIR.90.2.649; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DOLECKI GJ, 1991, BIOCHEM BIOPH RES CO, V180, P572, DOI 10.1016/S0006-291X(05)81103-9; FAN TPD, 1995, TRENDS PHARMACOL SCI, V16, P57, DOI 10.1016/S0165-6147(00)88979-8; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; FRATERSCHRODER M, 1987, P NATL ACAD SCI USA, V84, P5277, DOI 10.1073/pnas.84.15.5277; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HIRANO T, 1990, IMMUNOL TODAY, V11, P443, DOI 10.1016/0167-5699(90)90173-7; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LADOUX A, 1993, BIOCHEM BIOPH RES CO, V195, P1005, DOI 10.1006/bbrc.1993.2144; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LI J, 1995, J BIOL CHEM, V270, P308, DOI 10.1074/jbc.270.1.308; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAGLIONE D, 1993, GROWTH FACTORS, V8, P141, DOI 10.3109/08977199309046934; MATEO RB, 1994, AM J PHYSIOL, V266, pR1840, DOI 10.1152/ajpregu.1994.266.6.R1840; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; MINCHENKO A, 1994, LAB INVEST, V71, P374; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; MYOKEN Y, 1991, P NATL ACAD SCI USA, V88, P5819, DOI 10.1073/pnas.88.13.5819; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; SCHOTT RJ, 1993, CARDIOVASC RES, V27, P1155, DOI 10.1093/cvr/27.7.1155; SEHGAL PB, 1992, RES IMMUNOL, V143, P724, DOI 10.1016/0923-2494(92)80011-9; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; SOKER S, 1993, J BIOL CHEM, V268, P7685; STAVRI GT, 1995, FEBS LETT, V358, P311, DOI 10.1016/0014-5793(94)01458-D; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WEISZ A, 1992, J BIOL CHEM, V267, P25589; WILLIAMS B, 1995, CLIN SCI, V88, P141, DOI 10.1042/cs0880141; WON KA, 1990, MOL CELL BIOL, V10, P3965, DOI 10.1128/MCB.10.8.3965; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463	49	838	884	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					736	741		10.1074/jbc.271.2.736	http://dx.doi.org/10.1074/jbc.271.2.736			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557680	hybrid			2022-12-25	WOS:A1996TP88900023
J	Edelmann, HML; Kuhne, C; Petritsch, C; Ballou, LM				Edelmann, HML; Kuhne, C; Petritsch, C; Ballou, LM			Cell cycle regulation of p70 S6 kinase and p42/p44 mitogen-activated protein kinases in Swiss mouse 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; RIBOSOMAL PROTEIN-S6; RAPAMYCIN; GROWTH; PHOSPHORYLATION; EXPRESSION; P70(S6K); S6-KINASE; P42(MAPK); P44(MAPK)	We show here using synchronized Swiss mouse 3T3 fibroblasts that p70 S6 kinase (p70(S6k)) and mitogen-activated protein kinases (p42(mapk)/p44(mapk)) are not only activated at the G(0)/G(1) boundary, but also in cells progressing from M into G(1). p70(S6k) activity increases 20-fold in G(1) cells released from G(0). Throughout G(1), S, and G(2) it decreases constantly, so that during M phase low kinase activity is measured. The kinase is reactivated 10-fold when cells released from a nocodazole-induced metaphase block enter G(1) of the next cell cycle. p42(mapk)/ p44(mapk) in G(0) cells are activated transiently early in G(1) and are reactivated late in mitosis after nocodazole release. p70(S6k) activity is dependent on permanent signaling from growth factors at all stages of the cell cycle. Immunofluorescence studies showed that p70(S6k) and its isoform p85(S6k) become concentrated in localized spots in the nucleus at certain stages in the cell cycle. Cell cycle-dependent changes in p70(S6k) activity are associated with alterations in the phosphorylation state of the protein. However, examination of the regulation of a p70(S6k) mutant in which the four carboxyl-terminal phosphorylation sites are changed to acidic amino acids suggests that a mechanism independent of these phosphorylation sites controls the activity of the enzyme during the cell cycle.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Petritsch, Claudia/AAP-9597-2021					BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; COFFER PJ, 1994, BIOCHEM BIOPH RES CO, V198, P780, DOI 10.1006/bbrc.1994.1112; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; DEGROOT RP, 1994, CELL, V79, P81, DOI 10.1016/0092-8674(94)90402-2; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FERRARI S, 1994, CRIT REV BIOCHEM MOL, V29, P385, DOI 10.3109/10409239409083485; FRANCO R, 1990, J BIOL CHEM, V265, P4321; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1992, EMBO J, V11, P1743, DOI 10.1002/j.1460-2075.1992.tb05226.x; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NUSSE M, 1984, CELL TISSUE KINET, V17, P13, DOI 10.1111/j.1365-2184.1984.tb00564.x; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PERKINS AS, 1983, MOL CELL BIOL, V3, P1123, DOI 10.1128/MCB.3.6.1123; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PETRITSCH C, 1995, J BIOL CHEM, V270, P26619, DOI 10.1074/jbc.270.44.26619; PETRITSCH C, 1995, EUR J BIOCHEM, V230, P431, DOI 10.1111/j.1432-1033.1995.0431h.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RAIKOW RB, 1980, J CELL PHYSIOL, V102, P81, DOI 10.1002/jcp.1041020112; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; TOBEY RA, 1967, J CELL PHYSIOL, V70, P63, DOI 10.1002/jcp.1040700109; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; WILDEN PA, 1994, MOL ENDOCRINOL, V8, P558, DOI 10.1210/me.8.5.558; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	53	94	95	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					963	971		10.1074/jbc.271.2.963	http://dx.doi.org/10.1074/jbc.271.2.963			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557712	hybrid			2022-12-25	WOS:A1996TP88900055
J	Pan, BS; Johnson, RG				Pan, BS; Johnson, RG			Interaction of cardiotonic thiadiazinone derivatives with cardiac troponin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE TROPONIN; CALCIUM-BINDING SITES; NUCLEAR-MAGNETIC-RESONANCE; AMINO-ACID SEQUENCE; CONFORMATIONAL CHANGE; SLOW SKELETAL; HEART-MUSCLE; CONTRACTION; CALMODULIN; EMD-53998	The cardiotonic effects of thiadiazinone derivative EMD 57033 are mediated by direct actions on myofilaments (Lues, I., Beier, N., Jonas, R., Klockow, M., and Haeusler, G. J. (1993) Cardiovasc. Pharmacol. 21, 883-892). Cardiac troponin C has been postulated to be a potential target of the drug (White, J., Lee, J. A., Shah, N., and Orchard, C, H. (1993) Circ. Res. 73, 61-70). This study tested whether EMD 57033 interacts directly with recombinant human cardiac TnC (hcTnC), EMD 57033 caused concentration-dependent quenching of tyrosine (Tyr) fluorescence of hcTnC in the presence of Ca2+ (100 mu M) and little change of the fluorescence in the presence of Mg2+ (2 mM). K-d for the drug-hcTnC interaction in the presence of Ca2+, determined by Tyr fluorescence titrations, was approximately 40 mu M. The binding of EMD 57033 was stereo-selective: the optical isomer of EMD 57033 bound hcTnC much more weakly. The Ca2+ dependence and stereo-selectivity of EMD 57033 binding were substantiated by a dialysis-based direct binding assay. EMD 57033 was found to interfere with Ca2+-dependent binding of hydrophobic probe 1,1'-bi-(4-anilino)naphthalene-5,5'-disulfonate (bis-ANS) to hcTnC. The relationships between [Ca2+] and Tyr fluorescence of hcTnC and between [Ca2+] and bis-ANS fluorescence in the presence of hcTnC were substantially altered by EMD 57033 in the range of [Ca2+] where Ca2+/Mg2+ sites of hcTnC were titrated by Ca2+. EMD 57033 was found to bind as tightly to 2 Ca2+. hcTnC as to 3 Ca2+. hcTnC. These observations were interpreted as indicating that a EMD 57033-binding site is induced by Ca2+ binding, but not Mg2+ binding, to the Ca2+/Mg2+ sites of hcTnC. The drug-binding site most likely resides in the carboxyl domain of hcTnC.			Pan, BS (corresponding author), MERCK SHARP & DOHME LTD,RES LABS,DEPT PHARMACOL,WP44 B-122,W POINT,PA 19486, USA.							BIRDSALL B, 1983, ANAL BIOCHEM, V132, P353, DOI 10.1016/0003-2697(83)90020-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANDRA M, 1994, BIOCHEMISTRY-US, V33, P2961, DOI 10.1021/bi00176a028; COLLINS JH, 1977, J BIOL CHEM, V252, P6356; DALGARNO DC, 1984, BIOCHIM BIOPHYS ACTA, V791, P164, DOI 10.1016/0167-4838(84)90006-2; DRABIKOWSKI W, 1985, EUR J BIOCHEM, V151, P17, DOI 10.1111/j.1432-1033.1985.tb09063.x; GAHLMANN R, 1988, J MOL BIOL, V201, P379, DOI 10.1016/0022-2836(88)90145-3; Gambassi G., 1991, Acta Medica Romana, V29, P359; GAMBASSI G, 1993, AM J PHYSIOL, V264, pH728, DOI 10.1152/ajpheart.1993.264.3.H728; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GULATI J, 1992, J BIOL CHEM, V267, P25073; HEIDORN DB, 1988, BIOCHEMISTRY-US, V27, P909, DOI 10.1021/bi00403a011; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; JONAS R, 1992, BIOORG MED CHEM LETT, V2, P589, DOI 10.1016/S0960-894X(01)81203-8; KAWASAKI Y, 1972, BIOCHEM BIOPH RES CO, V47, P859; KRUDY GA, 1992, BIOCHEMISTRY-US, V31, P1595, DOI 10.1021/bi00121a003; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEE JA, 1993, CLIN SCI, V84, P141, DOI 10.1042/cs0840141; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7042, DOI 10.1021/bi00396a028; LUES I, 1993, J CARDIOVASC PHARM, V21, P883, DOI 10.1097/00005344-199306000-00006; MACLACHLAN LK, 1990, J BIOL CHEM, V265, P9764; MARBAN E, 1980, NATURE, V286, P845, DOI 10.1038/286845a0; NANKERVIS R, 1994, J CARDIOVASC PHARM, V24, P612, DOI 10.1097/00005344-199410000-00012; NEGELE JC, 1992, J BIOL CHEM, V267, P825; NGAI SM, 1994, J BIOL CHEM, V269, P2165; OVASKA M, 1991, PROTEINS, V11, P79, DOI 10.1002/prot.340110202; PAN BS, 1990, J MOL CELL CARDIOL, V22, P1117, DOI 10.1016/0022-2828(90)90075-D; PAN BS, 1987, J BIOL CHEM, V262, P7839; POTTER JD, 1975, J BIOL CHEM, V250, P4628; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SOLARO RJ, 1993, CIRC RES, V73, P981, DOI 10.1161/01.RES.73.6.981; STRAUSS JD, 1992, EUR J PHARM-MOLEC PH, V227, P437, DOI 10.1016/0922-4106(92)90163-P; STRIYNADKA NCJ, 1990, PROTEINS, V7, P234; STRYNADKA NCJ, 1988, PROTEINS, V3, P1, DOI 10.1002/prot.340030102; TREWHELLA J, 1989, BIOCHEMISTRY-US, V28, P1294, DOI 10.1021/bi00429a052; TSUDA S, 1990, BIOCHEMISTRY-US, V29, P4951, DOI 10.1021/bi00472a027; TSUDA S, 1988, BIOCHEMISTRY-US, V27, P4120, DOI 10.1021/bi00411a032; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; WHITE J, 1993, CIRC RES, V73, P61, DOI 10.1161/01.RES.73.1.61; WILKINSON JM, 1980, EUR J BIOCHEM, V103, P179, DOI 10.1111/j.1432-1033.1980.tb04302.x; ZOT HG, 1982, J BIOL CHEM, V257, P7678	45	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					817	823		10.1074/jbc.271.2.817	http://dx.doi.org/10.1074/jbc.271.2.817			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557691	hybrid			2022-12-25	WOS:A1996TP88900034
J	Shen, HF; Heacock, PN; Clancey, CJ; Dowhan, W				Shen, HF; Heacock, PN; Clancey, CJ; Dowhan, W			The CDS1 gene encoding CDP-diacylglycerol synthase in Saccharomyces cerevisiae is essential for cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; ESCHERICHIA-COLI; PHOSPHATIDYLSERINE SYNTHASE; PHOSPHATIDYLINOSITOL SYNTHASE; DIGLYCERIDE SYNTHETASE; MOLECULAR-CLONING; YEAST; MUTANTS; MEMBRANES; SEQUENCE	An open reading frame (CDS1) residing on chromosome II of Saccharomyces cerevisiae encodes a hydrophobic protein with a predicted molecular mass of 51,789 Da, which exhibits 29 and 37% amino acid sequence identities with CDP-diacylglycerol synthases reported from Escherichia coli and Drosophila, respectively, Induction of expression of a GAL1 promoter-driven CDS1 gene on a multicopy plasmid in a cds1 null mutant background resulted in synthase activity 10 times that of wild type cells and an elevation in the apparent initial rate of synthesis of phosphatidylinositol relative to phosphatidylserine. Without induction, activity was reduced to 10% of wild-type levels, which was sufficient to support growth but resulted in an inositol excretion phenotype, and had an opposite effect on the above phospholipid synthesis, Null cds1 mutants were incapable of spore germination or vegetative growth and could not be complemented under uninduced conditions with a GAL1 promoter-driven CDS1 gene on a low copy plasmid, Therefore, the essential CDS1 gene encodes the majority, if not all, of the synthase activity, The lack of consensus RNA splice sites derived from the genomic CDS1 sequence predicts that the multiple subcellular locations for synthase activities do not arise through RNA processing events.	UNIV TEXAS, SCH MED, DEPT BIOCHEM & MOLEC BIOL, HOUSTON, TX 77225 USA	University of Texas System					NIGMS NIH HHS [GM20487] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASHBURNER BP, 1995, MOL CELL BIOL, V15, P1709; BISHOP WR, 1988, ANNU REV CELL BIOL, V4, P579, DOI 10.1146/annurev.cb.04.110188.003051; BOGUTA M, 1994, MOL CELL BIOL, V14, P2298, DOI 10.1128/MCB.14.4.2298; CARMAN GM, 1992, METHOD ENZYMOL, V209, P242; CARMAN GM, 1992, METHOD ENZYMOL, V209, P298; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARMAN GM, 1992, METHOD ENZYMOL, V209, P305; CLANCEY CJ, 1993, J BIOL CHEM, V268, P24580; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOWHAN W, 1995, CELL MOL BIOL MEMBRA, V4, P189, DOI DOI 10.1016/S1874-5172(06)80013-1; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FUJIMURA HA, 1993, BIOTECHNIQUES, V14, P538; GANONG BR, 1980, J BIOL CHEM, V255, P1623; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P199; HOMANN MJ, 1985, J BACTERIOL, V163, P1265, DOI 10.1128/JB.163.3.1265-1266.1985; HOMANN MJ, 1987, J BACTERIOL, V169, P3276, DOI 10.1128/jb.169.7.3276-3280.1987; ICHO T, 1985, J BIOL CHEM, V260, P2078; Innis MA, 1990, PCR PROTOCOLS GUIDE; JANITOR M, 1993, CURR GENET, V24, P307, DOI 10.1007/BF00336781; KATO H, 1989, J BIOL CHEM, V264, P3116; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KINNEY AJ, 1990, J BACTERIOL, V172, P4115, DOI 10.1128/jb.172.7.4115-4117.1990; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; KOHLWEIN SD, 1988, J BACTERIOL, V170, P3778, DOI 10.1128/jb.170.8.3778-3781.1988; KUCHLER K, 1986, J BACTERIOL, V165, P901, DOI 10.1128/jb.165.3.901-910.1986; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MARTIN NC, 1994, BIOCHIMIE, V76, P1161, DOI 10.1016/0300-9084(94)90045-0; MCGEE TP, 1994, J BACTERIOL, V176, P6861, DOI 10.1128/JB.176.22.6861-6868.1994; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NASYMTH KA, 1980, CELL, V19, P753; NICKELS JT, 1994, J BIOL CHEM, V269, P11018; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NIKOLOFF DM, 1991, ANNU REV GENET, V25, P559; NOTHWEHR SF, 1994, J BIOL CHEM, V269, P10185; RAETZ CRH, 1990, J BIOL CHEM, V265, P1235; RUSSO P, 1991, EMBO J, V10, P563, DOI 10.1002/j.1460-2075.1991.tb07983.x; SAMBROOK F, 1989, MOL CLONING LABORATO; SCHNEIDER JC, 1987, NUCLEIC ACIDS RES, V15, P15; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITS PHM, 1994, YEAST, V10, pS75, DOI 10.1002/yea.320100010; SPENCER JFT, 1989, YEAST GENETICS MANUA, P3; SPERKAGOTTLIEB C, 1990, YEAST, V6, P331, DOI 10.1002/yea.320060406; TROTTER P, 1995, J BIOL CHEM, V270, P2062; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; UNO I, 1988, NATURE, V333, P188, DOI 10.1038/333188a0; WICKENS M, 1984, SCIENCE, V226, P1045, DOI 10.1126/science.6208611; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991; ZINSER E, 1995, YEAST, V11, P493, DOI 10.1002/yea.320110602	56	114	120	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					789	795		10.1074/jbc.271.2.789	http://dx.doi.org/10.1074/jbc.271.2.789			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557688	hybrid			2022-12-25	WOS:A1996TP88900031
J	Holland, EA; Beaton, SC; Becker, TM; Grulet, OMC; Peters, BA; Rizos, H; Kefford, RF; Mann, GJ				Holland, EA; Beaton, SC; Becker, TM; Grulet, OMC; Peters, BA; Rizos, H; Kefford, RF; Mann, GJ			Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds	ONCOGENE			English	Article						p16; CDKN2; familial melanoma; mutation linkage; cyclin dependent kinase inhibitor	FAMILIAL MELANOMA; LINKAGE ANALYSIS; LOCUS	CDKN2 has been implicated as a melanoma susceptibility gene in some kindreds with a family history of this disease, Mutation analysis of CDKN2 in 17 familial melanoma Australian kindreds revealed a paucity of exon mutations and none of the previously described disease-related mutations, One novel germline mutation was found in exon one, Arg24Pro, which segregates with melanoma in 1/17 kindreds, Two previously described polymorphisms, A1a148Thr and a base change at nucleotide 540 were detected and one novel polymorphism in the untranslated region of exon 3 (nucleotide 580) was also found, Together with other recent reports, these findings provide support for CDKN2 as a susceptibility locus for familial melanoma but suggest that other loci are involved in some hereditary melanoma kindreds.			Holland, EA (corresponding author), UNIV SYDNEY,WESTMEAD HOSP,DEPT MED ONCOL,WESTMEAD,NSW 2145,AUSTRALIA.		; Mann, Graham/G-4758-2014	Kefford, Richard/0000-0001-9251-9229; Becker, Therese/0000-0002-5636-9902; Rizos, Helen/0000-0002-2094-9198; Mann, Graham/0000-0003-1301-405X				CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CANNONALBRIGHT LA, 1994, GENOMICS, V23, P265, DOI 10.1006/geno.1994.1491; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GRUIS NA, 1995, AM J PATHOL, V146, P1199; GRUIS NA, 1993, MELANOMA RES, V3, P271; HOLLAND EA, 1994, ONCOGENE, V9, P1361; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEFFORD RF, 1991, CANCER GENET CYTOGEN, V51, P45, DOI 10.1016/0165-4608(91)90007-H; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MACGEOCH C, 1994, HUM MOL GENET, V3, P2195, DOI 10.1093/hmg/3.12.2195; MAMELKA PM, 1993, PEDIGREE DRAW VERSIO; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NANCARROW DJ, 1993, AM J HUM GENET, V53, P936; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Ott J., 1991, ANAL HUMAN GENETIC L; PETTY EM, 1993, AM J HUM GENET, V53, P96; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; Sambrook J, 1989, MOL CLONING LABORATO; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; WALKER GJ, 1994, ONCOGENE, V9, P819; WALKER GJ, 1995, 7TH LORN CANC C LORN; WEAVERFELDHAUS J, 1994, P NATL ACAD SCI USA, V91, P7563, DOI 10.1073/pnas.91.16.7563; XU L, 1994, CANCER RES, V54, P5262	34	96	97	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2289	2294						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570179				2022-12-25	WOS:A1995TK70200012
J	Ishino, M; Ohba, T; Sasaki, H; Sasaki, T				Ishino, M; Ohba, T; Sasaki, H; Sasaki, T			Molecular cloning of a cDNA encoding a phosphoprotein, Efs, which contains a Src homology 3 domain and associates with Fyn	ONCOGENE			English	Article						Src homology; fyn; yes; tyrosine phosphorylation; embryo	IDENTIFICATION; PROTEIN; CONSTRUCTION; SUBSTRATE; PAXILLIN; SEQUENCE; SYSTEM; CELLS	Src homology 2 and 3 (SH2 and SH3) domains mediate protein-protein interactions in intracellular signaling by protein-tyrosine kinases (PTKs), We have isolated cDNA clones from mouse embryo cDNA expression library that encode a new signaling protein which we call Efs (Embryonal Fyn-associated Substrate), The deduced amino acid sequence of 560 residues in length revealed one SH3 domain at its amino-terminal region, two proline-rich motifs with the consensus sequences of binding to Src-family SH3s, and a cluster of YXXP motifs that are possibly tyrosine-phosphorylated to serve as ligands binding to SH2 domains, Structure and alignment of these characteristic sequences are homologous to those of p130(Cas), but Efs and p130(Cas) are different proteins, Expression of the Efs gene was higher in placenta, embryo and brain than in other adult tissues, Transfection of COS-7 cells with a plasmid encoding an epitope-tagged Efs resulted in the expression of a 83 kDa protein, The epitope-tagged Efs was hyperphosphorylated when cotransfected with a vector expressing Fyn, In an in vitro kinase assay with the PCC4 cell lysate, Efs became phosphorylated on tyrosine residues and coprecipitated with p59(fyn) and p62(yes); the result suggests that Efs is a physiological substrate of these PTKs.	SAPPORO MED UNIV, SCH MED, CANC RES INST, DEPT BIOCHEM, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN	Sapporo Medical University								ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAUMANN G, 1994, EUR J IMMUNOL, V24, P1799, DOI 10.1002/eji.1830240812; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FLYNN DC, 1995, J BIOL CHEM, V270, P3894, DOI 10.1074/jbc.270.8.3894; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; SUDOL M, 1994, ONCOGENE, V9, P2145; SUDOL M, 1995, J BIOL CHEM, V270, P14733, DOI 10.1074/jbc.270.24.14733; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TSYGANKOV AY, 1994, J BIOL CHEM, V269, P7792; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YAMANASHI Y, 1993, P NATL ACAD SCI USA, V90, P3631, DOI 10.1073/pnas.90.8.3631; YAMSHITA Y, 1992, TUMOR RES, V27, P59; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	106	107	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2331	2338						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570184				2022-12-25	WOS:A1995TK70200017
J	Sitzmann, J; NobenTrauth, K; Klempnauer, KH				Sitzmann, J; NobenTrauth, K; Klempnauer, KH			Expression of mouse c-myb during embryonic development	ONCOGENE			English	Article						transcription factors; c-myb; A-myb; mouse development	B-MYB; A-MYB; CHICK-EMBRYO; MIM-1 GENE; DIFFERENTIATION; CDNA; PROLIFERATION; TRANSCRIPTION; HEMATOPOIESIS; REQUIRES	Three members of the myb gene family, designated as A-myb, B-myb and c-myb, have been described in many vertebrates, A large body of evidence indicates that the c-myb gene is essential for the development of most hematopoietic lineages, By contrast, the functions of A-myb and B-myb are less well understood. To further explore the relationship between the different myb family members we have compared the expression of A-myb and c-myb during mouse embryogenesis by Northern blotting and by in situ hybridization, In accordance with the important role of c-myb in the hematopoietic system, we detect high levels of c-myb expression in hematopoietic organs such as the fetal liver and the thymus, Surprisingly, we find that high levels of c-myb expression are not restricted to hematopoietic cells, We show that c-myb is strongly expressed in the neural retina and in epithelia of the respiratory tract, The side-by-side analysis of c-myb and A-myb expression clearly shows that both genes are expressed in different, but overlapping sets of tissues, Our results suggest that the function of c-myb may not be restricted to hematopoietic cells.	MAX PLANCK INST IMMUNOBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY	Max Planck Society								BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BROWN KE, 1992, J BIOL CHEM, V267, P4625; BURK O, 1991, EMBO J, V10, P3731; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DESBIENS X, 1991, DEVELOPMENT, V111, P699; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GOLAY J, 1991, BLOOD, V77, P149; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; LAM EWF, 1992, ONCOGENE, V7, P1185; LEON Y, 1992, DEV BIOL, V153, P407, DOI 10.1016/0012-1606(92)90126-2; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MCMAHON J, 1988, ONCOGENE, V3, P717; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PLAZA S, 1995, ONCOGENE, V10, P329; QUEVA C, 1992, DEVELOPMENT, V114, P125; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; THIELE CJ, 1987, J CLIN INVEST, V80, P801; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x	29	68	70	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2273	2279						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570177				2022-12-25	WOS:A1995TK70200010
J	Browning, JL; Miatkowski, K; Griffiths, DA; Bourdon, PR; Hession, C; Ambrose, CM; Meier, W				Browning, JL; Miatkowski, K; Griffiths, DA; Bourdon, PR; Hession, C; Ambrose, CM; Meier, W			Preparation and characterization of soluble recombinant heterotrimeric complexes of human lymphotoxins alpha and beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; T-CELL HYBRIDOMA; 33-KDA GLYCOPROTEIN; HETEROMERIC COMPLEX; SURFACE; TNF; PURIFICATION; EXPRESSION; PROTEIN; LINE	The lymphotoxin (LT) protein complex is a heteromer of alpha (LT-alpha, also called tumor necrosis factor (TNF)-beta) and beta (LT-beta) chains anchored to the membrane surface by the transmembrane domain of the LT-beta portion, Both proteins belong to the TNF family of ligands and receptors that regulate aspects of the immune and inflammatory systems, The LT complex is found on activated lymphocytes and binds to the lymphotoxin-beta receptor, which is generally present on nonlymphoid cells, The signaling function of this receptor-ligand pair is not precisely known but is believed to be involved in the development of the peripheral lymphoid organs, To analyze the properties of this complex, a soluble, biologically active form of the surface complex was desired, The LT-beta molecule was engineered into a secreted form and co-expressed with LT-alpha using baculovirus/insect cell technology, By exploiting receptor affinity columns, the LT-alpha 3, LT-alpha 2/beta 1, and LT-alpha 1/beta 2 forms were purified, All three molecules were trimers, and their biochemical properties are described, The level of LT-alpha 3-like components in the LT-alpha 1/beta 2 preparation was found to be 0.02% by following the activity of the preparation in a WEHI 164 cytotoxicity assay. LT-alpha 3 with an asparagine 50 mutation (D50N) cannot bind the TNF receptors, Heteromeric LT complexes were prepared with this mutant LT-alpha form, allowing a precise delineation of the extent of biological activity mediated by the TNF receptors, A LT-alpha 3 based cytotoxic activity was used to show that the LT-alpha 1/beta 2 form cannot readily scramble into a mixture of forms following various treatments and storage periods, This biochemical characterization of the LT heteromeric ligands and the demonstration of their stability provides a solid foundation for both biological studies and an analysis of the specificity of the LT-beta and TNF receptors for the various LT forms.	BIOGEN INC,DEPT IMMUNOL & INFLAMMAT,CAMBRIDGE,MA 02142; BIOGEN INC,DEPT MOLEC GENET,CAMBRIDGE,MA 02142	Biogen; Biogen	Browning, JL (corresponding author), BIOGEN INC,DEPT PROT ENGN,14 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.			Browning, Jeffrey/0000-0001-9168-5233				AGGARWAL BB, 1985, J BIOL CHEM, V260, P2334; ANDROLEWICZ MJ, 1992, J BIOL CHEM, V267, P2542; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BANKS TA, 1995, J IMMUNOL, V155, P1685; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BROWNING J, 1989, J IMMUNOL, V143, P1859; BROWNING JL, 1991, J IMMUNOL, V147, P1230; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; BROWNING JL, 1995, J IMMUNOL, V154, P33; BROWNING JL, 1996, J EXP MED, V183, P1; CHAI H, 1993, BIOTECHNOL APPL BIOC, V18, P259; CROWE PD, 1994, J IMMUNOL METHODS, V168, P79, DOI 10.1016/0022-1759(94)90212-7; CROWE PD, 1994, SCIENCE, V264, P707, DOI 10.1126/science.8171323; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; FUKUSHIMA K, 1993, ARCH BIOCHEM BIOPHYS, V304, P144, DOI 10.1006/abbi.1993.1332; GOH CR, 1991, PROTEIN ENG, V4, P785; HAINS JM, 1989, ARCH BIOCHEM BIOPHYS, V274, P417, DOI 10.1016/0003-9861(89)90454-2; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LOH KC, 1994, PROTEIN EXPRES PURIF, V5, P70, DOI 10.1006/prep.1994.1010; MALLETT S, 1991, IMMUNOL TODAY, V12, P220, DOI 10.1016/0167-5699(91)90033-P; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; SCHOENFELD HJ, 1991, J BIOL CHEM, V266, P3863; SEOW HF, 1989, BIO-TECHNOL, V7, P363, DOI 10.1038/nbt0489-363; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175; WARE CF, 1992, J IMMUNOL, V149, P3881	29	38	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8618	8626		10.1074/jbc.271.15.8618	http://dx.doi.org/10.1074/jbc.271.15.8618			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621492	hybrid			2022-12-25	WOS:A1996UE73000023
J	Hewitt, SM; Fraizer, GC; Wu, YJ; Rauscher, FJ; Saunders, GF				Hewitt, SM; Fraizer, GC; Wu, YJ; Rauscher, FJ; Saunders, GF			Differential function of Wilms' tumor gene WT1 splice isoforms in transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEIN; SUPPRESSOR WT1; PRODUCT; BINDING; LOCUS; IDENTIFICATION; REPRESSION	The Wilms' tumor gene, WT1, encodes a zinc finger transcription factor that can repress transcription of a number of genes. WT1 mRNA undergoes alternative splicing at two locations, yielding four different mRNA species and protein products. One alternative splice alters the zinc finger region of WT1, resulting in the addition of three amino acids, Lys-Thr-Ser (I(TS), between zinc fingers 3 and 4, altering the binding of WT1 to DNA. Here, we show that the WT1 protein with and without the KTS tripeptide can repress transcription from the human fall-length WT1 promoter. Repression of transcription by WT1 has been shown to require two WT1 binding sites. We examined WT1 repression of the human minimal WT1 promoter, which contains two potential WT1 binding motifs. WT1 lacking the KTS tripeptide (WT1-KTS) was unable to repress transcription from a minimal WT1 promoter of 104 base pairs, whereas WT1 containing the KTS tripeptide (WT1+KTS) repressed transcription from the minimal promoter. The ability of WT1+KTS to repress transcription where WT1-KTS could not provided a functional assay to define differential WT1 binding motifs based on the presence or the absence of the KTS tripeptides. me present data defining the differential consensus DNA binding motifs for WT1-KTS and WT1+KTS. We demonstrate that WT1 zinc finger 1 plays a role in the differential DNA binding specificity of WT1-KTS and WT1+KTS.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19107	University of Texas System; UTMD Anderson Cancer Center; The Wistar Institute				Hewitt, Stephen/0000-0001-8283-1788	NATIONAL CANCER INSTITUTE [P01CA034936, T32CA009299, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA34936, CA16672, T32 CA09299] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAMPBELL CE, 1994, ONCOGENE, V9, P583; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GOODYER P, 1995, ONCOGENE, V10, P1125; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; HEWITT SM, 1995, CANCER RES, V55, P5386; HOFMANN W, 1993, ONCOGENE, V8, P3123; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MADDEN SL, 1993, ONCOGENE, V8, P1712; MALIK KTA, 1994, FEBS LETT, V349, P75, DOI 10.1016/0014-5793(94)00642-3; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; PAVELETICH NP, 1991, SCIENCE, V252, P809; PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; TELERMAN A, 1992, ONCOGENE, V7, P2545; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WERNER H, 1994, J BIOL CHEM, V269, P12577	28	52	54	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8588	8592		10.1074/jbc.271.15.8588	http://dx.doi.org/10.1074/jbc.271.15.8588			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621487	hybrid			2022-12-25	WOS:A1996UE73000018
J	Tang, DC; Kang, HM; Jin, JP; Fraser, ED; Walsh, MP				Tang, DC; Kang, HM; Jin, JP; Fraser, ED; Walsh, MP			Structure-function relations of smooth muscle calponin - The critical role of serine 175	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN KINASE; HEAVY-MEROMYOSIN; MYOSIN; ACTIN; INHIBITION; PHOSPHORYLATION; PURIFICATION; TROPOMYOSIN; CALDESMON; MECHANISM	Calponin has been implicated in the regulation of smooth muscle contraction through its interaction with F-actin and inhibition of the actin-activated MgATPase activity of phosphorylated myosin, Both properties are lost following phosphorylation (primarily at serine 175) by protein kinase C or calmodulin-dependent protein kinase II, To evaluate further the functional importance of serine 175, wild-type calponin and three site-specific mutants (S175A, S175D, and S175T) were expressed in Escherichia coli and compared with calponin purified from chicken gizzard smooth muscle in terms of actin binding, actomyosin MgATPase inhibition, and phosphorylation by protein kinase C and calmodulin-dependent protein kinase II, The affinities of skeletal muscle F-actin for wild-type and S175T calponins were similar to that for the tissue-purified protein (K-d = 0.8, 1.3, and 1.0 mu M, respectively), whereas the affinities for S175A and S175D calponins were much lower (K-d = 26.8 and 44.2 mu M, respectively), Tissue-purified, wild-type, and S175T calponins displayed comparable inhibition of the smooth muscle actin-activated myosin MgATPase, whereas S175A and S175D calponins were much less effective. Phosphorylation confirmed serine 175 as the principal site of phosphorylation by both kinases, These results indicate that the hydroxyl side chain at position 175 of calponin plays a critical role in the binding of calponin to actin and inhibition of the cross-bridge cycling rate.	UNIV CALGARY, FAC MED, DEPT MED BIOCHEM, CALGARY, AB T2N 4N1, CANADA; UNIV CALGARY, FAC MED, SMOOTH MUSCLE RES GRP, CALGARY, AB T2N 4N1, CANADA	University of Calgary; University of Calgary				Jin, JP/0000-0001-9932-1063				ABE M, 1990, J BIOCHEM-TOKYO, V108, P835, DOI 10.1093/oxfordjournals.jbchem.a123289; ADAM LP, 1995, AM J PHYSIOL-CELL PH, V268, pC903, DOI 10.1152/ajpcell.1995.268.4.C903; ALLEN BG, 1994, J BIOL CHEM, V269, P29288; BARANY M, 1993, BIOCHIM BIOPHYS ACTA, V1179, P229, DOI 10.1016/0167-4889(93)90146-G; BONETKERRACHE A, 1995, BIOCHEM BIOPH RES CO, V206, P127, DOI 10.1006/bbrc.1995.1018; CARMICHAEL JD, 1994, CAN J PHYSIOL PHARM, V72, P1415, DOI 10.1139/y94-204; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; FRASER ED, 1995, BIOCHEMISTRY-US, V34, P9151, DOI 10.1021/bi00028a026; GERTHOFFER WT, 1994, CAN J PHYSIOL PHARM, V72, P1410, DOI 10.1139/y94-203; GIMONA M, 1992, EUR J BIOCHEM, V205, P1067, DOI 10.1111/j.1432-1033.1992.tb16875.x; GONG BJ, 1993, J BIOCHEM-TOKYO, V114, P453, DOI 10.1093/oxfordjournals.jbchem.a124197; HAEBERLE JR, 1994, J BIOL CHEM, V269, P12424; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORIUCHI KY, 1991, BIOCHEMISTRY-US, V30, P712, DOI 10.1021/bi00217a019; HORIUCHI KY, 1991, BIOCHEM BIOPH RES CO, V176, P1487, DOI 10.1016/0006-291X(91)90455-G; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; ITOH T, 1994, PFLUG ARCH EUR J PHY, V427, P301, DOI 10.1007/BF00374538; JIN JP, 1988, J BIOL CHEM, V263, P7309; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRER SS, 1972, BIOCHEMISTRY-US, V11, P1211, DOI 10.1021/bi00757a015; MEZGUELDI M, 1992, J BIOL CHEM, V267, P15943; MIKI M, 1992, BIOCHEM BIOPH RES CO, V187, P867, DOI 10.1016/0006-291X(92)91277-W; MINO T, 1995, BIOCHEM BIOPH RES CO, V208, P397, DOI 10.1006/bbrc.1995.1351; NAKAMURA F, 1993, J BIOL CHEM, V268, P6194; NGAI PK, 1984, BIOCHEM J, V218, P863, DOI 10.1042/bj2180863; NGAI PK, 1986, BIOCHEM INT, V12, P89; NISHIDA W, 1990, FEBS LETT, V268, P165, DOI 10.1016/0014-5793(90)80999-Y; OKAMOTO Y, 1978, J BIOCHEM, V83, P1375, DOI 10.1093/oxfordjournals.jbchem.a132046; PARKER CA, 1994, AM J PHYSIOL-CELL PH, V267, pC1262, DOI 10.1152/ajpcell.1994.267.5.C1262; PERSECHINI A, 1981, SCIENCE, V213, P1383, DOI 10.1126/science.6455737; SCOTTWOO GC, 1988, BIOCHEM J, V255, P817, DOI 10.1042/bj2550817; SHIRINSKY VP, 1992, J BIOL CHEM, V267, P15886; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SUTHERLAND C, 1994, J MUSCLE RES CELL M, V15, P440, DOI 10.1007/BF00122118; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; VANCOMPERNOLLE K, 1990, FEBS LETT, V274, P146, DOI 10.1016/0014-5793(90)81350-W; WALSH MP, 1993, AM J PHYSIOL, V265, pC1371, DOI 10.1152/ajpcell.1993.265.5.C1371; WALSH MP, 1983, METHOD ENZYMOL, V99, P279; WALSH MP, 1984, BIOCHEM J, V224, P117, DOI 10.1042/bj2240117; WINDER SJ, 1993, BIOCHEM J, V296, P827, DOI 10.1042/bj2960827; WINDER SJ, 1993, CELL SIGNAL, V5, P677, DOI 10.1016/0898-6568(93)90029-L; WINDER SJ, 1990, J BIOL CHEM, V265, P10148; WINDER SJ, 1992, BIOCHEM J, V286, P197, DOI 10.1042/bj2860197; ZOT HG, 1981, PREP BIOCHEM, V11, P381, DOI 10.1080/00327488108065530	45	49	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8605	8611		10.1074/jbc.271.15.8605	http://dx.doi.org/10.1074/jbc.271.15.8605			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621490	hybrid			2022-12-25	WOS:A1996UE73000021
J	Gudi, T; Huvar, I; Meinecke, M; Lohmann, SM; Boss, GR; Pilz, RB				Gudi, T; Huvar, I; Meinecke, M; Lohmann, SM; Boss, GR; Pilz, RB			Regulation of gene expression by cGMP-dependent protein kinase - Transactivation of the c-fos promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONCOGENE FOS; DNA-BINDING; CYCLIC-GMP; CAMP; TRANSCRIPTION; CREB; JUN; INDUCTION; DIMERIZATION; ACTIVATION	The cAMP/cAMP-dependent protein kinase (A-kinase) and Ca2+/calmodulin-dependent protein kinase (Cam-kinase) signal transduction pathways are well known to regulate gene transcription, but this has not been demonstrated directly for the cGMP/cGMP-dependent protein kinase (G-kinase) signal transduction pathway. Here we report that transfection of G-kinase into G-kinase-deficient cells causes activation of the human c-fos promoter in a strictly cGMP-dependent manner. The effect of G-kinase appeared to be mediated by several sequence elements, most notably the serum response element (SRE), the AP-1 binding site (FAP), and the cAMP response element (CRE), The magnitude of G-kinase transactivation of the fos promoter was similar to that of A-kinase, but there were significant differences between G-kinase and A-kinase activation of single enhancer elements and of a chimeric Gal4-CREB transcription factor, Our results indicate that G-kinase transduces signals to the nucleus independently of A-kinase or Ca2+, although it may target some of the same transcription factors as A-kinase and Cam-kinase.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR CANC,LA JOLLA,CA 92093; UNIV WURZBURG,MED KLIN,KLIN BIOCHEM & PATHOBIOCHEM,D-97080 WURZBURG,GERMANY	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Wurzburg				Boss, Gerry/0000-0002-9758-8714	NCI NIH HHS [CA01538] Funding Source: Medline; NIGMS NIH HHS [GM49360] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BUTT E, 1993, NEUROCHEM RES, V18, P27, DOI 10.1007/BF00966920; BUTT E, 1994, J BIOL CHEM, V269, P14509; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; DAY RN, 1989, J BIOL CHEM, V264, P431; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; FELLEYBOSCO E, 1994, AM J RESP CELL MOL, V11, P159, DOI 10.1165/ajrcmb.11.2.7519434; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; GONG JH, 1990, IMMUNOBIOLOGY, V182, P44, DOI 10.1016/S0171-2985(11)80582-6; HABY C, 1994, J NEUROCHEM, V62, P496; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JIANG H, 1992, J BIOL CHEM, V267, P1015; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LALLI E, 1994, J BIOL CHEM, V269, P17359; MAIER JAM, 1994, MOL CELL BIOL, V14, P1845, DOI 10.1128/MCB.14.3.1845; MECHAM RP, 1985, J BIOL CHEM, V260, P3255; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; PILZ RB, 1994, J BIOL CHEM, V269, P32155; PRYZWANSKY KB, 1995, J LEUKOCYTE BIOL, V57, P670, DOI 10.1002/jlb.57.4.670; RUTH P, 1993, P NATL ACAD SCI USA, V90, P2623, DOI 10.1073/pnas.90.7.2623; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; UEBERALL F, 1994, FEBS LETT, V352, P11; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	34	130	133	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4597	4600						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617718				2022-12-25	WOS:A1996TX69700008
J	Matsushita, M; Endo, Y; Taira, S; Sato, Y; Fujita, T; Ichikawa, N; Nakata, M; Mizuochi, T				Matsushita, M; Endo, Y; Taira, S; Sato, Y; Fujita, T; Ichikawa, N; Nakata, M; Mizuochi, T			A novel human serum lectin with collagen- and fibrinogen-like domains that functions as an opsonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE-BINDING PROTEIN; INFLUENZA-A VIRUSES; CARBOHYDRATE MOIETY; OLIGOSACCHARIDE CHAINS; BACTERICIDAL ACTIVITY; COMPLEMENT PATHWAY; CONGLUTININ BINDS; C1Q RECEPTOR; RECOGNITION; MANNAN	Collectins are C-type animal lectins with both collagenous and carbohydrate recognition domains and are involved in the first line host defense against pathogens, We report here a novel Ca2+-dependent and GlcNAc-binding lectin consisting of subunits of 35 kDa (P35) with a collagen-like sequence, When P35 is isolated from human serum, it forms a homopolymer by means of intermolecular disulfide bonding, as is the case with collectins, P35 cDNA was cloned from a human liver cDNA library, and the deduced amino acid sequence of 313 residues revealed that the mature form of P35 consists mainly of collagen- and fibrinogen-like domains, The latter contained two potential Ca2+-binding sites that may be involved in carbohydrate binding, The overall sequence of P35 was highly homologous to porcine ficolins alpha and beta. Northern blots of various human tissues showed that the major product of the 1.3-kilobase-long P35 transcript is expressed in liver, P35 enhanced phagocytosis of Salmonella typhimurium by neutrophils, suggesting an opsonic effect via the collagen region, P35 was found to bind to GlcNAc-conjugated bovine serum albumin, a neoglycoprotein, as web as to neoglycolipids containing complex-type oligosaccharides derived from glycoproteins, suggesting that P35 recognizes GlcNAc residues such as those found in microbial glycoconjugates and complex-type oligosaccharides. Therefore, P35 represents a new type of GlcNAc-binding lectin with structural and functional similarities to collectins involved in innate immunity.	FUKUSHIMA MED COLL,DEPT BIOCHEM,FUKUSHIMA 96012,JAPAN; TOKAI UNIV,DEPT APPL CHEM,BIOMED CHEM LAB,HIRATSUKA,KANAGAWA 25912,JAPAN	Fukushima Medical University; Tokai University								ANDERSEN O, 1991, SCAND J IMMUNOL, V33, P81, DOI 10.1111/j.1365-3083.1991.tb02494.x; BAKER NE, 1990, SCIENCE, V250, P1370, DOI 10.1126/science.2175046; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; CHILDS RA, 1989, BIOCHEM J, V262, P131, DOI 10.1042/bj2620131; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; EZEKOWITZ RAB, 1989, J EXP MED, V169, P185, DOI 10.1084/jem.169.1.185; HAGA JA, 1991, J BIOL CHEM, V266, P3695; HARTSHORN KL, 1993, J IMMUNOL, V151, P6265; HARTSHORN KL, 1993, J CLIN INVEST, V91, P1414, DOI 10.1172/JCI116345; HAURUM JS, 1993, AIDS, V7, P1307, DOI 10.1097/00002030-199310000-00002; HOLMSKOV U, 1994, IMMUNOL TODAY, V15, P67, DOI 10.1016/0167-5699(94)90136-8; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; ICHIJO H, 1993, J BIOL CHEM, V268, P14505; ICHIJO H, 1991, J BIOL CHEM, V266, P22459; IKEDA K, 1987, J BIOL CHEM, V262, P7451; JENSENIUS JC, 1994, BIOCHEM SOC T, V22, P95, DOI 10.1042/bst0220095; JONES FS, 1989, P NATL ACAD SCI USA, V86, P1905, DOI 10.1073/pnas.86.6.1905; KAWASAKI N, 1989, J BIOCHEM-TOKYO, V106, P483, DOI 10.1093/oxfordjournals.jbchem.a122878; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; KUROKI Y, 1994, J BIOL CHEM, V269, P25943; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN M, 1989, AIDS, V3, P793, DOI 10.1097/00002030-198912000-00003; LIANG CJ, 1980, J BIOCHEM-TOKYO, V88, P51; LOVELESS RW, 1989, BIOCHEM J, V258, P109, DOI 10.1042/bj2580109; MALHOTRA R, 1993, IMMUNOLOGY, V78, P341; MALHOTRA R, 1992, EUR J IMMUNOL, V22, P1437, DOI 10.1002/eji.1830220616; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; MATSUI T, 1992, J BIOL CHEM, V267, P8723; MATSUSHITA M, 1992, J EXP MED, V176, P1497, DOI 10.1084/jem.176.6.1497; MIZUOCHI T, 1982, J BIOCHEM-TOKYO, V92, P283, DOI 10.1093/oxfordjournals.jbchem.a133925; MIZUOCHI T, 1982, J IMMUNOL, V129, P2016; MIZUOCHI T, 1989, J BIOL CHEM, V264, P13834; Mizuochi T, 1993, Methods Mol Biol, V14, P55; MIZUOCHI T, 1991, TRENDS GLYCOSCI GLYC, V3, P435; NAKAJIMA T, 1974, J BIOL CHEM, V249, P7679; PEARSON CA, 1988, EMBO J, V7, P2977, DOI 10.1002/j.1460-2075.1988.tb03160.x; SASTRY K, 1993, CURR OPIN IMMUNOL, V5, P59, DOI 10.1016/0952-7915(93)90082-4; SATO T, 1994, INT IMMUNOL, V6, P665, DOI 10.1093/intimm/6.4.665; SCHWEINLE JE, 1989, J CLIN INVEST, V84, P1821, DOI 10.1172/JCI114367; TAI T, 1977, J BIOL CHEM, V252, P6687; TAKASAKI S, 1986, BIOCHEMISTRY-US, V25, P5709, DOI 10.1021/bi00367a054; THIEL S, 1992, IMMUNOPHARMACOLOGY, V24, P91, DOI 10.1016/0162-3109(92)90015-5; TURNER MW, 1994, BIOCHEM SOC T, V22, P88, DOI 10.1042/bst0220088; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	47	278	303	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2448	2454		10.1074/jbc.271.5.2448	http://dx.doi.org/10.1074/jbc.271.5.2448			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576206	hybrid			2022-12-25	WOS:A1996TT48800020
J	Mizobe, T; Maze, M; Lam, V; Suryanarayana, S; Kobilka, BK				Mizobe, T; Maze, M; Lam, V; Suryanarayana, S; Kobilka, BK			Arrangement of transmembrane domains in adrenergic receptors - Similarity to bacteriorhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SPECIFICITY; GENE	G protein-coupled receptors (GPCRs) have seven hydrophobic domains, which are thought to span the lipid bilayer as alpha helical transmembrane domains (TMDs), The tertiary structure of GPCRs has not been determined; however, molecular models of GPCRs have generally been based on bacteriorhodopsin, which is functionally unrelated to GPCRs but has a similar secondary structure, We sought to examine the validity of using bacteriorhodopsin as a scaffold for GPCR model building by experimentally determining the orientation of the TMDs of adrenergic receptors in the plasma membrane, In separate experiments, three sequential amino acid residues (Leu-310, Leu-311, Asn-312) in TMD VII of the beta(2) adrenoreceptor were mutated to the amino acids found in the homologous domain of the alpha(2) adrenoreceptor (Phe, Phe, Phe), Exchange of Asn-312 and Leu-311 in the beta(2) adrenoreceptor resulted in nonfunctional proteins, most likely due to incompatibility of the introduced bulky phenylalanine side chain with adjacent structural domains in the beta(2) adrenoreceptor. This structural incompatibility was ''repaired'' by replacing the specific beta(2) TMD sequence with an alpha(2) receptor sequence. TMD I and TMD II complemented the Asn-312 --> Phe mutation, and TMD III and TMD VI complemented the Leu-311 --> Phe mutation, These results indicate that TMDs I, II, III, and VI surround TMD VII in a counterclockwise orientation analogous to the orientation of TMDs in bacteriorhodopsin.	STANFORD UNIV,MED CTR,DEPT CELLULAR & MOLEC PHYSIOL,STANFORD,CA 94305; STANFORD UNIV,DEPT ANESTHESIA,STANFORD,CA 94305; STANFORD UNIV,DEPT MED,STANFORD,CA 94305; PALO ALTO VET AFFAIRS HLTH CARE SYST,PALO ALTO,CA 94304; STANFORD UNIV,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University				Kobilka, Brian/0000-0001-5958-3990	NINDS NIH HHS [R0 1 NS28471] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028471] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; DAHL SG, 1991, P NATL ACAD SCI USA, V88, P8111, DOI 10.1073/pnas.88.18.8111; Greenidge P A, 1994, Pharm Acta Helv, V68, P201, DOI 10.1016/0031-6865(94)90048-5; KOBILKA BK, 1987, P NATL ACAD SCI USA, V84, P46, DOI 10.1073/pnas.84.1.46; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; MAHONEYHUSS K, 1992, J MOL BIOL, V225, P859; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; SURYANARAYANA S, 1993, MOL PHARMACOL, V44, P111; SURYANARAYANA S, 1991, J BIOL CHEM, V266, P15488; SURYANARAYANA S, 1991, METHODS, V3, P193; UNGER VM, 1995, BIOPHYS J, V68, P1776, DOI 10.1016/S0006-3495(95)80354-1	14	70	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2387	2389		10.1074/jbc.271.5.2387	http://dx.doi.org/10.1074/jbc.271.5.2387			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576196	hybrid			2022-12-25	WOS:A1996TT48800010
J	Hao, HL; Moraes, CT				Hao, HL; Moraes, CT			Functional and molecular mitochondrial abnormalities associated with a C->T transition at position 3256 of the human mitochondrial genome - The effects of a pathogenic mitochondrial tRNA point mutation in organelle translation and RNA processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STROKE-LIKE EPISODES; PROTEIN-SYNTHESIS; TRANSFER RNALEU(UUR); LACTIC-ACIDOSIS; TRANSCRIPTION TERMINATION; SKELETAL-MUSCLE; MELAS SUBGROUP; DNA; MYOPATHY; MTDNA	We have previously identified a mitochondrial DNA polymorphism (a C --> T transition at position 3256, within the mitochondrial tRNA(Leu(UUR)) gene) in a patient with a multisystem disorder, Although there were several indicators suggesting a pathogenetic role for this mtDNA polymorphism, its heteroplasmic nature made functional and molecular studies difficult to interpret, We have now fused enucleated fibroblasts from the patient with a mtDNA-less cell line to generate transmitochondrial cybrids harboring different proportions of mutated and wild-type mtDNA, Individual clones harboring essentially 100% wild-type or >99% mutated mtDNAs were characterized and studied for respiratory capacity, respiratory chain enzymes activity, mitochondrial protein synthesis, and RNA steady state levels and processing. Our results showed that cell lines containing exclusively mutated mtDNAs respire poorly, overproduce lactic acid, and have significantly impaired activity of respiratory complexes I and IV. Molecular studies showed that mutant clones have a decrease in steady-state levels of mitochondrial tRNA(Leu(UUR)), and a partial impairment of mitochondrial protein synthesis and steady-state levels, suggesting that these molecular abnormalities are involved in the pathogenetic mechanism of the mtDNA 3256 mutation.	UNIV MIAMI, DEPT NEUROL, MIAMI, FL 33136 USA; UNIV MIAMI, DEPT ANAT & CELL BIOL, MIAMI, FL 33136 USA	University of Miami; University of Miami			Moraes, Carlos/AAT-3818-2021		NATIONAL EYE INSTITUTE [R01EY010804] Funding Source: NIH RePORTER; NEI NIH HHS [EY10804] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Attardi Giuseppe, 1993, P9; BINDOFF LA, 1993, J BIOL CHEM, V268, P19559; BOULET L, 1992, AM J HUM GENET, V51, P1187; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409; DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008; ERBA HP, 1988, MOL CELL BIOL, V8, P1775, DOI 10.1128/MCB.8.4.1775; GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119; HAYASHI JI, 1994, J BIOL CHEM, V269, P19060; HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KOGA Y, 1993, NUCLEIC ACIDS RES, V21, P657, DOI 10.1093/nar/21.3.657; KOGA Y, 1995, MUSCLE NERVE, pS119; KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2; LI H, 1991, Methods (Orlando), V2, P49, DOI 10.1016/S1046-2023(05)80125-2; MARIOTTI C, 1994, J CLIN INVEST, V93, P1102, DOI 10.1172/JCI117061; MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913; MORAES CT, 1992, AM J HUM GENET, V50, P934; MORTEN KJ, 1993, HUM MOL GENET, V2, P2081, DOI 10.1093/hmg/2.12.2081; SATO W, 1994, BIOCHEM MOL BIOL INT, V33, P1055; SCHON EA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P206, DOI 10.1016/S0005-2728(05)80021-0; SHOFFNER JM, 1995, NEUROLOGY, V45, P286, DOI 10.1212/WNL.45.2.286; SILVESTRI G, 1994, HUM MUTAT, V3, P37, DOI 10.1002/humu.1380030107; SWEENEY MG, 1993, Q J MED, V86, P709; TROUNCE I, 1996, IN PRESS METHODS ENZ; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WILSON GN, 1978, P NATL ACAD SCI USA, V75, P5367, DOI 10.1073/pnas.75.11.5367; ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D	34	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2347	2352		10.1074/jbc.271.4.2347	http://dx.doi.org/10.1074/jbc.271.4.2347			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567699	hybrid			2022-12-25	WOS:A1996TR32000081
J	Ray, R; Swamy, N; MacDonald, PN; Ray, S; Haussler, MR; Holick, MF				Ray, R; Swamy, N; MacDonald, PN; Ray, S; Haussler, MR; Holick, MF			Affinity labeling of the 1 alpha,25-dihydroxyvitamin D-3 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER CELL-PROLIFERATION; VITAMIN-D ANALOGS; 1,25-DIHYDROXYVITAMIN-D3 RECEPTOR; HORMONE RECEPTORS; GENE-EXPRESSION; INVITRO; BINDING; INVIVO; DNA	Genomic actions of the calciotropic hormone 1 alpha,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) involves a multistep process that is triggered by the highly specific binding of 1,25(OH)(2)D-3 to 1 alpha,25-dihydroxyvitamin D-3 receptor, VDR. In order to study this key step in the cascade, we synthesized 1 alpha,25-dihydroxy[26(27)-H-3]vitamin D-3-3-deoxy-3 beta-bromoacetate (1,25(OH)(2)[H-3]D-3-BE) and 1 alpha,25-dihydroxyvitaminD(3)-3 beta-[1-C-14]bromoacetate(1,25(OH)(2)D-3-[C-14]BE), binding-site directed analogs of 1,25(OH)(2)D-3, and affinity-labeled baculovirus-expressed recombinant human VDR (with 1,25(OH)(2)[H-3]D-3-BE), and naturally occurring VDRs in cytosols from calf thymus homogenate and rat osteosarcoma (ROS 17/2.8) cells (with 1, 25(OH)(2)D-3-[C-14]BE). In each case, specificity of labeling was demonstrated by the drastic reduction in labeling when the incubation was carried out in the presence of an excess of nonradioactive 1 alpha,25(OH)(2)D-3. These results strongly suggested that 1,25(OH)(2)[H-3]D-3-BE and 1,25(OH)(2)D-3-[C-14]BE covalently modified the 1,25(OH)(2)D-3-binding sites in baculovirus-expressed recombinant human VDR and naturally occurring calf thymus VDR and rat osteosarcoma VDR, respectively.	UNIV ARIZONA, COLL MED, DEPT BIOCHEM, TUCSON, AZ 85724 USA	University of Arizona	Ray, R (corresponding author), BOSTON UNIV, SCH MED, VITAMIN D LAB, 80 E CONCORD ST, BOSTON, MA 02118 USA.			Ray, Rahul/0000-0002-2078-2201; Haussler, Mark/0000-0002-7097-1801; Holick, Michael/0000-0001-6023-9062	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR015781, R01AR015781] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044337, R01DK047418] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 15781] Funding Source: Medline; NIDDK NIH HHS [R01 DK 47418, R01 DK 44337] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEGRETTO EA, 1985, J BIOL CHEM, V260, P139; ALLEGRETTO EA, 1987, J BIOL CHEM, V262, P1312; ALLEGRETTO EA, 1987, BIOCHEM BIOPH RES CO, V147, P479, DOI 10.1016/S0006-291X(87)80146-8; BINDERUP L, 1992, BIOCHEM PHARMACOL, V43, P1885, DOI 10.1016/0006-2952(92)90630-2; BINDERUP L, 1988, BIOCHEM PHARMACOL, V37, P889, DOI 10.1016/0006-2952(88)90177-3; BROWN TA, 1991, BIOCHIM BIOPHYS ACTA, V1073, P324, DOI 10.1016/0304-4165(91)90138-7; BROWN TA, 1991, ARCH BIOCHEM BIOPHYS, V286, P466, DOI 10.1016/0003-9861(91)90067-S; CARLSTEDTDUKE J, 1988, J BIOL CHEM, V263, P6842; COLSTON KW, 1989, LANCET, V1, P188; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P693, DOI 10.1016/0006-2952(92)90405-8; Darwish Hisham, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P89; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; HAUSSLER MR, 1986, ANNU REV NUTR, V6, P527, DOI 10.1146/annurev.nu.06.070186.002523; KATZENELLENBOGEN BS, 1993, J STEROID BIOCHEM, V47, P39, DOI 10.1016/0960-0760(93)90055-2; KRAGBALLE K, 1991, LANCET, V337, P193, DOI 10.1016/0140-6736(91)92157-W; LINK R, 1985, RECEPTORS, V2, P1; MACDONALD PN, 1994, SEMIN NEPHROL, V14, P101; MACDONALD PN, 1991, J BIOL CHEM, V266, P18808; MCDONNELL DP, 1989, MOL ENDOCRINOL, V3, P635, DOI 10.1210/mend-3-4-635; MCDONNELL DP, 1995, MOL ENDOCRINOL, V9, P659, DOI 10.1210/me.9.6.659; NAKAJIMA S, 1994, MOL ENDOCRINOL, V8, P159, DOI 10.1210/me.8.2.159; Pike J W, 1980, Methods Enzymol, V67, P508; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; RAY R, 1988, Steroids, V51, P623, DOI 10.1016/0039-128X(88)90057-8; RAY R, 1985, J CHEM SOC CHEM COMM, P702, DOI 10.1039/c39850000702; RAY R, 1993, STEROIDS, V58, P462, DOI 10.1016/0039-128X(93)90003-6; RAY R, 1994, BIOORG CHEM, V22, P276, DOI 10.1006/bioo.1994.1021; RAY R, 1985, BIOCHEM BIOPH RES CO, V132, P198, DOI 10.1016/0006-291X(85)91007-1; RAY S, 1994, 9TH P WORKSH VIT D O, P598; REINHARDT TA, 1984, J CLIN ENDOCR METAB, V58, P91, DOI 10.1210/jcem-58-1-91; Rodan GA, 1983, BONE MINERAL RES ANN, V2, P244; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SWAMY N, 1995, 17TH ANN M AM SOC S, V1; SWEET F, 1987, ENDOCR REV, V8, P154, DOI 10.1210/edrv-8-2-154	35	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2012	2017		10.1074/jbc.271.4.2012	http://dx.doi.org/10.1074/jbc.271.4.2012			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567652	hybrid			2022-12-25	WOS:A1996TR32000034
J	Suzuki, T; Morimura, S; Diccianni, MB; Yamada, R; Hochi, S; Hirabayashi, M; Yuki, A; Nomura, K; Kitagawa, T; Imagawa, M; Muramatsu, M				Suzuki, T; Morimura, S; Diccianni, MB; Yamada, R; Hochi, S; Hirabayashi, M; Yuki, A; Nomura, K; Kitagawa, T; Imagawa, M; Muramatsu, M			Activation of glutathione transferase P gene by lead requires glutathione transferase P enhancer I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL HEPATOCARCINOGENESIS; RAT-LIVER; S-TRANSFERASE; MAMMALIAN-CELLS; C-JUN; ONCOGENE; PROTEIN; DNA; METALLOTHIONEIN; EXPRESSION	Glutathione transferase P (GST-P) is specifically induced in rat liver and kidney by lead cation. The increase of GST-P mRNA after lead administration is blocked by actinomycin D, suggesting that GST-P production by lead is regulated at the transcriptional level. To further determine which part of the flanking region of the GST-P gene has the lead-responsive cis-element in vivo, we utilized transgenic rats with five different constructs having GST-P and/or chloramphenicol acetyltransferase coding sequence. We studied the effect of lead on these transgenic rats and on transfected NRK (normal rat kidney) cells and found that GST-P induction by lead is indeed regulated at the transcriptional level and that the GST-P enhancer I (GPEI) enhancer is an essential cis-element required for the activation of the GST-P gene by lead. GPEI consists of two AP-1 (c-Jun/c-Fos heterodimer) site-like sequences that are palindromically arranged and can bind AP-1. c-jun mRNA in the liver increased after lead administration and GST-P, and c-Jun had patchy expression in the same hepatocytes 24 h after lead exposure. These results suggest that activation of the GST-P gene by lead is mediated in major part by enhancer GPEI and that AP-1 may be involved at least partially. GPEI has been shown to have essential sequence information for the trans-activation of the GST-P gene during chemical hepatocarcinogenesis of the rat (Morimura, S., Suzuki, T., Hochi, S., Yuki, A., Nomura, K., Kitagawa, T., Nagatsu, I., Imagawa, M., and Muramatsu, M. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 2065-2068; Suzuki, T., Imagawa, M., Hirabayashi, M., Yuki, A., Hisatake, K., Nomura, K., Kitagawa, T., and Muramatsu, M. (1995) Cancer Res. 55, 2651-2655). The present study establishes that the same enhancer element does operate in the activation of the GST-P gene by lead regardless of the trans-activators involved.	SAITAMA MED SCH, DEPT BIOCHEM, MOROYAMA, SAITAMA 35004, JAPAN; YS NEW TECHNOL INST INC, ISHIBASHI, TOCHIGI 32905, JAPAN; JAPANESE FDN CANC RES, INST CANC, DEPT PATHOL, TOKYO 170, JAPAN; OSAKA UNIV, FAC PHARMACEUT SCI, DEPT ENVIRONM BIOCHEM, SUITA, OSAKA 565, JAPAN	Saitama Medical University; Japanese Foundation for Cancer Research; Osaka University			Hochi, Shinichi/T-4316-2019; , MitchDiccianni/AAF-8486-2019; Hirabayashi, Masumi/C-8935-2019	Hochi, Shinichi/0000-0001-5315-3471; , MitchDiccianni/0000-0002-5017-9585; Hirabayashi, Masumi/0000-0002-1059-5883				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; [Anonymous], 1991, CASARETT DOULLS TOXI, DOI DOI 10.1016/J.ETAP.2009.01.006; BOYCE SJ, 1993, BIOCHEM J, V294, P301, DOI 10.1042/bj2940301; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLUMBANO A, 1983, AM J PATHOL, V110, P83; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; IKEBUCHI H, 1986, BIOCHEM J, V233, P541, DOI 10.1042/bj2330541; IKEBUCHI H, 1986, BIOCHEM BIOPH RES CO, V136, P535, DOI 10.1016/0006-291X(86)90473-0; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KITAHARA A, 1984, CANCER RES, V44, P2698; KOO P, 1994, J BIOL CHEM, V269, P14601; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAEHARA Y, 1985, BIOCHEM BIOPH RES CO, V131, P800, DOI 10.1016/0006-291X(85)91310-5; MORIMURA S, 1993, P NATL ACAD SCI USA, V90, P2065, DOI 10.1073/pnas.90.5.2065; MORIMURA S, 1992, CELL GROWTH DIFFER, V3, P685; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; OKUDA A, 1990, EMBO J, V9, P1131, DOI 10.1002/j.1460-2075.1990.tb08219.x; OKUDA A, 1989, J BIOL CHEM, V264, P16919; OKUDA A, 1987, J BIOL CHEM, V262, P3858; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; ROOMI MW, 1986, CARCINOGENESIS, V7, P1643, DOI 10.1093/carcin/7.10.1643; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SAKAI M, 1989, CANCER RES, V49, P5633; SAKAI M, 1988, P NATL ACAD SCI USA, V85, P9456, DOI 10.1073/pnas.85.24.9456; Sambrook J, 1989, MOL CLONING LABORATO; SATO K, 1988, JPN J CANCER RES, V79, P556, DOI 10.1111/j.1349-7006.1988.tb00022.x; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHAPIRO SG, 1978, BIOCHEM J, V175, P833, DOI 10.1042/bj1750833; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; SOLT D, 1976, NATURE, V263, P701, DOI 10.1038/263701a0; STRAATEN F, 1983, P NATL ACAD SCI USA, V80, P3183; SUGIOKA Y, 1985, CANCER RES, V45, P365; SUGUOKA Y, 1985, NUCLEIC ACIDS RES, V13, P6049, DOI 10.1093/nar/13.17.6049; SUZUKI S, 1995, CARCINOGENESIS, V16, P567, DOI 10.1093/carcin/16.3.567; SUZUKI T, 1994, CARCINOGENESIS, V15, P1759, DOI 10.1093/carcin/15.8.1759; SUZUKI T, 1995, CANCER RES, V55, P2651; SUZUKI T, 1995, J CANCER RES CLIN, V55, P2651; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TEMPLETON DM, 1991, METHOD ENZYMOL, V205, P11	46	37	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1626	1632		10.1074/jbc.271.3.1626	http://dx.doi.org/10.1074/jbc.271.3.1626			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576162	hybrid			2022-12-25	WOS:A1996TQ52500058
J	Thick, J; Metcalfe, JA; Mak, YF; Beatty, D; Minegishi, M; Dyer, MJS; Lucas, G; Taylor, AMR				Thick, J; Metcalfe, JA; Mak, YF; Beatty, D; Minegishi, M; Dyer, MJS; Lucas, G; Taylor, AMR			Expression of either the TCL1 oncogene, or transcripts from its homologue MTCP1/c6.1B, in leukaemic and non-leukaemic T cells from ataxia telangiectasia patients	ONCOGENE			English	Article						ataxia telangiectasia; MTCP1; TCL1; leukaemia	CHRONIC LYMPHOCYTIC-LEUKEMIA; MOLECULAR ANALYSIS; CHAIN LOCUS; TRANSLOCATION; BREAKPOINT; GENE	Patients with the recessively inherited disorder ataxia telangiectasia (A-T) have a high level of specific chromosome translocations which can be easily observed in peripheral T cells and show a greatly increased predisposition to leukaemia/lymphoma, mainly of T cell origin, Some translocation cells proliferate into a large clone and may develop into T cell prolymphocytic leukaemia (T-PLL), By the time of diagnosis of T-PLL, the clone contains many more genetic changes in the form of additional translocations, T-PLL is also seen in non-A-T individuals where expression of either TCL1 (at 14q32) or the c6.1B/MTCP1 A1 transcript (at-Xq28) has been demonstrated in just a few instances, We show here, that expression of TCL1 occurs in leukaemic T cells from A-T patients with chromosome 14 rearrangements, Expression of TCL1 also occurs in the preleukaemic clone cells of A-T patients containing the primary translocation alone, Some expression of TCL1 could also be detected in randomly selected A-T patients without large cytogenetic clones and without any evidence of leukaemic change, We also show that expression of the B1 transcript from a second gene, MTCP1, occurred at a relatively high level only in two T-PLL tumours from A-T patients with t(X;14) translocations whereas the MTCP1/A1 transcript is much more widely expressed in both tumour and non tumour cells of A-T and non-A-T individuals.	UNIV BIRMINGHAM,SCH MED,INST CANC STUDIES,BIRMINGHAM B15 2TJ,W MIDLANDS,ENGLAND; UNIV CAPE TOWN,RED CROSS WAR MEM CHILDRENS HOSP,DEPT PAEDIAT & CHILD HLTH,RONDEBOSCH 7700,SOUTH AFRICA; TOHOKU UNIV,TB & CANC RES INST,DEPT PAEDIAT,SENDAI,MIYAGI 980,JAPAN; ROYAL CANC HOSP,CANC RES INST,SUTTON SM2 5NG,SURREY,ENGLAND; UNIV WALES COLL CARDIFF,DEPT HAEMATOL,CARDIFF CF4 4XN,S GLAM,WALES	University of Birmingham; University of Cape Town; Tohoku University; University of London; Institute of Cancer Research - UK; Cardiff University			Dyer, Martin/F-2691-2014	Dyer, Martin/0000-0002-5033-2236				BAER R, 1987, P NATL ACAD SCI USA, V84, P9069, DOI 10.1073/pnas.84.24.9069; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVEY MP, 1988, P NATL ACAD SCI USA, V85, P9287, DOI 10.1073/pnas.85.23.9287; FISCH P, 1993, ONCOGENE, V8, P3271; FU TB, 1994, CANCER RES, V54, P6297; GAW LM, 1987, EMBO J, V6, P2273; MADANI A, 1995, ONCOGENE, V10, P2259; MENGLEGAW L, 1988, P NATL ACAD SCI USA, V85, P9171, DOI 10.1073/pnas.85.23.9171; MINEGISHI M, 1991, LEUKEMIA, V5, P88; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; RUSSO G, 1989, P NATL ACAD SCI USA, V86, P602, DOI 10.1073/pnas.86.2.602; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SHERRINGTON PD, 1994, ONCOGENE, V9, P2377; SOULIER J, 1994, ONCOGENE, V9, P3565; Sparkes R.S., 1980, CANCER GENET CYTOGEN, V1, P329; STERN MH, 1993, ONCOGENE, V8, P2475; TAYLOR AMR, 1992, BRIT J CANCER, V66, P5, DOI 10.1038/bjc.1992.208; TAYLOR AMR, 1986, INT J CANCER, V37, P511, DOI 10.1002/ijc.2910370407; TAYLOR AMR, 1992, LEUKEMIA, V6, P961; TAYLOR AMR, 1982, ATAXIA TELANGIECTASI, P53; THICK J, 1994, LEUKEMIA, V8, P564; THICK J, 1992, GENE CHROMOSOME CANC, V5, P321, DOI 10.1002/gcc.2870050407; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; VIRGILIO L, 1993, P NATL ACAD SCI USA, V90, P9275, DOI 10.1073/pnas.90.20.9275	25	32	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					379	386						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570215				2022-12-25	WOS:A1996TR53800017
J	Ahmed, SA; McPhie, P; Miles, EW				Ahmed, SA; McPhie, P; Miles, EW			A thermally induced reversible conformational transition of the tryptophan synthase beta(2) subunit probed by the spectroscopic properties of pyridoxal phosphate and by enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; L-SERINE; 5'-PHOSPHATE; ALPHA; SYNTHETASE; MECHANISM; SPECTRA; INDOLE; BASES	A reversible thermally induced conformational transition of the beta(2) subunit of tryptophan synthase from Salmonella typhimurium has been detected by use of the pyridoxal 5'-phosphate coenzyme as a spectroscopic probe. Increasing the temperature converts the major form of pyridoxal 5'-phosphate bound to the beta(2) subunit from a ketoenamine species with lambda(max) at 410 nm to a enolimine species with lambda(max) at 336 nm (T-m = similar to 43 degrees C) and results in loss of the circular dichroism signal at 410 nm and of fluorescence emission at 510 nm, The results indicate that increasing the temperature favors a conformer of the enzyme that binds pyridoxal 5'-phosphate in a more nonpolar environment and leads to loss of asymmetric pyridoxal 5'-phosphate binding. The internal aldimine between pyridoxal 5'-phosphate and the E-amino group of lysine 87 is not disrupted by increased temperature because sodium borohydride treatment of the enzyme at either 15 or 60 degrees C results in covalent attachment of [4'-H-3]pyridoxal 5'-phosphate. The thermal transition of the beta(2) subunit below 60 degrees C produces reversible thermal inactivation (T-i = similar to 52 degrees C) and occurs at a much lower temperature than the major reversible unfolding at similar to 80 degrees C (Remeta, D. P., Miles, E. W., and Ginsburg, A. (1995) Pure Appl. Chem. 67, 1859-1866). Our new results indicate that the 410 nm absorbing species of pyridoxal 5'-phosphate is the catalytically active form of the cofactor in the beta(2) subunit and that the low temperature reversible conformational transition disturbs the active site and causes loss of catalytic activity.	NIDDKD, BIOCHEM PHARMACOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								AHMED SA, 1991, J BIOL CHEM, V266, P21548; BALK H, 1981, BIOCHEMISTRY-US, V20, P6391, DOI 10.1021/bi00525a017; CHAFFOTTE AF, 1983, BIOCHEMISTRY-US, V22, P2708, DOI 10.1021/bi00280a019; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P390, DOI 10.1073/pnas.51.3.390; Davis L, 1972, ENZYMES, P33; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; FAEDER EJ, 1970, BIOCHEMISTRY-US, V9, P4043, DOI 10.1021/bi00823a003; FAEDER EJ, 1971, BIOCHEMISTRY-US, V10, P1041; GOLDBERG ME, 1968, BIOCHEMISTRY-US, V7, P3662, DOI 10.1021/bi00850a045; HARRIS CM, 1976, BIOCHIM BIOPHYS ACTA, V421, P181, DOI 10.1016/0304-4165(76)90284-1; HEINERT D, 1962, J AM CHEM SOC, V84, P3257, DOI 10.1021/ja00876a009; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KALLEN RG, 1985, TRANSAMINASES, P37; LANE AN, 1983, EUR J BIOCHEM, V129, P571; METZLER CM, 1980, J AM CHEM SOC, V102, P6075, DOI 10.1021/ja00539a017; METZLER DE, 1955, J AM CHEM SOC, V77, P2431, DOI 10.1021/ja01614a022; Miles E W, 1995, Subcell Biochem, V24, P207; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1977, J BIOL CHEM, V252, P6594; MILES EW, 1982, J BIOL CHEM, V257, P4203; NAKAMOTO K, 1959, J AM CHEM SOC, V81, P5863, DOI 10.1021/ja01531a006; NAKAMOTO K, 1959, J AM CHEM SOC, V81, P5857, DOI 10.1021/ja01531a005; PACE CN, 1990, TRENDS BIOTECHNOL, V8, P93, DOI 10.1016/0167-7799(90)90146-O; REMETA DP, 1995, PURE APPL CHEM, V67, P1859, DOI 10.1351/pac199567111859; REMETA DP, 1993, BIOPHYS J, V64, pA175; REMETA DP, 1992, BIOPHYS J, V61, P213; RUVINOV SB, 1994, J BIOL CHEM, V269, P11703; SHALTIEL S, 1970, BIOCHEM BIOPH RES CO, V41, P594, DOI 10.1016/0006-291X(70)90054-9; SNELL EE, 1986, COENZYMES COFACTORS, V1, P1; YANG XJ, 1992, PROTEIN EXPRES PURIF, V3, P347, DOI 10.1016/1046-5928(92)90011-K	32	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8612	8617		10.1074/jbc.271.15.8612	http://dx.doi.org/10.1074/jbc.271.15.8612			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621491	hybrid			2022-12-25	WOS:A1996UE73000022
J	Irwin, M; McClintick, J; Costlow, C; Fortner, M; White, J; Gillin, JC				Irwin, M; McClintick, J; Costlow, C; Fortner, M; White, J; Gillin, JC			Partial night sleep deprivation reduces natural killer and cellular immune responses in humans	FASEB JOURNAL			English	Article						immunity; natural killer cell activity; interleukin-2	SLOW-WAVE SLEEP; INFECTIOUS-DISEASE; CELLS; INTERLEUKIN-1; LYMPHOCYTE; SECRETION; CORTISOL	Prolonged and severe sleep deprivation is associated with alterations of natural and cellular immune function, To determine whether alterations of immune function also occur after even a modest loss of sleep, the effects of early-night partial sleep deprivation on circulating numbers of white blood cells, natural killer (NK) cell number and cytotoxicity, lymphokine-activated killer (LAK) cell number and activity, and stimulated interleukin-2 (IL-2) production were studied in 42 medically and psychiatrically healthy male volunteers, After a night of sleep deprivation between 10 P.M. and 3 A.M., a reduction of natural immune responses as measured by Nh cell activity, Ng activity per number of NI( cells, LAK activity, and LAK activity per number of LAK precursors (CD16,56, CD25) was found, In addition, concanavalin A-stimulated IL-2 production was suppressed after sleep deprivation due to changes in both adherent and nonadherent cell populations, After a night of recovery sleep, NK activity returned to baseline levels and IL-2 production remained suppressed, These data implicate sleep in the modulation of immunity and demonstrate that even a modest disturbance of sleep produces a reduction of natural immune responses and T cell cytokine production.	UNIV CALIF SAN DIEGO, DEPT PSYCHIAT, SAN DIEGO, CA USA	University of California System; University of California San Diego	Irwin, M (corresponding author), SAN DIEGO VA MED CTR, DEPT PSYCHIAT V116A, 3350 LA JOLLA VILLAGE DR, SAN DIEGO, CA 92161 USA.		Irwin, Michael R./H-4870-2013	Irwin, Michael R./0000-0002-1502-8431	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000827] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH030914, R01MH046867, P50MH030914] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00827] Funding Source: Medline; NIMH NIH HHS [MH46867, MH30914] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKERSTEDT T, 1980, SLEEP, V3, P23, DOI 10.1093/sleep/3.1.23; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P1; BENCA RM, 1992, ARCH GEN PSYCHIAT, V49, P651; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; BLOOM ET, 1983, J IMMUNOL METHODS, V58, P323, DOI 10.1016/0022-1759(83)90360-5; BORN J, 1988, PSYCHONEUROENDOCRINO, V13, P233, DOI 10.1016/0306-4530(88)90021-2; BROWN R, 1989, Regional Immunology, V2, P321; BROWN R, 1989, Brain Behavior and Immunity, V3, P320, DOI 10.1016/0889-1591(89)90031-7; COVER H, 1993, RES PERSPECT PSYCHON, V90; CROSS RJ, 1992, J IMMUNOL, V148, P1347; CURTI R, 1982, MED LAV, V6, P564; DEMENT W, 1966, ELECTROEN CLIN NEURO, V20, P523, DOI 10.1016/0013-4694(66)90110-6; DINGES DF, 1994, J CLIN INVEST, V93, P1930, DOI 10.1172/JCI117184; EVERSON CA, 1993, AM J PHYSIOL, V265, pR1148, DOI 10.1152/ajpregu.1993.265.5.R1148; FAWZY FI, 1993, ARCH GEN PSYCHIAT, V50, P681; GILLIS S, 1978, J IMMUNOL, V120, P2027; HEILIG M, 1993, BRAIN BEHAV IMMUN, V7, P154, DOI 10.1006/brbi.1993.1017; HOHAGEN F, 1993, NEUROPSYCHOBIOLOGY, V28, P9, DOI 10.1159/000118993; HORNE J, 1988, WHY WE SLEEP FUNCTIO, P1; IRWIN M, 1994, PSYCHOSOM MED, V56, P493, DOI 10.1097/00006842-199411000-00004; IRWIN M, 1992, PSYCHOSOM MED, V54, P10, DOI 10.1097/00006842-199201000-00002; JARRETT DB, 1990, BIOL PSYCHIAT, V27, P497, DOI 10.1016/0006-3223(90)90441-4; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; KOFF WC, 1985, J IMMUNOL, V135, P350; KORN EL, 1984, IMMUNOBIOLOGY, V167, P431, DOI 10.1016/S0171-2985(84)80075-3; KRUEGER JM, 1990, INT J NEUROSCI, V51, P359, DOI 10.3109/00207459008999744; KRUEGER JM, 1990, CLIN IMMUNOL IMMUNOP, V57, P188, DOI 10.1016/0090-1229(90)90033-M; LEVY SM, 1989, NAT IMMUN CELL GROW, V8, P173; LUE FA, 1988, INT J NEUROSCI, V42, P179; MOLDOFSKY H, 1986, PSYCHOSOM MED, V48, P309, DOI 10.1097/00006842-198605000-00001; MOLDOFSKY H, 1989, FASEB J, V3, P1972, DOI 10.1096/fasebj.3.8.2785942; MORREY KM, 1994, J IMMUNOL, V153, P2671; MURRAY DR, 1992, CIRCULATION, V86, P203, DOI 10.1161/01.CIR.86.1.203; Nakano Y, 1982, J Hum Ergol (Tokyo), V11 Suppl, P131; OPP MR, 1994, BRAIN RES, V639, P57, DOI 10.1016/0006-8993(94)91764-7; OPP MR, 1994, AM J PHYSIOL, V266, pR688, DOI 10.1152/ajpregu.1994.266.3.R688; PALMBLAD J, 1976, J PSYCHOSOM RES, V20, P193, DOI 10.1016/0022-3999(76)90020-9; PALMBLAD J, 1979, PSYCHOSOM MED, V41, P273, DOI 10.1097/00006842-197906000-00001; PARRY BL, 1990, ARCH GEN PSYCHIAT, V47, P1139; PHILLIPS JH, 1986, J EXP MED, V164, P814, DOI 10.1084/jem.164.3.814; RECHTSCHAFFEN A, 1968, MANUAL STANDARDIZED, P1; REYNOLDS CF, 1987, ARCH GEN PSYCHIAT, V44, P982; SOMERS VK, 1993, NEW ENGL J MED, V328, P303, DOI 10.1056/NEJM199302043280502; TOTH LA, 1993, P SOC EXP BIOL MED, V203, P179, DOI 10.3181/00379727-203-43590; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1	45	323	338	1	35	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1996	10	5					643	653		10.1096/fasebj.10.5.8621064	http://dx.doi.org/10.1096/fasebj.10.5.8621064			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ055	8621064				2022-12-25	WOS:A1996UJ05500013
J	Sakamoto, H; Broekelmann, T; Cheresh, DA; Ramirez, F; Rosenbloom, J; Mecham, RP				Sakamoto, H; Broekelmann, T; Cheresh, DA; Ramirez, F; Rosenbloom, J; Mecham, RP			Cell-type specific recognition of RGD- and non-RGD-containing cell binding domains in fibrillin-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARFAN-SYNDROME; MICROFIBRILS; MODULATION; ATTACHMENT; ADHESION; PROTEIN; SURFACE; INTIMA	The fibrillins are large glycoprotein components of 10-nm microfibrils found in the extracellular matrix of most tissues, Microfibrils play a role in elastic fiber assembly and serve to link cells to elastic fibers in the extracellular matrix. To determine whether fibrillin-1 specifically interacts with receptors on cells from fibrillin-rich tissues, we evaluated whether two cell types that produce different types of fibrillin can adhere to purified fibrillin-1 in cell adhesion assays. Our results indicate that both cell types attach and spread on fibrillin-1 and that the RGD sequence in the fourth 8-cysteine motif mediates this interaction, Fibroblast attachment to fibrillin-1 was sensitive to inhibition by antibodies to the alpha v beta 3 receptor and by peptides encoding the RGD sequence in fibrillin-1 and the second RGD sequence in fibrillin-2. In contrast, adhesion of auricular chondroblasts to fibrillin-1 was only partially inhibited by these reagents, suggesting that some cell types recognize a second, non-RGD binding site within the fibrillin molecule, These findings confirm and extend ultrastructural studies that suggest a direct interaction between microfibrils and the cell surface and provide a functional explanation for how this association occurs.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; CUNY MT SINAI SCH MED, BROOKDALE CTR MOLEC BIOL, NEW YORK, NY 10029 USA; UNIV PENN, SCH DENT MED, PHILADELPHIA, PA 19104 USA	Washington University (WUSTL); Washington University (WUSTL); Scripps Research Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Pennsylvania					NATIONAL CANCER INSTITUTE [R37CA050286, R01CA050286] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026499, R01HL041926] Funding Source: NIH RePORTER; NCI NIH HHS [CA50286] Funding Source: Medline; NHLBI NIH HHS [HL-26499, HL-41926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHERESH DA, 1987, J BIOL CHEM, V262, P1434; CLEARY EG, 1983, INT REV CONNECT TISS, V10, P97; COTTAPEREIRA G, 1976, J INVEST DERMATOL, V66, P143, DOI 10.1111/1523-1747.ep12481882; DAVIS EC, 1993, TISSUE ENGINEERING, P26; DAVIS EC, 1994, J CELL SCI, V107, P727; DAVIS EC, 1993, CELL TISSUE RES, V272, P211, DOI 10.1007/BF00302726; FAULL RJ, 1993, J CELL BIOL, V121, P155, DOI 10.1083/jcb.121.1.155; GERRITY RG, 1972, EXP MOL PATHOL, V16, P382, DOI 10.1016/0014-4800(72)90012-3; GIBSON MA, 1989, J BIOL CHEM, V264, P4590; GIBSON MA, 1995, MOL CELL BIOL, V15, P6932; HORRIGAN SK, 1992, J BIOL CHEM, V267, P10087; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIELTY CM, 1992, J CELL SCI, V103, P445; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LEAK LV, 1968, J CELL BIOL, V36, P129, DOI 10.1083/jcb.36.1.129; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; LOW FN, 1961, ANAT REC, V139, P250; MARIENCHECK MC, 1995, CONNECT TISSUE RES, V31, P87, DOI 10.3109/03008209509028396; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; Mecham R.P., 1991, CELL BIOL EXTRACELLU, V2nd, P79; MECHAM RP, 1987, METHOD ENZYMOL, V144, P232; MOREN A, 1994, J BIOL CHEM, V269, P32469; SAKAI LY, 1991, J BIOL CHEM, V266, P14763; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WITHERS AP, 1994, J MED GENET, V31, P174; ZHANG H, 1994, J CELL BIOL, V124, P855, DOI 10.1083/jcb.124.5.855	26	148	153	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4916	4922						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617764				2022-12-25	WOS:A1996TX69700054
J	Fukami, K; Sawada, N; Endo, T; Takenawa, T				Fukami, K; Sawada, N; Endo, T; Takenawa, T			Identification of a phosphatidylinositol 4,5-bisphosphate-binding site in chicken skeletal muscle alpha-actinin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PURIFICATION; BINDING; GELSOLIN; DOMAIN	We previously reported that phosphatidylinositol 4,5-bisphosphate (PIP2) dramatically increases the gelating activity of smooth muscle alpha-actinin (Fukami, K., Furuhashi, K., Inagaki, M., Endo, T., Hatano, S., and Takenawa, T. (1992) Nature 359, 150-152) and that the hydrolysis of PIP2 on alpha-actinin by tyrosine kinase activation may be important in cytoskeletal reorganization (Fukami, K., Endo, T., Imamura, M., and Takenawa, T. (1994) J. Biol. Chem. 269, 1518-1522), Here we report that a proteolytic fragment with lysylendopeptidase comprising amino acids 168-184 (TAPYRNVNIQNFHLSWK) from striated muscle alpha-actinin contains a PIP2-binding site. A synthetic peptide composed of the 17 amino acids remarkably inhibited the activities of phospholipase C (PLC)-gamma 1 and -delta 1. Furthermore, we detected an interaction between PIP2 and a bacterially expressed alpha-actinin fragment (amino acids 137-259) by PLC inhibition assay, Point mutants in which arginine 172 or lysine 184 of alpha-actinin were replaced by isoleucine reduced the inhibitory effect on PLC activity by nearly half, Direct interactions between PIP2 and the peptide (amino acids 168-184) or the bacterially expressed protein (amino acids 137-259) were confirmed by enzyme-linked immunosorvent assay, We also found this region homologous to the sequence of the PIP2-binding site in spectrin and the pleckstrin homology domains of PLC-delta 1 and Grb7, Synthetic peptides from the homologous regions in spectrin and PLC-delta 1 inhibited PLC activities, These results indicate that residues 168-184 comprise a binding site for PIP2 in alpha-actinin and that similar sequences found in spectrin and PLC-delta 1 may be involved in the interaction with PIP2.	UNIV TOKYO,INST MED SCI,DEPT MOLEC ONCOL,MINATO KU,TOKYO 108,JAPAN; CHIBA UNIV,FAC SCI,DEPT BIOL,CHIBA 263,JAPAN	University of Tokyo; Chiba University								BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; CHAUHAN A, 1991, ARCH BIOCHEM BIOPHYS, V287, P283, DOI 10.1016/0003-9861(91)90480-7; DAMER CK, 1994, J BIOL CHEM, V269, P31115; EBASHI S, 1964, NATURE, V203, P645, DOI 10.1038/203645a0; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HOMMA Y, 1990, BIOCHEM J, V269, P13, DOI 10.1042/bj2690013; HUANG FL, 1991, J BIOL CHEM, V266, P8727; IMAMURA M, 1992, J BIOL CHEM, V267, P25927; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JESSE CH, 1995, NATURE, V374, P173; KIM JY, 1994, J BIOL CHEM, V269, P28214; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; SAIDO TC, 1993, J BIOL CHEM, V268, P7422; SCHACHT J, 1978, J LIPID RES, V19, P1063; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; TOKUUE Y, 1992, EXP CELL RES, V197, P158; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; VALLEE RB, 1993, NATURE, V365, P107, DOI 10.1038/365107a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YONAZAWA N, 1991, J BIOL CHEM, V266, P17218; YU FX, 1990, SCIENCE, V250, P1413, DOI 10.1126/science.2255912; YU FX, 1992, J BIOL CHEM, V267, P14616	38	109	112	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2646	2650		10.1074/jbc.271.5.2646	http://dx.doi.org/10.1074/jbc.271.5.2646			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576235	hybrid			2022-12-25	WOS:A1996TT48800049
J	Yokomizo, T; Ogawa, Y; Uozumi, N; Kume, K; Izumi, T; Shimizu, T				Yokomizo, T; Ogawa, Y; Uozumi, N; Kume, K; Izumi, T; Shimizu, T			cDNA cloning, expression, and mutagenesis study of leukotriene B-4 12-hydroxydehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; SITE-DIRECTED MUTAGENESIS; OMEGA-OXIDATION PRODUCTS; ARACHIDONIC-ACID; PORCINE LEUKOCYTES; DIHYDRO METABOLITES; HUMAN-ERYTHROCYTES; PURIFICATION; IDENTIFICATION; HYDROLASE	Leukotriene B-4 12-hydroxydehydrogenase catalyzes the conversion of leukotriene B-4 into its biologically less active metabolite, 12-oxo-leukotriene B-4, This is an initial and key step of metabolic inactivation of leukotriene B-4 in various tissues other than leukocytes, Here we report the cDNA cloning for porcine and human enzymes from kidney cDNA libraries. A full-length cDNA of the porcine enzyme contains an open reading frame consisting of 987 base pairs, corresponding to 329 amino acids. The human enzyme showed a 97.1% homology with the porcine enzyme. Northern blotting of human tissues revealed its high expression in the kidney, liver, and intestine but not in leukocytes. The porcine enzyme was expressed as a glutathione S-transferase fusion protein in Escherichia coli, which exhibited similar characteristics with the native enzyme. Because the enzymes have a homology, in part, with NAD(P)(+)-dependent alcohol dehydrogenases, a site-directed mutagenesis study was carried out. We found that three glycines at 152, 155, and 166 have crucial roles in the enzyme activity, possibly by producing an NADP(+) binding pocket.	UNIV TOKYO, FAC MED, DEPT BIOCHEM, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo			Yokomizo, Takehiko/P-5673-2016	Yokomizo, Takehiko/0000-0002-5219-1553; Kume, Kazuhiko/0000-0003-4232-1657				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARDAILLOU R, 1986, AM J MED, V81, P12, DOI 10.1016/0002-9343(86)90904-6; BAKER PJ, 1992, J MOL BIOL, V228, P662, DOI 10.1016/0022-2836(92)90848-E; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BOCANEGRA JA, 1993, BIOCHEMISTRY-US, V32, P2737, DOI 10.1021/bi00062a001; BOLL W, 1993, J BIOL CHEM, V268, P12901; BORGEAT P, 1979, J BIOL CHEM, V254, P2643; BROM J, 1988, IMMUNOLOGY, V64, P509; Cattell V, 1987, Nephrol Dial Transplant, V2, P154; COLONNA CF, 1986, J BIOL CHEM, V261, P15273; CZARNETZKI BM, 1985, PROSTAGLANDINS, V30, P5, DOI 10.1016/S0090-6980(85)80006-X; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; EDWARDS KJ, 1994, J MOL BIOL, V240, P501, DOI 10.1006/jmbi.1994.1463; EVANS JF, 1985, BIOCHIM BIOPHYS ACTA, V840, P43, DOI 10.1016/0304-4165(85)90160-6; FORDHUTCHINSON AW, 1983, PROSTAGLANDINS, V25, P29, DOI 10.1016/0090-6980(83)90132-6; GHOSH D, 1992, J STEROID BIOCHEM, V42, P849, DOI 10.1016/0960-0760(92)90093-X; GONZALEZ P, 1994, MOL BIOL EVOL, V11, P305; GOTOH Y, 1989, EUR J BIOCHEM, V179, P315, DOI 10.1111/j.1432-1033.1989.tb14557.x; HANSSON G, 1981, FEBS LETT, V130, P107, DOI 10.1016/0014-5793(81)80676-X; IKAI K, 1994, J INVEST DERMATOL, V102, P253, DOI 10.1111/1523-1747.ep12371772; IVERSEN L, 1993, J INVEST DERMATOL, V100, P293, DOI 10.1111/1523-1747.ep12469865; IZUMI T, 1986, BIOCHEM BIOPH RES CO, V134, P512, DOI 10.1016/S0006-291X(86)80450-8; KAEVER V, 1990, LIFE SCI, V46, P1465, DOI 10.1016/0024-3205(90)90463-2; KHANAPURE SP, 1995, J ORG CHEM, V60, P1806, DOI 10.1021/jo00111a044; KIKUTA Y, 1994, FEBS LETT, V348, P70, DOI 10.1016/0014-5793(94)00587-7; KIKUTA Y, 1993, J BIOL CHEM, V268, P9376; KUMLIN M, 1990, BIOCHIM BIOPHYS ACTA, V1044, P201, DOI 10.1016/0005-2760(90)90304-G; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; MA Q, 1992, J BIOL CHEM, V267, P22298; MCGEE J, 1985, J BIOL CHEM, V260, P2832; MEDINA JF, 1987, BIOCHEM BIOPH RES CO, V143, P697, DOI 10.1016/0006-291X(87)91410-0; MILNERWHITE EJ, 1995, TRENDS BIOCHEM SCI, V20, P374; MINAMI M, 1987, J BIOL CHEM, V262, P13873; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Okayama H, 1987, Methods Enzymol, V151, P434, DOI 10.1016/S0076-6879(87)51035-7; ORNING L, 1990, J BIOL CHEM, V265, P14911; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; POUPLANA LR, 1994, BIOCHEMISTRY-US, V33, P7047; POWELL WS, 1984, J BIOL CHEM, V259, P3082; POWELL WS, 1989, ADV PROSTAG THROMB L, V19, P112; POWELL WS, 1990, BIOCHIM BIOPHYS ACTA, V1044, P147, DOI 10.1016/0005-2760(90)90230-U; POWELL WS, 1989, J BIOL CHEM, V264, P5364; RADMARK O, 1984, J BIOL CHEM, V259, P2339; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; ROUZER CA, 1985, P NATL ACAD SCI USA, V82, P6040, DOI 10.1073/pnas.82.18.6040; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; SCHWEIZER M, 1989, NUCLEIC ACIDS RES, V17, P567, DOI 10.1093/nar/17.2.567; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SHAK S, 1985, J CLIN INVEST, V76, P1218, DOI 10.1172/JCI112077; SHAK S, 1984, J BIOL CHEM, V259, P181; SHIMIZU T, 1986, P NATL ACAD SCI USA, V83, P4175, DOI 10.1073/pnas.83.12.4175; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; SOBERMAN RJ, 1988, J BIOL CHEM, V263, P7996; SOBERMAN RJ, 1985, P NATL ACAD SCI USA, V82, P2292, DOI 10.1073/pnas.82.8.2292; SOLA J, 1992, J INVEST DERMATOL, V98, P333, DOI 10.1111/1523-1747.ep12499800; SPURNEY RF, 1991, KIDNEY INT, V39, P95, DOI 10.1038/ki.1991.12; SUMIMOTO H, 1990, J BIOCHEM, V108, P215, DOI 10.1093/oxfordjournals.jbchem.a123183; SUMIMOTO H, 1988, EUR J BIOCHEM, V172, P315, DOI 10.1111/j.1432-1033.1988.tb13889.x; UEDA N, 1986, J BIOL CHEM, V261, P7982; WAINWRIGHT SL, 1991, J BIOL CHEM, V266, P20899; WHEELAN P, 1993, J BIOL CHEM, V268, P25439; YOKOMIZO T, 1993, J BIOL CHEM, V268, P18128	63	60	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2844	2850		10.1074/jbc.271.5.2844	http://dx.doi.org/10.1074/jbc.271.5.2844			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576264	hybrid			2022-12-25	WOS:A1996TT48800078
J	Gupta, KP; Ward, NE; Gravitt, KR; Bergman, PJ; OBrian, CA				Gupta, KP; Ward, NE; Gravitt, KR; Bergman, PJ; OBrian, CA			Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-alpha pseudosubstrate peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-GLYCOPROTEIN; DRUG ACCUMULATION; CARCINOMA-CELLS; MCF-7 CELLS; INHIBITION; PHOSPHORYLATION; EXPRESSION; INVITRO; GENE; IDENTIFICATION	The predominant characteristics of multidrug resistant (MDR) cancer cells are broad spectrum resistance to chemotherapeutic agents and a pronounced defect in intracellular accumulation of the drugs, in association with overexpression of the drug efflux pump P-glycoprotein, Protein kinase C (PKC) phosphorylates the linker region of P-glycoprotein. Evidence has been presented that the isozyme PKC-alpha may contribute to the drug resistance phenotype of human breast cancer MCF7-MDR cells, PKC-alpha is markedly overexpressed in MCF7-MDR cells, and artificial overexpression of PRC-alpha in MCF7 constructs that overexpress P-glycoprotein significantly enhances the MDR phenotype of the cells in association with increased P-glycoprotein phosphorylation, Verapamil, cyclosporin A, and a number of other agents that compete with cytotoxic drugs for binding sites on P-glycoprotein can potently reverse MDR, but this is accompanied by severe toxicity in vivo. In this report, we demonstrate that an N-myristoylated peptide that contains a sequence corresponding to the pseudosubstrate region of PKC-alpha (P1) partially reverses multidrug resistance in MCF7-MDR cells by a novel mechanism that involves inhibition of PKC-alpha, P1 and two related PKC inhibitory N-myristoylated peptides restored intracellular accumulation of chemotherapeutic drugs in association with inhibition of the phosphorylation of three PKC-alpha substrates in MCF7-MDR cells: PKC-alpha, Raf-1 kinase, and P-glycoprotein. A fourth N-myristoylated peptide substrate analog of PKC, P7, did not affect drug accumulation in the MCF7-MDR cells and failed to inhibit the phosphorylation of the PKC-alpha substrates, The effects of P1 and verapamil on drug accumulation in MCF7-MDR cells were additive. P1 did not affect P-glycoprotein expression, MCF7-MDR cells were not cross-resistant to P1, which suggests that the peptide was not transported by P-glycoprotein. Furthermore, P1 was distinguished from MDR reversal agents such as verapamil and cyclosporin A by its inability to inhibit [H-3]azidopine photoaffinity labeling of P-glycoprotein. P1 actually increased [H-3]azidopine photoaffinity labeling of P-glycoprotein in MCF7-MDR cells, providing evidence that the effects of P1 on P-glycoprotein in MCF7-MDR cells are not restricted to inhibition of the phosphorylation of the pump, P1 may provide a basis for developing a new generation of MDR reversal agents that function by a novel mechanism that involves inhibition of PKC-alpha-catalyzed P-glycoprotein phosphorylation.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA-52460] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA052460] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMAD S, 1994, BIOCHEMISTRY-US, V33, P10313, DOI 10.1021/bi00200a011; ASAOKA Y, 1992, TRENDS BIOCHEM SCI, V17, P414, DOI 10.1016/0968-0004(92)90011-W; BARJA P, 1994, CELL IMMUNOL, V153, P28, DOI 10.1006/cimm.1994.1003; BATES SE, 1993, BIOCHEMISTRY-US, V32, P9156, DOI 10.1021/bi00086a022; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BRADY L, 1994, NATURE, V368, P692, DOI 10.1038/368692a0; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; CHAMBERS TC, 1992, MOL PHARMACOL, V41, P1008; CHEN G, 1993, CANCER RES, V53, P2544; CORNWELL MM, 1993, J BIOL CHEM, V268, P15347; DALTON W, 1994, J NIH RES, V6, P54; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DONG ZY, 1991, MOL PHARMACOL, V39, P563; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EICHHOLTZ T, 1993, J BIOL CHEM, V268, P1982; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; EPAND RM, 1990, TRENDS PHARMACOL SCI, V11, P317, DOI 10.1016/0165-6147(90)90234-Y; FERGUSON PJ, 1987, CANCER RES, V47, P433; FINE RL, 1988, P NATL ACAD SCI USA, V85, P582, DOI 10.1073/pnas.85.2.582; GOLDSTEIN LJ, 1989, J NATL CANCER I, V81, P116, DOI 10.1093/jnci/81.2.116; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GRAVITT KR, 1994, BIOCHEM PHARMACOL, V48, P375, DOI 10.1016/0006-2952(94)90110-4; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; IOANNIDES CG, 1990, CELL IMMUNOL, V131, P242, DOI 10.1016/0008-8749(90)90250-U; JAMESON BA, 1994, NATURE, V368, P744, DOI 10.1038/368744a0; KANG Y, 1994, CANCER RES, V54, P2952; KIUE A, 1990, CANCER RES, V50, P310; KLOPMAN G, 1992, CANCER RES, V52, P4121; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LEE SA, 1992, CANCER RES, V52, P3750; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MIYAMOTO K, 1993, CANCER RES, V53, P1555; OBRIAN CA, 1990, BIOCHEMISTRY-US, V29, P4278, DOI 10.1021/bi00470a003; OBRIAN CA, 1985, CANCER RES, V45, P2462; OBRIAN CA, 1989, FEBS LETT, V246, P78, DOI 10.1016/0014-5793(89)80257-1; OBRIAN CA, 1991, BIOCHEM PHARMACOL, V41, P797, DOI 10.1016/0006-2952(91)90083-H; OBRIAN CA, 1991, INVEST NEW DRUG, V9, P169, DOI 10.1007/BF00175084; OBRIAN CA, 1995, ALTERNATIVE MECHANIS, P173; ORR GA, 1993, J BIOL CHEM, V268, P25054; Posada J A, 1989, Cancer Commun, V1, P285; RAYMOND M, 1992, SCIENCE, V256, P232, DOI 10.1126/science.1348873; RICOUART A, 1989, BIOCHEM BIOPH RES CO, V165, P1382, DOI 10.1016/0006-291X(89)92757-5; SARKADI B, 1994, FASEB J, V8, P766, DOI 10.1096/fasebj.8.10.7914178; SATO W, 1990, BIOCHEM BIOPH RES CO, V173, P1252, DOI 10.1016/S0006-291X(05)80921-0; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SHAROM FJ, 1995, J BIOL CHEM, V270, P10334, DOI 10.1074/jbc.270.17.10334; TAMAI I, 1991, J BIOL CHEM, V266, P16796; WARD NE, 1993, BIOCHEMISTRY-US, V32, P11903, DOI 10.1021/bi00095a020; WEINSTEIN RS, 1991, CANCER RES, V51, P2720; YU G, 1991, CANCER COMMUN, V3, P181, DOI 10.3727/095535491820873263; ZHANG L, 1994, J BIOL CHEM, V269, P15973; ZHENG B, 1994, J BIOL CHEM, V269, P12332	54	61	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2102	2111		10.1074/jbc.271.4.2102	http://dx.doi.org/10.1074/jbc.271.4.2102			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567666	hybrid			2022-12-25	WOS:A1996TR32000048
J	Li, J; Cook, R; Dede, K; Chaiken, I				Li, J; Cook, R; Dede, K; Chaiken, I			Single chain human interleukin 5 and its asymmetric mutagenesis for mapping receptor binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULES; PROTEIN	Wild type human (h) interleukin 5 (wt IL5) is composed of two identical peptide chains linked by disulfide bonds. A gene encoding a single chain form of hIL5 dimer was constructed by linking the two hIL5 chain coding regions with a Gly-Gly linker. Expression of this gene in COS cells yielded a single chain IL5 protein (sc IL5) having biological activity similar to that of wt IL5, as judged by stimulation of human cell proliferation. Single chain and wt IL5 also had similar binding affinity for soluble IL5 receptor a chain, the specificity subunit of the IL5 receptor, as measured kinetically with an optical biosensor. The design of functionally active sc IL5 allowed asymmetric mutagenesis of the symmetrical IL5 molecule. Such mutagenesis was exemplified by changes at residues Glu-13, Arg-91, Glu-110, and Trp-lll. The receptor binding and bioactivity data obtained are consistent with a model in which residues from both IL5 monomers interact with the receptor cw chain, while the interaction likely is asymmetric due to the intrinsic asymmetry of folded receptor. The results demonstrate a general route to the further mapping of receptor and other binding sites on the surface of human IL5.	UNIV PENN,SCH MED,DIV RHEUMATOL,PHILADELPHIA,PA 19104; SMITHKLINE BEECHAM PHARMACEUT,DEPT MOLEC IMMUNOL,KING OF PRUSSIA,PA 19406	University of Pennsylvania; GlaxoSmithKline								AMES RS, 1995, J IMMUNOL, V154, P6355; BAZAN JF, 1992, SCIENCE, V257, P410, DOI 10.1126/science.1631562; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500, DOI 10.1164/ajrccm/146.2.500; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DEVOS R, 1993, J BIOL CHEM, V268, P6581; DIEDERICHS K, 1991, SCIENCE, V254, P1779, DOI 10.1126/science.1837174; GRABER P, 1995, J BIOL CHEM, V270, P15762, DOI 10.1074/jbc.270.26.15762; JOHANSON K, 1995, J BIOL CHEM, V270, P9459, DOI 10.1074/jbc.270.16.9459; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LI J, 1996, IN PRESS J MOL RECOG; MCKENZIE ANJ, 1991, EMBO J, V10, P1193, DOI 10.1002/j.1460-2075.1991.tb08060.x; MILBURN MV, 1993, NATURE, V363, P172, DOI 10.1038/363172a0; MORTON T, 1995, P NATL ACAD SCI USA, V92, P10879, DOI 10.1073/pnas.92.24.10879; MURATA Y, 1992, J EXP MED, V175, P341, DOI 10.1084/jem.175.2.341; Sanderson C J, 1992, Adv Pharmacol, V23, P163, DOI 10.1016/S1054-3589(08)60965-5; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TAVERNIER J, 1995, P NATL ACAD SCI USA, V92, P5194, DOI 10.1073/pnas.92.11.5194; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4	19	21	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1817	1820		10.1074/jbc.271.4.1817	http://dx.doi.org/10.1074/jbc.271.4.1817			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567620	hybrid			2022-12-25	WOS:A1996TR32000002
J	Aberle, H; Schwartz, H; Hoschuetzky, H; Kemler, R				Aberle, H; Schwartz, H; Hoschuetzky, H; Kemler, R			Single amino acid substitutions in proteins of the armadillo gene family abolish their binding to alpha-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; BETA-CATENIN; CADHERIN; PLAKOGLOBIN; HOMOLOG; DOMAIN	Analysis of the calcium-dependent cell adhesion molecule E-cadherin has led to the identification of catenins, which are necessary for cadherin function. Growing evidence that cadherins and catenins are subjected to genetic alterations in carcinogenesis makes it especially important to understand protein-protein interactions within the cadherin-catenin complex, Here we report the identification and analysis of the alpha-catenin binding site in plakoglobin (gamma-catenin). Using N- and C-terminal truncations of plakoglobin, we identified a domain of 29 amino acids necessary and sufficient for binding alpha-catenin. The alpha-catenin binding site is fully encoded within exon 3 of plakoglobin but only partially represented in Armadillo repeat 1. This suggests that exons rather than individual Arm repeats encode functional domains of plakoglobin. Site-directed mutagene sis identified residues in the alpha-catenin binding site indispensable for binding in vitro, Analogous mutations in beta-catenin and Armadillo had identical effects, Our re suits indicate that single amino acid mutations in the alpha-catenin binding site of homologs of Armadillo could prevent a stable association with alpha-catenin, thus affecting cadherin-mediated adhesion.	MAX PLANCK INST IMMUNBIOL,D-79108 FREIBURG,GERMANY	Max Planck Society			Aberle, Hermann/L-8461-2017	Aberle, Hermann/0000-0002-4864-6105; Schwartz, Hillel/0000-0002-3448-8652				ABERLE H, 1995, P NATL ACAD SCI USA, V92, P6384, DOI 10.1073/pnas.92.14.6384; ABERLE H, 1994, J CELL SCI, V107, P3655; BECKER KF, 1994, CANCER RES, V54, P3845; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BREEN E, 1993, CELL ADHES COMMUN, V1, P239, DOI 10.3109/15419069309097257; BUTZ S, 1994, PEPTIDE RES, V7, P20; BUTZ S, 1994, FEBS LETT, V355, P195, DOI 10.1016/0014-5793(94)01205-9; CROPP CS, 1994, CANCER RES, V54, P2548; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; GUSSOW D, 1989, NUCLEIC ACIDS RES, V17, P4000; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; HATZFELD M, 1994, J CELL SCI, V107, P2259; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; OYAMA T, 1994, CANCER RES, V54, P6282; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; ROSENTHAL E, 1993, BIOCHIM BIOPHYS ACTA, V1173, P337, DOI 10.1016/0167-4781(93)90134-Y; STAPPERT J, 1992, NUCLEIC ACIDS RES, V20, P624, DOI 10.1093/nar/20.3.624; Takeichi M, 1994, Prog Clin Biol Res, V390, P145; TSUKITA S, 1993, J CELL BIOL, V123, P1049, DOI 10.1083/jcb.123.5.1049; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247	34	149	151	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1520	1526		10.1074/jbc.271.3.1520	http://dx.doi.org/10.1074/jbc.271.3.1520			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576147	hybrid			2022-12-25	WOS:A1996TQ52500043
J	Ekiel, I; Abrahamson, M				Ekiel, I; Abrahamson, M			Folding-related dimerization of human cystatin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN GLOBULE STATE; BOVINE GROWTH-HORMONE; RAY CRYSTAL-STRUCTURE; ALPHA-LACTALBUMIN; CYSTEINE PROTEINASES; CEREBRAL-HEMORRHAGE; ESCHERICHIA-COLI; BONE-RESORPTION; COMPACT STATE; SPECTROSCOPY	With the aim to improve our understanding of the structural basis for protein self-association and aggregation, in particular in relationship to protein refolding and amyloid formation, folding-related processes for human cystatin C have been studied. Using NMR spectroscopy together with chromatographic and electrophoretic methods, a self-association process resulting in dimer formation for protein samples treated with denaturing agents as well as for samples subjected to low pH or high temperature conditions could be studied with amino acid resolution. In all three cases, the dimerization involves properly folded molecules and proceeds via the reactive site of the inhibitor, which leads to complete loss of its biological activity. This dimerization process has potential relevance for amyloid formation by the brain hemorrhage-causing Leu(68)-Gln variant of cystatin C. The results also indicate that cystatin C dimerization and inactivation may occur in acidified compartments in vivo, which could be relevant for the physiological regulation of cysteine proteinase activity.	UNIV LUND HOSP,DEPT CLIN CHEM,S-22185 LUND,SWEDEN	Lund University; Skane University Hospital	Ekiel, I (corresponding author), NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,PHARMACEUT BIOTECHNOL SECTOR,6100 ROYALMT AVE,MONTREAL,PQ H4P 2R2,CANADA.		Abrahamson, Magnus/CAG-9507-2022					ABRAHAMSON M, 1994, P NATL ACAD SCI USA, V91, P1416, DOI 10.1073/pnas.91.4.1416; ABRAHAMSON M, 1988, FEBS LETT, V236, P14, DOI 10.1016/0014-5793(88)80276-X; ABRAHAMSON M, 1990, BIOCHEM J, V268, P287, DOI 10.1042/bj2680287; ABRAHAMSON M, 1986, J BIOL CHEM, V261, P1282; ALBER T, 1989, ANNU REV BIOCHEM, V58, P765, DOI 10.1146/annurev.biochem.58.1.765; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BERTI PJ, 1993, THESIS MCGILL U MONT; BODE W, 1988, EMBO J, V7, P2593, DOI 10.1002/j.1460-2075.1988.tb03109.x; BRADER ML, 1991, TRENDS BIOCHEM SCI, V16, P341; Brange J., 1987, ADV MODELS THERAPY I, P85; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; BREMS DN, 1988, BIOCHEMISTRY-US, V27, P4541, DOI 10.1021/bi00412a048; CLELAND JL, 1993, CRIT REV THER DRUG, V10, P307; CLELAND JL, 1990, BIOCHEMISTRY-US, V29, P11072, DOI 10.1021/bi00502a009; CLELAND JL, 1991, ACS SYM SER, V470, P1; COLON W, 1992, BIOCHEMISTRY-US, V31, P8654, DOI 10.1021/bi00151a036; DALBOGE H, 1989, GENE, V79, P325, DOI 10.1016/0378-1119(89)90214-X; DELAISSE JM, 1984, BIOCHEM BIOPH RES CO, V125, P441, DOI 10.1016/0006-291X(84)90560-6; DEYOUNG LR, 1993, ACCOUNTS CHEM RES, V26, P614, DOI 10.1021/ar00036a002; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; DOLGIKH DA, 1985, EUR BIOPHYS J BIOPHY, V13, P109, DOI 10.1007/BF00256531; ENGH RA, 1993, J MOL BIOL, V234, P1060, DOI 10.1006/jmbi.1993.1659; FRANGIONE B, 1991, AMYLOID AND AMYLOIDOSIS 1990, P351; GHELIS C, 1982, PROTEIN FOLDING, P289; GHISO J, 1986, P NATL ACAD SCI USA, V83, P2974, DOI 10.1073/pnas.83.9.2974; Glatz C.E., 1992, STABILITY PROTEIN PH, P135; GLENNER GG, 1991, AMYLOID AND AMYLOIDOSIS 1990, P707; HALL A, 1995, J BIOL CHEM, V270, P5115, DOI 10.1074/jbc.270.10.5115; HONIG B, 1995, ADV PROTEIN CHEM, V46, P27, DOI 10.1016/S0065-3233(08)60331-9; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; JENSSON O, 1987, ACTA NEUROL SCAND, V76, P102, DOI 10.1111/j.1600-0404.1987.tb03553.x; JEPPSSON JO, 1979, CLIN CHEM, V25, P629; JOVIN TM, 1973, ANN NY ACAD SCI, V209, P477, DOI 10.1111/j.1749-6632.1973.tb47551.x; KAKEGAWA H, 1993, FEBS LETT, V321, P247, DOI 10.1016/0014-5793(93)80118-E; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LEHRMAN SR, 1991, BIOCHEMISTRY-US, V30, P5777, DOI 10.1021/bi00237a021; MCCUTCHEN SL, 1993, BIOCHEMISTRY-US, V32, P12119, DOI 10.1021/bi00096a024; MITRAKI A, 1987, EUR J BIOCHEM, V163, P29, DOI 10.1111/j.1432-1033.1987.tb10732.x; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; PACULA AA, 1989, ANNU REV GENET, V23, P289; PALSDOTTIR A, 1988, LANCET, V2, P603; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; STONE MJ, 1990, BLOOD, V75, P531; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; WETZEL R, 1992, STABILITY PROTEIN PH, P43; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WRIGHT LL, 1994, BIOPHYS J, V66, pA181; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P13	52	110	111	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1314	1321		10.1074/jbc.271.3.1314	http://dx.doi.org/10.1074/jbc.271.3.1314			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576118	hybrid			2022-12-25	WOS:A1996TQ52500014
J	ORegan, NE; Branch, P; Macpherson, P; Karran, P				ORegan, NE; Branch, P; Macpherson, P; Karran, P			hMSH2-independent DNA mismatch recognition by human proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-PAIR MISMATCHES; ESCHERICHIA-COLI; REPAIR SYNTHESIS; BINDING-PROTEIN; EXTRACTS; CELLS; SPECIFICITY	Two distinct mismatch binding activities are detected using bandshift assays with human cell extracts and DNA with mispairs at defined positions. One requires hMSH2 protein and is absent from extracts of LoVo cells, which contain a partial deletion of the hMSH2 gene. The second activity is independent of hMSH2 and is present at normal levels in LoVo and three other cell lines, which are defective in in vitro hMSH2-dependent binding. The two mismatch recognition activities are distinguished by their sensitivity to polycations and can be resolved by chromatography on MonoQ. hMSH2-independent activity has been purified extensively from wild-type cells and from a cell line deficient in hMSH2-dependent binding. The purified material preferentially recognizes A . C, some pyrimidine pyrimidine mismatches, and certain slipped mispaired structures. Binding exhibits some sequence preferences. The similar properties of the two mismatch binding activities suggest that they both contribute to mismatch repair.	IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND									AQUILINA G, 1994, P NATL ACAD SCI USA, V91, P8905, DOI 10.1073/pnas.91.19.8905; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BRANCH P, 1995, CANCER RES, V55, P2304; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BROWN TC, 1988, CELL, V54, P705, DOI 10.1016/S0092-8674(88)80015-1; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FEUERSTEIN BG, 1989, NUCLEIC ACIDS RES, V17, P6883, DOI 10.1093/nar/17.17.6883; FUJII H, 1989, J BIOL CHEM, V264, P10057; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; JIRICNY J, 1988, P NATL ACAD SCI USA, V85, P8860, DOI 10.1073/pnas.85.23.8860; KARRAN P, 1993, J BIOL CHEM, V268, P15878; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; REENAN RAG, 1992, GENETICS, V132, P975; STEPHENSON C, 1989, J BIOL CHEM, V264, P21177; UMAR A, 1994, J BIOL CHEM, V269, P14367; VARLET I, 1990, P NATL ACAD SCI USA, V87, P7883, DOI 10.1073/pnas.87.20.7883; WEI TF, 1992, BIOCHEMISTRY-US, V31, P6166, DOI 10.1021/bi00141a029; WORTH L, 1994, P NATL ACAD SCI USA, V91, P3238, DOI 10.1073/pnas.91.8.3238; YAO M, 1994, J BIOL CHEM, V269, P16260; YEH YC, 1994, J BIOL CHEM, V269, P15498	32	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1789	1796		10.1074/jbc.271.3.1789	http://dx.doi.org/10.1074/jbc.271.3.1789			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576184	hybrid			2022-12-25	WOS:A1996TQ52500080
J	vanBiesen, T; Hawes, BE; Raymond, JR; Luttrell, LM; Koch, WJ; Lefkowitz, RJ				vanBiesen, T; Hawes, BE; Raymond, JR; Luttrell, LM; Koch, WJ; Lefkowitz, RJ			G(o)-protein alpha-subunits activate mitogen-activated protein kinase via a novel protein kinase C-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTORS; GO-PROTEIN; CELLS; INHIBITION; PATHWAY; INVOLVEMENT; P21(RAS); TURNOVER; CURRENTS; GRB2	Mitogen-activated protein kinase (MAPK) is activated in response to both receptor tyrosine kinases and G-protein-coupled receptors, Recently, G(i)-coupled receptors, such as the alpha(2A) adrenergic receptor, were shown to mediate Ras-dependent MAPK activation via a pathway requiring G-protein beta gamma subunits (G(beta gamma)) and many of the same intermediates involved in receptor tyrosine kinase signaling. In contrast, G(q)-coupled receptors, such as the M(1) muscarinic acetylcholine receptor (M(1)AChR), activate MAPK via a pathway that is Ras-independent but requires the activity of protein kinase C(PKC). Here we show that, in Chinese hamster ovary cells, the M(1)AChR and platelet-activating factor receptor (PAFR) mediate MAPK activation via the alpha-subunit of the G(o) protein. G(o)-mediated MAPK activation was sensitive to treatment with pertussis toxin but insensitive to inhibition by a G beta gamma-sequestering peptide (beta ARK1ct), M(1)AChR and PAFR catalyzed G(o) alpha-subunit GTP exchange, and MAPK activation could be partially rescued by a pertussis toxin-insensitive mutant of G(o alpha) but not by similar mutants of G(i). G(o)-mediated MAPK activation was insensitive to inhibition by a dominant negative mutant of Ras(N17Ras) but was completely blocked by cellular depletion of PKC. Thus, M(1)AChR and PAFR, which have previously been shown to couple to G(q), are also coupled to G(o) to activate a novel PKC-dependent mitogenic signaling pathway.	DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT SURG,DURHAM,NC 27710; VET ADM MED CTR,MED SERV,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030927] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline; NINDS NIH HHS [NS30927] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAMPBELL V, 1993, J PHYSIOL-LONDON, V470, P1; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HONDA Z, 1994, J BIOL CHEM, V269, P2307; HOWE LR, 1993, J BIOL CHEM, V268, P20717; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; KROLL SD, 1991, P NATL ACAD SCI USA, V88, P5182, DOI 10.1073/pnas.88.12.5182; KROLL SD, 1992, J BIOL CHEM, V267, P23183; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; MIGEON JC, 1994, J BIOL CHEM, V269, P29146; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; MULHERON JG, 1994, J BIOL CHEM, V269, P12954; MULLANEY I, 1993, BIOCHEM J, V289, P125, DOI 10.1042/bj2890125; OFFERMANS S, 1995, MOL PHARMACOL, V45, P890; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; RAYMOND JR, 1994, J BIOL CHEM, V269, P13073; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; SHUKLA SD, 1991, LIPIDS, V26, P1028, DOI 10.1007/BF02536496; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; SQUINTO SP, 1989, J NEUROSCI RES, V24, P558, DOI 10.1002/jnr.490240414; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; TAUSSIG R, 1992, NEURON, V8, P799, DOI 10.1016/0896-6273(92)90100-R; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WU DQ, 1992, J BIOL CHEM, V267, P1811; YUE TL, 1992, MOL PHARMACOL, V41, P281	36	192	193	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1266	1269		10.1074/jbc.271.3.1266	http://dx.doi.org/10.1074/jbc.271.3.1266			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576109	hybrid			2022-12-25	WOS:A1996TQ52500005
J	Sacchi, N; Schiaffonati, L; Magnani, I; Pappalardo, C; Hughes, AJ; Darfler, M; Hoogeveen, AT				Sacchi, N; Schiaffonati, L; Magnani, I; Pappalardo, C; Hughes, AJ; Darfler, M; Hoogeveen, AT			Detection and subcellular localization of an AML1 chimeric protein in the t(8;21) positive acute myeloid leukemia	ONCOGENE			English	Article						acute myeloid leukemia; translocation (8;21); AML1 gene; chimeric protein	FUSION TRANSCRIPT; NUCLEAR FACTOR; VIRUS ENHANCERS; DNA-BINDING; GENE; RUNT; TRANSLOCATION; IDENTIFICATION; DOMAIN; CORE	AML1, a gene encoding a protein of the PEBP2/CBF family of transcription factors is disrupted by translocations associated with human leukemia. In the t(8;21) acute myelogenous leukemia (AML), AML1 was found fused to a gene on chromosome 8 that we designated CDR (also known as ETO and MTG8). Immunoprecipitation experiments followed by immunoblotting using a combination of antibodies against different epitopes of one of the predicted chimeric proteins encoded by a fully characterized fusion transcript enabled us to visualize a chimeric protein in the t(8;21) Kasumi-1 cell line. The estimated size of this protein is 64 kDa, Immunoblotting of leukemic blasts containing the t(8;21) detected a protein of the same size, Immunofluorescence experiments indicate that the chimeric protein is localized in the nucleus. A normal AML1 protein of 27 kDa was also detected in t(8;21) Kasumi-1 cells, It remains to be established by which mechanism the mutant AML1 isoform may contribute to the leukemogenesis process of t(8;21)-positive acute myeloid leukemia.	UNIV MILAN, SCH MED, DEPT PATHOL, I-20133 MILAN, ITALY; LIFE TECHNOL INC, GAITHERSBURG, MD USA; ERASMUS UNIV ROTTERDAM, SCH MED, DEPT CLIN GENET, ROTTERDAM, NETHERLANDS	University of Milan; Thermo Fisher Scientific; Erasmus University Rotterdam	Sacchi, N (corresponding author), UNIV MILAN, SCH MED, DEPT BIOL & GENET, VIA VIOTTI 3-5, I-20133 MILAN, ITALY.							ASOU H, 1991, BLOOD, V77, P2031; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BORAL AL, 1989, J VIROL, V63, P76, DOI 10.1128/JVI.63.1.76-84.1989; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DEGREEF GE, 1995, LEUKEMIA, V9, P282; ERICKSON P, 1992, BLOOD, V80, P1825; HARLOW E, 1988, ANTIBODIES LABORATOR; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1993, BLOOD, V81, P2728; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; OHKI M, 1993, SEMIN CANCER BIOL, V4, P369; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; SACCHI N, 1994, GENE CHROMOSOME CANC, V11, P226, DOI 10.1002/gcc.2870110405; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; THORNELL A, 1988, MOL CELL BIOL, V8, P1625, DOI 10.1128/MCB.8.4.1625; TIGHE JE, 1994, BLOOD, V84, P2115, DOI 10.1182/blood.V84.7.2115.bloodjournal8472115; VANDELOCHT LTF, 1994, LEUKEMIA, V8, P1780; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89	35	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					437	444						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570222				2022-12-25	WOS:A1996TR53800024
J	Savatier, P; Lapillonne, H; vanGrunsven, LA; Rudkin, B; Samarut, J				Savatier, P; Lapillonne, H; vanGrunsven, LA; Rudkin, B; Samarut, J			Withdrawal of differentiation inhibitory activity leukemia inhibitory factor up-regulates D-type cyclins and cyclin-dependent kinase inhibitors in mouse embryonic stem cells	ONCOGENE			English	Article						mouse embryonic stem cells; mouse embryo; cell cycle; G1-cyclins; cyclin-dependent kinase inhibitors; gastrulation; DIA/LIF	AUTORADIOGRAPHIC ANALYSIS; MESODERM FORMATION; DIFFERENT REGIONS; GENE-EXPRESSION; CARCINOMA-CELLS; RETINOIC ACID; T-GENE; FIBROBLASTS; PROTEIN; G(1)	The expression of E and D-type cyclins, Cyclin-Dependent Kinase (CDK) 2 and 4, as web as CDK inhibitors p21(Cip1) and p27(Kip1) were examined during in vitro differentiation of mouse embryonic stem (ES) cells. ES cells cultured in presence of Differentiation Inhibitory Activity/Leukemia Inhibitory Factor (DIA/LIF) express very low levels of cylin E/CDK2 complexes, p21(Cip1) and p27(Kip1) CDK inhibitors, while cylin D/CDK4-associated kinase activity is undetectable. Withdrawal of DIA/LIF, which induces differentiation, results in the progressive up-regulation of all. Up-regulation of D cyclins occurs through an increase in the steady-state levels of mRNA, concomitantly with the activation of Brachyury and Goosecoid, two early markers of mesoderm differentiation. Similarly, cells from the epiblast of the early postimplantation mouse embryo do not express any cyclin D/CDK4 complexes, These are progressively up-regulated at gastrulation and early organogenesis, DIA/LIF-stimulated ES cells are not growth-arrested by overexpression of p16(Ink4a), a specific inhibitor of CDK4 and CDK6. We propose that the G1/S transition may be regulated by a minimal mechanism in mouse embryonic stem cells. Induction of differentiation triggers the establishment of a more sophisticated mechanism involving both cyclin D/CDK4- and CDK inhibitor-associated control of G1-phase progression.			Savatier, P (corresponding author), ECOLE NORMALE SUPER LYON,LA INRA,UMR 49 CNRS,LAB BIOL MOLEC & CELLULAIRE,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE.		Samarut, Jacques/AAD-2587-2019; van Grunsven, Leo/E-5839-2010; SAVATIER, Pierre/J-4663-2014	van Grunsven, Leo/0000-0002-0990-7034; RUDKIN, Brian B./0000-0003-3700-1982				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; ANDO K, 1995, ONCOGENE, V10, P751; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BEDDINGTON RSP, 1981, J EMBRYOL EXP MORPH, V64, P87; BEDDINGTON RSP, 1982, J EMBRYOL EXP MORPH, V69, P265; BEDDINGTON RSP, 1983, J EMBRYOL EXP MORPH, V75, P189; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAMJANOV I, 1971, ROUX ARCH DEV BIOL, V167, P288; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DIWAN SB, 1976, J NATL CANCER I, V57, P937, DOI 10.1093/jnci/57.4.937; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS M, 1981, J REPROD FERTIL, V62, P625; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; HERRMANN BG, 1990, NATURE, V343, P617, DOI 10.1038/343617a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; ILES SA, 1977, J EMBRYOL EXP MORPH, V38, P63; JIANG W, 1993, ONCOGENE, V8, P3447; JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KLEINSMITH LJ, 1964, CANCER RES, V24, P1544; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KRANENBURG O, 1995, ONCOGENE, V10, P87; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1994, ONCOGENE, V9, P2159; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LUKAS J, 1995, MOL CELL BIOL, V15, P2660; MARTIN GR, 1980, SCIENCE, V209, P676; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCAULEY A, 1993, DEVELOPMENT, V117, P873; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MUMMERY CL, 1987, DEV BIOL, V121, P10, DOI 10.1016/0012-1606(87)90133-3; NICHOLS J, 1990, DEVELOPMENT, V110, P1341; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PALMERO I, 1993, ONCOGENE, V8, P1049; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3462; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROBERTSON EJ, 1986, EXPT APPROACHES MAMM, P475; ROGERS MB, 1991, DEVELOPMENT, V113, P815; ROSS ME, 1994, J NEUROSCI, V14, P6384; SAVATIER P, 1994, ONCOGENE, V9, P809; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; SOLTER D, 1980, INT J CANCER, V25, P341, DOI 10.1002/ijc.2910250306; SOLTER D, 1973, EXPERIENTIA, V29, P701, DOI 10.1007/BF01944785; TAM SW, 1994, ONCOGENE, V9, P2663; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	81	221	232	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					309	322						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570208				2022-12-25	WOS:A1996TR53800010
J	Ng, KKS; Drickamer, K; Weis, WI				Ng, KKS; Drickamer, K; Weis, WI			Structural analysis of monosaccharide recognition by rat liver mannose-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-RECOGNITION; CRYSTAL-STRUCTURES; HEPATIC LECTINS; CELL-ADHESION; P-SELECTIN; OLIGOSACCHARIDE; MANNAN; LIGAND; DOMAIN; COMPLEMENT	The structural basis of carbohydrate recognition by rat liver mannose-binding protein (MBP-C) has been explored by determining the three-dimensional structure of the C-type carbohydrate-recognition domain (CRD) of MBP-C using x-ray crystallography. The structure was solved by molecular replacement using rat serum mannose-binding protein (MBP-A) as a search model and was refined to maximum Bragg spacings of 1.7 Angstrom. Despite their almost identical folds, the dimeric structures formed by the two MBP CRDs differ dramatically. Complexes of MBP-C with methyl glycosides of mannose, N-acetylglucosamine, and fucose were prepared by soaking MBP-C crystals in solutions containing these sugars. Surprisingly, the pyranose ring of mannose is rotated 180 degrees relative to the orientation observed previously in MBP-A, but the local interactions between sugar and protein are preserved, For each of the bound sugars, vicinal, equatorial hydroxyl groups equivalent to the 3- and 4-OH groups of mannose directly coordinate Ca2+ and form hydrogen bonds with residues also serving as Ca2+ ligands, Few interactions are observed between other parts of the sugar and the protein. A complex formed between free galactose and MBP-C reveals a similar mode of binding, with the anomeric hydroxyl group serving as one of the Ca2+ ligands, A second binding site for mannose has also been observed in one of two copies in the asymmetric unit at a sugar concentration of 1.3 M. These structures explain how MBPs recognize a wide range of monosaccharides and suggest how fine specificity differences between MBP A and MBP-C may be achieved.	STANFORD UNIV, SCH MED, DEPT BIOL STRUCT, STANFORD, CA 94305 USA; COLUMBIA UNIV, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA	Stanford University; Columbia University			Weis, William I/G-1437-2011	Weis, William I/0000-0002-5583-6150; Ng, Kenneth K.S./0000-0001-7280-8445	NIGMS NIH HHS [GM50565, GM42628] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042628, R01GM050565] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGYAL SJ, 1972, AUST J CHEM, V25, P1695, DOI 10.1071/CH9721695; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; COOK WJ, 1977, METAL LIGAND INTER 2, P257; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DRICKAMER K, 1992, NATURE, V360, P183, DOI 10.1038/360183a0; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOLLENBAUGH D, 1993, BIOCHEMISTRY-US, V32, P2960, DOI 10.1021/bi00063a006; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; IKEDA K, 1987, J BIOL CHEM, V262, P7451; IOBST ST, 1994, J BIOL CHEM, V269, P15512; IOBST ST, 1994, J BIOL CHEM, V269, P15505; JEFFERY GA, 1991, HYDROGEN BONDING BIO; JOHNSON LN, 1988, CURR TOP MICROBIOL, V139, P81; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLYNE W, 1960, EXPERIENTIA, V16, P521, DOI 10.1007/BF02158433; KOGAN TP, 1995, J BIOL CHEM, V270, P14047, DOI 10.1074/jbc.270.23.14047; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LEE RT, 1991, J BIOL CHEM, V266, P4810; LEE RT, 1988, BIOCHEM BIOPH RES CO, V155, P1444, DOI 10.1016/S0006-291X(88)81303-2; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MIZUNO Y, 1981, J BIOL CHEM, V256, P4247; MORI K, 1988, ARCH BIOCHEM BIOPHYS, V264, P647, DOI 10.1016/0003-9861(88)90331-1; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; QUIOCHO FA, 1986, ANNU REV BIOCHEM, V55, P287, DOI 10.1146/annurev.bi.55.070186.001443; RAMKUMAR R, 1995, BIOCHEM J, V308, P237, DOI 10.1042/bj3080237; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; ROSE IA, 1980, P NATL ACAD SCI-BIOL, V77, P2439, DOI 10.1073/pnas.77.5.2439; SHERIFF S, 1994, NAT STRUCT BIOL, V1, P789, DOI 10.1038/nsb1194-789; SUPER M, 1990, CLIN EXP IMMUNOL, V79, P144; TSE YC, 1977, J AM CHEM SOC, V99, P611, DOI 10.1021/ja00444a051; WEIS WI, 1991, J BIOL CHEM, V266, P20678; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WEIS WI, 1994, STRUCTURE, V2, P1227, DOI 10.1016/S0969-2126(94)00124-3; 1994, CCP4 SUITE PROGRAMS	49	147	150	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					663	674		10.1074/jbc.271.2.663	http://dx.doi.org/10.1074/jbc.271.2.663			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557671	hybrid			2022-12-25	WOS:A1996TP88900014
J	Sato, S; Ward, CL; Krouse, ME; Wine, JJ; Kopito, RR				Sato, S; Ward, CL; Krouse, ME; Wine, JJ; Kopito, RR			Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETICS; CFTR	The common Delta F508 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) interferes with the biosynthetic folding of nascent CFTR polypeptides, leading to their retention and rapid degradation in an intracellular compartment proximal to the Gels apparatus, Neither the pathway by which wild-type CFTR folds nor the mechanism by which the Phe(508) deletion interferes with this process is well understood, We have investigated the effect of glycerol, a polyhydric alcohol known to stabilize protein conformation, on the folding of CFTR and Delta F508 in vivo. Incubation of transient and stable Delta F508 tranfectants with 10% glycerol induced a significant accumulation of Delta F508 protein bearing complex N-linked oligosaccharides, indicative of their transit to a compartment distal to the endoplasmic reticulum (ER). This accumulation was accompanied by an increase in mean whole cell cAMP activated chloride conductance, suggesting that the glycerol-rescued Delta F508 polypeptides form functional plasma membrane CFTR channels, These effects were dose- and time-dependent and fully reversible, Glycerol treatment also stabilized immature (core-glycosylated) Delta F508 and CFTR molecules that are normally degraded rapidly. These effects of glycerol were not due to a general disruption of ER quality control processes but appeared to correlate with the degree of temperature sensitivity of specific CFTR mutations, These data suggest a model in which glycerol serves to stabilize an otherwise unstable intermediate in CFTR biosynthesis, maintaining it in a conformation that is competent for folding and subsequent release from the ER quality control apparatus.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305; STANFORD UNIV,DEPT PSYCHOL,CYST FIBROSIS RES LAB,STANFORD,CA 94305	Stanford University; Stanford University					NIDDK NIH HHS [DK43994] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043994] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1995, AM J PHYSIOL-LUNG C, V268, pL615, DOI 10.1152/ajplung.1995.268.4.L615; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; FUKUDA M, 1988, J BIOL CHEM, V263, P5314; GEKKO K, 1981, BIOCHEMISTRY-US, V20, P4667, DOI 10.1021/bi00519a023; GUNDERSON KL, 1995, CELL, V82, P231, DOI 10.1016/0092-8674(95)90310-0; HAWTHORNE DC, 1964, GENETICS, V50, P829; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; KEREM BS, 1990, P NATL ACAD SCI USA, V87, P8447, DOI 10.1073/pnas.87.21.8447; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MA TH, 1994, J BIOL CHEM, V269, P21845; MARSHALL J, 1994, J BIOL CHEM, V269, P2978; RESTREPO D, 1989, AM J PHYSIOL, V257, pC520, DOI 10.1152/ajpcell.1989.257.3.C520; RUSSELL RRB, 1972, J BACTERIOL, V112, P661, DOI 10.1128/JB.112.2.661-665.1972; SAWANO H, 1992, FEBS LETT, V303, P11, DOI 10.1016/0014-5793(92)80466-T; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; TSUI LC, 1992, TRENDS GENET, V8, P392, DOI 10.1016/0168-9525(92)90301-J; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	22	448	465	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					635	638		10.1074/jbc.271.2.635	http://dx.doi.org/10.1074/jbc.271.2.635			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557666	hybrid			2022-12-25	WOS:A1996TP88900009
J	Saunders, C; Keefer, JR; Kennedy, AP; Wells, JN; Limbird, LE				Saunders, C; Keefer, JR; Kennedy, AP; Wells, JN; Limbird, LE			Receptors coupled to pertussis toxin-sensitive G-proteins traffic to opposite surfaces in Madin-Darby canine kidney cells - A(1) adenosine receptors achieve apical and alpha(2A) adrenergic receptors achieve basolateral localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTAGENESIS; EXPRESSION; CLONING; GENE	The alpha(2A) adrenergic receptor (alpha(2A)AR) previously was shown to be directly delivered to and retained on the lateral subdomain of renal epithelial cells. The present studies demonstrate that, in contrast, wild-type and epitope-tagged canine A(1) adenosine receptors (A(1)AdoR) are apically enriched (65-83%) in Madin-Darby canine kidney (MDCKII) and porcine renal epithelial (LLC-PKI) cells, based on surface biotinylation strategies detecting photoaffinity-labeled A(1)AdoR. Confocal micros copy corroborated the apical enrichment of the epitope-tagged A(1)AdoR. Metabolic labeling studies revealed that this steady-state polarization is achieved by direct delivery to both the apical (60-75%) and basolateral surface. Growth of A(1)AdoR-expressing cells as monolayers was achieved only following Transwell culture in the presence of A(1)AdoR antagonists, which decreased cell growth, suggesting that A(1)AdoR elicit MDCKII cell proliferation. The preferential apical but detectable basolateral localization of A(1)AdoR provides a molecular understanding of published reports that functional responses can be elicited following apical as well as basolateral delivery of adenosine agonists in varying renal preparations. These findings also suggest that receptor chimeras derived from the G(i)/G(o)-protein-coupled alpha(2A)AR and A(1)AdoR will be informative in revealing structural features critical for basolateral versus apical targeting.	VANDERBILT UNIV,MED CTR,DEPT PHARMACOL,NASHVILLE,TN 37209	Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021220] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43879] Funding Source: Medline; NIGMS NIH HHS [GM 21220-18] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; BARFUSS DW, 1992, KIDNEY INT, V41, P1143, DOI 10.1038/ki.1992.174; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; DALY JW, 1985, J MED CHEM, V28, P487, DOI 10.1021/jm00382a018; DEMPSEY PJ, 1994, J BIOL CHEM, V269, P16878; EDWARDS RM, 1994, AM J PHYSIOL, V266, pF791, DOI 10.1152/ajprenal.1994.266.5.F791; FISH EM, 1994, NEW ENGL J MED, V330, P1580; FRANCO M, 1989, AM J PHYSIOL, V257, pF231, DOI 10.1152/ajprenal.1989.257.2.F231; GUYER CA, 1990, J BIOL CHEM, V265, P17307; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KEEFER JR, 1995, FASEB J, V9, pA1405; LEVIER DG, 1992, AM J PHYSIOL, V263, pC729, DOI 10.1152/ajpcell.1992.263.4.C729; LINDEN J, 1991, FASEB J, V5, P2668, DOI 10.1096/fasebj.5.12.1916091; MEININGER CJ, 1990, AM J PHYSIOL, V258, pH198, DOI 10.1152/ajpheart.1990.258.1.H198; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; OJAKIAN GK, 1988, J CELL BIOL, V107, P2377, DOI 10.1083/jcb.107.6.2377; OLAH ME, 1992, J BIOL CHEM, V267, P10764; PRATT AD, 1986, AM J PHYSIOL, V251, pC167, DOI 10.1152/ajpcell.1986.251.2.C167; ROZENGURT E, 1982, EXP CELL RES, V139, P71, DOI 10.1016/0014-4827(82)90319-6; STUTTS MJ, 1995, AM J PHYSIOL-CELL PH, V268, pC425, DOI 10.1152/ajpcell.1995.268.2.C425; TUCKER AL, 1992, FEBS LETT, V297, P107, DOI 10.1016/0014-5793(92)80338-H; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YAGIL C, 1994, PFLUG ARCH EUR J PHY, V427, P225, DOI 10.1007/BF00374528; ZOLLER MJ, 1983, METHOD ENZYMOL, V100, P468	25	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					995	1002		10.1074/jbc.271.2.995	http://dx.doi.org/10.1074/jbc.271.2.995			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557716	hybrid			2022-12-25	WOS:A1996TP88900059
J	Cooper, HM; Armes, P; Britto, J; Gad, J; Wilks, AF				Cooper, HM; Armes, P; Britto, J; Gad, J; Wilks, AF			Cloning of the mouse homologue of the deleted in colorectal cancer gene (mDCC) and its expression in the developing mouse embryo	ONCOGENE			English	Article						DCC; tumorigenesis; sequence; embryogenesis; neural tube	TUMOR-SUPPRESSOR GENE; ADHESION MOLECULE NCAM; MESSENGER-RNA; FREQUENT LOSS; DCC; HETEROZYGOSITY; CARCINOMAS; GROWTH	Loss of DCC gene expression has now been demonstrated in a wide variety of metastatic cancers. Here we present the nucleotide sequence and predicted amino acid sequence of mouse DCC, Mouse and human DCC share 96% identity at the amino acid level, Analysis of DCC mRNA expression throughout the mid to late stages of gestation in the mouse, demonstrated that DCC mRNA is expressed at significantly higher levels in the developing mouse embryo than in any adult tissue, In addition, we show that an embryo-specific, alternatively spliced, form of DCC is expressed in day 9.5 through day 18.5 embryos. The expression of both alternatively spliced forms of DCC is developmentally regulated such that the embryonic form of DCC predominates in day 9.5 and 10.5 embryos. In the later stage embryos the expression of this alternatively spliced form of DCC is down-regulated with respect to that of the adult form, Whole-mount in situ hybridization of day 11.5 mouse embryos revealed that DCC mRNA is expressed at high levels in the developing brain and the neural tube, However, no DCC mRNA could be detected in any other embryonic tissue at this stage of development, These observations suggest that during embryogenesis DCC may play a pivotal role in the development of the central nervous system.	ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,MELBOURNE,VIC 3050,AUSTRALIA	Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Cooper, HM (corresponding author), LUDWIG INST CANC RES,MELBOURNE TUMOUR BIOL BRANCH,MELBOURNE,VIC 3050,AUSTRALIA.		Wilks, Andrew F/R-5542-2019; Cooper, Helen/G-3505-2010; COOPER, HOWARD/M-7304-2014; Cooper, Helen M/AAA-2182-2019	Cooper, Helen M/0000-0001-9838-5743; Wilks, Andrew F/0000-0002-8554-2399				Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BIXBY JL, 1991, ANNU REV CELL BIOL, V7, P117, DOI 10.1146/annurev.cellbio.7.1.117; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; CHOWCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; CHUONG CM, 1994, DEV BIOL, V164, P383, DOI 10.1006/dbio.1994.1208; CONLON RA, 1992, DEVELOPMENT, V116, P357; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DEVILEE P, 1991, ONCOGENE, V6, P311; DOHERTY P, 1992, NATURE, V356, P791, DOI 10.1038/356791a0; ENOMOTO T, 1995, BRIT J CANCER, V71, P462, DOI 10.1038/bjc.1995.94; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GAO X, 1993, CANCER RES, V53, P2723; GIMA T, 1994, INT J CANCER, V57, P480, DOI 10.1002/ijc.2910570407; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HOHNE MW, 1992, CANCER RES, V52, P2616; HUANG Y, 1992, CANCER RES, V52, P6525; IONO H, 1994, CANCER, V73, P1324; ITOH F, 1993, INT J CANCER, V53, P260, DOI 10.1002/ijc.2910530215; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLOR KG, 1992, CELL GROWTH DIFFER, V3, P609; MIRAGALL F, 1988, DEV BIOL, V129, P516, DOI 10.1016/0012-1606(88)90397-1; MIYAKE K, 1993, BLOOD, V82, P927; MIYAKE S, 1994, CANCER RES, V54, P3007; OELERICHS RB, 1993, ONCOGENE, V8, P11; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; PIERCEALL WE, 1994, DEV BIOL, V166, P654, DOI 10.1006/dbio.1994.1345; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; PORFIRI E, 1993, BLOOD, V81, P2696; REALE MA, 1994, CANCER RES, V54, P4493; RUGH R, 1991, MOUSE ITS REPRODUCTI; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECK AC, 1993, CANCER RES, V53, P5605; UCHINO S, 1992, CANCER RES, V52, P3099; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; ZORN AM, 1992, DEV BIOL, V149, P197, DOI 10.1016/0012-1606(92)90276-M	42	53	55	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2243	2254						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570174				2022-12-25	WOS:A1995TK70200007
J	Robert, F; Forget, D; Li, J; Greenblatt, J; Coulombe, B				Robert, F; Forget, D; Li, J; Greenblatt, J; Coulombe, B			Localization of subunits of transcription factors IIE and IIF immediately upstream of the transcriptional initiation site of the adenovirus major late promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; FACTOR TFIIE; MINIMAL SET; IDENTIFICATION; PURIFICATION; BINDING; SUFFICIENT; PROTEINS; DOMAINS; COMPLEX	The assembly of a preinitiation complex containing RNA polymerase II on promoter DNA is a complex process that involves several general transcription factors. Using 5-[N-(p-azidobenzoyl)-3-aminoallyl] photocross-linking, we previously determined the locations of the two large subunits of transcription factor (TF) IIA (A35 and A21), TATA box-binding protein (TBP), RNA polymerase II-associated protein (RAP) 30, and TFIIB along the Ad2 ML promoter. We have now localized TFIIE34 and RAP74 just upstream of the transcription start site. The two sub-units of TFIIF, RAP74 and RAP30, cross-linked to nucleotides that probed adjacent spaces on the same face of the DNA helix beginning just downstream of TBP at -19 and extending to -5. Specific photocross-linking of TFIIE34 required the presence TFIIE56. In addition, TFIIE and RAP74 strongly stimulated cross-linking of RAP30 and the large subunits of RNA polymerase II to position -19. Our topological data support the idea that RAP74 and TFIIE34 may be involved in melting of the promoter DNA upstream of the initiation site.	UNIV SHERBROOKE,FAC SCI,DEPT BIOL,SHERBROOKE,PQ J1K 2R1,CANADA; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L6,CANADA	University of Sherbrooke; University of Toronto			Robert, Francois/D-2316-2012					BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; Coulombe Benoit, 1992, Gene Expression, V2, P99; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GERARD M, 1991, J BIOL CHEM, V266, P20940; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; GREENBLATT J, 1991, CELL, V66, P1067, DOI 10.1016/0092-8674(91)90027-V; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HISATAKE K, 1993, NATURE, V363, P744, DOI 10.1038/363744a0; HODO HG, 1977, BIOCHEMISTRY-US, V16, P1334; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MCCRACKEN S, 1991, SCIENCE, V253, P900, DOI 10.1126/science.1652156; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P9163, DOI 10.1073/pnas.87.23.9163; OHKUMA Y, 1991, NATURE, V354, P398, DOI 10.1038/354398a0; PAN GH, 1994, J BIOL CHEM, V269, P30101; PARVIN JD, 1994, J BIOL CHEM, V269, P18414; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PETERSON MG, 1991, NATURE, V354, P369; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; SUMIMOTO H, 1991, NATURE, V354, P401, DOI 10.1038/354401a0; TIMMERS HTM, 1994, EMBO J, V13, P391, DOI 10.1002/j.1460-2075.1994.tb06273.x; TYREE CM, 1993, GENE DEV, V7, P1254, DOI 10.1101/gad.7.7a.1254; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WANG BQ, 1995, J BIOL CHEM, V270, P27035, DOI 10.1074/jbc.270.45.27035; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	36	58	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8517	8520		10.1074/jbc.271.15.8517	http://dx.doi.org/10.1074/jbc.271.15.8517			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621472	hybrid			2022-12-25	WOS:A1996UE73000003
J	Pelta, J; Livolant, F; Sikorav, JL				Pelta, J; Livolant, F; Sikorav, JL			DNA aggregation induced by polyamines and cobalthexamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONDENSED DNA; SPERMINE; PRECIPITATION; ORGANIZATION; LICL	We have studied the precipitation of short DNA molecules by the polycations spermidine, spermine, and cobalthexamine. The addition of these cations to a DNA solution leads first to the precipitation of the DNA; further addition resolubilizes the DNA pellet. The multivalent salt concentration required for resolubilization is essentially independent of the DNA concentration (between 1 mu g/ml and 1 mg/ml) and of the monovalent cation concentration present in the DNA solution (up to 100 mM). The DNA aggregates are anisotropic; those obtained in the presence of the polyamines spermidine and spermine generally contain a cholesteric liquid crystalline phase that flows spontaneously. In contrast this phase is never seen in the presence of cobalthexamine. We propose that the ability of polyamines to condense DNA in fluid structures is an essential feature of their biological functions.	CEA SACLAY, SERV BIOCHIM & GENET MOLEC, DEPT BIOL CELLULAIRE & MOLEC, F-91191 GIF SUR YVETTE, FRANCE; UNIV PARIS 11, PHYS SOLIDES LAB, F-91405 ORSAY, FRANCE	CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay				Sikorav, Jean-Louis/0000-0002-4453-4800; Pelta, Juan/0000-0002-1896-4137				BAEZA I, 1991, ORIGINS LIFE EVOL B, V21, P225; BLOOMFIELD VA, 1994, ACS SYM SER, V548, P195; BLOOMFIELD VA, 1980, BIOPHYS CHEM, V11, P339, DOI 10.1016/0301-4622(80)87006-2; BOROCHOV N, 1984, BIOPOLYMERS, V23, P1757, DOI 10.1002/bip.360230910; BOULIGAND Y, 1984, J PHYS-PARIS, V45, P1899, DOI 10.1051/jphys:0198400450120189900; Bungenberg de Jong H.G., 1949, COLLOID SCI, VII; Cohen S.S., 1971, INTRO POLYAMINES; DAMASCHUN G, 1986, STUD BIOPHYS, V112, P127; DELACRUZ MO, 1995, J CHEM PHYS, V103, P5781, DOI 10.1063/1.470459; DELSANTI M, 1994, ACS SYM SER, V548, P381; EDSALL JT, 1958, BIOPHYS CHEM, V1, P263; GOSULE LC, 1978, J MOL BIOL, V121, P311, DOI 10.1016/0022-2836(78)90366-2; HEBY O, 1971, H-S Z PHYSIOL CHEM, V352, P29, DOI 10.1515/bchm2.1971.352.1.29; HOOPES BC, 1981, NUCLEIC ACIDS RES, V9, P5493, DOI 10.1093/nar/9.20.5493; KRASNOW MA, 1982, J BIOL CHEM, V257, P2687; LEFORESTIER A, 1993, BIOPHYS J, V65, P56, DOI 10.1016/S0006-3495(93)81063-4; MA CL, 1994, BIOPHYS J, V67, P1678, DOI 10.1016/S0006-3495(94)80641-1; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MURPHY LD, 1994, BBA-GENE STRUCT EXPR, V1219, P277, DOI 10.1016/0167-4781(94)90049-3; OOSAWA F, 1971, POLYELECTROLYTES, P123; OPARIN A. I., 1965, ADVANCE ENZYMOL, V27, P347; OSLAND A, 1977, NUCLEIC ACIDS RES, V4, P685, DOI 10.1093/nar/4.3.685; RAU DC, 1992, BIOPHYS J, V61, P246, DOI 10.1016/S0006-3495(92)81831-3; RAZIN S, 1959, ARCH BIOCHEM BIOPHYS, V81, P36, DOI 10.1016/0003-9861(59)90173-0; SCHELLMAN JA, 1984, J MOL BIOL, V175, P313, DOI 10.1016/0022-2836(84)90351-6; SCHMID N, 1991, BIOCHEMISTRY-US, V30, P4357, DOI 10.1021/bi00231a035; SHAPIRO JT, 1969, BIOCHEMISTRY-US, V8, P3219, DOI 10.1021/bi00836a014; SIKORAV JL, 1994, BIOPHYS J, V67, P1387, DOI 10.1016/S0006-3495(94)80640-X; SPENCER M, 1962, NATURE, V194, P1014, DOI 10.1038/1941014a0; SUBIRANA JA, 1981, BIOPOLYMERS, V20, P2281, DOI 10.1002/bip.1981.360201019; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TIMSIT Y, 1991, J MOL BIOL, V221, P919, DOI 10.1016/0022-2836(91)80184-V; TIMSIT Y, 1991, THESIS U L PASTEUR S; WEIS A, 1970, BIOL POLYELECTROLYTE, P211; WEMMER DE, 1985, J MOL BIOL, V185, P457, DOI 10.1016/0022-2836(85)90418-8; WIDOM J, 1980, J MOL BIOL, V144, P431, DOI 10.1016/0022-2836(80)90330-7; WILSON RW, 1979, BIOCHEMISTRY-US, V18, P2192, DOI 10.1021/bi00578a009; WOLF B, 1977, BIOCHEMISTRY-US, V16, P3655, DOI 10.1021/bi00635a023; ZIMMERMAN SB, 1993, BIOCHIM BIOPHYS ACTA, V1216, P175, DOI 10.1016/0167-4781(93)90142-Z	39	302	306	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5656	5662		10.1074/jbc.271.10.5656	http://dx.doi.org/10.1074/jbc.271.10.5656			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621429	hybrid			2022-12-25	WOS:A1996TZ28600055
J	HermidaMatsumoto, ML; Chock, PB; Curran, T; Yang, DCH				HermidaMatsumoto, ML; Chock, PB; Curran, T; Yang, DCH			Ubiquitinylation of transcription factors c-Jun and c-Fos using reconstituted ubiquitinylating enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PURIFICATION; PROTOONCOGENES FOS; PROTEIN LIGASE; SYSTEM; DEGRADATION; EXPRESSION; RESOLUTION; PROTEASOME; COMPONENTS; INVIVO	Recombinant c-Jun and c-Fos were ubiquitinylated by the ubiquitin carrier enzymes E2(14K), E2(20K), or E2(32K) in the presence of the ubiquitin-activating enzyme, E1. Addition of ubiquitin protein ligase E3 substantially enhanced the E2(14K)-mediated ubiquitinylation of c-Jun and c-Fos, Truncated c-Jun and c-Fos mutant proteins including wbJun and wbFos were also ubiquitinylated under the same conditions, suggesting the sites of ubiquitinylation are located within the dimerization and DNA binding domains of c-Jun and c-Fos. The E3-dependent ubiquitinylation of c-Jun was inhibited upon the heterodimerization of c-Jun with c-Fos. Further addition of E2(20K) significantly enhanced ubiquitinylation of c-Jun in the heterodimer suggesting a regulatory role of E2(20K). Polyubiquitinylated c-Jun, wbFos, and wbJun, but not E2(20K)-ubiquitinylated c-Jun, were readily degraded by the ATP-dependent 26 S multicatalytic proteases. These results suggest that the temporal control of c-Jun and c-Fos may be regulated through the ubiquitinylation pathways, and the ubiquitinylation of c-Jun and c-Fos may in turn be regulated in response to the heterodimerization between them and the cooperation between E2(20K) and E3 mediated polyubiquitinylation.	GEORGETOWN UNIV, DEPT CHEM, WASHINGTON, DC 20057 USA; NHLBI, NIH, BIOCHEM LAB, BETHESDA, MD 20892 USA; ST JUDE CHILDRENS RES HOSP, DEPT DEV NEUROBIOL, MEMPHIS, TN 38105 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); St Jude Children's Research Hospital			Curran, Tom/C-1164-2008; Yang, David/A-7294-2009; Curran, Tom/F-5234-2018; Curran, Thomas/AAE-7631-2019; Curran, Tom/D-7515-2011	Curran, Tom/0000-0003-1444-7551; Curran, Tom/0000-0003-1444-7551; Curran, Thomas/0000-0003-1444-7551; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025848] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-25848] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; COOK J, 1988, BIOFACTORS, V1, P113; CURRAN T, 1984, CELL, V36, P259; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HERMIDARODRIGUE.L, 1993, THESIS GEORGETOWN U; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; ISHIDA N, 1993, FEBS LETT, V324, P345, DOI 10.1016/0014-5793(93)80148-N; JABBEN M, 1989, J BIOL CHEM, V264, P4998; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; KANAYAMA HO, 1992, EUR J BIOCHEM, V206, P567, DOI 10.1111/j.1432-1033.1992.tb16961.x; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; PAPAVASSILIOU AG, 1992, SCIENCE, V258, P1941, DOI 10.1126/science.1470918; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RECHSTEINER M, 1988, UBIQUITIN, P346; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9	31	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4930	4936						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617766				2022-12-25	WOS:A1996TX69700056
J	Okabayashi, Y; Sugimoto, Y; Totty, NF; Hsuan, J; Kido, Y; Sakaguchi, K; Gout, I; Waterfield, MD; Kasuga, M				Okabayashi, Y; Sugimoto, Y; Totty, NF; Hsuan, J; Kido, Y; Sakaguchi, K; Gout, I; Waterfield, MD; Kasuga, M			Interaction of Shc with adaptor protein adaptins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE PROTEINS; SIGNAL TRANSDUCTION; TYROSINE KINASES; CYTOPLASMIC DOMAIN; INVITRO BINDING; RECEPTOR; CLATHRIN; ASSOCIATION; INTERNALIZATION; IDENTIFICATION	The role of Shc as a substrate of receptors for growth factors and cytokines is well established. To gain further insight into the function of Shc in signal transduction, we used an affinity method to identify potential Shc-binding proteins, Incubation of bovine brain lysates with a glutathione S-transferase (GST)-Shc fusion protein immobilized on glutathione-Sepharose beads resulted in the binding of cellular proteins of similar to 115, 110, and 100 kDa as well as those of 50 and 17 kDa. Amino acid sequencing of tryptic peptides revealed that the 100-kDa protein was almost identical to beta-adaptin and that the 110- and 115-kDa proteins were almost identical to alpha(A)-adaptin. Using immunoblot analysis, anti-alpha-adaptin antibody recognized several proteins of 100 similar to 115 kDa, and anti-beta-adaptin antibody recognized a 100-kDa protein, suggesting that alpha(A)-, alpha(C)-, and beta-adaptins are bound to the GST-Shc fusion protein. Immunoblot analysis with anti-alpha-adaptin antibody revealed that alpha-adaptin was coimmunoprecipitated with Shc from PC12, KB, and COS cell lysates, suggesting a specific interaction of Shc and adaptins in intact cells. A binding study using mutant GST-Shc fusion proteins revealed that the collagen homologous region (amino acids 233-377) of Shc was required for adaptin binding. Conversely, the collagen homologous region of Shc inhibited the binding of adaptins to GST-Shc. In addition, adaptin was able to bind mutant fusion proteins containing amino acids 233-369, 233-355, 346-369, and 346-355 of Shc, but failed to bind a mutant containing amino acids 233-345, suggesting that amino acids 346-355 (RDLFDMKPFE) in the collagen homologous region of Shc are required for adaptin binding. Thus, this study indicates the specific interaction of Shc with alpha- and beta-adaptin components of plasma membrane adaptor proteins that are thought to be involved in receptor endocytosis.	LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research	Okabayashi, Y (corresponding author), KOBE UNIV, SCH MED, DEPT INTERNAL MED 2, CHUO KU, KOBE 650, JAPAN.		Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564				BALL CL, 1995, J CELL SCI, V108, P2865; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HABIB T, 1994, J BIOL CHEM, V269, P25243; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; PANAYOTOU G, 1993, BIOESSAYS, V15, P171, DOI 10.1002/bies.950150305; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SEGATTO O, 1993, ONCOGENE, V8, P2105; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SOSA MA, 1993, J BIOL CHEM, V268, P12537; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553	47	73	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5265	5269						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617812				2022-12-25	WOS:A1996TX69700102
J	Chen, LY; Chen, DY; Miaw, J; Hu, NT				Chen, LY; Chen, DY; Miaw, J; Hu, NT			XpsD, an outer membrane protein required for protein secretion by Xanthomonas campestris pv campestris, forms a multimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI K12; NUCLEOTIDE-SEQUENCE; PSEUDOMONAS-AERUGINOSA; PULLULANASE SECRETION; FILAMENTOUS PHAGE; VIBRIO-CHOLERAE; ERWINIA-CHRYSANTHEMI; MOLECULAR-CLONING; TYPE-4 FIMBRIAE	XpsD is an outer membrane lipoprotein, required for the secretion of extracellular enzymes by Xanthomonas campestris pv. campestris. Our previous studies indicated that when the xpsD gene was interrupted by transposon Tn5, extracellular enzymes were accumulated in the periplasm (Hu, N.-T., Hung, M.-N., Chiou, S.-J., Tang, F., Chiang, D.-C., Huang, H.-Y. and Wu, C.-Y. (1992) J. Bacteriol. 174, 2679-2687). In this study, we constructed a series of substitutions and deletion mutant xpsD genes to investigate the roles of NH2- and COOH-terminal halves of XpsD in protein secretory function. Among these secretion defective xpsD mutations, one group (encoded by pCD105, pYL4, pKdA6, and pKD2) caused secretion interference when co-expressed with wild type xpsD, but the other (encoded by pMH7, pKdPs, and pKDT) did not. Cross-linking studies and gel filtration chromatography analysis indicated that the wild type XpsD protein forms a multimer in its native state. Similar gel filtration analysis of xpsD mutants revealed positive correlations between multimer formation and secretion interfering properties exerted by the mutant XpsD proteins in the parental strain XC1701. Those mutant XpsD proteins (encoded by pCD105, pYL4, pKdA6, and pKD2) that caused secretion interference formed multimers that are similar to the wild type XpsD multimers and those (encoded by pMH7, pKdPs, and pKDT) that did not formed smaller ones. Furthermore, gel filtration and anion exchange chromatography analyses indicated that the wild type XpsD protein co-fractionated with XpsD(Delta 29-428) or XpsD(Delta 448-650) protein but not with XpsD(Delta 74-303) or XpsD(Delta 553-759) protein. We propose that the mutant XpsD(Delta 29-428) protein caused secretion interference primarily by forming mixed nonfunctional multimers with the wild type XpsD protein in XC1701(pCD105), whereas the mutant XpsD(Delta 74-303) did so by competing for unknown factor(s) in XC1701(pYL4).	NATL CHUNGHSING UNIV,AGR BIOTECHNOL LABS,TAICHUNG 40227,TAIWAN; NATL CHUNGHSING UNIV,INST MOLEC BIOL,TAICHUNG 40227,TAIWAN; CHUNG SHAN MED & DENT COLL,INST BIOCHEM,TAICHUNG,TAIWAN	National Chung Hsing University; National Chung Hsing University; Chung Shan Medical University								AKRIM M, 1993, MOL MICROBIOL, V10, P431, DOI 10.1111/j.1365-2958.1993.tb02674.x; ALLAOUI A, 1993, MOL MICROBIOL, V7, P59, DOI 10.1111/j.1365-2958.1993.tb01097.x; BORTOLIGERMAN I, 1994, MOL MICROBIOL, V11, P545, DOI 10.1111/j.1365-2958.1994.tb00335.x; BRISSETTE JL, 1990, J MOL BIOL, V211, P565, DOI 10.1016/0022-2836(90)90266-O; CONDEMINE G, 1992, MOL MICROBIOL, V6, P3199, DOI 10.1111/j.1365-2958.1992.tb01775.x; DENFERT C, 1989, J BIOL CHEM, V264, P17462; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; HARLOW E, 1985, ANTIBODIES LABORATOR, P92; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HILL DF, 1982, J VIROL, V44, P32, DOI 10.1128/JVI.44.1.32-46.1982; HIRST TR, 1987, P NATL ACAD SCI USA, V84, P7418, DOI 10.1073/pnas.84.21.7418; HOBBS M, 1993, MOL MICROBIOL, V10, P233, DOI 10.1111/j.1365-2958.1993.tb01949.x; HU NT, 1995, MICROBIOL-UK, V141, P1395, DOI 10.1099/13500872-141-6-1395; HU NT, 1992, J BACTERIOL, V174, P2679, DOI 10.1128/jb.174.8.2679-2687.1992; HU NT, 1992, J GEN MICROBIOL, V138, P1647, DOI 10.1099/00221287-138-8-1647; HUANG HC, 1992, J BACTERIOL, V174, P6878, DOI 10.1128/JB.174.21.6878-6885.1992; JAHNIG F, 1989, PREDICTION PROTEIN S, P707; JIANG B, 1992, MOL MICROBIOL, V6, P1351, DOI 10.1111/j.1365-2958.1992.tb00856.x; KANIGA K, 1994, MOL MICROBIOL, V13, P555, DOI 10.1111/j.1365-2958.1994.tb00450.x; KAZMIERCZAK BI, 1994, J MOL BIOL, V238, P187, DOI 10.1006/jmbi.1994.1280; LINDEBERG M, 1992, J BACTERIOL, V174, P7385, DOI 10.1128/jb.174.22.7385-7397.1992; LUCKEY M, 1980, P NATL ACAD SCI-BIOL, V77, P167, DOI 10.1073/pnas.77.1.167; LUITEN RGM, 1985, J VIROL, V56, P268, DOI 10.1128/JVI.56.1.268-276.1985; MARTIN PR, 1993, MOL MICROBIOL, V9, P857, DOI 10.1111/j.1365-2958.1993.tb01744.x; MICHIELS T, 1991, J BACTERIOL, V173, P4994, DOI 10.1128/jb.173.16.4994-5009.1991; PEEK JA, 1992, P NATL ACAD SCI USA, V89, P6210, DOI 10.1073/pnas.89.13.6210; PEETERS BPH, 1985, J MOL BIOL, V181, P27, DOI 10.1016/0022-2836(85)90322-5; PUGSLEY AP, 1991, MOL MICROBIOL, V5, P865, DOI 10.1111/j.1365-2958.1991.tb00760.x; PUGSLEY AP, 1992, P NATL ACAD SCI USA, V89, P12058, DOI 10.1073/pnas.89.24.12058; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; PUGSLEY AP, 1991, MOL MICROBIOL, V5, P343, DOI 10.1111/j.1365-2958.1991.tb02115.x; REEVES PJ, 1993, MOL MICROBIOL, V8, P443, DOI 10.1111/j.1365-2958.1993.tb01589.x; RUSSEL M, 1994, MOL MICROBIOL, V14, P357, DOI 10.1111/j.1365-2958.1994.tb01296.x; RUSSEL M, 1994, SCIENCE, V265, P612, DOI 10.1126/science.8036510; SALMOND GPC, 1993, TRENDS BIOCHEM SCI, V18, P7, DOI 10.1016/0968-0004(93)90080-7; STASSEN APM, 1992, J MOL EVOL, V34, P141; TOMB JF, 1991, GENE, V104, P1, DOI 10.1016/0378-1119(91)90457-M; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YU J, 1992, MOL MICROBIOL, V6, P1949, DOI 10.1111/j.1365-2958.1992.tb01368.x	39	52	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2703	2708		10.1074/jbc.271.5.2703	http://dx.doi.org/10.1074/jbc.271.5.2703			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576244	hybrid			2022-12-25	WOS:A1996TT48800058
J	Pato, MD; Sellers, JR; Preston, YA; Harvey, EV; Adelstein, RS				Pato, MD; Sellers, JR; Preston, YA; Harvey, EV; Adelstein, RS			Baculovirus expression of chicken nonmuscle heavy meromyosin II-B - Characterization of alternatively spliced isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN LIGHT CHAIN; PROTEIN-KINASE-C; SMOOTH-MUSCLE; PHOSPHORYLATION; REGION; ACTIN; CDNA; SUBFRAGMENT-1; NUCLEOTIDE; DIVERSITY	We have expressed two truncated isoforms of chicken nonmuscle myosin II-B using the baculovirus expression system, One of the expressed heavy meromyosins (HMM(exp)) consists of two 150-kDa myosin heavy chains (MHCs), comprising amino acids 1-1231 as well as two pairs of 20-kDa and 17-kDa myosin light chains (MLCs) in a 1:1:1 molar ratio, The second HMM(exp) was identical except that it contained an insert of 10 amino acids (PESPKPVKHQ) at the 25-50-kDa domain boundary in the subfragment-1 region of the MHC. These 10 amino acids include a consensus sequence (SPK) for proline directed kinases, Expressed HMMs were soluble at low ionic strength and bound to rabbit skeletal muscle actin in an ATP-dependent manner, These properties afforded a rapid purification of milligram quantities of expressed protein, Both isoforms were capable of moving actin filaments in an in vitro motility assay and manifested a greater than 20-fold activation of actin-activated MgATPase activity following phosphorylation of the 20-kDa MLC. HMM(exp) with the 10-amino acid insert was phosphorylated by Cdc2, Cdk5, and mitogen-activated protein kinase in vitro to 0.3-0.4 mol of PO4/mol of MHC The site phosphorylated in the MHC was identified as the serine residue present in the 10-amino acid insert and its presence was confirmed in bovine brain MHCs. Characterization of the baculovirus expressed noninserted and inserted MHC isoforms with respect to actin-activated MgATPase activity and ability to translocate actin filaments in an in vitro motility assay produced the following average values following MLC phosphorylation: noninserted HMM(exp), V-max 0.28 s(-1), K-m = 12.7 mu M; translocation rate = 0.077 mu m/s; inserted HMM(exp) V-max = 0.37 s(-1), K-m = 15.1 mu M; translocation rate = 0.092 mu m/s.	NHLBI,MOLEC CARDIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)				Adelstein, Robert/0000-0002-8683-2144				ADELSTEIN RS, 1981, J BIOL CHEM, V256, P7501; BABIJ P, 1993, NUCLEIC ACIDS RES, V21, P1467, DOI 10.1093/nar/21.6.1467; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BHATIADEY N, 1993, P NATL ACAD SCI USA, V90, P2856, DOI 10.1073/pnas.90.7.2856; BONET A, 1987, J BIOL CHEM, V262, P16524; CHOI OH, 1994, J BIOL CHEM, V269, P536; CHOI OH, 1996, IN PRESS J MUSCLE RE; CONRAD AH, 1995, CELL MOTIL CYTOSKEL, V31, P93, DOI 10.1002/cm.970310203; EISENBERG E, 1974, J BIOL CHEM, V249, P4742; HOMSHER E, 1992, AM J PHYSIOL, V262, pC714, DOI 10.1152/ajpcell.1992.262.3.C714; ITOH K, 1995, J BIOL CHEM, V270, P14533, DOI 10.1074/jbc.270.24.14533; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kawamoto S., 1995, Molecular Biology of the Cell, V6, p198A; KELLEY CA, 1990, J BIOL CHEM, V265, P17876; KELLEY CA, 1995, J BIOL CHEM, V270, P1395, DOI 10.1074/jbc.270.3.1395; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; KLEE CB, 1977, BIOCHEMISTRY-US, V16, P1017, DOI 10.1021/bi00624a033; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASH JA, 1990, NUCLEIC ACIDS RES, V18, P7176, DOI 10.1093/nar/18.23.7176; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LUDOWYKE RI, 1989, J BIOL CHEM, V264, P12492; MATSUURA M, 1995, FEBS LETT, V363, P246, DOI 10.1016/0014-5793(95)00326-5; MAUPIN P, 1994, J CELL SCI, V107, P3077; NAKABAYASHI H, 1991, FEBS LETT, V294, P144, DOI 10.1016/0014-5793(91)81362-C; ONISHI H, 1995, P NATL ACAD SCI USA, V92, P704, DOI 10.1073/pnas.92.3.704; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; POLLARD TD, 1973, J BIOL CHEM, V248, P4682; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SAEZ CG, 1990, P NATL ACAD SCI USA, V87, P1164, DOI 10.1073/pnas.87.3.1164; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATTERWHITE LL, 1992, J CELL BIOL, V118, P595, DOI 10.1083/jcb.118.3.595; SELLERS JR, 1982, J BIOL CHEM, V257, P3880; SELLERS JR, 1995, PROTEIN PROFILE, V2, P1323; SELLERS JR, 1993, MOTILITY ASSAYS MOTO, P23; SIMONS M, 1991, CIRC RES, V69, P530, DOI 10.1161/01.RES.69.2.530; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; TAKAHASHI M, 1992, J BIOL CHEM, V267, P17864; TRYBUS KM, 1994, J BIOL CHEM, V269, P20819; UMEMOTO S, 1989, J BIOL CHEM, V264, P1431; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; ZAVODNY PJ, 1988, NUCLEIC ACIDS RES, V16, P1214, DOI 10.1093/nar/16.3.1214	44	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2689	2695		10.1074/jbc.271.5.2689	http://dx.doi.org/10.1074/jbc.271.5.2689			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576242	hybrid			2022-12-25	WOS:A1996TT48800056
J	Gilligan, M; Welsh, GI; Flynn, A; Bujalska, I; Diggle, TA; Denton, RM; Proud, CG; Docherty, K				Gilligan, M; Welsh, GI; Flynn, A; Bujalska, I; Diggle, TA; Denton, RM; Proud, CG; Docherty, K			Glucose stimulates the activity of the guanine nucleotide-exchange factor eIF-2B in isolated rat islets of Langerhans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE-CHAIN INITIATION; RABBIT RETICULOCYTE LYSATE; EUKARYOTIC MESSENGER-RNAS; ELONGATION FACTOR-II; TRANSLATIONAL CONTROL; PROTEIN-SYNTHESIS; SECONDARY STRUCTURE; INSULIN-BIOSYNTHESIS; SKELETAL-MUSCLE; PHOSPHORYLATION	Over short time periods glucose controls insulin biosynthesis predominantly through effects on preexisting mRNA. However, the mechanisms underlying the translational control of insulin synthesis are unknown. The present study was carried out to determine the effect of glucose on the activity and/or phosphorylation status of eukaryotic initiation and elongation factors in islets, Glucose was found to increase the activity of the guanine nucleotide-exchange factor eIF-2B over a rapid time course (within 15 min) and over the same range of glucose concentrations as those that stimulate insulin synthesis (3-20 mM). A nonmetabolizable analogue of glucose (mannoheptulose), which does not stimulate insulin synthesis, failed to activate eIF-2B. The best characterized mechanism for modulating eIF-2B activity involves changes in the phosphorylation of the cu-subunit of its substrate eIF-2. However, in islets, no change in eIF-2 alpha phosphorylation was seen under conditions where eIF-2B activity was increased, implying that glucose regulates eIF-2B via an alternative pathway. Glucose also did not affect the phosphorylation states of three other regulatory translation factors. These are the cap-binding factor eIF-4E, 4E-binding protein-1, and elongation factor eEF-2, which do not therefore seem likely to be involved in modulating the translation of the preproinsulin mRNA under these conditions.	UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND	University of Birmingham; University of Bristol			Denton, Richard/ABC-9914-2020	Welsh, Gavin Iain/0000-0002-2148-6658; Proud, Christopher/0000-0003-0704-6442	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BU X, 1992, FEBS LETT, V301, P15, DOI 10.1016/0014-5793(92)80200-Z; BU X, 1991, FEBS LETT, V283, P219, DOI 10.1016/0014-5793(91)80592-Q; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DENSLOW ND, 1994, FASEB J, V8, pA1306; DHOLAKIA JN, 1988, P NATL ACAD SCI USA, V85, P51, DOI 10.1073/pnas.85.1.51; DHOLAKIA JN, 1986, P NATL ACAD SCI USA, V83, P6746, DOI 10.1073/pnas.83.18.6746; DIGGLE TA, 1995, BIOCHEM J, V306, P135, DOI 10.1042/bj3060135; GEY GEORGE 0., 1936, AMER JOUR CANCER, V27, P45; GROSS M, 1988, J BIOL CHEM, V263, P12486; GROSS M, 1989, J BIOL CHEM, V264, P21879; GUEST PC, 1989, BIOCHEM J, V257, P431, DOI 10.1042/bj2570431; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HURST RD, 1990, J MOL ENDOCRINOL, V4, P231, DOI 10.1677/jme.0.0040231; ITOH N, 1982, BIOCHEM INT, V4, P315; ITOH N, 1980, NATURE, V283, P100, DOI 10.1038/283100a0; JEFFREY IW, 1990, BIOCHIMIE, V72, P751, DOI 10.1016/0300-9084(90)90160-I; KIMBALL SR, 1995, BIOCHEM BIOPH RES CO, V212, P1074, DOI 10.1006/bbrc.1995.2079; KIMBALL SR, 1988, BIOCHEM BIOPH RES CO, V156, P706, DOI 10.1016/S0006-291X(88)80900-8; KNIGHT SW, 1992, J MOL ENDOCRINOL, V8, P225, DOI 10.1677/jme.0.0080225; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LIN TA, 1994, SCIENCE, V266, P635; LODISH HF, 1974, NATURE, V251, P385, DOI 10.1038/251385a0; LOMEDICO PT, 1977, SCIENCE, V198, P620, DOI 10.1126/science.918657; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MARIE S, 1993, J BIOL CHEM, V268, P23881; MEHTA HB, 1983, J BIOL CHEM, V258, P3438; MONTAGUE W, 1968, BIOCHEM J, V109, P333, DOI 10.1042/bj1090333; OLDFIELD S, 1992, EUR J BIOCHEM, V208, P73, DOI 10.1111/j.1432-1033.1992.tb17160.x; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PERMUTT MA, 1972, J BIOL CHEM, V247, P1194; PERMUTT MA, 1974, J BIOL CHEM, V249, P2738; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; PRICE NT, 1989, BIOCHIM BIOPHYS ACTA, V1008, P177, DOI 10.1016/0167-4781(80)90005-6; PROUD CG, 1992, CURR TOP CELL REGUL, V32, P243; REDPATH NT, 1992, ANAL BIOCHEM, V202, P340, DOI 10.1016/0003-2697(92)90115-N; REDPATH NT, 1993, EUR J BIOCHEM, V213, P689, DOI 10.1111/j.1432-1033.1993.tb17809.x; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; ROWLANDS AG, 1988, EUR J BIOCHEM, V175, P93, DOI 10.1111/j.1432-1033.1988.tb14170.x; SINGH LP, 1994, BIOCHEMISTRY-US, V33, P9152, DOI 10.1021/bi00197a018; Sonenberg N, 1993, CURR OPIN CELL BIOL, V5, P955, DOI 10.1016/0955-0674(93)90076-3; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; VANLINT J, 1993, ANAL BIOCHEM, V208, P132, DOI 10.1006/abio.1993.1018; WELSH GI, 1992, BIOCHEM J, V284, P19, DOI 10.1042/bj2840019; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459	53	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2121	2125		10.1074/jbc.271.4.2121	http://dx.doi.org/10.1074/jbc.271.4.2121			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567668	hybrid			2022-12-25	WOS:A1996TR32000050
J	Albini, A; Benelli, R; Presta, M; Rusnati, M; Ziche, M; Rubartelli, A; Paglialunga, G; Bussolino, F; Noonan, D				Albini, A; Benelli, R; Presta, M; Rusnati, M; Ziche, M; Rubartelli, A; Paglialunga, G; Bussolino, F; Noonan, D			HIV-tat protein is a heparin-binding angiogenic growth factor	ONCOGENE			English	Article						HIV; tat; heparin; growth factor; angiogenesis	HUMAN-IMMUNODEFICIENCY-VIRUS; FIBROBLAST GROWTH; KAPOSIS-SARCOMA; 3-DIMENSIONAL STRUCTURE; FUNCTIONAL DOMAINS; BASEMENT-MEMBRANE; ENDOTHELIAL-CELLS; BASIC DOMAIN; RECEPTOR; GENE	Transgenic animal studies have linked the expression of the HIV-1 tat gene to the appearance of Kaposi's sarcoma (KS)-like lesions. We have recently shown that recombinant tat is angiogenic in vivo, and that tat angiogenic response is enhanced by heparin. Also in the rabbit cornea model, recombinant HIV-1 tat alone is poorly angiogenic, but gives a good response when combined with heparin. Like many angiogenic growth factors, tat has a basic domain similar to that of several heparin binding angiogenic factors, including FGF, VEGF and HGF, suggesting that this region is important in endothelial cell activation. We show that tat binds heparin sepharose with a high affinity, similar to bFGF. Binding of tat to the cell surface is also modulated by heparin. Biological activities of tat, such as induction of endothelial cell growth, migration and invasion in vitro are all enhanced by low concentrations and inhibited by high concentrations of heparin, as has been shown for other heparin-binding angiogenic factors. Heparan sulfate is also effective, whereas the unsulfated polysaccharide K5 does not enhance tat activity. Furthermore, a peptide encompassing the tat basic domain is able to induce growth and migration of endothelial cells, while an adjacent peptide is not. Our data indicate that the tat basic domain plays a key role in its vascular cell activation properties, and strongly suggest that extracellular HIV-tat is essentially a 'new' heparin-binding angiogenic factor.	UNIV BRESCIA, DEPT BIOMED SCI & BIOTECHNOL, BRESCIA, ITALY; UNIV FLORENCE, DEPT PHARMACOL, FLORENCE, ITALY; UNIV TURIN, DEPT GENET BIOL & MED CHEM, TURIN, ITALY	University of Brescia; University of Florence; University of Turin	Albini, A (corresponding author), IST NAZL RIC CANC, I-16132 GENOA, ITALY.		Noonan, Douglas M/A-8620-2010; Bussolino, Federico/AES-3951-2022; Presta, Marco/B-4345-2010; Rubartelli, Anna/AAA-1259-2021; Benelli, Roberto/AAF-3143-2019; Rusnati, Marco/F-1168-2010; Bussolino, Federico/K-2500-2016	Noonan, Douglas M/0000-0001-8058-0719; Benelli, Roberto/0000-0002-9769-0954; Rusnati, Marco/0000-0001-9968-5908; PRESTA, Marco/0000-0002-4398-8376; Bussolino, Federico/0000-0002-5348-1341; Albini, Adriana/0000-0002-9624-5103				ALBINI A, 1987, J CELL BIOL, V105, P1867, DOI 10.1083/jcb.105.4.1867; ALBINI A, 1994, AIDS, V8, P1237, DOI 10.1097/00002030-199409000-00004; ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; ALBINI A, 1987, CANCER RES, V47, P3239; ARMES J, 1989, ADV CANCER RES, V53, P73; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BARILLARI G, 1992, J IMMUNOL, V149, P3727; BARNETT SW, 1994, SCIENCE, V266, P642, DOI 10.1126/science.7939718; BONIFACI N, 1995, AIDS, V9, P995, DOI 10.1097/00002030-199509000-00003; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUONAGURO L, 1994, J VIROL, V68, P2677, DOI 10.1128/JVI.68.4.2677-2682.1994; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CARMICHAEL J, 1987, CANCER RES, V47, P936; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; CORALLINI A, 1993, CANCER RES, V53, P5569; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; FEDARKO NS, 1986, J CELL BIOL, V102, P587, DOI 10.1083/jcb.102.2.587; FOLKMAN J, 1988, AM J PATHOL, V130, P393; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FRIEDMANKIEN AE, 1982, ANN INTERN MED, V96, P693, DOI 10.7326/0003-4819-96-6-693; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; GEIER SA, 1993, AIDS, V7, P746, DOI 10.1097/00002030-199305000-00027; GEIER SA, 1993, J AQUIR IMMUNE DEFIC, V6, P262; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOFMAN FM, 1993, BLOOD, V82, P2774; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ISHIHARA M, 1986, J BIOL CHEM, V261, P3575; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; MAGLIONE D, 1993, ONCOGENE, V8, P925; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MORTARINI R, 1992, CANCER RES, V52, P4499; NEWSOME DA, 1984, AM J OPHTHALMOL, V98, P590, DOI 10.1016/0002-9394(84)90245-9; PASSANITI A, 1992, LAB INVEST, V67, P519; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBBINS KC, 1983, NATURE, V305, P605, DOI 10.1038/305605a0; ROTH WK, 1992, AIDS, V6, P895, DOI 10.1097/00002030-199209000-00001; RUSNATI M, 1993, J CELL PHYSIOL, V154, P152, DOI 10.1002/jcp.1041540119; SAFAI B, 1985, ANN INTERN MED, V103, P744, DOI 10.7326/0003-4819-103-5-744; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; TESSLER S, 1994, J BIOL CHEM, V269, P12456; THOMPSON EW, 1991, CANCER RES, V51, P2670; VOGEL BE, 1993, J CELL BIOL, V121, P461, DOI 10.1083/jcb.121.2.461; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZICHE M, 1989, LAB INVEST, V61, P629; ZICHE M, 1994, J CLIN INVEST, V94, P2036, DOI 10.1172/JCI117557	60	134	141	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					289	297						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570206				2022-12-25	WOS:A1996TR53800008
J	Brown, CR; Doxsey, SJ; HongBrown, LQ; Martin, RL; Welch, WJ				Brown, CR; Doxsey, SJ; HongBrown, LQ; Martin, RL; Welch, WJ			Molecular chaperones and the centrosome - A role for TCP-1 in microtubule nucleation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-COMPLEX POLYPEPTIDE-1; HEAT-SHOCK PROTEINS; GAMMA-TUBULIN; CELLS; FILAMENTS; MEMBRANES	Molecular chaperones play an important role in facilitating the proper maturation of many newly synthesized proteins, Here we provide evidence that molecular chaperones also participate in regulating the assembly of the microtubule cytoskeleton, Via indirect immunofluorescence analysis, both hsp 73 and TCP-1 localized within the centrosome in interphase and mitotic cells, These proteins, along with the centrosome-specific protein, pericentrin, were also present within an enriched preparation of centrosomes, Because the centrosome serves as an initiation site for microtubule growth, we examined the ability of cells to regrow their microtubule network in the presence of hsp 73 or TCP-1 specific antibodies. Purified tubulin and GTP were added to cells following the depolymerization and extraction of cellular microtubules. Microtubules were observed to nucleate off the centrosome using this system, even in the presence of anti-hsp 73 antibodies, Incubation with anti-TCP-1 antibodies, however, blocked microtubule regrowth off the centrosome, Similarly, anti-TCP-1 antibodies microinjected into living cells first treated with nocodazole also inhibited the regrowth of the microtubule network following removal of the microtubule poison, Our results complement earlier genetic studies in yeast implicating a role for TCP-1 in microtubule mediated processes, and may help to explain the previously reported mitotic and meiotic abnormalities associated with TCP-1 mutations.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Massachusetts System; University of Massachusetts Worcester								ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; BORNENS M, 1987, CELL MOTIL CYTOSKEL, V8, P238, DOI 10.1002/cm.970080305; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; Brown CR, 1996, J BIOL CHEM, V271, P833, DOI 10.1074/jbc.271.2.833; CALARCOGILLAM PD, 1983, CELL, V35, P621, DOI 10.1016/0092-8674(83)90094-6; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; DOXSEY SJ, 1993, GUIDEBOOK CYTOSKELET; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; FRYMAN J, 1995, NATURE, V370, P111; GAO YJ, 1992, CELL, V69, P1043, DOI 10.1016/0092-8674(92)90622-J; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GREEN LAD, 1989, J BIOL CHEM, V264, P15210; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; JOSHI HC, 1992, NATURE, V356, P80, DOI 10.1038/356080a0; KARSENTI E, 1986, TRENDS BIOCHEM SCI, V11, P460, DOI 10.1016/0968-0004(86)90247-1; LEWIS VA, 1992, NATURE, V358, P249, DOI 10.1038/358249a0; LIM L, 1984, BIOCHEM J, V224, P677, DOI 10.1042/bj2240677; LINGAPPA JR, 1994, J CELL BIOL, V125, P99, DOI 10.1083/jcb.125.1.99; MELKI R, 1993, J CELL BIOL, V122, P1301, DOI 10.1083/jcb.122.6.1301; MELKI R, 1994, MOL CELL BIOL, V14, P2895, DOI 10.1128/MCB.14.5.2895; MIKLOS D, 1994, P NATL ACAD SCI USA, V91, P2743, DOI 10.1073/pnas.91.7.2743; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; RATTNER JB, 1991, EXP CELL RES, V195, P110, DOI 10.1016/0014-4827(91)90505-O; SILVER LM, 1987, GENET RES, V49, P51, DOI 10.1017/S0016672300026720; SILVER LM, 1987, DEV BIOL, V119, P605, DOI 10.1016/0012-1606(87)90063-7; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; STERNLICHT H, 1993, P NATL ACAD SCI USA, V90, P9422, DOI 10.1073/pnas.90.20.9422; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; TRENT JD, 1991, NATURE, V354, P490, DOI 10.1038/354490a0; URSIC D, 1991, MOL CELL BIOL, V11, P2629, DOI 10.1128/MCB.11.5.2629; WELCH WJ, 1985, ANN NY ACAD SCI, V455, P57, DOI 10.1111/j.1749-6632.1985.tb50403.x; WILLISON K, 1989, CELL, V57, P621, DOI 10.1016/0092-8674(89)90131-1; YAFFE MB, 1992, NATURE, V358, P245, DOI 10.1038/358245a0	36	77	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					824	832		10.1074/jbc.271.2.824	http://dx.doi.org/10.1074/jbc.271.2.824			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557692	hybrid			2022-12-25	WOS:A1996TP88900035
J	Brown, CR; HongBrown, LQ; Doxsey, SJ; Welch, WJ				Brown, CR; HongBrown, LQ; Doxsey, SJ; Welch, WJ			Molecular chaperones and the centrosome - A role for HSP 73 in centrosomal repair following heat shock treatment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOTOLERANT CELL; ANIMAL-CELLS; STRESS; PROTEIN-70; DROSOPHILA; FILAMENTS; INDUCTION	In the accompanying paper (Brown, C. R., Doxsey, S. J., Hong-Brown, L. W., Martin, R. L., and Welch, W. J. (1996) J. Biol. Chem. 271, 824-832) two molecular chaperones, hsp 73 and TCP-1, were shown to be integral components of the centrosome. Here we show that heat shock treatment adversely affects both the structure and function of the centrosome, and that hsp 73 plays a role in the repair of the organelle. After heat shock treatment, the centrosome could not be identified via indirect immunofluorescence and cells were unable to support microtubule regrowth. During recovery from heat shock, a strong correlation between the return of staining of three centrosomal antigens (hsp 73, TCP-1, and pericentrin) and the recovery of microtubule regrowth properties was found. Incubation of cells with glycerol, a protein protective agent, prevented the heat induced alterations in the structure/function of the centrosome. Likewise, the recovery of the structure and function of the centrosome after heat shock treatment was significantly accelerated in cells first made thermotolerant. We provide evidence that this process is related to the levels of hsp 73 since: 1) microinjection of hsp 73 antibody blocked centrosomal reassembly and microtubule regrowth abilities following heat shock; and 2) microinjection of purified hsp 73 protein prior to heat shock treatment accelerated both the repair and function of the organelle, similar to that observed for thermotolerant cells.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,WORCESTER,MA 01605	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Massachusetts System; University of Massachusetts Worcester								ASHBURNER M, 1979, CELL, V17, P241, DOI 10.1016/0092-8674(79)90150-8; BECKMANN RP, 1992, J CELL BIOL, V117, P1137, DOI 10.1083/jcb.117.6.1137; BLOSE SH, 1984, J CELL BIOL, V98, P847, DOI 10.1083/jcb.98.3.847; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; Brown CR, 1996, J BIOL CHEM, V271, P824, DOI 10.1074/jbc.271.2.824; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; CALARCOGILLAM PD, 1983, CELL, V35, P621, DOI 10.1016/0092-8674(83)90094-6; DEBEC A, 1990, J CELL SCI, V96, P403; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; EDINGTON BV, 1989, J CELL PHYSIOL, V139, P219, DOI 10.1002/jcp.1041390202; FRIEDMAN DI, 1984, MICROBIOL REV, V48, P299, DOI 10.1128/MMBR.48.4.299-325.1984; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GEORGOPOULOS C, 1990, STRESS PROTEINS BIOL, P191; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; Kalt Astrid, 1993, Trends in Cell Biology, V3, P118, DOI 10.1016/0962-8924(93)90174-Y; KARSENTI E, 1986, TRENDS BIOCHEM SCI, V11, P460, DOI 10.1016/0968-0004(86)90247-1; LINGAPPA JR, 1994, J CELL BIOL, V125, P99, DOI 10.1083/jcb.125.1.99; MARCAILLOU C, 1994, BIOCH CELL BIOL, V71, P507; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; MIZZEN LA, 1988, J CELL BIOL, V106, P1105, DOI 10.1083/jcb.106.4.1105; Thomas G P, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 2, P985; VIDAIR CA, 1995, J CELL PHYSIOL, V163, P194, DOI 10.1002/jcp.1041630122; VIDAIR CA, 1993, J CELL PHYSIOL, V154, P443, DOI 10.1002/jcp.1041540302; WELCH WJ, 1988, J CELL BIOL, V106, P1117, DOI 10.1083/jcb.106.4.1117; Welch WJ, 1990, STRESS PROTEINS BIOL, P223	26	61	63	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					833	840		10.1074/jbc.271.2.833	http://dx.doi.org/10.1074/jbc.271.2.833			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557693	hybrid			2022-12-25	WOS:A1996TP88900036
J	Logan, SK; Garabedian, MJ; Campbell, CE; Werb, Z				Logan, SK; Garabedian, MJ; Campbell, CE; Werb, Z			Synergistic transcriptional activation of the tissue inhibitor of metalloproteinases-1 promoter via functional interaction of AP-1 and Ets-1 transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS; REGULATORY ELEMENTS; COLLAGENASE GENE; BINDING-SITES; NULL MUTATION; TIMP GENE; EXPRESSION; PROTEIN; GROWTH; JUN	The tissue inhibitor of metalloproteinases-1 (TIMP-1) is an inhibitor of the extracellular matrix-degrading metalloproteinases, We characterized response elements that control TIMP-1 gene expression. One contains a binding site that selectively binds c-Fos and c-Jun in, vitro and confers a response to multiple AP-1 family members in vivo. Adjacent to this is a binding site for Ets domain proteins. Although c-Ets-1 alone did not activate transcription from this element, it enhanced transcription synergistically with AP-1 either in the context of the natural promoter or when the sequence was linked upstream of a heterologous promoter, Furthermore, a complex of c-Jun and c-Fos interacted with c-Ets-1 in vitro. These results suggest that AP-1 tethers c-Ets-1 to the TIMP-1 promoter via protein-protein interaction to achieve Ets dependent transcriptional regulation. Collectively, our results indicate that TIMP-1 expression is controlled by several DNA response elements that respond to variations in the level and activity of AP-1 and Ets transcriptional regulatory proteins.	UNIV CALIF SAN FRANCISCO, RADIOBIOL & ENVIRONM HLTH LAB, SAN FRANCISCO, CA 94143 USA; NYU, MED CTR, DEPT MICROBIOL, NEW YORK, NY 10016 USA; NYU, MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA; CLEVELAND CLIN FDN, DEPT CANC BIOL, CLEVELAND, OH 44195 USA	University of California System; University of California San Francisco; New York University; New York University; Cleveland Clinic Foundation				Logan, Susan/0000-0002-7904-5927	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD026732] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010306] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007106] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26732] Funding Source: Medline; NIDCR NIH HHS [DE10306] Funding Source: Medline; NIEHS NIH HHS [5 T32 ES07106] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADLER RR, 1990, DEVELOPMENT, V110, P211; ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BUTTICE G, 1991, NUCLEIC ACIDS RES, V19, P3723, DOI 10.1093/nar/19.13.3723; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COULOMBE B, 1988, MOL CELL BIOL, V8, P3227, DOI 10.1128/MCB.8.8.3227; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; FLENNIKEN AM, 1990, GENE DEV, V4, P1094, DOI 10.1101/gad.4.7.1094; GEWERT DR, 1987, EMBO J, V6, P651, DOI 10.1002/j.1460-2075.1987.tb04804.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN M, 1991, HORMONAL CONTROL REG, P235; Kerppola TK, 1991, CURR OPIN STRUC BIOL, V1, P71, DOI 10.1016/0959-440X(91)90014-K; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; KRAUT N, 1994, GENE DEV, V8, P33, DOI 10.1101/gad.8.1.33; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TREISMAN R, 1992, EMBO J, V11, P4631, DOI 10.1002/j.1460-2075.1992.tb05565.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	47	161	163	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					774	782		10.1074/jbc.271.2.774	http://dx.doi.org/10.1074/jbc.271.2.774			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557686	hybrid			2022-12-25	WOS:A1996TP88900029
J	Albakri, QA; Stuehr, DJ				Albakri, QA; Stuehr, DJ			Intracellular assembly of inducible NO synthase is limited by nitric oxide-mediated changes in heme insertion and availability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELLS; CYTOCHROME-P-450; BIOSYNTHESIS; MACROPHAGES; CALMODULIN; PATHWAY; SITE	Cytokines induce the mouse macrophage cell line RAW 264.7 to express cytokine-inducible nitric oxide synthase (iNOS), which is active only in dimeric form. Because dimerization of purified iNOS subunits requires tetrahydrobiopterin, heme, and L-arginine, we investigated if availability of these factors also influences intracellular assembly of dimeric iNOS. Following exposure to cytokines, iNOS protein was found to accumulate in a near linear manner over 16 h of further culture. In contrast, dimeric iNOS accumulated at a slower rate that continuously decreased during culture, resulting in only 25% of the accumulated iNOS protein being in dimeric form by 16 h. Further experiments argued against dimer instability or L-arginine and tetrahydrobiopterin availability as factors limiting NOS dimer accumulation. Blocking cellular NO synthesis with N-omega-nitro-L-arginine methyl ester (L-NAME) greatly increased iNOS dimer assembly, indicating NO synthesis limited iNOS dimerization. NO synthesis was found to prevent an increase in soluble heme level that was associated with iNOS induction in N-omega-nitro-L-arginine methyl ester-treated cells and also diminished heme insertion into iNOS. These NO-related defects were not reversed by adding heme precursors or hemin to the activated cell cultures. Measurement of iron release from activated cells demonstrated that endogenous NO synthesis substantially increased the release of Fe-59 to the medium. These observations suggest that iNOS dimerization is limited to a large extent by iNOS NO synthesis. NO appears to limit intracellular assembly of dimeric iNOS by preventing heme insertion and decreasing heme availability.	CLEVELAND CLIN FDN, RES INST, DEPT IMMUNOL, CLEVELAND, OH 44195 USA; CLEVELAND STATE UNIV, DEPT BIOL, CLEVELAND, OH 44195 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT PHYSIOL & BIOPHYS, CLEVELAND, OH 44106 USA	Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Case Western Reserve University					NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NCI NIH HHS [CA53914] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; FURUKAWA T, 1995, BIOCHEM J, V310, P533, DOI 10.1042/bj3100533; GARDNER LC, 1991, J BIOL CHEM, V266, P22010; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3539; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HARTENECK C, 1994, BIOCHEM J, V304, P683, DOI 10.1042/bj3040683; HIBBS JB, 1990, INT CONGR SER, V897, P189; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; KHATSENKO OG, 1993, P NATL ACAD SCI USA, V90, P11147, DOI 10.1073/pnas.90.23.11147; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; KLAUSNER RD, 1993, MOL BIOL CELL, V4, P1; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; MARSDEN PA, 1994, GENOMICS, V19, P183, DOI 10.1006/geno.1994.1039; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MORRISON GR, 1965, ANAL CHEM, V37, P1124, DOI 10.1021/ac60228a014; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OKEEFFE DH, 1978, J BIOL CHEM, V253, P3509; SAKAI N, 1992, MOL PHARMACOL, V43, P6; SASSA S, 1976, J EXP MED, V143, P305, DOI 10.1084/jem.143.2.305; SHEDLOFSKY SI, 1987, BIOCHEM J, V248, P229, DOI 10.1042/bj2480229; SHIRO Y, 1995, BIOCHEMISTRY-US, V34, P9052, DOI 10.1021/bi00028a014; SONO M, 1995, J BIOL CHEM, V270, P19943, DOI 10.1074/jbc.270.34.19943; STADLER J, 1994, P NATL ACAD SCI USA, V91, P3559, DOI 10.1073/pnas.91.9.3559; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TAKESHI F, 1980, ANAL BIOCHEM, V102, P176; TSUBAKI M, 1988, BIOCHEMISTRY-US, V27, P4856, DOI 10.1021/bi00413a041; WANG JL, 1993, J BIOL CHEM, V268, P22255; WANG WW, 1995, BIOCHEM BIOPH RES CO, V210, P1009, DOI 10.1006/bbrc.1995.1757; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; WEISS G, 1994, J EXP MED, V180, P969, DOI 10.1084/jem.180.3.969	42	134	139	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5414	5421		10.1074/jbc.271.10.5414	http://dx.doi.org/10.1074/jbc.271.10.5414			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621396	hybrid			2022-12-25	WOS:A1996TZ28600022
J	GitayGoren, H; Cohen, T; Tessler, S; Soker, S; Gengrinovitch, S; Rockwell, P; Klagsbrun, M; Levi, BZ; Neufeld, G				GitayGoren, H; Cohen, T; Tessler, S; Soker, S; Gengrinovitch, S; Rockwell, P; Klagsbrun, M; Levi, BZ; Neufeld, G			Selective binding of VEGF(121) to one of the three vascular endothelial growth factor receptors of vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-LIKE MOLECULES; FIBROBLAST GROWTH; TYROSINE KINASE; EXPRESSION; IDENTIFICATION; DIFFERENTIATION; ANGIOGENESIS; SURFACE; FAMILY; INVIVO	VEGF(121) and VEGF(165) are vascular endothelial growth factor splice variants that promote the proliferation of endothelial cells and angiogenesis. VEGF(165) contains the 44 additional amino acids encoded by exon 7 of the VEGF gene. These amino acids confer upon VEGF(165) a heparin binding capability which VEGF(121) lacks. I-125-VEGF(165) bound to three vascular endothelial growth factor (VEGF) receptors on endothelial cells, while I-125-VEGF(165) bound selectively only to the flk-1 VEGF receptor which corresponds to the larger of the three VEGF receptors. The binding of I-125-VEGF(121) to flk-1 was not affected by the removal of cell surface heparan sulfates or by heparin. Both VEGF(165) and VEGF(121) inhibited the binding of I-125-VEGF(121) to soluble extracellular domain of the flk-1 VEGF receptor in the absence of heparin. However, heparin potentiated the inhibitory effect of VEGF(165) by 23-fold. These results contrast with previous observations which have indicated that the binding of I-125-VEGF(165) to the flk-1 receptor is strongly dependent on heparin-like molecules. Further experiments showed that the receptor binding ability of VEGF(165) is susceptible to oxidative damage caused by oxidants such as H2O2 or chloramine-T. VEGF(121) was also damaged by oxidants but to a lesser extent. Heparin or cell surface heparan sulfates restored the flk-1 binding ability of damaged VEGF(165) but not the receptor binding ability of damaged VEGF(121). These observations suggest that alternative splicing can generate a diversity in growth factor signaling by determining receptor recognition patterns. They also indicate that the heparin binding ability of VEGF(165) may enable the restoration of damaged VEGF(165) function in processes such as inflammation or wound healing.	TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL; TECHNION ISRAEL INST TECHNOL,DEPT FOOD ENGN & BIOTECHNOL,IL-32000 HAIFA,ISRAEL; IMCLONE SYST INC,NEW YORK,NY 10014; CHILDRENS HOSP,DEPT BIOL CHEM,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Eli Lilly; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Neufeld, Gera/F-1524-2019					BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; BROWN LF, 1995, J IMMUNOL, V154, P2801; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1995, INT ARCH ALLERGY IMM, V107, P233, DOI 10.1159/000236988; FERRARA N, 1993, J CLIN INVEST, V91, P160, DOI 10.1172/JCI116166; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GENGRINOVITCH S, 1995, J BIOL CHEM, V270, P15059, DOI 10.1074/jbc.270.25.15059; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLOUET J, 1990, J BIOL CHEM, V265, P22071; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHIBUYA M, 1990, ONCOGENE, V5, P519; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TESSLER S, 1994, J BIOL CHEM, V269, P12456; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; VOLKIN DB, 1993, ARCH BIOCHEM BIOPHYS, V300, P30, DOI 10.1006/abbi.1993.1005; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	33	156	161	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5519	5523		10.1074/jbc.271.10.5519	http://dx.doi.org/10.1074/jbc.271.10.5519			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621410	hybrid			2022-12-25	WOS:A1996TZ28600036
J	Chinnaiyan, AM; Tepper, CG; Seldin, MF; ORourke, K; Kischkel, FC; Hellbardt, S; Krammer, PH; Peter, ME; Dixit, VM				Chinnaiyan, AM; Tepper, CG; Seldin, MF; ORourke, K; Kischkel, FC; Hellbardt, S; Krammer, PH; Peter, ME; Dixit, VM			FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; INDUCTION; ANTIGEN; DOMAIN; FAS	CD95 (Fas/APO-1) and tumor necrosis factor receptor-1 (TNFR-1) are related molecules that signal apoptosis. Recently, a number of novel binding proteins have been proposed to mediate the signaling of these death receptors. Here we report that an N-terminal truncation of one of these candidate signal transducers, FADD/MORT1, abrogates CD95-induced apoptosis, ceramide generation, and activation of the cell death protease Yama/CPP32. In addition, this dominant-negative derivative of FADD (FADD-DN) blocked TNF-induced apoptosis while not affecting NF-kappa B activation. FADD-DN bound both receptors, and in the case of CD95, it disrupted the assembly of a signaling complex. Taken together, our results functionally establish FADD as the apoptotic trigger of CD95 and TNFR-1.	UNIV MICHIGAN,SCH MED,DEPT PATHOL,ANN ARBOR,MI 48109; DUKE UNIV,MED CTR,DEPT MED,DIV RHEUMATOL & IMMUNOL,DURHAM,NC 27710; UNIV HEIDELBERG,GERMAN CANC RES CTR,TUMOR IMMUNOL PROGRAM,D-69120 HEIDELBERG,GERMANY	University of Michigan System; University of Michigan; Duke University; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg			dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Peter, Marcus Ernst/0000-0003-3216-036X	NATIONAL CANCER INSTITUTE [R01CA064803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041053] Funding Source: NIH RePORTER; NCI NIH HHS [CA64803] Funding Source: Medline; NIAMS NIH HHS [AR 41053] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAGLIONI C, 1992, TUMOR NECROSIS FACTO, P425; BIELAWSKA A, 1993, J BIOL CHEM, V268, P26226; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; DHEIN J, 1992, J IMMUNOL, V149, P3166; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU HM, 1994, J BIOL CHEM, V269, P30069; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JAATTELA M, 1995, ONCOGENE, V10, P2297; JAYADEV S, 1994, J BIOL CHEM, V269, P5757; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PREISS J, 1986, J BIOL CHEM, V261, P8597; PUSHKAREVA M, 1995, IMMUNOL TODAY, V16, P294, DOI 10.1016/0167-5699(95)80184-7; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SARMA V, 1992, J IMMUNOL, V148, P3302; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEPPER CG, 1995, P NATL ACAD SCI USA, V92, P8443, DOI 10.1073/pnas.92.18.8443; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530	33	680	728	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4961	4965						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617770				2022-12-25	WOS:A1996TX69700060
J	Cohen, BM; Green, JM; Foy, L; Fell, HP				Cohen, BM; Green, JM; Foy, L; Fell, HP			HER4-mediated biological and biochemical properties in NIH 3T3 cells - Evidence for HER1-HER4 heterodimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHOLIPASE-C-GAMMA; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; BREAST-CANCER; TUMOR-CELLS; TRANSFORMING PROTEIN; SH3 DOMAINS; ERBB-2	The EGF receptor family of tyrosine kinase growth factor receptors is expressed in a variety of cell types and has been implicated in the progression of certain human adenocarcinomas. The most recent addition to this family of receptors, HER4, was expressed in NIH 3T3 cells to determine its biological and biochemical characteristics. Cells expressing HER4 were responsive to heregulin beta 2 as demonstrated by an increase in HERA tyrosine phosphorylation and ability to form foci on a cell monolayer. HER4 exhibited in vitro kinase activity and was able to phosphorylate the regulatory subunit of phosphatidylinositol 3-kinase and SHC. Peptide competition studies identified tyrosine 1056 of HER4 as the phosphatidylinositol 3-kinase binding site and tyrosines 1188 and 1242 as two potential SHC binding sites. Interestingly, transfection of HER4 into NIH 3T3 cells conferred responsiveness to EGF with respect to colony formation in soft agar. It was also found that in response to heregulin beta 2, endogenous murine HER1 or transfected human HER1 became phosphorylated when HER4 was present. This demonstrates that HER1 and HER4 can exist in a heterodimer complex and likely activate each other by transphosphorylation.			Cohen, BM (corresponding author), BRISTOL MYERS SQUIBB CO, PHARMACEUT RES INST, DEPT MOLEC IMMUNOL, 3005 1ST AVE, SEATTLE, WA 98121 USA.		Cohen, Bruce M./AAZ-4986-2020					AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; BERCHUCK A, 1990, CANCER RES, V50, P4087; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CHALUPNY NJ, 1995, EUR J IMMUNOL, V25, P2978, DOI 10.1002/eji.1830251040; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; GIOVANELLA BC, 1991, INT J CANCER, V47, P66, DOI 10.1002/ijc.2910470113; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG SS, 1992, J BIOL CHEM, V267, P11508; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; JALLAL B, 1992, J BIOL CHEM, V267, P4357; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; KIM HH, 1994, J BIOL CHEM, V269, P24747; KING CR, 1988, EMBO J, V7, P1647, DOI 10.1002/j.1460-2075.1988.tb02991.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEMOINE NR, 1992, BRIT J CANCER, V66, P1116, DOI 10.1038/bjc.1992.420; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; OREILLY SM, 1991, BRIT J CANCER, V63, P444, DOI 10.1038/bjc.1991.102; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGATTO O, 1993, ONCOGENE, V8, P2105; SIEGALL CB, 1995, J BIOL CHEM, V270, P7625, DOI 10.1074/jbc.270.13.7625; SKINNER A, 1993, ONCOGENE, V8, P3393; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WAHL MI, 1989, P NATL ACAD SCI USA, V86, P1568, DOI 10.1073/pnas.86.5.1568; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	58	81	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4813	4818						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617750				2022-12-25	WOS:A1996TX69700040
J	Ismailov, II; Jovov, B; Fuller, CM; Berdiev, BK; Keeton, DA; Benos, DJ				Ismailov, II; Jovov, B; Fuller, CM; Berdiev, BK; Keeton, DA; Benos, DJ			G-protein regulation of outwardly rectified epithelial chloride channels incorporated into planar bilayer membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS AIRWAY; GTP-BINDING PROTEINS; FUNCTIONAL RECONSTITUTION; CL CHANNELS; ACTIVATION; KINASE; CFTR; CAMP; VOLTAGE; CELLS	Experiments were designed to test if immunopurified outwardly rectified chloride channels (ORCCs) and the cystic fibrosis transmembrane conductance regulator (CFTR) incorporated into planar lipid bilayers are regulated by G-proteins. pertussis toxin (PTX) (100 ng/ml) + NAD (1 mM) + ATP (1 mM) treatment of ORCC and CFTR in bilayers resulted in a 2-fold increase in single channel open probability (P-o) of ORCC but not of CFTR. Neither PTX, NAD, nor ATP alone affected the biophysical properties of either channel. Further, PTX conferred a linearity to the ORCC current-voltage curve, with a slope conductance of 80 +/- 3 picosiemens (pS) in the +/- 100 mV range of holding potentials. PKA-mediated phosphorylation of these PTX + NAD-treated channels further increased the P-o of the linear 80-pS channels from 0.66 +/- 0.05 to >0.9, and revealed the presence of a small (16 +/- 2 pS) linear channel in the membrane. PTX treatment of a CFTR immunodepleted protein preparation incorporated into bilayer membranes resulted in a similar increase in the P-o of the larger conductance channel and restored PKA-sensitivity that was lost after CFTR immunodepletion. The addition of guanosine 5'-3-O-(thio)triphosphate (100 mu M) to the cytoplasmic bathing solutions decreased the activity of the ORCC and increased its rectification at both negative and positive voltages. ADP-ribosylation of immunopurified material revealed the presence of a 41-kDa protein. These results demonstrate copurification of a channel-associated G-protein that is involved in the regulation of ORCC function.	UNIV ALABAMA,DEPT PHYSIOL & BIOPHYS,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham			Fuller, Cathy/B-4046-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048764] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 48764] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ O, 1985, J ELECTROPHYSIOL TEC, V12, P159; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BUREAU MH, 1992, J BIOL CHEM, V267, P8679; CLAPHAM DE, 1994, ANNU REV NEUROSCI, V17, P441; CLIFF WH, 1990, P NATL ACAD SCI USA, V87, P4956, DOI 10.1073/pnas.87.13.4956; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FULLER CM, 1992, AM J PHYSIOL, V262, pC396, DOI 10.1152/ajpcell.1992.262.2.C396; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; GUGGINO WB, 1993, J BIOENERG BIOMEMBR, V25, P27, DOI 10.1007/BF00768065; HALM DR, 1989, AM J PHYSIOL, V245, pC505; HWANG TC, 1989, SCIENCE, V244, P1351, DOI 10.1126/science.2472005; ISMAILOV II, 1994, J BIOL CHEM, V269, P10235; JOVOV B, 1995, J BIOL CHEM, V270, P1521, DOI 10.1074/jbc.270.4.1521; JOVOV B, 1995, J BIOL CHEM, V270, P29194, DOI 10.1074/jbc.270.49.29194; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGRIDGESMITH JE, 1983, BIOCHIM BIOPHYS ACTA, V731, P318, DOI 10.1016/0005-2736(83)90024-X; LI M, 1988, NATURE, V331, P358, DOI 10.1038/331358a0; LUTHIN DR, 1993, J BIOL CHEM, V268, P5990; RAN S, 1991, J BIOL CHEM, V266, P4782; RUSS M, 1994, EUR J BIOCHEM, V219, P325, DOI 10.1111/j.1432-1033.1994.tb19944.x; SCHOUMACHER RA, 1987, NATURE, V330, P752, DOI 10.1038/330752a0; SCHWIEBERT EM, 1992, P NATL ACAD SCI USA, V89, P10623, DOI 10.1073/pnas.89.22.10623; SCHWIEBERT EM, 1995, AM J PHYSIOL-CELL PH, V269, pC451, DOI 10.1152/ajpcell.1995.269.2.C451; SCHWIEBERT EM, 1994, AM J PHYSIOL, V267, pC272, DOI 10.1152/ajpcell.1994.267.1.C272; SCHWIEBERT EM, 1994, AM J PHYSIOL, V266, pC1464, DOI 10.1152/ajpcell.1994.266.5.C1464; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SHEPPARD DN, 1993, ANN NY ACAD SCI, V707, P275, DOI 10.1111/j.1749-6632.1993.tb38058.x; TILLY BC, 1992, J BIOL CHEM, V267, P9470; WELSH MJ, 1989, J CLIN INVEST, V84, P2002, DOI 10.1172/JCI114391	32	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4776	4780						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617745				2022-12-25	WOS:A1996TX69700035
J	Jung, YK; Miura, M; Yuan, JY				Jung, YK; Miura, M; Yuan, JY			Suppression of interleukin-1 beta-converting enzyme-mediated cell death by insulin-like growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; CONVERTING ENZYME; GENE CED-3; HOMOLOG; ENCODES; BCL-2	COS cells are resistant to cell death induced either by interleukin-1 beta-converting enzyme (*ICE) and ICE homolog (ICH-1(L)) overexpression or by serum deprivation. Cos cells deprived of serum undergo apoptosis after transfection with an ICE expression construct, but not an ICE-1(L) construct. ICE-mediated apoptosis of COS cells in serum-free medium is suppressed by insulin-like growth factor (IGF)-1 and insulin. Viability of Rat-1 cell line (Rat-1/ICE) expressing low levels of ICE-LacZ fusion protein is lower than those of cell lines expressing either both Bcl-2 and ICE or mutant ICE(Gly-->Ser) during serum deprivation, Enzymatic activation and processing of ICE are observed in cells induced to die by serum deprivation, which are suppressed by IGF-1. IGF-1 or insulin suppresses IGE-mediated cell death without affecting the expression levels of Bcl-2, Bcl-x, or Bar. Taken together, these results indicate that ICE is activated by growth factor deprivation, and IGF-1 is able to suppress ICE-mediated cell death through a mechanism independent of the expression of Bcl-2, Bcl-x, or Bar.	MASSACHUSETTS GEN HOSP E,CARDIOVASC RES CTR,BOSTON,MA 02129; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Harvard Medical School				Jung, Yong-Keun/0000-0002-9686-3120	NATIONAL INSTITUTE ON AGING [R01AG012859, R37AG012859] Funding Source: NIH RePORTER; NIA NIH HHS [AG12859-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIURA M, 1995, P NATL ACAD SCI USA, V92, P8318, DOI 10.1073/pnas.92.18.8318; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; PORCU P, 1994, ONCOGENE, V9, P2125; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; REISS K, 1992, ONCOGENE, V7, P2243; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; STEELEPERKINS G, 1988, J BIOL CHEM, V263, P11486; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	36	119	123	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5112	5117						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617790				2022-12-25	WOS:A1996TX69700080
J	Uemura, K; Yokota, Y; Kozutsumi, Y; Kawasaki, T				Uemura, K; Yokota, Y; Kozutsumi, Y; Kawasaki, T			A unique CD45 glycoform recognized by the serum mannan-binding protein in immature thymocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELLS; COMPLEMENT; LECTIN; ACTIVATION; SEQUENCE; MOUSE	The serum-mannan binding protein (S-MBP) is a calcium-dependent C-type lectin specific for mannose and N-acetylglucosamine. S-MBP is known as a host defense factor involved in innate immunity, where the target ligands for S-MBP should be on the surface of exogenous microorganisms. In this study, we tried to find endogenous ligands for this endogenous lectin, Among the cells tested, only the lymphocytes from thymus of BALB/c mice expressed ligands for S-MBP on their surface, those from bone marrow, spleen, mesenteric lymph nodes and peripheral blood all being negative, Interestingly, among the thymocytes, only the immature thymocytes with the CD4(+)CD8(+)CD3(low) phenotype expressed ligands for S-MBP, and ligands for S-MBP decreased on their maturation, A major cell surface glycoprotein bearing S-MBP ligands was isolated and identified as CD45RO, which is a transmembrane protein with tyrosine phosphatase activity, Deglycosylation experiments with N-glycanase and endoglycosidase H indicated that the S-MBP ligands on thymic CD45 are high mannose type or hybrid type N-linked oligosaccharides. This unique presentation of S-MBP ligands on this special CD45 isoform suggested the possibility that the oligosaccharide portion of CD45 on immature thymocytes is associated with the maturation, development or selection events of thymocytes.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,SAKYO KU,KYOTO 606,JAPAN	Kyoto University								ALEXANDER D, 1992, IMMUNOL TODAY, V13, P477, DOI 10.1016/0167-5699(92)90021-X; CHILDS RA, 1990, J BIOL CHEM, V265, P20770; HOLT P, 1994, SCAND J IMMUNOL, V39, P202, DOI 10.1111/j.1365-3083.1994.tb03361.x; IKEDA K, 1987, J BIOL CHEM, V262, P7451; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; JOHNSON NA, 1989, J BIOL CHEM, V264, P6220; KAWASAKI N, 1989, J BIOCHEM-TOKYO, V106, P483, DOI 10.1093/oxfordjournals.jbchem.a122878; KAWASAKI N, 1983, J BIOCHEM, V94, P937, DOI 10.1093/oxfordjournals.jbchem.a134437; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KOZUTSUMI Y, 1980, BIOCHEM BIOPH RES CO, V95, P658, DOI 10.1016/0006-291X(80)90836-0; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFRANCOIS L, 1987, J IMMUNOL, V139, P3718; NIEUWENHUIS P, 1988, IMMUNOL TODAY, V9, P372, DOI 10.1016/0167-5699(88)91236-4; OHTA M, 1990, J BIOL CHEM, V265, P1980; OHTA M, 1994, GLYCOCONJUGATE J, V11, P304, DOI 10.1007/BF00731203; OKA S, 1988, ARCH BIOCHEM BIOPHYS, V260, P257, DOI 10.1016/0003-9861(88)90448-1; ONG CJ, 1994, J IMMUNOL, V152, P3793; RAVIOLA E, 1972, J EXP MED, V136, P466, DOI 10.1084/jem.136.3.466; REISNER Y, 1976, CELL IMMUNOL, V25, P129, DOI 10.1016/0008-8749(76)90103-9; SATO T, 1993, BIOCHEMISTRY-US, V32, P12694, DOI 10.1021/bi00210a019; SGROI D, 1995, P NATL ACAD SCI USA, V92, P4026, DOI 10.1073/pnas.92.9.4026; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TAI T, 1977, BIOCHEM BIOPH RES CO, V78, P434, DOI 10.1016/0006-291X(77)91273-6; THIEL S, 1992, IMMUNOPHARMACOLOGY, V24, P91, DOI 10.1016/0162-3109(92)90015-5; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.immunol.7.1.339; WHITEHEART SW, 1990, CELL IMMUNOL, V125, P337, DOI 10.1016/0008-8749(90)90089-A; YOKOTA Y, 1995, J BIOCHEM-TOKYO, V117, P414, DOI 10.1093/jb/117.2.414	28	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4581	4584						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617714				2022-12-25	WOS:A1996TX69700004
J	Chu, YF; Lee, EYC; Schlender, KK				Chu, YF; Lee, EYC; Schlender, KK			Activation of protein phosphatase 1 - Formation of a metalloenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLASE-PHOSPHATASE; SKELETAL-MUSCLE; PHOSPHOPROTEIN PHOSPHATASE; DIVALENT-CATIONS; TRACE-ELEMENTS; EXPRESSION; ENZYME; PURIFICATION; FLUORIDE; ATP	The recombinant catalytic subunit of protein phosphatase 1 is produced as an inactive enzyme which can be activated by Mn2+ (Zhang, Z., Bai, G., Deans-Zirattu, S., Browner, M. F., and Lee, E. Y. C. (1992) J. Biol. Chem. 267, 1484-1490). In this report, we have investigated the effects of divalent cations on the activity of recombinant catalytic subunit of protein phosphatase 1. Latent phosphatase 1 can be activated by Co2+ or Mn2+, whereas other metal ions tested including Fe2+, Zn2+, Mg2+, Ca2+, Cu2+, or Ni2+ were not effective or were only weakly effective in activating the enzyme. The Mn2+ stimulated activity was susceptible to inactivation by EDTA; however, the Co2+-activated phosphatase was stable after dilution and chelation of the Co2+ with excess EDTA. After stable activation of phosphatase 1 using Co-57(2+), a stoichiometric amount of Co-57(2+) was shown to be tightly bound to phosphatase 1. These findings demonstrate for the first time the generation of a stable metalloenzyme form of phosphatase 1. Fe2+ reversibly deactivated the Co2+-stimulated activity, but did not displace the bound Co2+. Interestingly, treatment of the enzyme with a combination of Fe2+ and Zn2+ (but not the individual metal ions) significantly activated phosphatase 1. These results suggest that at least two metal binding sites exist on the enzyme and that protein phosphatase 1 may be an iron/zinc metalloprotein in vivo.	MED COLL OHIO, DEPT PHARMACOL, TOLEDO, OH 43699 USA; UNIV MIAMI, SCH MED, DEPT BIOCHEM & MOLEC BIOL, MIAMI, FL 33101 USA	University of Miami					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018512] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 36576] Funding Source: Medline; NIDDK NIH HHS [DK 18512] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUTIGAN DL, 1980, BIOCHEMISTRY-US, V19, P5787, DOI 10.1021/bi00566a019; BRAUTIGAN DL, 1982, BIOCHEMISTRY-US, V21, P1977, DOI 10.1021/bi00538a001; Burchell A, 1978, BIOCHEM SOC T, V6, P220, DOI 10.1042/bst0060220a; CAI LW, 1995, BIOCHEM BIOPH RES CO, V208, P274, DOI 10.1006/bbrc.1995.1334; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; CHU YF, 1994, BBA-PROTEIN STRUCT M, V1208, P45, DOI 10.1016/0167-4838(94)90158-9; DEFREYN G, 1979, Biochemical Society Transactions, V7, P1050; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HSIAO KJ, 1978, J BIOL CHEM, V253, P6901; IYENGAR V, 1988, CLIN CHEM, V34, P474; KATO K, 1972, J BIOL CHEM, V247, P7420; KATO K, 1975, J BIOCHEM-TOKYO, V77, P811, DOI 10.1093/oxfordjournals.jbchem.a130787; KHANDELWAL RL, 1980, BIOCHIM BIOPHYS ACTA, V618, P95; KHATRA BS, 1978, BIOCHEM BIOPH RES CO, V85, P647, DOI 10.1016/0006-291X(78)91211-1; KILLILEA SD, 1978, ARCH BIOCHEM BIOPHYS, V191, P638, DOI 10.1016/0003-9861(78)90402-2; MACKENZIE CW, 1980, BIOCHIM BIOPHYS ACTA, V614, P413, DOI 10.1016/0005-2744(80)90231-4; MERLEVEDE W, 1966, J BIOL CHEM, V241, P3517; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; ULLMAN B, 1975, BIOCHIM BIOPHYS ACTA, V403, P393, DOI 10.1016/0005-2744(75)90068-6; VERSIECK J, 1985, CRC CR REV CL LAB SC, V22, P97, DOI 10.3109/10408368509165788; VILLAMORUZZI E, 1984, J BIOL CHEM, V259, P5857; VINCENT JB, 1990, FEBS LETT, V263, P265, DOI 10.1016/0014-5793(90)81389-6; VINCENT JB, 1990, FASEB J, V4, P3009, DOI 10.1096/fasebj.4.12.2394317; YAN SCB, 1982, MOL CELL BIOCHEM, V42, P21; ZHANG Z, 1993, ADV PROTEIN PHOSPHAT, V7, P183; ZHANG ZJ, 1992, J BIOL CHEM, V267, P1484; ZHANG ZJ, 1993, ARCH BIOCHEM BIOPHYS, V303, P402, DOI 10.1006/abbi.1993.1301; ZHUO S, 1993, J BIOL CHEM, V268, P17754; ZHUO SQ, 1994, J BIOL CHEM, V269, P26234	35	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2574	2577		10.1074/jbc.271.5.2574	http://dx.doi.org/10.1074/jbc.271.5.2574			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576223	hybrid			2022-12-25	WOS:A1996TT48800037
J	Hunt, JE; Stevens, RL; Austen, KF; Zhang, J; Xia, ZN; Ghildyal, N				Hunt, JE; Stevens, RL; Austen, KF; Zhang, J; Xia, ZN; Ghildyal, N			Natural disruption of the mouse mast cell protease 7 gene in the C57BL/6 mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL PEPTIDE; MOLECULAR-CLONING; MESSENGER-RNA; SERINE PROTEASE; COMPLEMENTARY-DNA; HUMAN TRYPTASE; DIFFERENTIATION; TRANSCRIPTION; ACTIVATION; SEQUENCE	The C57BL/6 mouse differs from the BALB/c mouse in that its ear and skin mast cells and its progenitor bone marrow-derived mast cells (mBMMCs) do not express mouse mast cell protease (mMCP) 7. We now report that, as detected by nuclear run-on analysis, the mMCP-7 gene is transcribed in C57BL/6 mBMMCs at a rate comparable to that in BALB/c mBMMCs. Reverse transcriptase polymerase chain reaction analysis and sequencing of the product revealed that the ears of C57BL/6 mice contain small amounts of a mMCP-7 transcript that possesses a 98-base pair deletion. The deletion begins at a normally quiescent cryptic splice site (G(416)TGAG), 98 base pairs upstream of the normal exon 2/intron 2 splice site (G(514)TGAG), and introduces a premature stop codon in the alternatively spliced transcript. Thus, even if translated, the mature protein would consist of only 18 amino acids as compared to 245 amino acids in normal mMCP-7. Sequence analysis of the mMCP-7 gene in the C57BL/6 mouse revealed that the cryptic splice site is activated due to a G(514) --> A point mutation at the first nucleotide of the normal exon 2/intron 2 splice site. This is the first report of a mutation of a gene that encodes a mast cell secretory granule constituent that leads to its loss of expression. Moreover, the mMCP-7 gene is the first found in any species that sequentially has undergone a splice site mutation to cause retention of an intron and then a second splice site mutation to cause activation of a cryptic splice site.	BRIGHAM & WOMENS HOSP,DIV RHEUMATOL & IMMUNOL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital	Hunt, JE (corresponding author), HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115, USA.				NIAID NIH HHS [AI-23483, AI-22531, AI-07306] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022531, R01AI023483, T32AI007306, R01AI022531] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATWATER JA, 1990, ANNU REV GENET, V24, P519; BAUMANN B, 1985, EMBO J, V4, P351, DOI 10.1002/j.1460-2075.1985.tb03636.x; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P133; CHEN Z, 1993, J HISTOCHEM CYTOCHEM, V41, P961, DOI 10.1177/41.7.7685789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CROMLISH JA, 1987, J BIOL CHEM, V262, P1363; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; FRANCONI GM, 1989, J PHARMACOL EXP THER, V248, P947; GHILDYAL N, 1994, J IMMUNOL, V153, P2624; GREEN MC, 1991, HDB GENETICALLY STAN, P6; GREENBERG ME, 1994, CURRENT PROTOCOLS MO; GRUBER BL, 1989, J CLIN INVEST, V84, P1657, DOI 10.1172/JCI114344; GURISH MF, 1994, MAMM GENOME, V5, P656, DOI 10.1007/BF00411467; GURISH MF, 1993, J BIOL CHEM, V268, P11372; GURISH MF, 1995, IMMUNITY, V3, P175, DOI 10.1016/1074-7613(95)90087-X; IDE H, 1995, J BIOCHEM-TOKYO, V118, P210, DOI 10.1093/oxfordjournals.jbchem.a124880; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; LAGUNOFF D, 1991, ARCH BIOCHEM BIOPHYS, V291, P52, DOI 10.1016/0003-9861(91)90104-Q; MAIER M, 1983, J IMMUNOL, V130, P2352; MAQUAT LE, 1981, CELL, V27, P543, DOI 10.1016/0092-8674(81)90396-2; MCNEIL HP, 1991, J BIOL CHEM, V266, P20316; MCNEIL HP, 1992, P NATL ACAD SCI USA, V89, P11174, DOI 10.1073/pnas.89.23.11174; MILLER JS, 1990, J CLIN INVEST, V86, P864, DOI 10.1172/JCI114786; MILLER JS, 1989, J CLIN INVEST, V84, P1188, DOI 10.1172/JCI114284; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKAI K, 1994, GENE, V141, P171, DOI 10.1016/0378-1119(94)90567-3; PELTZ SW, 1993, GENE DEV, V7, P1737, DOI 10.1101/gad.7.9.1737; RAZIN E, 1984, J IMMUNOL, V132, P1479; REYNOLDS DS, 1989, J BIOL CHEM, V264, P20094; REYNOLDS DS, 1991, J BIOL CHEM, V266, P3847; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; RUOSS SJ, 1991, J CLIN INVEST, V88, P493, DOI 10.1172/JCI115330; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; SCHWARTZ LB, 1983, J IMMUNOL, V130, P1891; SCHWARTZ LB, 1981, J BIOL CHEM, V256, P1939; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; STACK MS, 1994, J BIOL CHEM, V269, P9416; STEVENS RL, 1994, P NATL ACAD SCI USA, V91, P128, DOI 10.1073/pnas.91.1.128; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; Trong H Le, 1989, BIOCHEMISTRY-US, V28, P391, DOI 10.1021/BI00427A054; VANDERSLICE P, 1989, BIOCHEMISTRY-US, V28, P4148, DOI 10.1021/bi00436a004; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811	47	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2851	2855		10.1074/jbc.271.5.2851	http://dx.doi.org/10.1074/jbc.271.5.2851			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576265	hybrid			2022-12-25	WOS:A1996TT48800079
J	Hazen, SL; Hsu, FF; Heinecke, JW				Hazen, SL; Hsu, FF; Heinecke, JW			p-hydroxyphenylacetaldehyde is the major product of L-tyrosine oxidation by activated human phagocytes - A chloride-dependent mechanism for the conversion of free amino acids into reactive aldehydes by myeloperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL MYRISTATE ACETATE; HYPOCHLOROUS ACID; HUMAN-NEUTROPHILS; PROTEINS; SYSTEM; LEUKOCYTES; CHLORINATION; MACROPHAGES; DITYROSINE; RADICALS	Reactive aldehydes generated during lipid peroxidation have been implicated in the pathogenesis of atherosclerosis as well as other inflammatory diseases, A potential catalyst for such reactions is myeloperoxidase, a hemeprotein secreted by activated phagocytes. We now report that activated neutrophils utilize the myeloperoxidase-H2O2-chloride system to convert L-tyrosine to p-hydroxyphenylacetaldehyde. Production of p-hydroxyphenylacetaldehyde was nearly quantitative at physiological concentrations of L-tyrosine and chloride, Aldehyde generation required myeloperoxidase, H2O2, L-tyrosine, and chloride ion; it was inhibited by the H2O2 scavenger catalase and by the heme poisons azide and cyanide. Phorbol ester- and calcium ionophore-stimulated human neutrophils likewise generated p-hydroxyphenylacetaldehyde from L-tyrosine by a pathway inhibited by azide, cyanide, and catalase, Aldehyde production accounted for 75% of H2O2 generated by optimally stimulated neutrophils at plasma concentrations of L-tyrosine and chloride, Collectively, these results indicate that activated phagocytes, under physiological conditions, utilize myeloperoxidase to execute the chloride dependent conversion of L-tyrosine to the lipid-soluble aldehyde, p-hydroxyphenylacetaldehyde, in near quantitative yield, Moreover, like aldehydes derived from lipid peroxidation, amino acid-derived aldehydes may exert potent biological effects in vascular lesions and other sites of inflammation.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,DIV ATHEROSCLEROSIS NUTR & LIPID RES,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Hazen, Stanley L/ABD-5845-2021	Hsu, Fong-Fu/0000-0001-5368-0183	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012293] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00954] Funding Source: Medline; NIA NIH HHS [O1 AG12293] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; AMADO R, 1984, METHOD ENZYMOL, V107, P377; Andersen S.O, 1966, ACTA PHYSIOL SC S263, V66, P1; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BUETTNER GR, 1993, ARCH BIOCHEM BIOPHYS, V300, P535, DOI 10.1006/abbi.1993.1074; CLARK RA, 1986, BIOCHEM BIOPH RES CO, V135, P451, DOI 10.1016/0006-291X(86)90015-X; FRIDOVICH I, 1985, CRC HDB METHODS OXYG, P213; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; HAZELL LJ, 1994, BIOCHEM J, V302, P297, DOI 10.1042/bj3020297; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HORI H, 1994, J BIOL CHEM, V269, P8388; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; LINDER M, 1991, NUTRITIONAL BIOCH ME, P98; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARQUEZ LA, 1994, J BIOL CHEM, V269, P7950; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; PEREIRA WE, 1973, BIOCHIM BIOPHYS ACTA, V313, P170, DOI 10.1016/0304-4165(73)90198-0; PRINCE RC, 1988, TRENDS BIOCHEM SCI, V13, P286, DOI 10.1016/0968-0004(88)90119-3; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; REDDY VY, 1994, J BIOL CHEM, V269, P4683; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; Schauenstein E., 1979, CIBA F S, V67, P225; SEALY RC, 1985, J AM CHEM SOC, V107, P3401, DOI 10.1021/ja00298a001; SEGAL AW, 1989, J CLIN INVEST, V83, P1785, DOI 10.1172/JCI114083; SHRINER RL, 1980, SYSTEMATIC IDENTIFIC; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; STRAUSS RR, 1971, INFECT IMMUN, V3, P595, DOI 10.1128/IAI.3.4.595-602.1971; THOMAS EL, 1982, BIOCHEMISTRY-US, V21, P6299, DOI 10.1021/bi00267a040; VISSERS MCM, 1991, ARCH BIOCHEM BIOPHYS, V285, P53, DOI 10.1016/0003-9861(91)90327-F; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; WHITE JG, 1974, AM J PATHOL, V75, P45; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; WINTERBOURN CC, 1985, BIOCHIM BIOPHYS ACTA, V840, P204, DOI 10.1016/0304-4165(85)90120-5; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; WRIGHT DG, 1977, AM J PATHOL, V87, P273; ZGLICZYNSKI JM, 1971, BIOCHIM BIOPHYS ACTA, V235, P419, DOI 10.1016/0005-2744(71)90281-6; ZHANG HF, 1993, J BIOL CHEM, V268, P5535; ZIMMERMAN GA, 1995, J NUTR, V125, pS1661	44	99	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1861	1867		10.1074/jbc.271.4.1861	http://dx.doi.org/10.1074/jbc.271.4.1861			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567631	hybrid			2022-12-25	WOS:A1996TR32000013
J	Muller, ML; IrkensKiesecker, U; Rubinstein, B; Taiz, L				Muller, ML; IrkensKiesecker, U; Rubinstein, B; Taiz, L			On the mechanism of hyperacidification in lemon - Comparison of the vacuolar H+-ATPase activities of fruits and epicotyls	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTON PUMP; BETA-VULGARIS; MAMMALIAN KIDNEY; CORN COLEOPTILES; STORAGE TISSUE; ACIDIFICATION; INHIBITOR; MEMBRANE; ACID; PURIFICATION	Lemon fruit vacuoles acidify their lumens to pH 2.5, 3 pH units lower than typical plant vacuoles. To study the mechanism of hyperacidification, the kinetics of ATP-driven proton pumping by tonoplast vesicles from lemon fruits and epicotyls were compared. Fruit vacuolar membranes were less permeable to protons than epicotyl membranes. H+ pumping by epicotyl membranes was chloride-dependent, stimulated by sulfate, and inhibited by the classical vacuolar ATPase (V-ATPase) inhibitors nitrate, bafilomycin, N-ethylmaleimide, and N,N'-dicyclohexylcarbodiimide. In addition, the epicotyl H+ pumping activity was inactivated by oxidation at room temperature, and oxidation was reversed by dithiothreitol. Cold inactivation of the epicotyl V-ATPase by nitrate (greater than or equal to 100 mM) was correlated with the release of V-1 complexes from the membrane. In contrast, H+ pumping by the fruit tonoplast-enriched membranes was chloride-independent, largely insensitive to the V-ATPase inhibitors, and resistant to oxidation. Unlike the epicotyl H+-ATPase, the fruit H+-ATPase activity was partially inhibited by 200 mu M vanadate. Cold inactivation treatment failed to inhibit H+ pumping activity of the fruit membranes, even though immunoblots showed that V-1 complexes were released from the membrane. However, cold inactivation doubled the percent inhibition by 200 mu M vanadate from 30% to 60%. These results suggest the presence of two H+-ATPases in the fruit preparation: a V-ATPase and an unidentified vanadate-sensitive H+-ATPase. Attempts to separate the two activities in their native membranes on linear sucrose density gradients were unsuccessful. However, following detergent-solubilization and centrifugation on a glycerol density gradient, the two ATPase activities were resolved: a nitrate-sensitive V-type ATPase that is also partially inhibited by 200 mu M vanadate, and an apparently novel vanadate-sensitive ATPase that is also partially inhibited by nitrate.	UNIV CALIF SANTA CRUZ,DEPT BIOL,SINSHEIMER LABS,SANTA CRUZ,CA 95064; UNIV MASSACHUSETTS,DEPT BIOL,AMHERST,MA 01003	University of California System; University of California Santa Cruz; University of Massachusetts System; University of Massachusetts Amherst								ABOUZAMZAM AM, 1970, J AM SOC HORTIC SCI, V95, P203; ALBERTY RA, 1969, J BIOL CHEM, V244, P3290; BENNETT AB, 1984, PLANT PHYSIOL, V74, P545, DOI 10.1104/pp.74.3.545; CHANSON A, 1985, PLANT PHYSIOL, V78, P232, DOI 10.1104/pp.78.2.232; CHATTERJEE D, 1992, J EXP BIOL, V172, P193; DAVIES JM, 1994, P NATL ACAD SCI USA, V91, P8547, DOI 10.1073/pnas.91.18.8547; FENG Y, 1992, J BIOL CHEM, V267, P19769; FENG Y, 1994, J BIOL CHEM, V269, P13224; Fiske CH, 1925, J BIOL CHEM, V66, P375; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; GRIFFITH CJ, 1986, PLANT PHYSIOL, V81, P120, DOI 10.1104/pp.81.1.120; GUERN J, 1989, PLANT PHYSIOL, V89, P27, DOI 10.1104/pp.89.1.27; KRAUSS W, 1987, PHOTOCHEM PHOTOBIOL, V45, P837, DOI 10.1111/j.1751-1097.1987.tb07892.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUTTGE U, 1987, NEW PHYTOL, V106, P593, DOI 10.1111/j.1469-8137.1987.tb00163.x; MAESHIMA M, 1989, J BIOL CHEM, V264, P20068; MAGNIN T, 1995, PLANT PHYSIOL, V109, P285, DOI 10.1104/pp.109.1.285; MANDALA S, 1986, J BIOL CHEM, V261, P2850; Martell A. E., 1977, CRITICAL STABILITY C, V3; MARTINOIA E, 1992, BOT ACTA, V105, P132; Meidner H., 1968, PHYSL STOMATA, P138; MELLMAN I, 1992, J EXP BIOL, V172, P39; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; MORIYAMA Y, 1988, ION PUMPS STRUCTURE, P387; MORIYASU Y, 1984, CELL STRUCT FUNCT, V9, P225, DOI 10.1247/csf.9.225; MULBERG AR, 1991, J BIOL CHEM, V264, P20590; RAUSCH T, 1985, PLANT PHYSIOL, V77, P881, DOI 10.1104/pp.77.4.881; REA PA, 1987, PHYSIOL PLANTARUM, V71, P131, DOI 10.1111/j.1399-3054.1987.tb04630.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHMIDT AL, 1993, ARCH BIOCHEM BIOPHYS, V301, P165, DOI 10.1006/abbi.1993.1129; Sinclair W.B., 1984, BIOCH PHYSL LEMON OT, P79; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TAIZ L, 1992, J EXP BIOL, V172, P113; TAIZ L, 1994, BBA-BIOMEMBRANES, V1194, P329, DOI 10.1016/0005-2736(94)90315-8; XIE XS, 1993, J BIOL CHEM, V268, P25063; ZHANG K, 1992, J BIOL CHEM, V267, P14539; ZHANG K, 1992, J BIOL CHEM, V267, P9701	38	105	109	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1916	1924						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567639				2022-12-25	WOS:A1996TR32000021
J	Nicolli, A; Basso, E; Petronilli, V; Wenger, RM; Bernardi, P				Nicolli, A; Basso, E; Petronilli, V; Wenger, RM; Bernardi, P			Interactions of cyclophilin with the mitochondrial inner membrane and regulation of the permeability transition pore, a cyclosporin A-sensitive channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; CALCIUM-RELEASE CHANNEL; LIVER-MITOCHONDRIA; BINDING-PROTEIN; IMMUNOSUPPRESSANT FK506; HEART-MITOCHONDRIA; DIVALENT-CATIONS; MODULATION; INHIBITION; MECHANISM	Mammalian mitochondria possess an inner membrane channel, the permeability transition pore (MTP), which can be inhibited by nanomolar concentrations of cyclosporin (CS) A. The molecular basis for MTP inhibition by CSA remains unclear. Mitochondria also possess a matrix cyclophilin (CyP) with a unique N-terminal sequence (CyP-M). To test the hypothesis that it interacts with the MTP, we have studied the interactions of CyP-M with rat liver mitochondria by Western blotting with a specific antibody against its unique N terminus. Although sonication in isotonic sucrose at pH 7.4 releases a large proportion of CyP-M, a sizeable CyP-M fraction sediments with submitochondrial particles at 150,000 x g. We show that the interactions of this CyP-M pool with submitochondrial particles are disrupted (i) by the addition of CSA, which inhibits the pore, but not of CSH, which does not, and (ii) by acidic pH condition, which also leads to selective inhibition of the MTP; furthermore, we show that the effect of acidic pH on CyP-M binding is prevented by diethylpyrocarbonate, which fully prevents the inhibitory effect of H+ on the MTP (Nicolli, A., Petronilli, V., and Bernardi, P. (1993) Biochemistry 32, 4461-4465). These data suggest that CyP-M binding is involved in opening of the MTP and that pore inhibition by CSA and protons may be due to unbinding of CyP-M from its putative binding site on the MTP. A role for CyP-M in MTP regulation is also supported by a study with a series of CSA derivatives with graded affinity for CyP, We show that with each derivative the potency at inhibition of the peptidylprolyl cis-trans-isomerase activity of CyP-M purified to homogeneity is similar to that displayed at inhibition of MTP opening, relative to that displayed by CSA, Decreased binding to CS P-M (but not CyP-A) and decreased efficiency at MTP inhibition is obtained by substitutions in position 8 while a 4-substituted, nonimmunosuppressive derivative is as effective as the native CSA molecule, indicating that calcineurin is not involved in MTP inhibition by CSA.	UNIV PADUA,SCH MED,DEPT BIOMED SCI,BIOPHYS & MEMBRANE BIOL LAB,I-35121 PADUA,ITALY; UNIV PADUA,SCH MED,CNR,STUDY BIOMEMBRANES UNIT,I-35121 PADUA,ITALY; SANDOZ PHARMA LTD,DEPT IMMUNOL,CH-4002 BASEL,SWITZERLAND	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Novartis; Sandoz			Bernardi, Paolo/C-3656-2008; Basso, Emy/F-7687-2015; Petronilli, Valeria/C-3558-2015	Bernardi, Paolo/0000-0001-9187-3736; Basso, Emy/0000-0003-2962-7213; Petronilli, Valeria/0000-0003-4026-6404				ANDREEVA L, 1994, EUR J BIOCHEM, V221, P261, DOI 10.1111/j.1432-1033.1994.tb18737.x; ANDREEVA L, 1995, EUR J BIOCHEM, V230, P1125, DOI 10.1111/j.1432-1033.1995.tb20664.x; BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; BERNARDI P, 1996, IN PRESS J BIOENERG; BRAM RJ, 1994, NATURE, V371, P355, DOI 10.1038/371355a0; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CONNERN CP, 1992, BIOCHEM J, V284, P381, DOI 10.1042/bj2840381; CONNERN CP, 1994, BIOCHEM J, V302, P321, DOI 10.1042/bj3020321; COSTANTINI P, 1995, TOXICOLOGY, V99, P77, DOI 10.1016/0300-483X(94)02997-9; CROMPTON M, 1988, BIOCHEM J, V255, P357; DAWSON TL, 1993, AM J PHYSIOL, V264, pC961, DOI 10.1152/ajpcell.1993.264.4.C961; DILISA F, 1995, J PHYSIOL-LONDON, V486, P1; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; EVTODIENKO YV, 1994, CELL CALCIUM, V15, P143, DOI 10.1016/0143-4160(94)90053-1; FISCHER G, 1984, BIOCHIM BIOPHYS ACTA, V791, P87, DOI 10.1016/0167-4838(84)90285-1; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P67, DOI 10.1016/0079-6107(94)00009-X; GRIFFITHS EJ, 1991, BIOCHEM J, V274, P611, DOI 10.1042/bj2740611; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HARRISON RK, 1990, BIOCHEMISTRY-US, V29, P3813, DOI 10.1021/bi00468a001; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HELEKAR SA, 1994, NEURON, V12, P179, DOI 10.1016/0896-6273(94)90162-7; HOEK JB, 1995, BBA-MOL BASIS DIS, V1271, P93, DOI 10.1016/0925-4439(95)00015-V; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; ICHAS F, 1994, FEBS LETT, V348, P211, DOI 10.1016/0014-5793(94)00615-6; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KE HM, 1993, P NATL ACAD SCI USA, V90, P3324, DOI 10.1073/pnas.90.8.3324; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENARTOWICZ E, 1991, J BIOENERG BIOMEMBR, V23, P679, DOI 10.1007/BF00785817; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MCGUINNESS OM, 1991, EUR J BIOCHEM, V194, P671; MIKOL V, 1994, PROTEIN ENG, V7, P597, DOI 10.1093/protein/7.5.597; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NICOLLI A, 1993, BIOCHEMISTRY-US, V32, P4461, DOI 10.1021/bi00067a039; NIKAIDO H, 1991, J BIOL CHEM, V266, P770; NOVGORODOV SA, 1992, J BIOL CHEM, V267, P16274; NOVGORODOV SA, 1991, BIOCHEM BIOPH RES CO, V180, P33, DOI 10.1016/S0006-291X(05)81250-1; PAPAGEORGIOU C, 1994, J MED CHEM, V37, P3674, DOI 10.1021/jm00048a002; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; PETRONILLI V, 1994, BBA-BIOENERGETICS, V1187, P255, DOI 10.1016/0005-2728(94)90122-8; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; PETRONILLI V, 1991, BIOCHIM BIOPHYS ACTA, V1058, P297, DOI 10.1016/S0005-2728(05)80250-6; ROSSER BG, 1995, GASTROENTEROLOGY, V108, P252, DOI 10.1016/0016-5085(95)90032-2; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SCHREIER MH, 1993, TRANSPLANT P, V25, P502; SEEBACH D, 1993, HELV CHIM ACTA, V76, P1564, DOI 10.1002/hlca.19930760415; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SZABO I, 1992, J BIOL CHEM, V267, P2940; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; WENGER RM, 1994, FEBS LETT, V340, P255, DOI 10.1016/0014-5793(94)80149-5; WENGER RM, 1988, TRANSPL P, V20, P313; YU LP, 1994, BBA-PROTEIN STRUCT M, V1209, P24, DOI 10.1016/0167-4838(94)90132-5; ZAHREBELSKI G, 1995, HEPATOLOGY, V21, P1361, DOI 10.1002/hep.1840210521; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZEDERLUTZ G, 1994, J CHROMATOGR B, V662, P301, DOI 10.1016/0378-4347(94)00211-8; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZYDOWSKY LD, 1992, PROTEIN SCI, V1, P1092, DOI 10.1002/pro.5560010903	67	414	425	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2185	2192		10.1074/jbc.271.4.2185	http://dx.doi.org/10.1074/jbc.271.4.2185			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567677	hybrid			2022-12-25	WOS:A1996TR32000059
J	Rangan, VS; Oskouian, B; Smith, S				Rangan, VS; Oskouian, B; Smith, S			Identification of an inverted CCAAT box motif in the fatty-acid synthase gene as an essential element for mediation of transcriptional regulation by cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; SITE; INDUCTION; PROMOTER; INVITRO; CELLS	The antagonistic effect of cAMP on the insulin-induced expression of fatty acid synthase (FAS) in liver could be mimicked in vitro using H4IIE hepatoma cells, both by measuring the response of the endogenous FAS gene and by assaying expression of transfected reporter genes containing promoter elements of the FAS gene. 5'-Deletion analysis and replacement mutagenesis revealed that an essential element required for cAMP antagonism of the insulin effect is an inverted CCAAT box located between nucleotides -99 and -92. DNase I footprinting and gel shift analysis revealed that this region can bind a protein present in nuclei of liver and spleen, organs that express high and undetectable levels of FAS, respectively. This protein is not a CCAAT/enhancer-binding protein, C/EBP. Thus, the FAS gene appears unusual in that the sequence element required for transcriptional regulation by cAMP is neither a cAMP response element (CRE) nor a binding site for AP-1, AP-2, or C/EBP. These results suggest that essential to the regulation of FAS transcription by cAMP is the interaction of an inverted CCAAT box motif with a constitutively produced trans-acting factor that either itself undergoes modification in response to cAMP or associates with a protein that is produced or modified by cAMP exposure.	CHILDRENS HOSP,OAKLAND RES INST,OAKLAND,CA 94609	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute					NIDDK NIH HHS [DK 42636] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042636] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLMANN DW, 1965, J LIPID RES, V6, P63; AMY CM, 1990, BIOCHEM J, V271, P675, DOI 10.1042/bj2710675; AMY CM, 1992, P NATL ACAD SCI USA, V89, P1105, DOI 10.1073/pnas.89.3.1105; BOSCH F, 1990, J BIOL CHEM, V265, P13677; BOULARAND S, 1995, J BIOL CHEM, V270, P3757, DOI 10.1074/jbc.270.8.3757; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; GEELEN MJH, 1980, DIABETES, V29, P1006, DOI 10.2337/diab.29.12.1006; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; KAGAWA N, 1990, J BIOL CHEM, V265, P11299; KINANE TB, 1993, J BIOL CHEM, V268, P24669; KINGSTON RE, 1989, CURRENT PROTOCOLS MO; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LI XB, 1994, J NEUROCHEM, V63, P28; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; NAKAMURA N, 1989, P NATL ACAD SCI USA, V86, P56, DOI 10.1073/pnas.86.1.56; Nepokroeff C M, 1975, Methods Enzymol, V35, P37, DOI 10.1016/0076-6879(75)35136-7; PARK K, 1993, J BIOL CHEM, V268, P17811; PAULAUSKIS JD, 1989, J BIOL CHEM, V264, P574; PAWLAK J, 1986, CANCER RES, V46, P4712; Sambrook J, 1989, MOL CLONING LABORATO; SELDEN RF, 1995, CURRENT PROTOCOLS MO; WOLF SS, 1994, BIOCHEM BIOPH RES CO, V203, P943, DOI 10.1006/bbrc.1994.2273; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	29	64	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2307	2312		10.1074/jbc.271.4.2307	http://dx.doi.org/10.1074/jbc.271.4.2307			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567694	hybrid			2022-12-25	WOS:A1996TR32000076
J	Rossi, SG; Rotundo, RL				Rossi, SG; Rotundo, RL			Transient interactions between collagen-tailed acetylcholinesterase and sulfated proteoglycans prior to immobilization on the extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE HEPARAN-SULFATE; RAT SKELETAL-MUSCLES; ASYMMETRIC ACETYLCHOLINESTERASE; BASAL LAMINA; NEUROMUSCULAR-JUNCTION; MOLECULAR-FORMS; SOLUBILIZATION; LOCALIZATION; MEMBRANE; AGRIN	Heparin is capable of solubilizing a subset of collagen-tailed (A(12)) acetylcholinesterase (AChE) molecules from skeletal muscle fibers, but cannot detach AChE from the synaptic basal lamina (Rossi, S. G., and Rotundo, R. L. (1993) J. Biol. Chem. 268, 19152-19159). In the present study, we used tissue-cultured quail myotubes to show that, like adult fibers, neither heparin- nor high salt-containing buffers detached AChE molecules from cell-surface clusters. Prelabeling clustered AChE molecules with anti-AChE monoclonal antibody 1A2 followed by incubation in heparin-containing medium showed that there was no reduction in the number or size of preexisting AChE clusters. In contrast, incubation of myotubes with culture medium containing heparin for up to 4 days reversibly blocked the accumulation of new cell-surface AChE molecules without affecting the rate of AChE synthesis or assembly. Newly synthesized A(12) AChE becomes tightly attached to the extracellular matrix following externalization, However, in the presence of heparin, blocking the initial interactions between A(12) AChE and the extracellular matrix results in release of AChE into the medium with a t(1/2) of similar to 3 h. Together, these results suggest that once A(12) AChE is localized on the cell surface, initially attached via electrostatic interactions, additional factors or events are responsible for its selective and more permanent retention on the basal lamina.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT R124,MIAMI,FL 33101	University of Miami					NATIONAL INSTITUTE ON AGING [R01AG005917] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG005917] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON MJ, 1983, J CELL BIOL, V97, P1396, DOI 10.1083/jcb.97.5.1396; ANGLISTER L, 1991, J CELL BIOL, V115, P755, DOI 10.1083/jcb.115.3.755; ANGLISTER L, 1985, J CELL BIOL, V101, P735, DOI 10.1083/jcb.101.3.735; BARAT A, 1986, FEBS LETT, V195, P209, DOI 10.1016/0014-5793(86)80162-4; BAYNE EK, 1984, J CELL BIOL, V99, P1486, DOI 10.1083/jcb.99.4.1486; BAYNE EK, 1981, COLD SPRING HARBOR R, V2, P259; BETZ W, 1973, J PHYSIOL-LONDON, V230, P673, DOI 10.1113/jphysiol.1973.sp010211; BON S, 1978, EUR J BIOCHEM, V85, P1, DOI 10.1111/j.1432-1033.1978.tb12207.x; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRANDAN E, 1987, FEBS LETT, V213, P159, DOI 10.1016/0014-5793(87)81483-7; BRANDAN E, 1985, J CELL BIOL, V101, P985, DOI 10.1083/jcb.101.3.985; BRANDAN E, 1984, BIOCHEM J, V221, P415, DOI 10.1042/bj2210415; BRANDAN E, 1986, J NEUROSCI RES, V15, P185, DOI 10.1002/jnr.490150208; FERNANDEZVALLE C, 1989, J BIOL CHEM, V264, P14043; FUENTES ME, 1993, NEURON, V10, P679, DOI 10.1016/0896-6273(93)90169-R; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HALL ZW, 1971, NATURE-NEW BIOL, V232, P62, DOI 10.1038/newbio232062a0; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; IMAI Y, 1994, ARCH BIOCHEM BIOPHYS, V312, P392, DOI 10.1006/abbi.1994.1324; JASMIN BJ, 1993, NEURON, V11, P467, DOI 10.1016/0896-6273(93)90151-G; JOHNSON CD, 1975, ANAL BIOCHEM, V64, P229, DOI 10.1016/0003-2697(75)90423-6; LIETH E, 1993, J NEUROSCI, V13, P2509, DOI 10.1523/JNEUROSCI.13-06-02509.1993; LOMO T, 1980, J PHYSIOL-LONDON, V303, P191, DOI 10.1113/jphysiol.1980.sp013280; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MELO F, 1993, FEBS LETT, V319, P249, DOI 10.1016/0014-5793(93)80556-A; NITKIN RM, 1987, J CELL BIOL, V105, P2471, DOI 10.1083/jcb.105.6.2471; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; PEREZTUR J, 1991, FEBS LETT, V286, P25, DOI 10.1016/0014-5793(91)80932-S; PEREZTUR J, 1991, NEUROSCI LETT, V126, P172, DOI 10.1016/0304-3940(91)90546-6; ROSSI SG, 1992, J CELL BIOL, V119, P1657, DOI 10.1083/jcb.119.6.1657; ROSSI SG, 1993, J BIOL CHEM, V268, P19152; ROTUNDO RL, 1980, CELL, V22, P595, DOI 10.1016/0092-8674(80)90369-4; ROTUNDO RL, 1990, J CELL BIOL, V110, P715, DOI 10.1083/jcb.110.3.715; ROTUNDO RL, 1984, J BIOL CHEM, V259, P3186; ROTUNDO RL, 1984, P NATL ACAD SCI-BIOL, V81, P479, DOI 10.1073/pnas.81.2.479; ROTUNDO RL, 1979, J BIOL CHEM, V254, P4790; RUBIN LL, 1985, P NATL ACAD SCI USA, V82, P7121, DOI 10.1073/pnas.82.20.7121; SANES JR, 1986, J CELL BIOL, V102, P420, DOI 10.1083/jcb.102.2.420; SWENARCHUK LE, 1990, DEVELOPMENT, V110, P51; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; TORRES JC, 1983, BIOCHEM J, V215, P201, DOI 10.1042/bj2150201; TORRES JC, 1983, FEBS LETT, V154, P265, DOI 10.1016/0014-5793(83)80162-8; VIGNY M, 1983, J BIOL CHEM, V258, P8794; WALLACE BG, 1985, NATURE, V315, P574, DOI 10.1038/315574a0; WALLACE BG, 1989, J NEUROSCI, V9, P1294; WEINBERG CB, 1979, DEV BIOL, V68, P631, DOI 10.1016/0012-1606(79)90233-1; YOUNKIN SG, 1982, J BIOL CHEM, V257, P13630	47	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1979	1987		10.1074/jbc.271.4.1979	http://dx.doi.org/10.1074/jbc.271.4.1979			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567647	hybrid			2022-12-25	WOS:A1996TR32000029
J	Seelan, RS; Gopalakrishnan, L; Scarpulla, RC; Grossman, LI				Seelan, RS; Gopalakrishnan, L; Scarpulla, RC; Grossman, LI			Cytochrome c oxidase subunit VIIa liver isoform - Characterization and identification of promoter elements in the bovine gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE ADP/ATP TRANSLOCATOR; TISSUE-SPECIFIC REGULATION; SYNTHASE BETA-SUBUNIT; TRANSCRIPTION FACTORS; ATP SYNTHASE; SKELETAL-MUSCLE; NUCLEAR GENE; IV GENE; EXPRESSION; HEART	Cytochrome c oxidase subunit VIIa is specified by two nuclear genes, one (COX7AH) producing a heart/muscle-specific isoform and the other (COX7AL) a form expressed in all tissues. We have isolated both genes to examine their transcriptional regulation. Here, me characterize the core promoter of COX7AL and show that a 92-base pair region Banking the 5'-end promotes most of the activity of this gene. The 92-bp basal promoter contains sites for the nuclear respiratory factors NRF-1 and NRF-2, which have been shown to contribute to the transcription of a number of nuclear genes involved in mitochondrial respiratory activity, and also at least four Sp1 motifs. We show that both the NRF-1 and NRF-2 binding sites are functional in COX7AL and present evidence suggesting that interaction between the NRF-1 site and an upstream element contributes to expression.	WAYNE STATE UNIV, SCH MED, CTR MOLEC MED & GENET, DETROIT, MI 48201 USA; NORTHWESTERN UNIV, SCH MED, DEPT CELL & MOLEC BIOL, CHICAGO, IL 60611 USA	Wayne State University; Northwestern University				Seelan, Ratnam/0000-0002-8925-1070	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048517, R56GM032525, R01GM032525] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32525, GM 48517] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN LA, 1995, J BIOL CHEM, V270, P110, DOI 10.1074/jbc.270.1.110; ANTHONY G, 1993, P NATL ACAD SCI USA, V90, P1652, DOI 10.1073/pnas.90.5.1652; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BASU A, 1993, J BIOL CHEM, V268, P4188; BONNE G, 1993, EUR J BIOCHEM, V217, P1099, DOI 10.1111/j.1432-1033.1993.tb18342.x; Bothwell A., 1990, METHODS CLONING ANAL; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CAPALDI RA, 1987, CURR TOP BIOENERG, V15, P91; CAPITANIO N, 1994, BIOCHEMISTRY-US, V33, P12521, DOI 10.1021/bi00207a020; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; CHAU CMA, 1992, J BIOL CHEM, V267, P6999; CHUNG AB, 1992, J BIOL CHEM, V267, P21154; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; EWART GD, 1991, FEBS LETT, V292, P79, DOI 10.1016/0014-5793(91)80839-U; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GROSSMAN LI, 1995, BBA-GENE STRUCT EXPR, V1260, P361, DOI 10.1016/0167-4781(94)00232-R; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; HOSHINAGA H, 1994, J BIOCHEM-TOKYO, V115, P194, DOI 10.1093/oxfordjournals.jbchem.a124317; KADENBACH B, 1981, FEBS LETT, V135, P1, DOI 10.1016/0014-5793(81)80932-5; KADENBACH B, 1986, J BIOENERG BIOMEMBR, V18, P39, DOI 10.1007/BF00743611; KADENBACH B, 1987, CURR TOP BIOENERG, V15, P113; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KUMAR G, 1992, GENE, V110, P101, DOI 10.1016/0378-1119(92)90450-4; LAMARCHE AEP, 1992, J BIOL CHEM, V267, P22473; LI K, 1990, J BIOL CHEM, V265, P20585; LIGHTOWLERS R, 1990, J BIOL CHEM, V265, P2677; Maxam A M, 1980, Methods Enzymol, V65, P499; POYTON RO, 1988, ANN NY ACAD SCI, V550, P289, DOI 10.1111/j.1749-6632.1988.tb35344.x; POYTON RO, 1992, BIOCHIM BIOPHYS ACTA, V1101, P252, DOI 10.1016/S0005-2728(05)80033-7; PREISS T, 1994, BBA-MOL CELL RES, V1221, P286, DOI 10.1016/0167-4889(94)90252-6; PREISS T, 1993, J BIOL CHEM, V268, P10659; ROHDICH F, 1993, BIOCHEMISTRY-US, V32, P8499, DOI 10.1021/bi00084a015; Sambrook J, 1989, MOL CLONING LABORATO; SCHILLACE R, 1994, BBA-BIOENERGETICS, V1188, P391, DOI 10.1016/0005-2728(94)90060-4; SCHLERF A, 1988, EMBO J, V7, P2387, DOI 10.1002/j.1460-2075.1988.tb03083.x; SEELAN RS, 1991, J BIOL CHEM, V266, P19752; SEELAN RS, 1993, GENOMICS, V18, P527; SEELAN RS, 1992, BIOCHEMISTRY-US, V31, P4696, DOI 10.1021/bi00134a024; TAANMAN JW, 1994, BIOCHEMISTRY-US, V33, P11833, DOI 10.1021/bi00205a020; TAANMAN JW, 1993, J BIOL CHEM, V268, P18754; TOMURA H, 1990, J BIOL CHEM, V265, P6525; TRUEBLOOD CE, 1988, MOL CELL BIOL, V8, P4537, DOI 10.1128/MCB.8.10.4537; VILLENA JA, 1994, J BIOL CHEM, V269, P32649; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATERLAND RA, 1991, J BIOL CHEM, V266, P4180; WEISHAUPT A, 1992, BIOCHEMISTRY-US, V31, P11477, DOI 10.1021/bi00161a028	52	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2112	2120		10.1074/jbc.271.4.2112	http://dx.doi.org/10.1074/jbc.271.4.2112			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567667	hybrid			2022-12-25	WOS:A1996TR32000049
J	Clegg, CH; Haugen, HS; Boring, LF				Clegg, CH; Haugen, HS; Boring, LF			Promoter sequences in the RI beta subunit gene of cAMP-dependent protein kinase required for transgene expression in mouse brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I REGULATORY SUBUNIT; NERVOUS-SYSTEM; RESPONSE ELEMENT; RECEPTOR GENE; DNA-BINDING; TATA-LESS; TRANSCRIPTION; REGION; CELLS; MECHANISMS	Neural-specific expression of the mouse regulatory type-I beta (RI beta) subunit gene of cAMP-dependent protein kinase is controlled by a fragment of genomic DNA comprised of a TATA-less promoter flanked by 1.5 kilobases of 5'-upstream sequence and a 1.8-kilobase intron. This DNA contains a complex arrangement of transcription factor binding motifs, and previous experiments have shown that many of these are recognized by proteins found in brain nuclear extract, To identify sequences critical for RIP expression in functional neurons, we performed a deletion analysis in transgenic mice. Evidence is presented that the GC-rich proximal promoter is responsible for cell type-specific expression in vivo because RI beta DNA containing as little as 17 base pairs (bp) of 5'-upstream sequence was functional in mouse brain. One likely regulatory element coincides with the start of transcription and includes an EGR-1 motif and 3 consecutive SP1 sites within a 21-bp interval, Maximal RI beta promoter activity required the adjacent 663 bp of 5'-upstream DNA where most, but not all, of the regulatory activity was localized between position -663 and -333. A 37-bp direct repeat lies within this region that contains 2 basic helix-loop-helix binding sites, each of which are overlapped by two steroid hormone receptor half-sites, and a shared AP1 consensus sequence, Intron I sequences were also tested, and deletion of a 388-bp region containing numerous Sp1-like sequences lowered transgene activity significantly, These results have identified specific regions of the RIP promoter that are required for the expression of this signal transduction protein in mouse neurons.			Clegg, CH (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST, 3005 1ST AVE, SEATTLE, WA 98121 USA.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X				BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CADD GG, 1990, J BIOL CHEM, V265, P19502; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CLEGG CH, 1994, MOL CELL NEUROSCI, V5, P153, DOI 10.1006/mcne.1994.1017; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; CROSBY SD, 1992, P NATL ACAD SCI USA, V89, P4739, DOI 10.1073/pnas.89.10.4739; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUDAI Y, 1987, CRC CR REV BIOCH MOL, V22, P221, DOI 10.3109/10409238709101484; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; JAN YN, 1993, P NATL ACAD SCI USA, V90, P8305, DOI 10.1073/pnas.90.18.8305; KLEBE RJ, 1969, J CELL BIOL, V43, pA69; LI RS, 1994, J BIOL CHEM, V269, P7941; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LUO ZJ, 1992, J BIOL CHEM, V267, P24738; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MASSA JS, 1991, DEV NEUROSCI-BASEL, V13, P47, DOI 10.1159/000112140; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MINER JN, 1992, GENE DEV, V6, P2491, DOI 10.1101/gad.6.12b.2491; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NEUMAN T, 1993, MOL BRAIN RES, V20, P199, DOI 10.1016/0169-328X(93)90042-N; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; PORTEUS MH, 1991, NEURON, V7, P221, DOI 10.1016/0896-6273(91)90260-7; PRICE M, 1992, NEURON, V8, P241, DOI 10.1016/0896-6273(92)90291-K; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; ROGERS KV, 1992, MOL ENDOCRINOL, V6, P1756, DOI 10.1210/me.6.10.1756; ROSENFELD MG, 1991, GENE DEV, V5, P897, DOI 10.1101/gad.5.6.897; ROSNER B, 1990, FUNDAMENTALS BIOSTAT, P304; RUVKUN G, 1991, CELL, V64, P475, DOI 10.1016/0092-8674(91)90227-P; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; STRUHL K, 1991, NEURON, V7, P177, DOI 10.1016/0896-6273(91)90256-Y; THOMAS M, 1993, EUR J BIOCHEM, V218, P143, DOI 10.1111/j.1432-1033.1993.tb18360.x; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YOON SO, 1992, NEURON, V9, P55, DOI 10.1016/0896-6273(92)90220-8	48	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1638	1644		10.1074/jbc.271.3.1638	http://dx.doi.org/10.1074/jbc.271.3.1638			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576164	hybrid			2022-12-25	WOS:A1996TQ52500060
J	Kevil, C; Carter, P; Hu, B; DeBenedetti, A				Kevil, C; Carter, P; Hu, B; DeBenedetti, A			Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation	ONCOGENE			English	Article						FGF-2; eIF-4E/F; breast cancer; translation/secretion	FIBROBLAST GROWTH-FACTOR; 5' NONTRANSLATED REGION; MOUTH-DISEASE-VIRUS; MESSENGER-RNA; PROTEIN-SYNTHESIS; INTERNAL INITIATION; MALIGNANT TRANSFORMATION; CELLS; EXPRESSION; SITE	The FGF-2 mRNA of most mammals contains a long and inhibitory 5' UTR in addition to at least two CUG codons upstream and in frame with the AUG start codon. These CUGs are used for translation initiation to generate several polypeptides, Cells overexpressing the translation initiation factor 4E produce and secrete large amounts of FGF-2, and particularly the largest, CUG1-initiated form. Overexpression of FGF-2 ia due to a translational enhancement of its mRNA, as indicated by its association with large polyribosomes in contrast to control cells, where it partitions mostly in fractions lighter than 80 S or small polyribosomes. Breast carcinomas expressing elevated eIF-4E also exhibit the large FGF-2 isoforms, which could play an important role in tumor angiogenesis. Translation of in vitro transcribed rat FGF-2 in reticulocyte lysates resulted in synthesis of four polypeptides, of similar size to those observed in vivo. Addition of purified eIF-4E preferentially increased translation of CUG1- and AUG-initiated isoforms. Since the different isoforms of FGF-2 may have different roles and intracellular distribution, the effects of the eIF-4 factors on FGF-2 expression could be important for the control of cell proliferation and differentiation.	LOUISIANA STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, SHREVEPORT, LA 71105 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport				Kevil, Christopher/0000-0003-0863-7260				ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ANANDAPPA SY, 1994, BRIT J CANCER, V69, P772, DOI 10.1038/bjc.1994.146; ANTHONY DD, 1991, J BIOL CHEM, V266, P10218; BARVE SS, 1994, J IMMUNOL, V152, P1171; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; CHAMPEME MH, 1994, MODERN PATHOL, V7, P900; CLEMENS MJ, 1987, TRANSCRIPTION TRANSL, P263; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DASSO MC, 1990, EUR J BIOCHEM, V187, P361, DOI 10.1111/j.1432-1033.1990.tb15313.x; De Benedetti Arrigo, 1994, Molecular and Cellular Differentiation, V2, P347; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DEBENEDETTI A, 1991, MOL CELL BIOL, V11, P5435, DOI 10.1128/MCB.11.11.5435; DONAHUE TF, 1988, CELL, V54, P621, DOI 10.1016/S0092-8674(88)80006-0; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Florkiewicz RZ, 1991, GROWTH FACTORS, V4, P265, DOI 10.3109/08977199109043912; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GOSPODAROWICZ D, 1987, J CELL PHYSIOL, P15; HALABAN R, 1988, ONCOGENE RES, V3, P177; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KEREKATTE V, 1995, INT J CANCER, V64, P27, DOI 10.1002/ijc.2910640107; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; KLEIN PS, 1994, SCIENCE, V265, P803, DOI 10.1126/science.8047887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUHN R, 1990, J VIROL, V64, P4625; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LE SY, 1993, NUCLEIC ACIDS RES, V21, P2445, DOI 10.1093/nar/21.10.2445; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; MORRISON RS, 1990, CANCER RES, V50, P2524; PAUSE A, 1993, CURR OPIN STRUC BIOL, V3, P953, DOI 10.1016/0959-440X(93)90161-D; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; RHOADS RE, 1988, TRENDS BIOCHEM SCI, V13, P52, DOI 10.1016/0968-0004(88)90028-X; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; Rhoads RE, 1991, CURR OPIN CELL BIOL, V3, P1019, DOI 10.1016/0955-0674(91)90123-G; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SCHEPER GC, 1992, J BIOL CHEM, V267, P7269; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SHANTZ LM, 1994, CANCER RES, V54, P2313; SHIMASAKI S, 1988, BIOCHEM BIOPH RES CO, V157, P256, DOI 10.1016/S0006-291X(88)80041-X; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SLACK J, 1994, MOL REPROD DEV, V39, P118, DOI 10.1002/mrd.1080390118; Sonenberg Nahum, 1993, Gene Expression, V3, P317; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; TAHARA SM, 1991, J BIOL CHEM, V266, P3594; THEILLET C, 1989, ONCOGENE, V4, P915; THOMAS AAM, 1992, NEW BIOL, V4, P404; THOMAS AAM, 1992, EUR J BIOCHEM, V207, P471, DOI 10.1111/j.1432-1033.1992.tb17073.x; THOMAS AAM, 1991, J VIROL, V65, P2953, DOI 10.1128/JVI.65.6.2953-2959.1991; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WELLSTEIN A, 1991, MOL F ONCOLOGY; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330	65	132	134	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2339	2348						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570185				2022-12-25	WOS:A1995TK70200018
J	MulliganPullyblank, P; Spitzer, JS; Gilden, BM; Fetrow, JS				MulliganPullyblank, P; Spitzer, JS; Gilden, BM; Fetrow, JS			Loop replacement and random mutagenesis of Omega-loop D, residues 70-84, in iso-1-cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; YEAST ISO-1-CYTOCHROME-C; CYTOCHROME-C; SACCHAROMYCES-CEREVISIAE; PHENOTYPIC SELECTION; PROTEIN STRUCTURES; FUNCTIONAL-ROLE; MUTANT FORMS; HEME LYASE; IMPORT	To study the role of omega loop D, residues 70-84, in the structure and function of yeast iso-l-cytochrome c, this loop was replaced with homologous and heterologous loops, A novel method was developed for rapid insertion of these mutations into the yeast chromosome at the CYC1 locus. The strains containing these loop replacement cytochromes cannot grow on nonfermentable carbon sources, indicating that the proteins are nonfunctional. Whole cell difference spectroscopy shows that no holocytochrome c is present; however, apoprotein is found by immunoblot analysis. Thus, apoprotein is present in these mutant strains, but it cannot bind heme and cannot compete with wild type apoprotein conversion to holoprotein. This is a unique example of a set of loop replacements that do not produce folded protein, and these results suggest that the loop D amino acid sequence in iso-1-cytochrome c plays a significant role in cytochrome c biosynthesis in vivo. To identify the significant amino acids in loop D, random mutagenesis of six highly conserved loop residues, Tyr-74, Ile-75, Pro-76, Gly-77, Thr-78, and Lys-79, was accomplished, Sequencing of the random mutants shows that strict conservation of none of these residues is required to produce a minimally functional cytochrome c, Preferences are found for small, hydrophilic or aromatic residues at position 74, hydrophobic residues at position 75, glycine and arginine at positions 76 and 77, and beta-branched amino acids at position 78. Implications for the role of loop D in the structure and function of iso-1-cytochrome c are discussed.	SUNY ALBANY,DEPT BIOL SCI,CTR MOLEC GENET,ALBANY,NY 12222	State University of New York (SUNY) System; State University of New York (SUNY) Albany				Fetrow, Jacquelyn/0000-0002-0528-2049	NIGMS NIH HHS [GM44829] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM044829] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEMANN RK, 1991, PROTEIN ENG, V4, P831, DOI 10.1093/protein/4.7.831; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bolivar F, 1979, Methods Enzymol, V68, P245; BOWLER BE, 1993, BIOCHEMISTRY-US, V32, P183, DOI 10.1021/bi00052a024; DUMONT MD, 1990, J BIOL CHEM, V265, P2733; DUMONT ME, 1991, MOL CELL BIOL, V11, P5487, DOI 10.1128/MCB.11.11.5487; Elliott W.B., 1971, DEV APPL SPECTROSC, P125, DOI [10.1007/978-1-4757-0782-3_5, DOI 10.1007/978-1-4757-0782-3_5]; ERNST JF, 1985, J BIOL CHEM, V260, P3225; FETROW JS, 1989, PROTEINS, V6, P372, DOI 10.1002/prot.340060404; FETROW JS, 1995, FASEB J, V9, P708, DOI 10.1096/fasebj.9.9.7601335; FUMO G, 1995, GENE, V164, P33, DOI 10.1016/0378-1119(95)00457-H; HAMPSEY DM, 1986, J BIOL CHEM, V261, P3259; HARPER JW, 1989, BIOCHEMISTRY-US, V28, P1875, DOI 10.1021/bi00430a067; HOLZSCHU D, 1987, J BIOL CHEM, V262, P7125; HYNES TR, 1989, NATURE, V339, P73, DOI 10.1038/339073a0; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LI LY, 1992, BIOCHEMISTRY-US, V31, P7826, DOI 10.1021/bi00149a012; LOUIE GV, 1990, J MOL BIOL, V214, P527, DOI 10.1016/0022-2836(90)90197-T; MATSUURA S, 1981, P NATL ACAD SCI-BIOL, V78, P4368, DOI 10.1073/pnas.78.7.4368; MATSUURA Y, 1982, J MOL BIOL, V156, P389, DOI 10.1016/0022-2836(82)90335-7; MILLER D, 1988, THESIS NW U CHICAGO; Moore G. R., 1990, CYTOCHROMES C EVOLUT; MURPHY MEP, 1993, PROTEIN SCI, V2, P1429, DOI 10.1002/pro.5560020907; NICHOLSON DW, 1988, J BIOL CHEM, V263, P19034; PETTIGREW GW, 1987, CYTOCHROMES C BIOL A; POMPLIANO DL, 1990, BIOCHEMISTRY-US, V29, P3186, DOI 10.1021/bi00465a005; POOLE LB, 1991, BIOCHEMISTRY-US, V30, P3621, DOI 10.1021/bi00229a005; RAMDAS L, 1986, BIOCHEMISTRY-US, V25, P6959, DOI 10.1021/bi00370a033; RAMDAS L, 1986, BIOCHEMISTRY-US, V25, P6952, DOI 10.1021/bi00370a032; RING CS, 1992, J MOL BIOL, V224, P685, DOI 10.1016/0022-2836(92)90553-V; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SALEMME FR, 1977, ANNU REV BIOCHEM, V46, P299, DOI 10.1146/annurev.bi.46.070177.001503; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWEINGRUBER ME, 1977, J BIOL CHEM, V252, P6577; SHERMAN F, 1974, GENETICS, V77, P255; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; TIMKOVICH R, 1976, J BIOL CHEM, V251, P4033; TIMKOVICH R, 1979, PORPHYRINS, P241; VENKATACHALAM CM, 1968, BIOPOLYMERS, V6, P1425, DOI 10.1002/bip.1968.360061006; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; YAMAMOTO T, 1992, YEAST, V8, P935, DOI 10.1002/yea.320081104; [No title captured]	47	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8633	8645		10.1074/jbc.271.15.8633	http://dx.doi.org/10.1074/jbc.271.15.8633			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621494	hybrid			2022-12-25	WOS:A1996UE73000025
J	Cavallini, L; Coassin, M; Borean, A; Alexandre, A				Cavallini, L; Coassin, M; Borean, A; Alexandre, A			Prostacyclin and sodium nitroprusside inhibit the activity of the platelet inositol 1,4,5-trisphosphate receptor and promote its phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-DEPENDENT PHOSPHORYLATION; FURA-2-LOADED HUMAN-PLATELETS; PROTEIN KINASE-C; CAPACITATIVE CALCIUM-ENTRY; CYCLIC-AMP; MEMBRANE-VESICLES; GUANOSINE 3',5'-MONOPHOSPHATE; INTRACELLULAR CA-2+; CA2+ MOBILIZATION; ACTIVATION	Prostaglandin I-2 (PGI(2)) and sodium nitroprusside (SNP) induce a rapid decay of the thrombin-promoted increase of [Ca2+](i) in aspirin-treated platelets incubated in the absence of external Ca2+, The mechanism of their effect was studied with a new method which utilizes ionomycin to increase [Ca2+](i), followed by bovine serum albumin (BSA) to remove the Ca2+ ionophore, The rapid decay of [Ca2+](i) after BSA is mostly due to the reuptake into the stores, since it is strongly inhibited by the endomembrane Ca2+-ATPase inhibitor thapsigargin, PGI(2) and SNP are without effect on the BSA-promoted decay both with and without thapsigargin, showing that they do not affect the activity of the Ca2+-ATPases, The fast decay of [Ca2+](i) after BSA is decreased by thrombin which produces the Ca2+ releaser inositol 1,4,5-trisphosphate (InsP(3)), thus counteracting the activity of the endomembrane Ca2+ pump, When added after thrombin, PGI(2) and SNP accelerate the BSA-activated decay of [Ca2+](i), However, under the same conditions, they do not decrease the concentration of InsP(3). In saponin-permeabilized platelets, cAMP and cGMP counteract the Ca2+ release induced by exogenous InsP(3). Their inhibitory effect disappears at high InsP, concentrations, This demonstrates that PGI(2) and SNP potentiate Ca2+ reuptake by inhibiting the InsP(3) receptor, Two bands of approximately 260 kDa are recognized by a monoclonal antibody recognizing the C-terminal region of the InsP(3) receptor, Both are phosphorylated rapidly, the heavier more intensely, in the presence of PGI(2) and SNP, The phosphorylation of the InsP(3) receptor is fast enough to be compatible with its involvement in the inhibition of the receptor by cyclic nucleotides.	UNIV PADUA,DIPARTIMENTO CHIM BIOL,CNR,CTR STUDIO BIOMEMBRANE,I-35121 PADUA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Padua								ADUNYAH SE, 1987, BIOCHIM BIOPHYS ACTA, V930, P401, DOI 10.1016/0167-4889(87)90013-9; ALONSO MT, 1991, BIOCHEM J, V280, P783, DOI 10.1042/bj2800783; BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BIRD GS, 1993, J BIOL CHEM, V268, P21486; BOURGUIGNON LYW, 1993, CELL BIOL INT, V17, P751, DOI 10.1006/cbir.1993.1136; BRONSTEIN I, 1989, J BIOLUM CHEMILUM, V4, P99, DOI 10.1002/bio.1170040116; BRUNE B, 1992, EUR J BIOCHEM, V207, P607, DOI 10.1111/j.1432-1033.1992.tb17087.x; BRUNE B, 1994, BIOCHEM J, V304, P993; BRUNE B, 1991, J BIOL CHEM, V266, P19232; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; CAVALLINI L, 1995, BIOCHEM J, V310, P449, DOI 10.1042/bj3100449; CAVALLINI L, 1994, EUR J BIOCHEM, V222, P693, DOI 10.1111/j.1432-1033.1994.tb18914.x; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; DEANA R, 1989, BIOCHIM BIOPHYS ACTA, V1014, P203, DOI 10.1016/0167-4889(89)90035-9; DIVIRGILIO F, 1988, BIOCHEM J, V256, P959, DOI 10.1042/bj2560959; DONI MG, 1993, ARCH BIOCHEM BIOPHYS, V301, P431, DOI 10.1006/abbi.1993.1167; DONI MG, 1988, BIOCHEM BIOPH RES CO, V156, P1316; DONI MG, 1994, BIOCHEM J, V303, P599, DOI 10.1042/bj3030599; DONI MG, 1991, BIOCHIM BIOPHYS ACTA, V1094, P323, DOI 10.1016/0167-4889(91)90093-D; ENOUF J, 1987, BIOCHIM BIOPHYS ACTA, V928, P76, DOI 10.1016/0167-4889(87)90087-5; FASOLATO C, 1993, J BIOL CHEM, V268, P20737; FEINSTEIN MB, 1983, BIOCHEM BIOPH RES CO, V113, P598, DOI 10.1016/0006-291X(83)91768-0; FERRIS CD, 1992, P NATL ACAD SCI USA, V54, P469; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GEIGER J, 1992, P NATL ACAD SCI USA, V89, P1031, DOI 10.1073/pnas.89.3.1031; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HETTASCH JM, 1987, BIOCHIM BIOPHYS ACTA, V931, P49, DOI 10.1016/0167-4889(87)90049-8; JOHANSSON JS, 1992, BIOCHIM BIOPHYS ACTA, V1105, P19, DOI 10.1016/0005-2736(92)90158-I; KAWAHARA Y, 1984, THROMB RES, V33, P203, DOI 10.1016/0049-3848(84)90181-6; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; LAPETINA EG, 1986, FEBS LETT, V195, P111, DOI 10.1016/0014-5793(86)80141-7; LEPEUCH CJ, 1983, BIOCHIM BIOPHYS ACTA, V731, P456, DOI 10.1016/0005-2736(83)90041-X; LEREA KM, 1987, P NATL ACAD SCI USA, V84, P5620, DOI 10.1073/pnas.84.16.5620; MAHAUTSMITH MP, 1990, J BIOL CHEM, V265, P10479; MAURICE DH, 1990, MOL PHARMACOL, V37, P671; MICHIKAWA T, 1994, J BIOL CHEM, V269, P9184; MIKOSHIBA K, 1993, TRENDS PHARMACOL SCI, V14, P86, DOI 10.1016/0165-6147(93)90069-V; NAKADE S, 1994, J BIOL CHEM, V269, P6735; NAKASHIMA S, 1986, BIOCHEM BIOPH RES CO, V135, P1099, DOI 10.1016/0006-291X(86)91041-7; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; OROURKE F, 1989, BIOCHEM J, V257, P715, DOI 10.1042/bj2570715; PANNOCCHIA A, 1985, BIOCHEM BIOPH RES CO, V127, P339, DOI 10.1016/S0006-291X(85)80164-9; PAPP B, 1993, CELL CALCIUM, V14, P531, DOI 10.1016/0143-4160(93)90074-G; POLLOCK WK, 1986, BIOCHEM BIOPH RES CO, V139, P308, DOI 10.1016/S0006-291X(86)80114-0; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; QUINTON TM, 1992, BIOCHEM BIOPH RES CO, V184, P893, DOI 10.1016/0006-291X(92)90675-B; RANDRIAMAMPITA C, 1995, J BIOL CHEM, V270, P29, DOI 10.1074/jbc.270.1.29; RANDRIAMAMPITA C, 1993, NATURE, V364, P808; RINK TJ, 1983, J PHYSIOL-LONDON, V338, pP66; RINK TJ, 1990, ANNU REV PHYSIOL, V52, P431, DOI 10.1146/annurev.ph.52.030190.002243; RINK TJ, 1987, J PHYSIOL-LONDON, V393, P513, DOI 10.1113/jphysiol.1987.sp016837; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SAGE SO, 1987, J BIOL CHEM, V262, P16364; SARGEANT P, 1992, CELL CALCIUM, V13, P553, DOI 10.1016/0143-4160(92)90035-Q; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SIESS W, 1989, BIOCHEM J, V258, P57, DOI 10.1042/bj2580057; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; TAKAI Y, 1981, BIOCHEM BIOPH RES CO, V101, P61, DOI 10.1016/S0006-291X(81)80010-1; THOMATSU T, 1989, BIOCHIM BIOPHYS ACTA, V1013, P190; WATSON SP, 1984, J BIOL CHEM, V259, P3199; WUYTACK F, 1994, J BIOL CHEM, V269, P1410; YAMANISHI J, 1983, THROMB RES, V32, P183, DOI 10.1016/0049-3848(83)90029-4; YOSHIDA K, 1989, CELL CALCIUM, V10, P299, DOI 10.1016/0143-4160(89)90056-0	63	98	105	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5545	5551		10.1074/jbc.271.10.5545	http://dx.doi.org/10.1074/jbc.271.10.5545			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621413	hybrid			2022-12-25	WOS:A1996TZ28600039
J	Wang, YP; Shin, WS; Kawaguchi, H; Inukai, M; Kato, M; Sakamoto, A; Uehara, Y; Miyamoto, M; Shimamoto, N; Korenaga, R; Ando, J; Toyooka, T				Wang, YP; Shin, WS; Kawaguchi, H; Inukai, M; Kato, M; Sakamoto, A; Uehara, Y; Miyamoto, M; Shimamoto, N; Korenaga, R; Ando, J; Toyooka, T			Contribution of sustained Ca2+ elevation for nitric oxide production in endothelial cells and subsequent modulation of Ca2+ transient in vascular smooth muscle cells in coculture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; RELAXING FACTOR; INTRACELLULAR CALCIUM; L-ARGININE; RELEASE; MECHANISMS; THAPSIGARGIN; SYNTHASE; STORES; CA-2+	To elucidate the intracellular Ca2+ (Ca-i(2+)) transient responsible for nitric oxide (NO) production in endothelial cells (ECs) and the subsequent Ca-i(2+) reduction in vascular smooth muscle cells (VSMCs), we administrated four agonists with different Ca-i(2+)-mobilizing mechanisms for both cells in iso- or coculture. We monitored the Ca-i(2+) of both cells by two-dimensional fura-2 imaging, simultaneously measuring NO production as NO2-. The order of potency of the agonists in terms of the peak Ca-i(2+) in ECs was bradykinin (100 nM > ATP (10 mu M) > ionomycin (50 nM) > thapsigargin (1 mu M). In contrast, the order in reference to both the extent of Ca-i(2+) reduction in cocultured VSMCs and the elevation in NO production over the level of basal release in ECs completely matched and was ranked as thapsigargin > ionomycin > ATP > bradykinin. Treatment by N-G-monomethyl-L-arginine monoacetate but not indomethacin or glybenclamide restored the Ca-i(2+), response in cocultured VSMCs to the isoculture level. In ECs, when the Ca2+ influx was blocked by Ni2+ or by chelating extracellular Ca2+, all four agonists markedly decreased NO production, the half decay time of the Ca-i(2+) degenerating phase, and the area under the Ca-i(2+) curve. The amount of produced NO hyperbolically correlated to the half decay time and the area under the Ca-i(2+) curve but not to the Ca-i(2+) peak level. Thus, the sustained elevation of Ca-i(2+) in ECs, mainly a result of Ca2+ influx, determines the active NO production and subsequent Ca-i(2+) reduction in adjacent VSMCs. Furthermore, L-arginine but not D-arginine or L-lysine at high dose (5 mM) without agonist enhanced the NO production, weakly reduced the Ca-i(2+) in ECs, and markedly decreased the Ca-i(2+) in VSMCs, demonstrating the autocrine and paracrine effects of NO (Shin, W. S., Sasaki, T., Kato, M., Hara, K., Seko, A., Yang, W. D., Shimamoto, N., Sugimoto, T., and Toyo-oka, T. (1992) J. Biol. Chem. 267, 20377-20382).	UNIV TOKYO,DEPT INTERNAL MED 2,HLTH SERV CTR,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,DEPT BIOMECH,TOKYO 113,JAPAN; TAKEDA CHEM IND LTD,MOLEC CHEM LAB,OSAKA 532,JAPAN	University of Tokyo; University of Tokyo; Takeda Chemical Industries								BIAN JH, 1991, J BIOL CHEM, V266, P8801; BLATTER LA, 1995, CIRC RES, V76, P922, DOI 10.1161/01.RES.76.5.922; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BOULANGER C, 1990, BRIT J PHARMACOL, V101, P152, DOI 10.1111/j.1476-5381.1990.tb12105.x; CASTILLO L, 1993, P NATL ACAD SCI USA, V90, P7749, DOI 10.1073/pnas.90.16.7749; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; EBASHI S, 1976, S SOC EXP BIOL, V30, P349; FLAVAHAN NA, 1992, CIRCULATION, V85, P1927, DOI 10.1161/01.CIR.85.5.1927; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURUKAWA KI, 1991, J BIOL CHEM, V266, P12337; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; HALLAM TJ, 1988, BIOCHEM J, V255, P179, DOI 10.1042/bj2550179; HECKER M, 1990, P NATL ACAD SCI USA, V87, P1812; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; KONISHI M, 1988, BIOPHYS J, V54, P1089, DOI 10.1016/S0006-3495(88)83045-5; KORENAGA R, 1994, BIOCHEM BIOPH RES CO, V198, P213, DOI 10.1006/bbrc.1994.1030; LUCKHOFF A, 1988, BRIT J PHARMACOL, V95, P189; LUCKHOFF A, 1986, J CELL PHYSIOL, V126, P414, DOI 10.1002/jcp.1041260312; LYNCH M, 1992, CELL CALCIUM, V13, P227, DOI 10.1016/0143-4160(92)90011-G; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MASUO M, 1991, CIRC RES, V69, P1327, DOI 10.1161/01.RES.69.5.1327; MITTAL CK, 1994, BIOCHEM BIOPH RES CO, V203, P8, DOI 10.1006/bbrc.1994.2141; NAKAKI T, 1990, LANCET, V336, P696, DOI 10.1016/0140-6736(90)92196-O; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; SCHMIDT K, 1989, EUR J PHARMACOL, V170, P157, DOI 10.1016/0014-2999(89)90536-0; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SHIN WS, 1992, J BIOL CHEM, V267, P20377; SHIN WS, 1991, CIRC RES, V69, P551, DOI 10.1161/01.RES.69.2.551; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TSUKAHARA H, 1993, BIOCHEM BIOPH RES CO, V193, P722, DOI 10.1006/bbrc.1993.1685; VANE JR, 1990, NEW ENGL J MED, V323, P27; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; YANG WD, 1994, BIOCHEM BIOPH RES CO, V264, P1146; YUI Y, 1991, J BIOL CHEM, V266, P3369	41	51	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5647	5655		10.1074/jbc.271.10.5647	http://dx.doi.org/10.1074/jbc.271.10.5647			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621428	hybrid			2022-12-25	WOS:A1996TZ28600054
J	Ichikawa, K; Ito, M; Hartshorne, DJ				Ichikawa, K; Ito, M; Hartshorne, DJ			Phosphorylation of the large subunit of myosin phosphatase and inhibition of phosphatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHATASE; ARTERIAL SMOOTH-MUSCLE; PROTEIN-KINASE-C; CA-2+; CALCIUM; ACID; IDENTIFICATION; SENSITIVITY; RAT	The partially purified myosin-bound phosphatase had an associated protein kinase that phosphorylated the holoenzyme, primarily on the large (130-kDa) subunit. Phosphorylation of the 130-kDa subunit resulted in inhibition of phosphatase activity. The major site of phosphorylation was threonine 654 of the 130-kDa subunit or threonine 695 of the 133-kDa isoform. Phosphorylation of the large subunit did not dissociate the holoenzyme. Dephosphorylation of the large subunit was achieved by the holoenzyme, and addition of the catalytic subunit of the type 2A enzyme did not increase the rate of dephosphorylation. The associated kinase was inhibited by chelerythrine, with half-maximal inhibition at approximately 5 mu M (in 150 mu M ATP). The associated kinase phosphorylated two synthetic peptides, one corresponding to the sequence flanking the phosphorylated threonine, Le. 648-661 of the 130-kDa subunit, and the other to a known protein kinase C substrate, i.e. a modified sequence from the autoinhibitory region of epsilon protein kinase C. The associated kinase was activated by arachidonic and oleic acid and to a lesser extent by myristic acid. The protein kinase that phosphorylated the 130-kDa subunit and resulted in inhibition of myosin phosphatase activity was not identified.	UNIV ARIZONA, MUSCLE BIOL GRP, TUCSON, AZ 85721 USA; MIE UNIV, SCH MED, DEPT INTERNAL MED 1, TSU, MIE 514, JAPAN	University of Arizona; Mie University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023615, P01HL020984] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 23615, HL 20984] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; ALLEN BG, 1994, TRENDS BIOCHEM SCI, V19, P362, DOI 10.1016/0968-0004(94)90112-0; ALLEN BG, 1994, J BIOL CHEM, V269, P29288; Beavo J A, 1974, Methods Enzymol, V38, P299; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRADLEY AB, 1987, J PHYSIOL-LONDON, V385, P437, DOI 10.1113/jphysiol.1987.sp016500; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; ERDODI F, 1995, IN PRESS BIOCH SMOOT; FUJIWARA T, 1989, J PHYSIOL-LONDON, V408, P535, DOI 10.1113/jphysiol.1989.sp017474; GERTHOFFER WT, 1991, AM J PHYSIOL, V261, pL15, DOI 10.1152/ajplung.1991.261.2.L15; GONG MC, 1995, J PHYSIOL-LONDON, V486, P113, DOI 10.1113/jphysiol.1995.sp020795; GONG MC, 1992, J BIOL CHEM, V267, P21492; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HIMPENS B, 1989, J PHYSIOL-LONDON, V413, P489, DOI 10.1113/jphysiol.1989.sp017665; IKEBE M, 1985, J BIOL CHEM, V260, P3146; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; KAWAMOTO S, 1989, J BIOL CHEM, V264, P2258; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1989, J BIOL CHEM, V264, P5339; KUBOTA Y, 1992, AM J PHYSIOL, V262, pC405, DOI 10.1152/ajpcell.1992.262.2.C405; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN BI, 1994, PROTEIN EXPRES PURIF, V5, P211, DOI 10.1006/prep.1994.1033; MASUO M, 1994, J GEN PHYSIOL, V104, P265, DOI 10.1085/jgp.104.2.265; MORGAN JP, 1984, J PHYSIOL-LONDON, V351, P155, DOI 10.1113/jphysiol.1984.sp015239; NISHIMURA J, 1988, BIOCHEM BIOPH RES CO, V157, P677, DOI 10.1016/S0006-291X(88)80303-6; OKUBO S, 1994, BIOCHEM BIOPH RES CO, V200, P429, DOI 10.1006/bbrc.1994.1467; OKUBO S, 1993, ADV PROTEIN PHOSPHAT, V7, P295; PERRIE WT, 1970, BIOCHEM J, V119, P31, DOI 10.1042/bj1190031; REMBOLD CM, 1988, CIRC RES, V63, P593, DOI 10.1161/01.RES.63.3.593; SASAKI K, 1990, JPN J CANCER RES, V81, P1272, DOI 10.1111/j.1349-7006.1990.tb02690.x; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SOMLYO AP, 1989, ADV PROTEIN PHOSPHAT, V5, P181; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; TRINKLEMULCAHY L, 1995, J BIOL CHEM, V270, P18191, DOI 10.1074/jbc.270.31.18191; WALSH MP, 1983, METHOD ENZYMOL, V99, P279	39	171	176	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4733	4740						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617739				2022-12-25	WOS:A1996TX69700029
J	Mertz, RJ; Worley, JF; Spencer, B; Johnson, JH; Dukes, ID				Mertz, RJ; Worley, JF; Spencer, B; Johnson, JH; Dukes, ID			Activation of stimulus-secretion coupling in pancreatic beta-cells by specific products of glucose metabolism - Evidence for privileged signaling by glycolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE K+ CHANNELS; INSULIN-SECRETION; PHOSPHOENOLPYRUVATE CARBOXYKINASE; ISLETS; DEHYDROGENASE; TRANSPORT; CALCIUM; RELEASE; DICHLOROACETATE; MECHANISMS	The energy requirements of most cells supplied with glucose are fulfilled by glycolytic and oxidative metabolism, yielding ATP. In pancreatic beta-cells, a rise in cytosolic ATP is also a critical signaling event, coupling closure of ATP-sensitive K+ channels (K-ATP) to insulin secretion via depolarization-driven increases in intracellular Ca2+ ([Ca2+](i)). We report that glycolytic but not Krebs cycle metabolism of glucose is critically involved in this signaling process. While inhibitors of glycolysis suppressed glucose-stimulated insulin secretion, blockers of pyruvate transport or Krebs cycle enzymes were without effect. While pyruvate was metabolized in islets to the same extent as glucose, it produced no stimulation of insulin secretion and did not block K-ATP. A membrane-permeant analog, methyl pyruvate, however, produced a block of K-ATP, a sustained rise in [Ca2+](i), and an increase in insulin secretion 6-fold the magnitude of that induced by glucose. These results indicate that ATP derived from mitochondrial pyruvate metabolism does not substantially contribute to the regulation of K-ATP, responses to a glucose challenge, supporting the notion of subcompartmentation of ATP within the beta-cell. Supranormal stimulation of the Krebs cycle by methyl pyruvate can, however, overwhelm intracellular partitioning of ATP and thereby drive insulin secretion.	GLAXO INC, RES INST, DEPT CELL PHYSIOL, RES TRIANGLE PK, NC 27709 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75216 USA	GlaxoSmithKline; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								AGIUS L, 1990, BIOCHEM J, V271, P387, DOI 10.1042/bj2710387; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT SJ, 1972, DIABETES, V21, P538, DOI 10.2337/diab.21.2.S538; ASHCROFT SJH, 1981, ISLETS LANGERHANS BI, P117; AZZONE GF, 1961, J BIOL CHEM, V236, P1510; BERNSTEIN IA, 1957, METHOD ENZYMOL, V4, P561, DOI 10.1016/0076-6879(57)04071-9; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CLARKE DD, 1991, NEUROCHEM RES, V16, P1055, DOI 10.1007/BF00965850; DEVOS A, 1995, 3 INT M PANCR ISL ST, P17; DEVRIES D, 1994, J NEUROL SCI, V124, P77, DOI 10.1016/0022-510X(94)90014-0; DUGGLEBY RG, 1974, J BIOL CHEM, V249, P175; DUKES ID, 1994, J BIOL CHEM, V269, P10979; DUKES ID, 1993, AM J PHYSIOL, V264, pE348, DOI 10.1152/ajpendo.1993.264.3.E348; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GILON P, 1992, J BIOL CHEM, V267, P20713; HELLMAN B, 1973, BIOCHEM J, V132, P775, DOI 10.1042/bj1320775; HOWELL SL, 1975, J CELL SCI, V19, P395; HUTTON JC, 1980, DIABETOLOGIA, V18, P395; JUNTTIBERGGREN L, 1994, J BIOL CHEM, V269, P14391; KOBAYASHI Y, 1994, AM J HUM GENET, V55, P206; LAI JCK, 1993, DEV NEUROSCI-BASEL, V15, P181, DOI 10.1159/000111334; MACDONALD MJ, 1989, ARCH BIOCHEM BIOPHYS, V269, P400, DOI 10.1016/0003-9861(89)90123-9; MACDONALD MJ, 1992, HORM METAB RES, V24, P158, DOI 10.1055/s-2007-1003284; MACDONALD MJ, 1985, DIABETES, V34, P246, DOI 10.2337/diabetes.34.3.246; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MALAISSE WJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P190, DOI 10.1016/0167-4889(87)90134-0; MATSCHINSKY FM, 1973, BIOCHEM BIOPH RES CO, V50, P193, DOI 10.1016/0006-291X(73)90826-7; MATTHEWS PM, 1995, HUM GENET, V96, P261; MCCONNELL HM, 1992, SCIENCE, V257, P1906, DOI 10.1126/science.1329199; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; PETER JB, 1972, BIOCHEMISTRY-US, V11, P2627, DOI 10.1021/bi00764a013; PHILIPSON LH, 1994, J BIOL CHEM, V269, P27787; PRESSEL DM, 1991, J MEMBRANE BIOL, V124, P239, DOI 10.1007/BF01994357; RAGAN CI, 1973, J BIOL CHEM, V248, P6876; ROE MW, 1994, AM J PHYSIOL, V266, pE852, DOI 10.1152/ajpendo.1994.266.6.E852; ROE MW, 1994, J BIOL CHEM, V269, P18279; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; ROE MW, 1993, J BIOL CHEM, V268, P9953; ROJAS E, 1994, ENDOCRINOLOGY, V134, P1771, DOI 10.1210/en.134.4.1771; ROSENTHAL M, 1992, CAN J PHYSIOL PHARM, V70, pS165, DOI 10.1139/y92-258; SEHLIN J, 1981, AM J PHYSIOL, V240, pC35, DOI 10.1152/ajpcell.1981.240.1.C35; SENER A, 1978, BIOCHEM J, V176, P217, DOI 10.1042/bj1760217; SENER A, 1992, J BIOL CHEM, V267, P13251; SMOLEN P, 1992, J MEMBRANE BIOL, V127, P9; SONNEWALD U, 1993, DEV NEUROSCI-BASEL, V15, P351, DOI 10.1159/000111355; SPENCER TL, 1976, BIOCHEM J, V154, P405, DOI 10.1042/bj1540405; STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6; Stryer L., 1988, BIOCHEMISTRY-US; SUGANO T, 1974, BIOCHIM BIOPHYS ACTA, V347, P340, DOI 10.1016/0005-2728(74)90074-7; TRENTHAM DR, 1968, BIOCHEM J, V109, P603, DOI 10.1042/bj1090603; WEISS JN, 1993, CARDIOVASC DRUG THER, V7, P499, DOI 10.1007/BF00877614; WEISS JN, 1987, SCIENCE, V238, P67, DOI 10.1126/science.2443972; WESTERGAARD N, 1995, NEUROSCI LETT, V185, P24, DOI 10.1016/0304-3940(94)11216-6; WHITEHOUSE S, 1974, BIOCHEM J, V141, P761, DOI 10.1042/bj1410761; WORLEY JF, 1994, J BIOL CHEM, V269, P14359; WORLEY JF, 1994, J BIOL CHEM, V269, P32055; ZAWALICH WS, 1992, ENDOCRINOLOGY, V131, P649, DOI 10.1210/en.131.2.649	61	89	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4838	4845						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617753	hybrid			2022-12-25	WOS:A1996TX69700043
J	Mieda, M; Haga, T; Saffen, DW				Mieda, M; Haga, T; Saffen, DW			Promoter region of the rat m4 muscarinic acetylcholine receptor gene contains a cell type-specific silencer element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNAS; INSITU HYBRIDIZATION; EXPRESSION; LOCALIZATION; BRAIN; IDENTIFICATION; TRANSCRIPTION; SUBTYPE; CLONING; FAMILY	We describe here the characterization of the rat m4 muscarinic acetylcholine receptor gene and the identification of its regulatory region, Two 5'-noncoding exons are located approximately 5 kilobases upstream from the coding exon, and at least two alternatively spliced variants of m4 mRNA are expressed in the neuronal cell line PC12D. There are two transcription initiation sites. The promoter region is CC-rich, contains no TATA-box, but has two potential CAAT boxes and several putative binding sites for transcription factors Sp1 and AP-2. We assessed the m4 promoter activity functionally in transient expression assays using luciferase as a reporter. The proximal 435-base pair (bp) sequence of the 5'-flanking region produced luciferase activity in both m4-expressing neuronal cell lines (PC12D and NG108-15) and non-neuronal cell lines (L6 and 3Y1B). A longer fragment containing an additional 638-bp sequence produced luciferase activity only in m4-expressing neuronal cell lines, These data suggest that the proximal 435-bp sequence contains a constitutive promoter and that a 638-bp sequence farther upstream contains a cell type-specific silencer element. A consensus sequence for the neural-restrictive silencer element is found within this 638-bp segment.			Mieda, M (corresponding author), UNIV TOKYO, FAC MED,INST BRAIN RES,DEPT BIOCHEM,BUNKYO KU, 7-3-1 HONGO, TOKYO 113, JAPAN.							ASHKENAZI A, 1988, COLD SPRING HARB SYM, V53, P263, DOI 10.1101/SQB.1988.053.01.033; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BEISCHLAG TV, 1995, BIOCHEMISTRY-US, V34, P5960, DOI 10.1021/bi00017a025; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BERNARD V, 1992, J NEUROSCI, V12, P3591; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1989, TRENDS PHARMACOL SCI, P11; BUCKLEY NJ, 1988, J NEUROSCI, V8, P4646; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS S, 1993, BIOCHIM BIOPHYS ACTA, V1172, P171, DOI 10.1016/0167-4781(93)90287-N; DICHIARA G, 1994, TRENDS NEUROSCI, V17, P228, DOI 10.1016/0166-2236(94)90005-1; DING DM, 1993, MOL BRAIN RES, V20, P181, DOI 10.1016/0169-328X(93)90040-V; FARRELL PJ, 1983, P NATL ACAD SCI-BIOL, V80, P1565, DOI 10.1073/pnas.80.6.1565; GAO B, 1993, GENE, V131, P243, DOI 10.1016/0378-1119(93)90300-R; HERSCH SM, 1994, J NEUROSCI, V14, P3351; KATOHSEMBA R, 1987, J NEUROSCI RES, V17, P36, DOI 10.1002/jnr.490170106; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; LEVEY AI, 1993, LIFE SCI, V52, P441, DOI 10.1016/0024-3205(93)90300-R; LEVEY AI, 1995, J NEUROSCI, V15, P4077; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; LIAO CF, 1989, J BIOL CHEM, V264, P7328; LYDON RG, 1995, CNS NEUROTRANSMITTER, P197; MAK JCW, 1993, LIFE SCI, V53, P1501, DOI 10.1016/0024-3205(93)90624-C; MAK JCW, 1992, AM J RESP CELL MOL, V7, P344, DOI 10.1165/ajrcmb/7.3.344; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MINOWA MT, 1992, P NATL ACAD SCI USA, V89, P3045, DOI 10.1073/pnas.89.7.3045; MINOWA T, 1992, BIOCHEMISTRY-US, V31, P8389, DOI 10.1021/bi00151a001; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; PADBURY JF, 1995, BIOCHEM BIOPH RES CO, V211, P254, DOI 10.1006/bbrc.1995.1804; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; TOTH M, 1994, MOL BRAIN RES, V27, P315, DOI 10.1016/0169-328X(94)90015-9; VILARO MT, 1991, NEUROSCIENCE, V40, P159, DOI 10.1016/0306-4522(91)90181-M; VILARO MT, 1990, NEUROSCI LETT, V114, P154, DOI 10.1016/0304-3940(90)90064-G; WEINER DM, 1990, P NATL ACAD SCI USA, V87, P7050, DOI 10.1073/pnas.87.18.7050; Wood I. C., 1993, Society for Neuroscience Abstracts, V19, P1338; ZHOU QY, 1992, J NEUROCHEM, V59, P1875, DOI 10.1111/j.1471-4159.1992.tb11023.x	40	40	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5177	5182						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617799				2022-12-25	WOS:A1996TX69700089
J	Moussaoui, M; Guasch, A; Boix, E; Cuchillo, CM; Nogues, MV				Moussaoui, M; Guasch, A; Boix, E; Cuchillo, CM; Nogues, MV			The role of non-catalytic binding subsites in the endonuclease activity of bovine pancreatic ribonuclease A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIQUID-CHROMATOGRAPHY; SITE; RNA; SEPARATION; EXISTENCE; CLEAVAGE; P2	Bovine pancreatic ribonuclease A catalyzes the depolymerization of RNA. There is much evidence that several subsites, in addition to the main catalytic site, are involved in the formation of the enzyme-substrate complex. This work analyzes the pattern of oligonucleotide formation by ribonuclease A using poly(C) as substrate. The poly(C) cleavage shows that the enzyme does not act in a random fashion but rather prefers the binding and cleavage of the longer substrate molecules and that the phosphodiester bond broken should be 6-7 residues apart from the end of the chain to be preferentially cleaved by ribonuclease A. The results demonstrate the model of the cleavage of an RNA chain based on the cooperative binding between the multisubsite binding structure of ribonuclease A and the phosphates of the polynucleotide (Pares, X., Nogues, M. V., de Llorens, R., and Cuchillo, C. M. (1991) in Essays in Biochemistry (Tipton, R. F., ed) Vol. 26, pp. 89-103, Portland Press Ltd., London). The contribution to the enzymatic process of the non-catalytic phosphate-binding subsite (p(2)) adjacent to the catalytic center has been analyzed in p(2) chemically modified ribonuclease A or by means of site-directed mutagenesis. In both cases deletion of p(2) abolishes the endonuclease activity of ribonuclease A, which is substituted by an exonuclease activity. All these results support the role of the multisubsite structure of the enzyme in the endonuclease activity and in the catalytic mechanism.	UNIV AUTONOMA BARCELONA, FAC CIENCIES, DEPT BIOQUIM & BIOL MOLEC, E-08193 BARCELONA, SPAIN; UNIV AUTONOMA BARCELONA, INST BIOL FONAMENTAL V VILLAR PALASI, E-08193 BARCELONA, SPAIN	Autonomous University of Barcelona; Autonomous University of Barcelona			Moussaoui, Mohammed/A-5172-2013; Nogues, M. Victoria/H-6100-2015; Boix, Ester/B-9038-2012; Guasch, Alicia/ABH-3427-2020; Moussaoui, Mohammed/Y-7259-2019	Moussaoui, Mohammed/0000-0001-6694-7692; Nogues, M. Victoria/0000-0002-7104-0961; Boix, Ester/0000-0003-1790-2142; Moussaoui, Mohammed/0000-0001-6694-7692				ALONSO J, 1985, J LIQ CHROMATOGR, V8, P299, DOI 10.1080/01483918508067079; ALONSO J, 1986, ARCH BIOCHEM BIOPHYS, V246, P681, DOI 10.1016/0003-9861(86)90324-3; ARUS C, 1981, BIOCHIM BIOPHYS ACTA, V660, P117, DOI 10.1016/0005-2744(81)90116-9; Blackburn P, 1982, ENZYMES, VXV, P317; BOIX E, 1994, J BIOL CHEM, V269, P2529; BOQUE L, 1994, J BIOL CHEM, V269, P19707; BRUNGER AT, 1985, P NATL ACAD SCI USA, V82, P8458, DOI 10.1073/pnas.82.24.8458; CUCHILLO CM, 1993, FEBS LETT, V333, P207, DOI 10.1016/0014-5793(93)80654-D; CUCHILLO CM, 1991, STRUCTURE, MECHANISM AND FUNCTION OF RIBONUCLEASES, P103; DELCARDAYRE SB, 1994, BIOCHEMISTRY-US, V33, P6031, DOI 10.1021/bi00186a001; DELLORENS R, 1989, PROTEIN ENG, V2, P417, DOI 10.1093/protein/2.6.417; Eftink M. R., 1987, HYDROLYTIC ENZYMES, P333; FERSHT A, 1985, ENZYME STRUCTURE MEC, P133; FILIPPI B, 1987, MACROMOLECULAR BIORE, P147; FONTECILLACAMPS JC, 1994, J BIOL CHEM, V269, P21526; GUASCH A, 1989, J CHROMATOGR, V473, P281, DOI 10.1016/S0021-9673(00)91311-6; IMURA N, 1965, J BIOCHEM-TOKYO, V58, P264, DOI 10.1093/oxfordjournals.jbchem.a128197; IRIE M, 1986, J BIOCHEM-TOKYO, V100, P1057, DOI 10.1093/oxfordjournals.jbchem.a121785; IRIE M, 1984, J BIOCHEM-TOKYO, V96, P89, DOI 10.1093/oxfordjournals.jbchem.a134833; IRIE M, 1984, J BIOCHEM-TOKYO, V95, P751, DOI 10.1093/oxfordjournals.jbchem.a134666; MCFARLAND GD, 1979, NUCLEIC ACIDS RES, V7, P1067, DOI 10.1093/nar/7.4.1067; MCPHERSON A, 1986, SCIENCE, V232, P765, DOI 10.1126/science.3961503; NOGUES MV, 1995, BBA-PROTEIN STRUCT M, V1253, P16, DOI 10.1016/0167-4838(95)00138-K; PARES X, 1991, ESSAYS BIOCHEM, V26, P89; PARES X, 1980, EUR J BIOCHEM, V105, P571, DOI 10.1111/j.1432-1033.1980.tb04534.x; RICHARDS FM, 1971, ENZYMES, V4, P647; RICHARDSON RM, 1990, BIOCHEM J, V267, P593, DOI 10.1042/bj2670593	27	29	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4687	4692						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617733				2022-12-25	WOS:A1996TX69700023
J	Pearn, MT; Randall, LL; Shortridge, RD; Burg, MG; Pak, WL				Pearn, MT; Randall, LL; Shortridge, RD; Burg, MG; Pak, WL			Molecular, biochemical, and electrophysiological characterization of Drosophila norpA mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PHOSPHOLIPASE-C; RHODOPSIN GENE; PHOTORECEPTOR DEACTIVATION; BINDING PROTEIN; CYCLIC-GMP; MELANOGASTER; EYE; PHOTOTRANSDUCTION; PURIFICATION	Inositol phosphate signaling has been implicated in a wide variety of eukaryotic cellular processes. In Drosophila, the phototransduction cascade is mediated by a phosphoinositide-specific phospholipase C (PLC) encoded by the norpA gene. We have characterized eight norpA mutants by electroretinogram (ERG), Western, molecular, and in vitro PLC activity analyses. ERG responses of the mutants show allele-dependent reductions in amplitudes and retardation in kinetics. The mutants also exhibit allele-dependent reductions in in vitro PLC activity levels and greatly reduced or undetectable NorpA protein levels. Three carry a missense mutation and five carry a nonsense mutation within the norpA coding sequence. In missense mutants, the amino acid substitution occurs at residues highly conserved among PLCs. These substitutions reduce the levels of both the NorpA protein and the PLC activity, with the reduction in PLC activity being greater than can be accounted for simply by the reduction in protein. The effects of the mutations on the amount and activity of the protein are much greater than their effects on the ERG, suggesting an amplification of the transduction signal at the effector (NorpA) protein level. Transgenic flies were generated by germline transformation of a null norpA mutant using a P-element construct containing the wild-type norpA cDNA driven by the ninaE promoter. Transformed flies show rescue of the electrophysiological phenotype in R1-R6 photoreceptors, but not in R7 or R8. The degeneration phenotype of R1-R6 photoreceptors is also rescued.	PURDUE UNIV, DEPT SCI BIOL, W LAFAYETTE, IN 47907 USA; SUNY BUFFALO, DEPT SCI BIOL, BUFFALO, NY 14214 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo					NEI NIH HHS [EY00033, EY07008] Funding Source: Medline; NATIONAL EYE INSTITUTE [T32EY007008, R37EY000033, R56EY000033, R01EY000033] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BACIGALUPO J, 1990, SER CENT ES, P27; BAIROCH A, 1990, FEBS LETT, V269, P454, DOI 10.1016/0014-5793(90)81214-9; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; BRISTOL A, 1988, COLD SPRING HARB SYM, V53, P915, DOI 10.1101/SQB.1988.053.01.105; BROWN CM, 1990, NUCLEIC ACIDS RES, V18, P6339, DOI 10.1093/nar/18.21.6339; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CROOKE ST, 1989, CELL CALCIUM, V10, P309, DOI 10.1016/0143-4160(89)90057-2; DEVARY O, 1987, P NATL ACAD SCI USA, V84, P6939, DOI 10.1073/pnas.84.19.6939; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; HARDIE RC, 1993, TRENDS NEUROSCI, V16, P371, DOI 10.1016/0166-2236(93)90095-4; HARDIE RC, 1983, BIOPHYS STRUCT MECH, V9, P171, DOI 10.1007/BF00537814; HARRIS WA, 1976, J PHYSIOL-LONDON, V256, P415; JOHNSON EC, 1986, J GEN PHYSIOL, V88, P651, DOI 10.1085/jgp.88.5.651; KATAN M, 1988, CELL, V54, P171, DOI 10.1016/0092-8674(88)90549-1; LARRIVEE DC, 1981, J GEN PHYSIOL, V78, P521, DOI 10.1085/jgp.78.5.521; LOLLEY RN, 1990, FASEB J, V4, P3001, DOI 10.1096/fasebj.4.12.1697545; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCKAY RR, 1995, J BIOL CHEM, V270, P13271, DOI 10.1074/jbc.270.22.13271; MELDRUM E, 1989, EUR J BIOCHEM, V182, P673, DOI 10.1111/j.1432-1033.1989.tb14878.x; MEYERTHOLEN EP, 1987, J COMP PHYSIOL A, V161, P793, DOI 10.1007/BF00610221; MINKE B, 1975, J COMP PHYSIOL, V98, P345, DOI 10.1007/BF00709805; MONTELL C, 1987, J NEUROSCI, V7, P1558; MORRIS AJ, 1990, SOC GEN PHY, V45, P61; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; PAK WL, 1969, NATURE, V222, P351, DOI 10.1038/222351a0; PAK WL, 1994, MOL GENETICS INHERIT, P29; PAK WL, 1991, PHOTOBIOL, V58, P871; PARK DG, 1993, J BIOL CHEM, V268, P3710; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNABEL P, 1993, EUR J BIOCHEM, V217, P1109, DOI 10.1111/j.1432-1033.1993.tb18343.x; SCHNEUWLY S, 1991, J BIOL CHEM, V266, P24314; SHORTRIDGE RD, 1991, J BIOL CHEM, V266, P12474; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STRYER L, 1983, COLD SPRING HARB SYM, V48, P841, DOI 10.1101/SQB.1983.048.01.087; SUH PG, 1988, CELL, V54, P161, DOI 10.1016/0092-8674(88)90548-X; Sved J, 1986, DROSOPH INF SERV, V63, P169; TAKEHIKO Y, 1993, P NATL ACAD SCI USA, V90, P1804; Thummel CS, 1992, DROS INF SERV, V71, P150; TOYOSHIMA S, 1990, J BIOL CHEM, V265, P14842; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1993, J BIOL CHEM, V268, P3704; YOSHIOKA T, 1985, J BIOCHEM-TOKYO, V98, P657, DOI 10.1093/oxfordjournals.jbchem.a135322; ZHU LQ, 1993, J BIOL CHEM, V268, P15994; ZUKER CS, 1987, J NEUROSCI, V7, P1550; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	55	115	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4937	4945						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617767				2022-12-25	WOS:A1996TX69700057
J	Koster, JC; Blanco, G; Mills, PB; Mercer, RW				Koster, JC; Blanco, G; Mills, PB; Mercer, RW			Substitutions of glutamate 781 in the Na,K-ATPase a subunit demonstrate reduced cation selectivity and an increased affinity for ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFECTED INSECT CELLS; MOLECULAR-CLONING; ALPHA-SUBUNIT; SODIUM-PUMP; EXPRESSION; DOMAIN; NA+,K+-ATPASE; OCCLUSION; LOCATION; BINDING	The intramembrane Glu(781) residue of the Na,K-ATPase alpha subunit has been postulated to have a role in the binding and/or occlusion of cations, To ascertain the role of Glu(781), th, residue was substituted with an aspartate, alanine, or lysine residue and the mutant Na,K-ATPases were coexpressed with the native beta 1 subunit in Sf9 insect cells using the baculovirus expression system. All alpha mutants are able to efficiently assemble with the beta 1 subunit and produce catalytically competent Na,K-ATPase molecules with hydrolytic activities comparable to that of the wild-type enzyme. Analysis of the kinetic properties of the mutated enzymes showed a decrease in apparent affinity for K+ compared to wild-type Na,K-ATPase, with the lysine and alanine substitutions displaying the greatest reduction, All Na,K-ATPase mutants demonstrated a significant increase in apparent affinity for ATP compared to wild-type Na,K-ATPase, while the sensitivity to the cardiotonic inhibitor, ouabain, was unchanged. The dependence on Na+, however, differs among the mutant enzymes with both the Glu(781) --> Asp and Glu(781) --> Ala mutants displaying a decrease in the apparent affinity for the cation, while the G1u(781) --> Lys mutant exhibits a modest increase, Furthermore, in the absence of K+, the Glu(781) --> Ala mutant displays a Na+-ATPase activity and a cellular Na+ influx suggesting that Na+ is substituting for K+ at the extracellular binding sites, The observation that trypsin digestion of the Glu(781) --> Ala mutant in Na+ medium produces a K+-stabilized tryptic fragment also intimates a decreased capacity of the mutant to discriminate between Na+ and K+ at the extracellular loading sites, All together, these data implicate Glu(781) of the Na,K-ATPase alpha subunit as an important coordinate of cation selectivity and activation, although the modest effect of G1u(781) --> Lys substitution seemingly precludes direct involvement of the residue in the cation binding process, In addition, the fifth membrane segment is proposed to represent an important communicative link between the extramembraneous ATP binding domain and the cation transport regions of the Na,K-ATPase.	WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)			Mercer, Robert/F-5918-2012		NIGMS NIH HHS [GM 39746] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039746, R01GM039746] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; BEAUGE L, 1983, BIOCHIM BIOPHYS ACTA, V729, P137, DOI 10.1016/0005-2736(83)90464-9; BLANCO G, 1995, BIOCHEMISTRY-US, V34, P319, DOI 10.1021/bi00001a039; BLANCO G, 1993, P NATL ACAD SCI USA, V90, P1824, DOI 10.1073/pnas.90.5.1824; BLOSTEIN R, 1983, J BIOL CHEM, V258, P7948; CAMPOS M, 1994, J BIOL CHEM, V269, P18028; CASTRO J, 1979, J BIOL CHEM, V254, P2221; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CORNELIUS F, 1991, BIOCHIM BIOPHYS ACTA, V1071, P19, DOI 10.1016/0304-4157(91)90011-K; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; DUNHAM PB, 1977, P NATL ACAD SCI USA, V74, P3099, DOI 10.1073/pnas.74.7.3099; FENG JN, 1995, CELL MOL BIOL RES, V41, P29; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GOLDSHLEGER R, 1992, P NATL ACAD SCI USA, V89, P6911, DOI 10.1073/pnas.89.15.6911; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JORGENSEN PL, 1977, BIOCHIM BIOPHYS ACTA, V466, P97, DOI 10.1016/0005-2736(77)90211-5; JORGENSEN PL, 1975, BIOCHIM BIOPHYS ACTA, V401, P399, DOI 10.1016/0005-2736(75)90239-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG FP, 1993, J CELL BIOL, V123, P485, DOI 10.1083/jcb.123.2.485; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1993, BIOCHEMISTRY-US, V32, P6737, DOI 10.1021/bi00077a029; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; MCCONAGHEY PD, 1962, J PHYSIOL-LONDON, V162, P485, DOI 10.1113/jphysiol.1962.sp006946; MERCER RW, 1981, BIOCHIM BIOPHYS ACTA, V648, P63, DOI 10.1016/0005-2736(81)90124-3; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; OBRIEN WJ, 1994, ARCH BIOCHEM BIOPHYS, V310, P32, DOI 10.1006/abbi.1994.1136; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; SCHNEIDER JW, 1985, P NATL ACAD SCI USA, V82, P6357, DOI 10.1073/pnas.82.18.6357; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041	31	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2413	2421		10.1074/jbc.271.5.2413	http://dx.doi.org/10.1074/jbc.271.5.2413			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576200	hybrid			2022-12-25	WOS:A1996TT48800014
J	PazElizur, T; Skaliter, R; Blumenstein, S; Livneh, Z				PazElizur, T; Skaliter, R; Blumenstein, S; Livneh, Z			beta*, a UV-inducible smaller form of the beta subunit sliding clamp of DNA polymerase III of Escherichia coli .1. Gene expression and regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEXA PROTEIN; RNA-POLYMERASE; SIGMA-FACTOR; HOLOENZYME; MUTAGENESIS; INDUCTION; REPRESSOR; PURIFICATION; INVITRO; CLONING	The 40.6-kDa beta subunit of DNA polymerase III of Escherichia coli is a sliding DNA clamp responsible for tethering the polymerase to DNA and endowing it with high processivity (Stukenberg, P. T., Studwell-Vaughan, P. S., and O'Donnell, M. (1991) J. Biol. Chem. 266, 11328-11334), UV irradiation of E. coli, induces a smaller 26-kDa form of the beta subunit, termed beta*, that, when overproduced from a plasmid, increases UV resistance of E. coli (Skaliter, R., Paz-Elizur, T., and Livneh, Z. (1996) J. Biol. Chem, 271, 2478-2481), Here we show that this protein is synthesized from a UV-inducible internal gene, termed dnaN*, that is located in-frame inside the coding region of dnaN, encoding the beta subunit, The initiation codon and the Shine-Dalgarno sequence of dnaN* were identified by site-directed mutagenesis. The dnaN* transcript was shown to be induced upon treatment with nalidixic acid, and transcriptional dnaN*-cat gene fusions were UV inducible, suggesting induction of dnaN* at the transcriptional level, Analysis of translational dnaN*-lacZ gene fusions revealed that UV induction was abolished in strains carrying the recA56, lexA3, Delta rpoH mutations, indicating involvement of both SOS and heat shock stress responses in the induction process, Expression of dnaN* represents a strategy of producing several proteins with related functional domains from a single gene.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ARMENGOD ME, 1986, GENE, V43, P183, DOI 10.1016/0378-1119(86)90206-4; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BERG OG, 1988, NUCLEIC ACIDS RES, V16, P5089, DOI 10.1093/nar/16.11.5089; BERNSTEIN JA, 1989, J BIOL CHEM, V264, P13066; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; CATTANEO R, 1989, TRENDS BIOCHEM SCI, V14, P165, DOI 10.1016/0968-0004(89)90266-1; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; ERICKSON JW, 1989, GENE DEV, V3, P1462, DOI 10.1101/gad.3.9.1462; GRANGERSCHNARR M, 1986, FEBS LETT, V198, P61, DOI 10.1016/0014-5793(86)81185-1; HENGGEARONIS R, 1993, CELL, V72, P165, DOI 10.1016/0092-8674(93)90655-A; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KENYON CJ, 1980, P NATL ACAD SCI-BIOL, V77, P2819, DOI 10.1073/pnas.77.5.2819; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1991, DNA REPLICATION; KRUEGER JH, 1984, P NATL ACAD SCI-BIOL, V81, P1499, DOI 10.1073/pnas.81.5.1499; KUSUKAWA N, 1988, GENE DEV, V2, P874, DOI 10.1101/gad.2.7.874; LESCA C, 1991, BIOCHIMIE, V73, P407, DOI 10.1016/0300-9084(91)90107-C; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1981, P NATL ACAD SCI-BIOL, V78, P4199, DOI 10.1073/pnas.78.7.4199; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LIVNEH Z, 1993, CRIT REV BIOCHEM MOL, V28, P465, DOI 10.3109/10409239309085136; MARKHAM BE, 1984, J MOL BIOL, V178, P237, DOI 10.1016/0022-2836(84)90142-6; Miller J.H., 1972, EXPT MOL GENETICS; NEIDHARDT FC, 1983, J BACTERIOL, V153, P597, DOI 10.1128/JB.153.2.597-603.1983; NILSSON B, 1983, NUCLEIC ACIDS RES, V11, P8019, DOI 10.1093/nar/11.22.8019; OHMORI H, 1984, GENE, V28, P159, DOI 10.1016/0378-1119(84)90253-1; Patrick MH., 1976, PHOTOCHEM PHOTOBIOL, V2, P35, DOI [10.1016/B978-0-12-734602-1.50008-3, DOI 10.1016/B978-0-12-734602-1.50008-3]; PAYNE NS, 1989, MUTAT RES, V218, P207, DOI 10.1016/0921-8777(89)90005-0; QUINONES A, 1991, MOL GEN GENET, V227, P9, DOI 10.1007/BF00260699; QUINONES A, 1989, EMBO J, V8, P587, DOI 10.1002/j.1460-2075.1989.tb03413.x; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SCHNARR M, 1985, BIOCHEMISTRY-US, V24, P2812, DOI 10.1021/bi00332a032; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SHAVITT O, 1989, J BIOL CHEM, V264, P11275; SIEGELE DA, 1992, J BACTERIOL, V174, P345, DOI 10.1128/jb.174.2.345-348.1992; Skaliter R, 1996, J BIOL CHEM, V271, P2478, DOI 10.1074/jbc.271.5.2478; Skaliter R, 1996, J BIOL CHEM, V271, P2491, DOI 10.1074/jbc.271.5.2491; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TADMOR Y, 1992, J BACTERIOL, V174, P2517, DOI 10.1128/jb.174.8.2517-2524.1992; TADMOR Y, 1994, MUTAT RES, V308, P53, DOI 10.1016/0027-5107(94)90198-8; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WANG QP, 1989, J BACTERIOL, V171, P4248, DOI 10.1128/JB.171.8.4248-4253.1989; YAMAMOTO K, 1985, MUTAT RES, V149, P297, DOI 10.1016/0027-5107(85)90144-7; ZABIN I, 1980, OPERON, P89; ZHOU YN, 1988, J BACTERIOL, V170, P3640, DOI 10.1128/jb.170.8.3640-3649.1988	49	9	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2482	2490		10.1074/jbc.271.5.2482	http://dx.doi.org/10.1074/jbc.271.5.2482			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576211	hybrid			2022-12-25	WOS:A1996TT48800025
J	Skaliter, R; PazElizur, T; Livneh, Z				Skaliter, R; PazElizur, T; Livneh, Z			A smaller form of the sliding clamp subunit of DNA polymerase III is induced by UV irradiation in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; HOLOENZYME; REPLICATION; MUTAGENESIS; PROTEINS; INVITRO; REPAIR; BYPASS; GENES	The beta subunit of DNA polymerase III holoenzyme of Escherichia coli is a 40.6-kDa protein that functions as a sliding DNA clamp (Stukenberg, P. T., Studwell-Vaughan, P. S., and O'Donnell, M. (1991) J. Biol. Chem. 266, 11328-11334), It is responsible for tethering the polymerase to DNA and endowing it with the high processivity required For DNA replication, Here and in a companion study (Paz-Elizur, T., Skaliter, R., Blumenstein, S., and Livneh, Z. (1996) J. Biol. Chem. 271, 2482-2490) we report that the dnaN gene, encoding the beta subunit, contains an internal in-frame gene, termed dnaN*, that encodes a smaller form of the beta subunit. The novel 26-kDa protein, termed beta*, is UV-inducible, and when overexpressed from a plasmid under an inducible promoter, it increases up to 6-fold the UV resistance of E. coli cells. These findings suggest that the beta* protein functions in a reaction associated with DNA repair or recovery of DNA replication in UV-irradiated cells.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								ARMENGOD ME, 1986, GENE, V43, P183, DOI 10.1016/0378-1119(86)90206-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BURGERS PMJ, 1981, P NATL ACAD SCI-BIOL, V78, P5391, DOI 10.1073/pnas.78.9.5391; CATTANEO R, 1989, TRENDS BIOCHEM SCI, V14, P165, DOI 10.1016/0968-0004(89)90266-1; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kornberg A., 1991, DNA REPLICATION; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KRUEGER JH, 1984, P NATL ACAD SCI-BIOL, V81, P1499, DOI 10.1073/pnas.81.5.1499; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LESCA C, 1991, BIOCHIMIE, V73, P407, DOI 10.1016/0300-9084(91)90107-C; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LIVNEH Z, 1993, CRIT REV BIOCHEM MOL, V28, P465, DOI 10.3109/10409239309085136; LIVNEH Z, 1986, P NATL ACAD SCI USA, V83, P4599, DOI 10.1073/pnas.83.13.4599; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHMORI H, 1984, GENE, V28, P159, DOI 10.1016/0378-1119(84)90253-1; Patrick MH., 1976, PHOTOCHEM PHOTOBIOL, V2, P35, DOI [10.1016/B978-0-12-734602-1.50008-3, DOI 10.1016/B978-0-12-734602-1.50008-3]; PazElizur T, 1996, J BIOL CHEM, V271, P2482, DOI 10.1074/jbc.271.5.2482; Sambrook J., 1989, MOL CLONING; SHWARTZ H, 1987, J BIOL CHEM, V262, P10518; SHWARTZ H, 1988, J BIOL CHEM, V263, P18277; SHWARTZ H, 1989, J BIOL CHEM, V264, P11275; Skaliter R, 1996, J BIOL CHEM, V271, P2491, DOI 10.1074/jbc.271.5.2491; TADMOR Y, 1992, J BACTERIOL, V174, P2517, DOI 10.1128/jb.174.8.2517-2524.1992; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233	28	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2478	2481		10.1074/jbc.271.5.2478	http://dx.doi.org/10.1074/jbc.271.5.2478			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576210	hybrid			2022-12-25	WOS:A1996TT48800024
J	Zariwala, M; Liu, E; Xiong, Y				Zariwala, M; Liu, E; Xiong, Y			Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15(INK4b) and p18(INK4c) in tumor-derived cell lines and primary tumors	ONCOGENE			English	Article						p18(Ink4c); INK CDK inhibitors; mutation		The growth suppressing activity of the retinoblastoma susceptibility gene product, pRb, is down regulated by cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) whose kinase activity is negatively regulated by CDK inhibitors of the pld family. We have examined the genomic status of two recently isolated p16-related CDK inhibitors, p15 and p18, in 15 normal and 73 tumor-derived cell lines established from 23 different tissues, as well as 26 invasive primary breast cancers and 20 acute myelogenous leukemias. p15 was found to be homozygously deleted in 22% of the tumor derived cell Lines, but no point mutations were found in either the cultured cells or the two types of primary tumors. With the exception of one breast cancer cell line, no deletions or mutations were found in the p18 gene in either cultured cell lines or primary tumors. These results indicate that mutation of the p18 gene occurs rarely in human tumors. Thus, while they share a very similar biochemical mechanism of inhibiting the kinase activity of CDK4 and CDK6, members of the p16 gene family play different roles in controlling cell proliferation and suppressing tumor growth.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill			Liu, Edison/C-4141-2008		NCI NIH HHS [CA 65572] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065572] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIECHE I, 1994, CANCER RES, V54, P4274; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUAN KL, IN PRESS MOL BIOL CE; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V52, P205; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; HE J, 1994, CANCER RES, V54, P5804; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNAPEK DF, 1995, CANCER RES, V55, P1607; KODURU PRK, IN PRESS BLOOD; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LI Y, 1994, CANCER RES, V54, P6078; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OTSUKI T, 1995, CANCER RES, V55, P1436; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; WASHIMI O, 1995, CANCER RES, V55, P514; XU L, 1994, CANCER RES, V54, P5262; YOSHIDA S, 1995, CANCER RES, V55, P2756; ZHANG SY, 1994, CANCER RES, V54, P5050	32	41	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					451	455						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570224				2022-12-25	WOS:A1996TR53800026
J	Lohret, TA; Murphy, RC; Drgon, T; Kinnally, KW				Lohret, TA; Murphy, RC; Drgon, T; Kinnally, KW			Activity of the mitochondrial multiple conductance channel is independent of the adenine nucleotide translocator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE; MODULATION; TRANSPORT; PORE	The functional relationship between the adenine nucleotide translocator (ANT) and the mitochondrial multiple conductance channel (MCC) was investigated using patch-clamp techniques. MCC activity with the same conductance, ion selectivity, voltage dependence, and peptide sensitivity could be reconstituted from inner membrane fractions derived from mitochondria of ANT-deficient and wild-type Saccharomyces cerevisiae. In addition, the MCC activity of mouse kidney mitoplasts was unaffected by carboxyatractyloside, a known inhibitor of ANT and inducer of a permeability transition. These results suggest that MCC activity is independent of ANT.	NEW YORK STATE DEPT HLTH,WADSWORTH CTR LABS & RES,DIV MOLEC MED,ALBANY,NY 12201; SUNY ALBANY,DEPT BIOMED SCI,ALBANY,NY 12222; SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222; COMENIUS UNIV BRATISLAVA,DEPT BIOCHEM,BRATISLAVA 84215,SLOVAKIA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; State University of New York (SUNY) System; State University of New York (SUNY) Albany; Comenius University Bratislava								ABRAHAM EH, 1993, P NATL ACAD SCI USA, V90, P312, DOI 10.1073/pnas.90.1.312; CAMPO ML, 1992, J BIOL CHEM, V267, P8123; CRIADO M, 1987, FEBS LETT, V224, P172, DOI 10.1016/0014-5793(87)80442-8; DAUM G, 1982, J BIOL CHEM, V257, P3028; DECKER GL, 1977, J ULTRA MOL STRUCT R, V59, P44, DOI 10.1016/S0022-5320(77)80027-0; DIERKS T, 1990, BIOCHIM BIOPHYS ACTA, V1028, P268, DOI 10.1016/0005-2736(90)90176-O; DRGON T, 1991, FEBS LETT, V289, P159, DOI 10.1016/0014-5793(91)81059-H; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; KINNALLY KW, 1992, J BIOENERG BIOMEMBR, V24, P99, DOI 10.1007/BF00769536; KINNALLY KW, 1993, P NATL ACAD SCI USA, V90, P1374, DOI 10.1073/pnas.90.4.1374; KINNALLY KW, 1991, BIOCHEM BIOPH RES CO, V176, P1183, DOI 10.1016/0006-291X(91)90410-9; KINNALLY KW, 1996, IN PRESS J BIOENERG, V28; KLINGENBERG M, 1980, J MEMBRANE BIOL, V56, P97, DOI 10.1007/BF01875961; KUNZELMANN K, 1994, J CELL PHYSIOL, V161, P393, DOI 10.1002/jcp.1041610302; LAST TA, 1983, J BIOL CHEM, V258, P2399; LOHRET TA, 1995, J BIOL CHEM, V270, P15950, DOI 10.1074/jbc.270.27.15950; LOHRET TA, 1995, BIOPHYS J, V68, P2299, DOI 10.1016/S0006-3495(95)80412-1; MANNELLA CA, 1982, J CELL BIOL, V94, P680, DOI 10.1083/jcb.94.3.680; MIRONOVA GD, 1986, BIOCHIM BIOPHYS ACTA, V861, P224, DOI 10.1016/0005-2736(86)90424-4; NOVGORODOV SA, 1994, ARCH BIOCHEM BIOPHYS, V311, P219, DOI 10.1006/abbi.1994.1230; SCHWARZ M, 1994, J BIOL CHEM, V269, P29481; SMITH JA, 1995, CURRENT PROTOCOLS MO; SOKOLOVE PM, 1996, IN PRESS J BIOENERG, V28; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; THEVENOD F, 1994, J BIOL CHEM, V269, P24410; TIKHONOVA IM, 1994, FEBS LETT, V337, P231, DOI 10.1016/0014-5793(94)80197-5; ZHANG JJ, 1994, AM J PHYSIOL-CELL PH, V267, pC1095, DOI 10.1152/ajpcell.1994.267.4.C1095; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZOROV DB, 1992, J BIOENERG BIOMEMBR, V24, P119, DOI 10.1007/BF00769538	30	53	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4846	4849						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617754				2022-12-25	WOS:A1996TX69700044
J	Nagasaki, A; Gotoh, T; Takeya, M; Yu, YJ; Takiguchi, M; Matsuzaki, H; Takatsuki, K; Mori, M				Nagasaki, A; Gotoh, T; Takeya, M; Yu, YJ; Takiguchi, M; Matsuzaki, H; Takatsuki, K; Mori, M			Coinduction of nitric oxide synthase, argininosuccinate synthetase, and argininosuccinate lyase in lipopolysaccharide-treated rats - RNA blot, immunoblot, and immunohistochemical analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; RELAXING FACTOR; HUMAN-LIVER; L-ARGININE; SEQUENCE; CDNA; BIOSYNTHESIS; UREA; GENE; PURIFICATION	Nitric oxide (NO) is synthesized from arginine by nitric oxide synthase (NOS), and citrulline which is generated can be recycled to arginine by argininosuccinate synthetase (AS) and argininosuccinate lyase (AL), Rats were injected with bacterial lipopolysaccharide (LPS), and expression of the inducible isoform of NOS (iNOS), AS, and AL was analyzed. In RNA blot analysis, iNOS mRNA was undetectable before the LPS treatment but was induced by LPS in the lung, heart, liver, and spleen, and less strongly in the skeletal muscle and testis, AS mRNA was induced in the lung and spleen, and AL mRNA was weakly induced in these tissues. AS and AL mRNAs were abundant in the control liver and remained unchanged after the treatment, Kinetic studies showed that iNOS mRNA increased rapidly in both spleen and lung, reached a maximum 2-5 h after the treatment, and decreased thereafter, On the other hand, AS mRNA increased more slowly and reached a maximum in 6-12 h (by about 10-fold in the spleen and 2-fold in the lung), AL mRNA in the spleen and lung increased slowly and remained high up to 24 h, In immunoblot analysis, increase of iNOS protein was evident in the lung, liver, and spleen, and there was an increase of AS protein in the lung and spleen, In immunohistochemical analysis, macrophages in the spleen that were negative for iNOS and AS before LPS treatment were strongly positive for both iNOS and AS after this treatment, As iNOS, AS, and AL were coinduced in rat tissues and cells, citrulline-arginine recycling seems to be important in NO synthesis under the conditions of stimulation.	KUMAMOTO UNIV,SCH MED,DEPT MOLEC GENET,KUMAMOTO 862,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT INTERNAL MED 2,KUMAMOTO 862,JAPAN; KUMAMOTO UNIV,SCH MED,DEPT PATHOL 2,KUMAMOTO 862,JAPAN	Kumamoto University; Kumamoto University; Kumamoto University								ABRAMSON RD, 1991, GENOMICS, V10, P126, DOI 10.1016/0888-7543(91)90492-W; AMAYA Y, 1988, J BIOCHEM-TOKYO, V103, P177, DOI 10.1093/oxfordjournals.jbchem.a122227; ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BOCK HGO, 1983, NUCLEIC ACIDS RES, V11, P6505, DOI 10.1093/nar/11.18.6505; BUTTERY LDK, 1994, LAB INVEST, V71, P755; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FREYTAG SO, 1984, MOL CELL BIOL, V4, P1978, DOI 10.1128/MCB.4.10.1978; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; HAVIR EA, 1965, J BIOL CHEM, V240, P3079; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; HOM GJ, 1995, J PHARMACOL EXP THER, V272, P452; ISOBE Y, 1977, ACTA HISTOCHEM CYTOC, V10, P161, DOI 10.1267/ahc.10.161; KATO H, 1976, J BIOCHEM-TOKYO, V79, P945, DOI 10.1093/oxfordjournals.jbchem.a131162; KIMBALL ME, 1980, BIOCHEMISTRY-US, V19, P705, DOI 10.1021/bi00545a015; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; LOWENSTEIN CJ, 1992, P NATL ACAD SCI USA, V89, P6711, DOI 10.1073/pnas.89.15.6711; LUSTY CJ, 1972, J BIOL CHEM, V247, P7010; MATSUBASA T, 1989, P NATL ACAD SCI USA, V86, P592, DOI 10.1073/pnas.86.2.592; MATSUBASA T, 1994, J BIOCHEM, V116, P1044, DOI 10.1093/oxfordjournals.jbchem.a124626; MITCHELL JA, 1990, EUR J PHARMACOL, V176, P253, DOI 10.1016/0014-2999(90)90541-D; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NUNOKAWA Y, 1993, BIOCHEM BIOPH RES CO, V191, P89, DOI 10.1006/bbrc.1993.1188; NUSSLER AK, 1994, J BIOL CHEM, V269, P1257; OBRIEN WE, 1981, BIOCHEMISTRY-US, V20, P2056, DOI 10.1021/bi00510a049; OBRIEN WE, 1986, P NATL ACAD SCI USA, V83, P7211, DOI 10.1073/pnas.83.19.7211; OHSHIMA H, 1992, BIOCHEM BIOPH RES CO, V187, P1291, DOI 10.1016/0006-291X(92)90443-O; PALEKAR AG, 1981, J BIOL CHEM, V256, P9192; RATNER S, 1973, ADV ENZYMOL RAMB, V39, P1; RATNER S, 1980, ANAL BIOCHEM, V106, P134, DOI 10.1016/0003-2697(80)90129-3; ROCHOVANSKY O, 1977, J BIOL CHEM, V252, P5287; SAHEKI T, 1977, J BIOCHEM, V81, P687, DOI 10.1093/oxfordjournals.jbchem.a131505; SATO K, 1995, J LEUKOCYTE BIOL, V57, P36, DOI 10.1002/jlb.57.1.36; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SURH LC, 1988, NUCLEIC ACIDS RES, V16, P9352, DOI 10.1093/nar/16.19.9352; WU GY, 1992, BIOCHEM J, V281, P45, DOI 10.1042/bj2810045; YU YJ, 1995, J BIOCHEM-TOKYO, V117, P952, DOI 10.1093/oxfordjournals.jbchem.a124826	39	118	121	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2658	2662		10.1074/jbc.271.5.2658	http://dx.doi.org/10.1074/jbc.271.5.2658			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576237	hybrid			2022-12-25	WOS:A1996TT48800051
J	Pedersen, PA; Rasmussen, JH; Jorgensen, PL				Pedersen, PA; Rasmussen, JH; Jorgensen, PL			Expression in high yield of pig alpha 1 beta 1 Na,K-ATPase and inactive mutants D369N and D807N in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; INFECTED INSECT CELLS; MEMBRANE H+-ATPASE; ALPHA-SUBUNIT; FUNCTIONAL EXPRESSION; MAMMALIAN KIDNEY; BINDING-SITE; YEAST; NA+,K+-ATPASE; PURIFICATION	Studies of structure-function relationships in Na,K-ATPase require high yield expression of inactive mutations in cells without endogenous Na,K-ATPase activity. In this work we developed a host/vector system for expression of fully active pig Na,K-ATPase as well as the inactive mutations D369N and D807N at high levels in Saccharomyces cerevisiae. The alpha 1- and beta 1-subunit cDNAs were inserted into a single 2-mu m-based plasmid with a high and regulatable copy number and strong galactose inducible promoters allowing for stoiehiometric alterations of gene dosage. The protease-deficient host strain was engineered to express high levels of GAL4 transactivating protein, thereby causing a 10-fold increase in expression to 32,500 +/- 3,000 [H-3]ouabain sites/cell. In one bioreactor run 150-200 g of yeast were produced with 54 +/- 5 mu g of Na,K-pump protein/g of cells. Through purification in membrane bound form the activity of the recombinant Na,K-ATPase was increased to 42-50 pmol/mg of protein. The Na,K dependence of ATP hydrolysis and the molar activity (4,500-7,000 min(-1)) were close to those of native pig kidney Na,K-ATPase. Mutations to the phosphorylation site (D369N) or presumptive cation sites (D807N), both devoid of Na,K-ATPase activity, were expressed in the yeast membrane at the same alpha-subunit concentration and [H-3]ouabain binding capacity as the wild type Na,K-ATPase. The high yield and absence of endogenous activity allowed assay of [H-3]ATP binding at equilibrium, demonstrating a remarkable 18-fold increase in affinity for ATP in consequence of reducing the negative charge at the phosphorylation site (D369N).			Pedersen, PA (corresponding author), UNIV COPENHAGEN, AUGUST KROGH INST, BIOMEMBRANE RES CTR, UNIV PK 13, DK-2100 COPENHAGEN OE, DENMARK.		Pedersen, Per Amstrup/M-4592-2014	Pedersen, Per Amstrup/0000-0001-8648-9748				BALDARI C, 1985, GENE, V35, P27, DOI 10.1016/0378-1119(85)90154-4; BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BELSHAM GJ, 1986, EUR J BIOCHEM, V156, P413, DOI 10.1111/j.1432-1033.1986.tb09598.x; BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; BLANCO G, 1994, P NATL ACAD SCI USA, V91, P8542, DOI 10.1073/pnas.91.18.8542; BLANCO G, 1993, P NATL ACAD SCI USA, V90, P1824, DOI 10.1073/pnas.90.5.1824; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CENTENO F, 1994, FEBS LETT, V354, P117, DOI 10.1016/0014-5793(94)01104-4; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DETOMASO AW, 1993, J BIOL CHEM, V268, P1470; EAKLE KA, 1992, P NATL ACAD SCI USA, V89, P2834, DOI 10.1073/pnas.89.7.2834; EAKLE KA, 1995, J BIOL CHEM, V270, P13937, DOI 10.1074/jbc.270.23.13937; Erhat E., 1983, J BACTERIOL, V156, P625; FUKASAWA T, 1980, J BIOL CHEM, V255, P2705; GEERING K, 1990, J MEMBRANE BIOL, V115, P109, DOI 10.1007/BF01869450; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOROWITZ B, 1990, J BIOL CHEM, V265, P4189; JABBAR MA, 1985, P NATL ACAD SCI USA, V82, P2019, DOI 10.1073/pnas.82.7.2019; JANOWICZ ZA, 1982, GENE, V20, P347, DOI 10.1016/0378-1119(82)90203-7; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JONES EW, 1991, METHOD ENZYMOL, V194, P428; JORGENSEN PL, 1986, BIOCHEMISTRY-US, V25, P2889; JORGENSEN PL, 1974, BIOCHIM BIOPHYS ACTA, V356, P36, DOI 10.1016/0005-2736(74)90292-2; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P29; JORGENSEN PL, 1982, BIOCHIM BIOPHYS ACTA, V694, P27, DOI 10.1016/0304-4157(82)90013-2; KUNTZWEILER TA, 1995, J BIOL CHEM, V270, P2993, DOI 10.1074/jbc.270.7.2993; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LOISON G, 1989, YEAST, V5, P497, DOI 10.1002/yea.320050609; MACLENNAN DH, 1992, ACTA PHYSIOL SCAND, V146, P141; MAHANTY SK, 1994, J BIOL CHEM, V269, P17705; NISHIMURA A, 1990, NUCLEIC ACIDS RES, V18, P6169, DOI 10.1093/nar/18.20.6169; NOGUCHI S, 1987, FEBS LETT, V225, P27, DOI 10.1016/0014-5793(87)81125-0; NORBY JG, 1988, METHOD ENZYMOL, V156, P191; OHTSUBO M, 1990, BIOCHIM BIOPHYS ACTA, V1021, P157, DOI 10.1016/0005-2736(90)90028-M; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; PALMGREN MG, 1993, FEBS LETT, V317, P216, DOI 10.1016/0014-5793(93)81279-9; PEDERSEN PA, 1992, ANN NY ACAD SCI, V671, P452, DOI 10.1111/j.1749-6632.1992.tb43827.x; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PURVIS IJ, 1987, NUCLEIC ACIDS RES, V15, P7963, DOI 10.1093/nar/15.19.7963; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; Rose MD., 1990, METHODS YEAST GENETI; Sambrook J, 1989, MOL CLONING LABORATO; SCHEINERBOBIS G, 1994, BBA-BIOMEMBRANES, V1193, P226, DOI 10.1016/0005-2736(94)90157-0; SCHULTZ LD, 1987, GENE, V61, P123, DOI 10.1016/0378-1119(87)90107-7; SCHULTZ LD, 1987, GENE, V54, P113, DOI 10.1016/0378-1119(87)90353-2; SHULL GE, 1986, BIOCHEMISTRY-US, V25, P8125, DOI 10.1021/bi00373a001; VANHUYSSE JW, 1993, BIOCHEMISTRY-US, V32, P819, DOI 10.1021/bi00054a012; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; WANG K, 1992, J BIOL CHEM, V267, P3577; Wickersham LJ, 1951, USDA TECH B, V1029; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	58	84	85	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2514	2522		10.1074/jbc.271.5.2514	http://dx.doi.org/10.1074/jbc.271.5.2514			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576215	hybrid			2022-12-25	WOS:A1996TT48800029
J	Heath, RJ; Rock, CO				Heath, RJ; Rock, CO			Regulation of fatty acid elongation and initiation by acyl acyl carrier protein in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS; SYNTHASE; INVIVO	Long chain acyl-acyl carrier protein (acyl-ACP) has been implicated as a physiological inhibitor of fatty acid biosynthesis since acyl-ACP degradation by thioesterase overexpression leads to constitutive, unregulated fatty acid production. The biochemical targets for acyl-ACP inhibition were unknown, and this work identified two biosynthetic enzymes that were sensitive to acyl-ACP feedback inhibition. Palmitoyl-ACP inhibited the incorporation of [C-14]malonyl-CoA into long chain fatty acids in cell-free extracts of Escherichia coli. A short chain acyl-ACP species with the electrophoretic properties of beta-hydroxybutyryl-ACP accumulated concomitant with the overall decrease in the amount of [C-14]malonyl-CoA incorporation, indicating that the first elongation cycle was targeted by acyl-ACP. All of the proteins required to catalyze the first round of fatty acid synthesis from acetyl-CoA plus malonyl-CoA in vivo were isolated, and the first fatty acid elongation cycle was reconstituted with these purified components. Analysis of the individual enzymes and the pattern of intermediate accumulation in the reconstituted system identified initiation of fatty acid synthesis by beta-ketoacyl-ACP synthase III (fabH) and enoyl-ACP reductase (fabI) in the elongation cycle as two steps attenuated by long chain acyl-ACP.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center				Heath, Richard/0000-0002-1795-1254	NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHO HS, 1995, J BIOL CHEM, V270, P4216, DOI 10.1074/jbc.270.9.4216; DORMANN P, 1995, ARCH BIOCHEM BIOPHYS, V316, P612, DOI 10.1006/abbi.1995.1081; HEATH RJ, 1994, J BIOL CHEM, V269, P26584; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; HEATH RJ, 1995, J BIOL CHEM, V270, P15531, DOI 10.1074/jbc.270.26.15531; JACKOWSKI S, 1989, J BIOL CHEM, V264, P7624; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; JACKOWSKI S, 1994, J BIOL CHEM, V269, P2921; JIANG P, 1994, J BACTERIOL, V176, P2814, DOI 10.1128/JB.176.10.2814-2821.1994; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; OHLROGGE J, 1995, ARCH BIOCHEM BIOPHYS, V317, P85; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; ROCK CO, 1979, J BIOL CHEM, V254, P7123; ROCK CO, 1982, J BIOL CHEM, V257, P10759; VOELKER TA, 1994, J BACTERIOL, V176, P7320, DOI 10.1128/JB.176.23.7320-7327.1994	16	187	226	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1833	1836		10.1074/jbc.271.4.1833	http://dx.doi.org/10.1074/jbc.271.4.1833			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567624	hybrid			2022-12-25	WOS:A1996TR32000006
J	Meng, JJ; Khan, S; Ip, W				Meng, JJ; Khan, S; Ip, W			Intermediate filament protein domain interactions as revealed by two-hybrid screens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COILED-COIL MOLECULES; FIBRILLARY ACIDIC PROTEIN; SACCHAROMYCES-CEREVISIAE; ASSEMBLY PROPERTIES; KERATIN FILAMENTS; NETWORK FORMATION; CROSS-LINKING; VIMENTIN; DESMIN; YEAST	All intermediate filament proteins possess three distinct domains: heads, rod and tail, and subdomains within the rod called helices 1A, 1B, 2A, and 2B, Subunit packing within a filament is a consequence of interactions among these domains, Several such interactions are known, but probably many more contribute to stabilizing filament structure. We examined a number of such potential interactions using the yeast two-hybrid system, Domains or subdomains of murine vimentin, a Type III intermediate filament protein, were fused with either the DNA-binding or trans-activating domain of GAL4, a transcription factor, Interaction between the vimentin domains/subdomains functionally reconstituted GAL4, thereby activating transcription of a GAL1-LacZ reporter gene. The oligomeric state at which the interactions took place, i.e, whether the domains/subdomains were dimeric or tetrameric as they interacted, was also determined, These studies revealed a number of interesting interactions, among which was a strong homotypic binding of helix 2B to form tetramers, They also demonstrated a lack of interaction among others expected to do so based on current structural models. From these results we deduced which of the candidates for interactions, suggested by current models, were true protein-protein interactions and which represented nearest-neighbors only, Thus, the A(11) and A(22) modes of molecular alignment identified by Steinert ef al. (Steinert, P. Ri,, Marekov, L, N., Fraser, R. D, B., and Parry, D, A, D. (1993) J, Mel. Biol. 230, 436-452) are probably true interactions, whereas the A(12) and A(CN) modes may describe adjacent but non-interacting molecules.			Meng, JJ (corresponding author), UNIV CINCINNATI,DEPT ANAT CELL BIOL & NEUROBIOL,CINCINNATI,OH 45267, USA.			Khan, Sohaib/0000-0002-0792-9109	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035973] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35973] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AEBI U, 1983, J CELL BIOL, V97, P1131, DOI 10.1083/jcb.97.4.1131; ATKINSON SJ, 1992, J MOL BIOL, V226, P7, DOI 10.1016/0022-2836(92)90118-4; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BADER BL, 1991, J CELL BIOL, V115, P1293, DOI 10.1083/jcb.115.5.1293; BIRKENBERGER L, 1990, J CELL BIOL, V111, P2063, DOI 10.1083/jcb.111.5.2063; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAM RJ, 1985, P NATL ACAD SCI USA, V82, P43, DOI 10.1073/pnas.82.1.43; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; ECKELT A, 1992, EUR J CELL BIOL, V58, P319; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; GEISLER N, 1992, EUR J BIOCHEM, V206, P841, DOI 10.1111/j.1432-1033.1992.tb16992.x; GRUEN LC, 1983, BIOCHEM J, V209, P587, DOI 10.1042/bj2090587; HEINS S, 1993, J CELL BIOL, V123, P1517, DOI 10.1083/jcb.123.6.1517; HERRMANN H, 1992, J MOL BIOL, V223, P637, DOI 10.1016/0022-2836(92)90980-X; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HITCHCOCKDEGREGORI SE, 1990, J MOL BIOL, V214, P885, DOI 10.1016/0022-2836(90)90343-K; KAUFMANN E, 1985, J MOL BIOL, V185, P733, DOI 10.1016/0022-2836(85)90058-0; KLYMKOWSKY MW, 1995, CURR OPIN CELL BIOL, V7, P46, DOI 10.1016/0955-0674(95)80044-1; KOUKLIS PD, 1993, J CELL SCI, V106, P919; KOUKLIS PD, 1991, J CELL BIOL, V114, P773, DOI 10.1083/jcb.114.4.773; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MAKROVA I, 1994, CELL MOTIL CYTOSKEL, V28, P265; MCCORMICK MB, 1993, J CELL BIOL, V122, P395, DOI 10.1083/jcb.122.2.395; MCLACHLAN AD, 1982, J MOL BIOL, V162, P693, DOI 10.1016/0022-2836(82)90396-5; MENG JJ, 1994, J BIOL CHEM, V269, P18679; MILAM L, 1982, J CELL BIOL, V94, P592, DOI 10.1083/jcb.94.3.592; PARRY D A D, 1992, Current Opinion in Cell Biology, V4, P94, DOI 10.1016/0955-0674(92)90064-J; PARRY DAD, 1977, J MOL BIOL, V113, P449, DOI 10.1016/0022-2836(77)90153-X; PARRY DAD, 1985, BIOCHEM BIOPH RES CO, V127, P1012, DOI 10.1016/S0006-291X(85)80045-0; QUINLAN RA, 1989, J CELL SCI, V93, P71; RAATS JMH, 1991, EUR J CELL BIOL, V56, P84; ROGERS KR, 1995, EUR J CELL BIOL, V66, P136; SIKORSKI RS, 1989, GENETICS, V122, P19; STEINERT PM, 1991, J STRUCT BIOL, V107, P175, DOI 10.1016/1047-8477(91)90020-W; STEINERT PM, 1993, BIOCHEMISTRY-US, V32, P10046, DOI 10.1021/bi00089a021; STEINERT PM, 1993, J BIOL CHEM, V268, P24916; STEINERT PM, 1993, J MOL BIOL, V230, P436, DOI 10.1006/jmbi.1993.1161; STEINERT PM, 1991, J STRUCT BIOL, V107, P157, DOI 10.1016/1047-8477(91)90019-S; STEWART M, 1989, J CELL BIOL, V109, P225, DOI 10.1083/jcb.109.1.225; Stewart M, 1993, CURR OPIN CELL BIOL, V5, P3, DOI 10.1016/S0955-0674(05)80002-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WOODS EF, 1984, INT J BIOL MACROMOL, V6, P277, DOI 10.1016/0141-8130(84)90008-4; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985	45	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1599	1604		10.1074/jbc.271.3.1599	http://dx.doi.org/10.1074/jbc.271.3.1599			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576158	hybrid			2022-12-25	WOS:A1996TQ52500054
J	Nakamura, S; Kozutsumi, Y; Sun, YD; Miyake, Y; Fujita, T; Kawasaki, T				Nakamura, S; Kozutsumi, Y; Sun, YD; Miyake, Y; Fujita, T; Kawasaki, T			Dual roles of sphingolipids in signaling of the escape from and onset of apoptosis in a mouse cytotoxic T-cell line, CTLL-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; KAPPA-B; INHIBITION; SPHINGOSINE; RECEPTOR	In our previous study, the sphingosine-like immuno-suppressant, ISP-1, was found to suppress the proliferation of an interleukin-2-dependent cytotoxic T cell line, CTLL-2, through the inhibition of serine palmitoyltransferase, which catalyzes the committed step of sphingolipid biosynthesis, Analysis of the effect of ISP-1 by flow cytometry revealed that the ISP-1-dependent decrease in cell number was not due to inhibition of the cell cycle progression of CTLL-2 cells but to the induction of ap optosis of the cells, The ISP-1-induced apoptosis was inhibited by the addition of sphingosine (2 mu m), suggesting that this ISP-1-induced apoptosis is triggered by the decrease in the intracellular levels of sphingolipids caused by the inhibition of serine palmitoyltransferase. However, another interleukin-2-dependent cell line, F7, which was derived from a mouse pro-B cell line, did not show ISP-1-dependent apoptosis, indicating that the effect of ISP-1 may be specific for a certain type of T cell lineage such as CTLL-2, On the other hand, a high dose of sphingosine (5 mu m) by itself induced the apoptosis of CTLL-2 cells, This sphingosine-dependent apoptosis was also observed with F7 cells, These results provide evidence that the intracellular levels of sphingolipids play an important role in the signaling of the escape from and onset of apoptosis of CTLL-2 cells.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT BIOL CHEM,SAKYO KU,KYOTO 606,JAPAN; SETSUNAN UNIV,FAC PHARMACEUT SCI,DEPT PHARMACEUT MFG CHEM,HIRAKATA,OSAKA 57301,JAPAN	Kyoto University; Setsunan University				Sun, Yidi/0000-0002-2157-1983				CIFONE MG, 1993, J EXP MED, V177, P1547; FUJITA T, 1994, J ANTIBIOT, V47, P208, DOI 10.7164/antibiotics.47.208; GILL BM, 1994, IMMUNOL REV, V142, P113, DOI 10.1111/j.1600-065X.1994.tb00885.x; GILLIS S, 1977, NATURE, V268, P154, DOI 10.1038/268154a0; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; GUNJI H, 1992, J CLIN INVEST, V89, P954, DOI 10.1172/JCI115677; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; IGARASHI Y, 1990, J BIOL CHEM, V265, P5385; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JI L, 1995, FEBS LETT, V358, P211, DOI 10.1016/0014-5793(94)01428-4; KHAN WA, 1990, BIOCHEM BIOPH RES CO, V172, P683, DOI 10.1016/0006-291X(90)90728-6; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MIKI I, 1993, J IMMUNOL METHODS, V164, P255, DOI 10.1016/0022-1759(93)90318-2; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OHTA H, 1995, CANCER RES, V55, P691; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P229, DOI 10.1080/09553009414550261; SCHROEDER JJ, 1994, J BIOL CHEM, V269, P3475; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SELINS KS, 1987, J IMMUNOL, V139, P3199; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; STEVENS VL, 1990, BIOCHIM BIOPHYS ACTA, V1051, P37, DOI 10.1016/0167-4889(90)90171-9; TAUCHI H, 1994, INT J RADIAT BIOL, V65, P449, DOI 10.1080/09553009414550521; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; YANG ZH, 1993, J BIOL CHEM, V268, P20520	27	65	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1255	1257		10.1074/jbc.271.3.1255	http://dx.doi.org/10.1074/jbc.271.3.1255			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576106	hybrid			2022-12-25	WOS:A1996TQ52500002
J	Ohtsuka, T; Shimizu, K; Yamamori, B; Kuroda, S; Takai, Y				Ohtsuka, T; Shimizu, K; Yamamori, B; Kuroda, S; Takai, Y			Activation of brain B-Raf protein kinase by Rap1B small GTP-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE EFFECTOR DOMAIN; INTACT HUMAN-PLATELETS; SMG P21; SUPPRESSOR ACTIVITY; EXCHANGE PROTEIN; MAP KINASE; IN-VITRO; PHOSPHORYLATION; GENE; ANTAGONIZES	Rap1 small GTP-binding protein has the same amino acid sequence at its effector domain as that of Pas. Rap1 has been shown to antagonize the Pas functions, such as the Pas-induced transformation of NIH 3T3 cells and the Ras-induced activation of the c-Raf-1 protein kinase-dependent mitogen activated protein (MAP) kinase cascade in Rat-1 cells, whereas we have shown that Rap1 as well as Pas stimulates DNA synthesis in Swiss 3T3 cells. We have established a cell-free assay system in which Pas activates bovine brain B-Raf protein kinase. Here we have used this assay system and examined the effect of Rap1 on the B-Raf activity to phosphorylate recombinant MAP kinase kinase (MEK). Recombinant Rap1B stimulated the activity of B-Raf, which was partially purified from bovine brain and immunoprecipitated by an anti-B-Raf antibody. The GTP-bound form was active, but the GDP-bound form was inactive. The fully posttranslationally lipid-modified form was active, but the unmodified form was nearly inactive. The maximum B-Raf activity stimulated by Rap1B was nearly the same as that stimulated by Ki-Ras. Rap1B enhanced the Ki-Ras-stimulated B-Raf activity in an additive manner. These results indicate that not only Ras but also Rap1 is involved in the activation of the E-Raf dependent MAP kinase cascade.	OSAKA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, SUITA, OSAKA 565, JAPAN; NATL INST PHYSIOL SCI, DEPT CELL PHYSIOL, OKAZAKI, AICHI 444, JAPAN	Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)			KURODA, SHINYA/G-4961-2014					ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CAMPA MJ, 1991, BIOCHEM BIOPH RES CO, V174, P1, DOI 10.1016/0006-291X(91)90475-M; CATLING AD, 1994, J BIOL CHEM, V269, P30014; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CORVAZIER E, 1992, BIOCHEM J, V281, P325, DOI 10.1042/bj2810325; ERHARDT P, 1995, MOL CELL BIOL, V15, P5524; FAURE M, 1994, J BIOL CHEM, V269, P7851; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; FRODIN M, 1994, J BIOL CHEM, V269, P6207; HATA Y, 1991, J BIOL CHEM, V266, P6571; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; ITOH T, 1993, J BIOL CHEM, V268, P3025; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JELINEK MA, 1992, ONCOGENE, V7, P1687; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KURODA S, 1995, J BIOL CHEM, V270, P2460, DOI 10.1074/jbc.270.6.2460; LABADIA ME, 1993, BIOCHEM BIOPH RES CO, V195, P1321, DOI 10.1006/bbrc.1993.2188; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LAZAROWSKI ER, 1989, BIOCHEM BIOPH RES CO, V161, P972, DOI 10.1016/0006-291X(89)91338-7; LEROSEY I, 1991, BIOCHEM BIOPH RES CO, V175, P430, DOI 10.1016/0006-291X(91)91582-W; MAGEE AI, 1992, BIOCHEM SOC T, V20, P497, DOI 10.1042/bst0200497; MALY FE, 1994, J BIOL CHEM, V269, P18743; MIURA Y, 1992, FEBS LETT, V297, P171, DOI 10.1016/0014-5793(92)80353-I; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; NAKANISHI H, 1994, BIOCHEM BIOPH RES CO, V198, P1255, DOI 10.1006/bbrc.1994.1177; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; ORITA S, 1993, J BIOL CHEM, V268, P25542; PIZON V, 1988, ONCOGENE, V3, P201; QUARCK R, 1994, FEBS LETT, V342, P159, DOI 10.1016/0014-5793(94)80492-3; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; SAKODA T, 1992, ONCOGENE, V7, P1705; SIESS W, 1990, BIOCHEM BIOPH RES CO, V170, P944, DOI 10.1016/0006-291X(90)92182-Y; STORM SM, 1990, ONCOGENE, V5, P345; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; YATANI A, 1991, J BIOL CHEM, V266, P22222; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	54	138	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1258	1261		10.1074/jbc.271.3.1258	http://dx.doi.org/10.1074/jbc.271.3.1258			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576107	hybrid			2022-12-25	WOS:A1996TQ52500003
J	Rodewald, HR; Sato, TN				Rodewald, HR; Sato, TN			Tie1, a receptor tyrosine kinase essential for vascular endothelial cell integrity, is not critical for the development of hematopoietic cells	ONCOGENE			English	Article						Tie1; receptor tyrosine kinase; hematopoietic stem cells; lymphocyte development; recombination-activating-gene (RAG)-2-deficient mice; colony-forming cells	MOLECULAR-CLONING; PROGENITOR CELLS; STEM-CELLS; C-KIT; EXPRESSION; MOUSE; FAMILY; GENES; MEMBER; DIFFERENTIATION	The receptor tyrosine kinase Tiel is expressed in both vascular endothelial cells and immature hematopoietic cells. Expression of a common signaling molecule in distinct cellular Lineages may suggest common ancestry of these lineages in ontogeny and/or utilization of shared signaling pathways, Tie l-deficient mice carrying a targeted insertional mutation in germ line show defects in endothelial cell integrity resulting in edema and hemorrhage. To analyse the potential role of this kinase in hematopoietic cells, we have now compared hematopoietic compartments in wildtype and Tiel-deficient mice, The results show: (1) Total cellularity is mildly reduced comparing Tie1(-/-) and wildtype fetal liver from day 15.5 of gestation, (2) In vitro colony assays and cell transfer experiments of fetal liver cells into lymphocyte-deficient recombination-activating-gene-2(-/-) mice reveal that Tie1(-/-) hematopoietic progenitor cells can generate myeloid lineages as well as T and B lymphocytes, (3) Tie1(-/-) fetal liver cells contain long-term (at least 4 months) bone marrow-reconstituting hematopoietic stem cells suggesting that this kinase is not critical for stem cell-engraftment nor self-renewal.	BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND; ROCHE INST MOLEC BIOL,ROCHE RES CTR,NUTLEY,NJ 07110	Roche Holding								ARMSTRONG E, 1993, LEUKEMIA, V7, P1585; AUGUSTIN HG, 1994, BIOESSAYS, V16, P901, DOI 10.1002/bies.950161208; COFFMAN RL, 1981, NATURE, V289, P681, DOI 10.1038/289681a0; DIALYNAS DP, 1983, IMMUNOL REV, V74, P29, DOI 10.1111/j.1600-065X.1983.tb01083.x; DUMONT DJ, 1993, ONCOGENE, V8, P1293; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; ERA T, 1994, IMMUNOL REV, V137, P35, DOI 10.1111/j.1600-065X.1994.tb00658.x; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; GULLEY ML, 1988, J IMMUNOL, V140, P3751; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NICOLA NA, 1981, BLOOD, V58, P376; NIENHUIS AW, 1985, CELL, V42, P421, DOI 10.1016/0092-8674(85)90099-6; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OGAWA M, 1993, DEVELOPMENT, V117, P1089; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; PAUL WE, 1989, CELL, V57, P521, DOI 10.1016/0092-8674(89)90121-9; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RAJEWSKY K, 1992, SCIENCE, V256, P483, DOI 10.1126/science.1570513; RISAU W, 1988, DEVELOPMENT, V102, P471; RODEWALD HR, 1994, EMBO J, V13, P4229, DOI 10.1002/j.1460-2075.1994.tb06743.x; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROSNET O, 1991, ONCOGENE, V6, P1641; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHNURCH H, 1993, DEVELOPMENT, V119, P957; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; Shortman K, 1990, Semin Immunol, V2, P3; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; UCHIDA N, 1993, CURR OPIN IMMUNOL, V5, P177, DOI 10.1016/0952-7915(93)90002-A; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ZIEGLER SF, 1993, ONCOGENE, V8, P663	41	45	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					397	404						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570217				2022-12-25	WOS:A1996TR53800019
J	Graber, MN; Alfonso, A; Gill, DL				Graber, MN; Alfonso, A; Gill, DL			Ca2+ pools and cell growth: Arachidonic acid induces recovery of cells growth-arrested by Ca2+ pool depletion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CALCIUM POOLS; THAPSIGARGIN; INHIBITION; TRANSPORT; PROTEINS; BINDING	The intracellular Ca2+ pump blocker, thapsigargin, induces emptying of Ca2+ pools and entry of DDT(1)MF-2 smooth muscle cells into a quiescent G(0)-like growth state, Although thapsigargin blocks pumps essentially irreversibly, high serum (20%) induces appearance of new pump protein, return of functional pools, and reentry of cells into the cell cycle (Waldron, R. T., Short, A. D., Meadows, J. J., Ghosh, T. K., and Gill, D. L. (1994) J. Biol. Chem. 269, 11927-11933). Through analysis of the effects of defined serum components and growth supplements, we reveal here that the factors in serum responsible for inducing recovery of Ca2+ pools and growth in thapsigargin-arrested DDT(1)MF-2 cells are exactly mimicked by the three essential fatty acids, arachidonic, linoleic, and alpha-linolenic acids. The EC(50) values for arachidonic and linoleic acids on growth induction of thapsigargin-arrested cells were the same, approximately 5 mu M. Nonessential fatty acids, including myristic, palmitic, stearic, oleic, and arachidic acids, were without any effect. Although not proven to be the active component of serum, levels of arachidonic and linoleic acids in serum were sufficient to explain serum-induced growth recovery. Significantly, arachidonic or linoleic acids induced complete recovery of bradykinin-sensitive Ca2+ pools within 6 h of treatment of thapsigargin-arrested cells. Protein synthesis inhibitors (cycloheximide or puromycin) completely blocked the appearance of serum-induced or arachidonic acid-induced agonist-sensitive pools, The sensitivity and fatty acid specificity of Ca2+ pool recovery in thapsigargin-arrested cells were almost identical to that for growth recovery. No pool or growth recovery was observed with 5,8,11,14-eicosatetraynoic acid, the nonmetabolizable analogue of arachidonic acid, suggesting that conversion to eicosanoids underlies the pool and growth recovery induced by essential fatty acids. The results provide not only further information on the link between Ca2+ pools and cell growth but also evidence for a potentially important signaling pathway involved in inducing transition from a stationary to a proliferative growth state.	UNIV MARYLAND,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21201	University System of Maryland; University of Maryland Baltimore			Alfonso, Amparo/GLN-2591-2022	Alfonso Rancano, Maria Amparo/0000-0003-1572-9016	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019304] Funding Source: NIH RePORTER; NINDS NIH HHS [NS19304] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BIAN JH, 1991, J BIOL CHEM, V266, P8801; CORNWELL DG, 1978, LIPIDS, V14, P194; CUNNINGHAM FM, 1994, LIPID MEDIATORS; DAMRON DS, 1993, CIRC RES, V72, P376, DOI 10.1161/01.RES.72.2.376; DAVIDSON GA, 1995, J BIOL CHEM, V270, P11731, DOI 10.1074/jbc.270.20.11731; GHOSH TK, 1989, NATURE, V340, P236, DOI 10.1038/340236a0; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; Gill Donald L., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P265; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; KOHOUT TA, 1995, J BIOL CHEM, V270, P20432, DOI 10.1074/jbc.270.35.20432; KUZNETSOV G, 1992, J BIOL CHEM, V267, P3932; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MACLENNAN DH, 1992, ANN NY ACAD SCI, V671, P1, DOI 10.1111/j.1749-6632.1992.tb43779.x; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SCOTT AS, 1971, J ANIM SCI, V33, P629; SHORT AD, 1993, J BIOL CHEM, V268, P25887; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SPECTOR AA, 1971, BIOCHEMISTRY-US, V10, P3229; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOBIAS LD, 1978, LIPIDS, V14, P181; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; WALDRON RT, 1994, J BIOL CHEM, V269, P11927	30	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					883	888		10.1074/jbc.271.2.883	http://dx.doi.org/10.1074/jbc.271.2.883			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557700	hybrid			2022-12-25	WOS:A1996TP88900043
J	Dorin, D; Cohen, L; DelVillar, K; Poullet, P; Mohr, R; Whiteway, M; Witte, O; Tamanoi, F				Dorin, D; Cohen, L; DelVillar, K; Poullet, P; Mohr, R; Whiteway, M; Witte, O; Tamanoi, F			Kir, a novel ras-family G-protein, induces invasive pseudohyphal growth in Saccharomyces cerevisiae	ONCOGENE			English	Article						Ras-family G-protein; Saccharomyces cerevisiae; pseudohyphae; MAP kinase cascade	PHEROMONE RESPONSE PATHWAY; FILAMENTOUS GROWTH; YEAST; SUBUNITS; ELEMENTS; HOMOLOG; DOMAIN; GENE; IRA2	Kir belongs to a novel class of Ras-family G-proteins which includes Gem and Rad, These proteins are unique among Ras super-family G-proteins since their expression is under transcriptional regulation in mammalian cells, To gain insight into the function of Kir, we took advantage of the well-defined signal transduction pathways of yeast, When kir is expressed in Saccharomyces cerevisiae, the transformants form pseudohyphae and exhibit invasive properties characteristic of yeast cells are undergoing a developmental transition induced by GTPase nitrogen starvation, Analysis of pseudohyphal signaling pathway mutants suggests that the Kir-induced pseudohyphae formation requires a MAP kinase cascade involving ste20, ste11, ste7 but not ste5 gene products, Furthermore, our results are consistent with the idea that Kir functions upstream of the STE20 kinase which plays a critical role in two distinct MAP kinase cascades.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90095 USA; NATL RES COUNCIL CANADA, BIOTECHNOL RES INST, MONTREAL, PQ H4P 2R2, CANADA	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; National Research Council Canada					NATIONAL CANCER INSTITUTE [R35CA053867, R01CA041996] Funding Source: NIH RePORTER; NCI NIH HHS [CA53867, CA41996] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; COHEN L, 1994, P NATL ACAD SCI USA, V91, P12448, DOI 10.1073/pnas.91.26.12448; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LIU HP, 1993, SCIENCE, V262, P1741, DOI 10.1126/science.8259520; MAGUIRE J, 1994, SCIENCE, V265, P241, DOI 10.1126/science.7912851; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; NOMOTO S, 1990, EMBO J, V9, P691, DOI 10.1002/j.1460-2075.1990.tb08161.x; QADOTA H, 1994, P NATL ACAD SCI USA, V91, P9317, DOI 10.1073/pnas.91.20.9317; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; SHERMAN F, 1986, FMETHODS YEAST GENET, P153; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; TANAKA K, 1992, MOL CELL BIOL, V12, P631, DOI 10.1128/MCB.12.2.631; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WRIGHT RM, 1993, CURR GENET, V23, P388, DOI 10.1007/BF00312623; ZHU JH, 1995, J BIOL CHEM, V270, P4805, DOI 10.1074/jbc.270.9.4805	24	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2267	2271						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570176				2022-12-25	WOS:A1995TK70200009
J	Subramanian, T; Boyd, JM; Chinnadurai, G				Subramanian, T; Boyd, JM; Chinnadurai, G			Functional substitution identifies a cell survival promoting domain common to adenovirus E1B 19 kDa and Bcl-2 proteins	ONCOGENE			English	Article						apoptosis; Bcl-2 family; E1B 19 kDa protein; p53; NH1 domain	TUMOR-NECROSIS-FACTOR; EARLY REGION E1B; LP+ LOCUS; DEATH; GENE; TRANSFORMATION; APOPTOSIS; ANTIGEN; DNA; ONCOGENE	The adenovirus E1B 19 kDa protein provides a cell survival function during adenovirus infection and facilitates efficient virus replication by preventing premature cell death. These functions resemble those performed by the protein coded by the proto-oncogene Bcl-2. The Bcl-2 protein, which provides a survival function in cells exposed to a number of cell death-inducing stimuli, can substitute for the 19 kDa protein during adenovirus infection, Although these two survival-promoting proteins are not overtly related by primary amino acid sequence, they appear to share short homologous sequences. In order to determine if these sequence motifs constitute common functional domains, we carried out domain exchanges between the 19 kDa and Bcl-2 proteins, Our results indicate that a seven amino acid region of the Bcl-2 protein (108-YRRDFAE-114) can efficiently substitute for the corresponding 19 kDa domain (47-YKWEFEE-53). Mutagenizing this domain in Bcl-2 abolishes the survival promoting activity of Bcl-2, Substitution of the 19 kDa sequences into Bcl-2 restores the survival promoting activity, albeit at reduced levels, Our results suggest that this domain (designated NH1) may constitute a common functional domain for the 19 kDa protein and survival promoting members of the Bcl-2 family of proteins.	ST LOUIS UNIV,MED CTR,INST MOLEC VIROL,ST LOUIS,MO 63110	Saint Louis University					NATIONAL CANCER INSTITUTE [R01CA031719, R01CA033616] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA033616, CA-31719, CA-33616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1992, CURRENT PROTOCOLS MO; BABISS LE, 1984, J VIROL, V52, P389, DOI 10.1128/JVI.52.2.389-395.1984; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, IN PRESS ONCOGENE; CHINNADURAI G, 1983, CELL, V33, P759, DOI 10.1016/0092-8674(83)90018-1; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GOODING LR, 1991, J VIROL, V65, P3083, DOI 10.1128/JVI.65.6.3083-3094.1991; GREEN M, 1983, J VIROL, V48, P604, DOI 10.1128/JVI.48.3.604-615.1983; HASHIMOTO S, 1991, INT IMMUNOL, V3, P343, DOI 10.1093/intimm/3.4.343; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; MCLORIE W, 1991, J GEN VIROL, V72, P1467, DOI 10.1099/0022-1317-72-6-1467; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PILDER S, 1984, J VIROL, V52, P664, DOI 10.1128/JVI.52.2.664-671.1984; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUBRAMANIAN T, 1984, J BIOL CHEM, V259, P1777; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; SUBRAMANIAN T, 1984, J VIROL, V52, P336, DOI 10.1128/JVI.52.2.336-343.1984; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; TAKEMORI N, 1984, J VIROL, V52, P793, DOI 10.1128/JVI.52.3.793-805.1984; TARODI B, 1993, INT J ONCOL, V3, P467; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	38	42	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2403	2409						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570192				2022-12-25	WOS:A1995TK70200025
J	Ferrari, M; Lucchini, G; Plevani, P; Foiani, M				Ferrari, M; Lucchini, G; Plevani, P; Foiani, M			Phosphorylation of the DNA polymerase alpha-primase B subunit is dependent on its association with the p180 polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; PROTEIN COMPLEX; S-PHASE; YEAST; REPLICATION; INVITRO; INITIATION; MEIOSIS; ORIGIN	The B subunit of the DNA polymerase (pol) alpha-primase complex executes an essential role at the initial stage of DNA replication in Saccharomyces cerevisiae and is phosphorylated in a cell cycle-dependent manner. In this report, we show that the four subunits of the yeast DNA polymerase alpha-primase complex are assembled throughout the cell cycle, and physical association between newly synthesized pol alpha (p180) and unphosphorylated B subunit (p86) occurs very rapidly, Therefore, B subunit phosphorylation does not appear to modulate p180 . p86 interaction, Conversely, by depletion experiments and by using a yeast mutant strain, which produces a low and constitutive level of the p180 polypeptide, we found that formation of the p180 p86 subcomplex is required for B subunit phosphorylation.	UNIV MILAN, DIPARTIMENTO GENET & BIOL MICRORGANISMI, I-20133 MILAN, ITALY	University of Milan			Foiani, Marco/M-8234-2014	Foiani, Marco/0000-0003-4795-834X; PLEVANI, PAOLO/0000-0003-1869-2626				BROOKE RG, 1991, J BIOL CHEM, V266, P10093; BROOKE RG, 1991, J BIOL CHEM, V266, P3005; CAMPBELL JL, 1993, J BIOL CHEM, V268, P25261; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; COVERLEY D, 1994, ANNU REV BIOCHEM, V63, P745, DOI 10.1146/annurev.bi.63.070194.003525; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; FALCONI MM, 1993, P NATL ACAD SCI USA, V90, P10519, DOI 10.1073/pnas.90.22.10519; FOIANI M, 1995, MOL CELL BIOL, V15, P883; FOIANI M, 1989, MOL CELL BIOL, V9, P3081, DOI 10.1128/MCB.9.7.3081; FOIANI M, 1994, MOL CELL BIOL, V14, P923, DOI 10.1128/MCB.14.2.923; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HURWITZ J, 1990, J BIOL CHEM, V265, P18043; JOHNSTON GC, 1983, EXP CELL RES, V149, P1, DOI 10.1016/0014-4827(83)90375-0; JOHNSTON LH, 1987, NUCLEIC ACIDS RES, V15, P5017, DOI 10.1093/nar/15.13.5017; JOHNSTON LH, 1990, MOL GEN GENET, V221, P44, DOI 10.1007/BF00280366; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; LONGHESE MP, 1993, GENETICS, V133, P183; NASHEUER HP, 1991, J BIOL CHEM, V266, P7893; PLEVANI P, 1985, J BIOL CHEM, V260, P7102; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANTOCANALE C, 1993, J BIOL CHEM, V268, P1343; SANTOCANALE C, 1992, GENE, V113, P199, DOI 10.1016/0378-1119(92)90396-7; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513	33	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8661	8666		10.1074/jbc.271.15.8661	http://dx.doi.org/10.1074/jbc.271.15.8661			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621497	Green Published, hybrid			2022-12-25	WOS:A1996UE73000028
J	Doiron, B; Cuif, MH; Chen, RH; Kahn, A				Doiron, B; Cuif, MH; Chen, RH; Kahn, A			Transcriptional glucose signaling through the glucose response element is mediated by the pentose phosphate pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; TRANSGENIC MICE; RAT HEPATOCYTES; EXPRESSION; METABOLISM; LIVER; CARBOHYDRATE; DEPLETION; PROMOTER; INSULIN	Glucose catabolism induces the expression of the L-type pyruvate kinase (L-PK) gene through the glucose response element (GIRE). The metabolic pathway used by glucose after its phosphorylation to glucose 6-phosphate by glucokinase to induce L-PK gene expression in hepatocytes remains unknown. The sugar alcohol xylitol is metabolized to xylulose 5-phosphate, an intermediate of the nonoxidative branch of the pentose phosphate pathway. In this study, we demonstrated that xylitol at low concentration (0.5 mM) induced the expression of the L-PK/CAT construct in glucose-responsive mhAT3F hepatoma cells at the same level as 20 mM glucose, while it did not affect intracellular concentration of glucose 6-phosphate significantly. The effect of xylitol on the induction of the L-PK gene expression was noncumulative with that of glucose since 20 mM glucose plus 5 mM xylitol induced the expression of the L-PK/CAT construct similarly to 20 nM glucose alone. In hepatocytes in primary culture, 5 mM xylitol induced accumulation of the L-PK mRNA even in the absence of insulin. Furthermore, the response to xylitol as well as glucose required the presence of a functional GIRE. It can be assumed from these results that glucose induces the expression of the L-PK gene through the nonoxidative branch of the pentose phosphate pathway. The effect of xylitol at low concentration suggests that the glucose signal to the transcriptional machinery is mediated by xylulose 5-phosphate.	INST COCHIN GENET MOLEC,INSERM,U129,F-75014 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)				Chen, Ruihuan/0000-0002-0641-2132				ANTOINE B, 1992, EXP CELL RES, V200, P175, DOI 10.1016/S0014-4827(05)80086-2; BAQUER NZ, 1973, BIOCHEM BIOPH RES CO, V52, P263, DOI 10.1016/0006-291X(73)90982-0; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLACKMORE PF, 1982, INT J BIOCHEM, V14, P171, DOI 10.1016/0020-711X(82)90136-7; CASAZZA JP, 1986, BIOCHEM J, V236, P635, DOI 10.1042/bj2360635; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COGNET M, 1991, J BIOL CHEM, V266, P7368; CUIF MH, 1993, J BIOL CHEM, V268, P13769; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DECAUX JF, 1991, J BIOL CHEM, V266, P3432; DILLS WL, 1994, PROTEIN EXPRES PURIF, V5, P259, DOI 10.1006/prep.1994.1039; DOIRON B, 1994, J BIOL CHEM, V269, P10213; FOUFELLE F, 1995, BIOCHEM J, V308, P521, DOI 10.1042/bj3080521; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HICKMAN J, 1958, J BIOL CHEM, V232, P737; HORECKER BL, 1955, ANNU REV BIOCHEM, V24, P207, DOI 10.1146/annurev.bi.24.070155.001231; JENKINS AB, 1986, INT J BIOCHEM, V18, P311, DOI 10.1016/0020-711X(86)90036-4; LEFRANCOISMARTINEZ AM, 1994, FASEB J, V8, P89, DOI 10.1096/fasebj.8.1.8299894; LEVRAT F, 1993, EXP CELL RES, V209, P307, DOI 10.1006/excr.1993.1315; LIU ZR, 1993, J BIOL CHEM, V268, P12787; MARIE S, 1993, J BIOL CHEM, V268, P23881; NISHIMURA M, 1994, J BIOL CHEM, V269, P26100; NISHIMURA M, 1995, J BIOL CHEM, V270, P26341, DOI 10.1074/jbc.270.44.26341; ROUSSEAU GG, 1994, BIOCHEM J, V303, P1; Sambrook J, 1989, MOL CLONING LABORATO; SHIN HM, 1992, J BIOL CHEM, V267, P13222; SHIN HM, 1994, J BIOL CHEM, V269, P9380; SHIN HM, 1995, J BIOL CHEM, V270, P21991; SLEIN MW, 1963, METHOD ENZYMAT AN, P1238; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; VINCENT MF, 1989, FASEB J, V3, P1862, DOI 10.1096/fasebj.3.7.2469615; VINCENT MF, 1989, FASEB J, V3, P1855, DOI 10.1096/fasebj.3.7.2523832; ZABOS P, 1978, P NATL ACAD SCI USA, V73, P5422	37	112	115	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5321	5324		10.1074/jbc.271.10.5321	http://dx.doi.org/10.1074/jbc.271.10.5321			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621383	hybrid			2022-12-25	WOS:A1996TZ28600009
J	Merrick, SE; Demoise, DC; Lee, VMY				Merrick, SE; Demoise, DC; Lee, VMY			Site-specific dephosphorylation of tau protein at Ser(202)/Thr(205) in response to microtubule depolymerization in cultured human neurons involves protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED HELICAL FILAMENTS; GLYCOGEN-SYNTHASE KINASE-3; ALZHEIMER-LIKE STATE; PHOSPHORYLATION SITES; NERVOUS-SYSTEM; HUMAN-BRAIN; NEUROFILAMENT PROTEINS; MONOCLONAL-ANTIBODIES; CYCLOSPORINE-A; NTERA-2 CELLS	Tau proteins isolated from paired helical filaments, the major building blocks of Alzheimer's disease neurofibrillary tangle, are abnormally phosphorylated and unable to bind microtubules. To examine the dynamics of tau phosphorylation and to identify specific tau phosphorylation sites involved in the stabilization of microtubules, we treated cultured postmitotic neuron-like cells (NT2N) derived from a human teratocarcinoma cell line (NTera2/D1) with drugs that depolymerize microtubules (i.e. colchicine or nocodazole). This led to the recovery of dephosphorylated tau from the NT2N cells as monitored by a relative increase in the electrophoretic mobility of tau and an increase in the turnover of [P-32]PO4-labeled tau. However, not all phosphorylation sites on tan are affected by colchicine or nocodazole. Ser(202)/Thr(205) appears to be completely and specifically dephosphorylated by protein phosphatase 2A since this dephosphorylation was blocked by inhibitors of protein phosphatase 2A but not by inhibitors of protein phosphatase 2B. These findings, together with the recent observation that protein phosphatase 2A is normally bound to microtubules in intact cells, suggest that the polymerization state of microtubules could modulate the phosphorylation state of tau at specific sites in the normal and Alzheimer's disease brain.	UNIV PENN,SCH MED,DAVID MAHONEY INST NEUROL SCI,PHILADELPHIA,PA 19104; UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania								BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; BIERNAT J, 1993, NEURON, V11, P153, DOI 10.1016/0896-6273(93)90279-Z; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BRAMBLETT GT, 1992, LAB INVEST, V66, P212; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; CORREAS I, 1992, J BIOL CHEM, V267, P15721; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; DREWES G, 1993, FEBS LETT, V336, P425, DOI 10.1016/0014-5793(93)80850-T; DREWES G, 1992, EMBO J, V11, P2131, DOI 10.1002/j.1460-2075.1992.tb05272.x; DRUBIN D, 1986, ANN NY ACAD SCI, V466, P257, DOI 10.1111/j.1749-6632.1986.tb38398.x; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; GOEDERT M, 1988, P NATL ACAD SCI USA, V85, P4051, DOI 10.1073/pnas.85.11.4051; GOEDERT M, 1995, NEUROSCI LETT, V189, P167, DOI 10.1016/0304-3940(95)11484-E; GOEDERT M, 1994, BIOCHEM J, V301, P871, DOI 10.1042/bj3010871; GOEDERT M, 1990, EMBO J, V9, P4225, DOI 10.1002/j.1460-2075.1990.tb07870.x; GOEDERT M, 1992, FEBS LETT, V312, P95, DOI 10.1016/0014-5793(92)81418-L; GOEDERT M, 1993, P NATL ACAD SCI USA, V90, P5066, DOI 10.1073/pnas.90.11.5066; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; GUSTKE N, 1994, BIOCHEMISTRY-US, V33, P9511, DOI 10.1021/bi00198a017; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; HARRIS KA, 1993, ANN NEUROL, V33, P77, DOI 10.1002/ana.410330113; HASEGAWA M, 1992, J BIOL CHEM, V267, P17047; HIMMLER A, 1989, MOL CELL BIOL, V9, P1389, DOI 10.1128/MCB.9.4.1389; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; KONDO J, 1988, NEURON, V1, P827, DOI 10.1016/0896-6273(88)90130-4; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KSIEZAKREDING H, 1990, J NEUROSCI RES, V25, P412, DOI 10.1002/jnr.490250319; LANG E, 1992, BIOCHEM BIOPH RES CO, V187, P783, DOI 10.1016/0006-291X(92)91264-Q; Lee V M, 1992, Curr Opin Neurobiol, V2, P653, DOI 10.1016/0959-4388(92)90034-I; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEE VMY, 1986, J NEUROSCI, V6, P514; LEE VMY, 1987, J NEUROSCI, V7, P3474; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MATSUO ES, 1994, NEURON, V13, P989, DOI 10.1016/0896-6273(94)90264-X; MATTSON MP, 1992, BRAIN RES, V582, P107, DOI 10.1016/0006-8993(92)90323-2; MAWALDEWAN M, 1994, J BIOL CHEM, V269, P30981; MERCKEN M, 1992, ACTA NEUROPATHOL, V84, P265, DOI 10.1007/BF00227819; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; OTVOS L, 1994, J NEUROSCI RES, V39, P669, DOI 10.1002/jnr.490390607; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCOTT CW, 1993, J BIOL CHEM, V268, P1166; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONTAG E, 1995, J CELL BIOL, V128, P1131, DOI 10.1083/jcb.128.6.1131; STEINER B, 1990, EMBO J, V9, P3539, DOI 10.1002/j.1460-2075.1990.tb07563.x; SZENDREI GI, 1993, J NEUROSCI RES, V34, P243, DOI 10.1002/jnr.490340212; TROJANOWSKI JQ, 1993, BRAIN PATHOL, V3, P45, DOI 10.1111/j.1750-3639.1993.tb00725.x; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; VALLEE RB, 1982, J CELL BIOL, V92, P435, DOI 10.1083/jcb.92.2.435; VULLIET R, 1992, J BIOL CHEM, V267, P22570; WATANABE A, 1993, J BIOL CHEM, V268, P25712; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4884, DOI 10.1073/pnas.85.13.4884; WISCHIK CM, 1988, P NATL ACAD SCI USA, V85, P4506, DOI 10.1073/pnas.85.12.4506; WOLOZIN BL, 1986, SCIENCE, V232, P648, DOI 10.1126/science.3083509; YANG SD, 1991, J PROTEIN CHEM, V10, P171, DOI 10.1007/BF01024781	67	80	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5589	5594		10.1074/jbc.271.10.5589	http://dx.doi.org/10.1074/jbc.271.10.5589			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621419	hybrid			2022-12-25	WOS:A1996TZ28600045
J	Bai, LQ; Fushimi, K; Sasaki, S; Marumo, F				Bai, LQ; Fushimi, K; Sasaki, S; Marumo, F			Structure of aquaporin-2 vasopressin water channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN	Aquaporin-2 (AQP-2) is a vasopressin-regulated water channel in the kidney collecting duct. AQP-2 is selectively permeable to water molecule and is translocated between the apical membrane and subapical endosomes in response to vasopressin. To investigate the localization and structure of the aqueous pathway of the AQP-2 water channel, a series of site-directed mutants was constructed and functionally analyzed. Insertion of N-glycosylation reporter sequence into each hydrophilic loop (HL) indicated that AQP-2 has a six-membrane spanning topology and that insertional mutations in HL-2 or HL-5 do not alter water channel function. Mercury-sensitive site of AQP-2 is located near the second asparagine-proline-alanine (NPA) domain at cysteine 181, but not near the first NPA domain. Replacement of HL-3 or HL-4 with the corresponding part of Escherichia coli glycerol facilitator abolished water channel function without changing plasma membrane expression of the channel protein. Introduction of cysteine residues in His-122, Asn-123, Gly-154, Asp-155, or Asn-156 induced partial mercury sensitivity, and point mutations in asparagine 123 significantly altered water permeability. Our results implicate that the structure of AQP-2 is different from models previously proposed for AQP-1 and that HL-3 and HL-4 are closely located to the aqueous pathway.	TOKYO MED & DENT UNIV,SCH MED,DEPT INTERNAL MED 2,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU)								AGRE P, 1993, AM J PHYSIOL, V265, pF463; CHANG XB, 1994, J BIOL CHEM, V269, P18572; CHEPELINSKY AB, 1994, HDB MEMBRANE CHANNEL, P413; CHRISPEELS MJ, 1994, PLANT PHYSIOL, V105, P9, DOI 10.1104/pp.105.1.9; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DEEN PMT, 1995, J CLIN INVEST, V95, P2291, DOI 10.1172/JCI117920; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DENKER BM, 1988, J BIOL CHEM, V263, P15634; FISCHBARG J, 1995, J MEMBRANE BIOL, V143, P177; FUSHIMI K, 1994, AM J PHYSIOL-RENAL, V267, pF573, DOI 10.1152/ajprenal.1994.267.4.F573; Fushimi K, 1995, Curr Opin Nephrol Hypertens, V4, P392, DOI 10.1097/00041552-199509000-00003; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HANDLER JS, 1988, AM J PHYSIOL, V255, pF375, DOI 10.1152/ajprenal.1988.255.3.F375; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; JUNG JS, 1994, J BIOL CHEM, V269, P14648; KANNO K, 1995, NEW ENGL J MED, V332, P1540, DOI 10.1056/NEJM199506083322303; KNEPPER MA, 1994, SEMIN NEPHROL, V14, P302; KUWAHARA M, 1995, J BIOL CHEM, V270, P10384, DOI 10.1074/jbc.270.18.10384; MAUREL C, 1994, J BIOL CHEM, V269, P11869; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; NIELSEN S, 1995, P NATL ACAD SCI USA, V92, P1013, DOI 10.1073/pnas.92.4.1013; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI S, 1994, J CLIN INVEST, V93, P1250, DOI 10.1172/JCI117079; SHI LB, 1994, J BIOL CHEM, V269, P10417; SKACH WR, 1994, J CELL BIOL, V125, P803, DOI 10.1083/jcb.125.4.803; TOUSTER O, 1970, J CELL BIOL, V47, P604, DOI 10.1083/jcb.47.3.604; VANLIEBURG AF, 1994, AM J HUM GENET, V55, P648; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; VERKMAN AS, 1992, ANNU REV PHYSIOL, V54, P97, DOI 10.1146/annurev.physiol.54.1.97; YAMAMOTO T, 1995, AM J PHYSIOL-CELL PH, V268, pC1546, DOI 10.1152/ajpcell.1995.268.6.C1546; YOUNG GPH, 1984, P NATL ACAD SCI-BIOL, V81, P5155, DOI 10.1073/pnas.81.16.5155	35	80	84	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5171	5176						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617798				2022-12-25	WOS:A1996TX69700088
J	Ismailov, II; Awayda, MS; Jovov, B; Berdiev, BK; Fuller, CM; Dedman, JR; Kaetzel, MA; Benos, DJ				Ismailov, II; Awayda, MS; Jovov, B; Berdiev, BK; Fuller, CM; Dedman, JR; Kaetzel, MA; Benos, DJ			Regulation of epithelial sodium channels by the cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NASAL EPITHELIUM; NA+ CHANNEL; RESPIRATORY EPITHELIUM; CHLORIDE CHANNELS; APICAL MEMBRANE; CFTR; TRANSPORT; MECHANISMS; AIRWAY	Cystic fibrosis airway epithelia exhibit enhanced Na+ reabsorption in parallel with diminished Cl- secretion. We tested the hypothesis that the cystic fibrosis transmembrane conductance regulator (CETR) directly affects epithelial Na+ channel activity by co-incorporating into planar lipid bilayers immunopurified bovine tracheal CFTR and either heterologously expressed rat epithelial Na+ channel (alpha,beta,gamma-rENaC) or an immunopurified bovine renal Na+ channel protein complex. The single channel open probability (P-o) of rENaC was decreased by 24% in the presence of CFTR. Protein kinase A (PHA) plus ATP activated CFTR, but did not have any effect on rENaC. CFTR also decreased the extent of elevation of the renal Na+ channel P-o following PRA-mediated phosphorylation. Moreover, the presence of CFTR prohibited the inward rectification of the gating of this renal Na+ channel normally induced by PRA-mediated phosphorylation, thus down-regulating inward Na+ current. This interaction between CFTR and Na+ channels occurs independently of whether or not wild-type CFTR is conducting anions. However, the nonconductive CFTR mutant, G551D CFTR, cannot substitute for the wild-type molecule. Our results indicate that CFTR can directly down-regulate single Na+ channel activity, thus accounting, at least in part, for the observed differences in Na+ transport between normal and cystic fibrosis-affected airway epithelia.	UNIV ALABAMA, DEPT PHYSIOL & BIOPHYS, BIRMINGHAM, AL 35294 USA; UNIV CINCINNATI, DEPT MOL & CELLULAR PHYSIOL, CINCINNATI, OH 45267 USA	University of Alabama System; University of Alabama Birmingham; University System of Ohio; University of Cincinnati			Fuller, Cathy/B-4046-2011		NIDDK NIH HHS [DK48764, DK 37206] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037206, R56DK037206, R01DK048764] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ O, 1985, J ELECTROPHYSIOL TEC, V12, P159; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; AWAYDA MS, 1995, AM J PHYSIOL-CELL PH, V268, pC1450, DOI 10.1152/ajpcell.1995.268.6.C1450; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BURCH LH, 1995, AM J PHYSIOL-CELL PH, V269, pC511, DOI 10.1152/ajpcell.1995.269.2.C511; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CHAN HC, 1992, J BIOL CHEM, V267, P8411; CHINET TC, 1993, AM J PHYSIOL, V265, pC1050, DOI 10.1152/ajpcell.1993.265.4.C1050; CHINET TC, 1994, AM J PHYSIOL, V266, pC1061, DOI 10.1152/ajpcell.1994.266.4.C1061; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; COSTANZO LS, 1980, AM J PHYSIOL, V239, pF478, DOI 10.1152/ajprenal.1980.239.5.F478; COTTON CU, 1987, J CLIN INVEST, V79, P80, DOI 10.1172/JCI112812; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; DUSZYK M, 1989, CAN J PHYSIOL PHARM, V67, P1362, DOI 10.1139/y89-217; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; FULLER CM, 1992, AM J PHYSIOL, V263, pC267, DOI 10.1152/ajpcell.1992.263.2.C267; GABRIEL SE, 1993, NATURE, V363, P263, DOI 10.1038/363263a0; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; HUSTED RF, 1995, J CLIN INVEST, V95, P644, DOI 10.1172/JCI117709; Ismailov II, 1996, J BIOL CHEM, V271, P807, DOI 10.1074/jbc.271.2.807; Ismailov II, 1995, BIOPHYS J, V69, P1789, DOI 10.1016/S0006-3495(95)80049-4; ISMAILOV II, 1994, J BIOL CHEM, V269, P10235; ISMAILOV II, 1995, J GEN PHYSIOL, V106, P445, DOI 10.1085/jgp.106.3.445; ISMAILOV II, 1996, IN PRESS J MEMBR BIO; JOVOV B, 1995, J BIOL CHEM, V270, P1521, DOI 10.1074/jbc.270.4.1521; JOVOV B, 1995, J BIOL CHEM, V270, P29194, DOI 10.1074/jbc.270.49.29194; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KNOWLES MR, 1993, PEDIATR PULM S, V9, P148; OBRODOVICH H, 1993, AM J PHYSIOL, V265, pC491, DOI 10.1152/ajpcell.1993.265.2.C491; OH YS, 1993, PROTEIN EXPRES PURIF, V4, P312, DOI 10.1006/prep.1993.1040; PEREZ G, 1994, BIOPHYS J, V66, P1022, DOI 10.1016/S0006-3495(94)80883-5; ROBSON AM, 1971, J PEDIATR-US, V79, P42, DOI 10.1016/S0022-3476(71)80056-2; SENYK O, 1995, AM J PHYSIOL-CELL PH, V268, pC1148, DOI 10.1152/ajpcell.1995.268.5.C1148; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Tsui L C, 1991, Adv Hum Genet, V20, P153; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WILLUMSEN NJ, 1991, AM J PHYSIOL, V261, pC319, DOI 10.1152/ajpcell.1991.261.2.C319; WILLUMSEN NJ, 1991, AM J PHYSIOL, V261, pC332, DOI 10.1152/ajpcell.1991.261.2.C332	43	139	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4725	4732						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617738				2022-12-25	WOS:A1996TX69700028
J	Klansek, JJ; Warner, GJ; Johnson, WJ; Glick, JM				Klansek, JJ; Warner, GJ; Johnson, WJ; Glick, JM			Compartmental isolation of cholesterol participating in the cytoplasmic cholesteryl ester cycle in Chinese hamster ovary 25-RA cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; NIEMANN-PICK DISEASE; ACYL-COENZYME-A; CULTURED FIBROBLASTS; HEPATOMA-CELLS; ESTERIFICATION; MACROPHAGES; ACCUMULATION; METABOLISM; RECEPTOR	Using the Chinese hamster ovary cell line, 25-RA, we have demonstrated that lipoprotein-derived cholesterol and endogenously synthesized cholesterol are selectively differentiated with respect to their cellular locations, These cells lack sterol-mediated regulation, spontaneously storing large amounts of esterified cholesterol, which turns over with a half-time of 7.5 h. When [H-3]cholesterol was provided to the cells in serum to trace cellular cholesterol, the specific activities of cellular free and esterified cholesterol (6238 +/- 273 and 5128 +/- 277 cpm/mu g, respectively) failed to equilibrate, indicating that bulk cellular free cholesterol is isolated from that participating in the cholesteryl ester cycle. Using [H-3]acetate to trace the fate of endogenously synthesized cholesterol, a failure of equilibration was also observed (specific activities of free and esterified cholesterol = 280 +/- 37 and 458 +/- 8 cpm/mu g, respectively), The lower specific activity of the precursor indicates that endogenously synthesized cholesterol is preferentially esterified, When cells radiolabeled with [H-3]acetate were post-incubated in the absence of radiolabel, the specific activity of the esterified cholesterol pool remained significantly higher than that of the free cholesterol, suggesting that cholesterol derived from hydrolysis of esterified cholesterol is preferentially re-esterified.	MED COLL PENN,PHILADELPHIA,PA 19129; HAHNEMANN UNIV,DEPT BIOCHEM,PHILADELPHIA,PA 19129	Drexel University; Drexel University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007443] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07443] Funding Source: Medline; PHS HHS [22633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARBOGAST LY, 1976, P NATL ACAD SCI USA, V73, P3680, DOI 10.1073/pnas.73.10.3680; BAMBERGER M, 1985, BIOCHEMISTRY-US, V24, P3693, DOI 10.1021/bi00335a044; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BROWN MS, 1975, P NATL ACAD SCI USA, V72, P2925, DOI 10.1073/pnas.72.8.2925; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG TY, 1982, BIOCHEMISTRY-US, V21, P5316, DOI 10.1021/bi00264a030; CHANG TY, 1980, J BIOL CHEM, V255, P7787; CHESTERTON CJ, 1968, J BIOL CHEM, V243, P1147; FOLCH J, 1957, J BIOL CHEM, V226, P497; GLICK JM, 1987, ATHEROSCLEROSIS, V64, P223, DOI 10.1016/0021-9150(87)90250-4; Gottesman M M, 1987, Methods Enzymol, V151, P3, DOI 10.1016/S0076-6879(87)51004-7; Gottesman M M, 1987, Methods Enzymol, V151, P113, DOI 10.1016/S0076-6879(87)51012-6; HAM RG, 1965, P NATL ACAD SCI USA, V53, P288, DOI 10.1073/pnas.53.2.288; HARRISON EH, 1990, J LIPID RES, V31, P2187; Hatch F T, 1968, Adv Lipid Res, V6, P1; HOSIE L, 1987, J BIOL CHEM, V262, P260; HUSSAIN MM, 1992, CURR OPIN LIPIDOL, V3, P173; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; KILSDONK EPC, 1995, J LIPID RES, V36, P505; KLANSEK JJ, 1995, J LIPID RES, V36, P2261; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1994, J BIOL CHEM, V269, P3411; LEONARD S, 1988, BIOCHIM BIOPHYS ACTA, V947, P101, DOI 10.1016/0304-4157(88)90021-4; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1992, J LIPID RES, V33, P1239; Liscum Laura, 1994, Current Opinion in Lipidology, V5, P221, DOI 10.1097/00041433-199405030-00010; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MAZZONE T, 1995, J LIPID RES, V36, P544; MCGOOKEY DJ, 1985, J CELL BIOL, V97, P1156; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; PENTCHEV PG, 1986, J BIOL CHEM, V261, P6775; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; REINHART MP, 1987, J BIOL CHEM, V262, P9649; REINHART MP, 1990, EXPERIENTIA, V46, P569; ROSS AC, 1984, J BIOL CHEM, V259, P815; SHIPLEY RA, 1972, TRACER METHODS IN VI, P1; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; SPECTOR AA, 1985, J LIPID RES, V26, P1015; TABAS I, 1986, J BIOL CHEM, V261, P3147; XU XX, 1991, J BIOL CHEM, V266, P17040; YANCEY PG, 1992, ARTERIOSCLER THROMB, V12, P1291, DOI 10.1161/01.ATV.12.11.1291; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910	48	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4923	4929						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617765				2022-12-25	WOS:A1996TX69700055
J	Leroy, P; Dessolin, S; Villageois, P; Moon, BC; Friedman, JM; Ailhaud, G; Dani, C				Leroy, P; Dessolin, S; Villageois, P; Moon, BC; Friedman, JM; Ailhaud, G; Dani, C			Expression of ob gene in adipose cells - Regulation by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLONING; ACID	The product of the recently cloned mouse obese (ob) gene is likely to play an important role in a loop regulating the size of the adipose tissue mass, The hormonal regulation of the ob gene could affect adiposity. To investigate this point, the effect of insulin on ob gene expression was examined in cells of the 3T3-F442A preadipocyte clonal line. ob mRNA is absent from exponentially growing, undifferentiated cells as well as from confluent preadipose cells, Terminal differentiation of preadipose to adipose cells leads to the expression of ob mRNA detected by a sensitive and quantitative ribonuclease protection assay, In adipose cells, the level of ob mRNA is sensitive to insulin in the nanomolar range of concentrations with an increase from an average of 1 copy to 5-10 copies/cell. The effect of insulin was fully reversible and takes place primarily at a transcriptional level, The ob mRNA shows a rapid turnover, with a half-life of approximately 2 h in the absence or presence of insulin, The level of secreted Ob protein is also regulated by insulin, These results indicate that the ob gene is expressed in mature fat cells only and support the possibility that insulin is an important regulator of ob gene expression.	ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; UNIV NICE SOPHIA ANTIPOLIS, FAC SCI, CTR BIOCHIM, CNRS, UMR 134, F-06108 NICE 2, FRANCE	Howard Hughes Medical Institute; Rockefeller University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			DANI, Christian/G-3639-2014	DANI, Christian/0000-0003-3228-0230; Ailhaud, Gerard/0000-0003-0596-2906				AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANI C, 1989, J BIOL CHEM, V264, P10119; DANI C, 1989, MOL CELL ENDOCRINOL, V63, P199, DOI 10.1016/0303-7207(89)90096-8; DEVOS P, 1995, J BIOL CHEM, V270, P15958, DOI 10.1074/jbc.270.27.15958; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HERVEY GR, 1959, J PHYSIOL-LONDON, V145, P336, DOI 10.1113/jphysiol.1959.sp006145; IBRAHIMI A, 1993, BIOCHEM J, V289, P141, DOI 10.1042/bj2890141; KARLSSON FA, 1979, ENDOCRINOLOGY, V104, P1383, DOI 10.1210/endo-104-5-1383; KENNEDY GC, 1953, PROC R SOC SER B-BIO, V140, P578, DOI 10.1098/rspb.1953.0009; LEROY P, 1992, DEV DYNAM, V194, P21, DOI 10.1002/aja.1001940104; LIEBELT RA, 1965, ANN NY ACAD SCI, V131, P559, DOI 10.1111/j.1749-6632.1965.tb34820.x; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; MAFFEI M, 1995, P NATL ACAD SCI USA, V92, P6957, DOI 10.1073/pnas.92.15.6957; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MASUZAKI H, 1995, DIABETES, V44, P855, DOI 10.2337/diabetes.44.7.855; MURAKAMI T, 1995, BIOCHEM BIOPH RES CO, V209, P944, DOI 10.1006/bbrc.1995.1589; OGAWA Y, 1995, J CLIN INVEST, V96, P1647, DOI 10.1172/JCI118204; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; ROBERTSON M, 1993, DEV GENET, V14, P165, DOI 10.1002/dvg.1020140303; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; TRAYHURN P, 1995, FEBS LETT, V368, P488, DOI 10.1016/0014-5793(95)00719-P; WEIGLE DS, 1995, J CLIN INVEST, V96, P2065, DOI 10.1172/JCI118254; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	27	287	294	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2365	2368		10.1074/jbc.271.5.2365	http://dx.doi.org/10.1074/jbc.271.5.2365			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576190	hybrid			2022-12-25	WOS:A1996TT48800004
J	Sakharov, DV; Nagelkerke, JF; Rijken, DC				Sakharov, DV; Nagelkerke, JF; Rijken, DC			Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis - Study with confocal microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; THROMBOLYTIC PROPERTIES; DEGRADED FIBRIN; GLU-PLASMINOGEN; THROMBI INVITRO; BINDING-SITES; ONE-CHAIN; UROKINASE; TRANSPORT; DEGRADATION	Binding of components of the fibrinolytic system to fibrin is important for the regulation of fibrinolysis. In this study, decomposition of the fibrin network and binding of plasminogen and plasminogen activators (PAs) to fibrin during lysis of a plasma clot were investigated with confocal microscopy using fluorescein-labeled preparations of fibrinogen, plasminogen, tissue-type PA (t-PA), and two chain urokinase type PA (tcu-PA). Lysis induced by PAs present throughout the plasma clot was accompanied by a gradual loss of fibrin content of fibers and by accumulation of plasminogen onto the fibers. Two sequential phases could be distinguished: a phase of prelysis, during which the fibrin network remained immobile, and a phase of final lysis, during which fibers moved with a tendency to shrink and even eventually disappeared. The two phases occurred simultaneously but in different locations when lysis was induced by PAs present in the plasma surrounding the clot. The zone of final lysis was located within a 5-8-mu m superficial layer, where fibers were mobile, and surface-associated fibrin agglomerates appeared. Plasminogen accumulated in these agglomerates up to 30-fold as compared with its concentration in the outer plasma, t-PA was also highly concentrated in the agglomerates, and tcu-PA bound to them slightly. The zone of prelysis, where plasminogen was moderately accumulated on the immobile fibers, was located deeper in the clot. This zone was much thinner in the case of t-PA-induced lysis than in the case of tcu-PA-induced lysis, reflecting the difference in penetration of the two PAs into the clot. We conclude that under conditions of diffusional transport of fibrinolytic enzymes from outside a plasma clot, extensive lysis is spatially restricted to a zone not exceeding 5-8 mu m from the dot surface, In this zone the structure of the fibrin network undergoes significant changes, and strikingly high accumulation of fibrinolytic components takes place.	LEIDEN UNIV,DIV TOXICOL,LEIDEN AMSTERDAM CTR DRUG RES,SYLVIUS LAB,2333 AL LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC	Sakharov, DV (corresponding author), TNO PG,GAUBIUS LAB,POB 2215,2301 CE LEIDEN,NETHERLANDS.							BAUER R, 1994, EUR BIOPHYS J BIOPHY, V23, P239, DOI 10.1007/BF00213574; BLINC A, 1992, THROMB HAEMOSTASIS, V68, P667; BLINC A, 1991, THROMB HAEMOSTASIS, V65, P549; BLINC A, 1994, THROMB HAEMOSTASIS, V71, P230; BLOMBACK B, 1989, BIOCHIM BIOPHYS ACTA, V997, P96, DOI 10.1016/0167-4838(89)90140-4; BLOMBACK B, 1994, THROMB RES, V75, P521, DOI 10.1016/0049-3848(94)90227-5; BOK RA, 1985, BIOCHEMISTRY-US, V24, P3279, DOI 10.1021/bi00334a031; CARR ME, 1992, THROMB HAEMOSTASIS, V67, P106; CARR ME, 1978, MACROMOLECULES, V11, P46, DOI 10.1021/ma60061a009; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DESERRANO VS, 1989, J PROTEIN CHEM, V8, P61, DOI 10.1007/BF01025079; DIAMOND SL, 1993, BIOPHYS J, V65, P2622, DOI 10.1016/S0006-3495(93)81314-6; DOOLITTLE RF, 1994, HAEMOSTASIS THROMBOS, P491; FLEURY V, 1991, BIOCHEMISTRY-US, V30, P7630, DOI 10.1021/bi00244a035; FOX KAA, 1985, CIRCULATION, V72, P1346, DOI 10.1161/01.CIR.72.6.1346; GAFFNEY PJ, 1994, HAEMOSTASIS THROMBOS, P549; GARMAN AJ, 1982, THROMB RES, V27, P311, DOI 10.1016/0049-3848(82)90078-0; HARPEL PC, 1985, J BIOL CHEM, V260, P4432; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; KRAUSE J, 1989, FIBRINOLYSIS, V3, P85, DOI 10.1016/0268-9499(89)90036-2; MATSUO O, 1981, THROMB HAEMOSTASIS, V45, P225; NISHINO N, 1991, THROMB HAEMOSTASIS, V66, P672; NOVOKHATNY VV, 1991, J BIOL CHEM, V266, P12994; PANNELL R, 1988, J CLIN INVEST, V81, P853, DOI 10.1172/JCI113394; PETERSEN LC, 1991, FIBRINOLYSIS, V5, P51, DOI 10.1016/0268-9499(91)90077-H; RIJKEN DC, 1981, J BIOL CHEM, V256, P7035; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; SAKHAROV DV, 1995, CIRCULATION, V92, P1883, DOI 10.1161/01.CIR.92.7.1883; SAKHAROV DV, 1995, THROMB HAEMOSTASIS, V73, P1136; SAKHAROV DV, 1994, FIBRINOLYSIS, V8, P116, DOI 10.1016/0268-9499(94)90268-2; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; THORSEN S, 1975, BIOCHIM BIOPHYS ACTA, V393, P55, DOI 10.1016/0005-2795(75)90216-0; TRANTHANG C, 1984, J CLIN INVEST, V74, P2009, DOI 10.1172/JCI111623; VARADI A, 1983, BIOCHEMISTRY-US, V22, P2440, DOI 10.1021/bi00279a021; VERHEIJEN JH, 1982, THROMB RES, V27, P377, DOI 10.1016/0049-3848(82)90055-X; WAGNER OF, 1989, J CLIN INVEST, V84, P647, DOI 10.1172/JCI114211; WEISEL JW, 1994, J MOL BIOL, V235, P1117, DOI 10.1006/jmbi.1994.1061; WU JH, 1995, ANAL BIOCHEM, V224, P83, DOI 10.1006/abio.1995.1011; WU JH, 1994, THROMB HAEMOSTASIS, V72, P105; ZAMARRON C, 1984, THROMB HAEMOSTASIS, V52, P19; ZIDANSEK A, 1991, THROMB HAEMOSTASIS, V65, P553	42	87	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2133	2138		10.1074/jbc.271.4.2133	http://dx.doi.org/10.1074/jbc.271.4.2133			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567670				2022-12-25	WOS:A1996TR32000052
J	Wu, WI; Liu, YS; Riedel, B; Wissing, JB; Fischl, AS; Carman, GM				Wu, WI; Liu, YS; Riedel, B; Wissing, JB; Fischl, AS; Carman, GM			Purification and characterization of diacylglycerol pyrophosphate phosphatase from Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHESIS; MIXED MICELLES; PHOSPHATIDYLINOSITOL SYNTHASE; PHOSPHATIDYLSERINE SYNTHASE; 104-KDA FORMS; KINASE; YEAST; INOSITOL; ENZYME; METABOLISM	Diacylglycerol pyrophosphate (DGPP) phosphatase is a novel membrane associated enzyme that catalyzes the dephosphorylation of the beta phosphate of DGPP to yield phosphatidate and P-i. DGPP phosphatase was purified 33,333-fold from Saccharomyces cerevisiae by a procedure that included Triton X-100 solubilization of microsomal membranes followed by chromatography with DE53, Affi-Gel Blue, hydroxylapatite, and Mono Q. The procedure resulted in the isolation of an apparent homogeneous protein with a subunit molecular mass of 34 kDa. DGPP phosphatase activity was associated with the 34-kDa protein, DGPP phosphatase had a broad pH optimum between 6.0 and 8.5 and was dependent on Trifon X-100 for maximum activity. The enzyme was inhibited by divalent cations, NaF, and pyrophosphate and was relatively insensitive 60 thioreactive agents. The turnover number (molecular activity) for the enzyme was 5.8 x 10(3) min(-1) at pH 6.5 and 30 degrees C. DGPP phosphatase exhibited typical saturation kinetics with respect to DGPP (K-m = 0.55 mol %). The K-m value for DGPP was 3-fold greater than its cellular concentration (0.18 mol %). DGPP phosphatase also catalyzed the dephosphorylation of phosphatidate, but this dephosphorylation was subsequent to the dephosphorylation of the beta phosphate of DGPP. The dependence of activity on phosphatidate (K-m = 2.2 mol %) was cooperative (Hill number = 2.0). DGPP was the preferred substrate for the enzyme with a specificity constant (V-max/K-m) 10-fold greater than that for phosphatidate. In addition, DGPP potently inhibited (K-i = 0.35 mol %) the dephosphorylation of phosphatidate by a competitive mechanism whereas phosphatidate did not inhibit the dephosphorylation of DGPP. DGPP was neither a substrate nor an inhibitor of pure phosphatidate phosphatase from S. cerevisiae. DGPP was synthesized from phosphatidate via the phosphatidate kinase reaction.	RUTGERS STATE UNIV, COOK COLL, NEW JERSEY AGR EXPT STN, DEPT FOOD SCI, NEW BRUNSWICK, NJ 08903 USA; GESELL BIOTECHNOL FORSCH MBH, D-38124 BRAUNSCHWEIG, GERMANY; UNIV RHODE ISL, DEPT FOOD SCI & NUTR, KINGSTON, RI 02892 USA	Rutgers State University New Brunswick; Gesellschaft fur Biotechnologische Forschung mbH; University of Rhode Island					NIGMS NIH HHS [GM-49214, GM-28140] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028140, R37GM028140, R29GM049214] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAELEE M, 1990, J BIOL CHEM, V265, P7221; Bailey K, 1944, BIOCHEM J, V38, P394, DOI 10.1042/bj0380394; BELUNIS CJ, 1988, J BIOL CHEM, V263, P18897; BHAT BG, 1994, J BIOL CHEM, V269, P13172; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARMAN GM, 1991, METHOD ENZYMOL, V197, P548; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CULBERTSON MR, 1975, GENETICS, V80, P23; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; GOMEZMUNOZ A, 1994, J BIOL CHEM, V269, P8937; GREENBERG ML, 1982, MOL GEN GENET, V186, P157, DOI 10.1007/BF00331845; HANSON BA, 1980, J LIPID RES, V21, P309; HEIM S, 1987, PLANT SCI, V49, P159, DOI 10.1016/0168-9452(87)90036-7; HEPPEL LA, 1951, J BIOL CHEM, V192, P87; JONES GA, 1993, J BIOL CHEM, V268, P20845; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTENBERG D, 1983, BIOCHIM BIOPHYS ACTA, V737, P285, DOI 10.1016/0304-4157(83)90004-7; LIN YP, 1989, J BIOL CHEM, V264, P8641; LIN YP, 1990, J BIOL CHEM, V265, P166; MEMON AR, 1990, J BIOL CHEM, V265, P14817; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; MORITZ A, 1992, J BIOL CHEM, V267, P7207; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; QUINLAN JJ, 1992, J BIOL CHEM, V267, P18013; ROBSON RJ, 1983, ACCOUNTS CHEM RES, V16, P251, DOI 10.1021/ar00091a003; Segel I.H., 1975, ENZYME KINETICS; SMITH SW, 1957, J BIOL CHEM, V228, P915; SOMMARIN M, 1988, BIOCHIM BIOPHYS ACTA, V958, P268, DOI 10.1016/0005-2760(88)90185-3; TANFORD C, 1974, BIOCHEMISTRY-US, V13, P2369, DOI 10.1021/bi00708a021; WALSH JP, 1986, J BIOL CHEM, V261, P6239; WISSING JB, 1993, PLANT PHYSIOL, V102, P1243, DOI 10.1104/pp.102.4.1243; WISSING JB, 1993, FEBS LETT, V315, P95, DOI 10.1016/0014-5793(93)81141-L; WISSING JB, 1994, PLANT PHYSIOL, V105, P903, DOI 10.1104/pp.105.3.903; WU WI, 1994, J BIOL CHEM, V269, P29495; WU WI, 1993, J BIOL CHEM, V268, P13830; YU CL, 1988, CELL, V52, P63, DOI 10.1016/0092-8674(88)90531-4	45	81	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1868	1876		10.1074/jbc.271.4.1868	http://dx.doi.org/10.1074/jbc.271.4.1868			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567632	Green Published, hybrid			2022-12-25	WOS:A1996TR32000014
J	Lewin, I; JacobHirsch, J; Zang, ZC; Kupershtein, V; Szallasi, Z; Rivera, J; Razin, E				Lewin, I; JacobHirsch, J; Zang, ZC; Kupershtein, V; Szallasi, Z; Rivera, J; Razin, E			Aggregation of the Fc epsilon RI in mast cells induces the synthesis of Fos-interacting protein and increases its DNA binding activity: The dependence on protein kinase C-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER; RBL-2H3 CELLS; EXPRESSION; JUN; TRANSCRIPTION; PROLIFERATION; FIBROBLASTS; ACTIVATION; EXOCYTOSIS; ISOZYMES	The ability of c-Fos to dimerize with various proteins creates transcription complexes which can exert their regulatory function on a variety of genes. One of the transcription factors that binds to c-Fos is the newly discovered Fos-interacting protein (FIP). In this report we present evidence for the regulation of the synthesis of FIP by a physiological stimulus. We found that the aggregation of the mast cell high affinity receptor for IgE (Fc epsilon RI) induced the synthesis of FIP and increased its DNA binding activity. Moreover, down-regulation of the isoenzyme protein kinase C-beta (PKC-beta) by a specific antisense phosphorothioate oligonucleotide resulted in profound inhibition of FIP Fos DNA binding activity. Thus, aggregation of the Fc epsilon RI on mast cells elicits a PKC-beta dependent signaling pathway which regulates FIP-Fos DNA binding activity.	HEBREW UNIV JERUSALEM,HADASSAH MED SCH,DEPT BIOCHEM,IL-91120 JERUSALEM,ISRAEL; NCI,CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB,BETHESDA,MD 20892; NIAMS,SECT CHEM IMMUNOL,BETHESDA,MD 20892	Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)				Szallasi, Zoltan/0000-0001-5395-7509				ASHENDEL CL, 1990, NUCLEIC ACIDS RES, V18, P5310; BARANES D, 1991, BLOOD, V78, P2354; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEWIN I, 1993, BLOOD, V82, P3745; MACKGREGOR PF, 1990, ONCOGENE, V5, P451; MISCHAK H, 1991, J IMMUNOL, V147, P3981; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OZAWA K, 1993, J BIOL CHEM, V268, P2280; OZAWA K, 1993, J BIOL CHEM, V268, P1749; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAZIN E, 1994, P NATL ACAD SCI USA, V91, P7722, DOI 10.1073/pnas.91.16.7722; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0	25	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1514	1519		10.1074/jbc.271.3.1514	http://dx.doi.org/10.1074/jbc.271.3.1514			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576146	hybrid			2022-12-25	WOS:A1996TQ52500042
J	Nishiura, H; Shibuya, Y; Matsubara, S; Tanase, S; Kambara, T; Yamamoto, T				Nishiura, H; Shibuya, Y; Matsubara, S; Tanase, S; Kambara, T; Yamamoto, T			Monocyte chemotactic factor in rheumatoid arthritis synovial tissue - Probably a cross-linked derivative of S19 ribosomal protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT FACTOR-H; MONONUCLEAR LEUKOCYTES; CELLS; SUBUNITS; POLYMORPHONUCLEAR; CHEMOATTRACTANTS; PURIFICATION; FLUIDS	The extracts of rheumatoid arthritis synovial lesions from seven patients possessed a strong chemotactic activity for monocytes and a negligible one for polymorphonuclear leukocytes. These results are consistent with a prominent histological feature of the synovial lesion, the mononuclear cell predominant infiltration. The major monocyte chemotactic factor in the synovial tissue extracts was purified to a single protein peak in reverse phase high performance liquid chromatography with a C4 column. NH2-terminal amino acid analysis of the initial 20 residues yielded a single sequence. Surprisingly, this sequence was completely identical to that of S19 ribosomal protein. The purified sample demonstrated two protein bands in SDS-polyacrylamide gel electrophoresis with apparent molecular masses of 34 and 68 kDa. These sizes were 2 and 4 times that of S19 ribosomal protein, suggesting that the chemotactic factor would be a dimer or tetramer of S19 ribosomal protein cross-linked by factor XIIIa. A recombinant human S19 ribosomal protein was prepared as a fusion protein with a maltose binding protein in Escherichia coli. After treatment with factor XIIIa, cross-linked recombinant S19 ribosomal protein exhibited the monocyte chemotactic activity, although the untreated recombinant protein did not.	KUMAMOTO UNIV,SCH MED,DEPT LAB MED,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,GRAD SCH MED SCI,DIV MOLEC PATHOL,KUMAMOTO 860,JAPAN; KUMAMOTO ORTHOPED HOSP,KUMAMOTO 862,JAPAN; NISHINIHON REHABILITAT SCH,KUMAMOTO 862,JAPAN	Kumamoto University; Kumamoto University								CIANCIOLO GJ, 1981, J CLIN INVEST, V67, P60, DOI 10.1172/JCI110033; DERRICK EK, 1993, HISTOPATHOLOGY, V22, P157, DOI 10.1111/j.1365-2559.1993.tb00095.x; EIKENBERRY EF, 1970, EUR J BIOCHEM, V12, P113, DOI 10.1111/j.1432-1033.1970.tb00827.x; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; FERNANDEZ HN, 1978, J IMMUNOL, V120, P109; FIRESTEIN GS, 1990, ARTHRITIS RHEUM, V33, P768, DOI 10.1002/art.1780330602; HARDY SJS, 1969, BIOCHEMISTRY-US, V8, P2897, DOI 10.1021/bi00835a031; HINDENNACH I, 1971, EUR J BIOCHEM, V23, P12, DOI 10.1111/j.1432-1033.1971.tb01585.x; IMAMURA T, 1992, BIOCHEM BIOPH RES CO, V185, P505, DOI 10.1016/0006-291X(92)91653-8; KUKITA I, 1987, INFLAMMATION, V11, P459, DOI 10.1007/BF00915989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LORAND L, 1990, P NATL ACAD SCI USA, V88, P82; MATSUBARA S, 1991, AM J PATHOL, V138, P1279; NIELSEN H, 1993, SCAND J IMMUNOL, V37, P39, DOI 10.1111/j.1365-3083.1993.tb01662.x; NISHIYORI A, 1994, J BIOL CHEM, V269, P1323; OHTSUKA H, 1993, IMMUNOLOGY, V80, P140; OKAMOTO M, 1992, BIOCHIM BIOPHYS ACTA, V1138, P53, DOI 10.1016/0925-4439(92)90151-C; OKAMOTO T, 1986, ACTA PATHOL JAPON, V36, P1109; PORATH J, 1967, NATURE, V215, P1491, DOI 10.1038/2151491a0; ROT A, 1987, P NATL ACAD SCI USA, V84, P7967, DOI 10.1073/pnas.84.22.7967; SCHIFFMANN E, 1975, P NATL ACAD SCI USA, V72, P109; SHERTON CC, 1974, MOL GEN GENET, V135, P97, DOI 10.1007/BF00264778; SHIBUYA Y, 1994, BBA-PROTEIN STRUCT M, V1206, P63, DOI 10.1016/0167-4838(94)90073-6; SUEKI H, 1993, LAB INVEST, V69, P160; THOMPSON HA, 1977, BIOCHEMISTRY-US, V16, P2221, DOI 10.1021/bi00629a028; TSURUTA T, 1993, AM J PATHOL, V142, P1848; WARD PA, 1971, J CLIN INVEST, V50, P606, DOI 10.1172/JCI106531; YOSHIMURA T, 1989, J IMMUNOL, V142, P1956; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387	29	67	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					878	882		10.1074/jbc.271.2.878	http://dx.doi.org/10.1074/jbc.271.2.878			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557699	hybrid			2022-12-25	WOS:A1996TP88900042
J	Rawlings, SL; Matt, GD; Huber, PW				Rawlings, SL; Matt, GD; Huber, PW			Analysis of the binding of Xenopus transcription factor IIIA to oocyte 5 S rRNA and to the 5 S rRNA gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL CONTROL REGION; RNA-PROTEIN INTERACTIONS; INDIVIDUAL ZINC FINGERS; LAEVIS OOCYTES; RIBOSOMAL-RNA; CRYSTAL-STRUCTURE; DNA RECOGNITION; FACTOR-TFIIIA; CHEMICAL NUCLEASES; FUNCTIONAL DOMAINS	Binding of transcription factor IIIA (TFIIIA) to site-specific mutants of Xenopus oocyte 5 S rRNA has been used to identify important recognition elements in the molecule. The putative base triple G(75):U-76:A(100) appears to determine the conformation of the loop E region whose integrity is especially important for binding of the factor, Proximal substitutions in helices IV and V indicate that the proper folding of loop E is also dependent on these structures, Mutations in helix V affect binding of TFIIIA to 5 S rRNA and to the gene similarly and provide evidence that zinc finger 5 makes sequence-specific contact through the major groove of both nucleic acids, Although fingers 1-3 are positioned along helix IV and loop D, mutations in this region, including those that disrupt the tetraloop or close the opening in the major groove of the helix created by the U-80:U-96 mismatch, have no impact on binding. Substitutions made at stem-loop junctions in the arm of the RNA comprised of helix II-loop B-helix III display minor decreases in affinity for TFIIIA. Despite the alignment of the factor along nearly the entire length of 5 S rRNA, the essential elements for high affinity binding are limited to the central region of the molecule. Analysis of the corresponding mutations in the gene confirm that box C and the intermediate element provide the high affinity sites for binding of the factor to the DNA. Despite the small thermodynamic contribution made by contacts to box A, mutations made in this element can cause substantial changes in the orientation of the carboxyl-terminal fingers along the 5'-end of the internal control region.	UNIV NOTRE DAME,DEPT CHEM & BIOCHEM,NOTRE DAME,IN 46556	University of Notre Dame								ANDERSEN J, 1986, J BIOL CHEM, V261, P2912; BAUDIN F, 1991, J MOL BIOL, V218, P69, DOI 10.1016/0022-2836(91)90874-6; BAUDIN F, 1989, NUCLEIC ACIDS RES, V17, P2043, DOI 10.1093/nar/17.5.2043; BAZETTJONES DP, 1989, MOL CELL BIOL, V9, P336, DOI 10.1128/MCB.9.1.336; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; BOGENHAGEN DF, 1992, NUCLEIC ACIDS RES, V20, P2639, DOI 10.1093/nar/20.11.2639; BOGENHAGEN DF, 1985, J BIOL CHEM, V260, P6466; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANCH AD, 1985, P NATL ACAD SCI USA, V82, P6590, DOI 10.1073/pnas.82.19.6590; CHOW CS, 1992, BIOCHEMISTRY-US, V31, P3534, DOI 10.1021/bi00128a030; CHRISTENSEN JH, 1991, FEBS LETT, V281, P181, DOI 10.1016/0014-5793(91)80388-J; CHRISTIANSEN J, 1987, EMBO J, V6, P453, DOI 10.1002/j.1460-2075.1987.tb04775.x; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; CLEMENS KR, 1993, SCIENCE, V260, P530, DOI 10.1126/science.8475383; CLEMENS KR, 1994, J MOL BIOL, V244, P23, DOI 10.1006/jmbi.1994.1701; DARBY MK, 1992, MOL CELL BIOL, V12, P3155, DOI 10.1128/MCB.12.7.3155; DARSILLO P, 1991, J BIOL CHEM, V266, P21075; DELRIO S, 1993, J MOL BIOL, V233, P567, DOI 10.1006/jmbi.1993.1536; DREW HR, 1984, CELL, V37, P491, DOI 10.1016/0092-8674(84)90379-9; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; ERWIN BG, 1981, ANAL BIOCHEM, V110, P291, DOI 10.1016/0003-2697(81)90194-9; FAIRALL L, 1992, NUCLEIC ACIDS RES, V20, P4727, DOI 10.1093/nar/20.18.4727; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; FAIRALL L, 1989, EMBO J, V8, P1809, DOI 10.1002/j.1460-2075.1989.tb03575.x; HANAS JS, 1983, P NATL ACAD SCI-BIOL, V80, P2142, DOI 10.1073/pnas.80.8.2142; HANSEN PK, 1993, J MOL BIOL, V233, P191, DOI 10.1006/jmbi.1993.1499; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; HAYES JJ, 1992, BIOCHEMISTRY-US, V31, P11600, DOI 10.1021/bi00161a045; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HUBER PW, 1984, P NATL ACAD SCI-BIOL, V81, P322, DOI 10.1073/pnas.81.2.322; HUBER PW, 1986, P NATL ACAD SCI USA, V83, P1593, DOI 10.1073/pnas.83.6.1593; HUBER PW, 1991, J BIOL CHEM, V266, P3278; HUBER PW, 1993, FASEB J, V7, P1367, DOI 10.1096/fasebj.7.14.7693534; HUBER PW, 1991, P NATL ACAD SCI USA, V88, P10801, DOI 10.1073/pnas.88.23.10801; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; MAJOWSKI K, 1987, EMBO J, V6, P3057, DOI 10.1002/j.1460-2075.1987.tb02612.x; Maxam A M, 1980, Methods Enzymol, V65, P499; MCBRYANT SJ, 1995, J MOL BIOL, V248, P44, DOI 10.1006/jmbi.1995.0201; MCCONKEY GA, 1988, GENE DEV, V2, P205, DOI 10.1101/gad.2.2.205; MCCONKEY GA, 1987, MOL CELL BIOL, V7, P486, DOI 10.1128/MCB.7.1.486; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MUNSON PJ, 1983, METHOD ENZYMOL, V92, P543; NEKLUDOVA L, 1994, P NATL ACAD SCI USA, V91, P6948, DOI 10.1073/pnas.91.15.6948; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; PICARD B, 1979, P NATL ACAD SCI USA, V76, P241, DOI 10.1073/pnas.76.1.241; PIELER T, 1983, FEBS LETT, V157, P283, DOI 10.1016/0014-5793(83)80562-6; PIELER T, 1985, EMBO J, V4, P1847, DOI 10.1002/j.1460-2075.1985.tb03859.x; PIELER T, 1985, EMBO J, V4, P3751, DOI 10.1002/j.1460-2075.1985.tb04144.x; PIELER T, 1987, CELL, V48, P91, DOI 10.1016/0092-8674(87)90359-X; PUGLISI JD, 1990, BIOCHEMISTRY-US, V29, P4215, DOI 10.1021/bi00469a026; RHODES D, 1986, CELL, V46, P123, DOI 10.1016/0092-8674(86)90866-4; ROLLINS MB, 1993, MOL CELL BIOL, V13, P4776, DOI 10.1128/MCB.13.8.4776; ROMANIUK PJ, 1985, NUCLEIC ACIDS RES, V13, P5369, DOI 10.1093/nar/13.14.5369; ROMANIUK PJ, 1989, BIOCHEMISTRY-US, V28, P1388, DOI 10.1021/bi00429a067; ROMANIUK PJ, 1990, J BIOL CHEM, V265, P17593; ROMANIUK PJ, 1988, NUCLEIC ACIDS RES, V16, P2295, DOI 10.1093/nar/16.5.2295; ROMBY P, 1990, BIOCHIMIE, V72, P437, DOI 10.1016/0300-9084(90)90068-R; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SANDS MS, 1987, MOL CELL BIOL, V7, P3985, DOI 10.1128/MCB.7.11.3985; SANDS MS, 1991, NUCLEIC ACIDS RES, V19, P1791, DOI 10.1093/nar/19.8.1791; SCHROTH GP, 1989, NATURE, V340, P487, DOI 10.1038/340487a0; SHANG ZG, 1988, ANAL BIOCHEM, V168, P156, DOI 10.1016/0003-2697(88)90023-1; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; SUCK D, 1988, NATURE, V332, P464, DOI 10.1038/332464a0; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; VELDHOEN N, 1994, BIOCHEMISTRY-US, V33, P7568, DOI 10.1021/bi00190a009; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; WESTHOF E, 1989, J MOL BIOL, V207, P417, DOI 10.1016/0022-2836(89)90264-7; WIMBERLY B, 1993, BIOCHEMISTRY-US, V32, P1078, DOI 10.1021/bi00055a013; WYATT JR, 1993, RNA WORLD, P465; YOU QM, 1991, BIOCHEMISTRY-US, V30, P2495, DOI 10.1021/bi00223a028; YOU QM, 1990, NUCLEIC ACIDS RES, V18, P5055, DOI 10.1093/nar/18.17.5055	81	16	16	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					869	877		10.1074/jbc.271.2.869	http://dx.doi.org/10.1074/jbc.271.2.869			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557698	hybrid			2022-12-25	WOS:A1996TP88900041
J	Ahn, MJ; Langenfeld, J; Moasser, MM; Rusch, V; Dmitrovsky, E				Ahn, MJ; Langenfeld, J; Moasser, MM; Rusch, V; Dmitrovsky, E			Growth suppression of transformed human bronchial epithelial cells by all-trans-retinoic acid occurs through specific retinoid receptors	ONCOGENE			English	Article						all-trans-retinoic acid; bronchial epithelial cells; retinoid receptors	ACUTE PROMYELOCYTIC LEUKEMIA; HUMAN LUNG-CANCER; X-RECEPTOR; THYROID-HORMONE; DIFFERENTIATION THERAPY; NUCLEAR RECEPTORS; RIBONUCLEIC-ACID; VITAMIN-A; ALPHA; BETA	The retinoids are reported to chemoprevent second aerodigestive tract cancers in patients with prior lung or head and neck cancers, Since those retinoids already examined in clinical trials do not induce major clinical responses in lung cancers, it is hypothesized that the beneficial chemoprevention activity in lung neoplasias occurs within 'fields' of carcinogen-transformed epithelial cells, To begin to investigate this retinoid action during lung carcinogenesis, the BZR-T33 ras transformed human bronchial epithelial cell line that grows in an anchorage independent manner was examined, This study reports, as compared to controls, that all-trans-retinoic acid (RA)-treatment suppresses BZR-T33 proliferation in monolayer cultures and in anchorage independent and cloning efficiency growth assays, RA induces RAR-gamma 2 > RAR gamma 1 in BZR-T33 cells but expression at the total cellular RNA level of RAR alpha and RXR alpha is not augmented by RA-treatment, RAR beta mRNA expression is repressed before and after RA-treatment and is only detected using a reverse transcription polymerase chain reaction (RT-PCR) assay, To determine directly which of these expressed retinoid receptors signals growth suppression, each receptor was individually transfected into BZR-T33 cells using episomal expression vectors, Growth inhibitory effects of these transfectants were compared to a control; episomal vector in colony efficiency assays, RAR gamma over-expression in the presence or absence of RA-treatment did not suppress BZR-T33 growth more than controls, In contrast, over-expression of the other examined retinoid receptors inhibited BZR-T33 cellular cloning efficiency prior to RA-treatment and in this decreasing order after RA-treatment: RAR alpha > RAR beta > RXR alpha, The findings reported here reveal that RA suppresses proliferation and cloning efficiency in this transformed human bronchial epithelial cell through specific retinoid receptors, Further work is needed to evaluate the role of RA or its nuclear receptors in inhibiting even earlier steps in lung carcinogenesis.	MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,DEPT MED,MOLEC MED LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,DEPT SURG,THORAC SERV,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,MOLEC PHARMACOL & THERAPEUT PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NATIONAL CANCER INSTITUTE [T32CA009512, R01CA054494] Funding Source: NIH RePORTER; NCI NIH HHS [2R01-CA54494-04, T32-CA-09512] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN MJ, 1995, ONCOGENE, V10, P2307; AMSTAD P, 1988, MOL CARCINOGEN, V1, P151, DOI 10.1002/mc.2940010303; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BRAND N, 1988, NATURE, V332, P851; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GEBERT JF, 1991, ONCOGENE, V6, P1859; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; Gudas Lorraine J., 1994, P443; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HOULE B, 1991, GENE CHROMOSOME CANC, V3, P358, DOI 10.1002/gcc.2870030506; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NERVI C, 1991, EXP CELL RES, V195, P163, DOI 10.1016/0014-4827(91)90512-S; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; REDDEL RR, 1988, CANCER RES, V48, P1904; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	46	30	31	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2357	2364						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570187				2022-12-25	WOS:A1995TK70200020
J	Komuro, I; Kudo, S; Yamazaki, T; Zou, YZ; Shiojima, I; Yazaki, Y				Komuro, I; Kudo, S; Yamazaki, T; Zou, YZ; Shiojima, I; Yazaki, Y			Mechanical stretch activates the stress-activated protein kinases in cardiac myocytes	FASEB JOURNAL			English	Article						cardiac hypertrophy; mechanical stress; the stress-activated protein kinase; gene expression; angiotensin II	GENE-EXPRESSION; PHOSPHORYLATION; HYPERTROPHY	We have recently shown that mechanical stress activates a phosphorylation cascade of protein kinases including Raf-1 and the extracellular signal-regulated kinases (ERKs) in cultured cardiac: myocytes partially through the enhanced secretion of angiotensin II, Osmotic stress in budding yeast has been shown to activate similar signaling molecules including Hog-1, a distant relative of the ERK family, In the present study, we examined whether mechanical stretch of cardiac myocytes activates the stress-activated protein kinases (SAPKs)/c-Jun NH2-terminal kinase, the mammalian homologs of yeast Hog-1 that regulate gene expression through activation of the transcription factor, AP-1, When cardiac myocytes of neonatal rats cultured on a deformable silicone dish were stretched, activity of SAPKs was increased from 10 min, peaked at 30 min, and gradually decreased thereafter, The increase in activity of SAPKs was proportional to the stretch, Unlike ERKs, the activation of SAPKs by stretching cardiac myocytes was not dependent on the secreted angiotensin II, The chelation of extracellular Ca2+ or down-regulation of protein kinase C did not attenuate activation of SAPKs by stretch, Transfection experiments using an AP-1 binding site-containing reporter gene revealed that stretch increases AP-1 activity in cardiac myocytes, In conclusion, Like osmotic stress in yeast, mechanical stretch activates SAPKs in cardiac myocytes without the participation of angiotensin II, These results suggest that the activation of SAPKs may regulate gene expression during mechanical stress-induced cardiac hypertrophy.			Komuro, I (corresponding author), UNIV TOKYO,SCH MED,DEPT MED 3,MOL CARDIOL DIV,BUNKYO KU,7-3-1 HONGO,TOKYO 113,JAPAN.							BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KOJIMA M, 1994, CIRCULATION, V89, P2204, DOI 10.1161/01.CIR.89.5.2204; KOMURO I, 1990, J BIOL CHEM, V265, P3595; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; KOMURO I, 1991, J BIOL CHEM, V266, P1265; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; LOKUTA AJ, 1994, J BIOL CHEM, V269, P4832; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; POMBO CM, 1994, J BIOL CHEM, V269, P26546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; YAMAZAKI T, 1995, CIRC RES, V77, P258, DOI 10.1161/01.RES.77.2.258; YAMAZAKI T, 1995, J CLIN INVEST, V96, P438, DOI 10.1172/JCI118054; YAMAZAKI T, 1993, J BIOL CHEM, V268, P12069	27	191	195	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1996	10	5					631	636		10.1096/fasebj.10.5.8621062	http://dx.doi.org/10.1096/fasebj.10.5.8621062			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ055	8621062				2022-12-25	WOS:A1996UJ05500011
J	Yang, NY; Shigeta, H; Shi, HP; Teng, CT				Yang, NY; Shigeta, H; Shi, HP; Teng, CT			Estrogen-related receptor, hERR1, modulates estrogen receptor-mediated response of human lactoferrin gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; REPRODUCTIVE-TRACT; HORMONE RECEPTORS; ORPHAN RECEPTORS; BINDING-PROTEIN; DNA-BINDING; FACTOR-I; MOUSE; EXPRESSION; ACTIVATION	We have shown previously that estrogen-stimulated transcription from the human lactoferrin gene in RL95-2 endometrium carcinoma cells is mediated through an imperfect estrogen response element (ERE) at the 5'-flanking region of the gene. Upstream from the ERE, a DNA sequence (-418 to -378, FP1) was selectively protected from DNase I digestion by nuclear extracts from endometrial and mammary gland cell lines. In this report, using the electrophoresis mobility shift assay, site-directed mutagenesis, and DNA methylation interference analyses, we show that three different nuclear proteins bind to the FP1 region (C1, C2, and C3 sites). The nuclear receptor, COUP-TF, binds to the C2 site. Mutations in the C1 binding region abolish C1 complex formation and reduce estrogen-dependent transcription from the lactoferrin ERE. When the imperfect ERE of the lactoferrin gene is converted to a perfect palindromic structure, the enhancing effect of the C1 binding element for estrogen responsiveness was abolished. me isolated a complementary DNA (cDNA) clone from an RL95-2 expression library that encodes the C1 site-binding protein. The encoded polypeptide maintains 99% amino acid identity with the previously described orphan nuclear receptor hERR1. A 2.2-kilobase mRNA was detected in RL95-2 cells by the newly isolated cDNA but not by the first 180 base pair of the published hERR1 sequence. By Western analysis, a major 42-kDa protein is detected in the RL95-2 nuclear extract with antibody generated against GST-hERR1 fusion protein. Finally, we show that the hERR1 interacts with the human estrogen receptor through protein-protein contacts.	NIEHS,NIH,GENE REGULAT GRP,REPROD & DEV TOXICOL LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)								ARNOLD RR, 1977, SCIENCE, V197, P263, DOI 10.1126/science.327545; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BROXMEYER HE, 1987, BLOOD CELLS, V13, P31; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; ESAGUY N, 1991, INFECT IMMUN, V59, P1117, DOI 10.1128/IAI.59.3.1117-1125.1991; ESPINAS ML, 1994, MOL CELL BIOL, V14, P4116, DOI 10.1128/MCB.14.6.4116; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GUIRAMAND J, 1995, J BIOL CHEM, V270, P7354, DOI 10.1074/jbc.270.13.7354; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; KRISHNAN V, 1994, J BIOL CHEM, V269, P15912; LAVORGNA G, 1991, SCIENCE, V252, P848, DOI 10.1126/science.1709303; LEGRAND D, 1992, BIOCHEMISTRY-US, V31, P9243, DOI 10.1021/bi00153a018; LIU YH, 1993, MOL CELL BIOL, V13, P1836, DOI 10.1128/MCB.13.3.1836; LIU YH, 1991, J BIOL CHEM, V266, P21880; LIU YH, 1994, MOL CELL ENDOCRINOL, V101, P167, DOI 10.1016/0303-7207(94)90231-3; LIU YH, 1992, MOL ENDOCRINOL, V6, P355, DOI 10.1210/me.6.3.355; Maniatis T., 1982, MOL CLONING; NEWBOLD RR, 1992, BIOL REPROD, V47, P903, DOI 10.1095/biolreprod47.5.903; NICHOLS BL, 1987, PEDIATR RES, V21, P563, DOI 10.1203/00006450-198706000-00011; PENTECOST BT, 1987, J BIOL CHEM, V262, P10134; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; SAWATZKI G, 1989, BLOOD CELLS, V15, P371; TENG CT, 1994, ADV EXP MED BIOL, V357, P183; TENG CT, 1989, ENDOCRINOLOGY, V124, P992, DOI 10.1210/endo-124-2-992; TENG CT, 1992, MOL ENDOCRINOL, V6, P1969, DOI 10.1210/me.6.11.1969; TENG CT, 1994, LACTOFERRIN STRUCTUR; TSUKIYAMA T, 1992, NUCLEIC ACIDS RES, V20, P1477, DOI 10.1093/nar/20.7.1477; UEDA H, 1990, NUCLEIC ACIDS RES, V19, P3689; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WALMER DK, 1995, CANCER RES, V55, P1168; WALMER DK, 1992, ENDOCRINOLOGY, V131, P1458, DOI 10.1210/en.131.3.1458; Wang Lee-Ho, 1991, Gene Expression, V1, P207; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; WIELAND S, 1991, EMBO J, V10, P2513, DOI 10.1002/j.1460-2075.1991.tb07791.x; WILEY SR, 1993, GENE DEV, V7, P2206, DOI 10.1101/gad.7.11.2206; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; WUPENG XS, 1992, MOL ENDOCRINOL, V6, P231, DOI 10.1210/me.6.2.231; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANG NY, 1994, ENDOCRINE, V2, P241; ZHANG HY, 1991, J BIOL CHEM, V266, P24332	57	175	188	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5795	5804		10.1074/jbc.271.10.5795	http://dx.doi.org/10.1074/jbc.271.10.5795			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621448	hybrid			2022-12-25	WOS:A1996TZ28600074
J	Azpiazu, I; Saltiel, AR; DePaoliRoach, AA; Lawrence, JC				Azpiazu, I; Saltiel, AR; DePaoliRoach, AA; Lawrence, JC			Regulation of both glycogen synthase and PHAS-I by insulin in rat skeletal muscle involves mitogen-activated protein kinase-independent and rapamycin-sensitive pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-TRANSPORT; S6 KINASE; SIGNAL-TRANSDUCTION; 3T3-L1 ADIPOCYTES; PHOSPHORYLATION; INITIATION; IDENTIFICATION; STIMULATION; EXPRESSION; MECHANISM	Incubating rat diaphragm muscles with insulin increased the glycogen synthase activity ratio (minus glucose 6-phosphate/plus glucose 6-phosphate) by approximately 2-fold. Insulin increased the activities of mitogen-activated protein (MAP) kinase and the M(r) = 90,000 isoform of ribosomal protein S6 kinase (Rsk) by approximately 1.5-2.0-fold. Epidermal growth factor (EGF) was more effective than insulin in increasing MAP kinase and Rsk activity, but in contrast to insulin, EGF did not affect glycogen synthase activity, The activation of both MAP kinase and Rsk by insulin was abolished by incubating muscles with the MAP kinase kinase (MEK) inhibitor, PD 098059; however, the MEK inhibitor did not significantly reduce the effect of insulin on activating glycogen synthase. Incubating muscles with concentrations of rapamycin that inhibited activation of p70(S6K) abolished the activation of glycogen synthase, Insulin also increased the phosphorylation of PHAS-I (phosphorylated heat- and acid-stable protein) and promoted the dissociation of the PHAS-I . eIF-4E complex. Increasing MAP kinase activity with EGF did not mimic the effect of insulin on PHAS-I phosphorylation, and the effect of insulin on increasing MAP kinase could be abolished with the MEK inhibitor without decreasing the effect of insulin on PHAS-I, The effects of insulin on PHAS-I were attenuated by rapamycin. Thus, activation of the MAP kinase/Rsk signaling pathway appears to be neither necessary nor sufficient for insulin action on glycogen synthase and PHAS-I in rat skeletal muscle. The results indicate that the effects of insulin on increasing the synthesis of glycogen and protein in skeletal muscle, two of the most important actions of the hormone, involve a rapamycin-sensitive mechanism that may include elements of the p70(S6K) signaling pathway.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; WARNER LAMBERT PARKE DAVIS, PHARMACEUT RES DIV, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA; INDIANA UNIV, SCH MED, DEPT MOLEC BIOL & BIOCHEM, INDIANAPOLIS, IN 46202 USA	Washington University (WUSTL); Pfizer; Indiana University System; Indiana University-Purdue University Indianapolis			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NIAMS NIH HHS [AR41180] Funding Source: Medline; NIDDK NIH HHS [DK36569, DK28312] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028312, R01DK036569] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHN NG, 1990, J BIOL CHEM, V265, P11495; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALTMANN M, 1993, TRENDS BIOCHEM SCI, V18, P429, DOI 10.1016/0968-0004(93)90143-B; BARON AD, 1988, AM J PHYSIOL, V255, pE769, DOI 10.1152/ajpendo.1988.255.6.E769; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHAN CP, 1987, J BIOL CHEM, V262, P276; CHAN CP, 1985, P NATL ACAD SCI USA, V82, P4563, DOI 10.1073/pnas.82.14.4563; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COHEN P, 1990, ADV SEC MESS PHOSPH, V24, P230; Cohen P., 1986, ENZYMES, VXVII, P461; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DANIEL PM, 1975, J PHYSIOL-LONDON, V247, P273, DOI 10.1113/jphysiol.1975.sp010931; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; DEPAOLIROACH AA, 1983, J BIOL CHEM, V258, P702; DONELLADEANA A, 1993, BIOCHIM BIOPHYS ACTA, V1178, P189, DOI 10.1016/0167-4889(93)90008-D; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FLAIM KE, 1980, AM J PHYSIOL, V239, pE88, DOI 10.1152/ajpendo.1980.239.1.E88; Goldberg A L, 1975, Methods Enzymol, V39, P82; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; JENSENIUS JC, 1981, J IMMUNOL METHODS, V46, P63, DOI 10.1016/0022-1759(81)90333-1; JUE T, 1989, P NATL ACAD SCI USA, V86, P1439, DOI 10.1073/pnas.86.5.1439; KELLY FJ, 1985, J BIOL CHEM, V260, P6677; KIMBALL SR, 1994, ANNU REV PHYSIOL, V56, P321, DOI 10.1146/annurev.ph.56.030194.001541; KIMBALL SR, 1990, ELLENBERG RIFKINS DI, P41; KRIEG J, 1988, METHOD ENZYMOL, V164, P575; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE JC, 1986, J BIOL CHEM, V261, P8556; LAWRENCE JC, 1978, J BIOL CHEM, V253, P2104; LAWRENCE JC, 1994, J BIOL CHEM, V269, P11595; LAWRENCE JC, 1992, ANNU REV PHYSIOL, V54, P177, DOI 10.1146/annurev.ph.54.030192.001141; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; LIN TA, 1996, IN PRESS DIABETOLOGI; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADER S, 1995, MOL CELL BIOL, V15, P4990; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MOULE SK, 1995, BIOCHEM J, V311, P595, DOI 10.1042/bj3110595; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SMITH RL, 1984, J BIOL CHEM, V259, P2201; SONENBERG N, 1994, BIOCHIMIE, V76, P839, DOI 10.1016/0300-9084(94)90185-6; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; SUTHERLAND C, 1993, EUR J BIOCHEM, V212, P581, DOI 10.1111/j.1432-1033.1993.tb17696.x; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; TAKEDA Y, 1975, J BIOL CHEM, V250, P8951; TANG PM, 1991, J BIOL CHEM, V266, P15782; THOMAS G, 1992, BIOCHEM SOC T, V20, P678, DOI 10.1042/bst0200678; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442; ZHOU GX, 1993, BIOCHEM BIOPH RES CO, V197, P578, DOI 10.1006/bbrc.1993.2518	75	140	140	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5033	5039						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617780				2022-12-25	WOS:A1996TX69700070
J	Kernohan, NM; Hupp, TR; Lane, DP				Kernohan, NM; Hupp, TR; Lane, DP			Modification of an N-terminal regulatory domain of T antigen restores p53-T antigen complex formation in the absence of an essential metal ion cofactor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; LARGE TUMOR-ANTIGEN; SIMIAN VIRUS-40; SV40-TRANSFORMED CELLS; MONOCLONAL-ANTIBODY; EMBRYO FIBROBLASTS; ESCHERICHIA-COLI; BINDING; TRANSFORMATION; PROTEIN	We have discovered that the ability of the tumor suppressor protein p53 to bind to the viral large T antigen (TAg) oncogene product is regulated by divalent cations, Both proteins were purified from an insect cell line infected with the appropriate baculovirus expression vector, In a two-site capture enzyme-linked immunosorbent assay, complex formation between the purified proteins is strictly dependent on the addition of specific concentrations of divalent metal ions, notably zinc, copper, cadmium, cobalt, manganese, and nickel, In the presence of zinc the pattern of proteolytic fragments obtained when TAg was subjected to proteolysis by endoproteinase Glu-C (V8) was strikingly different, supporting the idea that a conformational change in TAg associated with ion binding is required for it to complex with p53, Monoclonal antibody analysis provides supporting evidence for a conformational change, When TAg was captured onto an enzyme-linked immunosorbent assay plate coated with PAb 419 as opposed to many other anti-TAg antibodies, complex formation was completely independent of the presence of additional divalent cations, Our results suggest that the ability of p53 and TAg to form a stable complex in vitro is dependent upon a regulatory domain residing in the N terminus of TAg, zinc ions or the binding of a specific monoclonal antibody (PAb 419) provoking a conformational change in TAg that facilitates and supports complex formation.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT PATHOL, DUNDEE DD1 9SY, SCOTLAND	University of Dundee	Kernohan, NM (corresponding author), UNIV DUNDEE, INST MED SCI, CANC RES CAMPAIGN, CELL TRANSFORMAT GRP, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHALKLEY GE, 1994, EUR J BIOCHEM, V221, P167, DOI 10.1111/j.1432-1033.1994.tb18726.x; CHEN JD, 1992, ONCOGENE, V7, P1167; DANIELS DA, 1994, J MOL BIOL, V243, P639, DOI 10.1016/0022-2836(94)90038-8; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; GANNON J V, 1990, New Biologist, V2, P84; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HAINAUT P, 1993, CANCER RES, V53, P1739; Harlow E., 1988, ANTIBODIES LAB MANUA; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANE DP, 1986, CANCER CELL, V4, P387; LANE DP, 1989, ONCOGENES, P191; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LINDNER K, 1994, THESIS U DUNDEE DUND; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTON DM, 1987, MOL BIOL MED, V4, P63; LOEBER G, 1991, J VIROL, V65, P3167, DOI 10.1128/JVI.65.6.3167-3174.1991; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MAKOWSKE M, 1989, J BIOL CHEM, V264, P16155; MAXWELL SA, 1993, ONCOGENE, V8, P3421; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MILNER J, 1987, ONCOGENE, V1, P453; MOLE SE, 1987, PHILOS T ROY SOC B, V317, P455, DOI 10.1098/rstb.1987.0072; NELBACH ME, 1972, BIOCHEMISTRY-US, V11, P315, DOI 10.1021/bi00753a002; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PEDEN KWC, 1992, VIRUS GENES, V6, P107, DOI 10.1007/BF01703060; Rigby P. W. J., 1983, ADV VIRAL ONCOL, V3, P31; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; RUTILA JE, 1989, ONCOGENE RES, V4, P303; SCHMIEG FI, 1988, VIROLOGY, V164, P132, DOI 10.1016/0042-6822(88)90628-9; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SOMPAYRAC L, 1994, VIROLOGY, V200, P849, DOI 10.1006/viro.1994.1255; SOMPAYRAC L, 1991, VIROLOGY, V181, P412, DOI 10.1016/0042-6822(91)90516-E; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; SYMONDS HS, 1993, MOL CELL BIOL, V13, P3255, DOI 10.1128/MCB.13.6.3255; ZHU JY, 1991, J VIROL, V65, P2778, DOI 10.1128/JVI.65.6.2778-2790.1991; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991; ZIMARINO V, 1990, SCIENCE, V249, P546, DOI 10.1126/science.2200124	47	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4954	4960						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617769				2022-12-25	WOS:A1996TX69700059
J	Wozniak, M; Limbird, LE				Wozniak, M; Limbird, LE			The three alpha(2)-adrenergic receptor subtypes achieve basolateral localization in Madin-Darby canine kidney II cells via different targeting mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-ADRENERGIC RECEPTOR; ALPHA-2B-ADRENERGIC RECEPTOR; PROXIMAL TUBULE; RAT-KIDNEY; NA+; H+; IDENTIFICATION; EXPRESSION; MODULATION; BINDING	The present studies examined the localization of the alpha(2B)- and alpha(2C)-adrenergic receptor (AR) subtypes in polarized Madin-Darby canine kidney cells (MDCK II) and the mechanisms by which this is achieved. Previously we demonstrated that the alpha(2A)AR subtype is directly delivered to lateral subdomain of MDCK II cells. Surface biotinylation strategies demonstrated that the alpha(2B)AR, like the alpha(2A)AR, achieves 85-90% basolateral localization at steady-state. However, in contrast to the alpha(2A)AR, this polarization occurs after initial random insertion of the alpha(2B)AR into both apical and basolateral surfaces followed by selective retention on the lateral subdomain (t1/2 on the apical surface is 15-30 min; t1/2 on the basolateral surface is 8-10 h). The alpha(2C)AR also is enriched on the basolateral surface at steady-state and, like the alpha(2A)AR, is directly delivered there. Morphological evaluation of the epitope-tagged alpha(2A)AR, alpha(2B)AR, and alpha(2C)AR subtypes by laser confocal microscopy not only corroborated the biochemically-defined basolateral localization of all three alpha(2)AR subtypes but also revealed that the alpha(2C)AR uniquely exists in an intracellular compartment(s) as well. Immunofluorescence due to intracellular alpha(2C)AR partially overlaps that due to calnexin, a marker for endoplasmic reticulum, as well as that due to mannosidase II, a marker for the trans-Golgi network. Taken together, the present findings demonstrate that the alpha(2A)AR, alpha(2B)AR and alpha(2C)AR subtypes, which possess highly homologous structures and ultimately achieve similar polarization to the lateral surface of MDCK II cells, nonetheless manifest distinct trafficking itineraries.	VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043879] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43879] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHAN YL, 1980, J PHARMACOL EXP THER, V215, P65; CLARK JD, 1990, AM J PHYSIOL, V259, pF977, DOI 10.1152/ajprenal.1990.259.6.F977; GUYER CA, 1990, J BIOL CHEM, V265, P17307; KEEFER JR, 1993, J BIOL CHEM, V268, P11340; KEEFER JR, 1994, J BIOL CHEM, V269, P16425; KENNEDY ME, 1993, J BIOL CHEM, V268, P8003; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; LANIER SM, 1986, MOL PHARMACOL, V29, P219; LANIER SM, 1988, J BIOL CHEM, V263, P14491; LANIER SM, 1991, J BIOL CHEM, V266, P10470; LANIER SM, 1995, PHARM COMMUN, V6, P133; LE AQ, 1994, J BIOL CHEM, V269, P7514; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; MATSUSHIMA Y, 1987, JPN J PHARMACOL, V45, P284, DOI 10.1254/jjp.45.284; MOREMEN KW, 1991, J BIOL CHEM, V266, P16876; NORD EP, 1987, J CLIN INVEST, V80, P1755, DOI 10.1172/JCI113268; SUMMERS RJ, 1984, FED PROC, V43, P2917; THIGPEN AE, 1993, J BIOL CHEM, V268, P17404; UHLEN S, 1991, BRIT J PHARMACOL, V104, P657, DOI 10.1111/j.1476-5381.1991.tb12485.x; VONZASTROW M, 1993, J BIOL CHEM, V268, P763; WILSON AL, 1991, MOL PHARMACOL, V39, P481; ZENG DW, 1990, P NATL ACAD SCI USA, V87, P3102, DOI 10.1073/pnas.87.8.3102	22	85	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5017	5024						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617778				2022-12-25	WOS:A1996TX69700068
J	Yang, BX; Brown, D; Verkman, AS				Yang, BX; Brown, D; Verkman, AS			The mercurial insensitive water channel (AQP-4) forms orthogonal arrays in stably transfected Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLECTING DUCT; FREEZE-FRACTURE; PARTICLES; MEMBRANE; VASOPRESSIN; TRANSPORT; PROTEIN; CHIP28; RAT; RECONSTITUTION	The mercurial insensitive water channel (MIWC, AQP-4) is a water-selective transporter expressed at the basolateral plasma membrane of principal cells in kidney collecting duct, airway epithelium, and gastric parietal cells, as web as in astrocytes and skeletal muscle plasmalemma. Because these sites correspond to membranes where orthogonal arrays of particles (OAPs) have been observed by freeze-fracture electron microscopy, we tested the hypothesis that MIWC forms OAPs. Chinese hamster ovary cells were stably transfected with the coding sequence of rat MIWC under a cytomegalovirus promoter. Immunostaining of clonal cell populations showed MIWC expression at the plasma membrane. A single band at 31 kDa was detected on immunoblot. Cell fractionation by sucrose gradient centrifugation indicated strong MIWC expression in plasma membrane fractions with lesser expression in Golgi. Functional analysis by stopped-flow light scattering showed high mercurial insensitive water permeability in plasma membrane vesicles. Freeze-fracture electron microscopy showed distinct OAPs on the plasma membrane P-face of MIWC-expressing cells with morphology indistinguishable from that in basolateral membrane of kidney collecting duct; the E-face showed corresponding linear grooves (spacing, similar to 8 nm) in transfected cells and collecting duct. OAPs were not observed in control (empty vector-transfected) cells or CHIP28 (AQP1)-transfected cells in which disorganized intramembrane particle aggregates were found. These results provide direct evidence that a molecular water channel can spontaneously assemble in regular arrays.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42368] Funding Source: Medline; NIDDK NIH HHS [DK36451, DK35124] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1993, AM J PHYSIOL, V265, pF463; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; BJORNHOLM B, 1993, BIOCHEMISTRY-US, V32, P2954; BORDI C, 1986, ANAT REC, V215, P28, DOI 10.1002/ar.1092150105; BORDI C, 1986, ANAT REC, V215, P24; BROWN D, 1991, SEMIN NEPHROL, V11, P478; BROWN D, 1983, AM J PHYSIOL, V245, pC334, DOI 10.1152/ajpcell.1983.245.5.C334; BROWN D, 1983, NATURE, V302, P253, DOI 10.1038/302253a0; CHEVALIER J, 1974, CELL TISSUE RES, V152, P129, DOI 10.1007/BF00224690; DUNIA I, 1987, J CELL BIOL, V105, P1679, DOI 10.1083/jcb.105.4.1679; ELLISMAN MH, 1976, J CELL BIOL, V68, P752, DOI 10.1083/jcb.68.3.752; Folkesson HG, 1996, J CLIN INVEST, V97, P664, DOI 10.1172/JCI118463; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; FRIGERI A, 1995, J CELL SCI, V108, P2993; HARMANCI MC, 1980, AM J PHYSIOL, V239, pF560, DOI 10.1152/ajprenal.1980.239.6.F560; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; HATTON JD, 1982, J NEUROCYTOL, V11, P335, DOI 10.1007/BF01258250; HATTON JD, 1987, BIOCHIM BIOPHYS ACTA, V904, P373, DOI 10.1016/0005-2736(87)90387-7; HATTON JD, 1984, EPILEPSIA, V25, P145, DOI 10.1111/j.1528-1157.1984.tb04170.x; HIRSCH M, 1988, CELL TISSUE RES, V252, P165; JJUNG JS, 1994, J BIOL CHEM, V269, P14648; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; KACHADORIAN WA, 1975, SCIENCE, V190, P67, DOI 10.1126/science.809840; KATSURA T, 1995, P NATL ACAD SCI USA, V92, P7212, DOI 10.1073/pnas.92.16.7212; MA TH, 1993, J BIOL CHEM, V268, P22756; MITRA AK, 1994, BIOCHEMISTRY-US, V33, P12735, DOI 10.1021/bi00209a001; MULDERS SM, 1995, J BIOL CHEM, V270, P9010, DOI 10.1074/jbc.270.15.9010; NAKAMURA T, 1985, J ELECTRON MICROSC, V34, P364; NEUHAUS J, 1990, NEUROSCI LETT, V109, P163, DOI 10.1016/0304-3940(90)90556-O; ORCI L, 1981, INT REV CYTOL, V73, P183, DOI 10.1016/S0074-7696(08)61289-9; RASH JE, 1974, EXP CELL RES, V86, P187, DOI 10.1016/0014-4827(74)90670-3; SHI LB, 1995, BIOCHEMISTRY-US, V34, P8250, DOI 10.1021/bi00026a006; SHI LB, 1994, J BIOL CHEM, V269, P10417; Shi LB, 1996, BIOCHEMISTRY-US, V35, P538, DOI 10.1021/bi9520038; STAEHELIN LA, 1972, P NATL ACAD SCI USA, V69, P1318, DOI 10.1073/pnas.69.5.1318; STRANGE K, 1987, J MEMBRANE BIOL, V96, P763; SUZUKI M, 1984, BRAIN RES, V300, P141, DOI 10.1016/0006-8993(84)91348-9; VANHOEK AN, 1995, BIOCHEMISTRY-US, V34, P2212, DOI 10.1021/bi00007a015; VANHOEK AN, 1993, BIOCHEMISTRY-US, V32, P11847, DOI 10.1021/bi00095a013; VANHOEK AN, 1992, J BIOL CHEM, V267, P18267; VANOS CH, 1994, BBA-REV BIOMEMBRANES, V1197, P291; VERBAVATZ JM, 1994, J CELL SCI, V107, P1083; VERBAVATZ JM, 1993, J CELL BIOL, V123, P605, DOI 10.1083/jcb.123.3.605; Verkman AS, 1996, AM J PHYSIOL-CELL PH, V270, pC12, DOI 10.1152/ajpcell.1996.270.1.C12; WAKAYAMA Y, 1989, J NEUROL SCI, V91, P191, DOI 10.1016/0022-510X(89)90087-7; WALZ T, 1994, J BIOL CHEM, V269, P1383; WIDDICOMBE JH, 1987, CELL TISSUE RES, V247, P95, DOI 10.1007/BF00216551; YANG BX, 1995, J BIOL CHEM, V270, P22907, DOI 10.1074/jbc.270.39.22907; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; ZEUTHEN T, 1994, J MEMBRANE BIOL, V137, P179	50	218	227	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4577	4580						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617713				2022-12-25	WOS:A1996TX69700003
J	Hu, JG; Castets, F; Guevara, JL; VanEldik, LJ				Hu, JG; Castets, F; Guevara, JL; VanEldik, LJ			S100 beta stimulates inducible nitric oxide synthase activity and mRNA levels in rat cortical astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; GROWTH-FACTOR; NEURITE EXTENSION; CALCIUM; BRAIN; CELLS; LIPOPOLYSACCHARIDE; CALMODULIN; INDUCTION; GENE	The glia-derived, neurotrophic protein S100 beta has been implicated in development and maintenance of the nervous system, However, S100 beta has also been postulated to play a role in mechanisms of neuropathology, because of its specific localization and selective overexpression in Alzheimer's disease. To begin to address the question of whether S100 beta can induce potentially toxic signaling pathways, we examined the effects of the protein on nitric oxide synthase (NOS) activity in cultures of rat cortical astrocytes, S100 beta treatment of astrocytes induced a time- and dose-dependent increase in accumulation of the NO metabolite, nitrite, in the conditioned medium, The S100 beta- stimulated nitrite production was blocked by cycloheximide and by the NOS inhibitor N-nitro-L-arginine methylester, but not by the inactive D-isomer of the inhibitor. Direct measurement of NOS enzymatic activity in cell extracts and analysis of NOS mRNA levels showed that the NOS activated by S100 beta addition is the calcium-independent, inducible isoform, Furthermore, the specificity of the effects of S100 beta on activation of NOS was demonstrated by the inability of S100 alpha and calmodulin to induce an increase in nitrite levels, Our data indicate that S100 beta can induce a potent activation of inducible NOS in astrocytes, an observation that might have relevance to the role of S100 beta in neuropathology.	NORTHWESTERN UNIV, SCH MED, DEPT CELL & MOLEC BIOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, INST NEUROSCI, CHICAGO, IL 60611 USA	Northwestern University; Northwestern University					NATIONAL INSTITUTE ON AGING [R01AG011138, P01AG010208] Funding Source: NIH RePORTER; NIA NIH HHS [AG11138, AG10208] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ausubel F.M., 1993, CURRENT PROTOCOLS MO; AZMITIA EC, 1990, BRAIN RES, V516, P354, DOI 10.1016/0006-8993(90)90942-5; BARGER SW, 1995, BRAIN RES, V677, P167, DOI 10.1016/0006-8993(95)00160-R; BARGER SW, 1992, BIOCHIM BIOPHYS ACTA, V1160, P105, DOI 10.1016/0167-4838(92)90043-D; BARGER SW, 1992, J BIOL CHEM, V267, P9689; BHATTACHARYYA A, 1992, J NEUROBIOL, V23, P451, DOI 10.1002/neu.480230410; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; CHAO CC, 1992, J IMMUNOL, V149, P2736; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; DANIELSON PE, 1988, DNA-J MOLEC CELL BIO, V7, P261, DOI 10.1089/dna.1988.7.261; FANO G, 1993, NEUROSCIENCE, V53, P919, DOI 10.1016/0306-4522(93)90477-W; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HERTZBERG EL, 1987, METHOD ENZYMOL, V139, P445; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; JENSEN R, 1985, J NEUROCHEM, V45, P700, DOI 10.1111/j.1471-4159.1985.tb04048.x; KLIGMAN D, 1985, P NATL ACAD SCI USA, V82, P7136, DOI 10.1073/pnas.82.20.7136; LEE SC, 1993, J NEUROIMMUNOL, V46, P19, DOI 10.1016/0165-5728(93)90229-R; LEVISON SW, 1991, CULTURING NERVE CELL, P309; LIU JP, 1992, J NEUROSCI RES, V33, P248, DOI 10.1002/jnr.490330208; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUKAS TJ, 1988, METHOD ENZYMOL, V157, P328; MARIGGIO MA, 1994, NEUROSCIENCE, V60, P29, DOI 10.1016/0306-4522(94)90201-1; MARSOT P, 1991, J APPL PHYCOL, V3, P1, DOI 10.1007/BF00003914; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; MURPHY S, 1993, ASTROCYTES PHARM FUN; REEVES RH, 1994, P NATL ACAD SCI USA, V91, P5359, DOI 10.1073/pnas.91.12.5359; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; SELINFREUND RH, 1991, P NATL ACAD SCI USA, V88, P3554, DOI 10.1073/pnas.88.9.3554; SHENG JG, 1994, J NEUROSCI RES, V39, P398, DOI 10.1002/jnr.490390406; VANELDIK LJ, 1988, J BIOL CHEM, V263, P7830; VANELDIK LJ, 1994, BBA-MOL CELL RES, V1223, P398, DOI 10.1016/0167-4889(94)90101-5; VANELDIK LJ, 1991, BRAIN RES, V542, P280, DOI 10.1016/0006-8993(91)91579-P; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; VODOVOTZ Y, 1994, J IMMUNOL, V152, P4110; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	41	190	204	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2543	2547		10.1074/jbc.271.5.2543	http://dx.doi.org/10.1074/jbc.271.5.2543			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576219	hybrid			2022-12-25	WOS:A1996TT48800033
J	Klotz, KH; Bartoldus, I; Stegmann, T				Klotz, KH; Bartoldus, I; Stegmann, T			Membrane asymmetry is maintained during influenza-induced fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID ASYMMETRY; PLASMA-MEMBRANE; VESICLES; VIRUS; INVOLVEMENT; LIPOSOMES; PROBES	We have investigated the influence of influenza-induced membrane fusion on the transverse asymmetry of the viral and target membranes. Large unilamellar vesicles containing headgroup-labeled fluorescent phospholipid analogues in both leaflets of the membrane were treated with phospholipase D, converting all outer membrane phospholipids to phosphatidic acid and leading to the release of the fluorescent label from the outside leaflet. After fusion of virus with these liposomes, addition of the enzyme to the fusion product did not release fluorescent label again, indicating that the phospholipid analogues from the inner leaflet of the membranes had not appeared on the outer leaflet. Moreover, the integral membrane protein hemagglutinin, which is present on the outer leaflet of the viral membrane, was quantitatively digested with protease after fusion, indicating that hemagglutinin remained on the outer leaflet of the fusion product. Therefore, there is no merger of the inner with outer leaflets of the viral or the liposomal membrane during fusion, and transverse membrane asymmetry is maintained.	UNIV BASEL,BIOCTR,DEPT BIOPHYS CHEM,CH-4056 BASEL,SWITZERLAND	University of Basel								BENTZ J, 1993, VIRAL FUSION MECHANI; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; DEVAUX PF, 1992, ANNU REV BIOPH BIOM, V21, P417, DOI 10.1146/annurev.bb.21.060192.002221; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; FERYFORGUES S, 1993, J PHOTOCH PHOTOBIO A, V70, P229, DOI 10.1016/1010-6030(93)85048-D; GRUBER HJ, 1994, BBA-BIOMEMBRANES, V1189, P212, DOI 10.1016/0005-2736(94)90068-X; HUGHSON FM, 1995, CURR BIOL, V5, P265, DOI 10.1016/S0960-9822(95)00057-1; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; NEBEL S, 1995, BIOCHEMISTRY-US, V34, P5705, DOI 10.1021/bi00017a001; New R.R., 1990, LIPOSOMES PRACTICAL; NIR S, 1986, BIOCHEMISTRY-US, V25, P257, DOI 10.1021/bi00349a036; OHKI S, 1987, MOL MECHANISMS MEMBR; SIEGEL DP, 1993, BIOPHYS J, V65, P2124, DOI 10.1016/S0006-3495(93)81256-6; SIEGEL DP, 1993, VIRAL FUSION MECHANI, P475; STEGMANN T, 1994, CURR BIOL, V4, P551, DOI 10.1016/S0960-9822(00)00123-8; STEGMANN T, 1989, BIOCHEMISTRY-US, V28, P1698, DOI 10.1021/bi00430a041; STEGMANN T, 1986, J BIOL CHEM, V261, P966; STEINMAN RM, 1983, J CELL BIOL, V96, P1, DOI 10.1083/jcb.96.1.1; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; WILSCHUT J, 1986, CHEM PHYS LIPIDS, V40, P145, DOI 10.1016/0009-3084(86)90068-X; Wilschut J., 1990, MEMBRANE FUSION	27	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2383	2386		10.1074/jbc.271.5.2383	http://dx.doi.org/10.1074/jbc.271.5.2383			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576195	hybrid			2022-12-25	WOS:A1996TT48800009
J	Metherall, JE; Waugh, K; Li, HJ				Metherall, JE; Waugh, K; Li, HJ			Progesterone inhibits cholesterol biosynthesis in cultured cells - Accumulation of cholesterol precursors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; STEROL-REGULATED GENES; MUTANT HAMSTER-CELLS; HUMAN-FIBROBLASTS; PLASMA-MEMBRANE; RAT-LIVER; ACYL-COA; ESTERIFICATION; ACYLTRANSFERASE; METABOLISM	Cells acquire cholesterol through endogenous synthesis and through receptor-mediated uptake of cholesterol-rich low density lipoprotein (LDL), Esterification of LDL derived cholesterol is catalyzed by acyl-CoA:cholesterol acyltransferase (ACAT) in the endoplasmic reticulum (ER), Progesterone inhibits esterification, and, although the mechanism of inhibition is not completely understood, this inhibition results from progesterone's ability to inhibit the activity of multiple drug resistance (MDR) P-glycoproteins (P. DeBry and J. E. Metherall, submitted for publication), In the current manuscript, we demonstrate that progesterone inhibits cholesterol biosynthesis resulting in the accumulation of a number of sterol precursors, In Chinese hamster ovary (CHO) cells, high concentrations (100 mu M) Of progesterone completely blocked cholesterol production, resulting in the accumulation of lanosterol and a lanosterol precursor, Lower concentrations (40 mu M) of progesterone cause plasma membrane accumulation of several sterol products, The majority of these sterols are precursors of cholesterol since they were efficiently converted to cholesterol upon removal of progesterone from the culture medium, Although very high concentrations (>200 mu M) of progesterone killed CHO cells, their growth was restored by the addition of cholesterol to the growth medium, indicating that progesterone toxicity resulted from cholesterol auxotrophy, The effect of progesterone was not unique to CHO cells; progesterone also inhibited cholesterol biosynthesis in all human cell lines tested. These observations suggest that a common progesterone-sensitive pathway is involved in both cholesterol biosynthesis and the processing of LDL-derived cholesterol.	UNIV UTAH, ECCLES PROGRAM HUMAN MOLEC BIOL & GENET, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah	Metherall, JE (corresponding author), UNIV UTAH, DEPT HUMAN GENET, SALT LAKE CITY, UT 84112 USA.							BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BUTLER JD, 1992, J BIOL CHEM, V267, P23797; ECHEVARRIA F, 1990, J BIOL CHEM, V265, P8484; EVANS MJ, 1993, MOL CELL BIOL, V13, P5175, DOI 10.1128/MCB.13.9.5175; FIELD FJ, 1987, J LIPID RES, V28, P1057; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; LANGE Y, 1988, J BIOL CHEM, V263, P9366; LANGE Y, 1987, J BIOL CHEM, V262, P4433; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1994, J BIOL CHEM, V269, P3411; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LANGE Y, 1991, J LIPID RES, V32, P329; LANGE Y, 1989, J BIOL CHEM, V264, P3786; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; Metherall JE, 1996, J BIOL CHEM, V271, P2634, DOI 10.1074/jbc.271.5.2634; METHERALL JE, 1991, J BIOL CHEM, V266, P12734; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; PLEMENITAS A, 1990, J BIOL CHEM, V265, P17012; REINHART MP, 1987, J BIOL CHEM, V262, P9649; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; SUCKLING KE, 1985, J LIPID RES, V26, P647; TABAS I, 1988, J BIOL CHEM, V263, P1266; WILLIAMSON JR, 1969, METHOD ENZYMOL, V13, P505	28	78	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2627	2633		10.1074/jbc.271.5.2627	http://dx.doi.org/10.1074/jbc.271.5.2627			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576232	hybrid			2022-12-25	WOS:A1996TT48800046
J	Munoz, M; Serrador, J; SanchezMadrid, F; Teixido, J				Munoz, M; Serrador, J; SanchezMadrid, F; Teixido, J			A region of the integrin VLA alpha 4 subunit involved in homotypic cell aggregation and in fibronectin but not vascular cell adhesion molecule-1 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-4-BETA-1 INTEGRIN; T-CELLS; MONOCLONAL-ANTIBODIES; SURFACE EXPRESSION; COUNTER-RECEPTOR; SPLICED DOMAIN; LATE ANTIGEN-4; VLA-4; LYMPHOCYTES; DISTINCT	The VLA-4 (alpha 4 beta 1) integrin is involved in the adhesion of cells to fibronectin and vascular cell adhesion molecule-1 (VCAM-1). In order to study alpha 4 structure-function relationships, we have expressed mutated alpha 4 subunit by transfection into VLA-4-negative K562 cells, Substitutions at alpha 4 residues Ar-89-Asp(90), which show the highest surface probability indexes inside the N-terminal alpha(4/80) fragment, resulted in a reduction in the reactivity of all anti-alpha 4 epitope A monoclonal antibodies (mAbs) tested, compared with the reactivity with anti-alpha 4 epitopes B1, B2, and C mAb, both by transfectant flow cytometry, and by immunoprecipitation and SDS-polyacrylamide gel electrophoresis analysis of transfectant surface-iodinated proteins. In contrast, substitutions at nearby residues, Gln(101), Pro(102), and Ile(108) did not affect the reactivity of any anti-alpha 4 mAb representing the known alpha 4 epitopes. Homotypic cell aggregation triggered by anti-alpha 4 epitope A mAb was prevented in the transfectants expressing mutated alpha 4 Ar-89-Asp(90)Asp residues, while cell aggregation was fully achieved with either anti-alpha 4 epitope B2 or anti-beta 1 mAb, Mutations at alpha 4 residues Gln(101), Pro(102), and Ile(108) did not affect the homotypic cell aggregation of the transfectants expressing these mutations. In addition, the adhesion of mutant Arg(89)-Asp(90) alpha 4 transfectants to the connecting segment-1-containing fibronectin-40 (FN 40) fragment of fibronectin was diminished compared to wild type alpha 4 transfectants, as well as to other mutant alpha 4 transfectants. This adhesion to FN-40 was restored when the activating anti-beta 1 TS2/16 mAb was present in the adhesion assays. In contrast, adhesion to VCAM-1 was not affected by mutations at Arg(89)-Asp(90), nor at Gln(101), Pro(102), and Ile(108) alpha 4 residues. Altogether, these results indicate that alpha 4 residues Arg(89) and Asp(90) are included in a region involved in homotypic cell aggregation, as well as in adhesion to FN-40, but not to VCAM-1.	CSIC, CTR INVEST BIOL, DEPT INMUNOL, E-28006 MADRID, SPAIN; HOSP PRINCESA, SERV INMUNOL, E-28006 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Hospital de La Princesa			Teixidó, Joaquin/J-8543-2014; Sanchez-Madrid, Francisco/M-7889-2016; Serrador, Juan M/K-2718-2014	Sanchez-Madrid, Francisco/0000-0001-5303-0762; Serrador, Juan M/0000-0003-4710-3077				ABRAHAM WM, 1994, J CLIN INVEST, V93, P776, DOI 10.1172/JCI117032; ALTEVOGT P, 1995, J EXP MED, V182, P345, DOI 10.1084/jem.182.2.345; ARROYO AG, 1992, J CELL BIOL, V117, P659, DOI 10.1083/jcb.117.3.659; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARON JL, 1994, J CLIN INVEST, V93, P1700, DOI 10.1172/JCI117153; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BURKLY LC, 1994, DIABETES, V43, P529, DOI 10.2337/diabetes.43.4.529; CALVETE JJ, 1989, BIOCHEM J, V261, P561, DOI 10.1042/bj2610561; CAMPANERO MR, 1991, EUR J IMMUNOL, V21, P3045, DOI 10.1002/eji.1830211222; CAMPANERO MR, 1992, EUR J IMMUNOL, V22, P3111, DOI 10.1002/eji.1830221213; CAMPANERO MR, 1990, J CELL BIOL, V110, P2157, DOI 10.1083/jcb.110.6.2157; CARLOS TM, 1994, BLOOD, V84, P2068; CHISHOLM PL, 1993, EUR J IMMUNOL, V23, P682, DOI 10.1002/eji.1830230317; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; FERGUSON TA, 1993, J IMMUNOL, V150, P1172; GARCIAPARDO A, 1990, J IMMUNOL, V144, P3361; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HEMLER ME, 1990, IMMUNOL REV, V114, P45, DOI 10.1111/j.1600-065X.1990.tb00561.x; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1984, J IMMUNOL, V132, P3011; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KILSHAW PJ, 1990, EUR J IMMUNOL, V20, P2201, DOI 10.1002/eji.1830201008; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEMKE H, 1978, NATURE, V271, P249, DOI 10.1038/271249a0; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; MASUMOTO A, 1993, J CELL BIOL, V123, P245, DOI 10.1083/jcb.123.1.245; MOULD AP, 1991, J BIOL CHEM, V266, P3579; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; NAKAJIMA H, 1994, J EXP MED, V179, P1145, DOI 10.1084/jem.179.4.1145; OHASHI PS, 1985, NATURE, V316, P606, DOI 10.1038/316606a0; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; PODOLSKY DK, 1993, J CLIN INVEST, V92, P372, DOI 10.1172/JCI116575; POSTIGO AA, 1993, J IMMUNOL, V151, P2471; POSTIGO AA, 1993, RES IMMUNOL, V144, P723, DOI 10.1016/S0923-2494(93)80057-6; PRETOLANI M, 1994, J EXP MED, V180, P795, DOI 10.1084/jem.180.3.795; PULIDO R, 1991, J BIOL CHEM, V266, P10241; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; ROSEN GD, 1992, CELL, V69, P1107, DOI 10.1016/0092-8674(92)90633-N; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SANCHEZAPARICIO P, 1994, J CELL BIOL, V126, P271, DOI 10.1083/jcb.126.1.271; SANCHEZMADRID F, 1986, EUR J IMMUNOL, V16, P1343, DOI 10.1002/eji.1830161106; SCHIFFER SG, 1995, J BIOL CHEM, V270, P14270, DOI 10.1074/jbc.270.24.14270; SCHWEIGHOFFER T, 1993, J IMMUNOL, V151, P717; SHEPPARD AM, 1994, CELL ADHES COMMUN, V2, P27, DOI 10.3109/15419069409014200; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STEPP MA, 1994, CELL ADHES COMMUN, V2, P359, DOI 10.3109/15419069409014210; TAKADA Y, 1989, EMBO J, V8, P1361, DOI 10.1002/j.1460-2075.1989.tb03516.x; TEIXIDO J, 1992, J BIOL CHEM, V267, P1786; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1989, J CELL BIOL, V109, P1321, DOI 10.1083/jcb.109.3.1321; YABKOWITZ R, 1993, J IMMUNOL, V151, P149; YANG JT, 1995, DEVELOPMENT, V121, P549; YANG XD, 1993, P NATL ACAD SCI USA, V90, P10494, DOI 10.1073/pnas.90.22.10494; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	59	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2696	2702		10.1074/jbc.271.5.2696	http://dx.doi.org/10.1074/jbc.271.5.2696			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576243	hybrid, Green Published			2022-12-25	WOS:A1996TT48800057
J	LeBorgne, R; Griffiths, G; Hoflack, B				LeBorgne, R; Griffiths, G; Hoflack, B			Mannose 6-phosphate receptors and ADP-ribosylation factors cooperate for high affinity interaction of the AP-1 Golgi assembly proteins with membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-COATED PITS; GTP-BINDING PROTEIN; FACTOR-II RECEPTOR; BREFELDIN-A; GUANINE-NUCLEOTIDE; CYTOPLASMIC DOMAIN; VESICLE PROTEINS; INVITRO BINDING; 100-KD PROTEINS; ARF PROTEIN	Clathrin coat assembly in the trans-Golgi network, leading to the sequestration of the mannose 6-phosphate receptors (MPRs) into nascent vesicles, requires the ARF-1-dependent translocation of the cytosolic AP-1 Golgi assembly proteins onto the membranes of this organelle. The mechanistic role of the MPRs, i.e. the cargo molecules, in coat assembly is at present unclear. Using a GTP-dependent, brefeldin A-sensitive in vitro AP-1 binding assay, we have determined here the parameters of the AP-1 binding reaction. We demonstrate that, in addition of ARF-1, the MPRs contribute to create high affinity AP-1 binding sites (K-d approximate to 25 nM), since their number correlates the number of MPR molecules expressed in MPR-negative cells. The quantitative electron microscopy shows that these high affinity binding sites are present on trans-Golgi network membranes, as expected, and to some extent on early endosomes. The high affinity binding sites are lost when the MPRs or ARF-1 become rate-limiting components. Conversely, GTP gamma S (guanosine 5'-O-(3-triotriphosphate)), which increases the amount of membrane-bound ARF-1, mostly uncovers low affinity AP-1 binding sites (K-d approximate to 150 nM) on trans-Golgi network membranes, normally not detected in its absence. Collectively, these results argue that MPR sorting is highly coupled to the first step of coat assembly and that the MPRs, ARF-1, and possibly other proteins cooperate for high affinity interactions of AP-1.	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			HOFLACK, Bernard/AAZ-6668-2020					AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; CARTER IL, 1992, J CELL BIOL, V120, P37; CHANG MP, 1993, EMBO J, V12, P2169, DOI 10.1002/j.1460-2075.1993.tb05865.x; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; GEUZE HJ, 1992, HEPATIC ENDOCYTOSIS, P28; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; HEMER F, 1993, J BIOL CHEM, V268, P17108; KAHN RA, 1991, J BIOL CHEM, V266, P2606; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LEBORGNE R, 1993, J BIOL CHEM, V268, P22552; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LUDWIG T, 1993, EMBO J, V12, P5225, DOI 10.1002/j.1460-2075.1993.tb06218.x; LUDWIG T, 1994, EMBO J, V13, P3430, DOI 10.1002/j.1460-2075.1994.tb06648.x; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MERESSE S, 1993, J CELL BIOL, V120, P67, DOI 10.1083/jcb.120.1.67; MERESSE S, 1990, J BIOL CHEM, V265, P18833; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; ORCI L, 1991, CELL, V64, P1183; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; RABOUILLE C, 1995, J CELL SCI, V108, P1617; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON MS, 1990, J CELL BIOL, V111, P2319, DOI 10.1083/jcb.111.6.2319; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SEAMAN MNJ, 1993, J CELL BIOL, V123, P1093, DOI 10.1083/jcb.123.5.1093; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; von Figura K, 1991, Curr Opin Cell Biol, V3, P642, DOI 10.1016/0955-0674(91)90035-W; WONG DH, 1992, J CELL BIOL, V117, P1171, DOI 10.1083/jcb.117.6.1171; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	62	99	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2162	2170						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567674				2022-12-25	WOS:A1996TR32000056
J	Razdan, K; Kroll, MH				Razdan, K; Kroll, MH			Molecular cloning of a novel platelet protein showing homology to the angiotensin II receptor C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; TYPE-1 RECEPTOR; EXPRESSION; DNA; SEQUENCE; MUSCLE	Oligoscreening of a cDNA library obtained from 4 beta-phorbol 12-myristate 13-acetate-stimulated human erythroleukemia (HEL) cells resulted in the isolation of a novel clone coding for a protein with a calculated molecular mass of 8110 Da. This protein of 71 amino acids shows significant homology to the carboxyl-terminal regulatory domain of angiotensin II type 1 receptors. The homology encompasses four regions of amino acid residues thought to serve as consensus sequences for phosphorylation by serine/threonine kinases such as protein kinase C, which are key mediators of intracellular signaling. Reverse transcription-polymerase chain reaction identified the transcript in human platelets, human megakaryocytic DAMI cells, and HEL cells. High stringency Northern blotting revealed a tissue specific distribution of three transcript species, with predominant expression in skeletal muscle and pancreas. Rabbit anti-peptide antiserum was used to immunoblot protein lysates from washed resting platelets and from 4 beta-phorbol 12-myristate 13-acetate-stimulated DAMI and HEL cells. These immunoblots revealed the presence of an intense approximate to 8-kDa protein band in platelets and HEL cells and a faint band of identical size in DAMI cells.	RICE UNIV,HOUSTON,TX 77251	Rice University	Razdan, K (corresponding author), BAYLOR COLL MED,VET ADM MED CTR,HEMATOL ONCOL SECT 111H,2002 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002154] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL02154, HL02311] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; BERGSMA DJ, 1993, MOL PHARMACOL, V44, P277; BURNS KD, 1993, AM J PHYSIOL, V264, pF645, DOI 10.1152/ajprenal.1993.264.4.F645; CHANG JD, 1993, J BIOL CHEM, V268, P14208; ELLIOTT RM, 1989, ANAL BIOCHEM, V183, P89, DOI 10.1016/0003-2697(89)90176-0; GREENBERG SM, 1988, BLOOD, V72, P1968; HONG J, 1993, BIOCHEM BIOPH RES CO, V194, P756; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; ITAZAKI K, 1993, EUR J PHARM-MOLEC PH, V245, P147, DOI 10.1016/0922-4106(93)90122-P; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KROLL MH, 1993, J BIOL CHEM, V268, P3520; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; PAXTON WG, 1994, BIOCHEM BIOPH RES CO, V200, P260, DOI 10.1006/bbrc.1994.1443; RAZDAN K, 1994, BIOCHEM J, V302, P681, DOI 10.1042/bj3020681; Sambrook J, 1989, MOL CLONING LABORATO; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SASAMURA H, 1992, BIOCHEM BIOPH RES CO, V185, P253, DOI 10.1016/S0006-291X(05)80983-0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432	27	3	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2221	2224		10.1074/jbc.271.4.2221	http://dx.doi.org/10.1074/jbc.271.4.2221			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567682	hybrid			2022-12-25	WOS:A1996TR32000064
J	Sharma, S; Leonard, J; Lee, S; Chapman, HD; Leiter, EH; Montminy, MR				Sharma, S; Leonard, J; Lee, S; Chapman, HD; Leiter, EH; Montminy, MR			Pancreatic islet expression of the homeobox factor STF-1 relies on an E-box motif that binds USF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; CAMP RESPONSE ELEMENT; LOOP HELIX PROTEIN; INSULIN GENE; SOMATOSTATIN EXPRESSION; CELLS; ENHANCER; COMPLEX; REGION; DNA	The commitment of cells to specific lineages during development is determined in large part by the relative expression of various homeodomain (HOX) selector proteins, which mediate the activation of distinct genetic programs. But the mechanisms by which individual HOX genes are themselves targeted for expression in different cell types remain largely uncharacterized. Here, we demonstrate that STF-1, a homeodomain protein that functions in pancreatic morphogenesis and in glucose homeostasis is encoded by an ''orphan'' homeobox gene on mouse chromosome 5. When fused to a beta-galactosidase reporter gene, a 6.5-kilobase genomic fragment of 5'-flanking sequence from the STF-1 gene shows pancreatic islet specific activity in transgenic mice. Two distinct elements within the STF-1 promoter are required for islet-restricted expression: a distal enhancer sequence located between -3 and -6.5 kilobases and a proximal E-box sequence located at -104, which is recognized primarily by the helix loop helix/leucine zipper nuclear factor USF. As point mutations within the -104 E-box that disrupt USF binding correspondingly impair STF-1 promoter activity, our results demonstrate that USF is an important component of the regulatory apparatus which directs STF-1 expression to pancreatic islet cells.	SALK INST BIOL STUDIES, CLAYTON FDN LABS PEPTIDE BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, SCH MED, DEPT BIOL, LA JOLLA, CA 92037 USA; STRANG CORNELL CANC RES LAB, NEW YORK, NY 11203 USA; JACKSON LAB, BAR HARBOR, ME 04609 USA	Salk Institute; University of California System; University of California San Diego; Jackson Laboratory					NIDDK NIH HHS [DK36175, DK27722] Funding Source: Medline; NIGMS NIH HHS [GM07198] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036175, R01DK027722, R37DK027722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007198] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BONCINELLI E, 1988, HUM REPROD, V3, P880, DOI 10.1093/oxfordjournals.humrep.a136802; GENG YP, 1993, MOL CELL BIOL, V13, P4894, DOI 10.1128/MCB.13.8.4894; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; GITTES GK, 1992, P NATL ACAD SCI USA, V89, P1128, DOI 10.1073/pnas.89.3.1128; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GUZ Y, 1995, DEVELOPMENT, V121, P11; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LEONARD J, 1992, P NATL ACAD SCI USA, V89, P6247, DOI 10.1073/pnas.89.14.6247; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; MADSEN OD, 1986, J CELL BIOL, V103, P2025, DOI 10.1083/jcb.103.5.2025; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; PICTET RL, 1972, DEV BIOL, V29, P436, DOI 10.1016/0012-1606(72)90083-8; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; VALLEJO M, 1992, J BIOL CHEM, V267, P12868; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767	33	76	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2294	2299		10.1074/jbc.271.4.2294	http://dx.doi.org/10.1074/jbc.271.4.2294			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567692	hybrid			2022-12-25	WOS:A1996TR32000074
J	Yan, XW; Corbin, JD; Francis, SH; Lawrence, DS				Yan, XW; Corbin, JD; Francis, SH; Lawrence, DS			Precision targeting of protein kinases - An affinity label that inactivates the cGMP- but not the cAMP-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; SUBSTRATE-SPECIFICITY; SULFHYDRYL-GROUP; BOVINE HEART; PHOSPHORYLATION; SITE; PEPTIDES; PURIFICATION; ISOZYMES; ALPHA	Although the cAMP-dependent (PKA) and cGMP-dependent protein kinases (PKG) usually participate in unrelated biological processes, their enzymological properties are decidedly similar, Based upon the multitude of comparative studies conducted to date, it appears that these two enzymes exhibit very similar peptide substrate specificities, Furthermore, most inhibitors that have been reported for PKG serve in a nearly equal capacity for PKA, Consequently, the task of distinguishing between these enzymes, especially under in vivo conditions, has proved to be daunting, However, we have recently found that PKA will only phosphorylate non-amino acid residues whose alpha-configuration corresponds to that found in L-amino acids, whereas PKG will catalyze the phosphorylation of residues corresponding to both L- and D-amino acids (Wood, J., Mendelow, M., Yan, X., Corbin, J. D., Francis, S. H., and Lawrence, D. S. (1996) J. Biol. Chem. 271, 174-179). Based upon these results, we have designed a potent affinity label for PKG (K-I = 21.1 +/- 4.7 mu M), that has no measurable activity toward PKA, This represents the first example of an peptide-based inactivator that fully distinguishes between these two closely related enzymes, These results suggest that a similar strategy may provide highly specific inactivators for other protein kinases as well.	SUNY BUFFALO, DEPT CHEM, BUFFALO, NY 14260 USA; SUNY BUFFALO, DEPT MED CHEM, BUFFALO, NY 14260 USA; VANDERBILT UNIV, SCH MED, DEPT MOLEC PHYSIOL & BIOPHYS, NASHVILLE, TN 37232 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045989] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40029] Funding Source: Medline; NIGMS NIH HHS [GM45989] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG RN, 1978, BIOCHEMISTRY-US, V17, P2840, DOI 10.1021/bi00607a022; BRAMSON HN, 1982, J BIOL CHEM, V257, P575; BUTT E, 1994, J BIOL CHEM, V269, P14509; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; COLBRAN JL, 1992, J BIOL CHEM, V267, P9589; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; FRANCIS SH, 1991, METHOD ENZYMOL, V200, P332; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GLASS DB, 1982, J BIOL CHEM, V257, P1196; GLASS DB, 1986, J BIOL CHEM, V261, P2987; GLASS DB, 1979, J BIOL CHEM, V254, P9728; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO E, 1976, J BIOL CHEM, V251, P6287; HIDAKA H, 1992, ANNU REV PHARMACOL, V32, P377, DOI 10.1146/annurev.pharmtox.32.1.377; JIMENEZ JS, 1982, BIOCHEMISTRY-US, V21, P1623, DOI 10.1021/bi00536a024; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KUPFER A, 1979, P NATL ACAD SCI USA, V76, P3073, DOI 10.1073/pnas.76.7.3073; KWON YG, 1993, J AM CHEM SOC, V115, P7527, DOI 10.1021/ja00069a072; KWON YG, 1993, J BIOL CHEM, V268, P16725; KWON YG, 1993, J BIOL CHEM, V268, P10713; KWON YG, 1994, J BIOL CHEM, V269, P4839; LEE TR, 1994, BIOCHEMISTRY-US, V33, P4245, DOI 10.1021/bi00180a019; LEE TR, 1995, J BIOL CHEM, V270, P27022, DOI 10.1074/jbc.270.45.27022; LEE TR, 1995, J BIOL CHEM, V270, P5375, DOI 10.1074/jbc.270.10.5375; LEE TR, 1993, J AM CHEM SOC, V115, P9888, DOI 10.1021/ja00075a003; LEVITZKI A, 1991, EUR J BIOCHEM, V226, P1; LINCOLN TM, 1977, P NATL ACAD SCI USA, V74, P3239, DOI 10.1073/pnas.74.8.3239; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MITCHELL RD, 1995, BIOCHEMISTRY-US, V34, P528, DOI 10.1021/bi00002a018; MOBASHERY S, 1988, BIOCHEMISTRY-US, V28, P3691; NELSON NC, 1981, J BIOL CHEM, V256, P3743; PROROK M, 1989, J BIOCHEM BIOPH METH, V18, P167, DOI 10.1016/0165-022X(89)90001-8; PROROK M, 1990, J AM CHEM SOC, V112, P8626, DOI 10.1021/ja00179a081; RINK H, 1987, TETRAHEDRON LETT, V28, P3787, DOI 10.1016/S0040-4039(00)96384-6; SALERNO A, 1993, J BIOL CHEM, V268, P13043; SUGDEN PH, 1976, BIOCHEM J, V159, P409, DOI 10.1042/bj1590409; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; THOMAS NE, 1987, BIOCHEMISTRY-US, V26, P4471, DOI 10.1021/bi00388a043; WOOD J, 1995, J BIOL CHEM, V271, P174; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	40	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1845	1848		10.1074/jbc.271.4.1845	http://dx.doi.org/10.1074/jbc.271.4.1845			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567627	hybrid			2022-12-25	WOS:A1996TR32000009
J	Lee, KB; Lee, YC				Lee, KB; Lee, YC			Conformational studies of glycopeptides by energy transfer - Introduction of fluorophore at specific branches of biantennary glycopeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIANTENNARY GLYCOPEPTIDE; BOVINE FIBRINOGEN; ACID; FLEXIBILITY; GAMMA	Biantennary glycopeptides from bovine fibrinogen were fluorescence labeled at each branch specifically for conformational studies by fluorescence energy transfer, Glycopeptides (by Pronase digestion) were separated by anion-exchange chromatography based on the degree of sialylation, The major monosialyl biantennary glycopeptides (see below) were used as substrates for galactose oxidase and periodate oxidation. [GRAPHICS] Galactose oxidase was used to oxidize the terminal Gal6' located on the Man alpha(1-6)Man branch. The oxidized glycopeptides (containing 6-oxo-galactose) were modified with 2-(dansylamido)ethylamine by reductive amination. The N terminus of the peptide portion was then modified with naphthylacetic acid. Alternatively, the peptide portion of the monosialylated glycopeptide was first modified with naphthylacetic acid and the sialic acid located on the Man alpha(1-3)Man branch was oxidized with periodate under controlled conditions. The oxidized glycopeptides (oxo-sialic acid) were coupled with 2-(dansylamido)ethylamine by reductive amination. These doubly fluorescence-labeled glycopeptides were used for conformational studies of biantennary glycopeptides by energy transfer (see the accompanying article (Wu, P., Lee, K. B., Lee, Y. C., and Brand, L, (1996) J, Biol, Chem, 271, 1470-1474), Furthermore, the unmodified branch of the fluorescent labeled glycopeptides were digested stepwise with exoglycosidases, Resonance energy transfer experiments were done with each of the resulting derivatives to determine the effects of removing sugars at each stage of peeling on any conformational change on the resulting branch antennae.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218	Johns Hopkins University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK009970, R01DK009970] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049994] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 09970] Funding Source: Medline; NIGMS NIH HHS [GM 49994] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BROWN WM, 1989, NUCLEIC ACIDS RES, V17, P6397, DOI 10.1093/nar/17.15.6397; Clegg Robert M., 1995, Current Opinion in Biotechnology, V6, P103, DOI 10.1016/0958-1669(95)80016-6; DEBEIRE P, 1985, EUR J BIOCHEM, V151, P607, DOI 10.1111/j.1432-1033.1985.tb09147.x; DISTLER JJ, 1973, J BIOL CHEM, V248, P6772; EBERT RF, 1986, ANAL BIOCHEM, V154, P431, DOI 10.1016/0003-2697(86)90010-2; EDGE CJ, 1990, BIOCHEMISTRY-US, V29, P1971, DOI 10.1021/bi00460a001; FAN JQ, 1994, ANAL BIOCHEM, V219, P375, DOI 10.1006/abio.1994.1280; HAYES ML, 1979, J BIOL CHEM, V254, P8778; HOMANS SW, 1990, BIOCHEMISTRY-US, V29, P9110, DOI 10.1021/bi00491a003; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2167; LEE KB, 1994, ANAL BIOCHEM, V216, P358, DOI 10.1006/abio.1994.1053; MCKELVY JF, 1969, ARCH BIOCHEM BIOPHYS, V132, P99, DOI 10.1016/0003-9861(69)90341-5; MEDVED LV, 1988, FEBS LETT, V232, P56, DOI 10.1016/0014-5793(88)80385-5; OPDENAKKER G, 1993, FASEB J, V7, P1330, DOI 10.1096/fasebj.7.14.8224606; POPPE L, 1992, J BIOMOL NMR, V2, P109, DOI 10.1007/BF01875524; RICE KG, 1991, BIOCHEMISTRY-US, V30, P6646, DOI 10.1021/bi00241a003; RICE KG, 1993, BIOCHEMISTRY-US, V32, P7264, DOI 10.1021/bi00079a024; RICE KG, 1990, J BIOL CHEM, V265, P18423; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; SUGAHARA K, 1980, CLIN CHIM ACTA, V108, P493, DOI 10.1016/0009-8981(80)90360-5; TOWNSEND RR, 1982, J BIOL CHEM, V257, P9704; VANDENEIJNDEN DH, 1980, BIOCHEM BIOPH RES CO, V92, P839, DOI 10.1016/0006-291X(80)90779-2; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; WU PG, 1991, P NATL ACAD SCI USA, V88, P9355, DOI 10.1073/pnas.88.20.9355; Wu PG, 1996, J BIOL CHEM, V271, P1470, DOI 10.1074/jbc.271.3.1470; YAMAMOTO S, 1989, J BIOCHEM-TOKYO, V105, P1034, DOI 10.1093/oxfordjournals.jbchem.a122762; [No title captured]	27	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1462	1469		10.1074/jbc.271.3.1462	http://dx.doi.org/10.1074/jbc.271.3.1462			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576139	hybrid			2022-12-25	WOS:A1996TQ52500035
J	Wesselborg, S; Fruman, DA; Sagoo, JK; Bierer, BE; Burakoff, SJ				Wesselborg, S; Fruman, DA; Sagoo, JK; Bierer, BE; Burakoff, SJ			Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOSPORINE-A; INTERLEUKIN-4 GENE; BINDING-PROTEIN; TRANSCRIPTION; EXPRESSION; PROMOTER; CYCLOPHILIN; AFFINITY; ELEMENTS; TARGET	In T lymphocytes, the calcium/calmodulin-dependent serine/threonine phosphatase, calcineurin, plays a pivotal role in transducing membrane-associated signals to the nucleus. One of the putative targets of calcineurin is the pre-existing, cytosolic component of the nuclear factor of activated T cells (NFATp; also referred to as NFAT1), which is one of several transcription factors required for the expression of interleukin 2. Inhibition of calcineurin by the immunosuppressive drugs cyclo-sporin A and FK506 prevents dephosphorylation of NFATp and its translocation to the nucleus. However, a physical interaction between calcineurin and NFATp has not been demonstrated. Here we demonstrate the binding of NFATp from lysates of T cells to immobilized calcineurin. Stimulation of T cells with calcium ionophore induced a shift in the molecular weight of NFATp that is due to its dephosphorylation. This dephosphorylation was inhibited by treatment of T cells with cyclo-sporin A or FK506 prior to stimulation. Of note, both the phosphorylated and the dephosphorylated form of NFATp bound to calcineurin. Furthermore, the binding of both forms of NFATp to calcineurin was inhibited by pretreatment of calcineurin with a complex of FK506 and its ligand FKBP12. Taken together these data strongly suggest a direct interaction of calcineurin with NFATp and that this interaction does not depend upon the phosphorylation sites of NFATp affected by activation.	DANA FARBER CANC INST,DIV PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School				Bierer, Barbara/0000-0001-6448-8170; Wesselborg, Sebastian/0000-0002-5236-942X	NIAID NIH HHS [AI 32514] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BICKEL M, 1987, P NATL ACAD SCI USA, V84, P3274, DOI 10.1073/pnas.84.10.3274; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.biochem.63.1.1045; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GOLDFELD AE, 1993, J EXP MED, V178, P1365, DOI 10.1084/jem.178.4.1365; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JIN YJ, 1992, J BIOL CHEM, V267, P10942; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RAVICHANDRAN KS, 1994, J EXP MED, V179, P727, DOI 10.1084/jem.179.2.727; RUFF VA, 1995, J BIOL CHEM, V270, P22602, DOI 10.1074/jbc.270.38.22602; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TOCCI MJ, 1989, J IMMUNOL, V143, P718; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663	32	82	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1274	1277		10.1074/jbc.271.3.1274	http://dx.doi.org/10.1074/jbc.271.3.1274			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576111	hybrid			2022-12-25	WOS:A1996TQ52500007
J	AbuElneel, K; Karchi, M; Ravid, S				AbuElneel, K; Karchi, M; Ravid, S			Dictyostelium myosin II is regulated during chemotaxis by a novel protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN KINASE; CHEMOATTRACTANT-ELICITED INCREASES; THICK FILAMENTS; PHOSPHORYLATION; DISCOIDEUM; LOCALIZATION; PURIFICATION; CYTOSKELETON; CELLS; GENE	The myosin II heavy chain (MHC)-specific protein kinase C (MHC-PKC) isolated from Dictyostelium discoideum has been implicated in the regulation of myosin II assembly in response to the chemoattractant, cAMP (Ravid, S., and Spudich, J. A. (1989) J. Biol. Chem. 264, 15144-15150). Here we report that elimination of MHC-PKC results in the abolishment of MNC phosphorylation in response to cAMP. Cells devoid of MHC-PKC exhibit substantial myosin II overassembly, as well as aberrant cell polarization, chemotaxis, and morphological differentiation, Cells overexpressing the MHC-PKC contain highly phosphorylated MHC and exhibit impaired myosin II localization and no apparent cell polarization and chemotaxis. The results presented here provide direct evidence that MHC-PKC phosphorylates MHC in response to cAMP and plays an important role in the regulation of myosin II localization during chemotaxis.	HEBREW UNIV JERUSALEM, HADASSAH MED SCH, DEPT BIOCHEM, IL-91120 JERUSALEM, ISRAEL	Hebrew University of Jerusalem								BERLOT CH, 1985, CELL, V43, P307, DOI 10.1016/0092-8674(85)90036-4; BERLOT CH, 1987, J BIOL CHEM, V262, P3918; COTE GP, 1987, J BIOL CHEM, V262, P1065; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DYNES JL, 1989, P NATL ACAD SCI USA, V86, P7966, DOI 10.1073/pnas.86.20.7966; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; EGELHOFF TT, 1991, J CELL BIOL, V112, P677, DOI 10.1083/jcb.112.4.677; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; FUKUI Y, 1987, METHOD CELL BIOL, V28, P347; KNECHT DA, 1986, MOL CELL BIOL, V6, P3973, DOI 10.1128/MCB.6.11.3973; KUCZMARSKI ER, 1986, J MUSCLE RES CELL M, V7, P501, DOI 10.1007/BF01753566; KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEITING B, 1988, PLASMID, V20, P241, DOI 10.1016/0147-619X(88)90030-3; LUCKVIELMETTER D, 1990, FEBS LETT, V269, P239, DOI 10.1016/0014-5793(90)81163-I; MALCHOW D, 1981, EUR J BIOCHEM, V117, P213; MARUTA H, 1983, EMBO J, V2, P535, DOI 10.1002/j.1460-2075.1983.tb01459.x; NACHMIAS VT, 1989, CELL MOTIL CYTOSKEL, V13, P158, DOI 10.1002/cm.970130304; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PASTERNAK C, 1989, J CELL BIOL, V109, P203, DOI 10.1083/jcb.109.1.203; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RAHMSDORF HJ, 1978, FEBS LETT, V88, P322, DOI 10.1016/0014-5793(78)80203-8; RAVID S, 1992, P NATL ACAD SCI USA, V89, P5877, DOI 10.1073/pnas.89.13.5877; RAVID S, 1989, J BIOL CHEM, V264, P15144; Sambrook J, 1989, MOL CLONING LABORATO; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; VAILLANCOURT JP, 1988, J BIOL CHEM, V263, P10082; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; YUMURA S, 1985, NATURE, V314, P194, DOI 10.1038/314194a0; YUMURA S, 1992, J CELL BIOL, V117, P1231, DOI 10.1083/jcb.117.6.1231; ZIGMOND SH, 1988, METHOD ENZYMOL, V162, P65	32	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					977	984		10.1074/jbc.271.2.977	http://dx.doi.org/10.1074/jbc.271.2.977			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557714	hybrid			2022-12-25	WOS:A1996TP88900057
J	Blat, Y; Eisenbach, M				Blat, Y; Eisenbach, M			Oligomerization of the phosphatase CheZ upon interaction with the phosphorylated form of CheY - The signal protein of bacterial chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FLAGELLAR MOTOR; CYTOPLASMIC FRAGMENT; QUATERNARY STRUCTURE; ASPARTATE RECEPTOR; CELL ENVELOPES; TRANSDUCTION; BINDING; MUTANTS; GENES	Earlier studies have suggested that CheZ, the phosphatase of the signaling protein CheY in bacterial chemotaxis, may be in an oligomeric state both when bound to phosphorylated CheY (CheY similar to P) (Blat, Y., and Eisenbach, M. (1994) Biochemistry 33, 902-906) or free (Stock, A., and Stock, J. B. (1987) J. Bacteriol. 169, 3301-3311). The purpose of the current study was to determine the oligomeric state of free CheZ and to investigate whether it changes upon binding to CheY similar to P. By using either one of two different sets of cross-linking agents, free CheZ was found to be a dimer. The formation of the dimer was specific, as it was prevented by SDS which does not interfere with cross-linking mediated by random collisions. The dimeric form of CheZ was confirmed by sedimentation analysis, a cross-linking-free technique. In the presence of CheY similar to P (but not in the presence of non-phosphorylated CheY), a high molecular size crosslinked complex (90-200 kDa) was formed, in which the CheZ:CheY ratio was 2:1. The size of the oligomeric complex was estimated by fluorescence depolarization to be 4-5-fold larger than the dimer, suggesting that its size is in the order of 200 kDa. These results indicate that CheZ oligomerizes upon interaction with CheY similar to P3. This phosphorylation-dependent oligomerization may be a mechanism for regulating CheZ activity.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science				Eisenbach, Michael/0000-0001-9048-4720				ADLER J, 1966, SCIENCE, V153, P708, DOI 10.1126/science.153.3737.708; AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; ASWAD D, 1975, J MOL BIOL, V97, P225, DOI 10.1016/S0022-2836(75)80036-2; BARAK R, 1992, BIOCHEMISTRY-US, V31, P1821, DOI 10.1021/bi00121a034; BLAT Y, 1994, BIOCHEMISTRY-US, V33, P902, DOI 10.1021/bi00170a008; Blat Y, 1996, J BIOL CHEM, V271, P1232, DOI 10.1074/jbc.271.2.1232; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P454; CARPENTER FH, 1972, J BIOL CHEM, V247, P5580; CLEGG DO, 1984, P NATL ACAD SCI-BIOL, V81, P5056, DOI 10.1073/pnas.81.16.5056; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; EISENBACH M, 1990, J MOL BIOL, V211, P551, DOI 10.1016/0022-2836(90)90265-N; EISENBACH M, 1981, J BIOL CHEM, V256, P8807; EISENBACH M, 1985, SENSING RESPONSE MIC, P43; GIDDINGS JC, 1968, J PHYS CHEM-US, V72, P4397, DOI 10.1021/j100859a008; HAZELBAUER GL, 1993, CELL, V73, P15, DOI 10.1016/0092-8674(93)90156-K; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; LAZAZZERA BA, 1993, GENE DEV, V7, P1993, DOI 10.1101/gad.7.10.1993; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; LONG DG, 1992, BIOPHYS J, V62, P69, DOI 10.1016/S0006-3495(92)81782-4; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; LUKAT GS, 1990, BIOCHEMISTRY-US, V29, P5436, DOI 10.1021/bi00475a004; MACNAB RM, 1977, J MOL BIOL, V112, P1, DOI 10.1016/S0022-2836(77)80153-8; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MATSUMURA P, 1984, J BACTERIOL, V160, P36, DOI 10.1128/JB.160.1.36-41.1984; Matsumura P., 1990, S SOC GEN MICROBIOL, V46, P135; MUTOH N, 1986, J BACTERIOL, V165, P161, DOI 10.1128/jb.165.1.161-166.1986; NINFA EG, 1991, J BIOL CHEM, V266, P9764; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; PARKINSON JS, 1983, J BACTERIOL, V155, P265, DOI 10.1128/JB.155.1.265-274.1983; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; RAVID S, 1984, J BACTERIOL, V159, P433; RAVID S, 1984, J BACTERIOL, V158, P222, DOI 10.1128/JB.158.1.222-230.1984; RAVID S, 1986, P NATL ACAD SCI USA, V83, P7157, DOI 10.1073/pnas.83.19.7157; Satir B.H., 1991, MODERN CELL BIOL, P137; SEGALL JE, 1985, J BACTERIOL, V161, P51, DOI 10.1128/JB.161.1.51-59.1985; SMITH RA, 1980, P NATL ACAD SCI-BIOL, V77, P5370, DOI 10.1073/pnas.77.9.5370; STADTMAN ER, 1957, METHOD ENZYMOL, V3, P228, DOI 10.1016/S0076-6879(57)03379-0; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; STOCK AM, 1987, J BACTERIOL, V169, P3301, DOI 10.1128/jb.169.7.3301-3311.1987; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; WEBER G, 1953, ADV PROTEIN CHEM, V8, P415, DOI 10.1016/S0065-3233(08)60096-0; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6; YAMAGUCHI S, 1986, J BACTERIOL, V168, P1172, DOI 10.1128/jb.168.3.1172-1179.1986	52	45	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1226	1231		10.1074/jbc.271.2.1226	http://dx.doi.org/10.1074/jbc.271.2.1226			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557654	hybrid			2022-12-25	WOS:A1996TP88900091
J	DeLuca, P; Majello, B; Lania, L				DeLuca, P; Majello, B; Lania, L			Sp3 represses transcription when tethered to promoter DNA or targeted to promoter proximal RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; GENE-EXPRESSION; CLONING; FAMILY; SITE	Sp3 is a member of the Sp family of transcription factors, and it binds to the GC box with an affinity and specificity comparable with that of Spl. Previous studies have shown that Sp3 repressed Spl-mediated transcriptional activation, suggesting that Sp3 is an inhibitory member of the Sp family. The experiments described here demonstrate that Sp3 contains a portable repression domain that can function independently from the zinc finger DNA binding domain. We found that the amino-terminal region of Sp3 tethered to a promoter DNA by connecting to a heterologous DNA-binding protein domain represses transcriptional activation by different positive regulators. Moreover, we determined that Sp3 targeted to a promoter-proximal RNA sequence acts as a transcriptional repressor. Taken together, our results suggest that Sp3 functions as a repressor by protein-protein interaction with components of the general transcription complex.	UNIV NAPLES,DIPARTIMENTO GENET BIOL GEN & MOLEC,I-80134 NAPLES,ITALY; CNR,INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)			De Luca, Pasquale/AAL-5673-2021	De Luca, Pasquale/0000-0003-4289-6784; Majello, Barbara/0000-0003-2789-3585				CHANG CB, 1993, MOL CELL BIOL, V13, P7469, DOI 10.1128/MCB.13.12.7469; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HERSCHBACH BM, 1993, ANNU REV CELL BIOL, V9, P479, DOI 10.1146/annurev.cellbio.9.1.479; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; LILLIE JW, 1989, NATURE, V338, P38; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; PENGUE G, 1995, J VIROL, V69, P6577, DOI 10.1128/JVI.69.10.6577-6580.1995; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P631	20	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8533	8536		10.1074/jbc.271.15.8533	http://dx.doi.org/10.1074/jbc.271.15.8533			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621476	hybrid			2022-12-25	WOS:A1996UE73000007
J	Abraham, ST; Benscoter, H; Schworer, CM; Singer, HA				Abraham, ST; Benscoter, H; Schworer, CM; Singer, HA			In situ Ca2+ dependence for activation of Ca2+/calmodulin-independent protein kinase II in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-II; RAT-BRAIN; GROWTH-FACTOR; CA-2+; EXPRESSION; PHOSPHORYLATION; PURIFICATION; VASOPRESSIN; RECEPTORS; PATHWAYS	Activation of Ca2+/calmodulin (CaM)-dependent protein kinase II (CaM kinase II) and development of the Ca2+/CaM-independent (autonomous) form of the kinase was investigated in cultured vascular smooth muscle (VSM) cells, Within 15 s of ionomycin (1 mu M) exposure 52.7 +/- 4.4% of the kinase became autonomous, a response that was partially maintained for at least 10 min, This correlated with P-32 phosphorylation of CaM kinase II delta-subunits in situ and was abolished by pretreatment with the CaM kinase II inhibitor KN-93, The in situ Ca2+ dependence for generating autonomous CaM kinase II was determined in cells selectively permeabilized to Ca2+ and depleted of sarcoplasmic reticulum Ca2+ by pretreatment with thapsigargin. Analysis of the resulting curve revealed an EC(50) (concentration producing 50% of maximal response) of 692 +/- 28 nM [Ca2+](i), a maximum of 68 +/- 2% of the total activity becoming autonomous reflecting nearly complete activation of CaM kinase II and a Hill slope of 3, indicating a highly cooperative process, Based on this dependence and measured [Ca2+](i) responses in intact cells, increases in autonomous activity stimulated by angiotensin II, vasopressin and platelet-derived growth factor-BB (4.6-, 2-, and 1.7-fold, respectively) were unexpectedly high, In intact cells stimulated by ionomycin, the correlation between autonomous activity and [Ca2+](i) resulted in a parallel curve with an EC(50) of 304 +/- 23 nM [Ca2+](i), This apparent increase in Ca2+ sensitivity for generating autonomous activity in intact VSM cells was eliminated by thapsigargin pretreatment. We conclude that alteration of [Ca2+](i) over a physiological range activates CaM kinase II in VSM and that this process is facilitated by release of Ca2+ from intracellular pools which initiates cooperative autophosphorylation and consequent generation of autonomous CaM kinase II activity.	SIGFRIED & JANET WEIS CTR RES,GEISINGER CLIN,DANVILLE,PA 17822						NHLBI NIH HHS [HL49426] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049426, R56HL049426] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BULLEIT RF, 1988, NEURON, V1, P63, DOI 10.1016/0896-6273(88)90210-3; BURNIER M, 1994, AM J PHYSIOL, V266, pC1118, DOI 10.1152/ajpcell.1994.266.4.C1118; CARAMELO C, 1990, KIDNEY INT, V38, P47, DOI 10.1038/ki.1990.165; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHU A, 1990, BIOCHEMISTRY-US, V29, P5899, DOI 10.1021/bi00477a003; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; CRUZALEGUI FH, 1993, J BIOL CHEM, V268, P26171; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; FUKUNAGA K, 1982, J NEUROCHEM, V39, P1607, DOI 10.1111/j.1471-4159.1982.tb07994.x; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HIMPENS B, 1994, FASEB J, V8, P879, DOI 10.1096/fasebj.8.11.8070638; KARGACIN GJ, 1994, BIOPHYS J, V67, P262, DOI 10.1016/S0006-3495(94)80477-1; KLEE CB, 1988, MOL ASPECTS CELLULAR, V5, P35; KURET J, 1984, BIOCHEMISTRY-US, V23, P5495, DOI 10.1021/bi00318a018; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MACNICOL M, 1992, J BIOL CHEM, V267, P12197; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; PALLER MS, 1989, J RECEPTOR RES, V9, P95, DOI 10.3109/10799898909066047; PAULY RR, 1995, CIRCULATION, V91, P1107, DOI 10.1161/01.CIR.91.4.1107; PFEILSCHIFTER J, 1989, BIOCHEM J, V262, P285, DOI 10.1042/bj2620285; SCHWORER CM, 1993, J BIOL CHEM, V268, P14443; SMITH JB, 1986, AM J PHYSIOL, V250, pF759, DOI 10.1152/ajprenal.1986.250.5.F759; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; TAKATA S, 1990, AM J HYPERTENS, V3, pS227, DOI 10.1093/ajh/3.8.227; TANSEY MG, 1992, J BIOL CHEM, V267, P12511; TANSEY MG, 1994, J BIOL CHEM, V269, P9912; TOYOFUKU T, 1994, J BIOL CHEM, V269, P26492; WAHL M, 1993, MOL BIOL CELL, V4, P293, DOI 10.1091/mbc.4.3.293; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WENHAM RM, 1994, J BIOL CHEM, V269, P4947; YANO S, 1994, J BIOL CHEM, V269, P5428	45	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2506	2513		10.1074/jbc.271.5.2506	http://dx.doi.org/10.1074/jbc.271.5.2506			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576214	hybrid			2022-12-25	WOS:A1996TT48800028
J	Knall, C; Young, S; Nick, JA; Buhl, AM; Worthen, GS; Johnson, GL				Knall, C; Young, S; Nick, JA; Buhl, AM; Worthen, GS; Johnson, GL			Interleukin-8 regulation of the Ras/Raf/mitogen-activated protein kinase pathway in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; SIGNAL-TRANSDUCTION; MAP KINASE; CHEMOTACTIC FACTOR; RESPIRATORY BURST; IN-VITRO; RECEPTOR; RAS; PEPTIDE; PURIFICATION	Interleukin-8 (IL-8), the prototypic member of the CXC subfamily of chemokines, induces in neutrophils chemotaxis, the respiratory burst, granule release, and increased cell adhesion, The IL-8 receptor is a seven-transmembrane spanning receptor coupled to specific heterotrimeric G proteins including G(i) and G(16). IL-8 stimulation of its receptor on neutrophils activates Ras GTP loading and the mitogen-activated protein kinase (MAPK) pathway including Raf-1 and B-Raf. The properties of IL-8 stimulation of the MAPK pathway differ from those observed for chemoattractants such as C5a. Even though Ras GTP loading is similar for IL-8 and C5a, the maximal activation of Raf-1 and B-Raf is approximately 2-fold and 3-7-fold, respectively, less for IL-8 than that observed for C5a. Raf-1 activation is rapid but transient, returning to near basal levels by 10 min. B-Raf activation is slower in onset and does not return to basal levels for nearly 30 min, IL-8 activation of MAPK follows a time course suggesting an involvement of both Raf-1 and B-Raf. Surprisingly, wortmannin, at low concentrations, inhibits Raf-1, B-Raf, and MAPK activation in response to IL-8 and C5a demonstrating a role for phosphatidylinositol 3-kinase in the activation of Raf kinases in G protein-coupled receptor systems in human neutrophils. Furthermore, wortmannin inhibits IL-8 stimulated granule release and neutrophil adherence, These findings demonstrate the control of Raf kinases, the MAPK pathway and specific neutrophil functions by phosphatidylinositol 3-kinase enzymes.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PHARMACOL,DENVER,CO 80262; AARHUS UNIV,DEPT CHEM,DIV BIOSTRUCT CHEM,DK-8000 AARHUS,DENMARK	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Aarhus University	Knall, C (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI K1007,1400 JACKSON ST,DENVER,CO 80206, USA.				NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BAGGIOLINI M, 1987, EXP CELL RES, V169, P408, DOI 10.1016/0014-4827(87)90201-1; BAGGIOLINI M, 1992, INFLAMMATION BASIC P, P247; BESEMER J, 1989, J BIOL CHEM, V264, P17409; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BUHL AM, 1994, P NATL ACAD SCI USA, V91, P9190, DOI 10.1073/pnas.91.19.9190; CARVETH HJ, 1989, BIOCHEM BIOPH RES CO, V162, P387, DOI 10.1016/0006-291X(89)92009-3; COLDITZ I, 1989, AM J PATHOL, V134, P755; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; DERANLEAU DA, 1988, EXPERIENTIA, V44, P679, DOI 10.1007/BF01941029; DETMERS PA, 1990, J EXP MED, V171, P1155, DOI 10.1084/jem.171.4.1155; DEWALD B, 1988, J BIOL CHEM, V263, P16179; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; GROB PM, 1990, J BIOL CHEM, V265, P8311; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HASLETT C, 1985, AM J PATHOL, V119, P101; HENSON PM, 1978, J IMMUNOL, V121, P851; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEONARD EJ, 1991, J INVEST DERMATOL, V96, P690, DOI 10.1111/1523-1747.ep12470612; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OKADA T, 1994, J BIOL CHEM, V269, P3563; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PACCAUD JP, 1990, BIOCHEM BIOPH RES CO, V166, P187, DOI 10.1016/0006-291X(90)91929-M; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Ruderman JV, 1993, CURR OPIN CELL BIOL, V5, P207, DOI 10.1016/0955-0674(93)90104-X; SAMANTA AK, 1989, J EXP MED, V169, P1185, DOI 10.1084/jem.169.3.1185; SCHOEDER JM, 1986, J INVEST DERMATOL, V87, P53; SCHRODER JM, 1987, J IMMUNOL, V139, P3474; SHIRATO M, 1988, FEBS LETT, V234, P231, DOI 10.1016/0014-5793(88)81341-3; SITHANANDAM G, 1990, ONCOGENE, V5, P1775; SNYDERMAN R, 1986, J LEUKOCYTE BIOL, V40, P785, DOI 10.1002/jlb.40.6.785; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P421; SPIEGEL A M, 1992, Current Opinion in Cell Biology, V4, P203, DOI 10.1016/0955-0674(92)90034-A; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STEPHENS RM, 1992, MOL CELL BIOL, V12, P3733, DOI 10.1128/MCB.12.9.3733; STERNWEIS PC, 1994, CURR OPIN CELL BIOL, V6, P198, DOI 10.1016/0955-0674(94)90136-8; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; THELEN M, 1994, P NATL ACAD SCI USA, V91, P4960, DOI 10.1073/pnas.91.11.4960; TRUITT KE, 1994, J BIOL CHEM, V269, P5937; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALZ A, 1991, J LEUKOCYTE BIOL, V50, P279, DOI 10.1002/jlb.50.3.279; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Webster R O, 1978, Inflammation, V3, P129, DOI 10.1007/BF00910734; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WINITZ S, 1993, J BIOL CHEM, V268, P19196; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WYMANN MP, 1990, J BIOL CHEM, V265, P619; WYMANN MP, 1987, BIOCHEM BIOPH RES CO, V147, P361, DOI 10.1016/S0006-291X(87)80130-4; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	68	212	220	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2832	2838		10.1074/jbc.271.5.2832	http://dx.doi.org/10.1074/jbc.271.5.2832			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576262	hybrid			2022-12-25	WOS:A1996TT48800076
J	Rech, S; Wolin, C; Gunsalus, RP				Rech, S; Wolin, C; Gunsalus, RP			Properties of the periplasmic ModA molybdate-binding protein of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ACTIVE-TRANSPORT; CHLD LOCUS; GENE; IDENTIFICATION; TYPHIMURIUM; BACTERIA; NITRATE	The modABCD operon, located at 17 min on the Escherichia coli chromosome, encodes the protein components of a high affinity molybdate uptake system. Sequence analysis of the modA gene (GenBank L34009) predicts that it encodes a periplasmic binding protein based on the presence of a leader-like sequence at its N terminus. To examine the properties of the ModA protein, the modA structural gene was overexpressed, and its product was purified. The ModA protein was localized to the periplasmic space of the cell, and it was released following a gentle osmotic shock. The N-terminal sequence of ModA confirmed that a leader region of 24 amino acids was removed upon export from the cell. The apparent size of ModA is 31.6 kDa as determined by gel sieve chromatography, whereas it is 22.5 kDa when examined by SDS-polyacrylamide gel electrophoresis. A ligand-dependent protein mobility shift assay was devised using a native polyacrylamide gel electrophoresis protocol to examine binding of molybdate and other anions to the ModA periplasmic protein. Whereas molybdate and tungstate were bound with high affinity (similar to 5 mu M), sulfate, chromate, selenate, phosphate, and chlorate did not bind even when tested at 2 mM. A UV spectral assay revealed apparent K-d values of binding for molybdate and tungstate of 3 and 7 mu M, respectively, Strains defective in the modA gene were unable to transport molybdate unless high levels of the anion were supplied in the medium. Therefore the modA gene product is essential for high affinity molybdate uptake by the cell. Tungstate interference of molybdate acquisition by the cell is apparently due in part to the high affinity of the ModA protein for this anion.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021678] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21678] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS MD, 1989, J BIOL CHEM, V264, P15739; AMES GFL, 1994, METHOD ENZYMOL, V235, P234; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COPELAND R, 1995, METHODS PROTEIN ANAL, P160; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; GILSON E, 1982, NUCLEIC ACIDS RES, V10, P7449, DOI 10.1093/nar/10.22.7449; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; IZARD JW, 1994, MOL MICROBIOL, V13, P765, DOI 10.1111/j.1365-2958.1994.tb00469.x; JOHANN S, 1987, J BACTERIOL, V169, P1911, DOI 10.1128/jb.169.5.1911-1916.1987; KALMAN LV, 1988, J BACTERIOL, V170, P623, DOI 10.1128/jb.170.2.623-629.1988; KALMAN LV, 1990, J BACTERIOL, V172, P7049, DOI 10.1128/jb.172.12.7049-7056.1990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JH, 1990, J BACTERIOL, V172, P2079, DOI 10.1128/jb.172.4.2079-2087.1990; LUQUE F, 1993, MOL MICROBIOL, V7, P447, DOI 10.1111/j.1365-2958.1993.tb01136.x; MILLER JB, 1987, J BACTERIOL, V169, P1853, DOI 10.1128/jb.169.5.1853-1860.1987; OLAH GA, 1993, J BIOL CHEM, V268, P16241; OLIVER DB, 1987, ESCHERICHIA COLI SAL, P56; PFLUGRATH JW, 1988, J MOL BIOL, V200, P163, DOI 10.1016/0022-2836(88)90341-5; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; RECH S, 1995, J BACTERIOL, V177, P1023, DOI 10.1128/jb.177.4.1023-1029.1995; ROSENTEL JK, 1995, J BACTERIOL, V177, P4857, DOI 10.1128/jb.177.17.4857-4864.1995; RUDNICK DA, 1990, J BIOL CHEM, V265, P13370; SCOTT D, 1989, J BACTERIOL, V171, P1284, DOI 10.1128/jb.171.3.1284-1287.1989; SHUMAN HA, 1987, ANNU REV GENET, V21, P155, DOI 10.1146/annurev.ge.21.120187.001103; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; WANG G, 1993, J BACTERIOL, V175, P3031, DOI 10.1128/JB.175.10.3031-3042.1993	28	74	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2557	2562		10.1074/jbc.271.5.2557	http://dx.doi.org/10.1074/jbc.271.5.2557			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576221	hybrid			2022-12-25	WOS:A1996TT48800035
J	Bhattacharyya, DK; Lecomte, M; Rieke, CJ; Garavito, RM; Smith, WL				Bhattacharyya, DK; Lecomte, M; Rieke, CJ; Garavito, RM; Smith, WL			Involvement of arginine 120, glutamate 524, and tyrosine 355 in the binding of arachidonate and 2-phenylpropionic acid inhibitors to the cyclooxygenase active site of ovine prostaglandin endoperoxide H synthase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIME-DEPENDENT INHIBITION; ANTI-INFLAMMATORY DRUGS; HEME-BINDING; SHEEP; SYNTHETASE; HYDROPEROXIDASE; ACETYLATION; MICROSOMES; PEROXIDASE; CATALYSIS	Examination of the crystal structure of the ovine prostaglandin endoperoxide synthase-1 (PGHS-1)/S-flurbiprofen complex (Picot, D., Loll, P. J., and Garavito, R. M. (1994) Nature 367, 243-2491) suggests (a) that the carboxyl group of arachidonic acid interacts with the arginino group of Arg(120); (b) that Arg(120) forms an important salt bridge with Glu(524); and (c) that Tyr(355), which is in close proximity to Arg(120), could determine the stereochemical specificity of PGHS-1 toward 2-phenylpropionic acid inhibitors. To test these concepts, we used site-directed mutagenesis to prepare ovine PGHS-1 mutants having modifications of Arg(120) (R120K, R120Q, R120E), Glu(524) (E524D, E524Q, E524K), and Tyr(355) (Y355F) and examined the properties of the mutant enzymes expressed in COS-1 cells. All of the mutants retained at least part of their cyclooxygenase and peroxidase activities except the R120E mutant, which had no detectable activity. The K-m values of the R120K and R120Q mutants with arachidonic acid were 87 and 3300 mu M, respectively, versus 4 mu M for native PGHS-1. The R120Q mutant failed to undergo suicide inactivation during catalysis or time dependent inhibition by flurbiprofen. These results are consistent with Arg(120) binding the carboxylate group of arachidonate and suggest that interaction of the carboxylate group of substrates and inhibitors with Arg(120) is necessary for suicide inactivation and time-dependent inhibition, respectively. The K-m values for the E524D, E524Q, and E524K mutants were not significantly different from values obtained for the native PGHS-1, suggesting that this residue is not importantly involved in catalysis or substrate binding. The effect of modifications of Arg(120) and Tyr(355) on the stereospecificity of inhibitor binding were determined. Ratios of IC50 values for cyclooxygenase inhibition by D- and L-ibuprofen, a competitive cyclooxygenase inhibitor, were 32, 67, and 7.1 for native PGHS-1, R120Q PGHS-1, and Y355F PGHS-1, respectively. The decreased stereochemical specificity observed with the Y355F PGHS-1 mutant suggests that Tyr(355) is a determinant of the stereospecificity of PGHS-1 toward inhibitors of the 2-phenylpropionic acid class.	MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824	Michigan State University					NIDDK NIH HHS [DK22042, DK42509] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK022042, R01DK022042, R01DK042509] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1212; KULMACZ RJ, 1985, J BIOL CHEM, V260, P2572; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LASSMANN G, 1991, J BIOL CHEM, V266, P20045; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; MUTSAERS JHGM, 1985, EUR J BIOCHEM, V147, P569; OHKI S, 1979, J BIOL CHEM, V254, P829; OTTO JC, 1993, J BIOL CHEM, V268, P18234; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PAGELS WR, 1983, J BIOL CHEM, V258, P6517; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REGIER MK, 1995, ARCH BIOCHEM BIOPHYS, V317, P457, DOI 10.1006/abbi.1995.1188; ROME LH, 1975, P NATL ACAD SCI USA, V72, P4863, DOI 10.1073/pnas.72.12.4863; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN TY, 1974, PROSTAGLANDIN SYNTHE, P19; SHIMOKAWA T, 1991, J BIOL CHEM, V266, P6168; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SHIMOKAWA T, 1992, J BIOL CHEM, V267, P12387; SMITH WL, 1990, ADV PROSTAG THROMB L, V20, P14; SMITH WL, 1994, MET IONS BIOL SYST, V30, P163; SMITH WL, 1995, SEMIN NEPHROL, V15, P179; VANDEROUDERAA FJ, 1980, EUR J BIOCHEM, V109, P1; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WALENGA RW, 1986, PROSTAGLANDINS, V31, P625, DOI 10.1016/0090-6980(86)90170-X; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0	33	161	165	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2179	2184		10.1074/jbc.271.4.2179	http://dx.doi.org/10.1074/jbc.271.4.2179			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567676				2022-12-25	WOS:A1996TR32000058
J	Mathai, JC; Mori, S; Smith, BL; Preston, GM; Mohandas, N; Collins, M; vanZijl, PCM; Zeidel, ML; Agre, P				Mathai, JC; Mori, S; Smith, BL; Preston, GM; Mohandas, N; Collins, M; vanZijl, PCM; Zeidel, ML; Agre, P			Functional analysis of aquaporin-1 deficient red cells - The Colton-null phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; HUMAN-ERYTHROCYTES; WATER CHANNELS; PERMEABILITY; FAMILY	The aquaporin-1 (AQP1) water transport protein contains a polymorphism corresponding to the Colton red blood cell antigens. To define the fraction of membrane water permeability mediated by AQP1, red cells were obtained from human kindreds with the rare Colton-null phenotype. Homozygosity or heterozygosity for deletion of exon I in AQP1 correlated with total or partial deficiency of AQP1 protein. Homozygote red cell morphology appeared normal, but clinical laboratory studies revealed slightly reduced red cell life span in vivo; deformability studies revealed a slight reduction in membrane surface area. Diffusional water permeability (P-d) was measured under isotonic conditions by pulsed field gradient NMR. Osmotic water permeability (P-f) was measured by change in light scattering after rapid exposure of red cells to increased extracellular osmolality. AQP1 contributes similar to 64% (P-d = 1.5 x 10(-3) cm/s) of the total diffusional water permeability pathway, and lipid permeation apparently comprises similar to 23%. In contrast, AQP1 contributes >85% (P-f = 19 x 10(-3) cm/s) of the total osmotic water permeability pathway, and lipid permeation apparently comprises only similar to 10%. The ratio of AQP1-mediated P-f to P-d predicts the length of the aqueous pore to be 36 Angstrom.	JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT RADIOL, BALTIMORE, MD 21205 USA; UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV LIFE SCI, BERKELEY, CA 94720 USA; UNIV N CAROLINA, DEPT PATHOL, CHAPEL HILL, NC 27599 USA; UNIV PITTSBURGH, SCH MED, RENAL ELECTROLYTE DIV, PITTSBURGH, PA 15261 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of North Carolina; University of North Carolina Chapel Hill; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Van Zijl, Peter C/ABF-3732-2020; van Zijl, Peter C/B-8680-2008		NHLBI NIH HHS [HL33991, HL48268] Funding Source: Medline; NIDDK NIH HHS [DK26263] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL048268, R01HL033991, R01HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK026263, R01DK026263] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRASKO J, 1976, BIOCHIM BIOPHYS ACTA, V428, P304, DOI 10.1016/0304-4165(76)90038-6; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BRAHM J, 1982, J GEN PHYSIOL, V79, P791, DOI 10.1085/jgp.79.5.791; CHRISPEELS MJ, 1994, TRENDS BIOCHEM SCI, V19, P421, DOI 10.1016/0968-0004(94)90091-4; CLARK MR, 1983, BLOOD, V61, P899, DOI 10.1182/blood.V61.5.899.899; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DENKER BM, 1988, J BIOL CHEM, V263, P15634; Finkelstein A., 1987, WATER MOVEMENT LIPID; FISCHBARG J, 1990, P NATL ACAD SCI USA, V87, P3244, DOI 10.1073/pnas.87.8.3244; JAP BK, 1995, J MOL BIOL, V251, P413, DOI 10.1006/jmbi.1995.0444; JUNG JS, 1994, J BIOL CHEM, V269, P14648; Karger J., 1988, ADV MAGNETIC OPTICAL, P1; KNEPPER MA, 1994, P NATL ACAD SCI USA, V91, P6255, DOI 10.1073/pnas.91.14.6255; LACEY PA, 1987, TRANSFUSION, V27, P268, DOI 10.1046/j.1537-2995.1987.27387235637.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITT DG, 1974, BIOCHIM BIOPHYS ACTA, V373, P115, DOI 10.1016/0005-2736(74)90111-4; MACEY RI, 1970, BIOCHIM BIOPHYS ACTA, V211, P104, DOI 10.1016/0005-2736(70)90130-6; MITRA AK, 1995, NAT STRUCT BIOL, V2, P726, DOI 10.1038/nsb0995-726; MITRA AK, 1994, BIOCHEMISTRY-US, V33, P12735, DOI 10.1021/bi00209a001; MOON C, 1993, J BIOL CHEM, V268, P15772; MOURA TF, 1984, J MEMBRANE BIOL, V81, P105, DOI 10.1007/BF01868975; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; OLIVES B, 1995, J BIOL CHEM, V270, P15607, DOI 10.1074/jbc.270.26.15607; Press W. H., 1992, ART SCI COMPUTING; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; PRICE HD, 1969, J MOL BIOL, V41, P443, DOI 10.1016/0022-2836(69)90287-3; REDWOOD WR, 1969, J THEOR BIOL, V22, P1, DOI 10.1016/0022-5193(69)90075-7; SHI LB, 1994, J BIOL CHEM, V269, P10417; SMITH BL, 1994, J CLIN INVEST, V94, P1043, DOI 10.1172/JCI117418; SMITH BL, 1991, J BIOL CHEM, V266, P6407; STILLINGER FH, 1980, SCIENCE, V209, P451, DOI 10.1126/science.209.4455.451; WALZ T, 1994, J BIOL CHEM, V269, P1583; WALZ T, 1994, EMBO J, V13, P2985, DOI 10.1002/j.1460-2075.1994.tb06597.x; WALZ T, 1995, NAT STRUCT BIOL, V2, P730, DOI 10.1038/nsb0995-730; WANG JH, 1965, J PHYS CHEM-US, V69, P4412, DOI 10.1021/j100782a510; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P589, DOI 10.1021/bi00117a041; ZEIDEL ML, 1994, BIOCHEMISTRY-US, V33, P1606, DOI 10.1021/bi00172a042; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	42	102	107	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1309	1313		10.1074/jbc.271.3.1309	http://dx.doi.org/10.1074/jbc.271.3.1309			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576117	hybrid			2022-12-25	WOS:A1996TQ52500013
J	Ng, DHW; Watts, JD; Aebersold, R; Johnson, P				Ng, DHW; Watts, JD; Aebersold, R; Johnson, P			Demonstration of a direct interaction between p56(lck) and the cytoplasmic domain of CD45 in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CELL ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; PHOSPHOTYROSINE PHOSPHATASE; FUNCTIONAL COMPLEX; KINASE P56LCK; SH2 DOMAIN; ACTIVATION; EXPRESSION; LCK	p56(lck) is a potential in vivo substrate for the tyrosine-specific phosphatase, CD45. In this study, recombinant purified p56(lck) was found to specifically associate with recombinant CD45 cytoplasmic domain protein, but not to the cytoplasmic domain of another related tyrosine phosphatase, receptor protein-tyrosine phosphatase of. Under equilibrium binding conditions, the binding was saturable and occurred at a 1:1 molar stoichiometry. A fusion protein containing only the amino-terminal region of p56(lck) (residues 34-150) also bound to recombinant CD45, and further analysis of this region indicated that glutathione S-transferase fusion proteins of the unique amino-terminal region and the SH2 domain, but not the SH3 domain of p56(lck), bound to recombinant CD45. The SH2 domain protein bound with a higher affinity than the amino terminal region, but both were able to compete for the binding of p56(lck) to CD45, and when added together worked synergistically to compete for p56(lck) binding. The SH2 domain interaction with CD45 was specific as glutathione S-transferase-SH2 fusion proteins from p85 alpha subunit of phosphatidylinositol 3-kinase and SHC did not bind to CD45. In addition, this interaction occurred in the absence of any detectable tyrosine phosphorylation on CD45, suggesting a nonconventional SH2 domain interaction. p56(lck) is a potential in vivo substrate for the tyrosine-specific phosphatase, CD45. In this study, recombinant purified p56(lck) was found to specifically associate with recombinant CD45 cytoplasmic domain protein, but not to the cytoplasmic domain of another related tyrosine phosphatase, receptor protein-tyrosine phosphatase alpha. Under equilibrium binding conditions, the binding was saturable and occurred at a 1:1 molar stoichiometry. A fusion protein containing only the amino-terminal region of p56(lck) (residues 34-150) also bound to recombinant CD45, and further analysis of this region indicated that glutathione S-transferase fusion proteins of the unique amino-terminal region and the SH2 domain, but not the SH3 domain of p56(lck), bound to recombinant CD45. The SH2 domain protein bound with a higher affinity than the amino terminal region, but both were able to compete for the binding of p56(lck) to CD45, and when added together worked synergistically to compete for p56(lck) binding. The SH2 domain interaction with CD45 was specific as glutathione S-transferase-SH2 fusion proteins from p85 alpha subunit of phosphatidylinositol 3-kinase and SHC did not bind to CD45. In addition, this interaction occurred in the absence of any detectable tyrosine phosphorylation on CD45, suggesting a nonconventional SH2 domain interaction,	UNIV BRITISH COLUMBIA,DEPT MICROBIOL & IMMUNOL,VANCOUVER,BC V6T 1Z3,CANADA; UNIV WASHINGTON,DEPT MOLEC BIOTECHNOL,SEATTLE,WA 98195	University of British Columbia; University of Washington; University of Washington Seattle			Johnson, Pauline/G-9659-2019	Johnson, Pauline/0000-0001-7367-4653				AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BURNS CM, 1994, J BIOL CHEM, V269, P13594; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; CLARK MR, 1994, EMBO J, V13, P1911, DOI 10.1002/j.1460-2075.1994.tb06460.x; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; DAMUDE HG, 1995, BIOCHEMISTRY-US, V34, P2220, DOI 10.1021/bi00007a016; DIANZANI U, 1990, EUR J IMMUNOL, V20, P2249, DOI 10.1002/eji.1830201014; GERVAIS FG, 1995, MOL CELL BIOL, V15, P2393; GUTTINGER M, 1992, INT IMMUNOL, V4, P1325, DOI 10.1093/intimm/4.11.1325; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JIRIK FR, 1990, FEBS LETT, V273, P239, DOI 10.1016/0014-5793(90)81094-5; KITAMURA K, 1995, J BIOL CHEM, V270, P21151, DOI 10.1074/jbc.270.36.21151; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MITTLER RS, 1991, J IMMUNOL, V147, P3434; MUSTELIN T, 1992, EUR J IMMUNOL, V22, P1173, DOI 10.1002/eji.1830220510; MUSTELIN T, 1990, ONCOGENE, V5, P809; NG DHW, 1995, BIOCHEM BIOPH RES CO, V206, P302, DOI 10.1006/bbrc.1995.1042; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PERI KG, 1993, ONCOGENE, V8, P2765; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; ROSS SE, 1994, BIOCHEM BIOPH RES CO, V198, P88, DOI 10.1006/bbrc.1994.1013; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SHEN FW, 1981, MONOCLONAL ANTIBODIE, P25; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKEDA A, 1994, J BIOL CHEM, V269, P2357; THOMAS ML, 1987, P NATL ACAD SCI USA, V84, P5360, DOI 10.1073/pnas.84.15.5360; TONKS NK, 1990, J BIOL CHEM, V265, P10674; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WATTS JD, 1992, J BIOL CHEM, V267, P901; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	43	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1295	1300		10.1074/jbc.271.3.1295	http://dx.doi.org/10.1074/jbc.271.3.1295			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576115	hybrid			2022-12-25	WOS:A1996TQ52500011
J	Mai, S; HanleyHyde, J; Fluri, M				Mai, S; HanleyHyde, J; Fluri, M			c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines	ONCOGENE			English	Article						c-Myc deregulation; DHFR; genomic instability	DIHYDROFOLATE-REDUCTASE GENE; WILD-TYPE P53; DNA AMPLIFICATION; METHOTREXATE RESISTANCE; SV40 REPLICATION; CANCER; CYCLE; TRANSCRIPTION; EXPRESSION; ONCOGENES	We have analysed relative DHFR gene copy numbers in nine cell fines of various cell type and species origins. The cells studied expressed either low, low and inducible or constitutively elevated levels of c-Myc protein. DHFR gene amplification was observed only when c-Myc protein levels were upregulated. The amplification of the DHFR gene was transient in inducible cell Lines. Cell lines exhibiting constitutively deregulated c-Myc protein levels, however, showed both DHFR gene amplification and ongoing rearrangements of the DHFR locus. In contrast, the relative gene copy numbers of ribonucleotide reductase R1 subunit, ornithine decarboxylase, syndecan 2, glyceraldehyde-3-phosphate-dehydrogenase and cyclin C remained unaffected irrespective of c-Myc protein levels, suggesting a locus-specific genomic instability of the DHFR gene in cells with deregulated c-Myc protein levels. Overall, the results of the present study support the notion that DHFR gene amplification as a consequence of c-Myc deregulation may occur in a variety of cell lines irrespective of their cell type and species origins.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92837 USA	Scripps Research Institute	Mai, S (corresponding author), BASEL INST IMMUNOL, GRENZACHERSTR 487, CH-4005 BASEL, SWITZERLAND.		Mai, Sabine/E-5667-2017	Mai, Sabine/0000-0002-5797-2201				AHNEN DJ, 1992, CELL BIOCH S G, V16, P143; ALITALO K, 1985, TRENDS BIOCHEM SCI, V10, P194, DOI 10.1016/0968-0004(85)90190-2; ALMOUZNI G, 1993, GENE DEV, V7, P2033, DOI 10.1101/gad.7.10.2033; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENEVISTY N, 1992, GENE DEV, V6, P2513; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOURHIS J, 1991, CANCER RES, V51, P33; CHANG ACY, 1978, NATURE, V275, P617, DOI 10.1038/275617a0; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CLASSON M, 1993, GENE, V133, P153, DOI 10.1016/0378-1119(93)90633-E; CLASSON M, 1990, ONCOGENE, V5, P1371; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DELIDAKIS C, 1989, EMBO J, V8, P891, DOI 10.1002/j.1460-2075.1989.tb03450.x; DENIS N, 1991, ONCOGENE, V6, P1453; DIJKWEL PA, 1994, NUCLEIC ACIDS RES, V22, P4989, DOI 10.1093/nar/22.23.4989; ECKHARDT SG, 1994, P NATL ACAD SCI USA, V91, P6674, DOI 10.1073/pnas.91.14.6674; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FEO S, 1994, ONCOGENE, V9, P955; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; HANSON KD, 1994, MOL CELL BIOL, V14, P5748, DOI 10.1128/MCB.14.9.5748; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HUANG AP, 1994, EXP CELL RES, V213, P335, DOI 10.1006/excr.1994.1207; HUANG AP, 1995, CANCER RES, V55, P1758; HUANG AP, 1994, ONCOGENE, V9, P491; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KAHANA C, 1985, P NATL ACAD SCI USA, V82, P1673, DOI 10.1073/pnas.82.6.1673; KARN J, 1989, ONCOGENE, V4, P773; LAVI S, 1981, P NATL ACAD SCI-BIOL, V78, P6144, DOI 10.1073/pnas.78.10.6144; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Luecke-Huhle Christine, 1994, Carcinogenesis (Oxford), V15, P695; LUECKEHUHLE C, 1990, INT J RADIAT BIOL, V58, P577; LUECKEHUHLE C, 1989, MOL TOXICOL, V2, P237; MA C, 1990, MOL CELL BIOL, V10, P1338, DOI 10.1128/MCB.10.4.1338; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MAI S, 1990, UCLA SYM BI, V136, P319; MAI S, 1995, GENOME, V38, P780, DOI 10.1139/g95-099; MAI S, 1994, GENE, V148, P253, DOI 10.1016/0378-1119(94)90696-3; MAI S, 1994, NUCLEIC ACIDS RES, V22, P2264, DOI 10.1093/nar/22.12.2264; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARIANI BD, 1984, J BIOL CHEM, V259, P1901; MARYNEN P, 1989, J BIOL CHEM, V264, P7017; OTTO E, 1989, J BIOL CHEM, V264, P3390; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PIERCE A, 1992, J BIOL CHEM, V267, P3894; POTTER M, 1992, CARCINOGENESIS, V13, P1681, DOI 10.1093/carcin/13.10.1681; PRODY CA, 1989, P NATL ACAD SCI USA, V86, P690, DOI 10.1073/pnas.86.2.690; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sambrook J, 1989, MOL CLONING LABORATO; SANTELLI RV, 1991, MECH DEVELOP, V36, P59, DOI 10.1016/0925-4773(91)90072-E; SCHIMKE RT, 1978, SCIENCE, V202, P1051, DOI 10.1126/science.715457; SHAH DM, 1986, SCIENCE, V233, P478, DOI 10.1126/science.233.4762.478; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; STARK GR, 1984, ANNU REV BIOCHEM, V53, P447, DOI 10.1146/annurev.bi.53.070184.002311; TEMIN HM, 1988, CANCER RES, V48, P1697; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; TLSTY TD, 1990, P NATL ACAD SCI USA, V87, P3132, DOI 10.1073/pnas.87.8.3132; TLSTY TD, 1989, P NATL ACAD SCI USA, V86, P9441, DOI 10.1073/pnas.86.23.9441; TLSTY TD, 1984, MOL CELL BIOL, V4, P1050, DOI 10.1128/MCB.4.6.1050; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L; WAHL GM, 1989, CANCER RES, V49, P1333; WEINBERG RA, 1989, CANCER RES, V49, P3713; WOLFFE AP, 1991, J CELL SCI, V99, P210; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YALKINOGLU AO, 1991, J VIROL, V65, P3175, DOI 10.1128/JVI.65.6.3175-3184.1991; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	75	82	85	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					277	288						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570205				2022-12-25	WOS:A1996TR53800007
J	Waber, PG; Lee, NK; Nisen, PD				Waber, PG; Lee, NK; Nisen, PD			Frequent allelic loss at chromosome arm 3p is distinct from genetic alterations of the Von-Hippel Lindau tumor suppressor gene in head and neck cancer	ONCOGENE			English	Article						Von-Hippel Lindau Syndrome; chromosome 3; loss of heterozygosity; head and neck cancer	SQUAMOUS-CELL CARCINOMAS; UPPER AERODIGESTIVE TRACT; P53 MUTATIONS; DISEASE GENE; IDENTIFICATION; POLYMORPHISMS; LINES	Previous molecular genetic studies revealed that allelic loss of chromosome arm 3p is a frequent event in upper aerodigestive tract squamous cell carcinoma (UADT SCC), Recently, the Von-Hippel Lindau (VHL) tumor suppressor gene was identified at chromosome band 3p25-26. To determine if the VHL locus is altered in these tumors, a paired series of 26 tumors and blood from patients with UADT SCC that were previously shown to exhibit allelic loss of 3p were tested for LOH surrounding the VHL locus using four different polymorphic markers, All of the samples (100%) exhibited LOH for at least 1 marker, However, no LOH was detected using a polymorphism within exon 1 of the VHL gene which was informative for 18 of the 26 cases, Furthermore, mutations of the VHL gene could not be identified by single-strand conformation polymorphism, dideoxyfingerprint or direct DNA sequence analysis, In addition, the VHL gene was not inactivated by hypermethylation in any of the 26 tumor samples studied, These findings demonstrate that allelic loss of chromosome arm 3p in UADT SCC involves regions surrounding the VHL locus but does not include the VHL gene, The VHL gene, therefore, does not appear to be involved in the pathogenesis of UADT SCC.	UNIV TEXAS, SW MED CTR, DEPT PEDIAT, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT OTOLARYNGOL HEAD & NECK SURG, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BARDENHEUER W, 1994, GENOMICS, V19, P291, DOI 10.1006/geno.1994.1060; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; CHUNG KY, 1993, CANCER RES, V53, P1676; CROSSEY PA, 1994, HUM GENET, V93, P53; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; Jones Michael H., 1992, Human Molecular Genetics, V1, P131, DOI 10.1093/hmg/1.2.131; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEE NK, 1994, INT J ONCOL, V5, P205; LEE NK, 1994, ONCOL REP, V1, P637; LEE NK, 1993, ARCH OTOLARYNGOL, V119, P1125; LI H, 1993, HUM MOL GENET, V2, P1326, DOI 10.1093/hmg/2.8.1326; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; MAESTRO R, 1993, CANCER RES, V53, P5775; NAWROZ H, 1994, CANCER RES, V54, P1152; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RICHARDS FM, 1993, HUM MOL GENET, V2, P879, DOI 10.1093/hmg/2.7.879; Sambrook J, 1989, MOL CLONING LABORATO; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; SEKIDO Y, 1994, ONCOGENE, V9, P1599; SHUIN T, 1994, CANCER RES, V54, P2852; SOMERS KD, 1992, CANCER RES, V52, P5997; VANDERRIET P, 1994, CANCER RES, V54, P1156; WABER PG, 1993, CANCER RES, V53, P6028; WEBER JL, 1989, AM J HUM GENET, V44, P388; WU CL, 1994, CANCER RES, V54, P6484; YIN XY, 1993, INT J CANCER, V54, P322, DOI 10.1002/ijc.2910540226	32	36	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					365	369						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570213				2022-12-25	WOS:A1996TR53800015
J	Dong, WJ; Rosenfeld, SS; Wang, CK; Gordon, AM; Cheung, HC				Dong, WJ; Rosenfeld, SS; Wang, CK; Gordon, AM; Cheung, HC			Kinetic studies of calcium binding to the regulatory site of troponin C from cardiac muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOFIBRILLAR ADENOSINE-TRIPHOSPHATASE; SKELETAL-MUSCLE; MAGNESIUM BINDING; CA2+ BINDING; CONTRACTION; RESOLUTION; COMPLEXES; FRAGMENTS; PROTEIN; BINARY	We have studied the kinetics of the structural transitions induced by calcium binding to the single, regulatory site of cardiac troponin C by measuring the rates of calcium-mediated fluorescence changes with a monocysteine mutant of the protein (C35S) specifically labeled at Cys-84 with the fluorescent probe 2-[4'-(iodoacetamido)anilino]naphthalene-6-sulfonic acid. At 4 degrees C, the binding kinetics determined in the presence of Mg2+ was resolved into two phases with positive amplitude, which were completed in less than 100 ms, The rate of the fast phase increased linearly with [Ca2+] reaching a maximum of similar to 590 s(-1), and that of the slow phase was approximately 100 s(-1) and did not depend on Ca2+ concentration, Dissociation of bound Ca2+ from the regulatory site occurred with a rate of 102 s(-1), whereas the dissociation from the two high affinity sites was about two orders of magnitude slower, These results are consistent with the following scheme for the binding of Ca2+ to the regulatory site: [GRAPHICS] where the asterisks denote states with enhanced fluorescence, The apparent second-order rate constant for calcium binding is K(o)k(1) = 1.4 x 10(8) M(-1) s(-1). The two first-order transitions occur with observed rates of k(1) + k(-1) approximate to 590 s(-1) and k(2) + k(-2) approximate to 100 s(-1), and the binding of Ca2+ to the regulatory site is not a simple diffusion-controlled reaction. These transitions provide the first information on the rates of Ca2+-induced conformational changes involving helix movements in the regulatory domain.	UNIV ALABAMA,DEPT BIOCHEM & MOLEC GENET,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT NEUROL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham			Dong, Wenji/A-8579-2011		NIAMS NIH HHS [AR31239] Funding Source: Medline; NINDS NIH HHS [NS08383] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR031239] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENSON SW, 1960, F CHEM KINETICS, P33; Benvington P. R., 1969, DATA REDUCTION ERROR; Bernasconi C. F., 1976, RELAXATION KINETICS; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEUNG HC, 1987, BIOCHEMISTRY-US, V26, P5904, DOI 10.1021/bi00392a049; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLOSE R, 1965, J PHYSIOL-LONDON, V180, P542, DOI 10.1113/jphysiol.1965.sp007716; DONG WJ, 1995, BIOPHYS J, V68, P57; FABIATO A, 1988, METHOD ENZYMOL, V313, P653; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOLROYDE MJ, 1980, J BIOL CHEM, V255, P1688; IIO T, 1980, J BIOCHEM-TOKYO, V88, P1087, DOI 10.1093/oxfordjournals.jbchem.a133060; IIO T, 1982, J BIOCHEM-TOKYO, V92, P1141, DOI 10.1093/oxfordjournals.jbchem.a134030; ITO T, 1980, J BIOCHEM-TOKYO, V88, P547; JOHNSON JD, 1980, J BIOL CHEM, V255, P9635; JOHNSON JD, 1994, J BIOL CHEM, V269, P8919; KERRICK WGL, 1992, BIOPHYS J, V61, P156; LEAVIS PC, 1978, ARCH BIOCHEM BIOPHYS, V186, P411, DOI 10.1016/0003-9861(78)90453-8; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; MARTYN DA, 1988, J MUSCLE RES CELL M, V9, P428, DOI 10.1007/BF01774069; MEJBAUMKATZENELLENBOGEN W, 1959, CLIN CHIM ACTA, V4, P515, DOI 10.1016/0009-8981(59)90158-5; OVSAK M, 1991, PROTEINS, V11, P79; PARMACEK MS, 1989, J BIOL CHEM, V264, P13217; POTTER JD, 1975, J BIOL CHEM, V250, P4628; ROBERTSON SP, 1982, J BIOL CHEM, V257, P260; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; ROSENFELD SS, 1985, J BIOL CHEM, V260, P252; ROSENFELD SS, 1985, J BIOL CHEM, V260, P242; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; STRYNADK NCJ, 1989, ANNU REV BIOCHEM, V58, P591; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028; VANEERD JP, 1976, BIOCHEMISTRY-US, V15, P1171, DOI 10.1021/bi00650a033; WANG CK, 1985, BIOPHYS J, V48, P727, DOI 10.1016/S0006-3495(85)83831-5; WANG CK, 1986, J MOL BIOL, V191, P509, DOI 10.1016/0022-2836(86)90145-2; ZHANG MZ, 1992, BIOPHYS J, V61, P156; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	40	51	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					688	694		10.1074/jbc.271.2.688	http://dx.doi.org/10.1074/jbc.271.2.688			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557674	hybrid			2022-12-25	WOS:A1996TP88900017
J	Szczesna, D; Zhao, JJ; Potter, JD				Szczesna, D; Zhao, JJ; Potter, JD			The regulatory light chains of myosin modulate gross-bridge cycling in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPHOSPHORYLATED HEAVY-MEROMYOSIN; TROPONIN-C; PARTIAL EXTRACTION; PSOAS FIBERS; CAGED CA-2+; F-ACTIN; PHOSPHORYLATION; PROTEINS; CONTRACTION; PARVALBUMIN	We investigated the kinetics of Ca2+ activation of skeletal muscle contraction elicited by the photolysis of caged Ca2+, Previously we showed that partial extraction of the 18-kDa regulatory light chains (RLCs) of myosin decreased the rate of force development and was subsequently increased by similar to 20% following reconstitution with RLCs (Potter, J. D., Zhao, J. and Pan, B. S. (1992) FASEB J. 6, A1240), We extend here the RLC-extraction study to the complete removal of the RLCs, The complete removal of RLCs was achieved by a combination of 5,5'-dithiobis-(2-nitrobenzoic acid) and EDTA treatment followed by reduction of oxidized sulfydryl groups by dithiothreitol. Under these conditions the complete extraction of RLCs was accompanied by the extraction of endogenous troponin C, resulting in the loss of isometric tension, Steady state force was restored to 65-75% following troponin C reconstitution and increased to 75-85% as a result of RLC reincorporation into the fibers. The rates of force transients generated by UV-flash photolysis of 1-(2-nitro-4,5-dimethoxyphenyl)-N,N,N',N'-tetrakis[(oxycarbonyl)methyl]-1,2-ethanediamine) or nitrophenyl-EGTA, photoliberating bound Ca2+, decreased 2-fold after RLC extraction and troponin C reconstitution and then increased to the values of intact fibers after RLC reconstitution, These results support our earlier findings that the regulatory light chains of myosin play an important role in the kinetics of cross-bridge cycling.	UNIV MIAMI, SCH MED, DEPT MOLEC & CELLULAR PHARMACOL, MIAMI, FL 33101 USA	University of Miami					NIAMS NIH HHS [AR37701] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR037701] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BAGSHAW CR, 1977, FEBS LETT, V81, P386, DOI 10.1016/0014-5793(77)80560-7; CHEUNG WY, 1980, SCIENCE, V207, P19, DOI 10.1126/science.6243188; COLLINS JH, 1976, NATURE, V259, P699, DOI 10.1038/259699a0; DASILVA ACR, 1992, EUR J BIOCHEM, V204, P85; DIFFEE GM, 1995, BIOPHYS J, V68, P1443, DOI 10.1016/S0006-3495(95)80317-6; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; GOLDMAN YE, 1988, BIOPHYS J, V53, pA25; GUTH K, 1987, J BIOL CHEM, V262, P13627; HARTSHORNE DJ, 1982, BLOOD VESSELS, V19, P1; HOFMANN PA, 1990, J GEN PHYSIOL, V95, P477, DOI 10.1085/jgp.95.3.477; HOLROYDE MJ, 1979, J BIOL CHEM, V254, P6478; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; KAKOL I, 1987, BIOCHIM BIOPHYS ACTA, V913, P1, DOI 10.1016/0167-4838(87)90225-1; KENDRICK-JONES J, 1970, Journal of Molecular Biology, V54, P313, DOI 10.1016/0022-2836(70)90432-8; KENDRICKJONES J, 1981, J MUSCLE RES CELL M, V2, P347, DOI 10.1007/BF00711965; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MANNING DR, 1982, AM J PHYSIOL, V242, pC234, DOI 10.1152/ajpcell.1982.242.3.C234; METZGER JM, 1992, BIOPHYS J, V63, P460, DOI 10.1016/S0006-3495(92)81614-4; METZGER JM, 1989, J GEN PHYSIOL, V93, P855, DOI 10.1085/jgp.93.5.855; MOORE RL, 1984, AM J PHYSIOL, V247, pC462, DOI 10.1152/ajpcell.1984.247.5.C462; MOSS RL, 1992, CIRC RES, V70, P865, DOI 10.1161/01.RES.70.5.865; MOSS RL, 1982, J BIOL CHEM, V257, P8588; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; POTTER JD, 1992, FASEB J, V6, pA1240; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; SOBIESZEK A, 1977, J MOL BIOL, V112, P559, DOI 10.1016/S0022-2836(77)80164-2; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; STEPKOWSKI D, 1985, BIOCHIM BIOPHYS ACTA, V831, P321, DOI 10.1016/0167-4838(85)90114-1; SWEENEY HL, 1986, AM J PHYSIOL, V250, pC657, DOI 10.1152/ajpcell.1986.250.4.C657; SZCZESNA D, 1987, FEBS LETT, V210, P177, DOI 10.1016/0014-5793(87)81332-7; SZENTGYO.AG, 1973, J MOL BIOL, V74, P179, DOI 10.1016/0022-2836(73)90106-X; VANBUREN P, 1994, P NATL ACAD SCI USA, V91, P12403, DOI 10.1073/pnas.91.26.12403; WAGNER PD, 1982, METHOD ENZYMOL, V85, P72; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	41	30	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5246	5250						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617809				2022-12-25	WOS:A1996TX69700099
J	Cui, Z; Vance, DE				Cui, Z; Vance, DE			Expression of phosphatidylethanolamine N-methyltransferase-2 is markedly enhanced in long term choline-deficient rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; PROTEIN-KINASE-C; N-METHYLTRANSFERASE; MEMBRANE-FRACTION; LIVER; HEPATOCYTES; BIOSYNTHESIS; MECHANISM; CYTOSOL; BRAIN	When rats are fed a choline-deficient (CD) diet, acute fatty liver develops along with other biochemical changes. However, when choline deficiency is prolonged, the growth rate of CD rats is similar to that of control rats fed a choline-supplemented diet. Furthermore, CD rats maintain their levels of choline-containing lipids, such as phosphatidylcholine, lysophosphatidylcholine, and sphingomyelin. The mechanism for this compensation in CD rats was investigated, We screened the major tissues for the activities of two important enzymes involved in the biosynthesis of phosphatidylcholine, CTP:phosphocholine cytidylyltransferase (CT) and phosphatidylethanolamine N-methyltransferase (PEMT). Only the livers of CD rats had higher specific enzyme activities of PEMT and CT than control animals. The amount of PEMT2, one of two PEMTs in liver, increased 5-fold in CD rats after 6 weeks on the CD diet, A similar increase in the level of PEMT2 mRNA suggested that this activation was due to enhanced expression of the PEMT2 gene in CD livers. The labeling of phosphatidycholine in isolated hepatocytes from CD rats was consistent with the conversion of PE to PC being increased as a result of a higher expression of liver PEMT. We conclude that activation of PE methylation at the level of gene expression may be the mechanism by which CD rats compensate for the lack of dietary choline.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,DEPT BIOCHEM,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta								ANDRIAMAMPANDRY C, 1992, BIOCHEM J, V288, P267, DOI 10.1042/bj2880267; ANDRIAMAMPANDRY C, 1989, BIOCHEM J, V264, P555, DOI 10.1042/bj2640555; BLUSZTAJN JK, 1989, FEBS LETT, V243, P267, DOI 10.1016/0014-5793(89)80142-5; CHANDAR N, 1988, CARCINOGENESIS, V9, P259, DOI 10.1093/carcin/9.2.259; CUI Z, 1994, J BIOL CHEM, V269, P24531; CUI Z, 1993, J BIOL CHEM, V268, P16655; DACOSTA KA, 1993, J BIOL CHEM, V268, P2100; DAVIS RA, 1979, J BIOL CHEM, V254, P2010; EAGLE H, 1955, J EXP MED, V102, P595, DOI 10.1084/jem.102.5.595; ESKO JD, 1981, J BIOL CHEM, V256, P7388; FOLCH J, 1957, J BIOL CHEM, V226, P497; HOUWELING M, 1995, J BIOL CHEM, V270, P16277, DOI 10.1074/jbc.270.27.16277; HOUWELING M, 1993, EUR J BIOCHEM, V214, P927, DOI 10.1111/j.1432-1033.1993.tb17996.x; KUKSIS A, 1981, J CHROMATOGR, V224, P1, DOI 10.1016/S0378-4347(00)80133-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOMBARDI B, 1971, FED PROC, V30, P139; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RIDGWAY ND, 1989, J BIOL CHEM, V264, P1203; RIDGWAY ND, 1992, METHOD ENZYMOL, V209, P366; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SUNDLER R, 1975, J BIOL CHEM, V250, P3359; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANCE DE, 1988, PROG LIPID RES, V27, P61, DOI 10.1016/0163-7827(88)90005-7; VANCE DE, 1990, BIOCHEM CELL BIOL, V68, P1151, DOI 10.1139/o90-172; VANCE DE, 1979, TRENDS BIOCHEM SCI, V4, P145, DOI 10.1016/0968-0004(79)90001-X; VANCE JE, 1990, J BIOL CHEM, V265, P7248; WEINHOLD PA, 1986, J BIOL CHEM, V261, P5104; YAO ZM, 1990, J BIOL CHEM, V265, P4326; ZEISEL SH, 1994, ANNU REV NUTR, V14, P269, DOI 10.1146/annurev.nu.14.070194.001413; ZEISEL SH, 1981, ANNU REV NUTR, V1, P95, DOI 10.1146/annurev.nu.01.070181.000523	31	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2839	2843		10.1074/jbc.271.5.2839	http://dx.doi.org/10.1074/jbc.271.5.2839			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576263	hybrid			2022-12-25	WOS:A1996TT48800077
J	Hirabayashi, J; Ubukata, T; Kasai, K				Hirabayashi, J; Ubukata, T; Kasai, K			Purification and molecular characterization of a novel 16-kDa galectin from the nematode Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; AMINO-ACID-SEQUENCE; CHICK EMBRYONIC SKIN; CARBOHYDRATE RECOGNITION; ANIMAL LECTINS; HUMAN-PLACENTA; PROTEIN; GENE; LUNG; LACTOSE	In our previous study (Hirabayashi, J., Satoh, M., Ohyama, Y., and Kasai, K. (1992) J. Biochem. (Tokyo) 111, 553-555), two beta-galactoside-binding lectins (apparent subunit molecular masses, 16 and 32 kDa, respectively) were identified in the nematode Caenorhabditis elegans. The subsequent study revealed that the 32-kDa lectin is a member of the galectin family. Since the 32-kDa galectin was found to consist of two homologous domains (similar to 16 kDa), 16-kDa lectin was thought to be a degradation product of the 32-kDa galectin. To clarify this, the 16-kDa lectin was purified by an improved procedure employing extraction with a calcium-supplemented buffer. The purified 16-kDa lectin was found to exist as a dimer (similar to 30 kDa) and showed hemagglutinating activity toward trypsinized rabbit erythrocytes, which was inhibited by lactose. Almost the whole sequence of the 16-kDa polypeptide (approximately 95%, 135 amino acids) was determined after digestion with various proteases. Based on the obtained information, a full-length cDNA was cloned with the aid of RNA-polymerase chain reaction. The clone encoded 146 amino acids including initiator methionine (calculated molecular mass, 15,928 Da). Based on these results, it was concluded that the 16-kDa lectin is a novel member of the galectin family, but not a degradation product of the 32-kDa galectin as had previously thought. However, the 16-kDa galectin showed relatively low sequence similarities to both the N-terminal and the C-terminal domains of the 32-kDa galectin (28% and 27% identities, respectively) and to various vertebrate galectins (14-27%). Nonetheless, all of the critical amino acids involved in carbohydrate binding were conserved. These observations suggest that, in spite of phylogenic distance between nematodes and vertebrates, both the 16-kDa and 32-kDa nematode isolectins have conserved essentially the same function(s) as those of vertebrate galectins, probably through recognition of a key disaccharide moiety, ''N-acetyllactosamine.''			Hirabayashi, J (corresponding author), TEIKYO UNIV, FAC PHARMACEUT SCI, DEPT BIOL CHEM, SAGAMIKO, KANAGAWA 19901, JAPAN.							AHMED H, 1994, GLYCOBIOLOGY, V4, P545, DOI 10.1093/glycob/4.5.545; ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; ANDERSON RL, 1992, TRENDS GLYCOSCI GLYC, V4, P43; ARATA Y, IN PRESS HISTOCHEM J; ARATA Y, UNPUB; BACIC A, 1990, EXP PARASITOL, V71, P483, DOI 10.1016/0014-4894(90)90074-M; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BORGONIE G, 1994, HISTOCHEMISTRY, V101, P379, DOI 10.1007/BF00269000; BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CHIU ML, 1994, J BIOL CHEM, V269, P31770; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; COULSON A, 1988, NATURE, V335, P184, DOI 10.1038/335184a0; DESSEN A, 1995, BIOCHEMISTRY-US, V34, P4933, DOI 10.1021/bi00015a004; DEWAARD A, 1976, J BIOL CHEM, V251, P7581; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; GITT MA, 1992, J BIOL CHEM, V267, P10601; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; GITT MA, 1991, BIOCHEMISTRY-US, V30, P82, DOI 10.1021/bi00215a013; GITT MA, 1995, GLYCOCONJUGATE J, V12, P548; GRITZMACHER CA, 1992, BIOCHEMISTRY-US, V31, P9533, DOI 10.1021/bi00155a004; GUPTA D, 1994, BIOCHEMISTRY-US, V33, P5526, DOI 10.1021/bi00184a022; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; HIRABAYASHI J, 1989, FEBS LETT, V250, P161, DOI 10.1016/0014-5793(89)80711-2; HIRABAYASHI J, 1984, BIOCHEM BIOPH RES CO, V122, P938, DOI 10.1016/0006-291X(84)91181-1; HIRABAYASHI J, 1988, J BIOCHEM-TOKYO, V104, P1; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P23648; HIRABAYASHI J, 1993, GLYCOBIOLOGY, V3, P297, DOI 10.1093/glycob/3.4.297; HIRABAYASHI J, 1987, J BIOCHEM-TOKYO, V101, P775, DOI 10.1093/jb/101.3.775; HIRABAYASHI J, 1994, GLYCOCONJUGATE J, V11, P437, DOI 10.1007/BF00731280; HIRABAYASHI J, 1992, J BIOCHEM-TOKYO, V111, P553, DOI 10.1093/oxfordjournals.jbchem.a123794; HIRABAYASHI J, 1994, LECTINS BIOL BIOCH C, V10, P205; HIRABAYASHI J, UNPUB; HIRABAYASHI J, 1993, TRENDS GLYCOSCI GLYC, V5, P251; HUGHES RC, 1994, GLYCOBIOLOGY, V4, P5, DOI 10.1093/glycob/4.1.5; KOBILER D, 1978, DEV BIOL, V64, P265, DOI 10.1016/0012-1606(78)90077-5; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LEFFLER H, 1989, BIOCHEMISTRY-US, V261, P10119; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; LINK CD, 1992, GENETICS, V131, P867; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; MADSEN P, 1995, J BIOL CHEM, V270, P5823, DOI 10.1074/jbc.270.11.5823; MAGNALDO T, 1995, DEV BIOL, V168, P259, DOI 10.1006/dbio.1995.1078; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; ODA Y, 1984, BIOCHEM BIOPH RES CO, V123, P1215, DOI 10.1016/S0006-291X(84)80262-4; ODA Y, 1983, BIOCHIM BIOPHYS ACTA, V761, P237, DOI 10.1016/0304-4165(83)90071-5; ODA Y, 1993, J BIOL CHEM, V268, P5929; OHYAMA Y, 1986, BIOCHEM BIOPH RES CO, V134, P51, DOI 10.1016/0006-291X(86)90525-5; OHYAMA Y, 1988, J BIOCHEM-TOKYO, V104, P173, DOI 10.1093/oxfordjournals.jbchem.a122436; OZEKI Y, 1995, GLYCOBIOLOGY, V5, P255, DOI 10.1093/glycob/5.2.255; PFEIFER K, 1993, GLYCOBIOLOGY, V3, P179, DOI 10.1093/glycob/3.2.179; POIRIER F, 1993, DEVELOPMENT, V119, P1229; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; RAZ A, 1988, CANCER RES, V48, P645; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; Sambrook J, 1989, MOL CLONING LABORATO; SATO S, 1992, J BIOL CHEM, V267, P6983; SINOHARA Y, UNPUB; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; TARDY F, 1995, FEBS LETT, V359, P169, DOI 10.1016/0014-5793(95)00025-5; TARDY F, 1995, 16TH INT LECT M TOUL, P103; TEICHBERG VI, 1975, P NATL ACAD SCI USA, V72, P1383, DOI 10.1073/pnas.72.4.1383; Wood WB, 1988, NEMATODE CAENORHABDI	71	71	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2497	2505		10.1074/jbc.271.5.2497	http://dx.doi.org/10.1074/jbc.271.5.2497			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576213	hybrid			2022-12-25	WOS:A1996TT48800027
J	Liu, Z; Haas, AL; Diaz, LA; Conrad, CA; Giudice, GJ				Liu, Z; Haas, AL; Diaz, LA; Conrad, CA; Giudice, GJ			Characterization of a novel keratinocyte ubiquitin carrier protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIUBIQUITIN CHAIN; CONJUGATING ENZYMES; ACTIVATING ENZYME; DEGRADATION; PURIFICATION; POLYPEPTIDE; BREAKDOWN; MECHANISM; CLONING; RAD6	A novel member of the ubiquitin carrier protein family, designated E2(EPF), has been cloned by our laboratory and expressed in a bacterial system in an active form. Ubiquitin carrier proteins, or E2s, catalyze one step in a multistep process that leads to the covalent conjugation of ubiquitin to substrate proteins. In this paper, we show that recombinant E2(EPF) catalyzes auto/multiubiquitination, the conjugation of multiple ubiquitin molecules to itself. Multiubiquitination has been shown previously to be required for targeting of a substrate protein for rapid degradation. Using a rabbit reticulocyte lysate system, E2(EPF) was shown to support the degradation of a model substrate in an ATP- and ubiquitin-dependent fashion, In contrast to a previous study which showed that selective protein degradation in one system is dependent upon multiubiquitination via the lysine 48 residue of ubiquitin, multiubiquitination, and proteolytic targeting by E2(EPF) was shown here to be independent of the lysine 48 multiubiquitin linkage. This functional characterization of E2(EPF) revealed a combination of features that distinguishes this enzyme from all previously characterized members of the ubiquitin carrier protein family. These results also suggest several possible autoregulatory models for E2(EPF) involving auto- and multiubiquitination.	MED COLL WISCONSIN,DEPT DERMATOL,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226; VET AFFAIRS MED CTR,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR032081, R01AR032599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR32081, R01-AR32599] Funding Source: Medline; NIGMS NIH HHS [R01-GM34009] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; BUSCH H, 1981, MOL CELL BIOCHEM, V840, P173; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CIECHANOVER A, 1980, P NATL ACAD SCI-BIOL, V77, P1365, DOI 10.1073/pnas.77.3.1365; CIECHANOVER A, 1981, P NATL ACAD SCI-BIOL, V78, P761, DOI 10.1073/pnas.78.2.761; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P864, DOI 10.1073/pnas.74.3.864; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS A, 1990, J BIOL CHEM, V265, P21664; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HAAS AL, 1988, UBIQUITIN, P173; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1984, P NATL ACAD SCI-BIOL, V81, P7021, DOI 10.1073/pnas.81.22.7021; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOUGH R, 1987, J BIOL CHEM, V262, P8303; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; LIU Z, 1992, J BIOL CHEM, V267, P15829; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; NOCKER SV, 1991, P NATL ACAD SCI USA, V88, P10297; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PICKART CM, 1985, J BIOL CHEM, V260, P1573; QIN S, 1991, J BIOL CHEM, V266, P15549; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SIEGELMAN M, 1986, SCIENCE, V231, P823, DOI 10.1126/science.3003913; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STJOHN T, 1986, SCIENCE, V231, P845, DOI 10.1126/science.3003914; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630	39	23	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2817	2822		10.1074/jbc.271.5.2817	http://dx.doi.org/10.1074/jbc.271.5.2817			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576260	hybrid			2022-12-25	WOS:A1996TT48800074
J	Czarnecka, H; Yokoyama, S				Czarnecka, H; Yokoyama, S			Regulation of cellular cholesterol efflux by lecithin:cholesterol acyltransferase reaction through nonspecific lipid exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY LIPOPROTEIN DEFICIENCY; SMOOTH-MUSCLE CELLS; TANGIER DISEASE; APOLIPOPROTEINS; MACROPHAGES; METABOLISM	Erythrocyte was found lacking in reactivity to lipid-free apolipoproteins to generate pre-beta-high density lipoprotein (HDL) with the cellular lipid and, therefore, was used to study cellular cholesterol efflux to plasma lipoproteins exclusively by a nonspecific exchange mechanism. Over the range of hematocrit from 1-20% (cellular cholesterol pool of 2.5 mu g to 50 mu g per 250 mu l), the fractional rate of cellular cholesterol efflux to lipoprotein was constant, and, therefore, absolute efflux rate was a linear function of the hematocrit of this range. In the absence of lecithin:cholesterol acyltransferase (LCAT), the cholesterol influx rate from lipoproteins was equal to the efflux rate from erythrocyte resulting in no net transfer of cholesterol, with either HDL or low density lipoprotein. In the presence of LCAT in the mixture of HDL and erythrocyte, cholesterol was esterified exclusively in HDL regardless of the origin. When the hematocrit was low and efflux of cellular cholesterol. was slower than cholesterol esterification, the esterification of cell originating cholesterol did not directly enhance the efflux. With high hematocrit that gives faster cholesterol efflux, the efflux was increased directly by the cholesterol esterification. On the other hand, the LCAT reaction significantly reduced HDL-cholesterol influx, The LCAT reaction thus induces substantial net cholesterol efflux from erythrocytes through a nonspecific cholesterol exchange mechanism.	UNIV ALBERTA,LIPID & LIPOPROT RES GRP,EDMONTON,AB T6G 2S2,CANADA; UNIV ALBERTA,DEPT MED,HERITAGE MED RES CTR 332,EDMONTON,AB T6G 2S2,CANADA	University of Alberta; University of Alberta								AKANUMA Y, 1968, J LIPID RES, V9, P620; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CLIFTONBLIGH P, 1972, NEW ENGL J MED, V286, P567, DOI 10.1056/NEJM197203162861103; CZARNECKA H, 1995, BIOCHEMISTRY-US, V34, P4385, DOI 10.1021/bi00013a030; CZARNECKA H, 1993, J BIOL CHEM, V268, P19334; FIELDING C J, 1981, Proceedings of the National Academy of Sciences of the United States of America, V78, P3911, DOI 10.1073/pnas.78.6.3911; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GLOMSET JA, 1968, J LIPID RES, V9, P155; GLOMSET JA, 1983, METABOLIC BASIS INHE, P643; HARA H, 1992, BIOCHEMISTRY-US, V31, P2040, DOI 10.1021/bi00122a021; HARA H, 1991, J BIOL CHEM, V266, P3080; KILSDONK EPC, 1993, INT J BIOCHEM, V25, P219, DOI 10.1016/0020-711X(93)90009-4; KIM HD, 1976, AM J PHYSIOL, V230, P1676, DOI 10.1152/ajplegacy.1976.230.6.1676; KO KWS, 1994, J BIOL CHEM, V269, P28206; Li QQ, 1995, BBA-LIPID LIPID MET, V1259, P227, DOI 10.1016/0005-2760(95)00165-4; LI QQ, 1993, BIOCHEMISTRY-US, V32, P4597, DOI 10.1021/bi00068a016; MINDHAM MA, 1991, BIOCHEM J, V279, P503, DOI 10.1042/bj2790503; MURPHY JR, 1962, J LAB CLIN MED, V60, P86; OHTAKI S, 1983, ATHEROSCLEROSIS, V49, P79, DOI 10.1016/0021-9150(83)90009-6; RAY E, 1980, BIOCHIM BIOPHYS ACTA, V617, P318, DOI 10.1016/0005-2760(80)90174-5; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; SIMON JB, 1970, NEW ENGL J MED, V283, P841, DOI 10.1056/NEJM197010152831604; STEIN O, 1978, BIOCHIM BIOPHYS ACTA, V529, P309, DOI 10.1016/0005-2760(78)90074-7; YOKOYAMA S, 1982, J BIOCHEM, V91, P1267, DOI 10.1093/oxfordjournals.jbchem.a133811	24	95	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2023	2028		10.1074/jbc.271.4.2023	http://dx.doi.org/10.1074/jbc.271.4.2023			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567654	hybrid			2022-12-25	WOS:A1996TR32000036
J	Kinnunen, T; Raulo, E; Nolo, R; Maccarana, M; Lindahl, U; Rauvala, H				Kinnunen, T; Raulo, E; Nolo, R; Maccarana, M; Lindahl, U; Rauvala, H			Neurite outgrowth in brain neurons induced by heparin-binding growth-associated molecule (HB-GAM) depends on the specific interaction of HB-GAM with heparan sulfate at the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; MOUSE EMBRYOGENESIS; RETINOIC ACID; N-SYNDECAN; PROTEOGLYCANS; PROTEIN; CLONING; SEQUENCE; DEPOLYMERIZATION; DIFFERENTIATION	Heparin-binding growth-associated molecule (HB-GAM) is a cell surface- and extracellular matrix-associated protein that hues developing axons in vivo and promotes neurite outgrowth in vitro, Because N-syndecan (syndecan-3) was found to function as a receptor in HB-GAM-induced neurite outgrowth, we have now studied whether the heparan sulfate side chains of N-syndecan play a role in HB-GAM-neuron interactions, N-Syndecan from postnatal rat brain was found to inhibit HB-GAM-induced but not laminin-induced neurite outgrowth when added to the assay media. The inhibitory activity was abolished by treating N-syndecan with heparitinase, but it was retained in N-syndecan-derived free glycosaminoglycan chains, suggesting that N-syndecan heparan sulfate at the cell surface is involved in HB-GAM-induced neurite outgrowth. Binding to HB-GAM and inhibition of neurite outgrowth was observed with heparin-related polysaccharides only; galactosaminoglycans were inactive. Significant inhibition of neurite outgrowth was induced by heparin and by N-syndecan heparan sulfate but not by heparan sulfates from other sources. A minimum of 10 monosaccharide residues were required for HB-GAM binding, as well as for inhibition of HB-GAM-induced neurite outgrowth. Experiments with selectively desulfated heparins indicated that 2-O-sulfated iduronic acid units, in particular, are of importance to the interaction with HB-GAM, whereas glucosamine N-sulfate and 6-O-sulfate groups were implicated to a lesser extent, Structural analysis of N-syndecan from 6-day-old rat brain indicated that the heparan sulfate chains contain sequences of contiguous, N-sulfated disaccharide units with an unusually high proportion (82%) of 2-O-sulfated iduronic acid residues. We suggest that this property of N-syndecan heparan sulfate is essential for HB-GAM binding and induction of neurite outgrowth.	UNIV UPPSALA, CTR BIOMED, DEPT MED & PHYSIOL CHEM, S-75123 UPPSALA, SWEDEN; UNIV HELSINKI, DEPT BIOSCI, DIV BIOCHEM, SF-00014 HELSINKI, FINLAND	Uppsala University; University of Helsinki	Kinnunen, T (corresponding author), UNIV HELSINKI, INST BIOTECHNOL, MOLEC NEUROBIOL LAB, SF-00014 HELSINKI, FINLAND.		maccarana, marco/AAB-4764-2021	Maccarana, Marco/0000-0003-3549-8921; Raulo, Erkki/0000-0001-9113-3770; Rauvala, Heikki/0000-0001-7809-9811; Kinnunen, Dr Tarja K/0000-0001-5630-2233				BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CHERNOUSOV MA, 1993, J BIOL CHEM, V268, P16810; GALLAGHER JT, 1985, BIOCHEM J, V230, P665, DOI 10.1042/bj2300665; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; HAMPTON BS, 1992, MOL BIOL CELL, V3, P85, DOI 10.1091/mbc.3.1.85; JALKANEN M, 1993, TRENDS GLYCOSCI GLYC, V5, P107; KADOMATSU K, 1988, BIOCHEM BIOPH RES CO, V151, P1312, DOI 10.1016/S0006-291X(88)80505-9; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; Kretschmer P J, 1991, Growth Factors, V5, P99, DOI 10.3109/08977199109000275; KUO MD, 1990, J BIOL CHEM, V265, P18749; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; LETOURNEAU PC, 1994, J NEUROSCI, V14, P915, DOI 10.1523/JNEUROSCI.14-03-00915.1994; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; LINDAHL U, 1994, THROMB RES, V75, P1, DOI 10.1016/0049-3848(94)90136-8; LYON M, 1994, J BIOL CHEM, V269, P11216; LYON M, 1994, J BIOL CHEM, V269, P11208; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MATSUBARA S, 1990, J BIOL CHEM, V265, P9441; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; MOLLER HJ, 1993, ANAL BIOCHEM, V209, P169, DOI 10.1006/abio.1993.1098; NOLO R, 1995, NEUROSCI LETT, V191, P39, DOI 10.1016/0304-3940(94)11551-1; NORDENMAN B, 1981, BIOCHIM BIOPHYS ACTA, V672, P227, DOI 10.1016/0304-4165(81)90289-0; PEJLER G, 1987, J BIOL CHEM, V262, P5036; PENG HB, 1995, J NEUROSCI, V15, P3027; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAULO E, 1992, J BIOL CHEM, V267, P11408; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; RAUVALA H, 1988, J CELL BIOL, V107, P2293, DOI 10.1083/jcb.107.6.2293; RAUVALA H, 1994, DEV BRAIN RES, V79, P157, DOI 10.1016/0165-3806(94)90121-X; RIESENFELD J, 1982, J BIOL CHEM, V257, P7050; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; SPILLMANN D, 1994, CURR OPIN STRUC BIOL, V4, P677, DOI 10.1016/S0959-440X(94)90165-1; TEZUKA K, 1990, BIOCHEM BIOPH RES CO, V173, P246, DOI 10.1016/S0006-291X(05)81048-4; TYRELL DJ, 1993, J BIOL CHEM, V268, P4684; URIOS P, 1991, BIOCHEM BIOPH RES CO, V175, P617, DOI 10.1016/0006-291X(91)91610-O; WALKER A, 1994, J BIOL CHEM, V269, P931; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAUON A, 1991, CELL, V64, P841	44	114	117	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2243	2248		10.1074/jbc.271.4.2243	http://dx.doi.org/10.1074/jbc.271.4.2243			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567685	hybrid			2022-12-25	WOS:A1996TR32000067
J	Odagiri, H; Wang, J; German, MS				Odagiri, H; Wang, J; German, MS			Function of the human insulin promoter in primary cultured islet cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; PANCREATIC BETA-CELLS; NEGATIVE REGULATION; 5'-FLANKING REGION; BINDING PROTEINS; POLYMORPHIC REGION; II GENE; EXPRESSION; RAT; ENHANCER	Pancreatic islet beta cells regulate the rate of insulin gene transcription in response to a number of nutrients, the most potent of which is glucose. To test for its regulation by glucose, the promoter sequence was isolated from the human insulin gene. When linked to chloramphenicol acetyltransferase and transfected into primary islet cultures, the human insulin promoter is activated by glucose. In parallel islet transfections, glucose also activates the L-pyruvate kinase and islet amyloid polypeptide promoters and represses the branched chain ketoacid dehydrogenase E1a promoter, but it does not affect the beta cell glucose kinase promoter. Using deletion and substitution mutations of the proximal human insulin promoter, we mapped a metabolic response element to the E box, E1, at -100 base pairs relative to the transcription start site. Although the isolated E1 element responds to glucose, inclusion of either of two AT-rich sequences, A1 or A2/Cl on either side of E1, results in dramatic synergistic activation. Inclusion of A2/Cl also increases the response to glucose. The A2-E1-A1 region alone, however, does not explain all of the activity of the human insulin promoter in cultured islets, and other transcriptionally important elements likely contribute to the glucose response as well.	UNIV CALIF SAN FRANCISCO, HORMONE RES INST, SAN FRANCISCO, CA 94122 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94122 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021344, R37DK021344, R56DK021344] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK021344, DK-21344] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; BELL GI, 1980, NATURE, V284, P26, DOI 10.1038/284026a0; BELL GI, 1982, NATURE, V295, P31, DOI 10.1038/295031a0; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BOAM DSW, 1989, BIOCHEM J, V264, P233, DOI 10.1042/bj2640233; BOAM DSW, 1990, J BIOL CHEM, V265, P8285; CARTIER N, 1992, ONCOGENE, V7, P1413; CHUANG JL, 1993, J BIOL CHEM, V268, P8309; COGNET M, 1991, J BIOL CHEM, V266, P7368; CORDLE SR, 1991, MOL CELL BIOL, V11, P2881, DOI 10.1128/MCB.11.5.2881; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DOCHERTY K, 1994, FASEB J, V8, P20, DOI 10.1096/fasebj.8.1.8299887; DOMINGO M, 1992, J HISTOCHEM CYTOCHEM, V40, P665, DOI 10.1177/40.5.1374093; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; EMENS LA, 1992, P NATL ACAD SCI USA, V89, P7300, DOI 10.1073/pnas.89.16.7300; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; EPSTEIN PN, 1992, P NATL ACAD SCI USA, V89, P12038, DOI 10.1073/pnas.89.24.12038; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GERMAN MS, 1994, MOL CELL BIOL, V14, P4067, DOI 10.1128/MCB.14.6.4067; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; GERMAN MS, 1990, J BIOL CHEM, V265, P22063; GERMAN MS, 1991, MOL ENDOCRINOL, V5, P292, DOI 10.1210/mend-5-2-292; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; HAMMONDS P, 1987, FEBS LETT, V213, P149, DOI 10.1016/0014-5793(87)81481-3; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HWUNG YP, 1990, MOL CELL BIOL, V10, P1784, DOI 10.1128/MCB.10.4.1784; INAGAKI N, 1992, P NATL ACAD SCI USA, V89, P1045, DOI 10.1073/pnas.89.3.1045; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KARLSSON O, 1989, MOL CELL BIOL, V9, P823, DOI 10.1128/MCB.9.2.823; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; KENNEDY GC, 1995, NAT GENET, V9, P293, DOI 10.1038/ng0395-293; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; LIANG Y, 1994, DIABETES, V43, P1138, DOI 10.2337/diabetes.43.9.1138; LIU ZR, 1993, J BIOL CHEM, V268, P12787; MACDONALD MJ, 1991, J BIOL CHEM, V266, P1335; MACDONALD MJ, 1990, DIABETES, V39, P1461, DOI 10.2337/diabetes.39.12.1461; MACDONALD MJ, 1985, MOL CELL BIOCHEM, V68, P115; MARIE S, 1993, J BIOL CHEM, V268, P23881; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; NIR U, 1986, P NATL ACAD SCI USA, V83, P3180, DOI 10.1073/pnas.83.10.3180; NISHI M, 1989, MOL ENDOCRINOL, V3, P1775, DOI 10.1210/mend-3-11-1775; NOGUCHI T, 1991, BIOCHEM BIOPH RES CO, V181, P259, DOI 10.1016/S0006-291X(05)81411-1; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OWERBACH D, 1984, GENE, V32, P475, DOI 10.1016/0378-1119(84)90021-0; PARK CW, 1992, J BIOL CHEM, V267, P15642; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; SHEIH S, 1991, J BIOL CHEM, V266, P16708; SHELTON KD, 1992, MOL CELL BIOL, V12, P4578, DOI 10.1128/MCB.12.10.4578; SHIH HM, 1992, J BIOL CHEM, V267, P13222; TAKEDA J, 1989, FEBS LETT, V247, P41, DOI 10.1016/0014-5793(89)81236-0; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WEIHER H, 1983, SCIENCE, V219, P626, DOI 10.1126/science.6297005; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; YIN L, 1992, DIABETES, V41, P792	67	70	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1909	1915		10.1074/jbc.271.4.1909	http://dx.doi.org/10.1074/jbc.271.4.1909			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567638	hybrid			2022-12-25	WOS:A1996TR32000020
J	Mair, T; Muller, SC				Mair, T; Muller, SC			Traveling NADH and proton waves during oscillatory glycolysis in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RINM5F INSULINOMA CELLS; ATP ADP RATIO; SPIRAL WAVES; SPATIOTEMPORAL ORGANIZATION; EXCITABLE MEDIA; YEAST EXTRACTS; FREE CA-2+; MODEL	Propagation and mutual annihilation of circular and spiral NADH and proton waves were detected by spatially resolved spectrophotometry and fluorescent proton indicators in a biological in vitro system: an organelle-free yeast extract. Spontaneous wave generation during glycolytic sugar degradation is established after an induction period of about 1 h. Controlled wave initiation could be performed by local injection of the strong activator of phosphofructokinase, fructose 2,6-bisphosphate. A crucial role for wave initiation and control of pattern dynamics is attributed to the key enzyme of glycolysis, the allosterically regulated phosphofructokinase. An overall increase in the concentration of its positive effector AMP leads to the formation of rotating spirals. The dynamics of the observed wave patterns resemble that of self-organized calcium waves as recently found in frog eggs and heart cells.			Mair, T (corresponding author), MAX PLANCK INST MOLEK PHYSIOL,RHEINLANDDAMM 201,D-44139 DORTMUND,GERMANY.							AON MA, 1991, J CELL SCI, V99, P325; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BETZ A, 1965, ARCH BIOCHEM BIOPHYS, V109, P585, DOI 10.1016/0003-9861(65)90404-2; BOITEUX A, 1975, P NATL ACAD SCI USA, V72, P3829, DOI 10.1073/pnas.72.10.3829; BOITEUX A, 1978, FRONTIERS BIOL ENERG, V1, P789; CHANCE B, 1965, J BIOL CHEM, V240, P3170; CHANCE B, 1965, BIOCHEM Z, V341, P357; CORKEY BE, 1988, J BIOL CHEM, V263, P4247; CORKEY BE, 1988, J BIOL CHEM, V263, P4254; DAS J, 1991, BIOPHYS J, V60, P369, DOI 10.1016/S0006-3495(91)82062-8; DUKES ID, 1994, J BIOL CHEM, V269, P10979; GOLDBETER A, 1989, CELL CELL SIGNALING; GOLDBETT.A, 1973, P NATL ACAD SCI USA, V70, P3255, DOI 10.1073/pnas.70.11.3255; HERS HG, 1984, BIOCHEM SOC T, V12, P729, DOI 10.1042/bst0120729; Hess B, 1969, Adv Enzyme Regul, V7, P149, DOI 10.1016/0065-2571(69)90016-8; HESS B, 1968, HOPPESEYLERS Z PHYSL, V349, P157; JACOBSEN H, 1982, J BIOL CHEM, V257, P4001; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LIPP P, 1993, BIOPHYS J, V65, P2272, DOI 10.1016/S0006-3495(93)81316-X; MARMILLOT P, 1992, P NATL ACAD SCI USA, V89, P12103, DOI 10.1073/pnas.89.24.12103; MIKHAILOV AS, 1991, PHYSICA D, V52, P379, DOI 10.1016/0167-2789(91)90134-U; MULLER SC, 1985, BER BUNSEN PHYS CHEM, V89, P654, DOI 10.1002/bbpc.19850890618; MULLER SC, 1985, ANAL BIOCHEM, V146, P125, DOI 10.1016/0003-2697(85)90406-3; Nagy-Ungvarai Z, 1993, CHAOS, V3, P15, DOI 10.1063/1.165973; OROURKE B, 1994, SCIENCE, V265, P962, DOI 10.1126/science.8052856; SELKOV EE, 1968, EUR J BIOCHEM, V4, P79, DOI 10.1111/j.1432-1033.1968.tb00175.x; TORNHEIM K, 1991, J BIOL CHEM, V266, P15675; TREMONIA Y, 1981, P NATL ACAD SCI USA, V78, P2952; TYSON JJ, 1988, PHYSICA D, V32, P327, DOI 10.1016/0167-2789(88)90062-0; WINFREE AT, 1972, SCIENCE, V175, P634, DOI 10.1126/science.175.4022.634; ZAIKIN AN, 1970, NATURE, V225, P535, DOI 10.1038/225535b0	32	68	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					627	630		10.1074/jbc.271.2.627	http://dx.doi.org/10.1074/jbc.271.2.627			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557664	hybrid			2022-12-25	WOS:A1996TP88900007
J	Murga, C; RuizGomez, A; GarciaHiguera, I; Kim, CM; Benovic, JL; Mayor, F				Murga, C; RuizGomez, A; GarciaHiguera, I; Kim, CM; Benovic, JL; Mayor, F			High affinity binding of beta-adrenergic receptor kinase to microsomal membranes - Modulation of the activity of bound kinase by heterotrimeric G protein activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCARINIC ACETYLCHOLINE-RECEPTORS; AGONIST-DEPENDENT PHOSPHORYLATION; GAMMA-SUBUNITS; ADENYLATE-CYCLASE; REGULATORY COMPONENT; COUPLED RECEPTORS; TRANSLOCATION; RHODOPSIN; INHIBITION; BRAIN	The beta-adrenergic receptor kinase (beta ARK) modulates beta-adrenergic and other G protein-coupled receptors by rapidly phosphorylating agonist-occupied receptors at the plasma membrane. We have recently shown that beta ARK also associates with intracellular microsomal membranes both ''in vitro'' and ''in situ'' (Garcia-Higuera, I., Penela, P., Murga, C., Egea, G., Bonay, P., Benovic, J. L., and Mayor, F., Jr. (1994) J. Biol. Chem. 269, 1348-1355), thus suggesting a complex modulation of the subcellular distribution of beta ARK. In this report, we used recombinant [S-35]methionine-labeled beta ARK to show that this kinase interacts rapidly with a high affinity binding site (K-d of 20 +/- 1 nM) present in salt stripped rat liver microsomal membranes. Although beta ARK binding is not modulated by membrane preincubation with G protein activators, the activity of bound beta ARK toward rhodopsin or a synthetic peptide substrate was markedly enhanced upon stimulation of the endogenous heterotrimeric G proteins present in the microsomal membranes by AlF4- or mastoparan/guanosine 5'-(3-O-thio)triphosphate, thus strongly suggesting a functional link between these proteins and membrane-associated beta ARK. Interestingly, beta ARK association with microsomal membranes is not significantly affected by a fusion protein derived from the carboxyl terminus of beta ARK1 (the proposed location of the beta gamma subunit binding site), whereas it is markedly inhibited by fusion proteins corresponding to the amino terminal region of the kinase. The main determinants of binding appear to be localized to an <similarto>60-amino acid residue stretch (residues 88 to 145). Our results further indicate a functional relationship between beta ARK and heterotrimeric G proteins in different intracellular organelles, and suggest that additional proteins may be involved in modulating the cellular localization of the kinase through a new targeting domain of beta ARK.	UNIV AUTONOMA MADRID,CSIC,CTR BIOL MOLEC SEVERO OCHOA,E-28049 MADRID,SPAIN; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Jefferson University			Garcia-Higuera, Irene/L-5004-2014; Murga, Cristina/E-1965-2014; Ruiz-Gomez, Ana/ABF-3079-2021; Mayor, Federico/N-7644-2016; Ruiz-Gómez, Ana/H-2092-2015	Garcia-Higuera, Irene/0000-0001-6331-075X; Murga, Cristina/0000-0002-8964-4077; Ruiz-Gómez, Ana/0000-0002-1646-3072; Mayor Menendez, Federico/0000-0003-1434-8449	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALCH W E, 1992, Current Biology, V2, P157, DOI 10.1016/0960-9822(92)90276-G; BENOVIC JL, 1989, J BIOL CHEM, V264, P6707; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1986, NATURE, V321, P869, DOI 10.1038/321869a0; BENOVIC JL, 1987, J BIOL CHEM, V262, P17251; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; CHIDA K, 1994, MOL CELL BIOL, V14, P3782, DOI 10.1128/MCB.14.6.3782; CHUANG TT, 1992, J BIOL CHEM, V267, P6886; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DEALMEIDA JB, 1993, J CELL SCI, V106, P1239; DEBBURMAN SK, 1995, J BIOL CHEM, V270, P5742, DOI 10.1074/jbc.270.11.5742; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; FINAZZI D, 1994, J BIOL CHEM, V269, P13325; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GARCIAHIGUERA I, 1994, J BIOL CHEM, V269, P1348; GARCIAHIGUERA I, 1994, J CLIN INVEST, V93, P937, DOI 10.1172/JCI117099; GARCIAHIGUERA I, 1994, CELL SIGNAL TRANSDUCTION, SECOND MESSENGERS, AND PROTEIN PHOSPHORYLATION IN HEALTH AND DISEASE, P129; GARCIAHIGUERA I, 1992, FEBS LETT, V302, P61, DOI 10.1016/0014-5793(92)80285-O; HAGA K, 1994, J BIOL CHEM, V269, P12594; HAGA K, 1992, J BIOL CHEM, V267, P2222; HAGA K, 1990, FEBS LETT, V268, P43, DOI 10.1016/0014-5793(90)80968-O; HAGA T, 1994, J NEUROCHEM, V63, P400; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAUSKEN ZE, 1994, J BIOL CHEM, V269, P24245; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; INGLESE J, 1994, P NATL ACAD SCI USA, V91, P3637, DOI 10.1073/pnas.91.9.3637; INGLESE J, 1993, J BIOL CHEM, V268, P23735; KAMEYAMA K, 1993, J BIOL CHEM, V268, P7753; KATADA T, 1984, J BIOL CHEM, V259, P3586; KEHLENBACH RH, 1994, NATURE, V372, P804; KELLEHER DJ, 1988, MOL PHARMACOL, V34, P452; KIM CM, 1993, J BIOL CHEM, V268, P15412; KIM CM, 1993, RECEPTOR, V3, P39; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; KWATRA MM, 1993, J BIOL CHEM, V268, P9161; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LOUDON RP, 1994, J BIOL CHEM, V269, P22691; MAYOR F, 1987, J BIOL CHEM, V262, P6468; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MULLER S, 1993, P NATL ACAD SCI USA, V90, P10439, DOI 10.1073/pnas.90.22.10439; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PALCZEWSKI K, 1993, J BIOL CHEM, V268, P6004; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PEI G, 1994, P NATL ACAD SCI USA, V91, P3633, DOI 10.1073/pnas.91.9.3633; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; RICHARDSON RM, 1993, J BIOL CHEM, V268, P13650; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Ruiz-Gomez A., 1994, Society for Neuroscience Abstracts, V20, P1066; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; THISSEN JA, 1993, J BIOL CHEM, V268, P13780; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; YU H, 1992, J BIOL CHEM, V267, P20457	62	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					985	994		10.1074/jbc.271.2.985	http://dx.doi.org/10.1074/jbc.271.2.985			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557715	hybrid			2022-12-25	WOS:A1996TP88900058
J	vanVoorst, F; KiellandBrandt, MC; Winther, JR				vanVoorst, F; KiellandBrandt, MC; Winther, JR			Mutational analysis of the vacuolar sorting signal of procarboxypeptidase Y in yeast shows a low requirement for sequence conservation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-Y; SACCHAROMYCES-CEREVISIAE; TARGETING SIGNAL; PROPEPTIDE; GENE; MITOCHONDRIA; PROTEINS; PROTEASE; SYSTEM	The core of the vacuolar targeting signal of yeast carboxypeptidase Y (CPY) is recognized by the receptor Vps10p and consists of four contiguous amino acid residues, Gln(24)-Arg-Pro-Leu(27), near the amino terminus of the propeptide (Valls, L. A., Winther, J. R., and Stevens, T. H. (1990) J. Cell Biol. 111, 361-368; Marcusson, E. G., Horazdovsky, B. F., Cereghino, J. L, Gharakhanian, E., and Emr, S. D. (1994) Cell 77, 579-586). In order to determine the sequence specificity of the interaction with the sorting receptor, substitutions were introduced into this part of the propeptide by semirandom site-directed mutagenesis. The efficiency of vacuolar sorting by the mutants was determined by immunoprecipitation of CPY from pulse-labeled cells. It was found that amino acid residues Gln(24) and Leu(27) were the most important ones, While it appears that Gln(24) is essential for proper function, Leu(27) can be exchanged with the other hydrophobic amino acid residues, isoleucine, valine, and phenylalanine. Tolerance toward various substitutions for Arg(25) is fairly high, while substitution of pro(26) for uncharged amino acid residues also resulted in only weak missorting. In addition to the low requirement for sequence conservation, the position of the targeting element relative to the amino terminus of the propeptide was analyzed and found not to be critical.	CARLSBERG LAB, DEPT YEAST GENET, DK-2500 COPENHAGEN, DENMARK				Kielland-Brandt, Morten C./D-2563-2015; Winther, Jakob R./K-4451-2014	Winther, Jakob R./0000-0001-6995-9154; Kielland-Brandt, Morten/0000-0002-1272-3877				BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BARANSKI TJ, 1990, CELL, V63, P281, DOI 10.1016/0092-8674(90)90161-7; CHRISPEELS MJ, 1992, CELL, V68, P613, DOI 10.1016/0092-8674(92)90134-X; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HORAZDOVSKY BF, 1994, EMBO J, V13, P1297, DOI 10.1002/j.1460-2075.1994.tb06382.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MCINTYRE GF, 1994, J BIOL CHEM, V269, P567; MUKHTAR M, 1992, GENE, V121, P173, DOI 10.1016/0378-1119(92)90178-R; PELHAM HRB, 1987, ANN REV CELL BIOL, V5, P1; RAMOS C, 1994, J BIOL CHEM, V269, P7006; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1986, P NATL ACAD SCI USA, V83, P3248, DOI 10.1073/pnas.83.10.3248; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; SORENSEN P, 1993, BIOCHEMISTRY-US, V32, P12160; SORENSEN SO, 1994, EUR J BIOCHEM, V220, P19, DOI 10.1111/j.1432-1033.1994.tb18594.x; STEVENS TH, 1986, J CELL BIOL, V102, P1551, DOI 10.1083/jcb.102.5.1551; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; VALLS LA, 1990, J CELL BIOL, V111, P361, DOI 10.1083/jcb.111.2.361; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WINTHER JR, 1991, EUR J BIOCHEM, V197, P681, DOI 10.1111/j.1432-1033.1991.tb15959.x; WINTHER JR, 1991, P NATL ACAD SCI USA, V88, P9330, DOI 10.1073/pnas.88.20.9330	33	15	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					841	846		10.1074/jbc.271.2.841	http://dx.doi.org/10.1074/jbc.271.2.841			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557694	hybrid			2022-12-25	WOS:A1996TP88900037
J	Ziambaras, T; Rubin, DC; Perlmutter, DH				Ziambaras, T; Rubin, DC; Perlmutter, DH			Regulation of sucrase-isomaltase gene expression in human intestinal epithelial cells by inflammatory cytokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SMALL-INTESTINE; CRYPT-VILLUS AXIS; AMYLOID-A SAA; ALPHA-1-ANTITRYPSIN GENE; MESSENGER-RNA; BIOSYNTHESIS; MEMBRANE; CLEAVAGE; CACO-2; SITES	Using metabolic labeling techniques in human intestinal epithelial cell lines in tissue culture and in situ hybridization techniques in normal and inflamed (Crohn's) intestine, recent studies have shown that there is synthesis of acute phase proteins in enterocytes. Moreover, these studies have shown that acute phase protein biosynthesis in enterocytes is regulated by inflammatory cytokines in a manner characteristic of the physiologic acute phase response. In the course of these studies it was noticed that one inflammatory cytokine, interleukin-6 (IL-6), mediated selective down-regulation of the enterocyte-specific, differentiation-dependent integral membrane protein sucrase-isomaltase (SI) in the Caco2 intestinal epithelial cell line. In the current study we examined the effect of several other inflammatory cytokines interleukin-1 (IL-1 beta), tumor necrosis factor alpha (TNF alpha), and interferon gamma (IFN gamma) on synthesis of SI in Caco2 cells, examined the possibility that inflammatory cytokines affect the synthesis of other enterocyte integral membrane proteins using lactase as a prototype, and examined the possibility that SI gene expression was down-regulated in villous enterocytes in vivo during the local inflammatory response of Crohn's disease. The results show that IL-6 and IFN gamma each mediate a decrease and TNF alpha mediates an increase in synthesis of SI in Caco2 cells. The magnitude of down-regulation by IL-6 and IFN gamma is significantly greater than the up-regulation by TNF alpha. IL-1 beta has no effect on synthesis of SI. Synthesis of lactase is not affected by any of the cytokines. There is a marked specific decrease in SI gene expression in villous enterocytes in acutely inflamed Crohn's ileum as compared to adjacent uninflamed ileum and normal ileum. Taken together, these data show that inflammatory cytokines have specific and selective effects on the expression of the brush border hydrolase SI in tissue culture and in vivo and provide evidence for a previously unrecognized mechanism for disaccharidase deficiency in intestinal inflammation.	WASHINGTON UNIV,ST LOUIS CHILDRENS HOSP,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PEDIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110; ST LOUIS CHILDRENS HOSP,DIV GASTROENTEROL & NUTR,ST LOUIS,MO 63110	St. Louis Children's Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL)				Rubin, Deborah/0000-0002-4192-909X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045085] Funding Source: NIH RePORTER; NICHD NIH HHS [T32 HD07409] Funding Source: Medline; NIDDK NIH HHS [DK 45085] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHRENSTEDT O, 1990, NEW ENGL J MED, V322, P1345, DOI 10.1056/NEJM199005103221903; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BEAULIEU JF, 1989, J BIOL CHEM, V264, P20000; CROSS HS, 1991, AM J PHYSIOL, V261, pC1173; FALUS A, 1987, J IMMUNOL, V138, P856; HAFEEZ W, 1992, J CLIN INVEST, V89, P1214, DOI 10.1172/JCI115705; HAURI HP, 1979, P NATL ACAD SCI USA, V76, P5183, DOI 10.1073/pnas.76.10.5183; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HOFFMAN LR, 1991, J BIOL CHEM, V266, P21815; KIRSCHNER BS, 1981, GASTROENTEROLOGY, V61, P629; Kushner I, 1993, ACUTE PHASE PROTEINS, P4; MAIURI L, 1991, GASTROENTEROLOGY, V100, P359, DOI 10.1016/0016-5085(91)90203-W; MEEK RL, 1986, J EXP MED, V164, P2006, DOI 10.1084/jem.164.6.2006; MOLMENTI EP, 1993, J CLIN INVEST, V92, P2022, DOI 10.1172/JCI116797; MOLMENTI EP, 1993, J BIOL CHEM, V268, P14116; NAIM HY, 1988, J BIOL CHEM, V263, P7242; PASSWELL J, 1988, J CLIN INVEST, V82, P1676, DOI 10.1172/JCI113780; PERLMUTTER DH, 1984, J BIOL CHEM, V259, P380; PERLMUTTER DH, 1989, J BIOL CHEM, V264, P9485; PERLMUTTER DH, 1993, MULTIPLE SYSTEMS ORG, P229; PERLMUTTER DH, 1984, J CLIN INVEST, V84, P138; PINTO M, 1983, BIOL CELL, V47, P323; RAMADORI G, 1985, J IMMUNOL, V135, P3645; SARTOR RB, 1994, GASTROENTEROLOGY, V106, P533, DOI 10.1016/0016-5085(94)90614-9; SHAPIRO GL, 1991, AM J PHYSIOL, V261, pG847, DOI 10.1152/ajpgi.1991.261.5.G847; SIPE JD, 1985, BIOCHEMISTRY-US, V24, P2931, DOI 10.1021/bi00333a018; SUNDSTROM SA, 1989, J BIOL CHEM, V264, P16941; TRABER PG, 1990, BIOCHEM BIOPH RES CO, V173, P765, DOI 10.1016/S0006-291X(05)80853-8; TRABER PG, 1992, MOL CELL BIOL, V12, P3614, DOI 10.1128/MCB.12.8.3614; TRABER PG, 1992, AM J PHYSIOL, V262, pG123, DOI 10.1152/ajpgi.1992.262.1.G123; WOO P, 1987, J BIOL CHEM, V262, P15790; WU GD, 1994, J BIOL CHEM, V269, P17080; WU GD, 1992, J BIOL CHEM, V267, P7863	33	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1237	1242		10.1074/jbc.271.2.1237	http://dx.doi.org/10.1074/jbc.271.2.1237			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557656	hybrid			2022-12-25	WOS:A1996TP88900093
J	Chalikian, TV; Gindikin, VS; Breslauer, KJ				Chalikian, TV; Gindikin, VS; Breslauer, KJ			Spectroscopic and volumetric investigation of cytochrome c unfolding at alkaline pH: Characterization of the base-induced unfolded state at 25 degrees C	FASEB JOURNAL			English	Article						protein folding; ultrasonics; volume; adiabatic compressibility	PROTON-TRANSFER REACTIONS; GLOBULAR-PROTEINS; ULTRASONIC-ABSORPTION; AQUEOUS-SOLUTIONS; AMINO-ACIDS; STABILITY; COMPRESSIBILITY	We have measured at 25 degrees C the relative specific sound velocity increment, [u], and the partial specific volume, v degrees, of cytochrome c as a function of pH, Our data reveal that the base-induced native to unfolded transition of the protein is accompanied by a volume decrease of 0.014 cm(3) g(-1) and a compressibility decrease of 3.8 x 10(-6) cm(3) g(-1) bar(-1). These results allow us to conclude that, relative to a fully unfolded conformation, the base-denatured state of cytochrome c has only 70 to 80% of its surface area exposed to the solvent. Recently, we reported a similar result for the acid-denatured state of cytochrome c. Thus, insofar as solvent exposure is concerned, both the base- and the acid-induced unfolded states of cytochrome c retain some order, with 20 to 30% of their surface areas remaining solvent-inaccessible. We discuss the implications of this result in terms of defining potential intermediate states in protein folding pathways.	RUTGERS STATE UNIV,DEPT CHEM,WRIGHT & RIEMAN LABS,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick								Brandts J. F., 1969, STRUCTURE STABILITY, V2, P213; CHALIKIAN TV, 1992, J PHYS CHEM-US, V96, P876, DOI 10.1021/j100181a065; CHALIKIAN TV, 1994, BIOPHYS CHEM, V51, P89, DOI 10.1016/0301-4622(94)85007-0; CHALIKIAN TV, 1995, J MOL BIOL, V250, P291, DOI 10.1006/jmbi.1995.0377; CHALIKIAN TV, 1994, BIOPHYS J, V66, pA65; CHALIKIAN TV, 1996, IN PRESS P NATL ACAD; CHO KC, 1985, BIOCHIM BIOPHYS ACTA, V830, P36, DOI 10.1016/0167-4838(85)90128-1; CHOI PK, 1990, J ACOUST SOC AM, V87, P874, DOI 10.1121/1.398897; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; EGGERS F, 1973, REV SCI INSTRUM, V44, P969, DOI 10.1063/1.1686339; GEKKO K, 1986, BIOCHEMISTRY-US, V25, P6563, DOI 10.1021/bi00369a034; HUSSEY M, 1971, J PHYS CHEM-US, V75, P4012, DOI 10.1021/j100695a017; KANDA H, 1976, BIOPOLYMERS, V15, P785, DOI 10.1002/bip.1976.360150414; KHARAKOZ DP, 1993, BIOPOLYMERS, V33, P11, DOI 10.1002/bip.360330103; LEE B, 1991, P NATL ACAD SCI USA, V88, P5154, DOI 10.1073/pnas.88.12.5154; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MILLERO FJ, 1977, J ACOUST SOC AM, V61, P1492, DOI 10.1121/1.381449; NIKITIN SY, 1984, MOL BIOL+, V18, P685; NOLTING B, 1993, BIOCHEMISTRY-US, V32, P12319, DOI 10.1021/bi00097a007; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; Richards F. M., 1992, P1; ROBINSON JB, 1983, J BIOL CHEM, V258, P6772; RUPLEY JA, 1964, BIOCHEMISTRY-US, V3, P1648, DOI 10.1021/bi00899a008; SARVAZYAN AP, 1979, J PHYS CHEM-US, V83, P1796, DOI 10.1021/j100476a021; SARVAZYAN AP, 1991, ANNU REV BIOPHYS BIO, V20, P321, DOI 10.1146/annurev.bb.20.060191.001541; SARVAZYAN AP, 1982, ULTRASONICS, V20, P151, DOI 10.1016/0041-624X(82)90032-4; SHORTLE D, 1993, CURR OPIN STRUC BIOL, V3, P66, DOI 10.1016/0959-440X(93)90204-X; STELLWAGEN E, 1964, BIOCHEMISTRY-US, V3, P919, DOI 10.1021/bi00895a011; TAMURA Y, 1995, BIOCHEMISTRY-US, V34, P1878, DOI 10.1021/bi00006a008; Tanford C, 1970, Adv Protein Chem, V24, P1, DOI 10.1016/S0065-3233(08)60241-7; Theorell H, 1941, J AM CHEM SOC, V63, P1812, DOI 10.1021/ja01852a006; YANG AS, 1993, J MOL BIOL, V231, P459, DOI 10.1006/jmbi.1993.1294; ZANA R, 1972, J PHYS CHEM-US, V76, P1737, DOI 10.1021/j100656a012	35	41	41	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JAN	1996	10	1					164	170		10.1096/fasebj.10.1.8566538	http://dx.doi.org/10.1096/fasebj.10.1.8566538			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	TR328	8566538				2022-12-25	WOS:A1996TR32800022
J	Besser, D; Urich, M; Sakaue, M; Messerschmitt, A; BallmerHofer, K; Nagamine, Y				Besser, D; Urich, M; Sakaue, M; Messerschmitt, A; BallmerHofer, K; Nagamine, Y			Urokinase-type plasminogen activator gene regulation by polyomavirus middle-T antigen	ONCOGENE			English	Article						AP1; middle-T; plasminogen activator; polyomavirus; signal transduction	SIZED TUMOR-ANTIGEN; PHOSPHATIDYLINOSITOL KINASE; ONCOGENIC TRANSFORMATION; CELL-TRANSFORMATION; TYROSINE KINASES; GROWTH-FACTORS; RAT-CELLS; PROTEIN; EXPRESSION; VIRUS	Expression of polyomavirus middle-T antigen (middle-T) is involved in the formation of various tumors in vivo, e,g, hemangiomas and mammary gland tumors, Several genes have been shown to be activated in middle-T-expressing cells, but the underlying mechanisms have only been partially elucidated, Among the genes regulated by middle-T, the urokinase-type plasminogen activator (uPA) gene seems to be of primary importance for the development of the transformed phenotype, We have found that the uPA gene is highly expressed in eEnd2 cells derived from a hemangioma expressing middle-T, NIH3T3 cells show negligible levels of uPA mRNA but its expression was highly induced by infecting with a middle-T-expressing retrovirus, Middle-T did not affect uPA mRNA stability, Transient cotransfection experiments using a uPA-reporter gene construct and a middle-T expression vector showed that high uPA mRNA levels are due to increased uPA promoter activity, Analyses of various signaling molecules by transient cotransfection assays and in vitro kinase assays established that a signaling pathway involving c-Src, SOS, Ras, Raf-l and ERK is activated by middle-T in NIH3T3 cells, resulting in the activation of the uPA gene promoter via PEA3/AP1 elements, In contrast, in eEnd2 cells uPA gene induction is only partially dependent on this pathway, suggesting the involvement of additional signaling molecules in endothelial cells.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; KOBE UNIV,SCH MED,DEPT INTERNAL MED 2,CHUO KU,KOBE 650,JAPAN	Friedrich Miescher Institute for Biomedical Research; Kobe University			Besser, Daniel/A-8304-2012	Besser, Daniel/0000-0002-4958-9624; Ballmer-Hofer, Kurt/0000-0002-3800-9129				ANDRUS L, 1988, J BIOL CHEM, V263, P6183; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BESSER D, 1995, CELL GROWTH DIFFER, V6, P1009; Blasi F, 1990, Semin Cancer Biol, V1, P117; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CASSADY AI, 1991, NUCLEIC ACIDS RES, V19, P6839, DOI 10.1093/nar/19.24.6839; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DECLUE JE, 1993, MOL CELL BIOL, V13, P6799, DOI 10.1128/MCB.13.11.6799; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FLOTTRAHMEL B, 1992, NEUROREPORT, V3, P1077, DOI 10.1097/00001756-199212000-00011; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HERRIN DL, 1988, BIOTECHNIQUES, V6, P196; HORAK ID, 1989, J VIROL, V63, P2343, DOI 10.1128/JVI.63.5.2343-2347.1989; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; ITO Y, 1979, VIROLOGY, V98, P261, DOI 10.1016/0042-6822(79)90545-2; ITO Y, 1980, J VIROL, V35, P219, DOI 10.1128/JVI.35.1.219-232.1980; JELINEK MA, 1992, ONCOGENE, V7, P1687; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KORNBLUTH S, 1987, NATURE, V325, P171, DOI 10.1038/325171a0; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KWAAN HC, 1992, CANCER METAST REV, V11, P291, DOI 10.1007/BF01307184; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEE JS, 1994, J BIOL CHEM, V269, P2887; LEE JS, 1993, NUCLEIC ACIDS RES, V21, P3365, DOI 10.1093/nar/21.15.3365; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTE BM, 1995, ONCOGENE, V10, P167; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MUSER J, 1989, ONCOGENE, V4, P1433; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAMEH LE, 1991, ONCOGENE, V6, P1049; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHONTHAL A, 1992, P NATL ACAD SCI USA, V89, P4972, DOI 10.1073/pnas.89.11.4972; SEGAWA K, 1982, P NATL ACAD SCI-BIOL, V79, P6812, DOI 10.1073/pnas.79.22.6812; SEILERTUYNS A, 1981, J MOL BIOL, V151, P607, DOI 10.1016/0022-2836(81)90426-5; SRINIVAS S, 1994, P NATL ACAD SCI USA, V91, P10064, DOI 10.1073/pnas.91.21.10064; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; TIENARI J, 1991, CELL REGUL, V2, P285, DOI 10.1091/mbc.2.4.285; Tooze J, 1980, DNA TUMOR VIRUSES; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; URICH M, IN PRESS J BIOL CHEM; VASSALLI JD, 1994, FIBRINOLYSIS, V8, P172, DOI 10.1016/0268-9499(94)90715-3; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WILLIAMS RL, 1988, CELL, V52, P121; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7; ZHENG CF, 1994, J BIOL CHEM, V269, P19947; ZIEGLER A, 1990, J BIOL CHEM, V265, P21194	72	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2383	2391						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570190				2022-12-25	WOS:A1995TK70200023
J	VecseySemjen, B; Mollby, R; Gisou, F; vanderGoot, FG				VecseySemjen, B; Mollby, R; Gisou, F; vanderGoot, FG			Partial C-terminal unfolding is required for channel formation by staphylococcal alpha-toxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PROTEIN TOXINS; CIRCULAR-DICHROISM; LIPOSOME MEMBRANE; LIPID BILAYERS; AUREUS; MECHANISM; PH; OLIGOMERIZATION; AEROLYSIN; INSERTION	The pore-forming alpha-toxin from Staphylococcus aureus is secreted as a soluble monomeric protein. In order to form a transmembrane channel, the protein has to undergo oligomerization and membrane insertion, Previous studies have shown that channel formation is favored by acidic pH. We have analyzed the effect of pH on the kinetics of channel formation as well as on the conformation of the toxin, Using a variety of spectroscopic probes for protein structure, we have shown that alpha-toxin unfolded upon acidification and that the unfolding process occurred in at least three steps, The various steps could be selectively affected by modifying the salt concentration or the temperature. This unfolding was, however, only partial as the secondary structure remained native-like as witnessed by far UV CD measurements. The first unfolding step, corresponding to a region of the C-terminal half of the toxin, is of particular importance as it coincided with the exposure of hydrophobic patches on the surface of the protein as well as with the onset of channel formation, Our observations strongly suggest that transition of the C-terminal half of alpha-toxin to a molten globule-like state is required for channel formation.	UNIV GENEVA,DEPT BIOCHIM,CH-1211 GENEVA,SWITZERLAND; KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN	University of Geneva; Karolinska Institutet			van der Goot, Gisou G/B-2279-2012	van der Goot, Gisou G/0000-0002-8522-274X				ARNOLD K, 1992, BIOCHIM BIOPHYS ACTA, V1124, P88, DOI 10.1016/0005-2760(92)90130-N; BALLARD J, 1993, MOL MICROBIOL, V10, P627, DOI 10.1111/j.1365-2958.1993.tb00934.x; BHAKDI S, 1991, MICROBIOL REV, V55, P733, DOI 10.1128/MMBR.55.4.733-751.1991; BLOMQVIST L, 1987, FEBS LETT, V211, P127, DOI 10.1016/0014-5793(87)81422-9; BOULNOIS GJ, 1991, MOL MICROBIOL, V5, P2611, DOI 10.1111/j.1365-2958.1991.tb01969.x; FORTI S, 1989, EUR J BIOCHEM, V181, P767, DOI 10.1111/j.1432-1033.1989.tb14790.x; FRESKGARD PO, 1994, BIOCHEMISTRY-US, V33, P14281, DOI 10.1021/bi00251a041; GOUAUX JE, 1994, P NATL ACAD SCI USA, V91, P12828, DOI 10.1073/pnas.91.26.12828; HARSHMAN S, 1989, J BIOL CHEM, V264, P14978; HILDEBRAND A, 1991, J BIOL CHEM, V266, P17195; IKIGAI H, 1987, J BIOL CHEM, V262, P2156; IKIGAI H, 1985, BIOCHEM BIOPH RES CO, V130, P175, DOI 10.1016/0006-291X(85)90398-5; KOEHLER TM, 1991, MOL MICROBIOL, V5, P1501, DOI 10.1111/j.1365-2958.1991.tb00796.x; KRISHNASASTRY M, 1994, FEBS LETT, V356, P66, DOI 10.1016/0014-5793(94)01240-7; LIND I, 1987, ANAL BIOCHEM, V164, P84, DOI 10.1016/0003-2697(87)90371-X; LONDON E, 1992, MOL MICROBIOL, V6, P3277, DOI 10.1111/j.1365-2958.1992.tb02195.x; MANAVALAN P, 1983, NATURE, V305, P831, DOI 10.1038/305831a0; MANNING MC, 1989, BIOCHEMISTRY-US, V28, P8609, DOI 10.1021/bi00447a051; MCCARTNEY C, 1978, BACTERIAL TOXINS CEL, P89; MENESTRINA G, 1986, J MEMBRANE BIOL, V90, P177, DOI 10.1007/BF01869935; MENESTRINA G, 1992, FEMS MICROBIOL IMMUN, V105, P19; MILNE JC, 1994, J BIOL CHEM, V269, P20607; PALMER M, 1993, J BIOL CHEM, V268, P11963; PANCHAL RG, 1995, J BIOL CHEM, V270, P23072, DOI 10.1074/jbc.270.39.23072; PARKER MW, 1993, TRENDS BIOCHEM SCI, V18, P391, DOI 10.1016/0968-0004(93)90096-6; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; THELESTAM M, 1988, TOXICON, V26, P51, DOI 10.1016/0041-0101(88)90137-7; THELESTAM M, 1991, BIOCHIM BIOPHYS ACTA, V1062, P245, DOI 10.1016/0005-2736(91)90399-S; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; TOMITA T, 1992, J BIOL CHEM, V267, P13391; VALEVA A, 1995, BBA-BIOMEMBRANES, V1236, P213, DOI 10.1016/0005-2736(95)00060-G; Van Der Goot Francoise G., 1992, Trends in Cell Biology, V2, P343; VANDERGOOT FG, 1994, J BIOL CHEM, V269, P30496; VANDERGOOT FG, 1993, J BIOL CHEM, V268, P18272; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VANDERGOOT FG, 1993, BIOCHEMISTRY-US, V32, P2636, DOI 10.1021/bi00061a023; VANDERGOOT FG, 1994, TOXICOLOGY, V87, P1; VAZ WLC, 1978, EUR J BIOCHEM, V83, P299, DOI 10.1111/j.1432-1033.1978.tb12094.x; WALKER B, 1993, J BIOL CHEM, V268, P5285; WALKER B, 1994, PROTEIN ENG, V7, P91, DOI 10.1093/protein/7.1.91; WALKER B, 1992, J BIOL CHEM, V267, P21782; WARD RJ, 1994, BIOCHEMISTRY-US, V33, P7477, DOI 10.1021/bi00189a056; WINISKI AP, 1986, BIOCHEMISTRY-US, V25, P8206, DOI 10.1021/bi00373a013; WINISKI AP, 1988, BIOCHEMISTRY-US, V27, P386, DOI 10.1021/bi00401a058	44	32	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8655	8660		10.1074/jbc.271.15.8655	http://dx.doi.org/10.1074/jbc.271.15.8655			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621496	hybrid			2022-12-25	WOS:A1996UE73000027
J	Wery, S; Letourneur, M; Bertoglio, J; Pierre, J				Wery, S; Letourneur, M; Bertoglio, J; Pierre, J			Interleukin-4 induces activation of mitogen-activated protein kinase and phosphorylation of Shc in human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; CELLS; ASSOCIATION; RECEPTOR; CASCADE; GRB2	Most cytokines stimulate the p21(ras) pathway, leading to MAP kinase activation. One exception is interleukin-4 (IL-4), which has been shown not to activate this pathway in hematopoietic cells. However, IL-4 acts on a broad range of cells, including keratinocytes, in which it induces IL-6 production. We report here that IL-4 stimulation of human keratinocytic cell lines or primary cultures activates MAP kinase. In these cells, IL-4 stimulation induces the tyrosine phosphorylation of p42/44 MAP kinase as well as its catalytic activity, We also observed an increased phosphorylation of p46(shc), an SH2-containing protein involved in the Pas pathway, as a result of IL-4 stimulation in human keratinocytic cell lines but not in T lymphocytes.	FAC PHARM CHATENAY MALABRY,INSERM CJF 9301,F-92296 CHATENAY MALABRY,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay								AGBOTOUNOU WK, 1994, MOL PHARMACOL, V45, P922; AGBOTOUNOU WK, 1994, BIOCHEM PHARMACOL, V48, P505, DOI 10.1016/0006-2952(94)90280-1; AUGUSTINE JA, 1990, BIOCHIM BIOPHYS ACTA, V1052, P313, DOI 10.1016/0167-4889(90)90227-5; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAMEN JE, 1993, BLOOD, V82, P2296; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEROCQ JM, 1994, FEBS LETT, V343, P32, DOI 10.1016/0014-5793(94)80601-2; DERYNCK R, 1987, CANCER RES, V47, P707; ESSNER R, 1989, J IMMUNOL, V142, P3857; GOLD MR, 1994, J BIOL CHEM, V269, P5403; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; IZUHARA K, 1993, J BIOL CHEM, V268, P13097; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NOELHUDSON MS, 1995, IN VITRO CELL DEV, V31, P508; PAUL WE, 1991, BLOOD, V77, P1859; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RENNICK DM, 1992, IL4 STRUCTURE FUNCTI, P51; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TAYLORPAPADIMITRIOU J, 1982, CELL DIFFER DEV, V11, P169, DOI 10.1016/0045-6039(82)90008-2; TOBE K, 1995, J BIOL CHEM, V270, P5698, DOI 10.1074/jbc.270.11.5698; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WELHAM MJ, 1994, J BIOL CHEM, V269, P5865; WELHAM MJ, 1992, J IMMUNOL, V149, P1683; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407	36	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8529	8532		10.1074/jbc.271.15.8529	http://dx.doi.org/10.1074/jbc.271.15.8529			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621475	hybrid			2022-12-25	WOS:A1996UE73000006
J	Liu, X; Vega, QC; Decker, RA; Pandey, A; Worby, CA; Dixon, JE				Liu, X; Vega, QC; Decker, RA; Pandey, A; Worby, CA; Dixon, JE			Oncogenic RET receptors display different autophosphorylation sites and substrate binding specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ENDOCRINE NEOPLASIA; PROTEIN TYROSINE KINASE; EGF-RECEPTOR; PROTOONCOGENE; MUTATIONS; TYPE-2A	The c-ret proto-oncogene encodes a receptor tyrosine kinase which plays an important role in neural crest as well as kidney development, Genetic studies have demonstrated that germ line mutations in the ret oncogene are the direct cause of multiple endocrine neoplasia (MEN) 2A and 2B, familial medullary thyroid carcinoma (FMTC), and Hirschsprung's disease. However, despite the large body of genetic and biological evidence suggesting the importance of RET in development and neoplastic processes, the signal transduction mechanisms of RET remain unknown. To begin to understand the molecular mechanisms of the disease states caused by mutations in RET, the patterns of autophosphorylation of the wild-type RET and the MEN mutants were studied using site-directed mutagenesis and phosphopeptide mapping, Among the 6 autophosphorylation sites found in the wild-type RET receptor, the MEN2B mutant lacked phosphorylation at Tyr-1096, leading to decreased Grb2 binding, while simultaneously creating a new phosphorylation site. These changes in autophosphorylation suggest that the MEN2B mutation may result in the more aggressive MEN2B phenotype by altering the receptor's signaling capabilities.	UNIV MICHIGAN, SCH MED, DEPT BIOL CHEM, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT SURG, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Pandey, Akhilesh/B-4127-2009	Pandey, Akhilesh/0000-0001-9943-6127	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018024, K08DK002176, R01DK018849, R01DK018024] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02176, DK18024, DK18849] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; DECKER RA, 1989, JPN J SURG, V19, P645, DOI 10.1007/BF02471714; DECKER RA, 1992, SURGERY, V112, P1066; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; ITOH F, 1989, Tumor Research, V24, P1; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	22	120	128	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5309	5312		10.1074/jbc.271.10.5309	http://dx.doi.org/10.1074/jbc.271.10.5309			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621380	hybrid			2022-12-25	WOS:A1996TZ28600006
J	Vietor, I; Oliveira, IC; Vilcek, J				Vietor, I; Oliveira, IC; Vilcek, J			CCAAT box enhancer binding protein alpha(C/EBP-alpha) stimulates kappa B element-mediated transcription in transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNERGISTICALLY ACTIVATE TRANSCRIPTION; ALPHA-1-ACID GLYCOPROTEIN GENE; C/EBP FAMILY MEMBERS; DNA-BINDING; NUCLEAR FACTOR; GLUCOCORTICOID RECEPTOR; INFLAMMATORY CYTOKINES; INTERLEUKIN-8 GENE; EXPRESSION NF-IL6; ISOFORMS	A construct comprising three tandemly repeated copies of the kappa B element from the interleukin-8 gene linked to chloramphenicol acetyltransferase (CAT) (3xNF-kappa BCAT) was transcriptionally activated in normal human FS-4 fibroblasts by co-transfection with expression vectors for NF-kappa B p50, p65, or p52, Unexpectedly, a significant activation of 3xNF-kappa BCAT was also seen upon its co-transfection with the expression vector for CCAAT box enhancer binding protein alpha (C/EBP-alpha) (but not C/EBP-beta or C/EBP-delta), Stimulation by C/EBP-alpha required some other factor(s) present in FS-4 cells because no transcriptional activation of 3xNF-kappa BCAT was seen after co-transfection with C/EBP-alpha in F9 mouse embryonic carcinoma cells, known to be deficient in several transcription factors. To determine whether transcriptional activation was the result of interaction with one of the major NF-kappa B proteins, we co-transfected C/EBP-alpha with NF-kappa B p50, p65, p50 + p65, or p52 into F9 or FS-4 cells. No cooperative interaction was seen; in fact, C/EBP-alpha reduced p65-stimulated transcription, especially in F9 cells. Electrophoretic mobility shift assay with a kappa B probe revealed that the addition of recombinant C/EBP-alpha protein to nuclear extracts from untreated FS-4 cells resulted in the appearance of four bands. Only one of these bands was supershifted by antibody to p50, whereas antibodies to p65 or other NF-kappa B proteins had no effect. Our findings show that C/EBP-alpha may cause activation of some kappa B element-containing genes lacking C/EBP binding sites.	NYU,MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; SLOVAK ACAD SCI,INST EXPTL ENDOCRINOL,BRATISLAVA 83306,SLOVAKIA; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; Slovak Academy of Sciences; New York University					NATIONAL CANCER INSTITUTE [R35CA049731] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA49731] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1993, J BIOL CHEM, V268, P15681; ALAM T, 1992, J BIOL CHEM, V267, P5021; ALTMEYER A, 1995, J BIOL CHEM, V270, P25584, DOI 10.1074/jbc.270.43.25584; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; BLANK V, 1991, EMBO J, V10, P4159, DOI 10.1002/j.1460-2075.1991.tb04994.x; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BRASIER AR, 1994, KIDNEY INT, V46, P1564, DOI 10.1038/ki.1994.447; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHANG MS, 1994, J BIOL CHEM, V269, P25277; CHENKIANG S, 1993, CURR OPIN IMMUNOL, V5, P124, DOI 10.1016/0952-7915(93)90091-6; DIEHL JA, 1994, MOL CELL BIOL, V14, P6635, DOI 10.1128/MCB.14.10.6635; DUNN SM, 1994, BLOOD, V83, P2469, DOI 10.1182/blood.V83.9.2469.2469; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GAROUFALIS E, 1994, J VIROL, V68, P4707, DOI 10.1128/JVI.68.8.4707-4715.1994; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; HUANG JH, 1994, MOL CELL BIOL, V14, P4475, DOI 10.1128/MCB.14.7.4475; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KUNSCH C, 1994, J IMMUNOL, V153, P153; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LORIAUX MM, 1994, J BIOL CHEM, V269, P28839; MASSON N, 1992, MOL CELL BIOL, V12, P1096, DOI 10.1128/MCB.12.3.1096; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NISHIO Y, 1993, MOL CELL BIOL, V13, P1854, DOI 10.1128/MCB.13.3.1854; OLIVEIRA IC, 1994, MOL CELL BIOL, V14, P5300, DOI 10.1128/MCB.14.8.5300; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RAY A, 1995, J BIOL CHEM, V270, P7365, DOI 10.1074/jbc.270.13.7365; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; Sambrook J., 2002, MOL CLONING LAB MANU; SCOTT LM, 1992, BLOOD, V80, P1725; SHATTUCK RL, 1994, MOL CELL BIOL, V14, P791, DOI 10.1128/MCB.14.1.791; SHIMIZU H, 1994, GENE, V149, P305; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TEN RM, 1993, CR ACAD SCI III-VIE, V316, P496; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; VALLEJO M, 1993, P NATL ACAD SCI USA, V90, P4679, DOI 10.1073/pnas.90.10.4679; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P	55	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5595	5602		10.1074/jbc.271.10.5595	http://dx.doi.org/10.1074/jbc.271.10.5595			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621420	hybrid			2022-12-25	WOS:A1996TZ28600046
J	Lightner, DA; Holmes, DL; McDonagh, AF				Lightner, DA; Holmes, DL; McDonagh, AF			On the acid dissociation constants of bilirubin and biliverdin - pK(alpha) values from C-13 NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCONJUGATED BILIRUBIN; BILE-SALTS; IONIZATION; CHLOROFORM; CHEMISTRY; CONFORMATION; PHOTOTHERAPY; SOLUBILITY; METABOLISM; TRANSPORT	Biliverdin and bilirubin are naturally-occurring tetrapyrrolic bile pigments containing two propionic acid side chains, These side chains, and their propensity for ionization, are critical in the biological disposition of the pigments, Surprisingly, accurate dissociation constants for the propionic acid groups of biliverdin are unknown, and a wide range of values, extending over some 4 orders of magnitude, has been suggested for the K-alpha values of the propionic acid groups of bilirubin in aqueous solutions, Recently, pR(alpha) values of 6.7-9.3 have been reported for bilirubin-values much greater than the value of similar to 5 typical of propionic acid groups, These curiously high values, currently being used to explain the biological transport and metabolism of bilirubin and related compounds, have been attributed to intramolecular hydrogen bonding, We have determined the pK(alpha) values of 99% C-13-enriched ((CO2H)-C-13) [8(3),12(3)-C-13(2)]-mesobilirubin-XIII alpha, the corresponding biliverdin, and several monopropionic model compounds by C-13 NMR spectroscopy, This technique allows direct observation and quantitative measurement of the carboxylic acid and carboxylate anion carbon signals, Analysis of the variation of carboxyl C-13 NMR chemical shift with pH gave rubin pK(alpha) values of 4.2 and 4.9 and verdin pK(alpha) values of 3.9 and 5.3 in aqueous buffers containing only a very small quantity (0.086 mol fraction) of dimethyl sulfoxide, When extrapolated to water, the pK(alpha) values are essentially unchanged, The data provide the first experimentally-determined pK(alpha) values for a biliverdin, They indicate that intramolecular hydrogen bonding has little effect on the acid dissociation of bilirubin and suggest that the equilibrium acidity of the bilirubin carboxylic acid groups is not abnormally high but similar to the thermodynamic acidity found in other carboxylic acids, as originally suggested by Overbeek et al. (Overbeek, J. T. G., Vink, C. L. J., and Deenstra, H. (1955) Recl. Trav. Chim. Pays-Bas 74, 81-84).	UNIV NEVADA,DEPT BIOCHEM,RENO,NV 89557; UNIV CALIF SAN FRANCISCO,DIV GASTROENTEROL,SAN FRANCISCO,CA 94143	Nevada System of Higher Education (NSHE); University of Nevada Reno; University of California System; University of California San Francisco	Lightner, DA (corresponding author), UNIV NEVADA,DEPT CHEM,RENO,NV 89557, USA.				NICHD NIH HHS [HD-17779] Funding Source: Medline; NIDDK NIH HHS [DK-26307, DK-26743] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017779] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026307, P30DK026743] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENET LZ, 1967, J PHARM SCI, V56, P665, DOI 10.1002/jps.2600560602; BERK PD, 1994, SEMIN LIVER DIS, V14, P323, DOI 10.1055/s-2007-1007322; BOIADJIEV SE, 1992, J AM CHEM SOC, V114, P10123, DOI 10.1021/ja00052a006; BONNETT R, 1978, PROC R SOC SER B-BIO, V202, P249, DOI 10.1098/rspb.1978.0066; CABRAL DJ, 1986, J LIPID RES, V27, P334; CAREY MC, 1984, HEPATOLOGY, V4, pS223, DOI 10.1002/hep.1840040841; CAREY MC, 1986, BILE PIGMENTS JAUNDI, P81; CHANTOONI MK, 1975, J PHYS CHEM-US, V79, P1176, DOI 10.1021/j100579a007; CISTOLA DP, 1988, BIOCHEMISTRY-US, V27, P711, DOI 10.1021/bi00402a033; COHEN AN, 1980, PEDIATRICS, V65, P740; COWDURY JR, 1995, METABOLIC MOL BASES, V2, P2161; EBERSON L, 1963, ACTA CHEM SCAND, V17, P1552, DOI 10.3891/acta.chem.scand.17-1552; Eberson L., 1969, CHEM CARBOXYLIC ACID, P211; Falk H., 1989, CHEM LINEAR OLIGOPYR; GAWRONSKI JK, 1990, TETRAHEDRON, V46, P8053, DOI 10.1016/S0040-4020(01)81462-9; GRAY CH, 1961, J CHEM SOC, P2276, DOI 10.1039/jr9610002276; HAGEN R, 1969, J AM CHEM SOC, V91, P4504, DOI 10.1021/ja01044a032; HAHM JS, 1992, J LIPID RES, V33, P1123; HANSEN PE, 1979, ACTA CHEM SCAND B, V33, P281, DOI 10.3891/acta.chem.scand.33b-0281; HARMAN AD, 1993, J CHROMATOGR A, V652, P525, DOI 10.1016/0021-9673(93)83274-V; HOLMES DL, 1995, J HETEROCYCLIC CHEM, V32, P113, DOI 10.1002/jhet.5570320120; HOLMES DL, 1995, TETRAHEDRON, V51, P1607, DOI 10.1016/0040-4020(94)01052-2; KAPLAN D, 1983, ISRAEL J CHEM, V23, P177; KING EJ, 1965, INT ENCY PHYSICAL CH, V4; KING JF, 1963, TECHNIQUES ORGANIC C, V11, P319; KOLOSOV IV, 1977, ZH OBSHCH KHIM+, V47, P2149; KRASNER J, 1973, BIOCHEM MED METAB B, V7, P128, DOI 10.1016/0006-2944(73)90108-7; LEBAS G, 1980, ACTA CRYSTALLOGR B, V36, P3007, DOI 10.1107/S0567740880010692; LEE JJ, 1974, RES COMMUN CHEM PATH, V9, P763; LEE KS, 1976, PEDIATR RES, V10, P782, DOI 10.1203/00006450-197609000-00004; LONDON RE, 1980, J MAGN RESON, V38, P173, DOI 10.1016/0022-2364(80)90189-4; LUCASSEN J, 1961, DIAZO REACTION BILRU; MARKLEY JL, 1975, ACCOUNTS CHEM RES, V8, P70, DOI 10.1021/ar50086a004; McDonagh A. F., 1979, PORPHYRINS, VVI; MCDONAGH AF, 1985, PEDIATRICS, V75, P443; MCDONAGH AF, 1988, SEMIN LIVER DIS, V8, P272, DOI 10.1055/s-2008-1040549; MOROI Y, 1985, B CHEM SOC JPN, V58, P1426, DOI 10.1246/bcsj.58.1426; MUGNOLI A, 1983, ACTA CRYSTALLOGR C, V39, P1287, DOI 10.1107/S0108270183008252; MURACA M, 1988, SEMIN LIVER DIS, V8, P137, DOI 10.1055/s-2008-1040534; NOGALES D, 1995, J BIOL CHEM, V270, P73, DOI 10.1074/jbc.270.1.73; NOGALES DF, 1994, J LABELLED COMPD RAD, V34, P453, DOI 10.1002/jlcr.2580340508; OSTROW JD, 1994, J LIPID RES, V35, P1715; OSTROW JD, 1984, HEPATOLOGY, V4, pS38, DOI 10.1002/hep.1840040807; OSTROW JD, 1988, J LIPID RES, V29, P335; OVERBECK JTG, 1995, RECL TRAV CHIM PAY B, V74, P81; PERSON RV, 1994, J AM CHEM SOC, V116, P42, DOI 10.1021/ja00080a006; PHILLIPS J. N., 1960, REVS PURE AND APPL CHEM, V10, P35; PU YM, 1991, TETRAHEDRON, V47, P6163, DOI 10.1016/S0040-4020(01)86549-2; Serjeant E.P., 1979, IUPAC CHEM DATA SERI; SHELDRICK WS, 1983, ISRAEL J CHEM, V23, P155; SHELVER WL, 1994, J MOL STRUCT, V312, P1; SHROUT DP, 1993, SPECTROSC LETT, V26, P461, DOI 10.1080/00387019308011545; TIRIBELLI C, 1990, HEPATOLOGY, V11, P303, DOI 10.1002/hep.1840110222; TIRIBELLI C, 1993, HEPATOLOGY, V17, P715, DOI 10.1002/hep.1840170428; TIRIBELLI C, 1995, IN PRESS HEPATOLOGY; WENNBERG RP, 1988, PEDIATR RES, V23, P443, DOI 10.1203/00006450-198804000-00021; WESTHEIMER FH, 1956, J AM CHEM SOC, V78, P5309, DOI 10.1021/ja01601a042	57	57	59	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2397	2405		10.1074/jbc.271.5.2397	http://dx.doi.org/10.1074/jbc.271.5.2397			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576198	hybrid			2022-12-25	WOS:A1996TT48800012
J	Mynarcik, DC; Yu, GQ; Whittaker, J				Mynarcik, DC; Yu, GQ; Whittaker, J			Alanine-scanning mutagenesis of a C-terminal ligand binding domain of the insulin receptor alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; MONOCLONAL-ANTIBODIES; DETERMINANTS; SPECIFICITY; HORMONE; IDENTIFICATION; ECTODOMAIN; GENE; SITE; CHIMERAS	A recent affinity labeling study has suggested that amino acids 704-717 of the C terminus of the insulin receptor represent a contact site for insulin. To determine whether these amino acids are part of a ligand binding site, we have performed alanine-scanning mutagenesis of this region, Mutant cDNAs encoding recombinant secreted receptors were transiently expressed in 293 EBNA cells, and their insulin binding properties were evaluated, Of the 14 residues in this region only 4 amino acids, Asp-707, Val-712, Pro-716, and Arg-717, could be mutated to alanine without compromising insulin binding, The reduction in affinity resulting from the individual mutation of the remaining amino acids varied from an increase in K-d to 3.69 x 10(-9) M (Asn-711) to greater than 10(-6) M (Thr-704, Phe-705, Glu-706, and His-710); the K-d of native secreted recombinant receptor is 0.56 x 10(-9) M.	SUNY STONY BROOK, HLTH SCI CTR, DEPT MED, DIV ENDOCRINOL, STONY BROOK, NY 11794 USA; SUNY STONY BROOK, DEPT PHYSIOL & BIOPHYS, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NIDDK NIH HHS [R01DK 42171] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042171] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; DEMEYTS P, 1990, MOL ENDOCRINOL, V4, P409, DOI 10.1210/mend-4-3-409; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Ellis L, 1988, J Mol Recognit, V1, P25, DOI 10.1002/jmr.300010106; FRATTALI AL, 1992, J BIOL CHEM, V267, P19521; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HARLOW E, 1988, ANTIBODIES LABORATOR; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JOHNSON JD, 1988, P NATL ACAD SCI USA, V85, P7516, DOI 10.1073/pnas.85.20.7516; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; KUROSE T, 1994, J BIOL CHEM, V269, P29190; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PRIGENT SA, 1990, J BIOL CHEM, V265, P9970; Sambrook J, 1989, MOL CLONING LABORATO; SCHAEFER EM, 1992, J BIOL CHEM, V267, P23393; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; SCHUMACHER R, 1991, J BIOL CHEM, V266, P19288; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAUGH SM, 1989, BIOCHEMISTRY-US, V28, P3448, DOI 10.1021/bi00434a045; WEDEKIND F, 1989, BIOL CHEM H-S, V370, P251, DOI 10.1515/bchm3.1989.370.1.251; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WHITTAKER J, 1988, J BIOL CHEM, V263, P3063; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; YAMAGUCHI Y, 1991, ENDOCRINOLOGY, V129, P2058, DOI 10.1210/endo-129-4-2058; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938	36	74	94	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2439	2442		10.1074/jbc.271.5.2439	http://dx.doi.org/10.1074/jbc.271.5.2439			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576204	hybrid			2022-12-25	WOS:A1996TT48800018
J	Rajamohan, F; Cotrill, JA; Gould, F; Dean, DH				Rajamohan, F; Cotrill, JA; Gould, F; Dean, DH			Role of domain II, loop 2 residues of Bacillus thuringiensis CryIAb delta-endotoxin in reversible and irreversible binding to Manduca sexta and Heliothis virescens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; INSECTICIDAL CRYSTAL PROTEINS; BUTTERFLY PIERIS-BRASSICAE; MIDGUT MEMBRANE; BOMBYX-MORI; VESICLES; LEPIDOPTERAN; RESISTANCE; TOXINS; SPECIFICITY	Site-directed mutagenesis was used to examine the role of domain II, loop 2 residues, (368)RRPFNIGI(375), of Bacillus thuringiensis insecticidal protein CryIAb, Alanine substitution of residues (368)RRP(370), called B4, abolished potency toward Manduca sexta and Heliothis virescens, and the loss of toxicity was correlated directly to substantially reduced binding affinity to brush-border membrane vesicles (BBMV) prepared from the target insect midguts, These results indicated that these positive charges might be essential to orient the toxin to midgut receptor molecule(s), The role of residue Phe(371) of CryIAb toxin to M. sexta was investigated by substituting a series of residues at this position, Irreversible binding and toxicity were affected significantly by hydrophilic, aliphatic, and smaller side chain residues such as Cys, Val, Leu, and Ser but not by Tyr or Trp, A hydrophobic aromatic side chain residue at position 371 was therefore essential for irreversible binding of CryIAb toxin in M. sexta, The role of residues (370)PFNIGI(375) Of CryIAb toxin on H. virescens was also examined, Mutants D2 (deletion of residues 370-375), G374A (alanine substitution of Gly(374)), and I375A had reduced toxicity to H. virescens, In contrast to our findings with M. sexta, the reduction in toxicity of these mutants was correlated directly with loss of initial binding to H. virescens BBMV, indicating that these residues perform functionally distinct roles in binding and toxicity to different insects, In ligand blots, CryIAb recognized a major 210-kDa peptide in M. sexta BBMV and a 170-kDa peptide in H. virescens BBMV.	OHIO STATE UNIV, DEPT BIOCHEM, COLUMBUS, OH 43210 USA; N CAROLINA STATE UNIV, DEPT ENTOMOL, RALEIGH, NC 27695 USA	University System of Ohio; Ohio State University; University of North Carolina; North Carolina State University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029092] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI 29092] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRAVO A, 1992, J INVERTEBR PATHOL, V60, P247, DOI 10.1016/0022-2011(92)90005-O; BURTON R L, 1970, Journal of Economic Entomology, V63, P1969, DOI 10.1093/jee/63.6.1969; CHAMBERLIN ME, 1990, J EXP BIOL, V150, P467; CHEN XJ, 1993, P NATL ACAD SCI USA, V90, P9041, DOI 10.1073/pnas.90.19.9041; CUMMINGS CE, 1994, MICROBIOL-SGM, V140, P2737, DOI 10.1099/00221287-140-10-2737; ENGLISH LH, 1991, INSECT BIOCHEM, V21, P177, DOI 10.1016/0020-1790(91)90048-J; FERRE J, 1991, P NATL ACAD SCI USA, V88, P5119, DOI 10.1073/pnas.88.12.5119; GE AZ, 1991, J BIOL CHEM, V266, P17954; GOULD F, 1995, J ECON ENTOMOL, V88, P1545, DOI 10.1093/jee/88.6.1545; GOULD F, 1992, P NATL ACAD SCI USA, V89, P7986, DOI 10.1073/pnas.89.17.7986; HARVEY WR, 1990, METHOD ENZYMOL, V192, P599; HENDRICKX K, 1990, COMP BIOCHEM PHYS C, V95, P241, DOI 10.1016/0742-8413(90)90112-M; HOFMANN C, 1988, EUR J BIOCHEM, V173, P85, DOI 10.1111/j.1432-1033.1988.tb13970.x; HUBER HE, 1981, PATHOGENESIS INVERTE, P209; IHARA H, 1993, BIOSCI BIOTECH BIOCH, V57, P200, DOI 10.1271/bbb.57.200; KNOWLES BH, 1987, BIOCHIM BIOPHYS ACTA, V924, P509, DOI 10.1016/0304-4165(87)90167-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1992, J BIOL CHEM, V267, P3115; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; LU H, 1994, J BACTERIOL, V176, P5554, DOI 10.1128/JB.176.17.5554-5559.1994; MARTIN FG, 1995, J EXP BIOL, V198, P91; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; ODDOU P, 1991, EUR J BIOCHEM, V202, P673, DOI 10.1111/j.1432-1033.1991.tb16422.x; OPPERT B, 1994, BIOCHEM BIOPH RES CO, V198, P940, DOI 10.1006/bbrc.1994.1134; RAJAMOHAN F, 1995, J BACTERIOL, V177, P2276, DOI 10.1128/jb.177.9.2276-2282.1995; Raymond M., 1985, Cahiers O.R.S.T.O.M., Serie Entomologie Medicale et Parasitologie, V23, P117; SACCHI VF, 1986, FEBS LETT, V204, P213, DOI 10.1016/0014-5793(86)80814-6; SANGADALA S, 1994, J BIOL CHEM, V269, P10088; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ JL, 1993, J MEMBRANE BIOL, V132, P53, DOI 10.1007/BF00233051; SMITH GP, 1994, BIOCHEM J, V302, P611, DOI 10.1042/bj3020611; VADLAMUDI RK, 1993, J BIOL CHEM, V268, P12334; VANRIE J, 1990, SCIENCE, V247, P72, DOI 10.1126/science.2294593; WALTERS FS, 1994, INSECT BIOCHEM MOLEC, V24, P963, DOI 10.1016/0965-1748(94)90133-3; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; WOLFERSBERGER MG, 1990, EXPERIENTIA, V46, P475, DOI 10.1007/BF01954236	37	62	77	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2390	2396		10.1074/jbc.271.5.2390	http://dx.doi.org/10.1074/jbc.271.5.2390			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576197	hybrid			2022-12-25	WOS:A1996TT48800011
J	Wotton, D; Freeman, K; Shore, D				Wotton, D; Freeman, K; Shore, D			Multimerization of Hsp42p, a novel heat shock protein of Saccharomyces cerevisiae, is dependent on a conserved carboxyl-terminal sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; TELOMERE LENGTH; YEAST; GENES; HSP26; RAP1; PURIFICATION; DROSOPHILA; BINDING; SYSTEM	Rap1p is a transcriptional regulator of Saccharomyces cerevisiae, which plays roles in both transcriptional activation and silencing, To identify proteins involved in Rap1p-dependent regulation of transcription, we used the two-hybrid system to screen for Rap1p-interacting proteins. Two of the clones isolated from this screen encode a truncated protein with homology to small heat shock proteins (HSPs). Here we present an analysis of this novel S. cereuisiae HSP, which we name Hsp42p, Expression of HSP42 is regulated by a range of stress conditions similar to S. cerevisiae HSP26, with which Hsp42p shares most homology. However, HSP42 expression is more sensitive to increased salt concentration and to starvation and, in contrast to HSP26 is expressed in unstressed cells. Hsp42p interacts with itself in the two-hybrid assay. This interaction is dependent on a hydrophobic region which is conserved among small HSPs, Using bacterially expressed Hsp42p fusion proteins, we demonstrate that this is a direct interaction. Fractionation of yeast protein extracts by size demonstrates that all of the Hsp42p in these extracts is present in complexes with a molecular mass of greater than 200 kDa, suggesting that Hsp42p exists in high molecular mass complexes.			Wotton, D (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,701 W 168TH ST,NEW YORK,NY 10032, USA.		Shore, David/F-6240-2015	Shore, David/0000-0002-9859-143X; Wotton, David/0000-0002-4652-5350	NCI NIH HHS [CA09503-0] Funding Source: Medline; NIGMS NIH HHS [GM40094] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040094] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; AYME A, 1985, EMBO J, V4, P2949, DOI 10.1002/j.1460-2075.1985.tb04028.x; BARDWELL JCA, 1984, P NATL ACAD SCI-BIOL, V81, P848, DOI 10.1073/pnas.81.3.848; BENDIXEN C, 1994, NUCLEIC ACIDS RES, V22, P1778, DOI 10.1093/nar/22.9.1778; BENTLEY NJ, 1992, YEAST, V8, P95, DOI 10.1002/yea.320080204; BITTER GA, 1991, MOL GEN GENET, V231, P22, DOI 10.1007/BF00293817; BUCK SW, 1995, GENE DEV, V9, P370, DOI 10.1101/gad.9.3.370; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COLLIER NC, 1988, J CELL BIOL, V106, P1131, DOI 10.1083/jcb.106.4.1131; HARDY CFJ, 1992, MOL CELL BIOL, V12, P1209, DOI 10.1128/MCB.12.3.1209; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; INGOLIA TD, 1982, P NATL ACAD SCI USA, V79, P855; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KURTZ S, 1986, SCIENCE, V231, P1154, DOI 10.1126/science.3511530; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOOMIS WF, 1982, DEV BIOL, V90, P412, DOI 10.1016/0012-1606(82)90390-6; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; NAGAO RT, 1985, MOL CELL BIOL, V5, P3417, DOI 10.1128/MCB.5.12.3417; NISHIZAWA M, 1989, MOL CELL BIOL, V9, P442, DOI 10.1128/MCB.9.2.442; NOVER L, 1989, MOL CELL BIOL, V9, P1298, DOI 10.1128/MCB.9.3.1298; PETKO L, 1986, CELL, V45, P885, DOI 10.1016/0092-8674(86)90563-5; PLESOFSKYVIG N, 1990, J BIOL CHEM, V265, P15432; PRAEKELT UM, 1990, MOL GEN GENET, V223, P97, DOI 10.1007/BF00315801; ROSENBERG M, 1990, MICROBIAL CELL SURFA, P1; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SIKORSKI RS, 1989, GENETICS, V122, P19; SUSEK RE, 1989, MOL CELL BIOL, V9, P5265, DOI 10.1128/MCB.9.11.5265; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; SUSSEL L, 1993, MOL CELL BIOL, V13, P3919, DOI 10.1128/MCB.13.7.3919; VARELA JCS, 1992, MOL MICROBIOL, V6, P2183, DOI 10.1111/j.1365-2958.1992.tb01392.x; VIGNAIS ML, 1987, EMBO J, V6, P1451, DOI 10.1002/j.1460-2075.1987.tb02386.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	36	41	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2717	2723		10.1074/jbc.271.5.2717	http://dx.doi.org/10.1074/jbc.271.5.2717			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576246	hybrid			2022-12-25	WOS:A1996TT48800060
J	Ardehali, H; Yano, Y; Printz, RL; Koch, S; Whitesell, RR; May, JM; Granner, DK				Ardehali, H; Yano, Y; Printz, RL; Koch, S; Whitesell, RR; May, JM; Granner, DK			Functional organization of mammalian hexokinase II - Retention of catalytic and regulatory functions in both the NH2- and COOH-terminal halves	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN HEXOKINASE; AMINO-ACID SEQUENCE; STRUCTURAL DOMAIN; LIVER GLUCOKINASE; BINDING-SITE; CLONED CDNA; C-TERMINUS; ENZYME; LOCATION; GENE	The mammalian hexokinase (HK) family includes three closely related 100-kDa isoforms (HKI-III) that are thought to have arisen from a common 50-kDa precursor by gene duplication and tandem ligation. Previous studies of HKI indicated that a glucose B-phosphate (Glu-6-P)-regulated catalytic site resides in the COOH-terminal half of the molecule and that the NH2-terminal half contains only a Glu-6-P binding site. In contrast, we now show that proteins representing both halves of human and rat HKII have catalytic activity and that each is inhibited by Glu-6-P. The intact enzyme and the NH2 and COOH-terminal halves of the enzyme each increase glucose utilization when expressed in Xenopus oocytes. Mutations corresponding to either Asp-209 or Asp-657 in the intact enzyme completely inactivate the NH2- and COOH-terminal half enzymes, respectively. Mutation of either of these sites results in a 50% reduction of activity in the 100-kDa enzyme. Mutation of both sites results in a complete loss of activity. This suggests that each half of the HKII molecule retains catalytic activity within the 100-kDa protein. These observations indicate that HKI and HKII are functionally distinct and have evolved differently.	VANDERBILT UNIV,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MED,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK020593, R01DK046867, R01DK019925, P60DK020593] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46867, DK20593, DK19925] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREONE TL, 1989, J BIOL CHEM, V264, P363; ARORA KK, 1993, J BIOL CHEM, V268, P18259; BAIJAL M, 1992, ARCH BIOCHEM BIOPHYS, V298, P271, DOI 10.1016/0003-9861(92)90123-E; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P173, DOI 10.1016/0926-6569(63)90226-8; DEEB SS, 1993, BIOCHEM BIOPH RES CO, V197, P68, DOI 10.1006/bbrc.1993.2442; FROHLICH KU, 1985, GENE, V36, P105, DOI 10.1016/0378-1119(85)90074-5; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; LANGE AJ, 1991, BIOCHEM J, V277, P159, DOI 10.1042/bj2770159; MAGNUSON MA, 1989, P NATL ACAD SCI USA, V86, P4838, DOI 10.1073/pnas.86.13.4838; MOCHIZUKI Y, 1981, COMP BIOCHEM PHYS B, V70, P745, DOI 10.1016/0305-0491(81)90011-0; MOCHIZUKI Y, 1977, J BIOCHEM, V81, P1849, DOI 10.1093/oxfordjournals.jbchem.a131646; MORITA H, 1994, J CLIN INVEST, V94, P1373, DOI 10.1172/JCI117472; NEMATGORGANI M, 1986, ARCH BIOCHEM BIOPHYS, V251, P97, DOI 10.1016/0003-9861(86)90055-X; PRINTZ RL, 1995, DIABETES, V44, P290, DOI 10.2337/diabetes.44.3.290; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; SCHIRCH DM, 1987, ARCH BIOCHEM BIOPHYS, V254, P385, DOI 10.1016/0003-9861(87)90116-0; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; STORER AC, 1976, BIOCHEM J, V159, P7, DOI 10.1042/bj1590007; TIELENS AGM, 1994, J BIOL CHEM, V269, P24736; WHITE TK, 1990, ARCH BIOCHEM BIOPHYS, V277, P26, DOI 10.1016/0003-9861(90)90545-A; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7; WHITE TK, 1987, ARCH BIOCHEM BIOPHYS, V259, P402, DOI 10.1016/0003-9861(87)90506-6; WHITESELL RR, 1995, J CEREBR BLOOD F MET, V15, P814, DOI 10.1038/jcbfm.1995.102; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; YANAGAWA HA, 1978, INSECT BIOCHEM, V8, P293, DOI 10.1016/0020-1790(78)90040-9	25	65	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1849	1852		10.1074/jbc.271.4.1849	http://dx.doi.org/10.1074/jbc.271.4.1849			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567628	hybrid			2022-12-25	WOS:A1996TR32000010
J	Chowdhury, NR; Hays, RM; Bommineni, VR; Franki, N; Chowdhury, JR; Wu, CH; Wu, GY				Chowdhury, NR; Hays, RM; Bommineni, VR; Franki, N; Chowdhury, JR; Wu, CH; Wu, GY			Microtubular disruption prolongs the expression of human bilirubin-uridinediphosphoglucuronate-glucuronosyltransferase-1 gene transferred into Gunn rat livers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INVIVO; RECEPTOR; DELIVERY; HEPATOCYTES; PERSISTENCE; ENDOCYTOSIS; BILIRUBIN; LYSOSOMES; VESICLES; COMPLEX	DNA delivered to the liver by asialoglycoprotein receptor-mediated endocytosis is degraded in lysosomes within 48 h, To test the hypothesis that microtubular disruption should promote transgene persistence by interrupting endosomal translocation to lysosomes, plasmids containing bacterial chloramphenicol acetyltransferase (pSV2-CAT) or human bilirubin-UDP-glucuronosyltransferase-1 (pSVK3-hBUGT(1)) genes were complexed with asialoglycoprotein-polylysine conjugates, and 1 mg of the complexed DNA was injected intravenously into bilirubin-UDP-glucuronosyltransferase-deficient Gunn rats, 30 min before DNA injection, one group received 0.75 mg of colchicine/kg of body weight intraperitoneally, which was shown by immunofluorescent confocal microscopy to disrupt the microtubular network, Control rats received normal saline, In colchicine-pretreated rats receiving pSV2-CAT, hepatic chloramphenicol acetyltransferase activity persisted for 9-14 weeks, whereas in the saline pretreated group the activity was detectable for 48 h only, In colchicine-pretreated Gunn rats receiving pSVK3-hBUGT(1), the DNA persisted in liver for 10 weeks, bilirubin glucuronides were excreted in bile, and serum bilirubin levels declined by 25-35% in 2-4 weeks and remained reduced for 8 weeks, Without colchicine pretreatment, the DNA was detectable in liver for 2 days only, and serum bilirubin levels were not reduced, Thus, microtubular disruption provides a noninvasive method for prolonging the effect of liver-targeted gene therapy.	ALBERT EINSTEIN COLL MED, MARION BESSIN LIVER RES CTR, BRONX, NY 10461 USA; ALBERT EINSTEIN COLL MED, DIV GASTROINTESTINAL & LIVER DIS, BRONX, NY 10461 USA; ALBERT EINSTEIN COLL MED, DIV NEPHROL, DEPT MED, BRONX, NY 10461 USA; ALBERT EINSTEIN COLL MED, DEPT MOLEC GENET, BRONX, NY 10461 USA; UNIV CONNECTICUT, HLTH SCI CTR, DEPT MED, DIV GASTROENTEROL, FARMINGTON, CT 06030 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Connecticut					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046057, R01DK039137] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK 39137, R01-DK 46057] Funding Source: Medline; PHS HHS [R01 03858] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLEN RD, 1985, J CELL BIOL, V100, P1736, DOI 10.1083/jcb.100.5.1736; BOMMINENI VR, 1994, J BIOL CHEM, V269, P25200; BOSMA PJ, 1994, J BIOL CHEM, V269, P17960; CHOWDHURY J R, 1981, Hepatology, V1, P622; CHOWDHURY JR, 1992, PATHOPHYSIOLOGY BILE, P713; CHOWDHURY NR, 1993, J BIOL CHEM, V268, P11265; FEVERY J, 1971, BIOCHEM J, V125, P893; GOLTZ JS, 1992, P NATL ACAD SCI USA, V89, P7026, DOI 10.1073/pnas.89.15.7026; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM W, 1990, NATURE, V346, P318; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; OKA JA, 1983, BIOCHIM BIOPHYS ACTA, V763, P368, DOI 10.1016/0167-4889(83)90098-8; RITTER JK, 1992, J BIOL CHEM, V267, P3257; ROZDZIAL MM, 1986, CELL, V47, P1061, DOI 10.1016/0092-8674(86)90821-4; SCHMID K, 1967, BIOCHEM J, V104, P361, DOI 10.1042/bj1040361; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPIVAK W, 1985, BIOCHEM J, V225, P787, DOI 10.1042/bj2250787; TROTMAN BW, 1982, ANAL BIOCHEM, V121, P175, DOI 10.1016/0003-2697(82)90572-3; Weigel P H, 1993, Subcell Biochem, V19, P125; WHITEHEAD PH, 1966, BIOCHIM BIOPHYS ACTA, V124, P209, DOI 10.1016/0304-4165(66)90336-9; WILSON JM, 1992, J BIOL CHEM, V267, P11483; WILSON JM, 1992, J BIOL CHEM, V267, P963; WOLKOFF AW, 1984, J CELL BIOL, V98, P375, DOI 10.1083/jcb.98.2.375; WU CH, 1989, J BIOL CHEM, V264, P16985; WU GY, 1988, J BIOL CHEM, V263, P14621; WU GY, 1991, J BIOL CHEM, V266, P14338	26	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2341	2346		10.1074/jbc.271.4.2341	http://dx.doi.org/10.1074/jbc.271.4.2341			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567698	hybrid			2022-12-25	WOS:A1996TR32000080
J	Liu, Q; Kane, PM; Newman, PR; Forgac, M				Liu, Q; Kane, PM; Newman, PR; Forgac, M			Site-directed mutagenesis of the yeast V-ATPase B subunit (Vma2p)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; VESICLE PROTON PUMP; TRANSLOCATING ADENOSINE-TRIPHOSPHATASE; ESCHERICHIA-COLI F1-ATPASE; ALPHA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; CDNA SEQUENCE; BETA-SUBUNIT; GENES; MEMBRANES	The B subunit of the vacuolar (H+)-ATPase (V-ATPase) has previously been shown to participate in nucleotide binding and to possess significant sequence homology with the alpha subunit of the mitochondrial F-ATPase, which forms the major portion of the noncatalytic nucleotide binding sites and contributes several residues to the catalytic sites of this complex. Based upon the recent x-ray structure of the mitochondrial F-1 ATPase (Abrahams, J. P., Leslie, A. G., Lutter, R., and Walker, J. E. (1994) Nature 370, 621-628), site-directed mutagenesis of the yeast VMA2 gene has been carried out in a strain containing a deletion of this gene. VMA2 encodes the yeast V-ATPase B subunit (Vma2p). Mutations at two residues postulated to be contributed by Vma2p to the catalytic site (R381S and Y352S) resulted in a complete loss of ATPase activity and proton transport, with the former having a partial effect on V-ATPase assembly. Interestingly, substitution of Phe for Tyr-352 had only minor effects on activity (15-30% inhibition), suggesting the requirement for an aromatic ring at this position. Alteration of Tyr-370, which is postulated to be near the adenine binding pocket; at the noncatalytic sites, to Arg, Phe, or Ser caused a 30-50% inhibition of proton transport and ATPase activity, suggesting that an aromatic ring is not essential at this position. Finally, mutagenesis of residues in the region corresponding to the P-loop of the alpha subunit (H180K; H180G, H180D, N181V) also inhibited proton transport and ATPase activity by approximately 30-50%. None of the mutations in either the putative adenine binding pocket nor the P-loop region had any effect on the ability of Vma2p to correctly fold nor on the V-ATPase to correctly assemble. The significance of these results for the structure and function of the nucleotide binding sites on the B subunit is discussed.	TUFTS UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02111 USA; SUNY HLTH SCI CTR, DEPT BIOCHEM & MOLEC BIOL, SYRACUSE, NY 13210 USA	Tufts University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NIGMS NIH HHS [GM 50322, R01 GM034478, GM 34478] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034478, R01GM034478, R01GM050322] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADACHI I, 1990, J BIOL CHEM, V265, P967; ADACHI I, 1990, J BIOL CHEM, V265, P960; ARAI H, 1987, BIOCHEMISTRY-US, V26, P6632, DOI 10.1021/bi00395a011; ARAI H, 1988, J BIOL CHEM, V263, P8796; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BOWMAN BJ, 1988, J BIOL CHEM, V263, P14002; BOWMAN BJ, 1989, J BIOL CHEM, V264, P15606; BOWMAN EJ, 1988, J BIOL CHEM, V263, P13994; DENDA K, 1988, J BIOL CHEM, V263, P17251; FENG Y, 1992, J BIOL CHEM, V267, P5817; FORGAC M, 1992, J BIOENERG BIOMEMBR, V24, P341, DOI 10.1007/BF00762527; FORGAC M, 1989, PHYSIOL REV, V69, P765, DOI 10.1152/physrev.1989.69.3.765; FUTAI M, 1994, BBA-BIOENERGETICS, V1187, P165, DOI 10.1016/0005-2728(94)90104-X; GLUCK S, 1987, J BIOL CHEM, V262, P15780; GRAHAM LA, 1994, J BIOL CHEM, V269, P25974; HIRATA R, 1990, J BIOL CHEM, V265, P6726; HO MN, 1993, J BIOL CHEM, V268, P18286; INATOMI KI, 1989, J BIOL CHEM, V264, P10954; JOUNOUCHI M, 1993, J BIOCHEM-TOKYO, V114, P171, DOI 10.1093/oxfordjournals.jbchem.a124150; KANE PM, 1989, J BIOL CHEM, V264, P19236; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGGIO MB, 1987, J BIOL CHEM, V262, P8981; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; MANOLSON MF, 1985, J BIOL CHEM, V260, P2273; MANOLSON MF, 1988, J BIOL CHEM, V263, P17987; MORIYAMA Y, 1987, J BIOL CHEM, V262, P14723; NELSON H, 1994, J BIOL CHEM, V269, P24150; NELSON H, 1989, J BIOL CHEM, V264, P1775; NELSON H, 1990, P NATL ACAD SCI USA, V87, P3503, DOI 10.1073/pnas.87.9.3503; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PARRY RV, 1989, J BIOL CHEM, V264, P20025; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWEIKL H, 1989, J BIOL CHEM, V264, P11136; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; SOGA S, 1989, ARCH BIOCHEM BIOPHYS, V268, P643, DOI 10.1016/0003-9861(89)90332-9; SUPEKOVA L, 1995, J BIOL CHEM, V270, P13726; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; WARD JM, 1992, PLANT PHYSIOL, V99, P170, DOI 10.1104/pp.99.1.170; WEBER J, 1993, J BIOL CHEM, V268, P6241; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; ZHANG JM, 1995, J BIOL CHEM, V270, P15494, DOI 10.1074/jbc.270.26.15494; ZHANG JM, 1992, J BIOL CHEM, V267, P9773; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102; [No title captured]	50	61	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2018	2022		10.1074/jbc.271.4.2018	http://dx.doi.org/10.1074/jbc.271.4.2018			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567653	hybrid			2022-12-25	WOS:A1996TR32000035
J	Loftus, JC; Halloran, CE; Ginsberg, MH; Feigen, LP; Zablocki, JA; Smith, JW				Loftus, JC; Halloran, CE; Ginsberg, MH; Feigen, LP; Zablocki, JA; Smith, JW			The amino-terminal one-third of alpha(IIb) defines the ligand recognition specificity of integrin alpha(IIb)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; HOMOLOG-SCANNING MUTAGENESIS; PLATELET GPIIB-IIIA; ASP-BINDING DOMAIN; VITRONECTIN RECEPTOR; MONOCLONAL-ANTIBODY; ADHESION RECEPTOR; CELL-ADHESION; SITE; FIBRINOGEN	The integrin alpha subunits play a major role in the regulation of ligand binding specificity. To gain further insight into the regions of the alpha subunits that regulate ligand specificity, we have utilized alpha(v)/alpha(IIb) chimeras to identify regions of alpha(IIb) that when substituted for the homologous regions of alpha(v) switched the ligand binding phenotype of alpha(v) beta(3) to that of alpha(IIb)beta(3). We report that the ligand recognition specificity of beta(3) integrins is regulated by the amino-terminal one-third of the alpha subunit. Substitution of the amino-terminal portion of alpha(v) with the corresponding 334 residues of alpha(IIb) reconstituted reactivity with both alpha(IIb)beta(3)-specific activation dependent (PAC1) and -independent (OPG2) ligand mimetic antibodies in addition to small highly specific activation-dependent ligands. In contrast, substitution of the amino-terminal portion alone or the divalent cation repeats alone were not sufficient to change ligand binding specificity, These data in combination with previous studies demonstrate that integrin ligand recognition requires cooperation between elements in both the alpha and beta subunits and indicate that the ligand binding pocket is a structure assembled from elements of both the alpha and beta subunits.	GD SEARLE & CO, RES & DEV, SKOKIE, IL 60077 USA; LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA	Pfizer; Sanford Burnham Prebys Medical Discovery Institute	Loftus, JC (corresponding author), SCRIPPS RES INST, DEPT VASC BIOL, LA JOLLA, CA 92037 USA.				NHLBI NIH HHS [HL48728, HL42977] Funding Source: Medline; NIAMS NIH HHS [AR27214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048728, R29HL042977, R01HL042977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027214, R37AR027214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADLER M, 1991, SCIENCE, V253, P445, DOI 10.1126/science.1862345; ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; BAJT ML, 1992, J BIOL CHEM, V267, P22211; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BAJT ML, 1992, J BIOL CHEM, V267, P3789; BAJT ML, 1994, J BIOL CHEM, V269, P20913; BETTLER B, 1992, J BIOL CHEM, V267, P185; CHERESH DA, 1987, J BIOL CHEM, V262, P17703; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GULINO D, 1992, J BIOL CHEM, V267, P1001; HUANG X, 1994, MOL BIOL CELL, V4, pA282; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KOUNS WC, 1992, J BIOL CHEM, V267, P18844; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAM SCT, 1987, J BIOL CHEM, V262, P947; LAM SCT, 1992, J BIOL CHEM, V267, P5649; LANZA F, 1992, J CLIN INVEST, V89, P1995, DOI 10.1172/JCI115808; LEAHY DJ, 1992, SCIENCE, V258, P987, DOI 10.1126/science.1279805; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; LOFTUS JC, 1994, J BIOL CHEM, V269, P25235; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1989, BLOOD, V74, P14; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; PIDARD D, 1983, J BIOL CHEM, V258, P2582; RANDI AM, 1994, J BIOL CHEM, V269, P12395; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SAVAGE B, 1990, J BIOL CHEM, V265, P11766; SCARBOROUGH RM, 1991, J BIOL CHEM, V266, P9359; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1990, J BIOL CHEM, V265, P12267; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SUZUKI S, 1987, J BIOL CHEM, V262, P14080; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAUB R, 1989, J BIOL CHEM, V264, P259; TOMIYAMA Y, 1992, J BIOL CHEM, V267, P18085; TOMIYAMA Y, 1992, BLOOD, V79, P2303; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; ZABLOCKI JA, 1993, J MED CHEM, V36, P1811, DOI 10.1021/jm00065a003	53	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2033	2039		10.1074/jbc.271.4.2033	http://dx.doi.org/10.1074/jbc.271.4.2033			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567656	hybrid			2022-12-25	WOS:A1996TR32000038
J	Steenbergen, JF; Fay, FS				Steenbergen, JF; Fay, FS			The quantal nature of calcium release to caffeine in single smooth muscle cells results from activation of the sarcoplasmic reticulum Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; STORES; VESICLES; ATP	Calcium release from intracellular stores occurs in a graded manner in response to increasing concentrations of either inositol 1,4,5-trisphosphate or caffeine, To investigate the mechanism responsible for this quantal release phenomenon, [Ca2+] changes inside intracellular stores in isolated single smooth muscle cells were monitored with mag-fura 2. Following permeabilization with saponin or alpha-toxin the dye, loaded via its acetoxymethyl ester, was predominantly trapped in the sarcoplasmic reticulum (SR), Low caffeine concentrations in the absence of ATP induced only partial Ca2+ release; however, after inhibiting the calcium pump with thapsigargin the same stimulus released twice as much Ca2+. When the SR Ca2+-ATPase was rendered non-functional by depleting its ''ATP pool,'' submaximal caffeine doses almost fully emptied the stores of Ca2+. We conclude that quantal release of Ca2+ in response to caffeine in these smooth muscle cells is largely due to the activity of the SR Ca2+-ATPase, which appears to return a portion of the released Ca2+ back to the SR, even in the absence of ATP, Apparently the SR Ca2+-ATPase is fueled by ATP, which is either compartmentalized or bound to the SR.	UNIV MASSACHUSETTS,SCH MED,DEPT PHYSIOL,PROGRAM MOLEC MED,BIOMED IMAGING GRP,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL014523, R37HL014523] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14523] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOOTMAN MD, 1994, MOL CELL ENDOCRINOL, V98, P157, DOI 10.1016/0303-7207(94)90134-1; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; CARRINGTON WA, 1995, SCIENCE, V268, P1483, DOI 10.1126/science.7770772; CHEEK TR, 1994, BIOCHEM J, V301, P879, DOI 10.1042/bj3010879; CHEEK TR, 1993, J BIOL CHEM, V268, P27076; FAVERO TG, 1994, CELL CALCIUM, V15, P183, DOI 10.1016/0143-4160(94)90057-4; FAY FS, 1989, J MICROSC-OXFORD, V153, P133, DOI 10.1111/j.1365-2818.1989.tb00554.x; FAY FS, 1982, METHOD ENZYMOL, V85, P284; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; GUERRERO A, 1994, J GEN PHYSIOL, V104, P375, DOI 10.1085/jgp.104.2.375; HAJNOCZKY G, 1994, J BIOL CHEM, V269, P10280; HARDIN CD, 1992, J GEN PHYSIOL, V99, P21, DOI 10.1085/jgp.99.1.21; HIROSE K, 1994, NATURE, V372, P791; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; MERCER RW, 1981, J GEN PHYSIOL, V78, P547, DOI 10.1085/jgp.78.5.547; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MUALLEM S, 1989, J BIOL CHEM, V264, P205; RENARDROONEY DC, 1993, J BIOL CHEM, V268, P23601; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; VANDEPUT FHMM, 1994, J BIOL CHEM, V269, P12438; XU L, 1994, P NATL ACAD SCI USA, V91, P3294, DOI 10.1073/pnas.91.8.3294; YAGI S, 1988, P NATL ACAD SCI USA, V85, P4109, DOI 10.1073/pnas.85.11.4109	24	40	40	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1821	1824		10.1074/jbc.271.4.1821	http://dx.doi.org/10.1074/jbc.271.4.1821			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567621	hybrid			2022-12-25	WOS:A1996TR32000003
J	Liang, GS; Wolfgang, CD; Chen, BPC; Chen, TH; Hai, TW				Liang, GS; Wolfgang, CD; Chen, BPC; Chen, TH; Hai, TW			ATF3 gene - Genomic organization, promoter, and regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR ATF; ELEMENT-BINDING PROTEIN; AMP RESPONSE ELEMENT; NF-KAPPA-B; CYCLIC-AMP; C-FOS; PREINITIATION COMPLEX; CDNA CLONES; FACTOR CREB; DISTINCT	ATF3 gene, which encodes a member of the activating transcription factor/cAMP responsive element binding protein (ATF/CREB) family of transcription factors, is induced by many physiological stresses, As a step toward understanding the induction mechanisms, we isolated the human ATF3 gene and analyzed its genome organization and 5'-flanking region. We found that the human ATF3 mRNA is derived from four exons distributed over 15 kilobases. Sequence analysis of the 5'-flanking region revealed a consensus TATA box and a number of transcription factor binding sites including the AP-1, ATF/CRE, NF-kappa B, E2F, and Myc/Max binding sites. As another approach to understanding the mechanisms by which the ATF3 gene is induced by stress signals, we studied the regulation of the ATF3 gene in tissue culture cells by anisomycin, an approach that has been used to study the stress responses in tissue culture cells, We showed that anisomycin at a low concentration activates the ATF3 promoter and stabilizes the ATF3 mRNA, Significantly, co-transfection of DNAs expressing ATF2 and c-Jun activates the ATF3 promoter, A possible mechanism implicating the C-Jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK) stress-inducible signaling pathway in the induction of the ATF3 gene is discussed.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,OHIO STATE BIOCHEM PROGRAM,COLUMBUS,OH 43210; OHIO STATE UNIV,NEUROBIOTECHNOL CTR,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Hai, Tsonwin/E-3185-2011; Hai, Tsonwin/H-4480-2011	Hai, Tsonwin/0000-0003-4510-0315; Hai, Tsonwin/0000-0003-4510-0315	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046218] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46218] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P159; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHU HM, 1994, MOL ENDOCRINOL, V8, P59, DOI 10.1210/me.8.1.59; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DELABROUSSE FC, 1993, TRENDS GENET, V9, P151, DOI 10.1016/0168-9525(93)90149-C; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARA CJ, 1990, MOL CELL BIOL, V10, P1347, DOI 10.1128/MCB.10.4.1347; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIU F, 1993, J BIOL CHEM, V268, P6714; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SASSONECORSI P, 1994, EMBO J, V13, P4717, DOI 10.1002/j.1460-2075.1994.tb06797.x; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; YIN JCP, 1995, MOL CELL BIOL, V15, P5123; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	52	190	198	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1695	1701		10.1074/jbc.271.3.1695	http://dx.doi.org/10.1074/jbc.271.3.1695			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576171	hybrid			2022-12-25	WOS:A1996TQ52500067
J	MacKenzie, CR; Hirama, T; Deng, SJ; Bundle, DR; Narang, SA; Young, NM				MacKenzie, CR; Hirama, T; Deng, SJ; Bundle, DR; Narang, SA; Young, NM			Analysis by surface plasmon resonance of the influence of valence on the ligand binding affinity and kinetics of an anti-carbohydrate antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; CONSTANTS; SITE	The kinetics of ligand binding by Se155-4, an antibody specific for the Salmonella serogroup B O-polysaccharide, were studied by surface plasmon resonance, Because trace amounts of oligomers in Fab and single-chain antibody variable domain (scFv) preparations resulted in biphasic binding profiles that were difficult to analyze, all kinetic measurements were performed on purified monomeric fragments and, for certain mutant scFv, dimeric forms, Results obtained with monomeric forms indicated that the relatively low affinity of the antibody was due to rapid dissociation (k(off) approximate to 0.25 s(-1)), Dimeric forms generally showed off-rates that were approximately 20-fold slower and a 5-fold increase in association rate constants to approximately 2 x 10(5) M(-1) s(-1) Although the association phases for scFv dimers showed good curve fitting to a one component interaction model, the dissociation phases were biphasic, presumably because the availability and accessibility of sites on the antigen always leads to some monovalent attachment, The fast off-rate for dimers was the same as the monomer off-rate, Se155-4 IgG: off-rates were very similar to those observed for scFv dimer, whereas the on-rate was the same as that obtained with Fab and scFv monomer.	UNIV ALBERTA,DEPT CHEM,EDMONTON,AB T6G 2G2,CANADA	University of Alberta	MacKenzie, CR (corresponding author), NATL RES COUNCIL CANADA,INST BIOL SCI,100 SUSSEX DR,OTTAWA,ON K1A 0R6,CANADA.							BREWER CF, 1973, BIOCHEMISTRY-US, V12, P4448, DOI 10.1021/bi00746a023; BRUMMELL DA, 1993, BIOCHEMISTRY-US, V32, P1180, DOI 10.1021/bi00055a024; Bundle D. R, 1992, CURR OPIN STRUC BIOL, V2, P666, DOI DOI 10.1016/0959-440X(92)90199-H; BUNDLE DR, 1994, BIOCHEMISTRY-US, V33, P5172, DOI 10.1021/bi00183a022; COOPER LJN, 1994, MOL IMMUNOL, V31, P577, DOI 10.1016/0161-5890(94)90165-1; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; CROTHERS DM, 1972, IMMUNOCHEMISTRY, V9, P341, DOI 10.1016/0019-2791(72)90097-3; DENG SJ, 1995, P NATL ACAD SCI USA, V92, P4992, DOI 10.1073/pnas.92.11.4992; DENG SJ, 1994, J BIOL CHEM, V269, P9533; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; MAEDA H, 1977, BIOCHEMISTRY-US, V16, P4086, DOI 10.1021/bi00637a023; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PELLEQUER JL, 1993, MOL IMMUNOL, V30, P955, DOI 10.1016/0161-5890(93)90022-4; Sambrook J, 1989, MOL CLONING LABORATO; SHINOHARA Y, 1994, EUR J BIOCHEM, V223, P189, DOI 10.1111/j.1432-1033.1994.tb18982.x; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; SIGURSKJOLD BW, 1992, J BIOL CHEM, V267, P8371; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; TOONE EJ, 1994, CURR OPIN STRUC BIOL, V4, P719, DOI 10.1016/S0959-440X(94)90170-8; VANDERMERWE PA, 1994, BIOCHEMISTRY-US, V33, P10149, DOI 10.1021/bi00199a043; WHITLOW M, 1993, PROTEIN ENG, V6, P989, DOI 10.1093/protein/6.8.989; ZDANOV A, 1994, P NATL ACAD SCI USA, V91, P6423, DOI 10.1073/pnas.91.14.6423	24	132	141	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1527	1533		10.1074/jbc.271.3.1527	http://dx.doi.org/10.1074/jbc.271.3.1527			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576148	hybrid			2022-12-25	WOS:A1996TQ52500044
J	Lee, JM; Fournel, M; Veillette, A; Branton, PE				Lee, JM; Fournel, M; Veillette, A; Branton, PE			Association of CD45 with Lck and components of the Ras signalling pathway in pervanadate-treated mouse T-cell lines	ONCOGENE			English	Article						CD45; protein tyrosine phosphatase; T-cell activation; Lck; pervanadate	TYROSINE PROTEIN-KINASE; GUANINE-NUCLEOTIDE EXCHANGE; VAV PROTOONCOGENE PRODUCT; LEUKOCYTE-COMMON ANTIGEN; HUMAN LYMPHOCYTES-T; PHOSPHATASE CD45; ADAPTER PROTEIN; SH2 DOMAIN; B-CELLS; ACTIVATION	Pervanadate treatment of a mouse T-cell hybridoma cell line overexpressing an activated form of p56(lck) was shown to result in tyrosine phosphorylation of CD45. Immunoprecipitates prepared under mild lysis conditions using antibodies against CD45 contained a number of other proteins, including p56(lck), that were not evident in the absence of pervanadate treatment or in T cells lacking activated Lck, implying that under these conditions, CD45 is present within complexes containing Lck and other proteins. Analyses involving deletion mutants of p56(lck) indicated that interactions with CD45 did not absolutely require the SH2 and SH3 regions of Lck. Three proteins of the Ras signalling pathway were also shown to associated with CD45: the GTPase-activating protein for Ras (rasGAP), the signalling protein Grb2, and, possibly via complex formation with Grb2, the guanine nucleotide exchange factor mammalian son of sevenless (mSOS). In addition, CD45 was also found in immunoprecipitates prepared from these cells using an antiserum which recognizes Vav, It is possible that rasGAP, Grb2 and Vav bind to phosphotyrosine residues on CD45 via SH2 domains, and such interactions may be specific as other SH2-containing proteins, including phospholipase C alpha (PLC gamma), the p85 subunit of phosphatidylinositol 3-kinase (PI 3-kinase), She and Syp/PTP1D were not detectably associated with CD45 under the same conditions. These data suggested that in addition to its role as a protein tyrosine phosphatase, CD45 may participate in T-cell activation by serving as a membrane docking site for components of the Pas signalling pathway.	MCGILL UNIV, MCGILL CANC CTR, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, MCGILL CANC CTR, DEPT MED, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, MCGILL CANC CTR, DEPT ONCOL, MONTREAL, PQ H3G 1Y6, CANADA	McGill University; McGill University; McGill University								ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; AUTERO M, 1994, MOL CELL BIOL, V14, P1308, DOI 10.1128/MCB.14.2.1308; BARBEAU D, 1994, ONCOGENE, V9, P359; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BROOKSWILSON AR, 1989, MOL CELL BIOL, V9, P2214, DOI 10.1128/MCB.9.5.2214; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURNS CM, 1994, J BIOL CHEM, V269, P13594; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; FURUKAWA T, 1994, P NATL ACAD SCI USA, V91, P10928, DOI 10.1073/pnas.91.23.10928; GERVAIS FG, 1993, MOL CELL BIOL, V13, P7112, DOI 10.1128/MCB.13.11.7112; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; IIDA N, 1994, J BIOL CHEM, V269, P28576; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KORETZKY GA, 1993, J BIOL CHEM, V268, P8958; LEDBETTER JA, 1988, P NATL ACAD SCI USA, V85, P8628, DOI 10.1073/pnas.85.22.8628; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P21551; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, ONCOGENE, V5, P809; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; ROWLEY RB, 1993, CELL MOL BIOL RES, V39, P209; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SCHNEIDER H, 1995, EUR J IMMUNOL, V25, P1044, DOI 10.1002/eji.1830250428; SCHRAVEN B, 1991, EUR J IMMUNOL, V21, P2469, DOI 10.1002/eji.1830211025; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SCHRAVEN B, 1990, NATURE, V345, P71, DOI 10.1038/345071a0; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SPRINGER T, 1978, EUR J IMMUNOL, V8, P539, DOI 10.1002/eji.1830080802; STOVER DR, 1994, MOL CELL BIOL, V14, P5523, DOI 10.1128/MCB.14.8.5523; STOVER DR, 1991, P NATL ACAD SCI USA, V88, P7704, DOI 10.1073/pnas.88.17.7704; SU J, 1994, J BIOL CHEM, V269, P18731; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TAKEDA A, 1994, P NATL ACAD SCI USA, V88, P7734; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; VOLAREVIC S, 1990, P NATL ACAD SCI USA, V87, P7085, DOI 10.1073/pnas.87.18.7085; VOLAREVIC S, 1992, J EXP MED, V176, P835, DOI 10.1084/jem.176.3.835; WEIL R, 1994, J BIOL CHEM, V269, P22830; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS MJ, 1984, P NATL ACAD SCI-BIOL, V81, P6836, DOI 10.1073/pnas.81.21.6836; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	72	27	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					253	263						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570203				2022-12-25	WOS:A1996TR53800005
J	McKenna, WG; Bernhard, EJ; Markiewicz, DA; Rudoltz, MS; Maity, A; Muschel, RJ				McKenna, WG; Bernhard, EJ; Markiewicz, DA; Rudoltz, MS; Maity, A; Muschel, RJ			Regulation of radiation-induced apoptosis in oncogene-transfected fibroblasts: Influence of H-ras on the G2 delay	ONCOGENE			English	Article						apoptosis; G2 delay; X-rays; cyclin B1	IRRADIATED MURINE TUMORS; INDUCED MITOTIC DELAY; HAMSTER OVARY CELLS; DNA STRAND BREAKS; IONIZING-RADIATION; EMBRYO CELLS; HELA-CELLS; V-MYC; SACCHAROMYCES-CEREVISIAE; P34CDC2 KINASE	Primary fibroblasts, after serum withdrawal or after irradiation, do not undergo apoptosis. Myc-transfected fibroblasts, in contrast, undergo apoptosis upon serum withdrawal and after irradiation. We have studied the relationship of apoptosis induction to effects on the G2 phase cell cycle in a series of rat embryo cells transformed by ras(H) plus myc or immortalized by myc alone. In this system, while the presence of ras(H) had little effect on the extent of apoptosis induction by serum withdrawal, ras(H) greatly suppressed the apoptotic response of myc-transfected cells to X-rays. The cells into which ras(H) had been introduced showed a profound G2 arrest associated with suppression of cyclin B1 mRNA expression. In contrast, cells with myc alone had a minimal G2 delay after irradiation and no suppression of cyclin B1 mRNA expression, We hypothesize that ras(H), by influencing the G2 response of cells to X-rays, exerts an anti-apoptotic effect. In support of this hypothesis; we found that treatment of cells with caffeine, an agent that relieves the G2 delay after irradiation resulted in increased apoptosis in the irradiated cells, but not in control cells.	UNIV PENN,DEPT RADIAT ONCOL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania				Maity, Amit/0000-0001-7151-2845	NATIONAL CANCER INSTITUTE [R01CA064227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047439] Funding Source: NIH RePORTER; NCI NIH HHS [CA64227] Funding Source: Medline; NIGMS NIH HHS [GM47439] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARENDS MJ, 1993, BRIT J CANCER, V68, P1127, DOI 10.1038/bjc.1993.492; BERNHARD EJ, 1994, RADIAT RES, V140, P393, DOI 10.2307/3579118; BRACEY TS, 1995, ONCOGENE, V10, P2391; CARR AM, 1995, SEMIN CELL BIOL, V6, P65, DOI 10.1016/1043-4682(95)90002-0; CHANG EH, 1987, SCIENCE, V237, P1036, DOI 10.1126/science.3616624; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; ELDIERY WS, 1994, CANCER RES, V54, P1169; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS DL, 1993, CANCER RES, V53, P2133; FAN SJ, 1995, CANCER RES, V55, P1649; GORCZYCA W, 1993, CANCER RES, V53, P1945; GORCZYCA W, 1993, LEUKEMIA, V7, P659; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HURWITZ C, 1969, BIOPHYS J, V9, P607, DOI 10.1016/S0006-3495(69)86407-6; ILIAKIS G, 1990, CANCER RES, V50, P6575; KARBANDA S, 1994, ONCOGENE, V9, P3005; KASID U, 1987, SCIENCE, V237, P1039, DOI 10.1126/science.3616625; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LING CC, 1994, RADIOTHER ONCOL, V32, P129; LING CC, 1994, RADIOTHER ONCOL, V33, P17; LING CC, 1989, RADIAT RES, V120, P267, DOI 10.2307/3577713; LOCK RB, 1990, CANCER RES, V50, P3767; LOCK RB, 1994, CANCER RES, V54, P4933; LOCK RB, 1992, CANCER RES, V52, P1817; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAITY A, 1994, BIOCHEM BIOPH RES CO, V202, P908, DOI 10.1006/bbrc.1994.2016; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MARKIEWICZ DA, 1994, INT J RADIAT ONCOL, V28, P135, DOI 10.1016/0360-3016(94)90151-1; MCKENNA WG, 1990, CANCER RES, V50, P97; MCKENNA WG, 1991, RADIAT RES, V125, P283, DOI 10.2307/3578111; MCKENNA WG, 1990, INT J RADIAT ONCOL, V18, P849, DOI 10.1016/0360-3016(90)90407-B; MCKENNA WG, 1981, J BIOL CHEM, V265, P6435; MEYN RE, 1993, INT J RADIAT BIOL, V64, P583, DOI 10.1080/09553009314551801; Milas Luka, 1994, In Vivo (Attiki), V8, P665; MUSCHEL RJ, 1992, RADIAT RES, V132, P153, DOI 10.2307/3578520; MUSCHEL RJ, 1986, CANCER RES, V46, P4104; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; MUSHCEL R, 1985, AM J PATHOL, V121, P1; OCONNOR PM, 1993, J BIOL CHEM, V268, P8298; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; PALAYOOR ST, 1995, RADIAT RES, V141, P235, DOI 10.2307/3579000; POWELL SN, 1995, CANCER RES, V55, P1643; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P229, DOI 10.1080/09553009414550261; RADFORD IR, 1994, INT J RADIAT BIOL, V65, P217, DOI 10.1080/09553009414550251; RODEMANN HP, 1991, SCANNING MICROSCOPY, V5, P1135; ROWLEY R, 1992, RADIAT RES, V132, P144, DOI 10.2307/3578519; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; RUSSELL KJ, 1995, CANCER RES, V55, P1639; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; STEPHENS LC, 1991, RADIAT RES, V127, P308, DOI 10.2307/3577946; TOLMACH LJ, 1977, RADIAT RES, V71, P653, DOI 10.2307/3574633; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1992, RADIAT RES, V132, P141, DOI 10.2307/3578518; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHEN WN, 1995, RADIAT RES, V141, P170, DOI 10.2307/3579044	65	77	80	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					237	245						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570201				2022-12-25	WOS:A1996TR53800003
J	Ismailov, II; Awayda, MS; Berdiev, BK; Bubien, JK; Lucas, JE; Fuller, CM; Benos, DJ				Ismailov, II; Awayda, MS; Berdiev, BK; Bubien, JK; Lucas, JE; Fuller, CM; Benos, DJ			Triple-barrel organization of ENaC, a cloned epithelial Na+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG HEART-CELLS; POTASSIUM CHANNEL; SODIUM-CHANNEL; EXPRESSION; AMILORIDE; NEURONS; CLONING; BLOCK	A cloned rat epithelial Na+ channel (rENaC) was studied in planar lipid bilayers. Two forms of the channel were examined: channels produced by the alpha subunit alone and those formed by alpha, beta, and gamma subunits. The protein was derived from two sources: either from in vitro translation reaction followed by Sephadex column purification or from heterologous expression in Xenopus oocytes and isolation of plasma membranes. We found that either alpha-rENaC alone or alpha- in combination with beta- and gamma-rENaC, produced highly Na+-selective (P-Na/P-K = 10), amiloride-sensitive (K-i(amil) = 170 nm), and mechano-sensitive cation channels in planar bilayers. alpha-rENaC displayed a complicated gating mechanism: there was a nearly constitutively open 13-picosiemens (pS) state and a second 40-pS level that was achieved from the 13-pS level by a 26-pS transition. alpha-, beta-, gamma-rENaC showed primarily the 13-pS level. alpha-rENaC and alpha,beta,gamma-rENaC channels studied by patch clamp displayed the same gating pattern, albeit with >2-fold lowered conductance levels, i.e. 6 and 18 pS, respectively. Upon treatment of either channel with the sulfhydryl reducing agent dithiothreitol, both channels fluctuated among three independent 13-pS sublevels. Bathing each channel with a high salt solution (1.5 M NaCl) produced stochastic openings of 19 and 38 pS in magnitude between all three conductance levels. Different combinations of alpha-, beta, and gamma-rENaC in the reconstitution mixture did not produce channels of intermediate conductance levels. These findings suggest that functional ENaC is composed of three identical conducting elements and that their gating is concerted.	UNIV ALABAMA, DEPT PHYSIOL & BIOPHYS, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT MED, DIV NEPHROL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham			Fuller, Cathy/B-4046-2011		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK037206, R01DK037206] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37206] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AWAYDA MS, 1995, AM J PHYSIOL-CELL PH, V268, pC1450, DOI 10.1152/ajpcell.1995.268.6.C1450; BENOS DJ, 1982, AM J PHYSIOL, V242, pC131, DOI 10.1152/ajpcell.1982.242.3.C131; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; BENOS DJ, 1995, J MEMBRANE BIOL, V143, P1; BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; BRADFORD AL, 1995, AM J PHYSIOL-CELL PH, V269, pC601, DOI 10.1152/ajpcell.1995.269.3.C601; BURCH LH, 1995, AM J PHYSIOL-CELL PH, V269, pC511, DOI 10.1152/ajpcell.1995.269.2.C511; BUSATH D, 1988, BIOPHYS J, V53, P689, DOI 10.1016/S0006-3495(88)83150-3; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHAMPIGNY G, 1994, EMBO J, V13, P2177, DOI 10.1002/j.1460-2075.1994.tb06494.x; CHINET TC, 1993, AM J PHYSIOL, V265, pC1050, DOI 10.1152/ajpcell.1993.265.4.C1050; COLQUHOUN D, 1981, PROC R SOC SER B-BIO, V211, P205, DOI 10.1098/rspb.1981.0003; CULLCANDY SG, 1987, NATURE, V325, P525, DOI 10.1038/325525a0; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; FULLER CM, 1995, AM J PHYSIOL-CELL PH, V269, pC641, DOI 10.1152/ajpcell.1995.269.3.C641; GADALLAH MF, 1995, AM J KIDNEY DIS, V25, P829, DOI 10.1016/0272-6386(95)90564-2; GARTY H, 1986, J MEMBRANE BIOL, V90, P193, DOI 10.1007/BF01870126; HAMILL OP, 1983, NATURE, V305, P805, DOI 10.1038/305805a0; HAMILL OP, 1981, NATURE, V294, P462, DOI 10.1038/294462a0; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; ISMAIL II, 1996, IN PRESS AM J PHYSL; ISMAILOV II, 1994, J BIOL CHEM, V269, P10235; ISMAILOV II, 1995, J GEN PHYSIOL, V106, P445, DOI 10.1085/jgp.106.3.445; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; LIU QY, 1989, BIOPHYS J, V55, P415, DOI 10.1016/S0006-3495(89)82835-8; MA JJ, 1988, BIOPHYS J, V53, P387, DOI 10.1016/S0006-3495(88)83115-1; MATSUDA H, 1989, J PHYSIOL-LONDON, V413, P139, DOI 10.1113/jphysiol.1989.sp017646; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; MCDONALD FJ, 1994, AM J PHYSIOL, V266, pL728, DOI 10.1152/ajplung.1994.266.6.L728; MCDONALD FJ, 1995, AM J PHYSIOL-CELL PH, V268, pC1157, DOI 10.1152/ajpcell.1995.268.5.C1157; OBRODOVICH H, 1993, AM J PHYSIOL, V265, pC491, DOI 10.1152/ajpcell.1993.265.2.C491; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; PEREZ G, 1994, BIOPHYS J, V66, P1022, DOI 10.1016/S0006-3495(94)80883-5; PUOTI A, 1995, AM J PHYSIOL-CELL PH, V269, pC188, DOI 10.1152/ajpcell.1995.269.1.C188; RENARD S, 1994, J BIOL CHEM, V269, P12981; SAWYER DB, 1989, BIOCHEMISTRY-US, V28, P6571, DOI 10.1021/bi00442a007; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SCHINDLER H, 1984, P NATL ACAD SCI-BIOL, V81, P6222, DOI 10.1073/pnas.81.19.6222; SENYK O, 1995, AM J PHYSIOL-CELL PH, V268, pC1148, DOI 10.1152/ajpcell.1995.268.5.C1148; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WARNOCK DG, 1995, AM J KIDNEY DIS, V25, P924, DOI 10.1016/0272-6386(95)90576-6; WARNOCK DG, 1994, HOSP PRACT, V29, P95, DOI 10.1080/21548331.1994.11443050	49	86	90	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					807	816		10.1074/jbc.271.2.807	http://dx.doi.org/10.1074/jbc.271.2.807			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557690	hybrid			2022-12-25	WOS:A1996TP88900033
J	Sakakura, C; Igarashi, Y; Anand, JK; Sadozai, KK; Hakomori, S				Sakakura, C; Igarashi, Y; Anand, JK; Sadozai, KK; Hakomori, S			Plasmalopsychosine of human brain mimics the effect of nerve growth factor by activating its receptor kinase and mitogen-activated protein kinase in PC12 cells - Induction of neurite outgrowth and prevention of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GANGLIOSIDE-MEDIATED MODULATION; TYROSINE PHOSPHORYLATION; RAT-BRAIN; PSYCHOSINE; INHIBITION; LINE; DIFFERENTIATION; STAUROSPORINE; SPHINGOSINE; WELL	Plasmalopsychosine, a characteristic fatty aldehyde conjugate of beta-galactosylsphingosine (psychosine) found in brain white matter, enhances p140(trk) (Trk A) phosphorylation and mitogen-activated protein kinase (MAPK) activity and as a consequence induces neurite outgrowth in PC12 cells. The effect of plasmalopsychosine on neurite outgrowth and its prolonged activation of MAPK was similar to that of nerve growth factor (NGF), and the effect was specific to neuronal cells. Plasmalopsychosine was not capable of competing with cold chase-stable, high affinity binding of NGF to Trk A, indicating that plasmalopsychosine and NGF differ in terms of Trk A-activating mechanism. Tyrosine kinase inhibitors K-252a and staurosporine, known to inhibit the neurotrophic effect of NGF, also inhibited these effects of plasmalopsychosine, suggesting that plasmalopsychosine and NGF share a common signaling cascade. Plasmalopsychosine prevents apoptosis of PC12 cells caused by serum deprivation, indicating that it has ''neurotrophic factor-like'' activity. Taken together, these findings indicate that plasmalopsychosine may play an important role in development and maintenance of the vertebrate nervous system.	UNIV WASHINGTON, DEPT PATHOBIOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle	Sakakura, C (corresponding author), BIOMEMBRANE INST, SEATTLE, WA 98119 USA.				NCI NIH HHS [CA42505] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOTHWELL M, 1991, CELL, V65, P915, DOI 10.1016/0092-8674(91)90540-F; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; COOPER CE, 1993, BIOCHEM J, V290, P139, DOI 10.1042/bj2900139; FERRARI G, 1993, J NEUROSCI, V13, P1879; FERRARI G, 1995, J BIOL CHEM, V270, P3074, DOI 10.1074/jbc.270.7.3074; GREENE LA, 1980, ANNU REV NEUROSCI, V3, P353, DOI 10.1146/annurev.ne.03.030180.002033; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HANAI N, 1988, J BIOL CHEM, V263, P10915; HANAI N, 1988, J BIOL CHEM, V263, P6296; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HASHIMOTO S, 1989, J NEUROCHEM, V53, P1675, DOI 10.1111/j.1471-4159.1989.tb09230.x; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; ITO J, 1989, BRAIN RES, V481, P335, DOI 10.1016/0006-8993(89)90811-1; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KATOHSEMBA R, 1986, J CELL PHYSL, V1126, P147; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOIZUMI S, 1988, J NEUROSCI, V8, P715; KOJIMA N, 1994, J BIOL CHEM, V269, P30451; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LANDRETH GE, 1980, P NATL ACAD SCI-BIOL, V77, P4751, DOI 10.1073/pnas.77.8.4751; LEDEEN RW, 1990, FID RES FDN, V3, P17; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534, DOI 10.1152/physrev.1968.48.3.534; LYONS WE, 1994, P NATL ACAD SCI USA, V91, P3191, DOI 10.1073/pnas.91.8.3191; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATTIE M, 1994, J BIOL CHEM, V269, P3181; MIYATAKE T, 1972, BIOCHEM BIOPH RES CO, V48, P538, DOI 10.1016/0006-291X(72)90381-6; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; NILSSON O, 1982, J NEUROCHEM, V39, P709, DOI 10.1111/j.1471-4159.1982.tb07950.x; NUDELMAN ED, 1992, J BIOL CHEM, V267, P11007; OHTA H, 1995, CANCER RES, V55, P691; SADAHIRA Y, 1992, P NATL ACAD SCI USA, V89, P9686, DOI 10.1073/pnas.89.20.9686; SADOZAI KK, 1993, CARBOHYD RES, V241, P301, DOI 10.1016/0008-6215(93)80120-4; SKAPER SD, 1986, DEV BRAIN RES, V25, P21, DOI 10.1016/0165-3806(86)90148-3; TAGO H, 1986, J HISTOCHEM CYTOCHEM, V34, P1431, DOI 10.1177/34.11.2430009; TISCHLER AS, 1990, J NEUROCHEM, V55, P1159, DOI 10.1111/j.1471-4159.1990.tb03120.x; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TSUJI S, 1983, J BIOCHEM-TOKYO, V94, P303, DOI 10.1093/oxfordjournals.jbchem.a134344; TSUJI S, 1988, J NEUROCHEM, V50, P414, DOI 10.1111/j.1471-4159.1988.tb02928.x; TSUJI S, 1988, J BIOCHEM, V104, P498, DOI 10.1093/oxfordjournals.jbchem.a122498; VARON S, 1986, GANGLIOSIDES NEURONA, P215	42	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					946	952		10.1074/jbc.271.2.946	http://dx.doi.org/10.1074/jbc.271.2.946			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557709	hybrid			2022-12-25	WOS:A1996TP88900052
J	Casares, S; Ionov, Y; Ge, HY; Stanbridge, E; Perucho, M				Casares, S; Ionov, Y; Ge, HY; Stanbridge, E; Perucho, M			The microsatellite mutator phenotype of colon cancer cells is often recessive	ONCOGENE			English	Article						mutator mutations; genomic instability; microsatellites; somatic cell hybrids	COLORECTAL-CANCER; MISMATCH REPAIR; GENETIC INSTABILITY; CHAIN-REACTION; DNA; MUTATIONS; CARCINOMA; CARCINOGENESIS; SEQUENCES; HISTORY	A new mutator mechanism for tumorigenesis, characterized by somatic genomic instability (SGI) at simple repeated sequences (SRS) or microsatellites, underlies hereditary nonpolyposis colorectal cancer (HNPCC) and some sporadic tumors of the colon and other types, To determine whether the microsatellite mutator phenotype (MMP) is dominant or recessive, we generated somatic cell hybrids between a tumor cell line without SGI at SRS (D98OR) and colon carcinoma cell lines with relative low (HCT-15) and high (LS174-T) SGI at SRS, The normal fidelity of replication of these unstable sequences was observed in each of these cell hybrids, Fusion of HCT-1S/DLD-1 low instability cells, with LS174-T, HCT116 and LoVo cell Lines, all exhibiting relative high instability, also restored the replication fidelity of SRS in all of the hybrids, Hybrids between the high instability cell lines did not grow possibly because of senescence or apoptosis, These results indicate that, in the cell lines analysed, the characterized mutator phenotype of the mismatch repair system resulting in high SGI at SRS, and the uncharacterized mutator phenotype underlying low SGI at SRS, are both recessive, The results also suggest that different tumor cells of the MMP harbor distinct altered growth-related genes.	CALIF INST BIOL RES,LA JOLLA,CA 92037; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine				Perucho, Manuel/0000-0002-2169-2662				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRANCH P, 1995, NAT GENET, V9, P232; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BURKS RT, 1994, ONCOGENE, V9, P1163; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; DACOSTA LT, 1995, NAT GENET, V9, P10, DOI 10.1038/ng0195-10; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; HEARNE CM, 1992, TRENDS GENET, V8, P288, DOI 10.1016/0168-9525(92)90256-4; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KAHN SM, 1995, CARCINOGENESIS, V16, P1223, DOI 10.1093/carcin/16.5.1223; KNUDSON AG, 1985, CANCER RES, V45, P1437; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOI M, 1994, CANCER RES, V54, P4308; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOEB LA, 1991, CANCER RES, V51, P3075; LOEB LA, 1974, CANCER RES, V34, P2311; LOTHE RA, 1993, CANCER RES, V53, P5849; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PEINADO MA, 1992, P NATL ACAD SCI USA, V89, P10065, DOI 10.1073/pnas.89.21.10065; PEINADO MA, 1993, INT J ONCOL, V2, P123; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1993, CANCER RES, V53, P5853; REENAN RAG, 1992, GENETICS, V132, P963; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; Saxon P J, 1987, Methods Enzymol, V151, P313, DOI 10.1016/S0076-6879(87)51026-6; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; WEISSMAN B, 1980, CYTOGENET CELL GENET, V28, P227, DOI 10.1159/000131536; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; YEE CJ, 1994, CANCER RES, V54, P1641	51	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2303	2310						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570181				2022-12-25	WOS:A1995TK70200014
J	Park, SH; Weinberg, RA				Park, SH; Weinberg, RA			A putative effector of Ral has homology to Rho/Rac GTPase activating proteins	ONCOGENE			English	Article						Ral; Rho GTPase activating protein; protein interactions	PLATELET GN-PROTEINS; BINDING PROTEINS; GENE-PRODUCTS; IDENTIFICATION; EXPRESSION; RHO	We report here the cloning of a gene encoding a novel Pal interacting protein (RIP1) from a cDNA expression library using radiolabeled Pal as probe, RIP1 binds to Pal in a GTP-dependent manner, The 4.1 kb transcript of the RIP1 gene is present in all tissues analysed and encodes for a protein product of 648 residues, RIP1 shares sequence similarity with GAP proteins that are capable of activating the GTPase activity of members of the Rho/Rac family of GTPases, When tested, RIP1 could activate the GTPase activity of CDC42 and, to a lesser extent, Rad but not RhoA, Pas, or Pal. Activated Pal had no direct effect on the GTPase-activating ability of RIP1, in vitro.	MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)					NCI NIH HHS [CA39826-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BHULLAR RP, 1990, FEBS LETT, V260, P48, DOI 10.1016/0014-5793(90)80063-O; BHULLAR RP, 1992, FEBS LETT, V298, P61, DOI 10.1016/0014-5793(92)80022-9; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EMKEY R, 1991, J BIOL CHEM, V266, P9703; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLOFSSON B, 1988, ONCOGENE, V3, P231; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; WILDEY GM, 1993, BIOCHEM BIOPH RES CO, V194, P552, DOI 10.1006/bbrc.1993.1855	24	165	168	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2349	2355						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570186				2022-12-25	WOS:A1995TK70200019
J	Sekiya, F; Yoshida, M; Yamashita, T; Morita, T				Sekiya, F; Yoshida, M; Yamashita, T; Morita, T			Magnesium(II) is a crucial constituent of the blood coagulation cascade - Potentiation of coagulant activities of factor IX by Mg2+ ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-X; TISSUE FACTOR; ACTIVATION; PATHWAYS; THROMBIN; CALCIUM	We recently showed that not only Ca2+ ions but also Mg2+ ions play a crucial role in stabilizing the native conformation of coagulation factor IX. We here report that Mg2+ ions at physiological concentrations greatly augment the biological activities of factor IX. In clotting assays with dialyzed plasma, addition of Mg2+ ions enhanced the apparent coagulant activity of factor Ma, while that of factor Xa was scarcely affected, Activation of factor X by factor Ma in the presence of factor VIIIa, phospholipids, and Ca2+ ions was accelerated by Mg2+ ions, It appeared that the cation increased the affinity between factor Ma and factor VIIIa, thereby increasing the apparent catalytic efficacy of the enzyme. We also evaluated the effect of Mg2+ ions in the coagulation pathway initiated by tissue factor and found that activation of factor IX by factor VIIa-tissue factor was accelerated by the cation. Consequently, clotting of normal plasma induced by factor VIIa-tissue factor was shortened by the cation, while no such effect was observed in plasma deficient in factor IX or VIII. These results indicate that the previously unrecognized plasma component, Mg2+ ions, plays crucial roles in blood coagulation and, moreover, that contributions of factors IX and VIII in the coagulation cascade have been seriously underestimated in previous investigations.	MEIJI COLL PHARM, DEPT BIOCHEM, TANASHI, TOKYO 188, JAPAN	Meiji Pharmaceutical University								COLMAN RW, 1975, J CLIN INVEST, V56, P1650, DOI 10.1172/JCI108247; DAVIE EW, 1964, SCIENCE, V145, P1310, DOI 10.1126/science.145.3638.1310; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; FURIE B, 1992, NEW ENGL J MED, V326, P800; GILBERT GE, 1995, J BIOL CHEM, V270, P18500, DOI 10.1074/jbc.270.31.18500; HATHAWAY WE, 1965, BLOOD-J HEMATOL, V26, P521, DOI 10.1182/blood.V26.5.521.521; HOAK JC, 1966, LANCET, V2, P884; HOFFMAN M, 1995, BLOOD, V86, P1794, DOI 10.1182/blood.V86.5.1794.bloodjournal8651794; INOUE K, 1993, EUR J BIOCHEM, V218, P153, DOI 10.1111/j.1432-1033.1993.tb18361.x; JONES KC, 1994, J BIOL CHEM, V269, P23367; KAWABATA S, 1985, J BIOCHEM, V97, P1073, DOI 10.1093/oxfordjournals.jbchem.a135150; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; LAWSON JH, 1993, METHOD ENZYMOL, V222, P177; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LUCHTMANJONES L, 1995, ANN MED, V27, P47, DOI 10.3109/07853899509031935; MACFARLANE RG, 1964, NATURE, V202, P498, DOI 10.1038/202498a0; MANN KG, 1990, BLOOD, V76, P1; MILETICH JP, 1980, ANAL BIOCHEM, V105, P304, DOI 10.1016/0003-2697(80)90462-5; MORITA T, 1985, BIOCHEM BIOPH RES CO, V130, P841, DOI 10.1016/0006-291X(85)90493-0; NAITO K, 1991, J BIOL CHEM, V266, P7353; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; SEKIYA F, 1995, J BIOL CHEM, V270, P14325, DOI 10.1074/jbc.270.24.14325; Stryer L., 1995, BIOCHEMISTRY-US, P252; THOMPSON AR, 1986, BLOOD, V67, P565; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433	27	76	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8541	8544		10.1074/jbc.271.15.8541	http://dx.doi.org/10.1074/jbc.271.15.8541			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621478	hybrid			2022-12-25	WOS:A1996UE73000009
J	Denning, MF; Dlugosz, AA; Threadgill, DW; Magnuson, T; Yuspa, SH				Denning, MF; Dlugosz, AA; Threadgill, DW; Magnuson, T; Yuspa, SH			Activation of the epidermal growth factor receptor signal transduction pathway stimulates tyrosine phosphorylation of protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H-RAS ONCOGENE; PHORBOL ESTER; DIFFERENTIATION MARKERS; MOUSE KERATINOCYTES; EXPRESSION; ALPHA; CELLS; OVEREXPRESSION; METABOLISM; ISOZYMES	The expression of an oncogenic ras(Ha) gene in epidermal keratinocytes stimulates the tyrosine phosphorylation of protein kinase C delta and inhibits its enzymatic activity (Denning, M. F., Dlugosz, A. A., Howett, M. K., and Yuspa, S. H. (1993) J. Biol. Chem. 268, 26079-26081). Keratinocytes expressing an activated ras(Ha) gene secrete transforming growth factor alpha (TGF alpha) and have an altered response to differentiation signals involving protein kinase C (PKC), Because the neoplastic phenotype of v-ras(Ha) expressing keratinocytes can be partially mimicked in vitro by chronic treatment with TGF alpha and the G protein activator aluminum fluoride (AlF4-), we determined if TGF alpha or AlF4- could induce tyrosine phosphorylation of PKC delta. Treatment of primary keratinocyte cultures for 4 days with TGF alpha induced tyrosine phosphorylation of PKC delta, whereas AlF4- only slightly stimulated PKC delta tyrosine phosphorylation. The PKC delta that was tyrosine-phosphorylated in response to TGF alpha had reduced activity compared with the nontyrosine-phosphorylated PKC delta. Treatment of keratinocytes expressing a normal epidermal growth factor receptor (EGFR) with TGF alpha or epidermal growth factor for 5 min induced PKC delta tyrosine phosphorylation, This acute epidermal growth factor treatment did not induce tyrosine phosphorylation of PKC delta in keratinocytes isolated from waved-2 mice that have a defective epidermal growth factor receptor, In addition, the level of PKC delta tyrosine phosphorylation in v-ras(Ha)-transduced keratinocytes from EGFR null mice was substantially lower than in v-ras(Ha) transduced mild type cells, suggesting that activation of the EGFR is important for PKC delta tyrosine phosphorylation in ras transformation. However, purified EGFR did not phosphorylate recombinant PKC delta in vitro, whereas members of the Src family (c-Src, c-Fyn) and membrane preparations hom keratinocytes did, Furthermore, clearing c-Src or c-Fyn from keratinocyte membrane lysates decreased PKC delta tyrosine phosphorylation, and c-Src and c-Fyn isolated from keratinocytes treated with TGF alpha had increased kinase activity, Acute or chronic treatment with TGF alpha did not induce significant PKC delta translocation in contrast to the phorbol ester 12-O-tetradecanoylphorbol-13-acetate, which induced both translocation and tyrosine phosphorylation of PKC delta. This suggests that TGF alpha-induced tyrosine phosphorylation of PKC delta results from the activation of a tyrosine kinase rather than physical association of PKC delta with a membrane-anchored tyrosine kinase, Taken together, these results indicate that PKC delta activity is inhibited by tyrosine phosphorylation in response to EGFR-mediated signaling and activation of a member of the Src kinase family may be the proximal tyrosine kinase acting on PKC delta in keratinocytes.	NCI,LAB CELLULAR CARCINOGENESIS & TUMOR PROMOT,BETHESDA,MD 20892; CASE WESTERN RESERVE UNIV,DEPT GENET,CLEVELAND,OH 44106	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Case Western Reserve University			Threadgill, David W/N-4425-2013	Threadgill, David W/0000-0003-3538-1635				CHENG C, 1993, CELL GROWTH DIFFER, V4, P317; CHENG C, 1990, MOL CARCINOGEN, V3, P363, DOI 10.1002/mc.2940030608; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; CLEGHON V, 1994, J BIOL CHEM, V269, P17749; DENNING MF, 1993, J BIOL CHEM, V268, P26079; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; DIAZGUERRA M, 1992, CANCER RES, V52, P680; DIUGOSZ AA, 1994, CANCER RES, V54, P6413; DLUGOSZ AA, 1995, CANCER RES, V55, P1883; GLICK AB, 1991, MOL CARCINOGEN, V4, P210, DOI 10.1002/mc.2940040308; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; HALIOTIS T, 1990, INT J CANCER, V45, P1177, DOI 10.1002/ijc.2910450631; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LACAL JC, 1990, MOL CELL BIOL, V10, P2983, DOI 10.1128/MCB.10.6.2983; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE E, 1992, CARCINOGENESIS, V13, P2367, DOI 10.1093/carcin/13.12.2367; LEE E, 1991, J CELL PHYSIOL, V148, P106, DOI 10.1002/jcp.1041480113; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OZAWA K, 1993, J BIOL CHEM, V268, P1749; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; SIERKE SL, 1993, BIOCHEM BIOPH RES CO, V191, P45, DOI 10.1006/bbrc.1993.1182; SMITH H, 1995, P NATL ACAD SCI USA, V92, P9112; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; WANG XJ, 1994, MOL CARCINOGEN, V10, P15, DOI 10.1002/mc.2940100104; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; YUSPA SH, 1985, NATURE, V314, P459, DOI 10.1038/314459a0	50	175	177	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5325	5331		10.1074/jbc.271.10.5325	http://dx.doi.org/10.1074/jbc.271.10.5325			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621384	hybrid			2022-12-25	WOS:A1996TZ28600010
J	Estival, A; Monzat, V; Miquel, K; Gaubert, F; Hollande, E; Korc, M; Vaysse, N; Clemente, F				Estival, A; Monzat, V; Miquel, K; Gaubert, F; Hollande, E; Korc, M; Vaysse, N; Clemente, F			Differential regulation of fibroblast growth factor (FGF) receptor-1 mRNA and protein by two molecular forms of basic FGF - Modulation of FGFR-1 mRNA stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED ENDOTHELIAL-CELLS; 3T3 CELLS; NUCLEAR-LOCALIZATION; FACTOR CDNA; EXPRESSION; FAMILY; TRANSFORMATION; BINDING; PROLIFERATION; STIMULATION	To evaluate possible functional differences between basic fibroblast growth factor (FGF) 2 isoforms we analyzed the effects of the 18-kDa FGF-2 which mainly localizes in the cytosol and that of the nuclear-targeted 22.5-kDa form on FGF receptors (FGFR) expression. These peptides were expressed at low amounts through a retroviral-infection system. Point mutated FGF-2 cDNAs under the control of the beta-actin promoter were used to infect a pancreatic cell line (AR4-2J) which does not produce FGF-2. Saturation and competition binding studies with I-125-FGF-2 revealed a 3-fold increase in both high and low affinity receptors in cells expressing the 22.5-kDa form and a 2-fold increase only in the high affinity receptors in cells producing the 18-kDa form. K-d values and molecular weights of the high affinity receptors were unaffected. Increasing cell densities or cell treatment with exogenous FGF-2 resulted in FGFR down-regulation as in control cells. Neutralizing anti FGF-2 antibodies and suramin did not affect receptor density in control and in cells producing the 22.5-kDa form but further increased by 60 and 80%, respectively, the receptor level in cells synthesizing the 18-kDa form. These data suggest the involvement of the intracellular stored FGF-2 in FGFR up-regulation. Although all cells expressed FGFR-1, -2, and -3 mRNA only the FGFR-1 transcript was found increased, 6-fold in 22.5-kDa expressing cells and 3-fold in cell producing the shortest secreted isoform. The increase in FGFR-1 mRNA levels in the 22.5-kDa expressing cells was due to enhanced stability of the transcript. Confocal microscopy detected the presence of FGFR-1 at the cell surface whereas secretory isoforms of the receptor were not observed. Reverse transcriptase-polymerase chain reaction did not reveal significant differences in the expression of FGFR1 variants. In the 22.5-kDa expressing cells exogenous FGF-2 evoked a stronger translocation of the calcium-phospholipid-dependent PKC. These results indicate that the transfected FGF-2 isoforms up-regulated FGFR-1 mRNA and protein. The 22.5-kDa form acted by increasing FGFR-1 mRNA stability enhancing cell responses to exogenous FGF-2.	CHU RANGUEIL,INSERM,U151,F-31054 TOULOUSE,FRANCE; UNIV TOULOUSE 3,BIOL CELLULAIRE LAB,F-31062 TOULOUSE,FRANCE; UNIV CALIF IRVINE,DIV ENDOCRINOL DIABET & METAB,DEPT MED & BIOL CHEM,IRVINE,CA 92717	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of California System; University of California Irvine					NIDDK NIH HHS [DK-44948] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044948] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BENSAID M, 1992, INT J CANCER, V50, P796, DOI 10.1002/ijc.2910500522; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BIKFALVI A, 1995, J CELL BIOL, V129, P233, DOI 10.1083/jcb.129.1.233; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; COUDERC B, 1991, CELL REGUL, V2, P709, DOI 10.1091/mbc.2.9.709; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DELLERA P, 1991, EXP CELL RES, V192, P505, DOI 10.1016/0014-4827(91)90070-B; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ESTIVAL A, 1993, CANCER RES, V53, P1182; ESTIVAL A, 1992, GASTROENTEROLOGY, V103, P1851, DOI 10.1016/0016-5085(92)91444-9; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; GONZALEZ AM, 1994, ENDOCRINOLOGY, V134, P292; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KOBRIN MS, 1993, CANCER RES, V53, P4741; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MOROIANU J, 1994, BIOCHEMISTRY-US, V33, P12535, DOI 10.1021/bi00208a001; MORRISON RS, 1994, CANCER RES, V54, P2794; MOSCATELLI D, 1989, J CELL BIOL, V109, P2519, DOI 10.1083/jcb.109.5.2519; MOSCATELLI D, 1986, J CELL PHYSIOL, V129, P273, DOI 10.1002/jcp.1041290220; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; MOSCATELLI D, 1994, J CELL PHYSIOL, V160, P555, DOI 10.1002/jcp.1041600319; Naviaux Robert K., 1992, Current Opinion in Biotechnology, V3, P540, DOI 10.1016/0958-1669(92)90083-U; NEUFELD G, 1988, J CELL BIOL, V106, P1385, DOI 10.1083/jcb.106.4.1385; NEUFELD G, 1985, J BIOL CHEM, V260, P3860; OLWIN BB, 1990, J CELL BIOL, V110, P503, DOI 10.1083/jcb.110.2.503; PERTOVAARA L, 1993, BIOCHEM BIOPH RES CO, V191, P149, DOI 10.1006/bbrc.1993.1196; PRADEL P, 1993, BIOCHEM J, V290, P219, DOI 10.1042/bj2900219; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1989, ONCOGENE RES, V5, P101; RIZZINO A, 1988, CANCER RES, V48, P4266; RUSNATI M, 1993, J CELL PHYSIOL, V154, P152, DOI 10.1002/jcp.1041540119; SASADA R, 1988, MOL CELL BIOL, V8, P588, DOI 10.1128/MCB.8.2.588; VEOMETT G, 1989, BIOCHEM BIOPH RES CO, V159, P694, DOI 10.1016/0006-291X(89)90050-8; YAMANAKA Y, 1993, CANCER RES, V53, P5289; YAZAKI N, 1993, BIOCHIM BIOPHYS ACTA, V1172, P37, DOI 10.1016/0167-4781(93)90266-G	39	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5663	5670		10.1074/jbc.271.10.5663	http://dx.doi.org/10.1074/jbc.271.10.5663			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621430	hybrid			2022-12-25	WOS:A1996TZ28600056
J	Berg, DT; Calnek, DS; Grinnell, BW				Berg, DT; Calnek, DS; Grinnell, BW			Trans-repressor BEF-1 phosphorylation - A potential control mechanism for human ApoE gene regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E GENE; HYPERCHOLESTEROLEMIA; LIPOPROTEINS; MICE; RNA; TRANSCRIPTION; EXPRESSION; PROTEIN	Human apolipoprotein E is a plasma lipoprotein that appears to play an important protective role in the development of atherosclerosis. While little is known about the regulation of apoE, recent studies have shown that cytokines repress apoE synthesis both in vivo and in vitro, Furthermore, we have recently shown that the endogenous apoE gene is negatively regulated by the nuclear trans-repressor BEF-1 in the human HepG2 cell line. In this study we demonstrate that treatment of HepG2 cells with the cytokine interleukin-1 and interleukin-6 resulted in the induction of an isoform of BEF-1, designated B1. The induction of the B1 isoform could be blocked by the protein kinase inhibitor staurosporine, suggesting that B1 is a phosphorylated form of BEF-1, As further support, the B1 isoform could also be induced by phorbol ester, and subsequently inhibited by staurosporine, implicating a role for protein kinase C-mediated phosphorylation. Quantitation of the levels of the BEF-1 isoforms, and studies in the presence of cyclohexamide, provided evidence for the phosphorylation of an existing intracellular pool of BEF-1, with no change in the total intracellular level, Under conditions that generated increased levels of the B1 isoform, there was a concomitant and proportional decrease in the level of apoE mRNA. The effect did not appear to be the result of improved binding to the apoE regulatory region as the DNA binding affinity of B1 was identical to native BEF-1, Our data suggest that the regulation of apoE by BEF-1 is modulated by differential phosphorylation, possibly through the protein kinase C pathway.	LILLY CORP CTR,LILLY RES LABS,DIV CARDIOVASC RES,INDIANAPOLIS,IN 46285	Eli Lilly								AZROLAN N, 1990, J LIPID RES, V31, P1141; BERG DT, 1995, J BIOL CHEM, V270, P15447, DOI 10.1074/jbc.270.26.15447; BOULIKAS T, 1995, CRIT REV EUKAR GENE, V5, P1; CHANG DJ, 1990, J BIOL CHEM, V265, P9496; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAZIO S, 1994, J LIPID RES, V35, P408; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GRINNELL BW, 1988, MOL CELL BIOL, V8, P3448, DOI 10.1128/MCB.8.8.3448; HARDARDOTTIR I, 1994, LYMPHOKINE CYTOK RES, V13, P161; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; ONEILL LAJ, 1995, BBA-MOL CELL RES, V1266, P31, DOI 10.1016/0167-4889(94)00217-3; PAIK YK, 1988, J BIOL CHEM, V263, P13340; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1992, J INTERN MED, V231, P653, DOI 10.1111/j.1365-2796.1992.tb01254.x; REIFELMILLER AE, 1994, J BIOL CHEM, V269, P23861; REIFELMILLER AE, 1991, J BIOL CHEM, V266, P13873; ROSES AD, 1994, NEUROPSYCHOPHARMACOL, V10, P5; SAKLATVALA J, 1995, BRIT MED BULL, V51, P402, DOI 10.1093/oxfordjournals.bmb.a072969; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SMITH JD, 1988, J BIOL CHEM, V263, P8300; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; UTERMANN G, 1994, CURR BIOL, V4, P362, DOI 10.1016/S0960-9822(00)00081-6; WEISGRABER KH, 1990, ANN NY ACAD SCI, V598, P37, DOI 10.1111/j.1749-6632.1990.tb42274.x; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZUCKERMAN SH, 1992, ATHEROSCLEROSIS, V96, P203, DOI 10.1016/0021-9150(92)90066-P	32	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4589	4592						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617716				2022-12-25	WOS:A1996TX69700006
J	Howell, RM; Woodford, KJ; Weitzmann, MN; Usdin, K				Howell, RM; Woodford, KJ; Weitzmann, MN; Usdin, K			The chicken beta-globin gene promoter forms a novel ''cinched'' tetrahelical structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 REVERSE-TRANSCRIPTASE; DNA-REPLICATION INVITRO; ESCHERICHIA-COLI; INTERNAL REGIONS; BINDING PROTEIN; SUPERCOILED DNA; STRAND TRANSFER; SEQUENCE; TERMINUS; ARREST	We have previously shown that the G-rich sequence G(16)CG(GGT)(2)GG in the promoter region of the chicken beta-globin gene poses a formidable barrier to DNA synthesis in vitro (Woodford et al., 1994, J. Biol. Chem. 269, 27029-27035). The K+ requirement, template-strand specificity, template concentration independence, and involvement of Hoogsteen bonding suggested that the underlying basis of this new type of DNA synthesis arrest site might be an intrastrand tetrahelical structure. However, the arrest site lacks the four G-rich repeats that are a hallmark of previously described intramolecular tetraplexes and contains a number of noncanonical bases that would be expected to greatly destabilize such a structure. Here we report evidence for an unusual K+-dependent intrastrand ''cinched'' tetraplex. This structure has several unique features including the incorporation of bases other than guanine into the stem of the tetraplex, interaction between loop bases and bases in the flanking region, and base pairing between bases 3' and 5' of the tetrahelix-forming region to form a molecular ''cinch.'' This finding extends the range of sequences capable of tetraplex formation as well as our appreciation of the conformational complexity of the chicken beta-globin promoter.			Howell, RM (corresponding author), NIDDK,BIOCHEM PHARMACOL LAB,SECT GENOM STRUCT & FUNCT,BLDG 8,ROOM 202,8 CTR DR MSC 0830,BETHESDA,MD 20892, USA.							BARAN N, 1991, P NATL ACAD SCI USA, V88, P507, DOI 10.1073/pnas.88.2.507; BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEDINGER P, 1989, J BIOL CHEM, V264, P16880; BUISER RG, 1993, BIOCHIM BIOPHYS ACTA, V1216, P20, DOI 10.1016/0167-4781(93)90033-A; DAMBROSIO E, 1987, NUCLEIC ACIDS RES, V15, P3155, DOI 10.1093/nar/15.7.3155; DAY LE, 1981, BIOCHEMISTRY-US, V20, P2091, DOI 10.1021/bi00511a005; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; FRY M, 1992, P NATL ACAD SCI USA, V89, P763, DOI 10.1073/pnas.89.2.763; GERMINO J, 1981, CELL, V23, P681, DOI 10.1016/0092-8674(81)90431-1; GIOVANNANGELI C, 1993, P NATL ACAD SCI USA, V90, P10013, DOI 10.1073/pnas.90.21.10013; HIDAKA M, 1989, J BIOL CHEM, V264, P21031; HILL TM, 1989, P NATL ACAD SCI USA, V86, P1593, DOI 10.1073/pnas.86.5.1593; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KOHWI Y, 1989, NUCLEIC ACIDS RES, V17, P4493, DOI 10.1093/nar/17.12.4493; KOHWISHIGEMATSU T, 1983, P NATL ACAD SCI-BIOL, V80, P4389, DOI 10.1073/pnas.80.14.4389; KRAEMER KH, 1989, MUTAT RES, V220, P61, DOI 10.1016/0165-1110(89)90011-0; LAPIDOT A, 1989, NUCLEIC ACIDS RES, V17, P883, DOI 10.1093/nar/17.3.883; MCGHEE JD, 1981, CELL, V27, P45, DOI 10.1016/0092-8674(81)90359-7; MURCHIE AIH, 1994, EMBO J, V13, P993, DOI 10.1002/j.1460-2075.1994.tb06344.x; O'Neill R R, 1989, Appl Theor Electrophor, V1, P163; PALECEK E, 1987, GEN PHYSIOL BIOPHYS, V6, P327; PANYUTIN IG, 1990, P NATL ACAD SCI USA, V87, P867, DOI 10.1073/pnas.87.3.867; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SMITH MT, 1989, GENE, V85, P187, DOI 10.1016/0378-1119(89)90479-4; USDIN K, 1989, J BIOL CHEM, V264, P15681; USDIN K, 1989, J BIOL CHEM, V264, P20736; USDIN K, 1995, NUCLEIC ACIDS RES, V23, P4202, DOI 10.1093/nar/23.20.4202; WEAVER DT, 1984, J MOL BIOL, V180, P961, DOI 10.1016/0022-2836(84)90266-3; WEISMANSHOMER P, 1989, BIOCHEM BIOPH RES CO, V164, P1149, DOI 10.1016/0006-291X(89)91789-0; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WOODFORD KJ, 1994, J BIOL CHEM, V269, P27059	32	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5208	5214						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617804				2022-12-25	WOS:A1996TX69700094
J	Peters, JD; Furlong, MT; Asai, DJ; Harrison, ML; Geahlen, RL				Peters, JD; Furlong, MT; Asai, DJ; Harrison, ML; Geahlen, RL			Syk, activated by cross-linking the B-cell antigen receptor, localizes to the cytosol where it interacts with and phosphorylates alpha-tubulin on tyrosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CATALYTIC FRAGMENT; SYNTHETIC PEPTIDES; REGULATORY DOMAIN; KINASE P72(SYK); BOVINE THYMUS; FC-RECEPTORS; PROTEIN; MICROTUBULES; RI	Syk (p72(syk)) is a 72-kDa, nonreceptor, protein-tyrosine kinase that becomes tyrosine-phosphorylated and activated in B lymphocytes following aggregation of the B-cell. antigen receptor. To explore the subcellular location of activated Syk, anti-IgM-activated B-cells were fractionated into soluble and particulate fractions by ultracentrifugation. Activated and tyrosine-phosphorylated Syk was found predominantly in the soluble fraction and was not associated with components of the antigen receptor. Similarly, the activated forms of Syk and its homolog, ZAP-70, were found in soluble fractions prepared from pervanadate-treated Jurkat T-cells. A 54-kDa protein that co-immunoprecipitated with Syk from the soluble fraction of activated B-cells was identified by peptide mapping as alpha-tubulin. alpha-Tubulin was an excellent in vitro substrate for Syk and was phosphorylated on a single tyrosine present within an acidic stretch of amino acids located near the carboxyl terminus. alpha-Tubulin was phosphorylated on tyrosine in intact cells following aggregation of the B-cell antigen receptor in a reaction that was inhibited by the Syk-selective inhibitor, piceatannol. Thus, once activated, Syk releases from the aggregated antigen receptor complex and is free to associate with and phosphorylate soluble proteins including alpha-tubulin.	PURDUE UNIV,DEPT MED CHEM & MOL PHARMACOL,W LAFAYETTE,IN 47907; PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus				Geahlen, Robert/0000-0001-8400-2924	NATIONAL CANCER INSTITUTE [R01CA037372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049889, T32GM008298] Funding Source: NIH RePORTER; NCI NIH HHS [CA37372] Funding Source: Medline; NIGMS NIH HHS [GM08298, GM49889] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL A, 1993, J BIOL CHEM, V268, P15900; AKIYAMA T, 1986, J BIOL CHEM, V261, P4797; ASAI DJ, 1982, CELL MOTIL CYTOSKEL, V2, P599, DOI 10.1002/cm.970020608; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BURG DL, 1994, J BIOL CHEM, V269, P28136; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHUANG LT, 1994, CANCER RES, V54, P1286; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1994, J BIOL CHEM, V269, P28859; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COREY SJ, 1994, P NATL ACAD SCI USA, V91, P4683, DOI 10.1073/pnas.91.11.4683; COUTURE C, 1994, P NATL ACAD SCI USA, V91, P5301, DOI 10.1073/pnas.91.12.5301; DARBY C, 1994, J IMMUNOL, V152, P5429; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; GEAHLEN RL, 1994, MECHANISMS LYMPHOCYT, V5, P103; HARRISON ML, 1994, J BIOL CHEM, V269, P955; HEIDEMANN SR, 1980, DEV BIOL, V80, P489, DOI 10.1016/0012-1606(80)90421-2; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KIENER PA, 1993, J BIOL CHEM, V268, P24442; KITTS PA, 1993, BIOTECHNIQUES, V14, P810; LAW DA, 1993, CURR BIOL, V3, P645, DOI 10.1016/0960-9822(93)90062-S; LEY SC, 1994, EUR J IMMUNOL, V24, P99, DOI 10.1002/eji.1830240116; LIN JJ, 1992, J IMMUNOL, V149, P3182; LITTLE M, 1988, COMP BIOCHEM PHYS B, V90, P655, DOI 10.1016/0305-0491(88)90320-3; LOW PS, 1987, J BIOL CHEM, V262, P4592; MACCIONI RB, 1988, EMBO J, V7, P1957, DOI 10.1002/j.1460-2075.1988.tb03033.x; MACCIONI RB, 1986, EUR J BIOCHEM, V156, P375, DOI 10.1111/j.1432-1033.1986.tb09593.x; MAHRENHOLZ AM, 1988, BIOCHEM BIOPH RES CO, V155, P52, DOI 10.1016/S0006-291X(88)81048-9; MATTEN WT, 1990, J CELL BIOL, V111, P1959, DOI 10.1083/jcb.111.5.1959; MINAMI Y, 1995, IMMUNITY, V2, P89, DOI 10.1016/1074-7613(95)90081-0; NAGAI K, 1994, J BIOCHEM-TOKYO, V116, P1176, DOI 10.1093/oxfordjournals.jbchem.a124646; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; PRATT LF, 1988, EMBO J, V7, P931, DOI 10.1002/j.1460-2075.1988.tb02898.x; QIN SF, 1994, FEBS LETT, V345, P233, DOI 10.1016/0014-5793(94)00450-1; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; SAKAI K, 1991, FEBS LETT, V294, P104, DOI 10.1016/0014-5793(91)81352-9; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SCHIEVEN GL, 1993, J BIOL CHEM, V268, P16688; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Schmitt H, 1974, Methods Enzymol, V34, P623; SHIMOMURA R, 1993, BIOCHEM BIOPH RES CO, V192, P252, DOI 10.1006/bbrc.1993.1407; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SULLIVAN KF, 1984, J NEUROCHEM, V42, P1363, DOI 10.1111/j.1471-4159.1984.tb02796.x; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; VERA JC, 1988, P NATL ACAD SCI USA, V85, P6763, DOI 10.1073/pnas.85.18.6763; WANDOSELL F, 1987, J BIOL CHEM, V262, P8268; WANDOSELL F, 1986, J BIOL CHEM, V261, P332; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	59	126	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4755	4762						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617742				2022-12-25	WOS:A1996TX69700032
J	Cirri, P; Fiaschi, T; Chiarugi, P; Camici, G; Manao, G; Raugei, G; Ramponi, G				Cirri, P; Fiaschi, T; Chiarugi, P; Camici, G; Manao, G; Raugei, G; Ramponi, G			The molecular basis of the differing kinetic behavior of the two low molecular mass phosphotyrosine protein phosphatase isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RAT-LIVER; ISOENZYMES; DROSOPHILA; EVOLUTION	The low molecular mass phosphotyrosine protein phosphatase is a cytosolic enzyme of 18 kDa, Mammalian species contain a single gene that codifies for two distinct isoenzymes; they are produced through alternative splicing and thus differ only in the sequence from residue 40 to residue 73, Isoenzymes differ also in substrate specificity and in the sensitivity to activity modulators, In our study, we mutated a number of residues included in the alternative 40-73 sequence by substituting the residues present in the type 2 isoenzyme with those present in type 1 and subsequently examined the kinetic properties of the purified mutated proteins, The results enabled us to identify the molecular site that determines the kinetic characteristics of each isoform; the residue in position 50 plays the main role in the determination of substrate specificity, while the residues in both positions 49 and 50 are involved in the strong activation of the type 2 low M(r) phosphotyrosine protein phosphatase isoenzyme by purine compounds such as guanosine and cGMP, The sequence 49-50 is included in a loop whose N terminus is linked to the beta 2-strand and whose C terminus is linked to the alpha 2-helix; this loop is very near the active site pocket, Our findings suggest that this loop is involved both in the regulation of the enzyme activity and in the determination of the substrate specificity of the two low M(r) phosphotyrosine protein phosphatase isoenzymes.	UNIV FLORENCE,DEPT SCI BIOCHIM,I-50134 FLORENCE,ITALY	University of Florence			Chiarugi, Paola/CDD-7988-2022; Camici, Giovanni/H-1631-2018	Chiarugi, Paola/0000-0001-7655-2969; Camici, Giovanni/0000-0002-0523-0695; raugei, giovanni/0000-0003-1294-786X				BAHK YY, 1994, J BIOL CHEM, V269, P8240; BISHOP JM, 1985, TRENDS GENET, V1, P245, DOI 10.1016/0168-9525(85)90094-0; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CAMICI G, 1989, J BIOL CHEM, V264, P2560; CHIARUGI P, 1992, FEBS LETT, V310, P9, DOI 10.1016/0014-5793(92)81134-8; CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; CIRRI P, 1993, BIOCHIM BIOPHYS ACTA, V1161, P216, DOI 10.1016/0167-4838(93)90216-E; CIRRI P, 1995, BBA-GEN SUBJECTS, V1243, P129, DOI 10.1016/0304-4165(94)00055-3; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; DISSING J, 1991, J BIOL CHEM, V266, P20619; EFSTRATIADIS A, 1980, CELL, V21, P653, DOI 10.1016/0092-8674(80)90429-8; FUJIMOTO S, 1988, CHEM PHARM BULL, V36, P3020; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; KREBS EG, 1986, ENZYMES, V17; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANAO G, 1992, J PROTEIN CHEM, V11, P333, DOI 10.1007/BF01024871; MANAO G, 1991, 6TH P NAT M PROT 91, P96; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; MCLAUGHLIN S, 1993, J BIOL CHEM, V268, P6839; MONDESERT O, 1994, J BIOL CHEM, V269, P27996; OGRADY P, 1994, J BIOL CHEM, V269, P25193; STEFANI M, 1993, FEBS LETT, V326, P131, DOI 10.1016/0014-5793(93)81776-V; STONE RL, 1994, J BIOL CHEM, V269, P31323; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; TADDEI N, 1994, FEBS LETT, V350, P328, DOI 10.1016/0014-5793(94)00805-1; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; TSUJI S, 1994, P NATL ACAD SCI USA, V91, P9392, DOI 10.1073/pnas.91.20.9392; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WATT WB, 1994, GENETICS, V136, P11; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	31	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2604	2607		10.1074/jbc.271.5.2604	http://dx.doi.org/10.1074/jbc.271.5.2604			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576228	hybrid			2022-12-25	WOS:A1996TT48800042
J	Desaubry, L; Shoshani, I; Johnson, RA				Desaubry, L; Shoshani, I; Johnson, RA			2',5'-dideoxyadenosine 3'-polyphosphates are potent inhibitors of adenylyl cyclases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-MEDIATED INHIBITION; ADENOSINE; BRAIN; REQUIREMENTS; KINETICS; METAL	2',5'-Dideoxyadenosine 3'-di- and triphosphates were tested as inhibitors of brain adenylyl cyclases. With an IC50 similar to 40 nM, 2',5'-dideoxy-3'-ATP is the most potent nonprotein synthetic regulator of adenylyl cyclases thus far described. Neither 2',5'-dideoxy-3'-ADP nor 2',5'-dideoxy-3'-ATP inhibited activity by competition with substrate, and the linear noncompetitive inhibition observed was consistent with interaction via a distinct domain. The availability of this ligand will permit the development of a variety of probes that will be extremely useful in investigating adenylyl cyclase structure and the role(s) that this class of compound may play in physiologically regulating cell function.	SUNY STONY BROOK,HLTH SCI CTR,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Desaubry, Laurent G/R-5446-2017	Desaubry, Laurent G/0000-0002-1192-2970	NIDDK NIH HHS [DK38828] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038828] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUSHFIELD M, 1990, MOL PHARMACOL, V38, P848; DESAUBRY L, 1995, TETRAHEDRON LETT, V36, P995, DOI 10.1016/0040-4039(94)02424-A; FAIN JN, 1972, J BIOL CHEM, V247, P6866; FLORIO VA, 1983, MOL PHARMACOL, V24, P195; GARBERS DL, 1975, J BIOL CHEM, V250, P8449; HASLAM RJ, 1972, LIFE SCI 2-BIOCH GEN, V11, P1143, DOI 10.1016/0024-3205(72)90269-X; HASLAM RJ, 1978, BIOCHEM J, V176, P83, DOI 10.1042/bj1760083; JOHNSON RA, 1977, ARCH BIOCHEM BIOPHYS, V183, P216, DOI 10.1016/0003-9861(77)90435-0; JOHNSON RA, 1980, J BIOL CHEM, V255, P8252; JOHNSON RA, 1989, MOL PHARMACOL, V35, P681; JOHNSON RA, 1990, J BIOL CHEM, V265, P11595; JOHNSON RA, 1979, J BIOL CHEM, V254, P1094; JOHNSON RA, 1990, J BIOL CHEM, V265, P19035; KOESLING D, 1991, FASEB J, V5, P2785, DOI 10.1096/fasebj.5.13.1680765; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; LONDOS C, 1977, J BIOL CHEM, V252, P5951; LONDOS C, 1977, P NATL ACAD SCI USA, V74, P5482, DOI 10.1073/pnas.74.12.5482; LYONS E, 1994, FASEB J, V8, pA1418; MCKENZIE SG, 1973, CAN J PHYSIOL PHARM, V51, P190, DOI 10.1139/y73-027; PFEUFFER E, 1985, EMBO J, V4, P3675, DOI 10.1002/j.1460-2075.1985.tb04134.x; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; STUBNER D, 1989, FEBS LETT, V248, P155, DOI 10.1016/0014-5793(89)80452-1; STULL JT, 1977, J BIOL CHEM, V252, P851; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; WEINRYB I, 1974, BIOCHIM BIOPHYS ACTA, V334, P218, DOI 10.1016/0005-2744(74)90165-X; WOLFF J, 1981, ADV CYCL NUCL RES<D>, V14, P199; YEUNG SMH, 1990, J BIOL CHEM, V265, P16745	28	48	51	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2380	2382		10.1074/jbc.271.5.2380	http://dx.doi.org/10.1074/jbc.271.5.2380			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576194	hybrid			2022-12-25	WOS:A1996TT48800008
J	Schmidt, M; Rumenapp, U; Bienek, C; Keller, J; vonEichelStreiber, C; Jakobs, KH				Schmidt, M; Rumenapp, U; Bienek, C; Keller, J; vonEichelStreiber, C; Jakobs, KH			Inhibition of receptor signaling to phospholipase D by Clostridium difficile toxin B - Role of Rho proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN	Rho proteins have been reported to activate phospholipase D (PLD) in in vitro preparations. To examine the role of Rho proteins in receptor signaling to PLD, we studied the effect of Clostridium difficile toxin B, which glucosylates Rho proteins, on the regulation of PLD activity in human embryonic kidney (HEK) cells stably expressing the m3 muscarinic acetylcholine receptor (mAChR), Toxin B treatment of HEK cells potently and efficiently blocked mAChR-stimulated PLD. In contrast, basal and phorbol ester stimulated PLD activities were not or only slightly reduced. Cytochalasin B and Clostridium botulinum C2 toxin, mimicking the effect of toxin B on the actin cytoskeleton but without involving Rho proteins, had no effect on mAChR-stimulated PLD. Toxin B did not alter cell surface mAChR number and mAChR-stimulated binding of (guanosine 5'-O-(thio)triphosphate (GTP gamma S)) to G proteins. In addition to mAChR stimulated PLD, toxin B treatment also inhibited PLD activation by the direct G protein activators, AlF4- and GTP gamma S, studied in intact and permeabilized cells, respectively. Finally, C. botulinum C3 exoenzyme, which ADP-ribosylates Rho proteins, mimicked the inhibitory effect of toxin B on GTP gamma S-stimulated PLD activity. In conclusion, the data presented indicate that toxin B potently and selectively interferes with receptor coupling mechanisms to PLD, and furthermore suggest an essential role for Rho proteins in receptor signaling to PLD.	UNIV ESSEN GESAMTHSCH,INST PHARMAKOL,D-45122 ESSEN,GERMANY; UNIV MAINZ,INST MED MIKROBIOL & HYG,D-55101 MAINZ,GERMANY	University of Duisburg Essen; Johannes Gutenberg University of Mainz			Schmidt, Martina/C-5339-2018	Schmidt, Martina/0000-0003-3075-0630				AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; AKTORIES K, 1993, GTPASES BIOL, V1, P87; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CHONG LD, 1994, CELL, V75, P1137; CIESIELSKITRESKA J, 1989, EUR J CELL BIOL, V48, P191; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; JUST I, 1994, J BIOL CHEM, V269, P10706; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; SCHMIDT M, 1995, J BIOL CHEM, V270, P19949, DOI 10.1074/jbc.270.34.19949; SCHMIDT M, 1994, EUR J BIOCHEM, V225, P667, DOI 10.1111/j.1432-1033.1994.00667.x; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; VONEICHELSTREIBER C, 1987, MICROB PATHOGENESIS, V2, P307, DOI 10.1016/0882-4010(87)90073-8	25	104	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2422	2426		10.1074/jbc.271.5.2422	http://dx.doi.org/10.1074/jbc.271.5.2422			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576201	hybrid			2022-12-25	WOS:A1996TT48800015
J	Brisseau, GF; Grinstein, S; Hackam, DJ; Nordstrom, T; Manolson, MF; Khine, AA; Rotstein, OD				Brisseau, GF; Grinstein, S; Hackam, DJ; Nordstrom, T; Manolson, MF; Khine, AA; Rotstein, OD			Interleukin-1 increases vacuolar-type H+-ATPase activity in murine peritoneal macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CYTOPLASMIC PH REGULATION; CYCLIC-AMP; ENDOTHELIAL-CELLS; INTRACELLULAR PH; MAMMALIAN KIDNEY; PLASMA-MEMBRANE; PROTON PUMP; INVOLVEMENT; INDUCTION	Maintenance of cytoplasmic pH (pH(i)) within a narrow physiological range is crucial to normal cellular function. This is of particular relevance to phagocytic cells within the acidic inflammatory microenvironment where the pH(i) tends to be acid loaded. We have previously reported that a vacuolar-type H+-ATPase (V-ATPase) situated in the plasma membrane of macrophages and poised to extrude protons from the cytoplasmic to the extracellular space is an important pH(i) regulatory mechanism within the inflammatory milieu, Since this microenvironment is frequently characterized by the influx of cells known to release inflammatory cytokines, we performed studies to examine the effect of one such mediator molecule, interleukin-1 (IL-1), on pH(i) regulation in peritoneal macrophages. IL-1 caused a time- and dose-dependent increase in macrophage pH(i) recovery from an acute acid load. This effect was specific to IL-1 and was due to enhanced plasmalemmal V-ATPase activity. The increased V-ATPase activity by IL-1 occurred following a lag period of several hours and required de novo protein and mRNA synthesis. However, Northern blot analysis revealed that IL-1 did not exert its effect via alterations in the levels of mRNA transcripts for the A or B subunits of the V-ATPase complex, Finally, stimulation of both cAMP-dependent protein kinase and protein kinase C was required for the stimulatory effect of IL-1 on V-ATPase activity. Thus, cytokines present within the inflammatory milieu are able to modulate pH(i) regulatory mechanisms. These data may represent a novel mechanism whereby cytokines may improve cellular function at inflammatory sites.	TORONTO HOSP,DEPT SURG,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,TORONTO,ON M5G 1X8,CANADA; UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5G 2C4,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO,ON M5G 2C4,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Nordström, Tommy/H-9111-2016	Nordström, Tommy/0000-0002-2153-5819; Manolson, Morris/0000-0001-8755-5460; Hackam, David/0000-0001-5195-8807				BAE HR, 1990, NATURE, V348, P637, DOI 10.1038/348637a0; BETHEA JR, 1992, J CELL PHYSIOL, V152, P264, DOI 10.1002/jcp.1041520207; BRISSEAU GF, 1995, BLOOD, V85, P1025, DOI 10.1182/blood.V85.4.1025.bloodjournal8541025; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CARLSEN E, 1988, TRANSPLANTATION, V46, P575, DOI 10.1097/00007890-198810000-00022; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHN ZA, 1978, J IMMUNOL, V121, P813; CONQUER JA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P1, DOI 10.1016/0167-4889(92)90021-3; CONTI P, 1985, AGENTS ACTIONS, V17, P390; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DINARELLO CA, 1987, J IMMUNOL, V139, P1902; FALLON RJ, 1994, J BIOL CHEM, V269, P1101; FORD HR, 1989, ARCH SURG-CHICAGO, V124, P1422; GEILEN CC, 1992, FEBS LETT, V309, P381, DOI 10.1016/0014-5793(92)80811-T; GRINSTEIN S, 1986, AM J PHYSIOL, V250, pC283, DOI 10.1152/ajpcell.1986.250.2.C283; GRINSTEIN S, 1984, J GEN PHYSIOL, V83, P341, DOI 10.1085/jgp.83.3.341; GURICH RW, 1989, AM J PHYSIOL, V257, pF777, DOI 10.1152/ajprenal.1989.257.5.F777; KAPUS A, 1993, J GEN PHYSIOL, V102, P729, DOI 10.1085/jgp.102.4.729; KARNOVSKY ML, 1978, J IMMUNOL, V121, P809; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KRACHT M, 1993, J BIOL CHEM, V268, P21066; KRONBORG G, 1993, PEDIATR PULM, V15, P292, DOI 10.1002/ppul.1950150506; LADOUX A, 1988, EUR J BIOCHEM, V175, P455, DOI 10.1111/j.1432-1033.1988.tb14216.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BS, 1995, J BIOL CHEM, V270, P7320, DOI 10.1074/jbc.270.13.7320; LEMISCHKA I, 1982, NATURE, V300, P330, DOI 10.1038/300330a0; MAIER JAM, 1993, EXP CELL RES, V205, P52, DOI 10.1006/excr.1993.1057; NAKAZATO Y, 1991, J BIOL CHEM, V266, P14119; NANDA A, 1992, J BIOL CHEM, V267, P22740; NICOLLE LE, 1993, J UROLOGY, V149, P1049, DOI 10.1016/S0022-5347(17)36293-6; PUOPOLO K, 1992, J BIOL CHEM, V267, P3696; PUOPOLO K, 1991, J BIOL CHEM, V266, P24564; RAY K, 1992, BIOCHEM J, V282, P59, DOI 10.1042/bj2820059; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; SHIRAKAWA F, 1988, P NATL ACAD SCI USA, V85, P8201, DOI 10.1073/pnas.85.21.8201; SHUNTOH H, 1988, J NEUROCHEM, V51, P1565, DOI 10.1111/j.1471-4159.1988.tb01126.x; SIEBERT A, 1994, J BIOL CHEM, V269, P28329; SWALLOW CJ, 1990, BIOCHIM BIOPHYS ACTA, V1022, P203, DOI 10.1016/0005-2736(90)90115-5; SWALLOW CJ, 1990, SURGERY, V108, P363; SWALLOW CJ, 1988, J BIOL CHEM, V263, P19558; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; SWALLOW CJ, 1993, J CELL PHYSIOL, V157, P453, DOI 10.1002/jcp.1041570304; UHL J, 1989, J IMMUNOL, V142, P1576; VANHILLE B, 1993, J BIOL CHEM, V268, P7075; WALLACE BG, 1994, J CELL BIOL, V125, P661, DOI 10.1083/jcb.125.3.661; XIE XS, 1993, J BIOL CHEM, V268, P25063; ZEN K, 1994, EXP CELL RES, V215, P172, DOI 10.1006/excr.1994.1329; ZHANG K, 1992, J BIOL CHEM, V267, P14539; ZHANG K, 1992, J BIOL CHEM, V267, P9701	49	49	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2005	2011		10.1074/jbc.271.4.2005	http://dx.doi.org/10.1074/jbc.271.4.2005			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567651	hybrid			2022-12-25	WOS:A1996TR32000033
J	Schlegel, J; Peters, I; Orrenius, S; Miller, DK; Thornberry, NA; Yamin, TT; Nicholson, DW				Schlegel, J; Peters, I; Orrenius, S; Miller, DK; Thornberry, NA; Yamin, TT; Nicholson, DW			CPP32 apopain is a key interleukin 1 beta converting enzyme-like protease involved in Fas-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODES	Cysteine proteases of the interleukin 1 beta Converting Enzyme (ICE)/CED-3 family have been implicated in the effector process of apoptosis in several systems, including Fas-mediated apoptosis. We have recently isolated and partially characterized a protease present in extracts from anti-Fas antibody treated Jurkat T cells that promotes apoptotic changes in isolated nuclei (Schlegel, J., Peters, I., and Orrenius, S. (1995) FEES Lett, 364, 139-142), We now show that this protease cleaves poly(ADP-ribose) polymerase (PARP) with high efficiency and specificity. Both PARP proteolysis and the proapoptotic effects of the protease are inhibited by nanomolar concentrations of a selective inhibitor of apopain (CPP32), while an inhibitor of IL-1 beta converting enzyme is much less effective, requiring micromolar concentrations for the inhibition of the isolated protease. Kinetic analysis of the isolated protease reveals kinetic constants similar to those reported for apopain, The isolated protease is recognized by antibodies specific for CPP32/apopain but not by an anti-ICE antibody. Furthermore, a selective inhibitor of apopain prevents Fas-induced apoptosis in intact Jurkat T cells, We therefore conclude that CPP32/apopain is activated in Fas-induced apoptosis.	MERCK RES LABS,DEPT ENZYMOL,RAHWAY,NJ 07065; MERCK RES LABS,DEPT INFLAMMAT RES,RAHWAY,NJ 07065; MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOLEC BIOL,POINTE CLAIRE,PQ H9R 4P8,CANADA	Merck & Company; Merck & Company; Merck & Company	Schlegel, J (corresponding author), KAROLINSKA INST,INST ENVIRONM MED,DIV TOXICOL,POB 210,S-11346 STOCKHOLM,SWEDEN.							BARR PJ, 1994, BIO-TECHNOL, V12, P487, DOI 10.1038/nbt0594-487; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1994, TRENDS BIOCHEM SCI, V19, P26, DOI 10.1016/0968-0004(94)90170-8; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SCHLEGEL J, 1995, FEBS LETT, V364, P139, DOI 10.1016/0014-5793(95)00374-I; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WEIS M, 1995, EXP CELL RES, V219, P699, DOI 10.1006/excr.1995.1281; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	20	467	487	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1841	1844		10.1074/jbc.271.4.1841	http://dx.doi.org/10.1074/jbc.271.4.1841			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567626	hybrid			2022-12-25	WOS:A1996TR32000008
J	Biardi, L; Krisans, SK				Biardi, L; Krisans, SK			Compartmentalization of cholesterol biosynthesis - Conversion of mevalonate to farnesyl diphosphate occurs in the peroxisomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; ACETOACETYL-COA; ACETYL-COA; CELLS; MICROSOMES; REDUCTASE; MEMBRANES; DOLICHOL; KINASE	We have recently demonstrated that mevalonate kinase and farnesyl diphosphate (FPP) synthase are localized predominantly in peroxisomes, This observation raises the question regarding the subcellular localization of the enzymes that catalyze the individual steps in the pathway between mevalonate kinase and FPP synthase (phosphomevalonate kinase, mevalonate diphosphate decarboxylase, and isopentenyl diphosphate isomerase). These enzyme are found in the 100,000 x g supernatant fraction of cells or tissues and have been considered to be cytoplasmic proteins, In the current studies, we show that the activities of mevalonate kinase, phosphomevalonate kinase, and mevalonate diphosphate decarboxylase are equal in extracts prepared from intact cells and selectively permeabilized cells, which lack cytosolic enzymes. We also demonstrate structure-linked latency of phosphomevalonate kinase and mevalonate diphosphate decarboxylase that is consistent with a peroxisomal localization of these enzymes, Finally, we show that cholesterol biosynthesis from mevalonate can occur in selectively permeabilized cells lacking cytosolic components. These results suggest that the peroxisome is the major site of the synthesis of FPP from mevalonate, since all of the cholestrogenic enzymes involved in this conversion are localized in the peroxisome.	SAN DIEGO STATE UNIV,DEPT BIOL,SAN DIEGO,CA 92182	California State University System; San Diego State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044350, R01DK032852] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 32852, DK 44350] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APPELKVIST EL, 1989, EUR J BIOCHEM, V185, P503, DOI 10.1111/j.1432-1033.1989.tb15142.x; BEAUFAY H, 1974, J CELL BIOL, V61, P188, DOI 10.1083/jcb.61.1.188; BIARDI L, 1994, J BIOL CHEM, V269, P1197; BRUENGER E, 1986, ARCH BIOCHEM BIOPHYS, V248, P620, DOI 10.1016/0003-9861(86)90516-3; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GOULD SJ, 1990, J CELL BIOL, V110, P27, DOI 10.1083/jcb.110.1.27; HODGE VJ, 1991, BIOCHEM BIOPH RES CO, V181, P537, DOI 10.1016/0006-291X(91)91222-X; HOFFMANN GF, 1992, J INHERIT METAB DIS, V15, P738, DOI 10.1007/BF01800016; HOVIK R, 1991, J LIPID RES, V32, P993; KELLER GA, 1986, J CELL BIOL, V103, P875, DOI 10.1083/jcb.103.3.875; KELLER GA, 1985, P NATL ACAD SCI USA, V82, P770, DOI 10.1073/pnas.82.3.770; KELLER RK, 1989, CHEM PHYS LIPIDS, V51, P261, DOI 10.1016/0009-3084(89)90013-3; KRISANS SK, 1994, J BIOL CHEM, V269, P14165; KRISANS SK, 1988, J CELL BIOL, V107, P122; LEIGHTON F, 1968, J CELL BIOL, V37, P482, DOI 10.1083/jcb.37.2.482; NOLTMANN EA, 1966, METHOD ENZYMOL, V9, P557; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; SAWAMURA M, 1992, J BIOL CHEM, V267, P6051; STAMELLOS KD, 1992, J BIOL CHEM, V267, P5560; THOMPSON SL, 1990, J BIOL CHEM, V265, P5731; VERLEUR N, 1993, EUR J BIOCHEM, V218, P75, DOI 10.1111/j.1432-1033.1993.tb18353.x	22	86	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1784	1788		10.1074/jbc.271.3.1784	http://dx.doi.org/10.1074/jbc.271.3.1784			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576183	hybrid			2022-12-25	WOS:A1996TQ52500079
J	Hauser, CR; Gillham, NW; Boynton, JE				Hauser, CR; Gillham, NW; Boynton, JE			Translational regulation of chloroplast genes - Proteins binding to the 5'-untranslated regions of chloroplast mRNAs in Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYSTEM-II; WILD-TYPE; MESSENGER-RNAS; HIGHER-PLANTS; EXPRESSION; SEQUENCE; LIGHT; RESISTANCE; MUTATIONS; RIBOSOME	We have examined the effects of illumination, carbon source, and levels of chloroplast protein synthesis on trans-acting proteins that bind to the leaders of five representative chloroplast mRNAs, The accumulation of these five chloroplast mRNAs and the proteins they en code were measured in cells grown under identical conditions, Extracts from all cell types examined contain a minimum set of six chloroplast 5'-untranslated region (UTR)-binding proteins (81, 62, 56, 47, 38, and 15 kDa), Fractionation results suggest that multiple forms of the 81-, 62-, and 47 kDa proteins may exist, A 36-kDa protein was found in all cells except those deficient in chloroplast protein synthesis, Binding of the 81-, 47, and 38-kDa proteins to the rps12 leader is effectively competed by the atpB or rbcL 5'-UTRs, indicating that the same proteins bind to all three leaders. In contrast, these three proteins do not bind to the nuclear encoded alpha-1 tubulin leader, which bound novel proteins of 110, 70, and 43 kDa. Cis-acting sequences within the 5'-UTRs of two chloroplast mRNAs (rps7 and atpB) have been identified which are protected from digestion by RNase T1 by extracts enriched for the 81-, 47-, and 38-kDa proteins.	DUKE UNIV,DEPT BOT,DEV CELL & MOLEC BIOL GRP,DURHAM,NC 27708; DUKE UNIV,DEPT ZOOL,DEV CELL & MOLEC BIOL GRP,DURHAM,NC 27708	Duke University; Duke University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014046, R01GM019427] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-19427, GM-14046] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTLETT SG, 1979, MOL GEN GENET, V176, P199, DOI 10.1007/BF00273214; BISANZSEYER C, 1989, PLANT MOL BIOL, V12, P201, DOI 10.1007/BF00020505; BOUDREAU E, 1994, PLANT MOL BIOL, V24, P585, DOI 10.1007/BF00023556; BOURQUE DP, 1971, J CELL SCI, V8, P153; BOYNTON JE, 1973, P NATL ACAD SCI USA, V70, P3463, DOI 10.1073/pnas.70.12.3463; BOYNTON JE, 1972, J CELL SCI, V10, P267; BOYNTON JE, 1990, CURRENT RES PHOTOSYN, V3, P509; BRUNKE KJ, 1984, MOL CELL BIOL, V4, P1115, DOI 10.1128/MCB.4.6.1115; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; DENG XW, 1988, EMBO J, V7, P3301, DOI 10.1002/j.1460-2075.1988.tb03200.x; DRON M, 1982, NUCLEIC ACIDS RES, V10, P7609, DOI 10.1093/nar/10.23.7609; ERICKSON JM, 1984, P NATL ACAD SCI-BIOL, V81, P3617, DOI 10.1073/pnas.81.12.3617; ERICKSON JM, 1984, EMBO J, V3, P2753, DOI 10.1002/j.1460-2075.1984.tb02206.x; FROMM H, 1985, EMBO J, V4, P291, DOI 10.1002/j.1460-2075.1985.tb03628.x; GIBBS M, 1986, PLANT PHYSIOL, V82, P160, DOI 10.1104/pp.82.1.160; GILLHAM NW, 1994, ANNU REV GENET, V28, P71, DOI 10.1146/annurev.ge.28.120194.000443; GOLDSCHMIDTCLERMONT M, 1986, PLANT MOL BIOL, V6, P13, DOI 10.1007/BF00021302; GOLDSCHMIDTCLERMONT M, 1991, NUCLEIC ACIDS RES, V19, P4083, DOI 10.1093/nar/19.15.4083; GRUISSEM W, 1993, CRIT REV PLANT SCI, V12, P19, DOI 10.1080/07352689309382355; Gruissem W., 1993, CONTROL MRNA STABILI, P329; HARLOW E, 1988, ANTIBODIES LABORATOR; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HARRIS EH, 1977, MOL GEN GENET, V155, P249, DOI 10.1007/BF00272804; HAUSER CR, 1993, TRANSLATIONAL APPARATUS, P545; HEIFETZ PB, 1995, THESIS DUKE U DURHAM; JANG JC, 1994, PLANT CELL, V6, P1665, DOI 10.1105/tpc.6.11.1665; KINDLE KL, 1987, PLANT MOL BIOL, V9, P547, DOI 10.1007/BF00020532; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LIU XQ, 1989, PLANT MOL BIOL, V12, P385, DOI 10.1007/BF00017578; LIU XQ, 1989, J BIOL CHEM, V264, P16100; MALNOE P, 1988, J CELL BIOL, V106, P609, DOI 10.1083/jcb.106.3.609; MAYFIELD SP, 1994, J CELL BIOL, V127, P1537, DOI 10.1083/jcb.127.6.1537; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; NICKELSEN J, 1989, NUCLEIC ACIDS RES, V17, P9637, DOI 10.1093/nar/17.23.9637; ROBERTSON D, 1990, MOL GEN GENET, V221, P155, DOI 10.1007/BF00261715; Rochaix Jean-David, 1992, P249; SAKAMOTO W, 1994, PLANT J, V6, P503, DOI 10.1046/j.1365-313X.1994.6040503.x; Sambrook J, 1989, MOL CLONING LABORATO; SHEEN J, 1990, PLANT CELL, V2, P1027, DOI 10.1105/tpc.2.10.1027; SHEEN J, 1994, PHOTOSYNTH RES, V39, P427, DOI 10.1007/BF00014596; SHEPHERD HS, 1979, P NATL ACAD SCI USA, V76, P1353, DOI 10.1073/pnas.76.3.1353; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUROVOY A, 1993, J MOL BIOL, V229, P94, DOI 10.1006/jmbi.1993.1011; WOESSNER JP, 1986, GENE, V44, P17; WOESSNER JP, 1984, PLANT MOL BIOL, V3, P177, DOI 10.1007/BF00016065; ZERGES W, 1994, MOL CELL BIOL, V14, P5268, DOI 10.1128/MCB.14.8.5268; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	51	50	54	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1486	1497		10.1074/jbc.271.3.1486	http://dx.doi.org/10.1074/jbc.271.3.1486			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576143	hybrid			2022-12-25	WOS:A1996TQ52500039
J	Beck, CA; Zhang, YX; Weigel, NL; Edwards, DP				Beck, CA; Zhang, YX; Weigel, NL; Edwards, DP			Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; DNA-BINDING; DEPENDENT PHOSPHORYLATION; CONFORMATIONAL-CHANGES; RESPONSE ELEMENTS; ANTAGONIST RU486; BREAST-CANCER; IDENTIFICATION; ANTIPROGESTINS; FORM	Human progesterone receptor (PR) is phosphorylated on multiple serine residues; three sites (Ser(102), Ser(294), and Ser(345)) are inducible by hormone agonist, while at least six others are basally phosphorylated and exhibit a general increase in response to hormone. In this study we have used high performance liquid chromatography phosphopeptide mapping and manual peptide sequencing to investigate how two different progestin antagonists, RU486 and ZK98299, affect site specific phosphorylation of PR isolated from T47D breast cancer cells. As compared to the progestin agonist R5020, RU486 stimulated a similar increase in overall incorporation of [P-32]phosphate per PR molecule (2.5-2.6-fold for PR-A and 2.1-fold for PR-B), and at the site-specific level, RU486 stimulated both the basal and inducible sites to the same extent as R5020. In contrast, ZK98299 produced only a minimal increase in overall phosphorylation (1.2-fold for PR-A and 1.1-fold for PR-B) which was due to a reduced stimulation of the basal sites and failure to induce any of the three hormone-dependent sites. No inappropriate phosphorylation sites were detected in response to either RU486 or ZK98299. In cotreatment studies, ZK98299 blocked the increase in overall phosphorylation of PR induced by R5020, demonstrating that the failure of this antagonist to stimulate specific phosphorylation sites is not due to an inefficient interaction with PR in the intact cell. These results indicate that the biological effects of RU486 are not mediated by an alteration in the phosphorylation state of PR, whereas failure to promote phosphorylation of certain sites may contribute to the antagonist action of ZK98299. Additionally these results support the concept of two mechanistic classes of anti-progestins that affect PR differently in vivo.	UNIV COLORADO,HLTH SCI CTR,DEPT PATHOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,PROGRAM MOLEC BIOL,DENVER,CO 80262; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Baylor College of Medicine				Zhang, Yixian/0000-0002-6429-3127	NCI NIH HHS [P-30 CA46934, CA57539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057539, P30CA046934, R55CA057539] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALLAN GF, 1992, P NATL ACAD SCI USA, V89, P11750, DOI 10.1073/pnas.89.24.11750; ALLEN G, 1981, LABORATORY TECHNIQUE, P43; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; BAI WL, 1994, MOL ENDOCRINOL, V8, P1465, DOI 10.1210/me.8.11.1465; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; BOCQUEL MT, 1993, J STEROID BIOCHEM, V45, P205, DOI 10.1016/0960-0760(93)90334-S; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; CHAUCHEREAU A, 1991, J BIOL CHEM, V266, P18280; CHAUCHEREAU A, 1994, BIOCHEMISTRY-US, V33, P13295, DOI 10.1021/bi00249a016; DELABRE K, 1993, P NATL ACAD SCI USA, V90, P4421, DOI 10.1073/pnas.90.10.4421; DEMARZO AM, 1992, BIOCHEMISTRY-US, V31, P10491, DOI 10.1021/bi00158a012; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENTON RR, 1992, J BIOL CHEM, V267, P7263; EDWARDS DP, 1995, J STEROID BIOCHEM, V53, P449, DOI 10.1016/0960-0760(95)00091-D; EDWARDS DP, 1992, BIOCHEMISTRY-US, V31, P2482, DOI 10.1021/bi00124a007; ELASHRY D, 1989, MOL ENDOCRINOL, V3, P1545, DOI 10.1210/mend-3-10-1545; ESTES PA, 1987, BIOCHEMISTRY-US, V26, P6250, DOI 10.1021/bi00393a045; GUIOCHONMANTEL A, 1988, NATURE, V336, P695, DOI 10.1038/336695a0; HILLIARD GM, 1994, BIOCHEMISTRY-US, V33, P4300, DOI 10.1021/bi00180a026; HORWITZ KB, 1992, ENDOCR REV, V13, P146, DOI 10.1210/er.13.2.146; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KLEINHITPASS L, 1991, NUCLEIC ACIDS RES, V19, P1227, DOI 10.1093/nar/19.6.1227; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; KUIPER GGJM, 1994, MOL CELL ENDOCRINOL, V100, P103, DOI 10.1016/0303-7207(94)90287-9; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; POLETTI A, 1993, MOL ENDOCRINOL, V7, P241, DOI 10.1210/me.7.2.241; SARTORIUS CA, 1993, J BIOL CHEM, V268, P9262; SHERIDAN PL, 1989, J BIOL CHEM, V264, P6520; SULLIVAN S, 1991, ANAL BIOCHEM, V197, P65, DOI 10.1016/0003-2697(91)90356-X; TAKIMOTO GS, 1992, P NATL ACAD SCI USA, V89, P3050, DOI 10.1073/pnas.89.7.3050; TRUSS M, 1994, P NATL ACAD SCI USA, V91, P11333, DOI 10.1073/pnas.91.24.11333; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; VANLAAR JH, 1991, J BIOL CHEM, V266, P3734; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; WEIGEL NL, 1992, MOL ENDOCRINOL, V6, P1585, DOI 10.1210/me.6.10.1585; ZHANG Y, 1994, J BIOL CHEM, V269, P31304; ZHANG YX, 1995, MOL ENDOCRINOL, V9, P1029, DOI 10.1210/me.9.8.1029; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P605, DOI 10.1210/me.9.5.605	45	41	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1209	1217		10.1074/jbc.271.2.1209	http://dx.doi.org/10.1074/jbc.271.2.1209			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557652	hybrid			2022-12-25	WOS:A1996TP88900089
J	Chen, YR; Meyer, CF; Tan, TH				Chen, YR; Meyer, CF; Tan, TH			Persistent activation of c-Jun N-terminal kinase 1 (JNK1) in gamma radiation-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								The c-Jun N-terminal kinases (JNK) are activated by various stimuli, including UV light, interleukin-1, tumor necrosis factor-alpha (TNF-alpha), and CD28 costimulation. Induction of JNK by TNF-alpha, a strong apoptosis inducer, implies a possible role of JNK in the regulation of programmed cell death. Present studies show that lethal doses of gamma radiation (GR) induced JNK activities at the early phase of apoptosis in Jurkat T-cells. We demonstrate that JNK1 was activated by either the T-cell activation signals, anti-CD28 monoclonal antibody plus phorbol 12-myristate 13-acetate (PMA), or the apoptosis-inducing treatment, GR; however, the induction patterns were different, In contrast to the rapid and transient JNK1 activation caused by CD28 signaling plus PMA, GR induced a delayed and persistent JNK1 activation. This implies a distinct regulatory mechanism and specific function of JNK1 in irradiated cells. The nuclear and cytosolic JNK1 activities were simultaneously increased in the irradiated cells without an evident change in the protein levels. The abilities of GR to induce JNK1 activation and DNA fragmentation were correlated, Peripheral blood lymphocytes were more sensitive to GR than Jurkat cells in JNK1 induction. The responsiveness of JNK1 to GR suggests the involvement of JNK1 in the initiation of the apoptosis process.	BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030	Baylor College of Medicine			Tan, Tse-Hua/E-3983-2010; Chen, Yi-Rong/CAH-7991-2022; Chen, Yi-Rong/CAF-2186-2022; Chen, Yi-Rong/E-3991-2010; Tan, Tse-Hua/ABD-7080-2021	Tan, Tse-Hua/0000-0003-4969-3170; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Tan, Tse-Hua/0000-0003-4969-3170	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007483, R01AI038649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049875] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI38649, T32-AI7483] Funding Source: Medline; NIGMS NIH HHS [R01-GM49875] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYAN RG, 1994, MOL CELL BIOL, V14, P7933, DOI 10.1128/MCB.14.12.7933; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WARD JF, 1994, RADIAT RES, V138, pS85, DOI 10.2307/3578769; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106	18	743	756	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					631	634		10.1074/jbc.271.2.631	http://dx.doi.org/10.1074/jbc.271.2.631			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557665	hybrid			2022-12-25	WOS:A1996TP88900008
J	Trompeter, HI; Blankenburg, G; Brugger, B; Menne, J; Schiermeyer, A; Scholz, M; Soling, HD				Trompeter, HI; Blankenburg, G; Brugger, B; Menne, J; Schiermeyer, A; Scholz, M; Soling, HD			Variable nuclear cytoplasmic distribution of the 11.5-kDa zinc-binding protein (parathymosin-alpha) and identification of a bipartite nuclear localization signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PARATHYMOSIN; SEQUENCE; PROTHYMOSIN; NUCLEOTIDES; EXPRESSION; THYMOSINS; TISSUES; CLONING; CDNA	The 11.5-kDa zinc-binding protein (ZnBP, parathymosin-alpha), a potent inactivator of 1-phosphofructokinase, is found only in the cytoplasm of most tissues despite the presence of the putative nuclear localization signal PKRQKT. Recent reports on nuclear uptake of ZnBP could not exclude the participation of unspecific diffusion. We show here that wild-type ZnBP overexpressed in COS cells accumulates exclusively in the nucleus but that ZnBP with a mutated or deleted PKRQKT motif appears both in the nucleus and in the cytoplasm. In contrast, fusion proteins between ZnBP and parts of the endoplasmic reticulum protein calreticulin required the intact PKRQKT motif for nuclear import. The motif RKR, located nine amino acids upstream of the PKRQKT motif, is also involved in the active nuclear import of ZnBP. In contrast to rat hepatocytes and kidney cells in situ, which have ZnBP almost exclusively in the cytosol, we find ZnBP in Reuber H35 hepatoma cells and normal rat kidney cells only in the nuclei. Freshly isolated rat hepatocytes translocate their ZnBP to the nucleus in <24 h during standard cell culture conditions.	UNIV GOTTINGEN,ZENTRUM INNERE MED,KLIN BIOCHEM ABT,D-37075 GOTTINGEN,GERMANY	University of Gottingen			Schiermeyer, Andreas/I-2125-2013	Schiermeyer, Andreas/0000-0002-2057-4111				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BLANK V, 1917, TRENDS BIOCHEM SCI, V4, P135; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BRAND IA, 1986, J BIOL CHEM, V261, P5892; BRAND IA, 1991, EUR J CELL BIOL, V54, P157; BRAND IA, 1988, EUR J BIOCHEM, V177, P561, DOI 10.1111/j.1432-1033.1988.tb14407.x; BRAND IA, 1991, J BIOL CHEM, V266, P20984; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLINTON M, 1989, BIOCHEM BIOPH RES CO, V158, P855, DOI 10.1016/0006-291X(89)92801-5; CLINTON M, 1991, P NATL ACAD SCI USA, V88, P6608, DOI 10.1073/pnas.88.15.6608; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; HURT EC, 1993, FEBS LETT, V325, P76, DOI 10.1016/0014-5793(93)81417-X; KLEINEKE J, 1979, FEBS LETT, V107, P198, DOI 10.1016/0014-5793(79)80494-9; KOMIYAMA T, 1986, P NATL ACAD SCI USA, V83, P1242, DOI 10.1073/pnas.83.5.1242; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; MANROW RE, 1991, J BIOL CHEM, V266, P3916; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; PADGHAM CRW, 1993, BIOCHEM BIOPH RES CO, V197, P599, DOI 10.1006/bbrc.1993.2521; PANNEERSELVAM C, 1988, BIOCHEM BIOPH RES CO, V155, P539, DOI 10.1016/S0006-291X(88)80528-X; Sambrook J, 1989, MOL CLONING LABORATO; TROMPETER HI, 1992, FEBS LETT, V298, P245, DOI 10.1016/0014-5793(92)80068-R; TROMPETER HI, 1989, FEBS LETT, V253, P63, DOI 10.1016/0014-5793(89)80930-5; TSITSILONI OE, 1993, P NATL ACAD SCI USA, V90, P9504, DOI 10.1073/pnas.90.20.9504; WATTS JD, 1990, EUR J BIOCHEM, V192, P643, DOI 10.1111/j.1432-1033.1990.tb19271.x	29	13	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1187	1193		10.1074/jbc.271.2.1187	http://dx.doi.org/10.1074/jbc.271.2.1187			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557649	hybrid			2022-12-25	WOS:A1996TP88900086
J	Borrello, MG; Smith, DP; Pasini, B; Bongarzone, I; Greco, A; Lorenzo, MJ; Arighi, E; Miranda, C; Eng, C; Alberti, L; Bocciardi, R; Mondellini, P; Scopsi, L; Romeo, G; Ponder, BAJ; Pierotti, MA				Borrello, MG; Smith, DP; Pasini, B; Bongarzone, I; Greco, A; Lorenzo, MJ; Arighi, E; Miranda, C; Eng, C; Alberti, L; Bocciardi, R; Mondellini, P; Scopsi, L; Romeo, G; Ponder, BAJ; Pierotti, MA			RET activation by germline MEN2A and MEN2B mutations	ONCOGENE			English	Article						RET; receptor tyrosine kinase; multiple endocrine neoplasia type 2; inherited cancer syndrome; oncogene	MULTIPLE ENDOCRINE NEOPLASIA; NEUROBLASTOMA CELL-LINES; PROTO-ONCOGENE; TYROSINE KINASE; PROTOONCOGENE; EXPRESSION; DIFFERENTIATION; CARCINOMAS; SEQUENCE; GENE	The RET proto-oncogene encodes a receptor tyrosine kinase (TK), It has been shown that distinct germline mutations in the RET proto-oncogene are associated with the dominantly inherited cancer syndromes multiple endocrine neoplasia type 2A and 2B (MEN 2A and MEN 2B) and familial medullary thyroid carcinoma (FMTC) as well as Hirschsprung disease (HSCR), a congenital disorder characterised by absent enteric innervation, In this study, we have transfected NIH3T3 and PC12 phaeochromocytoma cells with MEN2A (Cys634-->Arg) and MEN2B (Met918-->Thr) RET constructs, Both caused transformation of the NIH3T3 cells and differentiation of PC12 cells, The Bet (MEN2A) and Bet (MEN2B) proteins were constitutively phosphorylated on tyrosine, and their in vitro kinase activity was significantly higher than that of the wild type protein, The MTC cell line TT carries a Cys634-->Trp MEN2A mutation, and we have shown by immunoelectronmicroscopy that Ret is clustered on the cell surface in a manner reminiscent of ligand-induced aggregation of cell surface receptors, RET is activated, as RET/PTC oncogene, by somatic rearrangements which link the TK domain to a constitutive dimerization interface in papillary thyroid carcinomas, We have compared the biological and biochemical activity of the TK domains of the wild type and MEN 2B Ret in the context of the RET/PTC, The results show that the MEN2B mutation significantly increases the TK domain enzymatic activity suggesting that dimerization may be still necessary for MEN 2B Bet to express its full activity.	IST NAZL TUMORI,DIV EXPTL ONCOL A,I-20133 MILAN,ITALY; UNIV CAMBRIDGE,ADDENBROOKES HOSP,CRC,HUMAN CANC GENET RES GRP,CAMBRIDGE CB2 2QQ,ENGLAND; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,BOSTON,MA 02115; IST GIANNINA GASLINI,GENET MOLEC LAB,I-16147 GENOA,ITALY; IST NAZL TUMORI,DIV ANAT PATHOL & CYTOL,I-20133 MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Genoa; IRCCS Istituto Giannina Gaslini; Fondazione IRCCS Istituto Nazionale Tumori Milan			Bocciardi, Renata/J-8577-2016; Pasini, Barbara/AHI-2004-2022; Pierotti, Marco Alessandro/AAC-4728-2022; Borrello, Maria Grazia/C-3161-2017; Bongarzone, Italia/B-9544-2017; Greco, Angela/C-1953-2017	Bocciardi, Renata/0000-0001-8415-3802; Pasini, Barbara/0000-0002-4373-1212; Pierotti, Marco Alessandro/0000-0002-7431-8332; Borrello, Maria Grazia/0000-0002-6854-2848; Bongarzone, Italia/0000-0003-2530-9170; Greco, Angela/0000-0003-2994-0349; Eng, Charis/0000-0002-3693-5145; Lorenzo, Maria Jesus/0000-0003-4416-0615				ASAI N, 1995, MOL CELL BIOL, V15, P1613; BIEDLER JL, 1978, CANCER RES, V38, P3751; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BUNONE G, 1995, CELL RES, V217, P92; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; FABIEN N, 1994, INT J ONCOL, V4, P623; FARNDON JR, 1986, BRIT J SURG, V73, P278, DOI 10.1002/bjs.1800730411; GRECO A, 1993, CELL GROWTH DIFFER, V4, P539; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Leong S, 1981, ADV THYROID NEOPLASI, P95; LORENZO MJ, 1995, ONCOGENE, V10, P1377; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAUE F, 1994, ENDOCRINOLOGY METABO, pR12; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SANTORO M, 1994, ONCOGENE, V9, P509; SCHIMKE RN, 1984, ANNU REV MED, V35, P25, DOI 10.1146/annurev.me.35.020184.000325; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SCOPSI L, 1992, ULTRASTRUCT PATHOL, V16, P351, DOI 10.3109/01913129209061363; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1991, ONCOGENE, V6, P2333; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TOKUYASU KT, 1989, HISTOCHEM J, V21, P163, DOI 10.1007/BF01007491; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	44	129	129	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2419	2427						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570194				2022-12-25	WOS:A1995TK70200027
J	Dorsey, MJ; Tae, HJ; Sollenberger, KG; Mascarenhas, NT; Johansen, LM; Taparowsky, EJ				Dorsey, MJ; Tae, HJ; Sollenberger, KG; Mascarenhas, NT; Johansen, LM; Taparowsky, EJ			B-ATF: A novel human bZIP protein that associates with members of the AP-1 transcription factor family	ONCOGENE			English	Article						leucine zipper; transcription factor; AP-1; two hybrid assays	GLUTATHIONE-S-TRANSFERASE; AMP RESPONSE ELEMENT; CYCLIC-AMP; DNA-BINDING; ESCHERICHIA-COLI; SIGNAL TRANSDUCTION; SOMATOSTATIN GENE; NUCLEAR-PROTEIN; TAX PROTEIN; FOS PROTEIN	A new member of the ATF/CREB family of transcription factors, called B-ATF, has been isolated from a cDNA library prepared from Epstein-Barr virus stimulated human B cells, B-ATF is a 125 amino acid nuclear protein possessing a basic leucine zipper domain that is most similar to the basic leucine zipper of ATF3. Northern blot analysis of polyadenylated mRNA isolated from a variety of human tissues and established cell lines indicates that the 1.0 kilobase B-ATF mRNA is expressed differentially, with the strongest hybridization detected in lung and in Raji Burkitt's lymphoma, Efficient homodimerization of the B-ATF protein cannot be detected using the yeast two hybrid system or using in vitro binding assays with glutathione-s-transferase-B-ATF and maltose binding protein-B-ATF fusion proteins produced in E. coli. However, a yeast two hybrid library screen has identified the human oncoprotein JunB as a specific binding partner for B-ATF, Glutathione-s-transferase-B-ATF heterodimerizes efficiently with in vitro translated JunB, c-Jun, and JunD, but only weakly associates with c-Fos, In addition, electrophoretic mobility shift assays demonstrate that a B-ATF/c-Jun protein complex can interact with DNA containing a consensus binding site for AP-1, suggesting that B-ATF functions as a tissue-specific modulator of the AP-1 transcription complex in human cells.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NCI NIH HHS [R01-CA42835, F32-CA61635] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042835, F32CA061635] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ARTANDI S, 1993, METHODS MOL GENET, V1, P267; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COLLINSHICOK J, 1994, MOL CELL BIOL, V14, P2837, DOI 10.1128/MCB.14.5.2837; DAVENPORT EA, 1992, EXP CELL RES, V202, P532, DOI 10.1016/0014-4827(92)90108-K; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P12; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; LASSAR AB, 1986, CELL, V47, P649, DOI 10.1016/0092-8674(86)90507-6; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1994, NATURE, V368, P520, DOI 10.1038/368520a0; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; Miller JH., 1972, EXPT MOL GENETICS; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NOMURA N, 1993, J BIOL CHEM, V268, P4259; OFIR R, 1990, NATURE, V348, P80, DOI 10.1038/348080a0; PESCINI R, 1994, J BIOL CHEM, V269, P1159; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Sambrook J, 1989, MOL CLONING LABORATO; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRATNER I, 1992, MOL CELL BIOL, V12, P998, DOI 10.1128/MCB.12.3.998; VAIDYA TB, 1992, GENE, V119, P223; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; YUTZEY KE, 1989, MOL CELL BIOL, V9, P1397, DOI 10.1128/MCB.9.4.1397; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	52	93	96	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2255	2265						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570175				2022-12-25	WOS:A1995TK70200008
J	vanWeering, DHJ; Medema, JP; vanPuijenbroek, A; Burgering, BMT; Baas, PD; Bos, JL				vanWeering, DHJ; Medema, JP; vanPuijenbroek, A; Burgering, BMT; Baas, PD; Bos, JL			Ret receptor tyrosine kinase activates extracellular signal-regulated kinase 2 in SK-N-MC cells	ONCOGENE			English	Article						Ret; Pas; Raf; signal transduction; MAP kinase; cAMP	PHOSPHORYLATION; PROTOONCOGENE; INHIBITION; MUTATIONS; COMPLEX; PROTEIN; CAMP; SHC	Ret is a receptor tyrosine kinase predominantly expressed in tissue derived from the neuroectoderm and is involved in multiple endocrine neoplasia type 2A and 2B, familiar medullary thyroid carcinoma, and Hirschsprung's disease, The ligand for the receptor is still unknown, Previously, using a human epidermal growth factor receptor - Ret chimaeric receptor (HERRet) stably transfected into fibroblasts, it was shown that Pet activation induces the activation of p21ras, but, surprisingly, activation of extracellular signal-regulated kinase 2 (ERK2) was not observed (Santoro et al, (1994), Mol. Cell, Biol., 14, 663), In this report we describe early signaling events induced by the activated HERRet fusion receptor in a cell line derived from neuroectodermal tissue, SK-N-MC, In these cells, activated HERRet induces tyrosine phosphorylation of She, complex formation of She with Grb2 and Sos and activation of p21ras, Importantly, also ERK2 is activated, This activation was strong and sustained for at least 2 h, Activation was abolished by the dominant negative p21ras(asn17) mutant, showing that activation of ERK2 is mediated by p21ras, These results suggest that Pet can induce ERK2 activation in a p21ras dependent manner in cells derived from tissue where Pet is endogenously expressed.	UNIV UTRECHT,PHYSIOL CHEM LAB,GRAD SCH DEV BIOL,3508 TA UTRECHT,NETHERLANDS; HUBRECHT LAB,GRAD SCH DEV BIOL,3584 CT UTRECHT,NETHERLANDS	Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)				Medema, Jan Paul/0000-0003-3045-2924				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; ASAI N, 1995, MOL CELL BIOL, V15, P1613; ATTIE T, 1994, HUM MOL GENET, V3, P1439; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; BASU T, 1994, ONCOGENE, V9, P3483; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; DEVRIESSMITS AMM, 1995, METHOD ENZYMOL, V255, P221; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LIPS CJM, 1994, NEW ENGL J MED, V331, P828, DOI 10.1056/NEJM199409293311302; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, ONCOGENE, V8, P2773; PRONK GJ, 1994, BBA-REV CANCER, V1198, P131, DOI 10.1016/0304-419X(94)90010-8; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TSUZUKI T, 1995, ONCOGENE, V10, P191; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	40	62	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2207	2214						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570170				2022-12-25	WOS:A1995TK70200003
J	Qazzaz, HMAM; Goudy, SL; Valdes, R				Qazzaz, HMAM; Goudy, SL; Valdes, R			Deglycosylated products of endogenous digoxin-like immunoreactive factor in mammalian tissue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PLASMA; SUBSTANCE; OUABAIN; SERUM; IDENTIFICATION; NA,K-ATPASE; BINDING; GLYCOSIDE; ACID	Digoxin-like immunoreactive factor (DLIF) from adrenal cortex is an endogenous molecule with structural features remarkably similar to those of digoxin, a plant-derived cardiac glycoside (Shaikh, I, M,, Lau, B. W, C,, Siegfried, B, A., and Valdes, R,, Jr, (1991) J, Biol, Chem. 266, 13672-13678), Two characteristic structural and functional features of digoxin are a lactone ring and three digitoxose sugars attached to a steroid nucleus, Digoxin is known to undergo deglycosylation during metabolism in humans. We now demonstrate the existence of several naturally occurring deglycosylated components of DLIF in human serum, The components are identified as DLIF-genin, DLIF-mono, and DLIF-bis, corresponding to the aglycone, and the aglycone with one and two sugars, respectively, Similar components are produced by acid-induced deglycosylation of DLIF isolated from bovine adrenal cortex, The elution pattern and sequence of DLIF-deglycosylation was identical to that of digoxin suggesting identical sugar stoichiometry, However, analysis of these newly discovered congeners by reverse-phase chromatography, spectrophotometry, antibody reactivity, and kinetics of deglycosylation, demonstrates that subtle structural and physical differences do exist when compared to digoxin, DLIF was chromatographically distinct from digoxin, and interestingly, the mobility of the DLIF-genin was shifted toward increased polarity relative to digoxigenin, DLIF and DLIF-bis, -mono, and -genin congeners have absorbance maxima at 216 nm, whereas digoxin and its congeners absorb at 220 nm, Reaction with specific antibodies directed at the lactone portion of these molecules shows DLIF and its deglycosylated congeners to be 10(3)-fold less reactive than digoxin, Kinetics of sugar removal suggests that DLIF is 8-fold more susceptible to deglycosylation than is digoxin, Two less polar DLIF components produced from the DLIF-genin have lambda(max) at 196 nm and are 4-fold less immunoreactive than DLIF, Our data suggest that subtle structural differences exist between DLIF and digoxin at or near the lactone ring as well as in the nature of the sugars. The presence of deglycosylated congeners of DLIF in human serum, including the less polar components, suggests in vivo deglycosylation of these factors, This is the first demonstration of the existence of naturally occurring deglycosylated derivatives of DLIF and establishes the likelihood of active metabolism of DLIF in mammals.	UNIV LOUISVILLE, SCH MED, DEPT PATHOL, LOUISVILLE, KY 40292 USA; UNIV LOUISVILLE, SCH MED, DEPT BIOCHEM, LOUISVILLE, KY 40292 USA	University of Louisville; University of Louisville					NHLBI NIH HHS [HL-R01-36172] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036172] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLAUSTEIN MP, 1993, AM J PHYSIOL, V264, pC1367, DOI 10.1152/ajpcell.1993.264.6.C1367; DELFERT DM, 1985, J CLIN IMMUNOASSAY, V8, P157; DELVA P, 1989, EUR J CLIN INVEST, V19, P95, DOI 10.1111/j.1365-2362.1989.tb00202.x; DENCE JB, 1980, STEROIDS PEPTIDES, P27; DOBKIN JF, 1983, SCIENCE, V220, P325; FROM AHL, 1990, MOL CELL BIOCHEM, V94, P157, DOI 10.1007/BF00214122; GAULT H, 1982, CLIN PHARMACOL THER, V31, P695, DOI 10.1038/clpt.1982.98; GAULT MH, 1984, NEPHRON, V37, P190; GAULT MH, 1977, J PHARM PHARMACOL, V29, P27, DOI 10.1111/j.2042-7158.1977.tb11232.x; GRAIG RH, 1991, J CLIN IMMUNOASSAY, V14, P245; GRAVES SW, 1984, J CLIN ENDOCR METAB, V58, P748, DOI 10.1210/jcem-58-4-748; GRAVES SW, 1983, ANN INTERN MED, V99, P604, DOI 10.7326/0003-4819-99-5-604; GRAVES SW, 1995, AM J HYPERTENS, V8, P5, DOI 10.1016/0895-7061(94)00167-A; GREENWOOD H, 1975, CLIN CHIM ACTA, V62, P213, DOI 10.1016/0009-8981(75)90230-2; GRUBER KA, 1980, NATURE, V287, P743, DOI 10.1038/287743a0; HADDY FJ, 1987, ISI ATLAS-PHARMACOL, V1, P119; HAMLYN JM, 1991, P NATL ACAD SCI USA, V88, P6259, DOI 10.1073/pnas.88.14.6259; Lichtstein D., 1992, Journal of Basic and Clinical Physiology and Pharmacology, V3, P269; LINGREL JB, 1990, PROG NUCLEIC ACID RE, V38, P37; LUDENS JH, 1991, HYPERTENSION, V17, P923, DOI 10.1161/01.HYP.17.6.923; MILLER JJ, 1994, CLIN CHEM, V40, P1898; MILLER JJ, 1990, J CLIN IMMUNOASSAY, V13, P56; NANJI AA, 1986, J CLIN PHARMACOL, V26, P152, DOI 10.1002/j.1552-4604.1986.tb02925.x; OBRIEN WJ, 1993, J BIOL CHEM, V268, P7707; QAZZAZ HMA, 1995, CLIN CHEM, V41, pS44; QAZZAZ HMAM, 1995, THER DRUG MONIT, V17, P53, DOI 10.1097/00007691-199502000-00009; ROSE AM, 1994, CLIN CHEM, V40, P1674; ROSE AM, 1994, J CLIN IMMUNOASSAY, V17, P53; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SECCOMBE DW, 1984, PEDIATR RES, V18, P1097, DOI 10.1203/00006450-198411000-00008; SHAIKH IM, 1991, J BIOL CHEM, V266, P13672; SOLDIN SJ, 1986, CLIN CHEM, V32, P5; STONE JA, 1988, CLIN CHEM, V34, P2547; SWEADNER KJ, 1991, OVERVIEW SUBUNIT DIV, P63; TEMPLETON JF, 1988, CAN J PHYSIOL PHARM, V66, P1420, DOI 10.1139/y88-231; THOMAS R, 1980, BURGERS MED CHEM, P47; TYMIAK AA, 1993, P NATL ACAD SCI USA, V90, P8189, DOI 10.1073/pnas.90.17.8189; VALDES R, 1983, J PEDIATR-US, V102, P947, DOI 10.1016/S0022-3476(83)80031-6; VALDES R, 1985, J CLIN ENDOCR METAB, V60, P1135, DOI 10.1210/jcem-60-6-1135; VALDES R, 1985, CLIN CHEM, V31, P1525; VALDES R, 1988, LIFE SCI, V42, P103, DOI 10.1016/0024-3205(88)90629-7; Valdes R Jr, 1985, Prog Clin Biol Res, V192, P229; ZHAO N, 1995, BIOCHEMISTRY-US, V34, P9893, DOI 10.1021/bi00031a010	43	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8731	8737		10.1074/jbc.271.15.8731	http://dx.doi.org/10.1074/jbc.271.15.8731			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621507	hybrid			2022-12-25	WOS:A1996UE73000038
J	Kawakatsu, H; Sakai, T; Takagaki, Y; Shinoda, Y; Saito, M; Owada, MK; Yano, J				Kawakatsu, H; Sakai, T; Takagaki, Y; Shinoda, Y; Saito, M; Owada, MK; Yano, J			A new monoclonal antibody which selectively recognizes the active form of Src tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-SRC; PLATELET-AGGREGATION; SIGNAL TRANSDUCTION; OVEREXPRESSER CELLS; SH3 DOMAINS; PP60C-SRC; PROTEIN; BINDING; ACTIVATION; EXPRESSION	Phosphorylation and dephosphorylation of Tyr-530 in human c-Src (Tyr-527 in avian c-Src) is critical in regulating c-Src kinase activity. So far, it has not been possible to distinguish the active and inactive forms in vivo. We now report a new monoclonal antibody that selectively recognizes the active form of c-Src. This antibody, termed clone 28, recognized a region adjacent to Tyr-530 (Q(529)YQP(532)) in the C-terminal regulatory domain of c-Src, and its binding was hindered by phosphorylation of this tyrosine as determined by peptide competition assay. Combined immunoprecipitation/Western blotting revealed that clone 28 reacted with a 60 kDa protein that was precipitated by mAb 327, a well known monoclonal antibody against v-Src and c-Src. Cyanogen bromide cleavage and two dimensional tryptic maps confirmed that clone 28 was specific for the active form (Tyr-530 not phosphorylated), whereas mAb 327 recognized the inactive form (Tyr-530 phosphorylated) as well as the active form. Clone 28 selectively immunoprecipitated the active form and augmented its kinase activity. Preabsorption experiments revealed that clone 28 could not completely immunoprecipitate the mAb 327 binding 60-kDa protein in either an in vitro or an in vivo phosphorylation system. These observations, taken together, strongly suggest the existence of multiple forms of c-Src as proposed by Cooper and Howell (1993) (Cooper, J. A., and Howell, B. (1993) Cell 73, 1051-1054). Using clone 28, we demonstrated a distinct localization of the active form of c-Src within cultured normal fibroblast cells. In liver tissue sections, we also examined the distribution of the active form in embryonic mice. Megakaryocytes were strongly stained, in contrast to completely negative immunoreactivity in hepatocytes, reticulocytes, and granulocytes. This result provides the first direct evidence that c-Src is highly activated in platelets.	JICHI MED SCH, INST HEMATOL, DIV HEMOPOIESIS, MINAMI KAWACHI, TOCHIGI 32904, JAPAN; KYOTO PHARMACEUT UNIV, INST MOLEC & CELLULAR BIOL PHARMACEUT SCI, KYOTO 607, JAPAN	Jichi Medical University; Kyoto Pharmaceutical University	Kawakatsu, H (corresponding author), NIPPON SHINYAKU CO LTD, DEPT BIOL MOLEC, RES LABS, KYOTO 601, JAPAN.							BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BRUGGE JS, 1987, J NEUROSCI RES, V18, P532, DOI 10.1002/jnr.490180405; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DAVIDPFEUTY T, 1993, J CELL SCI, V105, P613; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; Harlow E., 1988, ANTIBODIES LAB MANUA; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MARGOLIS B, 1992, CELL GROWTH DIFFER, V3, P73; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; ODA A, 1992, J BIOL CHEM, V267, P20075; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEPINSKY RB, 1983, J BIOL CHEM, V258, P1229; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SAKAI T, 1995, J CELL PHYSIOL, V165, P18, DOI 10.1002/jcp.1041650104; SAKAI T, 1993, EXP CELL RES, V206, P244, DOI 10.1006/excr.1993.1144; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUDOL M, 1989, MOL CELL BIOL, V9, P4545, DOI 10.1128/MCB.9.10.4545; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x	40	83	85	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5680	5685		10.1074/jbc.271.10.5680	http://dx.doi.org/10.1074/jbc.271.10.5680			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621432	hybrid			2022-12-25	WOS:A1996TZ28600058
J	SmithSorensen, B; Hijmans, EM; Beijersbergen, RL; Bernards, R				SmithSorensen, B; Hijmans, EM; Beijersbergen, RL; Bernards, R			Functional analysis of Burkitt's lymphoma mutant c-Myc proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; POINT MUTATIONS; GENE-EXPRESSION; CELL-CYCLE; TRANSCRIPTION; SEQUENCE; DOMAIN; REGION; TRANSACTIVATION; TRANSFORMATION	The c-myc gene encodes a sequence-specific DNA binding protein that activates transcription of cellular genes. Transcription activation by Myc proteins is regulated by phosphorylation of serine and threonine residues within the transactivation domain and by complex formation with the retinoblastoma-related protein p107. In Burkitt's lymphoma, missense mutations within the c-Myc transactivation domain have been found with high frequency. It has been reported that mutant c-Myc proteins derived from Burkitt's lymphoma cell lines are resistant to inhibition by p107, thus providing a rationale for the increased oncogenic activity of these mutant c-Myc proteins. It has been suggested that these mutant c-Myc proteins resist down-modulation by p107 because they lack cyclin A-cdk2-dependent phosphorylation. Here, we have examined three different Burkitt's lymphoma mutant c-Myc proteins found in primary Burkitt's lymphomas and one mutant c-Myc protein detected in a Burkitt's lymphoma cell line. All four have an unaltered ability to activate transcription and are sensitive to inhibition of transactivation by p107. Furthermore, we provide evidence that down-modulation of c-Myc transactivation by p107 does not require phosphorylation of the c-Myc transactivation domain by cyclin A-cdk2. Our data indicate that escape from p107-induced suppression is not a general consequence of all Burkitt's lymphoma-associated c-Myc mutations, suggesting that other mechanisms exist to deregulate c-Myc function.	NETHERLANDS CANC INST,DIV MOLEC CARCINOGENESIS,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Bernards, Rene/0000-0001-8677-3423; Beijersbergen, Roderick/0000-0003-0116-4130				ALBERT T, 1994, ONCOGENE, V9, P759; BARRETT J, 1992, MOL CELL BIOL, V12, P3130, DOI 10.1128/MCB.12.7.3130; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARDS R, 1995, CURR BIOL, V5, P859, DOI 10.1016/S0960-9822(95)00173-4; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CLARK HM, 1994, CANCER RES, V54, P3383; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FRYKBERG L, 1987, ONCOGENE, V1, P415; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HATEBOER G, 1993, P NATL ACAD SCI USA, V90, P8489, DOI 10.1073/pnas.90.18.8489; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P600; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5515; MAHESWARAN S, 1994, MOL CELL BIOL, V14, P1147, DOI 10.1128/MCB.14.2.1147; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MURPHY W, 1986, P NATL ACAD SCI USA, V83, P2939, DOI 10.1073/pnas.83.9.2939; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PULVERER BJ, 1994, ONCOGENE, V9, P59; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SETH A, 1991, J BIOL CHEM, V266, P23521; SHOWE LC, 1985, MOL CELL BIOL, V5, P501, DOI 10.1128/MCB.5.3.501; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SUEN TC, 1991, MOL CELL BIOL, V11, P354, DOI 10.1128/MCB.11.1.354; SYMONDS G, 1989, ONCOGENE, V4, P285; THOMPSON CR, 1986, NATURE, V314, P363; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; YANO T, 1993, ONCOGENE, V8, P2741; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	55	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5513	5518		10.1074/jbc.271.10.5513	http://dx.doi.org/10.1074/jbc.271.10.5513			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621409	Green Published, hybrid			2022-12-25	WOS:A1996TZ28600035
J	Soker, S; Fidder, H; Neufeld, G; Klagsbrun, M				Soker, S; Fidder, H; Neufeld, G; Klagsbrun, M			Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF(165) via its exon 7-encoded domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY FACTOR; TYROSINE KINASE; FACTOR FAMILY; ANGIOGENESIS; IDENTIFICATION; EXPRESSION; HEPARIN; SUGGEST; SITES; GENE	Vascular endothelial growth factor (VEGF), a potent angiogenic factor, uses two receptor tyrosine kinases, FLK/KDR and FLT, to mediate its activities. We have cross-linked I-125-VEGF(165) to the cell surface of various tumor cell lines and of human umbilical vein endothelial cells. High molecular mass (220 and 240 kDa) and/or lower molecular mass (165 and 175 kDa) labeled complexes were detected depending on the cell type. The 220- and 240-kDa labeled complexes were shown to contain FLT and FLK/KDR receptors, respectively. On the other hand, the 165- and 175-kDa complexes did not seem to contain FLK/KDR or FLT but instead appeared to contain novel VEGF receptors with relatively low molecular masses of approximately 120 and 130 kDa. These receptors were further characterized in breast cancer MDA MB 231 cells (231), which did not form the high molecular mass complexes and which did not express detectable amounts of flk/kdr or flt mRNA. The 231 cells displayed one VEGF(165) binding site, with a K-d of 2.8 x 10(-10) M and 0.95-1.1 x 10(5) binding sites per cell. By comparison, human umbilical vein endothelial cells had two binding sites, one with a K-d of 7.5 x 10(-12) M, presumably FLK/KDR, and the other with a K-d of 2 x 10(-10) M, a value similar to the VEGF binding sites on 231 cells. These lower affinity/molecular mass receptors on 231 cells cross-linked I-125-VEGF(165) to 231 cells. Cross-linking of I-125-GST-VEGF-exon 7 to 231 cells resulted in the formation of 150- and 160-kDa labeled complexes that presumably contained the 120- and 130-kDa lower affinity/molecular mass VEGF(165) receptors. It was concluded that certain tumor-derived cell lines express novel surface-associated receptors that selectively bind VEGF(165) via the exon 7-encoded domain, which is absent in VEGF(121).	CHILDRENS HOSP,DEPT SURG,BOSTON,MA 02115; CHILDRENS HOSP,DEPT PATHOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; TECHNION ISRAEL INST TECHNOL,DEPT BIOL,IL-32000 HAIFA,ISRAEL	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Technion Israel Institute of Technology			Neufeld, Gera/F-1524-2019		NCI NIH HHS [CA37392] Funding Source: Medline; NIGMS NIH HHS [GM47397] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA037392, R01CA037392, R56CA037392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047397] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARLEON B, 1994, J CELL BIOCHEM, V54, P56, DOI 10.1002/jcb.240540107; BREIER G, 1992, DEVELOPMENT, V114, P521; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; ENOMOTO T, 1994, BIOCHEM BIOPH RES CO, V202, P1716, DOI 10.1006/bbrc.1994.2133; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; GITAYGOREN H, 1993, BIOCHEM BIOPH RES CO, V190, P702, DOI 10.1006/bbrc.1993.1106; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; GITAYGOREN H, 1996, IN PRESS J BIOL CHEM, V271; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, CANCER RES, V52, P4821; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; KONDO S, 1994, BBA-MOL CELL RES, V1221, P211, DOI 10.1016/0167-4889(94)90016-7; LAEMLLI VK, 1970, NATURE, V227, P68; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MYOKEN Y, 1991, P NATL ACAD SCI USA, V88, P5819, DOI 10.1073/pnas.88.13.5819; OBERG C, 1994, GROWTH FACTORS, V10, P115, DOI 10.3109/08977199409010985; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; PARK JE, 1994, J BIOL CHEM, V269, P25646; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P915; PLATE KH, 1993, CANCER RES, V53, P5822; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; SEETHARAM L, 1995, ONCOGENE, V10, P135; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SOKER S, 1993, J BIOL CHEM, V268, P7685; SOKER S, 1994, BIOCHEM BIOPH RES CO, V203, P1339, DOI 10.1006/bbrc.1994.2329; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; TERMAN BI, 1991, ONCOGENE, V6, P1677; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; YOSHIDA A, 1996, IN PRESS GROWTH FACT, V12	49	278	300	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5761	5767		10.1074/jbc.271.10.5761	http://dx.doi.org/10.1074/jbc.271.10.5761			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621443	hybrid			2022-12-25	WOS:A1996TZ28600069
J	Candau, R; Berger, SL				Candau, R; Berger, SL			Structural and functional analysis of yeast putative adaptors - Evidence for an adaptor complex in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATORS; PROTEIN; TRANSFORMATION; ADA2; SITE; GENE	Putative transcriptional adaptor proteins are found in eukaryotes from yeast to humans and are required for full function of many eukaryotic acidic activators. To study their functional interactions, deletion mutations in the yeast adaptors ADA2, GCN5, and ADA3 were created. We defined a region within the middle of GCN5 required for interaction with ADA2 in vitro. We identified regions of ADA2 required for function in vivo and determined whether these same regions are involved in physical interaction of ADA2 with GCN5 or ADA3 in vitro. Two regions were crucial for ADA2 function in vivo, the amino terminus and a middle region. Immunoprecipitation analysis showed that the amino terminus of ADA2 was required for interaction with GCN5, while a region in the middle of ADA2 was necessary for interaction with ADA3. Deletions of the region that was required for interaction with ADA3 abolished dependence of lexA-ADA2 transcriptional activity on ADA3. Moreover, using coimmunoprecipitation analysis, physical interaction between ADA2, ADAS, and GCN5 was demonstrated in yeast extracts. Taken together, the physical interaction in vivo, along with the correlation observed between regions of ADA2 required for in vitro interaction with GCN5 and ADA3, and regions required for function in vivo, argue for the existence of a physiologically relevant adaptor complex.	WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA	The Wistar Institute				Berger, Shelley/0000-0001-5398-4400	NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER; NCI NIH HHS [CA10815] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; Candau R, 1996, MOL CELL BIOL, V16, P593; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; Harlow E, 1988, ANTIBODIES LABORATOR, P471; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSE MD, 1988, METHODS YEAST GENETI; SHERMAN F, 1994, GUIDE YEAST GENETICS, V194, P21; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; STOFFERS D, 1986, P NATL ACAD SCI USA, P735; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	46	100	101	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5237	5245						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617808				2022-12-25	WOS:A1996TX69700098
J	Khan, A; Ling, ZC; Landau, BR				Khan, A; Ling, ZC; Landau, BR			Quantifying the carboxylation of pyruvate in pancreatic islets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED INSULIN RELEASE; METHYL SUCCINATE; METABOLISM; GLUCOSE	Pyruvate has been estimated to enter the citric acid cycle in islets by carboxylation to the same extent or more than by decarboxylation. Those estimates were made assuming the dimethyl esters of [1,4-C-14]succinate and [2-3-C-14]succinate, incubated with islets at a concentration of 10 mM, gave the same ratio of (CO2)-C-14 yields as if [1-C-14]acetate and [2-C-14]acetate had been incubated. The labeled succinates, at 10 mM, but not 1 mM, are now shown to give ratios higher than the labeled acetates at those concentrations and therefore higher estimates when related to yields from [2-C-14]glucose and [6-C-14]glucose. Using the labeled acetate ratios in paired incubations, the rate of pyruvate carboxylation is still estimated to be about two-thirds the rate of pyruvate decarboxylation. Participation of the malic enzyme-catalyzed reaction explains the greater ratio of yields of (CO2)-C-14 from the succinates at 10 mM than 1 mM and increases in those ratios on glucose addition and can account for the removal from the citric acid cycle of oxaloacetate carbon formed in the carboxylation.	CASE WESTERN RESERVE UNIV,SCH MED,DIV CLIN & MOLEC ENDOCRINOL,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT BIOCHEM,CLEVELAND,OH 44106; KAROLINSKA HOSP,DEPT MOLEC MED,S-17176 STOCKHOLM,SWEDEN	Case Western Reserve University; Case Western Reserve University; Karolinska Institutet; Karolinska University Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK014507, R37DK014507] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 14507] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERNE C, 1975, BIOCHEM J, V152, P667, DOI 10.1042/bj1520667; HELLERSTROM C, 1975, HDB EXPT PHARM, V32, P57; KELLEHER JK, 1985, ANAL BIOCHEM, V151, P55, DOI 10.1016/0003-2697(85)90052-1; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V300, P201, DOI 10.1006/abbi.1993.1028; MACDONALD MJ, 1993, METABOLISM, V42, P1229, DOI 10.1016/0026-0495(93)90118-8; MACDONALD MJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P205, DOI 10.1006/abbi.1993.1413; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MACDONALD MJ, 1991, J BIOL CHEM, V266, P22392; MAGNUSSON I, 1991, J BIOL CHEM, V266, P6975; MALAISSE WJ, 1992, ARCH BIOCHEM BIOPHYS, V292, P244, DOI 10.1016/0003-9861(92)90075-8; MALAISSE WJ, 1980, MOL CELL ENDOCRINOL, V20, P171, DOI 10.1016/0303-7207(80)90080-5; ROGNSTAD R, 1972, J BIOL CHEM, V247, P6047	12	73	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2539	2542		10.1074/jbc.271.5.2539	http://dx.doi.org/10.1074/jbc.271.5.2539			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576218	hybrid			2022-12-25	WOS:A1996TT48800032
J	Waksman, M; Eli, Y; Liscovitch, M; Gerst, JE				Waksman, M; Eli, Y; Liscovitch, M; Gerst, JE			Identification and characterization of a gene encoding phospholipase D activity in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN; CLONING	me have identified an open reading frame on chromosome XI of the yeast, Saccharomyces cerevisiae, as encoding a protein with phospholipase D (PLD) activity, We have named this open reading frame, PLD1, and show that yeast bearing a disruption in this gene are unable to catalyze the hydrolysis of phosphatidylcholine, PLD1 encodes a hypothetical protein of 1683 amino acids and has a predicted molecular mass of 195 kDa, Yeast bearing disruptions at the PLD1 locus are morphologically normal and grow vegetatively like wildtype cells. In contrast, homozygous Delta pld1 diploid cells are unable to sporulate and do not produce asci under conditions that induce meiosis and sporulation in wildtype cells. Thus, PLD1 is likely to be essential for the meiotic cycle in yeast cells. This is the first identification of a eukaryotic, non-plant, phosphatidylcholine-hydrolyzing phospholipase D gene. Because the biological role of PLD is not well understood, we expect that Delta pld1 yeast will become a useful tool for the characterization of PLD functions as well as for the identification of mammalian PLD homologs.	WEIZMANN INST SCI,DEPT MOLEC GENET,IL-76100 REHOVOT,ISRAEL; WEIZMANN INST SCI,DEPT REGULAT BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Byers B, 1981, MOL BIOL YEAST SACCH, P59; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; COUVE A, 1994, J BIOL CHEM, V269, P23391; DANIN M, 1993, METHODS NEUROSCI, V118, P14; ELLA KM, 1995, BIOCHEM J, V307, P799, DOI 10.1042/bj3070799; EXTON JH, 1990, J BIOL CHEM, V265, P1; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; HODGSON ALM, 1990, J BACTERIOL, V172, P1256, DOI 10.1128/jb.172.3.1256-1261.1990; HONIGBERG SM, 1994, P NATL ACAD SCI USA, V91, P6559, DOI 10.1073/pnas.91.14.6559; HONIGBERG SM, 1992, GENETICS, V130, P703; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; KAHN RA, 1993, CELL, V75, P1045, DOI 10.1016/0092-8674(93)90314-G; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LISCOVITCH M, 1994, SIGNAL ACTIVATED PHO, P31; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MASSENBURG D, 1994, P NATL ACAD SCI USA, V91, P11718, DOI 10.1073/pnas.91.24.11718; PERTILE P, 1995, J BIOL CHEM, V270, P5130, DOI 10.1074/jbc.270.10.5130; Rose MD., 1990, METHODS YEAST GENETI; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAMBROOOK J, 1989, MOL CLONING LABORATO; WANG XM, 1994, J BIOL CHEM, V269, P20312	27	138	140	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2361	2364		10.1074/jbc.271.5.2361	http://dx.doi.org/10.1074/jbc.271.5.2361			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576189	hybrid			2022-12-25	WOS:A1996TT48800003
J	Boorer, KJ; Frommer, WB; Bush, DR; Kreman, M; Loo, DDF; Wright, EM				Boorer, KJ; Frommer, WB; Bush, DR; Kreman, M; Loo, DDF; Wright, EM			Kinetics and specificity of a H+ amino acid transporter from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE VESICLES; NA+ GLUCOSE COTRANSPORTER; XENOPUS-LAEVIS OOCYTES; SUGAR-BEET LEAVES; ELECTROGENIC PROPERTIES; MECHANISM; EXPRESSION; COTYLEDONS; VULGARIS; SYMPORTS	The amino acid transporter AAP1/NAT2 recently cloned from Arabidopsis thaliana was expressed in Xenopus oocytes, and we used electrophysiological, radiotracer flux, and electron microscopic methods to characterize the biophysical properties, kinetics, and specificity of the transporter. Uptake of alanine was H+-dependent increasing from 14 pmol/oocyte/h at 0.032 mu M H+ to 370 pmol/oocyte/h at 10 mu M H+. AAP1 was electrogenic; there was an amino acid-induced depolarization of the oocyte plasma membrane and net inward currents through the transporter due to the transport of amino acids. AAP1 transported a wide spectrum of amino acids favoring neutral amino acids with short side chains. The maximal current (i(max)) for alanine, proline, glutamine, histidine, and glutamate was voltage-and [H+](o)-dependent. Similarly, the i(max)(H) was voltage-and [amino acid](o)-dependent. The i(max) for both H+ and amino acid were dependent on the concentrations of their respective cosubstrates, suggesting that both ligands bind randomly to the transporter. The K-0.5 of the transporter for amino acids decreased as [H+](o) increased and was lower at negative membrane potentials. The K-0.5 for H+ was relatively voltage-independent and decreased as [amino acid](o) increased. This positive cooperativity suggests that the transporter operates via a simultaneous mechanism. The Hill coefficients n for amino acids and H+ were >1, suggesting that the transporter has more than one binding site for both H+ and amino acid, Freeze-fracture electron microscopy was used to estimate the number of transporters expressed in the plasma membrane of oocytes. The density of particles on the protoplasmic face of the plasma membrane of oocytes expressing AAP1 increased similar to 5-fold above water-injected controls and corresponded to a turnover number 350 to 800 s(-1).	INST GENBIOL FORSCH,D-14195 BERLIN,GERMANY; UNIV ILLINOIS,DEPT PLANT BIOL,URBANA,IL 61801; USDA ARS,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; United States Department of Agriculture (USDA)	Boorer, KJ (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,10833 LE CONTE AVE,LOS ANGELES,CA 90095, USA.		Frommer, Wolf B/A-8256-2008; Bush, Daniel R/AAG-8444-2019; Frommer, Wolf B/K-5042-2017	Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115; Bush, Daniel/0000-0002-9160-5077	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044602] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 44602] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOORER KJ, 1994, J BIOL CHEM, V269, P20417; BURKHARDT BC, 1992, PFLUGERS ARCH, V420, P83; BUSH DR, 1988, PLANT PHYSIOL, V88, P487, DOI 10.1104/pp.88.2.487; BUSH DR, 1993, ANNU REV PLANT PHYS, V44, P513, DOI 10.1146/annurev.pp.44.060193.002501; CAMPA MJ, 1989, J CELL PHYSIOL, V141, P645, DOI 10.1002/jcp.1041410324; CHO BH, 1983, BIOCHIM BIOPHYS ACTA, V735, P361, DOI 10.1016/0005-2736(83)90150-5; FISCHER WN, 1995, J BIOL CHEM, V270, P16315, DOI 10.1074/jbc.270.27.16315; FROMMER WB, 1994, PLANT MOL BIOL, V26, P1651, DOI 10.1007/BF00016495; FROMMER WB, 1993, P NATL ACAD SCI USA, V90, P5944, DOI 10.1073/pnas.90.13.5944; HSU LC, 1993, P NATL ACAD SCI USA, V90, P7441, DOI 10.1073/pnas.90.16.7441; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; KINRAIDE TB, 1980, PLANT PHYSIOL, V65, P1085, DOI 10.1104/pp.65.6.1085; KWART M, 1993, PLANT J, V4, P993, DOI 10.1046/j.1365-313X.1993.04060993.x; LI ZC, 1990, PLANT PHYSIOL, V94, P268, DOI 10.1104/pp.94.1.268; LI ZC, 1992, ARCH BIOCHEM BIOPHYS, V294, P519, DOI 10.1016/0003-9861(92)90719-D; LI ZC, 1991, PLANT PHYSIOL, V96, P1338, DOI 10.1104/pp.96.4.1338; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MEHARG AA, 1995, J MEMBRANE BIOL, V145, P49; PANAYOTOVAHEIERMANN M, 1994, J BIOL CHEM, V269, P21016; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; REINHOLD L, 1984, ANNU REV PLANT PHYS, V35, P45, DOI 10.1146/annurev.pp.35.060184.000401; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; TAYLOR MA, 1987, DEV BIOL, V124, P287, DOI 10.1016/0012-1606(87)90480-5; TAYLOR PM, 1989, J MEMBRANE BIOL, V112, P149, DOI 10.1007/BF01871276; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0; WESTON K, 1994, PLANTA, V196, P166; WILLIAMS LE, 1992, PLANTA, V186, P541, DOI 10.1007/BF00198034; WILLIAMS LE, 1990, PLANTA, V182, P540, DOI 10.1007/BF02341029; WYSE RE, 1984, PLANT PHYSIOL, V76, P865, DOI 10.1104/pp.76.4.865; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	32	83	87	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2213	2220		10.1074/jbc.271.4.2213	http://dx.doi.org/10.1074/jbc.271.4.2213			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567681				2022-12-25	WOS:A1996TR32000063
J	Deretic, D; PuleoScheppke, B; Trippe, C				Deretic, D; PuleoScheppke, B; Trippe, C			Cytoplasmic domain of rhodopsin is essential for post-Golgi vesicle formation in a retinal cell-free system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI; RETINITIS-PIGMENTOSA; SECRETORY PATHWAYS; BOVINE RHODOPSIN; RAB PROTEINS; FROG RETINA; NETWORK; DISSOCIATION; MEMBRANES; GENE	In retinal photoreceptors, highly polarized organization of the light-sensitive organelle, the rod outer segment, is maintained by the sorting of rhodopsin and its associated proteins into distinct post-Golgi vesicles that bud from the trans-Golgi network (TGN) and by their vectorial transport toward the rod outer segment. We have developed an assay that reconstitutes the formation of these vesicles in a retinal cell-free system. Vesicle formation in this cell-free assay is ATP-, GTP-, and cytosol-dependent. In frog retinas vesicle budding also proceeds at 0 degrees C, both in vivo and in vitro. Vesicles formed in vitro are indistinguishable from the vesicles formed in vivo by their buoyant density, protein composition, topology, and morphology. In addition to the previously identified G-proteins, these vesicles also contain rab11. Concurrently with vesicle budding, resident proteins are retained in the TGN. Collectively these data suggest that rhodopsin and its associated proteins are sorted upon exit from the TGN in this cell-free system. Removal of membrane-bound GTP-binding proteins of the rab family by rab GDP dissociation inhibitor completely abolishes formation of these vesicles and results in the retention of rhodopsin in the Golgi. A monoclonal antibody to the cytoplasmic (carboxyl terminal) domain of rhodopsin and its Fab fragments strongly inhibit vesicle formation and arrest newly synthesized rhodopsin in the TGN rather than the Golgi. Therefore rhodopsin sorting at the exit from the TGN is mediated by the interaction of its cytoplasmic domain with the intracellular sorting machinery.			Deretic, D (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,7703 FLOYD CURL DR,SAN ANTONIO,TX 78284, USA.				NEI NIH HHS [EY-6891] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adler R., 1986, RETINA MODEL CELL BI, P297; CHEN J, 1995, SCIENCE, V267, P374, DOI 10.1126/science.7824934; DAVEY J, 1985, CELL, V43, P643, DOI 10.1016/0092-8674(85)90236-3; DECURTIS I, 1989, CELL, V58, P719, DOI 10.1016/0092-8674(89)90106-2; DERETIC D, 1993, J CELL SCI, V106, P803; DERETIC D, 1991, J CELL BIOL, V113, P1281, DOI 10.1083/jcb.113.6.1281; DERETIC D, 1995, J CELL SCI, V108, P215; DERETIC D, 1995, PROG RETIN EYE RES, V14, P249, DOI 10.1016/1350-9462(94)00004-3; DERETIC D, 1994, J BIOL CHEM, V269, P16853; DERETIC D, 1993, METH NEUROSCI, V15, P108; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; HAMM HE, 1986, BIOCHEMISTRY-US, V25, P4512, DOI 10.1021/bi00364a010; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; JONES SM, 1993, J CELL BIOL, V122, P775, DOI 10.1083/jcb.122.4.775; LADINSKY MS, 1994, J CELL BIOL, V127, P29, DOI 10.1083/jcb.127.1.29; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; NARULA N, 1992, J CELL BIOL, V117, P27, DOI 10.1083/jcb.117.1.27; NATHANS J, 1989, VISION RES, V29, P907, DOI 10.1016/0042-6989(89)90105-3; NATHANS J, 1994, CELL, V78, P357, DOI 10.1016/0092-8674(94)90414-6; OHASHI M, 1994, J BIOL CHEM, V269, P24897; OLSON JE, 1992, NEURON, V9, P815; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; PAPERMASTER DS, 1975, BIOCHEMISTRY-US, V14, P1343, DOI 10.1021/bi00678a001; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PITTLER SJ, 1995, J CELL BIOL, V130, P431, DOI 10.1083/jcb.130.2.431; PITTLER SJ, 1992, FEBS LETT, V313, P103, DOI 10.1016/0014-5793(92)81422-I; ROOF DJ, 1994, INVEST OPHTH VIS SCI, V35, P4049; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SALAMERO J, 1990, P NATL ACAD SCI USA, V87, P7717, DOI 10.1073/pnas.87.19.7717; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1994, J NEUROSCI, V14, P5818; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TOOZE SA, 1990, CELL, V60, P837, DOI 10.1016/0092-8674(90)90097-X; TOOZE SA, 1992, METHOD ENZYMOL, V219, P81; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; URBE S, 1993, FEBS LETT, V334, P175, DOI 10.1016/0014-5793(93)81707-7; WEISS ER, 1994, BIOCHEMISTRY-US, V33, P7587, DOI 10.1021/bi00190a011	43	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2279	2286		10.1074/jbc.271.4.2279	http://dx.doi.org/10.1074/jbc.271.4.2279			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567690	hybrid			2022-12-25	WOS:A1996TR32000072
J	Daniel, S; Kim, KH				Daniel, S; Kim, KH			Sp1 mediates glucose activation of the acetyl-CoA carboxylase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; RNA POLYMERASE-II; CARBOHYDRATE RESPONSE ELEMENT; BOX-BINDING-PROTEINS; MAJOR LATE PROMOTER; TRANSCRIPTION FACTOR; MESSENGER-RNA; FATTY-ACIDS; DNA-BINDING; EXPRESSION	Acetyl-CoA carboxylase (ACC), the rate-limiting enzyme in the biosynthesis of fatty acids, is induced in the presence of high glucose levels, The ACC gene contains two promoters: promoter I (PI) expression is inducible under lipogenic conditions, while promoter II (PII) expression, even though constitutively expressed in all tissues, is also controlled under various physiological conditions, Examination of the expression pattern of a series of deletion constructs of PII showed that the region from -340 to -249 was essential for ACC induction, In addition, by electrophoretic mobility shift assays, supershift assays, and DNase I footprinting studies, we have detected the binding of the transcription factor Spl at the two GC-rich sequences located within the -340 to -249 region of promoter II, Mutations at the GC-rich sequences prevented binding of Spl, and the induction of the PII promoter was no longer observed, Cotransfection studies, in Drosophila Schneider SL2 cells, with the Spl expression vector and PII-CAT constructs, have further confirmed the activation of promoter II by Spl, In addition, we have identified Sp3, another member of the Spl family of transcription factors, as a second factor that can bind to the glucose response elements of PII.	PURDUE UNIV, DEPT BIOCHEM, W LAFAYETTE, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus					NATIONAL CANCER INSTITUTE [R01CA046882] Funding Source: NIH RePORTER; NCI NIH HHS [CA46882] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; BRUN T, 1993, J BIOL CHEM, V268, P18905; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; GOODRIDGE AG, 1987, ANNU REV NUTR, V7, P157, DOI 10.1146/annurev.nu.07.070187.001105; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LIU ZR, 1993, J BIOL CHEM, V268, P12787; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; LUO XC, 1990, NUCLEIC ACIDS RES, V18, P3249, DOI 10.1093/nar/18.11.3249; MELLOUL D, 1993, P NATL ACAD SCI USA, V90, P3865, DOI 10.1073/pnas.90.9.3865; MILTENBERGER RJ, 1995, CELL GROWTH DIFFER, V6, P549; Numa S, 1974, Curr Top Cell Regul, V8, P197; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SHIH HM, 1992, J BIOL CHEM, V267, P13222; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059; SIVARAM P, 1990, J BIOL CHEM, V265, P5774; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; TAPAROWSKY EJ, 1987, CANCER RES, V47, P4125; THOMPSON KS, 1991, J BIOL CHEM, V266, P8679; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888	41	97	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1385	1392		10.1074/jbc.271.3.1385	http://dx.doi.org/10.1074/jbc.271.3.1385			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576128	hybrid			2022-12-25	WOS:A1996TQ52500024
J	Froeschle, A; Carnac, G; Alric, S; Montarras, D; Pinset, C; RochetteEgly, C; Bonnieu, A				Froeschle, A; Carnac, G; Alric, S; Montarras, D; Pinset, C; RochetteEgly, C; Bonnieu, A			RXR alpha is essential for mediating the all-trans retinoic acid-induced growth arrest of C2 myogenic cells	ONCOGENE			English	Article						retinoic acid; RXR alpha; growth arrest; muscle cell	ACUTE PROMYELOCYTIC LEUKEMIA; X-RECEPTOR; THYROID-HORMONE; TERMINAL DIFFERENTIATION; LINE BA-HAN-1C; MUSCLE-CELLS; EXPRESSION; CLONING; MYOD1; GENE	In C2 muscle cells, retinoic acid (RA) induces growth arrest associated with terminal differentiation. These RA actions are presumed to be mediated through nuclear receptors (RARs and RXRs) that belong to the superfamily of ligand-dependent transcription factors, In this study, we have characterized a myogenic C2 subclone, that unlike parental cells, is resistant to growth inhibition and differentiation by RA, Examination of these RA-sensitive and resistant C2 cells for the expression of retinoid acid receptors revealed a lack of RXR alpha expression at the myoblast stage in resistant C2 cells, To determine the functions of RXR alpha, we introduced an RXR alpha expression vector into RA-resistant C2 cells by transient or stable transfections, Our results show that RXR alpha restores the response to RA in this subclone with respect to AP1 inhibition and growth arrest, These observations indicate that RXR alpha plays a crucial role in mediating RA induced growth arrest of C2 myogenic cells.	INRA,LAB DIFFERENCIAT CELLULAIRE & CROISSANCE,F-34060 MONTPELLIER 01,FRANCE; INST PASTEUR,DEPT BIOL MOLEC,URA 1148 CNRS,F-75724 PARIS 15,FRANCE; INST GENET & BIOL MOLEC & CELLULAIRE,CNRS,INSERM,ULP,F-67404 ILLKIRCH GRAFFENS,FRANCE	INRAE; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Bonnieu, Anne/ABA-7182-2020; Carnac, Gilles/N-6744-2018	Carnac, Gilles/0000-0002-3518-8774				ALBAGLICURIEL O, 1993, DIFFERENTIATION, V52, P201, DOI 10.1111/j.1432-0436.1993.tb00632.x; ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; ARNOLD HH, 1992, J CELL BIOL, V118, P877, DOI 10.1083/jcb.118.4.877; CARNAC G, 1993, ENDOCRINOLOGY, V133, P2171, DOI 10.1210/en.133.5.2171; CARNAC G, 1993, ONCOGENE, V8, P3103; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DE LUCA LM, 1991, FASEB J, V5, P2924; DEFACQUE H, 1994, BIOCHEM BIOPH RES CO, V203, P272, DOI 10.1006/bbrc.1994.2178; DOWNES M, 1994, ENDOCRINOLOGY, V134, P2658, DOI 10.1210/en.134.6.2658; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GABBERT HE, 1988, CANCER RES, V48, P5264; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Gudas Lorraine J., 1994, P443; HALEVY O, 1993, J CELL PHYSIOL, V154, P566, DOI 10.1002/jcp.1041540315; HEERY DM, 1993, P NATL ACAD SCI USA, V90, P4281, DOI 10.1073/pnas.90.9.4281; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hofmann Clementine, 1994, P387; Hong Waun Ki, 1994, P597; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; KIZAKI M, 1993, BLOOD, V82, P3592; KLEINHITPASS L, 1988, NUCLEIC ACIDS RES, V16, P647, DOI 10.1093/nar/16.2.647; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOVE JM, 1994, CURR OPIN CELL BIOL, V6, P825, DOI 10.1016/0955-0674(94)90051-5; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MINUCCI S, 1994, MOL CELL BIOL, V14, P360, DOI 10.1128/MCB.14.1.360; MOASSER MM, 1994, ONCOGENE, V9, P833; MOMOI T, 1992, BIOCHEM BIOPH RES CO, V187, P245, DOI 10.1016/S0006-291X(05)81484-6; MONTARRAS D, 1989, EMBO J, V8, P2203, DOI 10.1002/j.1460-2075.1989.tb08343.x; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; NAGY L, 1995, MOL CELL BIOL, V15, P3540; NILSEN DA, 1983, P NATL ACAD SCI USA, V80, P5198; PFAHL M, 1990, METHOD ENZYMOL, V189, P256; PINSET C, 1988, DIFFERENTIATION, V38, P28, DOI 10.1111/j.1432-0436.1988.tb00588.x; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YANGYEN HF, 1991, NEW BIOL, V3, P1206; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	53	14	14	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					411	421						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570219				2022-12-25	WOS:A1996TR53800021
J	Fernandez, LM; Puett, D				Fernandez, LM; Puett, D			Lys(583) in the third extracellular loop of the lutropin choriogonadotropin receptor is critical for signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHORIONIC-GONADOTROPIN RECEPTOR; HORMONE-BINDING; IDENTIFICATION; ACTIVATION; ASP(397); DNA	The lutropin/choriogonadotropin receptor (LH/CG-R) contains a relatively large extracellular domain, in addition to the seven transmembrane helices (TMH), three extracellular loops (ECL), and three intracellular loops typical of Cf protein coupled receptors, While high affinity ligand binding has been attributed to the N-terminal extracellular domain, there is evidence that portions of the three ECLs may function in ligand binding and transmembrane signaling. We have investigated the role of several ionizable amino acid residues of rat LW/CG-R in human choriogonadotropin (hCG) binding and hCG-mediated cAMP production, COS-7 cells were transfected with the pSVL expression vector containing cDNAs of either wild-type or mutant rat LH/CG-R. Several point mutants of Lys(583), located at the interface of ECL III and TMH VII, bound hCG like wild-type receptor but exhibited greatly diminished ligand-mediated signaling. Neither the point mutant, Lys(401) --> ASP (ECL I), nor the double mutant, Asp(397) --> Lys/Lys(583) --> Asp (ECLs I and III, respectively), showed significant hCG binding to intact cells; in detergent-solubilized cells, only the double mutant bound hCG. The mutants Arg(341) --> Glu (interface of the extracellular domain and TMH I) and Lys(488) --> Glu (ECL II) proved to be similar to wild-type receptor in binding and signaling. Our results establish that Lys(583) is important in signaling but not ligand binding, Its location on the opposite side of the membrane from G(s) precludes a direct interaction, thus emphasizing the importance of a conformational change in the receptor and suggesting that ligand binding to receptor and ligand-mediated receptor activation are dissociable phenomena.	UNIV GEORGIA,DEPT BIOCHEM & MOLEC BIOL,ATHENS,GA 30602; UNIV MIAMI,DEPT BIOCHEM & MOLEC BIOL,REPSCEND LABS,MIAMI,FL 33101	University System of Georgia; University of Georgia; University of Miami					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033973] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33973] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; DAVIS JS, 1994, CURR OPIN OBSTET GYN, V6, P254; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; FERNANDEZ LM, 1994, 76TH END SOC M AN, P444; GUDERMANN T, 1992, MOL ENDOCRINOL, V6, P272, DOI 10.1210/me.6.2.272; HIPKIN RW, 1992, MOL ENDOCRINOL, V6, P2210, DOI 10.1210/me.6.12.2210; HUANG JN, 1995, J BIOL CHEM, V270, P30023; JI I, 1993, J BIOL CHEM, V268, P20851; JI I, 1991, J BIOL CHEM, V266, P13076; JI IH, 1993, J BIOL CHEM, V268, P22971; JI L, 1991, ENDOCRINOLOGY, V128, P2648; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; KOSUGI S, 1994, FEBS LETT, V349, P89, DOI 10.1016/0014-5793(94)00646-6; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MOYLE WR, 1991, J BIOL CHEM, V266, P10807; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; ROCHE PC, 1985, ENDOCRINOLOGY, V117, P790, DOI 10.1210/endo-117-2-790; ROCHE PC, 1992, ENDOCRINOLOGY, V131, P268, DOI 10.1210/en.131.1.268; ROSEMBLIT N, 1988, ENDOCRINOLOGY, V123, P2284, DOI 10.1210/endo-123-5-2284; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SELDEN RF, 1992, CURRENT PROTOCOLS MO; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; THOMAS DM, 1994, ENDOCRINOLOGY, V135, P1902, DOI 10.1210/en.135.5.1902; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; VALOVE FM, 1994, ENDOCRINOLOGY, V135, P2657, DOI 10.1210/en.135.6.2657; WANG HY, 1993, MOL ENDOCRINOL, V7, P1437, DOI 10.1210/me.7.11.1437; WURTHNER JU, 1995, ENDOCRINE, V3, P579, DOI 10.1007/BF02953022; XIE YB, 1990, J BIOL CHEM, V265, P21411; ZHOU W, 1994, MOL PHARMACOL, V45, P165	33	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					925	930		10.1074/jbc.271.2.925	http://dx.doi.org/10.1074/jbc.271.2.925			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557706	hybrid			2022-12-25	WOS:A1996TP88900049
J	Rousselle, JC; Massot, O; Delepierre, M; Zifa, E; Rousseau, B; Fillion, G				Rousselle, JC; Massot, O; Delepierre, M; Zifa, E; Rousseau, B; Fillion, G			Isolation and characterization of an endogenous peptide from rat brain interacting specifically with the serotonergic 1B receptor subtypes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL 5-HT AUTORECEPTORS; BINDING-SITES; ACETYLCHOLINE-RELEASE; RECOGNITION SITES; MAMMALIAN BRAIN; FUNCTIONAL-ROLE; LIGAND; CITALOPRAM; MEMBRANES; TRIFLUOROMETHYLPHENYLPIPERAZINE	The existence of endogenous compounds interacting with the serotonergic system was previously postulated, In the present work, rat brain tissues were extracted by acidic and organic procedures, The resulting extract was tested for its capacity to interact with the binding of [H-3]5-hydroxytryptamine ([H-3]5-HT) to 5-HT1 receptors, Compounds responsible for the observed inhibitory activities were isolated and purified by high pressure liquid chromatography, A tetrapeptide corresponding to a novel amino acid sequence Leu-Ser-Ala-Leu (LSAL) was identified, It re duces the binding of [H-3]5-HT to 5-HT1 receptors at low concentration (IC50 = 10(-10) M), This effect corresponds to a specific interaction at 5-HT1B receptors since LSAL does not significantly affect other neurotransmitter bindings, LSAL appears heterogeneously distributed throughout the brain (hippocampus > cerebellum > striatum > brain stem) and in peripheral tissues (kidney > lung > stomach > blood > liver > spleen). Two other peptides, Leu-Ser (LS) and Ala-Leu (AL), were also purified, They hardly affected [H-3]5-HT binding compared with LSAL, They presumably represent degradation products of the functional peptide LSAL. The fact that LSAL interacts specifically with 5-HT1B receptors that inhibit the release of neurotransmitters and particularly that of 5-HT itself suggests that this peptide may be involved in mechanisms controlling 5-HT neurotransmission and, accordingly, may play an important role in pathophysiological functions related to 5-HT activity.	INST PASTEUR,UNITE PHARMACOL NEUROIMMUNOENDOCRINIENNE,F-75724 PARIS,FRANCE; INST PASTEUR,LAB RESONANCE MAGNET NUCL,F-75724 PARIS,FRANCE; CTR SACLAY,SERV MOLEC MARQUEES BIOL CELLULAIRE & MOLEC,F-91191 GIF SUR YVETTE,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								ADHAM N, 1992, MOL PHARMACOL, V41, P1; AGNATI LF, 1983, ACTA PHYSIOL SCAND, V117, P299, DOI 10.1111/j.1748-1716.1983.tb07210.x; ANGEL I, 1984, FEBS LETT, V171, P280, DOI 10.1016/0014-5793(84)80504-9; BARALDI M, 1979, SCIENCE, V205, P821, DOI 10.1126/science.462192; BARBACCIA ML, 1988, ANNU REV PHARMACOL, V28, P451; BARBACCIA ML, 1983, P NATL ACAD SCI-BIOL, V80, P5134, DOI 10.1073/pnas.80.16.5134; BARBACCIA ML, 1984, ANN NY ACAD SCI, V430, P103, DOI 10.1111/j.1749-6632.1984.tb14501.x; BLIER P, 1988, N-S ARCH PHARMACOL, V337, P246, DOI 10.1007/BF00168834; BOLANOS F, 1989, EUR J PHARMACOL, V168, P87, DOI 10.1016/0014-2999(89)90636-5; BOLANOSJIMENEZ F, 1993, EUR J PHARMACOL, V242, P1, DOI 10.1016/0014-2999(93)90002-Y; BRILEY M, 1993, CLIN NEUROPHARMACOL, V16, P387, DOI 10.1097/00002826-199310000-00002; BRUSOV OS, 1985, BIOL PSYCHIAT, V20, P235, DOI 10.1016/0006-3223(85)90053-8; CHAPUT Y, 1986, N-S ARCH PHARMACOL, V333, P342, DOI 10.1007/BF00500007; CIARANELLO RD, 1990, J PHARMACOL EXP THER, V252, P1347; COPPEN ALEC, 1967, BRIT J PSYCHIAT, V113, P1237, DOI 10.1192/bjp.113.504.1237; COTMAN CW, 1971, BIOCHIM BIOPHYS ACTA, V249, P380, DOI 10.1016/0005-2736(71)90117-9; ENGEL G, 1986, N-S ARCH PHARMACOL, V332, P1, DOI 10.1007/BF00633189; FIELDS JZ, 1977, BRAIN RES, V136, P578, DOI 10.1016/0006-8993(77)90084-1; FILLION G, 1981, NATURE, V292, P349, DOI 10.1038/292349a0; FUXE K, 1988, NEUROSCI LETT, V85, P163, DOI 10.1016/0304-3940(88)90448-X; GALZIN AM, 1985, J PHARMACOL EXP THER, V235, P200; GOZLAN H, 1983, NATURE, V305, P140, DOI 10.1038/305140a0; HANFT G, 1989, BRIT J PHARMACOL, V97, P691, DOI 10.1111/j.1476-5381.1989.tb12005.x; HARELDUPAS C, 1991, J NEUROCHEM, V56, P221, DOI 10.1111/j.1471-4159.1991.tb02584.x; HARTIG PR, 1992, TRENDS PHARMACOL SCI, V13, P152, DOI 10.1016/0165-6147(92)90053-9; HOYER D, 1989, TRENDS PHARMACOL SCI, V10, P130, DOI 10.1016/0165-6147(89)90159-4; HOYER D, 1994, PHARMACOL REV, V46, P157; HOYER D, 1985, EUR J PHARMACOL, V118, P1, DOI 10.1016/0014-2999(85)90657-0; LANGER SZ, 1982, J PHARMACOL EXP THER, V222, P220; LEYSEN JE, 1982, MOL PHARMACOL, V21, P301; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORET C, 1990, EUR J PHARMACOL, V180, P351, DOI 10.1016/0014-2999(90)90320-6; MURPHY TJ, 1989, J PHARMACOL EXP THER, V249, P535; NELSON DR, 1989, BIOCHEM PHARMACOL, V38, P1693, DOI 10.1016/0006-2952(89)90319-5; PALACIOS JM, 1993, METHODS NEUROSCI, V12, P238; PERT CB, 1973, SCIENCE, V179, P1011, DOI 10.1126/science.179.4077.1011; REHAVI M, 1985, LIFE SCI, V36, P687, DOI 10.1016/0024-3205(85)90174-2; SCHILDKRAUT JJ, 1965, AM J PSYCHIAT, V122, P509, DOI 10.1176/ajp.122.5.509; SIEVER LJ, 1991, PHARMACOL REV, V43, P509; STOCKMEIER CA, 1989, MOL PHARMACOL, V36, P903; TITELER M, 1985, EUR J PHARMACOL, V117, P145, DOI 10.1016/0014-2999(85)90486-8; TRAN VT, 1978, P NATL ACAD SCI USA, V75, P6290, DOI 10.1073/pnas.75.12.6290; YAMAMURA HI, 1974, P NATL ACAD SCI USA, V71, P1725, DOI 10.1073/pnas.71.5.1725	43	55	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					726	735		10.1074/jbc.271.2.726	http://dx.doi.org/10.1074/jbc.271.2.726			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557679	hybrid			2022-12-25	WOS:A1996TP88900022
J	Takahashi, K; Stamenkovic, I; Cutler, M; Saya, H; Tanabe, KK				Takahashi, K; Stamenkovic, I; Cutler, M; Saya, H; Tanabe, KK			CD44 hyaluronate binding influences growth kinetics and tumorigenicity of human colon carcinomas	ONCOGENE			English	Article						CD44; hyaluronate; colon carcinoma; adhesion molecule; metastases	LYMPHOCYTE-HOMING RECEPTOR; CELL-SURFACE GLYCOPROTEIN; NON-HODGKINS-LYMPHOMA; MONOCLONAL-ANTIBODIES; TUMOR-GROWTH; FIBRONECTIN RECEPTOR; ACID BINDING; EXPRESSION; ADHESION; VARIANT	CD44 is a cell surface receptor for hyaluronate that is implicated in the regulation of tumor growth and metastatic potential. Transformation of colon mucosa to carcinoma is associated with overexpression of several CD44 alternative splice variants. The functional roles of CD44 isoforms in colon carcinoma tumor progression remain unclear. CD44H expression is downregulated in colon carcinomas compared to paired normal mucosa. In the present study we demonstrate that reintroduction of CD44H back into colon carcinoma cells by stable transfection reduces their in vitro growth rate and tumorigenicity. Examination of several colon carcinoma cell lines and use of mutant CD44H reveal that this in vitro and irt vivo growth reduction requires the ability of CD44H to bind hyaluronate. These observations indicate that the CD44H downregulation associated with transformation of mucosa to colon carcinoma may provide the carcinoma cells with a growth advantage. Furthermore, the reduction in tumor growth rate mediated by reintroduction of CD44H into colon carcinoma cells is dependent on its ability to bind hyaluronate.	MASSACHUSETTS GEN HOSP, DEPT SURG, DIV SURG ONCOL, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02114 USA; KUMAMOTO UNIV, SCH MED, DEPT ONCOL, KUMAMOTO 860, JAPAN	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Kumamoto University			Saya, Hideyuki/J-4325-2013		NCI NIH HHS [CA64454, CA55735] Funding Source: Medline; NIDDK NIH HHS [DK433351] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064454, R01CA055735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BIRCH M, 1991, CANCER RES, V51, P6660; BROWN PJ, 1985, SCIENCE, V228, P1448, DOI 10.1126/science.4012302; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CANNISTRA SA, 1993, CANCER RES, V53, P3830; COOPER DL, 1992, BIOCHEM BIOPH RES CO, V182, P569, DOI 10.1016/0006-291X(92)91770-Q; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; FOX SB, 1994, CANCER RES, V54, P4539; GALLATIN WM, 1989, P NATL ACAD SCI USA, V86, P4654, DOI 10.1073/pnas.86.12.4654; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUO YJ, 1994, CANCER RES, V54, P422; GUO YJ, 1994, CANCER RES, V54, P1561; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; HOFMANN M, 1991, CANCER RES, V51, P5292; HORST E, 1990, LEUKEMIA, V4, P595; JALKANEN S, 1986, SCIENCE, V233, P556, DOI 10.1126/science.3726548; JALKANEN S, 1991, J CLIN INVEST, V87, P1835, DOI 10.1172/JCI115205; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JALKANEN ST, 1986, EUR J IMMUNOL, V16, P1195, DOI 10.1002/eji.1830161003; JOENSUU H, 1993, AM J PATHOL, V143, P867; JOENSUU H, 1993, BRIT J CANCER, V68, P428, DOI 10.1038/bjc.1993.354; KNUDSON W, 1993, P NATL ACAD SCI USA, V90, P4003, DOI 10.1073/pnas.90.9.4003; LESLEY J, 1992, J EXP MED, V175, P257, DOI 10.1084/jem.175.1.257; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MORIKAWA K, 1988, CANCER RES, V48, P1943; MULDER JWR, 1994, LANCET, V344, P1470, DOI 10.1016/S0140-6736(94)90290-9; NAGASAKA S, 1995, J NEUROSURG, V82, P858, DOI 10.3171/jns.1995.82.5.0858; PALS ST, 1989, BLOOD, V73, P885; PEACH RJ, 1993, J CELL BIOL, V122, P257, DOI 10.1083/jcb.122.1.257; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; REBER S, 1990, INT J CANCER, V46, P919, DOI 10.1002/ijc.2910460528; SCHREINER C, 1991, CANCER RES, V51, P1738; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; SY MS, 1992, J EXP MED, V176, P623, DOI 10.1084/jem.176.2.623; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; TANABE KK, 1995, ANN SURG, V222, P493; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TANABE KK, 1993, MOL CARCINOGEN, V7, P212, DOI 10.1002/mc.2940070403; THOMAS L, 1992, J CELL BIOL, V118, P971, DOI 10.1083/jcb.118.4.971; TOLG C, 1993, NUCLEIC ACIDS RES, V21, P1225, DOI 10.1093/nar/21.5.1225; TOOLE BP, 1979, P NATL ACAD SCI USA, V76, P6299, DOI 10.1073/pnas.76.12.6299; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; WIELENGA VJM, 1993, CANCER RES, V53, P4754; ZHANG LR, 1995, CANCER RES, V55, P428	56	53	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2223	2232						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570172				2022-12-25	WOS:A1995TK70200005
J	Vera, JC; Reyes, AM; Carcamo, JG; Velasquez, FV; Rivas, CI; Zhang, RH; Strobel, P; Iribarren, R; Scher, HI; Slebe, JC; Golde, DW				Vera, JC; Reyes, AM; Carcamo, JG; Velasquez, FV; Rivas, CI; Zhang, RH; Strobel, P; Iribarren, R; Scher, HI; Slebe, JC; Golde, DW			Genistein is a natural inhibitor of hexose and dehydroascorbic acid transport through the glucose transporter, GLUT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE SUGAR TRANSPORTER; TYROSINE KINASE INHIBITOR; CELL-CYCLE PROGRESSION; RAT ADIPOSE CELL; PLASMA-MEMBRANE; RECONSTITUTED LIPOSOMES; PHOSPHORYLATION STATE; INTRINSIC ACTIVITY; GENE LOCALIZATION; PROTEIN-KINASES	Genistein is a dietary-derived plant product that inhibits the activity of protein-tyrosine kinases, We show here that it is a potent inhibitor of the mammalian facilitative hexose transporter GLUT1, In human HL-60 cells, which express GLUT1, genistein inhibited the transport of dehydroascorbic acid, deoxyglucose, and methylglucose in a dose-dependent manner, Transport was not affected by daidzein, an inactive genistein analog that does not inhibit protein-tyrosine kinase activity, or by the general protein kinase inhibitor staurosporine, Genistein inhibited the uptake of deoxyglucose and dehydroascorbic acid in Chinese hamster ovary (CHO) cells overexpressing GLUT1 in a similar dose-dependent manner, Genistein also inhibited the uptake of deoxyglucose in human erythrocytes indicating that its effect on glucose transporter function is cell-independent, The inhibitory action of genistein on transport was instantaneous, with no additional effect observed in cells preincubated with it for various periods of time, Genistein did not alter the uptake of leucine by HL-60 cells, indicating that its inhibitory effect was specific for the glucose transporters, The inhibitory effect of genistein was of the competitive type, with a K-i of approximately 12 mu M for inhibition of the transport of both methylglucose and deoxyglucose. Binding studies showed that genistein inhibited glucose-displaceable binding of cytochalasin B to GLUT1 in erythrocyte ghosts in a competitive manner, with a K-i of 7 mu M. These data indicate that genistein inhibits the transport of dehydroascorbic acid and hexoses by directly interacting with the hexose transporter GLUT1 and interfering with its transport activity, rather than as a consequence of its known ability to inhibit protein-tyrosine kinases, These observations indicate that some of the many effects of genistein on cellular physiology may be related to its ability to disrupt the normal cellular flux of substrates through GLUT1, a hexose transporter universally expressed in cells, and is responsible for the basal uptake of glucose.	MEM SLOAN KETTERING CANC CTR, DEPT MED, NEW YORK, NY 10021 USA; UNIV AUSTRAL CHILE, FAC CIENCIAS, INST BIOQUIM, VALDIVIA, CHILE	Memorial Sloan Kettering Cancer Center; Universidad Austral de Chile	Vera, JC (corresponding author), MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC PHARMACOL & THERAPEUT, 1275 YORK AVE, BOX 451, NEW YORK, NY 10021 USA.			Carcamo, Juan Guillermo/0000-0002-2595-4375	NCI NIH HHS [P30 CA08748, R01 CA30388] Funding Source: Medline; NHLBI NIH HHS [R01 HL42107] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030388, P30CA008748] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042107] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; AXELROD JD, 1983, BIOCHEMISTRY-US, V22, P2222, DOI 10.1021/bi00278a025; AZUMA Y, 1993, CELL IMMUNOL, V152, P271, DOI 10.1006/cimm.1993.1287; BALDWIN SA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P17, DOI 10.1016/0304-4157(93)90015-G; BARNES S, 1995, J CELL BIOCHEM, P181; BEGUM N, 1993, J BIOL CHEM, V268, P3352; BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870; BIRNBAUM MJ, 1989, CELL, V57, P305, DOI 10.1016/0092-8674(89)90968-9; BROWN RS, 1993, CANCER, V72, P2979, DOI 10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO;2-X; BURANT CF, 1992, J BIOL CHEM, V267, P14523; CARRUTHERS A, 1989, BIOCHEMISTRY-US, V28, P8337, DOI 10.1021/bi00447a011; CARRUTHERS A, 1986, J BIOL CHEM, V261, P1028; CARRUTHERS A, 1990, PHYSIOL REV, V70, P1135, DOI 10.1152/physrev.1990.70.4.1135; CONSTANTINOU A, 1990, CANCER RES, V50, P2618; CUSHMAN SW, 1980, J BIOL CHEM, V255, P4758; DING DXH, 1994, P NATL ACAD SCI USA, V91, P2537, DOI 10.1073/pnas.91.7.2537; FISCHBARG J, 1990, P NATL ACAD SCI USA, V87, P3244, DOI 10.1073/pnas.87.8.3244; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690; GORCZYCA W, 1993, CANCER RES, V53, P3186; GORGA FR, 1981, BIOCHEMISTRY-US, V20, P5108, DOI 10.1021/bi00521a003; HARRISON SA, 1990, J BIOL CHEM, V265, P5793; HARRISON SA, 1992, J BIOL CHEM, V267, P3783; HAWKINS RA, 1994, CANCER INVEST, V12, P74, DOI 10.3109/07357909409021395; HEBERT DN, 1986, J BIOL CHEM, V261, P93; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; HELGERSON AL, 1987, J BIOL CHEM, V262, P5464; HOLMAN GD, 1986, BIOCHIM BIOPHYS ACTA, V855, P115, DOI 10.1016/0005-2736(86)90195-1; HUANG JM, 1992, J BIOL CHEM, V267, P15511; JAMES DE, 1989, P NATL ACAD SCI USA, V86, P8368, DOI 10.1073/pnas.86.21.8368; JARVIS SM, 1986, J BIOL CHEM, V261, P1077; JOOST HG, 1987, J BIOL CHEM, V262, P11261; KAKUDA DK, 1994, J EXP BIOL, V196, P93; KAYANO T, 1988, J BIOL CHEM, V263, P15245; KAYANO T, 1990, J BIOL CHEM, V265, P13276; KELLY GE, 1993, CLIN CHIM ACTA, V223, P9, DOI 10.1016/0009-8981(93)90058-C; KURIU A, 1991, BLOOD, V78, P2834; LEBWOHL DE, 1991, J BIOL CHEM, V266, P386; LEE JS, 1994, AM J PHYSIOL, V266, pC319, DOI 10.1152/ajpcell.1994.266.2.C319; LI BQ, 1993, P NATL ACAD SCI USA, V90, P8504, DOI 10.1073/pnas.90.18.8504; LINASSIER C, 1990, BIOCHEM PHARMACOL, V39, P187, DOI 10.1016/0006-2952(90)90664-7; LINNEKIN D, 1992, BLOOD, V80, P1896; MARKOVITS J, 1989, CANCER RES, V49, P5111; MATSUKAWA Y, 1993, CANCER RES, V53, P1328; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; NAKASHIMA S, 1991, MOL PHARMACOL, V39, P475; NIEWEG OE, 1993, CANCER, V71, P3920, DOI 10.1002/1097-0142(19930615)71:12<3920::AID-CNCR2820711220>3.0.CO;2-N; NISHIMURA H, 1991, P NATL ACAD SCI USA, V88, P11500, DOI 10.1073/pnas.88.24.11500; OKURA A, 1988, BIOCHEM BIOPH RES CO, V157, P183, DOI 10.1016/S0006-291X(88)80030-5; PETERSON G, 1993, PROSTATE, V22, P335, DOI 10.1002/pros.2990220408; REUSCH JEB, 1993, J BIOL CHEM, V268, P3348; SCHURMANN A, 1992, BIOCHEM J, V285, P223, DOI 10.1042/bj2850223; SHANAHAN MF, 1982, J BIOL CHEM, V257, P7290; SMITH RM, 1993, ARCH BIOCHEM BIOPHYS, V300, P238, DOI 10.1006/abbi.1993.1033; SOFUE M, 1993, BIOCHEM J, V292, P877, DOI 10.1042/bj2920877; SOFUE M, 1992, BIOCHEM J, V288, P669, DOI 10.1042/bj2880669; SUZUKI K, 1980, P NATL ACAD SCI-BIOL, V77, P2542, DOI 10.1073/pnas.77.5.2542; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; TRAGANOS F, 1992, CANCER RES, V52, P6200; VERA JC, 1994, BLOOD, V84, P1628; VERA JC, 1995, J BIOL CHEM, V270, P23706, DOI 10.1074/jbc.270.40.23706; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; VERA JC, 1991, MOL CELL BIOL, V11, P3407, DOI 10.1128/MCB.11.7.3407; WADDELL ID, 1992, BIOCHEM J, V286, P173, DOI 10.1042/bj2860173; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WATANABE T, 1991, CANCER RES, V51, P764; WHEELER TJ, 1989, BIOCHEMISTRY-US, V28, P3413, DOI 10.1021/bi00434a041; YAMAMOTO T, 1990, BIOCHEM BIOPH RES CO, V170, P223, DOI 10.1016/0006-291X(90)91263-R	68	109	112	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8719	8724		10.1074/jbc.271.15.8719	http://dx.doi.org/10.1074/jbc.271.15.8719			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621505	hybrid			2022-12-25	WOS:A1996UE73000036
J	Chernaya, G; Vazquez, M; Reeves, JP				Chernaya, G; Vazquez, M; Reeves, JP			Sodium-calcium exchange and store-dependent calcium influx in transfected Chinese hamster ovary cells expressing the bovine cardiac sodium-calcium exchanger - Acceleration of exchange activity in thapsigargin-treated cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; NA+-CA2+ EXCHANGE; INTRACELLULAR CALCIUM; ENDOPLASMIC-RETICULUM; NA/CA EXCHANGE; CA2+; STIMULATION; RELEASE; CA-2+; GENERATION	The effects of extracellular Na+ on store-dependent Ca2+ influx were compared for transfected Chinese hamster ovary cells expressing the bovine cardiac Na+-Ca2+ exchanger (CK1.4 cells) and vector-transfected control cells, Store-dependent Ca2+ influx was elicited by depletion of intracellular Ca2+ stores with ionomycin, thapsigargin, or extracellular ATP, a purinergic agonist, In each case, the rise in [Ca2+](i) upon the addition of extracellular Ca2+ was reduced in CK1.4 cells compared with control cells at physiological [Na+](o). When Li+ or NMDG was substituted for Na+, the CK1.4 cells showed a greater rise in [Ca2+](i) than control cells over the subsequent 3 min after the addition of Ca-o(2+). Under Na+-free conditions, SK&F 96365 (50 mu M), a blocker of store-operated Ca2+ channels, nearly abolished the thapsigargin-induced rise in [Ca2+](i) in the control cells but only partially inhibited this response in the CK1.4 cells, We conclude that in the CK1.4 cells, Ca2+ entry through store-operated channels was counteracted by Na-o(+)-dependent Ca2+ efflux at physiological [Na+](o), whereas Ca2+ entry was enhanced through Na-i(+)-dependent Ca2+ influx in the Na+-free medium. We examined the effects of thapsigargin on Ba2+ entry in the CK1.4 cells because Ba2+ is transported by the Na+-Ca2+ exchanger, but it enters these cells only poorly through store operated channels, and it is not sequestered by intracellular organelles, Thapsigargin treatment stimulated Ba2+ influx in a Na+-free medium, consistent with an acceleration of Ba2+ entry through the Na+-Ca2+ exchanger, We conclude that organellar Ca2+ release induces a regulatory activation of Na+-Ca2+ exchange activity.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT PHYSIOL,NEWARK,NJ 07103	Rutgers State University New Brunswick; Rutgers State University Medical Center					NHLBI NIH HHS [HL49932] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049932] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALKON DL, 1988, SCIENCE, V239, P998, DOI 10.1126/science.2830669; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLAUSTEIN MP, 1993, AM J PHYSIOL, V264, pC1367, DOI 10.1152/ajpcell.1993.264.6.C1367; CABELLO OA, 1993, BIOCHEM J, V295, P357, DOI 10.1042/bj2950357; CHEON J, 1988, J BIOL CHEM, V263, P2309; CIARDO A, 1990, EUR J PHARM-MOLEC PH, V188, P417, DOI 10.1016/0922-4106(90)90204-B; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; CONDRESCU M, 1995, J BIOL CHEM, V270, P9137, DOI 10.1074/jbc.270.16.9137; DIPOLO R, 1987, J GEN PHYSIOL, V90, P505, DOI 10.1085/jgp.90.4.505; DIPOLO R, 1979, J GEN PHYSIOL, V73, P91, DOI 10.1085/jgp.73.1.91; DIPOLO R, 1991, ANN NY ACAD SCI, V639, P100, DOI 10.1111/j.1749-6632.1991.tb17294.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HILGEMANN DW, 1991, NATURE, V352, P715, DOI 10.1038/352715a0; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; HILGEMANN DW, 1992, J PHYSIOL-LONDON, V454, P59, DOI 10.1113/jphysiol.1992.sp019254; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; IREDALE PA, 1993, BRIT J PHARMACOL, V110, P1305, DOI 10.1111/j.1476-5381.1993.tb13960.x; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; KWAN CY, 1990, J BIOL CHEM, V265, P678; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LIU CM, 1978, J BIOL CHEM, V253, P5892; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; MIURA Y, 1989, J GEN PHYSIOL, V93, P1129, DOI 10.1085/jgp.93.6.1129; PIJUAN V, 1993, AM J PHYSIOL, V264, pC1066, DOI 10.1152/ajpcell.1993.264.4.C1066; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Putney J W Jr, 1991, Adv Pharmacol, V22, P251, DOI 10.1016/S1054-3589(08)60037-X; RASGADOFLORES H, 1987, AM J PHYSIOL, V252, pC499, DOI 10.1152/ajpcell.1987.252.5.C499; RASGADOFLORES H, 1987, AM J PHYSIOL, V252, pC604, DOI 10.1152/ajpcell.1987.252.6.C604; REEVES JP, 1995, PHYSL PATHOPHYSIOLOG, P309; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TROSPER TL, 1983, BIOCHIM BIOPHYS ACTA, V731, P63, DOI 10.1016/0005-2736(83)90398-X; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	37	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5378	5385		10.1074/jbc.271.10.5378	http://dx.doi.org/10.1074/jbc.271.10.5378			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621391	hybrid			2022-12-25	WOS:A1996TZ28600017
J	Liu, BF; Xu, X; Fridman, R; Muallem, S; Kuo, TH				Liu, BF; Xu, X; Fridman, R; Muallem, S; Kuo, TH			Consequences of functional expression of the plasma membrane Ca2+ pump isoform 1a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; GENE-EXPRESSION; CA-2+ PUMP; INOSITOL TRISPHOSPHATE; MOLECULAR-CLONING; PANCREATIC ACINI; CELLS; OSCILLATIONS; ATPASE; HORMONE	The plasma membrane Ca2+-ATPase pump (PMCA) is an integral component of the Ca2+ signaling system which participates in signal transduction during agonist stimulated cell activation, To better understand the physiological function of the pump, isoform 1a (PMCA1a) was over-expressed in rat aortic endothelial cells using a stable transfection system under the control of a cytomegalovirus promoter, The cell lines selected after transfection with PMCA1a construct, expressed 3-4-fold increased pump protein which was mostly targeted to the plasma membrane as indicated by immunoperoxidase staining, Ca2+ uptake assays in a membrane preparation indicated a 3-4-fold increase in Ca2+ pumping activity in the transfected cells, and the expressed PMCA1a showed typical dependence on Ca2+ and calmodulin for stimulation of activity, Measure ment of [Ca2+](i) and [Ca2+](out) showed that expression of PMCA1a had a profound effect on different aspects of the Ca2+ signal, The peak increase in [Ca2+](i) evoked by ATP and/or thapsigargin was lower but the plateau phase was similar in the PMCA1a expressing cells, Accordingly, titration with ionomycin of Ca2+ content of internal stores, measurement of Ca2+ uptake into the thapsigargin- and oxalate-sensitive pool (endoplasmic reticulum) of isolated microsomes, Ca2+ uptake into streptolysin O-permeabilized cells, and analysis of SERCA mRNA and protein, showed that expression and activity of the SERCA pump was down-regulated in cells expressing PMCA1a pump, Expression of PMCA1a also down-regulated expression of the inositol 1,4,5-trisphosphate (IP3)-activated Ca2+ channel and the rate of IP3-mediated Ca2+ release in permeable cells, without affecting the affinity of the channel for IP3. On the other hand the rate of store depletion-dependent Ca2+ and Mn2+ influx (Ca2+ entry) into PMCA1a expressing cells was increased by about 2.6-fold, These changes prevented estimating the rate of pump mediated Ca2+ efflux from changes in [Ca2+](i). Measurement of [Ca2+](out) showed that the rate of Ca2+ efflux in cells expressing PMCA1a was about 1.45-fold higher than Neo controls, despite the 4-fold increase in the amount of functional pump protein, The overall study points to the flexibility, interdependence, and adaptability of the different components of the Ca2+ signaling systems to regulate the expression and activity of each component and maintain a nearly constant Ca2+ signal.	UNIV TEXAS,SW MED CTR,DEPT PHYSIOL,DALLAS,TX 76235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Liu, BF (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48201, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039481] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938, R01DK046591] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 39481] Funding Source: Medline; NIDDK NIH HHS [DK 46591, DK 38938] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; ANDERSON RG, 1994, CURRENT OPIN CELL BI, V5, P647; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOBE R, 1994, J BIOL CHEM, V269, P1417; BORKE JL, 1989, AM J PHYSIOL, V257, pF842, DOI 10.1152/ajprenal.1989.257.5.F842; BRUNDAGE RA, 1991, SCIENCE, V256, P677; BURK SE, 1989, J BIOL CHEM, V264, P18561; CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129; DUDDY SK, 1989, J BIOL CHEM, V264, P20863; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; ENYEDI A, 1994, J BIOL CHEM, V269, P41; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GUERINI D, 1995, J BIOL CHEM, V270, P14643, DOI 10.1074/jbc.270.24.14643; GUNTESKIHAMBLIN AM, 1988, J BIOL CHEM, V263, P15032; HUSSAIN A, 1995, J BIOL CHEM, V270, P12140, DOI 10.1074/jbc.270.20.12140; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KUO TH, 1991, J BIOL CHEM, V266, P2520; KUO TH, 1992, BIOCHIM BIOPHYS ACTA, V1138, P343, DOI 10.1016/0925-4439(92)90013-D; LYTTON J, 1988, J BIOL CHEM, V263, P15024; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MAGNIER C, 1992, J BIOL CHEM, V267, P15808; MUALLEM S, 1989, J BIOL CHEM, V264, P205; MUALLEM S, 1990, INTRACELLULAR CALCIU, P349; Muallem Shmuel, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P351; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RANDRIAMAMPITA C, 1990, J BIOL CHEM, V265, P18059; RINK TJ, 1987, J PHYSIOL-LONDON, V393, P513, DOI 10.1113/jphysiol.1987.sp016837; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; ROHRER DK, 1991, J BIOL CHEM, V266, P8638; SARKAR FH, 1993, DNA CELL BIOL, V12, P435, DOI 10.1089/dna.1993.12.435; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STAUFFER PL, 1993, J BIOL CHEM, V268, P19769; TEIPIKIN AV, 1992, J BIOL CHEM, V267, P3569; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; TORTORICI G, 1994, J BIOL CHEM, V269, P29621; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WALDRON RT, 1995, J BIOL CHEM, V270, P11955, DOI 10.1074/jbc.270.20.11955; WANG KKW, 1991, ARCH BIOCHEM BIOPHYS, V289, P103, DOI 10.1016/0003-9861(91)90448-R; WILLIAMS JA, 1980, CELL TISSUE RES, V210, P295; XU CS, 1995, FASEB J, V9, pA1066; ZHANG BX, 1992, J BIOL CHEM, V267, P24387; ZHANG BX, 1992, J BIOL CHEM, V267, P15419; ZVARITCH E, 1995, J BIOL CHEM, V270, P2679, DOI 10.1074/jbc.270.6.2679	44	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5536	5544		10.1074/jbc.271.10.5536	http://dx.doi.org/10.1074/jbc.271.10.5536			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621412	hybrid			2022-12-25	WOS:A1996TZ28600038
J	Muthukkumar, S; Sells, SF; Crist, SA; Rangnekar, VM				Muthukkumar, S; Sells, SF; Crist, SA; Rangnekar, VM			Interleukin-1 induces growth arrest by hypophosphorylation of the retinoblastoma susceptibility gene product RB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; LARGE T-ANTIGEN; CELL-CYCLE; TRANSCRIPTION FACTOR; TYROSINE KINASE; IL-1 RECEPTOR; CANCER-CELLS; FACTOR-BETA; PROTEIN; EXPRESSION	Interleukin-1 (IL-1) causes G(0)/G(1) phase growth arrest in human melanoma cells, A375-C6. Because hypophosphorylation of the retinoblastoma susceptibility gene product, RB, is one of the key events responsible for G(0)/G(1) phase growth arrest, we investigated whether IL-1 altered the phosphorylation status of RB protein in these cells. Exposure to IL-1 caused a time-dependent increase in hypophosphorylated RB that correlated with an accumulation of cells arrested in the G(0)/G(1) phase. The ability of IL-1 to cause hypophosphorylation of RB and growth arrest was abrogated by the SV40 large T antigen, which binds preferentially to hypophosphorylated RB, but not by the K1 mutant of the T antigen, which is defective in binding to RB. Furthermore, the cells were protected from IL-1-inducible growth inhibition by ectopic expression of dominant-negative mutants of the Rb gene, or the transcription factor E2F-1, which is a downstream target of RB. These results suggest that hypophosphorylated RB mediates the growth arrest induced by IL-1.	UNIV KENTUCKY,DEPT SURG,LEXINGTON,KY 40536; UNIV KENTUCKY,DIV UROL,LEXINGTON,KY 40536; UNIV KENTUCKY,DEPT MICROBIOL & IMMUNOL,LEXINGTON,KY 40536; UNIV KENTUCKY,MARKEY CANC CTR,LEXINGTON,KY 40536; UNIV KENTUCKY,GRAD CTR TOXICOL,LEXINGTON,KY 40536	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky					NATIONAL CANCER INSTITUTE [R29CA052837] Funding Source: NIH RePORTER; NCI NIH HHS [CA52837] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELIZARIO JE, 1991, CANCER RES, V51, P2379; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BOOKSTEIN R, 1991, Critical Reviews in Oncogenesis, V2, P211; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; DANFORTH DN, 1991, CANCER RES, V51, P1488; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DINARELLO CA, 1991, BLOOD, V77, P1627; ENDO Y, 1988, J IMMUNOL, V141, P2342; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FRYLING C, 1989, CANCER RES, V49, P3333; FUNG YKT, 1993, ONCOGENE, V8, P2659; GIOVINE FS, 1990, IMMUNOL TODAY, V11, P13; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KILIAN PL, 1991, CANCER RES, V51, P1823; KOCH I, 1995, BRIT J CANCER, V71, P794, DOI 10.1038/bjc.1995.154; LACHMAN LB, 1987, J IMMUNOL, V138, P2913; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LANDESMAN Y, 1992, ONCOGENE, V7, P1661; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; NEVINS JR, 1992, SCIENCE, V258, P424; ONOZAKI K, 1988, J IMMUNOL, V140, P112; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1995, MOL CELL BIOL, V15, P742; RANGNEKAR VV, 1991, J BIOL CHEM, V266, P2415; RANGNEKAR VV, 1992, J BIOL CHEM, V267, P6240; SCHMIDT JA, 1982, J IMMUNOL, V128, P2177; SELLS SF, 1995, MOL CELL BIOL, V15, P682; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E	52	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5733	5740		10.1074/jbc.271.10.5733	http://dx.doi.org/10.1074/jbc.271.10.5733			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621439	hybrid			2022-12-25	WOS:A1996TZ28600065
J	Porfiri, E; McCormick, F				Porfiri, E; McCormick, F			Regulation of epidermal growth factor receptor signaling by phosphorylation of the ras exchange factor hSOS1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; ACTIVATED PROTEIN-KINASE; TYROSINE KINASE; TRANSDUCTION PATHWAY; EGF RECEPTOR; T-ANTIGEN; GRB2; P21(RAS); BINDS; GENE	In response to stimulation with epidermal growth factor (EGF), the guanine nucleotide exchange factor human SOS1 (hSOS1) promotes the activation of Ras by forming a complex with Grb2 and the human EGF receptor (hEGFR). hSOS1 was phosphorylated in cells stimulated with EGF or phorbol 12-myristate 13-acetate or following co-transfection with activated Ras or Raf. Co-transfection with dominant negative Ras resulted in a decrease of EGF-induced hSOS1 phosphorylation. The mitogen-activated protein kinase (MAPK) phosphorylated hSOS1 in vitro within the carboxyl-terminal proline-rich domain. The same region of hSOS1 was phosphorylated in vivo, in cells stimulated with EGF. Tryptic phosphopeptide mapping showed that MAPK phosphorylated hSOS1 in vitro on sites which were also phosphorylated in vivo. Phosphorylation by MAPK did not affect hSOS1 binding to Grb2 in vitro. However, reconstitution of the hSOS1-Grb2-hEGFR complex showed that phosphorylation by MAPK markedly reduced the ability of hSOS1 to associate with the hEGFR through Grb2. Similarly, phosphorylated hSOS1 was unable to form a complex with She through Grb2. Thus phosphorylation of hSOS1, by affecting its interaction with the hEGFR or Shc, down-regulates signal transduction from the hEGFR to the Ras pathway.			Porfiri, E (corresponding author), ONYX PHARMACEUT,3031 RES DR,BLDG A,RICHMOND,CA 94806, USA.							BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HONEGGER AM, 1987, CELL, V51, P199, DOI 10.1016/0092-8674(87)90147-4; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG DCS, 1993, MOL CELL BIOL, V13, P2420, DOI 10.1128/MCB.13.4.2420; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MORRISON P, 1993, J BIOL CHEM, V268, P15536; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; UEKI K, 1994, J BIOL CHEM, V269, P15756; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WHITE MF, 1994, J BIOL CHEM, V269, P1; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249	40	92	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5871	5877		10.1074/jbc.271.10.5871	http://dx.doi.org/10.1074/jbc.271.10.5871			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621459	hybrid			2022-12-25	WOS:A1996TZ28600085
J	Chen, YY; Gill, GN				Chen, YY; Gill, GN			A heterodimeric nuclear protein complex binds two palindromic sequences in the proximal enhancer of the human erbB-2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; HUMAN-BREAST-CANCER; NEU ONCOGENE; C-ERBB-2 PROTOONCOGENE; EXPRESSION; OVEREXPRESSION; PROMOTER; NEUROBLASTOMAS; MECHANISMS; INITIATION	Increased expression of the protein-tyrosine kinase receptor ErbB-2 occurs frequently in human breast and ovarian cancer and causes transformation in experimental systems. Control of transcription of the erbB-2 gene is an important determinant of receptor expression. Within the human erbB-2 promoter, a 100-base pair (bp) region 5' to the TATA box enhances transcription 200-fold. Two palindromes present in this 100-bp region are important for both positive and negative transcriptional control. A nuclear palindrome binding protein (PBP) has been purified to near homogeneity using ion-exchange, DNA-affinity, and gel filtration chromatography. PBP is a heterodimer consisting of a 69-kDa alpha subunit that binds DNA and a 60-kDa beta subunit that appears to enhance subunit binding. DNase I footprinting and electrophoretic mobility shift assays indicate that PBP binds to the half-site of each palindrome with the;core recognition sequence TGGGAG. By DNA binding specificity and lack of immunological cross-reactivity, PBP is distinct from NF-kappa B and Ikaros, two proteins with related DNA binding specificities. PBP is proposed to be an important regulator of transcription of the erbB-2 gene.	UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK013149] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 13149] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; CHEN YY, 1994, ONCOGENE, V9, P2269; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERTL AP, 1993, GENE, V136, P361, DOI 10.1016/0378-1119(93)90496-P; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HUANG MC, 1986, P NATL ACAD SCI USA, V83, P261; HUDSON LG, 1990, J BIOL CHEM, V265, P4389; ISHII S, 1987, P NATL ACAD SCI USA, V84, P4374, DOI 10.1073/pnas.84.13.4374; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KOKAI Y, 1987, P NATL ACAD SCI USA, V84, P8498, DOI 10.1073/pnas.84.23.8498; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMOINE NR, 1990, EUR J CANCER, V26, P777, DOI 10.1016/0277-5379(90)90149-N; LEMOINE NR, 1990, ONCOGENE, V5, P237; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; MIYAGUCHI G, 1994, FEBS LETT, V348, P80; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P5056, DOI 10.1073/pnas.91.11.5056; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MIZUGUCHI G, 1994, FEBS LETT, V348, P80, DOI 10.1016/0014-5793(94)00578-8; MORI S, 1989, LAB INVEST, V61, P93; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PASLEAU F, 1993, ONCOGENE, V8, P849; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRESS MF, 1990, ONCOGENE, V5, P953; QUIRKE P, 1989, BRIT J CANCER, V60, P64, DOI 10.1038/bjc.1989.221; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAL M, 1987, MOL CELL BIOL, V7, P2597, DOI 10.1128/MCB.7.7.2597; WHITE MR, 1990, MOL CELL BIOL, V10, P6306; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	39	14	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5183	5188						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617800				2022-12-25	WOS:A1996TX69700090
J	Sanders, MC; Way, M; Sakai, J; Matsudaira, P				Sanders, MC; Way, M; Sakai, J; Matsudaira, P			Characterization of the actin cross-linking properties of the scruin-calmodulin complex from the acrosomal process of Limulus sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; FILAMENT; ENCODES; OVERLAY; BUNDLE; CELLS; GENE	During activation of the Limulus sperm acrosomal process, actin filaments undergo a change in twist that is linked with the conversion from a coiled to a straight scruin actin bundle. Since scruin had not been purified, its identity as an actin-binding protein has not been demonstrated. Using HECAMEG (methyl-6-O-(N-heptylcarbamoyl)-alpha-D-glucopyranoside) detergent extraction in concert with high calcium, we purified native scruin and identified it as an equimolar complex with calmodulin, I-125-Calmodulin overlays and calmodulin-Sepharose indicate that scruin binds calmodulin in calcium but not in EGTA. Overlay experiments also map the calmodulin binding site between the putative N- and C-terminal beta-propeller domains within residues 425-446. Immunofluorescence microscopy reveals that calmodulin colocalizes with scruin and actin in the coiled bundle. Although scruin binds calmodulin, pelleting assays and electron microscopy show that the scruin cross-links F-actin into bundles independently of calcium. Based on our biochemical and structural studies, we suggest a model to explain how scruin controls a change in twist of actin filaments during the acrosome reaction, We predict that calcium subtly alters scruin conformation through its calmodulin subunit and the conformation change in scruin causes a shift in the relative positions of the scruin-bound actin subunits.	MIT, WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)			Matsudaira, Paul/H-1475-2012	Matsudaira, Paul/0000-0002-8399-3276; Way, Michael/0000-0001-7207-2722	NATIONAL CANCER INSTITUTE [R01CA055621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052703] Funding Source: NIH RePORTER; NCI NIH HHS [CA55621] Funding Source: Medline; NIGMS NIH HHS [GM52703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BORK P, 1994, J MOL BIOL, V236, P1277, DOI 10.1016/0022-2836(94)90056-6; BULLITT ESA, 1988, J CELL BIOL, V107, P597, DOI 10.1083/jcb.107.2.597; CHANGYEH A, 1991, NUCLEIC ACIDS RES, V19, P3667, DOI 10.1093/nar/19.13.3667; DEROSIER D, 1980, J MOL BIOL, V137, P375, DOI 10.1016/0022-2836(80)90163-1; DEROSIER DJ, 1982, J CELL BIOL, V93, P324, DOI 10.1083/jcb.93.2.324; FLANAGAN SD, 1984, ANAL BIOCHEM, V140, P510, DOI 10.1016/0003-2697(84)90202-1; GLENNEY JR, 1983, METHOD ENZYMOL, V102, P204; GOMES AV, 1994, BIOESSAYS, V16, P853, DOI 10.1002/bies.950161113; GOPALAKRISHNA R, 1982, BIOCHEM BIOPH RES CO, V104, P830, DOI 10.1016/0006-291X(82)90712-4; HOWE CL, 1983, J CELL BIOL, V97, P974, DOI 10.1083/jcb.97.4.974; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; MASSUNG RF, 1994, VIROLOGY, V201, P215, DOI 10.1006/viro.1994.1288; MATSUDAIRA P, 1992, P73; OWEN C, 1993, J CELL BIOL, V123, P337, DOI 10.1083/jcb.123.2.337; Sambrook J, 1989, MOL CLONING LABORATO; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; SCHMID MF, 1991, J MOL BIOL, V221, P711, DOI 10.1016/0022-2836(91)80082-6; SCHMID MF, 1995, BIOPHYS J, V68, pS8; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; TILNEY LG, 1979, J CELL BIOL, V81, P229, DOI 10.1083/jcb.81.1.229; TILNEY LG, 1975, J CELL BIOL, V64, P289, DOI 10.1083/jcb.64.2.289; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; WAY M, 1995, J CELL SCI, V108, P3155; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9	24	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2651	2657		10.1074/jbc.271.5.2651	http://dx.doi.org/10.1074/jbc.271.5.2651			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576236	hybrid			2022-12-25	WOS:A1996TT48800050
J	Xu, C; Shi, WP; Rosen, BP				Xu, C; Shi, WP; Rosen, BP			The chromosomal arsR gene of Escherichia coli encodes a trans-acting metalloregulatory protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARSENICAL RESISTANCE OPERON; STAPHYLOCOCCUS-AUREUS; ANION PUMP; EXPRESSION; ARSENATE; IDENTIFICATION; CONSTRUCTION	Plasmid-encoded arsenical resistance (ars) operons confer high level resistance to arsenicals and antimonials, while the chromosomally encoded ars operon of Escherichia coli bestows low level resistance. The transcriptional start site of the chromosomal ars mRNA was mapped by primer extension, and putative -10 and -35 promoter recognition sites were identified. The arsR gene, the first gene in this operon, was cloned using polymerase chain reaction. The arsR gene product, the ArsR repressor, was expressed and purified. The results of gel mobility shift assays indicated that the repressor is a DNA binding protein that binds to a fragment of DNA containing the chromosomal ars promoter. The specific binding site, as determined by DNase I footprint analysis, spans 33 nucleotides in the promoter region, including the putative -35 promoter element. By construction and expression of a series of in-frame fusions between truncated arsR genes and the coding region for the mature form of beta-lactamase (blaM'), it was shown that ArsR is a trans-acting repressor that regulates expression of the chromosomal ars operon. In addition, the chromosomally-encoded repressor can regulate expression of the ars operon of plasmid R773, and the R773 repressor can cross-regulate expression from the chromosomal operon.	WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,DETROIT,MI 48201	Wayne State University				Rosen, Barry P./0000-0002-5230-4271	NIAID NIH HHS [AI19793] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019793] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROOMESMITH JK, 1986, GENE, V49, P341, DOI 10.1016/0378-1119(86)90370-7; CARLIN A, 1995, J BACTERIOL, V177, P981, DOI 10.1128/jb.177.4.981-986.1995; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CHEN CM, 1986, J BIOL CHEM, V261, P5030; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; DEY S, 1995, DRUG TRANSPORT ANTIM, P103; DIORIO C, 1995, J BACTERIOL, V177, P2050, DOI 10.1128/jb.177.8.2050-2056.1995; HEDGES RW, 1973, J BACTERIOL, V115, P459, DOI 10.1128/JB.115.1.459-460.1973; HOFFMAN RD, 1992, J BIOL CHEM, V267, P14005; IVEY DM, 1992, J BACTERIOL, V174, P4878, DOI 10.1128/JB.174.15.4878-4884.1992; JI GY, 1992, J BACTERIOL, V174, P3684, DOI 10.1128/JB.174.11.3684-3694.1992; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOBLEY HLT, 1984, ANTIMICROB AGENTS CH, V25, P157, DOI 10.1128/AAC.25.2.157; MORBY AP, 1993, NUCLEIC ACIDS RES, V21, P921, DOI 10.1093/nar/21.4.921; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; ROSEN BP, 1995, J BIOENERG BIOMEMBR, V27, P85, DOI 10.1007/BF02110335; ROSENSTEIN R, 1992, J BACTERIOL, V174, P3676, DOI 10.1128/JB.174.11.3676-3683.1992; ROSENSTEIN R, 1994, MOL GEN GENET, V242, P566, DOI 10.1007/BF00285280; Sambrook J, 1989, MOL CLONING LABORATO; SANFRANCISCO MJD, 1990, NUCLEIC ACIDS RES, V18, P619; SHI WP, 1994, J BIOL CHEM, V269, P19826; SILVER S, 1981, J BACTERIOL, V146, P983, DOI 10.1128/JB.146.3.983-996.1981; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TISA LS, 1990, J BIOL CHEM, V265, P190; WU J, 1991, MOL MICROBIOL, V5, P1331, DOI 10.1111/j.1365-2958.1991.tb00779.x; WU JH, 1993, J BIOL CHEM, V268, P52; YOON KP, 1991, J BACTERIOL, V173, P7643, DOI 10.1128/jb.173.23.7643-7649.1991	28	99	103	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2427	2432		10.1074/jbc.271.5.2427	http://dx.doi.org/10.1074/jbc.271.5.2427			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576202	hybrid			2022-12-25	WOS:A1996TT48800016
J	Galvan, A; Quesada, A; Fernandez, E				Galvan, A; Quesada, A; Fernandez, E			Nitrate and nitrite are transported by different specific transport systems and by a bispecific transporter in Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM SYNECHOCOCCUS PCC-7942; ASPERGILLUS-NIDULANS; GENE-CLUSTER; REDUCTASE; KINETICS; ASSIMILATION; ENCODES; AMMONIUM; MUTANTS; BARLEY	Nitrate transport mutants from Chlamydomonas reinhardtii and strains derived from them upon transformation with plasmids containing the C. reinhardtii nar2/Nrt2;1 or nar2/Nrt2;2 genes have been used to study nitrate and nitrite transport systems. Mutants lacking nitrate assimilation clustered genes showed a high affinity nitrite transporter activity (system 3), which was subject to ammonium inhibition and appeared to be independent of a functional nar2 gene. Transformants carrying nar2/Nrt2;2 recovered a high affinity nitrate transporter activity (system 2) and showed nitrite transport activities with properties similar 60 those in nontransformed cells. Transformants carrying nar2/Nrt2;1 recovered high affinity nitrate transporter activity (system 1) together with a considerably enhanced nitrite transport activity. Nitrite transport mediated by system 1 was very sensitive to inhibition by nitrate at mu M concentrations. Results strongly suggest that three nitrate assimilation related high affinity transport systems operate in C. reinhardtii: one specific for nitrite, a second one encoded by nar2/Nrt2;2 specific for nitrate, and another one encoded by nar2/Nrt2;1, which is bispecific for these two anions.	UNIV CORDOBA, FAC CIENCIAS, DEPT BIOQUIM & BIOL MOLEC, E-14071 CORDOBA, SPAIN	Universidad de Cordoba			Quesada, Alberto/H-2609-2015; Fernandez, Emilio/H-2892-2015; Galvan Cejudo, Aurora/A-9483-2010	Quesada, Alberto/0000-0001-9952-977X; Galvan Cejudo, Aurora/0000-0002-7564-2281; Fernandez Reyes, Emilio/0000-0001-5957-5392				ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; CABOCHE M, 1994, PLANT MOL BIOL REP, V12, P45; CORDOBA F, 1986, PLANT PHYSIOL, V82, P904, DOI 10.1104/pp.82.4.904; CORDOBA F, 1987, BIOCHIM BIOPHYS ACTA, V902, P287, DOI 10.1016/0005-2736(87)90196-9; CRAWFORD NM, 1993, ANNU REV GENET, V27, P115, DOI 10.1146/annurev.ge.27.120193.000555; DODDEMA H, 1979, PHYSIOL PLANTARUM, V45, P332, DOI 10.1111/j.1399-3054.1979.tb02593.x; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERNANDEZ E, 1984, CURR GENET, V8, P635, DOI 10.1007/BF00395710; FERNANDEZ E, 1989, P NATL ACAD SCI USA, V86, P6449, DOI 10.1073/pnas.86.17.6449; FLORENCIO FJ, 1983, PLANTA, V158, P288, DOI 10.1007/BF00397329; FLORES E, 1987, BIOCHIM BIOPHYS ACTA, V896, P103, DOI 10.1016/0005-2736(87)90361-0; GALVAN A, 1992, PLANT PHYSIOL, V98, P422, DOI 10.1104/pp.98.2.422; GLASS ADM, 1992, PLANT PHYSIOL, V99, P456, DOI 10.1104/pp.99.2.456; GUERRERO MG, 1981, ANNU REV PLANT PHYS, V32, P169, DOI 10.1146/annurev.pp.32.060181.001125; HARRIS EH, 1989, CHLAMYDOMONAS SOURCE, P419; HOFF T, 1994, PLANT CELL ENVIRON, V17, P489, DOI 10.1111/j.1365-3040.1994.tb00145.x; HOLE DJ, 1990, PLANT PHYSIOL, V93, P642, DOI 10.1104/pp.93.2.642; JOHNSTONE IL, 1990, GENE, V90, P181, DOI 10.1016/0378-1119(90)90178-T; KINDLE KL, 1989, J CELL BIOL, V109, P2589, DOI 10.1083/jcb.109.6.2589; LEVINE RP, 1960, ANNU REV MICROBIOL, V14, P197, DOI 10.1146/annurev.mi.14.100160.001213; LUQUE I, 1994, BBA-BIOENERGETICS, V1184, P296, DOI 10.1016/0005-2728(94)90236-4; MERCHAN F, 1995, PLANT MOL BIOL, V28, P759, DOI 10.1007/BF00021199; OMATA T, 1989, P NATL ACAD SCI USA, V86, P6612, DOI 10.1073/pnas.86.17.6612; OMATA T, 1993, MOL GEN GENET, V236, P193, DOI 10.1007/BF00277112; OMATA T, 1991, PLANT CELL PHYSIOL, V32, P151, DOI 10.1093/oxfordjournals.pcp.a078059; PRIETO R, 1993, MOL GEN GENET, V237, P429, DOI 10.1007/BF00279448; QUESADA A, 1994, PLANT MOL BIOL, V24, P185, DOI 10.1007/BF00040584; QUESADA A, 1994, PLANT J, V5, P407, DOI 10.1111/j.1365-313X.1994.00407.x; QUESADA A, 1993, MOL GEN GENET, V240, P387, DOI 10.1007/BF00280390; RANUM LPW, 1988, GENETICS, V120, P109; SIDDIQI MY, 1990, PLANT PHYSIOL, V93, P1426, DOI 10.1104/pp.93.4.1426; Snell FD, 1949, COLORIMETRIC METHODS, P804; SUEOKA N, 1967, J MOL BIOL, V25, P47, DOI 10.1016/0022-2836(67)90278-1; TSAY YF, 1993, CELL, V72, P705, DOI 10.1016/0092-8674(93)90399-B; UNKLES SE, 1991, P NATL ACAD SCI USA, V88, P204, DOI 10.1073/pnas.88.1.204; VANWINKLESWIFT KP, 1977, J PHYCOL, V13, P225; WATT DA, 1992, J EXP BOT, V43, P605, DOI 10.1093/jxb/43.5.605	37	86	90	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2088	2092		10.1074/jbc.271.4.2088	http://dx.doi.org/10.1074/jbc.271.4.2088			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567664				2022-12-25	WOS:A1996TR32000046
J	Giorgi, LB; Nixon, PJ; Merry, SAP; Joseph, DM; Durrant, JR; Rivas, JD; Barber, J; Porter, G; Klug, DR				Giorgi, LB; Nixon, PJ; Merry, SAP; Joseph, DM; Durrant, JR; Rivas, JD; Barber, J; Porter, G; Klug, DR			Comparison of primary charge separation in the photosystem II reaction center complex isolated from wild-type and D1-130 mutants of the cyanobacterium Synechocystis PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC REACTION CENTER; PICOSECOND FLUORESCENCE KINETICS; MANGANESE CLUSTER; RADICAL PAIR; D1; POLYPEPTIDE-D1; ASPARTATE-170; STABILITY; ENERGY; B-559	We compare primary charge separation in a photosystem II reaction center preparation isolated from a wildtype (WT) control strain of the cyanobacterium Synechocystis sp. PCC 6803 and from two site-directed mutants of Synechocystis in which residue 130 of the D1 polypeptide has been changed from a glutamine to either a glutamate (mutant D1-Gln130Glu), as in higher plant sequences, or a leucine residue (mutant D1 Gln130Leu). The D1-130 residue is thought to be close to the pheophytin electron acceptor. We show that, when P680 is photoselectively excited, the primary radical pair state P680(+)Ph(-) is formed with a time constant of 20-30 ps in the WT and both mutants; this time constant is very similar to that observed in Pisum sativum (a higher plant). We also show that a change in the residue at position D1-130 causes a shift in the peak of the pheophytin Q(x)-band. Nanosecond and picosecond transient absorption measurements indicate that the quantum yield of radical pair formation (phi(RP)), associated with the 20-30-ps component, is affected by the identity of the D1-130 residue. We find that, for the isolated photosystem II reaction center particle, phi(RP higher plant) > phi(RP D1-Gln130Glu mutant) > phi(RP WT) > phi(RP D1-Gln130Leu mutant). Furthermore, the spectroscopic and quantum yield differences we observe between the WT Synechocystis and higher plant photosystem II, seem to be reversed by mutating the D1-130 ligand so that it is the same as in higher plants. This result is consistent with the previously observed natural regulation of quantum yield in Synechococcus PS II by particular changes in the D1 polypeptide amino acid sequence (Clark, A. K., Hurry, V, M., Gustafsson, P.. and Oquist, G. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 11985-11989).	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, CTR PHOTOMOLEC SCI, PHOTOSYNTH GRP, LONDON SW7 2AY, ENGLAND; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT CHEM, LONDON SW7 2AY, ENGLAND	Imperial College London; Imperial College London	Giorgi, LB (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, CTR PHOTOMOLEC SCI, MOLEC DYNAM GRP, LONDON SW7 2AY, ENGLAND.		Durrant, James R/A-6198-2009; Klug, David R/F-3357-2011; De Las Rivas, Javier/G-5936-2014	Durrant, James R/0000-0001-8353-7345; Klug, David R/0000-0001-9301-1654; De Las Rivas, Javier/0000-0002-0984-9946; Nixon, Peter/0000-0003-1952-6937				ALIZADEH S, 1995, PHOTOSYNTH RES, V43, P165, DOI 10.1007/BF00042974; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BOERNER RJ, 1992, BIOCHEMISTRY-US, V31, P6660, DOI 10.1021/bi00144a005; BOOTH PJ, 1990, BIOCHIM BIOPHYS ACTA, V1016, P141, DOI 10.1016/0005-2728(90)90053-7; BOOTH PJ, 1991, BIOCHEMISTRY-US, V30, P7573, DOI 10.1021/bi00244a029; BYLINA EJ, 1988, NATURE, V336, P182, DOI 10.1038/336182a0; CHAPMAN DJ, 1989, PHOTOSYNTHETICA, V23, P411; CHAPMAN DJ, 1991, METHODS PLANT BIOCH, P171; CLARKE AK, 1993, P NATL ACAD SCI USA, V90, P11985, DOI 10.1073/pnas.90.24.11985; CRYSTALL B, 1989, FEBS LETT, V249, P75, DOI 10.1016/0014-5793(89)80019-5; DANIELIUS RV, 1987, FEBS LETT, V213, P241, DOI 10.1016/0014-5793(87)81498-9; DURRANT JR, 1992, P NATL ACAD SCI USA, V89, P11632, DOI 10.1073/pnas.89.23.11632; DURRANT JR, 1993, BIOCHEMISTRY-US, V32, P8259, DOI 10.1021/bi00083a029; GIORGI LB, 1994, BBA-BIOENERGETICS, V1186, P247, DOI 10.1016/0005-2728(94)90185-6; GOUNARIS K, 1989, BIOCHIM BIOPHYS ACTA, V973, P296, DOI 10.1016/S0005-2728(89)80435-9; GOUNARIS K, 1990, FEBS LETT, V265, P88, DOI 10.1016/0014-5793(90)80890-U; HASTINGS G, 1992, BIOCHEMISTRY-US, V31, P7638, DOI 10.1021/bi00148a027; KIRILOVSKY DL, 1992, BIOCHEMISTRY-US, V31, P2099, DOI 10.1021/bi00122a030; KLUG DR, 1995, CHEM PHYS, V194, P433, DOI 10.1016/0301-0104(95)00037-O; KOBAYASHI M, 1990, FEBS LETT, V260, P138, DOI 10.1016/0014-5793(90)80086-X; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; MATHIS P, 1989, FEBS LETT, V251, P241, DOI 10.1016/0014-5793(89)81462-0; MICHEL H, 1988, BIOCHEMISTRY-US, V27, P1, DOI 10.1021/bi00401a001; MIYAZAKI A, 1989, BIOCHIM BIOPHYS ACTA, V975, P142, DOI 10.1016/S0005-2728(89)80212-9; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P10859, DOI 10.1021/bi00159a029; NIXON PJ, 1992, BIOCHEMISTRY-US, V31, P942, DOI 10.1021/bi00118a041; NIXON PJ, 1994, 2ND P BBSRC R HILL S, P8; ORENSHAMIR M, 1995, BIOCHEMISTRY-US, V34, P5523, DOI 10.1021/bi00016a025; PAKRASI HB, 1992, PHOTOSYSTEMS STRUCTU, P231; RECH T, 1994, BIOCHEMISTRY-US, V33, P14768, DOI 10.1021/bi00253a015; ROELOFS TA, 1993, BIOCHIM BIOPHYS ACTA, V1143, P147, DOI 10.1016/0005-2728(93)90137-5; ROELOFS TA, 1991, BIOCHIM BIOPHYS ACTA, V1060, P237, DOI 10.1016/S0005-2728(05)80312-3; ROFFEY RA, 1991, P NATL ACAD SCI USA, V88, P9122, DOI 10.1073/pnas.88.20.9122; SEIBERT M, 1988, PLANT PHYSIOL, V87, P303, DOI 10.1104/pp.87.2.303; Seibert M, 1993, PHOTOSYNTHETIC REACT, VI, P319, DOI DOI 10.1016/B978-0-12-208661-8.50016-4; SVENSSON B, 1991, Z NATURFORSCH C, V46, P765; TAKAHASHI Y, 1987, BIOCHIM BIOPHYS ACTA, V893, P49, DOI 10.1016/0005-2728(87)90147-2; VACHA F, 1995, P NATL ACAD SCI USA, V92, P2929, DOI 10.1073/pnas.92.7.2929; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; ZHANG L, 1992, J BIOL CHEM, V267, P19054	40	63	65	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2093	2101		10.1074/jbc.271.4.2093	http://dx.doi.org/10.1074/jbc.271.4.2093			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567665	hybrid			2022-12-25	WOS:A1996TR32000047
J	Paul, P; Kamisaka, Y; Marks, DL; Pagano, RE				Paul, P; Kamisaka, Y; Marks, DL; Pagano, RE			Purification and characterization of UDPP-glucose:ceramide glucosyltransferase from rat liver Golgi membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED FIBROBLASTS; GLUCOSYLCERAMIDE SYNTHESIS; SPHINGOLIPID METABOLISM; PLASMA-MEMBRANE; SPHINGOMYELIN; APPARATUS; ACCEPTORS; TOPOLOGY; CELLS; ASSAY	We present a method for solubilizing and purifying UDP-Glc:ceramide glucosyltransferase (EC 2.4.1.80; glucosylceramide synthase (GCS)) from rat liver and present data on its substrate specificity. A Golgi membrane fraction was isolated, washed with N-lauroylsarcosine, and subsequently treated with 3[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate to solubilize the enzyme. GCS activity was monitored throughout purification using UDP-Glc and a fluorescent ceramide analog as substrates. Purification of GCS was achieved via a two-step dye-agarose chromatography procedure using UDP-Glc to elute the enzyme. This resulted in an enrichment >10,000-fold relative to the starting homogenate. The enzyme was further characterized by sedimentation on a glycerol gradient, I-125 labeling, and SDS-polyacrylamide gel electrophoresis, which demonstrated that two polypeptides (60-70 kDa) corresponded closely with GCS activity. Purified GCS was found to require exogenous phospholipids for activity, and optimal results were obtained using dioleoyl phosphatidylcholine. Studies of the substrate specificity of the purified enzyme demonstrated that it was stereospecific and dependent on the nature and chain length of the N-acyl-sphingosine or -sphinganine substrate. UDP-Glc was the preferred hexose donor, but TDP-glucose and CDP-glucose were also efficiently used. This study provides a basis for molecular characterization of this key enzyme in glycosphingolipid biosynthesis.	MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA	Mayo Clinic					NIGMS NIH HHS [R37GM22942] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM022942] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON G, 1987, LYSOSOMES THEIR ROLE, P61; BALCH WE, 1985, ARCH BIOCHEM BIOPHYS, V240, P413, DOI 10.1016/0003-9861(85)90046-3; BALLOU LR, 1992, IMMUNOL TODAY, V13, P339, DOI 10.1016/0167-5699(92)90167-6; BARPELED M, 1991, J BIOL CHEM, V266, P20953; BASU S, 1968, J BIOL CHEM, V243, P5802; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BERGERON JJM, 1982, J CELL BIOL, V92, P139, DOI 10.1083/jcb.92.1.139; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRETZ R, 1977, EUR J BIOCHEM, V77, P181, DOI 10.1111/j.1432-1033.1977.tb11656.x; CESTELLI A, 1979, BIOCHIM BIOPHYS ACTA, V572, P283, DOI 10.1016/0005-2760(79)90043-2; COSTANTINOCECCARINI E, 1975, ARCH BIOCHEM BIOPHYS, V167, P646, DOI 10.1016/0003-9861(75)90508-1; COSTE H, 1986, BIOCHIM BIOPHYS ACTA, V858, P6, DOI 10.1016/0005-2736(86)90285-3; DURIEUX I, 1990, INT J BIOCHEM, V22, P709, DOI 10.1016/0020-711X(90)90005-N; FRY DW, 1978, ANAL BIOCHEM, V90, P809, DOI 10.1016/0003-2697(78)90172-0; FUTERMAN AH, 1992, METHOD ENZYMOL, V209, P437; FUTERMAN AH, 1991, BIOCHEM J, V280, P295, DOI 10.1042/bj2800295; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GOLD P, 1983, J BIOL CHEM, V258, P2967; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HAGA T, 1977, J BIOL CHEM, V252, P5776; HAKOMORI S, 1994, PROG BRAIN RES, V101, P241; HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.iy.02.040184.000535; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HOLMES EH, 1987, J BIOCHEM-TOKYO, V101, P1095, DOI 10.1093/oxfordjournals.jbchem.a121974; ICHIKAWA S, 1994, P NATL ACAD SCI USA, V91, P2703, DOI 10.1073/pnas.91.7.2703; ICHIKAWA S, 1996, IN PRESS P NATL ACAD; INOKUCHI JI, 1987, J LIPID RES, V28, P565; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; JECKEL D, 1990, FEBS LETT, V261, P155, DOI 10.1016/0014-5793(90)80659-7; KANFER JN, 1983, HDB LIPID RES, V3, P167; KISHIMOTO Y, 1983, ENZYMES, P357; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KOVAL M, 1989, J CELL BIOL, V108, P2169, DOI 10.1083/jcb.108.6.2169; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN JM, 1991, J CELL SCI, V98, P205; LIPSKY NG, 1983, P NATL ACAD SCI-BIOL, V80, P2608, DOI 10.1073/pnas.80.9.2608; LIPSKY NG, 1985, J CELL BIOL, V100, P27, DOI 10.1083/jcb.100.1.27; LOWE CR, 1981, INT J BIOCHEM, V13, P33, DOI 10.1016/0020-711X(81)90133-6; MATERN H, 1990, EUR J BIOCHEM, V190, P99, DOI 10.1111/j.1432-1033.1990.tb15551.x; MERRILL AH, 1989, BIOCHIM BIOPHYS ACTA, V1010, P131, DOI 10.1016/0167-4889(89)90152-3; NESKOVIC NM, 1974, BIOCHIM BIOPHYS ACTA, V334, P301; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PAGANO RE, 1988, BIOCHEMISTRY-US, V27, P4439, DOI 10.1021/bi00412a034; RADIN NS, 1993, ADV LIPID RES, V26, P183; RIDGWAY ND, 1995, BBA-LIPID LIPID MET, V1256, P57, DOI 10.1016/0005-2760(95)00010-A; SCHMID G, 1982, EUR J BIOCHEM, V123, P363, DOI 10.1111/j.1432-1033.1982.tb19776.x; SCHNAAR R L, 1991, Glycobiology, V1, P477, DOI 10.1093/glycob/1.5.477; SCHWARZMANN G, 1987, METHOD ENZYMOL, V138, P319; STELLWAGEN E, 1990, METHOD ENZYMOL, V182, P343; SWEELEY CC, 1991, BIOCH LIPIDS LIPOPRO, P327; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VUNNAM RR, 1979, BIOCHIM BIOPHYS ACTA, V573, P73, DOI 10.1016/0005-2760(79)90174-7; WOJCIECHOWSKI ZA, 1979, BIOCHIM BIOPHYS ACTA, V570, P363, DOI 10.1016/0005-2744(79)90156-6	55	65	69	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2287	2293		10.1074/jbc.271.4.2287	http://dx.doi.org/10.1074/jbc.271.4.2287			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567691	hybrid			2022-12-25	WOS:A1996TR32000073
J	Straub, SG; Sharp, GWG				Straub, SG; Sharp, GWG			A wortmannin-sensitive signal transduction pathway is involved in the stimulation of insulin release by vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; NEUTROPHIL ACTIVATION; GLUCAGON-SECRETION; PEPTIDE; RAT; KINASE; CELLS; PANCREAS; RECEPTOR; PHOSPHORYLATION	Vasoactive intestinal polypeptide (VIP), pituitary adenylate cyclase-activating polypeptide-27 (PACAP-27), and PACAP-38 stimulated insulin release with EC(50) values of 0.15, 0.15, and 0.06 nM respectively, as expected for the VIP2/PACAP3 receptor subtype, Secretion was stimulated promptly and peaked at 6-10 min, At 30 min, the secretion rate was still 2-3-fold higher than the control rate, The peptides increased cyclic AMP and [Ca2+](i) transiently so that at 30 min they had returned to control values, Therefore, an additional signal is required to explain the prolonged stimulation of release, The prolonged effects, but not the acute effects of VIP and PACAP on insulin release were inhibited by low concentrations of wortmannin, a phosphatidylinositol 3-kinase (PI 3-kinase) inhibitor. While wortmannin inhibited PI 3-kinase activity in cell lysates, no activation by the peptides was seen, Therefore, the wortmannin-sensitive pathway is either dependent on basal PI 3-kinase activity, or another target for wortmannin is responsible for inhibition of the peptide-stimulated secretion, It is concluded that the acute stimulation of insulin release by VIP and PACAP is mediated by increased cyclic AMP and [Ca2+](i), whereas the sustained release is mediated by a novel wortmannin-sensitive pathway.			Straub, SG (corresponding author), CORNELL UNIV,COLL VET MED,DEPT PHARMACOL,ITHACA,NY 14853, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042063] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 42063] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE H, 1985, ENDOCRINOLOGY, V116, P1383, DOI 10.1210/endo-116-4-1383; ABSOOD A, 1992, REGUL PEPTIDES, V40, P323, DOI 10.1016/0167-0115(92)90519-Z; ANDERSSON M, 1992, REGUL PEPTIDES, V40, P41, DOI 10.1016/0167-0115(92)90082-6; ARIMURA A, 1992, REGUL PEPTIDES, V37, P287; BISHOP AE, 1980, DIABETOLOGIA, V18, P73, DOI 10.1007/BF01228307; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CARRASCOMARIN E, 1994, EUR J IMMUNOL, V24, P2031, DOI 10.1002/eji.1830240915; DEWALD B, 1988, J BIOL CHEM, V263, P16179; FAHRENKRUG J, 1993, PHARMACOL TOXICOL, V72, P354, DOI 10.1111/j.1600-0773.1993.tb01344.x; FRIDOLF T, 1992, CELL TISSUE RES, V269, P275, DOI 10.1007/BF00319618; GOEKE R, 1988, Molecular and Cellular Endocrinology, V60, P211; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KAWAI K, 1992, LIFE SCI, V50, P257, DOI 10.1016/0024-3205(92)90332-J; KIMURA C, 1990, BIOCHEM BIOPH RES CO, V166, P81, DOI 10.1016/0006-291X(90)91914-E; KOH SWM, 1991, BIOCHEM BIOPH RES CO, V174, P452, DOI 10.1016/0006-291X(91)91437-H; LAURENZA A, 1989, TRENDS PHARMACOL SCI, V10, P442, DOI 10.1016/S0165-6147(89)80008-2; LEECH CA, 1995, ENDOCRINOLOGY, V136, P1530, DOI 10.1210/en.136.4.1530; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; MIYATA A, 1990, BIOCHEM BIOPH RES CO, V170, P643, DOI 10.1016/0006-291X(90)92140-U; MUNGAN Z, 1991, PEPTIDES, V12, P559, DOI 10.1016/0196-9781(91)90101-T; NAKANISHI S, 1994, J BIOL CHEM, V269, P6528; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; POWIS G, 1994, CANCER RES, V54, P2419; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; SAID SI, 1986, J ENDOCRINOL INVEST, V9, P191, DOI 10.1007/BF03348097; SCHEBALIN M, 1977, AM J PHYSIOL, V232, pE197, DOI 10.1152/ajpendo.1977.232.2.E197; SCHECTERSON LC, 1991, MOL ENDOCRINOL, V5, P170, DOI 10.1210/mend-5-2-170; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; TSIEN RY, 1982, J CELL BIOL, V94, P325, DOI 10.1083/jcb.94.2.325; USDIN TB, 1994, ENDOCRINOLOGY, V135, P2662, DOI 10.1210/en.135.6.2662; VLAHOS CJ, 1992, FEBS LETT, V309, P242, DOI 10.1016/0014-5793(92)80781-B; WAHL MA, 1993, DIABETOLOGIA, V36, P920, DOI 10.1007/BF02374473; WHEELER MB, 1993, ENDOCRINOLOGY, V133, P57, DOI 10.1210/en.133.1.57; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; YADA T, 1994, J BIOL CHEM, V269, P1290; YANO H, 1993, J BIOL CHEM, V268, P25846	41	87	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	1996	271	3					1660	1668		10.1074/jbc.271.3.1660	http://dx.doi.org/10.1074/jbc.271.3.1660			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TQ525	8576167	hybrid			2022-12-25	WOS:A1996TQ52500063
J	Licht, JD; Shaknovich, R; English, MA; Melnick, A; Li, JY; Reddy, JC; Dong, S; Chen, SJ; Zelent, A; Waxman, S				Licht, JD; Shaknovich, R; English, MA; Melnick, A; Li, JY; Reddy, JC; Dong, S; Chen, SJ; Zelent, A; Waxman, S			Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor-alpha chimera generated in t(11;17)-associated acute promyelocytic leukemia	ONCOGENE			English	Article						retinoid; transcription; leukemia; zinc finger	ZINC-FINGER; RAR-ALPHA; RESPONSE ELEMENT; CELL-LINE; BETA-GENE; PROTEIN; FUSION; PML; IDENTIFICATION; TRANSLOCATION	Acute promyelocytic leukemia (APL) associated with chromosomal rearrangement t(11;17) is a distinct syndrome which, unlike typical t(15;17) APL, fails to respond to all-trans retinoic acid (ATRA) therapy. In t(11;17) the PLZF gene, encoding a Kruppel-like zinc finger protein, is fused to the retinoic acid receptor-alpha (RAR alpha) gene, yielding two classes of chimeric proteins, PLZF protein was found in the nucleus in a punctate speckled pattern that differed from the nuclear body expression pattern of the PML protein affected in t(15;17) APL. The reciprocal PLZF-RAR alpha and RAR alpha-PLZF fusion proteins were localized to the nucleus both in the presence and absence of ATRA, PLZF-RAR alpha, in combination with the retinoid X receptor (RXR) bound to a retinoic acid-responsive element (RARE) less efficiently than RAR alpha and formed multimeric DNA-protein complexes. PLZF-RAR alpha stimulated ATRA-dependent transcription of RARE-containing reporter genes with diminished activity compared to wild-type RAR alpha, In addition, PLZF-RAR alpha antagonized the function of coexpressed wild-type RAR alpha, an effect relieved by over-expression of RXR. Leukemogenesis in t(11;17) APL may be related to interference with ATRA-mediated differentiation due to sequestration of RXR by the PLZF-RAR alpha chimera. However, disruption of the function of the myeloid-specific PLZF protein may also play an important role.	MT SINAI MED CTR,DEPT MED,NEW YORK,NY 10029; SHANGHAI MED UNIV 2,RUI JIN HOSP,SHANGHAI INST HEMATOL,SHANGHAI,PEOPLES R CHINA; CANC RES INST,LEUKEMIA RES FUND,LONDON SW3 6JB,ENGLAND; MT SINAI SCH MED,DIV NEOPLAST DIS,NEW YORK,NY 10029	Icahn School of Medicine at Mount Sinai; Shanghai Jiao Tong University; University of London; Institute of Cancer Research - UK; Icahn School of Medicine at Mount Sinai	Licht, JD (corresponding author), MT SINAI MED CTR,BROOKDALE CTR MOLEC BIOL,BOX 1126,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.		Zelent, Arthur/B-3532-2009; Melnick, Ari/AAA-5763-2020; Licht, Jonathan/L-4239-2019	Zelent, Arthur/0000-0002-7968-9888; Licht, Jonathan/0000-0002-3942-1369	NCI NIH HHS [CA 59936] Funding Source: Medline; NIGMS NIH HHS [T32GM07280-17] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007280] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BANERJEE R, 1992, P NATL ACAD SCI USA, V89, P9996, DOI 10.1073/pnas.89.21.9996; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHOMIENNE C, 1991, J CLIN INVEST, V88, P2150, DOI 10.1172/JCI115547; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; COREY SJ, 1994, LEUKEMIA, V8, P1350; DANIEL MT, 1993, BLOOD, V82, P1858; DEFRANCO C, 1993, BIOCHEM BIOPH RES CO, V194, P425, DOI 10.1006/bbrc.1993.1837; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; ELBARADI T, 1991, MECH DEVELOP, V35, P155, DOI 10.1016/0925-4773(91)90015-X; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; GRIGNANI F, 1995, CANCER RES, V55, P440; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GUIDEZ F, 1994, LEUKEMIA, V8, P312; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HARLOW E, 1988, ANTIBODIES LABORATOR; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KLIEWER SA, 1992, NATURE, V355, P441; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LANOTTE M, 1991, BLOOD, V77, P1080; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LI JY, 1994, BLOOD, V84, pA41; LICHT JD, 1994, MOL CELL BIOL, V14, P4057, DOI 10.1128/MCB.14.6.4057; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; MATSUGI T, 1990, MOL CELL BIOL, V10, P1259, DOI 10.1128/MCB.10.3.1259; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PUVION DF, 1995, EXP CELL RES, V218, P9; REDNER RL, 1994, BLOOD, V84, pA375; REID A, 1995, IN PRESS BLOOD; ROUSSELOT P, 1994, ONCOGENE, V9, P545; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; TERRIS B, 1995, CANCER RES, V55, P1590; TESTA U, 1994, CANCER RES, V54, P4508; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZECHEL C, 1994, EMBO J, V13, P1425, DOI 10.1002/j.1460-2075.1994.tb06396.x; ZELENT A, 1994, BRIT J HAEMATOL, V86, P451, DOI 10.1111/j.1365-2141.1994.tb04773.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	57	87	87	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					323	336						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570209				2022-12-25	WOS:A1996TR53800011
J	Weih, F; Lira, SA; Bravo, R				Weih, F; Lira, SA; Bravo, R			Overexpression of RelB in transgenic mice does not affect I kappa B alpha levels: Differential regulation of RelA and RelB by the inhibitor protein	ONCOGENE			English	Article						RelB; I kappa B alpha; transgenic mice	TRANSCRIPTION FACTORS; ACTIVATION; INTERACTS; ENCODES; FAMILY	In mouse lymphoid tissues, RelB heterodimers represent the constitutive kappa B-binding activity, whereas RelA and c-Rel complexes most likely are involved in inducible kappa B-binding and gene activation. Our laboratory has previously shown that the potential excess of NF-kappa B activity in transgenic mice overexpressing RelA is counteracted by a dramatic increase in I kappa B alpha, mainly due to its increased stability through association with RelA. As an attempt to elucidate the in vivo mechanisms that lead to the constitutive DNA-binding activity of RelB heterodimers, we have generated mouse lines overexpressing a relB transgene in a position-independent and copy number-dependent manner, Expression of RelB in these transgenic animals is very high in immature thymocytes and restricted to T cell areas in secondary lymphoid tissues, In contrast to the results obtained with RelA-transgenic thymocytes, we demonstrate here that overexpression of RelB results in a dramatic increase in overall kappa B-binding activity, Interestingly, I kappa B alpha protein levels are not altered in the RelB-transgenic animals, indicating that within the same cell type RelA and RelB complexes are differentially regulated by I kappa B alpha.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC ONCOL,PRINCETON,NJ 08543	Bristol-Myers Squibb								ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ALLEN JM, 1992, MOL CELL BIOL, V12, P2758, DOI 10.1128/MCB.12.6.2758; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIDONATO JA, 1993, MOL CELL BIOL, V13, P1572; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P1184; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GRILLI M, 1993, INT REV CYTOL, V143, P1; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; LANG G, 1991, NUCLEIC ACIDS RES, V19, P5851, DOI 10.1093/nar/19.21.5851; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LERNBECHER T, 1994, EMBO J, V13, P4069; LEWIS DB, 1991, J EXP MED, V173, P89, DOI 10.1084/jem.173.1.89; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WEIH F, 1994, ONCOGENE, V9, P3289; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0	40	21	21	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					445	449						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570223				2022-12-25	WOS:A1996TR53800025
J	Bokemeyer, D; Sorokin, A; Yan, MH; Ahn, NG; Templeton, DJ; Dunn, MJ				Bokemeyer, D; Sorokin, A; Yan, MH; Ahn, NG; Templeton, DJ; Dunn, MJ			Induction of mitogen-activated protein kinase phosphatase 1 by the stress-activated protein kinase signaling pathway but not by extracellular signal-regulated kinase in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; TYROSINE-PHOSPHATASE; 3CH134; CELLS	The intracellular mechanisms involved in the activation of extracellular signal-regulated kinase (ERK) are relatively well understood. However, the intracellular signaling pathways which regulate the termination of ERK activity remain to be elucidated. Mitogen-activated protein kinase phosphatase 1 (MKP-1) has been shown to dephosphorylate and inactivate ERK in vitro and in vivo. In the present study, we show in NIH3T3 fibroblasts that activation of the stress-activated protein kinase (SAPK) pathway by either specific extracellular stress stimuli or via induction of MEKK, an upstream kinase of SAPK, results in MKP-1 gene expression, In contrast, selective stimulation of the ERK pathway by 12-O-tetradecanoylphorbol-13-acetate or following expression of constitutively active MEK, the upstream dual specificity kinase of ERK did not induce the transcription of MKP-1, Hence, these findings demonstrate the existence of cross-talk between the ERK and SAPK signaling cascades since activation of SAPK induced the expression of MKP-1 that can inactivate ERK, This mechanism may modulate the cellular response to stimuli which employ the SAPK signal transduction pathway.	CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PHYSIOL,DIV NEPHROL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PATHOL,CLEVELAND,OH 44106; UNIV COLORADO,DEPT CHEM & BIOCHEM,HOWARD HUGHES MED INST,BOULDER,CO 80309	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder			Templeton, Dennis J/F-7695-2011	Sorokin, Andrey/0000-0002-5660-0190	NHLBI NIH HHS [HL 22563] Funding Source: Medline; NIDDK NIH HHS [DK 41684] Funding Source: Medline; NIGMS NIH HHS [GM 48521] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022563, R01HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048521] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHARLES CH, 1992, ONCOGENE, V7, P187; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DERRIJARD B, 1994, CELL, V76, P1025; DERRIJARD B, 1995, SCIENCE, V267, P682; DUFF JL, 1993, J BIOL CHEM, V268, P26037; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; HILL CS, 1995, CELL, V80, P190; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; YAN MH, 1994, NATURE, V372, P798	22	154	156	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					639	642		10.1074/jbc.271.2.639	http://dx.doi.org/10.1074/jbc.271.2.639			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557667	hybrid			2022-12-25	WOS:A1996TP88900010
J	Nanevicz, T; Wang, L; Chen, M; Ishii, M; Coughlin, SR				Nanevicz, T; Wang, L; Chen, M; Ishii, M; Coughlin, SR			Thrombin receptor activating mutations - Alteration of an extracellular agonist recognition domain causes constitutive signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOLYTIC MECHANISM; CELLS; SITE	Constitutively active thrombin receptors were generated while constructing chimeric receptors to identify the structural basis for thrombin receptor agonist specificity, Substitution of eight amino acids from the Xenopus receptor's second extracellular loop (XECL2B) for the cognate sequence in the human thrombin receptor was sufficient to confer robust constitutive activity, Smaller substitutions within the XECL2B site yielded less constitutive activation, and substitution of several unrelated sequences at this site caused no activation, Expression of the XECL2B receptor caused high basal Ca-45 efflux in Xenopus oocytes and high basal phosphoinositide hydrolysis and reporter gene induction in COS cells, Of note, a mutant receptor in which all four of the Xenopus thrombin receptor's extracellular segments replaced the cognate human sequences showed much less constitutive activity than XECL2B and preserved responsiveness to agonist, This partial complementation of the XECL2B phenotype by addition of other Xenopus extracellular structures suggests that the XECL2B mutation causes constitutive activation by altering interactions among the human receptor's extracellular domains, Thus, a change in an extracellular loop of a G protein-coupled receptor can transmit information across the cell membrane to cause signaling, perhaps via a conformational change similar to that caused by agonist binding, Indeed, the site of the activating mutation in XECL2B coincides with a putative agonist-docking site, supporting the hypothesis that agonist interactions with the thrombin receptor's extracellular loops contribute to receptor activation.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DAIICHI RES CTR, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044907] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44907, HL07731] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; DOHLMAN HG, 1992, ANNU REV BIOCHEM, V60, P651; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; Glantz SA., 2012, PRIMER BIOSTATISTICS, V7; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HU QJ, 1995, MOL CELL BIOL, V15, P1169; HUNG DT, 1992, J CELL BIOL, V116, P827, DOI 10.1083/jcb.116.3.827; ISHII K, 1994, J BIOL CHEM, V269, P1125; ISHII K, 1993, J BIOL CHEM, V268, P9780; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KOPP P, 1995, NEW ENGL J MED, V332, P150, DOI 10.1056/NEJM199501193320304; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; LEFKOWITZ RJ, 1993, J CLIN INVEST, V92, P2089, DOI 10.1172/JCI116806; NANEVICZ T, 1995, J BIOL CHEM, V270, P21619, DOI 10.1074/jbc.270.37.21619; PARIS S, 1986, EMBO J, V5, P55, DOI 10.1002/j.1460-2075.1986.tb04177.x; PASCHKE R, 1994, J CLIN ENDOCR METAB, V79, P1785, DOI 10.1210/jc.79.6.1785; PORCELLINI A, 1994, J CLIN ENDOCR METAB, V79, P657, DOI 10.1210/jc.79.2.657; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; SPIEGEL AM, 1993, J CLIN INVEST, V92, P1119, DOI 10.1172/JCI116680; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939	25	100	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					702	706		10.1074/jbc.271.2.702	http://dx.doi.org/10.1074/jbc.271.2.702			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557676	hybrid			2022-12-25	WOS:A1996TP88900019
J	Chapman, ER; An, S; Edwardson, JM; Jahn, R				Chapman, ER; An, S; Edwardson, JM; Jahn, R			A novel function for the second C2 domain of synaptotagmin - Ca2+-triggered dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLES; PROTEIN; BINDING; RELEASE; DOCKING; PATHWAY; FUSION; RAB3A; GAP	Synaptotagmin serves as the major Ca2+ sensor for regulated exocytosis from neurons. While the mechanism by which synaptotagmin regulates membrane fusion remains unknown, studies using Drosophila indicate that the molecule functions as a multimeric complex and that its second C2 domain is essential for efficient excitation-secretion coupling. Here we describe biochemical data that may account for these phenomena. We report that Ca2+ causes synaptotagmin to oligomerize, primarily forming dimers, via its second C2 domain. This effect is specific for divalent cations that can stimulate exocytosis of synaptic vesicles (Ca2+ >> Ba2+, Sr2+ >> > Mg2+) and occurs with an EC(50) value of 3-10 mu M Ca2+. In contrast, a separate Ca2+-dependent interaction between synaptotagmin and syntaxin, a component of the fusion apparatus, occurs with an EC(50) value of similar to 100 mu M Ca2+ and involves the synergistic action of both C2 domains of synaptotagmin. We propose that Ca2+ triggers two consecutive protein-protein interactions: the formation of synaptotagmin dimers at low Ca2+ concentrations followed by the association of synaptotagmin dimers with syntaxin at higher Ca2+ concentrations. Our findings, in conjunction with physiological studies, indicate that the Ca2+-induced dimerization of synaptotagmin is important for the efficient regulation of exocytosis by Ca2+.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT CELL BIOL,BOYER CTR MOL MED,NEW HAVEN,CT 06510; UNIV CAMBRIDGE,DEPT PHARMACOL,CAMBRIDGE CB2 1QJ,ENGLAND	Howard Hughes Medical Institute; Yale University; University of Cambridge	Chapman, ER (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT PHARMACOL,BOYER CTR MOL MED,NEW HAVEN,CT 06510, USA.			Jahn, Reinhard/0000-0003-1542-3498; Chapman, Edwin/0000-0001-9787-8140				AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BROADIE K, 1994, P NATL ACAD SCI USA, V91, P10727, DOI 10.1073/pnas.91.22.10727; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; CHAPMAN ER, 1994, J BIOL CHEM, V269, P5735; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CHAPMAN ER, 1995, J BIOL CHEM, V270, P23667, DOI 10.1074/jbc.270.40.23667; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GARCIA EP, 1995, J CELL BIOL, V129, P105, DOI 10.1083/jcb.129.1.105; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GODA Y, 1994, P NATL ACAD SCI USA, V91, P12942, DOI 10.1073/pnas.91.26.12942; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HILBUSH BS, 1994, P NATL ACAD SCI USA, V91, P8195, DOI 10.1073/pnas.91.17.8195; HUDSON AW, 1995, P NATL ACAD SCI USA, V92, P5895, DOI 10.1073/pnas.92.13.5895; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; LITTLETON JT, 1994, P NATL ACAD SCI USA, V91, P10888, DOI 10.1073/pnas.91.23.10888; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MIZUTA M, 1994, J BIOL CHEM, V269, P11675; NEHER E, 1994, NATURE, V372, P316, DOI 10.1038/372316a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; PERIN M, 1990, NATURE, V343, P260; PERIN MS, 1991, J BIOL CHEM, V266, P632; PETRENKO AG, 1991, NATURE, V353, P65, DOI 10.1038/353065a0; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	40	180	184	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5844	5849		10.1074/jbc.271.10.5844	http://dx.doi.org/10.1074/jbc.271.10.5844			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621455	hybrid			2022-12-25	WOS:A1996TZ28600081
J	Lande, MB; Jo, I; Zeidel, ML; Somers, M; Harris, HW				Lande, MB; Jo, I; Zeidel, ML; Somers, M; Harris, HW			Phosphorylation of aquaporin-2 does not alter the membrane water permeability of rat papillary water channel-containing vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; AMINO-ACID-SEQUENCE; ANTIDIURETIC-HORMONE; COLLECTING TUBULE; INTRINSIC PROTEIN; EXPRESSION; CLONING; KIDNEY; DOMAIN; LOCALIZATION	Antidiuretic hormone modulates the water permeability (P-f) of epithelial cells in the rat kidney by vesicle-mediated insertion and removal of the aquaporin-2 (AQP-2) water channel. AQP-2 possesses a single consensus cAMP-dependent protein kinase A (PKA) phosphorylation site (Ser-256) hypothesized to regulate channel P-f (Kuwahara, M., Fushimi, K., Terada, Y., Bai, L., Sasaki, S., and Marumo, F. (1995) J. Biol. Chem. 270, 10384-10387). To test whether PRA phosphorylation of AQP-2 alters channel P-f, we compared the P-f values of purified AQP-2 endosomes after incubation with either PKA or alkaline phosphatase. Studies using [gamma-P-32]ATP reveal that AQP-2 endosomes contain endogenous PKA and phosphatase activities that add and remove P-32 label from AQP-2. However, the P-f (0.16 +/- 0.06 cm/s) of endosomes containing phosphorylated AQP-2 (0.7 +/- 0.3 mol of PO4/mol of protein) is not significantly different from the same AQP-2 endosomes where 95 +/- 8% of the phosphate has been removed (P-f 0.14 +/- 0.06 cm/s). These data do not support a role for PKA phosphorylation in alteration of AQP-2's P-f. Instead, AQP-2 phosphorylation by PKA may modulate AQP-2's distribution between plasma membrane and intracellular vesicle compartments.	CHILDRENS HOSP, DIV NEPHROL, BOSTON, MA 02115 USA; UNIV PITTSBURGH, PRESBYTERIAN UNIV HOSP, DEPT MED, LAB EPITHELIAL CELL BIOL, PITTSBURGH, PA 15213 USA	Harvard University; Boston Children's Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; UPMC Presbyterian					NHLBI NIH HHS [HL15157] Funding Source: Medline; NIDDK NIH HHS [DK43955, DK38874] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043955, R01DK038874] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1993, AM J PHYSIOL, V265, pF463; BARSONY J, 1990, P NATL ACAD SCI USA, V87, P1188, DOI 10.1073/pnas.87.3.1188; BORGESE F, 1992, P NATL ACAD SCI USA, V89, P6765, DOI 10.1073/pnas.89.15.6765; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1992, J BIOL CHEM, V267, P13376; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; COGHLAN VM, 1995, SCIENCE, V268, P247; CORBIN JD, 1975, J BIOL CHEM, V250, P218; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; ECHEVARRIA M, 1993, J GEN PHYSIOL, V101, P827, DOI 10.1085/jgp.101.6.827; EHRING GR, 1992, J MEMBRANE BIOL, V126, P75; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HARRIS HW, 1994, J BIOL CHEM, V269, P11993; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; HAYASHI M, 1994, J CLIN INVEST, V94, P1778, DOI 10.1172/JCI117525; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; KENT NA, 1990, NUCLEIC ACIDS RES, V18, P4256, DOI 10.1093/nar/18.14.4256; KNEPPER MA, 1994, P NATL ACAD SCI USA, V91, P6255, DOI 10.1073/pnas.91.14.6255; KNEPPER MA, 1993, AM J PHYSIOL, V265, pF214, DOI 10.1152/ajprenal.1993.265.2.F214; KUWAHARA M, 1995, J BIOL CHEM, V270, P10384, DOI 10.1074/jbc.270.18.10384; LAMPE PD, 1990, EUR J BIOCHEM, V194, P541, DOI 10.1111/j.1432-1033.1990.tb15650.x; LENCER WI, 1990, AM J PHYSIOL, V258, pC309, DOI 10.1152/ajpcell.1990.258.2.C309; LEVITAN IB, 1988, ANNU REV NEUROSCI, V11, P119, DOI 10.1146/annurev.neuro.11.1.119; LI M, 1993, SCIENCE, V261, P1439, DOI 10.1126/science.8396273; MARPLES D, 1995, AM J PHYSIOL-CELL PH, V269, pC655, DOI 10.1152/ajpcell.1995.269.3.C655; MOE OW, 1995, J CLIN INVEST, V96, P2187, DOI 10.1172/JCI118273; NEILSEN S, 1994, J AM SOC NEPHROL, V5, P276; NEILSEN S, 1993, AM J PHYSIOL, V265, pF225; NIELSEN S, 1993, AM J PHYSIOL, V265, pF204, DOI 10.1152/ajprenal.1993.265.2.F204; NIELSEN S, 1993, AM J PHYSIOL, V265, pF225, DOI 10.1152/ajprenal.1993.265.2.F225; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; RUBIN CS, 1972, J BIOL CHEM, V247, P6135; RUBIN CS, 1979, J BIOL CHEM, V254, P3797; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; SASAKI S, 1994, J CLIN INVEST, V93, P1250, DOI 10.1172/JCI117079; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; STAR RA, 1988, J CLIN INVEST, V81, P1879, DOI 10.1172/JCI113534; STRANGE K, 1988, J MEMBRANE BIOL, V103, P17, DOI 10.1007/BF01871929; VERKMAN AS, 1992, ANNU REV PHYSIOL, V54, P97, DOI 10.1146/annurev.physiol.54.1.97; Wade J B, 1981, Ann N Y Acad Sci, V372, P106, DOI 10.1111/j.1749-6632.1981.tb15464.x; ZEIDEL ML, 1992, AM J PHYSIOL, V263, pF62, DOI 10.1152/ajprenal.1992.263.1.F62; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; ZELIKOVIC I, 1994, J AM SOC NEPHROL, V5, P738	46	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5552	5557		10.1074/jbc.271.10.5552	http://dx.doi.org/10.1074/jbc.271.10.5552			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621414	hybrid			2022-12-25	WOS:A1996TZ28600040
J	Ferguson, DJ; Krzycki, JA; Grahame, DA				Ferguson, DJ; Krzycki, JA; Grahame, DA			Specific roles of Methylcobamide:Coenzyme M methyltransferase isozymes in metabolism of methanol and methylamines in Methanosarcina barkeri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-MONOXIDE DEHYDROGENASE; ACETATE; METHYLATION; EXTRACTS	An immunochemical approach was employed as a direct test for functional activities of isozymes of methylcobamide:coenzyme M methyltransferase (MT2-M and MT2-A) in the metabolic pathways of methane formation from: methanol, acetate, monomethylamine, dimethylamine, and trimethylamine. Specific removal of the MT2 isozymes from buffer soluble cell extracts of Methano-sarcina barkeri was accomplished by use of immobilized, affinity-purified, ovine polyclonal antibodies. Extracts of methanol-grown cells depleted of MT2-M lost entirely the ability to carry out conversion of methanol to 2-(methylthio)ethanesulfonate (methyl-CoM). Methanol:CoM methyl transfer activity was completely restored by addition of purified MT2-M, but no activity was recovered by addition of MT2-A In contrast, the activity of trimethylamine-grown cell extracts to convert monomethylamine and dimethylamine to methyl-CoM was lost almost entirely by immunosorptive removal of MT2-A. Addition of purified MT2-A, but not MT2-M, to the MT2-A-depleted extract fully reconstituted methyl-CoM formation from both mono- and dimethylamine. Interestingly, in extracts resolved of MT2-A, trimethylamine-dependent methylation of coenzyme M was observed at approximately 20% of the rate of controls not treated with antibody. Furthermore, both isozymes were effective in full restoration of trimethylamine conversion. Tests indicated that neither of the two MT2 isozymes are involved in methane formation from acetate. The results establish that MT2-A plays a specific role in metabolism of methylated amine substrates, whereas, MT2-M functions in methane formation from trimethylamine and methanol.	OHIO STATE UNIV,DEPT MICROBIOL,COLUMBUS,OH 43210; UNIFORMED SERV UNIV HLTH SCI,DEPT BIOCHEM,BETHESDA,MD 20814	University System of Ohio; Ohio State University; Uniformed Services University of the Health Sciences - USA				Ferguson, Donald/0000-0002-0595-3033				BLAYLOCK BA, 1968, ARCH BIOCHEM BIOPHYS, V124, P314, DOI 10.1016/0003-9861(68)90333-0; BLAYLOCK BA, 1964, BIOCHEM BIOPH RES CO, V17, P475, DOI 10.1016/0006-291X(64)90049-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKE SA, 1995, J BACTERIOL, V177, P4410, DOI 10.1128/jb.177.15.4410-4416.1995; CAO XJ, 1991, J BACTERIOL, V173, P5439, DOI 10.1128/jb.173.17.5439-5448.1991; FERRY JG, 1992, CRIT REV BIOCHEM MOL, V27, P473, DOI 10.3109/10409239209082570; GRAHAME DA, 1991, J BIOL CHEM, V266, P22227; GRAHAME DA, 1989, J BIOL CHEM, V264, P12890; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HIPPE H, 1979, P NATL ACAD SCI USA, V76, P494, DOI 10.1073/pnas.76.1.494; KINCAID RL, 1988, METHOD ENZYMOL, V159, P627; KING GM, 1984, GEOMICROBIOL J, V3, P275, DOI 10.1080/01490458409377807; KRZYCKI JA, 1989, J BIOL CHEM, V264, P7217; NAUMANN E, 1984, ARCH MICROBIOL, V138, P79, DOI 10.1007/BF00425412; VANDERMEIJDEN P, 1984, J BACTERIOL, V160, P629, DOI 10.1128/JB.160.2.629-635.1984; YELISEEV A, 1993, ARCH MICROBIOL, V159, P530, DOI 10.1007/BF00249031; Zinder Stephen H., 1993, P128; ZYDOWSKY LD, 1987, J AM CHEM SOC, V109, P7922, DOI 10.1021/ja00259a073	18	61	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					5189	5194						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617801				2022-12-25	WOS:A1996TX69700091
J	Liu, H; Lightfoot, R; Stevens, JL				Liu, H; Lightfoot, R; Stevens, JL			Activation of heat shock factor by alkylating agents is triggered by glutathione depletion and oxidation of protein thiols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; STRESS RESPONSE; LIPID-PEROXIDATION; ABNORMAL PROTEINS; COVALENT BINDING; MAMMALIAN-CELLS; HSP70; OLIGOMERIZATION	Transcriptional activation of heat shock protein genes is a common response to proteotoxic stress. Many drugs and chemicals that form reactive electrophiles modify protein structure by binding covalently to nucleophilic functional groups. Although many of these agents also activate transcription of the inducible member of the hsp70 gene family, it is not clear if covalent modification of cellular proteins per se is sufficient. Iodoacetamide (IDAM) is a prototypical alkylating toxicant that induces hsp70 transcription. However, IDAM-induced cell death is indirectly linked to protein alkylation through depletion of glutathione, induction of oxidative stress, and increased lipid peroxidation. Therefore, we determined if any of these secondary cytotoxic events might lead to activation of hsp7O transcription. IDAM treatment increased hsp70 transcription by activating heat shock transcription factor-1 (HSF1). The addition of antioxidants and iron or calcium chelators prevented cell death but did not prevent hsp70 transcription or HSF1 activation. However, the protein synthesis inhibitor cycloheximide blocked activation of hsp70 by low concentrations of IDAM. Furthermore, the addition of dithiothreitol (DTT) after IDAM removal blocked hsp70 transcription and HSF1 activation without altering IDAM binding. DTT had no effect on activation of HSF1 by hyperthermia. After IDAM treatment, cellular nonprotein and protein thiols had decreased to less than 20 and 70%, respectively, of the value in control cells. DTT treatment in situ prevented the loss of cellular protein thiols and blocked the formation of high molecular weight protein aggregates. Thus, alkylation of proteins is insufficient to activate hsp70 transcription and DNA binding of HSF1. However, cellular thiol-disulfide redox status and formation of disulfide linked aggregates of cellular proteins are linked to HSF1 activation and hsp70 transcriptional activation.	W ALTON JONES CELL SCI CTR,LAKE PLACID,NY 12946						NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038925, R01DK046267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005670] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38925, DK46267] Funding Source: Medline; NIEHS NIH HHS [ES05670] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ALLEVI P, 1995, FREE RADICAL BIO MED, V18, P107, DOI 10.1016/0891-5849(94)00096-3; AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; BECKMANN RP, 1992, J CELL BIOL, V117, P1137, DOI 10.1083/jcb.117.6.1137; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BRUCE JL, 1993, CANCER RES, V53, P12; CHEN Q, 1992, J BIOL CHEM, V267, P24322; CHEN Q, 1992, J BIOL CHEM, V267, P8207; CHEN Q, 1990, J BIOL CHEM, V265, P21603; CHEN Q, 1991, ARCH BIOCHEM BIOPHYS, V284, P422, DOI 10.1016/0003-9861(91)90318-D; CHEN Q, 1994, J CELL PHYSIOL, V161, P293, DOI 10.1002/jcp.1041610214; COHEN G, 1987, HDB METHODS OXYGEN R, P55; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DICE JF, 1994, BIOL HEAT SHOCK PROT, P137; DONATI YRA, 1990, BIOCHEM PHARMACOL, V40, P2571, DOI 10.1016/0006-2952(90)90573-4; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FREEMAN ML, 1995, J CELL PHYSL, V16, P356; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; HUANG LE, 1994, J BIOL CHEM, V269, P30718; HULL RN, 1976, IN VITRO CELL DEV B, V12, P670, DOI 10.1007/BF02797469; KANDROR O, 1994, J BIOL CHEM, V269, P23575; KIM D, 1995, J BIOL CHEM, V270, P15277, DOI 10.1074/jbc.270.25.15277; KIM DH, 1995, P NATL ACAD SCI USA, V92, P2126, DOI 10.1073/pnas.92.6.2126; KROES RA, 1991, P NATL ACAD SCI USA, V88, P4825, DOI 10.1073/pnas.88.11.4825; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEE KJ, 1988, J CELL PHYSIOL, V136, P411, DOI 10.1002/jcp.1041360304; LEVINSON W, 1980, BIOCHIM BIOPHYS ACTA, V606, P170, DOI 10.1016/0005-2787(80)90108-2; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Lis J.T., 1990, STRESS PROTEINS BIOL, P411; MIFFLIN LC, 1994, J BIOL CHEM, V269, P15710; Mitchell J. R., 1984, DRUG METABOLISM DRUG, P301; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MOSSER DD, 1990, P NATL ACAD SCI USA, V87, P3748, DOI 10.1073/pnas.87.10.3748; MOSSER DD, 1988, MOL CELL BIOL, V8, P4736, DOI 10.1128/MCB.8.11.4736; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PROSTKO CR, 1992, J BIOL CHEM, V267, P16751; RABINDRAN SK, 1994, MOL CELL BIOL, V14, P6552, DOI 10.1128/MCB.14.10.6552; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; SCHAEFER EL, 1988, CARCINOGENESIS, V9, P1733, DOI 10.1093/carcin/9.10.1733; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; SHERMAN MY, 1992, EMBO J, V11, P71; SHERTZER HG, 1990, TOXICOL APPL PHARM, V105, P19, DOI 10.1016/0041-008X(90)90355-X; SHI YH, 1995, MOL CELL BIOL, V15, P4309; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; WARDMAN P, 1988, GLUTATHIONE CONJUGAT, P44; WELCH WJ, 1984, J BIOL CHEM, V259, P4501; WELCH WJ, 1992, PHYSIOL REV, V72, P1063, DOI 10.1152/physrev.1992.72.4.1063; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; WU B, 1985, MOL CELL BIOL, V5, P330, DOI 10.1128/MCB.5.2.330; Wu C., 1994, BIOL HEAT SHOCK PROT, P395; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; ZUO JR, 1995, MOL CELL BIOL, V15, P4319; [No title captured]	66	164	166	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4805	4812						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617749				2022-12-25	WOS:A1996TX69700039
J	Otto, JC; Casey, PJ				Otto, JC; Casey, PJ			The hepatitis delta virus large antigen is farnesylated both in vitro and in animal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TRANSFERASE; PLASMA-MEMBRANE; REPLICATION; PRENYLATION; INHIBITION; IDENTIFICATION; ISOPRENYLATION; MEVALONATE; EXPRESSION; PRODUCT	The hepatitis delta virus large antigen (IHDAg) is a virally encoded protein that contains a prenylation signal sequence at its carboxyl terminus consisting of the tetrapeptide Cys-Arg-Pro-Gln. Although the presence of the Gln as the COOH-terminal residue generally specifies addition of the 15-carbon farnesyl isoprenoid, earlier reports had suggested that the protein is modified by the 20-carbon geranylgeranyl. The prenylation of IHDAg was examined in vitro using a fusion protein between glutathione S-transferase and the COOH-terminal 117 amino acids of IHDAg (GST-IHDAg). When recombinant GST-IHDAg was incubated with bovine brain cytosol in the presence of either farnesyl diphosphate or geranylgeranyl diphosphate, GST-IHDAg was preferentially farnesylated. Geranylgeranylation of the fusion protein was also observed, although at a rate considerably less than that of farnesylation. Using purified recombinant protein prenyltransferases, GST-IHDAg was found to be an excellent substrate (apparent K-m = 0.8 mu M) for protein farnesyltransferase (FTase), while modification by protein geranylgeranyltransferase I (GGTase I) was not detected. FTase was also able to catalyze geranylgeranylation of GST-IHDAg at a very low rate, suggesting that the low level of geranylgeranylation of GST-IHDAg observed in cytosolic preparations was mediated by FTase. Consistent with our observations on the in vitro prenylation of the GST-IHDAg fusion protein, isoprenoid analysis of authentic IHDAg expressed in COS cells demonstrated that the protein was farnesylated, Geranylgeranylation of IHDAg expressed in COS cells was not observed. As prenylation of IHDAg is required for the assembly of the hepatitis delta viral particle, these results suggest that inhibitors of FTase may be useful therapeutic agents for treatment of delta virus infection.	DUKE UNIV,MED CTR,DEPT MOLEC CANC BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University				Casey, Patrick/0000-0002-7366-9309	NIGMS NIH HHS [GM46372] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHANG FL, 1991, P NATL ACAD SCI USA, V88, P8490, DOI 10.1073/pnas.88.19.8490; CHANG MF, 1994, J VIROL, V68, P646, DOI 10.1128/JVI.68.2.646-653.1994; CHAO M, 1990, J VIROL, V64, P5066, DOI 10.1128/JVI.64.10.5066-5069.1990; CHEN PJ, 1992, J VIROL, V66, P2853, DOI 10.1128/JVI.66.5.2853-2859.1992; CHEN WJ, 1993, J BIOL CHEM, V268, P9675; ENDO A, 1992, J LIPID RES, V33, P1569; FARNSWORTH C C, 1990, Methods (Orlando), V1, P231, DOI 10.1016/S1046-2023(05)80322-6; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GLENN JS, 1992, SCIENCE, V256, P1331, DOI 10.1126/science.1598578; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HWANG SB, 1993, J VIROL, V67, P7659, DOI 10.1128/JVI.67.12.7659-7662.1993; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KIM CM, 1992, J BIOL CHEM, V267, P23113; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; KUO MYP, 1989, J VIROL, V63, P1945, DOI 10.1128/JVI.63.5.1945-1950.1989; LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355; LAZINSKI DW, 1993, J VIROL, V67, P2672, DOI 10.1128/JVI.67.5.2672-2680.1993; LEE CZ, 1994, VIROLOGY, V199, P169, DOI 10.1006/viro.1994.1109; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MOOMAW JF, 1995, METHOD ENZYMOL, V250, P12; MOORES SL, 1991, J BIOL CHEM, V266, P14603; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1993, ARCH BIOCHEM BIOPHYS, V301, P210, DOI 10.1006/abbi.1993.1135; RIZZETTO M, 1983, HEPATOLOGY, V3, P729; RYU WS, 1992, J VIROL, V66, P2310, DOI 10.1128/JVI.66.4.2310-2315.1992; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; WANG JG, 1992, J GEN VIROL, V73, P183, DOI 10.1099/0022-1317-73-1-183; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; ZHANG FL, 1994, J BIOL CHEM, V269, P23465; ZHANG FL, 1996, IN PRESS ANN REV BIO, V65	36	65	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	1996	271	9					4569	4572						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TX697	8617711				2022-12-25	WOS:A1996TX69700001
J	Baboshina, OV; Haas, AL				Baboshina, OV; Haas, AL			Novel multiubiquitin chain linkages catalyzed by the conjugating enzymes E2(EPF) and RAD6 are recognized by 26 S proteasome subunit 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CARRIER PROTEIN; HUMAN PAPILLOMAVIRUS TYPE-16; DEPENDENT PROTEOLYSIS; POLYUBIQUITIN CHAINS; ABNORMAL PROTEINS; ACTIVATING ENZYME; BINDING-SITES; YEAST RAD6; DEGRADATION; LIGASE	Targeting of substrates for degradation by the ATP, ubiquitin-dependent pathway requires formation of multiubiquitin chains in which the 8.6-kDa polypeptide is linked by isopeptide bonds between carboxyl termini and Lys-48 residues of successive monomers. Binding of Lys-48-linked chains by subunit 5 of the 26 S proteasome regulatory complex commits the attached target protein to degradation with concomitant release of free ubiquitin monomers following disassembly of the chains. Point mutants of ubiquitin (Lys --> Arg) were used to map the linkage specificity for ubiquitin-conjugating enzymes previously demonstrated to form novel multiubiquitin chains not attached through Lys-48. Recombinant human E2(EPF) catalyzed multiubiquitin chain formation exclusively through Lys-11 of ubiquitin while recombinant yeast RAD6 formed chains linked only through Lys-6, Multiubiquitin chains linked through Lys-6, Lys-11, or Lys-48 each bound to subunit 5 off partially purified human 26 S proteasome with comparable affinities. Since chains bearing different linkages are expected to pack into distinct structures, competition between Lys-11 and Lys-48 chains for binding to subunit 5 demonstrates that the latter possesses determinants for recognizing alternatively linked chains and precludes the existence of subunit 5 isoforms recognizing distinct structures, In addition, competition studies provided an estimate of K-d less than or equal to 18 nM for the intrinsic binding of Lys-48-linked chains of linkage number n > 4. This result suggests that the principal mechanistic advantage of multiubiquitin chain formation is to enhance the affinity of the associated substrate for the 26 S complex relative to that of unconjugated target protein. Complementation studies with E1/E2-depleted rabbit reticulocyte extract demonstrated RAD6 supported isopeptide ligase-dependent degradation only through Lys-48-linked chains, while E2(EPF) retained the ability to target a model radiolabeled substrate through Lys-11-linked chains. Therefore, the linkage specificity exhibited by these E2 isozymes depends on their catalytic context with respect to isopeptide ligase.	MED COLL WISCONSIN,DEPT BIOCHEM,MILWAUKEE,WI 53226	Medical College of Wisconsin					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034009] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34009] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BANERJEE A, 1993, J BIOL CHEM, V268, P5668; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; BURCH TJ, 1994, BIOCHEMISTRY-US, V33, P7300, DOI 10.1021/bi00189a035; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CIECHANOVER A, 1984, CELL, V37, P57, DOI 10.1016/0092-8674(84)90300-3; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; CIECHANOVER A, 1991, PROG CLIN BIOL RES, V366, P37; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CONRAD CA, 1995, FASEB J, V9, pA1473; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DRISCOLL J, 1994, HISTOL HISTOPATHOL, V9, P197; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; DUNTEN RL, 1991, J BIOL CHEM, V266, P3260; EVANS AC, 1985, BIOCHEMISTRY-US, V24, P2915, DOI 10.1021/bi00333a015; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; GALAN JM, 1994, BIOCHEM BIOPH RES CO, V201, P769, DOI 10.1006/bbrc.1994.1767; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GREGORI L, 1990, J BIOL CHEM, V265, P8354; HAAS A, 1990, J BIOL CHEM, V265, P21664; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1985, PREP BIOCHEM, V15, P49; HAAS AL, 1981, P NATL ACAD SCI-BIOL, V78, P6845, DOI 10.1073/pnas.78.11.6845; HAAS AL, 1985, J BIOL CHEM, V260, P2464; HAAS AL, 1991, J BIOL CHEM, V266, P5104; HAAS AL, 1988, J BIOL CHEM, V263, P13268; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HADARI T, 1992, J BIOL CHEM, V267, P719; HELLER H, 1990, J BIOL CHEM, V265, P6532; HERSHKO A, 1982, J BIOL CHEM, V257, P3964; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HILL CP, 1993, P NATL ACAD SCI USA, V90, P4136, DOI 10.1073/pnas.90.9.4136; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOCHSTRASSER M, 1991, P NATL ACAD SCI USA, V88, P4606, DOI 10.1073/pnas.88.11.4606; HOUGH R, 1987, J BIOL CHEM, V262, P8303; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; ISHIDA N, 1993, FEBS LETT, V324, P345, DOI 10.1016/0014-5793(93)80148-N; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; Liu Z, 1996, J BIOL CHEM, V271, P2817, DOI 10.1074/jbc.271.5.2817; LIU Z, 1992, J BIOL CHEM, V267, P15829; MOLINARI M, 1995, ONCOGENE, V10, P1849; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PICKART C, 1995, FASEB J, V9, pA1473; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PTAK C, 1994, J BIOL CHEM, V269, P26539; RABOY B, 1994, EUR J BIOCHEM, V221, P247, DOI 10.1111/j.1432-1033.1994.tb18735.x; REISS Y, 1989, J BIOL CHEM, V264, P10378; REISS Y, 1990, J BIOL CHEM, V265, P3685; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SOKOLIK CW, 1991, J BIOL CHEM, V266, P9100; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; SUNG P, 1991, EMBO J, V10, P2187, DOI 10.1002/j.1460-2075.1991.tb07754.x; WING SS, 1992, J BIOL CHEM, V267, P6495; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	64	175	189	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2823	2831		10.1074/jbc.271.5.2823	http://dx.doi.org/10.1074/jbc.271.5.2823			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576261	hybrid			2022-12-25	WOS:A1996TT48800075
J	Nuber, U; Schwarz, S; Kaiser, P; Schneider, R; Scheffner, M				Nuber, U; Schwarz, S; Kaiser, P; Schneider, R; Scheffner, M			Cloning of human ubiquitin-conjugating enzymes UbcH6 and UbcH7 (E2-F1) and characterization of their interaction with E6-AP and RSP5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE PROTEIN-DEGRADATION; REPAIR GENE RAD6; CARRIER PROTEIN; INVITRO MUTAGENESIS; ACTIVATING ENZYME; E6 ONCOPROTEIN; P53; YEAST; IDENTIFICATION; HOMOLOGS	E6-AP, a 100-kDa cellular protein, was originally identified through its interaction with the E6 protein of the oncogenic human papillomavirus types 16 and 18. The complex of E6-AP and E6 specifically interacts with p53 and mediates ubiquitination of p53 in concert with the E1 ubiquitin-activating enzyme and the E2 ubiquitin-conjugating enzyme UbcH5. Recent results suggest that E6-AP is representative of a family of putative ubiquitin-protein ligases. Members of this family are characterized by a conserved C-terminal region, termed beet domain. In this paper, we describe the isolation of two human E2s, designated as UbcH6 and UbcH7, that in addition to UbcH5 can interact with E6-AP. UbcH6 is a novel member of an evolutionally conserved subfamily of E2s that includes UbcH5 and Saccharomyces cerevisiae UBC4. Although UbcH7 does not appear to be a member of this subfamily, UbcH7 efficiently substitutes for UbcH5 in E6-AP-dependent ubiquitination. Surprisingly, UbcH6 was only weakly active in this particular assay, In addition, UbcH5 but not UbcH6 or UbcH7 efficiently interacts with the hect protein RSP5. These results indicate that E6-AP can interact with at least two species of E2 and that different hect proteins may interact with different E2s.	DEUTSCH KREBSFORSCHUNGSZENTRUM, ANGEW TUMORVIROL, D-69120 HEIDELBERG, GERMANY; UNIV INNSBRUCK, INST BIOCHEM, A-6020 INNSBRUCK, AUSTRIA	Helmholtz Association; German Cancer Research Center (DKFZ); University of Innsbruck			Scheffner, Martin/K-2940-2012	Scheffner, Martin/0000-0003-2229-0128				BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GIROD PA, 1993, PLANT J, V3, P545, DOI 10.1046/j.1365-313X.1993.03040545.x; GLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; HAAS AL, 1982, J BIOL CHEM, V257, P2543; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; JENTSCH S, 1992, ANNU REV GENET, V26, P177; KAISER P, 1994, J BIOL CHEM, V269, P8797; KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865; LIU Z, 1992, J BIOL CHEM, V267, P15829; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PLON SE, 1993, P NATL ACAD SCI USA, V90, P10484, DOI 10.1073/pnas.90.22.10484; Sambrook J, 1989, MOL CLONING LABORATO; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHNEIDER R, 1990, EMBO J, V9, P1431, DOI 10.1002/j.1460-2075.1990.tb08259.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; TREIER M, 1992, EMBO J, V11, P367, DOI 10.1002/j.1460-2075.1992.tb05059.x; ZHEN M, 1993, MOL CELL BIOL, V13, P1371, DOI 10.1128/MCB.13.3.1371	32	135	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2795	2800		10.1074/jbc.271.5.2795	http://dx.doi.org/10.1074/jbc.271.5.2795			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576257	hybrid			2022-12-25	WOS:A1996TT48800071
J	Muller, M; Bakos, E; Welker, E; Varadi, A; Germann, UA; Gottesman, MM; Morse, BS; Roninson, IB; Sarkadi, B				Muller, M; Bakos, E; Welker, E; Varadi, A; Germann, UA; Gottesman, MM; Morse, BS; Roninson, IB; Sarkadi, B			Altered drug-stimulated ATPase activity in mutants of the human multidrug resistance protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAIN; PURIFIED P-GLYCOPROTEIN; ESCHERICHIA-COLI; INSECT CELLS; MDR1; TRANSPORTER; EXPRESSION; MUTATIONS; GENE; RECONSTITUTION	The characteristics of P-glycoprotein (MDR1), an ATP-dependent drug extrusion pump responsible for the multidrug resistance of human cancer, were investigated in an in vitro expression system. The wild-type and several mutants of the human MDR1 cDNA were engineered into recombinant baculoviruses and the mutant proteins were expressed in Sf9 insect cells. In isolated cell membrane preparations of the virus-infected cells the MDR1-dependent drug-stimulated ATPase activity, and 8-azido-ATP binding to the MDR1 protein were studied. We found that when lysines 433 and/or 1076 were replaced by methionines in the ATP-binding domains, all these mutations abolished drug-stimulated ATPase activity independent of the MgATP concentrations applied. Photoaffinity labeling with 8-azido-ATP showed that the double lysine mutant had a decreased ATP-binding affinity. In the MDR1 mutant containing a Gly(185) to Val replacement we found no significant alteration in the maximum activity of the MDR1-ATPase or in its activation by verapamil and vinblastine, and this mutation did not modify the MgATP affinity or the 8-azido-ATP binding of the transporter either. However, the Gly(185) to Val mutation significantly increased the stimulation of the MDR1-ATPase by colchicine and etoposide, while slightly decreasing its stimulation by vincristine. These shifts closely correspond to the effects of this mutation on the drug-resistance profile, as observed in tumor cells. These data indicate that the Sf9-baculovirus expression system for MDR1 provides an efficient tool for examining structure-function relationships and molecular characteristics of this clinically important enzyme.	NATL INST HAEMATOL BLOOD TRANSFUS & IMMUNOL,H-1113 BUDAPEST,HUNGARY; HUNGARIAN ACAD SCI,BIOL RES CTR,INST ENZYMOL,H-1113 BUDAPEST,HUNGARY; NCI,BETHESDA,MD 20892; UNIV ILLINOIS,CHICAGO,IL 60612	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital			Sarkadi, Balazs/I-5024-2013; Welker, Ervin/AAC-6493-2022; Varadi, Andras/A-2055-2012					ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ALSHAWI MK, 1994, J BIOL CHEM, V269, P8986; AMBUDKAR SV, 1992, P NATL ACAD SCI USA, V89, P8472, DOI 10.1073/pnas.89.18.8472; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BIBI E, 1993, P NATL ACAD SCI USA, V90, P9209, DOI 10.1073/pnas.90.19.9209; BRUGGEMANN EP, 1992, J BIOL CHEM, V267, P21020; CARDARELLI CO, 1995, CANCER RES, V55, P1086; CHOI K, 1988, CELL, V53, P519, DOI 10.1016/0092-8674(88)90568-5; CORNWELL MM, 1987, FASEB J, V1, P51, DOI 10.1096/fasebj.1.1.2886389; CURRIER SJ, 1992, J BIOL CHEM, V267, P25153; DOIGE CA, 1993, BIOCHIM BIOPHYS ACTA, V1146, P65, DOI 10.1016/0005-2736(93)90339-2; DOIGE CA, 1992, BIOCHIM BIOPHYS ACTA, V1109, P149, DOI 10.1016/0005-2736(92)90078-Z; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1987, J BIOL CHEM, V262, P13685; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOLLO Z, 1994, BBA-BIOMEMBRANES, V1191, P384, DOI 10.1016/0005-2736(94)90190-2; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; KIOKA N, 1989, BIOCHEM BIOPH RES CO, V162, P224, DOI 10.1016/0006-291X(89)91985-2; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1994, J BIOL CHEM, V269, P7750; NEYFAKH AA, 1988, EXP CELL RES, V174, P168, DOI 10.1016/0014-4827(88)90152-8; OREILLY DR, 1992, BACULOVIRUS EXPRESSI, P216; PARSONAGE D, 1988, J BIOL CHEM, V263, P4740; RAO US, 1995, J BIOL CHEM, V270, P6686; SAFA AR, 1990, P NATL ACAD SCI USA, V87, P7225, DOI 10.1073/pnas.87.18.7225; SARKADI B, 1994, FASEB J, V8, P766, DOI 10.1096/fasebj.8.10.7914178; SARKADI B, 1992, J BIOL CHEM, V267, P4854; SCHINKEL AH, 1993, J BIOL CHEM, V268, P7474; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SHAROM FJ, 1993, J BIOL CHEM, V268, P24197; SHIMABUKU AM, 1992, J BIOL CHEM, V267, P4308; TANAKA S, 1990, BIOCHEM BIOPH RES CO, V166, P180, DOI 10.1016/0006-291X(90)91928-L; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; ZHANG L, 1994, J BIOL CHEM, V269, P15973	40	141	143	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1877	1883						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567633				2022-12-25	WOS:A1996TR32000015
J	Olive, M; Williams, SC; Dezan, C; Johnson, PF; Vinson, C				Olive, M; Williams, SC; Dezan, C; Johnson, PF; Vinson, C			Design of a C/EBP-specific, dominant-negative bZIP protein with both inhibitory and gain-of-function properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; LEUCINE ZIPPER PROTEINS; TRANSCRIPTION FACTOR; ALBUMIN GENE; ACTIVATOR PROTEIN; MAMMALIAN-CELLS; NUCLEAR-PROTEIN; MESSENGER-RNA; EXPRESSION; FAMILY	We have developed a bZIP protein, GBF-F, with both dominant-negative (DN) and gain-of-function properties, GBF-F is a chimera consisting of two components: the DNA binding (basic) region from the plant bZIP protein GBF-1 (GBF) and a leucine zipper (F) designed to preferentially heterodimerize with the C/EBP alpha leucine zipper. Biochemical studies show that GBF-F preferentially forms heterodimers with C/EBP alpha and thus binds a chimeric DNA sequence composed of the half-sites recognized by the C/EBP and GBF basic regions. Transient transfections in HepG2 hepatoma cells show that both components of GBF-F are necessary for inhibition of C/EBP alpha transactivation. When the C/EBP alpha leucine zipper is replaced with that of either GCN4 or VBP, the resulting protein can transactivate a C/EBP cis-element but is not inhibited by GBF-F, indicating that the specificity of dominant-negative action is determined by the leucine zipper. All known members of the C/EBP family contain similar leucine zipper regions and are inhibited by GBF-F, GBF-F also exhibits gain-of-function properties, since, with the essential cooperation of a C/EBP family member, it can transactivate a promoter containing the chimeric C/EBP\GBF site. This protein therefore has potential utility both as a dominant-negative inhibitor of C/EBP function and as an activator protein with novel DNA sequence specificity.	NCI, BIOCHEM LAB, BETHESDA, MD 20892 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Johnson, Peter/A-1940-2012	Johnson, Peter/0000-0002-4145-4725				AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; FAIRMAN R, 1993, P NATL ACAD SCI USA, V90, P10429, DOI 10.1073/pnas.90.22.10429; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; HAAS NB, 1995, MOL CELL BIOL, V15, P1923; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IYER SV, 1991, MOL CELL BIOL, V11, P4863, DOI 10.1128/MCB.11.10.4863; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRYLOV D, 1995, EMBO J, V14, P5329, DOI 10.1002/j.1460-2075.1995.tb00217.x; KRYLOV D, 1994, EMBO J, V13, P2849, DOI 10.1002/j.1460-2075.1994.tb06579.x; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NATSUKA S, 1992, BLOOD, V79, P460; OHNISHI ST, 1978, ANAL BIOCHEM, V86, P193, DOI 10.1016/0003-2697(78)90334-2; OLIPHANT AR, 1989, MOL CELL BIOL, V9, P2944, DOI 10.1128/MCB.9.7.2944; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SCHINDLER U, 1992, EMBO J, V11, P1261, DOI 10.1002/j.1460-2075.1992.tb05170.x; SCOTT LM, 1992, BLOOD, V80, P1725; SCREPANTI I, 1995, EMBO J, V14, P1932, DOI 10.1002/j.1460-2075.1995.tb07185.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SELLERS JW, 1990, MOL CELL BIOL, V10, P5077, DOI 10.1128/MCB.10.10.5077; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; VINSON CR, 1993, GENE DEV, V7, P1047, DOI 10.1101/gad.7.6.1047; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; ZARET KS, 1988, P NATL ACAD SCI USA, V85, P9076, DOI 10.1073/pnas.85.23.9076; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831	62	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2040	2047		10.1074/jbc.271.4.2040	http://dx.doi.org/10.1074/jbc.271.4.2040			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567657	hybrid			2022-12-25	WOS:A1996TR32000039
J	DoucRasy, S; Barrois, M; Fogel, S; Ahomadegbe, JC; Stehelin, D; Coll, J; Riou, G				DoucRasy, S; Barrois, M; Fogel, S; Ahomadegbe, JC; Stehelin, D; Coll, J; Riou, G			High incidence of loss of heterozygosity and abnormal imprinting of H19 and IGF2 genes in invasive cervical carcinomas. Uncoupling of H19 and IGF2 expression and biallelic hypomethylation of H19	ONCOGENE			English	Article						cervical cancer; H19; IGF2; loss of imprinting; allele switch; methylation	GROWTH FACTOR-II; BECKWITH-WIEDEMANN SYNDROME; WILMS-TUMOR; HUMAN CANCER; METHYLATION; RELAXATION; ALLELES; RNA	The few imprinted genes characterized so far include the insulin-like growth factor-2 gene (IGF2) coding for a foetal growth factor and the H19 gene whose normal function is unknown but which is likely to act as an RNA with an antitumour effect, IGF2 is expressed by the paternal allele and H19 by the maternal allele. This reciprocal expression is quite interesting because both H19 and IGF2 genes are located close to each other on chromosome 11p15.5 in a region subject to loss of heterozygosity (LOH), Moreover, loss of imprinting (LOI) or biallelic expression has been proposed as an epigenetic mechanism for tumorigenesis in a variety of human cancers including Wilms' tumour, In this study we report the LOH, LOI and methylation status of H19 and IGF2 genes in 29 invasive cervical carcinomas of different clinical stages, Fourteen (48%) and 13 (45%) tumours were heterozygous for H19 and IGF2 respectively, LOH for H19 and IGF2 genes were found in 2 of 14 (14%) and 3 of 13 (23%) informative tumours, respectively, LOI of H19 and IGF2 was detected in 2 of 12 (17%) and 5 of 10 (50%) tumours with no LOH, respectively, More interestingly, monoallelic expression of the otherwise silent H19 allele (allele switch) was observed in 2 of 12 (17%) tumours and biallelic expression of IGF2 was detected in one specimen of normal cervix adjacent to the tumour, The expressing H19 allele, and to a lower degree also the silent allele, were hypomethylated in tumours suggesting that demethylation of both H19 alleles may be associated with an early step of imprinting alteration. In cervical cancer H19 and IGF2 expressions could be independently regulated, In conclusion, our data suggest that H19 and IGF2 genes, via deletions and/or abnormal imprinting, could play a crucial role in a large proportion (58%) of cervical cancers where they may be associated with disease progression.	INST GUSTAVE ROUSSY,LAB PHARMACOL CLIN & MOLEC,F-94800 VILLEJUIF,FRANCE; INST PASTEUR,CNRS,URA 1160,F-59019 LILLE,FRANCE	UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris								BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; DOUCRASY S, 1993, INT J ONCOL, V2, P753; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HASHIMOTO K, 1995, NAT GENET, V9, P109, DOI 10.1038/ng0295-109; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; HOWLEY PM, 1991, CANCER RES, V51, pS5019; HU JF, 1995, MOL ENDOCRINOL, V9, P628, DOI 10.1210/me.9.5.628; JINNO Y, 1995, NAT GENET, V10, P318, DOI 10.1038/ng0795-318; KONDO M, 1995, ONCOGENE, V10, P1193; KOUFOS A, 1984, NATURE, V309, P170, DOI 10.1038/309170a0; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LI XR, 1995, ONCOGENE, V11, P221; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OHLSSON R, 1993, NAT GENET, V4, P94, DOI 10.1038/ng0593-94; PFEIFER K, 1994, GENE DEV, V8, P1867, DOI 10.1101/gad.8.16.1867; POIRIER F, 1991, DEVELOPMENT, V113, P1105; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; RANIER S, 1995, CANCER RES, V55, P1836; REIK W, 1994, HUM MOL GENET, V3, P1297, DOI 10.1093/hmg/3.8.1297; RIOU G, 1988, ONCOGENE, V3, P329; RIOU G, 1985, PAPILLOMAVIRUSES MOL, V32, P47; SCHNEID H, 1993, J MED GENET, V30, P353, DOI 10.1136/jmg.30.5.353; SCHOFIELD PN, 1992, INSULIN LIKE GROWTH; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SURANI MA, 1994, CURR OPIN CELL BIOL, V6, P390, DOI 10.1016/0955-0674(94)90031-0; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; TYCKO B, 1994, AM J PATHOL, V144, P431; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1993, AM J HUM GENET, V53, P113; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	41	111	119	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					423	430						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570220				2022-12-25	WOS:A1996TR53800022
J	Peverali, FA; Orioli, D; Tonon, L; Ciana, P; Bunone, G; Negri, M; DellaValle, G				Peverali, FA; Orioli, D; Tonon, L; Ciana, P; Bunone, G; Negri, M; DellaValle, G			Retinoic acid-induced growth arrest and differentiation of neuroblastoma cells are counteracted by N-myc and enhanced by max overexpressions	ONCOGENE			English	Article						differentiation; N-Myc; Max; neuroblastoma; proliferation; retinoic acid	HUMAN NEURO-BLASTOMA; C-MYC; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; EMBRYONIC LETHALITY; EXPRESSION; PROTEIN; LINES; GENE; PROGRESSION	N-myc expression is negatively regulated by retinoic acid (RA) which induces the growth arrest and differentiation of neuroblastoma (NB) cells. However, it has not been completely defined whether N-Myc promotes growth and/or antagonises neuronal differentiation of NE cells or whether the down regulation of N-myc occurs as a consequence of the onset of differentiation. By transfecting an N-myc gene construct into these cells, we found that the constitutive overexpression of N-myc stimulated proliferation in RA containing medium and, although these cells were still responsive to RA, they were no longer able to differentiate. Since N-Myc functions appear to be mediated by heterodimerization with Max, the ectopic overexpression of max in NE cells was also investigated, In contrast to N-Myc, Max strongly induced the differentiation by enhancing the effects of RA. Max-transfected cells rapidly arrested growth and differentiated fully within a few days of RA treatment. These findings suggest that the relative levels of N-Myc compared to Max appears to be crucial in stimulating neuroblastoma growth or differentiation, and may contribute to explain the remarkable clinical behaviour of neuroblastomas.	UNIV PAVIA,DIPARTIMENTO GENET & MICROBIOL A BUZZATI TRAV,I-27100 PAVIA,ITALY	University of Pavia			Ciana, Paolo/F-9224-2012; Peverali, Fiorenzo/J-2660-2012	Peverali, Fiorenzo/0000-0001-6717-6586; CIANA, PAOLO/0000-0001-5771-5638; ORIOLI, DONATA/0000-0002-3830-3408				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BIEDLER JL, 1978, CANCER RES, V38, P3751; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1992, AM J PEDIAT HEMATOL, V14, P111; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; GHAZAL P, 1992, P NATL ACAD SCI USA, V89, P7630, DOI 10.1073/pnas.89.16.7630; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PEVERALI FA, 1990, DIFFERENTIATION, V45, P61, DOI 10.1111/j.1432-0436.1990.tb00458.x; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; PIACENTINI M, 1992, INT J CANCER, V52, P271, DOI 10.1002/ijc.2910520220; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; STUNNENBERG HG, 1993, BIOESSAYS, V15, P309, DOI 10.1002/bies.950150504; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; THIELE CJ, 1988, EXP CELL BIOL, V56, P321; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	40	54	54	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					457	462						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570225				2022-12-25	WOS:A1996TR53800027
J	Brechtel, CE; Hu, LY; King, SC				Brechtel, CE; Hu, LY; King, SC			Substrate specificity of the Escherichia coli 4-aminobutyrate carrier encoded by gabP - Uptake and counterflow of structurally diverse molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-AMINOBUTYRATE; CLUSTER; GENE	Transport of 4-aminobutyrate into Escherichia coli is catalyzed by gab permease (GabP). Although published studies show that GabP is relatively specific, recognizing the common alpha-amino acids with low affinity, recent work from this laboratory indicates that a number of synthetic compounds are high affinity transport inhibitors (50% inhibition at 5-100 mu M). Here we present evidence that many of these structurally heterogeneous compounds not only inhibit transport but also function as alternative GabP substrates (i.e. a set of observations inconsistent with the idea that the core of the GabP transport channel exhibits rigid structural specificity for the native substrate, 4-aminobutyrate).	UNIV TEXAS,MED BRANCH,DEPT PHYSIOL & BIOPHYS,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston								DOVER S, 1972, J BACTERIOL, V110, P165, DOI 10.1128/JB.110.1.165-170.1972; FRANCO PJ, 1994, J BIOL CHEM, V269, P7379; GARCIA ML, 1983, BIOCHEMISTRY-US, V22, P2524, DOI 10.1021/bi00279a033; HELLER KB, 1981, FEBS LETT, V129, P253, DOI 10.1016/0014-5793(81)80177-9; KAHANE S, 1978, J BACTERIOL, V135, P295, DOI 10.1128/JB.135.2.295-299.1978; KING SC, 1995, J BIOL CHEM, V270, P19893, DOI 10.1074/jbc.270.34.19893; KING SC, 1995, J BACTERIOL, V177, P5381, DOI 10.1128/jb.177.18.5381-5382.1995; METZER E, 1979, J BACTERIOL, V137, P1111, DOI 10.1128/JB.137.3.1111-1118.1979; METZER E, 1990, J BACTERIOL, V172, P3250, DOI 10.1128/jb.172.6.3250-3256.1990; NIEGEMANN E, 1993, ARCH MICROBIOL, V160, P454, DOI 10.1007/BF00245306; ROSENBERG T, 1957, J GEN PHYSIOL, V41, P289, DOI 10.1085/jgp.41.2.289; STEIN WD, 1986, TRANSPORT DIFFUSION, P269; WILSON DM, 1981, BIOCHIM BIOPHYS ACTA, V649, P377, DOI 10.1016/0005-2736(81)90427-2; WONG PTS, 1970, BIOCHIM BIOPHYS ACTA, V196, P336, DOI 10.1016/0005-2736(70)90021-0; WRIGHT JK, 1986, BIOCHIM BIOPHYS ACTA, V854, P219, DOI 10.1016/0005-2736(86)90114-8; ZABOURA M, 1978, J BACTERIOL, V133, P447, DOI 10.1128/JB.133.2.447-451.1978	16	17	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					783	788		10.1074/jbc.271.2.783	http://dx.doi.org/10.1074/jbc.271.2.783			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557687	hybrid			2022-12-25	WOS:A1996TP88900030
J	Friedman, P; Haimovitz, R; Markman, O; Roberts, MF; Shinitzky, M				Friedman, P; Haimovitz, R; Markman, O; Roberts, MF; Shinitzky, M			Conversion of lysophospholipids to cyclic lysophosphatidic acid by phospholipase D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1-2-CYCLIC PHOSPHATE; PHOSPHATIDYLINOSITOL; ACTIVATION	Phospholipase D from Streptomyces chromofuscus hydrolyzes lysophosphatidylcholine or lysophosphatidylethanolamine in aqueous 1% Triton X-100 solution. In situ monitoring of this reaction by P-31 NMR revealed the formation of cyclic lysophosphatidic acid (1-acyl 2,3-cyclic glycerophosphate) as an intermediate which was hydrolyzed further by the enzyme at a functionally distinct active site to lysophosphatidic acid (lyso-PA). Synthetic cyclic lyso-PA (1-octanoyl 2,3-cyclic glycerophosphate) was found to be stable in aqueous neutral solutions at room temperature. It was hydrolyzed by the bacterial phospholipase D to lyso-PA at a rate which was approximately 4-fold slower than the rate of formation of cyclic lyso-PA. The addition of 5-10 mM sodium vanadate could partially inhibit the ring opening reaction and thus increase substantially the cyclic lyso-PA accumulation. Cyclic lyso-PA may act as a dormant configuration of the physiologically active lyso-PA or may even possess specific activities which await verification.	WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL; BOSTON COLL, DEPT CHEM, CHESTNUT HILL, MA 02167 USA	Weizmann Institute of Science; Boston College								[Anonymous], 1987, PHOSPHOLIPASES; BLACKBUR.GM, 1971, TETRAHEDRON, V27, P2903, DOI 10.1016/S0040-4020(01)98082-2; CLARKE N, 1976, BIOCHEM J, V153, P745, DOI 10.1042/bj1530745; CLARKE N, 1978, BIOCHEM J, V173, P579, DOI 10.1042/bj1730579; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; DAWSON RMC, 1971, BIOCHEM J, V122, P605, DOI 10.1042/bj1220605; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P103, DOI 10.1016/0005-2744(68)90248-9; Eibl H, 1981, Methods Enzymol, V72, P632; GALLAGHER G, 1987, METHODS STEREOCHEMIC, V8, P297; GRIFFITH OH, 1991, METHOD ENZYMOL, V197, P493; HOLBROOK PG, 1991, BIOCHIM BIOPHYS ACTA, V1084, P155, DOI 10.1016/0005-2760(91)90214-3; IMAMURA S, 1979, J BIOCHEM, V85, P79, DOI 10.1093/oxfordjournals.jbchem.a132334; JALINK K, 1994, BBA-REV CANCER, V1198, P185, DOI 10.1016/0304-419X(94)90013-2; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LISCOVITCH M, 1994, SIGNAL ACTIVATED PHO, P31; MAJERUS PW, 1986, SCIENCE, V234, P1519, DOI 10.1126/science.3024320; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; ROSS TS, 1986, J BIOL CHEM, V261, P1119; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SEGAL IH, 1975, ENZYME KINETICS; SHINITZKY M, 1993, J BIOL CHEM, V268, P14109; TENHOEVE W, 1985, J ORG CHEM, V50, P4508, DOI 10.1021/jo00223a018; TRACEY AS, 1988, J AM CHEM SOC, V110, P5869, DOI 10.1021/ja00225a044; WYKLE RL, 1991, METHOD ENZYMOL, V197, P583; WYKLE RL, 1980, BIOCHIM BIOPHYS ACTA, V619, P58, DOI 10.1016/0005-2760(80)90242-8; ZWALL RFA, 1974, METHOD ENZYMOL, V52, P154	27	40	41	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					953	957		10.1074/jbc.271.2.953	http://dx.doi.org/10.1074/jbc.271.2.953			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557710	hybrid			2022-12-25	WOS:A1996TP88900053
J	Huang, DY; Prystowsky, MB				Huang, DY; Prystowsky, MB			Identification of an essential cis-element near the transcription start site for transcriptional activation of the proliferating cell nuclear antigen gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-REGULATION; ESCHERICHIA-COLI; DNA-REPLICATION; FACTOR E2F; PCNA GENE; PROTEIN; EXPRESSION; PROMOTER; BINDING; CYCLIN	Interleukin 2 (IL-2) stimulates T lymphocyte proliferation and induces the expression of proliferating cell nuclear antigen (PCNA), a processivity factor for DNA polymerase delta. Previously, deletion analysis suggested cis-element(s) in the proximal region of the PCNA promoter (-40 to +143) are required for IL-2 induction in cloned T lymphocytes. The sequence 5'-TTGCGGGC-3' located at +10 to +17 is similar to the E2F consensus binding site and is required for optimal PCNA promoter activity. In IL-2-stimulated T cells, nuclear proteins are induced to bind to this sequence as demonstrated using electrophoretic mobility shift assay (EMSA), competition EMSA, and methylation interference analysis. A 180-kDa polypeptide was detected by UV cross-linking to bind specifically to the PCNA E2F-like sequence. Our data indicate that the protein bound to the PCNA E2F-like site is not one of the transcription factor E2F proteins. Our results demonstrate that the E2F-like sequence and the protein(s) binding to it are required for optimal PCNA promoter activity and IL-2 induction of PCNA expression.	UNIV PENN,SCH MED,GRAD GRP MOLEC BIOL,PHILADELPHIA,PA 19104; ALBERT EINSTEIN COLL MED,DEPT PATHOL,NEW YORK,NY 10461	University of Pennsylvania; Yeshiva University								ALDER H, 1992, NUCLEIC ACIDS RES, V20, P1769, DOI 10.1093/nar/20.7.1769; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BASERGA R, 1991, J CELL SCI, V98, P433; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOU QP, 1994, J BIOL CHEM, V269, P1306; FEUERSTEIN N, 1995, J BIOL CHEM, V270, P9454, DOI 10.1074/jbc.270.16.9454; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOFBAUER R, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P247; HUANG DY, 1994, MOL CELL BIOL, V14, P4233, DOI 10.1128/MCB.14.6.4233; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; Maniatis T., 1982, MOL CLONING; MATHEWS MB, 1989, GROWTH CONTROL CELL, P89; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MIYACHI K, 1978, J IMMUNOL, V121, P2228; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEVINS JR, 1992, SCIENCE, V258, P424; ORTEN DJ, 1994, J BIOL CHEM, V269, P32254; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; PRELICH HA, 1993, PCR TECHNOLOGY PRINC; PRYSTOWSKY MB, 1989, CELL GROWTH DIVISION, P95; ROSENBERG SA, 1984, SCIENCE, V223, P1412, DOI 10.1126/science.6367046; SABATH DE, 1986, P NATL ACAD SCI USA, V83, P4739, DOI 10.1073/pnas.83.13.4739; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SHIPMANAPPASAMY P, 1990, J BIOL CHEM, V265, P19180; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WONG RL, 1987, CELL IMMUNOL, V110, P443, DOI 10.1016/0008-8749(87)90137-7; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YOO WD, 1991, J VIROL, V65, P5391, DOI 10.1128/JVI.65.10.5391-5400.1991; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	55	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					1218	1225		10.1074/jbc.271.2.1218	http://dx.doi.org/10.1074/jbc.271.2.1218			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557653	hybrid			2022-12-25	WOS:A1996TP88900090
J	Smit, L; vanderHorst, G; Borst, J				Smit, L; vanderHorst, G; Borst, J			Sos, Vav, and C3G participate in B cell receptor-induced signaling pathways and differentially associate with Shc-Grb2, Crk, and Crk-L adaptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; EXCHANGE FACTOR; LEUCINE ZIPPER; V-CBL; PROTEIN; GENE; GRB2; RAS	B cell antigen receptor (BCR)-mediated signal transduction controls B cell proliferation and differentiation. The BCR activates Ras, presumably by the formation of a Shc-Grb2 adaptor complex, which recruits the Grb2-associated guanine nucleotide exchange factor Sos to the plasma membrane. In order to reveal additional BCR-induced signaling events involving the Grb2 adaptor, we undertook the isolation of Grb2-binding proteins. Using the yeast two-hybrid system and bacterial fusion proteins, Vav and C3G were identified as Grb2 binders. Vav is a putative nucleotide exchange factor and a target for BCR-induced tyrosine phosphorylation. C3G exerts nucleotide exchange activity on the Ras-related Rap1 protein. While Sos binds to both Grb2 Src homology-3 (SH3) domains, Vav was found to associate selectively with the carboxyl-terminal SH3 domain, while C3G bound selectively to the amino-terminal SH3 domain of bacterially expressed Grb2. Despite the association of Vav with Grb2 in vitro, we could not demonstrate an interaction between endogenous Vav and Grb2 molecules in primary B cells. Instead, Vav was found to inducibly associate with the Grb2-related adaptor protein Crk upon BCR stimulation. C3G did not bind to either Grb2, She, or Crk in vivo. Instead, C3G was found in association with the Crk-L adaptor, both before and after BCR stimulation. We show that Crk-L also participates in BCR signaling, since it inducibly interacts with tyrosine-phosphorylated Cbl. We conclude that, in addition to Sos, Vav and C3G play a role in BCR-mediated signal transduction. These guanine nucleotide exchange factors selectively associate with Grb2, Crk, and Crk-L, respectively, which may serve to direct them to different target molecules. Since Cbl binds to Grb2, Crk, as well as Crk-L, we hypothesize that Cbl may affect the function of all three exchangers.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Borst, Jannie/0000-0002-8043-5009; Smit, Linda/0000-0003-0025-269X				ADAMS JM, 1992, ONCOGENE, V7, P611; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BLAKE TJ, 1991, ONCOGENE, V6, P653; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; HART MJ, 1994, J BIOL CHEM, V269, P62; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RAMOSMORALES F, 1994, ONCOGENE, V9, P1917; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REIF K, 1994, J BIOL CHEM, V269, P14081; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAXTON TM, 1994, J IMMUNOL, V153, P623; SMIT L, 1994, J BIOL CHEM, V269, P20209; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VERSCHUREN MCM, 1993, LEUKEMIA, V7, P1939; WU J, 1995, MOL CELL BIOL, V15, P4337; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZMUIDZINAS A, 1995, EMBO J, V14, P1	51	106	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8564	8569		10.1074/jbc.271.15.8564	http://dx.doi.org/10.1074/jbc.271.15.8564			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621483	hybrid			2022-12-25	WOS:A1996UE73000014
J	Tjernberg, LO; Naslund, J; Lindqvist, F; Johansson, J; Karlstrom, AR; Thyberg, J; Terenius, L; Nordstedt, C				Tjernberg, LO; Naslund, J; Lindqvist, F; Johansson, J; Karlstrom, AR; Thyberg, J; Terenius, L; Nordstedt, C			Arrest of beta-amyloid fibril formation by a pentapeptide ligand	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PEPTIDE; PROTEIN; INVITRO; DEPOSITION; PRECURSOR	Polymerization of amyloid beta-peptide (A beta) into amyloid fibrils is a critical step in the pathogenesis of Alzheimer's disease, Here, we show that peptides incorporating a short A beta fragment (KLVFF; A beta(16-20)) can bind full-length A beta and prevent its assembly into amyloid fibrils, Through alanine substitution, it was demonstrated that amino acids Lys(16), Leu(17) and Phe(20) are critical for binding to A beta and inhibition of A beta fibril formation, A mutant A beta molecule, in which these residues had been substituted, had a markedly reduced capability of forming amyloid fibrils. The present data suggest that residues A beta(16-20) serve as a binding sequence during A beta polymerization and fibril formation, Moreover, the present KLVFF peptide may serve as a lead compound for the development of peptide and nonpeptide agents aimed at inhibiting A beta amyloidogenesis in vivo.	KAROLINSKA HOSP,DEPT CLIN NEUROSCI,LAB BIOCHEM & MOLEC PHARMACOL,S-17176 STOCKHOLM,SWEDEN; KAROLINSKA INST,DEPT MED BIOCHEM & BIOPHYS,S-17177 STOCKHOLM,SWEDEN; PHARMACIA & UPJOHN,DEPT BIOCHEM,S-11287 STOCKHOLM,SWEDEN; KAROLINSKA INST,MED NOBEL INST,DEPT CELL & MOLEC BIOL,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Pfizer; Pharmacia Corporation; Karolinska Institutet				Johansson, Jan/0000-0002-8719-4703	NHLBI NIH HHS [HL49571-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049571] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARROW CJ, 1991, SCIENCE, V253, P179, DOI 10.1126/science.1853202; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BURDICK D, 1992, J BIOL CHEM, V267, P546; CAMILLERI P, 1994, FEBS LETT, V341, P256, DOI 10.1016/0014-5793(94)80467-2; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1993, J BIOL CHEM, V268, P3021; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; JANSSON U, 1992, ADV BIOSENS, V2, P291; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MAGGIO JE, 1992, P NATL ACAD SCI USA, V89, P5462, DOI 10.1073/pnas.89.12.5462; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; NASLUND J, 1994, P NATL ACAD SCI USA, V91, P8378, DOI 10.1073/pnas.91.18.8378; NASLUND J, 1994, BIOCHEM BIOPH RES CO, V204, P780, DOI 10.1006/bbrc.1994.2527; NORDSTEDT C, 1994, J BIOL CHEM, V269, P30773; PIKE CJ, 1993, J NEUROSCI, V13, P1676; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; TURNELL WG, 1992, J MOL BIOL, V227, P1205, DOI 10.1016/0022-2836(92)90532-O; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003	27	800	861	6	140	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	1996	271	15					8545	8548		10.1074/jbc.271.15.8545	http://dx.doi.org/10.1074/jbc.271.15.8545			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UE730	8621479	hybrid			2022-12-25	WOS:A1996UE73000010
J	Mano, H; Yamashita, Y; Miyazato, A; Miura, Y; Ozawa, K				Mano, H; Yamashita, Y; Miyazato, A; Miura, Y; Ozawa, K			Tec protein-tyrosine kinase is an effector molecule of Lyn protein-tyrosine kinase	FASEB JOURNAL			English	Article						Src homology-3 domain; Tec homology domain	X-LINKED AGAMMAGLOBULINEMIA; HEMATOPOIETIC-CELLS; GENE; EXPRESSION; P60C-SRC; YEAST; SITE; SRC	The Tec family is a recently emerging subfamily among nonreceptor type protein-tyrosine kinases (PTKs) consisting of Tee, Txk, Btk, Bmx, and Itk/Tsk/Emt. They have a long amino-terminal unique region containing a pleckstrin homology domain and a Tec-homology domain, We could previously show that, through the Tec-homology domain, Tee is bound to Lyn kinase both in vitro and in vivo. Because Tec is coexpressed with Lyn in many hematopoietic cell types, it has been intriguing to investigate the biological role of the Tec-Lyn association, Here we demonstrate that Lyn can phosphorylate tyrosine residues of the Tee protein, and thereby activate Tec in 3T3 fibroblasts, However, coexpression of Tec has little effect on the phosphotyrosine-contents of Lyn. By using the in vitro kinase assay and the yeast system, we could prove that the Tec protein is a direct substrate of the Lyn kinase both in vitro and in vivo, From this evidence we conclude that Tec acts downstream of Lyn in intracellular signaling pathways, This is a novel case where one PTK is phosphorylated and regulated by another.	JICHI MED SCH,DEPT HEMATOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN	Jichi Medical University	Mano, H (corresponding author), JICHI MED SCH,DEPT MOLEC BIOL,YAKUSHIJI 3311-1,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.							BOLEN JB, 1993, ONCOGENE, V8, P2025; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4232, DOI 10.1073/pnas.85.12.4232; COOPER JA, 1987, ONCOGENE RES, V1, P297; COUTURE C, 1994, MOL CELL BIOL, V14, P5249, DOI 10.1128/MCB.14.8.5249; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Harlow E., 1988, ANTIBODIES LAB MANUA; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACHIDE M, 1995, ONCOGENE, V11, P619; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1995, BLOOD, V85, P343; MANO H, 1994, ONCOGENE, V9, P3205; MANO H, 1993, ONCOGENE, V8, P417; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SOMMERS CL, 1995, ONCOGENE, V11, P245; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; YAMADA N, 1993, BIOCHEM BIOPH RES CO, V192, P231, DOI 10.1006/bbrc.1993.1404	31	44	51	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	APR	1996	10	5					637	642		10.1096/fasebj.10.5.8621063	http://dx.doi.org/10.1096/fasebj.10.5.8621063			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	UJ055	8621063				2022-12-25	WOS:A1996UJ05500012
J	Chen, YG; Shields, D				Chen, YG; Shields, D			ADP-ribosylation factor-1 stimulates formation of nascent secretory vesicles from the trans-golgi network of endocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; GOLGI MEMBRANES; FACTOR ARF; MYRISTOYLATION; COP	ADP-ribosylation factor (ARF) is a small GTP-binding protein that has been implicated in intracellular vesicular transport, ARF regulates the budding of vesicles that mediate endoplasmic reticulum to Golgi and intra-Golgi transport. It also plays an important role in maintaining the function and morphology of the Golgi apparatus. Using a permeabilized cell system derived from GH(3) cells, we provide evidence that ARF-1 regulates the formation of nascent secretory vesicles from the trans-Golgi network. Both myristoylated and non-myristoylated forms of recombinant human ARF-1 enhanced secretory vesicle budding about 2-fold. A mutant lacking the first 17 N-terminal residues, as well as one that preferentially binds GDP (T31N) did not stimulate vesicle formation. In contrast, a mutant defective in GTP hydrolysis (Q71L) promoted vesicle budding. Strikingly, a peptide corresponding to the N terminus of human ARF-1 (amino acids 2-17) also stimulated vesicle budding from the trans-Golgi network, in marked contrast to its inhibitory effect on vesicular transport from the endoplasmic reticulum to Golgi. These data demonstrate that in endocrine cells, ARF-1 and in particular its N terminus play an essential role in the formation of secretory vesicles.	ALBERT EINSTEIN COLL MED, DEPT DEV & MOL BIOL, BRONX, NY 10461 USA; ALBERT EINSTEIN COLL MED, DEPT ANAT & STRUCT BIOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NCI NIH HHS [P30CA13330, CA09475] Funding Source: Medline; NIDDK NIH HHS [DK21860] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009475, P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021860, R01DK021860] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DONALDSON JG, 1994, CURR OPIN CELL BIOL, V6, P527, DOI 10.1016/0955-0674(94)90072-8; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; HAUN RS, 1993, J BIOL CHEM, V268, P7064; HELMS JB, 1993, J CELL BIOL, V121, P751, DOI 10.1083/jcb.121.4.751; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KAHN RA, 1995, J BIOL CHEM, V270, P143, DOI 10.1074/jbc.270.1.143; KTISTAKIS NT, 1995, P NATL ACAD SCI USA, V92, P4952, DOI 10.1073/pnas.92.11.4952; KTISTAKIS NT, 1995, MOL BIOL CELL, V6, P119; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STEARNS T, 1990, MOL CELL BIOL, V10, P6690, DOI 10.1128/MCB.10.12.6690; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; WEIDMAN PJ, 1994, J CELL BIOL, V127, P1815, DOI 10.1083/jcb.127.6.1815; XU HX, 1994, J BIOL CHEM, V269, P22875; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	28	50	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	1996	271	10					5297	5300		10.1074/jbc.271.10.5297	http://dx.doi.org/10.1074/jbc.271.10.5297			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TZ286	8621377	hybrid			2022-12-25	WOS:A1996TZ28600003
J	Cui, MZ; Parry, GCN; Oeth, P; Larson, H; Smith, M; Huang, RP; Adamson, ED; Mackman, N				Cui, MZ; Parry, GCN; Oeth, P; Larson, H; Smith, M; Huang, RP; Adamson, ED; Mackman, N			Transcriptional regulation of the tissue factor gene in human epithelial cells is mediated by Sp1 and EGR-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; BOX-BINDING-PROTEINS; SERUM GROWTH-FACTORS; C-FOS; HUMAN-FIBROBLASTS; RECOGNITION SITE; MESSENGER-RNA; 3T3 CELLS; PROMOTER; EXPRESSION	Tissue factor (TF) gene expression is rapidly induced in epithelial cells by phorbol 12-myristate 13-acetate and serum. We have shown that this induction is mediated by a novel serum response region (SRR) (-111 to +14 bp) within the human TF promoter. In this study, we characterized cis-acting genetic elements within the SRR that regulated basal and inducible expression of the TF gene in HeLa cells, Gel mobility shift assays using oligonucleotides spanning the entire SRR identified three 12-base pair (bp) motifs within subregions 1, 2, and 3 that bound constitutively expressed Sp1 and inducibly expressed EGR-1. Analysis of protein binding to these 12-bp motifs by competition with Sp1 and EGR-1 sites, mutation, and antibody supershift experiments indicated that they each contained distinct EGR-1 and Sp1 sites that overlapped by 6 bp. Functional studies using HeLa cells transfected with plasmids containing the wild-type TF promoter (-111 to +14 bp) or derivatives containing mutations in the three Sp1 and/or EGR-1 sites examined basal and inducible expression, The Sp1 sites mediated basal promoter activity, and both Sp1 and EGR-1 sites were required for maximal induction of the TF promoter by phorbol 12-myristate 13 acetate or serum. These data indicated that TF gene expression in HeLa cells was regulated by both Sp1 and EGR-1.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute				Cui, Mei-Zhen/0000-0003-4745-6999	NATIONAL CANCER INSTITUTE [R01CA067888] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER; NCI NIH HHS [CA67888] Funding Source: Medline; NHLBI NIH HHS [HL-16411] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACKERMAN SL, 1991, P NATL ACAD SCI USA, V88, P7523, DOI 10.1073/pnas.88.17.7523; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BLATTI SP, 1988, P NATL ACAD SCI USA, V85, P1119, DOI 10.1073/pnas.85.4.1119; BLOEM LJ, 1989, J CELL PHYSIOL, V139, P418, DOI 10.1002/jcp.1041390226; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN DA, 1992, EUR J IMMUNOL, V22, P2419, DOI 10.1002/eji.1830220935; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CAO XM, 1992, J BIOL CHEM, V267, P1345; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CUI MZ, 1994, ARTERIOSCLER THROMB, V14, P807, DOI 10.1161/01.ATV.14.5.807; DRAKE TA, 1989, AM J PATHOL, V134, P1087; EDGINGTON TS, 1991, THROMB HAEMOSTASIS, V66, P67; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GREENBERG ME, 1987, MOL CELL BIOL, V7, P1217, DOI 10.1128/MCB.7.3.1217; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HARTZELL S, 1989, MOL CELL BIOL, V9, P2567, DOI 10.1128/MCB.9.6.2567; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1989, MOL CELL BIOL, V9, P1790, DOI 10.1128/MCB.9.4.1790; MACKMAN N, 1990, P NATL ACAD SCI USA, V87, P2254, DOI 10.1073/pnas.87.6.2254; MACKMAN N, 1989, BIOCHEMISTRY-US, V28, P1755, DOI 10.1021/bi00430a050; MACKMAN N, 1993, AM J PATHOL, V143, P76; MACKMAN N, 1992, ARTERIOSCLER THROMB, V12, P474, DOI 10.1161/01.ATV.12.4.474; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOLL T, 1995, J BIOL CHEM, V270, P3849, DOI 10.1074/jbc.270.8.3849; OETH PA, 1994, MOL CELL BIOL, V14, P3772, DOI 10.1128/MCB.14.6.3772; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PEPPEL K, 1990, BIOTECHNIQUES, V9, P711; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RANGANATHAN G, 1991, J BIOL CHEM, V266, P496; SCARPATI EM, 1989, J BIOL CHEM, V264, P20705; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; THIEL G, 1994, J BIOL CHEM, V269, P15294; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VIRCA GD, 1990, BIOTECHNIQUES, V8, P370; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124	47	151	154	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2731	2739		10.1074/jbc.271.5.2731	http://dx.doi.org/10.1074/jbc.271.5.2731			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576248	hybrid			2022-12-25	WOS:A1996TT48800062
J	Matuschewski, K; Hauser, HP; Treier, M; Jentsch, S				Matuschewski, K; Hauser, HP; Treier, M; Jentsch, S			Identification of a novel family of ubiquitin-conjugating enzymes with distinct amino-terminal extensions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE PROTEIN-DEGRADATION; REPAIR GENE RAD6; SACCHAROMYCES-CEREVISIAE; CARRIER PROTEIN; CDC34 UBC3; ENCODES; INVITRO; DOMAIN; WHEAT	The ubiquitin/proteasome system is the main eukaryotic nonlysosomal protein degradation system. Substrate selectivity of this pathway is thought to be mediated in part by members of a large family of ubiquitin-conjugating (E2) enzymes, which catalyze the covalent attachment of ubiquitin to proteolytic substrates. E2 enzymes have a conserved similar to 150-residue so-called UBC domain, which harbors the cysteine residue required for enzyme-ubiquitin thioester formation. Some E2 enzymes possess additional carboxyl-terminal extensions that are involved in substrate specificity and intracellular localization of the enzyme. Here we describe a novel family of E2 enzymes from higher eukaryotes (Drosophila, mouse, and man) that have amino-terminal extensions but lack carboxyl-terminal extensions. We have identified four different variants of these enzymes that have virtually identical UBC domains (94% identity) but differ in their amino-terminal extensions. In yeast, these enzymes can partially complement mutants deficient in the UBC4 E2 enzyme. This indicates that members of this novel E2 family may operate in UBC4-related proteolytic pathways.	UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,D-69120 HEIDELBERG,GERMANY; BEHRING WERKE,W-3550 MARBURG,GERMANY; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; MAX PLANCK SOC,FRIEDRICH MIESCHER LAB,D-72076 TUBINGEN,GERMANY	Ruprecht Karls University Heidelberg; Howard Hughes Medical Institute; University of California System; University of California San Diego; Eberhard Karls University of Tubingen; Max Planck Society			Treier, Mathias/AAD-6388-2021	Matuschewski, Kai/0000-0001-6147-8591				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ASHBURNER M, 1989, DROSOPHILA LABORATOR; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; KAISER P, 1994, J BIOL CHEM, V269, P8797; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KOKEN M, 1991, P NATL ACAD SCI USA, V88, P3832, DOI 10.1073/pnas.88.9.3832; KOLMAN CJ, 1992, EMBO J, V11, P3081, DOI 10.1002/j.1460-2075.1992.tb05380.x; MURALIDHAR MG, 1993, NEURON, V11, P253, DOI 10.1016/0896-6273(93)90182-Q; OH CE, 1994, J NEUROSCI, V14, P3166; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SEUFERT W, 1990, NUCLEIC ACIDS RES, V18, P1638, DOI 10.1093/nar/18.6.1638; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; SILVER ET, 1992, EMBO J, V11, P3091, DOI 10.1002/j.1460-2075.1992.tb05381.x; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; SULLIVAN ML, 1989, P NATL ACAD SCI USA, V86, P9861, DOI 10.1073/pnas.86.24.9861; SUNG P, 1988, GENE DEV, V2, P1476, DOI 10.1101/gad.2.11.1476; TREIER M, 1992, EMBO J, V11, P367, DOI 10.1002/j.1460-2075.1992.tb05059.x; VANNOCKER S, 1991, P NATL ACAD SCI USA, V88, P10297, DOI 10.1073/pnas.88.22.10297; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; ZHEN M, 1993, MOL CELL BIOL, V13, P1371, DOI 10.1128/MCB.13.3.1371	36	52	60	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2789	2794		10.1074/jbc.271.5.2789	http://dx.doi.org/10.1074/jbc.271.5.2789			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576256	hybrid			2022-12-25	WOS:A1996TT48800070
J	Tworek, BL; Tuma, DJ; Casey, CA				Tworek, BL; Tuma, DJ; Casey, CA			Decreased binding of asialoglycoproteins to hepatocytes from ethanol-fed rats - Consequence of both impaired synthesis and inactivation of the asialoglycoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; ADMINISTRATION IMPAIRS; MEDIATED ENDOCYTOSIS; GALACTOSYL RECEPTORS; LIVER; INVITRO	Chronic ethanol administration alters the process of receptor-mediated endocytosis in isolated rat hepatocytes, Using the asialoglycoprotein receptor (ASGP-R) as a model, we have previously shown decreased binding of asialoglycoproteins to this receptor after as early as 1 week of ethanol administration, In the present study, we further analyzed the mechanism(s) responsible for this impairment by determining the ligand and antibody binding characteristics of the ASGP-R in rats fed ethanol over a B-week time course, The results presented here demonstrate that ethanol treatment for 4 days significantly impaired total ligand binding without affecting antibody binding, Ethanol administration for a longer period of 1-2 weeks resulted in intermediate impairments in both ligand and antibody binding, After 5 weeks of ethanol exposure, ligand and antibody binding were equally lowered, In contrast to total cellular receptor binding, surface binding of both ligand and antibody were decreased over the entire time course of ethanol administration. Our data indicate that the ASGP-R is initially inactivated during the time course of ethanol exposure and that a redistribution of surface receptors to intracellular compartments occurs. Northern blot analysis showed that there was a significant decrease in receptor mRNA content in the 5-week chronically fed animals but not in the animals fed for 1 week. In addition, after 5 weeks of ethanol feeding, biosynthetic labeling of the ASGP-R was decreased in the ethanol cells, indicating impaired synthesis of the ASGP-R. In summary, an early inactivation of the ASGP-R occurs during ethanol exposure followed by an actual decrease in protein and mRNA content for the receptor.	VET AFFAIRS MED CTR, LIVER STUDY UNIT, OMAHA, NE 68105 USA; UNIV NEBRASKA, MED CTR, DEPT INTERNAL MED, OMAHA, NE 68105 USA; UNIV NEBRASKA, MED CTR, DEPT BIOCHEM & MOLEC BIOL, OMAHA, NE 68105 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NIAAA NIH HHS [AA04961, AA07846] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA007846, R29AA007846, R01AA004961] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; CASEY CA, 1987, J BIOL CHEM, V262, P2704; CASEY CA, 1993, BIOCHEM BIOPH RES CO, V195, P1127, DOI 10.1006/bbrc.1993.2161; CASEY CA, 1989, ALCOHOL CLIN EXP RES, V13, P258, DOI 10.1111/j.1530-0277.1989.tb00323.x; CASEY CA, 1990, BIOCHIM BIOPHYS ACTA, V1052, P1, DOI 10.1016/0167-4889(90)90049-J; CASEY CA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P96, DOI 10.1016/0167-4889(92)90032-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS JC, 1988, HEPATOLOGY, V8, P108, DOI 10.1002/hep.1840080122; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HAYNES PA, 1994, J BIOL CHEM, V269, P33152; HOWARD DJ, 1982, J BIOL CHEM, V257, P2856; HUDGIN RL, 1974, J BIOL CHEM, V249, P5536; KURIYAMA K, 1971, LIFE SCI 2-BIOCH GEN, V10, P181, DOI 10.1016/0024-3205(71)90016-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBER CS, 1982, ALCOHOL CLIN EXP RES, V6, P523, DOI 10.1111/j.1530-0277.1982.tb05017.x; Maniatis T, 1989, MOL CLONING; MCABEE DD, 1991, J CELL BIOCHEM, V45, P59, DOI 10.1002/jcb.240450113; MCABEE DD, 1988, BIOCHEMISTRY-US, V27, P2061, DOI 10.1021/bi00406a037; MCPHAUL M, 1986, P NATL ACAD SCI USA, V83, P8863, DOI 10.1073/pnas.83.23.8863; MEDH JD, 1991, J BIOL CHEM, V266, P8771; MORTIMORE GE, 1972, J BIOL CHEM, V247, P2776; OHTAKE H, 1986, RES COMMUN CHEM PATH, V53, P213; OKA JA, 1983, J BIOL CHEM, V258, P253; SCHWARTZ AL, 1983, J BIOL CHEM, V258, P1249; TREICHEL U, 1995, PROTEIN EXPRES PURIF, V6, P251, DOI 10.1006/prep.1995.1032; WEIGEL PH, 1982, J BIOL CHEM, V257, P1201; WEIGEL PH, 1992, GLYCOCONJUGATES COMP, P421; ZERN MA, 1983, HEPATOLOGY, V3, P317; ZERN MA, 1985, GASTROENTEROLOGY, V89, P1123, DOI 10.1016/0016-5085(85)90219-7	29	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	1996	271	5					2531	2538		10.1074/jbc.271.5.2531	http://dx.doi.org/10.1074/jbc.271.5.2531			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TT488	8576217	hybrid			2022-12-25	WOS:A1996TT48800031
J	Guerra, C; Roncero, C; Porras, A; Fernandez, M; Benito, M				Guerra, C; Roncero, C; Porras, A; Fernandez, M; Benito, M			Triiodothyronine induces the transcription of the uncoupling protein gene and stabilizes its mRNA in fetal rat brown adipocyte primary cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICK-EMBRYO HEPATOCYTES; ADIPOSE-TISSUE; MESSENGER-RNA; THYROID-HORMONE; MALIC ENZYME; CELL-CULTURE; GDP-BINDING; L-THYROXINE; EXPRESSION; ACID	Confluent fetal rat brown adipocytes in primary culture showed an almost undetectable level of uncoupling protein (UCP) mRNA and a low mitochondrial content of functional UCP. Treatment of confluent cells with 10 nM triiodothyronine in a serum-free medium, in the absence of noradrenergic stimulation, increased the amount of UCP mRNA in a time-dependent manner, This effect was due to an increased UCP gene transcription rate and UCP mRNA stabilization, resulting in a higher content of immunoreactive mitochondrial UCP and functional UCP (detected by its ability to bind GDP), Thus, triiodothyronine might play a significant physiological role in the UCP expression throughout fetal development, when brown adipose tissue starts to differentiate and UCP is primarily expressed.	CSIC,CTR MIXTO,INST BIOQUIM,DEPT BIOQUIM & BIOL MOLEC 2,E-28040 MADRID,SPAIN; UNIV COMPLUTENSE,FAC FARM,E-28040 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); Complutense University of Madrid			Guerra, Carmen/K-5852-2014; Fernández, Margarita/H-9077-2015; Porras, Almudena/N-2121-2015; Roncero, Cesáreo/H-9039-2015	Fernández, Margarita/0000-0001-7207-2028; Porras, Almudena/0000-0002-6495-3308; Roncero, Cesáreo/0000-0001-7608-8553; Guerra, Carmen/0000-0002-3891-046X				BIANCO AC, 1992, ENDOCRINOLOGY, V130, P2625, DOI 10.1210/en.130.5.2625; BIANCO AC, 1987, ENDOCRINOLOGY, V120, P55, DOI 10.1210/endo-120-1-55; BIANCO AC, 1988, J BIOL CHEM, V263, P18168; BOUILLAUD F, 1985, P NATL ACAD SCI USA, V82, P445, DOI 10.1073/pnas.82.2.445; BOUILLAUD F, 1984, J BIOL CHEM, V259, P1583; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEESCOBAR GM, 1990, ENDOCRINOLOGY, V126, P2765, DOI 10.1210/endo-126-5-2765; DEESCOBAR GM, 1985, ENDOCRINOLOGY, V117, P1890, DOI 10.1210/endo-117-5-1890; GIRALT M, 1990, EUR J BIOCHEM, V193, P297, DOI 10.1111/j.1432-1033.1990.tb19336.x; GOLDMAN MJ, 1985, J BIOL CHEM, V260, P4404; GUERRA C, 1994, ENDOCRINOLOGY, V134, P1067, DOI 10.1210/en.134.3.1067; GUERRA C, 1994, BIOCHEM BIOPH RES CO, V201, P813, DOI 10.1006/bbrc.1994.1773; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; JACOBSSON A, 1987, FEBS LETT, V224, P353, DOI 10.1016/0014-5793(87)80483-0; KLAUS S, 1994, J CELL SCI, V107, P313; KLAUS S, 1991, J CELL BIOL, V115, P1783, DOI 10.1083/jcb.115.6.1783; KOZAK UC, 1994, ENDOCRINOLOGY, V134, P906, DOI 10.1210/en.134.2.906; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LORENZO M, 1988, BIOCHEM J, V251, P617, DOI 10.1042/bj2510617; Nechad M., 1986, BROWN ADIPOSE TISSUE; Nedergaard J., 1986, BROWN ADIPOSE TISSUE, P152; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; OBREGON MJ, 1989, BIOCHEM J, V259, P341, DOI 10.1042/bj2590341; OBREGON MJ, 1984, ENDOCRINOLOGY, V114, P305, DOI 10.1210/endo-114-1-305; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PICO C, 1994, BIOCHEM J, V302, P81, DOI 10.1042/bj3020081; PORRAS A, 1989, BIOCHEM BIOPH RES CO, V163, P541, DOI 10.1016/0006-291X(89)92171-2; PORRAS A, 1990, EUR J BIOCHEM, V187, P671, DOI 10.1111/j.1432-1033.1990.tb15352.x; PUIGSERVER P, 1992, BIOCHEM J, V284, P394; RABELO R, 1995, ENDOCRINOLOGY, V136, P1003, DOI 10.1210/en.136.3.1003; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; RICQUIER D, 1986, J BIOL CHEM, V261, P13905; RONCERO C, 1992, ARCH BIOCHEM BIOPHYS, V295, P258, DOI 10.1016/0003-9861(92)90516-Y; SALATI LM, 1991, J BIOL CHEM, V266, P4010; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; SILVA JE, 1988, MOL ENDOCRINOL, V2, P706, DOI 10.1210/mend-2-8-706; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; SUNDIN U, 1980, COMP BIOCHEM PHYS B, V65, P463, DOI 10.1016/0305-0491(80)90298-9; TRAYHURN P, 1987, American Journal of Physiology, V252, pE237; YEH WJ, 1993, AM J PHYSIOL, V265, pE252, DOI 10.1152/ajpendo.1993.265.2.E252	42	60	60	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2076	2081		10.1074/jbc.271.4.2076	http://dx.doi.org/10.1074/jbc.271.4.2076			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567662	hybrid			2022-12-25	WOS:A1996TR32000044
J	Musci, G; DiMarco, S; Bellenchi, GC; Calabrese, L				Musci, G; DiMarco, S; Bellenchi, GC; Calabrese, L			Reconstitution of ceruloplasmin by the Cu(I)-glutathione complex - Evidence for a role of Mg2+ and ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON DISEASE GENE; ENDOPLASMIC-RETICULUM; GLUTATHIONE DISULFIDE; CARCINOMA-CELLS; COPPER SITES; TRANSPORT; METALLOTHIONEIN; METABOLISM; TOXICITY; PROTEINS	The copper-glutathione complex (Cu(I)-GSH) efficiently acted in vitro as the source of Cu(I) in the reconstitution of apoceruloplasmin. Copper was found to reinstate in the various sites in a multistep process, with metal entry into the protein in a first phase, and a second step involving conformational changes of the protein leading to the recovery of the native structural and functional properties. This latter phase was found to be strongly facilitated by Mg2+ or Ca2+ and by ATP. Both Mg2+ and ATP had to be present for optimal reconstitution. These results may shed some light on the mechanisms governing the biosynthesis of ceruloplasmin in vivo. Cu(I)-GSH was the only complex able to reconstitute ceruloplasmin at neutral pH. Glutathione may thus function to shuttle the metal from the membrane copper pump, as the Wilson disease ATPase, and ceruloplasmin in the secretory compartments of the cell. The finding that ceruloplasmin acquires the native conformation after metal entry through a complex pathway triggered by Mg2+ and ATP suggests that they may act as physiological modulators of this process in vivo.	UNIV ROMA LA SAPIENZA, DEPT BIOCHEM SCI, I-00185 ROME, ITALY; UNIV MESSINA, DEPT ORGAN & BIOL CHEM, I-98166 MESSINA, ITALY; CIBA GEIGY LTD, DIV PHARMACEUT, DEPT CORE DRUG DISCOVERY TECHNOL, CH-4002 BASEL, SWITZERLAND; THIRD UNIV ROME, DEPT BIOL, I-00154 ROME, ITALY	Sapienza University Rome; University of Messina; Novartis			Di Marco, Stefania -/C-3859-2009; Musci, Giovanni/H-2862-2012	Musci, Giovanni/0000-0002-5196-709X; BELLENCHI, GIANCARLO/0000-0002-9302-0021				AISEN P, 1965, J BIOL CHEM, V240, P1974; ALLENDORF MD, 1985, P NATL ACAD SCI USA, V82, P3063, DOI 10.1073/pnas.82.10.3063; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; ANDREWS PA, 1987, CANCER CHEMOTH PHARM, V19, P149; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BROUWER M, 1992, BIOCHEMISTRY-US, V31, P4096, DOI 10.1021/bi00131a028; Brumby PE, 1967, METHOD ENZYMOL, V10, P473; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CALABRESE L, 1988, J BIOL CHEM, V263, P6480; CALABRESE L, 1989, J BIOL CHEM, V264, P6183; CIRIOLO MR, 1990, J BIOL CHEM, V265, P11030; COUSINS RJ, 1985, PHYSIOL REV, V65, P238, DOI 10.1152/physrev.1985.65.2.238; Danks DM, 1989, METABOLIC BASIS INHE, P1411; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FERREIRA AMD, 1993, BIOCHEM J, V292, P673, DOI 10.1042/bj2920673; FLEMING RE, 1991, AM J PHYSIOL, V260, pL68, DOI 10.1152/ajplung.1991.260.2.L68; FREEDMAN JH, 1989, J BIOL CHEM, V264, P5598; FREEDMAN JH, 1986, J BIOL CHEM, V261, P1840; Frieden E, 1980, Ciba Found Symp, V79, P93; FUKINO H, 1986, J TOXICOL ENV HEALTH, V19, P75, DOI 10.1080/15287398609530908; GOA J, 1953, J CLIN LAB INVEST, V37, P218; GUNTHER T, 1990, MET IONS BIOL SYST, V26, P193; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HANNA PM, 1988, BIOCHEM J, V256, P1001, DOI 10.1042/bj2561001; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KANG YJ, 1988, TOXICOLOGY, V48, P93; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCKEE DJ, 1971, BIOCHEMISTRY-US, V10, P3880, DOI 10.1021/bi00797a013; MEHRA RK, 1995, BIOCHEM J, V307, P697, DOI 10.1042/bj3070697; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P513, DOI 10.1016/0022-2836(89)90498-1; Minder W, 1936, Z KRISTALLOGR, V94, P137; MIYAJIMA H, 1987, NEUROLOGY, V37, P761, DOI 10.1212/WNL.37.5.761; MUSCI G, 1993, ARCH BIOCHEM BIOPHYS, V306, P111, DOI 10.1006/abbi.1993.1487; MUSCI G, 1995, BIOMETALS, V9; REED DJ, 1980, ANAL BIOCHEM, V106, P55, DOI 10.1016/0003-2697(80)90118-9; Ryden L., 1984, COPP PROTEINS COPP E, V3, P37; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SATO M, 1991, J BIOL CHEM, V266, P5128; SCHECHINGER T, 1986, BIOCHEM J, V240, P281, DOI 10.1042/bj2400281; SCHECHINGER T, 1988, INORG CHIM A-BIOINOR, V151, P265, DOI 10.1016/S0020-1693(00)90810-7; SINGHAL RK, 1987, FASEB J, V1, P220, DOI 10.1096/fasebj.1.3.2887478; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; TERADA K, 1995, BBA-MOL BASIS DIS, V1270, P58, DOI 10.1016/0925-4439(94)00072-X; YAMAGUCHI Y, 1993, BIOCHEM BIOPH RES CO, V197, P271, DOI 10.1006/bbrc.1993.2471; YOUNG J, 1993, J BIOL CHEM, V268, P19810; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	50	47	48	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					1972	1978		10.1074/jbc.271.4.1972	http://dx.doi.org/10.1074/jbc.271.4.1972			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567646	hybrid			2022-12-25	WOS:A1996TR32000028
J	Wang, Z; Horiuchi, KY; Chacko, S				Wang, Z; Horiuchi, KY; Chacko, S			Characterization of the functional domains on the C-terminal region of caldesmon using full-length and mutant caldesmon molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE THIN-FILAMENTS; GIZZARD SMOOTH-MUSCLE; HEAVY-MEROMYOSIN; ATPASE ACTIVITY; CALMODULIN-BINDING; ACTOMYOSIN ATPASE; ACTIN ACTIVATION; F-ACTIN; MYOSIN; TROPOMYOSIN	A series of C-terminal deletion mutants of chicken gizzard smooth muscle caldesmon (CaD) were made using a polymerase chain reaction cloning strategy and a baculovirus expression system, and the precise locations of the functional domains of CaD involved in the regulation of actomyosin ATPase and the binding of actin, tropomyosin, and calmodulin were analyzed. Our results reveal a high affinity calmodulin-binding domain that consists of at least three calmodulin-binding determinants localized in residues 690-717, 658-689, and 628-657. The residues between positions 718 and 756 and positions 598 and 627 have no detectable calmodulin-binding site. A high affinity tropomyosin-binding domain is located between residues 718 and 756. The 159 residues at the C terminus of CaD contain multiple actin-binding determinants; the major ones are localized in the regions between residues 718 and 756 and residues 690 and 717. The amino acid residues between positions 718 and 756 contain the major determinant involved in the inhibition of the actin activation of smooth muscle myosin ATPase since CaD-(1-717) caused only 30% of the inhibition produced by the full-length CaD. Further deletion between residues 690 and 717 (CaD-(1-689)) revealed a low level (10% of that seen for full-length CaD) of inhibition of the actomyosin ATPase. These data clearly demonstrate that the region of the last 66 amino acid residues at the CaD C terminus contains two or more major actin-binding motifs, one tropomyosin-binding domain, one high affinity calmodulin-binding determinant, and the domain that is responsible for the inhibition of the actin-activated ATPase of myosin.	UNIV PENN, SCH VET MED, DEPT PATHOBIOL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania					NIDDK NIH HHS [DK 39740, DK 47514] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047514, R01DK039740] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHACKO S, 1981, BIOCHEMISTRY-US, V20, P702, DOI 10.1021/bi00507a005; CHACKO S, 1977, P NATL ACAD SCI USA, V74, P129, DOI 10.1073/pnas.74.1.129; CHACKO S, 1990, J BIOL CHEM, V265, P2105; CHACKO S, 1994, J BIOL CHEM, V269, P15803; CHALOVICH JM, 1992, J BIOL CHEM, V267, P16644; DABROWSKA R, 1985, BIOCHIM BIOPHYS ACTA, V842, P70, DOI 10.1016/0304-4165(85)90295-8; DEDMAN JR, 1983, METHOD ENZYMOL, V102, P1; DOBROWOLSKI Z, 1988, BIOCHIM BIOPHYS ACTA, V956, P140, DOI 10.1016/0167-4838(88)90260-9; FUJII T, 1987, J BIOL CHEM, V262, P2757; GORECKA A, 1976, BIOCHEM BIOPH RES CO, V71, P325, DOI 10.1016/0006-291X(76)90286-2; GRACEFFA P, 1987, FEBS LETT, V218, P139, DOI 10.1016/0014-5793(87)81034-7; HEMRIC ME, 1990, J BIOL CHEM, V265, P19672; Horiuchi KY, 1995, BIOCHEMISTRY-US, V34, P16815, DOI 10.1021/bi00051a032; HORIUCHI KY, 1989, BIOCHEMISTRY-US, V28, P9111, DOI 10.1021/bi00449a023; HORIUCHI KY, 1991, BIOCHEMISTRY-US, V30, P712, DOI 10.1021/bi00217a019; HORIUCHI KY, 1988, BIOCHEMISTRY-US, V27, P8388, DOI 10.1021/bi00422a014; HORIUCHI KY, 1986, BIOCHEM BIOPH RES CO, V136, P962, DOI 10.1016/0006-291X(86)90426-2; Huber P. A. J., 1995, Biophysical Journal, V68, pA59; HUBER PAJ, 1993, J MUSCLE RES CELL M, V14, P385, DOI 10.1007/BF00121289; IKEBE M, 1988, J BIOL CHEM, V263, P3055; ISHII Y, 1985, BIOCHEMISTRY-US, V24, P6631, DOI 10.1021/bi00344a050; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASH JA, 1986, J BIOL CHEM, V261, P6155; LEHMAN W, 1990, ANN NY ACAD SCI, V599, P75, DOI 10.1111/j.1749-6632.1990.tb42366.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MABUCHI K, 1993, J MUSCLE RES CELL M, V14, P54, DOI 10.1007/BF00132180; MARSTON SB, 1985, J MUSCLE RES CELL M, V6, P669, DOI 10.1007/BF00712237; MARSTON SB, 1994, J BIOL CHEM, V269, P8134; MARSTON SB, 1985, BIOCHEM J, V231, P517, DOI 10.1042/bj2310517; MEZGUELDI M, 1994, J BIOL CHEM, V269, P12824; MILLER LK, 1988, ANNU REV MICROBIOL, V42, P177, DOI 10.1146/annurev.micro.42.1.177; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NGAI PK, 1984, J BIOL CHEM, V259, P3656; REDWOOD CS, 1993, J BIOL CHEM, V268, P10969; SOBLESZEK A, 1977, J MOL BIOL, V112, P559; SOBUE K, 1985, BIOCHEM BIOPH RES CO, V132, P645, DOI 10.1016/0006-291X(85)91181-7; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; VELAZ L, 1989, J BIOL CHEM, V264, P9602; VIBERT P, 1993, J CELL BIOL, V123, P313, DOI 10.1083/jcb.123.2.313; WANG CLA, 1991, J BIOL CHEM, V266, P9166; WANG Z, 1994, J MUSCLE RES CELL M, V15, P646, DOI 10.1007/BF00121072; YAMAKITA Y, 1992, J BIOL CHEM, V267, P12022; ZE W, 1993, MOL CELL BIOL, V13, P5348, DOI 10.1128/MCB.13.9.5348; ZHAN Q, 1991, J BIOL CHEM, V266, P21810	47	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	1996	271	4					2234	2242		10.1074/jbc.271.4.2234	http://dx.doi.org/10.1074/jbc.271.4.2234			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TR320	8567684	hybrid			2022-12-25	WOS:A1996TR32000066
J	Sandhu, AK; Kaur, GP; Reddy, DE; Rane, NS; Athwal, RS				Sandhu, AK; Kaur, GP; Reddy, DE; Rane, NS; Athwal, RS			A gene on 6q 14-21 restores senescence to immortal ovarian tumor cells	ONCOGENE			English	Article						cellular senescence; ovarian tumor; chromosome transfer; immortal cell growth	INDEFINITE DIVISION; SUPPRESSOR GENES; FREQUENT LOSS; HETEROZYGOSITY; CHROMOSOME-6; IDENTIFICATION; EXPRESSION; CARCINOMAS; INVITRO; CANCER	We have identified a gene on 6q14-21 which restores senescence to immortal ovarian tumor cells. Single gpt tagged human chromosomes, present in mouse/human monochromosomal hybrids, were introduced into immortal human and rat ovarian tumor cells via microcell fusion. Analysis of chromosome transfer clones for cell morphology and growth properties revealed that chromosome 6 or 6q restored senescence to both human and rat ovarian tumor cells while chromosomes 10 or 14 did not affect the proliferative potential of these cells. Reversion to immortal growth concordant with loss of the donor chromosome confirmed the presence of a senescence gene on 6q. During continuous maintenance of microcell hybrids in MX medium, rare immortal revertant clones grew out of the human and rat senescent cell populations. Analysis of independent revertant clones of rat cells, for chromosome 6 markers, revealed a common deletion of chromosomal region 6q14-21 in all revertants. Restoration of senescence following introduction of a gpt tagged chromosome segment 6q13-21 into human and rat ovarian tumor cells confirmed the location of a senescence gene in this region. In contrast, introduction of a chromosome 6 lacking the region 6q14-21 did not impart senescence in these cells. Based on these results we assigned the senescence gene (SEN 6A) to region 6q14-21.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								ADAMS AT, 1985, EXP CELL BIOL, V53, P181; ATHWAL RS, 1985, SOMAT CELL MOLEC GEN, V11, P177, DOI 10.1007/BF01534706; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CLIBY W, 1993, CANCER RES, V53, P2393; Del Senno L., 1992, Human Molecular Genetics, V1, P354; EHLEN T, 1990, ONCOGENE, V5, P219; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; GODWIN AK, 1992, J NATL CANCER I, V84, P592, DOI 10.1093/jnci/84.8.592; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARPER JW, 1993, CELL, V75, P805; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HENSLER PJ, 1994, MOL CELL BIOL, V14, P2291, DOI 10.1128/MCB.14.4.2291; KLEIN CB, 1991, SCIENCE, V251, P796, DOI 10.1126/science.1990442; LEE JH, 1990, CANCER RES, V50, P2724; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; NEGRINI M, 1994, CANCER RES, V54, P1331; NING Y, 1991, P NATL ACAD SCI USA, V88, P5635, DOI 10.1073/pnas.88.13.5635; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; OSBORNE RJ, 1994, BRIT J CANCER, V69, P429, DOI 10.1038/bjc.1994.79; PARASKEVA C, 1989, INT J CANCER, V43, P743, DOI 10.1002/ijc.2910430434; PEREIRASMITH OM, 1983, SCIENCE, V221, P964, DOI 10.1126/science.6879195; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RIMESSI P, 1994, ONCOGENE, V9, P3467; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAITO S, 1992, CANCER RES, V52, P5815; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TESTA JR, 1994, CANCER RES, V54, P2778; TEYSSIER JR, 1992, ANTICANCER RES, V12, P997; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WELCH DR, 1994, ONCOGENE, V9, P255; [No title captured]	42	57	57	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 18	1996	12	2					247	252						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570202				2022-12-25	WOS:A1996TR53800004
J	Naismith, JH; Field, RA				Naismith, JH; Field, RA			Structural basis of trimannoside recognition by concanavalin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED OLIGOSACCHARIDES; RAY CRYSTAL-STRUCTURE; X-RAY; LATHYRUS-OCHRUS; BINDING SITE; ISOLECTIN-I; COMPLEX; LECTIN; RESOLUTION; CARBOHYDRATE	Despite the fact that complex saccharides play an important role in many biological recognition processes, molecular level descriptions of protein-carbohydrate interactions are sparse. The legume lectin concanavalin A (con A), from Canavalia ensiformis, specifically recognizes the trimannoside core of many complex glycans. We have determined the crystal structure of a con A-trimannoside complex at 2.3-Angstrom resolution and now describe the trimannoside interaction with con A. All three sugar residues are in well defined difference electron density. The 1,6-linked mannose residue is bound at the previously reported monosaccharide binding site; the other two sugars bind in an extended cleft formed by residues Tyr-12, Pro-13, Asn-14, Thr-15, and Asp-16. Hydrogen bonds are formed between the protein and all three sugar residues. In particular, the 1,3-linked mannose residue makes a strong hydrogen bond with the main chain of the protein. In addition, a water molecule, which is conserved in other con A structures, plays an important role in anchoring the reducing sugar unit to the protein. The complex is further stabilized by van der Waals interactions. The structure provides a rationale for the high affinity of con A for N-linked glycans.			Naismith, JH (corresponding author), UNIV ST ANDREWS,CTR BIOMOLEC SCI,PURDIE BLDG,ST ANDREWS KY16 9ST,FIFE,SCOTLAND.		Naismith, James Henderson/AAB-8614-2020; Naismith, James Henderson/H-3408-2012	Naismith, James Henderson/0000-0001-6744-5061; Naismith, James Henderson/0000-0001-6744-5061; Field, Rob/0000-0001-8574-0275	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOURNE Y, 1990, J BIOL CHEM, V265, P18161; BOURNE Y, 1992, J BIOL CHEM, V267, P197; BOURNE Y, 1990, PROTEINS, V8, P365, DOI 10.1002/prot.340080410; BOURNE Y, 1990, J MOL BIOL, V214, P571, DOI 10.1016/0022-2836(90)90199-V; BOURNE Y, 1994, STRUCTURE, V2, P209, DOI 10.1016/S0969-2126(00)00022-8; BREMER EG, 1994, CURR TOP MEMBR, V40, P387, DOI 10.1016/S0070-2161(08)60989-2; BREWER CF, 1986, J BIOL CHEM, V261, P7306; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; CARVER JP, 1985, BIOPOLYMERS, V24, P49, DOI 10.1002/bip.360240106; CHERVENAK MC, 1995, BIOCHEMISTRY-US, V34, P5685, DOI 10.1021/bi00016a045; DACON DJ, 1988, J MOL GRAPHICS, V6, P219; DELBAERE LTJ, 1993, J MOL BIOL, V230, P950, DOI 10.1006/jmbi.1993.1212; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; EMMERICH C, 1994, ACTA CRYSTALLOGR D, V50, P749, DOI 10.1107/S0907444994002143; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GIANNIS A, 1994, ANGEW CHEM INT EDIT, V33, P178, DOI 10.1002/anie.199401781; GOLDSTEIN IJ, 1974, ANN NY ACAD SCI, V234, P283, DOI 10.1111/j.1749-6632.1974.tb53040.x; HAKOMORI S, 1991, CURR OPIN IMMUNOL, V3, P646, DOI 10.1016/0952-7915(91)90091-E; HOMANS SW, 1986, BIOCHEMISTRY-US, V25, P6342, DOI 10.1021/bi00368a076; HOMANS SW, 1987, BIOCHEMISTRY-US, V26, P6553, DOI 10.1021/bi00394a040; IMBERTY A, 1994, GLYCOBIOLOGY, V4, P351, DOI 10.1093/glycob/4.3.351; JONES CJP, 1992, HISTOCHEM J, V24, P319, DOI 10.1007/BF01046163; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUNGALWALA FB, 1994, NEUROCHEM RES, V19, P945, DOI 10.1007/BF00968704; KARLSSON KA, 1992, APMIS, V100, P71; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LORIS R, 1993, PROTEINS, V15, P205, DOI 10.1002/prot.340150210; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1149, DOI 10.1021/bi00171a014; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MUSSER JH, 1992, ANNU REP MED CHEM, V27, P301; NAISMITH JH, 1994, ACTA CRYSTALLOGR D, V50, P847, DOI 10.1107/S0907444994005287; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OTTWINOWSKI Z, 1993, 1993 P CCP4 STUD WEE, P56; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REDDY VS, 1992, INT J BIOL MACROMOL, V14, P185, DOI 10.1016/S0141-8130(05)80025-X; REEKE GN, 1975, J BIOL CHEM, V250, P1525; RICHARDSON M, 1984, EUR J BIOCHEM, V144, P101, DOI 10.1111/j.1432-1033.1984.tb08436.x; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; RINI JM, 1993, J BIOL CHEM, V268, P10126; Schnaar R L, 1992, Adv Pharmacol, V23, P35, DOI 10.1016/S1054-3589(08)60962-X; SHAANAN B, 1991, SCIENCE, V254, P862, DOI 10.1126/science.1948067; SPRINGER TA, 1990, ANNU REV CELL BIOL, V6, P359, DOI 10.1146/annurev.cellbio.6.1.359; Sumner JB, 1919, J BIOL CHEM, V37, P137; TOONE EJ, 1994, CURR OPIN STRUC BIOL, V4, P719, DOI 10.1016/S0959-440X(94)90170-8	47	253	262	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 12	1996	271	2					972	976		10.1074/jbc.271.2.972	http://dx.doi.org/10.1074/jbc.271.2.972			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TP889	8557713	hybrid			2022-12-25	WOS:A1996TP88900056
J	Connor, RJ; Pasquale, EB				Connor, RJ; Pasquale, EB			Genomic organization and alternatively processed forms of Cek5, a receptor protein-tyrosine kinase of the Eph subfamily	ONCOGENE			English	Article						exon-intron structure; alternative splicing; alternative polyadenylation; domain structure; gene family	GROWTH-FACTOR-RECEPTOR; FACTOR-I RECEPTOR; INSULIN-RECEPTOR; MESSENGER-RNA; GENE; IDENTIFICATION; EXPRESSION; EVOLUTION; ENCODES; LIGAND	The genomic organization of Cek5, a receptor tyrosine kinase of the Eph subfamily, was elucidated utilizing a strategy involving PCR amplification of Cek5 genomic DNA, Cek5 is the first Eph-related kinase for which the exon-intron structure of the entire coding region has been determined, The Cek5 gene spans over 35 kb and comprises at least 16 exons, The exon-intron structure of Cek5 can be correlated with the proposed domain structure of the Eph subfamily, with the exception of an Ig motif in the extracellular domain, Intron positions in the Cek5 gene coincide with the locations of the deletions, substitutions, or insertions that have been described in a number of Eph-related kinases. This suggests that alternative processing plays a major role in generating the structural variability observed in the Eph subfamily. Consistent with this hypothesis, analysis of the Cek5 gene indicated that: (i) a variant form of Cek5 containing an insertion in the juxtamembrane region (Cek5+) arises through the use of alternative 5' splice sites, and (ii) a soluble form of Cek5 comprising only the extracellular domain (Cek5s) may exist, which originates by alternative polyadenylation. RT-PCR analysis and RNase protection assays revealed the expression of both Cek5+ and Cek5s at various stages of chicken development.	LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [CA56721] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBOTT AM, 1992, J BIOL CHEM, V267, P10759; AGNES F, 1994, GENE, V145, P283, DOI 10.1016/0378-1119(94)90021-3; ANDRE C, 1992, ONCOGENE, V7, P685; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BLAKE CCF, 1985, INT REV CYTOL, V93, P149, DOI 10.1016/S0074-7696(08)61374-1; Bork P, 1992, CURR OPIN STRUC BIOL, V2, P413; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CECCHERINI I, 1993, BIOCHEM BIOPH RES CO, V196, P1288, DOI 10.1006/bbrc.1993.2392; CHAN J, 1991, ONCOGENE, V6, P1057; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CIOSSEK T, 1995, ONCOGENE, V10, P97; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DAVIS C G, 1990, New Biologist, V2, P410; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DOOLITTLE RF, 1992, PROTEIN SCI, V1, P191; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; FEENER EP, 1993, J BIOL CHEM, V268, P11256; FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883; GANDINO L, 1994, J BIOL CHEM, V269, P1815; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; KIYOKAWA E, 1994, CANCER RES, V54, P3645; KORHONEN J, 1994, ONCOGENE, V9, P395; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; LEE CC, 1994, J BIOL CHEM, V269, P19457; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARU Y, 1988, MOL CELL BIOL, V8, P3770, DOI 10.1128/MCB.8.9.3770; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; Moore DD, 1995, GLOB MOB SURV; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NIETO MA, 1992, DEVELOPMENT, V116, P1137; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OGRADY P, 1994, J BIOL CHEM, V269, P25193; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PASQUALE EB, 1994, DEV BIOL, V163, P491, DOI 10.1006/dbio.1994.1165; PASQUALE EB, 1992, J NEUROSCI, V12, P3956; Patthy L, 1991, CURR OPIN STRUC BIOL, V1, P351, DOI 10.1016/0959-440X(91)90033-P; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; ROGERS JH, 1989, TRENDS GENET, V5, P213, DOI 10.1016/0168-9525(89)90084-X; ROUER E, 1989, GENE, V84, P105, DOI 10.1016/0378-1119(89)90144-3; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULZ AS, 1993, ONCOGENE, V8, P509; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SEGATTO O, 1991, MOL CELL BIOL, V11, P3191, DOI 10.1128/MCB.11.6.3191; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHAO HN, 1994, J BIOL CHEM, V269, P26606; SIEVER DA, 1994, GENE, V148, P219, DOI 10.1016/0378-1119(94)90692-0; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SOANS C, 1994, ONCOGENE, V9, P3353; STAUBS PA, 1994, J BIOL CHEM, V269, P27186; SUDHOF TC, 1985, SCIENCE, V228, P893, DOI 10.1126/science.3873704; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VALENZUELA DM, 1995, ONCOGENE, V10, P1573; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	68	32	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	1995	11	11					2429	2438						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570195				2022-12-25	WOS:A1995TK70200028
J	Ekstrand, BC; Mansfield, TA; Bigner, SH; Fearon, ER				Ekstrand, BC; Mansfield, TA; Bigner, SH; Fearon, ER			DCC expression is altered by multiple mechanisms in brain tumors	ONCOGENE			English	Article						DCC (deleted in colorectal cancer) gene; brain tumor; tumor suppressor genes; chromosome 18q; glioblastoma; cancer genetics	MALIGNANT HUMAN GLIOMAS; CHROMOSOMAL-ABNORMALITIES; HUMAN MEDULLOBLASTOMA; COLORECTAL CANCERS; SUPPRESSOR GENES; HETEROZYGOSITY; AMPLIFICATION; ASTROCYTOMA; XENOGRAFTS; RNA	The DCC (deleted in colorectal cancer) candidate tumor suppressor gene spans greater than 1350 kilobases at chromosome 18q21.1 and encodes a transmembrane protein of unknown function. Although DCC is expressed in a number of adult tissues, its expression is highest in the brain and we have, therefore, undertaken studies to determine if DCC inactivation might contribute to tumors arising there, Decreased or absent DCC protein expression was noted in more than 50% of the thirty brain tumors studied. Although specific mutations in the DCC gene were not identified, a variety of mechanisms appeared to contribute to the altered DCC expression, including allelic loss, aberrant splicing of transcripts and allele-specific loss of transcripts. In total, the data suggest that DCC inactivation may be important in brain tumor pathogenesis.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510; DUKE UNIV,SCH MED,DEPT PATHOL,DURHAM,NC 27706	Yale University; Yale University; Yale University; Duke University					NICHD NIH HHS [HD07149] Funding Source: Medline; NIGMS NIH HHS [GM07205] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIGNER SH, 1988, CANCER RES, V48, P405; BIGNER SH, 1989, CANCER GENET CYTOGEN, V40, P111, DOI 10.1016/0165-4608(89)90152-0; BIGNER SH, 1988, CANCER GENET CYTOGEN, V30, P91, DOI 10.1016/0165-4608(88)90096-9; BIGNER SH, 1990, CANCER RES, V50, P2347; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHO KR, 1995, CURR OPIN GENET DEV, V5, P72, DOI 10.1016/S0959-437X(95)90056-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLEAVER JE, 1994, CELL, V76, P1, DOI 10.1016/0092-8674(94)90165-1; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; FAULKNER KW, 1983, J PEDIATR-US, V103, P600, DOI 10.1016/S0022-3476(83)80598-8; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1990, CANCER RES, V50, P5784; GIANI C, 1994, CANCER RES, V54, P6338; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HUMPHREY PA, 1988, CANCER RES, V48, P2231; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; ILINO H, 1994, CANCER, V73, P1324; ITOH F, 1993, INT J CANCER, V53, P260, DOI 10.1002/ijc.2910530215; JAMES CD, 1988, CANCER RES, V48, P5546; JEN J, 1994, CANCER RES, V54, P6353; JOSYLN G, 1991, CELL, V66, P601; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARLBOM AE, 1993, HUM GENET, V92, P169; KLEIHUES P, 1991, HISTOLOGICAL TYPING; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; KNUDSON AG, 1993, NAT GENET, V5, P103, DOI 10.1038/ng1093-103; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KORNBLITH PL, 1987, NEUROLOGIC ONCOLOGY, P35; KRAFT R, 1988, BIOTECHNIQUES, V6, P554; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LEON SP, 1994, NEUROSURGERY, V34, P708, DOI 10.1227/00006123-199404000-00021; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MIYAKE S, 1994, CANCER RES, V54, P3007; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; PIERCEALL WE, 1994, DEV BIOL, V166, P654, DOI 10.1006/dbio.1994.1345; PIERCEALL WE, 1994, J CELL BIOL, V124, P1017, DOI 10.1083/jcb.124.6.1017; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RASHEED BKA, 1994, CANCER RES, V54, P1324; REALE MA, 1994, CANCER RES, V54, P4493; ROYDS JA, 1986, ACTA NEUROPATHOL, V70, P320, DOI 10.1007/BF00686091; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHECK AC, 1993, CANCER RES, V53, P5605; SCHERER JH, 1940, AM J CANCER, V40, P159; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Schold S C Jr, 1983, J Neurooncol, V1, P5; SHATKIN AJ, 1969, FUNDAMENTAL TECHNIQU, P231; VIELMETTER J, 1994, J CELL BIOL, V127, P2009, DOI 10.1083/jcb.127.6.2009; WAINWRIGHT B, 1994, NAT GENET, V8, P3, DOI 10.1038/ng0994-3; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIKSTRAND CJ, 1983, CANCER RES, V43, P3327	54	44	45	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 7	1995	11	11					2393	2402						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK702	8570191				2022-12-25	WOS:A1995TK70200024
